Selegiline	Selegiline	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
postural	postural	ADJ	JJ	5	B-Disease
hypotension	hypotension	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
longitudinal	longitudinal	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
withdrawal	withdrawal	NOUN	NN	5	O
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
United	United	PROPN	NNP	9	O
Kingdom	Kingdom	PROPN	NNP	2	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	PROPN	NNP	9	I-Disease
Disease	Disease	PROPN	NNP	2	I-Disease
Research	Research	PROPN	NNP	2	O
Group	Group	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
UKPDRG	UKPDRG	PROPN	NNP	_	O
)	)	PUNCT	-RRB-	9	O
trial	trial	NOUN	NN	5	O
found	find	VERB	VBD	9	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
mortality	mortality	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
PD	PD	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
randomized	randomize	VERB	VBD	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
selegiline	selegiline	NOUN	NN	0	B-Chemical
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	NOUN	NN	0	I-Chemical
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
taking	take	VERB	VBG	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	NOUN	NN	0	I-Chemical
alone	alone	ADV	RB	9	O
.	.	PUNCT	.	9	O

Recently	recently	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
found	find	VERB	VBD	9	O
that	that	DET	DT	5	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
selegiline	selegiline	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	PROPN	NNP	0	I-Chemical
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
selective	selective	ADJ	JJ	9	O
systolic	systolic	ADJ	JJ	5	B-Disease
orthostatic	orthostatic	ADJ	JJ	5	I-Disease
hypotension	hypotension	NOUN	NN	5	I-Disease
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
abolished	abolish	VERB	VBN	3	O
by	by	ADP	IN	9	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
selegiline	selegiline	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
unwanted	unwanted	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
postural	postural	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
the	the	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
underlying	underlie	VERB	VBG	5	O
autonomic	autonomic	ADJ	JJ	5	O
failure	failure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aims	aim	NOUN	NNS	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
were	be	VERB	VBD	9	O
to	to	PART	TO	5	O
confirm	confirm	VERB	VB	9	O
our	-PRON-	DET	PRP$	5	O
previous	previous	ADJ	JJ	9	O
findings	finding	NOUN	NNS	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
separate	separate	ADJ	JJ	9	O
cohort	cohort	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
consequences	consequence	NOUN	NNS	5	O
of	of	ADP	IN	5	O
stopping	stop	VERB	VBG	5	O
selegiline	selegiline	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
expectation	expectation	NOUN	NN	5	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
might	may	VERB	MD	9	O
shed	shed	VERB	VB	9	O
light	light	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
by	by	ADP	IN	9	O
which	which	DET	WDT	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
causes	cause	VERB	VBZ	9	O
orthostatic	orthostatic	ADJ	JJ	5	B-Disease
hypotension	hypotension	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
responses	response	NOUN	NNS	5	O
to	to	ADP	IN	5	O
standing	standing	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
head	head	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
tilt	tilt	NOUN	NN	5	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
repeatedly	repeatedly	ADV	RB	5	O
in	in	ADP	IN	5	O
PD	pd	NOUN	NN	9	B-Disease
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
selegiline	selegiline	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
was	be	VERB	VBD	9	O
withdrawn	withdraw	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Head	Head	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
tilt	tilt	NOUN	NN	5	O
caused	cause	VERB	VBD	9	O
systolic	systolic	ADJ	JJ	5	B-Disease
orthostatic	orthostatic	ADJ	JJ	5	I-Disease
hypotension	hypotension	NOUN	NN	5	I-Disease
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
marked	mark	VERB	VBN	9	O
in	in	ADP	IN	5	O
six	six	NUM	CD	9	O
of	of	ADP	IN	5	O
20	20	NUM	CD	9	O
PD	pd	NOUN	NN	9	B-Disease
patients	patient	NOUN	NNS	5	O
on	on	ADP	IN	5	O
selegiline	selegiline	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
whom	whom	PRON	WP	5	O
lost	lose	VERB	VBD	9	O
consciousness	consciousness	NOUN	NN	5	O
with	with	ADP	IN	5	O
unrecordable	unrecordable	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressures	pressure	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
lesser	less	ADJ	JJR	9	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
orthostatic	orthostatic	ADJ	JJ	5	B-Disease
hypotension	hypotension	NOUN	NN	5	I-Disease
occurred	occur	VERB	VBD	9	O
with	with	ADP	IN	5	O
standing	standing	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Orthostatic	orthostatic	ADJ	JJ	5	B-Disease
hypotension	hypotension	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
ameliorated	ameliorate	VERB	VBN	9	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
selegiline	selegiline	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
totally	totally	ADV	RB	9	O
abolished	abolish	VERB	VBD	3	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Stopping	stop	VERB	VBG	5	O
selegiline	selegiline	NOUN	NN	0	B-Chemical
also	also	ADV	RB	9	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBD	9	B-Disease
the	the	DET	DT	5	I-Disease
supine	supine	NOUN	NN	5	I-Disease
systolic	systolic	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
diastolic	diastolic	ADJ	JJ	5	I-Disease
blood	blood	NOUN	NN	9	I-Disease
pressures	pressure	NOUN	NNS	5	I-Disease
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
previously	previously	ADV	RB	9	O
undescribed	undescribe	VERB	VBN	4	O
supine	supine	NOUN	NN	5	O
pressor	pressor	NOUN	NN	5	O
action	action	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
confirms	confirm	VERB	VBZ	9	O
our	-PRON-	DET	PRP$	5	O
previous	previous	ADJ	JJ	9	O
finding	finding	NOUN	NN	9	O
that	that	DET	WDT	5	O
selegiline	selegiline	VERB	VBP	0	B-Chemical
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	NOUN	NN	0	I-Chemical
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
selective	selective	ADJ	JJ	9	O
orthostatic	orthostatic	ADJ	JJ	5	B-Disease
hypotension	hypotension	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
possibilities	possibility	NOUN	NNS	5	O
that	that	ADP	IN	5	O
these	these	DET	DT	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
selective	selective	ADJ	JJ	9	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
monoamine	monoamine	NOUN	NN	0	O
oxidase	oxidase	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
of	of	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
metamphetamine	metamphetamine	NOUN	NN	5	B-Chemical
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
on	on	ADP	IN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
irrigation	irrigation	NOUN	NN	5	O
solutions	solution	NOUN	NNS	0	O
on	on	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
bladders	bladder	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
certain	certain	ADJ	JJ	5	O
irrigating	irrigating	NOUN	NN	5	O
fluids	fluid	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
bladder	bladder	NOUN	NN	9	O
for	for	ADP	IN	5	O
18	18	NUM	CD	7	O
hours	hour	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
shown	show	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
degradation	degradation	NOUN	NN	9	O
product	product	NOUN	NN	9	O
p	p	NOUN	NN	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
choloroaniline	choloroaniline	NOUN	NN	_	I-Chemical
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
factor	factor	NOUN	NN	9	O
in	in	ADP	IN	5	O
chlorhexidine	chlorhexidine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
digluconate	digluconate	ADJ	JJ	0	I-Chemical
associated	associate	VERB	VBN	9	O
erosive	erosive	ADJ	JJ	5	O
cystitis	cystitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
high	high	ADJ	JJ	9	O
percentage	percentage	NOUN	NN	9	O
of	of	ADP	IN	5	O
kanamycin	kanamycin	NOUN	NN	1	B-Chemical
-	-	PUNCT	HYPH	7	O
colistin	colistin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
povidone	povidone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
iodine	iodine	NOUN	NN	0	I-Chemical
irrigations	irrigation	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
erosive	erosive	ADJ	JJ	5	O
cystitis	cystitis	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
suggested	suggest	VERB	VBD	9	O
a	a	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
with	with	ADP	IN	5	O
human	human	ADJ	JJ	3	O
usage	usage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Picloxydine	picloxydine	ADJ	JJ	_	B-Chemical
irrigations	irrigation	NOUN	NNS	5	O
appeared	appear	VERB	VBD	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
lower	low	ADJ	JJR	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
erosive	erosive	ADJ	JJ	5	O
cystitis	cystitis	NOUN	NN	9	B-Disease
but	but	CCONJ	CC	9	O
further	further	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
would	would	VERB	MD	5	O
have	have	VERB	VB	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
performed	perform	VERB	VBN	9	O
before	before	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
recommended	recommend	VERB	VBN	5	O
for	for	ADP	IN	5	O
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
urological	urological	ADJ	JJ	5	O
procedures	procedure	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
tetrandrine	tetrandrine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
fangchinoline	fangchinoline	NOUN	NN	3	B-Chemical
on	on	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
human	human	ADJ	JJ	3	O
platelet	platelet	NOUN	NN	9	B-Disease
aggregation	aggregation	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Tetrandrine	Tetrandrine	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
TET	TET	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
fangchinoline	fangchinoline	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
FAN	FAN	PROPN	NNP	2	B-Chemical
)	)	PUNCT	-RRB-	9	O
are	be	VERB	VBP	5	O
two	two	NUM	CD	5	O
naturally	naturally	ADV	RB	9	O
occurring	occur	VERB	VBG	9	O
analogues	analogue	NOUN	NNS	0	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
bisbenzylisoquinoline	bisbenzylisoquinoline	NOUN	NN	0	B-Chemical
structure	structure	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
undertaken	undertake	VERB	VBN	5	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
TET	TET	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
FAN	FAN	PROPN	NNP	2	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
collagen	collagen	NOUN	NN	3	O
plus	plus	CCONJ	CC	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
EP	EP	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
platelet	platelet	NOUN	NN	9	B-Disease
aggregation	aggregation	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
blood	blood	NOUN	NN	9	B-Disease
coagulation	coagulation	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
vitro	vitro	X	FW	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
study	study	VERB	VBP	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
TET	TET	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
FAN	FAN	PROPN	NNP	2	B-Chemical
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
showed	show	VERB	VBD	9	O
the	the	DET	DT	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
by	by	ADP	IN	9	O
55	55	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
35	35	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
acetylsalicylic	acetylsalicylic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
ASA	ASA	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
positive	positive	ADJ	JJ	9	O
control	control	NOUN	NN	9	O
,	,	PUNCT	,	9	O
showed	show	VERB	VBD	9	O
only	only	ADV	RB	9	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
inhibition	inhibition	NOUN	NN	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
vitro	vitro	X	FW	3	O
human	human	ADJ	JJ	3	O
platelet	platelet	NOUN	NN	9	B-Disease
aggregations	aggregation	NOUN	NNS	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
agonists	agonist	NOUN	NNS	3	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
tests	test	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
TET	TET	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
FAN	FAN	PROPN	NNP	2	B-Chemical
showed	show	VERB	VBD	9	O
the	the	DET	DT	5	O
inhibitions	inhibition	NOUN	NNS	9	O
dose	dose	NOUN	NN	9	O
dependently	dependently	ADV	RB	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
neither	neither	CCONJ	CC	9	O
TET	TET	PROPN	NNP	9	B-Chemical
nor	nor	CCONJ	CC	9	O
FAN	FAN	PROPN	NNP	2	B-Chemical
showed	show	VERB	VBD	9	O
any	any	DET	DT	5	O
anticoagulation	anticoagulation	NOUN	NN	5	O
activities	activity	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
measurement	measurement	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
activated	activate	VERB	VBN	3	O
partial	partial	ADJ	JJ	9	O
thromboplastin	thromboplastin	NOUN	NN	5	O
time	time	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
APTT	APTT	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
prothrombin	prothrombin	NOUN	NN	9	O
time	time	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
PT	PT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
thrombin	thrombin	NOUN	NN	0	O
time	time	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
TT	TT	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
using	use	VERB	VBG	9	O
human	human	ADJ	JJ	3	O
-	-	PUNCT	HYPH	7	O
citrated	citrated	ADJ	JJ	0	O
plasma	plasma	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
antithrombosis	antithrombosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
TET	TET	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
FAN	FAN	PROPN	NNP	2	B-Chemical
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
mainly	mainly	ADV	RB	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
antiplatelet	antiplatelet	ADJ	JJ	5	O
aggregation	aggregation	NOUN	NN	9	O
activities	activity	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Angioedema	Angioedema	PROPN	NNP	5	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
ACE	ACE	PROPN	NNP	9	B-Chemical
inhibitors	inhibitor	NOUN	NNS	3	I-Chemical
:	:	PUNCT	:	9	O
common	common	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
inadequately	inadequately	ADV	RB	5	O
diagnosed	diagnose	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
estimated	estimate	VERB	VBN	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
angioedema	angioedema	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
converting	convert	VERB	VBG	9	I-Chemical
enzyme	enzyme	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
ACE	ACE	PROPN	NNP	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
inhibitor	inhibitor	NOUN	NN	3	I-Chemical
treatment	treatment	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
between	between	ADP	IN	5	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
7	7	NUM	CD	9	O
per	per	ADP	IN	9	O
thousand	thousand	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
potentially	potentially	ADV	RB	5	O
serious	serious	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
often	often	ADV	RB	5	O
preceded	precede	VERB	VBN	9	O
by	by	ADP	IN	9	O
minor	minor	ADJ	JJ	9	O
manifestations	manifestation	NOUN	NNS	5	O
that	that	DET	WDT	5	O
may	may	VERB	MD	5	O
serve	serve	VERB	VB	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
warning	warning	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
mood	mood	NOUN	NN	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
prevalence	prevalence	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
psychiatric	psychiatric	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
outpatient	outpatient	NOUN	NN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
sample	sample	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
paper	paper	NOUN	NN	5	O
attempts	attempt	VERB	VBZ	5	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
and	and	CCONJ	CC	5	O
compare	compare	VERB	VB	9	O
prevalence	prevalence	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
symptom	symptom	NOUN	NN	5	O
patterns	pattern	NOUN	NNS	5	O
of	of	ADP	IN	5	O
DSM	DSM	PROPN	NNP	4	O
substance	substance	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
mood	mood	NOUN	NN	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

243	243	NUM	CD	7	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
outpatients	outpatient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
mood	mood	NOUN	NN	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
CIMD	CIMD	PROPN	NNP	3	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
other	other	ADJ	JJ	5	O
mood	mood	NOUN	NN	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
no	no	DET	DT	9	O
mood	mood	NOUN	NN	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
on	on	ADP	IN	5	O
measures	measure	NOUN	NNS	5	O
of	of	ADP	IN	5	O
psychiatric	psychiatric	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
prevalence	prevalence	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
for	for	ADP	IN	5	O
CIMD	CIMD	PROPN	NNP	3	B-Disease
was	be	VERB	VBD	9	O
12	12	NUM	CD	9	O
%	%	NOUN	NN	9	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Introduction	introduction	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
DSM	DSM	PROPN	NNP	4	O
-	-	PUNCT	HYPH	7	O
IV	IV	PROPN	NNP	9	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
CIMD	CIMD	PROPN	NNP	3	B-Disease
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
substantially	substantially	ADV	RB	9	O
affect	affect	VERB	VB	9	O
rates	rate	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
depressive	depressive	ADJ	JJ	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
CIMD	CIMD	PROPN	NNP	3	B-Disease
had	have	VERB	VBD	9	O
symptom	symptom	NOUN	NN	5	O
severity	severity	NOUN	NN	5	O
levels	level	NOUN	NNS	3	O
between	between	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
and	and	CCONJ	CC	5	O
without	without	ADP	IN	9	O
a	a	DET	DT	5	O
mood	mood	NOUN	NN	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
some	some	DET	DT	5	O
validity	validity	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
new	new	ADJ	JJ	5	O
DSM	DSM	PROPN	NNP	4	O
-	-	PUNCT	HYPH	7	O
IV	IV	PROPN	NNP	9	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
CIMD	CIMD	PROPN	NNP	3	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
also	also	ADV	RB	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
requires	require	VERB	VBZ	5	O
further	further	ADJ	JJ	9	O
specification	specification	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
replication	replication	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
fucoidan	fucoidan	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
on	on	ADP	IN	5	O
collagenase	collagenase	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
intracerebral	intracerebral	ADJ	JJ	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Inflammatory	inflammatory	ADJ	JJ	9	O
cells	cell	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
postulated	postulate	VERB	VBN	9	O
to	to	PART	TO	5	O
mediate	mediate	VERB	VB	3	O
some	some	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	B-Disease
damage	damage	NOUN	NN	9	I-Disease
following	follow	VERB	VBG	9	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
stroke	stroke	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Intracerebral	intracerebral	ADJ	JJ	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
more	more	ADJ	JJR	5	O
inflammation	inflammation	NOUN	NN	9	B-Disease
than	than	ADP	IN	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
stroke	stroke	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
tested	test	VERB	VBD	9	O
the	the	DET	DT	5	O
sulfated	sulfate	VERB	VBN	0	O
polysaccharide	polysaccharide	NOUN	NN	0	O
fucoidan	fucoidan	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
to	to	PART	TO	5	O
reduce	reduce	VERB	VB	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
brain	brain	NOUN	NN	5	B-Disease
damage	damage	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
intracerebral	intracerebral	ADJ	JJ	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
bacterial	bacterial	ADJ	JJ	9	O
collagenase	collagenase	NOUN	NN	0	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
caudate	caudate	ADJ	JJ	5	O
nucleus	nucleus	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
seven	seven	NUM	CD	9	O
day	day	NOUN	NN	9	O
intravenous	intravenous	ADJ	JJ	0	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
fucoidan	fucoidan	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
h	h	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
vehicle	vehicle	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hematoma	hematoma	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
by	by	ADP	IN	9	O
magnetic	magnetic	ADJ	JJ	0	O
resonance	resonance	NOUN	NN	5	O
imaging	imaging	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Motor	motor	NOUN	NN	5	O
behavior	behavior	NOUN	NN	5	O
,	,	PUNCT	,	9	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
skilled	skilled	ADJ	JJ	5	O
forelimb	forelimb	NOUN	NN	5	O
function	function	NOUN	NN	9	O
were	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
repeatedly	repeatedly	ADV	RB	5	O
for	for	ADP	IN	5	O
six	six	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Fucoidan	fucoidan	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
exhibited	exhibit	VERB	VBD	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
impaired	impaired	ADJ	JJ	9	B-Disease
blood	blood	NOUN	NN	9	I-Disease
clotting	clotting	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
hemodilution	hemodilution	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
had	have	VERB	VBD	9	O
larger	large	ADJ	JJR	5	O
hematomas	hematoma	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
tended	tend	VERB	VBD	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
less	less	ADJ	JJR	5	O
inflammation	inflammation	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
vicinity	vicinity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hematoma	hematoma	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
three	three	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

They	-PRON-	PRON	PRP	5	O
showed	show	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
more	more	ADV	RBR	5	O
rapid	rapid	ADJ	JJ	5	O
improvement	improvement	NOUN	NN	5	O
of	of	ADP	IN	5	O
motor	motor	NOUN	NN	5	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
week	week	NOUN	NN	9	O
following	follow	VERB	VBG	9	O
hemorrhage	hemorrhage	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
better	well	ADJ	JJR	5	O
memory	memory	NOUN	NN	5	O
retention	retention	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
white	white	ADJ	JJ	9	B-Disease
matter	matter	NOUN	NN	5	I-Disease
edema	edema	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
eventual	eventual	ADJ	JJ	5	O
neuronal	neuronal	ADJ	JJ	3	B-Disease
loss	loss	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
adjacent	adjacent	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
hematoma	hematoma	NOUN	NN	5	B-Disease
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
differ	differ	VERB	VB	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Investigation	investigation	NOUN	NN	9	O
of	of	ADP	IN	5	O
more	more	ADV	RBR	5	O
specific	specific	ADJ	JJ	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
agents	agent	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
hemodiluting	hemodilute	VERB	VBG	9	O
agents	agent	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
warranted	warrant	VERB	VBN	9	O
in	in	ADP	IN	5	O
intracerebral	intracerebral	ADJ	JJ	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Recurarization	recurarization	NOUN	NN	_	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
recovery	recovery	NOUN	NN	9	O
room	room	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
recurarization	recurarization	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
recovery	recovery	NOUN	NN	9	O
room	room	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Accumulation	accumulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
atracurium	atracurium	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
intravenous	intravenous	ADJ	JJ	0	O
line	line	NOUN	NN	9	O
led	lead	VERB	VBN	9	O
to	to	ADP	IN	5	O
recurarization	recurarization	NOUN	NN	5	O
after	after	ADP	IN	9	O
flushing	flush	VERB	VBG	5	O
the	the	DET	DT	5	O
line	line	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
recovery	recovery	NOUN	NN	9	O
room	room	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
desaturation	desaturation	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
occurred	occur	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Circumstances	circumstance	NOUN	NNS	5	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
event	event	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
enabling	enable	VERB	VBG	5	O
a	a	DET	DT	5	O
neuromuscular	neuromuscular	ADJ	JJ	5	B-Disease
blockade	blockade	NOUN	NN	3	I-Disease
to	to	PART	TO	5	O
occur	occur	VERB	VB	5	O
,	,	PUNCT	,	9	O
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
small	small	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
relaxant	relaxant	NOUN	NN	0	O
,	,	PUNCT	,	9	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
haemodynamic	haemodynamic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
propofol	propofol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
ephedrine	ephedrine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
ASA	ASA	PROPN	NNP	9	O
groups	group	NOUN	NNS	9	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
marked	marked	ADJ	JJ	9	O
vasodilator	vasodilator	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
negative	negative	ADJ	JJ	9	O
inotropic	inotropic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
propofol	propofol	NOUN	NNS	0	B-Chemical
are	be	VERB	VBP	5	O
disadvantages	disadvantage	NOUN	NNS	5	O
in	in	ADP	IN	5	O
frail	frail	ADJ	JJ	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
adding	add	VERB	VBG	0	O
different	different	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
ephedrine	ephedrine	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
propofol	propofol	VERB	VB	0	B-Chemical
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
obtund	obtund	VERB	VB	5	O
the	the	DET	DT	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
response	response	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
haemodynamic	haemodynamic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
adding	add	VERB	VBG	0	O
15	15	NUM	CD	9	O
,	,	PUNCT	,	9	O
20	20	NUM	CD	9	O
or	or	CCONJ	CC	5	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
of	of	ADP	IN	5	O
ephedrine	ephedrine	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
of	of	ADP	IN	5	O
propofol	propofol	ADJ	JJ	0	B-Chemical
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
in	in	ADP	IN	5	O
40	40	NUM	CD	9	O
ASA	ASA	PROPN	NNP	9	O
3	3	NUM	CD	9	O
/	/	SYM	SYM	9	O
4	4	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
over	over	ADP	IN	5	O
60	60	NUM	CD	9	O
years	year	NOUN	NNS	5	O
presenting	present	VERB	VBG	5	O
for	for	ADP	IN	5	O
genito	genito	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
urinary	urinary	NOUN	NN	9	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
addition	addition	NOUN	NN	9	O
of	of	ADP	IN	5	O
ephedrine	ephedrine	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
propofol	propofol	ADJ	JJ	0	B-Chemical
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
method	method	NOUN	NN	5	O
of	of	ADP	IN	5	O
obtunding	obtund	VERB	VBG	5	O
the	the	DET	DT	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
response	response	NOUN	NN	9	O
to	to	PART	TO	5	O
propofol	propofol	VERB	VB	0	B-Chemical
at	at	ADP	IN	9	O
all	all	DET	DT	5	O
doses	dose	NOUN	NNS	0	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
marked	mark	VERB	VBD	9	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
ephedrine	ephedrine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
propofol	propofol	NOUN	NN	0	B-Chemical
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
majority	majority	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
occasionally	occasionally	ADV	RB	5	O
reaching	reach	VERB	VBG	5	O
high	high	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
in	in	ADP	IN	5	O
individual	individual	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
inducing	induce	VERB	VBG	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
would	would	VERB	MD	5	O
not	not	ADV	RB	5	O
recommend	recommend	VERB	VB	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
of	of	ADP	IN	5	O
any	any	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ephedrine	ephedrine	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
propofol	propofol	PROPN	NNP	0	B-Chemical
/	/	SYM	SYM	9	O
mixtures	mixture	NOUN	NNS	0	O
studied	study	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Gemcitabine	gemcitabine	ADJ	JJ	0	B-Chemical
plus	plus	CCONJ	CC	9	O
vinorelbine	vinorelbine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
nonsmall	nonsmall	NOUN	NN	3	B-Disease
cell	cell	NOUN	NN	3	I-Disease
lung	lung	NOUN	NN	9	I-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
patients	patient	NOUN	NNS	5	O
age	age	NOUN	NN	5	O
70	70	NUM	CD	9	O
years	year	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
older	old	ADJ	JJR	5	O
or	or	CCONJ	CC	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
cannot	cannot	VERB	VBP	5	O
receive	receive	ADJ	JJ	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

Oncopaz	Oncopaz	PROPN	NNP	_	O
Cooperative	Cooperative	PROPN	NNP	2	O
Group	Group	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Although	although	ADP	IN	9	O
the	the	DET	DT	5	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
nonsmall	nonsmall	NOUN	NN	3	B-Disease
cell	cell	NOUN	NN	3	I-Disease
lung	lung	NOUN	NN	9	I-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
NSCLC	nsclc	NOUN	NN	3	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
high	high	ADJ	JJ	9	O
among	among	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
few	few	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
available	available	ADJ	JJ	5	O
regarding	regard	VERB	VBG	5	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Recent	recent	ADJ	JJ	9	O
reports	report	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
single	single	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
vinorelbine	vinorelbine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
VNB	VNB	PROPN	NNP	4	B-Chemical
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
gemcitabine	gemcitabine	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
GEM	gem	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
may	may	VERB	MD	5	O
obtain	obtain	VERB	VB	5	O
a	a	DET	DT	5	O
response	response	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
20	20	NUM	CD	9	O
-	-	SYM	SYM	7	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
acceptable	acceptable	ADJ	JJ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
quality	quality	NOUN	NN	5	O
of	of	ADP	IN	5	O
life	life	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
GEM	GEM	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
VNB	VNB	PROPN	NNP	4	B-Chemical
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
NSCLC	nsclc	NOUN	NN	3	B-Disease
or	or	CCONJ	CC	5	O
those	those	DET	DT	5	O
with	with	ADP	IN	5	O
some	some	DET	DT	5	O
contraindication	contraindication	NOUN	NN	5	O
to	to	ADP	IN	5	O
receiving	receive	VERB	VBG	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Forty	forty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
nine	nine	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
NSCLC	NSCLC	PROPN	NNP	3	B-Disease
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
,	,	PUNCT	,	9	O
38	38	NUM	CD	7	O
of	of	ADP	IN	5	O
whom	whom	PRON	WP	5	O
were	be	VERB	VBD	9	O
age	age	NOUN	NN	5	O
>	>	X	XX	0	O
/	/	SYM	SYM	9	O
=	=	SYM	SYM	7	O
70	70	NUM	CD	9	O
years	year	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
11	11	NUM	CD	7	O
were	be	VERB	VBD	9	O
age	age	NOUN	NN	5	O
<	<	X	XX	0	O
70	70	NUM	CD	9	O
years	year	NOUN	NNS	5	O
but	but	CCONJ	CC	9	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
some	some	DET	DT	5	O
contraindication	contraindication	NOUN	NN	5	O
to	to	ADP	IN	5	O
receiving	receive	VERB	VBG	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
evaluable	evaluable	ADJ	JJ	9	O
for	for	ADP	IN	5	O
response	response	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
comprised	comprise	VERB	VBN	9	O
of	of	ADP	IN	5	O
VNB	VNB	PROPN	NNP	4	B-Chemical
,	,	PUNCT	,	9	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
plus	plus	CCONJ	CC	9	O
GEM	GEM	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
1000	1000	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
both	both	DET	DT	9	O
on	on	ADP	IN	5	O
Days	Days	PROPN	NNP	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
15	15	NUM	CD	9	O
every	every	DET	DT	5	O
28	28	NUM	CD	7	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
a	a	DET	DT	5	O
minimum	minimum	NOUN	NN	5	O
of	of	ADP	IN	5	O
three	three	NUM	CD	9	O
courses	course	NOUN	NNS	5	O
unless	unless	ADP	IN	9	O
progressive	progressive	ADJ	JJ	5	O
disease	disease	NOUN	NN	5	O
was	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
One	one	NUM	CD	5	O
hundred	hundred	NUM	CD	5	O
sixty	sixty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
five	five	NUM	CD	9	O
courses	course	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
median	median	NOUN	NN	9	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O

6	6	NUM	CD	9	O
courses	course	NOUN	NNS	5	O
per	per	ADP	IN	9	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
26	26	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
15	15	NUM	CD	9	O
-	-	SYM	SYM	7	O
41	41	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
attained	attain	VERB	VBD	9	O
a	a	DET	DT	5	O
complete	complete	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
11	11	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
22	22	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
achieved	achieve	VERB	VBD	5	O
a	a	DET	DT	5	O
partial	partial	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Eastern	Eastern	PROPN	NNP	4	O
Cooperative	Cooperative	PROPN	NNP	2	O
Oncology	Oncology	PROPN	NNP	2	O
Group	Group	PROPN	NNP	9	O
performance	performance	NOUN	NN	5	O
status	status	NOUN	NN	9	O
improved	improve	VERB	VBD	5	O
in	in	ADP	IN	5	O
35	35	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
those	those	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
value	value	NOUN	NN	9	O
>	>	X	XX	0	O
0	0	NUM	CD	7	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
relief	relief	NOUN	NN	5	O
of	of	ADP	IN	5	O
at	at	ADV	RB	9	O
least	least	ADJ	JJS	9	O
1	1	NUM	CD	9	O
symptom	symptom	NOUN	NN	5	O
without	without	ADP	IN	9	O
worsening	worsen	VERB	VBG	5	O
of	of	ADP	IN	5	O
other	other	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
in	in	ADP	IN	5	O
27	27	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
55	55	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
to	to	ADP	IN	5	O
progression	progression	NOUN	NN	9	O
was	be	VERB	VBD	9	O
16	16	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
survival	survival	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
33	33	NUM	CD	7	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Toxicity	toxicity	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
mild	mild	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Six	six	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
World	World	PROPN	NNP	5	O
Health	Health	PROPN	NNP	2	O
Organization	Organization	PROPN	NNP	2	O
Grade	Grade	PROPN	NNP	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
Grade	Grade	PROPN	NNP	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
Grade	Grade	PROPN	NNP	9	O
3	3	NUM	CD	9	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
died	die	VERB	VBD	9	O
of	of	ADP	IN	5	O
sepsis	sepsis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
age	age	NOUN	NN	5	O
of	of	ADP	IN	5	O
those	those	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
developing	develop	VERB	VBG	5	O
Grade	Grade	PROPN	NNP	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
remaining	remain	VERB	VBG	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
75	75	NUM	CD	9	O
years	year	NOUN	NNS	5	O
vs	vs	ADP	IN	7	O
.	.	PUNCT	.	9	O
72	72	NUM	CD	9	O
years	year	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
047	047	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
GEM	GEM	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
VNB	VNB	PROPN	NNP	4	B-Chemical
is	be	VERB	VBZ	5	O
moderately	moderately	ADV	RB	9	O
active	active	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
except	except	ADP	IN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
age	age	NOUN	NN	5	O
>	>	X	XX	0	O
/	/	SYM	SYM	9	O
=	=	SYM	SYM	7	O
75	75	NUM	CD	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
age	age	NOUN	NN	5	O
group	group	NOUN	NN	9	O
had	have	VERB	VBD	9	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
myelosuppression	myelosuppression	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
the	the	DET	DT	5	O
prophylactic	prophylactic	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
granulocyte	granulocyte	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
colony	colony	NOUN	NN	9	O
stimulating	stimulate	VERB	VBG	9	O
factor	factor	NOUN	NN	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
with	with	ADP	IN	5	O
this	this	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

New	new	ADJ	JJ	2	O
chemotherapy	chemotherapy	NOUN	NN	5	O
combinations	combination	NOUN	NNS	9	O
with	with	ADP	IN	5	O
higher	high	ADJ	JJR	9	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
lower	low	ADJ	JJR	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
are	be	VERB	VBP	5	O
needed	need	VERB	VBN	5	O
for	for	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
NSCLC	nsclc	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
selective	selective	ADJ	JJ	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
D4	d4	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
NRA0160	NRA0160	PROPN	NNP	_	B-Chemical
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
preclinical	preclinical	ADJ	JJ	9	O
neuropharmacological	neuropharmacological	ADJ	JJ	5	O
profile	profile	NOUN	NN	9	O
.	.	PUNCT	.	9	O

NRA0160	NRA0160	PROPN	NNP	_	B-Chemical
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorobenzylidene	fluorobenzylidene	PROPN	NNP	_	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
piperidin	piperidin	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
yl	yl	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
ethyl	ethyl	ADV	RB	0	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorophenyl	fluorophenyl	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
thiazole	thiazole	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
carboxamide	carboxamide	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
affinity	affinity	NOUN	NN	0	O
for	for	ADP	IN	5	O
human	human	ADJ	JJ	3	O
cloned	clone	VERB	VBN	1	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
D4	d4	NOUN	NN	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
D4	D4	PROPN	NNP	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
and	and	CCONJ	CC	5	O
D4	d4	NOUN	NN	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
receptors	receptor	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
Ki	Ki	PROPN	NNP	0	O
values	value	NOUN	NNS	5	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
nM	nm	NOUN	NN	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

NRA0160	NRA0160	PROPN	NNP	_	B-Chemical
is	be	VERB	VBZ	5	O
over	over	ADP	IN	5	O
20	20	NUM	CD	9	O
,	,	PUNCT	,	9	O
000fold	000fold	ADV	RB	_	O
more	more	ADV	RBR	5	O
potent	potent	ADJ	JJ	3	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
D4	d4	NOUN	NN	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
receptor	receptor	NOUN	NN	3	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
human	human	ADJ	JJ	3	O
cloned	clone	VERB	VBN	1	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
D2L	D2L	PROPN	NNP	3	O
receptor	receptor	NOUN	NN	3	O
.	.	PUNCT	.	9	O

NRA0160	NRA0160	PROPN	NNP	_	B-Chemical
has	have	VERB	VBZ	9	O
negligible	negligible	ADJ	JJ	9	O
affinity	affinity	NOUN	NN	0	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
human	human	ADJ	JJ	3	O
cloned	clone	VERB	VBN	1	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
D3	d3	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
Ki	Ki	PROPN	NNP	0	O
=	=	PROPN	NNP	7	O
39	39	NUM	CD	7	O
nM	nm	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
rat	rat	NOUN	NN	3	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
-	-	SYM	SYM	7	I-Chemical
HT	ht	NOUN	NN	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
2A	2a	NOUN	NN	9	O
receptors	receptor	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
Ki	Ki	PROPN	NNP	0	O
=	=	PROPN	NNP	7	O
180	180	NUM	CD	9	O
nM	nM	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
rat	rat	VERB	VB	3	O
alpha1	alpha1	ADJ	JJ	9	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
Ki	Ki	PROPN	NNP	0	O
=	=	PROPN	NNP	7	O
237	237	NUM	CD	7	O
nM	nm	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

NRA0160	NRA0160	PROPN	NNP	_	B-Chemical
and	and	CCONJ	CC	5	O
clozapine	clozapine	VERB	VB	5	B-Chemical
antagonized	antagonized	ADJ	JJ	3	O
locomotor	locomotor	NOUN	NN	5	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
MAP	MAP	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

NRA0160	NRA0160	PROPN	NNP	_	B-Chemical
and	and	CCONJ	CC	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
antagonized	antagonize	VERB	VBN	3	O
MAP	MAP	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
stereotyped	stereotyped	ADJ	JJ	5	O
behavior	behavior	NOUN	NN	5	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
their	-PRON-	DET	PRP$	5	O
effects	effect	NOUN	NNS	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
exceed	exceed	VERB	VB	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
inhibition	inhibition	NOUN	NN	3	O
,	,	PUNCT	,	9	O
even	even	ADV	RB	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
highest	high	ADJ	JJS	9	O
dose	dose	NOUN	NN	9	O
given	give	VERB	VBN	5	O
.	.	PUNCT	.	9	O

NRA0160	NRA0160	PROPN	NNP	_	B-Chemical
and	and	CCONJ	CC	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
significantly	significantly	ADV	RB	9	O
induced	induced	ADJ	JJ	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
their	-PRON-	DET	PRP$	5	O
effects	effect	NOUN	NNS	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
exceed	exceed	VERB	VB	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
induction	induction	NOUN	NN	3	O
even	even	ADV	RB	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
highest	high	ADJ	JJS	9	O
dose	dose	NOUN	NN	9	O
given	give	VERB	VBN	5	O
.	.	PUNCT	.	9	O

NRA0160	NRA0160	PROPN	NNP	_	B-Chemical
and	and	CCONJ	CC	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
significantly	significantly	ADV	RB	9	O
reversed	reverse	VERB	VBD	9	O
the	the	DET	DT	5	O
disruption	disruption	NOUN	NN	9	O
of	of	ADP	IN	5	O
prepulse	prepulse	NOUN	NN	5	O
inhibition	inhibition	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
PPI	PPI	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

NRA0160	NRA0160	PROPN	NNP	_	B-Chemical
and	and	CCONJ	CC	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
significantly	significantly	ADV	RB	9	O
shortened	shorten	VERB	VBD	9	O
the	the	DET	DT	5	O
phencyclidine	phencyclidine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
PCP	PCP	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
prolonged	prolong	VERB	VBN	9	O
swimming	swimming	NOUN	NN	5	O
latency	latency	NOUN	NN	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
water	water	NOUN	NN	0	O
maze	maze	NOUN	NN	5	O
task	task	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
NRA0160	NRA0160	PROPN	NNP	_	B-Chemical
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
unique	unique	ADJ	JJ	9	O
antipsychotic	antipsychotic	ADJ	JJ	5	O
activities	activity	NOUN	NNS	9	O
without	without	ADP	IN	9	O
the	the	DET	DT	5	O
liability	liability	NOUN	NN	5	O
of	of	ADP	IN	5	O
motor	motor	NOUN	NN	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
typical	typical	ADJ	JJ	9	O
of	of	ADP	IN	5	O
classical	classical	ADJ	JJ	9	O
antipsychotics	antipsychotic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Warfarin	Warfarin	PROPN	NNP	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
artery	artery	NOUN	NN	5	B-Disease
calcification	calcification	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
accelerated	accelerate	VERB	VBN	9	O
by	by	ADP	IN	9	O
growth	growth	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D	d	NOUN	NN	9	I-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
demonstrate	demonstrate	VERB	VBP	9	O
that	that	DET	DT	5	O
growth	growth	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D	d	ADJ	JJ	9	I-Chemical
treatment	treatment	NOUN	NN	9	O
enhance	enhance	VERB	VB	9	O
the	the	DET	DT	5	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
artery	artery	NOUN	NN	5	B-Disease
calcification	calcification	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
given	give	VERB	VBN	5	O
sufficient	sufficient	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
Warfarin	Warfarin	PROPN	NNP	5	B-Chemical
to	to	PART	TO	5	O
inhibit	inhibit	VERB	VB	3	O
gamma	gamma	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
carboxylation	carboxylation	NOUN	NN	0	O
of	of	ADP	IN	5	O
matrix	matrix	NOUN	NN	5	O
Gla	Gla	PROPN	NNP	1	O
protein	protein	NOUN	NN	1	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
calcification	calcification	NOUN	NN	5	B-Disease
inhibitor	inhibitor	NOUN	NN	3	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
expressed	express	VERB	VBN	3	O
by	by	ADP	IN	9	O
smooth	smooth	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
cells	cell	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
macrophages	macrophage	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
artery	artery	NOUN	NN	5	O
wall	wall	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
series	series	NOUN	NN	5	O
of	of	ADP	IN	5	O
experiments	experiment	NOUN	NNS	9	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
growth	growth	NOUN	NN	3	O
status	status	NOUN	NN	9	O
on	on	ADP	IN	5	O
artery	artery	NOUN	NN	5	B-Disease
calcification	calcification	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
Warfarin	Warfarin	PROPN	NNP	5	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
with	with	ADP	IN	5	O
Warfarin	Warfarin	PROPN	NNP	5	B-Chemical
caused	cause	VERB	VBD	9	O
massive	massive	ADJ	JJ	9	O
focal	focal	ADJ	JJ	5	O
calcification	calcification	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
artery	artery	NOUN	NN	5	I-Disease
media	medium	NOUN	NNS	9	O
in	in	ADP	IN	5	O
20	20	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
less	less	ADV	RBR	5	O
extensive	extensive	ADJ	JJ	5	O
focal	focal	ADJ	JJ	5	O
calcification	calcification	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
42	42	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
artery	artery	NOUN	NN	5	B-Disease
calcification	calcification	NOUN	NN	5	I-Disease
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
10	10	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
month	month	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
adult	adult	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
even	even	ADV	RB	5	O
after	after	ADP	IN	9	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
Warfarin	Warfarin	PROPN	NNP	5	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
directly	directly	ADV	RB	9	O
examine	examine	VERB	VB	9	O
the	the	DET	DT	5	O
importance	importance	NOUN	NN	5	O
of	of	ADP	IN	5	O
growth	growth	NOUN	NN	3	O
to	to	ADP	IN	5	O
Warfarin	Warfarin	PROPN	NNP	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
artery	artery	NOUN	NN	5	B-Disease
calcification	calcification	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
20	20	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
fed	feed	VERB	VBN	9	O
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
either	either	CCONJ	CC	9	O
an	an	DET	DT	5	O
ad	ad	NOUN	NN	9	O
libitum	libitum	NOUN	NN	9	O
diet	diet	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
a	a	DET	DT	5	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
restricted	restrict	VERB	VBN	9	O
diet	diet	NOUN	NN	9	O
that	that	DET	WDT	5	O
maintains	maintain	VERB	VBZ	9	O
weight	weight	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
prevents	prevent	VERB	VBZ	9	O
growth	growth	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Concurrent	concurrent	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
both	both	CCONJ	CC	9	O
dietary	dietary	ADJ	JJ	5	O
groups	group	NOUN	NNS	9	O
with	with	ADP	IN	5	O
Warfarin	Warfarin	PROPN	NNP	5	B-Chemical
produced	produce	VERB	VBD	9	O
massive	massive	ADJ	JJ	9	O
focal	focal	ADJ	JJ	5	O
calcification	calcification	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
artery	artery	NOUN	NN	5	I-Disease
media	medium	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ad	ad	NOUN	NN	9	O
libitum	libitum	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
fed	feed	VERB	VBN	9	O
rats	rat	NOUN	NNS	9	O
but	but	CCONJ	CC	9	O
no	no	DET	DT	9	O
detectable	detectable	ADJ	JJ	9	O
artery	artery	NOUN	NN	5	B-Disease
calcification	calcification	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
restricted	restrict	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
diet	diet	NOUN	NN	9	O
,	,	PUNCT	,	9	O
growth	growth	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
inhibited	inhibit	VERB	VBN	3	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
the	the	DET	DT	5	O
explanation	explanation	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
artery	artery	NOUN	NN	5	B-Disease
calcification	calcification	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
growth	growth	NOUN	NN	3	O
status	status	NOUN	NN	9	O
cannot	cannot	NOUN	NN	5	O
be	be	VERB	VB	5	O
determined	determine	VERB	VBN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
higher	high	ADJ	JJR	9	O
serum	serum	NOUN	NN	9	O
phosphate	phosphate	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
susceptibility	susceptibility	NOUN	NN	9	O
to	to	ADP	IN	5	O
artery	artery	NOUN	NN	5	B-Disease
calcification	calcification	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
higher	high	ADJ	JJR	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
phosphate	phosphate	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
young	young	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
ad	ad	NOUN	NN	9	O
libitum	libitum	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
fed	feed	VERB	VBN	9	O
rats	rat	NOUN	NNS	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
either	either	DET	DT	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
groups	group	NOUN	NNS	9	O
that	that	DET	WDT	5	O
was	be	VERB	VBD	9	O
resistant	resistant	ADJ	JJ	9	O
to	to	ADP	IN	5	O
Warfarin	Warfarin	PROPN	NNP	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
artery	artery	NOUN	NN	5	B-Disease
calcification	calcification	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
ie	ie	X	FW	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
10	10	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
month	month	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
restricted	restrict	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
diet	diet	NOUN	NN	9	O
,	,	PUNCT	,	9	O
growth	growth	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
inhibited	inhibit	VERB	VBN	3	O
young	young	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
observation	observation	NOUN	NN	9	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
susceptibility	susceptibility	NOUN	NN	9	O
to	to	ADP	IN	5	O
Warfarin	Warfarin	PROPN	NNP	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
artery	artery	NOUN	NN	5	B-Disease
calcification	calcification	NOUN	NN	5	I-Disease
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
higher	high	ADJ	JJR	9	O
serum	serum	ADJ	JJ	9	O
phosphate	phosphate	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
set	set	NOUN	NN	5	O
of	of	ADP	IN	5	O
experiments	experiment	NOUN	NNS	9	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
synergy	synergy	NOUN	NN	9	O
between	between	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D	d	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
Warfarin	Warfarin	PROPN	NNP	5	B-Chemical
in	in	ADP	IN	5	O
artery	artery	NOUN	NN	5	B-Disease
calcification	calcification	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D	d	NOUN	NN	9	I-Chemical
are	be	VERB	VBP	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
calcification	calcification	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
artery	artery	NOUN	NN	5	I-Disease
media	medium	NOUN	NNS	9	O
in	in	ADP	IN	5	O
as	as	ADV	RB	5	O
little	little	ADJ	JJ	9	O
as	as	ADP	IN	5	O
3	3	NUM	CD	9	O
to	to	PART	TO	5	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
K	k	NOUN	NN	9	I-Chemical
antagonist	antagonist	NOUN	NN	3	O
Warfarin	Warfarin	PROPN	NNP	5	B-Chemical
are	be	VERB	VBP	5	O
also	also	ADV	RB	9	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
calcification	calcification	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
artery	artery	NOUN	NN	5	I-Disease
media	medium	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
at	at	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
times	time	NOUN	NNS	5	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
or	or	CCONJ	CC	5	O
longer	longer	ADV	RBR	5	O
yet	yet	ADV	RB	9	O
not	not	ADV	RB	5	O
at	at	ADP	IN	9	O
1	1	NUM	CD	9	O
week	week	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
synergy	synergy	NOUN	NN	9	O
between	between	ADP	IN	5	O
these	these	DET	DT	5	O
2	2	NUM	CD	9	O
treatments	treatment	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
found	find	VERB	VBD	9	O
that	that	ADP	IN	5	O
concurrent	concurrent	ADJ	JJ	5	O
Warfarin	Warfarin	PROPN	NNP	5	B-Chemical
administration	administration	NOUN	NN	9	O
dramatically	dramatically	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
calcification	calcification	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
media	medium	NOUN	NNS	9	O
of	of	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D	d	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
at	at	ADP	IN	9	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
close	close	ADJ	JJ	5	O
parallel	parallel	NOUN	NN	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D	d	NOUN	NN	9	I-Chemical
dose	dose	NOUN	NN	9	O
on	on	ADP	IN	5	O
artery	artery	NOUN	NN	5	B-Disease
calcification	calcification	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D	d	NOUN	NN	9	I-Chemical
dose	dose	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D	d	NOUN	NN	9	I-Chemical
may	may	VERB	MD	5	O
induce	induce	VERB	VB	3	O
artery	artery	NOUN	NN	5	B-Disease
calcification	calcification	NOUN	NN	5	I-Disease
through	through	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
Warfarin	Warfarin	PROPN	NNP	5	B-Chemical
treatment	treatment	NOUN	NN	9	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
elevation	elevation	NOUN	NN	9	O
in	in	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D	d	NOUN	NN	9	I-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
synergy	synergy	NOUN	NN	9	O
between	between	ADP	IN	5	O
Warfarin	Warfarin	PROPN	NNP	5	B-Chemical
and	and	CCONJ	CC	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D	d	NOUN	NN	9	I-Chemical
is	be	VERB	VBZ	5	O
probably	probably	ADV	RB	9	O
best	best	ADV	RBS	5	O
explained	explain	VERB	VBN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	DET	WDT	5	O
Warfarin	Warfarin	PROPN	NNP	5	B-Chemical
inhibits	inhibit	VERB	VBZ	3	O
the	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
matrix	matrix	NOUN	NN	5	O
Gla	Gla	PROPN	NNP	1	O
protein	protein	NOUN	NN	1	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
calcification	calcification	NOUN	NN	5	B-Disease
inhibitor	inhibitor	NOUN	NN	3	O
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
matrix	matrix	NOUN	NN	5	O
Gla	Gla	PROPN	NNP	1	O
protein	protein	NOUN	NN	1	O
are	be	VERB	VBP	5	O
found	find	VERB	VBN	9	O
at	at	ADP	IN	9	O
sites	site	NOUN	NNS	9	O
of	of	ADP	IN	5	O
artery	artery	NOUN	NN	5	B-Disease
calcification	calcification	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D	d	NOUN	NN	9	I-Chemical
plus	plus	CCONJ	CC	9	O
Warfarin	Warfarin	PROPN	NNP	5	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
chemical	chemical	NOUN	NN	0	O
analysis	analysis	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
protein	protein	NOUN	NN	1	O
that	that	DET	WDT	5	O
accumulated	accumulate	VERB	VBD	9	O
was	be	VERB	VBD	9	O
indeed	indeed	ADV	RB	9	O
not	not	ADV	RB	5	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
carboxylated	carboxylate	VERB	VBN	0	I-Chemical
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
observations	observation	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
although	although	ADP	IN	9	O
the	the	DET	DT	5	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
carboxyglutamate	carboxyglutamate	NOUN	NN	7	I-Chemical
residues	residue	NOUN	NNS	1	O
of	of	ADP	IN	5	O
matrix	matrix	NOUN	NN	5	O
Gla	Gla	PROPN	NNP	1	O
protein	protein	NOUN	NN	1	O
are	be	VERB	VBP	5	O
apparently	apparently	ADV	RB	9	O
required	require	VERB	VBN	9	O
for	for	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
function	function	NOUN	NN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
calcification	calcification	NOUN	NN	5	B-Disease
inhibitor	inhibitor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
they	-PRON-	PRON	PRP	5	O
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
required	require	VERB	VBN	9	O
for	for	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
accumulation	accumulation	NOUN	NN	9	O
at	at	ADP	IN	9	O
calcification	calcification	NOUN	NN	5	B-Disease
sites	site	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Test	test	NOUN	NN	5	O
conditions	condition	NOUN	NNS	9	O
influence	influence	VERB	VBP	5	O
the	the	DET	DT	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
drug	drug	NOUN	NN	5	O
challenge	challenge	NOUN	NN	9	O
in	in	ADP	IN	5	O
rodents	rodent	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
studies	study	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
the	the	DET	DT	5	O
differential	differential	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
drug	drug	NOUN	NN	5	O
challenge	challenge	NOUN	NN	9	O
under	under	ADP	IN	9	O
varied	varied	ADJ	JJ	9	O
experimental	experimental	ADJ	JJ	5	O
test	test	NOUN	NN	5	O
conditions	condition	NOUN	NNS	9	O
routinely	routinely	ADV	RB	9	O
employed	employ	VERB	VBN	5	O
to	to	PART	TO	5	O
study	study	VERB	VB	9	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
behavioral	behavioral	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
neurophysiological	neurophysiological	ADJ	JJ	5	O
responses	response	NOUN	NNS	5	O
in	in	ADP	IN	5	O
rodents	rodent	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Apomorphine	Apomorphine	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
nonselective	nonselective	ADJ	JJ	0	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
agonist	agonist	NOUN	NN	3	I-Chemical
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
selected	select	VERB	VBN	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
biphasic	biphasic	ADJ	JJ	9	O
behavioral	behavioral	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
its	-PRON-	DET	PRP$	9	O
ability	ability	NOUN	NN	9	O
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
hypothermia	hypothermia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
produce	produce	VERB	VB	9	O
distinct	distinct	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
to	to	ADP	IN	5	O
dopamine	dopamine	VERB	VB	5	B-Chemical
turnover	turnover	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rodent	rodent	ADJ	JJ	9	O
brain	brain	NOUN	NN	5	O
.	.	PUNCT	.	9	O

From	from	ADP	IN	5	O
such	such	ADJ	JJ	5	O
experiments	experiment	NOUN	NNS	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
evidence	evidence	NOUN	NN	9	O
that	that	ADP	IN	5	O
characterization	characterization	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
detection	detection	NOUN	NN	9	O
of	of	ADP	IN	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
rodents	rodent	NOUN	NNS	9	O
critically	critically	ADV	RB	9	O
depends	depend	VERB	VBZ	5	O
upon	upon	ADP	IN	9	O
the	the	DET	DT	5	O
test	test	NOUN	NN	5	O
conditions	condition	NOUN	NNS	9	O
employed	employ	VERB	VBN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
detection	detection	NOUN	NN	9	O
of	of	ADP	IN	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
facilitated	facilitate	VERB	VBN	5	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
acclimatization	acclimatization	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
test	test	NOUN	NN	5	O
conditions	condition	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
test	test	NOUN	NN	5	O
conditions	condition	NOUN	NNS	9	O
can	can	VERB	MD	5	O
impact	impact	VERB	VB	5	O
upon	upon	ADP	IN	9	O
other	other	ADJ	JJ	5	O
physiological	physiological	ADJ	JJ	9	O
responses	response	NOUN	NNS	5	O
to	to	ADP	IN	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypothermia	hypothermia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
produced	produce	VERB	VBD	9	O
qualitatively	qualitatively	ADV	RB	9	O
different	different	ADJ	JJ	9	O
responses	response	NOUN	NNS	5	O
under	under	ADP	IN	9	O
novel	novel	ADJ	JJ	9	O
conditions	condition	NOUN	NNS	9	O
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
behaviors	behavior	NOUN	NNS	5	O
elicited	elicit	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
home	home	NOUN	NN	5	O
test	test	NOUN	NN	5	O
cage	cage	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
gross	gross	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
counts	count	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
exploratory	exploratory	NOUN	NN	5	O
box	box	NOUN	NN	9	O
only	only	ADV	RB	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
measures	measure	NOUN	NNS	5	O
of	of	ADP	IN	5	O
stereotypic	stereotypic	NOUN	NN	5	O
behavior	behavior	NOUN	NN	5	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
locomotion	locomotion	NOUN	NN	5	O
was	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
prominent	prominent	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
exploratory	exploratory	ADJ	JJ	5	O
box	box	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Dopamine	dopamine	NOUN	NN	0	B-Chemical
turnover	turnover	NOUN	NN	9	O
ratios	ratio	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
DOPAC	DOPAC	PROPN	NNP	0	B-Chemical
:	:	PUNCT	:	9	O
DA	DA	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
HVA	hva	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
DA	DA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
those	those	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
exploratory	exploratory	ADJ	JJ	5	O
box	box	NOUN	NN	9	O
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
home	home	NOUN	NN	5	O
cage	cage	NOUN	NN	5	O
counterparts	counterpart	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
reductions	reduction	NOUN	NNS	9	O
in	in	ADP	IN	5	O
striatal	striatal	ADJ	JJ	3	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
turnover	turnover	NOUN	NN	9	O
were	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
both	both	CCONJ	CC	9	O
novel	novel	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
home	home	NOUN	NN	5	O
cage	cage	NOUN	NN	5	O
environments	environment	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
implications	implication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
with	with	ADP	IN	5	O
particular	particular	ADJ	JJ	5	O
emphasis	emphasis	NOUN	NN	5	O
upon	upon	ADP	IN	9	O
conducting	conduct	VERB	VBG	5	O
psychopharmacological	psychopharmacological	ADJ	JJ	5	O
challenge	challenge	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
in	in	ADP	IN	5	O
rodents	rodent	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Hemolysis	hemolysis	NOUN	NN	0	B-Disease
of	of	ADP	IN	5	O
human	human	ADJ	JJ	3	O
erythrocytes	erythrocyte	NOUN	NNS	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
is	be	VERB	VBZ	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
disruption	disruption	NOUN	NN	9	O
of	of	ADP	IN	5	O
membrane	membrane	NOUN	NN	9	O
structure	structure	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Tamoxifen	Tamoxifen	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
TAM	TAM	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
antiestrogenic	antiestrogenic	ADJ	JJ	0	O
drug	drug	NOUN	NN	5	O
most	most	ADV	RBS	9	O
widely	widely	ADV	RB	5	O
prescribed	prescribe	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
of	of	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
induces	induce	VERB	VBZ	3	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
discoid	discoid	NOUN	NN	5	O
shape	shape	NOUN	NN	5	O
of	of	ADP	IN	5	O
erythrocytes	erythrocyte	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
work	work	NOUN	NN	5	O
evaluates	evaluate	VERB	VBZ	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
TAM	TAM	PROPN	NNP	3	B-Chemical
on	on	ADP	IN	5	O
isolated	isolate	VERB	VBN	9	O
human	human	ADJ	JJ	3	O
erythrocytes	erythrocyte	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
attempting	attempt	VERB	VBG	5	O
to	to	PART	TO	5	O
identify	identify	VERB	VB	9	O
the	the	DET	DT	5	O
underlying	underlie	VERB	VBG	5	O
mechanisms	mechanism	NOUN	NNS	9	O
on	on	ADP	IN	5	O
TAM	TAM	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
biomembranes	biomembrane	NOUN	NNS	0	O
in	in	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
cytostatic	cytostatic	ADJ	JJ	3	O
action	action	NOUN	NN	5	O
mechanisms	mechanism	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

TAM	TAM	PROPN	NNP	3	B-Chemical
induces	induce	VERB	VBZ	3	O
hemolysis	hemolysis	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
erythrocytes	erythrocyte	NOUN	NNS	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
function	function	NOUN	NN	9	O
of	of	ADP	IN	5	O
concentration	concentration	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
extension	extension	NOUN	NN	9	O
of	of	ADP	IN	5	O
hemolysis	hemolysis	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
variable	variable	ADJ	JJ	5	O
with	with	ADP	IN	5	O
erythrocyte	erythrocyte	NOUN	NN	9	O
samples	sample	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
microM	microM	PROPN	NNP	0	O
TAM	TAM	PROPN	NNP	3	B-Chemical
induces	induce	VERB	VBZ	3	O
total	total	ADJ	JJ	9	O
hemolysis	hemolysis	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
tested	test	VERB	VBN	9	O
suspensions	suspension	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
inducing	induce	VERB	VBG	3	O
extensive	extensive	ADJ	JJ	5	O
erythrocyte	erythrocyte	NOUN	NN	9	O
lysis	lysis	NOUN	NN	3	O
,	,	PUNCT	,	9	O
TAM	TAM	PROPN	NNP	3	B-Chemical
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
shift	shift	VERB	VB	9	O
the	the	DET	DT	5	O
osmotic	osmotic	ADJ	JJ	0	O
fragility	fragility	NOUN	NN	5	O
curves	curve	NOUN	NNS	5	O
of	of	ADP	IN	5	O
erythrocytes	erythrocyte	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
TAM	TAM	PROPN	NNP	3	B-Chemical
is	be	VERB	VBZ	5	O
prevented	prevent	VERB	VBN	9	O
by	by	ADP	IN	9	O
low	low	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tocopherol	tocopherol	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
T	t	NOUN	NN	3	I-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tocopherol	tocopherol	NOUN	NN	0	I-Chemical
acetate	acetate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
TAc	tac	NOUN	NN	7	I-Chemical
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
inactivated	inactivate	VERB	VBN	9	O
functional	functional	ADJ	JJ	9	O
hydroxyl	hydroxyl	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
indicating	indicate	VERB	VBG	9	O
that	that	ADP	IN	5	O
TAM	TAM	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hemolysis	hemolysis	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
membrane	membrane	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
further	further	ADV	RB	9	O
evidenced	evidence	VERB	VBN	9	O
by	by	ADP	IN	9	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
consumption	consumption	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
hemoglobin	hemoglobin	NOUN	NN	0	O
oxidation	oxidation	NOUN	NN	0	O
both	both	CCONJ	CC	9	O
determined	determine	VERB	VBD	9	O
in	in	ADP	IN	5	O
parallel	parallel	NOUN	NN	5	O
with	with	ADP	IN	5	O
TAM	TAM	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hemolysis	hemolysis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
that	that	ADP	IN	5	O
TAM	TAM	PROPN	NNP	3	B-Chemical
inhibits	inhibit	VERB	VBZ	3	O
the	the	DET	DT	5	O
peroxidation	peroxidation	NOUN	NN	0	O
of	of	ADP	IN	5	O
human	human	ADJ	JJ	3	O
erythrocytes	erythrocyte	NOUN	NNS	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
AAPH	AAPH	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
thus	thus	ADV	RB	9	O
ruling	rule	VERB	VBG	9	O
out	out	PART	RP	9	O
TAM	TAM	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cell	cell	NOUN	NN	3	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Hemolysis	hemolysis	NOUN	NN	0	B-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
TAM	TAM	PROPN	NNP	3	B-Chemical
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
preceded	precede	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
leakage	leakage	NOUN	NN	9	O
of	of	ADP	IN	5	O
K	K	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
cells	cell	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
also	also	ADV	RB	9	O
excluding	exclude	VERB	VBG	9	O
a	a	DET	DT	5	O
colloid	colloid	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
osmotic	osmotic	NOUN	NN	0	O
type	type	NOUN	NN	9	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
hemolysis	hemolysis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
osmotic	osmotic	ADJ	JJ	0	O
fragility	fragility	NOUN	NN	5	O
curves	curve	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
TAM	TAM	PROPN	NNP	3	B-Chemical
induces	induce	VERB	VBZ	3	O
release	release	NOUN	NN	9	O
of	of	ADP	IN	5	O
peripheral	peripheral	ADJ	JJ	9	O
proteins	protein	NOUN	NNS	1	O
of	of	ADP	IN	5	O
membrane	membrane	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
cytoskeleton	cytoskeleton	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
cytosol	cytosol	NOUN	NN	3	O
proteins	protein	NOUN	NNS	1	O
essentially	essentially	ADV	RB	9	O
bound	bind	VERB	VBN	9	O
to	to	PART	TO	5	O
band	band	VERB	VB	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O

Either	either	CCONJ	CC	9	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
T	t	NOUN	NN	3	I-Chemical
or	or	CCONJ	CC	5	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
TAc	tac	NOUN	NN	7	I-Chemical
increases	increase	NOUN	NNS	9	O
membrane	membrane	NOUN	NN	9	O
packing	packing	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
prevents	prevent	VERB	VBZ	9	O
TAM	TAM	PROPN	NNP	3	B-Chemical
partition	partition	NOUN	NN	5	O
into	into	ADP	IN	9	O
model	model	NOUN	NN	5	O
membranes	membrane	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
protection	protection	NOUN	NN	9	O
from	from	ADP	IN	9	O
hemolysis	hemolysis	NOUN	NN	9	B-Disease
by	by	ADP	IN	9	O
tocopherols	tocopherol	NOUN	NNS	0	B-Chemical
is	be	VERB	VBZ	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
decreased	decrease	VERB	VBN	9	O
TAM	TAM	PROPN	NNP	3	B-Chemical
incorporation	incorporation	NOUN	NN	0	O
in	in	ADP	IN	5	O
condensed	condensed	ADJ	JJ	9	O
membranes	membrane	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
structural	structural	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
erythrocyte	erythrocyte	NOUN	NN	9	O
membrane	membrane	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
consequently	consequently	ADV	RB	9	O
avoided	avoid	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
TAM	TAM	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hemolysis	hemolysis	NOUN	NN	9	B-Disease
results	result	NOUN	NNS	9	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
structural	structural	ADJ	JJ	9	O
perturbation	perturbation	NOUN	NN	5	O
of	of	ADP	IN	5	O
red	red	ADJ	JJ	9	O
cell	cell	NOUN	NN	3	O
membrane	membrane	NOUN	NN	9	O
,	,	PUNCT	,	9	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
framework	framework	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
erythrocyte	erythrocyte	NOUN	NN	9	O
membrane	membrane	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
cytoskeleton	cytoskeleton	NOUN	NN	3	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
high	high	ADJ	JJ	9	O
partition	partition	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
membrane	membrane	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
defects	defect	NOUN	NNS	9	O
explain	explain	VERB	VBP	9	O
the	the	DET	DT	5	O
abnormal	abnormal	ADJ	JJ	9	O
erythrocyte	erythrocyte	NOUN	NN	9	O
shape	shape	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
mechanical	mechanical	ADJ	JJ	5	O
stability	stability	NOUN	NN	9	O
promoted	promote	VERB	VBN	3	O
by	by	ADP	IN	9	O
TAM	TAM	PROPN	NNP	3	B-Chemical
,	,	PUNCT	,	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Additionally	additionally	ADV	RB	9	O
,	,	PUNCT	,	9	O
since	since	ADP	IN	9	O
membrane	membrane	NOUN	NN	9	O
leakage	leakage	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
final	final	ADJ	JJ	9	O
stage	stage	NOUN	NN	9	O
of	of	ADP	IN	5	O
cytotoxicity	cytotoxicity	NOUN	NN	3	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
disruption	disruption	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
structural	structural	ADJ	JJ	9	O
characteristics	characteristic	NOUN	NNS	5	O
of	of	ADP	IN	5	O
biomembranes	biomembrane	NOUN	NNS	0	O
by	by	ADP	IN	9	O
TAM	TAM	PROPN	NNP	3	B-Chemical
may	may	VERB	MD	5	O
contribute	contribute	VERB	VB	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
multiple	multiple	ADJ	JJ	5	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
anticancer	anticancer	NOUN	NN	0	O
action	action	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Changes	change	NOUN	NNS	9	O
of	of	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
ATP	ATP	PROPN	NNP	0	B-Chemical
affinities	affinity	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cardiac	cardiac	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
Na	na	INTJ	UH	0	B-Chemical
,	,	PUNCT	,	9	O
K	K	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
ATPase	ATPase	PROPN	NNP	1	O
during	during	ADP	IN	5	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
deficient	deficient	ADJ	JJ	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
,	,	PUNCT	,	9	O
NO	no	ADV	RB	9	B-Chemical
is	be	VERB	VBZ	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
variety	variety	NOUN	NN	5	O
of	of	ADP	IN	5	O
functions	function	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
NO	no	DET	DT	9	B-Chemical
synthesis	synthesis	NOUN	NN	9	O
induces	induce	NOUN	NNS	3	O
sustained	sustain	VERB	VBD	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
several	several	ADJ	JJ	9	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
intracellular	intracellular	ADJ	JJ	3	O
sodium	sodium	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
was	be	VERB	VBD	9	O
documented	document	VERB	VBN	9	O
in	in	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
tissue	tissue	NOUN	NN	9	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
molecular	molecular	ADJ	JJ	9	O
basis	basis	NOUN	NN	5	O
of	of	ADP	IN	5	O
disturbances	disturbance	NOUN	NNS	5	O
in	in	ADP	IN	5	O
transmembraneous	transmembraneous	ADJ	JJ	3	O
transport	transport	NOUN	NN	9	O
of	of	ADP	IN	5	O
Na	Na	PROPN	NNP	0	B-Chemical
+	+	X	XX	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
studied	study	VERB	VBD	9	O
the	the	DET	DT	5	O
response	response	NOUN	NN	9	O
of	of	ADP	IN	5	O
cardiac	cardiac	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
Na	na	INTJ	UH	0	B-Chemical
,	,	PUNCT	,	9	O
K	K	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
ATPase	ATPase	PROPN	NNP	1	O
to	to	ADP	IN	5	O
NO	no	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
deficient	deficient	ADJ	JJ	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
by	by	ADP	IN	9	O
NO	no	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
synthase	synthase	NOUN	NN	1	O
inhibition	inhibition	NOUN	NN	3	O
with	with	ADP	IN	5	O
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
N	n	NUM	CD	9	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
G	G	PROPN	NNP	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
nitro	nitro	ADJ	JJ	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
L	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
ester	ester	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
NAME	NAME	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
4	4	NUM	CD	9	O
four	four	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
NAME	NAME	PROPN	NNP	0	I-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
systolic	systolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
SBP	SBP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
increased	increase	VERB	VBD	9	O
by	by	ADP	IN	9	O
36	36	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
terminating	terminate	VERB	VBG	9	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
SBP	SBP	PROPN	NNP	9	O
recovered	recover	VERB	VBD	9	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
value	value	NOUN	NN	9	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
activating	activate	VERB	VBG	3	O
the	the	DET	DT	5	O
(	(	PUNCT	-LRB-	9	O
Na	na	INTJ	UH	0	B-Chemical
,	,	PUNCT	,	9	O
K	K	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
ATPase	ATPase	PROPN	NNP	1	O
with	with	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
substrate	substrate	NOUN	NN	0	O
ATP	ATP	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
Km	Km	PROPN	NNP	0	O
and	and	CCONJ	CC	5	O
Vmax	Vmax	PROPN	NNP	0	O
values	value	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
NO	no	DET	DT	9	B-Chemical
-	-	PUNCT	HYPH	7	O
deficient	deficient	ADJ	JJ	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
activation	activation	NOUN	NN	3	O
with	with	ADP	IN	5	O
Na	Na	PROPN	NNP	0	B-Chemical
+	+	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
Vmax	Vmax	PROPN	NNP	0	O
remained	remain	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
the	the	DET	DT	5	O
K	K	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
Na	Na	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
increased	increase	VERB	VBN	9	O
by	by	ADP	IN	9	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
a	a	DET	DT	5	O
profound	profound	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
affinity	affinity	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Na	Na	PROPN	NNP	0	B-Chemical
+	+	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
binding	bind	VERB	VBG	1	O
site	site	NOUN	NN	9	O
in	in	ADP	IN	5	O
NO	no	DET	DT	9	B-Chemical
-	-	PUNCT	HYPH	7	O
deficient	deficient	ADJ	JJ	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
recovery	recovery	NOUN	NN	9	O
from	from	ADP	IN	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
Na	na	INTJ	UH	0	B-Chemical
,	,	PUNCT	,	9	O
K	K	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
ATPase	ATPase	PROPN	NNP	1	O
increased	increase	VERB	VBD	9	O
,	,	PUNCT	,	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
higher	high	ADJ	JJR	9	O
affinity	affinity	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ATP	ATP	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
binding	bind	VERB	VBG	1	O
site	site	NOUN	NN	9	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
revealed	reveal	VERB	VBN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
lowered	lower	VERB	VBN	9	O
Km	Km	PROPN	NNP	0	O
value	value	NOUN	NN	9	O
for	for	ADP	IN	5	O
ATP	ATP	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
K	K	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
Na	Na	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
value	value	NOUN	NN	9	O
for	for	ADP	IN	5	O
Na	Na	PROPN	NNP	0	B-Chemical
+	+	CCONJ	CC	9	O
returned	return	VERB	VBD	5	O
to	to	PART	TO	5	O
control	control	NOUN	NN	9	O
value	value	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
NO	no	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
synthase	synthase	NOUN	NN	1	O
induced	induce	VERB	VBD	3	O
a	a	DET	DT	5	O
reversible	reversible	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
depressed	depressed	ADJ	JJ	5	B-Disease
Na	Na	PROPN	NNP	0	B-Chemical
+	+	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
extrusion	extrusion	NOUN	NN	9	O
from	from	ADP	IN	9	O
cardiac	cardiac	ADJ	JJ	5	O
cells	cell	NOUN	NNS	3	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
consequence	consequence	NOUN	NN	5	O
of	of	ADP	IN	5	O
deteriorated	deteriorate	VERB	VBN	5	O
Na	Na	PROPN	NNP	0	B-Chemical
+	+	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
binding	bind	VERB	VBG	1	O
properties	property	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
(	(	PUNCT	-LRB-	9	O
Na	na	INTJ	UH	0	B-Chemical
,	,	PUNCT	,	9	O
K	K	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
ATPase	ATPase	PROPN	NNP	1	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
values	value	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
extrusion	extrusion	NOUN	NN	9	O
of	of	ADP	IN	5	O
Na	Na	PROPN	NNP	0	B-Chemical
+	+	CCONJ	CC	9	O
from	from	ADP	IN	9	O
cardiac	cardiac	ADJ	JJ	5	O
cells	cell	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
normalized	normalize	VERB	VBN	9	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
revealed	reveal	VERB	VBN	9	O
by	by	ADP	IN	9	O
restoration	restoration	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
(	(	PUNCT	-LRB-	9	O
Na	na	INTJ	UH	0	B-Chemical
,	,	PUNCT	,	9	O
K	K	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
ATPase	ATPase	PROPN	NNP	1	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
bromocriptine	bromocriptine	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
conscious	conscious	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
that	that	ADP	IN	5	O
bromocriptine	bromocriptine	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
persisted	persist	VERB	VBD	9	O
after	after	ADP	IN	9	O
adrenalectomy	adrenalectomy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
(	(	PUNCT	-LRB-	9	O
i	i	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
central	central	ADJ	JJ	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
D2	d2	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
activation	activation	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
(	(	PUNCT	-LRB-	9	O
ii	ii	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
,	,	PUNCT	,	9	O
supporting	support	VERB	VBG	9	O
therefore	therefore	ADV	RB	5	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
dependent	dependent	ADJ	JJ	9	O
on	on	ADP	IN	5	O
sympathetic	sympathetic	ADJ	JJ	5	O
outflow	outflow	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
prolonged	prolong	VERB	VBN	9	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
could	could	VERB	MD	9	O
abolish	abolish	VERB	VB	9	O
bromocriptine	bromocriptine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
conscious	conscious	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
for	for	ADP	IN	5	O
15	15	NUM	CD	9	O
days	day	NOUN	NNS	9	O
caused	cause	VERB	VBD	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
hypertrophy	hypertrophy	NOUN	NN	9	I-Disease
without	without	ADP	IN	9	O
affecting	affect	VERB	VBG	9	O
baseline	baseline	NOUN	NN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
intravenous	intravenous	ADJ	JJ	0	O
bromocriptine	bromocriptine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
150	150	NUM	CD	0	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
induced	induce	VERB	VBD	3	O
significant	significant	ADJ	JJ	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Bromocriptine	Bromocriptine	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
unaffected	unaffected	ADJ	JJ	9	O
by	by	ADP	IN	9	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
reversed	reverse	VERB	VBN	9	O
to	to	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
effect	effect	NOUN	NN	9	O
that	that	DET	WDT	5	O
was	be	VERB	VBD	9	O
partly	partly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
domperidone	domperidone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Neither	neither	CCONJ	CC	9	O
cardiac	cardiac	ADJ	JJ	5	O
vagal	vagal	ADJ	JJ	5	O
nor	nor	CCONJ	CC	9	O
sympathetic	sympathetic	ADJ	JJ	5	O
tone	tone	NOUN	NN	5	O
was	be	VERB	VBD	9	O
altered	alter	VERB	VBN	9	O
by	by	ADP	IN	9	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
isolated	isolate	VERB	VBN	9	O
perfused	perfuse	VERB	VBN	0	O
heart	heart	NOUN	NN	5	O
preparations	preparation	NOUN	NNS	9	O
from	from	ADP	IN	9	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
pretreated	pretreate	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
maximal	maximal	NOUN	NN	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
left	leave	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	O
systolic	systolic	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
pretreated	pretreate	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
the	the	DET	DT	5	O
EC50	EC50	PROPN	NNP	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
left	leave	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	O
systolic	systolic	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
enhanced	enhance	VERB	VBN	3	O
approximately	approximately	ADV	RB	9	O
22	22	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
fold	fold	VERB	VB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
15	15	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
not	not	ADV	RB	5	O
only	only	ADV	RB	9	O
abolished	abolish	VERB	VBD	3	O
but	but	CCONJ	CC	9	O
reversed	reverse	VERB	VBD	9	O
bromocriptine	bromocriptine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
to	to	ADP	IN	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
effect	effect	NOUN	NN	9	O
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
mainly	mainly	ADV	RB	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
further	further	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
desensitization	desensitization	NOUN	NN	3	O
rather	rather	ADV	RB	5	O
than	than	ADP	IN	5	O
to	to	PART	TO	5	O
impairment	impairment	VERB	VB	5	O
of	of	ADP	IN	5	O
autonomic	autonomic	ADJ	JJ	5	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
.	.	PUNCT	.	9	O

They	-PRON-	PRON	PRP	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
conscious	conscious	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
bromocriptine	bromocriptine	NOUN	NN	0	B-Chemical
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
predominate	predominate	VERB	VB	9	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
mask	mask	VERB	VB	5	O
the	the	DET	DT	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
agonist	agonist	NOUN	NN	3	O
at	at	ADP	IN	9	O
peripheral	peripheral	ADJ	JJ	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
D2	d2	NOUN	NN	9	O
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
developmental	developmental	ADJ	JJ	9	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
ultrasound	ultrasound	ADJ	JJ	5	O
production	production	NOUN	NN	9	O
in	in	ADP	IN	5	O
infant	infant	NOUN	NN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Under	under	ADP	IN	9	O
controlled	control	VERB	VBN	5	O
conditions	condition	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
infant	infant	NOUN	NN	5	O
rats	rat	NOUN	NNS	9	O
emit	emit	VERB	VBP	5	O
ultrasonic	ultrasonic	ADJ	JJ	5	O
vocalizations	vocalization	NOUN	NNS	5	O
during	during	ADP	IN	5	O
extreme	extreme	ADJ	JJ	5	O
cold	cold	ADJ	JJ	9	O
exposure	exposure	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
alpha	alpha	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
agonist	agonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Previous	previous	ADJ	JJ	9	O
investigations	investigation	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
determined	determine	VERB	VBN	9	O
that	that	ADP	IN	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
ultrasound	ultrasound	ADJ	JJ	5	O
production	production	NOUN	NN	9	O
increases	increase	NOUN	NNS	9	O
through	through	ADP	IN	9	O
the	the	DET	DT	5	O
2nd	2nd	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
postpartum	postpartum	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
decreases	decrease	VERB	VBZ	9	O
thereafter	thereafter	ADV	RB	9	O
.	.	PUNCT	.	9	O

Given	give	VERB	VBN	9	O
that	that	ADP	IN	5	O
sympathetic	sympathetic	ADJ	JJ	5	O
neural	neural	ADJ	JJ	5	O
dominance	dominance	NOUN	NN	5	O
exhibits	exhibit	VERB	VBZ	9	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
developmental	developmental	ADJ	JJ	9	O
pattern	pattern	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
given	give	VERB	VBN	5	O
that	that	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
induces	induce	VERB	VBZ	3	O
sympathetic	sympathetic	ADJ	JJ	5	O
withdrawal	withdrawal	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
hypothesized	hypothesize	VERB	VBD	9	O
that	that	DET	DT	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
developmental	developmental	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
ultrasound	ultrasound	ADJ	JJ	5	O
production	production	NOUN	NN	9	O
would	would	VERB	MD	5	O
mirror	mirror	VERB	VB	5	O
each	each	DET	DT	5	O
other	other	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
experiment	experiment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
ultrasound	ultrasound	ADJ	JJ	5	O
production	production	NOUN	NN	9	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
,	,	PUNCT	,	9	O
15	15	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
20	20	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Age	age	NOUN	NN	7	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
ultrasound	ultrasound	ADJ	JJ	5	O
production	production	NOUN	NN	9	O
corresponded	correspond	VERB	VBN	9	O
with	with	ADP	IN	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
variables	variable	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
baseline	baseline	NOUN	NN	5	O
cardiac	cardiac	ADJ	JJ	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
experiment	experiment	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
discussed	discuss	VERB	VBN	5	O
with	with	ADP	IN	5	O
regard	regard	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	DET	WDT	5	O
ultrasound	ultrasound	ADJ	JJ	5	O
production	production	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
acoustic	acoustic	ADJ	JJ	5	O
by	by	ADP	IN	9	O
-	-	PUNCT	HYPH	7	O
product	product	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
physiological	physiological	ADJ	JJ	9	O
maneuver	maneuver	NOUN	NN	5	O
that	that	DET	WDT	5	O
compensates	compensate	VERB	VBZ	9	O
for	for	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
detrimental	detrimental	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Recurrent	recurrent	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
newer	new	ADJ	JJR	5	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptives	contraceptive	NOUN	NNS	5	I-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
thromboembolism	thromboembolism	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
epidemiological	epidemiological	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
that	that	DET	WDT	5	O
assessed	assess	VERB	VBD	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
thromboembolism	thromboembolism	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
VTE	VTE	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
newer	new	ADJ	JJR	5	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptives	contraceptive	NOUN	NNS	5	I-Chemical
(	(	PUNCT	-LRB-	9	O
OC	OC	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
distinguish	distinguish	VERB	VB	9	O
between	between	ADP	IN	5	O
patterns	pattern	NOUN	NNS	5	O
of	of	ADP	IN	5	O
OC	OC	PROPN	NNP	9	B-Chemical
use	use	NOUN	NN	5	O
,	,	PUNCT	,	9	O
namely	namely	ADV	RB	9	O
first	first	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
time	time	NOUN	NN	5	O
users	user	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
repeaters	repeater	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
switchers	switcher	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Data	datum	NOUN	NNS	5	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
Transnational	Transnational	PROPN	NNP	2	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
study	study	NOUN	NN	9	O
were	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
VTE	VTE	PROPN	NNP	5	B-Disease
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
latter	latter	ADJ	JJ	9	O
patterns	pattern	NOUN	NNS	5	O
of	of	ADP	IN	5	O
use	use	NOUN	NN	5	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
accounting	account	VERB	VBG	5	O
for	for	ADP	IN	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Over	over	ADP	IN	5	O
the	the	DET	DT	5	O
period	period	NOUN	NN	5	O
1993	1993	NUM	CD	2	O
-	-	SYM	SYM	7	O
1996	1996	NUM	CD	2	O
,	,	PUNCT	,	9	O
551	551	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
VTE	VTE	PROPN	NNP	5	B-Disease
were	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
in	in	ADP	IN	5	O
Germany	Germany	PROPN	NNP	2	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
UK	UK	PROPN	NNP	2	O
along	along	ADP	IN	9	O
with	with	ADP	IN	5	O
2066	2066	NUM	CD	7	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Totals	total	NOUN	NNS	7	O
of	of	ADP	IN	5	O
128	128	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
650	650	NUM	CD	9	O
controls	control	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
analysed	analyse	VERB	VBN	9	O
for	for	ADP	IN	5	O
repeat	repeat	NOUN	NN	9	O
use	use	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
135	135	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
622	622	NUM	CD	7	O
controls	control	NOUN	NNS	9	O
for	for	ADP	IN	5	O
switching	switch	VERB	VBG	5	O
patterns	pattern	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
adjusted	adjust	VERB	VBN	9	O
rate	rate	NOUN	NN	9	O
ratio	ratio	NOUN	NN	9	O
of	of	ADP	IN	5	O
VTE	VTE	PROPN	NNP	5	B-Disease
for	for	ADP	IN	5	O
repeat	repeat	NOUN	NN	9	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
third	third	ADJ	JJ	9	O
generation	generation	NOUN	NN	9	O
OC	OC	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
:	:	PUNCT	:	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
relative	relative	ADJ	JJ	9	O
to	to	PART	TO	5	O
repeat	repeat	VERB	VB	9	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
second	second	ADJ	JJ	9	O
generation	generation	NOUN	NN	9	O
pills	pill	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
:	:	PUNCT	:	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
-	-	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
switchers	switcher	NOUN	NNS	5	O
from	from	ADP	IN	9	O
second	second	ADJ	JJ	9	O
to	to	ADP	IN	5	O
third	third	ADJ	JJ	9	O
generation	generation	NOUN	NN	9	O
pills	pill	NOUN	NNS	5	O
relative	relative	ADJ	JJ	9	O
to	to	ADP	IN	5	O
switchers	switcher	NOUN	NNS	5	O
from	from	ADP	IN	9	O
third	third	ADJ	JJ	9	O
to	to	ADP	IN	5	O
second	second	ADJ	JJ	9	O
generation	generation	NOUN	NN	9	O
pills	pill	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
second	second	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
third	third	ADJ	JJ	9	O
generation	generation	NOUN	NN	9	O
agents	agent	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
equivalent	equivalent	ADJ	JJ	9	O
risks	risk	NOUN	NNS	5	O
of	of	ADP	IN	5	O
VTE	VTE	PROPN	NNP	5	B-Disease
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
used	use	VERB	VBN	5	O
repeatedly	repeatedly	ADV	RB	5	O
after	after	ADP	IN	9	O
interruption	interruption	NOUN	NN	5	O
periods	period	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
when	when	ADV	WRB	5	O
users	user	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
switched	switch	VERB	VBN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
generations	generation	NOUN	NNS	5	O
of	of	ADP	IN	5	O
pills	pill	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
analyses	analysis	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
higher	high	ADJ	JJR	9	O
risk	risk	NOUN	NN	5	O
observed	observe	VERB	VBN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
newer	new	ADJ	JJR	5	O
OC	OC	PROPN	NNP	9	B-Chemical
in	in	ADP	IN	5	O
other	other	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
inadequate	inadequate	ADJ	JJ	5	O
comparisons	comparison	NOUN	NNS	5	O
of	of	ADP	IN	5	O
pill	pill	NOUN	NN	5	O
users	user	NOUN	NNS	5	O
with	with	ADP	IN	5	O
different	different	ADJ	JJ	9	O
patterns	pattern	NOUN	NNS	5	O
of	of	ADP	IN	5	O
pill	pill	NOUN	NN	5	O
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Differential	differential	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
systemically	systemically	ADV	RB	9	O
administered	administer	VERB	VBN	9	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
dynamic	dynamic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
static	static	ADJ	JJ	5	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
intradermal	intradermal	ADJ	JJ	9	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
examined	examine	VERB	VBN	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
brush	brush	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
evoked	evoked	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
dynamic	dynamic	ADJ	JJ	5	O
)	)	PUNCT	-RRB-	9	O
pain	pain	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
punctate	punctate	NOUN	NN	4	O
-	-	PUNCT	HYPH	7	O
evoked	evoked	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
static	static	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
,	,	PUNCT	,	9	O
crossover	crossover	NOUN	NN	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
studied	study	VERB	VBD	9	O
12	12	NUM	CD	9	O
volunteers	volunteer	NOUN	NNS	5	O
in	in	ADP	IN	5	O
three	three	NUM	CD	9	O
experiments	experiment	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Capsaicin	Capsaicin	PROPN	NNP	0	B-Chemical
100	100	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
was	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
intradermally	intradermally	ADV	RB	3	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
volar	volar	ADJ	JJ	5	O
forearm	forearm	NOUN	NN	5	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
an	an	DET	DT	5	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
bolus	bolus	ADJ	JJ	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
over	over	ADP	IN	5	O
10	10	NUM	CD	9	O
min	min	NOUN	NN	0	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
7	7	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
min	min	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
or	or	CCONJ	CC	5	O
saline	saline	NOUN	NN	0	O
for	for	ADP	IN	5	O
50	50	NUM	CD	0	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Infusion	infusion	NOUN	NN	0	O
started	start	VERB	VBD	5	O
15	15	NUM	CD	9	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
following	follow	VERB	VBG	9	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
:	:	PUNCT	:	9	O
spontaneous	spontaneous	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
pain	pain	NOUN	NN	5	B-Disease
evoked	evoke	VERB	VBN	5	O
by	by	ADP	IN	9	O
punctate	punctate	NOUN	NN	4	O
and	and	CCONJ	CC	5	O
brush	brush	NOUN	NN	9	O
stimuli	stimulus	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
VAS	VAS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
areas	area	NOUN	NNS	5	O
of	of	ADP	IN	5	O
brush	brush	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
evoked	evoked	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
punctate	punctate	NOUN	NN	4	O
-	-	PUNCT	HYPH	7	O
evoked	evoke	VERB	VBN	5	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

Ketamine	Ketamine	PROPN	NNP	0	B-Chemical
reduced	reduce	VERB	VBD	9	O
both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
area	area	NOUN	NN	5	O
of	of	ADP	IN	5	O
brush	brush	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
evoked	evoked	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
punctate	punctate	NOUN	NN	4	O
-	-	PUNCT	HYPH	7	O
evoked	evoke	VERB	VBN	5	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
significantly	significantly	ADV	RB	9	O
and	and	CCONJ	CC	5	O
it	-PRON-	PRON	PRP	5	O
tended	tend	VERB	VBD	5	O
to	to	PART	TO	5	O
reduce	reduce	VERB	VB	5	O
brush	brush	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
evoked	evoke	VERB	VBN	5	O
pain	pain	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Lidocaine	Lidocaine	PROPN	NNP	0	B-Chemical
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
area	area	NOUN	NN	5	O
of	of	ADP	IN	5	O
punctate	punctate	NOUN	NN	4	O
-	-	PUNCT	HYPH	7	O
evoked	evoke	VERB	VBN	5	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
significantly	significantly	ADV	RB	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
tended	tend	VERB	VBD	5	O
to	to	PART	TO	5	O
reduce	reduce	VERB	VB	5	O
VAS	VAS	PROPN	NNP	5	O
scores	score	NOUN	NNS	5	O
of	of	ADP	IN	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
but	but	CCONJ	CC	9	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
evoked	evoked	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
differential	differential	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
static	static	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
dynamic	dynamic	ADJ	JJ	5	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
types	type	NOUN	NNS	9	O
of	of	ADP	IN	5	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
are	be	VERB	VBP	5	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
separate	separate	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
distinct	distinct	ADJ	JJ	9	O
pharmacology	pharmacology	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Development	development	NOUN	NN	2	O
of	of	ADP	IN	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
aggressive	aggressive	ADJ	JJ	5	B-Disease
behavior	behavior	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
comparison	comparison	NOUN	NN	9	O
of	of	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
male	male	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
female	female	ADJ	JJ	9	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
s	s	PROPN	NNPS	9	O
.	.	PUNCT	.	9	O
c	c	X	XX	9	O
.	.	PUNCT	.	9	O
once	once	ADV	RB	5	O
daily	daily	ADV	RB	5	O
)	)	PUNCT	-RRB-	9	O
aggressive	aggressive	ADJ	JJ	5	B-Disease
behavior	behavior	NOUN	NN	5	I-Disease
of	of	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
male	male	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
female	female	ADJ	JJ	9	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
obtained	obtain	VERB	VBN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
breeder	breeder	NOUN	NN	5	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
consecutive	consecutive	ADJ	JJ	5	O
sets	set	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
male	male	ADJ	JJ	9	O
animals	animal	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
repeated	repeat	VERB	VBD	5	O
apomorphine	apomorphine	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
induced	induce	VERB	VBD	3	O
a	a	DET	DT	5	O
gradual	gradual	ADJ	JJ	9	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
aggressive	aggressive	ADJ	JJ	5	B-Disease
behavior	behavior	NOUN	NN	5	I-Disease
as	as	ADP	IN	5	O
evidenced	evidence	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
intensity	intensity	NOUN	NN	5	O
of	of	ADP	IN	5	O
aggressiveness	aggressiveness	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
shortened	shortened	ADJ	JJ	9	O
latency	latency	NOUN	NN	5	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
attack	attack	NOUN	NN	5	O
toward	toward	ADP	IN	5	O
the	the	DET	DT	5	O
opponent	opponent	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
female	female	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
only	only	ADV	RB	9	O
a	a	DET	DT	5	O
weak	weak	ADJ	JJ	9	O
tendency	tendency	NOUN	NN	5	O
toward	toward	ADP	IN	5	O
aggressiveness	aggressiveness	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
demonstrates	demonstrate	VERB	VBZ	9	O
gender	gender	NOUN	NN	5	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
aggressive	aggressive	ADJ	JJ	5	B-Disease
behavior	behavior	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
indicates	indicate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
female	female	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
do	do	VERB	VBP	5	O
not	not	ADV	RB	5	O
fill	fill	VERB	VB	5	O
the	the	DET	DT	5	O
validation	validation	NOUN	NN	5	O
criteria	criterion	NOUN	NNS	5	O
for	for	ADP	IN	5	O
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
method	method	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Intracranial	intracranial	ADJ	JJ	5	B-Disease
aneurysms	aneurysm	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
cocaine	cocaine	NOUN	NN	5	B-Disease
abuse	abuse	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
prognostic	prognostic	ADJ	JJ	5	O
indicators	indicator	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
outcome	outcome	NOUN	NN	5	O
of	of	ADP	IN	5	O
subarachnoid	subarachnoid	NOUN	NN	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Disease
abuse	abuse	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
reportedly	reportedly	ADV	RB	9	O
poor	poor	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
study	study	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
reported	report	VERB	VBN	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
statistical	statistical	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
to	to	PART	TO	5	O
analyze	analyze	VERB	VB	9	O
the	the	DET	DT	5	O
variables	variable	NOUN	NNS	5	O
that	that	DET	WDT	5	O
influence	influence	NOUN	NN	5	O
outcome	outcome	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
admissions	admission	NOUN	NNS	5	O
during	during	ADP	IN	5	O
a	a	DET	DT	5	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
period	period	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
14	14	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
aneurysms	aneurysm	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
135	135	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
ruptured	ruptured	ADJ	JJ	5	B-Disease
aneurysms	aneurysm	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Disease
abuse	abuse	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Age	age	NOUN	NN	7	O
at	at	ADP	IN	9	O
presentation	presentation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
ictus	ictus	NOUN	NN	5	O
after	after	ADP	IN	9	O
intoxication	intoxication	NOUN	NN	9	O
,	,	PUNCT	,	9	O
Hunt	Hunt	PROPN	NNP	6	O
and	and	CCONJ	CC	5	O
Hess	Hess	PROPN	NNP	6	O
grade	grade	NOUN	NN	9	O
of	of	ADP	IN	5	O
subarachnoid	subarachnoid	NOUN	NN	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
size	size	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
aneurysm	aneurysm	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
location	location	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
aneurysm	aneurysm	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
Glasgow	Glasgow	PROPN	NNP	5	O
Outcome	Outcome	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
score	score	NOUN	NN	5	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
compared	compare	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
group	group	NOUN	NN	9	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
younger	young	ADJ	JJR	5	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
002	002	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
all	all	DET	DT	5	O
aneurysms	aneurysm	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
located	locate	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
anterior	anterior	ADJ	JJ	5	O
circulation	circulation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
majority	majority	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
aneurysms	aneurysm	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
smaller	small	ADJ	JJR	5	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
08	08	NUM	CD	7	O
mm	mm	NOUN	NNS	9	O
versus	versus	ADP	IN	9	O
11	11	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
mortality	mortality	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
morbidity	morbidity	NOUN	NN	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
significant	significant	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Hunt	Hunt	PROPN	NNP	6	O
and	and	CCONJ	CC	5	O
Hess	Hess	PROPN	NNP	6	O
grade	grade	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
005	005	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
age	age	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
007	007	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
predictors	predictor	NOUN	NNS	5	O
of	of	ADP	IN	5	O
outcome	outcome	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
aneurysms	aneurysm	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Cocaine	cocaine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
predisposed	predispose	VERB	VBN	5	O
aneurysmal	aneurysmal	ADJ	JJ	5	B-Disease
rupture	rupture	NOUN	NN	5	I-Disease
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
significantly	significantly	ADV	RB	9	O
earlier	early	ADJ	JJR	9	O
age	age	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
much	much	ADV	RB	5	O
smaller	small	ADJ	JJR	5	O
aneurysms	aneurysm	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Contrary	contrary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
published	publish	VERB	VBN	9	O
literature	literature	NOUN	NN	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
group	group	NOUN	NN	9	O
did	do	VERB	VBD	9	O
reasonably	reasonably	ADV	RB	5	O
well	well	ADV	RB	9	O
with	with	ADP	IN	5	O
aggressive	aggressive	ADJ	JJ	5	O
management	management	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
nimodipine	nimodipine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
outcome	outcome	NOUN	NN	5	O
after	after	ADP	IN	9	O
acute	acute	ADJ	JJ	9	B-Disease
stroke	stroke	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
Intravenous	Intravenous	PROPN	NNP	0	O
Nimodipine	Nimodipine	PROPN	NNP	0	B-Chemical
West	West	PROPN	NNP	4	O
European	European	PROPN	NNP	5	O
Stroke	Stroke	PROPN	NNP	5	B-Disease
Trial	Trial	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
INWEST	INWEST	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
found	find	VERB	VBD	9	O
a	a	DET	DT	5	O
correlation	correlation	NOUN	NN	9	O
between	between	ADP	IN	5	O
nimodipine	nimodipine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
reduction	reduction	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
blood	blood	NOUN	NN	9	I-Disease
pressure	pressure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
BP	BP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
unfavorable	unfavorable	ADJ	JJ	5	O
outcome	outcome	NOUN	NN	5	O
in	in	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
stroke	stroke	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
sought	seek	VERB	VBD	9	O
to	to	PART	TO	5	O
confirm	confirm	VERB	VB	9	O
this	this	DET	DT	5	O
correlation	correlation	NOUN	NN	9	O
with	with	ADP	IN	5	O
and	and	CCONJ	CC	5	O
without	without	ADP	IN	9	O
adjustment	adjustment	NOUN	NN	5	O
for	for	ADP	IN	5	O
prognostic	prognostic	ADJ	JJ	5	O
variables	variable	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
outcome	outcome	NOUN	NN	5	O
in	in	ADP	IN	5	O
subgroups	subgroup	NOUN	NNS	9	O
with	with	ADP	IN	5	O
increasing	increase	VERB	VBG	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
BP	BP	PROPN	NNP	9	B-Disease
reduction	reduction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
stroke	stroke	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
within	within	ADP	IN	9	O
24	24	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
consecutively	consecutively	ADV	RB	5	O
allocated	allocate	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
100	100	NUM	CD	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
h	h	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
nimodipine	nimodipine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
101	101	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
h	h	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
nimodipine	nimodipine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
94	94	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
correlation	correlation	NOUN	NN	9	O
between	between	ADP	IN	5	O
average	average	ADJ	JJ	5	O
BP	BP	PROPN	NNP	9	O
change	change	NOUN	NN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
2	2	NUM	CD	9	O
days	day	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
outcome	outcome	NOUN	NN	5	O
at	at	ADP	IN	9	O
day	day	NOUN	NN	9	O
21	21	NUM	CD	7	O
was	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Two	two	NUM	CD	9	O
hundred	hundred	NUM	CD	5	O
sixty	sixty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
analysis	analysis	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
92	92	NUM	CD	7	O
,	,	PUNCT	,	9	O
93	93	NUM	CD	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
80	80	NUM	CD	9	O
for	for	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
,	,	PUNCT	,	9	O
low	low	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Nimodipine	nimodipine	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
systolic	systolic	ADJ	JJ	5	I-Disease
BP	BP	PROPN	NNP	9	I-Disease
(	(	PUNCT	-LRB-	9	O
SBP	SBP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
diastolic	diastolic	ADJ	JJ	5	O
BP	BP	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
DBP	DBP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
from	from	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
few	few	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
multivariate	multivariate	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
correlation	correlation	NOUN	NN	9	O
between	between	ADP	IN	5	O
DBP	DBP	PROPN	NNP	9	B-Disease
reduction	reduction	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
worsening	worsening	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
neurological	neurological	ADJ	JJ	5	O
score	score	NOUN	NN	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
beta	beta	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
49	49	NUM	CD	7	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
048	048	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
DBP	DBP	PROPN	NNP	9	B-Disease
reduction	reduction	NOUN	NN	9	I-Disease
of	of	ADP	IN	5	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
group	group	NOUN	NN	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
adjusted	adjust	VERB	VBN	9	O
OR	or	CCONJ	CC	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
compound	compound	NOUN	NN	0	O
outcome	outcome	NOUN	NN	5	O
variable	variable	ADJ	JJ	5	O
death	death	NOUN	NN	9	B-Disease
or	or	CCONJ	CC	5	O
dependency	dependency	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
Barthel	Barthel	PROPN	NNP	5	O
Index	Index	PROPN	NNP	5	O
<	<	X	XX	0	O
60	60	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
n	n	NOUN	NN	9	O
/	/	SYM	SYM	9	O
N	n	NOUN	NN	9	O
=	=	SYM	SYM	7	O
25	25	NUM	CD	9	O
/	/	SYM	SYM	9	O
26	26	NUM	CD	7	O
,	,	PUNCT	,	9	O
OR	or	CCONJ	CC	9	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
16	16	NUM	CD	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
to	to	ADP	IN	5	O
101	101	NUM	CD	7	O
.	.	PUNCT	.	9	O
74	74	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
death	death	NOUN	NN	9	B-Disease
alone	alone	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
N	n	NOUN	NN	9	O
=	=	SYM	SYM	7	O
9	9	NUM	CD	7	O
/	/	SYM	SYM	9	O
26	26	NUM	CD	7	O
,	,	PUNCT	,	9	O
OR	or	CCONJ	CC	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
336	336	NUM	CD	7	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
131	131	NUM	CD	7	O
16	16	NUM	CD	9	O
.	.	PUNCT	.	9	O
619	619	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
all	all	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
n	n	NOUN	NN	9	O
/	/	SYM	SYM	9	O
N	n	NOUN	NN	9	O
=	=	SYM	SYM	7	O
62	62	NUM	CD	7	O
/	/	SYM	SYM	9	O
92	92	NUM	CD	7	O
and	and	CCONJ	CC	5	O
14	14	NUM	CD	7	O
/	/	SYM	SYM	9	O
92	92	NUM	CD	7	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
correlation	correlation	NOUN	NN	9	O
between	between	ADP	IN	5	O
SBP	SBP	PROPN	NNP	9	O
change	change	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
outcome	outcome	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
DBP	DBP	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
SBP	SBP	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
reduction	reduction	NOUN	NN	9	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
neurological	neurological	ADJ	JJ	5	O
worsening	worsen	VERB	VBG	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
intravenous	intravenous	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
nimodipine	nimodipine	NOUN	NN	0	B-Chemical
after	after	ADP	IN	9	O
acute	acute	ADJ	JJ	9	B-Disease
stroke	stroke	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
nimodipine	nimodipine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
conclusive	conclusive	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
do	do	VERB	VBP	5	O
not	not	ADV	RB	5	O
confirm	confirm	VERB	VB	9	O
or	or	CCONJ	CC	5	O
exclude	exclude	VERB	VB	9	O
a	a	DET	DT	5	O
neuroprotective	neuroprotective	ADJ	JJ	9	O
property	property	NOUN	NN	5	O
of	of	ADP	IN	5	O
nimodipine	nimodipine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Neonatal	neonatal	ADJ	JJ	9	O
pyridoxine	pyridoxine	NOUN	NN	0	B-Chemical
responsive	responsive	ADJ	JJ	9	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
isoniazid	isoniazid	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
17	17	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
infant	infant	NOUN	NN	5	O
on	on	ADP	IN	5	O
isoniazid	isoniazid	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
13	13	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADV	RB	0	O
daily	daily	ADV	RB	5	O
from	from	ADP	IN	9	O
birth	birth	NOUN	NN	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
maternal	maternal	ADJ	JJ	9	O
tuberculosis	tuberculosis	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
admitted	admit	VERB	VBN	5	O
after	after	ADP	IN	9	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
clonic	clonic	ADJ	JJ	5	B-Disease
fits	fit	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
underlying	underlie	VERB	VBG	5	O
infective	infective	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
biochemical	biochemical	NOUN	NN	9	O
cause	cause	NOUN	NN	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
found	find	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
fits	fit	NOUN	NNS	5	B-Disease
ceased	cease	VERB	VBD	5	O
within	within	ADP	IN	9	O
4	4	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
of	of	ADP	IN	5	O
administering	administer	VERB	VBG	9	O
intramuscular	intramuscular	ADJ	JJ	9	O
pyridoxine	pyridoxine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
an	an	DET	DT	5	O
aetiology	aetiology	NOUN	NN	5	O
of	of	ADP	IN	5	O
pyridoxine	pyridoxine	NOUN	NN	0	B-Chemical
deficiency	deficiency	NOUN	NN	9	O
secondary	secondary	ADJ	JJ	9	O
to	to	PART	TO	5	O
isoniazid	isoniazid	VERB	VB	0	B-Chemical
medication	medication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Ketamine	ketamine	NOUN	NN	0	B-Chemical
sedation	sedation	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
children	child	NOUN	NNS	5	O
'	'	PART	POS	9	O
s	s	PART	POS	9	O
fractures	fracture	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
emergency	emergency	NOUN	NN	5	O
department	department	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
There	there	ADV	EX	5	O
recently	recently	ADV	RB	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
a	a	DET	DT	5	O
resurgence	resurgence	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
utilization	utilization	NOUN	NN	9	O
of	of	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
unique	unique	ADJ	JJ	9	O
anesthetic	anesthetic	NOUN	NN	5	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
emergency	emergency	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
department	department	NOUN	NN	5	O
procedures	procedure	NOUN	NNS	5	O
requiring	require	VERB	VBG	5	O
sedation	sedation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
sedation	sedation	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
children	child	NOUN	NNS	5	O
'	'	PART	POS	9	O
s	s	PART	POS	9	O
fractures	fracture	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
emergency	emergency	NOUN	NN	5	O
department	department	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
One	one	NUM	CD	5	O
hundred	hundred	NUM	CD	5	O
and	and	CCONJ	CC	5	O
fourteen	fourteen	NUM	CD	9	O
children	child	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
average	average	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
years	year	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
twelve	twelve	NUM	CD	9	O
months	month	NOUN	NNS	5	O
to	to	ADP	IN	5	O
ten	ten	NUM	CD	9	O
years	year	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
ten	ten	NUM	CD	9	O
months	month	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
who	who	PRON	WP	5	O
underwent	undergo	VERB	VBD	5	O
closed	closed	ADJ	JJ	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
isolated	isolate	VERB	VBN	9	O
fracture	fracture	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
dislocation	dislocation	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
emergency	emergency	NOUN	NN	5	O
department	department	NOUN	NN	5	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
level	level	NOUN	NN	9	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
trauma	trauma	NOUN	NN	5	B-Disease
center	center	NOUN	NN	5	O
were	be	VERB	VBD	9	O
prospectively	prospectively	ADV	RB	5	O
evaluated	evaluate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Ketamine	Ketamine	PROPN	NNP	0	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
intravenously	intravenously	ADV	RB	0	O
(	(	PUNCT	-LRB-	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
two	two	NUM	CD	5	O
milligrams	milligram	NOUN	NNS	0	O
per	per	ADP	IN	9	O
kilogram	kilogram	NOUN	NN	0	O
of	of	ADP	IN	5	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
ninety	ninety	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
nine	nine	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
intramuscularly	intramuscularly	ADV	RB	0	O
(	(	PUNCT	-LRB-	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
four	four	NUM	CD	9	O
milligrams	milligram	NOUN	NNS	0	O
per	per	ADP	IN	9	O
kilogram	kilogram	NOUN	NN	0	O
of	of	ADP	IN	5	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
fifteen	fifteen	NUM	CD	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
board	board	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
certified	certify	VERB	VBN	5	O
emergency	emergency	NOUN	NN	5	O
physician	physician	NOUN	NN	5	O
skilled	skilled	ADJ	JJ	5	O
in	in	ADP	IN	5	O
airway	airway	NOUN	NN	5	O
management	management	NOUN	NN	5	O
supervised	supervise	VERB	VBD	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
monitored	monitor	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
registered	register	VERB	VBN	5	O
nurse	nurse	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Any	any	DET	DT	5	O
pain	pain	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
was	be	VERB	VBD	9	O
rated	rate	VERB	VBN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
orthopaedic	orthopaedic	ADJ	JJ	5	O
surgeon	surgeon	NOUN	NN	5	O
treating	treat	VERB	VBG	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
Children	Children	PROPN	NNPS	5	O
'	'	PART	POS	9	O
s	s	NOUN	NNS	9	O
Hospital	Hospital	PROPN	NNP	2	O
of	of	ADP	IN	5	O
Eastern	Eastern	PROPN	NNP	4	O
Ontario	Ontario	PROPN	NNP	2	O
Pain	Pain	PROPN	NNP	5	B-Disease
Scale	Scale	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
CHEOPS	CHEOPS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
average	average	ADJ	JJ	5	O
time	time	NOUN	NN	5	O
from	from	ADP	IN	9	O
intravenous	intravenous	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
manipulation	manipulation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
fracture	fracture	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
dislocation	dislocation	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
one	one	NUM	CD	5	O
minute	minute	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
thirty	thirty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
six	six	NUM	CD	9	O
seconds	second	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
twenty	twenty	NUM	CD	5	O
seconds	second	NOUN	NNS	5	O
to	to	ADP	IN	5	O
five	five	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
average	average	ADJ	JJ	5	O
time	time	NOUN	NN	5	O
from	from	ADP	IN	9	O
intramuscular	intramuscular	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
to	to	ADP	IN	5	O
manipulation	manipulation	NOUN	NN	5	O
was	be	VERB	VBD	9	O
four	four	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
forty	forty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
two	two	NUM	CD	5	O
seconds	second	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
sixty	sixty	ADJ	JJ	5	O
seconds	second	NOUN	NNS	5	O
to	to	ADP	IN	5	O
fifteen	fifteen	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
average	average	ADJ	JJ	5	O
score	score	NOUN	NN	5	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
Children	Children	PROPN	NNPS	5	O
'	'	PART	POS	9	O
s	s	NOUN	NNS	9	O
Hospital	Hospital	PROPN	NNP	2	O
of	of	ADP	IN	5	O
Eastern	Eastern	PROPN	NNP	4	O
Ontario	Ontario	PROPN	NNP	2	O
Pain	Pain	PROPN	NNP	5	B-Disease
Scale	Scale	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
points	point	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
to	to	PART	TO	5	O
10	10	NUM	CD	9	O
points	point	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
reflecting	reflect	VERB	VBG	5	O
minimal	minimal	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
no	no	DET	DT	9	O
pain	pain	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
fracture	fracture	NOUN	NN	5	B-Disease
reduction	reduction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Adequate	adequate	ADJ	JJ	5	O
fracture	fracture	NOUN	NN	5	B-Disease
reduction	reduction	NOUN	NN	9	O
was	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
in	in	ADP	IN	5	O
111	111	NUM	CD	7	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Ninety	ninety	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
nine	nine	NUM	CD	9	O
percent	percent	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
sixty	sixty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
eight	eight	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
sixty	sixty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
nine	nine	NUM	CD	9	O
parents	parent	NOUN	NNS	5	O
present	present	ADJ	JJ	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
were	be	VERB	VBD	9	O
pleased	pleased	ADJ	JJ	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
sedation	sedation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
would	would	VERB	MD	5	O
allow	allow	VERB	VB	5	O
it	-PRON-	PRON	PRP	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
again	again	ADV	RB	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
situation	situation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patency	patency	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
airway	airway	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
independent	independent	ADJ	JJ	9	O
respiration	respiration	NOUN	NN	9	O
were	be	VERB	VBD	9	O
maintained	maintain	VERB	VBN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
remained	remain	VERB	VBD	9	O
stable	stable	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Minor	minor	ADJ	JJ	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
included	include	VERB	VBD	5	O
nausea	nausea	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
thirteen	thirteen	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
emesis	emesis	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
eight	eight	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
thirteen	thirteen	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
nausea	nausea	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
clumsiness	clumsiness	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
evident	evident	ADJ	JJ	9	O
as	as	ADP	IN	5	O
ataxic	ataxic	ADJ	JJ	5	B-Disease
movements	movement	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
ten	ten	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
dysphoric	dysphoric	ADJ	JJ	5	B-Disease
reaction	reaction	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
sequelae	sequelae	NOUN	NN	5	O
were	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
hallucinations	hallucination	NOUN	NNS	5	B-Disease
or	or	CCONJ	CC	5	O
nightmares	nightmare	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Ketamine	Ketamine	PROPN	NNP	0	B-Chemical
reliably	reliably	ADV	RB	5	O
,	,	PUNCT	,	9	O
safely	safely	ADV	RB	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
quickly	quickly	ADV	RB	5	O
provided	provide	VERB	VBN	9	O
adequate	adequate	ADJ	JJ	5	O
sedation	sedation	NOUN	NN	5	O
to	to	PART	TO	5	O
effectively	effectively	ADV	RB	5	O
facilitate	facilitate	VERB	VB	5	O
the	the	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
children	child	NOUN	NNS	5	O
'	'	PART	POS	9	O
s	s	PART	POS	9	O
fractures	fracture	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
emergency	emergency	NOUN	NN	5	O
department	department	NOUN	NN	5	O
at	at	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
institution	institution	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Ketamine	ketamine	NOUN	NN	0	B-Chemical
should	should	VERB	MD	5	O
only	only	ADV	RB	9	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
environment	environment	NOUN	NN	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
emergency	emergency	NOUN	NN	5	O
department	department	NOUN	NN	5	O
,	,	PUNCT	,	9	O
where	where	ADV	WRB	5	O
proper	proper	ADJ	JJ	5	O
one	one	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
on	on	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
one	one	NUM	CD	5	O
monitoring	monitoring	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
used	use	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
board	board	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
certified	certify	VERB	VBN	5	O
physicians	physician	NOUN	NNS	5	O
skilled	skilled	ADJ	JJ	5	O
in	in	ADP	IN	5	O
airway	airway	NOUN	NN	5	O
management	management	NOUN	NN	5	O
are	be	VERB	VBP	5	O
directly	directly	ADV	RB	9	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
care	care	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cyclosporine	cyclosporine	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
microangiopathy	microangiopathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
microangiopathy	microangiopathy	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
TMA	tma	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
well	well	ADV	RB	9	O
documented	document	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Treatments	treatment	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
included	include	VERB	VBN	5	O
discontinuation	discontinuation	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
dose	dose	NOUN	NN	9	O
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
concurrent	concurrent	ADJ	JJ	5	O
plasma	plasma	NOUN	NN	9	O
exchange	exchange	NOUN	NN	9	O
,	,	PUNCT	,	9	O
plasma	plasma	NOUN	NN	9	O
infusion	infusion	NOUN	NN	0	O
,	,	PUNCT	,	9	O
anticoagulation	anticoagulation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
intravenous	intravenous	ADJ	JJ	0	O
immunoglobulin	immunoglobulin	NOUN	NN	3	O
G	g	NOUN	NN	9	O
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
recipients	recipient	NOUN	NNS	9	O
of	of	ADP	IN	5	O
organ	organ	NOUN	NN	5	O
transplantation	transplantation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
removing	remove	VERB	VBG	5	O
the	the	DET	DT	5	O
inciting	incite	VERB	VBG	5	O
agent	agent	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
without	without	ADP	IN	9	O
the	the	DET	DT	5	O
attendant	attendant	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
precipitating	precipitate	VERB	VBG	9	O
acute	acute	ADJ	JJ	9	O
rejection	rejection	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
graft	graft	NOUN	NN	5	O
loss	loss	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
decade	decade	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
seen	see	VERB	VBN	9	O
the	the	DET	DT	5	O
emergence	emergence	NOUN	NN	9	O
of	of	ADP	IN	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
potent	potent	ADJ	JJ	3	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
with	with	ADP	IN	5	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
virtually	virtually	ADV	RB	9	O
identical	identical	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
a	a	DET	DT	5	O
result	result	NOUN	NN	9	O
,	,	PUNCT	,	9	O
switching	switch	VERB	VBG	5	O
to	to	PART	TO	5	O
tacrolimus	tacrolimus	VERB	VB	0	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
viable	viable	ADJ	JJ	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
option	option	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
setting	setting	NOUN	NN	5	O
of	of	ADP	IN	5	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
TMA	tma	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

With	with	ADP	IN	5	O
the	the	DET	DT	5	O
more	more	ADV	RBR	5	O
widespread	widespread	ADJ	JJ	5	O
application	application	NOUN	NN	5	O
of	of	ADP	IN	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
organ	organ	NOUN	NN	5	O
transplantation	transplantation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
TMA	tma	NOUN	NN	9	B-Disease
has	have	VERB	VBZ	9	O
also	also	ADV	RB	9	O
been	be	VERB	VBN	9	O
recognized	recognize	VERB	VBN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
literature	literature	NOUN	NN	5	O
regarding	regard	VERB	VBG	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
recurrence	recurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
TMA	tma	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
exposed	expose	VERB	VBN	9	O
sequentially	sequentially	ADV	RB	9	O
to	to	PART	TO	5	O
cyclosporine	cyclosporine	VERB	VB	0	B-Chemical
and	and	CCONJ	CC	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
limited	limit	VERB	VBN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
living	live	VERB	VBG	5	O
donor	donor	NOUN	NN	9	O
renal	renal	ADJ	JJ	9	O
transplant	transplant	NOUN	NN	9	O
recipient	recipient	NOUN	NN	9	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
cyclosporine	cyclosporine	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
TMA	tma	NOUN	NN	9	B-Disease
that	that	DET	WDT	5	O
responded	respond	VERB	VBD	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
conjunction	conjunction	NOUN	NN	9	O
with	with	ADP	IN	5	O
plasmapheresis	plasmapheresis	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
fresh	fresh	ADJ	JJ	9	O
frozen	frozen	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
replacement	replacement	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Introduction	introduction	NOUN	NN	5	O
of	of	ADP	IN	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
alternative	alternative	ADJ	JJ	5	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
recurrence	recurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
TMA	TMA	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
subsequent	subsequent	ADJ	JJ	9	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
allograft	allograft	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
are	be	VERB	VBP	5	O
switched	switch	VERB	VBN	9	O
from	from	ADP	IN	9	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
tacrolimus	tacrolimus	VERB	VB	0	B-Chemical
or	or	CCONJ	CC	5	O
vice	vice	NOUN	NN	9	O
versa	versa	NOUN	NN	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
closely	closely	ADV	RB	9	O
monitored	monitor	VERB	VBN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
signs	sign	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
recurrent	recurrent	ADJ	JJ	5	O
TMA	tma	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Analgesic	analgesic	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
patients	patient	NOUN	NNS	5	O
on	on	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
controlled	control	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
crossover	crossover	NOUN	NN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Pain	pain	NOUN	NN	5	B-Disease
not	not	ADV	RB	5	O
responsive	responsive	ADJ	JJ	9	O
to	to	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
often	often	ADV	RB	5	O
problematic	problematic	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Animal	animal	ADJ	JJ	2	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
D	d	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aspartate	aspartate	NOUN	NN	1	I-Chemical
(	(	PUNCT	-LRB-	9	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
antagonists	antagonist	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
improving	improve	VERB	VBG	5	O
opioid	opioid	ADJ	JJ	5	O
analgesia	analgesia	NOUN	NN	5	O
in	in	ADP	IN	5	O
difficult	difficult	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
syndromes	syndrome	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
neuropathic	neuropathic	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
slow	slow	ADJ	JJ	5	O
bolus	bolus	NOUN	NN	0	O
of	of	ADP	IN	5	O
subhypnotic	subhypnotic	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
to	to	ADP	IN	5	O
10	10	NUM	CD	9	O
cancer	cancer	NOUN	NN	3	B-Disease
patients	patient	NOUN	NNS	5	O
whose	whose	DET	WP$	9	O
pain	pain	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
unrelieved	unrelieve	VERB	VBN	5	O
by	by	ADP	IN	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
crossover	crossover	NOUN	NN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Pain	pain	NOUN	NN	5	B-Disease
intensity	intensity	NOUN	NN	5	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
0	0	NUM	CD	7	O
to	to	PART	TO	5	O
10	10	NUM	CD	9	O
numerical	numerical	ADJ	JJ	5	O
scale	scale	NOUN	NN	5	O
;	;	PUNCT	:	9	O
nausea	nausea	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
vomiting	vomiting	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
drowsiness	drowsiness	NOUN	NN	5	O
,	,	PUNCT	,	9	O
confusion	confusion	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
dry	dry	ADJ	JJ	0	B-Disease
mouth	mouth	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
scale	scale	NOUN	NN	5	O
from	from	ADP	IN	9	O
0	0	NUM	CD	7	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
not	not	ADV	RB	5	O
at	at	ADV	RB	9	O
all	all	ADV	RB	5	O
,	,	PUNCT	,	9	O
slight	slight	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
lot	lot	NOUN	NN	5	O
,	,	PUNCT	,	9	O
awful	awful	ADJ	JJ	5	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
Mini	Mini	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
Mental	Mental	PROPN	NNP	5	O
State	State	PROPN	NNP	2	O
Examination	Examination	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
MMSE	MMSE	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
30	30	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
before	before	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
T0	T0	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
30	30	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
T30	T30	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
60	60	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
T60	T60	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
120	120	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
T120	t120	NOUN	NN	1	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
180	180	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
T180	t180	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Ketamine	Ketamine	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
saline	saline	VERB	VB	0	O
solution	solution	NOUN	NN	0	O
,	,	PUNCT	,	9	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
pain	pain	NOUN	NN	5	B-Disease
intensity	intensity	NOUN	NN	5	O
in	in	ADP	IN	5	O
almost	almost	ADV	RB	9	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
at	at	ADP	IN	9	O
both	both	DET	DT	9	O
doses	dose	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
relevant	relevant	ADJ	JJ	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
higher	high	ADJ	JJR	9	O
doses	dose	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Hallucinations	hallucination	NOUN	NNS	5	B-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
4	4	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
unpleasant	unpleasant	ADJ	JJ	5	O
sensation	sensation	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
"	"	PUNCT	``	5	O
empty	empty	ADJ	JJ	3	O
head	head	NOUN	NN	5	O
"	"	PUNCT	''	5	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
reported	report	VERB	VBN	9	O
by	by	ADP	IN	9	O
2	2	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
episodes	episode	NOUN	NNS	5	O
reversed	reverse	VERB	VBN	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
intravenously	intravenously	ADV	RB	0	O
.	.	PUNCT	.	9	O

Significant	significant	ADJ	JJ	9	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
drowsiness	drowsiness	NOUN	NN	5	O
were	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
marked	marked	ADJ	JJ	9	O
with	with	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
MMSE	MMSE	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
at	at	ADP	IN	9	O
T30	T30	PROPN	NNP	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
of	of	ADP	IN	5	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Ketamine	Ketamine	PROPN	NNP	0	B-Chemical
can	can	VERB	MD	5	O
improve	improve	VERB	VB	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
analgesia	analgesia	NOUN	NN	5	O
in	in	ADP	IN	5	O
difficult	difficult	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
syndromes	syndrome	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
neuropathic	neuropathic	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
central	central	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
taken	take	VERB	VBN	5	O
into	into	ADP	IN	9	O
account	account	NOUN	NN	5	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
when	when	ADV	WRB	5	O
using	use	VERB	VBG	9	O
higher	high	ADJ	JJR	9	O
doses	dose	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
observation	observation	NOUN	NN	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
tested	test	VERB	VBN	9	O
in	in	ADP	IN	5	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
prolonged	prolong	VERB	VBN	9	O
ketamine	ketamine	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Paclitaxel	paclitaxel	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
gemcitabine	gemcitabine	ADJ	JJ	3	B-Chemical
combination	combination	NOUN	NN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
within	within	ADP	IN	9	O
a	a	DET	DT	5	O
multidisciplinary	multidisciplinary	ADJ	JJ	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
approach	approach	NOUN	NN	5	O
in	in	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
nonsmall	nonsmall	NOUN	NN	3	B-Disease
cell	cell	NOUN	NN	3	I-Disease
lung	lung	NOUN	NN	9	I-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Cisplatin	Cisplatin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
combinations	combination	NOUN	NNS	9	O
improve	improve	VERB	VBP	5	O
quality	quality	NOUN	NN	5	O
of	of	ADP	IN	5	O
life	life	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
survival	survival	NOUN	NN	9	O
in	in	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
nonsmall	nonsmall	NOUN	NN	3	B-Disease
cell	cell	NOUN	NN	3	I-Disease
lung	lung	NOUN	NN	9	I-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
NSCLC	NSCLC	PROPN	NNP	3	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
emergence	emergence	NOUN	NN	9	O
of	of	ADP	IN	5	O
new	new	ADJ	JJ	5	O
active	active	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
might	may	VERB	MD	9	O
translate	translate	VERB	VB	5	O
into	into	ADP	IN	9	O
more	more	ADJ	JJR	5	O
effective	effective	ADJ	JJ	5	O
regimens	regimen	NOUN	NNS	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
objective	objective	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
feasibility	feasibility	NOUN	NN	5	O
,	,	PUNCT	,	9	O
response	response	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
gemcitabine	gemcitabine	ADJ	JJ	3	B-Chemical
combination	combination	NOUN	NN	9	O
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
metastatic	metastatic	ADJ	JJ	3	O
NSCLC	nsclc	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
five	five	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
naive	naive	ADJ	JJ	3	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Stage	stage	NOUN	NN	9	O
IV	IV	PROPN	NNP	9	O
NSCLC	NSCLC	PROPN	NNP	3	B-Disease
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
Eastern	Eastern	PROPN	NNP	4	O
Cooperative	Cooperative	PROPN	NNP	2	O
Oncology	Oncology	PROPN	NNP	2	O
Group	Group	PROPN	NNP	9	O
performance	performance	NOUN	NN	5	O
status	status	NOUN	NN	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
2	2	NUM	CD	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
135	135	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
given	give	VERB	VBN	5	O
intravenously	intravenously	ADV	RB	0	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
Day	day	NOUN	NN	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
120	120	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
given	give	VERB	VBN	5	O
intravenously	intravenously	ADV	RB	0	O
in	in	ADP	IN	5	O
6	6	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
Day	day	NOUN	NN	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
gemcitabine	gemcitabine	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
800	800	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
given	give	VERB	VBN	5	O
intravenously	intravenously	ADV	RB	0	O
in	in	ADP	IN	5	O
30	30	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
Days	day	NOUN	NNS	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
every	every	DET	DT	5	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
responding	respond	VERB	VBG	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
scheduled	schedule	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
consolidation	consolidation	NOUN	NN	5	O
radiotherapy	radiotherapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
24	24	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
preplanned	preplanne	VERB	VBN	5	O
second	second	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
line	line	NOUN	NN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
after	after	ADP	IN	9	O
disease	disease	NOUN	NN	5	O
progression	progression	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
response	response	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
rates	rate	NOUN	NNS	5	O
reported	report	VERB	VBD	9	O
refer	refer	VERB	VBP	5	O
only	only	ADV	RB	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
regimen	regiman	NOUN	NNS	5	O
given	give	VERB	VBN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
All	all	DET	PDT	9	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
for	for	ADP	IN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
;	;	PUNCT	:	9	O
34	34	NUM	CD	7	O
were	be	VERB	VBD	9	O
examinable	examinable	ADJ	JJ	5	O
for	for	ADP	IN	5	O
response	response	NOUN	NN	9	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
objective	objective	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
73	73	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
[	[	PUNCT	-LRB-	9	O
CI	CI	PROPN	NNP	7	O
]	]	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
55	55	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
-	-	SYM	SYM	7	O
87	87	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
4	4	NUM	CD	9	O
complete	complete	ADJ	JJ	9	O
responses	response	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

According	accord	VERB	VBG	5	O
to	to	ADP	IN	5	O
intention	intention	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
treat	treat	VERB	VB	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
71	71	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
53	53	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
-	-	SYM	SYM	7	O
85	85	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
154	154	NUM	CD	7	O
courses	course	NOUN	NNS	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
intensity	intensity	NOUN	NN	5	O
was	be	VERB	VBD	9	O
131	131	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
97	97	NUM	CD	7	O
.	.	NOUN	NN	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
117	117	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
97	97	NUM	CD	7	O
.	.	NOUN	NN	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
1378	1378	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
gemcitabine	gemcitabine	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
86	86	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

World	World	PROPN	NNP	5	O
Health	Health	PROPN	NNP	2	O
Organization	Organization	PROPN	NNP	2	O
Grade	Grade	PROPN	NNP	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
39	39	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
one	one	NUM	CD	5	O
treatment	treatment	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
death	death	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Nonhematologic	nonhematologic	ADJ	JJ	7	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
mild	mild	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
a	a	DET	DT	5	O
median	median	ADJ	JJ	9	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
of	of	ADP	IN	5	O
22	22	NUM	CD	7	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
progression	progression	NOUN	NN	9	O
free	free	ADJ	JJ	9	O
survival	survival	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
7	7	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
survival	survival	NOUN	NN	9	O
time	time	NOUN	NN	5	O
was	be	VERB	VBD	9	O
16	16	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
gemcitabine	gemcitabine	NOUN	NN	3	B-Chemical
is	be	VERB	VBZ	5	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
shows	show	VERB	VBZ	9	O
high	high	ADJ	JJ	9	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
NSCLC	nsclc	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
merits	merit	VERB	VBZ	5	O
further	further	ADJ	JJ	9	O
comparison	comparison	NOUN	NN	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
regimens	regimen	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Serotonergic	serotonergic	ADJ	JJ	5	B-Chemical
antidepressants	antidepressant	NOUN	NNS	5	I-Chemical
and	and	CCONJ	CC	5	O
urinary	urinary	ADJ	JJ	9	B-Disease
incontinence	incontinence	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Many	many	ADJ	JJ	5	O
new	new	ADJ	JJ	5	O
serotonergic	serotonergic	NOUN	NN	5	B-Chemical
antidepressants	antidepressant	NOUN	NNS	5	I-Chemical
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
introduced	introduce	VERB	VBN	9	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
past	past	ADJ	JJ	5	O
decade	decade	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
urinary	urinary	ADJ	JJ	9	B-Disease
incontinence	incontinence	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
listed	list	VERB	VBN	9	O
as	as	ADP	IN	5	O
one	one	NUM	CD	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
in	in	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
package	package	NOUN	NN	5	O
inserts	insert	NOUN	NNS	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
only	only	ADV	RB	9	O
one	one	NUM	CD	5	O
report	report	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
concerns	concern	VERB	VBZ	5	O
2	2	NUM	CD	9	O
male	male	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
experienced	experience	VERB	VBD	5	O
incontinence	incontinence	NOUN	NN	5	B-Disease
while	while	ADP	IN	9	O
taking	take	VERB	VBG	5	O
venlafaxine	venlafaxine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
paper	paper	NOUN	NN	5	O
the	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
describe	describe	VERB	VBP	5	O
2	2	NUM	CD	9	O
female	female	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
incontinence	incontinence	NOUN	NN	5	B-Disease
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
reuptake	reuptake	NOUN	NN	0	O
inhibitors	inhibitor	NOUN	NNS	3	O
paroxetine	paroxetine	VERB	VBP	0	B-Chemical
and	and	CCONJ	CC	5	O
sertraline	sertraline	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
third	third	NOUN	NN	9	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
this	this	DET	DT	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
venlafaxine	venlafaxine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
2	2	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
3	3	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
taking	take	VERB	VBG	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
carbonate	carbonate	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blockers	blocker	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
both	both	DET	DT	9	O
of	of	ADP	IN	5	O
which	which	DET	WDT	5	O
could	could	VERB	MD	9	O
have	have	VERB	VB	5	O
contributed	contribute	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
incontinence	incontinence	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Animal	animal	NOUN	NN	2	O
studies	study	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
incontinence	incontinence	NOUN	NN	5	B-Disease
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
serotonergic	serotonergic	VERB	VB	5	B-Chemical
antidepressants	antidepressant	NOUN	NNS	5	I-Chemical
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
5HT4	5ht4	NUM	CD	3	O
receptors	receptor	NOUN	NNS	3	O
found	find	VERB	VBN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
bladder	bladder	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
research	research	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
needed	need	VERB	VBN	5	O
to	to	PART	TO	5	O
delineate	delineate	VERB	VB	9	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
troubling	troubling	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
how	how	ADV	WRB	5	O
best	good	ADJ	JJS	5	O
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
it	-PRON-	PRON	PRP	5	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
:	:	PUNCT	:	9	O
differential	differential	ADJ	JJ	9	O
sensitivity	sensitivity	NOUN	NN	9	O
of	of	ADP	IN	5	O
six	six	NUM	CD	9	O
inbred	inbreed	VERB	VBN	9	O
mouse	mouse	NOUN	NN	3	O
strains	strain	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

Mature	mature	ADJ	JJ	9	O
male	male	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
female	female	ADJ	JJ	9	O
mice	mouse	NOUN	NNS	3	O
from	from	ADP	IN	9	O
six	six	NUM	CD	9	O
inbred	inbreed	VERB	VBN	9	O
stains	stain	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
for	for	ADP	IN	5	O
susceptibility	susceptibility	NOUN	NN	9	O
to	to	ADP	IN	5	O
behavioral	behavioral	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Cocaine	Cocaine	PROPN	NNP	5	B-Chemical
was	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
ip	ip	NOUN	NN	0	O
over	over	ADP	IN	5	O
a	a	DET	DT	5	O
range	range	NOUN	NN	9	O
of	of	ADP	IN	5	O
doses	dose	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
-	-	SYM	SYM	7	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
behavior	behavior	NOUN	NN	5	O
was	be	VERB	VBD	9	O
monitored	monitor	VERB	VBN	9	O
for	for	ADP	IN	5	O
20	20	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Seizure	Seizure	PROPN	NNP	5	B-Disease
end	end	NOUN	NN	9	O
points	point	NOUN	NNS	5	O
included	include	VERB	VBD	5	O
latency	latency	NOUN	NN	5	O
to	to	PART	TO	5	O
forelimb	forelimb	VERB	VB	5	O
or	or	CCONJ	CC	5	O
hindlimb	hindlimb	NOUN	NN	9	O
clonus	clonus	NOUN	NN	5	O
,	,	PUNCT	,	9	O
latency	latency	NOUN	NN	5	O
to	to	PART	TO	5	O
clonic	clonic	VERB	VB	5	O
running	run	VERB	VBG	5	O
seizure	seizure	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
latency	latency	NOUN	NN	5	O
to	to	ADP	IN	5	O
jumping	jump	VERB	VBG	5	O
bouncing	bounce	VERB	VBG	5	O
seizure	seizure	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
range	range	NOUN	NN	9	O
of	of	ADP	IN	5	O
strain	strain	NOUN	NN	1	O
specific	specific	ADJ	JJ	9	O
sensitivities	sensitivity	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
documented	document	VERB	VBN	9	O
with	with	ADP	IN	5	O
A	A	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
J	J	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
SJL	SJL	PROPN	NNP	3	O
mice	mouse	NOUN	NNS	3	O
being	be	VERB	VBG	5	O
most	most	ADV	RBS	9	O
sensitive	sensitive	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
C57BL	C57BL	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
6J	6J	PROPN	NNP	3	O
most	most	ADV	RBS	9	O
resistant	resistant	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

DBA	DBA	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
2J	2j	NOUN	NN	3	O
,	,	PUNCT	,	9	O
BALB	BALB	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
cByJ	cByJ	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
NZW	NZW	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
LacJ	LacJ	PROPN	NNP	3	O
strains	strain	NOUN	NNS	1	O
exhibited	exhibit	VERB	VBN	9	O
intermediate	intermediate	ADJ	JJ	9	O
sensitivity	sensitivity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

EEG	EEG	PROPN	NNP	5	O
recordings	recording	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
made	make	VERB	VBN	5	O
in	in	ADP	IN	5	O
SJL	SJL	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
A	A	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
J	J	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
C57BL	C57BL	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
6J	6j	ADJ	JJ	3	O
mice	mouse	NOUN	NNS	3	O
revealing	reveal	VERB	VBG	9	O
a	a	DET	DT	5	O
close	close	ADJ	JJ	5	O
correspondence	correspondence	NOUN	NN	5	O
between	between	ADP	IN	5	O
electrical	electrical	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
behavior	behavior	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Additionally	additionally	ADV	RB	9	O
,	,	PUNCT	,	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
determined	determine	VERB	VBN	9	O
in	in	ADP	IN	5	O
hippocampus	hippocampus	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
cortex	cortex	NOUN	NN	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
different	different	ADJ	JJ	9	O
between	between	ADP	IN	5	O
sensitive	sensitive	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
resistant	resistant	ADJ	JJ	9	O
strains	strain	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

Additional	additional	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
murine	murine	NOUN	NN	3	O
strains	strain	NOUN	NNS	1	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
useful	useful	ADJ	JJ	5	O
for	for	ADP	IN	5	O
investigating	investigate	VERB	VBG	5	O
genetic	genetic	ADJ	JJ	5	O
influences	influence	NOUN	NNS	5	O
on	on	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Hypotension	hypotension	NOUN	NN	7	B-Disease
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
tizanidine	tizanidine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
converting	convert	VERB	VBG	9	O
enzyme	enzyme	ADJ	JJ	0	O
inhibitor	inhibitor	NOUN	NN	3	O
for	for	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Centrally	centrally	ADV	RB	5	O
acting	act	VERB	VBG	9	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
adrenergic	adrenergic	NOUN	NN	9	O
agonists	agonist	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
several	several	ADJ	JJ	9	O
pharmacologic	pharmacologic	ADJ	JJ	9	O
agents	agent	NOUN	NNS	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
spasticity	spasticity	NOUN	NN	5	B-Disease
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
disorders	disorder	NOUN	NNS	5	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
central	central	ADJ	JJ	5	I-Disease
nervous	nervous	ADJ	JJ	5	I-Disease
system	system	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
spasticity	spasticity	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
certain	certain	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
cardiorespiratory	cardiorespiratory	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Adults	adult	NOUN	NNS	9	O
chronically	chronically	ADV	RB	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
converting	convert	VERB	VBG	9	O
enzyme	enzyme	ADJ	JJ	0	O
inhibitors	inhibitor	NOUN	NNS	3	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
limited	limited	ADJ	JJ	5	O
ability	ability	NOUN	NN	9	O
to	to	PART	TO	5	O
respond	respond	VERB	VB	5	O
to	to	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
sympathetic	sympathetic	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
simultaneously	simultaneously	ADV	RB	5	O
blocked	block	VERB	VBN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
present	present	VERB	VBP	9	O
a	a	DET	DT	5	O
10	10	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
boy	boy	NOUN	NN	5	O
chronically	chronically	ADV	RB	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
lisinopril	lisinopril	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
converting	convert	VERB	VBG	9	O
enzyme	enzyme	ADJ	JJ	0	O
inhibitor	inhibitor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
addition	addition	NOUN	NN	9	O
of	of	ADP	IN	5	O
tizanidine	tizanidine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
agonist	agonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
spasticity	spasticity	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
interaction	interaction	NOUN	NN	9	O
of	of	ADP	IN	5	O
tizanidine	tizanidine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
antihypertensive	antihypertensive	ADJ	JJ	5	O
agents	agent	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
kept	keep	VERB	VBN	9	O
in	in	ADP	IN	5	O
mind	mind	NOUN	NN	5	O
when	when	ADV	WRB	5	O
prescribing	prescribe	VERB	VBG	5	O
therapy	therapy	NOUN	NN	5	O
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
either	either	CCONJ	CC	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
spasticity	spasticity	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
such	such	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
mouse	mouse	NOUN	NN	3	O
lines	line	NOUN	NNS	3	O
selected	select	VERB	VBN	9	O
for	for	ADP	IN	5	O
differential	differential	ADJ	JJ	9	O
sensitivities	sensitivity	NOUN	NNS	9	O
to	to	ADP	IN	5	O
beta	beta	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
carboline	carboline	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
are	be	VERB	VBP	5	O
also	also	ADV	RB	9	O
differentially	differentially	ADV	RB	9	O
sensitive	sensitive	ADJ	JJ	9	O
to	to	ADP	IN	5	O
various	various	ADJ	JJ	9	O
pharmacological	pharmacological	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
other	other	ADJ	JJ	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
A	a	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
receptor	receptor	NOUN	NN	3	O
ligands	ligand	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
mouse	mouse	NOUN	NN	3	O
lines	line	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
selectively	selectively	ADV	RB	3	O
bred	breed	VERB	VBN	9	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
sensitivity	sensitivity	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
BS	BS	PROPN	NNP	9	O
line	line	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
resistance	resistance	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
BR	BR	PROPN	NNP	9	O
line	line	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
methyl	methyl	NOUN	NN	0	B-Chemical
beta	beta	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
carboline	carboline	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
carboxylate	carboxylate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
beta	beta	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
CCM	CCM	PROPN	NNP	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
inverse	inverse	NOUN	NN	5	O
agonist	agonist	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
A	a	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
receptor	receptor	NOUN	NN	3	O
benzodiazepine	benzodiazepine	NOUN	NN	5	B-Chemical
site	site	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
aim	aim	NOUN	NN	5	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
characterize	characterize	VERB	VB	9	O
both	both	DET	DT	9	O
lines	line	NOUN	NNS	3	O
'	'	PART	POS	9	O
sensitivities	sensitivity	NOUN	NNS	9	O
to	to	ADP	IN	5	O
various	various	ADJ	JJ	9	O
physiological	physiological	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
other	other	ADJ	JJ	5	O
ligands	ligand	NOUN	NNS	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
A	a	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
receptor	receptor	NOUN	NN	3	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
measured	measure	VERB	VBD	9	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
anxiolysis	anxiolysis	NOUN	NN	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
elevated	elevated	ADJ	JJ	9	O
plus	plus	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
maze	maze	NOUN	NN	5	O
test	test	NOUN	NN	5	O
,	,	PUNCT	,	9	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
sedation	sedation	NOUN	NN	5	O
by	by	ADP	IN	9	O
recording	record	VERB	VBG	5	O
the	the	DET	DT	5	O
vigilance	vigilance	NOUN	NN	5	O
states	state	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
picrotoxin	picrotoxin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
pentylenetetrazol	pentylenetetrazol	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
after	after	ADP	IN	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
injections	injection	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Results	result	NOUN	NNS	9	O
presented	present	VERB	VBN	5	O
here	here	ADV	RB	5	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
differential	differential	ADJ	JJ	9	O
sensitivities	sensitivity	NOUN	NNS	9	O
of	of	ADP	IN	5	O
BS	BS	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
BR	BR	PROPN	NNP	9	O
lines	line	NOUN	NNS	3	O
to	to	ADP	IN	5	O
beta	beta	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
CCM	ccm	NOUN	NN	9	I-Chemical
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
extended	extend	VERB	VBN	5	O
to	to	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
picrotoxin	picrotoxin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
pentylenetetrazol	pentylenetetrazol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
a	a	DET	DT	5	O
genetic	genetic	ADJ	JJ	5	O
selection	selection	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
general	general	ADJ	JJ	5	O
sensitivity	sensitivity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
resistance	resistance	NOUN	NN	9	O
to	to	ADP	IN	5	O
several	several	ADJ	JJ	9	O
ligands	ligand	NOUN	NNS	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
A	a	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
receptor	receptor	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Propylthiouracil	propylthiouracil	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
perinuclear	perinuclear	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
staining	stain	VERB	VBG	3	O
antineutrophil	antineutrophil	NOUN	NN	3	O
cytoplasmic	cytoplasmic	ADJ	JJ	3	O
autoantibody	autoantibody	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
vasculitis	vasculitis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
conjunction	conjunction	NOUN	NN	9	O
with	with	ADP	IN	5	O
pericarditis	pericarditis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
describe	describe	VERB	VB	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
propylthiouracil	propylthiouracil	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
vasculitis	vasculitis	NOUN	NN	5	B-Disease
manifesting	manifest	VERB	VBG	5	O
with	with	ADP	IN	5	O
pericarditis	pericarditis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
present	present	VERB	VBP	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
hyperthyroidism	hyperthyroidism	NOUN	NN	5	B-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
propylthiouracil	propylthiouracil	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
whom	whom	PRON	WP	5	O
a	a	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
of	of	ADP	IN	5	O
pericarditis	pericarditis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
fever	fever	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
glomerulonephritis	glomerulonephritis	NOUN	NN	3	B-Disease
developed	develop	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Serologic	serologic	ADJ	JJ	9	O
testing	testing	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
immunologic	immunologic	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
done	do	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
pericardial	pericardial	ADJ	JJ	5	O
biopsy	biopsy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
25	25	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
Graves	Graves	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
febrile	febrile	ADJ	JJ	5	B-Disease
illness	illness	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
pericarditis	pericarditis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
confirmed	confirm	VERB	VBN	9	O
by	by	ADP	IN	9	O
biopsy	biopsy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Serologic	serologic	ADJ	JJ	9	O
evaluation	evaluation	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
perinuclear	perinuclear	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
staining	stain	VERB	VBG	3	O
antineutrophil	antineutrophil	NOUN	NN	3	O
cytoplasmic	cytoplasmic	ADJ	JJ	3	O
autoantibodies	autoantibody	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
pANCA	pANCA	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
against	against	ADP	IN	9	O
myeloperoxidase	myeloperoxidase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
MPO	MPO	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Propylthiouracil	propylthiouracil	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
withdrawn	withdraw	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
she	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
month	month	NOUN	NN	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
prednisone	prednisone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
alleviated	alleviate	VERB	VBD	9	O
her	-PRON-	DET	PRP$	5	O
symptoms	symptom	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
literature	literature	NOUN	NN	5	O
review	review	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
no	no	DET	DT	9	O
prior	prior	ADJ	JJ	9	O
reports	report	NOUN	NNS	9	O
of	of	ADP	IN	5	O
pericarditis	pericarditis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
MPO	mpo	ADJ	JJ	0	O
pANCA	pANCA	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
vasculitis	vasculitis	NOUN	NN	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
propylthio	propylthio	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
uracil	uracil	NOUN	NN	0	I-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Pericarditis	Pericarditis	PROPN	NNP	7	B-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
manifestation	manifestation	NOUN	NN	5	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
vasculitis	vasculitis	NOUN	NN	5	B-Disease
attributable	attributable	ADJ	JJ	9	O
to	to	ADP	IN	5	O
propylthio	propylthio	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
uracil	uracil	NOUN	NN	0	I-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Repeated	repeat	VERB	VBN	5	O
transient	transient	ADJ	JJ	9	O
anuria	anuria	NOUN	NN	5	B-Disease
following	follow	VERB	VBG	9	O
losartan	losartan	ADJ	JJ	0	B-Chemical
administration	administration	NOUN	NN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
solitary	solitary	ADJ	JJ	5	O
kidney	kidney	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
70	70	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
man	man	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
solitary	solitary	ADJ	JJ	5	O
kidney	kidney	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
chronic	chronic	VERB	VB	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
two	two	NUM	CD	5	O
episodes	episode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
transient	transient	ADJ	JJ	9	O
anuria	anuria	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
losartan	losartan	ADJ	JJ	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
hospitalized	hospitalize	VERB	VBN	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
diuretics	diuretic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
systolic	systolic	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
losartan	losartan	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
prescribed	prescribe	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Surprisingly	surprisingly	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
of	of	ADP	IN	5	O
losartan	losartan	ADJ	JJ	0	B-Chemical
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
sudden	sudden	ADJ	JJ	5	O
anuria	anuria	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
lasted	last	VERB	VBD	5	O
eight	eight	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
despite	despite	ADP	IN	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
furosemide	furosemide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
amine	amine	NOUN	NN	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
week	week	NOUN	NN	9	O
later	later	ADV	RB	9	O
,	,	PUNCT	,	9	O
by	by	ADP	IN	9	O
mistake	mistake	NOUN	NN	5	O
,	,	PUNCT	,	9	O
losartan	losartan	ADJ	JJ	0	B-Chemical
was	be	VERB	VBD	9	O
prescribed	prescribe	VERB	VBN	5	O
again	again	ADV	RB	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
second	second	ADJ	JJ	9	O
episode	episode	NOUN	NN	5	O
of	of	ADP	IN	5	O
transient	transient	ADJ	JJ	9	O
anuria	anuria	NOUN	NN	5	B-Disease
lasting	last	VERB	VBG	5	O
10	10	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
these	these	DET	DT	5	O
two	two	NUM	CD	5	O
episodes	episode	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
his	-PRON-	DET	PRP$	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
diminished	diminish	VERB	VBD	9	O
but	but	CCONJ	CC	9	O
no	no	DET	DT	9	O
severe	severe	ADJ	JJ	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Ultimately	ultimately	ADV	RB	5	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
arteriography	arteriography	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
70	70	NUM	CD	9	O
-	-	SYM	SYM	7	O
80	80	NUM	CD	9	O
%	%	NOUN	NN	9	O
renal	renal	ADJ	JJ	9	B-Disease
artery	artery	NOUN	NN	5	I-Disease
stenosis	stenosis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
renal	renal	ADJ	JJ	9	B-Disease
artery	artery	NOUN	NN	5	I-Disease
stenosis	stenosis	NOUN	NN	5	I-Disease
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
diuretic	diuretic	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
certainly	certainly	ADV	RB	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
strong	strong	ADJ	JJ	9	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
renin	renin	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
system	system	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
RAS	RAS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Under	under	ADP	IN	9	O
such	such	ADJ	JJ	5	O
conditions	condition	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
II	II	PROPN	NNP	9	I-Chemical
receptor	receptor	NOUN	NN	3	O
blockade	blockade	NOUN	NN	3	O
by	by	ADP	IN	9	O
losartan	losartan	ADJ	JJ	0	B-Chemical
probably	probably	ADV	RB	9	O
induced	induce	VERB	VBD	3	O
a	a	DET	DT	5	O
critical	critical	ADJ	JJ	9	O
fall	fall	NOUN	NN	5	O
in	in	ADP	IN	5	O
glomerular	glomerular	ADJ	JJ	5	O
filtration	filtration	NOUN	NN	0	O
pressure	pressure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
highlights	highlight	VERB	VBZ	5	O
the	the	DET	DT	5	O
fact	fact	NOUN	NN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
II	II	PROPN	NNP	9	I-Chemical
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
losartan	losartan	NOUN	NN	0	B-Chemical
can	can	VERB	MD	5	O
cause	cause	VERB	VB	5	O
serious	serious	ADJ	JJ	5	O
unexpected	unexpected	ADJ	JJ	9	O
complications	complication	NOUN	NNS	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
renovascular	renovascular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
with	with	ADP	IN	5	O
extreme	extreme	ADJ	JJ	5	O
caution	caution	NOUN	NN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
setting	setting	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Calcineurin	calcineurin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
inhibitor	inhibitor	NOUN	NN	3	O
induced	induce	VERB	VBD	3	O
pain	pain	NOUN	NN	5	B-Disease
syndrome	syndrome	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CIPS	CIPS	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
severe	severe	ADJ	JJ	5	O
disabling	disable	VERB	VBG	5	O
complication	complication	NOUN	NN	5	O
after	after	ADP	IN	9	O
organ	organ	NOUN	NN	5	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Bone	bone	NOUN	NN	9	O
pain	pain	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
transplantation	transplantation	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
frequent	frequent	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
that	that	DET	WDT	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
several	several	ADJ	JJ	9	O
diseases	disease	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
strategies	strategy	NOUN	NNS	5	O
depend	depend	VERB	VBP	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
correct	correct	ADJ	JJ	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
pain	pain	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Nine	nine	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
feet	foot	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
registered	register	VERB	VBN	5	O
after	after	ADP	IN	9	O
transplantation	transplantation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Bone	bone	NOUN	NN	9	O
scans	scan	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
an	an	DET	DT	5	O
increased	increased	ADJ	JJ	9	O
tracer	tracer	NOUN	NN	0	O
uptake	uptake	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
foot	foot	NOUN	NN	5	O
bones	bone	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Magnetic	magnetic	ADJ	JJ	5	O
resonance	resonance	NOUN	NN	5	O
imaging	imaging	NOUN	NN	5	O
demonstrated	demonstrate	VERB	VBN	9	O
bone	bone	NOUN	NN	5	B-Disease
marrow	marrow	NOUN	NN	3	I-Disease
oedema	oedema	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
painful	painful	ADJ	JJ	5	O
bones	bone	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Pain	Pain	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
explained	explain	VERB	VBN	5	O
by	by	ADP	IN	9	O
other	other	ADJ	JJ	5	O
diseases	disease	NOUN	NNS	5	O
causing	cause	VERB	VBG	9	O
foot	foot	NOUN	NN	5	O
pain	pain	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
like	like	ADP	IN	9	O
reflex	reflex	ADJ	JJ	5	B-Disease
sympathetic	sympathetic	ADJ	JJ	5	I-Disease
dystrophy	dystrophy	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
polyneuropathy	polyneuropathy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
Morton	Morton	PROPN	NNP	6	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	NOUN	NN	9	I-Disease
neuralgia	neuralgia	ADJ	JJ	5	I-Disease
,	,	PUNCT	,	9	O
gout	gout	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
osteoporosis	osteoporosis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
avascular	avascular	ADJ	JJ	5	B-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
intermittent	intermittent	ADJ	JJ	5	B-Disease
claudication	claudication	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
orthopaedic	orthopaedic	ADJ	JJ	5	O
foot	foot	NOUN	NN	5	B-Disease
deformities	deformity	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
stress	stress	NOUN	NN	9	B-Disease
fractures	fracture	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
hyperparathyroidism	hyperparathyroidism	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
or	or	CCONJ	CC	5	O
tacrolimus	tacrolimus	VERB	VB	0	B-Chemical
trough	trough	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blockers	blocker	NOUN	NNS	9	O
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
relief	relief	NOUN	NN	5	O
of	of	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
Calcineurin	Calcineurin	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
inhibitor	inhibitor	NOUN	NN	3	O
Induced	Induced	PROPN	NNP	9	O
Pain	Pain	PROPN	NNP	5	B-Disease
Syndrome	Syndrome	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
CIPS	CIPS	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
severe	severe	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
is	be	VERB	VBZ	5	O
accurately	accurately	ADV	RB	5	O
diagnosed	diagnose	VERB	VBN	5	O
by	by	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
typical	typical	ADJ	JJ	9	O
presentation	presentation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
magnetic	magnetic	ADJ	JJ	0	O
resonance	resonance	NOUN	NN	5	O
imaging	imaging	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
bone	bone	NOUN	NN	5	O
scans	scan	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Incorrect	incorrect	ADJ	JJ	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
will	will	VERB	MD	5	O
lead	lead	VERB	VB	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
life	life	NOUN	NN	5	O
quality	quality	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
suffering	suffer	VERB	VBG	5	O
from	from	ADP	IN	9	O
CIPS	CIPS	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

Brain	brain	NOUN	NN	9	O
natriuretic	natriuretic	ADJ	JJ	9	O
peptide	peptide	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
predictor	predictor	NOUN	NN	5	O
of	of	ADP	IN	5	O
anthracycline	anthracycline	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Anthracyclines	anthracycline	NOUN	NNS	0	B-Chemical
are	be	VERB	VBP	5	O
effective	effective	ADJ	JJ	5	O
antineoplastic	antineoplastic	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
they	-PRON-	PRON	PRP	5	O
frequently	frequently	ADV	RB	5	O
cause	cause	VERB	VBP	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
conventional	conventional	ADJ	JJ	5	O
anthracycline	anthracycline	ADJ	JJ	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
highlights	highlight	VERB	VBZ	5	O
a	a	DET	DT	5	O
need	need	NOUN	NN	5	O
to	to	PART	TO	5	O
search	search	VERB	VB	5	O
for	for	ADP	IN	5	O
methods	method	NOUN	NNS	5	O
that	that	DET	WDT	5	O
are	be	VERB	VBP	5	O
highly	highly	ADV	RB	9	O
sensitive	sensitive	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
capable	capable	ADJ	JJ	9	O
of	of	ADP	IN	5	O
predicting	predict	VERB	VBG	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
measured	measure	VERB	VBD	9	O
the	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
natriuretic	natriuretic	ADJ	JJ	9	O
peptide	peptide	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
BNP	BNP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
BNP	BNP	PROPN	NNP	9	O
might	may	VERB	MD	9	O
serve	serve	VERB	VB	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
simple	simple	ADJ	JJ	5	O
diagnostic	diagnostic	ADJ	JJ	5	O
indicator	indicator	NOUN	NN	9	O
of	of	ADP	IN	5	O
anthracycline	anthracycline	ADV	RB	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
daunorubicin	daunorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DNR	DNR	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
regimen	regimen	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Thirteen	thirteen	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
DNR	dnr	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
regimen	regimen	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cardiac	cardiac	ADJ	JJ	9	O
functions	function	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
with	with	ADP	IN	5	O
radionuclide	radionuclide	NOUN	NN	5	O
angiography	angiography	NOUN	NN	5	O
before	before	ADP	IN	9	O
chemotherapies	chemotherapy	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
atrial	atrial	ADJ	JJ	5	O
natriuretic	natriuretic	ADJ	JJ	9	O
peptide	peptide	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
ANP	ANP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
BNP	BNP	PROPN	NNP	9	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
radionuclide	radionuclide	NOUN	NN	5	O
angiography	angiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
congestive	congestive	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
failure	failure	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
completion	completion	NOUN	NN	5	O
of	of	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
diagnosed	diagnose	VERB	VBN	5	O
as	as	ADP	IN	5	O
having	have	VERB	VBG	5	O
subclinical	subclinical	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
completion	completion	NOUN	NN	5	O
of	of	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
BNP	BNP	PROPN	NNP	9	O
in	in	ADP	IN	5	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
subclinical	subclinical	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
increased	increase	VERB	VBD	9	O
above	above	ADP	IN	9	O
the	the	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
limit	limit	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
40	40	NUM	CD	9	O
pg	pg	NOUN	NN	7	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
detection	detection	NOUN	NN	9	O
of	of	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
subclinical	subclinical	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
by	by	ADP	IN	9	O
radionuclide	radionuclide	NOUN	NN	5	O
angiography	angiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
hand	hand	NOUN	NN	5	O
,	,	PUNCT	,	9	O
BNP	BNP	PROPN	NNP	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
increase	increase	VERB	VB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
without	without	ADP	IN	9	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
given	give	VERB	VBN	5	O
DNR	dnr	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
even	even	ADV	RB	5	O
at	at	ADP	IN	9	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
700	700	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
ANP	ANP	PROPN	NNP	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
always	always	ADV	RB	5	O
increase	increase	VERB	VB	9	O
in	in	ADP	IN	5	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
subclinical	subclinical	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
preliminary	preliminary	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
BNP	BNP	PROPN	NNP	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
useful	useful	ADJ	JJ	5	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
early	early	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
sensitive	sensitive	ADJ	JJ	9	O
indicator	indicator	NOUN	NN	9	O
of	of	ADP	IN	5	O
anthracycline	anthracycline	ADV	RB	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Nephrotoxicity	nephrotoxicity	NOUN	NN	0	B-Disease
of	of	ADP	IN	5	O
combined	combine	VERB	VBN	9	O
cephalothin	cephalothin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
regimen	regimen	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
acute	acute	ADJ	JJ	9	B-Disease
tubular	tubular	ADJ	JJ	9	I-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
characterized	characterize	VERB	VBN	9	O
clinically	clinically	ADV	RB	5	O
by	by	ADP	IN	9	O
acute	acute	ADJ	JJ	9	O
oliguric	oliguric	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
they	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
receiving	receive	VERB	VBG	9	O
a	a	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
cephalothin	cephalothin	NOUN	NN	0	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	I-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
are	be	VERB	VBP	5	O
given	give	VERB	VBN	5	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
regimen	regimen	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
observed	observe	VERB	VBN	9	O
very	very	ADV	RB	5	O
carefully	carefully	ADV	RB	5	O
for	for	ADP	IN	5	O
early	early	ADJ	JJ	9	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
antibiotic	antibiotic	ADJ	JJ	5	O
combination	combination	NOUN	NN	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
avoided	avoid	VERB	VBN	5	O
especially	especially	ADV	RB	5	O
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
should	should	VERB	MD	5	O
not	not	ADV	RB	5	O
be	be	VERB	VB	5	O
given	give	VERB	VBN	5	O
this	this	DET	DT	5	O
regimen	regimen	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
vivo	vivo	NOUN	NNS	3	O
protection	protection	NOUN	NN	9	O
of	of	ADP	IN	5	O
dna	dna	NOUN	NN	1	O
damage	damage	NOUN	NN	9	O
associated	associate	VERB	VBN	9	O
apoptotic	apoptotic	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
necrotic	necrotic	ADJ	JJ	3	B-Disease
cell	cell	NOUN	NN	3	O
deaths	death	NOUN	NNS	5	O
during	during	ADP	IN	5	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
amiodarone	amiodarone	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
lung	lung	NOUN	NN	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
IH636	ih636	NOUN	NN	9	B-Chemical
grape	grape	NOUN	NN	4	I-Chemical
seed	seed	NOUN	NN	4	I-Chemical
proanthocyanidin	proanthocyanidin	NOUN	NN	0	I-Chemical
extract	extract	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Grape	Grape	PROPN	NNP	4	B-Chemical
seed	seed	NOUN	NN	4	I-Chemical
extract	extract	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
primarily	primarily	ADV	RB	9	O
a	a	DET	DT	5	O
mixture	mixture	NOUN	NN	0	O
of	of	ADP	IN	5	O
proanthocyanidins	proanthocyanidin	NOUN	NNS	0	B-Chemical
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
modulate	modulate	VERB	VB	9	O
a	a	DET	DT	5	O
wide	wide	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
range	range	NOUN	NN	9	O
of	of	ADP	IN	5	O
biological	biological	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
pharmacological	pharmacological	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
toxicological	toxicological	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
which	which	DET	WDT	5	O
are	be	VERB	VBP	5	O
mainly	mainly	ADV	RB	9	O
cytoprotective	cytoprotective	ADJ	JJ	3	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
assessed	assess	VERB	VBD	9	O
the	the	DET	DT	5	O
ability	ability	NOUN	NN	9	O
of	of	ADP	IN	5	O
IH636	ih636	NOUN	NN	9	B-Chemical
grape	grape	NOUN	NN	4	I-Chemical
seed	seed	NOUN	NN	4	I-Chemical
proanthocyanidin	proanthocyanidin	NOUN	NN	0	I-Chemical
extract	extract	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
GSPE	GSPE	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
AAP	AAP	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
AMI	AMI	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
lung	lung	NOUN	NN	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Experimental	experimental	ADJ	JJ	9	O
design	design	NOUN	NN	5	O
consisted	consist	VERB	VBD	5	O
of	of	ADP	IN	5	O
four	four	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
control	control	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
vehicle	vehicle	NOUN	NN	3	O
alone	alone	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
GSPE	gspe	VERB	VB	0	B-Chemical
alone	alone	ADV	RB	9	O
,	,	PUNCT	,	9	O
drug	drug	NOUN	NN	5	O
alone	alone	ADV	RB	9	O
and	and	CCONJ	CC	5	O
GSPE	GSPE	PROPN	NNP	0	B-Chemical
+	+	SYM	SYM	9	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
the	the	DET	DT	5	O
cytoprotection	cytoprotection	NOUN	NN	3	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
orally	orally	ADV	RB	0	O
gavaged	gavage	VERB	VBN	0	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	PUNCT	.	9	O
Kg	Kg	PROPN	NNP	0	O
GSPE	GSPE	PROPN	NNP	0	B-Chemical
for	for	ADP	IN	5	O
7	7	NUM	CD	9	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
days	day	NOUN	NNS	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
organ	organ	NOUN	NN	5	O
specific	specific	ADJ	JJ	9	O
three	three	NUM	CD	9	O
drugs	drug	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
AAP	AAP	PROPN	NNP	9	B-Chemical
:	:	PUNCT	:	9	O
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	PUNCT	.	9	O
Kg	Kg	PROPN	NNP	0	O
for	for	ADP	IN	5	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
;	;	PUNCT	:	9	O
AMI	AMI	PROPN	NNP	9	B-Chemical
:	:	PUNCT	:	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
Kg	Kg	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
four	four	NUM	CD	9	O
days	day	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
:	:	PUNCT	:	9	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	PUNCT	NFP	9	O
Kg	Kg	PROPN	NNP	0	O
for	for	ADP	IN	5	O
48	48	NUM	CD	9	O
h	h	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Parameters	parameter	NOUN	NNS	9	O
of	of	ADP	IN	5	O
study	study	NOUN	NN	9	O
included	include	VERB	VBD	5	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
chemistry	chemistry	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
ALT	ALT	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
BUN	BUN	PROPN	NNP	0	O
and	and	CCONJ	CC	5	O
CPK	CPK	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
orderly	orderly	ADJ	JJ	5	O
fragmentation	fragmentation	NOUN	NN	9	O
of	of	ADP	IN	5	O
genomic	genomic	ADJ	JJ	9	O
DNA	dna	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
both	both	CCONJ	CC	9	O
endonuclease	endonuclease	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
independent	independent	ADJ	JJ	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
microscopic	microscopic	ADJ	JJ	9	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
damage	damage	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
protection	protection	NOUN	NN	9	O
in	in	ADP	IN	5	O
corresponding	correspond	VERB	VBG	9	O
PAS	PAS	PROPN	NNP	9	O
stained	stain	VERB	VBN	3	O
tissues	tissue	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
GSPE	GSPE	VERB	VBN	0	B-Chemical
preexposure	preexposure	NOUN	NN	5	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
AAP	AAP	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
AMI	AMI	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
provided	provide	VERB	VBN	9	O
near	near	ADP	IN	9	O
complete	complete	ADJ	JJ	9	O
protection	protection	NOUN	NN	9	O
in	in	ADP	IN	5	O
terms	term	NOUN	NNS	5	O
of	of	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
chemistry	chemistry	NOUN	NN	0	O
changes	change	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
ALT	ALT	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
BUN	BUN	PROPN	NNP	0	O
and	and	CCONJ	CC	5	O
CPK	CPK	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
DNA	dna	NOUN	NN	9	O
fragmentation	fragmentation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Histopathological	histopathological	ADJ	JJ	9	O
examination	examination	NOUN	NN	5	O
of	of	ADP	IN	5	O
kidney	kidney	NOUN	NN	9	O
,	,	PUNCT	,	9	O
heart	heart	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
lung	lung	NOUN	NN	9	O
sections	section	NOUN	NNS	9	O
revealed	reveal	VERB	VBN	9	O
moderate	moderate	ADJ	JJ	9	O
to	to	PART	TO	5	O
massive	massive	ADJ	JJ	9	O
tissue	tissue	NOUN	NN	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
variety	variety	NOUN	NN	5	O
of	of	ADP	IN	5	O
morphological	morphological	ADJ	JJ	9	O
aberrations	aberration	NOUN	NNS	5	O
by	by	ADP	IN	9	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
three	three	NUM	CD	9	O
drugs	drug	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
GSPE	GSPE	PROPN	NNP	0	B-Chemical
preexposure	preexposure	NOUN	NN	5	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
presence	presence	NOUN	NN	9	O
.	.	PUNCT	.	9	O

GSPE	GSPE	PROPN	NNP	0	B-Chemical
+	+	SYM	SYM	9	O
drug	drug	NOUN	NN	5	O
exposed	expose	VERB	VBN	9	O
tissues	tissue	NOUN	NNS	9	O
exhibited	exhibit	VERB	VBD	9	O
minor	minor	ADJ	JJ	9	O
residual	residual	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
near	near	ADP	IN	9	O
total	total	ADJ	JJ	9	O
recovery	recovery	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Additionally	additionally	ADV	RB	9	O
,	,	PUNCT	,	9	O
histopathological	histopathological	ADJ	JJ	9	O
alterations	alteration	NOUN	NNS	9	O
mirrored	mirror	VERB	VBD	9	O
both	both	DET	DT	9	O
serum	serum	ADJ	JJ	9	O
chemistry	chemistry	NOUN	NN	0	O
changes	change	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
pattern	pattern	NOUN	NN	9	O
of	of	ADP	IN	5	O
DNA	dna	NOUN	NN	9	O
fragmentation	fragmentation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Interestingly	interestingly	ADV	RB	9	O
,	,	PUNCT	,	9	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
,	,	PUNCT	,	9	O
AAP	AAP	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
AMI	AMI	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
induced	induce	VERB	VBD	3	O
apoptotic	apoptotic	ADJ	JJ	3	O
death	death	NOUN	NN	9	O
in	in	ADP	IN	5	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
necrosis	necrosis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
respective	respective	ADJ	JJ	9	O
organs	organ	NOUN	NNS	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
very	very	ADV	RB	5	O
effectively	effectively	ADV	RB	5	O
blocked	block	VERB	VBN	3	O
by	by	ADP	IN	9	O
GSPE	GSPE	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
AAP	AAP	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
AMI	AMI	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
undergo	undergo	VERB	VBP	9	O
biotransformation	biotransformation	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
are	be	VERB	VBP	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
produce	produce	VERB	VB	9	O
damaging	damage	VERB	VBG	9	O
radicals	radical	NOUN	NNS	0	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
protection	protection	NOUN	NN	9	O
by	by	ADP	IN	9	O
GSPE	GSPE	PROPN	NNP	0	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
linked	link	VERB	VBN	9	O
to	to	ADP	IN	5	O
both	both	DET	DT	9	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
metabolism	metabolism	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
detoxification	detoxification	NOUN	NN	9	O
of	of	ADP	IN	5	O
cytotoxic	cytotoxic	NOUN	NN	3	O
radicals	radical	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
its	-PRON-	DET	PRP$	9	O
'	'	PUNCT	``	9	O
presumed	presume	VERB	VBN	9	O
contribution	contribution	NOUN	NN	9	O
to	to	ADP	IN	5	O
DNA	dna	NOUN	NN	9	O
repair	repair	NOUN	NN	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
another	another	DET	DT	9	O
important	important	ADJ	JJ	9	O
attribute	attribute	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
played	play	VERB	VBD	9	O
a	a	DET	DT	5	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
chemoprevention	chemoprevention	NOUN	NN	5	O
process	process	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Additionally	additionally	ADV	RB	9	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
been	be	VERB	VBN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
report	report	NOUN	NN	5	O
on	on	ADP	IN	5	O
AMI	AMI	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
apoptotic	apoptotic	ADJ	JJ	3	O
death	death	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
lung	lung	NOUN	NN	9	O
tissue	tissue	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Taken	take	VERB	VBN	9	O
together	together	ADV	RB	9	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
events	event	NOUN	NNS	5	O
undoubtedly	undoubtedly	ADV	RB	5	O
establish	establish	VERB	VBP	5	O
GSPE	GSPE	PROPN	NNP	0	B-Chemical
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
abundant	abundant	ADJ	JJ	9	O
bioavailability	bioavailability	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
power	power	NOUN	NN	5	O
to	to	PART	TO	5	O
defend	defend	VERB	VB	5	O
multiple	multiple	ADJ	JJ	5	O
target	target	NOUN	NN	9	O
organs	organ	NOUN	NNS	9	O
from	from	ADP	IN	9	O
toxic	toxic	ADJ	JJ	0	O
assaults	assault	NOUN	NNS	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
structurally	structurally	ADV	RB	9	O
diverse	diverse	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
functionally	functionally	ADV	RB	9	O
different	different	ADJ	JJ	9	O
entities	entity	NOUN	NNS	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Antidepressant	antidepressant	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
mania	mania	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
identification	identification	NOUN	NN	9	O
of	of	ADP	IN	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Concerns	concern	NOUN	NNS	5	O
about	about	ADP	IN	5	O
possible	possible	ADJ	JJ	5	O
risks	risk	NOUN	NNS	5	O
of	of	ADP	IN	5	O
switching	switching	NOUN	NN	5	O
to	to	ADP	IN	5	O
mania	mania	NOUN	NN	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
antidepressants	antidepressant	NOUN	NNS	5	B-Chemical
continue	continue	VERB	VBP	5	O
to	to	PART	TO	5	O
interfere	interfere	VERB	VB	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
establishment	establishment	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
optimal	optimal	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
paradigm	paradigm	NOUN	NN	5	O
for	for	ADP	IN	5	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
depression	depression	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
response	response	NOUN	NN	9	O
of	of	ADP	IN	5	O
44	44	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
meeting	meet	VERB	VBG	5	O
DSM	DSM	PROPN	NNP	4	O
-	-	PUNCT	HYPH	7	O
IV	IV	PROPN	NNP	9	O
criteria	criterion	NOUN	NNS	5	O
for	for	ADP	IN	5	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
to	to	ADP	IN	5	O
naturalistic	naturalistic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
for	for	ADP	IN	5	O
at	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
6	6	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
Montgomery	Montgomery	PROPN	NNP	6	O
-	-	PUNCT	HYPH	7	O
Asberg	Asberg	PROPN	NNP	6	O
Depression	Depression	PROPN	NNP	5	O
Rating	Rating	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
Bech	Bech	PROPN	NNP	6	O
-	-	PUNCT	HYPH	7	O
Rafaelson	Rafaelson	PROPN	NNP	2	O
Mania	Mania	PROPN	NNP	5	O
Rating	Rating	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
experienced	experience	VERB	VBD	5	O
a	a	DET	DT	5	O
manic	manic	ADJ	JJ	5	B-Disease
or	or	CCONJ	CC	5	O
hypomanic	hypomanic	ADJ	JJ	5	B-Disease
switch	switch	NOUN	NN	9	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
who	who	PRON	WP	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
on	on	ADP	IN	5	O
several	several	ADJ	JJ	9	O
variables	variable	NOUN	NNS	5	O
including	include	VERB	VBG	9	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
sex	sex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
diagnosis	diagnosis	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
DSM	DSM	PROPN	NNP	4	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
IV	IV	PROPN	NNP	9	I-Disease
bipolar	bipolar	NOUN	NN	5	I-Disease
I	-PRON-	PRON	PRP	9	I-Disease
vs	vs	VERB	VBP	7	O
.	.	PUNCT	.	9	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
II	II	PROPN	NNP	9	I-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
previous	previous	ADJ	JJ	9	O
manic	manic	ADJ	JJ	5	B-Disease
episodes	episode	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
antidepressant	antidepressant	ADJ	JJ	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
used	use	VERB	VBN	5	O
(	(	PUNCT	-LRB-	9	O
electroconvulsive	electroconvulsive	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
vs	vs	ADP	IN	7	O
.	.	PUNCT	.	9	O
antidepressant	antidepressant	ADJ	JJ	5	B-Chemical
drugs	drug	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
more	more	ADV	RBR	5	O
particularly	particularly	ADV	RB	5	O
,	,	PUNCT	,	9	O
selective	selective	ADJ	JJ	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
reuptake	reuptake	NOUN	NN	0	I-Chemical
inhibitors	inhibitor	NOUN	NNS	3	I-Chemical
[	[	PUNCT	-LRB-	9	O
SSRIs	ssri	NOUN	NNS	5	B-Chemical
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
use	use	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
mood	mood	NOUN	NN	5	O
stabilizers	stabilizer	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
vs	vs	ADP	IN	7	O
.	.	PUNCT	.	9	O
anticonvulsants	anticonvulsant	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
temperament	temperament	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
assessed	assess	VERB	VBN	9	O
during	during	ADP	IN	5	O
a	a	DET	DT	5	O
normothymic	normothymic	ADJ	JJ	9	O
period	period	NOUN	NN	5	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
hyperthymia	hyperthymia	NOUN	NN	5	O
component	component	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Semi	Semi	PROPN	NNP	5	O
-	-	ADJ	JJ	7	O
structured	structured	ADJ	JJ	5	O
Affective	Affective	PROPN	NNP	5	O
Temperament	Temperament	PROPN	NNP	5	O
Interview	Interview	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Switches	switch	NOUN	NNS	5	O
to	to	ADP	IN	5	O
hypomania	hypomania	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
mania	mania	NOUN	NN	5	B-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
27	27	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
N	n	NOUN	NN	9	O
=	=	SYM	SYM	7	O
12	12	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
24	24	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
subgroup	subgroup	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
SSRIs	ssri	NOUN	NNS	5	B-Chemical
[	[	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
/	/	SYM	SYM	9	O
33	33	NUM	CD	7	O
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
16	16	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
N	n	NOUN	NN	9	O
=	=	SYM	SYM	7	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
experienced	experience	VERB	VBD	5	O
manic	manic	ADJ	JJ	5	B-Disease
episodes	episode	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
11	11	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
N	n	NOUN	NN	9	O
=	=	SYM	SYM	7	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
experienced	experience	VERB	VBD	5	O
hypomanic	hypomanic	ADJ	JJ	5	B-Disease
episodes	episode	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Sex	sex	NOUN	NN	7	O
,	,	PUNCT	,	9	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
diagnosis	diagnosis	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
bipolar	bipolar	ADV	RB	5	B-Disease
I	-PRON-	PRON	PRP	9	I-Disease
vs	vs	VERB	VBP	7	O
.	.	PUNCT	.	9	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
II	II	PROPN	NNP	9	I-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
additional	additional	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
affect	affect	VERB	VB	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
switching	switching	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
mood	mood	NOUN	NN	5	O
switches	switch	NOUN	NNS	5	O
seemed	seem	VERB	VBD	9	O
not	not	ADV	RB	5	O
to	to	PART	TO	5	O
differ	differ	VERB	VB	9	O
between	between	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
an	an	DET	DT	5	O
anticonvulsant	anticonvulsant	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
those	those	DET	DT	5	O
receiving	receive	VERB	VBG	9	O
no	no	DET	DT	9	O
mood	mood	NOUN	NN	5	O
stabilizer	stabilizer	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
mood	mood	NOUN	NN	5	O
switches	switch	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
less	less	ADV	RBR	5	O
frequent	frequent	ADJ	JJ	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
/	/	SYM	SYM	9	O
26	26	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
not	not	ADV	RB	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
44	44	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
/	/	SYM	SYM	9	O
18	18	NUM	CD	7	O
;	;	PUNCT	:	9	O
p	p	PUNCT	LS	7	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
04	04	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
previous	previous	ADJ	JJ	9	O
manic	manic	ADJ	JJ	5	B-Disease
episodes	episode	NOUN	NNS	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
affect	affect	VERB	VB	9	O
the	the	DET	DT	5	O
probability	probability	NOUN	NN	5	O
of	of	ADP	IN	5	O
switching	switching	NOUN	NN	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
score	score	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
hyperthymia	hyperthymia	NOUN	NN	5	O
component	component	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Semistructured	Semistructured	PROPN	NNP	5	O
Affective	Affective	PROPN	NNP	5	O
Temperament	Temperament	PROPN	NNP	5	O
Interview	Interview	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
greater	great	ADJ	JJR	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
switching	switching	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
008	008	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
mood	mood	NOUN	NN	5	O
switching	switch	VERB	VBG	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
antidepressant	antidepressant	NOUN	NN	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Particular	particular	ADJ	JJ	5	O
attention	attention	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
paid	pay	VERB	VBN	5	O
to	to	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
hyperthymic	hyperthymic	ADJ	JJ	5	O
temperament	temperament	NOUN	NN	5	O
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
have	have	VERB	VBP	5	O
a	a	DET	DT	5	O
greater	great	ADJ	JJR	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
mood	mood	NOUN	NN	5	O
switches	switch	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Peritubular	peritubular	ADJ	JJ	0	O
capillary	capillary	ADJ	JJ	0	O
basement	basement	NOUN	NN	3	O
membrane	membrane	NOUN	NN	9	O
reduplication	reduplication	NOUN	NN	5	O
in	in	ADP	IN	5	O
allografts	allograft	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
native	native	ADJ	JJ	9	O
kidney	kidney	NOUN	NN	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
clinicopathologic	clinicopathologic	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
278	278	NUM	CD	7	O
consecutive	consecutive	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	O
specimens	specimen	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
An	an	DET	DT	5	O
association	association	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
found	find	VERB	VBN	9	O
between	between	ADP	IN	5	O
transplant	transplant	NOUN	NN	9	B-Disease
glomerulopathy	glomerulopathy	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
TG	TG	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
reduplication	reduplication	NOUN	NN	5	O
of	of	ADP	IN	5	O
peritubular	peritubular	ADJ	JJ	3	O
capillary	capillary	ADJ	JJ	0	O
basement	basement	NOUN	NN	3	O
membranes	membrane	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
PTCR	ptcr	NOUN	NN	1	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
such	such	DET	PDT	5	O
an	an	DET	DT	5	O
association	association	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
of	of	ADP	IN	5	O
practical	practical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
theoretical	theoretical	ADJ	JJ	5	O
importance	importance	NOUN	NN	5	O
,	,	PUNCT	,	9	O
only	only	ADV	RB	9	O
one	one	NUM	CD	5	O
prospective	prospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
tried	try	VERB	VBN	5	O
to	to	PART	TO	5	O
confirm	confirm	VERB	VB	9	O
it	-PRON-	PRON	PRP	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
examined	examine	VERB	VBD	9	O
278	278	NUM	CD	7	O
consecutive	consecutive	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	O
specimens	specimen	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
from	from	ADP	IN	9	O
135	135	NUM	CD	7	O
transplants	transplant	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
143	143	NUM	CD	7	O
native	native	ADJ	JJ	9	O
kidneys	kidney	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
ultrastructural	ultrastructural	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
PTCR	PTCR	PROPN	NNP	1	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
allografts	allograft	NOUN	NNS	5	O
with	with	ADP	IN	5	O
TG	TG	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
also	also	ADV	RB	9	O
examined	examine	VERB	VBD	9	O
grafts	graft	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
rejection	rejection	NOUN	NN	5	O
,	,	PUNCT	,	9	O
recurrent	recurrent	NOUN	NN	5	O
glomerulonephritis	glomerulonephritis	ADJ	JJ	3	B-Disease
,	,	PUNCT	,	9	O
chronic	chronic	ADJ	JJ	5	B-Disease
allograft	allograft	NOUN	NN	5	I-Disease
nephropathy	nephropathy	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
stable	stable	ADJ	JJ	9	O
grafts	graft	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
"	"	PUNCT	``	5	O
protocol	protocol	NOUN	NN	9	O
biopsies	biopsy	NOUN	NNS	9	O
"	"	PUNCT	''	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Native	native	ADJ	JJ	9	O
kidney	kidney	NOUN	NN	9	O
specimens	specimen	NOUN	NNS	9	O
included	include	VERB	VBD	5	O
a	a	DET	DT	5	O
wide	wide	ADJ	JJ	5	O
range	range	NOUN	NN	9	O
of	of	ADP	IN	5	O
glomerulopathies	glomerulopathie	NOUN	NNS	5	B-Disease
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
microangiopathy	microangiopathy	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
malignant	malignant	ADJ	JJ	3	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
acute	acute	ADJ	JJ	9	O
interstitial	interstitial	ADJ	JJ	9	B-Disease
nephritis	nephritis	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
acute	acute	ADJ	JJ	9	B-Disease
tubular	tubular	ADJ	JJ	9	I-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
found	find	VERB	VBD	9	O
PTCR	PTCR	PROPN	NNP	1	O
in	in	ADP	IN	5	O
14	14	NUM	CD	7	O
of	of	ADP	IN	5	O
15	15	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
TG	TG	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
7	7	NUM	CD	9	O
transplant	transplant	NOUN	NN	9	O
biopsy	biopsy	NOUN	NN	5	O
specimens	specimen	NOUN	NNS	9	O
without	without	ADP	IN	9	O
TG	TG	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
13	13	NUM	CD	7	O
of	of	ADP	IN	5	O
143	143	NUM	CD	7	O
native	native	ADJ	JJ	9	O
kidney	kidney	NOUN	NN	9	O
biopsy	biopsy	NOUN	NN	5	O
specimens	specimen	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
13	13	NUM	CD	7	O
included	include	VERB	VBD	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
malignant	malignant	ADJ	JJ	3	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
microangiopathy	microangiopathy	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
lupus	lupus	NOUN	NN	9	B-Disease
nephritis	nephritis	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
Henoch	Henoch	PROPN	NNP	2	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
Schonlein	Schonlein	PROPN	NNP	2	I-Disease
nephritis	nephritis	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
crescentic	crescentic	ADJ	JJ	5	O
glomerulonephritis	glomerulonephritis	NOUN	NN	3	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Mild	Mild	PROPN	NNP	9	O
PTCR	PTCR	PROPN	NNP	1	O
in	in	ADP	IN	5	O
allografts	allograft	NOUN	NNS	5	O
without	without	ADP	IN	9	O
TG	TG	PROPN	NNP	9	B-Disease
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
predict	predict	VERB	VB	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
significant	significant	ADJ	JJ	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
after	after	ADP	IN	9	O
follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
periods	period	NOUN	NNS	5	O
of	of	ADP	IN	5	O
between	between	ADP	IN	5	O
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
in	in	ADP	IN	5	O
transplants	transplant	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
strong	strong	ADJ	JJ	9	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
developed	develop	VERB	VBN	5	O
PTCR	ptcr	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
TG	TG	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
the	the	DET	DT	5	O
significance	significance	NOUN	NN	9	O
of	of	ADP	IN	5	O
mild	mild	ADJ	JJ	9	O
PTCR	ptcr	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
predictive	predictive	ADJ	JJ	5	O
value	value	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
TG	TG	PROPN	NNP	9	B-Disease
is	be	VERB	VBZ	5	O
unclear	unclear	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

PTCR	ptcr	NOUN	NN	1	O
also	also	ADV	RB	9	O
occurs	occur	VERB	VBZ	9	O
in	in	ADP	IN	5	O
certain	certain	ADJ	JJ	5	O
native	native	ADJ	JJ	9	O
kidney	kidney	NOUN	NN	9	B-Disease
diseases	disease	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
though	though	ADP	IN	9	O
the	the	DET	DT	5	O
association	association	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
as	as	ADV	RB	5	O
strong	strong	ADJ	JJ	9	O
as	as	ADP	IN	5	O
that	that	DET	DT	5	O
for	for	ADP	IN	5	O
TG	TG	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
repeated	repeat	VERB	VBN	5	O
endothelial	endothelial	ADJ	JJ	3	B-Disease
injury	injury	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
immunologic	immunologic	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
lesion	lesion	NOUN	NN	5	O
both	both	CCONJ	CC	9	O
in	in	ADP	IN	5	O
allografts	allograft	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
native	native	ADJ	JJ	9	O
kidneys	kidney	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Caffeine	caffeine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrhythmia	arrhythmia	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
an	an	DET	DT	5	O
unrecognised	unrecognised	ADJ	JJ	5	O
danger	danger	NOUN	NN	5	O
of	of	ADP	IN	5	O
healthfood	healthfood	NOUN	NN	_	O
products	product	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
a	a	DET	DT	5	O
25	25	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
existing	exist	VERB	VBG	5	O
mitral	mitral	ADJ	JJ	5	B-Disease
valve	valve	NOUN	NN	5	I-Disease
prolapse	prolapse	NOUN	NN	5	I-Disease
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
intractable	intractable	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
consuming	consume	VERB	VBG	5	O
a	a	DET	DT	5	O
"	"	PUNCT	``	5	O
natural	natural	ADJ	JJ	5	O
energy	energy	NOUN	NN	5	O
"	"	PUNCT	''	5	O
guarana	guarana	NOUN	NN	0	O
health	health	NOUN	NN	5	O
drink	drink	NOUN	NN	5	O
containing	contain	VERB	VBG	0	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
highlights	highlight	VERB	VBZ	5	O
the	the	DET	DT	5	O
need	need	NOUN	NN	5	O
for	for	ADP	IN	5	O
adequate	adequate	ADJ	JJ	5	O
labelling	labelling	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
such	such	ADJ	JJ	5	O
products	product	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Conformationally	conformationally	ADV	RB	0	O
restricted	restrict	VERB	VBD	9	O
analogs	analog	NOUN	NNS	0	O
of	of	ADP	IN	5	O
BD1008	BD1008	PROPN	NNP	_	B-Chemical
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
antisense	antisense	ADJ	JJ	3	O
oligodeoxynucleotide	oligodeoxynucleotide	NOUN	NN	3	B-Chemical
targeting	target	VERB	VBG	3	O
sigma1	sigma1	NOUN	NN	3	O
receptors	receptor	NOUN	NNS	3	O
produce	produce	VERB	VBP	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
cocaine	cocaine	ADJ	JJ	5	B-Chemical
effects	effect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Cocaine	cocaine	NOUN	NN	5	B-Chemical
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
ability	ability	NOUN	NN	9	O
to	to	PART	TO	5	O
interact	interact	VERB	VB	9	O
with	with	ADP	IN	5	O
sigma	sigma	NOUN	NN	9	O
receptors	receptor	NOUN	NNS	3	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
these	these	DET	DT	5	O
proteins	protein	NOUN	NNS	1	O
mediate	mediate	VERB	VBP	3	O
some	some	DET	DT	5	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
behavioral	behavioral	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
three	three	NUM	CD	9	O
novel	novel	ADJ	JJ	9	O
sigma	sigma	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
ligands	ligand	NOUN	NNS	3	O
with	with	ADP	IN	5	O
antagonist	antagonist	NOUN	NN	3	O
activity	activity	NOUN	NN	9	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
in	in	ADP	IN	5	O
Swiss	Swiss	PROPN	NNP	2	O
Webster	Webster	PROPN	NNP	6	O
mice	mouse	NOUN	NNS	3	O
:	:	PUNCT	:	9	O
BD1018	BD1018	PROPN	NNP	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
3S	3S	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dichlorophenyl	dichlorophenyl	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
ethyl	ethyl	ADV	RB	0	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
diazabicyclo	diazabicyclo	NOUN	NN	0	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
.	.	PUNCT	.	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
.	.	PUNCT	.	9	I-Chemical
0	0	PUNCT	NFP	7	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
nonane	nonane	ADV	RB	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
BD1063	BD1063	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dichlorophenyl	dichlorophenyl	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
ethyl	ethyl	ADV	RB	0	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methylpiperazine	methylpiperazine	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
LR132	LR132	PROPN	NNP	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
1R	1r	NOUN	NN	9	O
,	,	PUNCT	,	9	O
2S	2s	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
cis	cis	X	XX	9	O
-	-	PUNCT	HYPH	7	O
N	n	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
[	[	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
dichlorophenyl	dichlorophenyl	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
ethyl	ethyl	ADV	RB	0	O
]	]	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
pyrrolidinyl	pyrrolidinyl	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
cyclohexylamine	cyclohexylamine	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Competition	competition	NOUN	NN	9	O
binding	binding	NOUN	NN	1	O
assays	assay	NOUN	NNS	3	O
demonstrated	demonstrate	VERB	VBD	9	O
that	that	ADP	IN	5	O
all	all	DET	DT	5	O
three	three	NUM	CD	9	O
compounds	compound	NOUN	NNS	0	O
have	have	VERB	VBP	5	O
high	high	ADJ	JJ	9	O
affinities	affinity	NOUN	NNS	9	O
for	for	ADP	IN	5	O
sigma1	sigma1	NOUN	NN	3	O
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
three	three	NUM	CD	9	O
compounds	compound	NOUN	NNS	0	O
vary	vary	VERB	VBP	5	O
in	in	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
affinities	affinity	NOUN	NNS	9	O
for	for	ADP	IN	5	O
sigma2	sigma2	ADJ	JJ	9	O
receptors	receptor	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
exhibit	exhibit	VERB	VB	9	O
negligible	negligible	ADJ	JJ	9	O
affinities	affinity	NOUN	NNS	9	O
for	for	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
opioid	opioid	NOUN	NN	5	O
,	,	PUNCT	,	9	O
GABA	GABA	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
A	A	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
behavioral	behavioral	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
BD1018	BD1018	PROPN	NNP	_	B-Chemical
,	,	PUNCT	,	9	O
BD1063	bd1063	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
LR132	lr132	NOUN	NN	_	B-Chemical
significantly	significantly	ADV	RB	9	O
attenuated	attenuate	VERB	VBD	3	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
lethality	lethality	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
LR132	lr132	NOUN	NN	_	B-Chemical
prevented	prevent	VERB	VBN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
lethality	lethality	NOUN	NN	3	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
proportion	proportion	NOUN	NN	9	O
of	of	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
protection	protection	NOUN	NN	9	O
provided	provide	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
putative	putative	ADJ	JJ	1	O
antagonists	antagonist	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
characterized	characterize	VERB	VBN	9	O
sigma	sigma	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
di	di	ADJ	JJ	2	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
o	o	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tolylguanidine	tolylguanidine	NOUN	NN	_	I-Chemical
(	(	PUNCT	-LRB-	9	O
DTG	DTG	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
sigma	sigma	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
BD1031	bd1031	NOUN	NN	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
3R	3R	PROPN	NNP	1	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dichlorophenyl	dichlorophenyl	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
ethyl	ethyl	ADV	RB	0	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
diazabicyclo	diazabicyclo	NOUN	NN	0	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
.	.	PUNCT	.	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
.	.	PUNCT	.	9	I-Chemical
0	0	PUNCT	NFP	7	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
nonane	nonane	ADV	RB	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
each	each	DET	DT	5	O
worsened	worsen	VERB	VBD	5	O
the	the	DET	DT	5	O
behavioral	behavioral	ADJ	JJ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
where	where	ADV	WRB	5	O
alone	alone	ADV	RB	9	O
,	,	PUNCT	,	9	O
they	-PRON-	PRON	PRP	5	O
produced	produce	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
locomotion	locomotion	NOUN	NN	5	O
,	,	PUNCT	,	9	O
BD1018	BD1018	PROPN	NNP	_	B-Chemical
,	,	PUNCT	,	9	O
BD1063	bd1063	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
LR132	LR132	PROPN	NNP	_	B-Chemical
significantly	significantly	ADV	RB	9	O
attenuated	attenuate	VERB	VBD	3	O
the	the	DET	DT	5	O
locomotor	locomotor	NOUN	NN	5	O
stimulatory	stimulatory	ADJ	JJ	3	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
further	further	ADV	RB	9	O
validate	validate	VERB	VB	9	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	DET	WDT	5	O
the	the	DET	DT	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
cocaine	cocaine	ADJ	JJ	5	B-Chemical
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
ligands	ligand	NOUN	NNS	3	O
involved	involve	VERB	VBN	9	O
antagonism	antagonism	NOUN	NN	9	O
of	of	ADP	IN	5	O
sigma	sigma	NOUN	NN	9	O
receptors	receptor	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
antisense	antisense	NOUN	NN	3	O
oligodeoxynucleotide	oligodeoxynucleotide	ADV	RB	3	B-Chemical
against	against	ADP	IN	9	O
sigma1	sigma1	NOUN	NN	3	O
receptors	receptor	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
significantly	significantly	ADV	RB	9	O
attenuate	attenuate	VERB	VB	9	O
the	the	DET	DT	5	O
convulsive	convulsive	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	O
locomotor	locomotor	NOUN	NN	5	O
stimulatory	stimulatory	ADJ	JJ	3	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Together	together	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
data	data	NOUN	NN	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
functional	functional	ADJ	JJ	9	O
antagonism	antagonism	NOUN	NN	9	O
of	of	ADP	IN	5	O
sigma	sigma	NOUN	NN	9	O
receptors	receptor	NOUN	NNS	3	O
is	be	VERB	VBZ	5	O
capable	capable	ADJ	JJ	9	O
of	of	ADP	IN	5	O
attenuating	attenuate	VERB	VBG	9	O
a	a	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
behaviors	behavior	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Ranitidine	Ranitidine	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	O
interstitial	interstitial	ADJ	JJ	9	B-Disease
nephritis	nephritis	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
cadaveric	cadaveric	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	O
allograft	allograft	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Ranitidine	Ranitidine	PROPN	NNP	0	B-Chemical
frequently	frequently	ADV	RB	5	O
is	be	VERB	VBZ	5	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
preventing	prevent	VERB	VBG	9	O
peptic	peptic	ADJ	JJ	5	O
ulceration	ulceration	NOUN	NN	5	O
after	after	ADP	IN	9	O
renal	renal	ADJ	JJ	9	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
occasionally	occasionally	ADV	RB	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
interstitial	interstitial	ADJ	JJ	9	B-Disease
nephritis	nephritis	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
native	native	ADJ	JJ	9	O
kidneys	kidney	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
are	be	VERB	VBP	5	O
no	no	DET	DT	9	O
similar	similar	ADJ	JJ	9	O
reports	report	NOUN	NNS	9	O
with	with	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
ranitidine	ranitidine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	O
interstitial	interstitial	ADJ	JJ	9	B-Disease
nephritis	nephritis	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
recipient	recipient	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
cadaveric	cadaveric	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	O
allograft	allograft	NOUN	NN	5	O
presenting	present	VERB	VBG	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
allograft	allograft	NOUN	NN	5	O
dysfunction	dysfunction	NOUN	NN	9	O
within	within	ADP	IN	9	O
48	48	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
of	of	ADP	IN	5	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
biopsy	biopsy	NOUN	NN	5	O
specimen	speciman	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
pathognomonic	pathognomonic	ADJ	JJ	5	O
features	feature	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
eosinophilic	eosinophilic	ADJ	JJ	5	O
infiltration	infiltration	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
interstitial	interstitial	ADJ	JJ	9	O
compartment	compartment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Allograft	allograft	NOUN	NN	7	O
function	function	NOUN	NN	9	O
improved	improve	VERB	VBN	5	O
rapidly	rapidly	ADV	RB	9	O
and	and	CCONJ	CC	5	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
after	after	ADP	IN	9	O
stopping	stop	VERB	VBG	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Liver	liver	NOUN	NN	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
propylthiouracil	propylthiouracil	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
report	report	NOUN	NN	5	O
presents	present	VERB	VBZ	5	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
laboratory	laboratory	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
light	light	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
electron	electron	VERB	VB	0	O
microscopic	microscopic	ADJ	JJ	9	O
observations	observation	NOUN	NNS	9	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
active	active	ADJ	JJ	9	I-Disease
(	(	PUNCT	-LRB-	9	I-Disease
aggressive	aggressive	ADJ	JJ	5	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
propylthiouracil	propylthiouracil	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
list	list	NOUN	NN	5	O
of	of	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
that	that	DET	WDT	5	O
must	must	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
liver	liver	NOUN	NN	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Withdrawal	withdrawal	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
emergent	emergent	NOUN	NN	5	I-Disease
rabbit	rabbit	NOUN	NN	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
dose	dose	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Rabbit	rabbit	NOUN	NN	3	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
RS	RS	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
prolonged	prolong	VERB	VBN	9	O
neuroleptic	neuroleptic	ADJ	JJ	5	O
medication	medication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
we	-PRON-	PRON	PRP	5	O
present	present	VERB	VBP	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
withdrawal	withdrawal	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
emergent	emergent	NOUN	NN	5	I-Disease
RS	RS	PROPN	NNP	9	I-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
kind	kind	NOUN	NN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
RS	RS	PROPN	NNP	9	B-Disease
during	during	ADP	IN	5	O
dose	dose	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
symptom	symptom	NOUN	NN	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
successfully	successfully	ADV	RB	5	O
with	with	ADP	IN	5	O
trihexyphenidyl	trihexyphenidyl	NOUN	NN	0	B-Chemical
anticholinergic	anticholinergic	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
underlying	underlie	VERB	VBG	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
withdrawal	withdrawal	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
emergent	emergent	NOUN	NN	5	I-Disease
RS	RS	PROPN	NNP	9	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
been	be	VERB	VBN	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
pharmacological	pharmacological	ADJ	JJ	9	O
profile	profile	NOUN	NN	9	O
of	of	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
the	the	DET	DT	5	O
pathophysiologic	pathophysiologic	ADJ	JJ	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
system	system	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
RS	RS	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

Pharmacokinetic	pharmacokinetic	ADJ	JJ	0	O
/	/	SYM	SYM	9	O
pharmacodynamic	pharmacodynamic	ADJ	JJ	5	O
assessment	assessment	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
E4031	E4031	PROPN	NNP	3	B-Chemical
,	,	PUNCT	,	9	O
cisapride	cisapride	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
terfenadine	terfenadine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
terodiline	terodiline	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
monophasic	monophasic	ADJ	JJ	5	O
action	action	NOUN	NN	5	O
potential	potential	ADJ	JJ	9	O
duration	duration	NOUN	NN	5	O
in	in	ADP	IN	5	O
dog	dog	NOUN	NN	5	O
.	.	PUNCT	.	9	O

1	1	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

Torsades	torsade	NOUN	NNS	2	B-Disease
de	de	ADP	IN	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
TDP	tdp	NOUN	NN	0	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
potentially	potentially	ADV	RB	5	O
fatal	fatal	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
QT	QT	PROPN	NNP	5	O
interval	interval	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
monophasic	monophasic	ADJ	JJ	5	O
action	action	NOUN	NN	5	O
potential	potential	ADJ	JJ	9	O
duration	duration	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MAPD	MAPD	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

TDP	tdp	NOUN	NN	0	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effect	effect	NOUN	NN	9	O
that	that	DET	WDT	5	O
has	have	VERB	VBZ	9	O
led	lead	VERB	VBN	9	O
to	to	ADP	IN	5	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
several	several	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
market	market	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
e	e	NOUN	NN	9	O
.	.	PUNCT	.	9	O
g	g	NOUN	NN	0	O
.	.	PUNCT	.	9	O
terfenadine	terfenadine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
terodiline	terodiline	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

2	2	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
potential	potential	NOUN	NN	9	O
of	of	ADP	IN	5	O
compounds	compound	NOUN	NNS	0	O
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
TDP	tdp	NOUN	NN	0	B-Disease
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
by	by	ADP	IN	9	O
monitoring	monitor	VERB	VBG	5	O
their	-PRON-	DET	PRP$	5	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
MAPD	MAPD	PROPN	NNP	5	O
in	in	ADP	IN	5	O
dog	dog	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Four	four	NUM	CD	9	O
compounds	compound	NOUN	NNS	0	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
increase	increase	VERB	VB	9	O
QT	QT	PROPN	NNP	5	O
interval	interval	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
cause	cause	VERB	VB	5	O
TDP	tdp	NOUN	NN	0	B-Disease
were	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
:	:	PUNCT	:	9	O
terfenadine	terfenadine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
terodiline	terodiline	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
cisapride	cisapride	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
E4031	e4031	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
basis	basis	NOUN	NN	5	O
that	that	DET	WDT	5	O
only	only	ADV	RB	9	O
free	free	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
systemic	systemic	ADJ	JJ	9	O
circulation	circulation	NOUN	NN	9	O
will	will	VERB	MD	5	O
elicit	elicit	VERB	VB	9	O
a	a	DET	DT	5	O
pharmacological	pharmacological	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
target	target	NOUN	NN	9	O
,	,	PUNCT	,	9	O
free	free	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
in	in	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
were	be	VERB	VBD	9	O
selected	select	VERB	VBN	9	O
to	to	PART	TO	5	O
mimic	mimic	VERB	VB	9	O
the	the	DET	DT	5	O
free	free	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
exposures	exposure	NOUN	NNS	5	O
in	in	ADP	IN	5	O
man	man	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Infusion	infusion	NOUN	NN	0	O
regimens	regimen	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
that	that	ADP	IN	5	O
rapidly	rapidly	ADV	RB	9	O
achieved	achieve	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
maintained	maintain	VERB	VBD	9	O
target	target	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
in	in	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
data	datum	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
free	free	ADJ	JJ	9	O
concentration	concentration	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
MAPD	MAPD	PROPN	NNP	5	O
were	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
for	for	ADP	IN	5	O
these	these	DET	DT	5	O
compounds	compound	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

3	3	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
free	free	ADJ	JJ	9	O
ED50	ED50	PROPN	NNP	0	O
in	in	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
for	for	ADP	IN	5	O
terfenadine	terfenadine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
nM	nm	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
terodiline	terodiline	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
76	76	NUM	CD	7	O
nM	nm	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
cisapride	cisapride	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
nM	nM	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
E4031	E4031	PROPN	NNP	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
nM	nm	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
closely	closely	ADV	RB	9	O
correlate	correlate	VERB	VB	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
free	free	ADJ	JJ	9	O
concentration	concentration	NOUN	NN	0	O
in	in	ADP	IN	5	O
man	man	NOUN	NN	5	O
causing	cause	VERB	VBG	9	O
QT	QT	PROPN	NNP	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
compounds	compound	NOUN	NNS	0	O
that	that	DET	WDT	5	O
have	have	VERB	VBP	5	O
shown	show	VERB	VBN	9	O
TDP	tdp	NOUN	NN	0	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
clinic	clinic	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
terfenadine	terfenadine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
terodiline	terodiline	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
cisapride	cisapride	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
little	little	ADJ	JJ	9	O
differentiation	differentiation	NOUN	NN	3	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
dog	dog	NOUN	NN	5	O
ED50	ED50	PROPN	NNP	0	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
efficacious	efficacious	ADJ	JJ	5	O
free	free	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
in	in	ADP	IN	5	O
man	man	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
<	<	X	XX	0	O
10	10	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
fold	fold	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
reflecting	reflect	VERB	VBG	5	O
their	-PRON-	DET	PRP$	5	O
limited	limited	ADJ	JJ	5	O
safety	safety	NOUN	NN	5	O
margins	margin	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
underline	underline	VERB	VBP	9	O
the	the	DET	DT	5	O
need	need	NOUN	NN	5	O
to	to	PART	TO	5	O
maximize	maximize	VERB	VB	5	O
the	the	DET	DT	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
ratio	ratio	NOUN	NN	9	O
with	with	ADP	IN	5	O
respect	respect	NOUN	NN	9	O
to	to	ADP	IN	5	O
TDP	tdp	NOUN	NN	0	B-Disease
in	in	ADP	IN	5	O
potential	potential	ADJ	JJ	9	O
development	development	NOUN	NN	9	O
candidates	candidate	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
importance	importance	NOUN	NN	5	O
of	of	ADP	IN	5	O
using	use	VERB	VBG	9	O
free	free	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
concentrations	concentration	NOUN	NNS	0	O
in	in	ADP	IN	5	O
pharmacokinetic	pharmacokinetic	ADJ	JJ	5	O
/	/	SYM	SYM	9	O
pharmacodynamic	pharmacodynamic	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Bladder	bladder	NOUN	NN	9	O
retention	retention	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
urine	urine	NOUN	NN	9	I-Disease
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
continuous	continuous	ADJ	JJ	5	O
intravenous	intravenous	ADJ	JJ	0	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
2	2	NUM	CD	9	O
case	case	NOUN	NN	5	O
reports	report	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Sedation	Sedation	PROPN	NNP	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
commonly	commonly	ADV	RB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
neonate	neonate	NOUN	NN	9	O
to	to	PART	TO	5	O
decrease	decrease	VERB	VB	9	O
the	the	DET	DT	5	O
stress	stress	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
pain	pain	NOUN	NN	5	B-Disease
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
noxious	noxious	ADJ	JJ	5	O
stimuli	stimulus	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
invasive	invasive	ADJ	JJ	5	O
procedures	procedure	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
neonatal	neonatal	ADJ	JJ	9	O
intensive	intensive	ADJ	JJ	5	O
care	care	NOUN	NN	5	O
unit	unit	NOUN	NN	5	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
to	to	PART	TO	5	O
facilitate	facilitate	VERB	VB	5	O
synchrony	synchrony	NOUN	NN	5	O
between	between	ADP	IN	5	O
ventilator	ventilator	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
breaths	breath	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Fentanyl	Fentanyl	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
opioid	opioid	NOUN	NN	5	O
analgesic	analgesic	NOUN	NN	5	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
frequently	frequently	ADV	RB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
neonatal	neonatal	ADJ	JJ	9	O
intensive	intensive	ADJ	JJ	5	O
care	care	NOUN	NN	5	O
unit	unit	NOUN	NN	5	O
setting	set	VERB	VBG	5	O
for	for	ADP	IN	5	O
these	these	DET	DT	5	O
very	very	ADJ	JJ	5	O
purposes	purpose	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Various	various	ADJ	JJ	9	O
reported	report	VERB	VBD	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
include	include	VERB	VBP	5	O
chest	chest	NOUN	NN	5	B-Disease
wall	wall	NOUN	NN	5	I-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
depression	depression	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
urinary	urinary	ADJ	JJ	9	B-Disease
bladder	bladder	NOUN	NN	9	I-Disease
retention	retention	NOUN	NN	9	I-Disease
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
pelvocalyceal	pelvocalyceal	NOUN	NN	5	O
dilatation	dilatation	NOUN	NN	5	O
mimicking	mimic	VERB	VBG	9	O
hydronephrosis	hydronephrosis	NOUN	NN	5	B-Disease
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
continuous	continuous	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Fatal	fatal	ADJ	JJ	5	O
myeloencephalopathy	myeloencephalopathy	NOUN	NN	9	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
accidental	accidental	ADJ	JJ	5	O
intrathecal	intrathecal	ADJ	JJ	3	O
vincristin	vincristin	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
on	on	ADP	IN	5	O
two	two	NUM	CD	5	O
fatal	fatal	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
accidental	accidental	ADJ	JJ	5	O
intrathecal	intrathecal	ADJ	JJ	3	O
vincristine	vincristine	ADJ	JJ	0	B-Chemical
instillation	instillation	NOUN	NN	0	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
old	old	ADJ	JJ	5	O
girl	girl	NOUN	NN	5	O
with	with	ADP	IN	5	O
recurrent	recurrent	ADJ	JJ	5	O
acute	acute	ADJ	JJ	9	B-Disease
lymphoblastic	lymphoblastic	ADJ	JJ	3	I-Disease
leucemia	leucemia	NOUN	NN	2	I-Disease
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
57	57	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
with	with	ADP	IN	5	O
lymphoblastic	lymphoblastic	ADJ	JJ	3	B-Disease
lymphoma	lymphoma	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
girl	girl	NOUN	NN	5	O
died	die	VERB	VBD	9	O
seven	seven	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
man	man	NOUN	NN	5	O
four	four	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
intrathecal	intrathecal	ADJ	JJ	3	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
vincristine	vincristine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Clinically	clinically	ADV	RB	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
was	be	VERB	VBD	9	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
opistothonus	opistothonus	NOUN	NN	_	B-Disease
,	,	PUNCT	,	9	I-Disease
sensory	sensory	ADJ	JJ	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
motor	motor	NOUN	NN	5	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
ascending	ascend	VERB	VBG	5	O
paralysis	paralysis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Histological	histological	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
immunohistochemical	immunohistochemical	ADJ	JJ	3	O
investigations	investigation	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
HE	HE	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
LFB	LFB	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
CD	CD	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
68	68	NUM	CD	7	O
,	,	PUNCT	,	9	O
Neurofilament	Neurofilament	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
revealed	reveal	VERB	VBD	9	O
degeneration	degeneration	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
myelin	myelin	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	I-Disease
axons	axon	NOUN	NNS	5	I-Disease
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
pseudocystic	pseudocystic	ADJ	JJ	5	B-Disease
transformation	transformation	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
areas	area	NOUN	NNS	5	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
vincristine	vincristine	VERB	VB	0	B-Chemical
,	,	PUNCT	,	9	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
secondary	secondary	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
with	with	ADP	IN	5	O
numerous	numerous	ADJ	JJ	9	O
prominent	prominent	ADJ	JJ	9	O
macrophages	macrophage	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
course	course	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
histopathological	histopathological	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
presented	present	VERB	VBN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
reported	report	VERB	VBN	9	O
cases	case	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
given	give	VERB	VBN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
better	better	ADV	RBR	5	O
controlled	control	VERB	VBN	5	O
regimen	regiman	NOUN	NNS	5	O
for	for	ADP	IN	5	O
administering	administer	VERB	VBG	9	O
vincristine	vincristine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
intrathecal	intrathecal	ADJ	JJ	3	O
chemotherapy	chemotherapy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
recommended	recommend	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Palpebral	palpebral	ADJ	JJ	7	B-Disease
twitching	twitch	VERB	VBG	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
depressed	depressed	ADJ	JJ	5	B-Disease
adolescent	adolescent	NOUN	NN	5	O
on	on	ADP	IN	5	O
citalopram	citalopram	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Current	current	ADJ	JJ	9	O
estimates	estimate	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
between	between	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
children	child	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
adolescents	adolescent	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
major	major	ADJ	JJ	9	B-Disease
depression	depression	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
favorable	favorable	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
citalopram	citalopram	NOUN	NN	0	B-Chemical
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
15	15	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
boy	boy	NOUN	NN	5	O
with	with	ADP	IN	5	O
major	major	ADJ	JJ	9	B-Disease
depression	depression	NOUN	NN	5	I-Disease
who	who	PRON	WP	5	O
exhibited	exhibit	VERB	VBD	9	O
palpebral	palpebral	ADJ	JJ	5	B-Disease
twitching	twitching	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
his	-PRON-	DET	PRP$	5	O
first	first	ADJ	JJ	9	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
been	be	VERB	VBN	9	O
a	a	DET	DT	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
citalopram	citalopram	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
remitted	remit	VERB	VBD	5	O
with	with	ADP	IN	5	O
redistribution	redistribution	NOUN	NN	9	O
of	of	ADP	IN	5	O
doses	dose	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
sulphasalazine	sulphasalazine	NOUN	NN	0	B-Chemical
syndrome	syndrome	NOUN	NN	5	O
strikes	strike	NOUN	NNS	5	O
again	again	ADV	RB	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
34	34	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
lady	lady	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
constellation	constellation	NOUN	NN	5	O
of	of	ADP	IN	5	O
dermatitis	dermatitis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
fever	fever	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
lymphadenopathy	lymphadenopathy	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
beginning	begin	VERB	VBG	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
17th	17th	ADJ	JJ	5	O
day	day	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
sulphasalazine	sulphasalazine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
sero	sero	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
negative	negative	ADJ	JJ	9	O
rheumatoid	rheumatoid	NOUN	NN	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Cervical	cervical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
inguinal	inguinal	ADJ	JJ	5	O
lymph	lymph	NOUN	NN	9	O
node	node	NOUN	NN	5	O
biopsies	biopsy	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
the	the	DET	DT	5	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
necrotising	necrotising	NOUN	NN	5	O
lymphadenitis	lymphadenitis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
erythrophagocytosis	erythrophagocytosis	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
prominent	prominent	ADJ	JJ	9	O
eosinophilic	eosinophilic	NOUN	NN	5	O
infiltrates	infiltrate	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
without	without	ADP	IN	9	O
viral	viral	ADJ	JJ	9	O
inclusion	inclusion	NOUN	NN	5	O
bodies	body	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
suggestive	suggestive	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	B-Disease
drug	drug	NOUN	NN	5	I-Disease
reaction	reaction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O
A	a	DET	DT	9	O
week	week	NOUN	NN	9	O
later	later	ADV	RB	9	O
,	,	PUNCT	,	9	O
fulminant	fulminant	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
induced	induce	VERB	VBN	3	I-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
nuclear	nuclear	ADJ	JJ	3	O
autoantibodies	autoantibody	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
markers	marker	NOUN	NNS	3	O
of	of	ADP	IN	5	O
autoimmunity	autoimmunity	NOUN	NN	3	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
multi	multi	ADJ	JJ	9	B-Disease
-	-	ADJ	JJ	7	I-Disease
organ	organ	ADJ	JJ	5	I-Disease
failure	failure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
sepsis	sepsis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
supervened	supervene	VERB	VBN	5	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
subsequently	subsequently	ADV	RB	9	O
died	die	VERB	VBD	9	O
some	some	DET	DT	5	O
5	5	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
commencement	commencement	NOUN	NN	5	O
of	of	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
drug	drug	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O
Post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
mortem	mortem	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
massive	massive	ADJ	JJ	9	B-Disease
hepatocellular	hepatocellular	ADJ	JJ	9	I-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
acute	acute	ADJ	JJ	9	O
hypersensitivity	hypersensitivity	NOUN	NN	9	O
myocarditis	myocarditis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
focal	focal	ADJ	JJ	5	O
acute	acute	ADJ	JJ	9	O
tubulo	tubulo	NOUN	NN	2	O
-	-	PUNCT	HYPH	7	O
interstitial	interstitial	ADJ	JJ	9	O
nephritis	nephritis	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
extensive	extensive	ADJ	JJ	5	O
bone	bone	NOUN	NN	5	B-Disease
marrow	marrow	NOUN	NN	3	I-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
malignancy	malignancy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
thought	think	VERB	VBN	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
clinico	clinico	ADJ	JJ	2	O
-	-	PUNCT	HYPH	7	O
pathological	pathological	ADJ	JJ	5	O
features	feature	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
chronology	chronology	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
case	case	NOUN	NN	5	O
bore	bear	VERB	VBD	5	O
the	the	DET	DT	5	O
hallmarks	hallmark	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
so	so	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
called	call	VERB	VBN	5	O
"	"	PUNCT	``	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
sulphasalazine	sulphasalazine	NOUN	NN	0	B-Chemical
syndrome	syndrome	NOUN	NN	5	O
"	"	PUNCT	''	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
often	often	ADV	RB	5	O
fatal	fatal	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
immunoallergic	immunoallergic	ADJ	JJ	5	O
reaction	reaction	NOUN	NN	9	O
to	to	PART	TO	5	O
sulphasalazine	sulphasalazine	VERB	VB	0	B-Chemical
.	.	PUNCT	.	9	O

Intravenous	intravenous	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
prochlorperazine	prochlorperazine	NOUN	NN	0	B-Chemical
by	by	ADP	IN	9	O
15	15	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
minute	minute	NOUN	NN	5	O
infusion	infusion	NOUN	NN	0	O
versus	versus	ADP	IN	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
minute	minute	NOUN	NN	5	O
bolus	bolus	NOUN	NN	0	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
affect	affect	VERB	VB	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
akathisia	akathisia	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
prospective	prospective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
controlled	control	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

STUDY	study	NOUN	NN	2	O
OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
sought	seek	VERB	VBD	9	O
to	to	PART	TO	5	O
compare	compare	VERB	VB	9	O
the	the	DET	DT	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
akathisia	akathisia	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
prochlorperazine	prochlorperazine	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
minute	minute	NOUN	NN	5	O
bolus	bolus	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
15	15	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
minute	minute	NOUN	NN	5	O
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
conducted	conduct	VERB	VBD	9	O
a	a	DET	DT	5	O
prospective	prospective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
emergency	emergency	NOUN	NN	5	O
department	department	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
central	central	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
city	city	NOUN	NN	5	O
teaching	teaching	NOUN	NN	5	O
hospital	hospital	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
aged	age	VERB	VBD	9	O
18	18	NUM	CD	7	O
years	year	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
older	old	ADJ	JJR	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
prochlorperazine	prochlorperazine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
headache	headache	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
nausea	nausea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
vomiting	vomiting	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
eligible	eligible	ADJ	JJ	5	O
for	for	ADP	IN	5	O
inclusion	inclusion	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Study	study	NOUN	NN	5	O
participants	participant	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomized	randomize	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
of	of	ADP	IN	5	O
prochlorperazine	prochlorperazine	NOUN	NN	0	B-Chemical
administered	administer	VERB	VBD	9	O
intravenously	intravenously	ADV	RB	0	O
by	by	ADP	IN	9	O
means	mean	NOUN	NNS	5	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
minute	minute	NOUN	NN	5	O
push	push	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
bolus	bolus	NOUN	NN	0	O
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
diluted	dilute	VERB	VBN	0	O
in	in	ADP	IN	5	O
50	50	NUM	CD	0	O
mL	ml	NOUN	NN	0	O
of	of	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
solution	solution	NOUN	NN	0	O
administered	administer	VERB	VBN	9	O
by	by	ADP	IN	9	O
means	mean	NOUN	NNS	5	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
infusion	infusion	NOUN	NN	0	O
during	during	ADP	IN	5	O
a	a	DET	DT	5	O
15	15	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
minute	minute	NOUN	NN	5	O
period	period	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
infusion	infusion	NOUN	NN	0	O
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
main	main	ADJ	JJ	5	O
outcome	outcome	NOUN	NN	5	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
study	study	NOUN	NN	9	O
participants	participant	NOUN	NNS	5	O
experiencing	experience	VERB	VBG	5	O
akathisia	akathisia	NOUN	NN	5	B-Disease
within	within	ADP	IN	9	O
60	60	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
of	of	ADP	IN	5	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Akathisia	Akathisia	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
defined	define	VERB	VBN	5	O
as	as	ADP	IN	5	O
either	either	CCONJ	CC	9	O
a	a	DET	DT	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
restlessness	restlessness	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
agitation	agitation	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
a	a	DET	DT	5	O
change	change	NOUN	NN	9	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
reported	report	VERB	VBN	9	O
akathisia	akathisia	NOUN	NN	5	B-Disease
rating	rating	NOUN	NN	5	O
scale	scale	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
change	change	NOUN	NN	9	O
of	of	ADP	IN	5	O
at	at	ADV	RB	9	O
least	least	ADJ	JJS	9	O
1	1	NUM	CD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
investigator	investigator	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
observed	observe	VERB	VBN	9	O
akathisia	akathisia	NOUN	NN	5	B-Disease
rating	rating	NOUN	NN	5	O
scale	scale	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
intensity	intensity	NOUN	NN	5	O
of	of	ADP	IN	5	O
headache	headache	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
nausea	nausea	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
100	100	NUM	CD	0	O
-	-	PUNCT	HYPH	7	O
mm	mm	NOUN	NN	9	O
visual	visual	ADJ	JJ	5	O
analog	analog	NOUN	NN	0	O
scale	scale	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
One	one	NUM	CD	5	O
hundred	hundred	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
enrolled	enrol	VERB	VBN	5	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
study	study	NOUN	NN	9	O
participant	participant	NOUN	NN	5	O
was	be	VERB	VBD	9	O
excluded	exclude	VERB	VBN	9	O
after	after	ADP	IN	9	O
protocol	protocol	NOUN	NN	9	O
violation	violation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Seventy	seventy	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
three	three	NUM	CD	9	O
percent	percent	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
73	73	NUM	CD	7	O
/	/	SYM	SYM	9	O
99	99	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
participants	participant	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
for	for	ADP	IN	5	O
headache	headache	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
70	70	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
70	70	NUM	CD	9	O
/	/	SYM	SYM	9	O
99	99	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
nausea	nausea	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
bolus	bolus	NOUN	NN	0	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
26	26	NUM	CD	7	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
13	13	NUM	CD	7	O
/	/	SYM	SYM	9	O
50	50	NUM	CD	0	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
akathisia	akathisia	NOUN	NN	5	B-Disease
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
32	32	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
16	16	NUM	CD	9	O
/	/	SYM	SYM	9	O
49	49	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
infusion	infusion	NOUN	NN	0	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
Delta	Delta	PROPN	NNP	9	O
=	=	SYM	SYM	7	O
-	-	PUNCT	:	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
[	[	PUNCT	-LRB-	9	O
CI	CI	PROPN	NNP	7	O
]	]	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
24	24	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	ADP	IN	5	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
difference	difference	NOUN	NN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
bolus	bolus	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
infusion	infusion	NOUN	NN	0	O
groups	group	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
percentage	percentage	NOUN	NN	9	O
of	of	ADP	IN	5	O
participants	participant	NOUN	NNS	5	O
who	who	PRON	WP	5	O
saw	see	VERB	VBD	5	O
a	a	DET	DT	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
headache	headache	NOUN	NN	5	B-Disease
intensity	intensity	NOUN	NN	5	O
within	within	ADP	IN	9	O
30	30	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
was	be	VERB	VBD	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	ADP	IN	5	O
33	33	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
percentage	percentage	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
nausea	nausea	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	ADP	IN	5	O
29	29	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
akathisia	akathisia	NOUN	NN	5	B-Disease
when	when	ADV	WRB	5	O
prochlorperazine	prochlorperazine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
by	by	ADP	IN	9	O
means	mean	NOUN	NNS	5	O
of	of	ADP	IN	5	O
15	15	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
minute	minute	NOUN	NN	5	O
intravenous	intravenous	ADJ	JJ	0	O
infusion	infusion	NOUN	NN	0	O
versus	versus	ADP	IN	9	O
a	a	DET	DT	5	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
minute	minute	NOUN	NN	5	O
intravenous	intravenous	ADJ	JJ	0	O
push	push	NOUN	NN	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
detected	detect	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
prochlorperazine	prochlorperazine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
headache	headache	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
nausea	nausea	NOUN	NN	5	B-Disease
likewise	likewise	ADV	RB	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
appear	appear	VERB	VB	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
no	no	DET	DT	9	O
formal	formal	ADJ	JJ	5	O
statistical	statistical	ADJ	JJ	5	O
comparisons	comparison	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
made	make	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Combined	combine	VERB	VBN	9	O
antiretroviral	antiretroviral	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
causes	cause	VERB	VBZ	9	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
elevates	elevate	NOUN	NNS	9	O
plasma	plasma	NOUN	NN	9	O
lactate	lactate	VERB	VBP	0	B-Chemical
in	in	ADP	IN	5	O
transgenic	transgenic	ADJ	JJ	3	O
AIDS	AIDS	PROPN	NNP	5	B-Disease
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Highly	highly	ADV	RB	9	O
active	active	ADJ	JJ	9	O
antiretroviral	antiretroviral	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
HAART	HAART	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
CM	CM	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
elevated	elevated	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
lactate	lactate	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
LA	LA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
AIDS	AIDS	PROPN	NNP	5	B-Disease
through	through	ADP	IN	9	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
determine	determine	VERB	VB	9	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
events	event	NOUN	NNS	5	O
from	from	ADP	IN	9	O
HAART	HAART	PROPN	NNP	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
hemizygous	hemizygous	ADJ	JJ	1	O
transgenic	transgenic	ADJ	JJ	3	O
AIDS	AIDS	PROPN	NNP	5	B-Disease
mice	mouse	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
NL4	NL4	PROPN	NNP	1	O
-	-	PUNCT	:	7	O
3Delta	3delta	NUM	CD	_	O
gag	gag	NOUN	NN	1	O
/	/	SYM	SYM	9	O
pol	pol	NOUN	NN	1	O
;	;	PUNCT	:	9	O
TG	TG	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
wild	wild	ADJ	JJ	1	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
FVB	FVB	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
n	n	CCONJ	CC	9	O
littermates	littermate	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
HAART	HAART	PROPN	NNP	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
zidovudine	zidovudine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
indinavir	indinavir	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
vehicle	vehicle	NOUN	NN	3	O
control	control	NOUN	NN	9	O
for	for	ADP	IN	5	O
10	10	NUM	CD	9	O
days	day	NOUN	NNS	9	O
or	or	CCONJ	CC	5	O
35	35	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
termination	termination	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
experiments	experiment	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
mice	mouse	NOUN	NNS	3	O
underwent	undergo	VERB	VBD	5	O
echocardiography	echocardiography	NOUN	NN	5	O
,	,	PUNCT	,	9	O
quantitation	quantitation	NOUN	NN	9	O
of	of	ADP	IN	5	O
abundance	abundance	NOUN	NN	9	O
of	of	ADP	IN	5	O
molecular	molecular	ADJ	JJ	9	O
markers	marker	NOUN	NNS	3	O
of	of	ADP	IN	5	O
CM	CM	PROPN	NNP	9	B-Disease
(	(	PUNCT	-LRB-	9	O
ventricular	ventricular	ADJ	JJ	5	O
mRNA	mRNA	NOUN	NNS	3	O
encoding	encode	VERB	VBG	1	O
atrial	atrial	ADJ	JJ	5	O
natriuretic	natriuretic	ADJ	JJ	9	O
factor	factor	NOUN	NN	9	O
[	[	PUNCT	-LRB-	9	O
ANF	ANF	PROPN	NNP	3	O
]	]	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
sarcoplasmic	sarcoplasmic	ADJ	JJ	0	O
calcium	calcium	NOUN	NN	0	B-Chemical
ATPase	ATPase	PROPN	NNP	1	O
[	[	PUNCT	-LRB-	9	O
SERCA2	SERCA2	PROPN	NNP	3	O
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
determination	determination	NOUN	NN	9	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
LA	LA	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

Myocardial	myocardial	ADJ	JJ	9	O
histologic	histologic	ADJ	JJ	9	O
features	feature	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
semiquantitatively	semiquantitatively	ADV	RB	9	O
and	and	CCONJ	CC	5	O
results	result	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
confirmed	confirm	VERB	VBN	9	O
by	by	ADP	IN	9	O
transmission	transmission	NOUN	NN	5	O
electron	electron	NOUN	NN	0	O
microscopy	microscopy	NOUN	NN	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
35	35	NUM	CD	9	O
days	day	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
TG	TG	PROPN	NNP	9	O
+	+	CCONJ	CC	9	O
HAART	HAART	PROPN	NNP	5	O
cohort	cohort	NOUN	NN	9	O
,	,	PUNCT	,	9	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	O
mass	mass	NOUN	NN	9	O
increased	increase	VERB	VBD	9	O
160	160	NUM	CD	9	O
%	%	NOUN	NN	9	O
by	by	ADP	IN	9	O
echocardiography	echocardiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Molecularly	molecularly	ADV	RB	9	O
,	,	PUNCT	,	9	O
ANF	ANF	PROPN	NNP	3	O
mRNA	mRNA	PROPN	NNP	3	O
increased	increase	VERB	VBD	9	O
250	250	NUM	CD	0	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
SERCA2	SERCA2	PROPN	NNPS	3	O
mRNA	mRNA	PROPN	NNP	3	O
decreased	decrease	VERB	VBD	9	O
57	57	NUM	CD	7	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Biochemically	biochemically	ADV	RB	9	O
,	,	PUNCT	,	9	O
LA	LA	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
elevated	elevate	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mM	mM	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Pathologically	pathologically	ADV	RB	5	O
,	,	PUNCT	,	9	O
granular	granular	ADJ	JJ	9	O
cytoplasmic	cytoplasmic	ADJ	JJ	3	O
changes	change	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
myocytes	myocyte	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
enlarged	enlarge	VERB	VBN	9	O
,	,	PUNCT	,	9	O
damaged	damage	VERB	VBN	9	O
mitochondria	mitochondria	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Findings	finding	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
confirmed	confirm	VERB	VBN	9	O
ultrastructurally	ultrastructurally	ADV	RB	3	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
changes	change	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
other	other	ADJ	JJ	5	O
cohorts	cohort	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
10	10	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
only	only	ADV	RB	9	O
ANF	ANF	PROPN	NNP	3	O
was	be	VERB	VBD	9	O
elevated	elevate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
TG	TG	PROPN	NNP	9	O
+	+	CCONJ	CC	9	O
HAART	HAART	PROPN	NNP	5	O
cohort	cohort	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Results	result	NOUN	NNS	9	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
cumulative	cumulative	ADJ	JJ	5	O
HAART	HAART	PROPN	NNP	5	O
caused	cause	VERB	VBD	9	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
CM	CM	PROPN	NNP	9	B-Disease
with	with	ADP	IN	5	O
elevated	elevated	ADJ	JJ	9	O
LA	LA	PROPN	NNP	9	B-Chemical
in	in	ADP	IN	5	O
AIDS	AIDS	PROPN	NNP	5	B-Disease
transgenic	transgenic	ADJ	JJ	3	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
Phase	Phase	PROPN	NNP	9	O
II	II	PROPN	NNP	9	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
plus	plus	CCONJ	CC	9	O
WR	WR	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2721	2721	PROPN	NNP	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
amifostine	amifostine	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
breast	breast	NOUN	NN	3	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
:	:	PUNCT	:	9	O
an	an	DET	DT	5	O
Eastern	Eastern	PROPN	NNP	4	O
Cooperative	Cooperative	PROPN	NNP	2	O
Oncology	Oncology	PROPN	NNP	2	O
Group	Group	PROPN	NNP	9	O
Study	Study	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
E8188	E8188	PROPN	NNP	_	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Cisplatin	Cisplatin	PROPN	NNP	0	B-Chemical
has	have	VERB	VBZ	9	O
minimal	minimal	ADJ	JJ	9	O
antitumor	antitumor	ADJ	JJ	3	O
activity	activity	NOUN	NN	9	O
when	when	ADV	WRB	5	O
used	use	VERB	VBN	5	O
as	as	ADP	IN	5	O
second	second	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
or	or	CCONJ	CC	5	O
third	third	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
line	line	NOUN	NN	9	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
breast	breast	NOUN	NN	3	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Older	old	ADJ	JJR	5	O
reports	report	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
an	an	DET	DT	5	O
objective	objective	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
when	when	ADV	WRB	5	O
60	60	NUM	CD	9	O
-	-	SYM	SYM	7	O
120	120	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
of	of	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
is	be	VERB	VBZ	5	O
administered	administer	VERB	VBN	9	O
every	every	DET	DT	5	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
response	response	NOUN	NN	9	O
effect	effect	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
observed	observe	VERB	VBN	9	O
with	with	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
limiting	limit	VERB	VBG	9	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
e	e	NOUN	NN	9	O
.	.	PUNCT	.	9	O
g	g	NOUN	NN	0	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
ototoxicity	ototoxicity	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
have	have	VERB	VBP	5	O
limited	limit	VERB	VBN	5	O
its	-PRON-	DET	PRP$	9	O
use	use	NOUN	NN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

WR	WR	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2721	2721	NUM	CD	7	I-Chemical
or	or	CCONJ	CC	5	O
amifostine	amifostine	NOUN	NN	0	B-Chemical
initially	initially	ADV	RB	9	O
was	be	VERB	VBD	9	O
developed	develop	VERB	VBN	5	O
to	to	PART	TO	5	O
protect	protect	VERB	VB	9	O
military	military	ADJ	JJ	5	O
personnel	personnel	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
event	event	NOUN	NN	5	O
of	of	ADP	IN	5	O
nuclear	nuclear	ADJ	JJ	3	O
war	war	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Amifostine	Amifostine	PROPN	NNP	0	B-Chemical
subsequently	subsequently	ADV	RB	9	O
was	be	VERB	VBD	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
protect	protect	VERB	VB	9	O
normal	normal	ADJ	JJ	9	O
tissues	tissue	NOUN	NNS	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
toxic	toxic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
alkylating	alkylate	VERB	VBG	0	B-Chemical
agents	agent	NOUN	NNS	5	I-Chemical
and	and	CCONJ	CC	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
without	without	ADP	IN	9	O
decreasing	decrease	VERB	VBG	9	O
the	the	DET	DT	5	O
antitumor	antitumor	ADJ	JJ	3	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Early	early	ADJ	JJ	9	O
trials	trial	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
amifostine	amifostine	NOUN	NN	0	B-Chemical
also	also	ADV	RB	9	O
suggested	suggest	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
ototoxicity	ototoxicity	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
neuropathy	neuropathy	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
Phase	Phase	PROPN	NNP	9	O
II	II	PROPN	NNP	9	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
plus	plus	CCONJ	CC	9	O
amifostine	amifostine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
progressive	progressive	ADJ	JJ	5	O
metastatic	metastatic	ADJ	JJ	3	O
breast	breast	NOUN	NN	3	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
received	receive	VERB	VBN	9	O
one	one	NUM	CD	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
one	one	NUM	CD	5	O
,	,	PUNCT	,	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
regimen	regiman	NOUN	NNS	5	O
for	for	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
amifostine	amifostine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
910	910	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	VERB	VBZ	7	O
intravenously	intravenously	ADV	RB	0	O
over	over	ADP	IN	5	O
15	15	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
completion	completion	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
amifostine	amifostine	ADJ	JJ	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
,	,	PUNCT	,	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
120	120	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
over	over	ADP	IN	5	O
30	30	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Intravenous	intravenous	ADJ	JJ	0	O
hydration	hydration	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
mannitol	mannitol	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
every	every	DET	DT	5	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
until	until	ADP	IN	5	O
disease	disease	NOUN	NN	5	O
progression	progression	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Forty	forty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
enrolled	enrol	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
which	which	DET	WDT	5	O
7	7	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
16	16	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
ineligible	ineligible	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
median	median	NOUN	NN	9	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
cycles	cycle	NOUN	NNS	9	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
37	37	NUM	CD	9	O
eligible	eligible	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Six	six	NUM	CD	9	O
partial	partial	ADJ	JJ	9	O
responses	response	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
for	for	ADP	IN	5	O
an	an	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
16	16	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Most	Most	ADJ	JJS	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
57	57	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
stopped	stop	VERB	VBD	9	O
treatment	treatment	NOUN	NN	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
disease	disease	NOUN	NN	5	O
progression	progression	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Neurologic	neurologic	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
52	52	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Seven	seven	NUM	CD	9	O
different	different	ADJ	JJ	9	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
threatening	threaten	VERB	VBG	5	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
while	while	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
amifostine	amifostine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
16	16	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Neither	neither	CCONJ	CC	9	O
a	a	DET	DT	5	O
tumor	tumor	NOUN	NN	3	B-Disease
-	-	PUNCT	HYPH	7	O
protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
nor	nor	CCONJ	CC	9	O
reduced	reduce	VERB	VBN	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
tissues	tissue	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
addition	addition	NOUN	NN	9	O
of	of	ADP	IN	5	O
amifostine	amifostine	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Oral	oral	ADJ	JJ	9	B-Chemical
contraceptives	contraceptive	NOUN	NNS	5	I-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
An	an	DET	DT	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptives	contraceptive	NOUN	NNS	5	I-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
all	all	DET	DT	5	O
,	,	PUNCT	,	9	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
investigated	investigate	VERB	VBD	9	O
this	this	DET	DT	5	O
association	association	NOUN	NN	9	O
,	,	PUNCT	,	9	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
progestagen	progestagen	NOUN	NN	0	B-Chemical
included	include	VERB	VBN	5	O
in	in	ADP	IN	5	O
third	third	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
e	e	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
desogestrel	desogestrel	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
gestodene	gestodene	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
second	second	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
e	e	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
levonorgestrel	levonorgestrel	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptives	contraceptive	NOUN	NNS	5	I-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
prothrombotic	prothrombotic	ADJ	JJ	5	O
mutations	mutation	NOUN	NNS	1	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
a	a	DET	DT	5	O
nationwide	nationwide	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
population	population	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
,	,	PUNCT	,	9	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
identified	identify	VERB	VBD	9	O
and	and	CCONJ	CC	5	O
enrolled	enrol	VERB	VBD	5	O
248	248	NUM	CD	7	O
women	woman	NOUN	NNS	5	O
18	18	NUM	CD	7	O
through	through	ADP	IN	9	O
49	49	NUM	CD	7	O
years	year	NOUN	NNS	5	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
had	have	VERB	VBN	9	O
a	a	DET	DT	5	O
first	first	ADJ	JJ	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
between	between	ADP	IN	5	O
1990	1990	NUM	CD	2	O
and	and	CCONJ	CC	5	O
1995	1995	NUM	CD	2	O
and	and	CCONJ	CC	5	O
925	925	NUM	CD	7	O
control	control	NOUN	NN	9	O
women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
not	not	ADV	RB	5	O
had	have	VERB	VBN	9	O
a	a	DET	DT	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
matched	match	VERB	VBN	9	O
for	for	ADP	IN	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
calendar	calendar	NOUN	NN	5	O
year	year	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
index	index	NOUN	NN	5	O
event	event	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
area	area	NOUN	NN	5	O
of	of	ADP	IN	5	O
residence	residence	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Subjects	subject	NOUN	NNS	5	O
supplied	supply	VERB	VBD	9	O
information	information	NOUN	NN	5	O
on	on	ADP	IN	5	O
oral	oral	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
contraceptive	contraceptive	NOUN	NN	5	I-Chemical
use	use	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
major	major	ADJ	JJ	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
analysis	analysis	NOUN	NN	9	O
for	for	ADP	IN	5	O
factor	factor	NOUN	NN	9	O
V	V	PROPN	NNP	9	O
Leiden	Leiden	PROPN	NNP	2	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
G20210A	G20210A	PROPN	NNP	5	O
mutation	mutation	NOUN	NN	1	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
prothrombin	prothrombin	NOUN	NN	9	O
gene	gene	NOUN	NN	1	O
was	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
in	in	ADP	IN	5	O
217	217	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
763	763	NUM	CD	7	O
controls	control	NOUN	NNS	9	O
RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
odds	odd	NOUN	NNS	5	O
ratio	ratio	NOUN	NN	9	O
for	for	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
among	among	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
used	use	VERB	VBD	5	O
any	any	DET	DT	5	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
combined	combined	ADJ	JJ	9	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptive	contraceptive	NOUN	NN	5	I-Chemical
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
nonusers	nonuser	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
percent	percent	NOUN	NN	5	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
adjusted	adjust	VERB	VBN	9	O
odds	odd	NOUN	NNS	5	O
ratio	ratio	NOUN	NN	9	O
was	be	VERB	VBD	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
percent	percent	NOUN	NN	5	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
to	to	ADP	IN	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
among	among	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
used	use	VERB	VBD	5	O
second	second	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptives	contraceptive	NOUN	NNS	5	I-Chemical
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
percent	percent	NOUN	NN	5	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
among	among	ADP	IN	5	O
those	those	DET	DT	5	O
who	who	PRON	WP	5	O
used	use	VERB	VBD	5	O
third	third	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptives	contraceptive	NOUN	NNS	5	I-Chemical
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
used	use	VERB	VBD	5	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptives	contraceptive	NOUN	NNS	5	I-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
odds	odd	NOUN	NNS	5	O
ratio	ratio	NOUN	NN	9	O
was	be	VERB	VBD	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
percent	percent	NOUN	NN	5	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
those	those	DET	DT	5	O
without	without	ADP	IN	9	O
a	a	DET	DT	5	O
prothrombotic	prothrombotic	ADJ	JJ	5	O
mutation	mutation	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
percent	percent	NOUN	NN	5	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
to	to	PART	TO	5	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
those	those	DET	DT	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
mutation	mutation	NOUN	NN	1	O
CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
among	among	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
used	use	VERB	VBD	5	O
second	second	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptives	contraceptive	NOUN	NNS	5	I-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
with	with	ADP	IN	5	O
respect	respect	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
third	third	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptives	contraceptive	NOUN	NNS	5	I-Chemical
were	be	VERB	VBD	9	O
inconclusive	inconclusive	ADJ	JJ	9	O
but	but	CCONJ	CC	9	O
suggested	suggest	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
was	be	VERB	VBD	9	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
second	second	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptives	contraceptive	NOUN	NNS	5	I-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
among	among	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
used	use	VERB	VBD	5	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptives	contraceptive	NOUN	NNS	5	I-Chemical
whether	whether	ADP	IN	9	O
or	or	CCONJ	CC	5	O
not	not	ADV	RB	5	O
they	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
prothrombotic	prothrombotic	ADJ	JJ	5	O
mutation	mutation	NOUN	NN	1	O
.	.	PUNCT	.	9	O

End	end	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
stage	stage	NOUN	NN	9	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
ESRD	esrd	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
orthotopic	orthotopic	ADJ	JJ	3	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
OLTX	OLTX	PROPN	NNP	2	O
)	)	PUNCT	-RRB-	9	O
using	use	VERB	VBG	9	O
calcineurin	calcineurin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
immunotherapy	immunotherapy	NOUN	NN	5	O
:	:	PUNCT	:	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
development	development	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
calcineurin	calcineurin	NOUN	NN	3	O
inhibitors	inhibitor	NOUN	NNS	3	O
cyclosporine	cyclosporine	VERB	VBP	0	B-Chemical
and	and	CCONJ	CC	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
both	both	DET	DT	9	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
nephrotoxic	nephrotoxic	ADJ	JJ	5	B-Disease
.	.	PUNCT	.	9	O

Their	-PRON-	DET	PRP$	5	O
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
orthotopic	orthotopic	ADJ	JJ	3	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
OLTX	OLTX	PROPN	NNP	2	O
)	)	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
dramatically	dramatically	ADV	RB	9	O
improved	improve	VERB	VBN	5	O
success	success	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Recently	recently	ADV	RB	9	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
have	have	VERB	VBP	5	O
had	have	VERB	VBN	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
are	be	VERB	VBP	5	O
presenting	present	VERB	VBG	5	O
after	after	ADP	IN	9	O
OLTX	OLTX	PROPN	NNP	2	O
with	with	ADP	IN	5	O
end	end	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
stage	stage	NOUN	NN	9	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
ESRD	esrd	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
retrospective	retrospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
examines	examine	VERB	VBZ	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
and	and	CCONJ	CC	5	O
chronic	chronic	VERB	VB	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
CRF	CRF	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
OLTX	OLTX	PROPN	NNP	2	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
an	an	DET	DT	5	O
OLTX	OLTX	PROPN	NNP	2	O
only	only	ADV	RB	9	O
from	from	ADP	IN	9	O
June	June	PROPN	NNP	2	O
1985	1985	NUM	CD	2	O
through	through	ADP	IN	9	O
December	December	PROPN	NNP	2	O
of	of	ADP	IN	5	O
1994	1994	NUM	CD	2	O
who	who	PRON	WP	5	O
survived	survive	VERB	VBD	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
postoperatively	postoperatively	ADV	RB	5	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
834	834	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
prospectively	prospectively	ADV	RB	5	O
collected	collected	ADJ	JJ	9	O
database	database	NOUN	NN	5	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
source	source	NOUN	NN	5	O
of	of	ADP	IN	5	O
information	information	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
divided	divide	VERB	VBN	5	O
into	into	ADP	IN	9	O
three	three	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
Controls	control	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
CRF	CRF	PROPN	NNP	9	B-Disease
or	or	CCONJ	CC	5	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
748	748	NUM	CD	7	O
;	;	PUNCT	:	9	O
CRF	CRF	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
sustained	sustain	VERB	VBD	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	VERB	VBP	0	B-Chemical
>	>	X	XX	0	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
41	41	NUM	CD	7	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
45	45	NUM	CD	9	O
.	.	PUNCT	.	9	O

Groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
for	for	ADP	IN	5	O
preoperative	preoperative	ADJ	JJ	5	O
laboratory	laboratory	NOUN	NN	9	O
variables	variable	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
diagnosis	diagnosis	NOUN	NN	5	O
,	,	PUNCT	,	9	O
postoperative	postoperative	ADJ	JJ	5	O
variables	variable	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
survival	survival	NOUN	NN	9	O
,	,	PUNCT	,	9	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
survival	survival	NOUN	NN	9	O
from	from	ADP	IN	9	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
At	at	ADP	IN	9	O
13	13	NUM	CD	7	O
years	year	NOUN	NNS	5	O
after	after	ADP	IN	9	O
OLTX	OLTX	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
CRF	CRF	PROPN	NNP	9	B-Disease
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
control	control	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
CRF	CRF	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
preoperative	preoperative	ADJ	JJ	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
greater	great	ADJ	JJR	5	O
percentage	percentage	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hepatorenal	hepatorenal	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
higher	high	ADJ	JJR	9	O
percentage	percentage	NOUN	NN	9	O
requirement	requirement	NOUN	NN	9	O
for	for	ADP	IN	5	O
dialysis	dialysis	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
postoperatively	postoperatively	ADV	RB	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Multivariate	multivariate	ADJ	JJ	5	O
stepwise	stepwise	ADJ	JJ	5	O
logistic	logistic	ADJ	JJ	5	O
regression	regression	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
using	use	VERB	VBG	9	O
preoperative	preoperative	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
postoperative	postoperative	ADJ	JJ	5	O
variables	variable	NOUN	NNS	5	O
identified	identify	VERB	VBD	9	O
that	that	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
average	average	ADJ	JJ	5	O
at	at	ADP	IN	9	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
postoperatively	postoperatively	ADV	RB	5	O
were	be	VERB	VBD	9	O
independent	independent	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
CRF	CRF	PROPN	NNP	9	B-Disease
or	or	CCONJ	CC	5	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
with	with	ADP	IN	5	O
odds	odd	NOUN	NNS	5	O
ratios	ratio	NOUN	NNS	9	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Overall	overall	ADJ	JJ	9	O
survival	survival	NOUN	NN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
OLTX	OLTX	PROPN	NNP	2	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
different	different	ADJ	JJ	9	O
among	among	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
by	by	ADP	IN	9	O
year	year	NOUN	NN	5	O
13	13	NUM	CD	7	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
survival	survival	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
only	only	ADV	RB	9	O
28	28	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
54	54	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
developing	develop	VERB	VBG	5	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
survival	survival	NOUN	NN	9	O
after	after	ADP	IN	9	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
of	of	ADP	IN	5	O
27	27	NUM	CD	7	O
%	%	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
hemodialysis	hemodialysis	NOUN	NN	5	O
versus	versus	ADP	IN	9	O
71	71	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
developing	develop	VERB	VBG	5	O
ESRD	ESRD	PROPN	NNPS	5	B-Disease
who	who	PRON	WP	5	O
subsequently	subsequently	ADV	RB	9	O
received	receive	VERB	VBD	9	O
kidney	kidney	NOUN	NN	9	O
transplants	transplant	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
are	be	VERB	VBP	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
10	10	NUM	CD	9	O
years	year	NOUN	NNS	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
OLTX	OLTX	NOUN	NNS	2	O
have	have	VERB	VBP	5	O
CRF	CRF	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
decreases	decrease	VERB	VBZ	9	O
survival	survival	NOUN	NN	9	O
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
in	in	ADP	IN	5	O
those	those	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
dialysis	dialysis	NOUN	NN	5	O
only	only	ADV	RB	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
develop	develop	VERB	VBP	5	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
have	have	VERB	VBP	5	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
preoperative	preoperative	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
are	be	VERB	VBP	5	O
more	more	ADV	RBR	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
hepatorenal	hepatorenal	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
various	various	ADJ	JJ	9	O
times	time	NOUN	NNS	5	O
postoperatively	postoperatively	ADV	RB	5	O
is	be	VERB	VBZ	5	O
more	more	ADV	RBR	5	O
predictive	predictive	ADJ	JJ	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
CRF	CRF	PROPN	NNP	9	B-Disease
or	or	CCONJ	CC	5	O
ESRD	esrd	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

New	new	ADJ	JJ	2	O
strategies	strategy	NOUN	NNS	5	O
for	for	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
immunosuppression	immunosuppression	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
needed	need	VERB	VBN	5	O
to	to	PART	TO	5	O
decrease	decrease	VERB	VB	9	O
this	this	DET	DT	5	O
complication	complication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Epileptic	epileptic	ADJ	JJ	5	B-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
following	follow	VERB	VBG	9	O
cortical	cortical	ADJ	JJ	5	O
application	application	NOUN	NN	5	O
of	of	ADP	IN	5	O
fibrin	fibrin	NOUN	NN	0	O
sealants	sealant	NOUN	NNS	5	O
containing	contain	VERB	VBG	0	O
tranexamic	tranexamic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Fibrin	Fibrin	PROPN	NNP	0	O
sealants	sealant	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
FS	FS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
derived	derive	VERB	VBN	9	O
from	from	ADP	IN	9	O
human	human	ADJ	JJ	3	O
plasma	plasma	NOUN	NN	9	O
are	be	VERB	VBP	5	O
frequently	frequently	ADV	RB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
neurosurgery	neurosurgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
increase	increase	VERB	VB	9	O
clot	clot	NOUN	NN	5	O
stability	stability	NOUN	NN	9	O
,	,	PUNCT	,	9	O
FS	FS	PROPN	NNP	9	O
typically	typically	ADV	RB	5	O
contain	contain	VERB	VBP	9	O
aprotinin	aprotinin	NOUN	NN	0	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
natural	natural	ADJ	JJ	5	O
fibrinolysis	fibrinolysis	NOUN	NN	5	O
inhibitor	inhibitor	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Recently	recently	ADV	RB	9	O
,	,	PUNCT	,	9	O
synthetic	synthetic	ADJ	JJ	0	O
fibrinolysis	fibrinolysis	NOUN	NN	5	O
inhibitors	inhibitor	NOUN	NNS	3	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
tranexamic	tranexamic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
tAMCA	tamca	NUM	CD	_	B-Chemical
)	)	PUNCT	-RRB-	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
considered	consider	VERB	VBN	5	O
as	as	ADP	IN	5	O
substitutes	substitute	NOUN	NNS	5	O
for	for	ADP	IN	5	O
aprotinin	aprotinin	NOUN	NN	0	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
tAMCA	tAMCA	PROPN	NNP	_	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
wanted	want	VERB	VBD	5	O
to	to	PART	TO	5	O
study	study	VERB	VB	9	O
whether	whether	ADP	IN	9	O
tAMCA	tAMCA	PROPN	NNP	_	B-Chemical
retains	retain	VERB	VBZ	9	O
its	-PRON-	DET	PRP$	9	O
convulsive	convulsive	ADJ	JJ	5	B-Disease
action	action	NOUN	NN	5	O
if	if	ADP	IN	5	O
incorporated	incorporate	VERB	VBN	9	O
into	into	ADP	IN	9	O
a	a	DET	DT	5	O
FS	fs	NOUN	NN	9	O
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
FS	fs	NOUN	NN	9	O
containing	contain	VERB	VBG	0	O
aprotinin	aprotinin	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
different	different	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
tAMCA	tamca	NUM	CD	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
47	47	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
applied	apply	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
pial	pial	ADJ	JJ	5	O
surface	surface	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cortex	cortex	NOUN	NN	5	O
of	of	ADP	IN	5	O
anaesthetized	anaesthetized	ADJ	JJ	0	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
response	response	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
using	use	VERB	VBG	9	O
electroencephalography	electroencephalography	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
by	by	ADP	IN	9	O
monitoring	monitor	VERB	VBG	5	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
behaviour	behaviour	NOUN	NN	5	O
during	during	ADP	IN	5	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
recovery	recovery	NOUN	NN	9	O
from	from	ADP	IN	9	O
anaesthesia	anaesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

FINDINGS	finding	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
FS	fs	NOUN	NN	9	O
containing	contain	VERB	VBG	0	O
tAMCA	tamca	NUM	CD	_	B-Chemical
caused	cause	VERB	VBN	9	O
paroxysmal	paroxysmal	ADJ	JJ	5	O
brain	brain	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
distinct	distinct	ADJ	JJ	9	O
convulsive	convulsive	ADJ	JJ	5	B-Disease
behaviours	behaviour	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
increased	increase	VERB	VBD	9	O
with	with	ADP	IN	5	O
increasing	increase	VERB	VBG	9	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
tAMCA	tamca	NUM	CD	_	B-Chemical
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
FS	FS	PROPN	NNP	9	O
containing	contain	VERB	VBG	0	O
47	47	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
tAMCA	tamca	NUM	CD	_	B-Chemical
evoked	evoke	VERB	VBN	5	O
generalized	generalized	ADJ	JJ	5	B-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
tested	test	VERB	VBN	9	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
while	while	ADP	IN	9	O
the	the	DET	DT	5	O
lowest	low	ADJ	JJS	9	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
tAMCA	tAMCA	PROPN	NNP	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
only	only	ADV	RB	9	O
evoked	evoke	VERB	VBD	5	O
brief	brief	ADJ	JJ	5	O
episodes	episode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
jerk	jerk	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
correlated	correlate	VERB	VBN	9	O
convulsive	convulsive	ADJ	JJ	5	B-Disease
potentials	potential	NOUN	NNS	5	O
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
of	of	ADP	IN	5	O
6	6	NUM	CD	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
FS	FS	PROPN	NNP	9	O
containing	contain	VERB	VBG	0	O
aprotinin	aprotinin	NOUN	NN	0	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
evoke	evoke	VERB	VB	5	O
any	any	DET	DT	5	O
paroxysmal	paroxysmal	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

INTERPRETATION	interpretation	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Tranexamic	Tranexamic	PROPN	NNP	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
retains	retain	VERB	VBZ	9	O
its	-PRON-	DET	PRP$	9	O
convulsive	convulsive	ADJ	JJ	5	B-Disease
action	action	NOUN	NN	5	O
within	within	ADP	IN	9	O
FS	FS	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
FS	fs	NOUN	NN	9	O
containing	contain	VERB	VBG	0	O
tAMCA	tamca	NUM	CD	_	B-Chemical
for	for	ADP	IN	5	O
surgery	surgery	NOUN	NN	5	O
within	within	ADP	IN	9	O
or	or	CCONJ	CC	5	O
close	close	ADJ	JJ	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
CNS	CNS	PROPN	NNP	9	O
may	may	VERB	MD	5	O
pose	pose	VERB	VB	5	O
a	a	DET	DT	5	O
substantial	substantial	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Sequential	sequential	ADJ	JJ	5	O
observations	observation	NOUN	NNS	9	O
of	of	ADP	IN	5	O
exencephaly	exencephaly	NOUN	NN	3	B-Disease
and	and	CCONJ	CC	5	O
subsequent	subsequent	ADJ	JJ	9	O
morphological	morphological	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
by	by	ADP	IN	9	O
mouse	mouse	NOUN	NN	3	O
exo	exo	NOUN	NN	1	O
utero	utero	NOUN	NN	9	O
development	development	NOUN	NN	9	O
system	system	NOUN	NN	5	O
:	:	PUNCT	:	9	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
transformation	transformation	NOUN	NN	9	O
from	from	ADP	IN	9	O
exencephaly	exencephaly	NOUN	NN	3	B-Disease
to	to	ADP	IN	5	O
anencephaly	anencephaly	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Anencephaly	Anencephaly	PROPN	NNP	7	B-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
suggested	suggest	VERB	VBN	9	O
to	to	PART	TO	5	O
develop	develop	VERB	VB	5	O
from	from	ADP	IN	9	O
exencephaly	exencephaly	NOUN	NN	3	B-Disease
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
little	little	ADJ	JJ	9	O
direct	direct	ADJ	JJ	9	O
experimental	experimental	ADJ	JJ	5	O
evidence	evidence	NOUN	NN	9	O
to	to	PART	TO	5	O
support	support	VERB	VB	5	O
this	this	DET	DT	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
transformation	transformation	NOUN	NN	9	O
remains	remain	VERB	VBZ	9	O
unclear	unclear	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
examined	examine	VERB	VBD	9	O
this	this	DET	DT	5	O
theory	theory	NOUN	NN	5	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
exo	exo	ADJ	JJ	1	O
utero	utero	ADJ	JJ	9	O
development	development	NOUN	NN	9	O
system	system	NOUN	NN	5	O
that	that	DET	WDT	5	O
allows	allow	VERB	VBZ	5	O
direct	direct	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
sequential	sequential	ADJ	JJ	5	O
observations	observation	NOUN	NNS	9	O
of	of	ADP	IN	5	O
mid	mid	NOUN	NN	9	O
-	-	NOUN	NN	7	O
to	to	ADP	IN	5	O
late	late	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
gestation	gestation	NOUN	NN	9	O
mouse	mouse	NOUN	NN	3	O
embryos	embryo	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
observed	observe	VERB	VBD	9	O
the	the	DET	DT	5	O
exencephaly	exencephaly	NOUN	NN	3	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
azacytidine	azacytidine	NOUN	NN	3	I-Chemical
at	at	ADP	IN	9	O
embryonic	embryonic	ADJ	JJ	3	O
day	day	NOUN	NN	9	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
E13	e13	ADJ	JJ	3	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
let	let	VERB	VB	5	O
the	the	DET	DT	5	O
embryos	embryo	NOUN	NNS	3	O
develop	develop	VERB	VB	5	O
exo	exo	VERB	VBN	1	O
utero	utero	NOUN	NN	9	O
until	until	ADP	IN	5	O
E18	E18	PROPN	NNP	3	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
re	re	NOUN	NN	5	O
-	-	ADJ	JJ	7	O
observed	observe	VERB	VBD	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
embryos	embryo	NOUN	NNS	3	O
at	at	ADP	IN	9	O
E18	E18	PROPN	NNP	3	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
confirmed	confirm	VERB	VBD	9	O
several	several	ADJ	JJ	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
transformation	transformation	NOUN	NN	9	O
from	from	ADP	IN	9	O
exencephaly	exencephaly	NOUN	NN	3	B-Disease
to	to	ADP	IN	5	O
anencephaly	anencephaly	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
many	many	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
exencephalic	exencephalic	ADJ	JJ	3	B-Disease
brain	brain	NOUN	NN	5	O
tissue	tissue	NOUN	NN	9	O
was	be	VERB	VBD	9	O
preserved	preserve	VERB	VBN	9	O
with	with	ADP	IN	5	O
more	more	ADJ	JJR	5	O
or	or	CCONJ	CC	5	O
less	less	ADJ	JJR	5	O
reduction	reduction	NOUN	NN	9	O
during	during	ADP	IN	5	O
this	this	DET	DT	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
analyze	analyze	VERB	VB	9	O
the	the	DET	DT	5	O
transformation	transformation	NOUN	NN	9	O
patterns	pattern	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
classified	classify	VERB	VBD	5	O
the	the	DET	DT	5	O
exencephaly	exencephaly	NOUN	NN	3	B-Disease
by	by	ADP	IN	9	O
size	size	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
shape	shape	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
exencephalic	exencephalic	ADJ	JJ	3	B-Disease
tissue	tissue	NOUN	NN	9	O
into	into	ADP	IN	9	O
several	several	ADJ	JJ	9	O
types	type	NOUN	NNS	9	O
at	at	ADP	IN	9	O
E13	E13	PROPN	NNP	3	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
E18	E18	PROPN	NNP	3	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
transformation	transformation	NOUN	NN	9	O
of	of	ADP	IN	5	O
exencephalic	exencephalic	ADJ	JJ	3	B-Disease
tissue	tissue	NOUN	NN	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
simply	simply	ADV	RB	5	O
size	size	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
all	all	DET	DT	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
anencephaly	anencephaly	NOUN	NN	5	B-Disease
at	at	ADP	IN	9	O
E18	E18	PROPN	NNP	3	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
resulted	result	VERB	VBD	9	O
from	from	ADP	IN	9	O
embryos	embryo	NOUN	NNS	3	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
large	large	ADJ	JJ	5	O
amount	amount	NOUN	NN	9	O
of	of	ADP	IN	5	O
exencephalic	exencephalic	ADJ	JJ	3	B-Disease
tissue	tissue	NOUN	NN	9	O
at	at	ADP	IN	9	O
E13	E13	PROPN	NNP	3	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O

Microscopic	microscopic	ADJ	JJ	9	O
observation	observation	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
the	the	DET	DT	5	O
configuration	configuration	NOUN	NN	5	O
of	of	ADP	IN	5	O
exencephaly	exencephaly	NOUN	NN	3	B-Disease
at	at	ADP	IN	9	O
E13	E13	PROPN	NNP	3	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
frequent	frequent	ADJ	JJ	5	O
hemorrhaging	hemorrhaging	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
detachment	detachment	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
neural	neural	ADJ	JJ	5	O
plate	plate	NOUN	NN	0	O
from	from	ADP	IN	9	O
surface	surface	NOUN	NN	9	O
ectoderm	ectoderm	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
exencephalic	exencephalic	ADJ	JJ	3	B-Disease
head	head	NOUN	NN	5	O
at	at	ADP	IN	9	O
E15	E15	PROPN	NNP	3	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
multiple	multiple	ADJ	JJ	5	O
modes	mode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
exencephalic	exencephalic	ADJ	JJ	3	B-Disease
tissue	tissue	NOUN	NN	9	O
at	at	ADP	IN	9	O
E18	E18	PROPN	NNP	3	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O

From	from	ADP	IN	5	O
observations	observation	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
vasculature	vasculature	NOUN	NN	5	O
,	,	PUNCT	,	9	O
altered	altered	ADJ	JJ	9	O
distribution	distribution	NOUN	NN	9	O
patterns	pattern	NOUN	NNS	5	O
of	of	ADP	IN	5	O
vessels	vessel	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
exencephalic	exencephalic	ADJ	JJ	3	B-Disease
head	head	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	DET	DT	5	O
overgrowth	overgrowth	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
exencephalic	exencephalic	ADJ	JJ	3	B-Disease
neural	neural	ADJ	JJ	5	O
tissue	tissue	NOUN	NN	9	O
causes	cause	VERB	VBZ	9	O
the	the	DET	DT	5	O
altered	altered	ADJ	JJ	9	O
distribution	distribution	NOUN	NN	9	O
patterns	pattern	NOUN	NNS	5	O
of	of	ADP	IN	5	O
vessels	vessel	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
subsequent	subsequent	ADJ	JJ	9	O
peripheral	peripheral	ADJ	JJ	9	O
circulatory	circulatory	ADJ	JJ	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
hemorrhaging	hemorrhage	VERB	VBG	5	B-Disease
in	in	ADP	IN	5	O
various	various	ADJ	JJ	9	O
parts	part	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
exencephalic	exencephalic	ADJ	JJ	3	B-Disease
head	head	NOUN	NN	5	O
,	,	PUNCT	,	9	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
multiple	multiple	ADJ	JJ	5	O
modes	mode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
tissue	tissue	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
during	during	ADP	IN	5	O
transformation	transformation	NOUN	NN	9	O
from	from	ADP	IN	9	O
exencephaly	exencephaly	NOUN	NN	3	B-Disease
to	to	ADP	IN	5	O
anencephaly	anencephaly	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

99mTc	99mTc	PUNCT	LS	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
glucarate	glucarate	NOUN	NN	0	I-Chemical
for	for	ADP	IN	5	O
detection	detection	NOUN	NN	9	O
of	of	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Infarct	Infarct	PROPN	NNP	5	B-Disease
-	-	PUNCT	HYPH	7	O
avid	avid	ADJ	JJ	9	O
radiopharmaceuticals	radiopharmaceutical	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
necessary	necessary	ADJ	JJ	5	O
for	for	ADP	IN	5	O
rapid	rapid	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
timely	timely	ADJ	JJ	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
animal	animal	NOUN	NN	5	O
model	model	NOUN	NN	5	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
produce	produce	VERB	VB	9	O
infarction	infarction	NOUN	NN	5	B-Disease
implies	imply	VERB	VBZ	5	O
artery	artery	NOUN	NN	5	O
ligation	ligation	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
chemical	chemical	NOUN	NN	0	O
induction	induction	NOUN	NN	3	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
easily	easily	ADV	RB	5	O
obtained	obtain	VERB	VBN	9	O
with	with	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
new	new	ADJ	JJ	5	O
infarct	infarct	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	O
avid	avid	ADJ	JJ	9	O
radiopharmaceutical	radiopharmaceutical	NOUN	NN	5	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
glucaric	glucaric	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
prepared	prepare	VERB	VBN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hospital	hospital	NOUN	NN	5	O
radiopharmacy	radiopharmacy	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
INCMNSZ	INCMNSZ	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

99mTc	99mTc	PUNCT	LS	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
glucarate	glucarate	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
easy	easy	ADJ	JJ	5	O
to	to	PART	TO	5	O
prepare	prepare	VERB	VB	9	O
,	,	PUNCT	,	9	O
stable	stable	ADJ	JJ	9	O
for	for	ADP	IN	5	O
96	96	NUM	CD	9	O
h	h	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
study	study	VERB	VB	9	O
its	-PRON-	DET	PRP$	9	O
biodistribution	biodistribution	NOUN	NN	0	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Histological	histological	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
demonstrated	demonstrate	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
developed	develop	VERB	VBD	5	O
an	an	DET	DT	5	O
infarct	infarct	NOUN	NN	9	B-Disease
18	18	NUM	CD	7	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
biodistribution	biodistribution	NOUN	NN	0	O
studies	study	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
rapid	rapid	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
clearance	clearance	NOUN	NN	9	O
via	via	ADP	IN	9	O
the	the	DET	DT	5	O
kidneys	kidney	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
99mTc	99mtc	NUM	CD	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
glucarate	glucarate	NOUN	NN	0	I-Chemical
administration	administration	NOUN	NN	9	O
the	the	DET	DT	5	O
standardised	standardised	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	O
uptake	uptake	NOUN	NN	0	O
value	value	NOUN	NN	9	O
S	S	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
h	h	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
UV	uv	NOUN	NN	0	O
was	be	VERB	VBD	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
in	in	ADP	IN	5	O
infarcted	infarcte	VERB	VBN	3	O
rat	rat	NOUN	NN	3	O
heart	heart	NOUN	NN	5	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
six	six	NUM	CD	9	O
times	time	NOUN	NNS	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

ROIs	ROIs	PROPN	NNP	5	O
drawn	draw	VERB	VBN	5	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
gamma	gamma	NOUN	NN	9	O
camera	camera	NOUN	NN	5	O
images	image	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
ratio	ratio	NOUN	NN	9	O
of	of	ADP	IN	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
image	image	NOUN	NN	5	O
quality	quality	NOUN	NN	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
high	high	ADJ	JJ	9	O
contrast	contrast	NOUN	NN	9	O
images	image	NOUN	NNS	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
obtained	obtain	VERB	VBN	9	O
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
96	96	NUM	CD	9	O
h	h	NOUN	NN	0	O
stability	stability	NOUN	NN	9	O
makes	make	VERB	VBZ	5	O
it	-PRON-	PRON	PRP	5	O
an	an	DET	DT	5	O
ideal	ideal	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
to	to	PART	TO	5	O
detect	detect	VERB	VB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
early	early	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Bupropion	Bupropion	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Zyban	Zyban	PROPN	NNP	7	B-Chemical
)	)	PUNCT	-RRB-	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Bupropion	bupropion	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
monocyclic	monocyclic	ADJ	JJ	0	O
antidepressant	antidepressant	NOUN	NN	5	B-Chemical
structurally	structurally	ADV	RB	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Zyban	Zyban	PROPN	NNP	7	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
sustained	sustain	VERB	VBN	5	O
-	-	PUNCT	HYPH	7	O
release	release	NOUN	NN	9	O
formulation	formulation	NOUN	NN	5	O
of	of	ADP	IN	5	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
recently	recently	ADV	RB	9	O
released	release	VERB	VBN	9	O
in	in	ADP	IN	5	O
Ireland	Ireland	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
smoking	smoking	NOUN	NN	5	O
cessation	cessation	NOUN	NN	5	O
aid	aid	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
since	since	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
'	'	PUNCT	''	9	O
s	s	VERB	VBZ	9	O
introduction	introduction	NOUN	NN	9	O
,	,	PUNCT	,	9	O
12	12	NUM	CD	9	O
overdose	overdose	NOUN	NN	0	B-Disease
cases	case	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
to	to	ADP	IN	5	O
The	the	DET	DT	5	O
National	National	PROPN	NNP	2	O
Poisons	Poisons	PROPN	NNPS	2	O
Information	Information	PROPN	NNP	5	O
Centre	Centre	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

8	8	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Common	Common	PROPN	NNP	9	O
features	feature	NOUN	NNS	5	O
included	include	VERB	VBD	5	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
drowsiness	drowsiness	NOUN	NN	5	O
,	,	PUNCT	,	9	O
hallucinations	hallucination	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
severe	severe	ADJ	JJ	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrhythmias	arrhythmia	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
was	be	VERB	VBD	9	O
resuscitated	resuscitate	VERB	VBN	5	O
following	follow	VERB	VBG	9	O
a	a	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
recovered	recover	VERB	VBD	9	O
without	without	ADP	IN	9	O
sequelae	sequelae	ADV	RB	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
31	31	NUM	CD	7	O
year	year	NOUN	NN	5	O
old	old	ADJ	JJ	5	O
female	female	NOUN	NN	9	O
who	who	PRON	WP	5	O
required	require	VERB	VBD	9	O
admission	admission	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
Intensive	Intensive	PROPN	NNP	2	O
Care	Care	PROPN	NNP	2	O
Unit	unit	NOUN	NN	2	O
for	for	ADP	IN	5	O
ventilation	ventilation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
full	full	ADJ	JJ	5	O
supportive	supportive	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
following	follow	VERB	VBG	9	O
ingestion	ingestion	NOUN	NN	9	O
of	of	ADP	IN	5	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
5g	5g	NUM	CD	0	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Recurrent	Recurrent	PROPN	NNP	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
broad	broad	ADJ	JJ	5	O
complex	complex	ADJ	JJ	9	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
successfully	successfully	ADV	RB	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Zyban	Zyban	PROPN	NNP	7	B-Chemical
caused	cause	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
neurological	neurological	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
cardiovascular	cardiovascular	ADJ	JJ	5	I-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
overdose	overdose	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
toxic	toxic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
when	when	ADV	WRB	5	O
prescribing	prescribe	VERB	VBG	5	O
it	-PRON-	PRON	PRP	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
smoking	smoking	NOUN	NN	5	O
cessation	cessation	NOUN	NN	5	O
aid	aid	NOUN	NN	5	O
.	.	PUNCT	.	9	O

GLEPP1	glepp1	INTJ	UH	3	O
receptor	receptor	VERB	VB	3	O
tyrosine	tyrosine	NOUN	NN	3	B-Chemical
phosphatase	phosphatase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
Ptpro	Ptpro	PROPN	NNP	1	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
PAN	PAN	PROPN	NNP	0	B-Chemical
nephrosis	nephrosis	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
marker	marker	NOUN	NN	3	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
podocyte	podocyte	NOUN	NN	3	O
injury	injury	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Glomerular	glomerular	ADJ	JJ	9	O
epithelial	epithelial	ADJ	JJ	3	O
protein	protein	NOUN	NN	1	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
GLEPP1	GLEPP1	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
podocyte	podocyte	NOUN	NN	3	O
receptor	receptor	NOUN	NN	3	O
membrane	membrane	NOUN	NN	9	O
protein	protein	NOUN	NN	1	O
tyrosine	tyrosine	NOUN	NN	3	B-Chemical
phosphatase	phosphatase	NOUN	NN	0	O
located	locate	VERB	VBN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
apical	apical	ADJ	JJ	9	O
cell	cell	NOUN	NN	3	O
membrane	membrane	NOUN	NN	9	O
of	of	ADP	IN	5	O
visceral	visceral	ADJ	JJ	9	O
glomerular	glomerular	ADJ	JJ	5	O
epithelial	epithelial	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
foot	foot	NOUN	NN	5	O
processes	process	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
receptor	receptor	NOUN	NN	3	O
plays	play	VERB	VBZ	9	O
a	a	DET	DT	5	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
regulating	regulate	VERB	VBG	9	O
the	the	DET	DT	5	O
structure	structure	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
function	function	NOUN	NN	9	O
of	of	ADP	IN	5	O
podocyte	podocyte	NOUN	NN	3	O
foot	foot	NOUN	NN	5	O
process	process	NOUN	NN	5	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
better	better	ADV	RB	5	O
understand	understand	VERB	VB	5	O
the	the	DET	DT	5	O
utility	utility	NOUN	NN	5	O
of	of	ADP	IN	5	O
GLEPP1	GLEPP1	PROPN	NNP	3	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
marker	marker	NOUN	NN	3	O
of	of	ADP	IN	5	O
glomerular	glomerular	ADJ	JJ	5	B-Disease
injury	injury	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
amount	amount	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
distribution	distribution	NOUN	NN	9	O
of	of	ADP	IN	5	O
GLEPP1	GLEPP1	PROPN	NNP	3	O
protein	protein	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
mRNA	mRNA	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
by	by	ADP	IN	9	O
immunohistochemistry	immunohistochemistry	NOUN	NN	3	O
,	,	PUNCT	,	9	O
Western	western	ADJ	JJ	3	O
blot	blot	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
RNase	RNase	PROPN	NNP	0	O
protection	protection	NOUN	NN	9	O
assay	assay	VERB	VBP	3	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
podocyte	podocyte	NOUN	NN	3	O
injury	injury	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Puromycin	Puromycin	PROPN	NNP	0	B-Chemical
aminonucleoside	aminonucleoside	ADP	IN	0	I-Chemical
nephrosis	nephrosis	NOUN	NN	0	B-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
single	single	ADJ	JJ	9	O
intraperitoneal	intraperitoneal	ADJ	JJ	0	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
puromycin	puromycin	NOUN	NN	3	B-Chemical
aminonucleoside	aminonucleoside	ADP	IN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
PAN	PAN	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
100g	100g	PROPN	NNP	0	O
BW	BW	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Tissues	tissue	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
at	at	ADP	IN	9	O
0	0	NUM	CD	7	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
7	7	NUM	CD	9	O
,	,	PUNCT	,	9	O
11	11	NUM	CD	7	O
,	,	PUNCT	,	9	O
21	21	NUM	CD	7	O
,	,	PUNCT	,	9	O
45	45	NUM	CD	9	O
,	,	PUNCT	,	9	O
80	80	NUM	CD	9	O
and	and	CCONJ	CC	5	O
126	126	NUM	CD	7	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
PAN	PAN	PROPN	NNP	0	B-Chemical
injection	injection	NOUN	NN	9	O
so	so	ADP	IN	5	O
as	as	ADP	IN	5	O
to	to	PART	TO	5	O
include	include	VERB	VB	5	O
both	both	DET	DT	9	O
the	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
phase	phase	NOUN	NN	5	O
of	of	ADP	IN	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
foot	foot	NOUN	NN	5	O
process	process	NOUN	NN	5	O
effacement	effacement	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
days	day	NOUN	NNS	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
11	11	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
chronic	chronic	ADJ	JJ	5	O
phase	phase	NOUN	NN	5	O
of	of	ADP	IN	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	B-Disease
(	(	PUNCT	-LRB-	9	O
days	day	NOUN	NNS	9	O
45	45	NUM	CD	9	O
-	-	SYM	SYM	7	O
126	126	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
day	day	NOUN	NN	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
GLEPP1	GLEPP1	PROPN	NNP	3	O
protein	protein	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
mRNA	mRNA	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
range	range	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
265	265	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
79	79	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
x	x	SYM	SYM	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
moles	mole	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
glomerulus	glomerulus	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
100	100	NUM	CD	0	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
15	15	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
41	41	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
x	x	SYM	SYM	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
moles	mole	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
glomerulus	glomerulus	NOUN	NN	9	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
005	005	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
urinary	urinary	ADJ	JJ	9	O
protein	protein	NOUN	NN	1	O
content	content	NOUN	NN	9	O
from	from	ADP	IN	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
to	to	ADP	IN	5	O
99	99	NUM	CD	7	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
61	61	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
podocalyxin	podocalyxin	NOUN	NN	3	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
change	change	VERB	VB	9	O
significantly	significantly	ADV	RB	9	O
at	at	ADP	IN	9	O
this	this	DET	DT	5	O
time	time	NOUN	NN	5	O
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
day	day	NOUN	NN	9	O
11	11	NUM	CD	7	O
,	,	PUNCT	,	9	O
GLEPP1	GLEPP1	PROPN	NNP	3	O
protein	protein	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
mRNA	mRNA	PROPN	NNP	3	O
had	have	VERB	VBD	9	O
begun	begin	VERB	VBN	5	O
to	to	PART	TO	5	O
return	return	VERB	VB	5	O
towards	towards	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
day	day	NOUN	NN	9	O
45	45	NUM	CD	9	O
-	-	SYM	SYM	7	O
126	126	NUM	CD	7	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
time	time	NOUN	NN	5	O
when	when	ADV	WRB	5	O
glomerular	glomerular	ADJ	JJ	5	O
scarring	scarring	NOUN	NN	5	O
was	be	VERB	VBD	9	O
present	present	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
GLEPP1	GLEPP1	PROPN	NNP	3	O
was	be	VERB	VBD	9	O
absent	absent	ADJ	JJ	9	O
from	from	ADP	IN	9	O
glomerulosclerotic	glomerulosclerotic	ADJ	JJ	3	O
areas	area	NOUN	NNS	5	O
although	although	ADP	IN	9	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
glomerular	glomerular	NOUN	NN	5	O
content	content	NOUN	NN	9	O
of	of	ADP	IN	5	O
GLEPP1	GLEPP1	PROPN	NNP	3	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
different	different	ADJ	JJ	9	O
from	from	ADP	IN	9	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
GLEPP1	GLEPP1	PROPN	NNP	3	O
expression	expression	NOUN	NN	3	O
,	,	PUNCT	,	9	O
unlike	unlike	ADP	IN	9	O
podocalyxin	podocalyxin	NOUN	NN	3	O
,	,	PUNCT	,	9	O
reflects	reflect	VERB	VBZ	5	O
podocyte	podocyte	NOUN	NN	3	O
injury	injury	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
PAN	PAN	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

GLEPP1	glepp1	ADP	IN	3	O
expression	expression	NOUN	NN	3	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
useful	useful	ADJ	JJ	5	O
marker	marker	NOUN	NN	3	O
of	of	ADP	IN	5	O
podocyte	podocyte	NOUN	NN	3	O
injury	injury	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Antithymocyte	antithymocyte	NOUN	NN	7	B-Chemical
globulin	globulin	NOUN	NN	9	I-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
D	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
penicillamine	penicillamine	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
antithymocyte	antithymocyte	NOUN	NN	3	B-Chemical
globulin	globulin	NOUN	NN	9	I-Chemical
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
D	d	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
penicillamine	penicillamine	NOUN	NN	0	I-Chemical
therapy	therapy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Bone	bone	NOUN	NN	9	O
marrow	marrow	NOUN	NN	3	O
recovery	recovery	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
peripheral	peripheral	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
recovery	recovery	NOUN	NN	9	O
were	be	VERB	VBD	9	O
complete	complete	ADJ	JJ	9	O
1	1	NUM	CD	9	O
month	month	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
blood	blood	NOUN	NN	9	O
transfusion	transfusion	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
therapies	therapy	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
necessary	necessary	ADJ	JJ	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
2	2	NUM	CD	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
antithymocyte	antithymocyte	NOUN	NN	3	B-Chemical
globulin	globulin	NOUN	NN	9	I-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
optimal	optimal	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
D	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
penicillamine	penicillamine	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Metamizol	metamizol	NOUN	NN	0	B-Chemical
potentiates	potentiate	NOUN	NNS	3	O
morphine	morphine	NOUN	NN	0	B-Chemical
antinociception	antinociception	NOUN	NN	3	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
constipation	constipation	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
work	work	NOUN	NN	5	O
evaluates	evaluate	VERB	VBZ	5	O
the	the	DET	DT	5	O
antinociceptive	antinociceptive	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
constipating	constipate	VERB	VBG	5	B-Disease
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
s	s	PROPN	NNPS	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
177	177	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
s	s	PROPN	NNPS	9	O
.	.	PUNCT	.	9	O
c	c	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
metamizol	metamizol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
acutely	acutely	ADV	RB	9	O
and	and	CCONJ	CC	5	O
chronically	chronically	ADV	RB	9	O
treated	treat	VERB	VBN	3	O
(	(	PUNCT	-LRB-	9	O
once	once	ADV	RB	5	O
a	a	DET	DT	5	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
12	12	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
13th	13th	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
antinociceptive	antinociceptive	NOUN	NN	0	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
nociception	nociception	NOUN	NN	5	O
,	,	PUNCT	,	9	O
pain	pain	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
functional	functional	ADJ	JJ	9	O
impairment	impairment	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
charcoal	charcoal	NOUN	NN	0	B-Chemical
meal	meal	NOUN	NN	5	O
test	test	NOUN	NN	5	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
intestinal	intestinal	ADJ	JJ	9	O
transit	transit	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Simultaneous	simultaneous	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
metamizol	metamizol	NOUN	NN	0	B-Chemical
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
markedly	markedly	ADV	RB	9	O
antinociceptive	antinociceptive	ADJ	JJ	0	O
potentiation	potentiation	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
increasing	increasing	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
298	298	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
139	139	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
36	36	NUM	CD	9	O
units	unit	NOUN	NNS	9	O
area	area	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ua	ua	ADV	RB	5	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
repeated	repeat	VERB	VBN	5	O
administration	administration	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
280	280	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
17	17	NUM	CD	7	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
131	131	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
22	22	NUM	CD	7	O
ua	ua	NOUN	NN	5	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Antinociceptive	antinociceptive	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
chronically	chronically	ADV	RB	9	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
39	39	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
10	10	NUM	CD	9	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
18	18	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
au	au	NOUN	NNS	2	O
)	)	PUNCT	-RRB-	9	O
while	while	ADP	IN	9	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
antinociception	antinociception	NOUN	NN	3	O
was	be	VERB	VBD	9	O
remained	remain	VERB	VBN	9	O
similar	similar	ADJ	JJ	9	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
298	298	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
280	280	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
17	17	NUM	CD	7	O
au	au	NOUN	NNS	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
antinociceptive	antinociceptive	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
were	be	VERB	VBD	9	O
partially	partially	ADV	RB	9	O
prevented	prevent	VERB	VBN	9	O
by	by	ADP	IN	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
naloxone	naloxone	ADV	RB	0	B-Chemical
s	s	NOUN	NN	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O

(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
the	the	DET	DT	5	O
partial	partial	ADJ	JJ	9	O
involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
opioidergic	opioidergic	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
synergism	synergism	NOUN	NN	9	O
observed	observe	VERB	VBD	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
independent	independent	ADJ	JJ	9	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
inhibited	inhibit	VERB	VBD	3	O
the	the	DET	DT	5	O
intestinal	intestinal	ADJ	JJ	9	O
transit	transit	NOUN	NN	9	O
in	in	ADP	IN	5	O
48	48	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
38	38	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
after	after	ADP	IN	9	O
acute	acute	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
chronic	chronic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
that	that	ADP	IN	5	O
tolerance	tolerance	NOUN	NN	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
develop	develop	VERB	VB	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
constipating	constipate	VERB	VBG	5	B-Disease
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
inhibited	inhibit	VERB	VBD	3	O
intestinal	intestinal	ADJ	JJ	9	O
transit	transit	NOUN	NN	9	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
regardless	regardless	ADV	RB	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
that	that	ADP	IN	5	O
metamizol	metamizol	NOUN	NN	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
potentiate	potentiate	VERB	VB	3	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
constipation	constipation	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
show	show	VERB	VBP	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
interaction	interaction	NOUN	NN	9	O
between	between	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
metamizol	metamizol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
chronically	chronically	ADV	RB	9	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
combination	combination	NOUN	NN	9	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
useful	useful	ADJ	JJ	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Ifosfamide	ifosfamide	ADJ	JJ	0	B-Chemical
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
presenting	present	VERB	VBG	5	O
with	with	ADP	IN	5	O
asterixis	asterixis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

CNS	CNS	PROPN	NNP	9	O
toxic	toxic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
antineoplastic	antineoplastic	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
IFX	IFX	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
are	be	VERB	VBP	5	O
frequent	frequent	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
include	include	VERB	VBP	5	O
a	a	DET	DT	5	O
variety	variety	NOUN	NN	5	O
of	of	ADP	IN	5	O
neurological	neurological	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
that	that	DET	WDT	5	O
can	can	VERB	MD	5	O
limit	limit	VERB	VB	5	O
drug	drug	NOUN	NN	5	O
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
51	51	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
severe	severe	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
disabling	disable	VERB	VBG	5	O
negative	negative	ADJ	JJ	9	O
myoclonus	myoclonus	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
upper	upper	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
lower	low	ADJ	JJR	9	O
extremities	extremity	NOUN	NNS	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
plasmacytoma	plasmacytoma	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
awake	awake	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
revealed	reveal	VERB	VBD	9	O
no	no	DET	DT	9	O
changes	change	NOUN	NNS	9	O
of	of	ADP	IN	5	O
mental	mental	ADJ	JJ	5	O
status	status	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
rest	rest	NOUN	NN	5	O
there	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
further	further	ADJ	JJ	9	O
motor	motor	NOUN	NN	5	O
symptoms	symptom	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Cranial	cranial	ADJ	JJ	5	O
magnetic	magnetic	ADJ	JJ	0	O
resonance	resonance	NOUN	NN	5	O
imaging	imaging	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
extensive	extensive	ADJ	JJ	5	O
laboratory	laboratory	NOUN	NN	9	O
studies	study	NOUN	NNS	9	O
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
reveal	reveal	VERB	VB	9	O
structural	structural	ADJ	JJ	9	B-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
brain	brain	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
metabolic	metabolic	NOUN	NN	9	B-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
electroencephalogram	electroencephalogram	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
continuous	continuous	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
generalized	generalized	ADJ	JJ	5	O
irregular	irregular	ADJ	JJ	5	O
slowing	slow	VERB	VBG	5	O
with	with	ADP	IN	5	O
admixed	admix	VERB	VBN	9	O
periodic	periodic	ADJ	JJ	5	O
triphasic	triphasic	NOUN	NN	5	O
waves	wave	NOUN	NNS	5	O
indicating	indicate	VERB	VBG	9	O
symptomatic	symptomatic	ADJ	JJ	5	O
encephalopathy	encephalopathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
within	within	ADP	IN	9	O
12	12	NUM	CD	9	O
h	h	NOUN	NN	0	O
the	the	DET	DT	5	O
asterixis	asterixis	NOUN	NN	5	B-Disease
resolved	resolve	VERB	VBD	9	O
completely	completely	ADV	RB	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
described	describe	VERB	VBN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
asterixis	asterixis	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
ifosfamide	ifosfamide	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
normal	normal	ADJ	JJ	9	O
laboratory	laboratory	NOUN	NN	9	O
findings	finding	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
imaging	image	VERB	VBG	5	O
studies	study	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
resolution	resolution	NOUN	NN	5	O
of	of	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
negative	negative	ADJ	JJ	9	O
myoclonus	myoclonus	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
IFX	IFX	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

Antagonism	antagonism	NOUN	NN	3	O
between	between	ADP	IN	5	O
interleukin	interleukin	NOUN	NN	3	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
erythropoietin	erythropoietin	NOUN	NN	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
azidothymidine	azidothymidine	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
anemia	anemia	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
endothelial	endothelial	NOUN	NN	3	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Azidothymidine	Azidothymidine	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
AZT	AZT	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
anemia	anemia	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
reversed	reverse	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
IGF	IGF	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
IL	IL	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
3	3	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
fusion	fusion	NOUN	NN	1	O
protein	protein	NOUN	NN	1	O
of	of	ADP	IN	5	O
insulin	insulin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
growth	growth	NOUN	NN	3	O
factor	factor	NOUN	NN	9	O
II	II	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
IGF	IGF	PROPN	NNP	3	O
II	II	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
interleukin	interleukin	NOUN	NN	3	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
interleukin	interleukin	NOUN	NN	3	O
3	3	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
IL	IL	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
3	3	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
erythropoietin	erythropoietin	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
EPO	EPO	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
are	be	VERB	VBP	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
act	act	VERB	VB	9	O
synergistically	synergistically	ADV	RB	9	O
on	on	ADP	IN	5	O
hematopoietic	hematopoietic	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
proliferation	proliferation	NOUN	NN	3	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
,	,	PUNCT	,	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
IGF	IGF	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
IL	IL	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
3	3	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
EPO	EPO	PROPN	NNP	3	O
in	in	ADP	IN	5	O
AZT	AZT	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
mice	mouse	NOUN	NNS	3	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
red	red	ADJ	JJ	9	O
cells	cell	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
EPO	EPO	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
IGF	IGF	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
IL	IL	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
3	3	PROPN	NNP	9	O
or	or	CCONJ	CC	5	O
EPO	EPO	PROPN	NNP	3	O
alone	alone	ADV	RB	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
tested	test	VERB	VBD	9	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
antagonistic	antagonistic	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
IL	IL	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
3	3	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
EPO	EPO	PROPN	NNP	3	O
on	on	ADP	IN	5	O
erythroid	erythroid	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
endothelial	endothelial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Bovine	bovine	ADJ	JJ	2	O
liver	liver	NOUN	NN	9	O
erythroid	erythroid	NOUN	NN	3	O
cells	cell	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
cultured	culture	VERB	VBN	3	O
on	on	ADP	IN	5	O
monolayers	monolayer	NOUN	NNS	3	O
of	of	ADP	IN	5	O
human	human	ADJ	JJ	3	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
endothelial	endothelial	NOUN	NN	3	O
cells	cell	NOUN	NNS	3	O
previously	previously	ADV	RB	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
EPO	EPO	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
IGF	IGF	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
IL	IL	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
thymidine	thymidine	NOUN	NN	0	B-Chemical
incorporation	incorporation	NOUN	NN	0	O
into	into	ADP	IN	9	O
both	both	CCONJ	CC	9	O
erythroid	erythroid	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
endothelial	endothelial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
cultures	culture	NOUN	NNS	3	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
treated	treated	ADJ	JJ	3	O
with	with	ADP	IN	5	O
IGF	IGF	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
IL	IL	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
3	3	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
EPO	EPO	PROPN	NNP	3	O
.	.	PUNCT	.	9	O

Endothelial	endothelial	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
culture	culture	NOUN	NN	9	O
supernatants	supernatant	NOUN	NNS	3	O
separated	separate	VERB	VBN	9	O
by	by	ADP	IN	9	O
ultrafiltration	ultrafiltration	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
ultracentrifugation	ultracentrifugation	NOUN	NN	0	O
from	from	ADP	IN	9	O
cells	cell	NOUN	NNS	3	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
EPO	EPO	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
IL	IL	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
3	3	PROPN	NNP	9	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBD	9	O
thymidine	thymidine	NOUN	NN	0	B-Chemical
incorporation	incorporation	NOUN	NN	0	O
into	into	ADP	IN	9	O
erythroid	erythroid	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
identical	identical	ADJ	JJ	9	O
fractions	fraction	NOUN	NNS	0	O
obtained	obtain	VERB	VBN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
media	medium	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cells	cell	NOUN	NNS	3	O
cultured	culture	VERB	VBN	3	O
with	with	ADP	IN	5	O
EPO	EPO	PROPN	NNP	3	O
alone	alone	ADV	RB	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
endothelial	endothelial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
treated	treat	VERB	VBN	3	O
simultaneously	simultaneously	ADV	RB	5	O
with	with	ADP	IN	5	O
EPO	EPO	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
IL	IL	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
have	have	VERB	VBP	5	O
a	a	DET	DT	5	O
negative	negative	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
erythroid	erythroid	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
production	production	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
release	release	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
cholinergic	cholinergic	NOUN	NN	3	O
convulsant	convulsant	NOUN	NN	0	O
sensitivity	sensitivity	NOUN	NN	9	O
in	in	ADP	IN	5	O
withdrawal	withdrawal	NOUN	NN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
prone	prone	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
withdrawal	withdrawal	NOUN	NN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
resistant	resistant	ADJ	JJ	9	O
selected	select	VERB	VBN	9	O
mouse	mouse	NOUN	NN	3	O
lines	line	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
septo	septo	ADJ	JJ	2	O
-	-	PUNCT	HYPH	7	O
hippocampal	hippocampal	ADJ	JJ	3	O
cholinergic	cholinergic	NOUN	NN	3	O
pathway	pathway	NOUN	NN	3	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
epileptogenesis	epileptogenesis	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
genetic	genetic	ADJ	JJ	5	O
factors	factor	NOUN	NNS	9	O
influence	influence	VERB	VBP	5	O
the	the	DET	DT	5	O
response	response	NOUN	NN	9	O
to	to	PART	TO	5	O
cholinergic	cholinergic	VERB	VB	3	O
agents	agent	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
limited	limited	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
available	available	ADJ	JJ	5	O
on	on	ADP	IN	5	O
cholinergic	cholinergic	ADJ	JJ	3	O
involvement	involvement	NOUN	NN	9	O
in	in	ADP	IN	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
withdrawal	withdrawal	NOUN	NN	5	O
severity	severity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
cholinergic	cholinergic	NOUN	NN	3	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
responsiveness	responsiveness	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
withdrawal	withdrawal	NOUN	NN	5	O
was	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
genetic	genetic	ADJ	JJ	5	O
animal	animal	NOUN	NN	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
ethanol	ethanol	NOUN	NN	0	B-Chemical
withdrawal	withdrawal	NOUN	NN	5	O
severity	severity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Cholinergic	Cholinergic	PROPN	NNP	3	O
convulsant	convulsant	NOUN	NN	0	O
sensitivity	sensitivity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
in	in	ADP	IN	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
na	na	NOUN	NN	7	O
ve	ve	PROPN	NNP	9	O
Withdrawal	Withdrawal	PROPN	NNP	5	O
Seizure	Seizure	PROPN	NNP	5	B-Disease
-	-	PUNCT	HYPH	7	O
Prone	Prone	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
WSP	WSP	PROPN	NNP	4	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
-	-	PUNCT	:	7	O
Resistant	resistant	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
WSR	WSR	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
carbachol	carbachol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
neostigmine	neostigmine	NOUN	NN	0	B-Chemical
via	via	ADP	IN	9	O
timed	time	VERB	VBN	5	O
tail	tail	NOUN	NN	9	O
vein	vein	NOUN	NN	5	O
infusion	infusion	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
latencies	latency	NOUN	NNS	5	O
to	to	PART	TO	5	O
onset	onset	VERB	VB	5	O
of	of	ADP	IN	5	O
tremor	tremor	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
clonus	clonus	NOUN	NN	5	O
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
converted	convert	VERB	VBN	9	O
to	to	PART	TO	5	O
threshold	threshold	VERB	VB	5	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
also	also	ADV	RB	9	O
used	use	VERB	VBD	5	O
microdialysis	microdialysis	NOUN	NN	5	O
to	to	PART	TO	5	O
measure	measure	VERB	VB	5	O
basal	basal	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
stimulated	stimulate	VERB	VBN	3	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
ACh	ACh	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
release	release	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
CA1	CA1	PROPN	NNPS	3	O
region	region	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Potassium	potassium	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
applied	apply	VERB	VBN	5	O
by	by	ADP	IN	9	O
reverse	reverse	ADJ	JJ	9	O
dialysis	dialysis	NOUN	NN	5	O
twice	twice	ADV	RB	9	O
,	,	PUNCT	,	9	O
separated	separate	VERB	VBN	9	O
by	by	ADP	IN	9	O
75	75	NUM	CD	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Hippocampal	Hippocampal	PROPN	NNP	3	O
ACh	ACh	PROPN	NNP	0	B-Chemical
also	also	ADV	RB	9	O
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
during	during	ADP	IN	5	O
testing	test	VERB	VBG	5	O
for	for	ADP	IN	5	O
handling	handle	VERB	VBG	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Sensitivity	sensitivity	NOUN	NN	9	O
to	to	ADP	IN	5	O
several	several	ADJ	JJ	9	O
convulsion	convulsion	NOUN	NN	5	B-Disease
endpoints	endpoint	NOUN	NNS	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
carbachol	carbachol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
neostigmine	neostigmine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
greater	great	ADJ	JJR	5	O
in	in	ADP	IN	5	O
WSR	WSR	PROPN	NNP	5	O
versus	versus	ADP	IN	9	O
WSP	WSP	PROPN	NNP	4	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
microdialysis	microdialysis	NOUN	NN	5	O
experiments	experiment	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
lines	line	NOUN	NNS	3	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
differ	differ	VERB	VB	9	O
in	in	ADP	IN	5	O
basal	basal	NOUN	NN	3	O
release	release	NOUN	NN	9	O
of	of	ADP	IN	5	O
ACh	ach	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
50	50	NUM	CD	0	O
mM	mM	PROPN	NNP	0	O
KCl	KCl	NOUN	NNS	0	B-Chemical
increased	increase	VERB	VBD	9	O
ACh	ach	NOUN	NN	0	B-Chemical
output	output	NOUN	NN	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
lines	line	NOUN	NNS	3	O
of	of	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
release	release	NOUN	NN	9	O
of	of	ADP	IN	5	O
ACh	ach	NOUN	NN	0	B-Chemical
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
application	application	NOUN	NN	5	O
of	of	ADP	IN	5	O
KCl	KCl	NOUN	NNS	0	B-Chemical
was	be	VERB	VBD	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
fold	fold	VERB	VB	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
WSP	WSP	PROPN	NNP	4	O
versus	versus	ADP	IN	9	O
WSR	WSR	PROPN	NNP	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
hippocampal	hippocampal	ADJ	JJ	3	O
ACh	ach	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
during	during	ADP	IN	5	O
testing	test	VERB	VBG	5	O
for	for	ADP	IN	5	O
handling	handle	VERB	VBG	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
extracellular	extracellular	ADJ	JJ	9	O
ACh	ACh	NOUN	NNS	0	B-Chemical
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
elevated	elevate	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
192	192	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
WSP	WSP	PROPN	NNP	4	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
was	be	VERB	VBD	9	O
nonsignificantly	nonsignificantly	ADV	RB	5	O
elevated	elevate	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
59	59	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
WSR	WSR	PROPN	NNP	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
cholinergic	cholinergic	NOUN	NN	3	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
postsynaptic	postsynaptic	ADJ	JJ	3	O
sensitivity	sensitivity	NOUN	NN	9	O
to	to	PART	TO	5	O
cholinergic	cholinergic	VERB	VB	3	O
convulsants	convulsant	NOUN	NNS	0	B-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
ethanol	ethanol	NOUN	NN	0	B-Chemical
withdrawal	withdrawal	NOUN	NN	5	O
severity	severity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
implicate	implicate	ADJ	JJ	9	O
cholinergic	cholinergic	NOUN	NN	3	O
mechanisms	mechanism	NOUN	NNS	9	O
in	in	ADP	IN	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
withdrawal	withdrawal	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Specifically	specifically	ADV	RB	9	O
,	,	PUNCT	,	9	O
WSP	WSP	PROPN	NNP	4	O
mice	mouse	NOUN	NNS	3	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
lower	low	ADJ	JJR	9	O
sensitivity	sensitivity	NOUN	NN	9	O
to	to	PART	TO	5	O
cholinergic	cholinergic	VERB	VB	3	O
convulsants	convulsant	NOUN	NNS	0	B-Disease
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
WSR	WSR	PROPN	NNP	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
postsynaptic	postsynaptic	ADJ	JJ	3	O
receptor	receptor	NOUN	NN	3	O
desensitization	desensitization	NOUN	NN	3	O
brought	bring	VERB	VBN	5	O
on	on	PART	RP	5	O
by	by	ADP	IN	9	O
higher	high	ADJ	JJR	9	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
cholinergic	cholinergic	NOUN	NN	3	O
neurons	neuron	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Capsaicin	capsaicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
muscle	muscle	NOUN	NN	9	B-Disease
pain	pain	NOUN	NN	5	I-Disease
alters	alter	VERB	VBZ	9	O
the	the	DET	DT	5	O
excitability	excitability	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
human	human	ADJ	JJ	3	O
jaw	jaw	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
stretch	stretch	NOUN	NN	9	O
reflex	reflex	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pathophysiology	pathophysiology	NOUN	NN	9	O
of	of	ADP	IN	5	O
painful	painful	ADJ	JJ	5	O
temporomandibular	temporomandibular	ADJ	JJ	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
fully	fully	ADV	RB	9	O
understood	understand	VERB	VBN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
evidence	evidence	NOUN	NN	9	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
muscle	muscle	NOUN	NN	9	B-Disease
pain	pain	NOUN	NN	5	I-Disease
modulates	modulate	NOUN	NNS	9	O
motor	motor	NOUN	NN	5	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
characteristic	characteristic	ADJ	JJ	9	O
ways	way	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
tested	test	VERB	VBD	9	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	DET	DT	5	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
nociceptive	nociceptive	ADJ	JJ	5	B-Disease
muscle	muscle	NOUN	NN	9	I-Disease
afferent	afferent	NOUN	NN	5	O
fibers	fiber	NOUN	NNS	9	O
would	would	VERB	MD	5	O
be	be	VERB	VB	5	O
linked	link	VERB	VBN	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
excitability	excitability	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
human	human	ADJ	JJ	3	O
jaw	jaw	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
stretch	stretch	NOUN	NN	9	O
reflex	reflex	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
whether	whether	ADP	IN	9	O
this	this	DET	DT	5	O
process	process	NOUN	NN	5	O
would	would	VERB	MD	5	O
be	be	VERB	VB	5	O
sensitive	sensitive	ADJ	JJ	9	O
to	to	ADP	IN	5	O
length	length	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
velocity	velocity	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
stretch	stretch	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Capsaicin	Capsaicin	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
micro	micro	ADJ	JJ	0	O
g	g	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
masseter	masseter	NOUN	NN	5	O
muscle	muscle	NOUN	NN	9	O
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
pain	pain	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
11	11	NUM	CD	7	O
healthy	healthy	ADJ	JJ	5	O
volunteers	volunteer	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
latency	latency	NOUN	NN	5	O
reflex	reflex	NOUN	NN	5	O
responses	response	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
evoked	evoke	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
masseter	masseter	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
temporalis	temporalis	NOUN	NN	5	O
muscles	muscle	NOUN	NNS	5	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
stretch	stretch	ADJ	JJ	9	O
device	device	NOUN	NN	5	O
with	with	ADP	IN	5	O
different	different	ADJ	JJ	9	O
velocities	velocity	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
displacements	displacement	NOUN	NNS	5	O
before	before	ADV	RB	9	O
,	,	PUNCT	,	9	O
during	during	ADP	IN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
pain	pain	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
normalized	normalized	ADJ	JJ	9	O
reflex	reflex	NOUN	NN	5	O
amplitude	amplitude	NOUN	NN	5	O
increased	increase	VERB	VBD	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
velocity	velocity	NOUN	NN	5	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
given	give	VERB	VBN	5	O
displacement	displacement	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
remained	remain	VERB	VBD	9	O
constant	constant	ADJ	JJ	9	O
with	with	ADP	IN	5	O
different	different	ADJ	JJ	9	O
displacements	displacement	NOUN	NNS	5	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
given	give	VERB	VBN	5	O
velocity	velocity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
normalized	normalized	ADJ	JJ	9	O
reflex	reflex	NOUN	NN	5	O
amplitude	amplitude	NOUN	NN	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
during	during	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
only	only	ADV	RB	9	O
at	at	ADP	IN	9	O
faster	fast	ADJ	JJR	5	O
stretches	stretch	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
painful	painful	ADJ	JJ	5	B-Disease
muscle	muscle	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Increased	increase	VERB	VBN	9	O
sensitivity	sensitivity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
fusimotor	fusimotor	NOUN	NN	5	O
system	system	NOUN	NN	5	O
during	during	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
muscle	muscle	NOUN	NN	9	B-Disease
pain	pain	NOUN	NN	5	I-Disease
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
one	one	NUM	CD	5	O
likely	likely	ADJ	JJ	5	O
mechanism	mechanism	NOUN	NN	9	O
to	to	PART	TO	5	O
explain	explain	VERB	VB	9	O
the	the	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
HT1B	ht1b	NOUN	NN	3	O
receptor	receptor	NOUN	NN	3	O
ligands	ligand	NOUN	NNS	3	O
microinjected	microinjecte	VERB	VBN	3	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
accumbal	accumbal	ADJ	JJ	5	O
shell	shell	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
core	core	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
locomotor	locomotor	NOUN	NN	5	B-Disease
hyperactivity	hyperactivity	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
HT1B	ht1b	NOUN	NN	3	O
receptor	receptor	NOUN	NN	3	O
ligands	ligand	NOUN	NNS	3	O
microinjected	microinjecte	VERB	VBN	3	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
subregions	subregion	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
nucleus	nucleus	NOUN	NN	9	O
accumbens	accumben	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
the	the	DET	DT	5	O
shell	shell	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
core	core	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
locomotor	locomotor	NOUN	NN	5	B-Disease
hyperactivity	hyperactivity	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Male	Male	PROPN	NNP	7	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
implanted	implant	VERB	VBN	9	O
bilaterally	bilaterally	ADV	RB	5	O
with	with	ADP	IN	5	O
cannulae	cannulae	NOUN	NN	5	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
accumbens	accumben	NOUN	NNS	5	O
shell	shell	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
core	core	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
then	then	ADV	RB	9	O
were	be	VERB	VBD	9	O
locally	locally	ADV	RB	5	O
injected	inject	VERB	VBN	3	O
with	with	ADP	IN	5	O
GR	GR	PROPN	NNP	9	B-Chemical
55562	55562	NUM	CD	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
an	an	DET	DT	5	O
antagonist	antagonist	NOUN	NN	3	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
HT1B	HT1B	PROPN	NNP	3	O
receptors	receptor	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
CP	CP	PROPN	NNP	9	B-Chemical
93129	93129	NUM	CD	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
an	an	DET	DT	5	O
agonist	agonist	NOUN	NN	3	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
HT1B	HT1B	PROPN	NNP	3	O
receptors	receptor	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Given	give	VERB	VBN	9	O
alone	alone	ADV	RB	9	O
to	to	ADP	IN	5	O
any	any	DET	DT	5	O
accumbal	accumbal	ADJ	JJ	5	O
subregion	subregion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
GR	GR	PROPN	NNP	9	B-Chemical
55562	55562	NUM	CD	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
side	side	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
CP	CP	PROPN	NNP	9	B-Chemical
93129	93129	NUM	CD	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
side	side	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
change	change	VERB	VB	9	O
basal	basal	NOUN	NN	3	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Systemic	systemic	ADJ	JJ	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

GR	GR	PROPN	NNP	9	B-Chemical
55562	55562	NUM	CD	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
side	side	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
administered	administer	VERB	VBD	9	O
intra	intra	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
accumbens	accumben	NOUN	NNS	5	O
shell	shell	NOUN	NN	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	,	7	O
dependently	dependently	ADV	RB	3	O
attenuated	attenuate	VERB	VBD	3	O
the	the	DET	DT	5	O
psychostimulant	psychostimulant	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
locomotor	locomotor	NOUN	NN	5	B-Disease
hyperactivity	hyperactivity	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Such	such	ADJ	JJ	5	O
attenuation	attenuation	NOUN	NN	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
which	which	DET	WDT	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
injected	inject	VERB	VBN	3	O
with	with	ADP	IN	5	O
GR	GR	PROPN	NNP	9	B-Chemical
55562	55562	NUM	CD	9	I-Chemical
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
accumbens	accumben	NOUN	NNS	5	O
core	core	NOUN	NN	9	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
injected	inject	VERB	VBN	3	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
accumbens	accumben	NOUN	NNS	5	O
shell	shell	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
the	the	DET	DT	5	O
core	core	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
before	before	ADP	IN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
CP	CP	PROPN	NNP	9	B-Chemical
93129	93129	NUM	CD	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
side	side	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
enhanced	enhance	VERB	VBD	3	O
the	the	DET	DT	5	O
locomotor	locomotor	NOUN	NN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
maximum	maximum	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
being	be	VERB	VBG	5	O
observed	observe	VERB	VBN	9	O
after	after	ADP	IN	9	O
10	10	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
side	side	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
agonist	agonist	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
later	later	ADJ	JJ	9	O
enhancement	enhancement	NOUN	NN	9	O
was	be	VERB	VBD	9	O
attenuated	attenuate	VERB	VBN	3	O
after	after	ADP	IN	9	O
intra	intra	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
accumbens	accumben	NOUN	NNS	5	O
shell	shell	NOUN	NN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
GR	GR	PROPN	NNP	9	B-Chemical
55562	55562	NUM	CD	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
side	side	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
findings	finding	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
induced	induce	VERB	VBN	3	O
hyperlocomotion	hyperlocomotion	NOUN	NN	3	B-Disease
is	be	VERB	VBZ	5	O
modified	modify	VERB	VBN	9	O
by	by	ADP	IN	9	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
HT1B	ht1b	NOUN	NN	3	O
receptor	receptor	NOUN	NN	3	O
ligands	ligand	NOUN	NNS	3	O
microinjected	microinjecte	VERB	VBN	3	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
accumbens	accumben	NOUN	NNS	5	O
shell	shell	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
core	core	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
modification	modification	NOUN	NN	9	O
consisting	consist	VERB	VBG	9	O
in	in	ADP	IN	5	O
inhibitory	inhibitory	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
facilitatory	facilitatory	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
HT1B	ht1b	NOUN	NN	3	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
GR	GR	PROPN	NNP	9	B-Chemical
55562	55562	NUM	CD	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
agonist	agonist	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
CP	CP	PROPN	NNP	9	B-Chemical
93129	93129	NUM	CD	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
other	other	ADJ	JJ	5	O
words	word	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
accumbal	accumbal	ADJ	JJ	5	O
shell	shell	NOUN	NN	9	O
5	5	NUM	CD	9	O
-	-	PUNCT	:	7	O
HT1B	HT1B	PROPN	NNP	3	O
receptors	receptor	NOUN	NNS	3	O
play	play	VERB	VBP	9	O
a	a	DET	DT	5	O
permissive	permissive	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
behavioural	behavioural	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
psychostimulant	psychostimulant	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cocaine	cocaine	NOUN	NN	5	B-Chemical
related	relate	VERB	VBN	9	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
are	be	VERB	VBP	5	O
we	-PRON-	PRON	PRP	5	O
seeing	see	VERB	VBG	5	O
the	the	DET	DT	5	O
tip	tip	NOUN	NN	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
iceberg	iceberg	NOUN	NN	5	O
?	?	PUNCT	.	5	O

The	the	DET	DT	5	O
recreational	recreational	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
is	be	VERB	VBZ	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
emergency	emergency	NOUN	NN	5	O
nurse	nurse	NOUN	NN	5	O
ought	ought	VERB	MD	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
familiar	familiar	ADJ	JJ	5	O
with	with	ADP	IN	5	O
some	some	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
consequences	consequence	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
particular	particular	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
tendency	tendency	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
to	to	PART	TO	5	O
produce	produce	VERB	VB	9	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
ought	ought	VERB	MD	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mind	mind	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
emergency	emergency	NOUN	NN	5	O
nurse	nurse	NOUN	NN	5	O
when	when	ADV	WRB	5	O
faced	face	VERB	VBN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
young	young	ADJ	JJ	5	O
victim	victim	NOUN	NN	5	O
of	of	ADP	IN	5	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
who	who	PRON	WP	5	O
is	be	VERB	VBZ	5	O
otherwise	otherwise	ADV	RB	9	O
at	at	ADP	IN	9	O
low	low	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
discussed	discuss	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
dilemmas	dilemma	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Finally	finally	ADV	RB	9	O
,	,	PUNCT	,	9	O
moral	moral	ADJ	JJ	5	O
issues	issue	NOUN	NNS	5	O
relating	relate	VERB	VBG	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
testing	testing	NOUN	NN	5	O
of	of	ADP	IN	5	O
potential	potential	ADJ	JJ	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
will	will	VERB	MD	5	O
be	be	VERB	VB	5	O
addressed	address	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Crossover	crossover	NOUN	NN	5	O
comparison	comparison	NOUN	NN	9	O
of	of	ADP	IN	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
preference	preference	NOUN	NN	5	O
for	for	ADP	IN	5	O
rizatriptan	rizatriptan	NOUN	NN	5	B-Chemical
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
versus	versus	ADP	IN	9	O
ergotamine	ergotamine	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
migraine	migraine	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Rizatriptan	Rizatriptan	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
1B	1B	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
1D	1d	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
receptor	receptor	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
with	with	ADP	IN	5	O
rapid	rapid	ADJ	JJ	5	O
oral	oral	ADJ	JJ	9	O
absorption	absorption	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
early	early	ADJ	JJ	9	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
migraine	migraine	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
randomized	randomize	VERB	VBD	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
crossover	crossover	NOUN	NN	5	O
outpatient	outpatient	NOUN	NN	5	O
study	study	NOUN	NN	9	O
assessed	assess	VERB	VBD	9	O
the	the	DET	DT	5	O
preference	preference	NOUN	NN	5	O
for	for	ADP	IN	5	O
1	1	NUM	CD	9	O
rizatriptan	rizatriptan	NOUN	NN	5	B-Chemical
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
tablet	tablet	NOUN	NN	0	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
ergotamine	ergotamine	NOUN	NN	0	B-Chemical
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
tablets	tablet	NOUN	NNS	0	O
in	in	ADP	IN	5	O
439	439	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
treating	treat	VERB	VBG	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
migraine	migraine	ADJ	JJ	5	B-Disease
attack	attack	NOUN	NN	5	O
with	with	ADP	IN	5	O
each	each	DET	DT	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
expressing	express	VERB	VBG	3	O
a	a	DET	DT	5	O
preference	preference	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
89	89	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
twice	twice	DET	PDT	9	O
as	as	ADV	RB	5	O
many	many	ADJ	JJ	5	O
preferred	preferred	ADJ	JJ	5	O
rizatriptan	rizatriptan	NOUN	NN	5	B-Chemical
to	to	ADP	IN	5	O
ergotamine	ergotamine	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
69	69	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
30	30	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Faster	fast	ADJ	JJR	5	O
relief	relief	NOUN	NN	5	O
of	of	ADP	IN	5	O
headache	headache	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
important	important	ADJ	JJ	9	O
reason	reason	NOUN	NN	5	O
for	for	ADP	IN	5	O
preference	preference	NOUN	NN	5	O
,	,	PUNCT	,	9	O
cited	cite	VERB	VBN	5	O
by	by	ADP	IN	9	O
67	67	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
preferring	prefer	VERB	VBG	5	O
rizatriptan	rizatriptan	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
54	54	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
preferred	prefer	VERB	VBD	5	O
ergotamine	ergotamine	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
co	co	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
primary	primary	ADJ	JJ	9	O
endpoint	endpoint	NOUN	NN	5	O
of	of	ADP	IN	5	O
being	be	VERB	VBG	5	O
pain	pain	NOUN	NN	5	B-Disease
free	free	ADJ	JJ	9	O
at	at	ADP	IN	9	O
2	2	NUM	CD	9	O
h	h	NOUN	NN	0	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
in	in	ADP	IN	5	O
favor	favor	NOUN	NN	9	O
of	of	ADP	IN	5	O
rizatriptan	rizatriptan	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Forty	forty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
nine	nine	NUM	CD	9	O
percent	percent	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
pain	pain	NOUN	NN	5	B-Disease
free	free	ADJ	JJ	9	O
2	2	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
rizatriptan	rizatriptan	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
24	24	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
ergotamine	ergotamine	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
rizatriptan	rizatriptan	NOUN	NN	5	B-Chemical
being	be	VERB	VBG	5	O
superior	superior	ADJ	JJ	5	O
within	within	ADP	IN	9	O
1	1	NUM	CD	9	O
h	h	NOUN	NN	0	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Headache	headache	NOUN	NN	7	B-Disease
relief	relief	NOUN	NN	5	O
at	at	ADP	IN	9	O
2	2	NUM	CD	9	O
h	h	NOUN	NN	0	O
was	be	VERB	VBD	9	O
75	75	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
for	for	ADP	IN	5	O
rizatriptan	rizatriptan	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
47	47	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
for	for	ADP	IN	5	O
ergotamine	ergotamine	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
rizatriptan	rizatriptan	NOUN	NN	5	B-Chemical
being	be	VERB	VBG	5	O
superior	superior	ADJ	JJ	5	O
to	to	ADP	IN	5	O
ergotamine	ergotamine	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
within	within	ADP	IN	9	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
of	of	ADP	IN	5	O
dosing	dose	VERB	VBG	9	O
.	.	PUNCT	.	9	O

Almost	almost	ADV	RB	5	O
36	36	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
taking	take	VERB	VBG	5	O
rizatriptan	rizatriptan	NOUN	NN	5	B-Chemical
were	be	VERB	VBD	9	O
pain	pain	NOUN	NN	5	B-Disease
free	free	ADJ	JJ	9	O
at	at	ADP	IN	9	O
2	2	NUM	CD	9	O
h	h	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
recurrence	recurrence	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
need	need	VERB	VB	5	O
for	for	ADP	IN	5	O
additional	additional	ADJ	JJ	9	O
medication	medication	NOUN	NN	5	O
within	within	ADP	IN	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
on	on	ADP	IN	5	O
ergotamine	ergotamine	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Rizatriptan	Rizatriptan	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
superior	superior	ADJ	JJ	5	O
to	to	ADP	IN	5	O
ergotamine	ergotamine	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
proportions	proportion	NOUN	NNS	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
nausea	nausea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
vomiting	vomiting	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
phonophobia	phonophobia	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
photophobia	photophobia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
2	2	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
drug	drug	NOUN	NN	5	O
intake	intake	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

More	More	ADJ	JJR	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
(	(	PUNCT	-LRB-	9	O
completely	completely	ADV	RB	9	O
,	,	PUNCT	,	9	O
very	very	ADV	RB	5	O
or	or	CCONJ	CC	5	O
somewhat	somewhat	ADV	RB	5	O
)	)	PUNCT	-RRB-	9	O
satisfied	satisfy	VERB	VBD	5	O
2	2	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
rizatriptan	rizatriptan	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
69	69	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
at	at	ADP	IN	9	O
2	2	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
ergotamine	ergotamine	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
38	38	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Recurrence	recurrence	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
31	31	NUM	CD	7	O
.	.	NOUN	NN	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
with	with	ADP	IN	5	O
rizatriptan	rizatriptan	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
with	with	ADP	IN	5	O
ergotamine	ergotamine	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
active	active	ADJ	JJ	9	O
treatments	treatment	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
incidence	incidence	NOUN	NN	5	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
rizatriptan	rizatriptan	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
ergotamine	ergotamine	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
dizziness	dizziness	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
nausea	nausea	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
and	and	CCONJ	CC	5	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
somnolence	somnolence	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Severe	severe	ADJ	JJ	9	O
ocular	ocular	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
orbital	orbital	ADJ	JJ	5	I-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
after	after	ADP	IN	9	O
intracarotid	intracarotid	NOUN	NN	0	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
recurrent	recurrent	ADJ	JJ	5	O
glioblastomas	glioblastoma	NOUN	NNS	3	B-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Glioblastoma	Glioblastoma	PROPN	NNP	3	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
malignant	malignant	ADJ	JJ	3	B-Disease
tumor	tumor	NOUN	NN	3	I-Disease
that	that	DET	WDT	5	O
occurs	occur	VERB	VBZ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cerebrum	cerebrum	NOUN	NN	9	O
during	during	ADP	IN	5	O
adulthood	adulthood	NOUN	NN	5	O
.	.	PUNCT	.	9	O

With	with	ADP	IN	5	O
current	current	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
regimens	regimen	NOUN	NNS	5	O
including	include	VERB	VBG	9	O
combined	combine	VERB	VBN	9	O
surgery	surgery	NOUN	NN	5	O
,	,	PUNCT	,	9	O
radiation	radiation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
average	average	ADJ	JJ	5	O
life	life	NOUN	NN	5	O
expectancy	expectancy	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
limited	limit	VERB	VBN	5	O
to	to	ADP	IN	5	O
approximately	approximately	ADV	RB	9	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
glioblastoma	glioblastoma	NOUN	NN	3	B-Disease
sometimes	sometimes	ADV	RB	5	O
have	have	VERB	VBP	5	O
intracarotid	intracarotid	NOUN	NN	0	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
carcinostatics	carcinostatic	NOUN	NNS	9	O
added	add	VERB	VBN	0	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
regimen	regimen	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Generally	generally	ADV	RB	5	O
,	,	PUNCT	,	9	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
said	say	VERB	VBN	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
milder	milder	NOUN	NN	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
than	than	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
whose	whose	DET	WP$	9	O
ocular	ocular	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
orbital	orbital	ADJ	JJ	5	I-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
are	be	VERB	VBP	5	O
well	well	ADV	RB	9	O
known	know	VERB	VBN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
experienced	experience	VERB	VBD	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
ocular	ocular	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
orbital	orbital	ADJ	JJ	5	I-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
after	after	ADP	IN	9	O
intracarotid	intracarotid	NOUN	NN	0	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
infrequently	infrequently	ADV	RB	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
58	58	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
received	receive	VERB	VBD	9	O
an	an	DET	DT	5	O
intracarotid	intracarotid	NOUN	NN	0	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
recurrent	recurrent	ADJ	JJ	5	O
glioblastomas	glioblastoma	NOUN	NNS	3	B-Disease
in	in	ADP	IN	5	O
his	-PRON-	DET	PRP$	5	O
left	left	ADJ	JJ	5	O
temporal	temporal	ADJ	JJ	5	O
lobe	lobe	NOUN	NN	5	O
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
complained	complain	VERB	VBD	5	O
of	of	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
visual	visual	ADJ	JJ	5	I-Disease
disturbance	disturbance	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
ipsilateral	ipsilateral	ADJ	JJ	5	I-Disease
eye	eye	NOUN	NN	5	I-Disease
30	30	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Various	various	ADJ	JJ	9	O
ocular	ocular	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
findings	finding	NOUN	NNS	9	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
were	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
He	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
corticosteroids	corticosteroid	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
glycerin	glycerin	VERB	VB	0	B-Chemical
for	for	ADP	IN	5	O
6	6	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
the	the	DET	DT	5	O
intraocular	intraocular	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
elevation	elevation	NOUN	NN	9	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
secondary	secondary	ADJ	JJ	9	O
acute	acute	ADJ	JJ	9	O
angle	angle	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
closure	closure	NOUN	NN	5	O
glaucoma	glaucoma	NOUN	NN	5	B-Disease
decreased	decrease	VERB	VBD	9	O
and	and	CCONJ	CC	5	O
ocular	ocular	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
diminished	diminish	VERB	VBD	9	O
,	,	PUNCT	,	9	O
inexorable	inexorable	ADJ	JJ	5	O
papilledema	papilledema	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
exudative	exudative	ADJ	JJ	5	O
retinal	retinal	ADJ	JJ	5	B-Disease
detachment	detachment	NOUN	NN	9	I-Disease
continued	continue	VERB	VBD	9	O
for	for	ADP	IN	5	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Finally	finally	ADV	RB	9	O
,	,	PUNCT	,	9	O
6	6	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
later	later	ADV	RB	9	O
,	,	PUNCT	,	9	O
diffuse	diffuse	VERB	VB	5	O
chorioretinal	chorioretinal	ADJ	JJ	5	B-Disease
atrophy	atrophy	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
optic	optic	ADJ	JJ	5	B-Disease
atrophy	atrophy	NOUN	NN	5	I-Disease
occurred	occur	VERB	VBD	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
vision	vision	NOUN	NN	5	O
in	in	ADP	IN	5	O
his	-PRON-	DET	PRP$	5	O
left	left	ADJ	JJ	5	O
eye	eye	NOUN	NN	5	O
was	be	VERB	VBD	9	O
lost	lose	VERB	VBN	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
When	when	ADV	WRB	9	O
performing	perform	VERB	VBG	5	O
intracarotid	intracarotid	NOUN	NN	0	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
must	must	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
potentially	potentially	ADV	RB	5	O
blinding	blind	VERB	VBG	5	O
ocular	ocular	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
recommended	recommend	VERB	VBN	5	O
that	that	ADP	IN	5	O
further	further	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
investigations	investigation	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
undertaken	undertake	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
effort	effort	NOUN	NN	5	O
to	to	PART	TO	5	O
minimize	minimize	VERB	VB	5	O
such	such	ADJ	JJ	5	O
severe	severe	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Visual	visual	ADJ	JJ	5	B-Disease
hallucinations	hallucination	NOUN	NNS	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
zonisamide	zonisamide	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Zonisamide	Zonisamide	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
broad	broad	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
spectrum	spectrum	NOUN	NN	9	O
antiepileptic	antiepileptic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
various	various	ADJ	JJ	9	O
types	type	NOUN	NNS	9	O
of	of	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
visual	visual	ADJ	JJ	5	B-Disease
hallucinations	hallucination	NOUN	NNS	5	I-Disease
have	have	VERB	VBP	5	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
agent	agent	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
describe	describe	VERB	VBP	5	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
experienced	experience	VERB	VBD	5	O
complex	complex	ADJ	JJ	9	O
visual	visual	ADJ	JJ	5	B-Disease
hallucinations	hallucination	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
altered	alter	VERB	VBD	9	O
mental	mental	ADJ	JJ	5	O
status	status	NOUN	NN	9	O
after	after	ADP	IN	9	O
zonisamide	zonisamide	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
begun	begin	VERB	VBN	5	O
or	or	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
dosage	dosage	NOUN	NN	9	O
increased	increase	VERB	VBD	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
three	three	NUM	CD	9	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
diagnosed	diagnose	VERB	VBN	5	O
earlier	earlier	ADV	RBR	9	O
with	with	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
electroencephalogram	electroencephalogram	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
EEG	EEG	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
findings	finding	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
abnormal	abnormal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
monitoring	monitoring	NOUN	NN	5	O
,	,	PUNCT	,	9	O
visual	visual	ADJ	JJ	5	B-Disease
hallucinations	hallucination	NOUN	NNS	5	I-Disease
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
correlate	correlate	VERB	VB	9	O
with	with	ADP	IN	5	O
EEG	EEG	PROPN	NNP	5	O
readings	reading	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
nor	nor	CCONJ	CC	9	O
did	do	VERB	VBD	9	O
video	video	NOUN	NN	5	O
recording	recording	NOUN	NN	5	O
capture	capture	NOUN	NN	5	O
any	any	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
described	describe	VERB	VBN	9	O
events	event	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

None	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
experienced	experience	VERB	VBN	5	O
visual	visual	ADJ	JJ	5	B-Disease
hallucinations	hallucination	NOUN	NNS	5	I-Disease
before	before	ADP	IN	9	O
this	this	DET	DT	5	O
event	event	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
only	only	ADJ	JJ	9	O
recent	recent	ADJ	JJ	5	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
introduction	introduction	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
dosage	dosage	NOUN	NN	9	O
of	of	ADP	IN	5	O
zonisamide	zonisamide	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

With	with	ADP	IN	5	O
either	either	DET	DT	9	O
discontinuation	discontinuation	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
dosage	dosage	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
the	the	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
disappeared	disappear	VERB	VBD	9	O
and	and	CCONJ	CC	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
recur	recur	VERB	VB	5	O
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
observations	observation	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
reports	report	NOUN	NNS	9	O
will	will	VERB	MD	5	O
help	help	VERB	VB	5	O
clarify	clarify	VERB	VB	9	O
this	this	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Until	until	ADP	IN	5	O
then	then	ADV	RB	9	O
,	,	PUNCT	,	9	O
clinicians	clinician	NOUN	NNS	5	O
need	need	VERB	VBP	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
zonisamide	zonisamide	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
drugs	drug	NOUN	NNS	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
de	de	NOUN	NN	2	O
novo	novo	NOUN	NN	9	O
absence	absence	NOUN	NN	3	B-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
present	present	VERB	VBP	9	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
de	de	X	FW	2	O
novo	novo	NOUN	NN	9	O
absence	absence	NOUN	NN	3	B-Disease
epilepsy	epilepsy	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
vigabatrin	vigabatrin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
the	the	DET	DT	5	O
underlying	underlie	VERB	VBG	5	O
diseases	disease	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
prognosis	prognosis	NOUN	NN	5	O
for	for	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
de	de	NOUN	NN	2	O
novo	novo	NOUN	NN	9	O
absence	absence	NOUN	NN	3	B-Disease
seizure	seizure	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
good	good	ADJ	JJ	5	O
because	because	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
subsides	subside	VERB	VBZ	5	O
rapidly	rapidly	ADV	RB	9	O
after	after	ADP	IN	9	O
discontinuing	discontinue	VERB	VBG	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
offending	offend	VERB	VBG	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminobutyric	aminobutyric	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
transmitted	transmit	VERB	VBN	5	O
thalamocortical	thalamocortical	ADJ	JJ	5	O
circuitry	circuitry	NOUN	NN	5	O
accounts	account	NOUN	NNS	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
part	part	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
underlying	underlie	VERB	VBG	5	O
neurophysiology	neurophysiology	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	B-Disease
epilepsy	epilepsy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
de	de	NOUN	NN	2	O
novo	novo	NOUN	NN	9	O
absence	absence	NOUN	NN	3	B-Disease
seizure	seizure	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
rare	rare	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
pro	pro	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
absence	absence	ADJ	JJ	3	O
drugs	drug	NOUN	NNS	5	O
can	can	VERB	MD	5	O
only	only	ADV	RB	9	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
a	a	DET	DT	5	O
promoting	promote	VERB	VBG	9	O
factor	factor	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
underlying	underlie	VERB	VBG	5	O
epileptogenecity	epileptogenecity	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
synergistic	synergistic	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
accompanying	accompany	VERB	VBG	5	O
drugs	drug	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
required	require	VERB	VBN	9	O
to	to	PART	TO	5	O
trigger	trigger	VERB	VB	9	O
the	the	DET	DT	5	O
de	de	X	FW	2	O
novo	novo	NOUN	NN	9	O
absence	absence	NOUN	NN	3	B-Disease
seizure	seizure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
aggravation	aggravation	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
whenever	whenever	ADV	WRB	5	O
an	an	DET	DT	5	O
unexpected	unexpected	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
frequency	frequency	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
new	new	ADJ	JJ	5	O
seizure	seizure	NOUN	NN	5	B-Disease
types	type	NOUN	NNS	9	O
appear	appear	VERB	VBP	9	O
following	follow	VERB	VBG	9	O
a	a	DET	DT	5	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
understanding	understand	VERB	VBG	5	O
the	the	DET	DT	5	O
underlying	underlie	VERB	VBG	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
absence	absence	NOUN	NN	3	B-Disease
epilepsy	epilepsy	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
can	can	VERB	MD	5	O
avoid	avoid	VERB	VB	5	O
the	the	DET	DT	5	O
inappropriate	inappropriate	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
anticonvulsants	anticonvulsant	NOUN	NNS	5	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
prevent	prevent	VERB	VB	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
absence	absence	NOUN	NN	3	B-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Prenatal	prenatal	ADJ	JJ	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
programs	program	NOUN	NNS	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Dexamethasone	Dexamethasone	PROPN	NNP	0	O
is	be	VERB	VBZ	5	O
frequently	frequently	ADV	RB	5	O
administered	administer	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
developing	develop	VERB	VBG	5	O
fetus	fetus	NOUN	NN	5	O
to	to	PART	TO	5	O
accelerate	accelerate	VERB	VB	9	O
pulmonary	pulmonary	ADJ	JJ	5	O
development	development	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
if	if	ADP	IN	5	O
prenatal	prenatal	ADJ	JJ	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
programmed	program	VERB	VBD	5	O
a	a	DET	DT	5	O
progressive	progressive	ADJ	JJ	5	O
increase	increase	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
blood	blood	NOUN	NN	9	I-Disease
pressure	pressure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Pregnant	pregnant	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
either	either	CCONJ	CC	9	O
vehicle	vehicle	NOUN	NN	3	O
or	or	CCONJ	CC	5	O
2	2	NUM	CD	9	O
daily	daily	ADJ	JJ	5	O
intraperitoneal	intraperitoneal	ADJ	JJ	0	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
gestational	gestational	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
11	11	NUM	CD	7	O
and	and	CCONJ	CC	5	O
12	12	NUM	CD	9	O
,	,	PUNCT	,	9	O
13	13	NUM	CD	7	O
and	and	CCONJ	CC	5	O
14	14	NUM	CD	7	O
,	,	PUNCT	,	9	O
15	15	NUM	CD	9	O
and	and	CCONJ	CC	5	O
16	16	NUM	CD	9	O
,	,	PUNCT	,	9	O
17	17	NUM	CD	7	O
and	and	CCONJ	CC	5	O
18	18	NUM	CD	7	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
19	19	NUM	CD	7	O
and	and	CCONJ	CC	5	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O

Offspring	offspring	NOUN	NN	9	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
administered	administer	VERB	VBD	9	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
days	day	NOUN	NNS	9	O
15	15	NUM	CD	9	O
and	and	CCONJ	CC	5	O
16	16	NUM	CD	9	O
gestation	gestation	NOUN	NN	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
glomerular	glomerular	ADJ	JJ	5	I-Disease
number	number	NOUN	NN	9	I-Disease
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
control	control	NOUN	NN	9	O
at	at	ADP	IN	9	O
6	6	NUM	CD	9	O
to	to	PART	TO	5	O
9	9	NUM	CD	7	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
22	22	NUM	CD	7	O
527	527	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
509	509	NUM	CD	7	O
versus	versus	ADP	IN	9	O
28	28	NUM	CD	7	O
050	050	NUM	CD	2	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
561	561	NUM	CD	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
comparable	comparable	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
percent	percent	NOUN	NN	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
glomeruli	glomeruli	NOUN	NN	9	O
measured	measure	VERB	VBN	9	O
at	at	ADP	IN	9	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Six	six	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
9	9	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
month	month	NOUN	NN	5	O
old	old	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
receiving	receive	VERB	VBG	9	O
prenatal	prenatal	ADJ	JJ	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
days	day	NOUN	NNS	9	O
17	17	NUM	CD	7	O
and	and	CCONJ	CC	5	O
18	18	NUM	CD	7	O
of	of	ADP	IN	5	O
gestation	gestation	NOUN	NN	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
17	17	NUM	CD	7	O
%	%	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
glomeruli	glomeruli	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
23	23	NUM	CD	7	O
380	380	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
587	587	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Male	male	ADJ	JJ	7	O
rats	rat	NOUN	NNS	9	O
that	that	DET	WDT	5	O
received	receive	VERB	VBD	9	O
prenatal	prenatal	ADJ	JJ	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
days	day	NOUN	NNS	9	O
15	15	NUM	CD	9	O
and	and	CCONJ	CC	5	O
16	16	NUM	CD	9	O
,	,	PUNCT	,	9	O
17	17	NUM	CD	7	O
and	and	CCONJ	CC	5	O
18	18	NUM	CD	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
13	13	NUM	CD	7	O
and	and	CCONJ	CC	5	O
14	14	NUM	CD	7	O
of	of	ADP	IN	5	O
gestation	gestation	NOUN	NN	9	O
had	have	VERB	VBD	9	O
elevated	elevate	VERB	VBN	9	B-Disease
blood	blood	NOUN	NN	9	I-Disease
pressures	pressure	NOUN	NNS	5	I-Disease
at	at	ADP	IN	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
latter	latter	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
glomerular	glomerular	ADJ	JJ	5	I-Disease
number	number	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Adult	Adult	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
given	give	VERB	VBN	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
days	day	NOUN	NNS	9	O
15	15	NUM	CD	9	O
and	and	CCONJ	CC	5	O
16	16	NUM	CD	9	O
of	of	ADP	IN	5	O
gestation	gestation	NOUN	NN	9	O
had	have	VERB	VBD	9	O
more	more	ADJ	JJR	5	O
glomeruli	glomerulus	NOUN	NNS	9	O
with	with	ADP	IN	5	O
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	B-Disease
than	than	ADP	IN	5	O
control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
shows	show	VERB	VBZ	9	O
that	that	ADP	IN	5	O
prenatal	prenatal	ADJ	JJ	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
results	result	NOUN	NNS	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
glomerular	glomerular	ADJ	JJ	5	I-Disease
number	number	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
when	when	ADV	WRB	5	O
administered	administer	VERB	VBN	9	O
at	at	ADP	IN	9	O
specific	specific	ADJ	JJ	9	O
points	point	NOUN	NNS	5	O
during	during	ADP	IN	5	O
gestation	gestation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Hypertension	Hypertension	PROPN	NNP	7	B-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
that	that	DET	WDT	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
glomeruli	glomerulus	NOUN	NNS	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
group	group	NOUN	NN	9	O
that	that	DET	WDT	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
glomerular	glomerular	ADJ	JJ	5	I-Disease
number	number	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
glomerular	glomerular	ADJ	JJ	5	I-Disease
number	number	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
the	the	DET	DT	5	O
sole	sole	ADJ	JJ	9	O
cause	cause	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Kidney	kidney	NOUN	NN	9	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
morphology	morphology	NOUN	NN	9	O
after	after	ADP	IN	9	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
A	a	NOUN	NN	9	I-Chemical
,	,	PUNCT	,	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Sirolimus	Sirolimus	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
SRL	SRL	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
may	may	VERB	MD	5	O
supplement	supplement	VERB	VB	9	O
calcineurin	calcineurin	VERB	VB	3	O
inhibitors	inhibitor	NOUN	NNS	3	O
in	in	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
organ	organ	NOUN	NN	5	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
are	be	VERB	VBP	5	O
nephrotoxic	nephrotoxic	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
SRL	SRL	PROPN	NNP	0	B-Chemical
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
act	act	VERB	VB	9	O
differently	differently	ADV	RB	9	O
displaying	display	VERB	VBG	9	O
only	only	ADJ	JJ	9	O
minor	minor	ADJ	JJ	9	O
nephrotoxic	nephrotoxic	ADJ	JJ	5	B-Disease
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
this	this	DET	DT	5	O
question	question	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
still	still	ADV	RB	5	O
open	open	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
protocols	protocol	NOUN	NNS	5	O
where	where	ADV	WRB	5	O
SRL	SRL	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
calcineurin	calcineurin	NOUN	NN	3	O
inhibitor	inhibitor	NOUN	NN	3	O
indications	indication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
synergistic	synergistic	ADJ	JJ	9	O
nephrotoxic	nephrotoxic	ADJ	JJ	5	B-Disease
effect	effect	NOUN	NN	9	O
were	be	VERB	VBD	9	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
further	further	ADV	RB	9	O
the	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
morphological	morphological	ADJ	JJ	9	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
kidneys	kidney	NOUN	NNS	9	O
of	of	ADP	IN	5	O
male	male	ADJ	JJ	9	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
either	either	DET	DT	9	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
A	A	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
CsA	CsA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
FK506	FK506	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
SRL	SRL	PROPN	NNP	0	B-Chemical
as	as	ADP	IN	5	O
monotherapies	monotherapie	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
in	in	ADP	IN	5	O
different	different	ADJ	JJ	9	O
combinations	combination	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
For	for	ADP	IN	9	O
a	a	DET	DT	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
CsA	CsA	PROPN	NNP	0	B-Chemical
15	15	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
given	give	VERB	VBN	5	O
orally	orally	ADV	RB	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
FK506	fk506	NOUN	NN	3	B-Chemical
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
given	give	VERB	VBN	5	O
orally	orally	ADV	RB	0	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
SRL	SRL	PROPN	NNP	0	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
given	give	VERB	VBN	5	O
intraperitoneally	intraperitoneally	ADV	RB	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
once	once	ADV	RB	5	O
a	a	DET	DT	5	O
day	day	NOUN	NN	9	O
as	as	ADP	IN	5	O
these	these	DET	DT	5	O
doses	dose	NOUN	NNS	0	O
have	have	VERB	VBP	5	O
earlier	earlier	ADV	RBR	9	O
been	be	VERB	VBN	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
achieve	achieve	VERB	VB	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
in	in	ADP	IN	5	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
'	'	PUNCT	``	9	O
conscious	conscious	ADJ	JJ	5	O
catheterized	catheterized	ADJ	JJ	5	O
rat	rat	NOUN	NN	3	O
'	'	PUNCT	''	9	O
model	model	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
glomerular	glomerular	ADJ	JJ	5	O
filtration	filtration	NOUN	NN	0	O
rate	rate	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
GFR	GFR	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
clearance	clearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
Cr	Cr	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
EDTA	EDTA	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
morphological	morphological	ADJ	JJ	9	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
kidneys	kidney	NOUN	NNS	9	O
included	include	VERB	VBD	5	O
a	a	DET	DT	5	O
semi	semi	ADV	RB	5	O
-	-	ADJ	JJ	7	O
quantitative	quantitative	ADJ	JJ	9	O
scoring	scoring	NOUN	NN	5	O
system	system	NOUN	NN	5	O
analysing	analyse	VERB	VBG	5	O
the	the	DET	DT	5	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
striped	striped	ADJ	JJ	4	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
subcapsular	subcapsular	ADJ	JJ	5	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
basophilic	basophilic	NOUN	NN	3	O
tubules	tubule	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
plus	plus	CCONJ	CC	9	O
an	an	DET	DT	5	O
additional	additional	ADJ	JJ	9	O
stereological	stereological	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
grade	grade	NOUN	NN	9	O
of	of	ADP	IN	5	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cortex	cortex	NOUN	NN	5	O
stained	stain	VERB	VBN	3	O
with	with	ADP	IN	5	O
Sirius	Sirius	PROPN	NNP	0	O
Red	Red	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
CsA	CsA	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
FK506	FK506	PROPN	NNP	3	B-Chemical
and	and	CCONJ	CC	5	O
SRL	SRL	PROPN	NNP	0	B-Chemical
all	all	DET	DT	5	O
significantly	significantly	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
GFR	GFR	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
further	further	ADJ	JJ	9	O
deterioration	deterioration	NOUN	NN	5	O
was	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
when	when	ADV	WRB	5	O
CsA	CsA	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
either	either	DET	DT	9	O
FK506	FK506	PROPN	NNP	3	B-Chemical
or	or	CCONJ	CC	5	O
SRL	SRL	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
the	the	DET	DT	5	O
GFR	GFR	PROPN	NNP	5	O
remained	remain	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
group	group	NOUN	NN	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
FK506	FK506	PROPN	NNP	3	B-Chemical
plus	plus	CCONJ	CC	9	O
SRL	SRL	PROPN	NNP	0	B-Chemical
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
any	any	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
single	single	ADJ	JJ	9	O
substances	substance	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
morphological	morphological	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
presented	present	VERB	VBD	5	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
pattern	pattern	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
semi	semi	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
quantitative	quantitative	ADJ	JJ	9	O
scoring	scoring	NOUN	NN	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
worst	bad	ADJ	JJS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
group	group	NOUN	NN	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
CsA	CsA	PROPN	NNP	0	B-Chemical
plus	plus	CCONJ	CC	9	O
SRL	SRL	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
grade	grade	NOUN	NN	9	O
of	of	ADP	IN	5	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
also	also	ADV	RB	9	O
showed	show	VERB	VBD	9	O
the	the	DET	DT	5	O
highest	high	ADJ	JJS	9	O
proportion	proportion	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
different	different	ADJ	JJ	9	O
from	from	ADP	IN	9	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
FK506	FK506	PROPN	NNP	3	B-Chemical
plus	plus	CCONJ	CC	9	O
SRL	SRL	PROPN	NNP	0	B-Chemical
combination	combination	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
only	only	ADV	RB	9	O
a	a	DET	DT	5	O
marginally	marginally	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
rat	rat	NOUN	NN	3	O
study	study	NOUN	NN	9	O
demonstrated	demonstrate	VERB	VBD	9	O
a	a	DET	DT	5	O
synergistic	synergistic	ADJ	JJ	9	O
nephrotoxic	nephrotoxic	ADJ	JJ	5	B-Disease
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
CsA	CsA	PROPN	NNP	0	B-Chemical
plus	plus	CCONJ	CC	9	O
SRL	SRL	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
FK506	FK506	PROPN	NNP	3	B-Chemical
plus	plus	CCONJ	CC	9	O
SRL	SRL	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
better	better	ADV	RBR	5	O
tolerated	tolerate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
troponin	troponin	NOUN	NN	9	O
I	-PRON-	PRON	PRP	9	O
and	and	CCONJ	CC	5	O
T	T	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
as	as	ADP	IN	5	O
markers	marker	NOUN	NNS	3	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiomyopathy	cardiomyopathy	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
relationship	relationship	NOUN	NN	5	O
with	with	ADP	IN	5	O
echocardiographic	echocardiographic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
histological	histological	ADJ	JJ	9	O
findings	finding	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Cardiac	cardiac	ADJ	JJ	9	O
troponins	troponin	NOUN	NNS	5	O
I	-PRON-	PRON	PRP	9	O
(	(	PUNCT	-LRB-	9	O
cTnI	cTnI	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
T	T	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
cTnT	ctnt	NUM	CD	3	O
)	)	PUNCT	-RRB-	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
highly	highly	ADV	RB	9	O
sensitive	sensitive	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
specific	specific	ADJ	JJ	9	O
markers	marker	NOUN	NNS	3	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
cell	cell	NOUN	NN	3	I-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
diagnostic	diagnostic	ADJ	JJ	5	O
value	value	NOUN	NN	9	O
of	of	ADP	IN	5	O
cTnI	cTnI	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
cTnT	ctnt	NUM	CD	3	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
we	-PRON-	PRON	PRP	5	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
serial	serial	ADJ	JJ	9	O
cTnI	cTnI	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
cTnT	ctnt	NUM	CD	3	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
monitored	monitor	VERB	VBN	9	O
by	by	ADP	IN	9	O
echocardiography	echocardiography	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
histological	histological	ADJ	JJ	9	O
examinations	examination	NOUN	NNS	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	METHODS	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Thirty	thirty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
five	five	NUM	CD	9	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
DOX	DOX	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
weekly	weekly	ADJ	JJ	5	O
for	for	ADP	IN	5	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
8	8	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
total	total	ADJ	JJ	9	O
cumulative	cumulative	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
12	12	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
BW	BW	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Ten	ten	NUM	CD	9	O
rats	rat	NOUN	NNS	9	O
received	receive	VERB	VBD	9	O
saline	saline	NOUN	NN	0	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

cTnI	cTnI	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
with	with	ADP	IN	5	O
Access	Access	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
R	r	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
ng	ng	ADP	IN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
research	research	NOUN	NN	5	O
immunoassay	immunoassay	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
pg	pg	NOUN	NN	7	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
cTnT	ctnt	NUM	CD	3	O
,	,	PUNCT	,	9	O
CK	ck	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
MB	MB	PROPN	NNP	0	O
mass	mass	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
CK	ck	NOUN	NN	9	O
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
using	use	VERB	VBG	9	O
transthoracic	transthoracic	NOUN	NN	5	O
echocardiography	echocardiography	NOUN	NN	5	O
,	,	PUNCT	,	9	O
anterior	anterior	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
posterior	posterior	ADJ	JJ	5	O
wall	wall	NOUN	NN	5	O
thickness	thickness	NOUN	NN	5	O
,	,	PUNCT	,	9	O
LV	LV	PROPN	NNP	9	O
diameters	diameter	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
LV	LV	PROPN	NNP	9	O
fractional	fractional	ADJ	JJ	5	O
shortening	shortening	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
FS	FS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
before	before	ADP	IN	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
or	or	CCONJ	CC	5	O
saline	saline	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
weeks	week	NOUN	NNS	9	O
6	6	NUM	CD	9	O
and	and	CCONJ	CC	5	O
9	9	NUM	CD	7	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
surviving	survive	VERB	VBG	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Histology	histology	NOUN	NN	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
in	in	ADP	IN	5	O
DOX	dox	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
rats	rat	NOUN	NNS	9	O
at	at	ADP	IN	9	O
6	6	NUM	CD	9	O
and	and	CCONJ	CC	5	O
9	9	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
DOX	dox	NOUN	NN	0	B-Chemical
dose	dose	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Eighteen	eighteen	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
rats	rat	NOUN	NNS	9	O
died	die	VERB	VBD	9	O
prematurely	prematurely	ADV	RB	5	O
of	of	ADP	IN	5	O
general	general	ADJ	JJ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
9	9	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

End	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
diastolic	diastolic	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
ED	ED	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
end	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
systolic	systolic	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ES	ES	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
LV	LV	PROPN	NNP	9	O
diameters	diameter	NOUN	NNS	5	O
/	/	SYM	SYM	9	O
BW	BW	PROPN	NNP	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
LV	LV	PROPN	NNP	9	O
FS	FS	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
after	after	ADP	IN	9	O
9	9	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
parameters	parameter	NOUN	NNS	5	O
remained	remain	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
in	in	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Histological	histological	ADJ	JJ	9	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
hearts	heart	NOUN	NNS	3	O
from	from	ADP	IN	9	O
all	all	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
given	give	VERB	VBN	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
revealed	reveal	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
slight	slight	ADJ	JJ	9	O
degrees	degree	NOUN	NNS	5	O
of	of	ADP	IN	5	O
perivascular	perivascular	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
interstitial	interstitial	ADJ	JJ	9	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
7	7	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
18	18	NUM	CD	7	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
degeneration	degeneration	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
myocyte	myocyte	NOUN	NN	3	O
vacuolisation	vacuolisation	NOUN	NN	3	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Only	only	ADV	RB	9	O
five	five	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
controls	control	NOUN	NNS	9	O
exhibited	exhibit	VERB	VBD	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
very	very	ADV	RB	5	O
slight	slight	ADJ	JJ	9	O
perivascular	perivascular	ADJ	JJ	3	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
rise	rise	NOUN	NN	9	O
in	in	ADP	IN	5	O
cTnT	ctnt	NUM	CD	3	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
rats	rat	NOUN	NNS	9	O
after	after	ADP	IN	9	O
cumulative	cumulative	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
12	12	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
in	in	ADP	IN	5	O
comparison	comparison	NOUN	NN	9	O
with	with	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

cTnT	ctnt	NUM	CD	3	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
after	after	ADP	IN	9	O
12	12	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
found	find	VERB	VBD	9	O
after	after	ADP	IN	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
DOX	DOX	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Maximal	Maximal	PROPN	NNP	9	O
cTnI	cTnI	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
pg	pg	NOUN	NN	7	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
cTnT	ctnt	NUM	CD	3	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
in	in	ADP	IN	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
rats	rat	NOUN	NNS	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
006	006	NUM	CD	7	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
007	007	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

cTnI	cTnI	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
ng	ng	ADP	IN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
CK	CK	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
MB	MB	PROPN	NNP	0	O
mass	mass	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
CK	CK	PROPN	NNP	9	O
remained	remain	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
in	in	ADP	IN	5	O
DOX	DOX	PROPN	NNP	0	B-Chemical
rats	rat	NOUN	NNS	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
markers	marker	NOUN	NNS	3	O
remained	remain	VERB	VBD	9	O
stable	stable	ADJ	JJ	9	O
in	in	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
data	datum	NOUN	NNS	5	O
revealed	reveal	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
correlation	correlation	NOUN	NN	9	O
between	between	ADP	IN	5	O
maximal	maximal	NOUN	NN	9	O
cTnT	ctnt	NUM	CD	3	O
and	and	CCONJ	CC	5	O
ED	ED	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
ES	ES	PROPN	NNP	3	O
LV	LV	PROPN	NNP	9	O
diameters	diameter	NOUN	NNS	5	O
/	/	SYM	SYM	9	O
BW	BW	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
81	81	NUM	CD	7	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
65	65	NUM	CD	7	O
;	;	PUNCT	:	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
relationship	relationship	NOUN	NN	5	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
between	between	ADP	IN	5	O
maximal	maximal	NOUN	NN	9	O
cTnT	ctnt	NUM	CD	3	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	O
morphological	morphological	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
between	between	ADP	IN	5	O
LV	LV	PROPN	NNP	9	O
diameters	diameter	NOUN	NNS	5	O
/	/	SYM	SYM	9	O
BW	BW	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
histological	histological	ADJ	JJ	9	O
findings	finding	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Among	among	ADP	IN	9	O
markers	marker	NOUN	NNS	3	O
of	of	ADP	IN	5	O
ischemic	ischemic	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
after	after	ADP	IN	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
cTnT	ctnt	NUM	CD	3	O
showed	show	VERB	VBD	9	O
the	the	DET	DT	5	O
greatest	great	ADJ	JJS	9	O
ability	ability	NOUN	NN	9	O
to	to	PART	TO	5	O
detect	detect	VERB	VB	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
echocardiographic	echocardiographic	ADJ	JJ	5	O
detection	detection	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
histological	histological	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
discrepancy	discrepancy	NOUN	NN	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
amount	amount	NOUN	NN	9	O
of	of	ADP	IN	5	O
cTnI	cTnI	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
cTnT	ctnt	NUM	CD	3	O
after	after	ADP	IN	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
probably	probably	ADV	RB	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
heterogeneity	heterogeneity	NOUN	NN	9	O
in	in	ADP	IN	5	O
cross	cross	NOUN	NN	5	O
-	-	NOUN	NNS	7	O
reactivities	reactivity	NOUN	NNS	9	O
of	of	ADP	IN	5	O
mAbs	mAbs	PROPN	NNP	3	O
to	to	ADP	IN	5	O
various	various	ADJ	JJ	9	O
cTnI	cTnI	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
cTnT	ctnt	NUM	CD	3	O
forms	form	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
likely	likely	ADJ	JJ	5	O
that	that	ADP	IN	5	O
cTnT	ctnt	NUM	CD	3	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
after	after	ADP	IN	9	O
DOX	DOX	PROPN	NNP	0	B-Chemical
indicates	indicate	VERB	VBZ	9	O
cell	cell	NOUN	NN	3	O
damage	damage	NOUN	NN	9	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
magnitude	magnitude	NOUN	NN	5	O
of	of	ADP	IN	5	O
injury	injury	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
cTnT	ctnt	NUM	CD	3	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
useful	useful	ADJ	JJ	5	O
marker	marker	NOUN	NN	3	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
prediction	prediction	NOUN	NN	5	O
of	of	ADP	IN	5	O
experimentally	experimentally	ADV	RB	9	O
induced	induce	VERB	VBN	3	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
possibly	possibly	ADV	RB	9	O
for	for	ADP	IN	5	O
cardioprotective	cardioprotective	ADJ	JJ	9	O
experiments	experiment	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Octreotide	octreotide	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypoxemia	hypoxemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
premature	premature	ADJ	JJ	9	O
neonates	neonate	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
report	report	VERB	VBP	5	O
2	2	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
premature	premature	ADJ	JJ	9	O
neonates	neonate	NOUN	NNS	9	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
enterocutaneous	enterocutaneous	ADJ	JJ	5	O
fistula	fistula	NOUN	NN	5	B-Disease
complicating	complicate	VERB	VBG	5	O
necrotizing	necrotize	VERB	VBG	5	B-Disease
enterocolitis	enterocolitis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Pulmonary	pulmonary	ADJ	JJ	9	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
developed	develop	VERB	VBD	5	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
somatostatin	somatostatin	ADJ	JJ	3	O
analogue	analogue	NOUN	NN	0	O
,	,	PUNCT	,	9	O
octreotide	octreotide	ADV	RB	0	B-Chemical
,	,	PUNCT	,	9	O
to	to	PART	TO	5	O
enhance	enhance	VERB	VB	9	O
resolution	resolution	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
fistula	fistula	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
discuss	discuss	VERB	VBP	5	O
the	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
complication	complication	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
recommend	recommend	VERB	VB	5	O
caution	caution	NOUN	NN	5	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
risk	risk	NOUN	NN	5	O
premature	premature	ADJ	JJ	9	O
neonates	neonate	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
thromboembolism	thromboembolism	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
prescribed	prescribe	VERB	VBD	5	O
cyproterone	cyproterone	NOUN	NN	0	B-Chemical
acetate	acetate	ADJ	JJ	0	I-Chemical
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
ethinyl	ethinyl	ADJ	JJ	0	B-Chemical
estradiol	estradiol	NOUN	NNS	0	I-Chemical
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
nested	nested	ADJ	JJ	9	O
cohort	cohort	NOUN	NN	9	O
analysis	analysis	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Cyproterone	Cyproterone	PROPN	NNP	0	B-Chemical
acetate	acetate	NOUN	NN	0	I-Chemical
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
ethinyl	ethinyl	ADJ	JJ	0	B-Chemical
estradiol	estradiol	NOUN	NNS	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
CPA	CPA	PROPN	NNP	9	B-Chemical
/	/	SYM	SYM	9	O
EE	ee	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
licensed	license	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
UK	UK	PROPN	NNP	2	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acne	acne	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
hirsutism	hirsutism	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
is	be	VERB	VBZ	5	O
also	also	ADV	RB	9	O
a	a	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
option	option	NOUN	NN	5	O
for	for	ADP	IN	5	O
polycystic	polycystic	ADJ	JJ	5	B-Disease
ovary	ovary	ADJ	JJ	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
PCOS	PCOS	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Previous	previous	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
demonstrated	demonstrate	VERB	VBN	9	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
thromboembolism	thromboembolism	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
VTE	VTE	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
CPA	CPA	PROPN	NNP	9	B-Chemical
/	/	SYM	SYM	9	O
EE	EE	PROPN	NNP	9	B-Chemical
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
conventional	conventional	ADJ	JJ	5	O
combined	combine	VERB	VBN	9	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptives	contraceptive	NOUN	NNS	5	I-Chemical
(	(	PUNCT	-LRB-	9	O
COCs	COCs	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
believe	believe	VERB	VBP	5	O
the	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
those	those	DET	DT	5	O
studies	study	NOUN	NNS	9	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
been	be	VERB	VBN	9	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
residual	residual	ADJ	JJ	9	O
confounding	confounding	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
General	General	PROPN	NNP	2	O
Practice	Practice	PROPN	NNP	5	O
Research	Research	PROPN	NNP	2	O
Database	Database	PROPN	NNP	2	O
we	-PRON-	PRON	PRP	5	O
conducted	conduct	VERB	VBD	9	O
a	a	DET	DT	5	O
cohort	cohort	NOUN	NN	9	O
analysis	analysis	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
study	study	NOUN	NN	9	O
nested	nest	VERB	VBN	9	O
within	within	ADP	IN	9	O
a	a	DET	DT	5	O
population	population	NOUN	NN	5	O
of	of	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
aged	age	VERB	VBN	9	O
between	between	ADP	IN	5	O
15	15	NUM	CD	9	O
and	and	CCONJ	CC	5	O
39	39	NUM	CD	7	O
years	year	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acne	acne	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
hirsutism	hirsutism	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
PCOS	PCOS	PROPN	NNP	9	B-Disease
to	to	PART	TO	5	O
estimate	estimate	VERB	VB	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
VTE	VTE	PROPN	NNP	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
CPA	CPA	PROPN	NNP	9	B-Chemical
/	/	SYM	SYM	9	O
EE	ee	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
age	age	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
adjusted	adjust	VERB	VBN	9	O
incidence	incidence	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
ratio	ratio	NOUN	NN	9	O
for	for	ADP	IN	5	O
CPA	cpa	NOUN	NN	9	B-Chemical
/	/	SYM	SYM	9	O
EE	EE	PROPN	NNP	9	B-Chemical
versus	versus	ADP	IN	9	O
conventional	conventional	ADJ	JJ	5	O
COCs	COCs	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
20	20	NUM	CD	9	O
[	[	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CI	CI	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
35	35	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
58	58	NUM	CD	7	O
]	]	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Using	use	VERB	VBG	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
reference	reference	NOUN	NN	9	O
group	group	NOUN	NN	9	O
women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
using	use	VERB	VBG	9	O
oral	oral	ADJ	JJ	9	O
contraception	contraception	NOUN	NN	5	O
,	,	PUNCT	,	9	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
recent	recent	ADJ	JJ	5	O
pregnancy	pregnancy	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
menopausal	menopausal	NOUN	NN	5	O
symptoms	symptom	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
analysis	analysis	NOUN	NN	9	O
gave	give	VERB	VBD	9	O
an	an	DET	DT	5	O
adjusted	adjust	VERB	VBN	9	O
odds	odd	NOUN	NNS	5	O
ratio	ratio	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
(	(	PUNCT	-LRB-	9	O
adj	adj	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
44	44	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
67	67	NUM	CD	7	O
-	-	SYM	SYM	7	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
08	08	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
CPA	CPA	PROPN	NNP	9	B-Chemical
/	/	SYM	SYM	9	O
EE	ee	NOUN	NN	9	B-Chemical
use	use	NOUN	NN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
OR	OR	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
adj	adj	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
58	58	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
60	60	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
18	18	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
conventional	conventional	ADJ	JJ	5	O
COCs	coc	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
demonstrated	demonstrate	VERB	VBN	9	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
VTE	VTE	PROPN	NNP	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
CPA	cpa	NOUN	NN	9	B-Chemical
/	/	SYM	SYM	9	O
EE	ee	NOUN	NN	9	B-Chemical
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acne	acne	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
hirsutism	hirsutism	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
PCOS	PCOS	PROPN	NNP	9	B-Disease
although	although	ADP	IN	9	O
residual	residual	ADJ	JJ	9	O
confounding	confound	VERB	VBG	5	O
by	by	ADP	IN	9	O
indication	indication	NOUN	NN	5	O
cannot	cannot	NOUN	NN	5	O
be	be	VERB	VB	5	O
excluded	exclude	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
gum	gum	NOUN	NN	0	B-Chemical
Arabic	Arabic	PROPN	NNP	5	I-Chemical
on	on	ADP	IN	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
preliminary	preliminary	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
work	work	NOUN	NN	5	O
we	-PRON-	PRON	PRP	5	O
assessed	assess	VERB	VBD	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
gum	gum	NOUN	NN	0	B-Chemical
Arabic	Arabic	PROPN	NNP	5	I-Chemical
on	on	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
gentamicin	gentamicin	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
GM	GM	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
vehicle	vehicle	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
mL	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
of	of	ADP	IN	5	O
distilled	distilled	ADJ	JJ	0	O
water	water	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
w	w	NOUN	NN	0	O
/	/	SYM	SYM	9	O
v	v	ADV	RB	0	O
cellulose	cellulose	VERB	VBD	0	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
gum	gum	NOUN	NN	0	B-Chemical
Arabic	Arabic	PROPN	NNP	5	I-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
mL	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
w	w	NOUN	NN	0	O
/	/	SYM	SYM	9	O
v	v	NOUN	NN	0	O
aqueous	aqueous	ADJ	JJ	0	O
suspension	suspension	NOUN	NN	0	O
of	of	ADP	IN	5	O
gum	gum	NOUN	NN	0	B-Chemical
Arabic	arabic	ADJ	JJ	5	I-Chemical
powder	powder	NOUN	NN	0	O
,	,	PUNCT	,	9	O
orally	orally	ADV	RB	0	O
for	for	ADP	IN	5	O
10	10	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
gum	gum	NOUN	NN	0	B-Chemical
Arabic	Arabic	PROPN	NNP	5	I-Chemical
concomitantly	concomitantly	ADV	RB	9	O
with	with	ADP	IN	5	O
GM	GM	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
80mg	80mg	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
intramuscularly	intramuscularly	ADV	RB	0	O
,	,	PUNCT	,	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
six	six	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
period	period	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Nephrotoxicity	nephrotoxicity	NOUN	NN	0	B-Disease
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
measuring	measure	VERB	VBG	9	O
the	the	DET	DT	5	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
urea	urea	ADJ	JJ	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
reduced	reduce	VERB	VBN	9	O
glutathione	glutathione	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
GSH	GSH	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
cortex	cortex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
by	by	ADP	IN	9	O
light	light	ADJ	JJ	9	O
microscopic	microscopic	ADJ	JJ	9	O
examination	examination	NOUN	NN	5	O
of	of	ADP	IN	5	O
kidney	kidney	NOUN	NN	9	O
sections	section	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicated	indicate	VERB	VBD	9	O
that	that	ADP	IN	5	O
concomitant	concomitant	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
gum	gum	NOUN	NN	0	B-Chemical
Arabic	Arabic	PROPN	NNP	5	I-Chemical
and	and	CCONJ	CC	5	O
GM	GM	PROPN	NNP	9	B-Chemical
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
urea	urea	ADJ	JJ	0	B-Chemical
by	by	ADP	IN	9	O
about	about	ADV	RB	5	O
183	183	NUM	CD	7	O
and	and	CCONJ	CC	5	O
239	239	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
432	432	NUM	CD	7	O
and	and	CCONJ	CC	5	O
346	346	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
cellulose	cellulose	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
GM	GM	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
cortical	cortical	ADJ	JJ	5	O
GSH	GSH	PROPN	NNP	0	B-Chemical
by	by	ADP	IN	9	O
21	21	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
27	27	NUM	CD	7	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cellulose	cellulose	NOUN	NN	0	O
plus	plus	CCONJ	CC	9	O
GM	GM	PROPN	NNP	9	B-Chemical
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
The	the	DET	DT	5	O
GM	GM	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
proximal	proximal	ADJ	JJ	9	O
tubular	tubular	ADJ	JJ	9	B-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
appeared	appear	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
slightly	slightly	ADV	RB	9	O
less	less	ADV	RBR	5	O
severe	severe	ADJ	JJ	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
given	give	VERB	VBN	5	O
GM	GM	PROPN	NNP	9	B-Chemical
together	together	ADV	RB	9	O
with	with	ADP	IN	5	O
gum	gum	NOUN	NN	0	B-Chemical
Arabic	arabic	ADJ	JJ	5	I-Chemical
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
those	those	DET	DT	5	O
given	give	VERB	VBN	5	O
GM	GM	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
cellulose	cellulose	NOUN	NN	0	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
inferred	infer	VERB	VBN	5	O
that	that	ADP	IN	5	O
gum	gum	NOUN	NN	0	B-Chemical
Arabic	arabic	ADJ	JJ	5	I-Chemical
treatment	treatment	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
induced	induce	VERB	VBN	3	O
a	a	DET	DT	5	O
modest	modest	ADJ	JJ	9	O
amelioration	amelioration	NOUN	NN	9	O
of	of	ADP	IN	5	O
some	some	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
histological	histological	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
biochemical	biochemical	ADJ	JJ	9	O
indices	index	NOUN	NNS	5	O
of	of	ADP	IN	5	O
GM	GM	PROPN	NNP	9	B-Chemical
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
work	work	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
warranted	warrant	VERB	VBN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
treatments	treatment	NOUN	NNS	9	O
on	on	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
functional	functional	ADJ	JJ	9	O
aspects	aspect	NOUN	NNS	5	O
in	in	ADP	IN	5	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
s	s	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
involved	involve	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Increased	increase	VERB	VBN	9	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
thromboembolism	thromboembolism	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
docetaxel	docetaxel	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
thalidomide	thalidomide	VERB	VB	0	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
androgen	androgen	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
independent	independent	ADJ	JJ	9	O
prostate	prostate	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

STUDY	study	NOUN	NN	2	O
OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
thromboembolism	thromboembolism	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
VTE	VTE	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
androgen	androgen	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
independent	independent	ADJ	JJ	9	O
prostate	prostate	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
docetaxel	docetaxel	NOUN	NN	0	B-Chemical
alone	alone	ADV	RB	9	O
or	or	CCONJ	CC	5	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Retrospective	retrospective	ADJ	JJ	9	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
randomized	randomize	VERB	VBN	5	O
phase	phase	NOUN	NN	5	O
II	II	PROPN	NNP	9	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

SETTING	set	VERB	VBG	2	O
:	:	PUNCT	:	9	O
National	National	PROPN	NNP	2	O
Institutes	Institutes	PROPN	NNPS	2	O
of	of	ADP	IN	5	O
Health	Health	PROPN	NNP	2	O
clinical	clinical	ADJ	JJ	5	O
research	research	NOUN	NN	5	O
center	center	NOUN	NN	5	O
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Seventy	seventy	NUM	CD	5	O
men	man	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
aged	age	VERB	VBN	9	O
50	50	NUM	CD	0	O
-	-	SYM	SYM	7	O
80	80	NUM	CD	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
androgen	androgen	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
independent	independent	ADJ	JJ	9	O
prostate	prostate	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

INTERVENTION	intervention	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Each	each	DET	DT	5	O
patient	patient	NOUN	NN	5	O
received	receive	VERB	VBD	9	O
either	either	CCONJ	CC	9	O
intravenous	intravenous	ADJ	JJ	0	O
docetaxel	docetaxel	NOUN	NN	0	B-Chemical
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
/	/	SYM	SYM	9	O
week	week	NOUN	NN	9	O
for	for	ADP	IN	5	O
3	3	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
1	1	NUM	CD	9	O
week	week	NOUN	NN	9	O
off	off	ADV	RB	5	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
continuous	continuous	ADJ	JJ	5	O
oral	oral	ADJ	JJ	9	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
every	every	DET	DT	5	O
evening	evening	NOUN	NN	5	O
plus	plus	CCONJ	CC	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
docetaxel	docetaxel	NOUN	NN	0	B-Chemical
regimen	regimen	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
cycle	cycle	NOUN	NN	9	O
was	be	VERB	VBD	9	O
repeated	repeat	VERB	VBN	5	O
until	until	ADP	IN	5	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
excessive	excessive	ADJ	JJ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
or	or	CCONJ	CC	5	O
disease	disease	NOUN	NN	5	O
progression	progression	NOUN	NN	9	O
.	.	PUNCT	.	9	O

MEASUREMENTS	measurement	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
MAIN	main	ADJ	JJ	2	O
RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
None	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
23	23	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
docetaxel	docetaxel	NOUN	NN	0	B-Chemical
alone	alone	ADV	RB	9	O
developed	develop	VERB	VBD	5	O
VTE	VTE	PROPN	NNP	5	B-Disease
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
9	9	NUM	CD	7	O
of	of	ADP	IN	5	O
47	47	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
19	19	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
docetaxel	docetaxel	NOUN	NN	0	B-Chemical
plus	plus	CCONJ	CC	9	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
developed	develop	VERB	VBN	5	O
VTE	VTE	PROPN	NNP	5	B-Disease
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
025	025	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
addition	addition	NOUN	NN	9	O
of	of	ADP	IN	5	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
docetaxel	docetaxel	VERB	VB	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
prostate	prostate	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
significantly	significantly	ADV	RB	9	O
increases	increase	VERB	VBZ	9	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
VTE	VTE	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

Clinicians	clinician	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
complication	complication	NOUN	NN	5	O
when	when	ADV	WRB	5	O
adding	add	VERB	VBG	0	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
chemotherapeutic	chemotherapeutic	ADJ	JJ	3	O
regimens	regimen	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Ticlopidine	ticlopidine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cholestatic	cholestatic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
report	report	VERB	VB	5	O
2	2	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
ticlopidine	ticlopidine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cholestatic	cholestatic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
investigate	investigate	VERB	VB	9	O
its	-PRON-	DET	PRP$	9	O
mechanism	mechanism	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
compare	compare	VERB	VB	9	O
the	the	DET	DT	5	O
observed	observed	ADJ	JJ	9	O
main	main	ADJ	JJ	5	O
characteristics	characteristic	NOUN	NNS	5	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
published	publish	VERB	VBN	9	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
SUMMARIES	summary	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Two	two	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
prolonged	prolong	VERB	VBN	9	O
cholestatic	cholestatic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
after	after	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
ticlopidine	ticlopidine	NOUN	NN	0	B-Chemical
following	follow	VERB	VBG	9	O
percutaneous	percutaneous	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
angioplasty	angioplasty	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
complete	complete	ADJ	JJ	9	O
remission	remission	NOUN	NN	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

T	t	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
cell	cell	NOUN	NN	3	O
stimulation	stimulation	NOUN	NN	3	O
by	by	ADP	IN	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
ticlopidine	ticlopidine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
demonstrated	demonstrate	VERB	VBN	9	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

DISCUSSION	discussion	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Cholestatic	cholestatic	ADJ	JJ	7	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
antiplatelet	antiplatelet	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
ticlopidine	ticlopidine	NOUN	NN	0	B-Chemical
;	;	PUNCT	:	9	O
several	several	ADJ	JJ	9	O
cases	case	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
but	but	CCONJ	CC	9	O
few	few	ADJ	JJ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
English	English	PROPN	NNP	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
jaundice	jaundice	NOUN	NN	5	B-Disease
following	follow	VERB	VBG	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
ticlopidine	ticlopidine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
showed	show	VERB	VBD	9	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
laboratory	laboratory	NOUN	NN	9	O
characteristics	characteristic	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cholestatic	cholestatic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
resolved	resolve	VERB	VBD	9	O
after	after	ADP	IN	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Hepatitis	Hepatitis	PROPN	NNP	9	B-Disease
may	may	VERB	MD	5	O
develop	develop	VERB	VB	5	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
run	run	VERB	VB	5	O
a	a	DET	DT	5	O
prolonged	prolong	VERB	VBN	9	O
course	course	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
complete	complete	ADJ	JJ	9	O
remission	remission	NOUN	NN	5	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
reported	report	VERB	VBN	9	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
objective	objective	ADJ	JJ	5	O
causality	causality	NOUN	NN	5	O
assessment	assessment	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
event	event	NOUN	NN	5	O
was	be	VERB	VBD	9	O
probably	probably	ADV	RB	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
ticlopidine	ticlopidine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
ticlopidine	ticlopidine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cholestasis	cholestasis	NOUN	NN	5	B-Disease
are	be	VERB	VBP	5	O
unclear	unclear	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Immune	Immune	PROPN	NNP	9	O
mechanisms	mechanism	NOUN	NNS	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
suggested	suggest	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
T	t	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
cell	cell	NOUN	NN	3	O
stimulation	stimulation	NOUN	NN	3	O
study	study	NOUN	NN	9	O
reported	report	VERB	VBN	9	O
here	here	ADV	RB	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Cholestatic	cholestatic	ADJ	JJ	7	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
ticlopidine	ticlopidine	NOUN	NN	0	B-Chemical
that	that	DET	WDT	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
immune	immune	ADJ	JJ	3	O
mediated	mediate	VERB	VBN	3	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
monitored	monitor	VERB	VBN	9	O
with	with	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
function	function	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
along	along	ADP	IN	9	O
with	with	ADP	IN	5	O
complete	complete	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
cell	cell	NOUN	NN	3	O
counts	count	VERB	VBZ	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
complication	complication	NOUN	NN	5	O
will	will	VERB	MD	5	O
be	be	VERB	VB	5	O
observed	observe	VERB	VBN	9	O
even	even	ADV	RB	5	O
less	less	ADV	RBR	5	O
often	often	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
future	future	NOUN	NN	5	O
as	as	ADP	IN	5	O
ticlopidine	ticlopidine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
being	be	VERB	VBG	5	O
replaced	replace	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
newer	new	ADJ	JJR	5	O
antiplatelet	antiplatelet	NOUN	NN	5	O
agent	agent	NOUN	NN	9	O
clopidogrel	clopidogrel	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Epithelial	epithelial	ADJ	JJ	3	O
sodium	sodium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
ENaC	ENaC	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
subunit	subunit	NOUN	NN	1	O
mRNA	mRNA	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
protein	protein	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
puromycin	puromycin	ADJ	JJ	3	B-Chemical
aminonucleoside	aminonucleoside	ADV	RB	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
experimental	experimental	ADJ	JJ	5	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
urinary	urinary	ADJ	JJ	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
excretion	excretion	NOUN	NN	0	O
is	be	VERB	VBZ	5	O
decreased	decrease	VERB	VBN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
early	early	ADJ	JJ	9	O
phase	phase	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
molecular	molecular	ADJ	JJ	9	O
mechanism	mechanism	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
s	s	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
salt	salt	NOUN	NN	0	O
retention	retention	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
completely	completely	ADV	RB	9	O
elucidated	elucidate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rate	rate	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
limiting	limit	VERB	VBG	9	O
constituent	constituent	NOUN	NN	9	O
of	of	ADP	IN	5	O
collecting	collect	VERB	VBG	5	O
duct	duct	NOUN	NN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
transport	transport	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
epithelial	epithelial	ADJ	JJ	3	O
sodium	sodium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
ENaC	ENaC	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
abundance	abundance	NOUN	NN	9	O
of	of	ADP	IN	5	O
ENaC	ENaC	PROPN	NNP	3	O
subunit	subunit	NOUN	NN	1	O
mRNAs	mrnas	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
proteins	protein	NOUN	NNS	1	O
in	in	ADP	IN	5	O
puromycin	puromycin	NOUN	NN	3	B-Chemical
aminonucleoside	aminonucleoside	ADP	IN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
PAN	PAN	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
time	time	NOUN	NN	5	O
courses	course	NOUN	NNS	5	O
of	of	ADP	IN	5	O
urinary	urinary	ADJ	JJ	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
excretion	excretion	NOUN	NN	0	O
,	,	PUNCT	,	9	O
plasma	plasma	NOUN	NN	9	O
aldosterone	aldosterone	NOUN	NN	9	B-Chemical
concentration	concentration	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
either	either	DET	DT	9	O
PAN	PAN	PROPN	NNP	0	B-Chemical
or	or	CCONJ	CC	5	O
vehicle	vehicle	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
relative	relative	ADJ	JJ	9	O
amounts	amount	NOUN	NNS	9	O
of	of	ADP	IN	5	O
alphaENaC	alphaENaC	PROPN	NNP	_	O
,	,	PUNCT	,	9	O
betaENaC	betaENaC	PROPN	NNP	_	O
and	and	CCONJ	CC	5	O
gammaENaC	gammaENaC	PROPN	NNP	_	O
mRNAs	mRNAs	PROPN	NNP	3	O
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
in	in	ADP	IN	5	O
kidneys	kidney	NOUN	NNS	9	O
from	from	ADP	IN	9	O
these	these	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
by	by	ADP	IN	9	O
real	real	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
time	time	NOUN	NN	5	O
quantitative	quantitative	ADJ	JJ	9	O
TaqMan	TaqMan	PROPN	NNP	9	O
PCR	PCR	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
amounts	amount	NOUN	NNS	9	O
of	of	ADP	IN	5	O
proteins	protein	NOUN	NNS	1	O
by	by	ADP	IN	9	O
Western	western	ADJ	JJ	3	O
blot	blot	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
kinetics	kinetic	NOUN	NNS	9	O
of	of	ADP	IN	5	O
urinary	urinary	ADJ	JJ	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
excretion	excretion	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
appearance	appearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
were	be	VERB	VBD	9	O
comparable	comparable	ADJ	JJ	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
reported	report	VERB	VBN	9	O
previously	previously	ADV	RB	9	O
.	.	PUNCT	.	9	O

Sodium	sodium	NOUN	NN	0	B-Chemical
retention	retention	NOUN	NN	9	O
occurred	occur	VERB	VBD	9	O
on	on	ADP	IN	5	O
days	day	NOUN	NNS	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
after	after	ADP	IN	9	O
PAN	PAN	PROPN	NNP	0	B-Chemical
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
up	up	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
alphaENaC	alphaENaC	PROPN	NNP	_	O
and	and	CCONJ	CC	5	O
betaENaC	betaENaC	PROPN	NNP	_	O
mRNA	mRNA	NOUN	NNS	3	O
abundance	abundance	VERB	VBP	9	O
on	on	ADP	IN	5	O
days	day	NOUN	NNS	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
preceded	precede	VERB	VBN	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
retention	retention	NOUN	NN	9	O
on	on	ADP	IN	5	O
days	day	NOUN	NNS	9	O
2	2	NUM	CD	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O

Conversely	conversely	ADV	RB	9	O
,	,	PUNCT	,	9	O
down	down	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
alphaENaC	alphaENaC	PROPN	NNP	_	O
,	,	PUNCT	,	9	O
betaENaC	betaENaC	PROPN	NNP	_	O
and	and	CCONJ	CC	5	O
gammaENaC	gammaENaC	PROPN	NNP	_	O
mRNA	mRNA	PROPN	NNP	3	O
expression	expression	NOUN	NN	3	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
3	3	NUM	CD	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
aldosterone	aldosterone	NOUN	NN	9	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
return	return	NOUN	NN	5	O
of	of	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
excretion	excretion	NOUN	NN	0	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
values	value	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
amounts	amount	NOUN	NNS	9	O
of	of	ADP	IN	5	O
alphaENaC	alphaENaC	PROPN	NNP	_	O
,	,	PUNCT	,	9	O
betaENaC	betaENaC	PROPN	NNP	_	O
and	and	CCONJ	CC	5	O
gammaENaC	gammaENaC	PROPN	NNP	_	O
proteins	protein	NOUN	NNS	1	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
increased	increase	VERB	VBN	9	O
during	during	ADP	IN	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
sodium	sodium	NOUN	NN	0	B-Chemical
retention	retention	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
ENaC	ENaC	PROPN	NNP	3	O
mRNA	mRNA	NOUN	NNS	3	O
expression	expression	NOUN	NN	3	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
alphaENaC	alphaenac	ADJ	JJ	_	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
increased	increase	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
very	very	ADV	RB	5	O
early	early	ADJ	JJ	9	O
phase	phase	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
escape	escape	VERB	VB	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
regulation	regulation	NOUN	NN	9	O
by	by	ADP	IN	9	O
aldosterone	aldosterone	NOUN	NN	9	B-Chemical
after	after	ADP	IN	9	O
day	day	NOUN	NN	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O

Sub	sub	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
chronic	chronic	ADJ	JJ	5	O
low	low	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
vinyl	vinyl	NOUN	NN	0	I-Chemical
GABA	GABA	PROPN	NNP	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
vigabatrin	vigabatrin	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
inhibits	inhibit	VERB	VBZ	3	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
nucleus	nucleus	NOUN	NN	9	O
accumbens	accumben	NOUN	NNS	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

RATIONALE	RATIONALE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
Vinyl	Vinyl	PROPN	NNP	0	I-Chemical
GABA	GABA	PROPN	NNP	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
GVG	GVG	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
irreversibly	irreversibly	ADV	RB	9	O
inhibits	inhibit	VERB	VBZ	3	O
GABA	GABA	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
transaminase	transaminase	PROPN	NNP	0	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
receptor	receptor	ADJ	JJ	3	O
mediated	mediate	VERB	VBN	3	O
inhibition	inhibition	NOUN	NN	3	O
requires	require	VERB	VBZ	5	O
de	de	X	FW	2	O
novo	novo	NOUN	NN	9	O
synthesis	synthesis	NOUN	NN	9	O
for	for	ADP	IN	5	O
restoration	restoration	NOUN	NN	5	O
of	of	ADP	IN	5	O
functional	functional	ADJ	JJ	9	O
GABA	GABA	PROPN	NNP	0	B-Chemical
catabolism	catabolism	NOUN	NN	9	O
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Given	give	VERB	VBN	9	O
its	-PRON-	DET	PRP$	9	O
preclinical	preclinical	ADJ	JJ	9	O
success	success	NOUN	NN	5	O
for	for	ADP	IN	5	O
treating	treat	VERB	VBG	5	O
substance	substance	NOUN	NN	5	B-Disease
abuse	abuse	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
visual	visual	ADJ	JJ	5	B-Disease
field	field	NOUN	NN	5	I-Disease
defects	defect	NOUN	NNS	9	I-Disease
(	(	PUNCT	-LRB-	9	O
VFD	VFD	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
cumulative	cumulative	ADJ	JJ	5	O
lifetime	lifetime	NOUN	NN	5	O
exposure	exposure	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
explored	explore	VERB	VBD	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
sub	sub	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
chronic	chronic	NOUN	NN	5	O
low	low	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
GVG	GVG	PROPN	NNP	0	B-Chemical
on	on	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
nucleus	nucleus	NOUN	NN	9	O
accumbens	accumben	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
NAcc	NAcc	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
DA	DA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Using	use	VERB	VBG	9	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
microdialysis	microdialysis	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
compared	compare	VERB	VBD	9	O
acute	acute	ADJ	JJ	9	O
exposure	exposure	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
450	450	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
identical	identical	ADJ	JJ	9	O
sub	sub	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
chronic	chronic	NOUN	NN	5	O
exposure	exposure	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
150	150	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
or	or	CCONJ	CC	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
washout	washout	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Finally	finally	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
low	low	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
150	150	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
washout	washout	NOUN	NN	0	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Sub	sub	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
chronic	chronic	ADJ	JJ	5	O
GVG	GVG	PROPN	NNP	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
inhibited	inhibit	VERB	VBD	3	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
for	for	ADP	IN	5	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
exceeded	exceed	VERB	VBD	9	O
in	in	ADP	IN	5	O
magnitude	magnitude	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
duration	duration	NOUN	NN	5	O
the	the	DET	DT	5	O
identical	identical	ADJ	JJ	9	O
acute	acute	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Sub	sub	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
chronic	chronic	ADJ	JJ	5	O
low	low	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
GVG	gvg	NOUN	NN	0	B-Chemical
potentiates	potentiate	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
extends	extend	VERB	VBZ	9	O
the	the	DET	DT	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
effectively	effectively	ADV	RB	5	O
reducing	reduce	VERB	VBG	9	O
cumulative	cumulative	ADJ	JJ	5	O
exposures	exposure	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
VFDS	VFDS	PROPN	NNP	_	O
.	.	PUNCT	.	9	O

MR	MR	PROPN	NNP	9	O
imaging	image	VERB	VBG	5	O
with	with	ADP	IN	5	O
quantitative	quantitative	ADJ	JJ	9	O
diffusion	diffusion	NOUN	NN	5	O
mapping	mapping	NOUN	NN	5	O
of	of	ADP	IN	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
organ	organ	NOUN	NN	5	O
transplant	transplant	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
objective	objective	NOUN	NN	5	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
brain	brain	NOUN	NN	5	O
MR	MR	PROPN	NNP	9	O
imaging	image	VERB	VBG	5	O
findings	finding	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
utility	utility	NOUN	NN	5	O
of	of	ADP	IN	5	O
diffusion	diffusion	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
weighted	weight	VERB	VBN	5	O
(	(	PUNCT	-LRB-	9	O
DW	DW	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
imaging	image	VERB	VBG	5	O
in	in	ADP	IN	5	O
organ	organ	NOUN	NN	5	O
transplant	transplant	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
neurologic	neurologic	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
during	during	ADP	IN	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Brain	Brain	PROPN	NNP	9	O
MR	MR	PROPN	NNP	9	O
studies	study	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
DW	DW	PROPN	NNP	0	O
imaging	imaging	NOUN	NN	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
prospectively	prospectively	ADV	RB	5	O
performed	perform	VERB	VBN	9	O
in	in	ADP	IN	5	O
14	14	NUM	CD	7	O
organ	organ	NOUN	NN	5	O
transplant	transplant	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
neurologic	neurologic	ADJ	JJ	5	B-Disease
complications	complication	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
each	each	DET	DT	5	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
abnormalities	abnormality	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
MR	MR	PROPN	NNP	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
MR	MR	PROPN	NNP	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
1	1	NUM	CD	9	O
month	month	NOUN	NN	5	O
later	later	ADV	RB	9	O
.	.	PUNCT	.	9	O

Apparent	apparent	ADJ	JJ	9	O
diffusion	diffusion	NOUN	NN	5	O
coefficient	coefficient	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ADC	adc	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
values	value	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
MR	MR	PROPN	NNP	9	O
study	study	NOUN	NN	9	O
were	be	VERB	VBD	9	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
reversibility	reversibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
lesions	lesion	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
14	14	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
35	35	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
white	white	ADJ	JJ	9	B-Disease
matter	matter	NOUN	NN	5	I-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
putaminal	putaminal	ADJ	JJ	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
8	8	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
57	57	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
findings	finding	NOUN	NNS	9	O
on	on	ADP	IN	5	O
initial	initial	ADJ	JJ	9	O
MR	MR	PROPN	NNP	9	O
images	image	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
white	white	ADJ	JJ	9	B-Disease
matter	matter	NOUN	NN	5	I-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
80	80	NUM	CD	9	O
.	.	NOUN	NN	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
showed	show	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
ADC	adc	NOUN	NN	5	O
values	value	NOUN	NNS	5	O
on	on	ADP	IN	5	O
initial	initial	ADJ	JJ	9	O
MR	MR	PROPN	NNP	9	O
images	image	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
all	all	DET	DT	5	O
showed	show	VERB	VBD	9	O
complete	complete	ADJ	JJ	9	O
resolution	resolution	NOUN	NN	5	O
on	on	ADP	IN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
images	image	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
remaining	remain	VERB	VBG	9	O
1	1	NUM	CD	9	O
patient	patient	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
.	.	NOUN	NN	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
showed	show	VERB	VBD	9	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
ADC	adc	NOUN	NN	5	O
value	value	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
showed	show	VERB	VBD	9	O
incomplete	incomplete	ADJ	JJ	9	O
resolution	resolution	NOUN	NN	5	O
with	with	ADP	IN	5	O
cortical	cortical	ADJ	JJ	5	B-Disease
laminar	laminar	NOUN	NN	5	I-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Diffusion	diffusion	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
weighted	weight	VERB	VBN	5	O
imaging	imaging	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
useful	useful	ADJ	JJ	5	O
in	in	ADP	IN	5	O
predicting	predict	VERB	VBG	5	O
the	the	DET	DT	5	O
outcomes	outcome	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
lesions	lesion	NOUN	NNS	5	O
of	of	ADP	IN	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
transport	transport	NOUN	NN	9	O
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
with	with	ADP	IN	5	O
cortisol	cortisol	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
deficient	deficient	ADJ	JJ	3	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
nitric	nitric	NOUN	NN	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
system	system	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
cortisol	cortisol	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
investigate	investigate	VERB	VBP	9	O
whether	whether	ADP	IN	9	O
abnormalities	abnormality	NOUN	NNS	9	O
in	in	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
uptake	uptake	NOUN	NN	0	O
contribute	contribute	VERB	VBP	9	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
deficiency	deficiency	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Eight	eight	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
men	man	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
recruited	recruit	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Hydrocortisone	hydrocortisone	NOUN	NN	0	B-Chemical
acetate	acetate	VERB	VB	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
orally	orally	ADV	RB	0	O
every	every	DET	DT	5	O
6	6	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
for	for	ADP	IN	5	O
24	24	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
fixed	fix	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
salt	salt	NOUN	NN	0	O
diet	diet	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
150	150	NUM	CD	0	O
mmol	mmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Crossover	crossover	NOUN	NN	5	O
studies	study	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
apart	apart	ADV	RB	9	O
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
milliliters	milliliter	NOUN	NNS	0	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
was	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
for	for	ADP	IN	5	O
isolation	isolation	NOUN	NN	9	O
of	of	ADP	IN	5	O
peripheral	peripheral	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
mononuclear	mononuclear	NOUN	NN	3	O
cells	cell	NOUN	NNS	3	O
after	after	ADP	IN	9	O
each	each	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
uptake	uptake	NOUN	NN	0	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
in	in	ADP	IN	5	O
mononuclear	mononuclear	NOUN	NN	3	O
cells	cell	NOUN	NNS	3	O
incubated	incubate	VERB	VBN	0	O
with	with	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
to	to	PART	TO	5	O
300	300	NUM	CD	0	O
micromol	micromol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
incorporating	incorporate	VERB	VBG	5	O
100	100	NUM	CD	0	O
nmol	nmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
[	[	PUNCT	-LRB-	9	B-Chemical
3H	3h	NOUN	NN	0	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
l	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
at	at	ADP	IN	9	O
37	37	NUM	CD	9	O
degrees	degree	NOUN	NNS	5	O
C	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Forearm	Forearm	PROPN	NNP	7	O
[	[	PUNCT	-LRB-	9	B-Chemical
3H	3h	NOUN	NN	0	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
L	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
extraction	extraction	NOUN	NN	9	O
was	be	VERB	VBD	9	O
calculated	calculate	VERB	VBN	5	O
after	after	ADP	IN	9	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
[	[	PUNCT	-LRB-	9	B-Chemical
3H	3h	NOUN	NN	0	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
L	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
brachial	brachial	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
100	100	NUM	CD	0	O
nCi	nCi	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
for	for	ADP	IN	5	O
80	80	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Deep	deep	ADJ	JJ	9	O
forearm	forearm	ADJ	JJ	5	O
venous	venous	ADJ	JJ	5	O
samples	sample	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
collected	collect	VERB	VBN	9	O
for	for	ADP	IN	5	O
determination	determination	NOUN	NN	9	O
of	of	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
extraction	extraction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Plasma	plasma	ADJ	JJ	0	O
cortisol	cortisol	NOUN	NN	5	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
raised	raise	VERB	VBN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
active	active	ADJ	JJ	9	O
phase	phase	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
323	323	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
43	43	NUM	CD	7	O
to	to	PART	TO	5	O
1082	1082	NUM	CD	7	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
245	245	NUM	CD	7	O
mmol	mmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Systolic	systolic	ADJ	JJ	7	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
elevated	elevate	VERB	VBN	9	O
by	by	ADP	IN	9	O
an	an	DET	DT	5	O
average	average	NOUN	NN	5	O
of	of	ADP	IN	5	O
7	7	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
.	.	PUNCT	.	9	O

Neither	neither	CCONJ	CC	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
transport	transport	NOUN	NN	9	O
into	into	ADP	IN	9	O
mononuclear	mononuclear	NOUN	NN	3	O
cells	cell	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
placebo	placebo	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
active	active	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
26	26	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
vs	vs	ADP	IN	7	O
29	29	NUM	CD	7	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
pmol	pmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
10	10	NUM	CD	9	O
000	000	NUM	CD	9	O
cells	cell	NOUN	NNS	3	O
per	per	ADP	IN	9	O
5	5	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
an	an	DET	DT	5	O
l	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
300	300	NUM	CD	0	O
micromol	micromol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
nor	nor	CCONJ	CC	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
extraction	extraction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
forearm	forearm	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
at	at	ADP	IN	9	O
80	80	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
active	active	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
868	868	NUM	CD	7	O
904	904	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
434	434	NUM	CD	7	O
962	962	NUM	CD	7	O
vs	vs	ADP	IN	7	O
2	2	NUM	CD	9	O
013	013	NUM	CD	7	O
910	910	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
770	770	NUM	CD	9	O
619	619	NUM	CD	7	O
disintegrations	disintegration	NOUN	NNS	0	O
per	per	ADP	IN	9	O
minute	minute	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
cortisol	cortisol	NOUN	NN	5	B-Chemical
treatment	treatment	NOUN	NN	9	O
;	;	PUNCT	:	9	O
ie	ie	PUNCT	LS	5	O
,	,	PUNCT	,	9	O
that	that	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
uptake	uptake	NOUN	NN	0	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
cortisol	cortisol	NOUN	NN	5	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
cortisol	cortisol	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
increases	increase	NOUN	NNS	9	B-Disease
in	in	ADP	IN	5	I-Disease
blood	blood	NOUN	NN	9	I-Disease
pressure	pressure	NOUN	NN	5	I-Disease
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
abnormalities	abnormality	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
l	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
transport	transport	NOUN	NN	9	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Amount	amount	NOUN	NN	9	O
of	of	ADP	IN	5	O
bleeding	bleeding	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
hematoma	hematoma	NOUN	NN	5	B-Disease
size	size	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
collagenase	collagenase	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
intracerebral	intracerebral	ADJ	JJ	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aggravated	aggravated	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
on	on	ADP	IN	5	O
intracerebral	intracerebral	ADJ	JJ	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
ICH	ICH	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
stroke	stroke	NOUN	NN	5	B-Disease
patients	patient	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
estimated	estimate	VERB	VBN	5	O
carefully	carefully	ADV	RB	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
therefore	therefore	ADV	RB	5	O
established	establish	VERB	VBD	9	O
sensitive	sensitive	ADJ	JJ	9	O
quantification	quantification	NOUN	NN	9	O
methods	method	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
provided	provide	VERB	VBD	9	O
a	a	DET	DT	5	O
rat	rat	NOUN	NN	3	O
ICH	ICH	PROPN	NNP	5	B-Disease
model	model	NOUN	NN	5	O
for	for	ADP	IN	5	O
detection	detection	NOUN	NN	9	O
of	of	ADP	IN	5	O
ICH	ICH	PROPN	NNP	5	B-Disease
deterioration	deterioration	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
ICH	ICH	PROPN	NNP	5	B-Disease
intrastriatally	intrastriatally	ADV	RB	3	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
014	014	NUM	CD	2	O
-	-	PUNCT	HYPH	7	O
unit	unit	NOUN	NN	5	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
070	070	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
unit	unit	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
350	350	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
unit	unit	NOUN	NN	5	O
collagenase	collagenase	NOUN	NN	0	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
amount	amount	NOUN	NN	9	O
of	of	ADP	IN	5	O
bleeding	bleeding	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
hemoglobin	hemoglobin	NOUN	NN	0	O
assay	assay	NOUN	NN	3	O
developed	develop	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
morphologically	morphologically	ADV	RB	4	O
determined	determined	ADJ	JJ	9	O
hematoma	hematoma	NOUN	NN	5	B-Disease
volume	volume	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
amounts	amount	VERB	VBZ	9	O
and	and	CCONJ	CC	5	O
hematoma	hematoma	NOUN	NN	5	B-Disease
volumes	volume	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
correlated	correlate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
hematoma	hematoma	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
014	014	NUM	CD	2	O
-	-	PUNCT	HYPH	7	O
unit	unit	NOUN	NN	5	O
collagenase	collagenase	NOUN	NN	0	O
was	be	VERB	VBD	9	O
adequate	adequate	ADJ	JJ	5	O
to	to	PART	TO	5	O
detect	detect	VERB	VB	9	O
ICH	ICH	PROPN	NNP	5	B-Disease
deterioration	deterioration	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
ICH	ICH	PROPN	NNP	5	B-Disease
induction	induction	NOUN	NN	3	O
using	use	VERB	VBG	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
014	014	NUM	CD	2	O
-	-	PUNCT	HYPH	7	O
unit	unit	NOUN	NN	5	O
collagenase	collagenase	NOUN	NN	0	O
,	,	PUNCT	,	9	O
heparin	heparin	ADV	RB	0	B-Chemical
enhanced	enhance	VERB	VBD	3	O
the	the	DET	DT	5	O
hematoma	hematoma	NOUN	NN	5	B-Disease
volume	volume	NOUN	NN	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
-	-	PUNCT	:	7	O
fold	fold	VERB	VB	9	O
over	over	ADV	RB	5	O
that	that	DET	DT	5	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
control	control	NOUN	NN	9	O
ICH	ICH	PROPN	NNP	5	B-Disease
animals	animal	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
bleeding	bleed	VERB	VBG	5	B-Disease
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
-	-	NOUN	NN	7	O
fold	fold	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
sensitive	sensitive	ADJ	JJ	9	O
hemoglobin	hemoglobin	NOUN	NN	0	O
assay	assay	NOUN	NN	3	O
is	be	VERB	VBZ	5	O
useful	useful	ADJ	JJ	5	O
for	for	ADP	IN	5	O
ICH	ICH	PROPN	NNP	5	B-Disease
detection	detection	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
model	model	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
small	small	ADJ	JJ	9	O
ICH	ICH	PROPN	NNP	5	B-Disease
induced	induce	VERB	VBN	3	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
collagenase	collagenase	NOUN	NN	0	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
that	that	DET	WDT	5	O
may	may	VERB	MD	5	O
affect	affect	VERB	VB	9	O
ICH	ICH	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

Estradiol	Estradiol	PROPN	NNP	0	B-Chemical
reduces	reduce	VERB	VBZ	9	O
seizure	seizure	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hippocampal	hippocampal	ADJ	JJ	3	B-Disease
injury	injury	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
ovariectomized	ovariectomize	VERB	VBN	3	O
female	female	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Estrogens	estrogen	NOUN	NNS	5	O
protect	protect	VERB	VBP	9	O
ovariectomized	ovariectomize	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
from	from	ADP	IN	9	O
hippocampal	hippocampal	ADJ	JJ	3	B-Disease
injury	injury	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
kainic	kainic	NOUN	NN	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
SE	se	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
compared	compare	VERB	VBD	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
17beta	17beta	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
estradiol	estradiol	NOUN	NNS	0	I-Chemical
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
male	male	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
ovariectomized	ovariectomize	VERB	VBN	3	O
female	female	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
subjected	subject	VERB	VBN	9	O
to	to	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
SE	SE	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

Rats	rat	NOUN	NNS	9	O
received	receive	VERB	VBD	9	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
17beta	17beta	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
estradiol	estradiol	NOUN	NNS	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
rat	rat	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
oil	oil	NOUN	NN	0	O
once	once	ADV	RB	5	O
daily	daily	ADV	RB	5	O
for	for	ADP	IN	5	O
four	four	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

SE	SE	PROPN	NNP	9	B-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
20	20	NUM	CD	9	O
h	h	DET	DT	0	O
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
terminated	terminate	VERB	VBD	9	O
3	3	NUM	CD	9	O
h	h	ADV	RB	0	O
later	later	ADV	RB	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
silver	silver	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
stained	stain	VERB	VBN	3	O
CA3	CA3	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
CA1	CA1	PROPN	NNP	3	O
hippocampal	hippocampal	ADJ	JJ	3	O
neurons	neuron	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
2	2	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
SE	SE	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

17beta	17beta	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
Estradiol	Estradiol	PROPN	NNP	0	I-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
alter	alter	VERB	VB	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
first	first	ADJ	JJ	9	O
clonus	clonus	NOUN	NN	5	O
in	in	ADP	IN	5	O
ovariectomized	ovariectomize	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
but	but	CCONJ	CC	9	O
accelerated	accelerate	VERB	VBD	9	O
it	-PRON-	PRON	PRP	5	O
in	in	ADP	IN	5	O
males	male	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

17beta	17beta	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
Estradiol	Estradiol	PROPN	NNP	0	I-Chemical
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
argyrophilic	argyrophilic	ADJ	JJ	5	O
neurons	neuron	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
CA1	CA1	PROPN	NNPS	3	O
and	and	CCONJ	CC	5	O
CA3	CA3	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
C	C	PROPN	NNP	9	O
sectors	sector	NOUN	NNS	5	O
of	of	ADP	IN	5	O
ovariectomized	ovariectomize	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
males	male	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
estradiol	estradiol	NOUN	NNS	0	B-Chemical
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
score	score	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
estradiol	estradiol	NOUN	NNS	0	B-Chemical
on	on	ADP	IN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
threshold	threshold	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
damage	damage	NOUN	NN	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
altered	alter	VERB	VBN	9	O
by	by	ADP	IN	9	O
sex	sex	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hormonal	hormonal	ADJ	JJ	9	O
environment	environment	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Pseudoacromegaly	Pseudoacromegaly	PROPN	NNP	_	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
minoxidil	minoxidil	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Acromegaly	Acromegaly	PROPN	NNP	5	B-Disease
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
endocrine	endocrine	NOUN	NN	9	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
excessive	excessive	ADJ	JJ	5	O
growth	growth	NOUN	NN	3	O
hormone	hormone	NOUN	NN	9	O
secretion	secretion	NOUN	NN	3	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
anterior	anterior	ADJ	JJ	5	O
pituitary	pituitary	ADJ	JJ	3	O
gland	gland	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Significant	significant	ADJ	JJ	9	O
disfiguring	disfigure	VERB	VBG	5	O
changes	change	NOUN	NNS	9	O
occur	occur	VERB	VBP	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
bone	bone	NOUN	NN	5	O
,	,	PUNCT	,	9	O
cartilage	cartilage	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
soft	soft	ADJ	JJ	5	O
tissue	tissue	NOUN	NN	9	O
hypertrophy	hypertrophy	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
the	the	DET	DT	5	O
thickening	thickening	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
skin	skin	NOUN	NN	5	O
,	,	PUNCT	,	9	O
coarsening	coarsening	NOUN	NN	5	O
of	of	ADP	IN	5	O
facial	facial	ADJ	JJ	5	O
features	feature	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cutis	cutis	VERB	VB	5	B-Disease
verticis	verticis	NOUN	NN	4	I-Disease
gyrata	gyrata	NOUN	NN	4	I-Disease
.	.	PUNCT	.	9	O

Pseudoacromegaly	Pseudoacromegaly	PROPN	NNP	_	B-Disease
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
hand	hand	NOUN	NN	5	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
similar	similar	ADJ	JJ	9	O
acromegaloid	acromegaloid	NOUN	NN	5	O
features	feature	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
elevated	elevated	ADJ	JJ	9	O
growth	growth	NOUN	NN	3	O
hormone	hormone	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
insulin	insulin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
growth	growth	NOUN	NN	3	O
factor	factor	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
present	present	VERB	VBP	9	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
pseudoacromegaly	pseudoacromegaly	NOUN	NN	5	B-Disease
that	that	DET	WDT	5	O
resulted	result	VERB	VBD	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
minoxidil	minoxidil	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
an	an	DET	DT	5	O
unusually	unusually	ADV	RB	9	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
pseudoacromegaly	pseudoacromegaly	NOUN	NN	5	B-Disease
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
minoxidil	minoxidil	NOUN	NN	0	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Combined	combined	ADJ	JJ	9	O
androgen	androgen	NOUN	NN	3	O
blockade	blockade	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
anemia	anemia	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
prostate	prostate	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
patients	patient	NOUN	NNS	5	O
without	without	ADP	IN	9	O
bone	bone	NOUN	NN	5	O
involvement	involvement	NOUN	NN	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
combined	combined	ADJ	JJ	9	O
androgen	androgen	NOUN	NN	3	O
blockade	blockade	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
CAB	CAB	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
anemia	anemia	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
prostate	prostate	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
patients	patient	NOUN	NNS	5	O
without	without	ADP	IN	9	O
bone	bone	NOUN	NN	5	O
involvement	involvement	NOUN	NN	9	O
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Forty	forty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
biopsy	biopsy	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
proven	prove	VERB	VBN	5	O
prostatic	prostatic	ADJ	JJ	9	B-Disease
adenocarcinoma	adenocarcinoma	NOUN	NN	3	I-Disease
[	[	PUNCT	-LRB-	9	O
26	26	NUM	CD	7	O
with	with	ADP	IN	5	O
stage	stage	NOUN	NN	9	O
C	c	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
T3N0M0	T3N0M0	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
16	16	NUM	CD	9	O
with	with	ADP	IN	5	O
stage	stage	NOUN	NN	9	O
D1	D1	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
T3N1M0	T3N1M0	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
]	]	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
CAB	CAB	PROPN	NNP	9	O
[	[	PUNCT	-LRB-	9	O
leuprolide	leuprolide	NOUN	NN	0	B-Chemical
acetate	acetate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
LHRH	LHRH	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
A	A	PROPN	NNP	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
75	75	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
intramuscularly	intramuscularly	ADV	RB	0	O
,	,	PUNCT	,	9	O
every	every	DET	DT	5	O
28	28	NUM	CD	7	O
days	day	NOUN	NNS	9	O
plus	plus	CCONJ	CC	9	O
250	250	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
flutamide	flutamide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
tid	tid	NOUN	NN	0	O
,	,	PUNCT	,	9	O
per	per	ADP	IN	9	O
Os	Os	PROPN	NNP	0	O
]	]	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
for	for	ADP	IN	5	O
anemia	anemia	NOUN	NN	9	B-Disease
by	by	ADP	IN	9	O
physical	physical	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
laboratory	laboratory	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
subsequent	subsequent	ADJ	JJ	9	O
intervals	interval	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
CAB	CAB	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Hb	hb	INTJ	UH	9	O
,	,	PUNCT	,	9	O
PSA	PSA	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
Testosterone	Testosterone	PROPN	NNP	0	B-Chemical
measurements	measurement	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
stage	stage	NOUN	NN	9	O
D2	d2	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
disease	disease	NOUN	NN	5	O
,	,	PUNCT	,	9	O
abnormal	abnormal	ADJ	JJ	9	O
hemoglobin	hemoglobin	NOUN	NN	0	O
level	level	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
liver	liver	NOUN	NN	9	O
function	function	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
that	that	DET	WDT	5	O
were	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
upper	upper	ADJ	JJ	9	O
limits	limit	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
excluded	exclude	VERB	VBN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
six	six	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
hemoglobin	hemoglobin	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
Hb	Hb	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
declined	decline	VERB	VBN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
from	from	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
of	of	ADP	IN	5	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
to	to	ADP	IN	5	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
,	,	PUNCT	,	9	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
,	,	PUNCT	,	9	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
and	and	CCONJ	CC	5	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
at	at	ADP	IN	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
CAB	CAB	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Severe	severe	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
clinically	clinically	ADV	RB	5	O
evident	evident	ADJ	JJ	9	O
anemia	anemia	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
Hb	Hb	PROPN	NNP	9	O
<	<	X	XX	0	O
11	11	NUM	CD	7	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
with	with	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
6	6	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
CAB	CAB	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
anemia	anemia	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
normochromic	normochromic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
normocytic	normocytic	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
six	six	NUM	CD	9	O
months	month	NOUN	NNS	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
CAB	CAB	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
anemia	anemia	NOUN	NN	9	B-Disease
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
Hb	Hb	PROPN	NNP	9	O
mean	mean	ADJ	JJ	5	O
value	value	NOUN	NN	9	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
X	x	NOUN	NN	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SE	se	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
mild	mild	ADJ	JJ	9	O
anemia	anemia	NOUN	NN	9	B-Disease
with	with	ADP	IN	5	O
Hb	Hb	PROPN	NNP	9	O
mean	mean	ADJ	JJ	5	O
value	value	NOUN	NN	9	O
of	of	ADP	IN	5	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
17	17	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
X	x	NOUN	NN	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SE	se	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
anemia	anemia	NOUN	NN	9	B-Disease
at	at	ADP	IN	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
CAB	CAB	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
predictable	predictable	ADJ	JJ	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
Hb	Hb	PROPN	NNP	9	O
baseline	baseline	NOUN	NN	5	O
value	value	NOUN	NN	9	O
of	of	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
after	after	ADP	IN	9	O
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
CAB	CAB	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
CAB	cab	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
anemia	anemia	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
prostate	prostate	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
patients	patient	NOUN	NNS	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
correlate	correlate	VERB	VB	9	O
with	with	ADP	IN	5	O
T	T	PROPN	NNP	3	O
baseline	baseline	NOUN	NN	5	O
values	value	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
T	t	NOUN	NN	3	O
<	<	X	XX	0	O
3	3	NUM	CD	9	O
ng	ng	ADP	IN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
versus	versus	ADP	IN	9	O
T	T	PROPN	NNP	3	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
3	3	NUM	CD	9	O
ng	ng	ADP	IN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
age	age	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
<	<	X	XX	0	O
76	76	NUM	CD	7	O
yrs	yrs	NOUN	NN	7	O
versus	versus	ADP	IN	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
76	76	NUM	CD	7	O
yrs	yrs	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
stage	stage	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
stage	stage	NOUN	NN	9	O
C	c	NOUN	NN	9	O
versus	versus	ADP	IN	9	O
stage	stage	NOUN	NN	9	O
D1	d1	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Severe	severe	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
clinically	clinically	ADV	RB	5	O
evident	evident	ADJ	JJ	9	O
anemia	anemia	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
easily	easily	ADV	RB	5	O
corrected	correct	VERB	VBN	5	O
by	by	ADP	IN	9	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
injections	injection	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
times	time	NOUN	NNS	5	O
/	/	SYM	SYM	9	O
week	week	NOUN	NN	9	O
for	for	ADP	IN	5	O
1	1	NUM	CD	9	O
month	month	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
recombinant	recombinant	ADJ	JJ	3	O
erythropoietin	erythropoietin	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
rHuEPO	rhuepo	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
beta	beta	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Our	-PRON-	DET	PRP$	9	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
rHuEPO	rhuepo	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
beta	beta	NOUN	NN	9	O
correctable	correctable	ADJ	JJ	5	O
CAB	cab	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
anemia	anemia	NOUN	NN	9	B-Disease
occurs	occur	VERB	VBZ	9	O
in	in	ADP	IN	5	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
prostate	prostate	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
patients	patient	NOUN	NNS	5	O
after	after	ADP	IN	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Delirium	delirium	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
treatment	treatment	NOUN	NN	9	O
:	:	PUNCT	:	9	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
associated	associate	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Incidence	incidence	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
for	for	ADP	IN	5	O
delirium	delirium	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
treatment	treatment	NOUN	NN	9	O
require	require	VERB	VBP	5	O
further	further	ADJ	JJ	9	O
clarification	clarification	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
used	use	VERB	VBD	5	O
computerized	computerized	ADJ	JJ	5	O
pharmacy	pharmacy	NOUN	NN	5	O
records	record	VERB	VBZ	5	O
to	to	PART	TO	5	O
identify	identify	VERB	VB	9	O
all	all	DET	DT	5	O
adult	adult	NOUN	NN	9	O
psychiatric	psychiatric	ADJ	JJ	5	B-Disease
inpatients	inpatient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
1995	1995	NUM	CD	2	O
-	-	SYM	SYM	7	O
96	96	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
reviewed	review	VERB	VBD	9	O
their	-PRON-	DET	PRP$	5	O
medical	medical	ADJ	JJ	5	O
records	record	NOUN	NNS	5	O
to	to	PART	TO	5	O
score	score	VERB	VB	5	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
delirium	delirium	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
tested	test	VERB	VBN	9	O
associations	association	NOUN	NNS	5	O
with	with	ADP	IN	5	O
potential	potential	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Subjects	subject	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
139	139	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
72	72	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
67	67	NUM	CD	7	O
men	man	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
aged	age	VERB	VBN	9	O
40	40	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
hospitalized	hospitalize	VERB	VBN	5	O
for	for	ADP	IN	5	O
24	24	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
23	23	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
given	give	VERB	VBN	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
gradually	gradually	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
average	average	ADJ	JJ	5	O
daily	daily	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
282	282	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
203	203	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
45	45	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
45	45	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
16	16	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Delirium	Delirium	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
diagnosed	diagnose	VERB	VBN	5	O
in	in	ADP	IN	5	O
14	14	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
incidence	incidence	NOUN	NN	5	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
48	48	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
/	/	SYM	SYM	9	O
person	person	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
years	year	NOUN	NNS	5	O
of	of	ADP	IN	5	O
exposure	exposure	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
71	71	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
cases	case	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
moderate	moderate	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
severe	severe	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Associated	associated	ADJ	JJ	9	O
factors	factor	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
co	co	VERB	VBN	9	O
-	-	NOUN	NN	7	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
centrally	centrally	ADV	RB	5	O
antimuscarinic	antimuscarinic	ADJ	JJ	5	O
agents	agent	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
poor	poor	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
outcome	outcome	NOUN	NN	5	O
,	,	PUNCT	,	9	O
older	old	ADJ	JJR	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
longer	long	ADJ	JJR	5	O
hospitalization	hospitalization	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
by	by	ADP	IN	9	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
increasing	increase	VERB	VBG	9	O
cost	cost	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
sex	sex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
diagnosis	diagnosis	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
medical	medical	ADJ	JJ	5	O
co	co	NOUN	NN	9	O
-	-	NOUN	NN	7	O
morbidity	morbidity	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
daily	daily	ADJ	JJ	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
fell	fall	VERB	VBD	5	O
with	with	ADP	IN	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
unrelated	unrelated	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Delirium	Delirium	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
inpatients	inpatient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
in	in	ADP	IN	5	O
older	old	ADJ	JJR	5	O
patients	patient	NOUN	NNS	5	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
other	other	ADJ	JJ	5	O
central	central	ADJ	JJ	5	O
anticholinergics	anticholinergic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Delirium	Delirium	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
inconsistently	inconsistently	ADV	RB	5	O
recognized	recognize	VERB	VBN	9	O
clinically	clinically	ADV	RB	5	O
in	in	ADP	IN	5	O
milder	milder	NOUN	NN	9	O
cases	case	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
length	length	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
of	of	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
stay	stay	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
higher	high	ADJ	JJR	9	O
costs	cost	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
inferior	inferior	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
outcome	outcome	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Neuroprotective	neuroprotective	ADJ	JJ	0	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
MPEP	MPEP	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
mGluR5	mglur5	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
outflow	outflow	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
hyperthermia	hyperthermia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
metabotropic	metabotropic	ADJ	JJ	3	O
glutamate	glutamate	ADJ	JJ	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
5	5	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
mGluR5	mGluR5	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
toxic	toxic	ADJ	JJ	0	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
neurones	neurone	NOUN	NNS	3	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Methamphetamine	Methamphetamine	PROPN	NNP	7	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
sc	sc	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
administered	administer	VERB	VBD	9	O
five	five	NUM	CD	9	O
times	time	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
metabolites	metabolite	NOUN	NNS	0	O
in	in	ADP	IN	5	O
striatal	striatal	ADJ	JJ	3	O
tissue	tissue	NOUN	NN	9	O
when	when	ADV	WRB	5	O
measured	measure	VERB	VBN	9	O
72	72	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
selective	selective	ADJ	JJ	9	O
antagonist	antagonist	NOUN	NN	3	O
of	of	ADP	IN	5	O
mGluR5	mGluR5	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
6	6	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
phenylethynyl	phenylethynyl	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
pyridine	pyridine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
MPEP	MPEP	PROPN	NNP	0	B-Chemical
;	;	PUNCT	:	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
ip	ip	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
administered	administer	VERB	VBN	9	O
five	five	NUM	CD	9	O
times	time	NOUN	NNS	5	O
immediately	immediately	ADV	RB	9	O
before	before	ADP	IN	9	O
each	each	DET	DT	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
injection	injection	NOUN	NN	9	O
reversed	reverse	VERB	VBD	9	O
the	the	DET	DT	5	O
above	above	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
mentioned	mention	VERB	VBN	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
single	single	ADJ	JJ	9	O
MPEP	MPEP	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
ip	ip	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
injection	injection	NOUN	NN	9	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
basal	basal	NOUN	NN	3	O
extracellular	extracellular	ADJ	JJ	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
level	level	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
release	release	NOUN	NN	9	O
stimulated	stimulate	VERB	VBN	3	O
either	either	CCONJ	CC	9	O
by	by	ADP	IN	9	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
sc	sc	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
by	by	ADP	IN	9	O
intrastriatally	intrastriatally	ADV	RB	3	O
administered	administer	VERB	VBN	9	O
veratridine	veratridine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
microM	microm	NUM	CD	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
transiently	transiently	ADV	RB	3	O
diminished	diminish	VERB	VBD	9	O
the	the	DET	DT	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
sc	sc	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperthermia	hyperthermia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
reduced	reduce	VERB	VBN	9	O
basal	basal	NOUN	NN	3	O
body	body	NOUN	NN	5	O
temperature	temperature	NOUN	NN	0	O
.	.	PUNCT	.	9	O

MPEP	MPEP	PROPN	NNP	0	B-Chemical
administered	administer	VERB	VBD	9	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
at	at	ADP	IN	9	O
high	high	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
500	500	NUM	CD	0	O
microM	microM	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
increased	increase	VERB	VBN	9	O
extracellular	extracellular	ADJ	JJ	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
lower	low	ADJ	JJR	9	O
concentrations	concentration	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
-	-	SYM	SYM	7	O
100	100	NUM	CD	0	O
microM	microM	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
devoid	devoid	ADJ	JJ	9	O
of	of	ADP	IN	5	O
any	any	DET	DT	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
blockade	blockade	NOUN	NN	3	O
of	of	ADP	IN	5	O
mGluR5	mGluR5	PROPN	NNP	3	O
by	by	ADP	IN	9	O
MPEP	MPEP	PROPN	NNP	0	B-Chemical
may	may	VERB	MD	5	O
protect	protect	VERB	VB	9	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
neurones	neurone	NOUN	NNS	3	O
against	against	ADP	IN	9	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Neuroprotection	neuroprotection	NOUN	NN	3	O
rendered	render	VERB	VBN	9	O
by	by	ADP	IN	9	O
MPEP	MPEP	PROPN	NNP	0	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
efflux	efflux	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
blockade	blockade	NOUN	NN	3	O
of	of	ADP	IN	5	O
extrastriatal	extrastriatal	ADJ	JJ	5	O
mGluR5	mglur5	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
hyperthermia	hyperthermia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Protective	protective	ADJ	JJ	9	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
neuroactive	neuroactive	ADJ	JJ	5	O
steroids	steroid	NOUN	NNS	9	B-Chemical
against	against	ADP	IN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
kindled	kindle	VERB	VBN	5	O
-	-	PUNCT	HYPH	7	O
seizures	seizure	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Neuroactive	neuroactive	ADJ	JJ	7	O
steroids	steroid	NOUN	NNS	9	B-Chemical
demonstrate	demonstrate	VERB	VBP	9	O
pharmacological	pharmacological	ADJ	JJ	9	O
actions	action	NOUN	NNS	5	O
that	that	DET	WDT	5	O
have	have	VERB	VBP	5	O
relevance	relevance	NOUN	NN	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
host	host	NOUN	NN	9	O
of	of	ADP	IN	5	O
neurological	neurological	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
psychiatric	psychiatric	ADJ	JJ	5	I-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

They	-PRON-	PRON	PRP	5	O
offer	offer	VERB	VBP	5	O
protection	protection	NOUN	NN	9	O
against	against	ADP	IN	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
range	range	NOUN	NN	9	O
of	of	ADP	IN	5	O
models	model	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
seem	seem	VERB	VBP	5	O
to	to	PART	TO	5	O
inhibit	inhibit	VERB	VB	3	O
certain	certain	ADJ	JJ	5	O
stages	stage	NOUN	NNS	9	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	B-Disease
dependence	dependence	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
preclinical	preclinical	ADJ	JJ	9	O
assessments	assessment	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
two	two	NUM	CD	5	O
endogenous	endogenous	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
one	one	NUM	CD	5	O
synthetic	synthetic	ADJ	JJ	0	O
neuroactive	neuroactive	ADJ	JJ	5	O
steroid	steroid	NOUN	NN	9	B-Chemical
that	that	DET	WDT	5	O
positively	positively	ADV	RB	9	O
modulate	modulate	VERB	VBP	9	O
the	the	DET	DT	5	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminobutyric	aminobutyric	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
GABA	GABA	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
A	a	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
receptor	receptor	NOUN	NN	3	O
against	against	ADP	IN	9	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
sensitivity	sensitivity	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
convulsant	convulsant	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
engendered	engender	VERB	VBN	5	O
by	by	ADP	IN	9	O
repeated	repeat	VERB	VBN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
administration	administration	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
seizure	seizure	VERB	VB	5	B-Disease
kindling	kindling	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Allopregnanolone	Allopregnanolone	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
3alpha	3alpha	NUM	CD	1	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxy	hydroxy	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5alpha	5alpha	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
pregnan	pregnan	NOUN	NN	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
20	20	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
one	one	NUM	CD	5	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
pregnanolone	pregnanolone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
3alpha	3alpha	NUM	CD	1	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxy	hydroxy	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5beta	5beta	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
pregnan	pregnan	NOUN	NN	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
20	20	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
one	one	NUM	CD	5	I-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
ganaxolone	ganaxolone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
a	a	DET	DT	5	O
synthetic	synthetic	ADJ	JJ	0	O
derivative	derivative	NOUN	NN	0	O
of	of	ADP	IN	5	O
allopregnanolone	allopregnanolone	NOUN	NN	0	B-Chemical
3alpha	3alpha	NUM	CD	1	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxy	hydroxy	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
3beta	3beta	NUM	CD	1	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5alpha	5alpha	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
pregnan	pregnan	NOUN	NN	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
20	20	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
one	one	NUM	CD	5	I-Chemical
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
for	for	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
ability	ability	NOUN	NN	9	O
to	to	PART	TO	5	O
suppress	suppress	VERB	VB	3	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
anticonvulsant	anticonvulsant	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
development	development	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
antiepileptogenic	antiepileptogenic	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
kindled	kindle	VERB	VBN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
male	male	NOUN	NN	9	O
,	,	PUNCT	,	9	O
Swiss	Swiss	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
Webster	Webster	PROPN	NNP	6	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Kindled	Kindled	PROPN	NNP	7	O
seizures	seizure	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
daily	daily	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
60	60	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
for	for	ADP	IN	5	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
positive	positive	ADJ	JJ	9	O
GABA	GABA	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
A	a	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
modulators	modulator	NOUN	NNS	9	O
suppressed	suppress	VERB	VBD	3	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
kindled	kindle	VERB	VBN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
only	only	ADV	RB	9	O
allopregnanolone	allopregnanolone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
ganaxolone	ganaxolone	NOUN	NN	0	B-Chemical
inhibited	inhibit	VERB	VBD	3	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
kindling	kindle	VERB	VBG	5	O
.	.	PUNCT	.	9	O

Allopregnanolone	allopregnanolone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
pregnanolone	pregnanolone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
ganaxolone	ganaxolone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
also	also	ADV	RB	9	O
reduced	reduce	VERB	VBD	9	O
cumulative	cumulative	ADJ	JJ	5	O
lethality	lethality	NOUN	NN	3	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
kindling	kindling	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
demonstrate	demonstrate	VERB	VBP	9	O
that	that	ADP	IN	5	O
some	some	DET	DT	5	O
neuroactive	neuroactive	ADJ	JJ	5	O
steroids	steroid	NOUN	NNS	9	B-Chemical
attenuate	attenuate	VERB	VBP	9	O
convulsant	convulsant	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
sensitizing	sensitize	VERB	VBG	3	O
properties	property	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
add	add	VERB	VB	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
growing	grow	VERB	VBG	9	O
literature	literature	NOUN	NN	5	O
on	on	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
potential	potential	ADJ	JJ	9	O
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
modulation	modulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
of	of	ADP	IN	5	O
abuse	abuse	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
humoral	humoral	ADJ	JJ	3	O
modulators	modulator	NOUN	NNS	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
increase	increase	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
locomotor	locomotor	NOUN	NN	5	I-Disease
activity	activity	NOUN	NN	9	I-Disease
of	of	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
humoral	humoral	ADJ	JJ	3	O
modulators	modulator	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
increase	increase	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
locomotor	locomotor	NOUN	NN	5	I-Disease
activity	activity	NOUN	NN	9	I-Disease
of	of	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
HC1	HC1	PROPN	NNP	0	O
produced	produce	VERB	VBD	9	O
a	a	DET	DT	5	O
marked	marked	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
locomotor	locomotor	NOUN	NN	5	I-Disease
activity	activity	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
potentiated	potentiate	VERB	VBN	3	O
by	by	ADP	IN	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
attenuated	attenuate	VERB	VBN	3	O
by	by	ADP	IN	9	O
physostigmine	physostigmine	ADJ	JJ	0	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
both	both	CCONJ	CC	9	O
methscopolamine	methscopolamine	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
neostigmine	neostigmine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
do	do	VERB	VBP	5	O
not	not	ADV	RB	5	O
penetrate	penetrate	VERB	VB	9	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
brain	brain	NOUN	NN	5	O
barrier	barrier	NOUN	NN	5	O
,	,	PUNCT	,	9	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Pretreatment	pretreatment	NOUN	NN	3	O
of	of	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyltyrosine	methyltyrosine	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
hour	hour	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
tyrosine	tyrosine	NOUN	NN	3	B-Chemical
hydroxylase	hydroxylase	NOUN	NN	1	O
,	,	PUNCT	,	9	O
significantly	significantly	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
increasing	increase	VERB	VBG	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
hand	hand	NOUN	NN	5	O
,	,	PUNCT	,	9	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
p	p	NOUN	NN	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
chlorophenylalamine	chlorophenylalamine	NOUN	NN	_	I-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
X	x	NOUN	NN	9	O
320	320	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
24	24	NUM	CD	9	O
hr	hr	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
depletor	depletor	NOUN	NN	0	O
,	,	PUNCT	,	9	O
caused	cause	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
study	study	NOUN	NN	9	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
increasing	increase	VERB	VBG	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
release	release	NOUN	NN	9	O
of	of	ADP	IN	5	O
catecholamines	catecholamine	NOUN	NNS	9	B-Chemical
from	from	ADP	IN	9	O
adrenergic	adrenergic	NOUN	NN	9	O
neurons	neuron	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
.	.	PUNCT	.	9	O

And	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
acts	act	NOUN	NNS	9	O
by	by	ADP	IN	9	O
retarding	retard	VERB	VBG	9	O
the	the	DET	DT	5	O
release	release	NOUN	NN	9	O
of	of	ADP	IN	5	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
some	some	DET	DT	5	O
central	central	ADJ	JJ	5	O
cholinergic	cholinergic	NOUN	NN	3	O
synapses	synapsis	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
also	also	ADV	RB	9	O
suggested	suggest	VERB	VBN	9	O
from	from	ADP	IN	9	O
collected	collect	VERB	VBN	9	O
evidence	evidence	NOUN	NN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
increasing	increase	VERB	VBG	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
mechanisms	mechanism	NOUN	NNS	9	O
different	different	ADJ	JJ	9	O
from	from	ADP	IN	9	O
those	those	DET	DT	5	O
which	which	DET	WDT	5	O
mediate	mediate	VERB	VBP	3	O
the	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
increasing	increase	VERB	VBG	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
uninephrectomy	uninephrectomy	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
high	high	ADJ	JJ	9	O
protein	protein	NOUN	NN	1	O
feeding	feed	VERB	VBG	5	O
on	on	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
chronic	chronic	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
were	be	VERB	VBD	9	O
subjected	subject	VERB	VBN	9	O
to	to	ADP	IN	5	O
high	high	ADJ	JJ	9	O
protein	protein	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
HP	HP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
feeding	feeding	NOUN	NN	5	O
,	,	PUNCT	,	9	O
uninephrectomy	uninephrectomy	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
NX	NX	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
a	a	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
attempt	attempt	NOUN	NN	5	O
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
glomerular	glomerular	ADJ	JJ	5	O
hyperfiltration	hyperfiltration	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
further	further	ADJ	JJ	9	O
progression	progression	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Newborn	newborn	ADJ	JJ	9	O
female	female	ADJ	JJ	9	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
fed	feed	VERB	VBN	9	O
a	a	DET	DT	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
diet	diet	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
mmol	mmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
8	8	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
then	then	ADV	RB	9	O
randomized	randomize	VERB	VBD	5	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
diet	diet	NOUN	NN	9	O
,	,	PUNCT	,	9	O
HP	HP	PROPN	NNP	9	O
diet	diet	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
40	40	NUM	CD	9	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
19	19	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
NX	NX	PROPN	NNP	9	O
or	or	CCONJ	CC	5	O
HP	HP	PROPN	NNP	9	O
+	+	CCONJ	CC	9	O
NX	nx	NOUN	NN	9	O
for	for	ADP	IN	5	O
another	another	DET	DT	9	O
8	8	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Corresponding	correspond	VERB	VBG	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
lithium	lithium	ADJ	JJ	0	B-Chemical
pretreated	pretreate	VERB	VBN	3	O
groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
generated	generate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
comparing	compare	VERB	VBG	9	O
all	all	DET	DT	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
treated	treat	VERB	VBN	3	O
versus	versus	ADP	IN	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
lithium	lithium	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
glomerular	glomerular	ADJ	JJ	5	O
filtration	filtration	NOUN	NN	0	O
rate	rate	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
GFR	GFR	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
without	without	ADP	IN	9	O
significant	significant	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
effective	effective	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
as	as	ADP	IN	5	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
marker	marker	NOUN	NN	3	O
secreted	secrete	VERB	VBN	3	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
proximal	proximal	ADJ	JJ	9	O
tubules	tubule	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
clearance	clearance	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Consequently	consequently	ADV	RB	9	O
,	,	PUNCT	,	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
fall	fall	NOUN	NN	5	O
in	in	ADP	IN	5	O
filtration	filtration	NOUN	NN	0	O
fraction	fraction	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
fractional	fractional	ADJ	JJ	5	O
Li	Li	PROPN	NNP	6	B-Chemical
excretion	excretion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Lithium	Lithium	PROPN	NNP	0	B-Chemical
also	also	ADV	RB	9	O
caused	cause	VERB	VBD	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
systolic	systolic	ADJ	JJ	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

HP	HP	PROPN	NNP	9	O
failed	fail	VERB	VBD	9	O
to	to	ADP	IN	5	O
accentuante	accentuante	VERB	VB	_	O
progression	progression	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
fact	fact	NOUN	NN	9	O
tended	tend	VERB	VBD	5	O
to	to	PART	TO	5	O
increase	increase	VERB	VB	9	O
GFR	GFR	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
decrease	decrease	NOUN	NN	9	O
plasma	plasma	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
in	in	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
pretreated	pretreate	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

NX	NX	PROPN	NNP	9	O
caused	cause	VERB	VBD	9	O
an	an	DET	DT	5	O
additive	additive	ADJ	JJ	9	O
deterioration	deterioration	NOUN	NN	5	O
in	in	ADP	IN	5	O
GFR	GFR	PROPN	NNP	5	O
which	which	DET	WDT	5	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
ameliorated	ameliorate	VERB	VBN	9	O
by	by	ADP	IN	9	O
HP	HP	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

NX	NX	PROPN	NNP	9	O
+	+	CCONJ	CC	9	O
HP	HP	PROPN	NNP	9	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
further	further	ADJ	JJ	9	O
rise	rise	NOUN	NN	9	O
in	in	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
in	in	ADP	IN	5	O
Li	Li	PROPN	NNP	6	B-Chemical
-	-	PUNCT	HYPH	7	O
pretreated	pretreate	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
Li	Li	PROPN	NNP	6	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
even	even	ADV	RB	5	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
GFR	GFR	PROPN	NNP	5	O
is	be	VERB	VBZ	5	O
only	only	ADV	RB	9	O
modestly	modestly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
arterial	arterial	ADJ	JJ	5	O
systolic	systolic	ADJ	JJ	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
the	the	DET	DT	5	O
decline	decline	NOUN	NN	9	O
in	in	ADP	IN	5	O
GFR	GFR	PROPN	NNP	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
corresponding	corresponding	ADJ	JJ	9	O
fall	fall	NOUN	NN	5	O
in	in	ADP	IN	5	O
effective	effective	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
functional	functional	ADJ	JJ	9	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
formation	formation	NOUN	NN	9	O
of	of	ADP	IN	5	O
nonfiltrating	nonfiltrate	VERB	VBG	_	O
atubular	atubular	ADJ	JJ	5	O
glomeruli	glomerulus	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
fractional	fractional	ADJ	JJ	5	O
reabsorption	reabsorption	NOUN	NN	0	O
of	of	ADP	IN	5	O
tubular	tubular	ADJ	JJ	9	O
fluid	fluid	NOUN	NN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
proximal	proximal	ADJ	JJ	9	O
tubules	tubule	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
reduced	reduce	VERB	VBN	9	O
,	,	PUNCT	,	9	O
leaving	leave	VERB	VBG	5	O
the	the	DET	DT	5	O
distal	distal	ADJ	JJ	9	O
delivery	delivery	NOUN	NN	5	O
unchanged	unchanged	ADJ	JJ	9	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
250	250	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

Treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
Crohn	Crohn	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	NOUN	NN	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
fusidic	fusidic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
:	:	PUNCT	:	9	O
an	an	DET	DT	5	O
antibiotic	antibiotic	ADJ	JJ	5	O
with	with	ADP	IN	5	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
properties	property	NOUN	NNS	9	O
similar	similar	ADJ	JJ	9	O
to	to	PART	TO	5	O
cyclosporin	cyclosporin	VERB	VB	0	B-Chemical
.	.	PUNCT	.	9	O

Fusidic	Fusidic	PROPN	NNP	0	O
acid	acid	NOUN	NN	0	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
antibiotic	antibiotic	NOUN	NN	5	O
with	with	ADP	IN	5	O
T	T	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
cell	cell	NOUN	NN	3	O
specific	specific	ADJ	JJ	9	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
cyclosporin	cyclosporin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
need	need	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
new	new	ADJ	JJ	5	O
treatments	treatment	NOUN	NNS	9	O
for	for	ADP	IN	5	O
Crohn	Crohn	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	NOUN	NN	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
pilot	pilot	NOUN	NN	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
undertaken	undertake	VERB	VBN	5	O
to	to	PART	TO	5	O
estimate	estimate	VERB	VB	5	O
the	the	DET	DT	5	O
pharmacodynamics	pharmacodynamic	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
tolerability	tolerability	NOUN	NN	5	O
of	of	ADP	IN	5	O
fusidic	fusidic	NOUN	NN	0	B-Chemical
acid	acid	ADJ	JJ	0	I-Chemical
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
active	active	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
therapy	therapy	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
resistant	resistant	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Eight	eight	NUM	CD	9	O
Crohn	Crohn	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Fusidic	Fusidic	PROPN	NNP	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
orally	orally	ADV	RB	0	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
t	t	NOUN	NN	5	O
.	.	PUNCT	.	9	O
d	d	X	XX	9	O
.	.	PUNCT	.	9	O
s	s	X	XX	9	O
.	.	PUNCT	.	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
planned	plan	VERB	VBN	5	O
to	to	PART	TO	5	O
last	last	ADJ	JJ	5	O
8	8	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
disease	disease	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
primarily	primarily	ADV	RB	9	O
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
modified	modify	VERB	VBN	9	O
individual	individual	ADJ	JJ	5	O
grading	grading	NOUN	NN	5	O
score	score	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
of	of	ADP	IN	5	O
8	8	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
63	63	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
improved	improve	VERB	VBN	5	O
during	during	ADP	IN	5	O
fusidic	fusidic	ADJ	JJ	0	B-Chemical
acid	acid	ADJ	JJ	0	I-Chemical
treatment	treatment	NOUN	NN	9	O
:	:	PUNCT	:	9	O
3	3	NUM	CD	9	O
at	at	ADP	IN	9	O
two	two	NUM	CD	5	O
weeks	week	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
after	after	ADP	IN	9	O
four	four	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
serious	serious	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
dose	dose	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
was	be	VERB	VBD	9	O
required	require	VERB	VBN	9	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
nausea	nausea	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Biochemically	biochemically	ADV	RB	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
alkaline	alkaline	NOUN	NN	0	O
phosphatases	phosphatase	NOUN	NNS	1	O
was	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
in	in	ADP	IN	5	O
5	5	NUM	CD	9	O
of	of	ADP	IN	5	O
8	8	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
63	63	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
greatest	great	ADJ	JJS	9	O
increases	increase	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
those	those	DET	DT	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
elevated	elevate	VERB	VBN	9	O
levels	level	NOUN	NNS	3	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
reversed	reverse	VERB	VBD	9	O
to	to	PART	TO	5	O
pre	pre	VERB	VB	9	O
-	-	ADJ	JJ	7	O
treatment	treatment	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
after	after	ADP	IN	9	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
pilot	pilot	NOUN	NN	5	O
study	study	NOUN	NN	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
fusidic	fusidic	NOUN	NN	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
of	of	ADP	IN	5	O
benefit	benefit	NOUN	NN	5	O
in	in	ADP	IN	5	O
selected	select	VERB	VBN	9	O
chronic	chronic	ADJ	JJ	5	O
active	active	ADJ	JJ	9	O
Crohn	Crohn	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
whom	whom	PRON	WP	5	O
conventional	conventional	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
ineffective	ineffective	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
there	there	ADV	EX	5	O
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
exist	exist	VERB	VB	9	O
a	a	DET	DT	5	O
scientific	scientific	ADJ	JJ	5	O
rationale	rationale	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
fusidic	fusidic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
cytokine	cytokine	NOUN	NN	3	O
level	level	NOUN	NN	9	O
in	in	ADP	IN	5	O
inflammatory	inflammatory	ADJ	JJ	3	B-Disease
bowel	bowel	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
further	further	ADV	RB	9	O
investigated	investigate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
depressive	depressive	ADJ	JJ	5	B-Disease
status	status	NOUN	NN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
topical	topical	ADJ	JJ	0	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blockers	blocker	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Depression	depression	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
sexual	sexual	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
side	side	VERB	VB	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
topical	topical	ADJ	JJ	0	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blockers	blocker	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
performed	perform	VERB	VBD	9	O
a	a	DET	DT	5	O
preliminary	preliminary	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
any	any	DET	DT	5	O
difference	difference	NOUN	NN	9	O
between	between	ADP	IN	5	O
a	a	DET	DT	5	O
non	non	ADJ	JJ	9	O
selective	selective	ADJ	JJ	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blocker	blocker	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
timolol	timolol	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blocker	blocker	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
betaxolol	betaxolol	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
regarding	regard	VERB	VBG	5	O
CNS	CNS	PROPN	NNP	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Eight	eight	NUM	CD	9	O
glaucomatous	glaucomatous	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
chronically	chronically	ADV	RB	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
timolol	timolol	NOUN	NN	0	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
/	/	SYM	SYM	9	O
12h	12h	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
suffering	suffer	VERB	VBG	5	O
from	from	ADP	IN	9	O
depression	depression	NOUN	NN	5	B-Disease
diagnosed	diagnose	VERB	VBN	5	O
through	through	ADP	IN	9	O
DMS	DMS	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
III	III	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
R	r	NOUN	NN	9	O
criteria	criterion	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
the	the	DET	DT	5	O
six	six	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
month	month	NOUN	NN	5	O
follow	follow	VERB	VB	5	O
up	up	PART	RP	5	O
,	,	PUNCT	,	9	O
depression	depression	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
quantified	quantify	VERB	VBN	9	O
through	through	ADP	IN	9	O
the	the	DET	DT	5	O
Beck	Beck	PROPN	NNP	6	O
and	and	CCONJ	CC	5	O
Zung	Zung	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
Conde	Conde	PROPN	NNP	6	O
scales	scale	VERB	VBZ	5	O
every	every	DET	DT	5	O
two	two	NUM	CD	5	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
blind	blind	ADJ	JJ	5	O
cross	cross	NOUN	NN	5	O
-	-	ADJ	JJ	7	O
over	over	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
with	with	ADP	IN	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
under	under	ADP	IN	9	O
timolol	timolol	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
presented	present	VERB	VBD	5	O
higher	high	ADJ	JJR	9	O
depression	depression	NOUN	NN	5	B-Disease
values	value	NOUN	NNS	5	O
measured	measure	VERB	VBN	9	O
through	through	ADP	IN	9	O
the	the	DET	DT	5	O
Beck	Beck	PROPN	NNP	6	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
Zung	Zung	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
Conde	Conde	PROPN	NNP	6	O
scales	scale	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
vs	vs	ADP	IN	7	O
control	control	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
betaxolol	betaxolol	NOUN	NN	0	B-Chemical
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
less	less	ADJ	JJR	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
depression	depression	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
inducer	inducer	NOUN	NN	3	O
than	than	ADP	IN	5	O
timolol	timolol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
predisposed	predispose	VERB	VBN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Protection	protection	NOUN	NN	2	O
against	against	ADP	IN	9	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
toward	toward	ADP	IN	5	O
striatal	striatal	ADJ	JJ	3	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
neurons	neuron	NOUN	NNS	3	O
in	in	ADP	IN	5	O
rodents	rodent	NOUN	NNS	9	O
by	by	ADP	IN	9	O
LY274614	LY274614	PROPN	NNP	_	B-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
excitatory	excitatory	ADJ	JJ	5	O
amino	amino	NOUN	NN	1	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
antagonist	antagonist	NOUN	NN	3	O
.	.	PUNCT	.	9	O

LY274614	ly274614	NOUN	NN	_	B-Chemical
,	,	PUNCT	,	9	O
3SR	3sr	NUM	CD	2	B-Chemical
,	,	PUNCT	,	9	I-Chemical
4aRS	4ars	NUM	CD	_	I-Chemical
,	,	PUNCT	,	9	I-Chemical
6SR	6sr	NUM	CD	2	I-Chemical
,	,	PUNCT	,	9	I-Chemical
8aRS	8ars	NUM	CD	_	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
6	6	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
phosphonomethyl	phosphonomethyl	NOUN	NN	0	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
decahydr	decahydr	NOUN	NN	_	I-Chemical
oisoquinoline	oisoquinoline	NOUN	NN	_	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
carboxylic	carboxylic	NOUN	NN	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
described	describe	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
potent	potent	ADJ	JJ	3	O
antagonist	antagonist	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
D	d	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aspartate	aspartate	NOUN	NN	1	I-Chemical
(	(	PUNCT	-LRB-	9	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
subtype	subtype	NOUN	NN	9	O
of	of	ADP	IN	5	O
glutamate	glutamate	ADJ	JJ	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
its	-PRON-	DET	PRP$	9	O
ability	ability	NOUN	NN	9	O
to	to	PART	TO	5	O
antagonize	antagonize	VERB	VB	3	O
the	the	DET	DT	5	O
prolonged	prolonged	ADJ	JJ	9	O
depletion	depletion	NOUN	NN	3	O
of	of	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
by	by	ADP	IN	9	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
iprindole	iprindole	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
single	single	ADJ	JJ	9	O
18	18	NUM	CD	7	O
.	.	NOUN	NN	9	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
hemisulfate	hemisulfate	NOUN	NN	0	O
,	,	PUNCT	,	9	O
given	give	VERB	VBN	5	O
to	to	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
pretreated	pretreate	VERB	VBN	3	O
with	with	ADP	IN	5	O
iprindole	iprindole	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
persistent	persistent	ADJ	JJ	5	O
depletion	depletion	NOUN	NN	3	O
of	of	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
1	1	NUM	CD	9	O
week	week	NOUN	NN	9	O
later	later	ADV	RB	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
prolonged	prolonged	ADJ	JJ	9	O
depletion	depletion	NOUN	NN	3	O
of	of	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
was	be	VERB	VBD	9	O
antagonized	antagonize	VERB	VBN	3	O
by	by	ADP	IN	9	O
dizocilpine	dizocilpine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	PROPN	NNP	7	I-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
competitive	competitive	ADJ	JJ	9	O
antagonist	antagonist	NOUN	NN	3	O
of	of	ADP	IN	5	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
receptors	receptor	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
by	by	ADP	IN	9	O
LY274614	LY274614	PROPN	NNP	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
a	a	DET	DT	5	O
competitive	competitive	ADJ	JJ	9	O
antagonist	antagonist	NOUN	NN	3	O
of	of	ADP	IN	5	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
receptors	receptor	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
LY274614	LY274614	PROPN	NNP	_	B-Chemical
was	be	VERB	VBD	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
being	be	VERB	VBG	5	O
maximum	maximum	ADJ	JJ	5	O
at	at	ADP	IN	9	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
40	40	NUM	CD	9	O
mgkg	mgkg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
LY274614	LY274614	PROPN	NNP	_	B-Chemical
was	be	VERB	VBD	9	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
antagonizing	antagonize	VERB	VBG	3	O
the	the	DET	DT	5	O
depletion	depletion	NOUN	NN	3	O
of	of	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
given	give	VERB	VBN	5	O
as	as	ADV	RB	5	O
long	long	ADJ	JJ	5	O
as	as	ADP	IN	5	O
8	8	NUM	CD	9	O
hr	hr	INTJ	UH	0	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
when	when	ADV	WRB	5	O
given	give	VERB	VBN	5	O
24	24	NUM	CD	9	O
hr	hr	NOUN	NN	0	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Depletion	depletion	NOUN	NN	3	O
of	of	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
antagonized	antagonize	VERB	VBN	3	O
when	when	ADV	WRB	5	O
LY274614	LY274614	PROPN	NNP	_	B-Chemical
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
;	;	PUNCT	:	9	O
LY274614	LY274614	PROPN	NNP	_	B-Chemical
protected	protect	VERB	VBN	9	O
when	when	ADV	WRB	5	O
given	give	VERB	VBN	5	O
up	up	PART	RP	5	O
to	to	ADP	IN	5	O
4	4	NUM	CD	9	O
hr	hr	INTJ	UH	0	O
after	after	ADP	IN	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
when	when	ADV	WRB	5	O
given	give	VERB	VBN	5	O
8	8	NUM	CD	9	O
or	or	CCONJ	CC	5	O
24	24	NUM	CD	9	O
hr	hr	NOUN	NNS	0	O
after	after	ADP	IN	9	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
prolonged	prolonged	ADJ	JJ	9	O
depletion	depletion	NOUN	NN	3	O
of	of	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
given	give	VERB	VBN	5	O
multiple	multiple	ADJ	JJ	5	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
antagonized	antagonize	VERB	VBN	3	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	:	7	O
dependently	dependently	ADV	RB	3	O
and	and	CCONJ	CC	5	O
completely	completely	ADV	RB	9	O
by	by	ADP	IN	9	O
LY274614	LY274614	PROPN	NNP	_	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
strengthen	strengthen	VERB	VBP	5	O
the	the	DET	DT	5	O
evidence	evidence	NOUN	NN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
related	related	ADJ	JJ	9	O
compounds	compound	NOUN	NNS	0	O
toward	toward	ADP	IN	5	O
nigrostriatal	nigrostriatal	ADJ	JJ	3	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
neurons	neuron	NOUN	NNS	3	O
involves	involve	VERB	VBZ	5	O
NMDA	nmda	ADJ	JJ	3	B-Chemical
receptors	receptor	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
LY274614	ly274614	NOUN	NN	_	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
NMDA	nmda	ADJ	JJ	3	B-Chemical
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
with	with	ADP	IN	5	O
long	long	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
lasting	last	VERB	VBG	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
effects	effect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Ketoconazole	Ketoconazole	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
neurologic	neurologic	ADJ	JJ	5	B-Disease
sequelae	sequelae	ADV	RB	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
77	77	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
y	y	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBN	5	O
weakness	weakness	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
extremities	extremity	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
legs	leg	NOUN	NNS	5	B-Disease
paralysis	paralysis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
dysarthria	dysarthria	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
tremor	tremor	NOUN	NN	5	B-Disease
1	1	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
ingestion	ingestion	NOUN	NN	9	O
of	of	ADP	IN	5	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
ketoconazole	ketoconazole	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
in	in	ADP	IN	5	O
his	-PRON-	DET	PRP$	5	O
life	life	NOUN	NN	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
complaints	complaint	NOUN	NNS	5	O
faded	fade	VERB	VBD	5	O
away	away	ADV	RB	5	O
within	within	ADP	IN	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Few	few	ADJ	JJ	9	O
days	day	NOUN	NNS	9	O
later	later	ADV	RBR	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
used	use	VERB	VBD	5	O
another	another	DET	DT	9	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
ketoconazole	ketoconazole	NOUN	NN	0	B-Chemical
tablet	tablet	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
within	within	ADP	IN	9	O
an	an	DET	DT	5	O
hour	hour	NOUN	NN	0	O
experienced	experience	VERB	VBD	5	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
picture	picture	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
resolved	resolve	VERB	VBD	9	O
again	again	ADV	RB	9	O
spontaneously	spontaneously	ADV	RB	5	O
within	within	ADP	IN	9	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Laboratory	laboratory	NOUN	NN	2	O
evaluations	evaluation	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
head	head	NOUN	NN	5	O
CT	CT	PROPN	NNP	9	O
scan	scan	NOUN	NN	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
illustrates	illustrate	VERB	VBZ	5	O
the	the	DET	DT	5	O
need	need	NOUN	NN	5	O
for	for	ADP	IN	5	O
close	close	ADJ	JJ	5	O
vigilance	vigilance	NOUN	NN	5	O
in	in	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	B-Disease
drug	drug	NOUN	NN	5	I-Disease
reactions	reaction	NOUN	NNS	9	I-Disease
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
elderly	elderly	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Development	development	NOUN	NN	2	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
monkeys	monkey	NOUN	NNS	5	O
may	may	VERB	MD	5	O
depend	depend	VERB	VB	5	O
upon	upon	ADP	IN	9	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
symptom	symptom	NOUN	NN	5	O
onset	onset	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Levodopa	Levodopa	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
LIDs	LIDs	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
present	present	VERB	VBP	9	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
problem	problem	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
PD	pd	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
interdependence	interdependence	NOUN	NN	5	O
of	of	ADP	IN	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
in	in	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
populations	population	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
difficult	difficult	ADJ	JJ	5	O
to	to	PART	TO	5	O
independently	independently	ADV	RB	9	O
examine	examine	VERB	VB	9	O
factors	factor	NOUN	NNS	9	O
that	that	DET	WDT	5	O
may	may	VERB	MD	5	O
influence	influence	VERB	VB	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
LIDs	LIDs	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

Using	use	VERB	VBG	9	O
macaque	macaque	NOUN	NN	9	O
monkeys	monkey	NOUN	NNS	5	O
with	with	ADP	IN	5	O
different	different	ADJ	JJ	9	O
types	type	NOUN	NNS	9	O
of	of	ADP	IN	5	O
MPTP	MPTP	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
parkinsonism	parkinsonism	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
evaluated	evaluate	VERB	VBD	9	O
the	the	DET	DT	5	O
degree	degree	NOUN	NN	5	O
to	to	PART	TO	5	O
which	which	DET	WDT	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
symptom	symptom	NOUN	NN	5	O
progression	progression	NOUN	NN	9	O
,	,	PUNCT	,	9	O
symptom	symptom	NOUN	NN	5	O
severity	severity	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
and	and	CCONJ	CC	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
LIDs	LIDs	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

Monkeys	monkey	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
MPTP	mptp	ADJ	JJ	3	B-Chemical
exposure	exposure	NOUN	NN	9	O
,	,	PUNCT	,	9	O
rapid	rapid	ADJ	JJ	5	O
symptom	symptom	NOUN	NN	5	O
onset	onset	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
short	short	ADJ	JJ	5	O
symptom	symptom	NOUN	NN	5	O
duration	duration	NOUN	NN	5	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
between	between	ADP	IN	5	O
11	11	NUM	CD	7	O
and	and	CCONJ	CC	5	O
24	24	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
daily	daily	ADJ	JJ	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
monkeys	monkey	NOUN	NNS	5	O
with	with	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
MPTP	mptp	ADJ	JJ	3	B-Chemical
exposure	exposure	NOUN	NN	9	O
,	,	PUNCT	,	9	O
slow	slow	ADJ	JJ	5	O
symptom	symptom	NOUN	NN	5	O
progression	progression	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
long	long	ADJ	JJ	5	O
symptom	symptom	NOUN	NN	5	O
duration	duration	NOUN	NN	5	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
resistant	resistant	ADJ	JJ	9	O
to	to	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
LIDs	LIDs	PROPN	NNP	5	B-Disease
(	(	PUNCT	-LRB-	9	O
e	e	NOUN	NN	9	O
.	.	PUNCT	.	9	O
g	g	NOUN	NN	0	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
developed	develop	VERB	VBD	5	O
no	no	ADV	RB	9	O
sooner	sooner	ADV	RBR	5	O
than	than	ADP	IN	5	O
146	146	NUM	CD	7	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
administration	administration	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
similarly	similarly	ADV	RB	9	O
symptomatic	symptomatic	ADJ	JJ	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
start	start	NOUN	NN	9	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
responses	response	NOUN	NNS	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
distinct	distinct	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
propensity	propensity	NOUN	NN	5	O
to	to	PART	TO	5	O
develop	develop	VERB	VB	5	O
LIDs	lid	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
monkeys	monkey	NOUN	NNS	5	O
with	with	ADP	IN	5	O
different	different	ADJ	JJ	9	O
rates	rate	NOUN	NNS	5	O
of	of	ADP	IN	5	O
symptom	symptom	NOUN	NN	5	O
progression	progression	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
symptom	symptom	NOUN	NN	5	O
durations	duration	NOUN	NNS	5	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
and	and	CCONJ	CC	5	O
demonstrate	demonstrate	VERB	VB	9	O
the	the	DET	DT	5	O
value	value	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
models	model	NOUN	NNS	5	O
for	for	ADP	IN	5	O
further	further	ADV	RB	9	O
studying	study	VERB	VBG	5	O
the	the	DET	DT	5	O
pathophysiology	pathophysiology	NOUN	NN	9	O
of	of	ADP	IN	5	O
LIDs	LIDs	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
diet	diet	NOUN	NN	9	O
promoting	promote	VERB	VBG	9	O
sugar	sugar	NOUN	NN	0	B-Disease
dependency	dependency	NOUN	NN	5	I-Disease
causes	cause	VERB	VBZ	9	O
behavioral	behavioral	ADJ	JJ	5	B-Disease
cross	cross	ADJ	JJ	5	I-Disease
-	-	NOUN	NN	7	I-Disease
sensitization	sensitization	NOUN	NN	9	I-Disease
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
low	low	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Previous	previous	ADJ	JJ	9	O
research	research	NOUN	NN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
laboratory	laboratory	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
shown	show	VERB	VBN	9	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
diet	diet	NOUN	NN	9	O
of	of	ADP	IN	5	O
intermittent	intermittent	ADJ	JJ	5	O
excessive	excessive	ADJ	JJ	5	O
sugar	sugar	NOUN	NN	0	O
consumption	consumption	NOUN	NN	5	O
produces	produce	VERB	VBZ	9	O
a	a	DET	DT	5	O
state	state	NOUN	NN	5	O
with	with	ADP	IN	5	O
neurochemical	neurochemical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
behavioral	behavioral	ADJ	JJ	5	O
similarities	similarity	NOUN	NNS	9	O
to	to	ADP	IN	5	O
drug	drug	NOUN	NN	5	B-Disease
dependency	dependency	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
examined	examine	VERB	VBD	9	O
whether	whether	ADP	IN	9	O
female	female	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
on	on	ADP	IN	5	O
various	various	ADJ	JJ	9	O
regimens	regimen	NOUN	NNS	5	O
of	of	ADP	IN	5	O
sugar	sugar	NOUN	NN	0	O
access	access	NOUN	NN	5	O
would	would	VERB	MD	5	O
show	show	VERB	VB	9	O
behavioral	behavioral	ADJ	JJ	5	B-Disease
cross	cross	ADJ	JJ	5	I-Disease
-	-	NOUN	NN	7	I-Disease
sensitization	sensitization	NOUN	NN	9	I-Disease
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
low	low	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
a	a	DET	DT	5	O
30	30	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
min	min	NOUN	NN	0	O
baseline	baseline	NOUN	NN	5	O
measure	measure	NOUN	NN	5	O
of	of	ADP	IN	5	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
day	day	NOUN	NN	9	O
0	0	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
maintained	maintain	VERB	VBN	9	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
cyclic	cyclic	ADJ	JJ	0	O
diet	diet	NOUN	NN	9	O
of	of	ADP	IN	5	O
12	12	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
h	h	NOUN	NN	0	O
deprivation	deprivation	NOUN	NN	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
12	12	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
h	h	NOUN	NN	0	O
access	access	NOUN	NN	5	O
to	to	ADP	IN	5	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
sucrose	sucrose	NOUN	NN	0	B-Chemical
solution	solution	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
chow	chow	NOUN	NN	0	O
pellets	pellet	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
h	h	DET	DT	0	O
access	access	NOUN	NN	5	O
starting	start	VERB	VBG	9	O
4	4	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
dark	dark	ADJ	JJ	9	O
period	period	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
21	21	NUM	CD	7	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
again	again	ADV	RB	9	O
for	for	ADP	IN	5	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
beginning	beginning	NOUN	NN	5	O
of	of	ADP	IN	5	O
days	day	NOUN	NNS	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
21	21	NUM	CD	7	O
of	of	ADP	IN	5	O
sugar	sugar	NOUN	NN	0	O
access	access	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Beginning	begin	VERB	VBG	5	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
22	22	NUM	CD	7	O
,	,	PUNCT	,	9	O
all	all	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
maintained	maintain	VERB	VBN	9	O
on	on	ADP	IN	5	O
ad	ad	NOUN	NN	9	O
libitum	libitum	NOUN	NN	9	O
chow	chow	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Nine	nine	NUM	CD	9	O
days	day	NOUN	NNS	9	O
later	later	ADV	RB	9	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
low	low	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
that	that	DET	WDT	5	O
had	have	VERB	VBD	9	O
experienced	experience	VERB	VBN	5	O
cyclic	cyclic	ADJ	JJ	0	O
sucrose	sucrose	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
chow	chow	NOUN	NN	0	O
were	be	VERB	VBD	9	O
hyperactive	hyperactive	ADJ	JJ	9	B-Disease
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
four	four	NUM	CD	9	O
control	control	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
ad	ad	NOUN	NN	9	O
libitum	libitum	NOUN	NN	9	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
sucrose	sucrose	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
chow	chow	NOUN	NN	0	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
injection	injection	NOUN	NN	9	O
,	,	PUNCT	,	9	O
cyclic	cyclic	ADJ	JJ	0	O
chow	chow	NOUN	NN	0	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
injection	injection	NOUN	NN	9	O
,	,	PUNCT	,	9	O
ad	ad	NOUN	NN	9	O
libitum	libitum	NOUN	NN	9	O
chow	chow	NOUN	NN	0	O
with	with	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
cyclic	cyclic	ADJ	JJ	0	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
sucrose	sucrose	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
chow	chow	NOUN	NN	0	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
saline	saline	NOUN	NN	0	O
injection	injection	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
diet	diet	NOUN	NN	9	O
comprised	comprise	VERB	VBN	9	O
of	of	ADP	IN	5	O
alternating	alternate	VERB	VBG	5	O
deprivation	deprivation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
access	access	NOUN	NN	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
sugar	sugar	NOUN	NN	0	O
solution	solution	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
chow	chow	NOUN	NN	0	O
produces	produce	VERB	VBZ	9	O
bingeing	binge	VERB	VBG	5	O
on	on	ADP	IN	5	O
sugar	sugar	NOUN	NN	0	O
that	that	DET	WDT	5	O
leads	lead	VERB	VBZ	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
long	long	ADJ	JJ	5	O
lasting	last	VERB	VBG	5	O
state	state	NOUN	NN	5	O
of	of	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
sensitivity	sensitivity	NOUN	NN	9	O
to	to	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
possibly	possibly	ADV	RB	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
lasting	lasting	ADJ	JJ	5	O
alteration	alteration	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Reversible	reversible	ADJ	JJ	0	O
dilated	dilate	VERB	VBN	5	B-Disease
cardiomyopathy	cardiomyopathy	NOUN	NN	5	I-Disease
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
amphotericin	amphotericin	ADV	RB	0	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
dilated	dilate	VERB	VBN	5	B-Disease
cardiomyopathy	cardiomyopathy	ADJ	JJ	5	I-Disease
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
congestive	congestive	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
2	2	NUM	CD	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
amphotericin	amphotericin	PROPN	NNP	0	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
AmB	AmB	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
disseminated	disseminate	VERB	VBN	5	O
coccidioidomycosis	coccidioidomycosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

His	-PRON-	DET	PRP$	9	O
echocardiographic	echocardiographic	ADJ	JJ	5	O
abnormalities	abnormality	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
resolved	resolve	VERB	VBN	9	O
after	after	ADP	IN	9	O
posaconazole	posaconazole	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
substituted	substitute	VERB	VBN	0	O
for	for	ADP	IN	5	O
AmB	AmB	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
important	important	ADJ	JJ	9	O
to	to	PART	TO	5	O
recognize	recognize	VERB	VB	9	O
the	the	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
potentially	potentially	ADV	RB	5	O
reversible	reversible	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
AmB	AmB	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

NO	no	ADV	RB	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
migraine	migraine	ADJ	JJ	5	B-Disease
attack	attack	NOUN	NN	5	O
:	:	PUNCT	:	9	O
strong	strong	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
calcitonin	calcitonin	NOUN	NN	3	B-Chemical
gene	gene	NOUN	NN	1	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
related	relate	VERB	VBN	9	I-Chemical
peptide	peptide	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
CGRP	CGRP	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
concentration	concentration	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
negative	negative	ADJ	JJ	9	O
correlation	correlation	NOUN	NN	9	O
with	with	ADP	IN	5	O
platelet	platelet	NOUN	NN	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
release	release	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
calcitonin	calcitonin	NOUN	NN	3	B-Chemical
gene	gene	NOUN	NN	1	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
related	relate	VERB	VBN	9	I-Chemical
peptide	peptide	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
CGRP	CGRP	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
concentration	concentration	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
platelet	platelet	NOUN	NN	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxytriptamine	hydroxytriptamine	NOUN	NN	_	I-Chemical
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	B-Chemical
-	-	SYM	SYM	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
content	content	NOUN	NN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
immediate	immediate	ADJ	JJ	5	O
headache	headache	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
delayed	delay	VERB	VBN	9	O
genuine	genuine	ADJ	JJ	5	O
migraine	migraine	ADJ	JJ	5	B-Disease
attack	attack	NOUN	NN	5	O
provoked	provoke	VERB	VBN	9	O
by	by	ADP	IN	9	O
nitroglycerin	nitroglycerin	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Fifteen	fifteen	NUM	CD	9	O
female	female	ADJ	JJ	9	O
migraineurs	migraineur	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	I-Disease
without	without	ADP	IN	9	I-Disease
aura	aura	NOUN	NN	5	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
and	and	CCONJ	CC	5	O
eight	eight	NUM	CD	9	O
controls	control	NOUN	NNS	9	O
participated	participate	VERB	VBD	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Sublingual	sublingual	ADJ	JJ	5	O
nitroglycerin	nitroglycerin	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Blood	blood	NOUN	NN	9	O
was	be	VERB	VBD	9	O
collected	collect	VERB	VBN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
antecubital	antecubital	ADJ	JJ	5	O
vein	vein	NOUN	NN	5	O
four	four	NUM	CD	9	O
times	time	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
60	60	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
nitroglycerin	nitroglycerin	ADJ	JJ	5	B-Chemical
application	application	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
60	60	NUM	CD	9	O
and	and	CCONJ	CC	5	O
120	120	NUM	CD	9	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
beginning	beginning	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
migraine	migraine	ADJ	JJ	5	B-Disease
attack	attack	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VBP	5	O
344	344	NUM	CD	7	O
and	and	CCONJ	CC	5	O
404	404	NUM	CD	7	O
min	min	NOUN	NN	0	O
;	;	PUNCT	:	9	O
12	12	NUM	CD	9	O
subjects	subject	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
those	those	DET	DT	5	O
subjects	subject	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
migraine	migraine	ADJ	JJ	5	B-Disease
attack	attack	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
subjects	subject	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
schedule	schedule	NOUN	NN	5	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Plasma	plasma	NOUN	NN	0	O
CGRP	CGRP	PROPN	NNP	3	B-Chemical
concentration	concentration	NOUN	NN	0	O
increased	increase	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
migraine	migraine	ADJ	JJ	5	B-Disease
attack	attack	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
migraine	migraine	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
both	both	DET	DT	9	O
change	change	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
peak	peak	NOUN	NN	9	O
,	,	PUNCT	,	9	O
showed	show	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
positive	positive	ADJ	JJ	9	O
correlations	correlation	NOUN	NNS	5	O
with	with	ADP	IN	5	O
migraine	migraine	ADJ	JJ	5	B-Disease
headache	headache	NOUN	NN	5	B-Disease
intensity	intensity	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
plasma	plasma	VERB	VB	9	O
CGRP	CGRP	PROPN	NNP	3	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
change	change	VERB	VB	9	O
during	during	ADP	IN	5	O
immediate	immediate	ADJ	JJ	5	O
headache	headache	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
subjects	subject	NOUN	NNS	5	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
migraine	migraine	ADJ	JJ	5	B-Disease
attack	attack	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Basal	Basal	PROPN	NNP	9	O
CGRP	CGRP	PROPN	NNP	3	B-Chemical
concentration	concentration	NOUN	NN	0	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
and	and	CCONJ	CC	5	O
platelet	platelet	VERB	VB	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
content	content	NOUN	NN	9	O
tended	tend	VERB	VBD	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
subjects	subject	NOUN	NNS	5	O
who	who	PRON	WP	5	O
experienced	experience	VERB	VBD	5	O
a	a	DET	DT	5	O
migraine	migraine	ADJ	JJ	5	B-Disease
attack	attack	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Platelet	platelet	ADJ	JJ	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
content	content	NOUN	NN	9	O
decreased	decrease	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
nitroglycerin	nitroglycerin	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
subjects	subject	NOUN	NNS	5	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
migraine	migraine	ADJ	JJ	5	B-Disease
attack	attack	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
no	no	DET	DT	9	O
consistent	consistent	ADJ	JJ	9	O
change	change	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
migraine	migraine	ADJ	JJ	5	B-Disease
attack	attack	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
fact	fact	NOUN	NN	9	O
that	that	DET	WDT	5	O
plasma	plasma	NOUN	NN	9	O
CGRP	cgrp	NOUN	NN	3	B-Chemical
concentration	concentration	NOUN	NN	0	O
correlates	correlate	VERB	VBZ	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
timing	timing	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
migraine	migraine	ADJ	JJ	5	B-Disease
headache	headache	NOUN	NN	5	B-Disease
suggests	suggest	VERB	VBZ	9	O
a	a	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
CGRP	cgrp	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
migraine	migraine	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
release	release	NOUN	NN	9	O
from	from	ADP	IN	9	O
platelets	platelet	NOUN	NNS	3	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
provoke	provoke	VERB	VB	9	O
migraine	migraine	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
even	even	ADV	RB	5	O
counteract	counteract	VERB	VB	9	O
the	the	DET	DT	5	O
headache	headache	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
concomitant	concomitant	ADJ	JJ	9	O
CGRP	CGRP	PROPN	NNP	3	B-Chemical
release	release	NOUN	NN	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Hyperbaric	hyperbaric	ADJ	JJ	2	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
control	control	NOUN	NN	9	O
of	of	ADP	IN	5	O
intractable	intractable	ADJ	JJ	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
intractable	intractable	ADJ	JJ	5	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
Wegener	Wegener	PROPN	NNP	2	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	NOUN	NN	9	I-Disease
granulomatosis	granulomatosis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Conservative	conservative	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
bladder	bladder	NOUN	NN	9	O
irrigation	irrigation	NOUN	NN	5	O
with	with	ADP	IN	5	O
physiological	physiological	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
instillation	instillation	NOUN	NN	0	O
of	of	ADP	IN	5	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
F2	f2	NOUN	NN	9	I-Chemical
alpha	alpha	NOUN	NN	9	I-Chemical
,	,	PUNCT	,	9	O
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
totally	totally	ADV	RB	9	O
control	control	VERB	VB	9	O
hemorrhage	hemorrhage	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
then	then	ADV	RB	9	O
used	use	VERB	VBD	5	O
hyperbaric	hyperbaric	ADJ	JJ	5	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
an	an	DET	DT	5	O
absolute	absolute	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
atm	atm	NOUN	NN	0	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
a	a	DET	DT	5	O
week	week	NOUN	NN	9	O
for	for	ADP	IN	5	O
8	8	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
bleeding	bleeding	NOUN	NN	5	B-Disease
ceased	cease	VERB	VBD	5	O
completely	completely	ADV	RB	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
remained	remain	VERB	VBD	9	O
free	free	ADJ	JJ	9	O
of	of	ADP	IN	5	O
hematuria	hematuria	NOUN	NN	5	B-Disease
thereafter	thereafter	ADV	RB	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
future	future	NOUN	NN	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
form	form	NOUN	NN	9	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
can	can	VERB	MD	5	O
offer	offer	VERB	VB	5	O
a	a	DET	DT	5	O
safe	safe	ADJ	JJ	5	O
alternative	alternative	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	B-Disease
psychosis	psychosis	NOUN	NN	5	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
nonepileptic	nonepileptic	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
psychosis	psychosis	NOUN	NN	5	B-Disease
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
antiepileptic	antiepileptic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
usually	usually	ADV	RB	5	O
attributed	attribute	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
interaction	interaction	NOUN	NN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
brain	brain	NOUN	NN	5	O
substratum	substratum	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
antiepileptic	antiepileptic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
nonepileptic	nonepileptic	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
psychosis	psychosis	NOUN	NN	5	B-Disease
following	follow	VERB	VBG	9	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
trigeminal	trigeminal	ADJ	JJ	5	B-Disease
neuralgia	neuralgia	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
psychotic	psychotic	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
that	that	DET	WDT	5	O
occur	occur	VERB	VBP	5	O
following	follow	VERB	VBG	9	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
medication	medication	NOUN	NN	5	O
,	,	PUNCT	,	9	O
unrelated	unrelated	ADJ	JJ	9	O
to	to	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Risks	risk	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
consumption	consumption	NOUN	NN	5	O
of	of	ADP	IN	5	O
beverages	beverage	NOUN	NNS	5	O
containing	contain	VERB	VBG	0	O
quinine	quinine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
the	the	DET	DT	5	O
United	United	PROPN	NNP	9	O
States	States	PROPN	NNP	9	O
Food	Food	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
Drug	Drug	PROPN	NNP	5	O
Administration	Administration	PROPN	NNP	2	O
banned	ban	VERB	VBD	5	O
its	-PRON-	DET	PRP$	9	O
use	use	NOUN	NN	5	O
for	for	ADP	IN	5	O
nocturnal	nocturnal	ADJ	JJ	5	B-Disease
leg	leg	NOUN	NN	5	I-Disease
cramps	cramp	NOUN	NNS	5	I-Disease
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
lack	lack	NOUN	NN	9	O
of	of	ADP	IN	5	O
safety	safety	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
efficacy	efficacy	NOUN	NN	9	O
,	,	PUNCT	,	9	O
quinine	quinine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
widely	widely	ADV	RB	5	O
available	available	ADJ	JJ	5	O
in	in	ADP	IN	5	O
beverages	beverage	NOUN	NNS	5	O
including	include	VERB	VBG	9	O
tonic	tonic	NOUN	NN	5	O
water	water	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
bitter	bitter	ADJ	JJ	5	O
lemon	lemon	NOUN	NN	4	O
.	.	PUNCT	.	9	O

Numerous	numerous	ADJ	JJ	9	O
anecdotal	anecdotal	ADJ	JJ	5	O
reports	report	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
products	product	NOUN	NNS	9	O
containing	contain	VERB	VBG	0	O
quinine	quinine	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
produce	produce	VERB	VB	9	O
neurological	neurological	ADJ	JJ	5	B-Disease
complications	complication	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
confusion	confusion	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
altered	alter	VERB	VBD	9	O
mental	mental	ADJ	JJ	5	O
status	status	NOUN	NN	9	O
,	,	PUNCT	,	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
coma	coma	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
in	in	ADP	IN	5	O
older	old	ADJ	JJR	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Psychologists	psychologist	NOUN	NNS	5	O
need	need	VERB	VBP	5	O
to	to	PART	TO	5	O
inquire	inquire	VERB	VB	5	O
about	about	ADP	IN	5	O
consumption	consumption	NOUN	NN	5	O
of	of	ADP	IN	5	O
quinine	quinine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
beverages	beverage	NOUN	NNS	5	O
as	as	ADP	IN	5	O
part	part	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
evaluation	evaluation	NOUN	NN	5	O
process	process	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Transient	transient	ADJ	JJ	9	O
platypnea	platypnea	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
orthodeoxia	orthodeoxia	NOUN	NN	5	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
like	like	ADJ	JJ	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
propafenone	propafenone	NOUN	NN	0	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
young	young	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
Ebstein	Ebstein	PROPN	NNP	5	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	NOUN	NNS	9	I-Disease
anomaly	anomaly	ADJ	JJ	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
report	report	NOUN	NN	5	O
we	-PRON-	PRON	PRP	5	O
describe	describe	VERB	VBP	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
37	37	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
white	white	ADJ	JJ	9	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
Ebstein	Ebstein	PROPN	NNP	5	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	NOUN	NN	9	I-Disease
anomaly	anomaly	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
syndrome	syndrome	NOUN	NN	5	O
called	call	VERB	VBN	5	O
platypnea	platypnea	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
orthodeoxia	orthodeoxia	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
massive	massive	ADJ	JJ	9	O
right	right	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
left	leave	VERB	VBN	5	O
interatrial	interatrial	NOUN	NN	5	O
shunting	shunt	VERB	VBG	5	O
with	with	ADP	IN	5	O
transient	transient	ADJ	JJ	9	O
profound	profound	ADJ	JJ	9	O
hypoxia	hypoxia	NOUN	NN	3	B-Disease
and	and	CCONJ	CC	5	O
cyanosis	cyanosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
shunt	shunt	NOUN	NN	5	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
via	via	ADP	IN	9	O
a	a	DET	DT	5	O
patent	patent	NOUN	NN	5	B-Disease
foramen	foraman	NOUN	NNS	5	I-Disease
ovale	ovale	NOUN	NN	4	I-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
pulmonary	pulmonary	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
probably	probably	ADV	RB	9	O
precipitated	precipitate	VERB	VBN	0	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
propafenone	propafenone	NOUN	NN	0	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
caused	cause	VERB	VBD	9	O
biventricular	biventricular	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
negative	negative	ADJ	JJ	9	O
inotropic	inotropic	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
peripheral	peripheral	ADJ	JJ	9	O
vasodilatory	vasodilatory	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
gave	give	VERB	VBD	9	O
rise	rise	NOUN	NN	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	ADJ	JJ	5	O
atrial	atrial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
left	left	ADJ	JJ	5	O
one	one	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
consequent	consequent	ADJ	JJ	9	O
stretching	stretching	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
foramen	foraman	NOUN	NNS	5	O
ovale	ovale	NOUN	NN	4	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
creation	creation	NOUN	NN	5	O
of	of	ADP	IN	5	O
massive	massive	ADJ	JJ	9	O
right	right	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
left	left	ADJ	JJ	5	O
shunting	shunting	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
case	case	NOUN	NN	5	O
this	this	DET	DT	5	O
interatrial	interatrial	ADJ	JJ	5	O
shunt	shunt	NOUN	NN	5	O
was	be	VERB	VBD	9	O
very	very	ADV	RB	5	O
accurately	accurately	ADV	RB	5	O
detected	detect	VERB	VBN	9	O
at	at	ADP	IN	9	O
bubble	bubble	NOUN	NN	5	O
contrast	contrast	NOUN	NN	9	O
echocardiography	echocardiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Noxious	noxious	ADJ	JJ	5	O
chemical	chemical	NOUN	NN	0	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
facial	facial	ADJ	JJ	5	O
mucosa	mucosa	NOUN	NN	9	O
increases	increase	VERB	VBZ	9	O
intracranial	intracranial	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
through	through	ADP	IN	9	O
a	a	DET	DT	5	O
trigemino	trigemino	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
parasympathetic	parasympathetic	ADJ	JJ	5	O
reflex	reflex	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
an	an	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
for	for	ADP	IN	5	O
vascular	vascular	ADJ	JJ	5	B-Disease
dysfunctions	dysfunction	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
cluster	cluster	NOUN	NN	9	B-Disease
headache	headache	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Cluster	cluster	NOUN	NN	9	B-Disease
headache	headache	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
typical	typical	ADJ	JJ	9	O
autonomic	autonomic	ADJ	JJ	5	O
dysfunctions	dysfunction	NOUN	NNS	5	O
including	include	VERB	VBG	9	O
facial	facial	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
intracranial	intracranial	ADJ	JJ	5	B-Disease
vascular	vascular	NOUN	NN	5	I-Disease
disturbances	disturbance	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
the	the	DET	DT	5	O
trigeminal	trigeminal	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
cranial	cranial	ADJ	JJ	5	O
parasympathetic	parasympathetic	ADJ	JJ	5	O
systems	system	NOUN	NNS	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
mediating	mediate	VERB	VBG	9	O
these	these	DET	DT	5	O
dysfunctions	dysfunction	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
was	be	VERB	VBD	9	O
developed	develop	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
to	to	PART	TO	5	O
measure	measure	VERB	VB	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
lacrimation	lacrimation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
intracranial	intracranial	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
following	follow	VERB	VBG	9	O
noxious	noxious	ADJ	JJ	5	O
chemical	chemical	NOUN	NN	0	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
facial	facial	ADJ	JJ	5	O
mucosa	mucosa	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
was	be	VERB	VBD	9	O
monitored	monitor	VERB	VBN	9	O
in	in	ADP	IN	5	O
arteries	artery	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
exposed	expose	VERB	VBN	9	O
cranial	cranial	ADJ	JJ	5	O
dura	dura	ADJ	JJ	5	O
mater	mater	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
parietal	parietal	ADJ	JJ	5	O
cortex	cortex	NOUN	NN	5	O
using	use	VERB	VBG	9	O
laser	laser	NOUN	NN	5	O
Doppler	Doppler	PROPN	NNP	5	O
flowmetry	flowmetry	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Capsaicin	Capsaicin	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
applied	apply	VERB	VBN	5	O
to	to	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
nasal	nasal	NOUN	NN	5	O
mucosa	mucosa	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
increases	increase	NOUN	NNS	9	B-Disease
in	in	ADP	IN	5	I-Disease
dural	dural	ADJ	JJ	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
cortical	cortical	ADJ	JJ	5	I-Disease
blood	blood	NOUN	NN	9	I-Disease
flow	flow	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
provoked	provoke	VERB	VBD	9	O
lacrimation	lacrimation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
responses	response	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
blocked	block	VERB	VBN	3	O
by	by	ADP	IN	9	O
systemic	systemic	ADJ	JJ	9	O
pre	pre	ADJ	JJ	9	O
-	-	NOUN	NN	7	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
hexamethonium	hexamethonium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
evoked	evoked	ADJ	JJ	5	O
increases	increase	NOUN	NNS	9	B-Disease
in	in	ADP	IN	5	I-Disease
dural	dural	ADJ	JJ	5	I-Disease
blood	blood	NOUN	NN	9	I-Disease
flow	flow	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
abolished	abolish	VERB	VBN	3	O
by	by	ADP	IN	9	O
topical	topical	ADJ	JJ	0	O
pre	pre	ADJ	JJ	9	O
-	-	NOUN	NN	7	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
atropine	atropine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
[	[	PUNCT	-LRB-	9	O
Lys1	Lys1	PROPN	NNP	1	O
,	,	PUNCT	,	9	O
Pro2	Pro2	PROPN	NNP	1	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
Arg3	Arg3	PROPN	NNP	1	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
Tyr6	Tyr6	PROPN	NNP	1	O
]	]	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
VIP	vip	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
vasoactive	vasoactive	ADJ	JJ	5	O
intestinal	intestinal	ADJ	JJ	9	O
polypeptide	polypeptide	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
VIP	VIP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
onto	onto	ADP	IN	0	O
the	the	DET	DT	5	O
exposed	expose	VERB	VBN	9	O
dura	dura	ADJ	JJ	5	O
mater	mater	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
noxious	noxious	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
facial	facial	ADJ	JJ	5	O
mucosa	mucosa	NOUN	NN	9	O
increases	increase	VERB	VBZ	9	O
intracranial	intracranial	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
lacrimation	lacrimation	NOUN	NN	5	O
via	via	ADP	IN	9	O
a	a	DET	DT	5	O
trigemino	trigemino	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
parasympathetic	parasympathetic	ADJ	JJ	5	O
reflex	reflex	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
responses	response	NOUN	NNS	5	O
seem	seem	VERB	VBP	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
release	release	NOUN	NN	9	O
of	of	ADP	IN	5	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
VIP	vip	NOUN	NN	9	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
meninges	meninge	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Similar	similar	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
cluster	cluster	NOUN	NN	9	B-Disease
headache	headache	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Organophosphate	organophosphate	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
neuropathological	neuropathological	ADJ	JJ	5	B-Disease
damages	damage	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

Such	such	ADJ	JJ	5	O
organophosphorus	organophosphorus	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
OP	op	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
compounds	compound	NOUN	NNS	0	O
as	as	ADP	IN	5	O
diisopropylfluorophosphate	diisopropylfluorophosphate	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DFP	DFP	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
sarin	sarin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
soman	soman	ADJ	JJ	0	B-Chemical
are	be	VERB	VBP	5	O
potent	potent	ADJ	JJ	3	O
inhibitors	inhibitor	NOUN	NNS	3	O
of	of	ADP	IN	5	O
acetylcholinesterases	acetylcholinesterase	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
AChEs	AChEs	PROPN	NNP	4	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
butyrylcholinesterases	butyrylcholinesterase	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
BChEs	BChEs	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
OPs	op	NOUN	NNS	5	B-Chemical
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
irreversible	irreversible	ADJ	JJ	9	O
binding	binding	NOUN	NN	1	O
with	with	ADP	IN	5	O
AChEs	AChEs	PROPN	NNP	4	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CNS	CNS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
elevates	elevate	VERB	VBZ	9	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
ACh	ACh	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
subcutaneously	subcutaneously	ADV	RB	3	O
(	(	PUNCT	-LRB-	9	O
SC	SC	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
administered	administer	VERB	VBD	9	O
antidotes	antidote	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
combinations	combination	NOUN	NNS	9	O
in	in	ADP	IN	5	O
DFP	DFP	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
BW	BW	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
intoxication	intoxication	NOUN	NN	9	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
9	9	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
10	10	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
weeks	week	NOUN	NNS	9	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
Han	Han	PROPN	NNP	6	O
-	-	PUNCT	HYPH	7	O
Wistar	Wistar	PROPN	NNP	9	O
male	male	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
received	receive	VERB	VBD	9	O
AChE	AChE	PROPN	NNPS	0	O
reactivator	reactivator	NOUN	NN	0	O
pralidoxime	pralidoxime	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
2PAM	2PAM	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
.	.	NOUN	NN	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
BW	BW	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
anticonvulsant	anticonvulsant	ADJ	JJ	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
BW	BW	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
A	a	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
N	N	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
6	6	NUM	CD	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
cyclopentyl	cyclopentyl	NOUN	NN	0	I-Chemical
adenosine	adenosine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
CPA	CPA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
BW	BW	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
dizocilpine	dizocilpine	NOUN	NN	0	B-Chemical
maleate	maleate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
MK801	mk801	NOUN	NN	3	O
hydrogen	hydrogen	NOUN	NN	0	O
maleate	maleate	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
BW	BW	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
combinations	combination	NOUN	NNS	9	O
with	with	ADP	IN	5	O
cholinolytic	cholinolytic	ADJ	JJ	0	O
drug	drug	NOUN	NN	5	O
atropine	atropine	NOUN	NN	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
.	.	NOUN	NNS	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
BW	BW	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
immediately	immediately	ADV	RB	9	O
or	or	CCONJ	CC	5	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
single	single	ADJ	JJ	9	O
SC	sc	NOUN	NN	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
DFP	DFP	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
received	receive	VERB	VBD	9	O
atropine	atropine	NOUN	NN	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
also	also	ADV	RB	9	O
saline	saline	VERB	VB	0	O
and	and	CCONJ	CC	5	O
olive	olive	ADJ	JJ	4	O
oil	oil	NOUN	NN	0	O
instead	instead	ADV	RB	5	O
of	of	ADP	IN	5	O
other	other	ADJ	JJ	5	O
antidotes	antidote	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
DFP	DFP	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
terminated	terminate	VERB	VBN	9	O
either	either	CCONJ	CC	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
DFP	DFP	PROPN	NNP	0	B-Chemical
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
DFP	DFP	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
atropine	atropine	NOUN	NN	0	B-Chemical
showed	show	VERB	VBD	9	O
severe	severe	ADJ	JJ	5	O
typical	typical	ADJ	JJ	9	O
OP	op	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
toxicity	toxicity	NOUN	NN	9	B-Disease
signs	sign	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
CPA	cpa	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
2PAM	2pam	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
DFP	DFP	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
atropine	atropine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
treatments	treatment	NOUN	NNS	9	O
prevented	prevent	VERB	VBD	9	O
,	,	PUNCT	,	9	O
delayed	delay	VERB	VBN	9	O
or	or	CCONJ	CC	5	O
shortened	shorten	VERB	VBN	9	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
serious	serious	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
poisoning	poisoning	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Atropine	Atropine	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
MK801	MK801	PROPN	NNP	3	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
offer	offer	VERB	VB	5	O
any	any	DET	DT	5	O
additional	additional	ADJ	JJ	9	O
protection	protection	NOUN	NN	9	O
against	against	ADP	IN	9	O
DFP	DFP	PROPN	NNP	0	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
CPA	cpa	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
2PAM	2PAM	PROPN	NNP	0	B-Chemical
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
atropine	atropine	NOUN	NN	0	B-Chemical
prevented	prevent	VERB	VBD	9	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
serious	serious	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
poisoning	poisoning	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
thus	thus	ADV	RB	9	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
DFP	DFP	PROPN	NNP	0	B-Chemical
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
pyridoxine	pyridoxine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
behavioral	behavioral	ADJ	JJ	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
unmasked	unmask	VERB	VBN	5	O
by	by	ADP	IN	9	O
isoniazid	isoniazid	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
girl	girl	NOUN	NN	5	O
had	have	VERB	VBD	9	O
behavioral	behavioral	ADJ	JJ	5	B-Disease
deterioration	deterioration	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
hyperkinesis	hyperkinesis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
irritability	irritability	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
sleeping	sleep	VERB	VBG	5	B-Disease
difficulties	difficulty	NOUN	NNS	5	I-Disease
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
isoniazid	isoniazid	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
pharmacologic	pharmacologic	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
pyridoxine	pyridoxine	NOUN	NN	0	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
disappearance	disappearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
discontinuing	discontinue	VERB	VBG	5	O
isoniazid	isoniazid	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
pattern	pattern	NOUN	NN	9	O
of	of	ADP	IN	5	O
behavior	behavior	NOUN	NN	5	O
was	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
that	that	DET	WDT	5	O
was	be	VERB	VBD	9	O
controlled	control	VERB	VBN	5	O
by	by	ADP	IN	9	O
pyridoxine	pyridoxine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
placebo	placebo	NOUN	NN	9	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
niacinamide	niacinamide	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
as	as	ADV	RB	5	O
effective	effective	ADJ	JJ	5	O
as	as	ADP	IN	5	O
pyridoxine	pyridoxine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Periodic	periodic	ADJ	JJ	5	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
pyridoxine	pyridoxine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
return	return	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hyperkinesis	hyperkinesis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
pyridoxal	pyridoxal	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
was	be	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
periods	period	NOUN	NNS	5	O
of	of	ADP	IN	5	O
relapse	relapse	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Metabolic	metabolic	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
suggested	suggest	VERB	VBD	9	O
a	a	DET	DT	5	O
block	block	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
kynurenine	kynurenine	ADJ	JJ	0	B-Chemical
pathway	pathway	NOUN	NN	3	O
of	of	ADP	IN	5	O
tryptophan	tryptophan	NOUN	NN	0	B-Chemical
metabolism	metabolism	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
followed	follow	VERB	VBN	9	O
for	for	ADP	IN	5	O
six	six	NUM	CD	9	O
years	year	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
has	have	VERB	VBZ	9	O
required	require	VERB	VBN	9	O
pharmacologic	pharmacologic	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
pyridoxine	pyridoxine	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
her	-PRON-	DET	PRP$	5	O
behavior	behavior	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Recurrent	recurrent	ADJ	JJ	5	O
excitation	excitation	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
dentate	dentate	ADJ	JJ	3	O
gyrus	gyrus	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
murine	murine	ADJ	JJ	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
temporal	temporal	ADJ	JJ	5	B-Disease
lobe	lobe	NOUN	NN	5	I-Disease
epilepsy	epilepsy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
systemic	systemic	ADJ	JJ	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
injection	injection	NOUN	NN	9	O
causes	cause	VERB	VBZ	9	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
SE	SE	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
eventual	eventual	ADJ	JJ	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
mossy	mossy	NOUN	NN	5	O
fiber	fiber	NOUN	NN	5	O
sprouting	sprout	VERB	VBG	3	O
in	in	ADP	IN	5	O
C57BL	C57BL	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
6	6	NUM	CD	9	O
and	and	CCONJ	CC	5	O
CD1	CD1	PROPN	NNP	3	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
physiological	physiological	ADJ	JJ	9	O
correlates	correlate	NOUN	NNS	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
events	event	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
identified	identify	VERB	VBN	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Population	population	NOUN	NN	5	O
responses	response	NOUN	NNS	5	O
in	in	ADP	IN	5	O
granule	granule	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
dentate	dentate	ADJ	JJ	3	O
gyrus	gyrus	NOUN	NN	5	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
in	in	ADP	IN	5	O
transverse	transverse	NOUN	NN	5	O
slices	slice	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ventral	ventral	ADJ	JJ	5	O
hippocampus	hippocampus	NOUN	NN	9	O
from	from	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
untreated	untreated	ADJ	JJ	3	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
Mg	Mg	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
+	+	SYM	SYM	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
bathing	bathing	NOUN	NN	5	O
medium	medium	NOUN	NN	0	O
containing	contain	VERB	VBG	0	O
bicuculline	bicuculline	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
conditions	condition	NOUN	NNS	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
increase	increase	VERB	VB	9	O
excitability	excitability	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
slices	slice	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
electrical	electrical	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hilus	hilus	NOUN	NN	3	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
population	population	NOUN	NN	5	O
spike	spike	ADJ	JJ	5	O
in	in	ADP	IN	5	O
granule	granule	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
from	from	ADP	IN	9	O
control	control	NOUN	NN	9	O
mice	mouse	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
mice	mouse	NOUN	NNS	3	O
that	that	DET	WDT	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
experience	experience	VERB	VB	5	O
SE	SE	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
SE	SE	PROPN	NNP	9	B-Disease
survivors	survivor	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
similar	similar	ADJ	JJ	9	O
stimulation	stimulation	NOUN	NN	3	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
population	population	NOUN	NN	5	O
spike	spike	NOUN	NN	5	O
followed	follow	VERB	VBD	9	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
variable	variable	ADJ	JJ	5	O
latency	latency	NOUN	NN	5	O
,	,	PUNCT	,	9	O
by	by	ADP	IN	9	O
negative	negative	ADJ	JJ	9	O
DC	DC	PROPN	NNP	3	O
shifts	shift	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
repetitive	repetitive	ADJ	JJ	5	O
afterdischarges	afterdischarge	NOUN	NNS	5	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
60	60	NUM	CD	9	O
s	s	NOUN	NN	9	O
duration	duration	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
blocked	block	VERB	VBN	3	O
by	by	ADP	IN	9	O
ionotropic	ionotropic	ADJ	JJ	3	O
glutamate	glutamate	ADJ	JJ	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
antagonists	antagonist	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Focal	focal	ADJ	JJ	9	O
glutamate	glutamate	ADJ	JJ	0	B-Chemical
photostimulation	photostimulation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
granule	granule	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
layer	layer	NOUN	NN	9	O
at	at	ADP	IN	9	O
sites	site	NOUN	NNS	9	O
distant	distant	ADJ	JJ	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
recording	recording	NOUN	NN	5	O
pipette	pipette	NOUN	NN	0	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
population	population	NOUN	NN	5	O
responses	response	NOUN	NNS	5	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
30	30	NUM	CD	9	O
s	s	NOUN	NN	9	O
duration	duration	NOUN	NN	5	O
in	in	ADP	IN	5	O
slices	slice	NOUN	NNS	9	O
from	from	ADP	IN	9	O
SE	SE	PROPN	NNP	9	B-Disease
survivors	survivor	NOUN	NNS	5	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
other	other	ADJ	JJ	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
support	support	VERB	VBP	5	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	ADP	IN	5	O
SE	se	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
mossy	mossy	NOUN	NN	5	O
fiber	fiber	NOUN	NN	5	O
sprouting	sprouting	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
synaptic	synaptic	ADJ	JJ	5	O
reorganization	reorganization	NOUN	NN	9	O
are	be	VERB	VBP	5	O
relevant	relevant	ADJ	JJ	5	O
characteristics	characteristic	NOUN	NNS	5	O
of	of	ADP	IN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
development	development	NOUN	NN	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
murine	murine	NOUN	NN	3	O
strains	strain	NOUN	NNS	1	O
,	,	PUNCT	,	9	O
resembling	resemble	VERB	VBG	9	O
rat	rat	NOUN	NN	3	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
human	human	ADJ	JJ	3	O
temporal	temporal	ADJ	JJ	5	B-Disease
lobe	lobe	NOUN	NN	5	I-Disease
epilepsy	epilepsy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Urinary	urinary	ADJ	JJ	9	B-Disease
bladder	bladder	NOUN	NN	9	I-Disease
cancer	cancer	NOUN	NN	3	I-Disease
in	in	ADP	IN	5	O
Wegener	Wegener	PROPN	NNP	2	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	NOUN	NN	9	I-Disease
granulomatosis	granulomatosis	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
risks	risk	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
relation	relation	NOUN	NN	5	O
to	to	PART	TO	5	O
cyclophosphamide	cyclophosphamide	VERB	VB	0	B-Chemical
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
assess	assess	VERB	VB	5	O
and	and	CCONJ	CC	5	O
characterise	characterise	VERB	VB	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
relation	relation	NOUN	NN	5	O
to	to	PART	TO	5	O
cyclophosphamide	cyclophosphamide	VERB	VB	0	B-Chemical
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Wegener	Wegener	PROPN	NNP	2	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	NOUN	NN	9	I-Disease
granulomatosis	granulomatosis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
the	the	DET	DT	5	O
population	population	NOUN	NN	5	O
based	base	VERB	VBN	5	O
,	,	PUNCT	,	9	O
nationwide	nationwide	ADJ	JJ	5	O
Swedish	Swedish	PROPN	NNP	5	O
Inpatient	Inpatient	PROPN	NNP	5	O
Register	Register	PROPN	NNP	5	O
a	a	DET	DT	5	O
cohort	cohort	NOUN	NN	9	O
of	of	ADP	IN	5	O
1065	1065	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Wegener	Wegener	PROPN	NNP	2	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	NOUN	NN	9	I-Disease
granulomatosis	granulomatosis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
1969	1969	NUM	CD	2	O
-	-	SYM	SYM	7	O
95	95	NUM	CD	7	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Through	through	ADP	IN	5	O
linkage	linkage	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
Swedish	Swedish	PROPN	NNP	5	O
Cancer	Cancer	PROPN	NNP	2	B-Disease
Register	Register	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
all	all	DET	DT	5	O
subjects	subject	NOUN	NNS	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
cohort	cohort	NOUN	NN	9	O
diagnosed	diagnose	VERB	VBN	5	O
with	with	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
were	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Nested	nest	VERB	VBN	9	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
cohort	cohort	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
matched	matched	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
to	to	PART	TO	5	O
estimate	estimate	VERB	VB	5	O
the	the	DET	DT	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
bladder	bladder	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
using	use	VERB	VBG	9	O
odds	odd	NOUN	NNS	5	O
ratios	ratio	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
ORs	or	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
as	as	ADP	IN	5	O
relative	relative	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
cohort	cohort	NOUN	NN	9	O
the	the	DET	DT	5	O
cumulative	cumulative	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
after	after	ADP	IN	9	O
Wegener	Wegener	PROPN	NNP	2	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	NOUN	NN	9	I-Disease
granulomatosis	granulomatosis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
relative	relative	ADJ	JJ	9	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
Wegener	Wegener	PROPN	NNP	2	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	NOUN	NN	9	I-Disease
granulomatosis	granulomatosis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
estimated	estimate	VERB	VBN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
cumulative	cumulative	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
among	among	ADP	IN	5	O
cases	case	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
11	11	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
25	25	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
113	113	NUM	CD	7	O
g	g	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
25	25	NUM	CD	9	O
g	g	NOUN	NN	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
doubled	double	VERB	VBD	9	O
for	for	ADP	IN	5	O
every	every	DET	DT	5	O
10	10	NUM	CD	9	O
g	g	NOUN	NN	0	O
increment	increment	NOUN	NN	9	O
in	in	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CI	CI	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
0	0	PUNCT	NFP	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
to	to	ADP	IN	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
duration	duration	NOUN	NN	5	O
longer	long	ADJ	JJR	5	O
than	than	ADP	IN	5	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
eightfold	eightfold	ADJ	JJ	9	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
to	to	ADP	IN	5	O
69	69	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
absolute	absolute	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cohort	cohort	NOUN	NN	9	O
reached	reach	VERB	VBD	9	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
16	16	NUM	CD	9	O
years	year	NOUN	NNS	5	O
after	after	ADP	IN	9	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
Wegener	Wegener	PROPN	NNP	2	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	NOUN	NN	9	I-Disease
granulomatosis	granulomatosis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
was	be	VERB	VBD	9	O
(	(	PUNCT	-LRB-	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
significantly	significantly	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
twice	twice	ADV	RB	9	O
as	as	ADV	RB	5	O
common	common	ADJ	JJ	5	O
as	as	ADP	IN	5	O
expected	expect	VERB	VBN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
Wegener	Wegener	PROPN	NNP	2	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	NOUN	NN	9	I-Disease
granulomatosis	granulomatosis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
response	response	NOUN	NN	9	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
high	high	ADJ	JJ	9	O
cumulative	cumulative	ADJ	JJ	5	O
risks	risk	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
entire	entire	ADJ	JJ	9	O
cohort	cohort	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
also	also	ADV	RB	9	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
operating	operate	VERB	VBG	5	O
even	even	ADV	RB	5	O
before	before	ADP	IN	9	O
Wegener	Wegener	PROPN	NNP	2	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	NOUN	NN	9	I-Disease
granulomatosis	granulomatosis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Differential	differential	ADJ	JJ	9	O
modulation	modulation	NOUN	NN	9	O
by	by	ADP	IN	9	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
of	of	ADP	IN	5	O
alpha2	alpha2	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
I1	i1	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
imidazoline	imidazoline	ADJ	JJ	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
female	female	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
recently	recently	ADV	RB	9	O
shown	show	VERB	VBN	9	O
that	that	ADP	IN	5	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
negatively	negatively	ADV	RB	9	O
modulates	modulate	VERB	VBZ	9	O
the	the	DET	DT	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
mixed	mixed	ADJ	JJ	9	O
alpha2	alpha2	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
I1	i1	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
receptor	receptor	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
female	female	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
implicates	implicate	VERB	VBZ	9	O
the	the	DET	DT	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
autonomic	autonomic	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
interaction	interaction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
investigated	investigate	VERB	VBD	9	O
whether	whether	ADP	IN	9	O
this	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
involves	involve	VERB	VBZ	5	O
interaction	interaction	NOUN	NN	9	O
with	with	ADP	IN	5	O
alpha2	alpha2	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
I1	i1	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Changes	change	NOUN	NNS	9	O
evoked	evoke	VERB	VBN	5	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
intraperitoneal	intraperitoneal	ADJ	JJ	0	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
rilmenidine	rilmenidine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
600	600	NUM	CD	0	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyldopa	methyldopa	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
selective	selective	ADJ	JJ	9	O
I1	I1	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
alpha2	alpha2	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
receptor	receptor	NOUN	NN	3	O
agonists	agonist	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
hemodynamic	hemodynamic	ADJ	JJ	5	O
variability	variability	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
in	in	ADP	IN	5	O
radiotelemetered	radiotelemetered	ADJ	JJ	_	O
sham	sham	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
operated	operate	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
ovariectomized	ovariectomize	VERB	VBN	3	O
(	(	PUNCT	-LRB-	9	O
Ovx	Ovx	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
female	female	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
12	12	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
wk	wk	NOUN	NN	9	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
replacement	replacement	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
time	time	NOUN	NN	5	O
domain	domain	NOUN	NN	1	O
indexes	index	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hemodynamic	hemodynamic	ADJ	JJ	5	O
variability	variability	NOUN	NN	5	O
were	be	VERB	VBD	9	O
employed	employ	VERB	VBN	5	O
:	:	PUNCT	:	9	O
the	the	DET	DT	5	O
standard	standard	ADJ	JJ	5	O
deviation	deviation	NOUN	NN	5	O
of	of	ADP	IN	5	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
measure	measure	NOUN	NN	5	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
variability	variability	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
standard	standard	ADJ	JJ	5	O
deviation	deviation	NOUN	NN	5	O
of	of	ADP	IN	5	O
beat	beat	VERB	VBN	5	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
beat	beat	VERB	VBN	5	O
intervals	interval	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
SDRR	SDRR	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
root	root	NOUN	NN	5	O
mean	mean	VERB	VBP	5	O
square	square	NOUN	NN	5	O
of	of	ADP	IN	5	O
successive	successive	ADJ	JJ	5	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
R	r	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
wave	wave	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
R	r	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
wave	wave	NOUN	NN	5	O
intervals	interval	NOUN	NNS	5	O
as	as	ADP	IN	5	O
measures	measure	NOUN	NNS	5	O
of	of	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
variability	variability	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
sham	sham	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
operated	operate	VERB	VBN	5	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
rilmenidine	rilmenidine	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyldopa	methyldopa	NOUN	NN	0	I-Chemical
elicited	elicit	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
that	that	DET	WDT	5	O
lasted	last	VERB	VBD	5	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
5	5	NUM	CD	9	O
h	h	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
reductions	reduction	NOUN	NNS	9	O
in	in	ADP	IN	5	O
standard	standard	ADJ	JJ	5	O
deviation	deviation	NOUN	NN	5	O
of	of	ADP	IN	5	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

SDRR	SDRR	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
only	only	ADV	RB	9	O
by	by	ADP	IN	9	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyldopa	methyldopa	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Ovx	Ovx	PROPN	NNP	0	O
significantly	significantly	ADV	RB	9	O
enhanced	enhance	VERB	VBD	3	O
the	the	DET	DT	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyldopa	methyldopa	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
contrast	contrast	NOUN	NN	9	O
to	to	ADP	IN	5	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
rilmenidine	rilmenidine	NOUN	NN	0	B-Chemical
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
enhanced	enhance	VERB	VBN	3	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyldopa	methyldopa	NOUN	NN	0	I-Chemical
hypotension	hypotension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
Ovx	Ovx	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
paralleled	parallel	VERB	VBN	9	O
with	with	ADP	IN	5	O
further	further	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
SDRR	SDRR	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	B-Disease
reduced	reduced	ADJ	JJ	9	I-Disease
locomotor	locomotor	NOUN	NN	5	I-Disease
activity	activity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Estrogen	estrogen	NOUN	NN	9	O
replacement	replacement	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
17beta	17beta	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
estradiol	estradiol	NOUN	NNS	0	I-Chemical
subcutaneous	subcutaneous	ADJ	JJ	9	O
pellet	pellet	NOUN	NN	0	O
,	,	PUNCT	,	9	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
12	12	NUM	CD	9	O
wk	wk	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
Ovx	Ovx	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
restored	restore	VERB	VBD	3	O
the	the	DET	DT	5	O
hemodynamic	hemodynamic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
locomotor	locomotor	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyldopa	methyldopa	NOUN	NN	0	I-Chemical
to	to	ADP	IN	5	O
sham	sham	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
operated	operate	VERB	VBN	5	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
downregulates	downregulate	VERB	VBZ	3	O
alpha2	alpha2	NOUN	NN	9	O
-	-	PUNCT	:	7	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
I1	i1	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
receptor	receptor	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
highlight	highlight	VERB	VB	5	O
a	a	DET	DT	5	O
role	role	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	O
autonomic	autonomic	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
in	in	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyldopa	methyldopa	ADJ	JJ	0	I-Chemical
-	-	PUNCT	HYPH	7	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
interaction	interaction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Severe	severe	ADJ	JJ	9	O
reversible	reversible	ADJ	JJ	9	O
left	leave	VERB	VBD	5	B-Disease
ventricular	ventricular	ADJ	JJ	5	I-Disease
systolic	systolic	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
diastolic	diastolic	ADJ	JJ	5	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
accidental	accidental	ADJ	JJ	5	O
iatrogenic	iatrogenic	ADJ	JJ	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

Catecholamine	catecholamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
excess	excess	NOUN	NN	9	O
of	of	ADP	IN	5	O
endogenous	endogenous	ADJ	JJ	3	O
catecholamines	catecholamine	NOUN	NNS	9	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
recognized	recognize	VERB	VBN	9	O
for	for	ADP	IN	5	O
decades	decade	NOUN	NNS	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
phenomenon	phenomenon	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
reports	report	NOUN	NNS	9	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
iatrogenic	iatrogenic	ADJ	JJ	5	O
overdose	overdose	NOUN	NN	0	B-Disease
are	be	VERB	VBP	5	O
rare	rare	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
35	35	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
whose	whose	DET	WP$	9	O
cervix	cervix	NOUN	NN	5	O
uteri	uteri	NOUN	NN	9	O
was	be	VERB	VBD	9	O
inadvertently	inadvertently	ADV	RB	5	O
injected	inject	VERB	VBN	3	O
with	with	ADP	IN	5	O
8	8	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
of	of	ADP	IN	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
developed	develop	VERB	VBD	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
stunning	stunning	ADJ	JJ	5	I-Disease
that	that	DET	WDT	5	O
was	be	VERB	VBD	9	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
severe	severe	ADJ	JJ	5	O
hemodynamic	hemodynamic	ADJ	JJ	5	O
compromise	compromise	NOUN	NN	5	O
,	,	PUNCT	,	9	O
profound	profound	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
albeit	albeit	ADP	IN	9	O
transient	transient	NOUN	NN	9	O
,	,	PUNCT	,	9	O
left	leave	VERB	VBD	5	B-Disease
ventricular	ventricular	ADJ	JJ	5	I-Disease
systolic	systolic	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
diastolic	diastolic	ADJ	JJ	5	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
only	only	ADV	RB	9	O
modestly	modestly	ADV	RB	9	O
elevated	elevated	ADJ	JJ	9	O
biochemical	biochemical	ADJ	JJ	9	O
markers	marker	NOUN	NNS	3	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
case	case	NOUN	NN	5	O
illustrates	illustrate	VERB	VBZ	5	O
the	the	DET	DT	5	O
serious	serious	ADJ	JJ	5	O
consequences	consequence	NOUN	NNS	5	O
of	of	ADP	IN	5	O
medical	medical	ADJ	JJ	5	O
errors	error	NOUN	NNS	5	O
that	that	DET	WDT	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
avoided	avoid	VERB	VBN	5	O
through	through	ADP	IN	9	O
improved	improve	VERB	VBN	5	O
medication	medication	NOUN	NN	5	O
labeling	labeling	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
staff	staff	NOUN	NN	5	O
supervision	supervision	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cardioprotective	cardioprotective	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
tincture	tincture	NOUN	NN	0	B-Chemical
of	of	ADP	IN	5	I-Chemical
Crataegus	Crataegus	PROPN	NNP	4	I-Chemical
on	on	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Tincture	tincture	NOUN	NN	4	B-Chemical
of	of	ADP	IN	5	I-Chemical
Crataegus	Crataegus	PROPN	NNP	4	I-Chemical
(	(	PUNCT	-LRB-	9	O
TCR	TCR	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
alcoholic	alcoholic	ADJ	JJ	5	B-Chemical
extract	extract	NOUN	NN	0	I-Chemical
of	of	ADP	IN	5	I-Chemical
the	the	DET	DT	5	I-Chemical
berries	berry	NOUN	NNS	4	I-Chemical
of	of	ADP	IN	5	I-Chemical
hawthorn	hawthorn	NOUN	NN	4	I-Chemical
(	(	PUNCT	-LRB-	9	O
Crataegus	Crataegus	PROPN	NNP	4	B-Chemical
oxycantha	oxycantha	PROPN	NNP	4	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
herbal	herbal	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
homeopathic	homeopathic	ADJ	JJ	5	O
medicine	medicine	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
done	do	VERB	VBN	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
TCR	TCR	PROPN	NNP	3	B-Chemical
on	on	ADP	IN	5	O
experimentally	experimentally	ADV	RB	9	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Pretreatment	pretreatment	NOUN	NN	3	O
of	of	ADP	IN	5	O
TCR	TCR	PROPN	NNP	3	B-Chemical
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mL	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
100	100	NUM	CD	0	O
g	g	NOUN	NN	0	O
bodyweight	bodyweight	NOUN	NN	5	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
orally	orally	ADV	RB	0	O
for	for	ADP	IN	5	O
30	30	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
prevented	prevent	VERB	VBD	9	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
lipid	lipid	NOUN	NN	0	O
peroxidation	peroxidation	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
marker	marker	NOUN	NN	3	O
enzymes	enzyme	NOUN	NNS	1	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
85	85	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
kg	kg	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
s	s	NOUN	NN	9	O
.	.	PUNCT	.	9	O
c	c	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
days	day	NOUN	NNS	9	O
at	at	ADP	IN	9	O
an	an	DET	DT	5	O
interval	interval	NOUN	NN	5	O
of	of	ADP	IN	5	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

TCR	TCR	PROPN	NNP	3	B-Chemical
prevented	prevent	VERB	VBD	9	O
the	the	DET	DT	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
antioxidant	antioxidant	ADJ	JJ	0	O
enzymes	enzyme	NOUN	NNS	1	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
heart	heart	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
ADP	ADP	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
stimulated	stimulate	VERB	VBN	3	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
uptake	uptake	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
respiratory	respiratory	ADJ	JJ	5	O
coupling	coupling	NOUN	NN	9	O
ratio	ratio	NOUN	NN	9	O
.	.	PUNCT	.	9	O

TCR	TCR	PROPN	NNP	3	B-Chemical
protected	protect	VERB	VBD	9	O
against	against	ADP	IN	9	O
pathological	pathological	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
heart	heart	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
TCR	TCR	PROPN	NNP	3	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
useful	useful	ADJ	JJ	5	O
in	in	ADP	IN	5	O
preventing	prevent	VERB	VBG	9	O
the	the	DET	DT	5	O
damage	damage	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
heart	heart	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
tinnitus	tinnitus	NOUN	NN	5	B-Disease
by	by	ADP	IN	9	O
intratympanic	intratympanic	ADJ	JJ	5	O
instillation	instillation	NOUN	NN	0	O
of	of	ADP	IN	5	O
lignocaine	lignocaine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
2	2	NUM	CD	9	O
per	per	ADP	IN	9	O
cent	cent	NOUN	NN	5	O
through	through	ADP	IN	9	O
ventilation	ventilation	NOUN	NN	5	O
tubes	tube	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Idiopathic	idiopathic	ADJ	JJ	5	B-Disease
subjective	subjective	ADJ	JJ	5	I-Disease
tinnitus	tinnitus	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
IST	IST	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
obscure	obscure	ADJ	JJ	5	O
otological	otological	ADJ	JJ	5	O
pathologies	pathology	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
paper	paper	NOUN	NN	5	O
presents	present	VERB	VBZ	5	O
the	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treating	treat	VERB	VBG	5	O
IST	IST	PROPN	NNP	5	B-Disease
by	by	ADP	IN	9	O
intratympanic	intratympanic	ADJ	JJ	5	O
instillation	instillation	NOUN	NN	0	O
of	of	ADP	IN	5	O
lignocaine	lignocaine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
2	2	NUM	CD	9	O
per	per	ADP	IN	9	O
cent	cent	NOUN	NN	5	O
through	through	ADP	IN	9	O
a	a	DET	DT	5	O
grommet	grommet	NOUN	NN	5	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
five	five	NUM	CD	9	O
weekly	weekly	ADJ	JJ	5	O
courses	course	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Fifty	fifty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
suffering	suffer	VERB	VBG	5	O
from	from	ADP	IN	9	O
intractable	intractable	ADJ	JJ	5	O
tinnitus	tinnitus	NOUN	NN	5	B-Disease
entered	enter	VERB	VBD	5	O
this	this	DET	DT	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
only	only	ADV	RB	9	O
nine	nine	NUM	CD	9	O
finished	finish	VERB	VBD	5	O
all	all	DET	DT	5	O
five	five	NUM	CD	9	O
courses	course	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
tinnitus	tinnitus	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
almost	almost	ADV	RB	9	O
completely	completely	ADV	RB	9	O
abolished	abolish	VERB	VBN	3	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
in	in	ADP	IN	5	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
nine	nine	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
the	the	DET	DT	5	O
decompensated	decompensate	VERB	VBN	5	O
tinnitus	tinnitus	NOUN	NN	5	B-Disease
changed	change	VERB	VBD	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
compensated	compensated	ADJ	JJ	5	O
one	one	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
suggest	suggest	VERB	VBP	9	O
this	this	DET	DT	5	O
mode	mode	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
that	that	DET	WDT	5	O
were	be	VERB	VBD	9	O
previously	previously	ADV	RB	9	O
treated	treat	VERB	VBN	3	O
by	by	ADP	IN	9	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
acupuncture	acupuncture	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
biofeedback	biofeedback	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
disappointing	disappointing	ADJ	JJ	5	O
results	result	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
warned	warn	VERB	VBN	5	O
about	about	ADP	IN	5	O
the	the	DET	DT	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
vertigo	vertigo	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
vomiting	vomiting	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
subsides	subside	VERB	VBZ	5	O
gradually	gradually	ADV	RB	9	O
with	with	ADP	IN	5	O
every	every	DET	DT	5	O
new	new	ADJ	JJ	5	O
instillation	instillation	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
tinnitus	tinnitus	NOUN	NN	5	B-Disease
may	may	VERB	MD	5	O
not	not	ADV	RB	5	O
disappear	disappear	VERB	VB	5	O
but	but	CCONJ	CC	9	O
will	will	VERB	MD	5	O
be	be	VERB	VB	5	O
alleviated	alleviate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
enabling	enable	VERB	VBG	5	O
them	-PRON-	PRON	PRP	5	O
to	to	PART	TO	5	O
cope	cope	VERB	VB	5	O
more	more	ADV	RBR	5	O
easily	easily	ADV	RB	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
disease	disease	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
lead	lead	VERB	VB	5	O
a	a	DET	DT	5	O
more	more	ADV	RBR	5	O
normal	normal	ADJ	JJ	9	O
life	life	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
alpha3	alpha3	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
beta4	beta4	NOUN	NN	1	O
nicotinic	nicotinic	ADJ	JJ	0	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
subunits	subunit	NOUN	NNS	1	O
are	be	VERB	VBP	5	O
necessary	necessary	ADJ	JJ	5	O
for	for	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
hypolocomotion	hypolocomotion	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Binding	bind	VERB	VBG	9	O
of	of	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
nicotinic	nicotinic	ADJ	JJ	0	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
receptors	receptor	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
nAChRs	nachr	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O
elicits	elicit	VERB	VBZ	9	O
a	a	DET	DT	5	O
series	series	NOUN	NN	5	O
of	of	ADP	IN	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
behaviors	behavior	NOUN	NNS	5	O
that	that	DET	WDT	5	O
go	go	VERB	VBP	5	O
from	from	ADP	IN	9	O
altered	altered	ADJ	JJ	9	O
exploration	exploration	NOUN	NN	5	O
,	,	PUNCT	,	9	O
sedation	sedation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
tremors	tremor	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
to	to	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
death	death	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

nAChRs	nachr	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
pentameric	pentameric	ADJ	JJ	1	O
ion	ion	NOUN	NN	0	O
channels	channel	NOUN	NNS	9	O
usually	usually	ADV	RB	5	O
composed	compose	VERB	VBN	9	O
of	of	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
beta	beta	NOUN	NN	9	O
subunits	subunit	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
gene	gene	NOUN	NN	1	O
cluster	cluster	NOUN	NN	9	O
comprises	comprise	VERB	VBZ	9	O
the	the	DET	DT	5	O
alpha3	alpha3	NOUN	NN	3	O
,	,	PUNCT	,	9	O
alpha5	alpha5	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
beta4	beta4	NOUN	NN	1	O
subunits	subunit	NOUN	NNS	1	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
coassemble	coassemble	ADJ	JJ	1	O
to	to	PART	TO	5	O
form	form	VERB	VB	9	O
functional	functional	ADJ	JJ	9	O
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
beta4	beta4	NOUN	NN	1	O
subunits	subunit	NOUN	NNS	1	O
in	in	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
hypolocomotion	hypolocomotion	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
beta4	beta4	NOUN	NN	1	O
homozygous	homozygous	ADJ	JJ	1	O
null	null	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
beta4	beta4	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
alpha3	alpha3	ADJ	JJ	3	O
heterozygous	heterozygous	ADJ	JJ	1	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

beta4	beta4	PROPN	NNP	1	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
less	less	ADV	RBR	5	O
sensitive	sensitive	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
both	both	CCONJ	CC	9	O
at	at	ADP	IN	9	O
low	low	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
measured	measure	VERB	VBN	9	O
as	as	ADP	IN	5	O
decreased	decrease	VERB	VBN	9	O
exploration	exploration	NOUN	NN	5	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
open	open	ADJ	JJ	5	O
field	field	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
measured	measure	VERB	VBN	9	O
as	as	ADP	IN	5	O
sensitivity	sensitivity	NOUN	NN	9	O
to	to	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Using	use	VERB	VBG	9	O
in	in	ADP	IN	5	O
situ	situ	ADJ	JJ	9	O
hybridization	hybridization	NOUN	NN	9	O
probes	probe	NOUN	NNS	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
alpha3	alpha3	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
alpha5	alpha5	NOUN	NN	3	O
subunits	subunit	NOUN	NNS	1	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
alpha5	alpha5	NOUN	NN	3	O
mRNA	mRNA	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
unchanged	unchanged	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
alpha3	alpha3	ADJ	JJ	3	O
mRNA	mRNA	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
selectively	selectively	ADV	RB	3	O
decreased	decrease	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mitral	mitral	ADJ	JJ	5	O
cell	cell	NOUN	NN	3	O
layer	layer	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
olfactory	olfactory	ADJ	JJ	5	O
bulb	bulb	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
inferior	inferior	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
superior	superior	ADJ	JJ	5	O
colliculus	colliculus	NOUN	NN	5	O
of	of	ADP	IN	5	O
beta4	beta4	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
brains	brain	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

alpha3	alpha3	PROPN	NNP	3	O
+	+	PUNCT	-LRB-	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
partially	partially	ADV	RB	9	O
resistant	resistant	ADJ	JJ	9	O
to	to	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
wild	wild	ADJ	JJ	1	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
littermates	littermate	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

mRNA	mRNA	NOUN	NNS	3	O
levels	level	NOUN	NNS	3	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
alpha5	alpha5	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
beta4	beta4	NOUN	NN	1	O
subunits	subunit	NOUN	NNS	1	O
were	be	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
in	in	ADP	IN	5	O
alpha3	alpha3	NOUN	NN	3	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
brains	brain	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Together	together	ADV	RB	9	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
beta4	beta4	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
alpha3	alpha3	ADJ	JJ	3	O
subunits	subunit	NOUN	NNS	1	O
are	be	VERB	VBP	5	O
mediators	mediator	NOUN	NNS	9	O
of	of	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
hypolocomotion	hypolocomotion	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
sevoflurane	sevoflurane	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
lidocaine	lidocaine	ADV	RBR	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
sevoflurane	sevoflurane	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
lidocaine	lidocaine	ADV	RBR	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
cats	cat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
convulsive	convulsive	ADJ	JJ	5	B-Disease
threshold	threshold	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SD	sd	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
41	41	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

l	l	X	XX	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
lidocaine	lidocaine	ADJ	JJR	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
kg	kg	ADP	IN	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O
min	min	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
increasing	increase	VERB	VBG	9	O
significantly	significantly	ADV	RB	9	O
to	to	ADP	IN	5	O
66	66	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

l	l	X	XX	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
tidal	tidal	ADJ	JJ	5	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
sevoflurane	sevoflurane	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
threshold	threshold	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
61	61	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
l	l	X	XX	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
during	during	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
sevoflurane	sevoflurane	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
significant	significant	ADJ	JJ	9	O
from	from	ADP	IN	9	O
that	that	DET	DT	5	O
during	during	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
sevoflurane	sevoflurane	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
a	a	DET	DT	5	O
celling	celling	NOUN	NN	9	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
convulsive	convulsive	ADJ	JJ	5	B-Disease
threshold	threshold	NOUN	NN	5	O
between	between	ADP	IN	5	O
sevoflurane	sevoflurane	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
enflurane	enflurane	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rise	rise	NOUN	NN	9	O
in	in	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
became	become	VERB	VBD	9	O
less	less	ADV	RBR	5	O
marked	marked	ADJ	JJ	9	O
when	when	ADV	WRB	5	O
higher	high	ADJ	JJR	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
sevoflurane	sevoflurane	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
enflurane	enflurane	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
at	at	ADP	IN	9	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
decreased	decrease	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
sevoflurane	sevoflurane	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
enflurane	enflurane	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
measured	measure	VERB	VBN	9	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
systolic	systolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
became	become	VERB	VBD	9	O
70	70	NUM	CD	9	O
mmHg	mmHg	NOUN	NNS	7	O
.	.	PUNCT	.	9	O

Apamin	Apamin	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
blocker	blocker	NOUN	NN	0	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
channels	channel	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
intracerebroventricularly	intracerebroventricularly	ADV	RB	3	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
anesthetized	anesthetize	VERB	VBN	0	O
with	with	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
sevoflurane	sevoflurane	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
anticonvulsive	anticonvulsive	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Apamin	Apamin	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
ng	ng	ADP	IN	0	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
tendency	tendency	NOUN	NN	5	O
to	to	PART	TO	5	O
decrease	decrease	VERB	VB	9	O
the	the	DET	DT	5	O
convulsive	convulsive	ADJ	JJ	5	B-Disease
threshold	threshold	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
21	21	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
to	to	ADP	IN	5	O
19	19	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
l	l	X	XX	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
but	but	CCONJ	CC	9	O
this	this	DET	DT	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
sevoflurane	sevoflurane	NOUN	NN	0	B-Chemical
reduces	reduce	VERB	VBZ	9	O
the	the	DET	DT	5	O
convulsive	convulsive	ADJ	JJ	5	B-Disease
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	ADJ	JJR	0	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
but	but	CCONJ	CC	9	O
carries	carry	VERB	VBZ	9	O
some	some	DET	DT	5	O
risk	risk	NOUN	NN	5	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
circulatory	circulatory	ADJ	JJ	5	O
depression	depression	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Cardiac	cardiac	ADJ	JJ	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
observed	observe	VERB	VBD	9	O
in	in	ADP	IN	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

INTRODUCTION	INTRODUCTION	PROPN	NNP	5	O
:	:	PUNCT	:	9	O
Cyclophosphamide	Cyclophosphamide	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
alkylating	alkylate	VERB	VBG	0	O
agent	agent	NOUN	NN	9	O
given	give	VERB	VBN	5	O
frequently	frequently	ADV	RB	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
component	component	NOUN	NN	9	O
of	of	ADP	IN	5	O
many	many	ADJ	JJ	5	O
conditioning	conditioning	NOUN	NN	5	O
regimens	regimen	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
its	-PRON-	DET	PRP$	9	O
nonhematological	nonhematological	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
limiting	limit	VERB	VBG	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
cardiomyopathy	cardiomyopathy	ADJ	JJ	5	B-Disease
.	.	PUNCT	.	9	O

STUDY	STUDY	PROPN	NNP	2	O
DESIGN	DESIGN	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
combined	combine	VERB	VBD	9	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
melphalan	melphalan	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
thiotepa	thiotepa	NOUN	NNS	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
carboplatin	carboplatin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
triple	triple	ADJ	JJ	9	O
sequential	sequential	ADJ	JJ	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
regimen	regiman	NOUN	NNS	5	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Analysis	analysis	NOUN	NN	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
on	on	ADP	IN	5	O
61	61	NUM	CD	7	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
responsive	responsive	ADJ	JJ	9	O
metastatic	metastatic	ADJ	JJ	3	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
receiving	receive	VERB	VBG	9	O
96	96	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
h	h	DET	DT	0	O
infusional	infusional	ADJ	JJ	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
part	part	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
triple	triple	ADJ	JJ	9	O
sequential	sequential	ADJ	JJ	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
regimen	regiman	NOUN	NNS	5	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
peritransplant	peritransplant	ADJ	JJ	5	O
congestive	congestive	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
failure	failure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
CHF	CHF	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
following	following	ADJ	JJ	9	O
pretreatment	pretreatment	ADJ	JJ	0	O
characteristics	characteristic	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
electrocardiogram	electrocardiogram	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
EKG	EKG	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
abnormalities	abnormality	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
prior	prior	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	O
history	history	NOUN	NN	5	O
,	,	PUNCT	,	9	O
smoking	smoking	NOUN	NN	5	O
,	,	PUNCT	,	9	O
diabetes	diabetes	NOUN	NN	5	B-Disease
mellitus	mellitus	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
prior	prior	ADJ	JJ	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
anthracyclines	anthracycline	NOUN	NNS	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
left	left	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
sided	sided	ADJ	JJ	5	O
chest	chest	NOUN	NN	5	O
irradiation	irradiation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Six	six	NUM	CD	9	O
of	of	ADP	IN	5	O
61	61	NUM	CD	7	O
women	woman	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
developed	develop	VERB	VBD	5	O
clinically	clinically	ADV	RB	5	O
reversible	reversible	ADJ	JJ	9	O
grade	grade	NOUN	NN	9	O
3	3	NUM	CD	9	O
CHF	CHF	PROPN	NNP	9	B-Disease
following	follow	VERB	VBG	9	O
infusional	infusional	ADJ	JJ	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
median	median	ADJ	JJ	9	O
percent	percent	NOUN	NN	5	O
decline	decline	NOUN	NN	9	O
in	in	ADP	IN	5	O
ejection	ejection	NOUN	NN	5	O
fraction	fraction	NOUN	NN	9	O
of	of	ADP	IN	5	O
31	31	NUM	CD	7	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Incidence	incidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
transient	transient	ADJ	JJ	9	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
comparable	comparable	ADJ	JJ	9	O
to	to	ADP	IN	5	O
previous	previous	ADJ	JJ	9	O
recorded	record	VERB	VBN	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Older	old	ADJ	JJR	5	O
age	age	NOUN	NN	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
CHF	CHF	PROPN	NNP	9	B-Disease
development	development	NOUN	NN	9	O
;	;	PUNCT	:	9	O
with	with	ADP	IN	5	O
median	median	ADJ	JJ	9	O
ages	age	NOUN	NNS	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
entire	entire	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
developing	develop	VERB	VBG	5	O
CHF	CHF	PROPN	NNP	9	B-Disease
of	of	ADP	IN	5	O
45	45	NUM	CD	9	O
and	and	CCONJ	CC	5	O
59	59	NUM	CD	7	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
association	association	NOUN	NN	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
pretreatment	pretreatment	ADJ	JJ	0	O
characteristics	characteristic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
As	as	ADP	IN	9	O
a	a	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
oncologists	oncologist	NOUN	NNS	5	O
should	should	VERB	MD	5	O
carefully	carefully	ADV	RB	5	O
monitor	monitor	VERB	VB	5	O
fluid	fluid	ADJ	JJ	5	O
balance	balance	NOUN	NN	5	O
in	in	ADP	IN	5	O
older	old	ADJ	JJR	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Routine	Routine	PROPN	NNP	5	O
EKG	EKG	PROPN	NNP	5	O
monitoring	monitoring	NOUN	NN	5	O
during	during	ADP	IN	5	O
infusional	infusional	ADJ	JJ	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
predict	predict	VERB	VB	5	O
CHF	CHF	PROPN	NNP	9	B-Disease
development	development	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Tremor	Tremor	PROPN	NNP	5	B-Disease
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
salbutamol	salbutamol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
quantified	quantify	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
laser	laser	NOUN	NN	5	O
pointer	pointer	NOUN	NN	5	O
technique	technique	NOUN	NN	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
study	study	VERB	VB	9	O
tremor	tremor	NOUN	NN	5	B-Disease
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
salbutamol	salbutamol	NOUN	NN	0	B-Chemical
an	an	DET	DT	5	O
easily	easily	ADV	RB	5	O
applicable	applicable	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
quick	quick	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
low	low	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
priced	price	VERB	VBN	5	O
method	method	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
needed	need	VERB	VBN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
new	new	ADJ	JJ	5	O
method	method	NOUN	NN	5	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
commercially	commercially	ADV	RB	0	O
available	available	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
pen	pen	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
shaped	shape	VERB	VBN	5	O
laser	laser	NOUN	NN	5	O
pointer	pointer	NOUN	NN	5	O
was	be	VERB	VBD	9	O
developed	develop	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
sensitivity	sensitivity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
reproducibility	reproducibility	NOUN	NN	5	O
,	,	PUNCT	,	9	O
reference	reference	NOUN	NN	9	O
values	value	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
agreement	agreement	NOUN	NN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
questionnaire	questionnaire	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	METHODS	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Tremor	Tremor	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
laser	laser	NOUN	NN	5	O
pointer	pointer	NOUN	NN	5	O
technique	technique	NOUN	NN	5	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
determine	determine	VERB	VB	9	O
sensitivity	sensitivity	NOUN	NN	9	O
we	-PRON-	PRON	PRP	5	O
assessed	assess	VERB	VBD	9	O
tremor	tremor	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
44	44	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
obstructive	obstructive	ADJ	JJ	5	B-Disease
lung	lung	NOUN	NN	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
cumulative	cumulative	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
salbutamol	salbutamol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Subjects	subject	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
asked	ask	VERB	VBN	5	O
to	to	PART	TO	5	O
aim	aim	VERB	VB	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
centre	centre	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
target	target	NOUN	NN	9	O
,	,	PUNCT	,	9	O
subdivided	subdivide	VERB	VBN	9	O
in	in	ADP	IN	5	O
concentric	concentric	ADJ	JJ	5	O
circles	circle	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
from	from	ADP	IN	9	O
5	5	NUM	CD	9	O
m	m	NUM	CD	9	O
distance	distance	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
circle	circle	NOUN	NN	9	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
the	the	DET	DT	5	O
participant	participant	NOUN	NN	5	O
succeeded	succeed	VERB	VBD	5	O
to	to	PART	TO	5	O
aim	aim	NOUN	NN	5	O
was	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
in	in	ADP	IN	5	O
millimetres	millimetre	NOUN	NNS	5	O
radius	radius	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
another	another	DET	DT	9	O
series	series	NOUN	NN	5	O
of	of	ADP	IN	5	O
measurements	measurement	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
reproducibility	reproducibility	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
reference	reference	NOUN	NN	9	O
values	value	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
tremor	tremor	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
in	in	ADP	IN	5	O
65	65	NUM	CD	7	O
healthy	healthy	ADJ	JJ	5	O
subjects	subject	NOUN	NNS	5	O
in	in	ADP	IN	5	O
three	three	NUM	CD	9	O
sessions	session	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
9	9	NUM	CD	7	O
a	a	DET	DT	5	O
.	.	PUNCT	.	9	O
m	m	NOUN	NN	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
m	m	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
and	and	CCONJ	CC	5	O
9	9	NUM	CD	7	O
a	a	DET	DT	5	O
.	.	PUNCT	.	9	O
m	m	NOUN	NN	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
week	week	NOUN	NN	9	O
later	later	ADV	RB	9	O
.	.	PUNCT	.	9	O

Postural	postural	ADJ	JJ	5	O
tremor	tremor	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
arm	arm	NOUN	NN	5	O
horizontally	horizontally	ADV	RB	5	O
outstretched	outstretche	VERB	VBD	5	O
rest	rest	NOUN	NN	5	O
tremor	tremor	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
arm	arm	NOUN	NN	5	O
supported	support	VERB	VBN	9	O
by	by	ADP	IN	9	O
an	an	DET	DT	5	O
armrest	armr	ADJ	JJS	5	O
and	and	CCONJ	CC	5	O
finally	finally	ADV	RB	9	O
tremor	tremor	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
after	after	ADP	IN	9	O
holding	hold	VERB	VBG	5	O
a	a	DET	DT	5	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
kg	kg	NOUN	NN	0	O
weight	weight	NOUN	NN	9	O
until	until	ADP	IN	5	O
exhaustion	exhaustion	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Inter	inter	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
observer	observer	NOUN	NN	5	O
variability	variability	NOUN	NN	5	O
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
series	series	NOUN	NN	5	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Tremor	Tremor	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
simultaneously	simultaneously	ADV	RB	5	O
by	by	ADP	IN	9	O
two	two	NUM	CD	5	O
independent	independent	ADJ	JJ	9	O
observers	observer	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Salbutamol	Salbutamol	PROPN	NNP	0	B-Chemical
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
tremor	tremor	NOUN	NN	5	B-Disease
severity	severity	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
way	way	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Within	within	ADP	IN	9	O
healthy	healthy	ADJ	JJ	5	O
adults	adult	NOUN	NNS	5	O
no	no	DET	DT	9	O
age	age	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
dependency	dependency	NOUN	NN	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
found	find	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
b	b	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
262	262	NUM	CD	7	O
mm	mm	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
year	year	NOUN	NN	5	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
72	72	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
agreement	agreement	NOUN	NN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
questionnaire	questionnaire	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
tremor	tremor	NOUN	NN	5	B-Disease
severity	severity	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
093	093	NUM	CD	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
53	53	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Postural	postural	ADJ	JJ	5	O
tremor	tremor	NOUN	NN	5	B-Disease
showed	show	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
third	third	ADJ	JJ	9	O
session	session	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
07	07	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Support	support	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
arm	arm	NOUN	NN	5	O
decreased	decrease	VERB	VBD	9	O
tremor	tremor	NOUN	NN	5	B-Disease
severity	severity	NOUN	NN	5	O
,	,	PUNCT	,	9	O
exhaustion	exhaustion	NOUN	NN	9	O
increased	increase	VERB	VBN	9	O
tremor	tremor	NOUN	NN	5	B-Disease
severity	severity	NOUN	NN	5	O
significantly	significantly	ADV	RB	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
good	good	ADJ	JJ	5	O
agreement	agreement	NOUN	NN	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
between	between	ADP	IN	5	O
two	two	NUM	CD	5	O
independent	independent	ADJ	JJ	9	O
observers	observer	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
interclass	interclass	VERB	VB	5	O
correlation	correlation	NOUN	NN	9	O
coefficient	coefficient	NOUN	NN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
72	72	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

DISCUSSION	discussion	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Quantifying	quantify	VERB	VBG	5	O
tremor	tremor	NOUN	NN	5	B-Disease
by	by	ADP	IN	9	O
using	use	VERB	VBG	9	O
an	an	DET	DT	5	O
inexpensive	inexpensive	ADJ	JJ	5	O
laser	laser	NOUN	NN	5	O
pointer	pointer	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
exception	exception	NOUN	NN	9	O
of	of	ADP	IN	5	O
children	child	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
<	<	X	XX	0	O
12	12	NUM	CD	9	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
a	a	DET	DT	5	O
sensitive	sensitive	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
reproducible	reproducible	ADJ	JJ	5	O
method	method	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Safety	safety	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
raloxifene	raloxifene	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
multiple	multiple	ADJ	JJ	5	O
outcomes	outcome	NOUN	NNS	5	O
of	of	ADP	IN	5	O
raloxifene	raloxifene	ADJ	JJ	0	B-Chemical
evaluation	evaluation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
examine	examine	VERB	VB	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
raloxifene	raloxifene	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
major	major	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
that	that	DET	WDT	5	O
occur	occur	VERB	VBP	5	O
with	with	ADP	IN	5	O
postmenopausal	postmenopausal	NOUN	NN	5	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
therapy	therapy	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
tamoxifen	tamoxifen	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
Multiple	Multiple	PROPN	NNP	5	O
Outcomes	Outcomes	PROPN	NNP	5	O
of	of	ADP	IN	5	O
Raloxifene	Raloxifene	PROPN	NNP	0	B-Chemical
Evaluation	Evaluation	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
multicenter	multicenter	NOUN	NN	5	O
,	,	PUNCT	,	9	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
,	,	PUNCT	,	9	O
enrolled	enrol	VERB	VBD	5	O
7	7	NUM	CD	9	O
,	,	PUNCT	,	9	O
705	705	NUM	CD	7	O
postmenopausal	postmenopausal	NOUN	NN	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
osteoporosis	osteoporosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Women	woman	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
assigned	assign	VERB	VBN	5	O
to	to	PART	TO	5	O
raloxifene	raloxifene	VERB	VB	0	B-Chemical
60	60	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
120	120	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Outcomes	Outcomes	PROPN	NNP	5	O
included	include	VERB	VBD	5	O
venous	venous	ADJ	JJ	5	B-Disease
thromboembolism	thromboembolism	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
cataracts	cataract	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
gallbladder	gallbladder	NOUN	NN	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
endometrial	endometrial	ADJ	JJ	9	B-Disease
hyperplasia	hyperplasia	NOUN	NN	9	I-Disease
or	or	CCONJ	CC	5	I-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
During	during	ADP	IN	5	O
a	a	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
raloxifene	raloxifene	NOUN	NNS	0	B-Chemical
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
thromboembolism	thromboembolism	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
relative	relative	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
[	[	PUNCT	-LRB-	9	O
RR	RR	PROPN	NNP	9	O
]	]	PUNCT	-RRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
[	[	PUNCT	-LRB-	9	O
CI	CI	PROPN	NNP	7	O
]	]	PUNCT	-RRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
excess	excess	ADJ	JJ	9	O
event	event	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
per	per	ADP	IN	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
woman	woman	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
years	year	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
0	0	PROPN	NNP	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
needed	need	VERB	VBN	5	O
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
1	1	NUM	CD	9	O
event	event	NOUN	NN	5	O
was	be	VERB	VBD	9	O
170	170	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
100	100	NUM	CD	0	O
-	-	SYM	SYM	7	O
582	582	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
over	over	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Risk	risk	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
raloxifene	raloxifene	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
group	group	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
2	2	NUM	CD	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
decreased	decrease	VERB	VBD	9	O
to	to	ADP	IN	5	O
about	about	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
rate	rate	NOUN	NN	9	O
as	as	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
group	group	NOUN	NN	9	O
thereafter	thereafter	ADV	RB	9	O
.	.	PUNCT	.	9	O

Raloxifene	Raloxifene	PROPN	NNP	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
increase	increase	VERB	VB	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
cataracts	cataract	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
RR	RR	PROPN	NNP	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
;	;	SYM	SYM	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
gallbladder	gallbladder	NOUN	NN	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
RR	RR	PROPN	NNP	9	O
1	1	NUM	CD	9	O
.	.	NOUN	NN	9	O
0	0	NUM	CD	7	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
endometrial	endometrial	ADJ	JJ	9	B-Disease
hyperplasia	hyperplasia	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
RR	RR	PROPN	NNP	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
endometrial	endometrial	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
RR	RR	PROPN	NNP	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
;	;	SYM	SYM	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Raloxifene	Raloxifene	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
thromboembolism	thromboembolism	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
cataracts	cataract	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
gallbladder	gallbladder	NOUN	NN	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
endometrial	endometrial	ADJ	JJ	9	B-Disease
hyperplasia	hyperplasia	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
endometrial	endometrial	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

LEVEL	LEVEL	PROPN	NNP	2	O
OF	of	ADP	IN	2	O
EVIDENCE	EVIDENCE	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
I	-PRON-	PRON	PRP	9	O

Optimization	optimization	NOUN	NN	5	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

While	while	ADP	IN	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
no	no	DET	DT	9	O
single	single	ADJ	JJ	9	O
correct	correct	ADJ	JJ	5	O
starting	starting	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
for	for	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
many	many	ADJ	JJ	5	O
individuals	individual	NOUN	NNS	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
started	start	VERB	VBN	5	O
on	on	ADP	IN	5	O
either	either	CCONJ	CC	9	O
the	the	DET	DT	5	O
25	25	NUM	CD	9	O
/	/	SYM	SYM	9	O
100	100	NUM	CD	0	O
or	or	CCONJ	CC	5	O
controlled	control	VERB	VBN	5	O
-	-	PUNCT	HYPH	7	O
release	release	NOUN	NN	9	O
formula	formula	NOUN	NN	9	O
,	,	PUNCT	,	9	O
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
general	general	ADJ	JJ	5	O
rule	rule	NOUN	NN	5	O
not	not	ADV	RB	5	O
to	to	PART	TO	5	O
attempt	attempt	VERB	VB	5	O
to	to	PART	TO	5	O
titrate	titrate	VERB	VB	9	O
carbidopa	carbidopa	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
point	point	NOUN	NN	5	O
of	of	ADP	IN	5	O
"	"	PUNCT	``	5	O
normality	normality	NOUN	NN	5	O
,	,	PUNCT	,	9	O
"	"	PUNCT	''	5	O
which	which	DET	WDT	5	O
can	can	VERB	MD	5	O
lead	lead	VERB	VB	5	O
to	to	ADP	IN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
physician	physician	NOUN	NN	5	O
should	should	VERB	MD	5	O
also	also	ADV	RB	9	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
proper	proper	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
any	any	DET	DT	5	O
adjunctive	adjunctive	ADJ	JJ	5	O
medications	medication	NOUN	NNS	5	O
;	;	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
combined	combined	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
become	become	VERB	VBN	5	O
the	the	DET	DT	5	O
standard	standard	ADJ	JJ	5	O
approach	approach	NOUN	NN	5	O
to	to	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
emerging	emerge	VERB	VBG	5	O
difficulties	difficulty	NOUN	NNS	5	O
require	require	VERB	VBP	5	O
a	a	DET	DT	5	O
reassessment	reassessment	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
approaches	approach	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
dosage	dosage	NOUN	NN	9	O
adjustment	adjustment	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
introduction	introduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
agonist	agonist	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Other	other	ADJ	JJ	9	O
possible	possible	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
-	-	PUNCT	:	7	O
-	-	PUNCT	HYPH	7	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
gastrointestinal	gastrointestinal	ADJ	JJ	9	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
orthostatic	orthostatic	ADJ	JJ	5	B-Disease
hypotension	hypotension	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
psychosis	psychosis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
sleep	sleep	NOUN	NN	5	B-Disease
disturbances	disturbance	NOUN	NNS	5	I-Disease
or	or	CCONJ	CC	5	O
parasomnias	parasomnia	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
drug	drug	NOUN	NN	5	O
interactions	interaction	NOUN	NNS	9	O
-	-	PUNCT	:	7	O
-	-	PUNCT	:	7	O
also	also	ADV	RB	9	O
require	require	VERB	VBP	5	O
carefully	carefully	ADV	RB	5	O
monitored	monitor	VERB	VBN	9	O
individual	individual	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Nonpharmacologic	nonpharmacologic	ADJ	JJ	5	O
concerns	concern	NOUN	NNS	5	O
can	can	VERB	MD	5	O
help	help	VERB	VB	5	O
the	the	DET	DT	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
patient	patient	NOUN	NN	5	O
achieve	achieve	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
maintain	maintain	VERB	VB	5	O
optimal	optimal	ADJ	JJ	5	O
functioning	functioning	NOUN	NN	5	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
daily	daily	ADJ	JJ	5	O
exercise	exercise	NOUN	NN	5	O
,	,	PUNCT	,	9	O
physical	physical	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
involvement	involvement	NOUN	NN	9	O
with	with	ADP	IN	5	O
support	support	NOUN	NN	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Long	long	ADJ	JJ	9	O
term	term	NOUN	NN	5	O
audiological	audiological	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
beta	beta	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
thalassemic	thalassemic	NOUN	NN	5	I-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
objective	objective	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
identify	identify	VERB	VB	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
monitor	monitor	VERB	VB	5	O
the	the	DET	DT	5	O
progression	progression	NOUN	NN	9	O
of	of	ADP	IN	5	O
hearing	hear	VERB	VBG	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
young	young	ADJ	JJ	5	O
adults	adult	NOUN	NNS	5	O
with	with	ADP	IN	5	O
beta	beta	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
thalassemia	thalassemia	NOUN	NN	9	I-Disease
major	major	NOUN	NN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
One	one	NUM	CD	5	O
hundred	hundred	NUM	CD	5	O
and	and	CCONJ	CC	5	O
four	four	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
104	104	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
aged	age	VERB	VBN	9	O
6	6	NUM	CD	9	O
-	-	SYM	SYM	7	O
35	35	NUM	CD	9	O
years	year	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
17	17	NUM	CD	7	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
participated	participate	VERB	VBD	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
regular	regular	ADJ	JJ	5	O
transfusion	transfusion	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
chelation	chelation	NOUN	NN	0	O
program	program	NOUN	NN	5	O
maintaining	maintain	VERB	VBG	9	O
a	a	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
hemoglobin	hemoglobin	NOUN	NN	0	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
gr	gr	NOUN	NN	9	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
.	.	PUNCT	.	9	O

Subjects	subject	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
receiving	receive	VERB	VBG	9	O
desferrioxamine	desferrioxamine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DFO	DFO	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
chelation	chelation	NOUN	NN	0	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
daily	daily	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
50	50	NUM	CD	0	O
-	-	SYM	SYM	7	O
60	60	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
days	day	NOUN	NNS	9	O
a	a	DET	DT	5	O
week	week	NOUN	NN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
six	six	NUM	CD	9	O
years	year	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
then	then	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
to	to	ADP	IN	5	O
40	40	NUM	CD	9	O
-	-	SYM	SYM	7	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
following	following	ADJ	JJ	9	O
eight	eight	NUM	CD	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
followed	follow	VERB	VBN	9	O
for	for	ADP	IN	5	O
8	8	NUM	CD	9	O
-	-	SYM	SYM	7	O
14	14	NUM	CD	7	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Overall	overall	ADV	RB	9	O
,	,	PUNCT	,	9	O
21	21	NUM	CD	7	O
out	out	ADP	IN	9	O
of	of	ADP	IN	5	O
104	104	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
frequency	frequency	NOUN	NN	5	O
sensorineural	sensorineural	ADJ	JJ	5	B-Disease
hearing	hearing	NOUN	NN	5	I-Disease
loss	loss	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
SNHL	SNHL	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
either	either	CCONJ	CC	9	O
unilateral	unilateral	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
bilateral	bilateral	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
ototoxic	ototoxic	ADJ	JJ	5	B-Disease
factor	factor	NOUN	NN	9	O
,	,	PUNCT	,	9	O
other	other	ADJ	JJ	5	O
than	than	ADP	IN	5	O
DFO	DFO	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
any	any	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
SNHL	SNHL	PROPN	NNP	5	B-Disease
presented	present	VERB	VBD	5	O
with	with	ADP	IN	5	O
relatively	relatively	ADV	RB	5	O
lower	low	ADJ	JJR	9	O
serum	serum	ADJ	JJ	9	O
ferritin	ferritin	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
with	with	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
hearing	hearing	NOUN	NN	5	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Subjects	subject	NOUN	NNS	5	O
with	with	ADP	IN	5	O
SNHL	SNHL	PROPN	NNP	5	B-Disease
were	be	VERB	VBD	9	O
submitted	submit	VERB	VBN	9	O
to	to	ADP	IN	5	O
DFO	dfo	ADJ	JJ	0	B-Chemical
reduction	reduction	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
temporary	temporary	ADJ	JJ	5	O
withdrawal	withdrawal	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Following	follow	VERB	VBG	9	O
intervention	intervention	NOUN	NN	5	O
,	,	PUNCT	,	9	O
7	7	NUM	CD	9	O
out	out	ADP	IN	9	O
of	of	ADP	IN	5	O
21	21	NUM	CD	7	O
affected	affect	VERB	VBN	9	O
patients	patient	NOUN	NNS	5	O
recovered	recover	VERB	VBD	9	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
remained	remain	VERB	VBD	9	O
stable	stable	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
demonstrated	demonstrate	VERB	VBN	9	O
aggravation	aggravation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
indicative	indicative	ADJ	JJ	9	O
of	of	ADP	IN	5	O
DFO	dfo	NOUN	NN	0	B-Chemical
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
contributing	contribute	VERB	VBG	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
hearing	hearing	NOUN	NN	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Regular	regular	ADJ	JJ	5	O
audiologic	audiologic	NOUN	NN	5	O
evaluation	evaluation	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
imperative	imperative	ADJ	JJ	5	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
thalassemic	thalassemic	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
so	so	ADP	IN	5	O
that	that	ADP	IN	5	O
early	early	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
recognized	recognize	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
judiciously	judiciously	ADV	RB	5	O
adjusted	adjust	VERB	VBN	9	O
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
or	or	CCONJ	CC	5	O
reverse	reverse	VERB	VB	9	O
hearing	hearing	NOUN	NN	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Individual	individual	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
ACE	ACE	PROPN	NNP	9	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
predict	predict	VERB	VBP	5	O
susceptibility	susceptibility	NOUN	NN	9	O
to	to	ADP	IN	5	O
adriamycin	adriamycin	ADV	RB	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
renal	renal	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
man	man	NOUN	NN	5	O
,	,	PUNCT	,	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
converting	convert	VERB	VBG	9	O
enzyme	enzyme	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
ACE	ACE	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
ACE	ACE	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
I	I	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
D	D	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
genotype	genotype	NOUN	NN	9	O
,	,	PUNCT	,	9	O
are	be	VERB	VBP	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
prognosis	prognosis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
raises	raise	VERB	VBZ	9	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	ADP	IN	5	O
individual	individual	ADJ	JJ	5	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
ACE	ACE	PROPN	NNP	9	O
activity	activity	NOUN	NN	9	O
are	be	VERB	VBP	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
susceptibility	susceptibility	NOUN	NN	9	O
to	to	ADP	IN	5	O
inflicted	inflict	VERB	VBN	5	O
damage	damage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
studied	study	VERB	VBD	9	O
the	the	DET	DT	5	O
predictive	predictive	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
ACE	ACE	PROPN	NNP	9	O
activity	activity	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
adriamycin	adriamycin	NOUN	NN	3	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Renal	Renal	PROPN	NNP	9	O
ACE	ACE	PROPN	NNP	9	O
activity	activity	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
Hip	Hip	PROPN	NNP	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
His	His	PROPN	NNP	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
Leu	Leu	PROPN	NNP	1	I-Chemical
cleavage	cleavage	NOUN	NN	1	O
by	by	ADP	IN	9	O
cortical	cortical	ADJ	JJ	5	O
homogenates	homogenate	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
renal	renal	ADJ	JJ	9	O
biopsy	biopsy	NOUN	NN	5	O
in	in	ADP	IN	5	O
27	27	NUM	CD	7	O
adult	adult	NOUN	NN	9	O
male	male	ADJ	JJ	9	O
Wistar	wistar	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
1	1	NUM	CD	9	O
week	week	NOUN	NN	9	O
of	of	ADP	IN	5	O
recovery	recovery	NOUN	NN	9	O
,	,	PUNCT	,	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
adriamycin	adriamycin	ADJ	JJ	3	B-Chemical
[	[	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	CCONJ	CC	0	O
intravenously	intravenously	ADV	RB	0	O
(	(	PUNCT	-LRB-	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
18	18	NUM	CD	7	O
;	;	PUNCT	:	9	O
controls	control	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
saline	saline	VERB	VBP	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
9	9	NUM	CD	7	O
]	]	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Proteinuria	Proteinuria	PROPN	NNP	7	B-Disease
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
every	every	DET	DT	5	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
12	12	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
sacrificed	sacrifice	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
kidneys	kidney	NOUN	NNS	9	O
harvested	harvest	VERB	VBN	3	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
As	as	ADP	IN	9	O
anticipated	anticipate	VERB	VBN	5	O
,	,	PUNCT	,	9	O
adriamycin	adriamycin	ADJ	JJ	3	B-Chemical
elicited	elicit	VERB	VBN	9	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
range	range	NOUN	NN	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
renal	renal	ADJ	JJ	9	B-Disease
interstitial	interstitial	ADJ	JJ	9	I-Disease
damage	damage	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
mild	mild	ADJ	JJ	9	O
focal	focal	ADJ	JJ	5	B-Disease
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Baseline	baseline	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	O
ACE	ACE	PROPN	NNP	9	O
positively	positively	ADV	RB	9	O
correlated	correlate	VERB	VBD	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
relative	relative	ADJ	JJ	9	O
rise	rise	NOUN	NN	9	O
in	in	ADP	IN	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
after	after	ADP	IN	9	O
adriamycin	adriamycin	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
62	62	NUM	CD	7	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
renal	renal	ADJ	JJ	9	O
interstitial	interstitial	ADJ	JJ	9	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
smooth	smooth	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
actin	actin	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
49	49	NUM	CD	7	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
interstitial	interstitial	ADJ	JJ	9	O
macrophage	macrophage	NOUN	NN	3	O
influx	influx	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
56	56	NUM	CD	7	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
interstitial	interstitial	ADJ	JJ	9	O
collagen	collagen	NOUN	NN	3	O
III	III	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
53	53	NUM	CD	7	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
glomerular	glomerular	ADJ	JJ	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
smooth	smooth	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
actin	actin	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
74	74	NUM	CD	7	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
glomerular	glomerular	ADJ	JJ	5	O
desmin	desmin	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
48	48	NUM	CD	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Baseline	baseline	ADJ	JJ	9	O
renal	renal	NOUN	NN	9	O
ACE	ACE	PROPN	NNP	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
correlate	correlate	VERB	VB	9	O
with	with	ADP	IN	5	O
focal	focal	ADJ	JJ	5	B-Disease
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
22	22	NUM	CD	7	O
,	,	PUNCT	,	9	O
NS	NS	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
controls	control	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
predictive	predictive	ADJ	JJ	5	O
values	value	NOUN	NNS	5	O
for	for	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
parameters	parameter	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Individual	individual	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
ACE	ACE	PROPN	NNP	9	O
activity	activity	NOUN	NN	9	O
predict	predict	VERB	VBP	5	O
the	the	DET	DT	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
adriamycin	adriamycin	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
renal	renal	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
outbred	outbreed	VERB	VBN	9	O
rat	rat	NOUN	NN	3	O
strain	strain	NOUN	NN	1	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
supports	support	VERB	VBZ	9	O
the	the	DET	DT	5	O
assumption	assumption	NOUN	NN	5	O
that	that	ADP	IN	5	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
ACE	ACE	PROPN	NNP	9	O
activity	activity	NOUN	NN	9	O
predispose	predispose	NOUN	NN	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
less	less	ADV	RBR	5	O
favourable	favourable	ADJ	JJ	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Recurrent	recurrent	ADJ	JJ	5	O
acute	acute	ADJ	JJ	9	O
interstitial	interstitial	ADJ	JJ	9	B-Disease
nephritis	nephritis	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
azithromycin	azithromycin	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
14	14	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
girl	girl	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
reported	report	VERB	VBN	9	O
with	with	ADP	IN	5	O
recurrent	recurrent	NOUN	NN	5	O
,	,	PUNCT	,	9	O
azithromycin	azithromycin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
,	,	PUNCT	,	9	O
acute	acute	ADJ	JJ	9	O
interstitial	interstitial	ADJ	JJ	9	B-Disease
nephritis	nephritis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
episode	episode	NOUN	NN	5	O
was	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
severe	severe	ADJ	JJ	5	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
although	although	ADP	IN	9	O
both	both	DET	DT	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
intensive	intensive	ADJ	JJ	5	O
corticosteroid	corticosteroid	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
remained	remain	VERB	VBD	9	O
impaired	impaired	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
most	most	ADJ	JJS	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
antibiotic	antibiotic	ADJ	JJ	5	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	O
interstitial	interstitial	ADJ	JJ	9	B-Disease
nephritis	nephritis	NOUN	NN	9	I-Disease
are	be	VERB	VBP	5	O
benign	benign	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
self	self	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
limited	limit	VERB	VBN	5	O
,	,	PUNCT	,	9	O
some	some	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
at	at	ADP	IN	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
permanent	permanent	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Spironolactone	Spironolactone	PROPN	NNP	7	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
renal	renal	ADJ	JJ	9	B-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
hyperkalemia	hyperkalemia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
previous	previous	ADJ	JJ	9	O
randomized	randomize	VERB	VBN	5	O
controlled	control	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
evaluating	evaluate	VERB	VBG	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
spironolactone	spironolactone	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
patients	patient	NOUN	NNS	5	O
reported	report	VERB	VBD	9	O
a	a	DET	DT	5	O
low	low	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
hyperkalemia	hyperkalemia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
treatments	treatment	NOUN	NNS	9	O
for	for	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
have	have	VERB	VBP	5	O
changed	change	VERB	VBN	9	O
since	since	ADP	IN	9	O
the	the	DET	DT	5	O
benefits	benefit	NOUN	NNS	5	O
of	of	ADP	IN	5	O
spironolactone	spironolactone	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
complications	complication	NOUN	NNS	5	O
may	may	VERB	MD	5	O
differ	differ	VERB	VB	9	O
in	in	ADP	IN	5	O
current	current	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
practice	practice	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
therefore	therefore	ADV	RB	5	O
sought	seek	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
prevalence	prevalence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
associations	association	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hyperkalemia	hyperkalemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
spironolactone	spironolactone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
performed	perform	VERB	VBD	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
control	control	NOUN	NN	9	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
spironolactone	spironolactone	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
clinical	clinical	ADJ	JJ	5	O
practice	practice	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cases	case	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
hyperkalemia	hyperkalemia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
K	K	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
>	>	X	XX	0	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
mEq	mEq	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
Cr	Cr	PROPN	NNP	0	B-Chemical
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dL	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
they	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
randomly	randomly	ADV	RB	5	O
selected	select	VERB	VBN	9	O
controls	control	NOUN	NNS	9	O
per	per	ADP	IN	9	O
case	case	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
characteristics	characteristic	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
medications	medication	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
serum	serum	ADJ	JJ	9	O
chemistries	chemistry	NOUN	NNS	5	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
time	time	NOUN	NN	5	O
periods	period	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Sixty	sixty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
seven	seven	NUM	CD	9	O
of	of	ADP	IN	5	O
926	926	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
.	.	NOUN	NN	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
required	require	VERB	VBN	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
spironolactone	spironolactone	NOUN	NN	0	B-Chemical
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
hyperkalemia	hyperkalemia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
33	33	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
34	34	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
hyperkalemia	hyperkalemia	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
older	old	ADJ	JJR	5	O
and	and	CCONJ	CC	5	O
more	more	ADV	RBR	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
diabetes	diabete	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
had	have	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
baseline	baseline	NOUN	NN	5	O
serum	serum	ADJ	JJ	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
lower	low	ADJ	JJR	9	O
baseline	baseline	NOUN	NN	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
supplement	supplement	NOUN	NN	9	O
doses	dose	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blockers	blocker	NOUN	NNS	9	O
than	than	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
134	134	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
renal	renal	ADJ	JJ	9	B-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
had	have	VERB	VBD	9	O
lower	low	ADJ	JJR	9	O
baseline	baseline	NOUN	NN	5	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
higher	high	ADJ	JJR	9	O
baseline	baseline	NOUN	NN	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
required	require	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
loop	loop	NOUN	NN	9	O
diuretics	diuretic	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
thiazide	thiazide	NOUN	NN	5	B-Chemical
diuretics	diuretic	NOUN	NNS	5	O
than	than	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Spironolactone	Spironolactone	PROPN	NNP	7	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperkalemia	hyperkalemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
are	be	VERB	VBP	5	O
more	more	ADV	RBR	5	O
common	common	ADJ	JJ	5	O
in	in	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
clinical	clinical	ADJ	JJ	5	O
experience	experience	NOUN	NN	5	O
than	than	ADP	IN	5	O
reported	report	VERB	VBN	9	O
previously	previously	ADV	RB	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
difference	difference	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
explained	explain	VERB	VBN	5	O
by	by	ADP	IN	9	O
patient	patient	ADJ	JJ	5	O
comorbidities	comorbiditie	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
more	more	ADV	RBR	5	O
frequent	frequent	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blockers	blocker	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
reserpine	reserpine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
subchronic	subchronic	ADJ	JJ	0	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
treatments	treatment	NOUN	NNS	9	O
change	change	VERB	VBP	9	O
synaptosomal	synaptosomal	ADJ	JJ	3	O
brain	brain	NOUN	NN	5	O
glutamate	glutamate	VERB	VBP	0	B-Chemical
uptake	uptake	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
elicit	elicit	ADJ	JJ	9	O
orofacial	orofacial	ADJ	JJ	5	B-Disease
dyskinesia	dyskinesia	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Reserpine	reserpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	:	7	O
and	and	CCONJ	CC	5	O
haloperidol	haloperidol	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
orofacial	orofacial	ADJ	JJ	5	B-Disease
dyskinesia	dyskinesia	NOUN	NN	5	I-Disease
are	be	VERB	VBP	5	O
putative	putative	ADJ	JJ	1	O
animal	animal	NOUN	NN	5	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
tardive	tardive	ADJ	JJ	5	B-Disease
dyskinesia	dyskinesia	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
TD	TD	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
whose	whose	DET	WP$	9	O
pathophysiology	pathophysiology	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
free	free	ADJ	JJ	9	O
radical	radical	ADJ	JJ	0	O
generation	generation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
induced	induce	VERB	VBD	3	O
orofacial	orofacial	ADJ	JJ	5	B-Disease
dyskinesia	dyskinesia	NOUN	NN	5	I-Disease
by	by	ADP	IN	9	O
acute	acute	ADJ	JJ	9	O
reserpine	reserpine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
subchronic	subchronic	ADJ	JJ	0	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
administration	administration	NOUN	NN	9	O
to	to	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Reserpine	reserpine	NOUN	NN	0	B-Chemical
injection	injection	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
one	one	NUM	CD	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
s	s	PROPN	NNPS	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
every	every	DET	DT	5	O
other	other	ADJ	JJ	5	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
vacuous	vacuous	ADJ	JJ	5	O
chewing	chewing	NOUN	NN	5	O
,	,	PUNCT	,	9	O
tongue	tongue	NOUN	NN	5	O
protrusion	protrusion	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
facial	facial	ADJ	JJ	5	O
twitching	twitching	NOUN	NN	5	O
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Haloperidol	haloperidol	NOUN	NN	7	B-Chemical
administration	administration	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
one	one	NUM	CD	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
12	12	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
once	once	ADV	RB	5	O
a	a	DET	DT	5	O
week	week	NOUN	NN	9	O
s	s	NOUN	NN	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
caused	cause	VERB	VBD	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
vacuous	vacuous	ADJ	JJ	5	O
chewing	chewing	NOUN	NN	5	O
,	,	PUNCT	,	9	O
tongue	tongue	NOUN	NN	5	O
protrusion	protrusion	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
facial	facial	ADJ	JJ	5	O
twitching	twitch	VERB	VBG	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
four	four	NUM	CD	9	O
weekly	weekly	ADJ	JJ	5	O
evaluations	evaluation	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
the	the	DET	DT	5	O
treatments	treatment	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
behavioral	behavioral	ADJ	JJ	5	O
observation	observation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
glutamate	glutamate	VERB	VB	0	B-Chemical
uptake	uptake	NOUN	NN	0	O
by	by	ADP	IN	9	O
segments	segment	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
was	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
decreased	decrease	VERB	VBN	9	O
glutamate	glutamate	ADJ	JJ	0	B-Chemical
uptake	uptake	NOUN	NN	0	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
subcortical	subcortical	ADJ	JJ	5	O
parts	part	NOUN	NNS	5	O
of	of	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
reserpine	reserpine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Importantly	importantly	ADV	RB	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
glutamate	glutamate	ADJ	JJ	0	B-Chemical
uptake	uptake	NOUN	NN	0	O
correlates	correlate	NOUN	NNS	9	O
negatively	negatively	ADV	RB	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
orofacial	orofacial	ADJ	JJ	5	B-Disease
diskinesia	diskinesia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
early	early	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
glutamate	glutamate	ADJ	JJ	0	B-Chemical
transport	transport	NOUN	NN	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
vacuous	vacuous	ADJ	JJ	5	O
chewing	chew	VERB	VBG	5	O
movements	movement	NOUN	NNS	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Ceftriaxone	ceftriaxone	NOUN	NN	7	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
biliary	biliary	ADJ	JJ	5	B-Disease
pseudolithiasis	pseudolithiasis	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
paediatric	paediatric	ADJ	JJ	5	O
surgical	surgical	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
well	well	ADV	RB	9	O
known	know	VERB	VBN	9	O
that	that	ADP	IN	5	O
ceftriaxone	ceftriaxone	NOUN	NN	0	B-Chemical
leads	lead	VERB	VBZ	9	O
to	to	ADP	IN	5	O
pseudolithiasis	pseudolithiasis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
experimental	experimental	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
also	also	ADV	RB	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
situations	situation	NOUN	NNS	5	O
causing	cause	VERB	VBG	9	O
gallbladder	gallbladder	NOUN	NN	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
fasting	fast	VERB	VBG	9	O
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
role	role	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
pseudolithiasis	pseudolithiasis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
prospectively	prospectively	ADV	RB	5	O
evaluated	evaluate	VERB	VBD	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
importance	importance	NOUN	NN	5	O
of	of	ADP	IN	5	O
pseudolithiasis	pseudolithiasis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
paediatric	paediatric	ADJ	JJ	5	O
surgical	surgical	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
ceftriaxone	ceftriaxone	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
often	often	ADV	RB	5	O
had	have	VERB	VBD	9	O
to	to	PART	TO	5	O
fast	fast	VERB	VB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
operative	operative	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Fifty	fifty	NUM	CD	9	O
children	child	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
ceftriaxone	ceftriaxone	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
by	by	ADP	IN	9	O
serial	serial	ADJ	JJ	9	O
abdominal	abdominal	ADJ	JJ	5	O
sonograms	sonogram	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
those	those	DET	DT	5	O
,	,	PUNCT	,	9	O
13	13	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
26	26	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
developed	develop	VERB	VBD	5	O
biliary	biliary	ADJ	JJ	5	O
pathology	pathology	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Comparison	Comparison	PROPN	NNP	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
pseudolithiasis	pseudolithiasis	NOUN	NN	5	B-Disease
revealed	reveal	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
with	with	ADP	IN	5	O
respect	respect	NOUN	NN	9	O
to	to	ADP	IN	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
sex	sex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
starvation	starvation	NOUN	NN	9	O
variables	variable	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
pseudolithiasis	pseudolithiasis	NOUN	NN	5	B-Disease
resolved	resolve	VERB	VBD	9	O
spontaneously	spontaneously	ADV	RB	5	O
within	within	ADP	IN	9	O
a	a	DET	DT	5	O
short	short	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
pseudolithiasis	pseudolithiasis	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
fasting	fast	VERB	VBG	9	O
.	.	PUNCT	.	9	O

Coronary	coronary	ADJ	JJ	5	B-Disease
aneurysm	aneurysm	NOUN	NNS	5	I-Disease
after	after	ADP	IN	9	O
implantation	implantation	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
eluting	eluting	NOUN	NN	0	O
stent	stent	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Formation	formation	NOUN	NN	9	O
of	of	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
aneurysm	aneurysm	NOUN	NNS	5	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
stenting	stente	VERB	VBG	5	O
with	with	ADP	IN	5	O
bare	bare	ADJ	JJ	5	O
metal	metal	NOUN	NN	0	O
stents	stent	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
eluting	elute	VERB	VBG	0	O
stents	stent	NOUN	NNS	5	O
may	may	VERB	MD	5	O
induce	induce	VERB	VB	3	O
toxic	toxic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
vessel	vessel	NOUN	NN	5	O
wall	wall	NOUN	NN	5	O
with	with	ADP	IN	5	O
incomplete	incomplete	ADJ	JJ	9	O
stent	stent	NOUN	NN	5	O
apposition	apposition	NOUN	NN	5	O
,	,	PUNCT	,	9	O
aneurysm	aneurysm	NOUN	NNS	5	B-Disease
formation	formation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
potential	potential	NOUN	NN	9	O
of	of	ADP	IN	5	O
stent	stent	NOUN	NN	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
vessel	vessel	NOUN	NN	5	B-Disease
rupture	rupture	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
present	present	VERB	VBP	9	O
a	a	DET	DT	5	O
43	43	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
aneurysm	aneurysm	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
a	a	DET	DT	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
eluting	eluting	NOUN	NN	0	O
stent	stent	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
asymptomatic	asymptomatic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
aneurysm	aneurysm	NOUN	NNS	5	B-Disease
was	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
routine	routine	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Angiography	angiography	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
intracoronary	intracoronary	ADJ	JJ	5	O
ultrasound	ultrasound	NOUN	NN	5	O
demonstrated	demonstrate	VERB	VBD	9	O
lack	lack	NOUN	NN	9	O
of	of	ADP	IN	5	O
contact	contact	NOUN	NN	5	O
between	between	ADP	IN	5	O
stent	stent	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
vessel	vessel	ADJ	JJ	5	O
wall	wall	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
15	15	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
mm	mm	NOUN	NN	9	O
long	long	ADJ	JJ	5	O
segment	segment	NOUN	NN	9	O
with	with	ADP	IN	5	O
maximal	maximal	ADJ	JJ	9	O
aneurysm	aneurysm	NOUN	NNS	5	B-Disease
diameter	diameter	NOUN	NN	9	O
of	of	ADP	IN	5	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mm	mm	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
successfully	successfully	ADV	RB	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
graft	graft	NOUN	NN	5	O
stent	stent	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Causes	cause	NOUN	NNS	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
microangiopathy	microangiopathy	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
kidney	kidney	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Thrombotic	thrombotic	ADJ	JJ	5	B-Disease
microangiopathy	microangiopathy	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
known	know	VERB	VBN	9	O
problem	problem	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
following	follow	VERB	VBG	9	O
renal	renal	ADJ	JJ	9	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
postrenal	postrenal	ADJ	JJ	5	O
transplantation	transplantation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
microangiopathy	microangiopathy	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
often	often	ADV	RB	5	O
a	a	DET	DT	5	O
reflection	reflection	NOUN	NN	5	O
of	of	ADP	IN	5	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
uremic	uremic	ADJ	JJ	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
aimed	aim	VERB	VBD	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
causes	cause	NOUN	NNS	9	O
of	of	ADP	IN	5	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
microangiopathy	microangiopathy	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
population	population	NOUN	NN	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
transplantation	transplantation	NOUN	NN	9	O
recipients	recipient	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
discuss	discuss	VERB	VB	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

MATERIALS	material	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
causes	cause	NOUN	NNS	9	O
of	of	ADP	IN	5	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
microangiopathy	microangiopathy	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
a	a	DET	DT	5	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
from	from	ADP	IN	9	O
June	June	PROPN	NNP	2	O
2003	2003	NUM	CD	2	O
to	to	ADP	IN	5	O
June	June	PROPN	NNP	2	O
2004	2004	NUM	CD	2	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
King	King	PROPN	NNP	6	O
Fahad	Fahad	PROPN	NNP	2	O
National	National	PROPN	NNP	2	O
Guard	Guard	PROPN	NNP	2	O
Hospital	Hospital	PROPN	NNP	2	O
in	in	ADP	IN	5	O
Riyadh	Riyadh	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Saudi	Saudi	PROPN	NNP	4	O
Arabia	Arabia	PROPN	NNP	4	O
,	,	PUNCT	,	9	O
by	by	ADP	IN	9	O
reviewing	review	VERB	VBG	5	O
the	the	DET	DT	5	O
slides	slide	NOUN	NNS	9	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
transplant	transplant	NOUN	NN	9	O
biopsies	biopsy	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
25	25	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
performed	perform	VERB	VBN	9	O
during	during	ADP	IN	5	O
this	this	DET	DT	5	O
interval	interval	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Pre	Pre	PROPN	NNP	9	O
-	-	ADJ	JJ	7	O
and	and	CCONJ	CC	5	O
posttransplant	posttransplant	ADJ	JJ	5	O
crossmatching	crossmatching	NOUN	NN	5	O
was	be	VERB	VBD	9	O
done	do	VERB	VBN	9	O
when	when	ADV	WRB	5	O
possible	possible	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Five	five	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
microangiopathy	microangiopathy	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
cases	case	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
25	25	NUM	CD	9	O
transplantations	transplantation	NOUN	NNS	5	O
performed	perform	VERB	VBN	9	O
at	at	ADP	IN	9	O
King	King	PROPN	NNP	6	O
Fahad	Fahad	PROPN	NNP	2	O
National	National	PROPN	NNP	2	O
Guard	Guard	PROPN	NNP	2	O
Hospital	Hospital	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
2	2	NUM	CD	9	O
transplantations	transplantation	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
performed	perform	VERB	VBN	9	O
abroad	abroad	ADV	RB	5	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
referred	refer	VERB	VBN	5	O
to	to	ADP	IN	5	O
us	-PRON-	PRON	PRP	5	O
for	for	ADP	IN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
case	case	NOUN	NN	5	O
was	be	VERB	VBD	9	O
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
both	both	DET	DT	9	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
fifth	fifth	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
had	have	VERB	VBD	9	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
microangiopathy	microangiopathy	NOUN	NN	5	I-Disease
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
antiphospholipid	antiphospholipid	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	B-Disease
lupus	lupus	NOUN	NN	9	I-Disease
erythematosus	erythematosus	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
-	-	PUNCT	HYPH	7	O
frequent	frequent	ADJ	JJ	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
uremic	uremic	ADJ	JJ	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
following	follow	VERB	VBG	9	O
renal	renal	ADJ	JJ	9	O
transplantation	transplantation	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
recurrence	recurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
uremic	uremic	ADJ	JJ	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Other	other	ADJ	JJ	9	O
causes	cause	NOUN	NNS	9	O
include	include	VERB	VBP	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
procoagulant	procoagulant	ADJ	JJ	9	O
status	status	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
antibody	antibody	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
rejection	rejection	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
found	find	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
-	-	PUNCT	HYPH	7	O
frequent	frequent	ADJ	JJ	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
microangiopathy	microangiopathy	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
drug	drug	NOUN	NN	5	O
related	relate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
secondary	secondary	ADJ	JJ	9	O
mainly	mainly	ADV	RB	9	O
to	to	PART	TO	5	O
cyclosporine	cyclosporine	VERB	VB	0	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
microangiopathy	microangiopathy	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
percentage	percentage	NOUN	NN	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Comparison	comparison	NOUN	NN	9	O
of	of	ADP	IN	5	O
developmental	developmental	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
selective	selective	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
selective	selective	ADJ	JJ	9	O
cyclooxygenase	cyclooxygenase	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
inhibitors	inhibitor	NOUN	NNS	3	O
in	in	ADP	IN	5	O
CRL	CRL	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
(	(	PUNCT	-LRB-	9	O
WI	WI	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
WUBR	WUBR	PROPN	NNP	_	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
DFU	dfu	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
piroxicam	piroxicam	NOUN	NN	0	B-Chemical
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Cyclooxygenase	Cyclooxygenase	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
COX	COX	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
inhibitors	inhibitor	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
often	often	ADV	RB	5	O
ingested	ingested	ADJ	JJ	0	O
drugs	drug	NOUN	NNS	5	O
during	during	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Unlike	unlike	ADP	IN	9	O
general	general	ADJ	JJ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
data	datum	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
their	-PRON-	DET	PRP$	5	O
prenatal	prenatal	ADJ	JJ	5	O
toxic	toxic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
extensively	extensively	ADV	RB	9	O
studied	study	VERB	VBN	9	O
before	before	ADV	RB	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
experiment	experiment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
developmental	developmental	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
selective	selective	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
piroxicam	piroxicam	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
selective	selective	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
DFU	DFU	PROPN	NNP	5	B-Chemical
;	;	PUNCT	:	9	O
5	5	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
5	5	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dimethyl	dimethyl	ADV	RB	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorophenyl	fluorophenyl	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methylsulphonyl	methylsulphonyl	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
phenyl	phenyl	PROPN	NNP	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
5H	5H	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
furanon	furanon	NOUN	NN	_	I-Chemical
)	)	PUNCT	-RRB-	9	O
COX	COX	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
inhibitors	inhibitor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Drugs	drug	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
separately	separately	ADV	RB	9	O
,	,	PUNCT	,	9	O
orally	orally	ADV	RB	0	O
once	once	ADV	RB	5	O
daily	daily	ADV	RB	5	O
dosed	dose	VERB	VBD	0	O
to	to	ADP	IN	5	O
pregnant	pregnant	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
from	from	ADP	IN	9	O
day	day	NOUN	NN	9	O
8	8	NUM	CD	9	O
to	to	ADP	IN	5	O
21	21	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
GD1	GD1	PROPN	NNP	1	O
=	=	SYM	SYM	7	O
plug	plug	NOUN	NN	5	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Doses	dose	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
set	set	VERB	VBN	5	O
at	at	ADP	IN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
.	.	PUNCT	.	9	O
0mg	0mg	NOUN	NN	7	O
/	/	PUNCT	,	9	O
kg	kg	NOUN	NN	0	O
for	for	ADP	IN	5	O
piroxicam	piroxicam	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
and	and	CCONJ	CC	5	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O
0mg	0mg	NOUN	NN	7	O
/	/	PUNCT	,	9	O
kg	kg	NOUN	NN	0	O
for	for	ADP	IN	5	O
DFU	DFU	PROPN	NNP	5	B-Chemical
.	.	PUNCT	.	9	O

Fetuses	fetus	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
delivered	deliver	VERB	VBN	5	O
on	on	ADP	IN	5	O
GD	GD	PROPN	NNP	9	O
21	21	NUM	CD	7	O
and	and	CCONJ	CC	5	O
routinely	routinely	ADV	RB	9	O
examined	examine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Comprehensive	comprehensive	ADJ	JJ	2	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
developmental	developmental	ADJ	JJ	9	O
measurements	measurement	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
done	do	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pooled	pooled	ADJ	JJ	9	O
statistical	statistical	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
for	for	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
septal	septal	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	I-Disease
VSD	VSD	PROPN	NNP	5	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
and	and	CCONJ	CC	5	I-Disease
midline	midline	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	I-Disease
MD	MD	PROPN	NNP	9	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
defects	defect	NOUN	NNS	9	I-Disease
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
for	for	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
fetuses	fetus	NOUN	NNS	9	O
exposed	expose	VERB	VBN	9	O
to	to	PART	TO	5	O
piroxicam	piroxicam	VERB	VB	0	B-Chemical
,	,	PUNCT	,	9	O
selective	selective	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
selective	selective	ADJ	JJ	9	O
COX	COX	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
inhibitor	inhibitor	NOUN	NN	3	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
present	present	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
historic	historic	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Maternal	maternal	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
intrauterine	intrauterine	ADJ	JJ	5	B-Disease
growth	growth	NOUN	NN	3	I-Disease
retardation	retardation	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
increase	increase	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
external	external	ADJ	JJ	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
skeletal	skeletal	ADJ	JJ	9	I-Disease
variations	variation	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
highest	high	ADJ	JJS	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
piroxicam	piroxicam	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Decrease	decrease	NOUN	NN	9	O
of	of	ADP	IN	5	O
fetal	fetal	ADJ	JJ	9	O
length	length	NOUN	NN	9	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
only	only	ADJ	JJ	9	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
DFU	DFU	PROPN	NNP	5	B-Chemical
developmental	developmental	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
observed	observe	VERB	VBD	9	O
in	in	ADP	IN	5	O
pups	pup	NOUN	NNS	9	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
highest	high	ADJ	JJS	9	O
compound	compound	NOUN	NN	0	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Lack	lack	NOUN	NN	9	O
of	of	ADP	IN	5	O
teratogenicity	teratogenicity	NOUN	NN	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
piroxicam	piroxicam	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
DFU	DFU	PROPN	NNP	5	B-Chemical
-	-	PUNCT	HYPH	7	O
exposed	expose	VERB	VBN	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Prenatal	prenatal	ADJ	JJ	5	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
selective	selective	ADJ	JJ	9	O
COX	COX	PROPN	NNP	9	O
inhibitors	inhibitor	NOUN	NNS	3	O
increases	increase	VERB	VBZ	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
VSD	VSD	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
MD	MD	PROPN	NNP	9	O
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
historic	historic	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
with	with	ADP	IN	5	O
selective	selective	ADJ	JJ	9	O
COX	COX	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
inhibitors	inhibitor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Both	both	DET	DT	9	O
selective	selective	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
selective	selective	ADJ	JJ	9	O
COX	COX	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
inhibitors	inhibitor	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
toxic	toxic	ADJ	JJ	0	O
for	for	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
fetuses	fetus	NOUN	NNS	9	O
when	when	ADV	WRB	5	O
administered	administer	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
highest	high	ADJ	JJS	9	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Unlike	unlike	ADP	IN	9	O
DFU	DFU	PROPN	NNP	5	B-Chemical
,	,	PUNCT	,	9	O
piroxicam	piroxicam	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
highly	highly	ADV	RB	9	O
toxic	toxic	ADJ	JJ	0	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
dams	dam	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Prenatal	prenatal	ADJ	JJ	5	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
selective	selective	ADJ	JJ	9	O
COX	COX	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
inhibitors	inhibitor	NOUN	NNS	3	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
increase	increase	VERB	VB	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
septal	septal	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
midline	midline	ADJ	JJ	5	I-Disease
defects	defect	NOUN	NNS	9	I-Disease
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
selective	selective	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
historic	historic	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Lone	lone	ADJ	JJ	6	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
creatine	creatine	NOUN	NN	0	B-Chemical
monohydrate	monohydrate	ADJ	JJ	0	O
supplementation	supplementation	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Atrial	atrial	ADJ	JJ	7	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
young	young	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
without	without	ADP	IN	9	O
structural	structural	ADJ	JJ	9	O
heart	heart	NOUN	NN	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
rare	rare	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
population	population	NOUN	NN	5	O
,	,	PUNCT	,	9	O
reversible	reversible	ADJ	JJ	9	O
causes	cause	NOUN	NNS	9	O
must	must	VERB	MD	5	O
be	be	VERB	VB	5	O
identified	identify	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
resolved	resolve	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Thyroid	Thyroid	PROPN	NNP	9	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
illicit	illicit	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
stimulant	stimulant	NOUN	NN	5	O
use	use	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
acute	acute	ADJ	JJ	9	B-Disease
alcohol	alcohol	NOUN	NN	5	I-Disease
intoxication	intoxication	NOUN	NN	9	I-Disease
are	be	VERB	VBP	5	O
among	among	ADP	IN	5	O
these	these	DET	DT	5	O
causes	cause	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
30	30	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
Caucasian	caucasian	ADJ	JJ	9	O
man	man	NOUN	NN	5	O
who	who	PRON	WP	5	O
came	come	VERB	VBD	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
emergency	emergency	NOUN	NN	5	O
department	department	NOUN	NN	5	O
in	in	ADP	IN	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
rapid	rapid	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
.	.	PUNCT	.	9	O

His	-PRON-	DET	PRP$	9	O
medical	medical	ADJ	JJ	5	O
history	history	NOUN	NN	5	O
was	be	VERB	VBD	9	O
unremarkable	unremarkable	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
except	except	ADP	IN	9	O
for	for	ADP	IN	5	O
minor	minor	ADJ	JJ	9	O
fractures	fracture	NOUN	NNS	5	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
fingers	finger	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
foot	foot	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Thyroid	Thyroid	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
stimulating	stimulate	VERB	VBG	9	O
hormone	hormone	NOUN	NN	9	O
,	,	PUNCT	,	9	O
magnesium	magnesium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
within	within	ADP	IN	9	O
normal	normal	ADJ	JJ	9	O
limits	limit	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
urine	urine	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
screen	screen	NOUN	NN	5	O
was	be	VERB	VBD	9	O
negative	negative	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
was	be	VERB	VBD	9	O
denied	deny	VERB	VBN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
questioned	question	VERB	VBN	5	O
about	about	ADP	IN	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
herbal	herbal	ADJ	JJ	5	O
products	product	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
supplements	supplement	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
creatine	creatine	NOUN	NN	0	B-Chemical
monohydrate	monohydrate	NOUN	NN	0	O
was	be	VERB	VBD	9	O
revealed	reveal	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
hospital	hospital	NOUN	NN	5	O
,	,	PUNCT	,	9	O
anticoagulated	anticoagulate	VERB	VBN	5	O
with	with	ADP	IN	5	O
unfractionated	unfractionated	ADJ	JJ	9	O
heparin	heparin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
given	give	VERB	VBN	5	O
intravenous	intravenous	ADJ	JJ	0	O
diltiazem	diltiazem	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
rate	rate	NOUN	NN	9	O
control	control	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
intravenous	intravenous	ADJ	JJ	0	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
rhythm	rhythm	NOUN	NN	5	O
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
discharged	discharge	VERB	VBN	5	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
24	24	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
later	later	ADV	RB	9	O
,	,	PUNCT	,	9	O
he	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
receiving	receive	VERB	VBG	9	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
plans	plan	NOUN	NNS	5	O
for	for	ADP	IN	5	O
echocardiography	echocardiography	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
nuclear	nuclear	ADJ	JJ	3	O
imaging	imaging	NOUN	NN	5	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
perfusion	perfusion	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Exogenous	exogenous	ADJ	JJ	3	O
creatine	creatine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
used	use	VERB	VBN	5	O
by	by	ADP	IN	9	O
athletes	athlete	NOUN	NNS	5	O
to	to	PART	TO	5	O
theoretically	theoretically	ADV	RB	5	O
improve	improve	VERB	VB	5	O
exercise	exercise	NOUN	NN	5	O
performance	performance	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Vegetarians	Vegetarians	PROPN	NNPS	7	O
may	may	VERB	MD	5	O
also	also	ADV	RB	9	O
take	take	VERB	VB	5	O
creatine	creatine	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
replace	replace	VERB	VB	5	O
what	what	PRON	WP	5	O
they	-PRON-	PRON	PRP	5	O
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
consuming	consume	VERB	VBG	5	O
from	from	ADP	IN	9	O
meat	meat	NOUN	NN	5	O
,	,	PUNCT	,	9	O
fish	fish	NOUN	NN	4	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
animal	animal	NOUN	NN	5	O
products	product	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Previous	previous	ADJ	JJ	9	O
anecdotal	anecdotal	ADJ	JJ	5	O
reports	report	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
linked	link	VERB	VBN	9	O
creatine	creatine	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Clinicians	clinician	NOUN	NNS	5	O
must	must	VERB	MD	5	O
be	be	VERB	VB	5	O
diligent	diligent	ADJ	JJ	2	O
when	when	ADV	WRB	5	O
interviewing	interview	VERB	VBG	5	O
patients	patient	NOUN	NNS	5	O
about	about	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
drug	drug	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
histories	history	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
include	include	VERB	VBP	5	O
questions	question	NOUN	NNS	5	O
about	about	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
herbal	herbal	ADJ	JJ	5	O
products	product	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
dietary	dietary	ADJ	JJ	5	O
supplements	supplement	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
important	important	ADJ	JJ	9	O
to	to	PART	TO	5	O
report	report	VERB	VB	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
frequently	frequently	ADV	RB	5	O
consumed	consume	VERB	VBN	5	O
supplements	supplement	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
herbal	herbal	ADJ	JJ	5	O
products	product	NOUN	NNS	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
Food	Food	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
Drug	Drug	PROPN	NNP	5	O
Administration	Administration	PROPN	NNP	2	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Seizures	seizure	NOUN	NNS	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
metabolite	metabolite	ADJ	JJ	0	O
benzoylecgonine	benzoylecgonine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
half	half	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
life	life	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
t1	t1	NOUN	NN	9	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
is	be	VERB	VBZ	5	O
relatively	relatively	ADV	RB	5	O
short	short	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
some	some	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
consequences	consequence	NOUN	NNS	5	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
use	use	NOUN	NN	5	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
strokes	stroke	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
can	can	VERB	MD	5	O
occur	occur	VERB	VB	5	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
exposure	exposure	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
led	lead	VERB	VBD	9	O
us	-PRON-	PRON	PRP	5	O
to	to	PART	TO	5	O
hypothesize	hypothesize	VERB	VB	9	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
metabolite	metabolite	NOUN	NN	0	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
some	some	DET	DT	5	O
of	of	ADP	IN	5	O
those	those	DET	DT	5	O
delayed	delay	VERB	VBN	9	O
sequelae	sequelae	ADV	RB	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
evaluated	evaluate	VERB	VBD	9	O
the	the	DET	DT	5	O
potential	potential	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
major	major	ADJ	JJ	9	O
metabolite	metabolite	NOUN	NN	0	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
benzoylecgonine	benzoylecgonine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
BE	BE	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
separate	separate	ADJ	JJ	9	O
equimolar	equimolar	ADJ	JJ	0	O
doses	dose	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
mumol	mumol	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
either	either	DET	DT	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
or	or	CCONJ	CC	5	O
BE	be	VERB	VB	9	B-Chemical
were	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
ventricularly	ventricularly	ADV	RB	3	O
in	in	ADP	IN	5	O
unanesthetized	unanesthetized	ADJ	JJ	5	O
juvenile	juvenile	ADJ	JJ	4	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Treated	treated	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
then	then	ADV	RB	9	O
evaluated	evaluate	VERB	VBN	9	O
for	for	ADP	IN	5	O
incidence	incidence	NOUN	NN	5	O
,	,	PUNCT	,	9	O
latency	latency	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
seizure	seizure	VERB	VB	5	B-Disease
pattern	pattern	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
for	for	ADP	IN	5	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
without	without	ADP	IN	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

BE	be	VERB	VB	9	B-Chemical
-	-	PUNCT	HYPH	7	O
Induced	induced	ADJ	JJ	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
occurred	occur	VERB	VBD	9	O
more	more	ADV	RBR	5	O
frequently	frequently	ADV	RB	5	O
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
longer	long	ADJ	JJR	5	O
latencies	latency	NOUN	NNS	5	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
equimolar	equimolar	ADJ	JJ	0	O
amounts	amount	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Whereas	whereas	ADP	IN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
best	best	ADV	RB	5	O
characterized	characterize	VERB	VBN	9	O
as	as	ADP	IN	5	O
brief	brief	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
generalized	generalize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
tonic	tonic	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
death	death	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
those	those	DET	DT	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
BE	BE	PROPN	NNP	9	B-Chemical
were	be	VERB	VBD	9	O
prolonged	prolong	VERB	VBN	9	O
,	,	PUNCT	,	9	O
often	often	ADV	RB	5	O
multiple	multiple	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
mixed	mixed	ADJ	JJ	9	O
in	in	ADP	IN	5	O
type	type	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
rarely	rarely	ADV	RB	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
death	death	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Electrical	electrical	ADJ	JJ	5	O
recordings	recording	NOUN	NNS	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
rhythmic	rhythmic	ADJ	JJ	5	O
progression	progression	NOUN	NN	9	O
in	in	ADP	IN	5	O
EEG	EEG	PROPN	NNP	5	O
frequency	frequency	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
voltage	voltage	NOUN	NN	5	O
with	with	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
seizure	seizure	NOUN	NN	5	B-Disease
expression	expression	NOUN	NN	3	O
.	.	PUNCT	.	9	O

BE	be	VERB	VB	9	B-Chemical
-	-	PUNCT	HYPH	7	O
Injected	injected	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
that	that	DET	WDT	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
have	have	VERB	VB	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
had	have	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
more	more	ADJ	JJR	5	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
than	than	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
injected	inject	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
without	without	ADP	IN	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
finding	finding	NOUN	NN	9	O
that	that	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	:	7	O
and	and	CCONJ	CC	5	O
BE	be	ADV	RB	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
differ	differ	VERB	VBP	9	O
in	in	ADP	IN	5	O
several	several	ADJ	JJ	9	O
respects	respect	NOUN	NNS	5	O
suggests	suggest	VERB	VBZ	9	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
one	one	NUM	CD	5	O
mechanism	mechanism	NOUN	NN	9	O
for	for	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
emphasizes	emphasize	VERB	VBZ	5	O
the	the	DET	DT	5	O
importance	importance	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
metabolite	metabolite	NOUN	NN	0	O
,	,	PUNCT	,	9	O
BE	be	VERB	VB	9	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
HT6	ht6	NOUN	NN	1	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
Ro4368554	ro4368554	NOUN	NN	_	B-Chemical
restores	restore	VERB	VBZ	3	O
memory	memory	NOUN	NN	5	O
performance	performance	NOUN	NN	5	O
in	in	ADP	IN	5	O
cholinergic	cholinergic	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
serotonergic	serotonergic	NOUN	NN	5	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
memory	memory	NOUN	NN	5	B-Disease
deficiency	deficiency	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Antagonists	antagonist	NOUN	NNS	3	O
at	at	ADP	IN	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
type	type	NOUN	NN	9	O
6	6	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	ht	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
receptors	receptor	NOUN	NNS	3	O
show	show	VERB	VBP	9	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
learning	learning	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
memory	memory	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
the	the	DET	DT	5	O
underlying	underlie	VERB	VBG	5	O
mechanism	mechanism	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
s	s	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
well	well	ADV	RB	9	O
understood	understand	VERB	VBN	5	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
may	may	VERB	MD	5	O
involve	involve	VERB	VB	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
ACh	ACh	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
sought	seek	VERB	VBD	9	O
to	to	PART	TO	5	O
characterize	characterize	VERB	VB	9	O
the	the	DET	DT	5	O
cognitive	cognitive	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
enhancing	enhance	VERB	VBG	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
antagonist	antagonist	NOUN	NN	3	O
Ro4368554	Ro4368554	PROPN	NNP	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
benzenesulfonyl	benzenesulfonyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
7	7	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
piperazin	piperazin	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
yl	yl	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
1H	1h	ADJ	JJ	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
indole	indole	ADJ	JJ	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
rat	rat	NOUN	NN	3	O
object	object	NOUN	NN	5	O
recognition	recognition	NOUN	NN	5	O
task	task	NOUN	NN	5	O
employing	employ	VERB	VBG	9	O
a	a	DET	DT	5	O
cholinergic	cholinergic	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
serotonergic	serotonergic	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
(	(	PUNCT	-LRB-	9	O
tryptophan	tryptophan	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
TRP	trp	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
depletion	depletion	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
deficient	deficient	ADJ	JJ	3	O
model	model	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
compared	compare	VERB	VBD	9	O
its	-PRON-	DET	PRP$	9	O
pattern	pattern	NOUN	NN	9	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
with	with	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
acetylcholinesterase	acetylcholinesterase	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
metrifonate	metrifonate	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Initial	initial	ADJ	JJ	9	O
testing	testing	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
time	time	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
forgetting	forgetting	NOUN	NN	5	O
task	task	NOUN	NN	5	O
employing	employ	VERB	VBG	9	O
a	a	DET	DT	5	O
24	24	NUM	CD	9	O
-	-	SYM	SYM	7	O
h	h	NOUN	NN	0	O
delay	delay	NOUN	NN	5	O
between	between	ADP	IN	5	O
training	training	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
testing	testing	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
metrifonate	metrifonate	NOUN	NN	0	B-Chemical
improved	improve	VERB	VBN	5	O
object	object	NOUN	NN	5	O
recognition	recognition	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
at	at	ADP	IN	9	O
10	10	NUM	CD	9	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
Ro4368554	ro4368554	NOUN	NN	_	B-Chemical
was	be	VERB	VBD	9	O
inactive	inactive	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
,	,	PUNCT	,	9	O
Ro4368554	Ro4368554	PROPN	NNP	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
intraperitoneally	intraperitoneally	ADV	RB	0	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
metrifonate	metrifonate	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
reversed	reverse	VERB	VBN	9	O
memory	memory	NOUN	NN	5	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
TRP	trp	NOUN	NN	9	B-Chemical
depletion	depletion	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
Ro4368554	Ro4368554	PROPN	NNP	_	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
improve	improve	VERB	VB	5	O
a	a	DET	DT	5	O
time	time	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
retention	retention	NOUN	NN	9	O
deficit	deficit	NOUN	NN	5	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
reversed	reverse	VERB	VBD	9	O
a	a	DET	DT	5	O
cholinergic	cholinergic	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
serotonergic	serotonergic	ADJ	JJ	5	O
memory	memory	NOUN	NN	5	B-Disease
deficit	deficit	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
that	that	ADP	IN	5	O
both	both	DET	DT	9	O
mechanisms	mechanism	NOUN	NNS	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
facilitation	facilitation	NOUN	NN	5	O
of	of	ADP	IN	5	O
object	object	NOUN	NN	5	O
memory	memory	NOUN	NN	5	O
by	by	ADP	IN	9	O
Ro4368554	Ro4368554	PROPN	NNP	_	B-Chemical
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
possibly	possibly	ADV	RB	9	O
,	,	PUNCT	,	9	O
other	other	ADJ	JJ	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT	HT	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
receptor	receptor	NOUN	NN	3	O
antagonists	antagonist	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
anticocaine	anticocaine	ADJ	JJ	_	O
monoclonal	monoclonal	ADJ	JJ	3	O
antibody	antibody	NOUN	NN	3	O
GNC92H2	gnc92h2	NOUN	NN	_	B-Chemical
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
immunotherapy	immunotherapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Disease
overdose	overdose	NOUN	NN	0	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
illicit	illicit	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
continues	continue	VERB	VBZ	5	O
in	in	ADP	IN	5	O
epidemic	epidemic	NOUN	NN	5	O
proportions	proportion	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Disease
overdose	overdose	NOUN	NN	0	I-Disease
remains	remain	VERB	VBZ	9	O
elusive	elusive	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Current	current	ADJ	JJ	9	O
protein	protein	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
technology	technology	NOUN	NN	5	O
offers	offer	VERB	VBZ	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
venue	venue	NOUN	NN	5	O
by	by	ADP	IN	9	O
which	which	DET	WDT	5	O
antibodies	antibody	NOUN	NNS	3	O
bind	bind	VERB	VBP	1	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
stream	stream	NOUN	NN	5	O
,	,	PUNCT	,	9	O
inactivating	inactivate	VERB	VBG	9	O
its	-PRON-	DET	PRP$	9	O
toxic	toxic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
potential	potential	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
anticocaine	anticocaine	NOUN	NN	_	O
antibody	antibody	NOUN	NN	3	O
GNC92H2	gnc92h2	NOUN	NN	_	B-Chemical
was	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Disease
overdose	overdose	NOUN	NN	0	I-Disease
.	.	PUNCT	.	9	O

Swiss	swiss	ADJ	JJ	2	O
albino	albino	ADJ	JJ	3	O
mice	mouse	NOUN	NNS	3	O
prepared	prepare	VERB	VBN	0	O
with	with	ADP	IN	5	O
intrajugular	intrajugular	ADJ	JJ	0	O
catheters	catheter	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
in	in	ADP	IN	5	O
photocell	photocell	NOUN	NN	5	O
cages	cage	NOUN	NNS	5	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
93	93	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
LD50	LD50	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
GNC92H2	gnc92h2	NOUN	NN	_	B-Chemical
infusions	infusion	NOUN	NNS	9	O
ranging	range	VERB	VBG	9	O
from	from	ADP	IN	9	O
30	30	NUM	CD	9	O
to	to	ADP	IN	5	O
190	190	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

GNC92H2	gnc92h2	NOUN	NN	_	B-Chemical
was	be	VERB	VBD	9	O
delivered	deliver	VERB	VBN	5	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADV	RB	9	O
,	,	PUNCT	,	9	O
concomitantly	concomitantly	ADV	RB	9	O
or	or	CCONJ	CC	5	O
3	3	NUM	CD	9	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Significant	significant	ADJ	JJ	9	O
blockade	blockade	NOUN	NN	3	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
higher	high	ADJ	JJR	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
GNC92H2	GNC92H2	PROPN	NNP	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
190	190	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
where	where	ADV	WRB	5	O
premorbid	premorbid	ADJ	JJ	5	O
behaviors	behavior	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
seizures	seizure	VERB	VBZ	5	B-Disease
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
77	77	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
death	death	NOUN	NN	9	B-Disease
by	by	ADP	IN	9	O
72	72	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Importantly	importantly	ADV	RB	9	O
,	,	PUNCT	,	9	O
GNC92H2	GNC92H2	PROPN	NNP	_	B-Chemical
prevented	prevent	VERB	VBD	9	O
death	death	NOUN	NN	9	B-Disease
even	even	ADV	RB	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
cocaine	cocaine	ADJ	JJ	5	B-Chemical
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
support	support	VERB	VBP	5	O
the	the	DET	DT	5	O
important	important	ADJ	JJ	9	O
potential	potential	NOUN	NN	9	O
of	of	ADP	IN	5	O
GNC92H2	GNC92H2	PROPN	NNP	_	B-Chemical
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
tool	tool	NOUN	NN	5	O
against	against	ADP	IN	9	O
cocaine	cocaine	NOUN	NN	5	B-Disease
overdose	overdose	NOUN	NN	0	I-Disease
.	.	PUNCT	.	9	O

Electrocardiographic	electrocardiographic	ADJ	JJ	5	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
psychiatrically	psychiatrically	ADV	RB	5	O
hospitalized	hospitalize	VERB	VBN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
abusers	abuser	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
electrocardiograms	electrocardiogram	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
ECG	ECG	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
99	99	NUM	CD	7	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
abusing	abuse	VERB	VBG	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
ECGs	ecg	NOUN	NNS	5	O
of	of	ADP	IN	5	O
50	50	NUM	CD	0	O
schizophrenic	schizophrenic	ADJ	JJ	5	B-Disease
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Eleven	eleven	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
abusers	abuser	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
none	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
controls	control	NOUN	NNS	9	O
had	have	VERB	VBD	9	O
ECG	ECG	PROPN	NNP	5	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
defined	define	VERB	VBN	5	O
as	as	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
ischemia	ischemia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
bundle	bundle	NOUN	NN	5	B-Disease
branch	branch	NOUN	NN	5	I-Disease
block	block	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Behavioral	behavioral	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
urotensin	urotensin	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
II	II	PROPN	NNP	9	I-Chemical
centrally	centrally	ADV	RB	5	O
administered	administer	VERB	VBN	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Urotensin	Urotensin	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
II	II	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
U	U	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
II	II	PROPN	NNP	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
receptors	receptor	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
widely	widely	ADV	RB	5	O
distributed	distribute	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Intracerebroventricular	intracerebroventricular	ADJ	JJ	3	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
c	c	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
U	U	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
II	II	PROPN	NNP	9	I-Chemical
causes	cause	NOUN	NNS	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
stimulates	stimulate	VERB	VBZ	3	O
prolactin	prolactin	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
thyrotropin	thyrotropin	ADJ	JJ	9	O
secretion	secretion	NOUN	NN	3	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
behavioral	behavioral	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
centrally	centrally	ADV	RB	5	O
administered	administer	VERB	VBN	9	O
U	U	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
II	II	PROPN	NNP	9	I-Chemical
have	have	VERB	VBP	5	O
received	receive	VERB	VBN	9	O
little	little	ADJ	JJ	9	O
attention	attention	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
tested	test	VERB	VBD	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
c	c	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
U	U	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
II	II	PROPN	NNP	9	I-Chemical
on	on	ADP	IN	5	O
behavioral	behavioral	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
metabolic	metabolic	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
endocrine	endocrine	NOUN	NN	9	O
responses	response	NOUN	NNS	5	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
graded	graded	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
U	U	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
II	II	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
ng	ng	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
mouse	mouse	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
provoked	provoke	VERB	VBD	9	O
:	:	PUNCT	:	9	O
(	(	PUNCT	-LRB-	9	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
head	head	NOUN	NN	5	O
dips	dip	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hole	hole	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
board	board	NOUN	NN	5	O
test	test	NOUN	NN	5	O
;	;	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
entries	entry	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
white	white	ADJ	JJ	9	O
chamber	chamber	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
black	black	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
-	-	PUNCT	HYPH	7	O
white	white	ADJ	JJ	9	O
compartment	compartment	NOUN	NN	9	O
test	test	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
entries	entry	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
platform	platform	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
open	open	ADJ	JJ	5	O
arms	arm	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
plus	plus	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
maze	maze	NOUN	NN	5	O
test	test	NOUN	NN	5	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
(	(	PUNCT	-LRB-	9	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
immobility	immobility	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
forced	force	VERB	VBN	5	O
-	-	PUNCT	HYPH	7	O
swimming	swimming	NOUN	NN	5	O
test	test	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
tail	tail	NOUN	NN	9	O
suspension	suspension	NOUN	NN	0	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Intracerebroventricular	intracerebroventricular	ADJ	JJ	3	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
U	U	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
II	II	PROPN	NNP	9	I-Chemical
also	also	ADV	RB	9	O
caused	cause	VERB	VBD	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
:	:	PUNCT	:	9	O
food	food	NOUN	NN	5	O
intake	intake	NOUN	NN	5	O
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
100	100	NUM	CD	0	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
ng	ng	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
mouse	mouse	NOUN	NN	3	O
,	,	PUNCT	,	9	O
water	water	NOUN	NN	0	O
intake	intake	NOUN	NN	5	O
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
100	100	NUM	CD	0	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
ng	ng	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
mouse	mouse	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
horizontal	horizontal	ADJ	JJ	5	O
locomotion	locomotion	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
ng	ng	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
mouse	mouse	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Whatever	whatever	DET	WDT	5	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
U	U	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
II	II	PROPN	NNP	9	I-Chemical
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
body	body	NOUN	NN	5	O
temperature	temperature	NOUN	NN	0	O
,	,	PUNCT	,	9	O
nociception	nociception	NOUN	NN	5	O
,	,	PUNCT	,	9	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
penile	penile	NOUN	NN	5	B-Disease
erection	erection	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
climbing	climbing	NOUN	NN	5	O
behavior	behavior	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
stress	stress	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
plasma	plasma	NOUN	NN	9	O
corticosterone	corticosterone	NOUN	NN	3	B-Chemical
level	level	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Taken	take	VERB	VBN	9	O
together	together	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
demonstrates	demonstrate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
U	U	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
II	II	PROPN	NNP	9	I-Chemical
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
ng	ng	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
mouse	mouse	NOUN	NN	3	O
induces	induce	VERB	VBZ	3	O
anxiogenic	anxiogenic	ADJ	JJ	5	O
-	-	PUNCT	:	7	O
and	and	CCONJ	CC	5	O
depressant	depressant	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
mouse	mouse	NOUN	NN	3	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
U	U	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
II	II	PROPN	NNP	9	I-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
aspects	aspect	NOUN	NNS	5	O
of	of	ADP	IN	5	O
psychiatric	psychiatric	ADJ	JJ	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Learning	learning	NOUN	NN	5	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
under	under	ADP	IN	9	O
amnesia	amnesia	NOUN	NN	5	B-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
pentobarbital	pentobarbital	ADJ	JJ	0	B-Chemical
.	.	PUNCT	.	9	O

Dissociated	dissociate	VERB	VBN	3	O
learning	learning	NOUN	NN	5	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
state	state	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
state	state	NOUN	NN	5	O
of	of	ADP	IN	5	O
amnesia	amnesia	NOUN	NN	5	B-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
pentobarbital	pentobarbital	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
ip	ip	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
carried	carry	VERB	VBN	9	O
out	out	PART	RP	9	O
.	.	PUNCT	.	9	O

Rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
trained	train	VERB	VBN	5	O
to	to	PART	TO	5	O
approach	approach	VERB	VB	5	O
a	a	DET	DT	5	O
shelf	shelf	NOUN	NN	5	O
where	where	ADV	WRB	5	O
they	-PRON-	PRON	PRP	5	O
received	receive	VERB	VBD	9	O
food	food	NOUN	NN	5	O
reinforcement	reinforcement	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
Group	Group	PROPN	NNP	9	O
1	1	NUM	CD	9	O
the	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
trained	train	VERB	VBN	5	O
under	under	ADP	IN	9	O
the	the	DET	DT	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
pentobarbital	pentobarbital	ADJ	JJ	0	B-Chemical
to	to	PART	TO	5	O
run	run	VERB	VB	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
shelf	shelf	NOUN	NN	5	O
as	as	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
state	state	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
Group	Group	PROPN	NNP	9	O
2	2	NUM	CD	9	O
the	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
trained	train	VERB	VBN	5	O
to	to	PART	TO	5	O
approach	approach	VERB	VB	5	O
different	different	ADJ	JJ	9	O
shelves	shelf	NOUN	NNS	5	O
in	in	ADP	IN	5	O
different	different	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
states	state	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
shown	show	VERB	VBN	9	O
that	that	ADP	IN	5	O
memory	memory	NOUN	NN	5	B-Disease
dissociation	dissociation	NOUN	NN	9	I-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
parameters	parameter	NOUN	NNS	5	O
of	of	ADP	IN	5	O
training	training	NOUN	NN	5	O
under	under	ADP	IN	9	O
the	the	DET	DT	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
pentobarbital	pentobarbital	ADJ	JJ	0	B-Chemical
between	between	ADP	IN	5	O
Groups	Groups	PROPN	NNP	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
were	be	VERB	VBD	9	O
revealed	reveal	VERB	VBN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
dissociated	dissociate	VERB	VBN	3	O
state	state	NOUN	NN	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
pentobarbital	pentobarbital	ADJ	JJ	0	B-Chemical
is	be	VERB	VBZ	5	O
formed	form	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
participation	participation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
information	information	NOUN	NN	5	O
perception	perception	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
raloxifene	raloxifene	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
on	on	ADP	IN	5	O
fibrinolysis	fibrinolysis	NOUN	NN	5	O
markers	marker	NOUN	NNS	3	O
:	:	PUNCT	:	9	O
TAFI	tafi	NOUN	NN	9	O
,	,	PUNCT	,	9	O
tPA	tpa	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
PAI	PAI	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Markers	marker	NOUN	NNS	9	O
of	of	ADP	IN	5	O
fibrinolysis	fibrinolysis	NOUN	NN	5	O
,	,	PUNCT	,	9	O
thrombin	thrombin	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
activatable	activatable	ADJ	JJ	0	O
fibrinolysis	fibrinolysis	NOUN	NN	5	O
inhibitor	inhibitor	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
TAFI	TAFI	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
tissue	tissue	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
plasminogen	plasminogen	NOUN	NN	3	O
activator	activator	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
tPA	tpa	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
plasminogen	plasminogen	NOUN	NN	3	O
activator	activator	NOUN	NN	3	O
inhibitor	inhibitor	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
PAI	PAI	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
raloxifene	raloxifene	ADJ	JJ	0	B-Chemical
administration	administration	NOUN	NN	9	O
in	in	ADP	IN	5	O
postmenopausal	postmenopausal	NOUN	NN	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHODS	METHODS	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Thirty	thirty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
nine	nine	NUM	CD	9	O
postmenopausal	postmenopausal	NOUN	NN	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
osteopenia	osteopenia	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
osteoporosis	osteoporosis	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
prospective	prospective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
controlled	control	VERB	VBN	5	O
clinical	clinical	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
five	five	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
raloxifene	raloxifene	ADJ	JJ	0	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
60	60	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
plus	plus	CCONJ	CC	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Age	age	NOUN	NN	7	O
-	-	PUNCT	HYPH	7	O
matched	match	VERB	VBN	9	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
14	14	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
only	only	ADJ	JJ	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Plasma	plasma	ADJ	JJ	0	O
TAFI	tafi	NOUN	NN	9	O
,	,	PUNCT	,	9	O
tPA	tpa	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
PAI	PAI	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
antigen	antigen	NOUN	NN	3	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
by	by	ADP	IN	9	O
commercially	commercially	ADV	RB	0	O
available	available	ADJ	JJ	5	O
ELISA	ELISA	PROPN	NNP	3	O
kits	kit	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Variations	variation	NOUN	NNS	9	O
of	of	ADP	IN	5	O
individuals	individual	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
Wilcoxon	Wilcoxon	PROPN	NNP	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Relationship	relationship	NOUN	NN	9	O
between	between	ADP	IN	5	O
those	those	DET	DT	5	O
markers	marker	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
demographic	demographic	ADJ	JJ	5	O
characteristics	characteristic	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Three	three	NUM	CD	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
raloxifene	raloxifene	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
TAFI	TAFI	PROPN	NNP	9	O
antigen	antigen	NOUN	NN	3	O
concentrations	concentration	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
16	16	NUM	CD	9	O
%	%	NOUN	NN	9	O
change	change	NOUN	NN	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
tPA	tpa	NUM	CD	9	O
antigen	antigen	NOUN	NN	3	O
concentrations	concentration	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
change	change	NOUN	NN	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
correlation	correlation	NOUN	NN	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
between	between	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
TAFI	TAFI	PROPN	NNP	9	O
antigen	antigen	NOUN	NN	3	O
concentrations	concentration	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
amenorrhea	amenorrhea	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
;	;	PUNCT	:	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
33	33	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
thromboembolism	thromboembolism	NOUN	NN	5	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
raloxifene	raloxifene	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
tPA	tpa	NUM	CD	9	O
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
TAFI	tafi	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Valproate	valproate	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
encephalopathy	encephalopathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Valproate	valproate	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
syndrome	syndrome	NOUN	NN	5	O
that	that	DET	WDT	5	O
may	may	VERB	MD	5	O
manifest	manifest	VERB	VB	5	O
in	in	ADP	IN	5	O
otherwise	otherwise	ADV	RB	9	O
normal	normal	ADJ	JJ	9	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
individuals	individual	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
even	even	ADV	RB	5	O
present	present	VERB	VB	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
have	have	VERB	VBP	5	O
tolerated	tolerate	VERB	VBN	9	O
this	this	DET	DT	5	O
medicine	medicine	NOUN	NN	5	O
well	well	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
past	past	NOUN	NN	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
usually	usually	ADV	RB	5	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
necessarily	necessarily	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
hyperammonemia	hyperammonemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
EEG	EEG	PROPN	NNP	5	O
shows	show	VERB	VBZ	9	O
characteristic	characteristic	ADJ	JJ	9	O
triphasic	triphasic	NOUN	NN	5	O
waves	wave	NOUN	NNS	5	O
in	in	ADP	IN	5	O
most	most	ADJ	JJS	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
this	this	DET	DT	5	O
complication	complication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
valproate	valproate	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
is	be	VERB	VBZ	5	O
presented	present	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
problems	problem	NOUN	NNS	5	O
in	in	ADP	IN	5	O
diagnosing	diagnose	VERB	VBG	5	O
this	this	DET	DT	5	O
condition	condition	NOUN	NN	5	O
are	be	VERB	VBP	5	O
subsequently	subsequently	ADV	RB	9	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Recurrent	recurrent	ADJ	JJ	5	O
dysphonia	dysphonia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
acitretin	acitretin	ADJ	JJ	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
woman	woman	NOUN	NN	5	O
complaining	complain	VERB	VBG	5	O
of	of	ADP	IN	5	O
dysphonia	dysphonia	NOUN	NN	5	B-Disease
while	while	ADP	IN	9	O
she	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
by	by	ADP	IN	9	O
acitretin	acitretin	ADJ	JJ	0	B-Chemical
.	.	PUNCT	.	9	O

Her	-PRON-	DET	PRP$	5	O
symptoms	symptom	NOUN	NNS	5	O
totally	totally	ADV	RB	9	O
regressed	regress	VERB	VBN	5	O
after	after	ADP	IN	9	O
drug	drug	NOUN	NN	5	O
withdrawal	withdrawal	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
reappeared	reappear	VERB	VBD	9	O
when	when	ADV	WRB	5	O
acitretin	acitretin	ADJ	JJ	0	B-Chemical
was	be	VERB	VBD	9	O
reintroduced	reintroduce	VERB	VBN	9	O
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
knowledge	knowledge	NOUN	NN	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
acitretin	acitretin	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dysphonia	dysphonia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
pharmacological	pharmacological	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
on	on	ADP	IN	5	O
mucous	mucous	ADJ	JJ	5	O
membranes	membrane	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Nitro	Nitro	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
L	L	PROPN	NNP	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
ester	ester	NOUN	NN	0	I-Chemical
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
protector	protector	NOUN	NN	5	O
against	against	ADP	IN	9	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
ototoxicity	ototoxicity	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
NO	no	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
inhibitor	inhibitor	NOUN	NN	3	O
nitro	nitro	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
L	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
arginine	arginine	NOUN	NN	0	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
ester	ester	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
NAME	NAME	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
may	may	VERB	MD	5	O
act	act	VERB	VB	9	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
otoprotectant	otoprotectant	NOUN	NN	9	O
against	against	ADP	IN	9	O
high	high	ADJ	JJ	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
frequency	frequency	NOUN	NN	5	I-Disease
hearing	hearing	NOUN	NN	5	I-Disease
loss	loss	NOUN	NN	9	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
further	further	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
needed	need	VERB	VBN	5	O
to	to	PART	TO	5	O
confirm	confirm	VERB	VB	9	O
this	this	DET	DT	5	O
.	.	PUNCT	.	9	O
Aminoglycoside	Aminoglycoside	PROPN	NNP	0	B-Chemical
antibiotics	antibiotic	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
still	still	ADV	RB	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
by	by	ADP	IN	9	O
virtue	virtue	NOUN	NN	5	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
low	low	ADJ	JJ	9	O
cost	cost	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Their	-PRON-	DET	PRP$	5	O
ototoxicity	ototoxicity	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
serious	serious	ADJ	JJ	5	O
health	health	NOUN	NN	5	O
problem	problem	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
ototoxic	ototoxic	ADJ	JJ	5	B-Disease
mechanism	mechanism	NOUN	NN	9	O
involves	involve	VERB	VBZ	5	O
the	the	DET	DT	5	O
production	production	NOUN	NN	9	O
of	of	ADP	IN	5	O
NO	no	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
need	need	VERB	VBP	5	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
NO	no	DET	DT	9	B-Chemical
inhibitors	inhibitor	NOUN	NNS	3	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
aminoglycoside	aminoglycoside	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
sensorineural	sensorineural	ADJ	JJ	5	B-Disease
hearing	hearing	NOUN	NN	5	I-Disease
loss	loss	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
we	-PRON-	PRON	PRP	5	O
used	use	VERB	VBD	5	O
30	30	NUM	CD	9	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
27	27	NUM	CD	7	O
of	of	ADP	IN	5	O
which	which	DET	WDT	5	O
had	have	VERB	VBD	9	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
instilled	instill	VERB	VBN	9	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
middle	middle	ADJ	JJ	9	O
ear	ear	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
otoprotectant	otoprotectant	ADJ	JJ	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
NAME	NAME	PROPN	NNP	0	I-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
topically	topically	ADV	RB	0	O
to	to	ADP	IN	5	O
12	12	NUM	CD	9	O
/	/	SYM	SYM	9	O
27	27	NUM	CD	7	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Its	-PRON-	DET	PRP$	5	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
in	in	ADP	IN	5	O
terms	term	NOUN	NNS	5	O
of	of	ADP	IN	5	O
attenuation	attenuation	NOUN	NN	9	O
of	of	ADP	IN	5	O
hearing	hear	VERB	VBG	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
shifts	shift	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
auditory	auditory	NOUN	NN	5	O
brainstem	brainstem	NOUN	NN	5	O
response	response	NOUN	NN	9	O
threshold	threshold	NOUN	NN	5	O
.	.	PUNCT	.	9	O

L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
NAME	NAME	PROPN	NNP	0	I-Chemical
reduced	reduce	VERB	VBD	9	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hearing	hearing	NOUN	NN	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
frequency	frequency	NOUN	NN	5	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
gave	give	VERB	VBD	9	O
no	no	DET	DT	9	O
protection	protection	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
middle	middle	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
low	low	ADJ	JJ	9	O
frequencies	frequency	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Safety	safety	NOUN	NN	5	O
profile	profile	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
lozenge	lozenge	NOUN	NN	0	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
gum	gum	NOUN	NN	0	O
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
smokers	smoker	NOUN	NNS	5	O
with	with	ADP	IN	5	O
underlying	underlie	VERB	VBG	5	O
medical	medical	ADJ	JJ	5	O
conditions	condition	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
12	12	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
,	,	PUNCT	,	9	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
open	open	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
label	label	NOUN	NN	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Nicotine	nicotine	NOUN	NN	0	B-Chemical
polacrilex	polacrilex	NOUN	NN	5	O
lozenges	lozenge	NOUN	NNS	0	O
deliver	deliver	VERB	VBP	5	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
27	27	NUM	CD	7	O
%	%	NOUN	NN	9	O
more	more	ADJ	JJR	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
equivalent	equivalent	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
polacrilex	polacrilex	NOUN	NN	5	O
gum	gum	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
lozenge	lozenge	NOUN	NN	0	O
has	have	VERB	VBZ	9	O
raised	raise	VERB	VBN	9	O
questions	question	NOUN	NNS	5	O
about	about	ADP	IN	5	O
the	the	DET	DT	5	O
relative	relative	ADJ	JJ	9	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
lozenge	lozenge	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
gum	gum	NOUN	NN	0	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
objective	objective	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
compare	compare	VERB	VB	9	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
profiles	profile	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
mg	mg	NOUN	NN	0	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
lozenge	lozenge	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
mg	mg	NOUN	NN	0	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
gum	gum	NOUN	NN	0	O
in	in	ADP	IN	5	O
smokers	smoker	NOUN	NNS	5	O
with	with	ADP	IN	5	O
selected	select	VERB	VBN	9	O
label	label	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
restricted	restrict	VERB	VBN	9	O
diseases	disease	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
multicenter	multicenter	NOUN	NN	5	O
,	,	PUNCT	,	9	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
open	open	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
label	label	NOUN	NN	9	O
study	study	NOUN	NN	9	O
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
smokers	smoker	NOUN	NNS	5	O
with	with	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
not	not	ADV	RB	5	O
controlled	control	VERB	VBN	5	O
by	by	ADP	IN	9	O
medication	medication	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
diabetes	diabetes	NOUN	NN	5	B-Disease
mellitus	mellitus	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomized	randomize	VERB	VBN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
1	1	NUM	CD	9	O
:	:	SYM	SYM	9	O
1	1	NUM	CD	9	O
ratio	ratio	NOUN	NN	9	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
the	the	DET	DT	5	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
mg	mg	NOUN	NN	0	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
lozenge	lozenge	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
4	4	NUM	CD	9	O
-	-	SYM	SYM	7	O
mg	mg	NOUN	NN	0	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
gum	gum	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Safety	safety	NOUN	NN	5	O
assessments	assessment	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
made	make	VERB	VBN	5	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
6	6	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
12	12	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
start	start	NOUN	NN	9	O
of	of	ADP	IN	5	O
product	product	NOUN	NN	9	O
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Nine	nine	NUM	CD	9	O
hundred	hundred	NUM	CD	5	O
one	one	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomized	randomize	VERB	VBN	5	O
to	to	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
447	447	NUM	CD	7	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
the	the	DET	DT	5	O
lozenge	lozenge	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
454	454	NUM	CD	9	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
the	the	DET	DT	5	O
gum	gum	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
safety	safety	NOUN	NN	5	O
population	population	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
majority	majority	NOUN	NN	9	O
were	be	VERB	VBD	9	O
women	woman	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
52	52	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
'	'	PART	POS	9	O
mean	mean	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
was	be	VERB	VBD	9	O
53	53	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
their	-PRON-	DET	PRP$	5	O
mean	mean	ADJ	JJ	5	O
weight	weight	NOUN	NN	9	O
was	be	VERB	VBD	9	O
193	193	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
pounds	pound	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
they	-PRON-	PRON	PRP	5	O
smoked	smoke	VERB	VBD	5	O
a	a	DET	DT	5	O
mean	mean	NOUN	NN	5	O
of	of	ADP	IN	5	O
25	25	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
cigarettes	cigarette	NOUN	NNS	5	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
hundred	hundred	NUM	CD	5	O
fifty	fifty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
264	264	NUM	CD	7	O
taking	take	VERB	VBG	5	O
the	the	DET	DT	5	O
lozenge	lozenge	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
289	289	NUM	CD	7	O
taking	take	VERB	VBG	5	O
the	the	DET	DT	5	O
gum	gum	NOUN	NN	0	O
,	,	PUNCT	,	9	O
used	use	VERB	VBD	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
product	product	NOUN	NN	9	O
for	for	ADP	IN	5	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	NOUN	NNS	7	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
per	per	ADP	IN	9	O
week	week	NOUN	NN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
evaluable	evaluable	ADJ	JJ	9	O
population	population	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
lozenge	lozenge	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
gum	gum	NOUN	NN	0	O
were	be	VERB	VBD	9	O
equally	equally	ADV	RB	9	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
despite	despite	ADP	IN	9	O
increased	increase	VERB	VBN	9	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
lozenge	lozenge	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
2	2	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
product	product	NOUN	NN	9	O
use	use	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
evaluation	evaluation	NOUN	NN	5	O
population	population	NOUN	NN	5	O
:	:	PUNCT	:	9	O
55	55	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
lozenge	lozenge	NOUN	NN	0	O
,	,	PUNCT	,	9	O
54	54	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
gum	gum	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
entire	entire	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
safety	safety	NOUN	NN	5	O
population	population	NOUN	NN	5	O
:	:	PUNCT	:	9	O
63	63	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
58	58	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Stratification	stratification	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
by	by	ADP	IN	9	O
sex	sex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
concurrent	concurrent	ADJ	JJ	5	O
smoking	smoking	NOUN	NN	5	O
,	,	PUNCT	,	9	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
product	product	NOUN	NN	9	O
use	use	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
revealed	reveal	VERB	VBD	9	O
no	no	DET	DT	9	O
clinically	clinically	ADV	RB	5	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
lozenge	lozenge	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
gum	gum	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
nausea	nausea	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
16	16	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
to	to	ADP	IN	5	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
hiccups	hiccup	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
to	to	ADP	IN	5	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
headache	headache	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
Cl	Cl	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
.	.	NOUN	NN	9	O
0	0	NUM	CD	7	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Serious	serious	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
11	11	NUM	CD	7	O
and	and	CCONJ	CC	5	O
13	13	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
respective	respective	ADJ	JJ	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Fewer	few	ADJ	JJR	5	O
than	than	ADP	IN	5	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
either	either	DET	DT	9	O
group	group	NOUN	NN	9	O
were	be	VERB	VBD	9	O
considered	consider	VERB	VBN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
investigator	investigator	NOUN	NN	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
worsening	worsening	NOUN	NN	5	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
overall	overall	ADJ	JJ	5	O
disease	disease	NOUN	NN	5	O
condition	condition	NOUN	NN	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
majority	majority	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
60	60	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
experienced	experience	VERB	VBD	5	O
no	no	DET	DT	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
disease	disease	NOUN	NN	5	O
status	status	NOUN	NN	9	O
from	from	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
mg	mg	NOUN	NN	0	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
lozenge	lozenge	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
mg	mg	NOUN	NN	0	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
gum	gum	NOUN	NN	0	O
had	have	VERB	VBD	9	O
comparable	comparable	ADJ	JJ	9	O
safety	safety	NOUN	NN	5	O
profiles	profile	NOUN	NNS	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
label	label	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
restricted	restrict	VERB	VBN	9	O
medical	medical	ADJ	JJ	5	O
conditions	condition	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Pharmacological	pharmacological	ADJ	JJ	9	O
modulation	modulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
brain	brain	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
during	during	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
central	central	ADJ	JJ	5	O
sensitization	sensitization	NOUN	NN	9	O
states	state	NOUN	NNS	5	O
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Abnormal	abnormal	ADJ	JJ	9	O
processing	processing	NOUN	NN	5	O
of	of	ADP	IN	5	O
somatosensory	somatosensory	ADJ	JJ	5	O
inputs	input	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
central	central	ADJ	JJ	5	O
sensitization	sensitization	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
accounting	account	VERB	VBG	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
enhanced	enhance	VERB	VBN	3	O
pain	pain	NOUN	NN	5	B-Disease
sensitivity	sensitivity	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
skin	skin	NOUN	NN	5	O
surrounding	surround	VERB	VBG	9	O
tissue	tissue	NOUN	NN	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
secondary	secondary	ADJ	JJ	9	B-Disease
hyperalgesia	hyperalgesia	NOUN	NN	3	I-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Secondary	secondary	ADJ	JJ	9	B-Disease
hyperalgesia	hyperalgesia	NOUN	NN	3	I-Disease
shares	share	NOUN	NNS	9	O
clinical	clinical	ADJ	JJ	5	O
characteristics	characteristic	NOUN	NNS	5	O
with	with	ADP	IN	5	O
neurogenic	neurogenic	ADJ	JJ	5	B-Disease
hyperalgesia	hyperalgesia	NOUN	NN	3	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
neuropathic	neuropathic	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Abnormal	abnormal	ADJ	JJ	9	O
brain	brain	NOUN	NN	5	O
responses	response	NOUN	NNS	5	O
to	to	ADP	IN	5	O
somatosensory	somatosensory	ADJ	JJ	5	O
stimuli	stimulus	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
in	in	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
subjects	subject	NOUN	NNS	5	O
during	during	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
central	central	ADJ	JJ	5	O
sensitization	sensitization	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
gabapentin	gabapentin	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
drug	drug	NOUN	NN	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
neuropathic	neuropathic	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
processing	processing	NOUN	NN	5	O
of	of	ADP	IN	5	O
nociceptive	nociceptive	ADJ	JJ	5	O
information	information	NOUN	NN	5	O
in	in	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
central	central	ADJ	JJ	5	O
sensitization	sensitization	NOUN	NN	9	O
states	state	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Using	use	VERB	VBG	9	O
functional	functional	ADJ	JJ	9	O
magnetic	magnetic	ADJ	JJ	0	O
resonance	resonance	NOUN	NN	5	O
imaging	imaging	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
fMRI	fMRI	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
volunteers	volunteer	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
studied	study	VERB	VBD	9	O
the	the	DET	DT	5	O
gabapentin	gabapentin	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
modulation	modulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
nociceptive	nociceptive	ADJ	JJ	5	O
mechanical	mechanical	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
skin	skin	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
secondary	secondary	ADJ	JJ	9	B-Disease
hyperalgesia	hyperalgesia	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
gabapentin	gabapentin	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
800	800	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
per	per	ADP	IN	9	O
os	os	X	FW	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
found	find	VERB	VBD	9	O
that	that	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
i	i	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
gabapentin	gabapentin	NOUN	NN	5	B-Chemical
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
activations	activation	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
bilateral	bilateral	ADJ	JJ	5	O
operculoinsular	operculoinsular	ADJ	JJ	5	O
cortex	cortex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
independently	independently	ADV	RB	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
central	central	ADJ	JJ	5	O
sensitization	sensitization	NOUN	NN	9	O
;	;	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
ii	ii	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
gabapentin	gabapentin	NOUN	NN	5	B-Chemical
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
activation	activation	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
brainstem	brainstem	NOUN	NN	5	O
,	,	PUNCT	,	9	O
only	only	ADV	RB	9	O
during	during	ADP	IN	5	O
central	central	ADJ	JJ	5	O
sensitization	sensitization	NOUN	NN	9	O
;	;	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
iii	iii	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
gabapentin	gabapentin	NOUN	NN	5	B-Chemical
suppressed	suppress	VERB	VBD	3	O
stimulus	stimulus	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
deactivations	deactivation	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
only	only	ADV	RB	9	O
during	during	ADP	IN	5	O
central	central	ADJ	JJ	5	O
sensitization	sensitization	NOUN	NN	9	O
;	;	PUNCT	:	9	O
this	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
robust	robust	ADJ	JJ	5	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
activation	activation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
observed	observed	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
baseline	baseline	ADJ	JJ	5	O
fMRI	fMRI	PROPN	NNP	5	O
signal	signal	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
gabapentin	gabapentin	NOUN	NN	5	B-Chemical
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
measurable	measurable	ADJ	JJ	9	O
antinociceptive	antinociceptive	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
stronger	strong	ADJ	JJR	9	O
antihyperalgesic	antihyperalgesic	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
most	most	ADV	RBS	9	O
evident	evident	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
areas	area	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
deactivation	deactivation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
thus	thus	ADV	RB	9	O
supporting	support	VERB	VBG	9	O
the	the	DET	DT	5	O
concept	concept	NOUN	NN	5	O
that	that	ADP	IN	5	O
gabapentin	gabapentin	NOUN	NN	5	B-Chemical
is	be	VERB	VBZ	5	O
more	more	ADV	RBR	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
modulating	modulate	VERB	VBG	9	O
nociceptive	nociceptive	ADJ	JJ	5	O
transmission	transmission	NOUN	NN	5	O
when	when	ADV	WRB	5	O
central	central	ADJ	JJ	5	O
sensitization	sensitization	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
present	present	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Investigation	investigation	NOUN	NN	9	O
of	of	ADP	IN	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
involvement	involvement	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
several	several	ADJ	JJ	9	O
aspects	aspect	NOUN	NNS	5	O
of	of	ADP	IN	5	O
epileptogenesis	epileptogenesis	NOUN	NN	5	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
energy	energy	NOUN	NN	5	O
generation	generation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
control	control	NOUN	NN	9	O
of	of	ADP	IN	5	O
cell	cell	NOUN	NN	3	O
death	death	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
neurotransmitter	neurotransmitter	ADJ	JJ	9	O
synthesis	synthesis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
free	free	ADJ	JJ	9	O
radical	radical	ADJ	JJ	0	O
(	(	PUNCT	-LRB-	9	O
FR	FR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
production	production	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Increased	increased	ADJ	JJ	9	O
production	production	NOUN	NN	9	O
of	of	ADP	IN	5	O
FRs	fr	NOUN	NNS	5	O
may	may	VERB	MD	5	O
cause	cause	VERB	VB	5	O
mtDNA	mtdna	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
decreased	decreased	ADJ	JJ	9	O
activities	activity	NOUN	NNS	9	O
of	of	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
phosphorylation	phosphorylation	NOUN	NN	3	O
complexes	complex	NOUN	NNS	9	O
containing	contain	VERB	VBG	0	O
mtDNA	mtDNA	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
encoded	encode	VERB	VBN	1	O
subunits	subunit	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
investigated	investigate	VERB	VBD	9	O
whether	whether	ADP	IN	9	O
increased	increase	VERB	VBN	9	O
generation	generation	NOUN	NN	9	O
of	of	ADP	IN	5	O
FR	FR	PROPN	NNP	9	O
during	during	ADP	IN	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
would	would	VERB	MD	5	O
be	be	VERB	VB	5	O
sufficient	sufficient	ADJ	JJ	9	O
to	to	PART	TO	5	O
provoke	provoke	VERB	VB	9	O
abnormalities	abnormality	NOUN	NNS	9	O
in	in	ADP	IN	5	O
mtDNA	mtDNA	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
cytochrome	cytochrome	ADJ	JJ	0	O
c	c	DET	DT	9	O
oxidase	oxidase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
CCO	CCO	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
complex	complex	ADJ	JJ	9	O
IV	IV	PROPN	NNP	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
respiratory	respiratory	ADJ	JJ	5	O
chain	chain	NOUN	NN	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
chronic	chronic	ADJ	JJ	5	O
phase	phase	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
temporal	temporal	ADJ	JJ	5	B-Disease
lobe	lobe	NOUN	NN	5	I-Disease
epilepsy	epilepsy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

DNA	dna	NOUN	NN	9	O
analysis	analysis	NOUN	NN	9	O
revealed	reveal	VERB	VBD	9	O
low	low	ADJ	JJ	9	O
amounts	amount	NOUN	NNS	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
kb	kb	NOUN	NN	1	O
mtDNA	mtdna	ADJ	JJ	9	O
deletion	deletion	NOUN	NN	1	O
but	but	CCONJ	CC	9	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
frequency	frequency	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
quantity	quantity	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
experimental	experimental	ADJ	JJ	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
find	find	VERB	VB	5	O
abnormalities	abnormality	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
distribution	distribution	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
mtDNA	mtDNA	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
encoded	encode	VERB	VBN	1	O
subunit	subunit	NOUN	NN	1	O
of	of	ADP	IN	5	O
CCO	CCO	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
CCO	CCO	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
I	I	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
a	a	DET	DT	5	O
relative	relative	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
CCO	CCO	PROPN	NNP	5	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
nuclear	nuclear	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
encoded	encode	VERB	VBN	1	O
subunits	subunit	NOUN	NNS	1	O
(	(	PUNCT	-LRB-	9	O
CCO	CCO	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
IV	IV	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
SDH	SDH	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
fp	fp	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
abnormality	abnormality	NOUN	NN	9	O
in	in	ADP	IN	5	O
CCO	CCO	PROPN	NNP	5	O
activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
through	through	ADP	IN	9	O
histochemistry	histochemistry	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
evidences	evidence	NOUN	NNS	9	O
of	of	ADP	IN	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
previously	previously	ADV	RB	9	O
published	publish	VERB	VBN	9	O
studies	study	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
our	-PRON-	DET	PRP$	5	O
results	result	NOUN	NNS	9	O
do	do	VERB	VBP	5	O
not	not	ADV	RB	5	O
suggest	suggest	VERB	VB	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
FRs	fr	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
generated	generate	VERB	VBN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
phase	phase	NOUN	NN	5	O
,	,	PUNCT	,	9	O
determined	determine	VERB	VBD	9	O
important	important	ADJ	JJ	9	O
abnormalities	abnormality	NOUN	NNS	9	O
in	in	ADP	IN	5	O
mtDNA	mtDNA	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
CCO	CCO	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
I	I	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
CCO	CCO	PROPN	NNP	5	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blocker	blocker	NOUN	NN	0	O
nitrendipine	nitrendipine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
nephrosclerosis	nephrosclerosis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
renovascular	renovascular	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blocker	blocker	NOUN	NN	0	O
nitrendipine	nitrendipine	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
converting	convert	VERB	VBG	9	O
enzyme	enzyme	ADJ	JJ	0	O
inhibitor	inhibitor	NOUN	NN	3	O
enalapril	enalapril	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
albuminuria	albuminuria	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
renal	renal	ADJ	JJ	9	O
hemodynamics	hemodynamic	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
morphology	morphology	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
nonclipped	nonclipped	ADJ	JJ	9	O
kidney	kidney	NOUN	NN	9	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
two	two	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
kidney	kidney	NOUN	NN	9	O
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
clip	clip	NOUN	NN	5	O
renovascular	renovascular	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Six	six	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
clipping	clip	VERB	VBG	5	O
of	of	ADP	IN	5	O
one	one	NUM	CD	5	O
renal	renal	ADJ	JJ	9	O
artery	artery	NOUN	NN	5	O
,	,	PUNCT	,	9	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
178	178	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
assigned	assign	VERB	VBN	5	O
to	to	ADP	IN	5	O
three	three	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
untreated	untreated	ADJ	JJ	3	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
enalapril	enalapril	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
nitrendipine	nitrendipine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Sham	Sham	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
operated	operate	VERB	VBN	5	O
rats	rat	NOUN	NNS	9	O
served	serve	VERB	VBD	9	O
as	as	ADP	IN	5	O
normotensive	normotensive	ADJ	JJ	9	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
128	128	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
6	6	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
renal	renal	ADJ	JJ	9	O
hemodynamics	hemodynamic	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
glomerular	glomerular	ADJ	JJ	5	O
filtration	filtration	NOUN	NN	0	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
anesthetized	anesthetized	ADJ	JJ	0	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	O
tissue	tissue	NOUN	NN	9	O
was	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
for	for	ADP	IN	5	O
determination	determination	NOUN	NN	9	O
of	of	ADP	IN	5	O
glomerular	glomerular	ADJ	JJ	5	O
size	size	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
sclerosis	sclerosis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Enalapril	Enalapril	PROPN	NNP	0	B-Chemical
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
nitrendipine	nitrendipine	NOUN	NN	0	B-Chemical
reduced	reduce	VERB	VBD	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
significantly	significantly	ADV	RB	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
6	6	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
glomerular	glomerular	ADJ	JJ	5	O
filtration	filtration	NOUN	NN	0	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
different	different	ADJ	JJ	9	O
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
studied	study	VERB	VBN	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
increased	increase	VERB	VBD	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
albumin	albumin	NOUN	NN	0	O
excretion	excretion	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	B-Disease
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
change	change	VERB	VB	9	O
after	after	ADP	IN	9	O
enalapril	enalapril	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
nitrendipine	nitrendipine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
group	group	NOUN	NN	9	O
albuminuria	albuminuria	NOUN	NN	9	B-Disease
increased	increase	VERB	VBD	9	O
from	from	ADP	IN	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
progressively	progressively	ADV	RB	9	O
to	to	ADP	IN	5	O
163	163	NUM	CD	7	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
55	55	NUM	CD	7	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
19	19	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
9	9	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
24	24	NUM	CD	9	O
hr	hr	NOUN	NNS	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	B-Disease
index	index	NOUN	NN	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
nitrendipine	nitrendipine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
group	group	NOUN	NN	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
38	38	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
versus	versus	ADP	IN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
13	13	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
04	04	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
glomerular	glomerular	ADJ	JJ	5	O
size	size	NOUN	NN	9	O
was	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
nitrendipine	nitrendipine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
17	17	NUM	CD	7	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
mm2	mm2	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
but	but	CCONJ	CC	9	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
enalapril	enalapril	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
15	15	NUM	CD	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
mm2	mm2	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
17	17	NUM	CD	7	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
mm2	mm2	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
250	250	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

Ketoconazole	Ketoconazole	PROPN	NNP	0	B-Chemical
induced	induce	VERB	VBD	3	O
torsades	torsade	NOUN	NNS	5	B-Disease
de	de	X	FW	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
without	without	ADP	IN	9	O
concomitant	concomitant	ADJ	JJ	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
QT	QT	PROPN	NNP	5	O
interval	interval	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
prolonging	prolong	VERB	VBG	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Ketoconazole	Ketoconazole	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
proarrhythmic	proarrhythmic	ADJ	JJ	5	O
without	without	ADP	IN	9	O
concomitant	concomitant	ADJ	JJ	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
QT	QT	PROPN	NNP	5	O
interval	interval	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
prolonging	prolong	VERB	VBG	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
markedly	markedly	ADV	RB	9	O
prolonged	prolonged	ADJ	JJ	9	B-Disease
QT	QT	PROPN	NNP	5	I-Disease
interval	interval	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
torsades	torsade	NOUN	NNS	5	B-Disease
de	de	X	FW	2	I-Disease
pointes	pointe	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
TdP	tdp	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
taking	take	VERB	VBG	5	O
ketoconazole	ketoconazole	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
fungal	fungal	ADJ	JJ	4	B-Disease
infection	infection	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Her	-PRON-	DET	PRP$	5	O
QT	QT	PROPN	NNP	5	O
interval	interval	NOUN	NN	5	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
upon	upon	ADP	IN	9	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
ketoconazole	ketoconazole	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Genetic	genetic	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
find	find	VERB	VB	5	O
any	any	DET	DT	5	O
mutation	mutation	NOUN	NN	1	O
in	in	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
genes	gene	NOUN	NNS	1	O
that	that	DET	WDT	5	O
encode	encode	VERB	VBP	1	O
cardiac	cardiac	ADJ	JJ	5	O
IKr	ikr	NOUN	NN	5	O
channel	channel	NOUN	NN	9	O
proteins	protein	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
postulate	postulate	VERB	VBP	9	O
that	that	ADP	IN	5	O
by	by	ADP	IN	9	O
virtue	virtue	NOUN	NN	5	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
direct	direct	ADJ	JJ	9	O
blocking	blocking	NOUN	NN	3	O
action	action	NOUN	NN	5	O
on	on	ADP	IN	5	O
IKr	IKr	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
ketoconazole	ketoconazole	NOUN	NN	0	B-Chemical
alone	alone	ADV	RB	9	O
may	may	VERB	MD	5	O
prolong	prolong	VERB	VB	9	O
QT	QT	PROPN	NNP	5	O
interval	interval	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
induce	induce	VERB	VB	3	O
TdP	tdp	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
calls	call	VERB	VBZ	5	O
for	for	ADP	IN	5	O
attention	attention	NOUN	NN	5	O
when	when	ADV	WRB	5	O
ketoconazole	ketoconazole	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
administered	administer	VERB	VBN	9	O
to	to	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
for	for	ADP	IN	5	O
acquired	acquire	VERB	VBN	5	O
long	long	ADJ	JJ	5	B-Disease
QT	QT	PROPN	NNP	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Cerebral	cerebral	ADJ	JJ	5	B-Disease
vasculitis	vasculitis	NOUN	NN	5	I-Disease
following	follow	VERB	VBG	9	O
oral	oral	ADJ	JJ	9	O
methylphenidate	methylphenidate	NOUN	NN	5	B-Chemical
intake	intake	NOUN	NN	5	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
adult	adult	NOUN	NN	9	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Methylphenidate	Methylphenidate	PROPN	NNP	5	B-Chemical
is	be	VERB	VBZ	5	O
structurally	structurally	ADV	RB	9	O
and	and	CCONJ	CC	5	O
functionally	functionally	ADV	RB	9	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Cerebral	cerebral	ADJ	JJ	5	B-Disease
vasculitis	vasculitis	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Disease
abuse	abuse	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
well	well	ADV	RB	9	O
documented	document	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
rare	rare	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
ischaemic	ischaemic	ADJ	JJ	5	B-Disease
stroke	stroke	NOUN	NN	5	I-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
after	after	ADP	IN	9	O
methylphenidate	methylphenidate	ADJ	JJ	5	B-Chemical
intake	intake	NOUN	NN	5	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
63	63	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
female	female	NOUN	NN	9	O
who	who	PRON	WP	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
methylphenidate	methylphenidate	ADJ	JJ	5	B-Chemical
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
suffered	suffer	VERB	VBD	5	O
from	from	ADP	IN	9	O
multiple	multiple	ADJ	JJ	5	O
ischaemic	ischaemic	ADJ	JJ	5	B-Disease
strokes	stroke	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
consider	consider	VERB	VBP	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
vasculitis	vasculitis	NOUN	NN	5	I-Disease
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
likely	likely	ADJ	JJ	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
recurrent	recurrent	ADJ	JJ	5	O
ischaemic	ischaemic	ADJ	JJ	5	B-Disease
strokes	stroke	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
any	any	DET	DT	5	O
pathological	pathological	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
diagnostic	diagnostic	ADJ	JJ	5	O
work	work	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
methylphenidate	methylphenidate	ADJ	JJ	5	B-Chemical
mediated	mediate	VERB	VBN	3	O
vasculitis	vasculitis	NOUN	NN	5	B-Disease
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
neurological	neurological	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
methylphenidate	methylphenidate	ADJ	JJ	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effect	effect	NOUN	NN	9	O
,	,	PUNCT	,	9	O
though	though	ADP	IN	9	O
very	very	ADV	RB	5	O
rare	rare	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
represents	represent	VERB	VBZ	9	O
one	one	NUM	CD	5	O
more	more	ADJ	JJR	5	O
reason	reason	NOUN	NN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
very	very	ADV	RB	5	O
restrictive	restrictive	ADJ	JJ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
methylphenidate	methylphenidate	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

MDMA	MDMA	PROPN	NNP	5	B-Chemical
polydrug	polydrug	NOUN	NN	5	O
users	user	NOUN	NNS	5	O
show	show	VERB	VBP	9	O
process	process	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
specific	specific	ADJ	JJ	9	O
central	central	ADJ	JJ	5	O
executive	executive	ADJ	JJ	5	O
impairments	impairment	NOUN	NNS	5	O
coupled	couple	VERB	VBN	9	O
with	with	ADP	IN	5	O
impaired	impaired	ADJ	JJ	9	B-Disease
social	social	ADJ	JJ	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
emotional	emotional	ADJ	JJ	5	I-Disease
judgement	judgement	NOUN	NN	5	I-Disease
processes	process	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
recent	recent	ADJ	JJ	5	O
years	year	NOUN	NNS	5	O
working	work	VERB	VBG	5	O
memory	memory	NOUN	NN	5	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
users	user	NOUN	NNS	5	O
of	of	ADP	IN	5	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methylenedioxymethamphetamine	methylenedioxymethamphetamine	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
aimed	aim	VERB	VBN	5	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
impact	impact	NOUN	NN	5	O
of	of	ADP	IN	5	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
use	use	NOUN	NN	5	O
on	on	ADP	IN	5	O
three	three	NUM	CD	9	O
separate	separate	ADJ	JJ	9	O
central	central	ADJ	JJ	5	O
executive	executive	NOUN	NN	5	O
processes	process	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
set	set	VERB	VBN	5	O
shifting	shifting	NOUN	NN	5	O
,	,	PUNCT	,	9	O
inhibition	inhibition	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
memory	memory	NOUN	NN	5	O
updating	updating	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
also	also	ADV	RB	9	O
on	on	ADP	IN	5	O
"	"	PUNCT	``	5	O
prefrontal	prefrontal	ADJ	JJ	5	O
"	"	PUNCT	''	5	O
mediated	mediate	VERB	VBN	3	O
social	social	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
emotional	emotional	ADJ	JJ	5	O
judgement	judgement	NOUN	NN	5	O
processes	process	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Fifteen	fifteen	NUM	CD	9	O
polydrug	polydrug	ADJ	JJ	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
15	15	NUM	CD	9	O
polydrug	polydrug	ADJ	JJ	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
ecstasy	ecstasy	ADJ	JJ	5	B-Chemical
user	user	NOUN	NN	5	O
controls	control	NOUN	NNS	9	O
completed	complete	VERB	VBD	5	O
a	a	DET	DT	5	O
general	general	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
use	use	NOUN	NN	5	O
questionnaire	questionnaire	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
Brixton	Brixton	PROPN	NNP	5	O
Spatial	Spatial	PROPN	NNP	5	O
Anticipation	Anticipation	PROPN	NNP	5	O
task	task	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
set	set	NOUN	NN	5	O
shifting	shifting	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
Backward	Backward	PROPN	NNP	5	O
Digit	Digit	PROPN	NNP	5	O
Span	Span	PROPN	NNP	5	O
procedure	procedure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
memory	memory	NOUN	NN	5	O
updating	updating	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
Inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
Return	Return	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
inhibition	inhibition	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
emotional	emotional	ADJ	JJ	5	O
intelligence	intelligence	NOUN	NN	5	O
scale	scale	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
Tromso	Tromso	PROPN	NNP	2	O
Social	Social	PROPN	NNP	5	O
Intelligence	Intelligence	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
Dysexecutive	Dysexecutive	PROPN	NNP	5	O
Questionnaire	Questionnaire	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
DEX	DEX	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
polydrug	polydrug	NOUN	NN	5	O
controls	control	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
MDMA	MDMA	PROPN	NNP	5	B-Chemical
polydrug	polydrug	NOUN	NN	5	O
users	user	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
impairments	impairment	NOUN	NNS	5	O
in	in	ADP	IN	5	O
set	set	NOUN	NN	5	O
shifting	shifting	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
memory	memory	NOUN	NN	5	O
updating	updating	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
also	also	ADV	RB	9	O
in	in	ADP	IN	5	O
social	social	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
emotional	emotional	ADJ	JJ	5	O
judgement	judgement	NOUN	NN	5	O
processes	process	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
latter	latter	ADJ	JJ	9	O
two	two	NUM	CD	5	O
deficits	deficit	NOUN	NNS	5	O
remained	remain	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
after	after	ADP	IN	9	O
controlling	control	VERB	VBG	9	O
for	for	ADP	IN	5	O
other	other	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
lend	lend	VERB	VBP	5	O
further	further	ADJ	JJ	9	O
support	support	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
proposal	proposal	NOUN	NN	5	O
that	that	DET	WDT	5	O
cognitive	cognitive	ADJ	JJ	5	O
processes	process	NOUN	NNS	5	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
prefrontal	prefrontal	ADJ	JJ	5	O
cortex	cortex	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
impaired	impair	VERB	VBN	9	O
by	by	ADP	IN	9	O
recreational	recreational	ADJ	JJ	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Phase	phase	VERB	VB	9	O
II	II	PROPN	NNP	9	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
amsacrine	amsacrine	NOUN	NN	0	B-Chemical
analogue	analogue	NOUN	NN	0	O
CI	CI	PROPN	NNP	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
921	921	PROPN	NNP	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
NSC	NSC	PROPN	NNP	3	B-Chemical
343499	343499	NUM	CD	_	I-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
non	non	ADJ	JJ	9	B-Disease
-	-	ADJ	JJ	7	I-Disease
small	small	ADJ	JJ	9	I-Disease
cell	cell	NOUN	NN	3	I-Disease
lung	lung	NOUN	NN	9	I-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

CI	CI	PROPN	NNP	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
921	921	PROPN	NNP	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
NSC	NSC	PROPN	NNP	3	B-Chemical
343499	343499	NUM	CD	_	I-Chemical
;	;	PUNCT	:	9	O
9	9	NUM	CD	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methoxy	methoxy	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
methylsulphonyl	methylsulphonyl	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
amino	amino	NOUN	NN	1	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
phenyl	phenyl	NOUN	NN	0	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
amino	amino	NOUN	NN	1	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
N	n	NOUN	NN	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
5	5	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dimethyl	dimethyl	ADV	RB	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
acridinecarboxamide	acridinecarboxamide	NOUN	NN	_	I-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
topoisomerase	topoisomerase	NOUN	NN	1	O
II	ii	NUM	CD	9	O
poison	poison	NOUN	NN	9	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
experimental	experimental	ADJ	JJ	5	O
antitumour	antitumour	ADJ	JJ	3	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
by	by	ADP	IN	9	O
15	15	NUM	CD	9	O
min	min	NOUN	NN	0	O
infusion	infusion	NOUN	NN	0	O
to	to	ADP	IN	5	O
16	16	NUM	CD	9	O
evaluable	evaluable	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
non	non	ADJ	JJ	9	B-Disease
-	-	ADJ	JJ	7	I-Disease
small	small	ADJ	JJ	9	I-Disease
cell	cell	NOUN	NN	3	I-Disease
lung	lung	NOUN	NN	9	I-Disease
cancer	cancer	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
NSCLC	nsclc	NOUN	NN	3	B-Disease
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
prior	prior	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
9	9	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
relapse	relapse	NOUN	NN	5	O
following	follow	VERB	VBG	9	O
surgery	surgery	NOUN	NN	5	O
/	/	SYM	SYM	9	O
radiotherapy	radiotherapy	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
648	648	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NNS	7	O
divided	divide	VERB	VBD	5	O
over	over	ADP	IN	5	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
repeated	repeat	VERB	VBD	5	O
every	every	DET	DT	5	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
phase	phase	NOUN	NN	5	O
I	-PRON-	PRON	PRP	9	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
median	median	ADJ	JJ	9	O
performance	performance	NOUN	NN	5	O
status	status	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
WHO	who	PRON	WP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
median	median	ADJ	JJ	9	O
age	age	NOUN	NN	5	O
of	of	ADP	IN	5	O
61	61	NUM	CD	7	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
histology	histology	NOUN	NN	9	O
comprised	comprise	VERB	VBD	9	O
squamous	squamous	ADJ	JJ	5	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
adenocarcinoma	adenocarcinoma	NOUN	NN	3	B-Disease
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
mixed	mixed	ADJ	JJ	9	O
histology	histology	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
bronchio	bronchio	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
alveolar	alveolar	ADJ	JJ	3	I-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
large	large	ADJ	JJ	5	O
cell	cell	NOUN	NN	3	O
undifferentiated	undifferentiated	ADJ	JJ	3	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Neutropenia	Neutropenia	PROPN	NNP	7	B-Disease
grade	grade	NOUN	NN	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
or	or	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
was	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
15	15	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
infections	infection	NOUN	NNS	5	B-Disease
with	with	ADP	IN	5	O
recovery	recovery	NOUN	NN	9	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
grand	grand	ADJ	JJ	5	O
mal	mal	NOUN	NN	2	O
seizures	seizure	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Grade	grade	VERB	VB	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
or	or	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
nausea	nausea	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
vomiting	vomiting	NOUN	NN	5	B-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
66	66	NUM	CD	7	O
%	%	NOUN	NN	9	O
courses	course	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
phlebitis	phlebitis	VERB	VBP	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
infusion	infusion	NOUN	NN	0	O
arm	arm	NOUN	NN	5	O
in	in	ADP	IN	5	O
37	37	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

1	1	NUM	CD	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
squamous	squamous	ADJ	JJ	5	B-Disease
cell	cell	NOUN	NN	3	I-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
achieved	achieve	VERB	VBD	5	O
a	a	DET	DT	5	O
partial	partial	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
lasting	last	VERB	VBG	5	O
5	5	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
testing	testing	NOUN	NN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
tumour	tumour	NOUN	NN	3	B-Disease
types	type	NOUN	NNS	9	O
using	use	VERB	VBG	9	O
multiple	multiple	ADJ	JJ	5	O
daily	daily	ADJ	JJ	5	O
schedules	schedule	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
warranted	warrant	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Pharmacokinetics	pharmacokinetic	NOUN	NNS	0	O
of	of	ADP	IN	5	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
HCl	HCl	NOUN	NNS	0	I-Chemical
when	when	ADV	WRB	5	O
administered	administer	VERB	VBN	9	O
with	with	ADP	IN	5	O
cinacalcet	cinacalcet	NOUN	NN	0	B-Chemical
HCl	HCl	NOUN	NNS	0	I-Chemical
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
vitro	vitro	NOUN	NN	3	O
work	work	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
demonstrated	demonstrate	VERB	VBN	9	O
that	that	ADP	IN	5	O
cinacalcet	cinacalcet	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
strong	strong	ADJ	JJ	9	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
cytochrome	cytochrome	ADJ	JJ	0	O
P450	P450	PROPN	NNP	1	O
isoenzyme	isoenzyme	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
CYP	CYP	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
2D6	2d6	NUM	CD	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
cinacalcet	cinacalcet	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
CYP2D6	cyp2d6	NOUN	NN	9	O
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
using	use	VERB	VBG	9	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
probe	probe	NOUN	NN	9	O
substrate	substrate	NOUN	NN	0	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Seventeen	seventeen	NUM	CD	9	O
subjects	subject	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
genotyped	genotype	VERB	VBN	9	O
as	as	ADP	IN	5	O
CYP2D6	cyp2d6	NOUN	NN	9	O
extensive	extensive	ADJ	JJ	5	O
metabolizers	metabolizer	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
enrolled	enrol	VERB	VBN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
open	open	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
label	label	NOUN	NN	9	O
,	,	PUNCT	,	9	O
crossover	crossover	NOUN	NN	5	O
study	study	NOUN	NN	9	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
oral	oral	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
two	two	NUM	CD	5	O
separate	separate	ADJ	JJ	9	O
occasions	occasion	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
once	once	ADV	RB	5	O
alone	alone	ADV	RB	9	O
and	and	CCONJ	CC	5	O
once	once	ADV	RB	5	O
after	after	ADP	IN	9	O
multiple	multiple	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
cinacalcet	cinacalcet	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
90	90	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
for	for	ADP	IN	5	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Blood	blood	NOUN	NN	9	O
samples	sample	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
predose	predose	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
72	72	NUM	CD	9	O
h	h	NOUN	NN	0	O
postdose	postdose	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Fourteen	fourteen	NUM	CD	9	O
subjects	subject	NOUN	NNS	5	O
completed	complete	VERB	VBD	5	O
both	both	DET	DT	9	O
treatment	treatment	NOUN	NN	9	O
arms	arm	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Relative	relative	ADJ	JJ	9	O
to	to	PART	TO	5	O
desipramine	desipramine	VERB	VB	0	B-Chemical
alone	alone	ADV	RB	9	O
,	,	PUNCT	,	9	O
mean	mean	VERB	VB	5	O
AUC	AUC	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
C	C	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
max	max	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
increased	increase	VERB	VBD	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
-	-	ADV	RB	7	O
fold	fold	VERB	VB	9	O
when	when	ADV	WRB	5	O
coadministered	coadministere	VERB	VBN	0	O
with	with	ADP	IN	5	O
cinacalcet	cinacalcet	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
t	t	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
z	z	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
longer	long	ADJ	JJR	5	O
when	when	ADV	WRB	5	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
coadministered	coadministere	VERB	VBN	0	O
with	with	ADP	IN	5	O
cinacalcet	cinacalcet	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
21	21	NUM	CD	7	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
versus	versus	ADP	IN	9	O
43	43	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
hs	hs	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
t	t	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
max	max	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
regimens	regimen	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Fewer	few	ADJ	JJR	5	O
subjects	subject	NOUN	NNS	5	O
reported	report	VERB	VBD	9	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
following	follow	VERB	VBG	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
alone	alone	ADV	RB	9	O
than	than	ADP	IN	5	O
when	when	ADV	WRB	5	O
receiving	receive	VERB	VBG	9	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
cinacalcet	cinacalcet	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
33	33	NUM	CD	7	O
versus	versus	ADP	IN	9	O
86	86	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
frequent	frequent	ADJ	JJ	5	O
of	of	ADP	IN	5	O
which	which	DET	WDT	5	O
(	(	PUNCT	-LRB-	9	O
nausea	nausea	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
headache	headache	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
either	either	DET	DT	9	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
cinacalcet	cinacalcet	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
demonstrates	demonstrate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
cinacalcet	cinacalcet	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
strong	strong	ADJ	JJ	9	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
CYP2D6	CYP2D6	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
during	during	ADP	IN	5	O
concomitant	concomitant	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
cinacalcet	cinacalcet	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
dose	dose	NOUN	NN	9	O
adjustment	adjustment	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
necessary	necessary	ADJ	JJ	5	O
for	for	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
that	that	DET	WDT	5	O
demonstrate	demonstrate	VERB	VBP	9	O
a	a	DET	DT	5	O
narrow	narrow	ADJ	JJ	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
index	index	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
are	be	VERB	VBP	5	O
metabolized	metabolize	VERB	VBN	0	O
by	by	ADP	IN	9	O
CYP2D6	CYP2D6	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
:	:	PUNCT	:	9	O
acute	acute	ADJ	JJ	9	O
unintentional	unintentional	ADJ	JJ	5	O
carbachol	carbachol	NOUN	NN	0	B-Chemical
intoxication	intoxication	NOUN	NN	9	O
.	.	PUNCT	.	9	O

INTRODUCTION	introduction	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Intoxications	intoxication	NOUN	NNS	2	O
with	with	ADP	IN	5	O
carbachol	carbachol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
muscarinic	muscarinic	ADJ	JJ	3	O
cholinergic	cholinergic	NOUN	NN	3	O
receptor	receptor	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
are	be	VERB	VBP	5	O
rare	rare	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
an	an	DET	DT	5	O
interesting	interesting	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
investigating	investigate	VERB	VBG	5	O
a	a	DET	DT	5	O
(	(	PUNCT	-LRB-	9	O
near	near	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
fatal	fatal	ADJ	JJ	5	O
poisoning	poisoning	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
son	son	NOUN	NN	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
84	84	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
male	male	NOUN	NN	9	O
discovered	discover	VERB	VBD	9	O
a	a	DET	DT	5	O
newspaper	newspaper	NOUN	NN	5	O
report	report	NOUN	NN	5	O
stating	state	VERB	VBG	5	O
clinical	clinical	ADJ	JJ	5	O
success	success	NOUN	NN	5	O
with	with	ADP	IN	5	O
plant	plant	NOUN	NN	4	O
extracts	extract	NOUN	NNS	0	O
in	in	ADP	IN	5	O
Alzheimer	Alzheimer	PROPN	NNP	5	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mode	mode	NOUN	NN	5	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
was	be	VERB	VBD	9	O
said	say	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
comparable	comparable	ADJ	JJ	9	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
synthetic	synthetic	ADJ	JJ	0	O
compound	compound	NOUN	NN	0	O
'	'	PUNCT	``	9	O
carbamylcholin	carbamylcholin	NOUN	NN	_	B-Chemical
'	'	PUNCT	''	9	O
;	;	PUNCT	:	9	O
that	that	ADV	RB	5	O
is	is	ADV	RB	5	O
,	,	PUNCT	,	9	O
carbachol	carbachol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
bought	buy	VERB	VBD	5	O
25	25	NUM	CD	9	O
g	g	NOUN	NN	0	O
of	of	ADP	IN	5	O
carbachol	carbachol	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
pure	pure	ADJ	JJ	9	O
substance	substance	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
pharmacy	pharmacy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
father	father	NOUN	NN	5	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
400	400	NUM	CD	0	O
to	to	PART	TO	5	O
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Carbachol	carbachol	NOUN	NN	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
in	in	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
urine	urine	NOUN	NN	9	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
of	of	ADP	IN	5	O
hospital	hospital	NOUN	NN	5	O
admission	admission	NOUN	NN	5	O
were	be	VERB	VBD	9	O
analysed	analyse	VERB	VBN	9	O
by	by	ADP	IN	9	O
HPLC	HPLC	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
mass	mass	NOUN	NN	9	O
spectrometry	spectrometry	NOUN	NN	0	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Minutes	minute	NOUN	NNS	5	O
after	after	ADP	IN	9	O
oral	oral	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBN	5	O
nausea	nausea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
sweating	sweating	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
finally	finally	ADV	RB	9	O
collapsed	collapse	VERB	VBD	5	O
.	.	PUNCT	.	9	O

Bradycardia	Bradycardia	PROPN	NNP	7	B-Disease
,	,	PUNCT	,	9	O
cholinergic	cholinergic	NOUN	NN	3	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
asystole	asystole	ADV	RB	5	B-Disease
occurred	occur	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Initial	initial	ADJ	JJ	9	O
cardiopulmonary	cardiopulmonary	ADJ	JJ	5	O
resuscitation	resuscitation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
immediate	immediate	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
atropine	atropine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
furosemide	furosemide	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
successful	successful	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
hospital	hospital	NOUN	NN	5	O
admission	admission	NOUN	NN	5	O
,	,	PUNCT	,	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
intubated	intubate	VERB	VBN	5	O
,	,	PUNCT	,	9	O
bradyarrhythmic	bradyarrhythmic	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
100	100	NUM	CD	0	O
/	/	SYM	SYM	9	O
65	65	NUM	CD	7	O
mmHg	mmhg	NOUN	NN	7	O
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
signs	sign	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
hyperhidrosis	hyperhidrosis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
hypersalivation	hypersalivation	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
bronchorrhoea	bronchorrhoea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
severe	severe	ADJ	JJ	5	O
miosis	miosis	NOUN	NN	5	B-Disease
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
electrocardiographic	electrocardiographic	ADJ	JJ	5	O
finding	finding	NOUN	NN	9	O
was	be	VERB	VBD	9	O
atrio	atrio	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
ventricular	ventricular	ADJ	JJ	5	I-Disease
dissociation	dissociation	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
atropine	atropine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
per	per	ADP	IN	9	O
24	24	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
were	be	VERB	VBD	9	O
necessary	necessary	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
extubated	extubate	VERB	VBN	5	O
1	1	NUM	CD	9	O
week	week	NOUN	NN	9	O
later	later	ADV	RB	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
increased	increase	VERB	VBN	9	O
dyspnoea	dyspnoea	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
bronchospasm	bronchospasm	NOUN	NNS	5	B-Disease
necessitated	necessitated	ADJ	JJ	5	O
reintubation	reintubation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Respiratory	respiratory	ADJ	JJ	9	B-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
further	further	ADV	RB	9	O
worsened	worsen	VERB	VBN	5	O
by	by	ADP	IN	9	O
Proteus	Proteus	PROPN	NNP	4	B-Disease
mirabilis	mirabilis	ADJ	JJ	4	I-Disease
infection	infection	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
severe	severe	ADJ	JJ	5	O
bronchoconstriction	bronchoconstriction	NOUN	NN	5	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
week	week	NOUN	NN	9	O
later	later	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
again	again	ADV	RB	9	O
extubated	extubate	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
later	later	ADV	RB	9	O
was	be	VERB	VBD	9	O
transferred	transfer	VERB	VBN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
peripheral	peripheral	ADJ	JJ	9	O
ward	ward	NOUN	NN	5	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
next	next	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
he	-PRON-	PRON	PRP	5	O
died	die	VERB	VBD	9	O
,	,	PUNCT	,	9	O
probably	probably	ADV	RB	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Serum	serum	ADJ	JJ	9	O
samples	sample	NOUN	NNS	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
second	second	ADJ	JJ	9	O
days	day	NOUN	NNS	9	O
contained	contain	VERB	VBD	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
l	l	X	XX	0	O
carbachol	carbachol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
corresponding	correspond	VERB	VBG	9	O
urine	urine	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
amounted	amount	VERB	VBD	9	O
to	to	ADP	IN	5	O
374	374	NUM	CD	7	O
and	and	CCONJ	CC	5	O
554	554	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
l	l	NOUN	NN	0	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
started	start	VERB	VBD	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
media	media	NOUN	NN	9	O
report	report	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
popular	popular	ADJ	JJ	5	O
newspaper	newspaper	NOUN	NN	5	O
,	,	PUNCT	,	9	O
initiated	initiate	VERB	VBN	9	O
by	by	ADP	IN	9	O
published	publish	VERB	VBN	9	O
,	,	PUNCT	,	9	O
peer	peer	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
reviewed	review	VERB	VBN	9	O
research	research	NOUN	NN	5	O
on	on	ADP	IN	5	O
herbals	herbal	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
involved	involve	VERB	VBN	9	O
human	human	ADJ	JJ	3	O
failure	failure	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
history	history	NOUN	NN	5	O
,	,	PUNCT	,	9	O
medical	medical	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
analytical	analytical	ADJ	JJ	5	O
method	method	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
determination	determination	NOUN	NN	9	O
of	of	ADP	IN	5	O
carbachol	carbachol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
urine	urine	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
developed	develop	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
analysed	analysed	ADJ	JJ	9	O
carbachol	carbachol	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
exceeded	exceed	VERB	VBD	9	O
the	the	DET	DT	5	O
supposed	suppose	VERB	VBN	5	O
serum	serum	ADJ	JJ	9	O
level	level	NOUN	NN	9	O
resulting	result	VERB	VBG	9	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
factor	factor	NOUN	NN	9	O
of	of	ADP	IN	5	O
130	130	NUM	CD	9	O
to	to	ADP	IN	5	O
260	260	NUM	CD	9	O
.	.	PUNCT	.	9	O

Especially	especially	ADV	RB	9	O
in	in	ADP	IN	5	O
old	old	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
intensivists	intensivist	NOUN	NNS	5	O
should	should	VERB	MD	5	O
consider	consider	VERB	VB	5	O
intoxications	intoxication	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
with	with	ADP	IN	5	O
cholinergics	cholinergic	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
cardiovascular	cardiovascular	ADJ	JJ	5	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Pharmacological	pharmacological	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
potential	potential	NOUN	NN	9	O
of	of	ADP	IN	5	O
Daucus	Daucus	PROPN	NNP	4	O
carota	carota	NOUN	NN	4	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
dysfunctions	dysfunction	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
aimed	aim	VERB	VBN	5	O
at	at	ADP	IN	9	O
investigating	investigate	VERB	VBG	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
Daucus	Daucus	PROPN	NNP	4	O
carota	carota	NOUN	NN	4	O
seeds	seed	NOUN	NNS	4	O
on	on	ADP	IN	5	O
cognitive	cognitive	ADJ	JJ	5	O
functions	function	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
total	total	ADJ	JJ	9	O
serum	serum	ADJ	JJ	9	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
brain	brain	NOUN	NN	5	O
cholinesterase	cholinesterase	NOUN	NN	0	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
ethanolic	ethanolic	ADJ	JJ	0	O
extract	extract	NOUN	NN	0	B-Chemical
of	of	ADP	IN	5	I-Chemical
Daucus	Daucus	PROPN	NNP	4	I-Chemical
carota	carota	NOUN	NN	4	I-Chemical
seeds	seed	NOUN	NNS	4	I-Chemical
(	(	PUNCT	-LRB-	9	O
DCE	DCE	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
orally	orally	ADV	RB	0	O
in	in	ADP	IN	5	O
three	three	NUM	CD	9	O
doses	dose	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
,	,	PUNCT	,	9	O
200	200	NUM	CD	0	O
,	,	PUNCT	,	9	O
400	400	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
seven	seven	NUM	CD	9	O
successive	successive	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
to	to	ADP	IN	5	O
different	different	ADJ	JJ	9	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
young	young	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
aged	aged	ADJ	JJ	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Elevated	elevated	ADJ	JJ	9	O
plus	plus	CCONJ	CC	9	O
maze	maze	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
apparatus	apparatus	NOUN	NN	9	O
served	serve	VERB	VBD	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
exteroceptive	exteroceptive	ADJ	JJ	5	O
behavioral	behavioral	ADJ	JJ	5	O
models	model	NOUN	NNS	5	O
for	for	ADP	IN	5	O
testing	test	VERB	VBG	5	O
memory	memory	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Diazepam	diazepam	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
,	,	PUNCT	,	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	:	7	O
and	and	CCONJ	CC	5	O
ageing	age	VERB	VBG	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
amnesia	amnesia	NOUN	NN	5	B-Disease
served	serve	VERB	VBD	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
interoceptive	interoceptive	ADJ	JJ	5	O
behavioral	behavioral	ADJ	JJ	5	O
models	model	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

DCE	DCE	PROPN	NNP	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
200	200	NUM	CD	0	O
,	,	PUNCT	,	9	O
400	400	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
showed	show	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
memory	memory	NOUN	NN	5	O
scores	score	NOUN	NNS	5	O
of	of	ADP	IN	5	O
young	young	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
aged	aged	ADJ	JJ	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
memory	memory	NOUN	NN	5	O
improvement	improvement	NOUN	NN	5	O
evoked	evoke	VERB	VBN	5	O
by	by	ADP	IN	9	O
DCE	DCE	PROPN	NNP	5	B-Chemical
was	be	VERB	VBD	9	O
23	23	NUM	CD	7	O
%	%	NOUN	NN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
35	35	NUM	CD	9	O
%	%	NOUN	NN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
400	400	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
in	in	ADP	IN	5	O
young	young	ADJ	JJ	5	O
mice	mouse	NOUN	NNS	3	O
using	use	VERB	VBG	9	O
elevated	elevate	VERB	VBN	9	O
plus	plus	CCONJ	CC	9	O
maze	maze	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Similarly	similarly	ADV	RB	9	O
,	,	PUNCT	,	9	O
significant	significant	ADJ	JJ	9	O
improvements	improvement	NOUN	NNS	5	O
in	in	ADP	IN	5	O
memory	memory	NOUN	NN	5	O
scores	score	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
using	use	VERB	VBG	9	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
apparatus	apparatus	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
aged	aged	ADJ	JJ	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
DCE	DCE	PROPN	NNP	5	B-Chemical
reversed	reverse	VERB	VBD	9	O
the	the	DET	DT	5	O
amnesia	amnesia	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	NOUN	NN	9	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Daucus	daucus	NOUN	NN	4	B-Chemical
carota	carota	NOUN	NN	4	I-Chemical
extract	extract	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
200	200	NUM	CD	0	O
,	,	PUNCT	,	9	O
400	400	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
reduced	reduce	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
acetylcholinesterase	acetylcholinesterase	NOUN	NN	0	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
in	in	ADP	IN	5	O
young	young	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
aged	aged	ADJ	JJ	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
cholinesterase	cholinesterase	NOUN	NN	0	O
activity	activity	NOUN	NN	9	O
evoked	evoke	VERB	VBN	5	O
by	by	ADP	IN	9	O
DCE	DCE	PROPN	NNP	5	B-Chemical
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
400	400	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
was	be	VERB	VBD	9	O
22	22	NUM	CD	7	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
young	young	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
19	19	NUM	CD	7	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
aged	aged	ADJ	JJ	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
remarkable	remarkable	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
total	total	ADJ	JJ	9	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
,	,	PUNCT	,	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
23	23	NUM	CD	7	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
young	young	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
21	21	NUM	CD	7	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
aged	aged	ADJ	JJ	9	O
animals	animal	NOUN	NNS	9	O
with	with	ADP	IN	5	O
this	this	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
DCE	DCE	PROPN	NNP	5	B-Chemical
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
DCE	DCE	PROPN	NNP	5	B-Chemical
may	may	VERB	MD	5	O
prove	prove	VERB	VB	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
useful	useful	ADJ	JJ	5	O
remedy	remedy	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
dysfunctions	dysfunction	NOUN	NNS	5	I-Disease
on	on	ADP	IN	5	O
account	account	NOUN	NN	5	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
multifarious	multifarious	ADJ	JJ	5	O
beneficial	beneficial	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
,	,	PUNCT	,	9	O
memory	memory	NOUN	NN	5	O
improving	improve	VERB	VBG	5	O
property	property	NOUN	NN	5	O
,	,	PUNCT	,	9	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
lowering	lower	VERB	VBG	9	O
property	property	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
anticholinesterase	anticholinesterase	NOUN	NN	0	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Valproic	Valproic	PROPN	NNP	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
induced	induce	VERB	VBD	3	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
19	19	NUM	CD	7	O
new	new	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
in	in	ADP	IN	5	O
Germany	Germany	PROPN	NNP	2	O
from	from	ADP	IN	9	O
1994	1994	NUM	CD	2	O
to	to	ADP	IN	5	O
2003	2003	NUM	CD	2	O
-	-	PUNCT	:	7	O
-	-	PUNCT	:	7	O
a	a	DET	DT	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
associated	associate	VERB	VBN	9	O
to	to	ADP	IN	5	O
VPA	VPA	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
therapy	therapy	PROPN	NNP	5	O
not	not	ADV	RB	5	O
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
young	young	ADJ	JJ	5	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Valproic	Valproic	PROPN	NNP	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
VPA	VPA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
broad	broad	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
spectrum	spectrum	NOUN	NN	9	O
antiepileptic	antiepileptic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
is	be	VERB	VBZ	5	O
usually	usually	ADV	RB	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
tolerated	tolerate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Rare	rare	ADJ	JJ	9	O
serious	serious	ADJ	JJ	5	O
complications	complication	NOUN	NNS	5	O
may	may	VERB	MD	5	O
occur	occur	VERB	VB	5	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
haemorrhagic	haemorrhagic	ADJ	JJ	5	O
pancreatitis	pancreatitis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
bone	bone	NOUN	NN	5	B-Disease
marrow	marrow	NOUN	NN	3	I-Disease
suppression	suppression	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
VPA	VPA	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
VPA	VPA	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
encephalopathy	encephalopathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
typical	typical	ADJ	JJ	9	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
VPA	VPA	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
are	be	VERB	VBP	5	O
impaired	impaired	ADJ	JJ	9	B-Disease
consciousness	consciousness	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
sometimes	sometimes	ADV	RB	5	O
marked	mark	VERB	VBD	9	O
EEG	EEG	PROPN	NNP	5	O
background	background	NOUN	NN	9	O
slowing	slow	VERB	VBG	5	O
,	,	PUNCT	,	9	O
increased	increase	VERB	VBD	9	O
seizure	seizure	NOUN	NN	5	B-Disease
frequency	frequency	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
hyperammonemia	hyperammonemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
still	still	ADV	RB	5	O
no	no	DET	DT	9	O
proof	proof	NOUN	NN	5	O
of	of	ADP	IN	5	O
causative	causative	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
VPA	VPA	PROPN	NNP	9	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
only	only	ADV	RB	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
assumed	assume	VERB	VBN	5	O
causal	causal	ADJ	JJ	5	O
relation	relation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
19	19	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
VPA	VPA	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
in	in	ADP	IN	5	O
Germany	Germany	PROPN	NNP	2	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
years	year	NOUN	NNS	5	O
1994	1994	NUM	CD	2	O
to	to	ADP	IN	5	O
2003	2003	NUM	CD	2	O
,	,	PUNCT	,	9	O
none	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
whom	whom	PRON	WP	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
published	publish	VERB	VBN	9	O
previously	previously	ADV	RB	9	O
.	.	PUNCT	.	9	O

Cerebral	cerebral	ADJ	JJ	5	B-Disease
haemorrhage	haemorrhage	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
-	-	PUNCT	:	7	O
the	the	DET	DT	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
drug	drug	NOUN	NN	5	O
interactions	interaction	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
,	,	PUNCT	,	9	O
severity	severity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
preventability	preventability	NOUN	NN	5	O
of	of	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
haemorrhages	haemorrhage	NOUN	NNS	5	I-Disease
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
warfarin	warfarin	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
drug	drug	NOUN	NN	5	O
interactions	interaction	NOUN	NNS	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
living	live	VERB	VBG	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
county	county	NOUN	NN	5	O
of	of	ADP	IN	5	O
Osterg	Osterg	PROPN	NNP	_	O
tland	tland	NOUN	NN	9	O
,	,	PUNCT	,	9	O
Sweden	Sweden	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
diagnosed	diagnose	VERB	VBN	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
haemorrhage	haemorrhage	NOUN	NN	5	I-Disease
at	at	ADP	IN	9	O
three	three	NUM	CD	9	O
hospitals	hospital	NOUN	NNS	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
period	period	NOUN	NN	5	O
2000	2000	NUM	CD	9	O
-	-	SYM	SYM	7	O
2002	2002	NUM	CD	2	O
were	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Medical	medical	ADJ	JJ	2	O
records	record	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
retrospectively	retrospectively	ADV	RB	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
whether	whether	ADP	IN	9	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
drug	drug	NOUN	NN	5	O
interactions	interaction	NOUN	NNS	9	O
could	could	VERB	MD	9	O
have	have	VERB	VB	5	O
caused	cause	VERB	VBN	9	O
the	the	DET	DT	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
haemorrhage	haemorrhage	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
proportion	proportion	NOUN	NN	9	O
of	of	ADP	IN	5	O
possibly	possibly	ADV	RB	9	O
avoidable	avoidable	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
interactions	interaction	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
estimated	estimate	VERB	VBN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Among	among	ADP	IN	9	O
593	593	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
haemorrhage	haemorrhage	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
59	59	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
as	as	ADP	IN	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
imply	imply	VERB	VBP	9	O
an	an	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
/	/	SYM	SYM	9	O
100	100	NUM	CD	0	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
treatment	treatment	NOUN	NN	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
59	59	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
26	26	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
44	44	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
fatal	fatal	ADJ	JJ	5	O
outcome	outcome	NOUN	NN	5	O
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
136	136	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
warfarin	warfarin	ADJ	JJ	5	B-Chemical
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
warfarin	warfarin	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
drug	drug	NOUN	NN	5	O
interaction	interaction	NOUN	NN	9	O
could	could	VERB	MD	9	O
have	have	VERB	VB	5	O
contributed	contribute	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
haemorrhage	haemorrhage	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
24	24	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
41	41	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
7	7	NUM	CD	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
the	the	DET	DT	5	O
bleeding	bleed	VERB	VBG	5	B-Disease
complication	complication	NOUN	NN	5	O
was	be	VERB	VBD	9	O
considered	consider	VERB	VBN	5	O
being	be	VERB	VBG	5	O
possible	possible	ADJ	JJ	5	O
to	to	PART	TO	5	O
avoid	avoid	VERB	VB	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Warfarin	warfarin	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
haemorrhages	haemorrhage	NOUN	NNS	5	I-Disease
are	be	VERB	VBP	5	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
problem	problem	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
fatality	fatality	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Almost	almost	ADV	RB	5	O
half	half	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cases	case	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
warfarin	warfarin	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
drug	drug	NOUN	NN	5	O
interaction	interaction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
proportion	proportion	NOUN	NN	9	O
of	of	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
haemorrhages	haemorrhage	NOUN	NNS	5	I-Disease
might	may	VERB	MD	9	O
have	have	VERB	VB	5	O
been	be	VERB	VBN	9	O
prevented	prevent	VERB	VBN	9	O
if	if	ADP	IN	5	O
greater	great	ADJ	JJR	5	O
caution	caution	NOUN	NN	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
taken	take	VERB	VBN	5	O
when	when	ADV	WRB	5	O
prescribing	prescribe	VERB	VBG	5	O
drugs	drug	NOUN	NNS	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
interact	interact	VERB	VB	9	O
with	with	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Antipsychotic	antipsychotic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
profile	profile	NOUN	NN	9	O
of	of	ADP	IN	5	O
thioperamide	thioperamide	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
H3	H3	PROPN	NNP	1	O
-	-	PUNCT	HYPH	7	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Experimental	experimental	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
evidence	evidence	NOUN	NN	9	O
points	point	NOUN	NNS	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
central	central	ADJ	JJ	5	O
histaminergic	histaminergic	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
study	study	VERB	VB	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
histamine	histamine	NOUN	NN	0	B-Chemical
H	h	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
receptor	receptor	NOUN	NN	3	O
ligands	ligand	NOUN	NNS	3	O
on	on	ADP	IN	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
climbing	climbing	NOUN	NN	5	O
behavior	behavior	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
locomotor	locomotor	NOUN	NN	5	O
activities	activity	NOUN	NNS	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Catalepsy	Catalepsy	PROPN	NNP	0	B-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
s	s	PROPN	NNPS	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
s	s	PROPN	NNPS	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
studying	study	VERB	VBG	5	O
climbing	climb	VERB	VBG	5	O
behavior	behavior	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
locomotor	locomotor	NOUN	NN	5	O
activities	activity	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

(	(	PUNCT	-LRB-	9	B-Chemical
R	r	NOUN	NN	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
alpha	alpha	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methylhistamine	methylhistamine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
RAMH	RAMH	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
c	c	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
thioperamide	thioperamide	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
THP	THP	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
per	per	ADP	IN	9	O
se	se	X	FW	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
cause	cause	VERB	VB	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
THP	THP	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
75	75	NUM	CD	9	O
,	,	PUNCT	,	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
15	15	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
1	1	NUM	CD	9	O
h	h	NOUN	NN	0	O
prior	prior	ADV	RB	9	O
to	to	PART	TO	5	O
haloperidol	haloperidol	ADV	RB	5	B-Chemical
resulted	result	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
times	time	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
pretreatment	pretreatment	ADJ	JJ	0	O
with	with	ADP	IN	5	O
RAMH	RAMH	PROPN	NNP	3	B-Chemical
significantly	significantly	ADV	RB	9	O
reversed	reverse	VERB	VBD	9	O
such	such	DET	PDT	5	O
an	an	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
THP	THP	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

RAMH	ramh	VERB	VB	3	B-Chemical
per	per	ADP	IN	9	O
se	se	X	FW	9	O
showed	show	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
locomotor	locomotor	NOUN	NN	5	O
time	time	NOUN	NN	5	O
,	,	PUNCT	,	9	O
distance	distance	NOUN	NN	5	O
traveled	travel	VERB	VBD	5	O
and	and	CCONJ	CC	5	O
average	average	ADJ	JJ	5	O
speed	speed	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
THP	THP	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
per	per	X	FW	9	O
se	se	X	FW	9	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
these	these	DET	DT	5	O
parameters	parameter	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
THP	THP	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
75	75	NUM	CD	9	O
and	and	CCONJ	CC	5	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
reduced	reduce	VERB	VBN	9	O
locomotor	locomotor	NOUN	NN	5	O
time	time	NOUN	NN	5	O
,	,	PUNCT	,	9	O
distance	distance	NOUN	NN	5	O
traveled	travel	VERB	VBD	5	O
and	and	CCONJ	CC	5	O
average	average	ADJ	JJ	5	O
speed	speed	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Pretreatment	pretreatment	NOUN	NN	3	O
with	with	ADP	IN	5	O
RAMH	RAMH	PROPN	NNP	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
c	c	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
could	could	VERB	MD	9	O
partially	partially	ADV	RB	9	O
reverse	reverse	VERB	VB	9	O
such	such	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
THP	THP	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
75	75	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Climbing	climb	VERB	VBG	5	O
behavior	behavior	NOUN	NN	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
THP	THP	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Such	such	DET	PDT	5	O
an	an	DET	DT	5	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
reversed	reverse	VERB	VBN	9	O
in	in	ADP	IN	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
RAMH	RAMH	PROPN	NNP	3	B-Chemical
.	.	PUNCT	.	9	O

THP	THP	PROPN	NNP	0	B-Chemical
exhibited	exhibit	VERB	VBD	9	O
an	an	DET	DT	5	O
antipsychotic	antipsychotic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
profile	profile	NOUN	NN	9	O
by	by	ADP	IN	9	O
potentiating	potentiate	VERB	VBG	3	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
reducing	reduce	VERB	VBG	9	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
reducing	reduce	VERB	VBG	9	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
climbing	climbing	NOUN	NN	5	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Such	such	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
THP	THP	PROPN	NNP	0	B-Chemical
were	be	VERB	VBD	9	O
reversed	reverse	VERB	VBN	9	O
by	by	ADP	IN	9	O
RAMH	RAMH	PROPN	NNP	3	B-Chemical
indicating	indicate	VERB	VBG	9	O
the	the	DET	DT	5	O
involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
histamine	histamine	NOUN	NN	0	B-Chemical
H	h	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Findings	finding	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
a	a	DET	DT	5	O
potential	potential	NOUN	NN	9	O
for	for	ADP	IN	5	O
H	h	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
receptor	receptor	NOUN	NN	3	O
antagonists	antagonist	NOUN	NNS	3	O
in	in	ADP	IN	5	O
improving	improve	VERB	VBG	5	O
the	the	DET	DT	5	O
refractory	refractory	ADJ	JJ	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Cauda	Cauda	PROPN	NNP	7	B-Disease
equina	equina	VERB	VBD	4	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
epidural	epidural	ADJ	JJ	5	O
steroid	steroid	NOUN	NN	9	B-Chemical
injection	injection	NOUN	NN	9	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Conventional	conventional	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
methods	method	NOUN	NNS	5	O
of	of	ADP	IN	5	O
lumbusacral	lumbusacral	ADJ	JJ	_	O
radiculopathy	radiculopathy	NOUN	NN	5	B-Disease
are	be	VERB	VBP	5	O
physical	physical	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
epidural	epidural	ADJ	JJ	5	O
steroid	steroid	NOUN	NN	9	B-Chemical
injections	injection	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
oral	oral	ADJ	JJ	9	O
medications	medication	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
spinal	spinal	ADJ	JJ	5	O
manipulative	manipulative	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cauda	Cauda	PROPN	NNP	7	B-Disease
equina	equina	NOUN	NN	4	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
epidural	epidural	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
following	follow	VERB	VBG	9	O
case	case	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
cauda	cauda	NOUN	NN	9	B-Disease
equina	equina	NOUN	NN	4	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
possibly	possibly	ADV	RB	9	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
epidural	epidural	ADJ	JJ	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
triamcinolone	triamcinolone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

CLINICAL	CLINICAL	PROPN	NNP	2	O
FEATURES	FEATURES	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
50	50	NUM	CD	0	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
low	low	ADJ	JJ	9	B-Disease
back	back	ADV	RB	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
right	right	ADJ	JJ	5	I-Disease
leg	leg	NOUN	NN	5	I-Disease
pain	pain	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
scheduled	schedule	VERB	VBN	5	O
for	for	ADP	IN	5	O
epidural	epidural	ADJ	JJ	5	O
steroid	steroid	NOUN	NN	9	B-Chemical
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

INTERVENTION	INTERVENTION	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
OUTCOME	OUTCOME	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
An	an	DET	DT	5	O
18	18	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
gauge	gauge	NOUN	NN	5	O
Touhy	Touhy	PROPN	NNP	5	O
needle	needle	NOUN	NN	5	O
was	be	VERB	VBD	9	O
inserted	insert	VERB	VBN	9	O
until	until	ADP	IN	5	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
resistance	resistance	NOUN	NN	9	O
occurred	occur	VERB	VBD	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
L4	L4	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
level	level	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Spread	Spread	PROPN	NNP	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
contrast	contrast	NOUN	NN	9	O
medium	medium	NOUN	NN	0	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
epidural	epidural	ADJ	JJ	5	O
space	space	NOUN	NN	5	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
radiographic	radiographic	ADJ	JJ	5	O
imaging	imaging	NOUN	NN	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
verifying	verify	VERB	VBG	9	O
the	the	DET	DT	5	O
epidural	epidural	ADJ	JJ	5	O
space	space	NOUN	NN	5	O
,	,	PUNCT	,	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
triamcinolone	triamcinolone	ADJ	JJ	0	B-Chemical
diacetate	diacetate	NOUN	NN	0	I-Chemical
were	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
the	the	DET	DT	5	O
injection	injection	NOUN	NN	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
radicular	radicular	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
later	later	ADV	RB	9	O
,	,	PUNCT	,	9	O
she	-PRON-	PRON	PRP	5	O
complained	complain	VERB	VBD	5	O
of	of	ADP	IN	5	O
perineal	perineal	ADJ	JJ	5	O
numbness	numbness	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
lower	low	ADJ	JJR	9	B-Disease
extremity	extremity	NOUN	NN	5	I-Disease
weakness	weakness	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
neurologic	neurologic	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
loss	loss	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
sensation	sensation	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
saddle	saddle	NOUN	NN	5	O
area	area	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
medial	medial	ADJ	JJ	5	O
aspect	aspect	NOUN	NN	5	O
of	of	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
right	right	ADJ	JJ	5	O
leg	leg	NOUN	NN	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
perception	perception	NOUN	NN	5	O
of	of	ADP	IN	5	O
pinprick	pinprick	NOUN	NN	5	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Deep	deep	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
tendon	tendon	NOUN	NN	5	O
reflexes	reflex	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
especially	especially	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	ADJ	JJ	5	O
leg	leg	NOUN	NN	5	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
unable	unable	ADJ	JJ	9	O
to	to	PART	TO	5	O
urinate	urinate	VERB	VB	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
symptoms	symptom	NOUN	NNS	5	O
improved	improve	VERB	VBD	5	O
slightly	slightly	ADV	RB	9	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
next	next	ADJ	JJ	9	O
few	few	ADJ	JJ	5	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
gradual	gradual	ADJ	JJ	9	O
return	return	NOUN	NN	5	O
of	of	ADP	IN	5	O
motor	motor	NOUN	NN	5	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
ability	ability	NOUN	NN	9	O
of	of	ADP	IN	5	O
feeling	feel	VERB	VBG	5	O
Foley	Foley	PROPN	NNP	6	O
catheter	catheter	NOUN	NN	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
completely	completely	ADV	RB	9	O
resolved	resolve	VERB	VBN	9	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
next	next	ADJ	JJ	9	O
8	8	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Complications	complication	NOUN	NNS	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
epidural	epidural	ADJ	JJ	5	O
steroid	steroid	NOUN	NN	9	B-Chemical
injections	injection	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
rare	rare	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
continued	continue	VERB	VBN	9	O
vigilance	vigilance	NOUN	NN	5	O
for	for	ADP	IN	5	O
neurologic	neurologic	ADJ	JJ	5	B-Disease
deterioration	deterioration	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
epidural	epidural	ADJ	JJ	5	O
steroid	steroid	NOUN	NN	9	B-Chemical
injections	injection	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
important	important	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
atherosclerosis	atherosclerosis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
postmenopausal	postmenopausal	NOUN	NN	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
study	study	VERB	VB	9	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
androgen	androgen	NOUN	NN	3	O
treatment	treatment	NOUN	NN	9	O
on	on	ADP	IN	5	O
atherosclerosis	atherosclerosis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
postmenopausal	postmenopausal	NOUN	NN	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
a	a	DET	DT	5	O
population	population	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
study	study	NOUN	NN	9	O
in	in	ADP	IN	5	O
513	513	NUM	CD	7	O
naturally	naturally	ADV	RB	9	O
postmenopausal	postmenopausal	VERB	VB	5	O
women	woman	NOUN	NNS	5	O
aged	age	VERB	VBN	9	O
54	54	NUM	CD	7	O
-	-	SYM	SYM	7	O
67	67	NUM	CD	7	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
studied	study	VERB	VBD	9	O
the	the	DET	DT	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
self	self	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
reported	report	VERB	VBN	9	O
intramuscularly	intramuscularly	ADV	RB	0	O
administered	administer	VERB	VBN	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
estradiol	estradiol	NOUN	NN	0	B-Chemical
-	-	PUNCT	,	7	I-Chemical
and	and	CCONJ	CC	5	I-Chemical
testosterone	testosterone	NOUN	NN	9	I-Chemical
esters	ester	NOUN	NNS	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
aortic	aortic	ADJ	JJ	9	O
atherosclerosis	atherosclerosis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Aortic	aortic	ADJ	JJ	9	O
atherosclerosis	atherosclerosis	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
diagnosed	diagnose	VERB	VBN	5	O
by	by	ADP	IN	9	O
radiographic	radiographic	ADJ	JJ	5	O
detection	detection	NOUN	NN	9	O
of	of	ADP	IN	5	O
calcified	calcify	VERB	VBN	5	O
deposits	deposit	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
abdominal	abdominal	ADJ	JJ	5	O
aorta	aorta	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
reflect	reflect	VERB	VB	5	O
intima	intima	ADV	RB	5	O
atherosclerosis	atherosclerosis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Hormone	hormone	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
users	user	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
never	never	ADV	RB	5	O
users	user	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Intramuscular	intramuscular	ADJ	JJ	0	O
hormone	hormone	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
use	use	NOUN	NN	5	O
for	for	ADP	IN	5	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
longer	longer	ADV	RBR	5	O
was	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
by	by	ADP	IN	9	O
25	25	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
almost	almost	ADV	RB	9	O
half	half	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
women	woman	NOUN	NNS	5	O
severe	severe	VERB	VBD	5	O
atherosclerosis	atherosclerosis	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
aorta	aorta	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
present	present	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
11	11	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
without	without	ADP	IN	9	O
hormone	hormone	NOUN	NN	9	O
use	use	VERB	VBP	5	O
severe	severe	ADJ	JJ	5	O
atherosclerosis	atherosclerosis	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
aorta	aorta	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
adjusted	adjust	VERB	VBN	9	O
for	for	ADP	IN	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
years	year	NOUN	NNS	5	O
since	since	ADP	IN	9	O
menopause	menopause	NOUN	NN	5	O
,	,	PUNCT	,	9	O
smoking	smoking	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
body	body	NOUN	NN	5	O
mass	mass	NOUN	NN	9	O
index	index	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
association	association	NOUN	NN	9	O
remained	remain	VERB	VBD	9	O
after	after	ADP	IN	9	O
additional	additional	ADJ	JJ	9	O
adjustment	adjustment	NOUN	NN	5	O
for	for	ADP	IN	5	O
diabetes	diabetes	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
,	,	PUNCT	,	9	O
systolic	systolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
association	association	NOUN	NN	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
for	for	ADP	IN	5	O
hormone	hormone	NOUN	NN	9	O
use	use	NOUN	NN	5	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
may	may	VERB	MD	5	O
adversely	adversely	ADV	RB	5	O
affect	affect	VERB	VB	9	O
atherosclerosis	atherosclerosis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
postmenopausal	postmenopausal	NOUN	NN	5	O
women	woman	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
androgen	androgen	NOUN	NN	3	O
replacement	replacement	NOUN	NN	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
women	woman	NOUN	NNS	5	O
may	may	VERB	MD	5	O
not	not	ADV	RB	5	O
be	be	VERB	VB	5	O
harmless	harmless	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Optimising	optimise	VERB	VBG	5	O
stroke	stroke	NOUN	NN	5	B-Disease
prevention	prevention	NOUN	NN	5	O
in	in	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
valvular	valvular	ADJ	JJ	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Atrial	atrial	ADJ	JJ	7	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
substantial	substantial	ADJ	JJ	9	O
morbidity	morbidity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
mortality	mortality	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Pooled	pool	VERB	VBN	9	O
data	datum	NOUN	NNS	5	O
from	from	ADP	IN	9	O
trials	trial	NOUN	NNS	5	O
comparing	compare	VERB	VBG	9	O
antithrombotic	antithrombotic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
have	have	VERB	VBP	5	O
shown	show	VERB	VBN	9	O
that	that	DET	DT	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
reduces	reduce	VERB	VBZ	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
stroke	stroke	NOUN	NN	5	B-Disease
by	by	ADP	IN	9	O
62	62	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
that	that	DET	DT	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
alone	alone	ADV	RB	9	O
reduces	reduce	VERB	VBZ	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
by	by	ADP	IN	9	O
22	22	NUM	CD	7	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Overall	overall	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
risk	risk	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
is	be	VERB	VBZ	5	O
superior	superior	ADJ	JJ	5	O
to	to	PART	TO	5	O
aspirin	aspirin	VERB	VB	9	B-Chemical
in	in	ADP	IN	5	O
preventing	prevent	VERB	VBG	9	O
strokes	stroke	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
relative	relative	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
36	36	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Ximelagatran	Ximelagatran	PROPN	NNP	7	B-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
oral	oral	ADJ	JJ	9	O
direct	direct	ADJ	JJ	9	O
thrombin	thrombin	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
as	as	ADV	RB	5	O
efficient	efficient	ADJ	JJ	5	O
as	as	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
K	k	NOUN	NN	9	I-Chemical
antagonist	antagonist	NOUN	NN	3	O
drugs	drug	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
embolic	embolic	ADJ	JJ	5	B-Disease
events	event	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
recently	recently	ADV	RB	9	O
withdrawn	withdraw	VERB	VBN	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
abnormal	abnormal	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
function	function	NOUN	NN	9	I-Disease
tests	test	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
ACTIVE	ACTIVE	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
W	W	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
Atrial	Atrial	PROPN	NNP	7	B-Disease
Fibrillation	Fibrillation	PROPN	NNP	5	I-Disease
Clopidogrel	Clopidogrel	PROPN	NNP	0	B-Chemical
Trial	Trial	PROPN	NNP	5	O
with	with	ADP	IN	5	O
Irbesartan	Irbesartan	PROPN	NNP	0	B-Chemical
for	for	ADP	IN	5	O
Prevention	Prevention	PROPN	NNP	2	O
of	of	ADP	IN	5	O
Vascular	Vascular	PROPN	NNP	9	O
Events	Events	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
study	study	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
demonstrated	demonstrate	VERB	VBN	9	O
that	that	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
is	be	VERB	VBZ	5	O
superior	superior	ADJ	JJ	5	O
to	to	PART	TO	5	O
platelet	platelet	VERB	VB	9	O
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
clopidogrel	clopidogrel	VERB	VB	0	B-Chemical
plus	plus	CCONJ	CC	9	O
aspirin	aspirin	ADV	RB	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
prevention	prevention	NOUN	NN	5	O
af	af	X	FW	2	O
embolic	embolic	ADJ	JJ	5	B-Disease
events	event	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Idraparinux	Idraparinux	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
Factor	Factor	PROPN	NNP	9	O
Xa	Xa	PROPN	NNP	9	O
inhibitor	inhibitor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
being	be	VERB	VBG	5	O
evaluated	evaluate	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Angiotensin	angiotensin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
converting	convert	VERB	VBG	9	O
enzyme	enzyme	ADJ	JJ	0	O
inhibitors	inhibitor	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
II	II	PROPN	NNP	9	I-Chemical
receptor	receptor	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
blocking	block	VERB	VBG	3	O
drugs	drug	NOUN	NNS	5	O
hold	hold	VERB	VBP	5	O
promise	promise	NOUN	NN	5	O
in	in	ADP	IN	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
through	through	ADP	IN	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
remodelling	remodelling	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Preliminary	preliminary	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
statins	statin	NOUN	NNS	5	B-Chemical
could	could	VERB	MD	9	O
interfere	interfere	VERB	VB	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
recurrence	recurrence	NOUN	NN	5	O
after	after	ADP	IN	9	O
electrical	electrical	ADJ	JJ	5	O
cardioversion	cardioversion	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Finally	finally	ADV	RB	9	O
,	,	PUNCT	,	9	O
percutaneous	percutaneous	ADJ	JJ	5	O
methods	method	NOUN	NNS	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
exclusion	exclusion	NOUN	NN	5	O
of	of	ADP	IN	5	O
left	left	ADJ	JJ	5	O
atrial	atrial	ADJ	JJ	5	O
appendage	appendage	NOUN	NN	9	O
are	be	VERB	VBP	5	O
under	under	ADP	IN	9	O
investigation	investigation	NOUN	NN	9	O
in	in	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
risk	risk	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
oxidant	oxidant	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
atorvastatin	atorvastatin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

1	1	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

Dexamethasone	Dexamethasone	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Dex	Dex	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
endothelial	endothelial	ADJ	JJ	3	O
dysfunction	dysfunction	NOUN	NN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
NO	no	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
deficiency	deficiency	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
superoxide	superoxide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
O2	o2	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
)	)	PUNCT	-RRB-	9	O
production	production	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Atorvastatin	Atorvastatin	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Ato	Ato	PROPN	NNP	2	B-Chemical
)	)	PUNCT	-RRB-	9	O
possesses	possess	VERB	VBZ	9	O
pleiotropic	pleiotropic	ADJ	JJ	9	O
properties	property	NOUN	NNS	9	O
that	that	DET	WDT	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
to	to	PART	TO	5	O
improve	improve	VERB	VB	5	O
endothelial	endothelial	ADJ	JJ	3	O
function	function	NOUN	NN	9	O
through	through	ADP	IN	9	O
increased	increase	VERB	VBN	9	O
availability	availability	NOUN	NN	5	O
of	of	ADP	IN	5	O
NO	no	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
reduced	reduce	VERB	VBN	9	O
O2	O2	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
production	production	NOUN	NN	9	O
in	in	ADP	IN	5	O
various	various	ADJ	JJ	9	O
forms	form	NOUN	NNS	9	O
of	of	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
investigated	investigate	VERB	VBD	9	O
whether	whether	ADP	IN	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
Ato	Ato	PROPN	NNP	2	B-Chemical
could	could	VERB	MD	9	O
prevent	prevent	VERB	VB	5	O
endothelial	endothelial	ADJ	JJ	3	O
NO	no	DET	DT	9	B-Chemical
synthase	synthase	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
eNOS	eNOS	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
downregulation	downregulation	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
O2	O2	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
in	in	PROPN	NNP	5	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
SD	SD	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
thereby	thereby	ADV	RB	9	O
reducing	reduce	VERB	VBG	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

2	2	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

Male	Male	PROPN	NNP	7	O
SD	sd	NOUN	NN	7	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
30	30	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
Ato	Ato	PROPN	NNP	2	B-Chemical
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
in	in	ADP	IN	5	O
drinking	drinking	NOUN	NN	5	O
water	water	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
tap	tap	NOUN	NN	5	O
water	water	NOUN	NN	0	O
for	for	ADP	IN	5	O
15	15	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Dexamethasone	Dexamethasone	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
s	s	NOUN	NN	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
saline	saline	NOUN	NN	0	O
was	be	VERB	VBD	9	O
started	start	VERB	VBN	5	O
after	after	ADP	IN	9	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
in	in	ADP	IN	5	O
Ato	Ato	PROPN	NNP	2	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
treated	treated	ADJ	JJ	3	O
rats	rat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
continued	continue	VERB	VBD	9	O
for	for	ADP	IN	5	O
11	11	NUM	CD	7	O
-	-	SYM	SYM	7	O
13	13	NUM	CD	7	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Systolic	systolic	ADJ	JJ	7	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
SBP	SBP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
on	on	ADP	IN	5	O
alternate	alternate	ADJ	JJ	9	O
days	day	NOUN	NNS	9	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
tail	tail	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
cuff	cuff	NOUN	NN	5	O
method	method	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Endothelial	endothelial	ADJ	JJ	3	O
function	function	NOUN	NN	9	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
vasorelaxation	vasorelaxation	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
phenylephrine	phenylephrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
vasoconstriction	vasoconstriction	NOUN	NN	9	O
in	in	ADP	IN	5	O
aortic	aortic	ADJ	JJ	9	O
segments	segment	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Vascular	Vascular	PROPN	NNP	9	O
eNOS	eNOS	PROPN	NNP	3	O
mRNA	mRNA	PROPN	NNP	3	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
semi	semi	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
quantitative	quantitative	ADJ	JJ	9	O
reverse	reverse	ADJ	JJ	9	O
transcription	transcription	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
polymerase	polymerase	NOUN	NN	1	O
chain	chain	NOUN	NN	9	O
reaction	reaction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

3	3	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
Dex	Dex	PROPN	NNP	3	B-Chemical
alone	alone	ADV	RB	9	O
,	,	PUNCT	,	9	O
SBP	SBP	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
from	from	ADP	IN	9	O
109	109	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
to	to	ADP	IN	5	O
133	133	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
mmHg	mmHg	PROPN	NNP	7	O
on	on	ADP	IN	5	O
Days	day	NOUN	NNS	9	O
4	4	NUM	CD	9	O
and	and	CCONJ	CC	5	O
Day	Day	PROPN	NNP	9	O
14	14	NUM	CD	7	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
Ato	Ato	PROPN	NNP	2	B-Chemical
+	+	SYM	SYM	9	O
Dex	Dex	PROPN	NNP	3	B-Chemical
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
SBP	SBP	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
from	from	ADP	IN	9	O
113	113	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
to	to	ADP	IN	5	O
119	119	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
mmHg	mmHg	PROPN	NNP	7	O
on	on	ADP	IN	5	O
Days	day	NOUN	NNS	9	O
4	4	NUM	CD	9	O
to	to	ADP	IN	5	O
14	14	NUM	CD	7	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
SBP	SBP	PROPN	NNP	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
group	group	NOUN	NN	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
Dex	Dex	PROPN	NNP	3	B-Chemical
alone	alone	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Endothelial	endothelial	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
relaxation	relaxation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
eNOS	eNOS	PROPN	NNP	3	O
mRNA	mRNA	PROPN	NNP	3	O
expression	expression	NOUN	NN	3	O
were	be	VERB	VBD	9	O
greater	great	ADJ	JJR	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Dex	Dex	PROPN	NNP	3	B-Chemical
+	+	SYM	SYM	9	O
Ato	Ato	PROPN	NNP	2	B-Chemical
group	group	NOUN	NN	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Dex	Dex	PROPN	NNP	3	B-Chemical
only	only	ADV	RB	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
and	and	CCONJ	CC	5	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Aortic	aortic	ADJ	JJ	9	O
superoxide	superoxide	ADJ	JJ	0	B-Chemical
production	production	NOUN	NN	9	O
was	be	VERB	VBD	9	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Dex	Dex	PROPN	NNP	3	B-Chemical
+	+	SYM	SYM	9	O
Ato	Ato	PROPN	NNP	2	B-Chemical
group	group	NOUN	NN	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
group	group	NOUN	NN	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
Dex	Dex	PROPN	NNP	3	B-Chemical
alone	alone	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

4	4	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
Ato	Ato	PROPN	NNP	2	B-Chemical
improved	improve	VERB	VBN	5	O
endothelial	endothelial	ADJ	JJ	3	O
function	function	NOUN	NN	9	O
,	,	PUNCT	,	9	O
reduced	reduce	VERB	VBN	9	O
superoxide	superoxide	ADJ	JJ	0	B-Chemical
production	production	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
reduced	reduce	VERB	VBD	9	O
SBP	SBP	PROPN	NNP	9	O
in	in	ADP	IN	5	O
Dex	Dex	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
SD	sd	NOUN	NN	7	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Severe	severe	ADJ	JJ	9	O
citrate	citrate	ADJ	JJ	0	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
complicating	complicate	VERB	VBG	5	O
volunteer	volunteer	NOUN	NN	5	O
apheresis	apheresis	NOUN	NN	5	O
platelet	platelet	NOUN	NN	9	O
donation	donation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
citrate	citrate	ADJ	JJ	0	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
during	during	ADP	IN	5	O
volunteer	volunteer	NOUN	NN	5	O
donor	donor	NOUN	NN	9	O
apheresis	apheresis	NOUN	NN	5	O
platelet	platelet	NOUN	NN	9	O
collection	collection	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
donor	donor	NOUN	NN	9	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
40	40	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
female	female	NOUN	NN	9	O
,	,	PUNCT	,	9	O
first	first	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
time	time	NOUN	NN	5	O
apheresis	apheresis	NOUN	NN	5	O
platelet	platelet	NOUN	NN	9	O
donor	donor	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Past	past	ADJ	JJ	5	O
medical	medical	ADJ	JJ	5	O
history	history	NOUN	NN	5	O
was	be	VERB	VBD	9	O
remarkable	remarkable	ADJ	JJ	9	O
for	for	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
hyperlipidemia	hyperlipidemia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
depression	depression	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Reported	report	VERB	VBN	5	O
medications	medication	NOUN	NNS	5	O
included	include	VERB	VBD	5	O
bumetanide	bumetanide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
pravastatin	pravastatin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
paroxetine	paroxetine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
start	start	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
procedure	procedure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
donor	donor	NOUN	NN	9	O
noted	note	VERB	VBD	9	O
tingling	tingle	VERB	VBG	5	O
around	around	ADP	IN	5	O
the	the	DET	DT	5	O
mouth	mouth	NOUN	NN	5	O
,	,	PUNCT	,	9	O
hands	hand	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
feet	foot	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
then	then	ADV	RB	9	O
very	very	ADV	RB	5	O
rapidly	rapidly	ADV	RB	9	O
developed	develop	VERB	VBD	5	O
acute	acute	ADJ	JJ	9	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
facial	facial	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
extremity	extremity	NOUN	NN	5	O
tetany	tetany	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Empirical	empirical	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
calcium	calcium	NOUN	NN	0	B-Chemical
gluconate	gluconate	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
initiated	initiate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
muscle	muscle	NOUN	NN	9	B-Disease
contractions	contraction	NOUN	NNS	5	I-Disease
slowly	slowly	ADV	RB	5	O
subsided	subside	VERB	VBN	5	O
over	over	ADP	IN	5	O
approximately	approximately	ADV	RB	9	O
10	10	NUM	CD	9	O
to	to	PART	TO	5	O
15	15	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
events	event	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
severe	severe	ADJ	JJ	5	O
reaction	reaction	NOUN	NN	9	O
to	to	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
chelation	chelation	NOUN	NN	0	O
by	by	ADP	IN	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
citrate	citrate	NOUN	NN	0	I-Chemical
anticoagulant	anticoagulant	NOUN	NN	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
symptomatic	symptomatic	ADJ	JJ	5	O
systemic	systemic	ADJ	JJ	9	O
hypocalcemia	hypocalcemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Upon	upon	ADP	IN	9	O
additional	additional	ADJ	JJ	9	O
retrospective	retrospective	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
that	that	ADP	IN	5	O
bumetanide	bumetanide	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
loop	loop	NOUN	NN	9	B-Chemical
diuretic	diuretic	ADJ	JJ	5	I-Chemical
that	that	DET	WDT	5	O
may	may	VERB	MD	5	O
cause	cause	VERB	VB	5	O
significant	significant	ADJ	JJ	9	O
hypocalcemia	hypocalcemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
careful	careful	ADJ	JJ	5	O
screening	screening	NOUN	NN	5	O
for	for	ADP	IN	5	O
medications	medication	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
underlying	underlie	VERB	VBG	5	O
conditions	condition	NOUN	NNS	9	O
predisposing	predispose	VERB	VBG	5	O
to	to	ADP	IN	5	O
hypocalcemia	hypocalcemia	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
recommended	recommend	VERB	VBN	5	O
to	to	PART	TO	5	O
help	help	VERB	VB	5	O
prevent	prevent	VERB	VB	5	O
severe	severe	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
citrate	citrate	VERB	VB	0	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Laboratory	laboratory	NOUN	NN	2	O
measurement	measurement	NOUN	NN	5	O
of	of	ADP	IN	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
procedure	procedure	ADJ	JJ	5	O
serum	serum	ADJ	JJ	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
in	in	ADP	IN	5	O
selected	select	VERB	VBN	9	O
donors	donor	NOUN	NNS	9	O
may	may	VERB	MD	5	O
identify	identify	VERB	VB	9	O
cases	case	NOUN	NNS	5	O
requiring	require	VERB	VBG	5	O
heightened	heighten	VERB	VBN	5	O
vigilance	vigilance	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
case	case	NOUN	NN	5	O
also	also	ADV	RB	9	O
illustrates	illustrate	VERB	VBZ	5	O
the	the	DET	DT	5	O
importance	importance	NOUN	NN	5	O
of	of	ADP	IN	5	O
maintaining	maintain	VERB	VBG	9	O
preparedness	preparedness	NOUN	NN	5	O
for	for	ADP	IN	5	O
managing	manage	VERB	VBG	5	O
rare	rare	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
serious	serious	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
in	in	ADP	IN	5	O
volunteer	volunteer	NOUN	NN	5	O
apheresis	apheresis	NOUN	NN	5	O
blood	blood	NOUN	NN	9	O
donors	donor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Sirolimus	sirolimus	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Sirolimus	sirolimus	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
immunosuppressant	immunosuppressant	NOUN	NN	9	O
with	with	ADP	IN	5	O
potent	potent	ADJ	JJ	3	O
antiproliferative	antiproliferative	ADJ	JJ	3	O
actions	action	NOUN	NNS	5	O
through	through	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
ability	ability	NOUN	NN	9	O
to	to	PART	TO	5	O
inhibit	inhibit	VERB	VB	3	O
the	the	DET	DT	5	O
raptor	raptor	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
mammalian	mammalian	ADJ	JJ	9	O
target	target	NOUN	NN	9	O
of	of	ADP	IN	5	O
rapamycin	rapamycin	NOUN	NN	3	B-Chemical
protein	protein	NOUN	NN	1	O
kinase	kinase	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Sirolimus	sirolimus	NOUN	NN	0	B-Chemical
represents	represent	VERB	VBZ	9	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
advance	advance	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	O
allograft	allograft	NOUN	NN	5	O
rejection	rejection	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
chronic	chronic	ADJ	JJ	5	O
allograft	allograft	NOUN	NN	5	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Its	-PRON-	DET	PRP$	5	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
therapy	therapy	NOUN	NN	5	O
of	of	ADP	IN	5	O
glomerulonephritis	glomerulonephritis	ADJ	JJ	3	B-Disease
,	,	PUNCT	,	9	O
autoimmunity	autoimmunity	NOUN	NN	3	B-Disease
,	,	PUNCT	,	9	O
cystic	cystic	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
diseases	disease	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
is	be	VERB	VBZ	5	O
under	under	ADP	IN	9	O
investigation	investigation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
share	share	VERB	VB	5	O
the	the	DET	DT	5	O
vasomotor	vasomotor	NOUN	NN	5	O
renal	renal	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
exhibited	exhibit	VERB	VBN	9	O
by	by	ADP	IN	9	O
calcineurin	calcineurin	NOUN	NN	3	O
inhibitors	inhibitor	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
designated	designate	VERB	VBN	9	O
a	a	DET	DT	5	O
'	'	PUNCT	``	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
nephrotoxic	nephrotoxic	ADJ	JJ	5	B-Disease
drug	drug	NOUN	NN	5	O
'	'	PUNCT	''	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
clinical	clinical	ADJ	JJ	5	O
reports	report	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
,	,	PUNCT	,	9	O
under	under	ADP	IN	9	O
some	some	DET	DT	5	O
circumstances	circumstance	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
common	common	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
factor	factor	NOUN	NN	9	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
existing	exist	VERB	VBG	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
damage	damage	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
are	be	VERB	VBP	5	O
multifactorial	multifactorial	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
glomerular	glomerular	ADJ	JJ	5	O
capillary	capillary	ADJ	JJ	0	O
pressure	pressure	NOUN	NN	5	O
following	follow	VERB	VBG	9	O
calcineurin	calcineurin	NOUN	NN	3	O
inhibitor	inhibitor	NOUN	NN	3	O
withdrawal	withdrawal	NOUN	NN	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
also	also	ADV	RB	9	O
been	be	VERB	VBN	9	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
directly	directly	ADV	RB	9	O
causes	cause	VERB	VBZ	9	O
increased	increase	VERB	VBN	9	O
glomerular	glomerular	ADJ	JJ	5	O
permeability	permeability	NOUN	NN	0	O
/	/	SYM	SYM	9	O
injury	injury	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
evidence	evidence	NOUN	NN	9	O
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
currently	currently	ADV	RB	5	O
inconclusive	inconclusive	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
in	in	ADP	IN	5	O
delayed	delay	VERB	VBN	9	O
graft	graft	NOUN	NN	5	O
function	function	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
suppression	suppression	NOUN	NN	9	O
of	of	ADP	IN	5	O
compensatory	compensatory	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	O
cell	cell	NOUN	NN	3	O
proliferation	proliferation	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
survival	survival	NOUN	NN	9	O
/	/	SYM	SYM	9	O
repair	repair	NOUN	NN	9	O
processes	process	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
these	these	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
occur	occur	VERB	VBP	5	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
their	-PRON-	DET	PRP$	5	O
occurrence	occurrence	NOUN	NN	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
minimised	minimise	VERB	VBN	5	O
by	by	ADP	IN	9	O
knowledge	knowledge	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
molecular	molecular	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
appropriate	appropriate	ADJ	JJ	5	O
patient	patient	ADJ	JJ	5	O
populations	population	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
close	close	ADJ	JJ	5	O
monitoring	monitoring	NOUN	NN	5	O
of	of	ADP	IN	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
,	,	PUNCT	,	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
converting	convert	VERB	VBG	9	O
enzyme	enzyme	ADJ	JJ	0	O
inhibitors	inhibitor	NOUN	NNS	3	O
or	or	CCONJ	CC	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
II	II	PROPN	NNP	9	I-Chemical
receptor	receptor	NOUN	NN	3	O
blockers	blocker	NOUN	NNS	9	O
if	if	ADP	IN	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
occurs	occur	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
withdrawal	withdrawal	NOUN	NN	5	O
if	if	ADP	IN	5	O
needed	need	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
allograft	allograft	NOUN	NN	5	O
studies	study	NOUN	NNS	9	O
using	use	VERB	VBG	9	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
de	de	X	FW	2	O
novo	novo	NOUN	NN	9	O
immunosuppression	immunosuppression	NOUN	NN	5	O
along	along	ADP	IN	9	O
with	with	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
laboratory	laboratory	NOUN	NN	9	O
studies	study	NOUN	NNS	9	O
will	will	VERB	MD	5	O
refine	refine	VERB	VB	5	O
these	these	DET	DT	5	O
issues	issue	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
future	future	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Proteinuria	proteinuria	VERB	VB	7	B-Disease
after	after	ADP	IN	9	O
conversion	conversion	NOUN	NN	9	O
to	to	PART	TO	5	O
sirolimus	sirolimus	VERB	VB	0	B-Chemical
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
transplant	transplant	NOUN	NN	9	O
recipients	recipient	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Sirolimus	Sirolimus	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
SRL	SRL	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
potent	potent	ADJ	JJ	3	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
.	.	PUNCT	.	9	O

More	more	ADV	RBR	5	O
recently	recently	ADV	RB	9	O
,	,	PUNCT	,	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
consequence	consequence	NOUN	NN	5	O
of	of	ADP	IN	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
the	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
remained	remain	VERB	VBN	9	O
unclear	unclear	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
retrospectively	retrospectively	ADV	RB	5	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
records	record	NOUN	NNS	5	O
of	of	ADP	IN	5	O
25	25	NUM	CD	9	O
renal	renal	ADJ	JJ	9	O
transplant	transplant	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
or	or	CCONJ	CC	5	O
displayed	display	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
after	after	ADP	IN	9	O
SRL	SRL	PROPN	NNP	0	B-Chemical
conversion	conversion	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	ADJ	JJ	5	O
cohort	cohort	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
14	14	NUM	CD	7	O
men	man	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
11	11	NUM	CD	7	O
women	woman	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
SRL	SRL	PROPN	NNP	0	B-Chemical
as	as	ADP	IN	5	O
conversion	conversion	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
allograft	allograft	NOUN	NN	5	I-Disease
nephropathy	nephropathy	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
CAN	CAN	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
15	15	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
neoplasia	neoplasia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
Kaposi	Kaposi	PROPN	NNP	9	B-Disease
'	'	PART	POS	9	I-Disease
s	s	NOUN	NN	9	I-Disease
sarcoma	sarcoma	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
Four	four	NUM	CD	9	O
skin	skin	NOUN	NN	5	B-Disease
cancers	cancer	NOUN	NNS	9	I-Disease
,	,	PUNCT	,	9	O
One	one	NUM	CD	5	O
intestinal	intestinal	ADJ	JJ	9	B-Disease
tumors	tumor	NOUN	NNS	3	I-Disease
,	,	PUNCT	,	9	O
One	one	NUM	CD	5	O
renal	renal	ADJ	JJ	9	B-Disease
cell	cell	NOUN	NN	3	I-Disease
carsinom	carsinom	NOUN	NN	_	I-Disease
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
BK	BK	PROPN	NNP	9	O
virus	virus	NOUN	NN	9	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

SRL	SRL	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
started	start	VERB	VBN	5	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
mean	mean	NOUN	NN	5	O
of	of	ADP	IN	5	O
78	78	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
42	42	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
to	to	ADP	IN	5	O
163	163	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Mean	mean	VERB	VB	9	O
follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
on	on	ADP	IN	5	O
SRL	SRL	PROPN	NNP	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
20	20	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
12	12	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
to	to	ADP	IN	5	O
43	43	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Proteinuria	Proteinuria	PROPN	NNP	7	B-Disease
increased	increase	VERB	VBD	9	O
from	from	ADP	IN	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
445	445	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
to	to	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
before	before	ADP	IN	9	O
conversion	conversion	NOUN	NN	9	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
to	to	ADP	IN	5	O
12	12	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
conversion	conversion	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Before	before	ADP	IN	9	O
conversion	conversion	NOUN	NN	9	O
8	8	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
32	32	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
afterwards	afterwards	ADV	RB	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
28	28	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
proteinuria	proteinuria	VERB	VBP	9	B-Disease
remained	remain	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
increased	increase	VERB	VBD	9	O
in	in	ADP	IN	5	O
68	68	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
it	-PRON-	PRON	PRP	5	O
increased	increase	VERB	VBD	9	O
by	by	ADP	IN	9	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
100	100	NUM	CD	0	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
eight	eight	NUM	CD	9	O
percent	percent	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
range	range	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Biopsies	biopsy	NOUN	NNS	9	O
performed	perform	VERB	VBN	9	O
in	in	ADP	IN	5	O
five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
revealed	reveal	VERB	VBD	9	O
new	new	ADJ	JJ	5	O
pathological	pathological	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
One	one	NUM	CD	5	O
membranoproliferative	membranoproliferative	ADJ	JJ	5	B-Disease
glomerulopathy	glomerulopathy	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
interstitial	interstitial	ADJ	JJ	9	B-Disease
nephritis	nephritis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
persistently	persistently	ADV	RB	9	O
good	good	ADJ	JJ	5	O
graft	graft	NOUN	NN	5	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Serum	Serum	PROPN	NNP	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
values	value	NOUN	NNS	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
change	change	VERB	VB	9	O
significantly	significantly	ADV	RB	9	O
:	:	PUNCT	:	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
98	98	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
before	before	ADP	IN	9	O
SRL	SRL	PROPN	NNP	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
53	53	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
at	at	ADP	IN	9	O
last	last	ADJ	JJ	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
14	14	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
grafts	graft	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
lost	lose	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
dialysis	dialysis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
displayed	display	VERB	VBD	9	O
CAN	CAN	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
Kaposi	Kaposi	PROPN	NNP	9	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PUNCT	HYPH	9	I-Disease
sarcoma	sarcoma	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Mean	mean	VERB	VB	9	O
urinary	urinary	ADJ	JJ	9	O
protein	protein	NOUN	NN	1	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
dialysis	dialysis	NOUN	NN	5	O
was	be	VERB	VBD	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
26	26	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
to	to	ADP	IN	5	O
12	12	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
after	after	ADP	IN	9	O
conversion	conversion	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Mean	mean	VERB	VB	9	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	VERB	VBP	0	B-Chemical
level	level	NOUN	NN	9	O
before	before	ADP	IN	9	O
conversion	conversion	NOUN	NN	9	O
was	be	VERB	VBD	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
21	21	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
and	and	CCONJ	CC	5	O
thereafter	thereafter	ADV	RB	9	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
93	93	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Heavy	heavy	ADJ	JJ	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
common	common	ADJ	JJ	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
SRL	SRL	PROPN	NNP	0	B-Chemical
as	as	ADP	IN	5	O
rescue	rescue	NOUN	NN	3	O
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
conversion	conversion	NOUN	NN	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
have	have	VERB	VBP	5	O
not	not	ADV	RB	5	O
developed	develop	VERB	VBN	5	O
advanced	advanced	ADJ	JJ	5	O
CAN	can	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
proteinuria	proteinuria	VERB	VB	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
de	de	X	FW	2	O
novo	novo	X	FW	9	O
glomerular	glomerular	ADJ	JJ	5	O
pathology	pathology	NOUN	NN	5	O
under	under	ADP	IN	9	O
SRL	SRL	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
requires	require	VERB	VBZ	5	O
further	further	ADJ	JJ	9	O
investigation	investigation	NOUN	NN	9	O
by	by	ADP	IN	9	O
renal	renal	ADJ	JJ	9	O
biopsy	biopsy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Long	long	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
of	of	ADP	IN	5	O
ifosfamide	ifosfamide	ADJ	JJ	0	B-Chemical
renal	renal	ADJ	JJ	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
for	for	ADP	IN	5	O
malignant	malignant	ADJ	JJ	3	B-Disease
mesenchymal	mesenchymal	ADJ	JJ	3	I-Disease
tumors	tumor	NOUN	NNS	3	I-Disease
:	:	PUNCT	:	9	O
an	an	DET	DT	5	O
International	International	PROPN	NNP	2	O
Society	Society	PROPN	NNP	2	O
of	of	ADP	IN	5	O
Pediatric	Pediatric	PROPN	NNP	2	O
Oncology	Oncology	PROPN	NNP	2	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
of	of	ADP	IN	5	O
74	74	NUM	CD	7	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
malignant	malignant	ADJ	JJ	3	B-Disease
mesenchymal	mesenchymal	ADJ	JJ	3	I-Disease
tumors	tumor	NOUN	NNS	3	I-Disease
in	in	ADP	IN	5	O
complete	complete	ADJ	JJ	9	O
remission	remission	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
who	who	PRON	WP	5	O
have	have	VERB	VBP	5	O
received	receive	VERB	VBN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
ifosfamide	ifosfamide	ADJ	JJ	0	B-Chemical
chemotherapy	chemotherapy	NOUN	NN	5	O
protocol	protocol	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
International	International	PROPN	NNP	2	O
Society	Society	PROPN	NNP	2	O
of	of	ADP	IN	5	O
Pediatric	Pediatric	PROPN	NNP	2	O
Oncology	Oncology	PROPN	NNP	2	O
Malignant	Malignant	PROPN	NNP	7	B-Disease
Mesenchymal	Mesenchymal	PROPN	NNP	3	I-Disease
Tumor	Tumor	PROPN	NNP	9	I-Disease
Study	Study	PROPN	NNP	5	O
84	84	NUM	CD	7	O
[	[	PUNCT	-LRB-	9	O
SIOP	SIOP	PROPN	NNP	5	O
MMT	MMT	PROPN	NNP	5	O
84	84	NUM	CD	7	O
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
completion	completion	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Total	total	ADJ	JJ	7	O
cumulative	cumulative	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
36	36	NUM	CD	9	O
or	or	CCONJ	CC	5	O
60	60	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
of	of	ADP	IN	5	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
six	six	NUM	CD	9	O
or	or	CCONJ	CC	5	O
10	10	NUM	CD	9	O
cycles	cycle	NOUN	NNS	9	O
of	of	ADP	IN	5	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	I-Chemical
vincristine	vincristine	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	I-Chemical
and	and	CCONJ	CC	5	I-Chemical
dactinomycin	dactinomycin	VERB	VB	0	I-Chemical
[	[	PUNCT	-LRB-	9	O
IVA	iva	NOUN	NN	9	B-Chemical
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

None	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
received	receive	VERB	VBN	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Ages	age	NOUN	NNS	5	O
ranged	range	VERB	VBD	9	O
from	from	ADP	IN	9	O
4	4	NUM	CD	9	O
months	month	NOUN	NNS	5	O
to	to	ADP	IN	5	O
17	17	NUM	CD	7	O
years	year	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
58	58	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
males	male	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
42	42	NUM	CD	7	O
females	female	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
primary	primary	ADJ	JJ	9	O
tumor	tumor	NOUN	NN	3	B-Disease
site	site	NOUN	NN	9	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
head	head	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
neck	neck	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
was	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
by	by	ADP	IN	9	O
measuring	measure	VERB	VBG	9	O
plasma	plasma	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
urinary	urinary	NOUN	NN	9	O
electrolytes	electrolyte	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
glucosuria	glucosuria	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
aminoaciduria	aminoaciduria	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	O
urinary	urinary	NOUN	NN	9	O
pH	pH	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
osmolarity	osmolarity	NOUN	NN	0	O
,	,	PUNCT	,	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
clearance	clearance	NOUN	NN	9	O
,	,	PUNCT	,	9	O
phosphate	phosphate	VERB	VB	0	B-Chemical
tubular	tubular	ADJ	JJ	9	O
reabsorption	reabsorption	NOUN	NN	0	O
,	,	PUNCT	,	9	O
beta	beta	NOUN	NN	9	O
2	2	NUM	CD	9	O
microglobulinuria	microglobulinuria	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
lysozymuria	lysozymuria	NOUN	NNS	_	O
.	.	PUNCT	.	9	O

Fifty	fifty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
eight	eight	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
78	78	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	O
tests	test	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
16	16	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
22	22	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
renal	renal	ADJ	JJ	9	B-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
subsets	subset	NOUN	NNS	3	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
from	from	ADP	IN	9	O
this	this	DET	DT	5	O
latter	latter	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
:	:	PUNCT	:	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
included	include	VERB	VBD	5	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
population	population	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
major	major	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
Fanconi	Fanconi	PROPN	NNP	9	B-Disease
'	'	PART	POS	9	I-Disease
s	s	NOUN	NN	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
TDFS	TDFS	PROPN	NNP	_	B-Disease
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
included	include	VERB	VBD	5	O
five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
elevated	elevated	ADJ	JJ	9	O
beta	beta	NOUN	NN	9	O
2	2	NUM	CD	9	O
microglobulinuria	microglobulinuria	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
low	low	ADJ	JJ	9	O
phosphate	phosphate	NOUN	NN	0	B-Chemical
reabsorption	reabsorption	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
remaining	remain	VERB	VBG	9	O
seven	seven	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
isolated	isolate	VERB	VBN	9	O
beta	beta	NOUN	NN	9	O
2	2	NUM	CD	9	O
microglobulinuria	microglobulinuria	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Severe	severe	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
higher	high	ADJ	JJR	9	O
cumulative	cumulative	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
60	60	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
of	of	ADP	IN	5	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
younger	young	ADJ	JJR	5	O
age	age	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
2	2	NUM	CD	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
years	year	NOUN	NNS	5	O
old	old	ADJ	JJ	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
predominance	predominance	NOUN	NN	9	O
of	of	ADP	IN	5	O
vesicoprostatic	vesicoprostatic	ADJ	JJ	5	O
tumor	tumor	NOUN	NN	3	B-Disease
involvement	involvement	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
low	low	ADJ	JJ	9	O
percentage	percentage	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
TDFS	TDFS	PROPN	NNP	_	O
must	must	VERB	MD	5	O
be	be	VERB	VB	5	O
evaluated	evaluate	VERB	VBN	9	O
with	with	ADP	IN	5	O
respect	respect	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
mesenchymal	mesenchymal	ADJ	JJ	3	B-Disease
tumors	tumor	NOUN	NNS	3	I-Disease
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Progressive	progressive	ADJ	JJ	5	O
myopathy	myopathy	NOUN	NN	9	B-Disease
with	with	ADP	IN	5	O
up	up	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
MHC	MHC	PROPN	NNP	3	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
associated	associate	VERB	VBD	9	O
with	with	ADP	IN	5	O
statin	statin	NOUN	NN	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Statins	statin	NOUN	NNS	7	B-Chemical
can	can	VERB	MD	5	O
cause	cause	VERB	VB	5	O
a	a	DET	DT	5	O
necrotizing	necrotize	VERB	VBG	5	O
myopathy	myopathy	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
hyperCKaemia	hyperCKaemia	PROPN	NNP	9	B-Disease
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
reversible	reversible	ADJ	JJ	9	O
on	on	ADP	IN	5	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

What	what	PRON	WP	5	O
is	be	VERB	VBZ	5	O
less	less	ADV	RBR	5	O
well	well	ADV	RB	9	O
known	know	VERB	VBN	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
phenomenon	phenomenon	NOUN	NN	5	O
whereby	whereby	ADV	WRB	5	O
statins	statin	NOUN	NNS	5	B-Chemical
may	may	VERB	MD	5	O
induce	induce	VERB	VB	3	O
a	a	DET	DT	5	O
myopathy	myopathy	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
persists	persist	VERB	VBZ	9	O
or	or	CCONJ	CC	5	O
may	may	VERB	MD	5	O
progress	progress	VERB	VB	5	O
after	after	ADP	IN	9	O
stopping	stop	VERB	VBG	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
muscle	muscle	NOUN	NN	9	O
pathology	pathology	NOUN	NN	5	O
in	in	ADP	IN	5	O
8	8	NUM	CD	9	O
such	such	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
had	have	VERB	VBD	9	O
myofibre	myofibre	ADJ	JJ	3	O
necrosis	necrosis	NOUN	NN	9	B-Disease
but	but	CCONJ	CC	9	O
only	only	ADV	RB	9	O
3	3	NUM	CD	9	O
had	have	VERB	VBD	9	O
an	an	DET	DT	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
infiltrate	infiltrate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
all	all	DET	DT	5	O
cases	case	NOUN	NNS	5	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
diffuse	diffuse	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
multifocal	multifocal	ADJ	JJ	5	O
up	up	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
MHC	MHC	PROPN	NNP	3	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
expression	expression	NOUN	NN	3	O
even	even	ADV	RB	5	O
in	in	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
necrotic	necrotic	ADJ	JJ	3	B-Disease
fibres	fibre	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Progressive	progressive	ADJ	JJ	5	O
improvement	improvement	NOUN	NN	5	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
7	7	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
after	after	ADP	IN	9	O
commencement	commencement	NOUN	NN	5	O
of	of	ADP	IN	5	O
prednisolone	prednisolone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
case	case	NOUN	NN	5	O
spontaneously	spontaneously	ADV	RB	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
observations	observation	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
statins	statin	NOUN	NNS	5	B-Chemical
may	may	VERB	MD	5	O
initiate	initiate	VERB	VB	9	O
an	an	DET	DT	5	O
immune	immune	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
myopathy	myopathy	NOUN	NN	9	B-Disease
that	that	DET	WDT	5	O
persists	persist	VERB	VBZ	9	O
after	after	ADP	IN	9	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
responds	respond	VERB	VBZ	9	O
to	to	ADP	IN	5	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
myopathy	myopathy	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
uncertain	uncertain	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
may	may	VERB	MD	5	O
involve	involve	VERB	VB	5	O
the	the	DET	DT	5	O
induction	induction	NOUN	NN	3	O
by	by	ADP	IN	9	O
statins	statin	NOUN	NNS	5	B-Chemical
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
endoplasmic	endoplasmic	ADJ	JJ	3	O
reticulum	reticulum	NOUN	NN	9	O
stress	stress	NOUN	NN	9	O
response	response	NOUN	NN	9	O
with	with	ADP	IN	5	O
associated	associate	VERB	VBN	9	O
up	up	PART	RP	5	O
-	-	PUNCT	HYPH	7	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
MHC	MHC	PROPN	NNP	3	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
expression	expression	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
antigen	antigen	NOUN	NN	3	O
presentation	presentation	NOUN	NN	5	O
by	by	ADP	IN	9	O
muscle	muscle	NOUN	NN	9	O
fibres	fibre	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Use	Use	PROPN	NNP	5	O
of	of	ADP	IN	5	O
chromosome	chromosome	NOUN	NN	1	O
substitution	substitution	NOUN	NN	9	O
strains	strain	NOUN	NNS	1	O
to	to	PART	TO	5	O
identify	identify	VERB	VB	9	O
seizure	seizure	VERB	VB	5	B-Disease
susceptibility	susceptibility	NOUN	NN	9	O
loci	loci	NOUN	NN	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Seizure	seizure	VERB	VB	5	B-Disease
susceptibility	susceptibility	NOUN	NN	9	O
varies	vary	VERB	VBZ	9	O
among	among	ADP	IN	5	O
inbred	inbreed	VERB	VBN	9	O
mouse	mouse	NOUN	NN	3	O
strains	strain	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

Chromosome	chromosome	NOUN	NN	9	O
substitution	substitution	NOUN	NN	9	O
strains	strain	NOUN	NNS	1	O
(	(	PUNCT	-LRB-	9	O
CSS	CSS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
chromosome	chromosome	NOUN	NN	1	O
from	from	ADP	IN	9	O
one	one	NUM	CD	5	O
inbred	inbreed	VERB	VBN	9	O
strain	strain	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
donor	donor	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
transferred	transfer	VERB	VBN	9	O
onto	onto	ADP	IN	0	O
a	a	DET	DT	5	O
second	second	ADJ	JJ	9	O
strain	strain	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
host	host	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
by	by	ADP	IN	9	O
repeated	repeat	VERB	VBN	5	O
backcrossing	backcrossing	NOUN	NN	9	O
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
identify	identify	VERB	VB	9	O
quantitative	quantitative	ADJ	JJ	9	O
trait	trait	NOUN	NN	5	O
loci	loci	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
QTLs	qtl	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
that	that	DET	WDT	5	O
contribute	contribute	VERB	VBP	9	O
to	to	PART	TO	5	O
seizure	seizure	VERB	VB	5	B-Disease
susceptibility	susceptibility	NOUN	NN	9	O
.	.	PUNCT	.	9	O

QTLs	qtl	NOUN	NNS	9	O
for	for	ADP	IN	5	O
susceptibility	susceptibility	NOUN	NN	9	O
to	to	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
temporal	temporal	ADJ	JJ	5	B-Disease
lobe	lobe	NOUN	NN	5	I-Disease
epilepsy	epilepsy	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
have	have	VERB	VBP	5	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
CSS	css	NOUN	NN	5	O
have	have	VERB	VBP	5	O
not	not	ADV	RB	5	O
previously	previously	ADV	RB	9	O
been	be	VERB	VBN	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
localize	localize	VERB	VB	9	O
seizure	seizure	NOUN	NN	5	B-Disease
susceptibility	susceptibility	NOUN	NN	9	O
genes	gene	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
QTLs	qtl	NOUN	NNS	9	O
identified	identify	VERB	VBD	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
B6	b6	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
host	host	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
x	x	PUNCT	NFP	9	O
A	a	NOUN	NN	9	O
/	/	SYM	SYM	9	O
J	J	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
donor	donor	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
CSS	css	NOUN	NN	5	O
panel	panel	NOUN	NN	3	O
to	to	PART	TO	5	O
localize	localize	VERB	VB	9	O
genes	gene	NOUN	NNS	1	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
susceptibility	susceptibility	NOUN	NN	9	O
to	to	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
hundred	hundred	NUM	CD	5	O
fifty	fifty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
five	five	NUM	CD	9	O
adult	adult	NOUN	NN	9	O
male	male	ADJ	JJ	9	O
CSS	css	NOUN	NN	5	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
58	58	NUM	CD	7	O
B6	b6	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
39	39	NUM	CD	7	O
A	a	NOUN	NN	9	O
/	/	SYM	SYM	9	O
J	J	PROPN	NNP	9	O
were	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
for	for	ADP	IN	5	O
susceptibility	susceptibility	NOUN	NN	9	O
to	to	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Highest	high	ADJ	JJS	7	O
stage	stage	NOUN	NN	9	O
reached	reach	VERB	VBD	9	O
and	and	CCONJ	CC	5	O
latency	latency	NOUN	NN	5	O
to	to	ADP	IN	5	O
each	each	DET	DT	5	O
stage	stage	NOUN	NN	9	O
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
for	for	ADP	IN	5	O
all	all	DET	DT	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

B6	b6	NOUN	NN	3	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
resistant	resistant	ADJ	JJ	9	O
to	to	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
slower	slow	ADJ	JJR	9	O
to	to	PART	TO	5	O
reach	reach	VERB	VB	5	O
stages	stage	NOUN	NNS	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
A	a	NOUN	NN	9	O
/	/	SYM	SYM	9	O
J	J	PROPN	NNP	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
CSS	css	NOUN	NN	5	O
for	for	ADP	IN	5	O
Chromosomes	Chromosomes	PROPN	NNP	9	O
10	10	NUM	CD	9	O
and	and	CCONJ	CC	5	O
18	18	NUM	CD	7	O
progressed	progress	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
severe	severe	ADJ	JJ	5	O
stages	stage	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
diverging	diverge	VERB	VBG	5	O
dramatically	dramatically	ADV	RB	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
B6	B6	PROPN	NNP	3	O
phenotype	phenotype	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Latencies	latency	NOUN	NNS	5	O
to	to	ADP	IN	5	O
stages	stage	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
significantly	significantly	ADV	RB	9	O
shorter	short	ADJ	JJR	9	O
for	for	ADP	IN	5	O
CSS10	CSS10	PROPN	NNP	_	O
and	and	CCONJ	CC	5	O
CSS18	CSS18	PROPN	NNP	3	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

CSS	css	NOUN	NN	5	O
mapping	mapping	NOUN	NN	5	O
suggests	suggest	VERB	VBZ	9	O
seizure	seizure	VERB	VBP	5	B-Disease
susceptibility	susceptibility	NOUN	NN	9	O
loci	loci	NOUN	NN	9	O
on	on	ADP	IN	5	O
mouse	mouse	NOUN	NN	3	O
Chromosomes	Chromosomes	PROPN	NNP	9	O
10	10	NUM	CD	9	O
and	and	CCONJ	CC	5	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
approach	approach	NOUN	NN	5	O
provides	provide	VERB	VBZ	5	O
a	a	DET	DT	5	O
framework	framework	NOUN	NN	5	O
for	for	ADP	IN	5	O
identifying	identify	VERB	VBG	5	O
potentially	potentially	ADV	RB	5	O
novel	novel	ADJ	JJ	9	O
homologous	homologous	ADJ	JJ	1	O
candidate	candidate	NOUN	NN	9	O
genes	gene	NOUN	NNS	1	O
for	for	ADP	IN	5	O
human	human	ADJ	JJ	3	O
temporal	temporal	ADJ	JJ	5	B-Disease
lobe	lobe	NOUN	NN	5	I-Disease
epilepsy	epilepsy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
vitro	vitro	NOUN	NN	3	O
characterization	characterization	NOUN	NN	9	O
of	of	ADP	IN	5	O
parasympathetic	parasympathetic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
sympathetic	sympathetic	ADJ	JJ	5	O
responses	response	NOUN	NNS	5	O
in	in	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cystitis	cystitis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cystitis	cystitis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
,	,	PUNCT	,	9	O
detrusor	detrusor	NOUN	NN	5	O
function	function	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
impaired	impair	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
muscarinic	muscarinic	ADJ	JJ	3	O
receptors	receptor	NOUN	NNS	3	O
altered	alter	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Whether	whether	ADP	IN	9	O
or	or	CCONJ	CC	5	O
not	not	ADV	RB	5	O
the	the	DET	DT	5	O
neuronal	neuronal	ADJ	JJ	3	O
transmission	transmission	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
cystitis	cystitis	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
presently	presently	ADV	RB	9	O
investigated	investigate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Responses	response	NOUN	NNS	5	O
of	of	ADP	IN	5	O
urinary	urinary	ADJ	JJ	9	O
strip	strip	NOUN	NN	5	O
preparations	preparation	NOUN	NNS	9	O
from	from	ADP	IN	9	O
control	control	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
pretreated	pretreate	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
to	to	ADP	IN	5	O
electrical	electrical	ADJ	JJ	5	O
field	field	NOUN	NN	5	O
stimulation	stimulation	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
to	to	ADP	IN	5	O
agonists	agonist	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
muscarinic	muscarinic	ADJ	JJ	3	O
,	,	PUNCT	,	9	O
adrenergic	adrenergic	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
purinergic	purinergic	NOUN	NN	3	O
receptor	receptor	NOUN	NN	3	O
antagonists	antagonist	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Generally	generally	ADV	RB	5	O
,	,	PUNCT	,	9	O
atropine	atropine	NOUN	NN	0	B-Chemical
reduced	reduce	VERB	VBN	9	O
contractions	contraction	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
in	in	ADP	IN	5	O
contrast	contrast	NOUN	NN	9	O
to	to	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
also	also	ADV	RB	9	O
reduced	reduce	VERB	VBD	9	O
responses	response	NOUN	NNS	5	O
to	to	ADP	IN	5	O
low	low	ADJ	JJ	9	O
electrical	electrical	ADJ	JJ	5	O
field	field	NOUN	NN	5	O
stimulation	stimulation	NOUN	NN	3	O
intensity	intensity	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
Hz	Hz	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
inflamed	inflame	VERB	VBN	3	O
preparations	preparation	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
both	both	DET	DT	9	O
types	type	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
purinoceptor	purinoceptor	NOUN	NN	3	O
desensitization	desensitization	NOUN	NN	3	O
with	with	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
beta	beta	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methylene	methylene	NOUN	NN	0	I-Chemical
adenosine	adenosine	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5	5	NUM	CD	9	I-Chemical
'	'	PUNCT	''	9	I-Chemical
-	-	PUNCT	:	7	I-Chemical
triphosphate	triphosphate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
alpha	alpha	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
beta	beta	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
meATP	meatp	NUM	CD	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
caused	cause	VERB	VBD	9	O
further	further	ADJ	JJ	9	O
reductions	reduction	NOUN	NNS	9	O
at	at	ADP	IN	9	O
low	low	ADJ	JJ	9	O
frequencies	frequency	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
<	<	X	XX	0	O
10	10	NUM	CD	9	O
Hz	Hz	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
muscarinic	muscarinic	ADJ	JJ	3	O
receptor	receptor	NOUN	NN	3	O
antagonists	antagonist	VERB	VBZ	3	O
atropine	atropine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
diphenylacetoxy	diphenylacetoxy	ADJ	JJ	_	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
N	n	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methylpiperidine	methylpiperidine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
DAMP	damp	NOUN	NN	3	I-Chemical
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
'	'	PUNCT	``	9	O
M	M	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
M	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
M	m	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
selective	selective	ADJ	JJ	9	O
'	'	PUNCT	''	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
methoctramine	methoctramine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
'	'	PUNCT	``	9	O
M	M	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
selective	selective	ADJ	JJ	9	O
'	'	PUNCT	''	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
pirenzepine	pirenzepine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
'	'	PUNCT	``	9	O
M	M	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
selective	selective	ADJ	JJ	9	O
'	'	PUNCT	''	9	O
)	)	PUNCT	-RRB-	9	O
antagonized	antagonize	VERB	VBD	3	O
the	the	DET	DT	5	O
tonic	tonic	NOUN	NN	5	O
component	component	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
electrical	electrical	ADJ	JJ	5	O
field	field	NOUN	NN	5	O
stimulation	stimulation	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
evoked	evoke	VERB	VBN	5	O
contractile	contractile	NOUN	NN	9	O
response	response	NOUN	NN	9	O
more	more	ADV	RBR	5	O
potently	potently	ADV	RB	3	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
phasic	phasic	NOUN	NN	5	O
component	component	NOUN	NN	9	O
.	.	PUNCT	.	9	O

4	4	PUNCT	LS	9	B-Chemical
-	-	PUNCT	:	7	I-Chemical
DAMP	DAMP	PROPN	NNP	3	I-Chemical
inhibited	inhibit	VERB	VBD	3	O
the	the	DET	DT	5	O
tonic	tonic	NOUN	NN	5	O
contractions	contraction	NOUN	NNS	5	O
in	in	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
more	more	ADV	RBR	5	O
potently	potently	ADV	RB	3	O
than	than	ADP	IN	5	O
methoctramine	methoctramine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
pirenzepine	pirenzepine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
inflamed	inflame	VERB	VBN	3	O
preparations	preparation	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
muscarinic	muscarinic	ADJ	JJ	3	O
receptor	receptor	NOUN	NN	3	O
antagonism	antagonism	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
phasic	phasic	NOUN	NN	5	O
component	component	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
electrical	electrical	ADJ	JJ	5	O
field	field	NOUN	NN	5	O
stimulation	stimulation	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
evoked	evoke	VERB	VBN	5	O
contraction	contraction	NOUN	NN	9	O
was	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
pirenzepine	pirenzepine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	B-Chemical
-	-	PUNCT	:	7	I-Chemical
DAMP	damp	VERB	VB	3	I-Chemical
antagonism	antagonism	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
tonic	tonic	NOUN	NN	5	O
component	component	NOUN	NN	9	O
was	be	VERB	VBD	9	O
much	much	ADV	RB	5	O
less	less	ADV	RBR	5	O
efficient	efficient	ADJ	JJ	5	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
to	to	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
methoctramine	methoctramine	NOUN	NN	0	B-Chemical
increased	increase	VERB	VBN	9	O
-	-	PUNCT	:	7	O
-	-	PUNCT	HYPH	7	O
instead	instead	ADV	RB	5	O
of	of	ADP	IN	5	O
decreased	decrease	VERB	VBN	9	O
-	-	PUNCT	:	7	O
-	-	PUNCT	HYPH	7	O
the	the	DET	DT	5	O
tonic	tonic	NOUN	NN	5	O
responses	response	NOUN	NNS	5	O
at	at	ADP	IN	9	O
high	high	ADJ	JJ	9	O
frequencies	frequency	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

While	while	ADP	IN	9	O
contractions	contraction	NOUN	NNS	5	O
to	to	ADP	IN	5	O
carbachol	carbachol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
ATP	ATP	PROPN	NNP	0	B-Chemical
were	be	VERB	VBD	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
in	in	ADP	IN	5	O
inflamed	inflame	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
control	control	NOUN	NN	9	O
strips	strip	NOUN	NNS	0	O
when	when	ADV	WRB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
reference	reference	NOUN	NN	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
response	response	NOUN	NN	9	O
,	,	PUNCT	,	9	O
isoprenaline	isoprenaline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
relaxations	relaxation	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
smaller	small	ADJ	JJR	5	O
in	in	ADP	IN	5	O
inflamed	inflame	VERB	VBN	3	O
strips	strip	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
cystitis	cystitis	ADJ	JJ	9	B-Disease
substantial	substantial	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
efferent	efferent	ADJ	JJ	5	O
functional	functional	ADJ	JJ	9	O
responses	response	NOUN	NNS	5	O
occur	occur	VERB	VBP	5	O
.	.	PUNCT	.	9	O

While	while	ADP	IN	9	O
postjunctional	postjunctional	ADJ	JJ	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
relaxations	relaxation	NOUN	NNS	0	O
are	be	VERB	VBP	5	O
reduced	reduce	VERB	VBN	9	O
,	,	PUNCT	,	9	O
effects	effect	NOUN	NNS	9	O
by	by	ADP	IN	9	O
prejunctional	prejunctional	ADJ	JJ	0	O
inhibitory	inhibitory	ADJ	JJ	3	O
muscarinic	muscarinic	ADJ	JJ	3	O
receptors	receptor	NOUN	NNS	3	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
increased	increase	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Direct	direct	ADJ	JJ	9	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
hyperpolarization	hyperpolarization	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
activated	activate	VERB	VBN	3	O
cyclic	cyclic	ADJ	JJ	0	B-Chemical
nucleotide	nucleotide	NOUN	NN	1	I-Chemical
-	-	PUNCT	HYPH	7	O
gated	gate	VERB	VBN	3	O
pacemaker	pacemaker	NOUN	NN	5	O
channels	channel	NOUN	NNS	9	O
by	by	ADP	IN	9	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
sympathetic	sympathetic	ADJ	JJ	5	O
tone	tone	NOUN	NN	5	O
represents	represent	VERB	VBZ	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
strategy	strategy	NOUN	NN	5	O
for	for	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
chronic	chronic	ADJ	JJ	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
presynaptic	presynaptic	ADJ	JJ	3	O
alpha2	alpha2	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptors	adrenoceptor	NOUN	NNS	3	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
widely	widely	ADV	RB	5	O
accepted	accept	VERB	VBN	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
antisympathetic	antisympathetic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
other	other	ADJ	JJ	5	O
target	target	NOUN	NN	9	O
proteins	protein	NOUN	NNS	1	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
postulated	postulate	VERB	VBN	9	O
to	to	PART	TO	5	O
contribute	contribute	VERB	VB	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
actions	action	NOUN	NNS	5	O
of	of	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
test	test	VERB	VB	5	O
whether	whether	ADP	IN	9	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
elicits	elicit	VERB	VBZ	9	O
pharmacological	pharmacological	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
independent	independent	ADJ	JJ	9	O
of	of	ADP	IN	5	O
alpha2	alpha2	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptors	adrenoceptor	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
have	have	VERB	VBP	5	O
generated	generate	VERB	VBN	9	O
mice	mouse	NOUN	NNS	3	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
targeted	target	VERB	VBN	9	O
deletion	deletion	NOUN	NN	1	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
3	3	NUM	CD	9	O
alpha2	alpha2	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
subtypes	subtype	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
alpha2ABC	alpha2abc	NOUN	NN	_	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Alpha2ABC	alpha2abc	NOUN	NN	_	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
completely	completely	ADV	RB	9	O
unresponsive	unresponsive	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
analgesic	analgesic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
hypnotic	hypnotic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
significantly	significantly	ADV	RB	9	O
lowered	lower	VERB	VBD	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
in	in	ADP	IN	5	O
alpha2ABC	alpha2ABC	PROPN	NNP	_	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
mice	mouse	NOUN	NNS	3	O
by	by	ADP	IN	9	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
150	150	NUM	CD	0	O
bpm	bpm	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Clonidine	Clonidine	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
conscious	conscious	ADJ	JJ	5	O
alpha2ABC	alpha2ABC	PROPN	NNP	_	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
mice	mouse	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
32	32	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
26	26	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
in	in	ADP	IN	5	O
wild	wild	ADJ	JJ	1	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
similar	similar	ADJ	JJ	9	O
bradycardic	bradycardic	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
isolated	isolate	VERB	VBN	9	O
spontaneously	spontaneously	ADV	RB	5	O
beating	beat	VERB	VBG	5	O
right	right	ADV	RB	5	O
atria	atria	ADV	RB	9	O
from	from	ADP	IN	9	O
alpha2ABC	alpha2abc	NOUN	NN	_	O
-	-	PUNCT	HYPH	7	O
knockout	knockout	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
wild	wild	ADJ	JJ	1	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Clonidine	Clonidine	PROPN	NNP	0	B-Chemical
inhibited	inhibit	VERB	VBD	3	O
the	the	DET	DT	5	O
native	native	ADJ	JJ	9	O
pacemaker	pacemaker	NOUN	NN	5	O
current	current	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
I	i	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
f	f	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
isolated	isolated	ADJ	JJ	9	O
sinoatrial	sinoatrial	ADJ	JJ	5	O
node	node	NOUN	NN	5	O
pacemaker	pacemaker	NOUN	NN	5	O
cells	cell	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
I	i	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
f	f	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
generating	generate	VERB	VBG	9	O
hyperpolarization	hyperpolarization	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
activated	activate	VERB	VBN	3	O
cyclic	cyclic	ADJ	JJ	0	B-Chemical
nucleotide	nucleotide	NOUN	NN	1	I-Chemical
-	-	PUNCT	HYPH	7	O
gated	gate	VERB	VBN	3	O
(	(	PUNCT	-LRB-	9	O
HCN	HCN	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
2	2	NUM	CD	9	O
and	and	CCONJ	CC	5	O
HCN4	HCN4	PROPN	NNP	3	O
channels	channel	NOUN	NNS	9	O
in	in	ADP	IN	5	O
transfected	transfecte	VERB	VBN	3	O
HEK293	HEK293	PROPN	NNP	3	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
a	a	DET	DT	5	O
consequence	consequence	NOUN	NN	5	O
of	of	ADP	IN	5	O
blocking	block	VERB	VBG	3	O
I	-PRON-	PRON	PRP	9	O
(	(	PUNCT	-LRB-	9	O
f	f	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
slope	slope	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
diastolic	diastolic	ADJ	JJ	5	O
depolarization	depolarization	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
pacemaker	pacemaker	NOUN	NN	5	O
potentials	potential	NOUN	NNS	5	O
in	in	ADP	IN	5	O
sinoatrial	sinoatrial	ADJ	JJ	5	O
node	node	NOUN	NN	5	O
cells	cell	NOUN	NNS	3	O
from	from	ADP	IN	9	O
wild	wild	ADJ	JJ	1	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
alpha2ABC	alpha2abc	NOUN	NN	_	O
-	-	PUNCT	HYPH	7	O
knockout	knockout	NOUN	NN	3	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Direct	direct	ADJ	JJ	9	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
HCN	HCN	PROPN	NNP	0	O
pacemaker	pacemaker	NOUN	NN	5	O
channels	channel	NOUN	NNS	9	O
contributes	contribute	VERB	VBZ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
bradycardic	bradycardic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
clonidine	clonidine	ADJ	JJ	0	B-Chemical
gene	gene	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
targeted	target	VERB	VBN	9	O
mice	mouse	NOUN	NNS	3	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
represent	represent	VERB	VBP	9	O
novel	novel	ADJ	JJ	9	O
structures	structure	NOUN	NNS	9	O
for	for	ADP	IN	5	O
future	future	ADJ	JJ	5	O
HCN	HCN	PROPN	NNP	0	O
channel	channel	NOUN	NN	9	O
inhibitors	inhibitor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Granulomatous	granulomatous	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
combination	combination	NOUN	NN	9	B-Chemical
of	of	ADP	IN	5	I-Chemical
amoxicillin	amoxicillin	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	I-Chemical
clavulanic	clavulanic	NOUN	NN	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
amoxicillin	amoxicillin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
clavulanic	clavulanic	NOUN	NN	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
with	with	ADP	IN	5	O
histologic	histologic	ADJ	JJ	9	O
multiple	multiple	ADJ	JJ	5	O
granulomas	granuloma	NOUN	NNS	9	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
lesion	lesion	NOUN	NN	5	O
broadens	broaden	VERB	VBZ	5	O
the	the	DET	DT	5	O
spectrum	spectrum	NOUN	NN	9	O
of	of	ADP	IN	5	O
liver	liver	NOUN	NN	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
combination	combination	NOUN	NN	9	O
,	,	PUNCT	,	9	O
mainly	mainly	ADV	RB	9	O
represented	represent	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
benign	benign	ADJ	JJ	5	O
cholestatic	cholestatic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
association	association	NOUN	NN	9	O
of	of	ADP	IN	5	O
granulomas	granuloma	NOUN	NNS	9	B-Disease
and	and	CCONJ	CC	5	O
eosinophilia	eosinophilia	NOUN	NNS	3	B-Disease
favor	favor	VERB	VBP	9	O
an	an	DET	DT	5	O
immunoallergic	immunoallergic	ADJ	JJ	5	O
mechanism	mechanism	NOUN	NN	9	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
penicillin	penicillin	NOUN	NN	0	B-Chemical
derivatives	derivative	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
amoxicillin	amoxicillin	VERB	VB	0	B-Chemical
alone	alone	ADV	RB	9	O
are	be	VERB	VBP	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
such	such	ADJ	JJ	5	O
types	type	NOUN	NNS	9	O
of	of	ADP	IN	5	O
lesions	lesion	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
amoxicillin	amoxicillin	NOUN	NN	0	B-Chemical
component	component	NOUN	NN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
a	a	DET	DT	5	O
potentiating	potentiating	ADJ	JJ	3	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
clavulanic	clavulanic	NOUN	NN	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
might	may	VERB	MD	9	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Dobutamine	dobutamine	NOUN	NN	0	B-Chemical
stress	stress	NOUN	NN	9	O
echocardiography	echocardiography	NOUN	NN	5	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
sensitive	sensitive	ADJ	JJ	9	O
indicator	indicator	NOUN	NN	9	O
of	of	ADP	IN	5	O
diminished	diminished	ADJ	JJ	9	O
myocardial	myocardial	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
asymptomatic	asymptomatic	ADJ	JJ	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
survivors	survivor	NOUN	NNS	5	O
of	of	ADP	IN	5	O
childhood	childhood	NOUN	NN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

Doxorubicin	Doxorubicin	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
anticancer	anticancer	NOUN	NN	0	O
chemotherapeutic	chemotherapeutic	ADJ	JJ	3	O
agent	agent	NOUN	NN	9	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
acute	acute	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
chronic	chronic	ADJ	JJ	5	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
develop	develop	VERB	VB	5	O
a	a	DET	DT	5	O
more	more	ADV	RBR	5	O
sensitive	sensitive	ADJ	JJ	9	O
echocardiographic	echocardiographic	ADJ	JJ	5	O
screening	screening	NOUN	NN	5	O
test	test	NOUN	NN	5	O
for	for	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
damage	damage	NOUN	NN	9	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
cohort	cohort	NOUN	NN	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
using	use	VERB	VBG	9	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
infusion	infusion	NOUN	NN	0	O
to	to	PART	TO	5	O
differentiate	differentiate	VERB	VB	9	O
asymptomatic	asymptomatic	ADJ	JJ	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
survivors	survivor	NOUN	NNS	5	O
of	of	ADP	IN	5	O
childhood	childhood	NOUN	NN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
from	from	ADP	IN	9	O
healthy	healthy	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Echocardiographic	echocardiographic	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
21	21	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
age	age	NOUN	NN	5	O
16	16	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
treated	treat	VERB	VBN	3	O
from	from	ADP	IN	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
to	to	PART	TO	5	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
years	year	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
median	median	NOUN	NN	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
before	before	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
with	with	ADP	IN	5	O
27	27	NUM	CD	7	O
to	to	ADP	IN	5	O
532	532	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
196	196	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
echocardiographic	echocardiographic	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
from	from	ADP	IN	9	O
12	12	NUM	CD	9	O
normal	normal	ADJ	JJ	9	O
age	age	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
matched	match	VERB	VBN	9	O
control	control	NOUN	NN	9	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Graded	grade	VERB	VBN	5	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
infusions	infusion	NOUN	NNS	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
kg	kg	VERB	VB	0	O
per	per	ADP	IN	9	O
min	min	NOUN	NN	0	O
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Echocardiographic	Echocardiographic	PROPN	NNP	5	O
Doppler	Doppler	PROPN	NNP	5	O
studies	study	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
before	before	ADP	IN	9	O
infusion	infusion	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
15	15	NUM	CD	9	O
min	min	NOUN	NN	0	O
of	of	ADP	IN	5	O
infusion	infusion	NOUN	NN	0	O
at	at	ADP	IN	9	O
each	each	DET	DT	5	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Dobutamine	dobutamine	NOUN	NN	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
at	at	ADP	IN	9	O
10	10	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
kg	kg	VERB	VB	0	O
per	per	ADP	IN	9	O
min	min	NOUN	NN	0	O
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
after	after	ADP	IN	9	O
six	six	NUM	CD	9	O
studies	study	NOUN	NNS	9	O
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
incidence	incidence	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
important	important	ADJ	JJ	9	O
findings	finding	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
that	that	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
values	value	NOUN	NNS	5	O
in	in	ADP	IN	5	O
control	control	NOUN	NN	9	O
subjects	subject	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
end	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
systolic	systolic	NOUN	NN	5	O
left	leave	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	O
posterior	posterior	ADJ	JJ	5	O
wall	wall	NOUN	NN	5	O
dimension	dimension	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
percent	percent	NOUN	NN	5	O
of	of	ADP	IN	5	O
left	left	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	O
posterior	posterior	ADJ	JJ	5	O
wall	wall	NOUN	NN	5	O
thickening	thickening	NOUN	NN	5	O
in	in	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
at	at	ADP	IN	9	O
baseline	baseline	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
these	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
clearly	clearly	ADV	RB	9	O
delineated	delineate	VERB	VBN	5	O
with	with	ADP	IN	5	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
stimulation	stimulation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

End	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
systolic	systolic	NOUN	NN	5	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	O
posterior	posterior	ADJ	JJ	5	O
wall	wall	NOUN	NN	5	O
dimension	dimension	NOUN	NN	5	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
11	11	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
mm	mm	NOUN	NN	9	O
versus	versus	ADP	IN	9	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
for	for	ADP	IN	5	O
control	control	NOUN	NN	9	O
subjects	subject	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

End	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
systolic	systolic	NOUN	NN	5	O
left	leave	VERB	VBD	5	O
ventricular	ventricular	ADJ	JJ	5	O
posterior	posterior	ADJ	JJ	5	O
wall	wall	NOUN	NN	5	O
dimension	dimension	NOUN	NN	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	VERB	VB	0	O
per	per	ADP	IN	9	O
min	min	NOUN	NN	0	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
infusion	infusion	NOUN	NN	0	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
versus	versus	ADP	IN	9	O
19	19	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
mm	mm	NOUN	NNS	9	O
for	for	ADP	IN	5	O
control	control	NOUN	NN	9	O
subjects	subject	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
250	250	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

Influence	influence	NOUN	NN	9	O
of	of	ADP	IN	5	O
smoking	smoke	VERB	VBG	5	B-Chemical
on	on	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
cochlea	cochlea	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Does	do	VERB	VBZ	5	O
smoking	smoke	VERB	VBG	5	B-Chemical
during	during	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
affect	affect	VERB	VBP	9	O
the	the	DET	DT	5	O
amplitudes	amplitude	NOUN	NNS	5	O
of	of	ADP	IN	5	O
transient	transient	ADJ	JJ	9	O
evoked	evoke	VERB	VBN	5	O
otoacoustic	otoacoustic	ADJ	JJ	5	O
emissions	emission	NOUN	NNS	5	O
in	in	ADP	IN	5	O
newborns	newborn	NOUN	NNS	5	O
?	?	PUNCT	.	5	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Maternal	maternal	ADJ	JJ	9	O
tobacco	tobacco	NOUN	NN	5	O
smoking	smoking	NOUN	NN	5	B-Chemical
has	have	VERB	VBZ	9	O
negative	negative	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
fetal	fetal	ADJ	JJ	9	O
growth	growth	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
smoking	smoking	NOUN	NN	5	B-Chemical
during	during	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
developing	develop	VERB	VBG	5	O
cochlea	cochlea	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
estimated	estimate	VERB	VBN	5	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
smoking	smoking	NOUN	NN	5	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
positively	positively	ADV	RB	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
hearing	hear	VERB	VBG	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
adults	adult	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
objective	objective	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
maternal	maternal	ADJ	JJ	9	O
smoking	smoking	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
transient	transient	ADJ	JJ	9	O
evoked	evoke	VERB	VBN	5	O
otoacoustic	otoacoustic	ADJ	JJ	5	O
emissions	emission	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
TEOAEs	teoae	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
neonates	neonate	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
undertaken	undertake	VERB	VBN	5	O
as	as	ADP	IN	5	O
part	part	NOUN	NN	9	O
of	of	ADP	IN	5	O
neonatal	neonatal	ADJ	JJ	9	O
screening	screening	NOUN	NN	5	O
for	for	ADP	IN	5	O
hearing	hear	VERB	VBG	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
involved	involve	VERB	VBD	9	O
both	both	DET	DT	9	O
ears	ear	NOUN	NNS	5	O
of	of	ADP	IN	5	O
200	200	NUM	CD	0	O
newborns	newborn	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Newborns	newborn	NOUN	NNS	5	O
whose	whose	DET	WP$	9	O
mothers	mother	NOUN	NNS	5	O
reported	report	VERB	VBD	9	O
smoking	smoke	VERB	VBG	5	B-Chemical
during	during	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	X	XX	7	O
200	200	NUM	CD	0	O
ears	ear	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
newborns	newborn	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	X	XX	7	O
200	200	NUM	CD	0	O
ears	ear	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
whose	whose	DET	WP$	9	O
mothers	mother	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
non	non	ADJ	JJ	9	O
-	-	NOUN	NNS	7	O
smokers	smoker	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
tobacco	tobacco	NOUN	NN	5	O
was	be	VERB	VBD	9	O
characterized	characterize	VERB	VBN	9	O
as	as	ADP	IN	5	O
low	low	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
<	<	X	XX	0	O
5	5	NUM	CD	9	O
cigarettes	cigarette	NOUN	NNS	5	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
88	88	NUM	CD	7	O
ears	ear	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
moderate	moderate	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
cigarettes	cigarette	NOUN	NNS	5	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
<	<	X	XX	0	O
10	10	NUM	CD	9	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
76	76	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
high	high	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
10	10	NUM	CD	9	O
cigarettes	cigarette	NOUN	NNS	5	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
36	36	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
exposed	expose	VERB	VBN	9	O
neonates	neonate	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
TEOAEs	teoae	NOUN	NNS	5	O
mean	mean	VERB	VBP	5	O
response	response	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
across	across	ADP	IN	5	O
frequency	frequency	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
mean	mean	VERB	VB	5	O
amplitude	amplitude	NOUN	NN	5	O
at	at	ADP	IN	9	O
4000Hz	4000hz	NUM	CD	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
exposed	expose	VERB	VBN	9	O
neonates	neonate	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Comparisons	comparison	NOUN	NNS	9	O
between	between	ADP	IN	5	O
exposed	expose	VERB	VBN	9	O
newborns	newborn	NOUN	NNS	5	O
'	'	PART	POS	9	O
subgroups	subgroup	NOUN	NNS	9	O
revealed	reveal	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
by	by	ADP	IN	9	O
comparing	compare	VERB	VBG	9	O
each	each	DET	DT	5	O
subgroup	subgroup	NOUN	NN	9	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
found	find	VERB	VBD	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
decreases	decrease	NOUN	NNS	9	B-Disease
of	of	ADP	IN	5	I-Disease
TEOAEs	teoae	NOUN	NNS	5	I-Disease
amplitudes	amplitude	NOUN	NNS	5	I-Disease
at	at	ADP	IN	9	O
4000Hz	4000hz	NUM	CD	9	O
for	for	ADP	IN	5	O
all	all	DET	DT	5	O
three	three	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Mean	mean	ADJ	JJ	9	O
TEOAEs	teoae	NOUN	NNS	5	O
responses	response	NOUN	NNS	5	O
of	of	ADP	IN	5	O
highly	highly	ADV	RB	9	O
exposed	expose	VERB	VBN	9	O
newborns	newborn	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
comparison	comparison	NOUN	NN	9	O
to	to	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
utero	utero	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
tobacco	tobacco	NOUN	NN	5	O
smoking	smoking	NOUN	NN	5	B-Chemical
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
small	small	ADJ	JJ	9	O
impact	impact	NOUN	NN	5	O
on	on	ADP	IN	5	O
outer	outer	ADJ	JJ	9	O
hair	hair	NOUN	NN	5	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
seem	seem	VERB	VBP	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
equally	equally	ADV	RB	9	O
true	true	ADJ	JJ	5	O
for	for	ADP	IN	5	O
all	all	DET	DT	5	O
exposed	expose	VERB	VBN	9	O
newborns	newborn	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
regardless	regardless	ADV	RB	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
exposure	exposure	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
needed	need	VERB	VBN	5	O
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
establish	establish	VERB	VB	5	O
a	a	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
negative	negative	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
maternal	maternal	ADJ	JJ	9	O
smoking	smoking	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
neonate	neonate	NOUN	NN	9	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
hearing	hear	VERB	VBG	5	O
acuity	acuity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Simvastatin	Simvastatin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
bilateral	bilateral	ADJ	JJ	5	O
leg	leg	NOUN	NN	5	O
compartment	compartment	NOUN	NN	9	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
myonecrosis	myonecrosis	NOUN	NN	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
hypothyroidism	hypothyroidism	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
54	54	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
hypothyroid	hypothyroid	ADJ	JJ	9	B-Disease
male	male	NOUN	NN	9	O
taking	take	VERB	VBG	5	O
thyroxine	thyroxine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
bilateral	bilateral	ADJ	JJ	5	O
leg	leg	NOUN	NN	5	O
compartment	compartment	NOUN	NN	9	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
myonecrosis	myonecrosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Urgent	urgent	ADJ	JJ	5	O
fasciotomies	fasciotomie	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
made	make	VERB	VBD	5	O
an	an	DET	DT	5	O
uneventful	uneventful	ADJ	JJ	5	O
recovery	recovery	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
likely	likely	ADJ	JJ	5	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
complication	complication	NOUN	NN	5	O
will	will	VERB	MD	5	O
be	be	VERB	VB	5	O
seen	see	VERB	VBN	9	O
more	more	ADV	RBR	5	O
often	often	ADV	RB	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
worldwide	worldwide	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
approval	approval	NOUN	NN	5	O
for	for	ADP	IN	5	O
all	all	DET	DT	5	O
arteriopathic	arteriopathic	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Neuroinflammation	neuroinflammation	NOUN	NN	3	B-Disease
and	and	CCONJ	CC	5	O
behavioral	behavioral	ADJ	JJ	5	B-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
after	after	ADP	IN	9	O
neonatal	neonatal	ADJ	JJ	9	O
terbutaline	terbutaline	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
implications	implication	NOUN	NNS	5	O
for	for	ADP	IN	5	O
autism	autism	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Autism	autism	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
neurodevelopmental	neurodevelopmental	ADJ	JJ	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
presenting	present	VERB	VBG	5	O
before	before	ADP	IN	9	O
3	3	NUM	CD	9	O
years	year	NOUN	NNS	5	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
with	with	ADP	IN	5	O
deficits	deficit	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	I-Disease
communication	communication	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
social	social	ADJ	JJ	5	I-Disease
skills	skill	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
repetitive	repetitive	ADJ	JJ	5	B-Disease
behaviors	behavior	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
genetic	genetic	ADJ	JJ	5	O
influences	influence	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
recent	recent	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
prenatal	prenatal	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
chemical	chemical	NOUN	NN	0	O
exposures	exposure	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
for	for	ADP	IN	5	O
autism	autism	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Terbutaline	Terbutaline	PROPN	NNP	7	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
beta2	beta2	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
agonist	agonist	NOUN	NN	3	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
arrest	arrest	VERB	VB	3	O
preterm	preterm	ADJ	JJ	5	B-Disease
labor	labor	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
concordance	concordance	NOUN	NN	9	O
for	for	ADP	IN	5	O
autism	autism	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
dizygotic	dizygotic	ADJ	JJ	5	O
twins	twin	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
studied	study	VERB	VBD	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
terbutaline	terbutaline	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
microglial	microglial	ADJ	JJ	3	O
activation	activation	NOUN	NN	3	O
in	in	ADP	IN	5	O
different	different	ADJ	JJ	9	O
brain	brain	NOUN	NN	5	O
regions	region	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
behavioral	behavioral	ADJ	JJ	5	O
outcomes	outcome	NOUN	NNS	5	O
in	in	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Newborn	newborn	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
terbutaline	terbutaline	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
daily	daily	ADV	RB	5	O
on	on	ADP	IN	5	O
postnatal	postnatal	ADJ	JJ	9	O
days	day	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
PN	PN	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
2	2	NUM	CD	9	O
to	to	ADP	IN	5	O
5	5	NUM	CD	9	O
or	or	CCONJ	CC	5	O
PN	PN	PROPN	NNP	9	O
11	11	NUM	CD	7	O
to	to	ADP	IN	5	O
14	14	NUM	CD	7	O
and	and	CCONJ	CC	5	O
examined	examine	VERB	VBN	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
PN	PN	PROPN	NNP	9	O
30	30	NUM	CD	9	O
.	.	PUNCT	.	9	O

Immunohistochemical	immunohistochemical	ADJ	JJ	3	O
studies	study	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
terbutaline	terbutaline	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
PN	PN	PROPN	NNP	9	O
2	2	NUM	CD	9	O
to	to	PART	TO	5	O
5	5	NUM	CD	9	O
produced	produce	VERB	VBD	9	O
a	a	DET	DT	5	O
robust	robust	ADJ	JJ	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
microglial	microglial	ADJ	JJ	3	O
activation	activation	NOUN	NN	3	O
on	on	ADP	IN	5	O
PN	PN	PROPN	NNP	9	O
30	30	NUM	CD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cerebral	cerebral	ADJ	JJ	5	O
cortex	cortex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
in	in	ADP	IN	5	O
cerebellar	cerebellar	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
cerebrocortical	cerebrocortical	ADJ	JJ	3	O
white	white	ADJ	JJ	9	O
matter	matter	NOUN	NN	5	O
.	.	PUNCT	.	9	O

None	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
given	give	VERB	VBN	5	O
terbutaline	terbutaline	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
PN	PN	PROPN	NNP	9	O
11	11	NUM	CD	7	O
to	to	ADP	IN	5	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
behavioral	behavioral	ADJ	JJ	5	O
tests	test	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
animals	animal	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
terbutaline	terbutaline	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
PN	PN	PROPN	NNP	9	O
2	2	NUM	CD	9	O
to	to	PART	TO	5	O
5	5	NUM	CD	9	O
showed	show	VERB	VBD	9	O
consistent	consistent	ADJ	JJ	9	O
patterns	pattern	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hyper	hyper	NOUN	NN	5	O
-	-	NOUN	NN	7	O
reactivity	reactivity	NOUN	NN	9	O
to	to	ADP	IN	5	O
novelty	novelty	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
aversive	aversive	ADJ	JJ	5	O
stimuli	stimulus	NOUN	NNS	5	O
when	when	ADV	WRB	5	O
assessed	assess	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
open	open	ADJ	JJ	5	O
field	field	NOUN	NN	5	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
acoustic	acoustic	ADJ	JJ	5	O
startle	startle	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
findings	finding	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
beta2	beta2	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
overstimulation	overstimulation	NOUN	NN	5	O
during	during	ADP	IN	5	O
an	an	DET	DT	5	O
early	early	ADJ	JJ	9	O
critical	critical	ADJ	JJ	9	O
period	period	NOUN	NN	5	O
results	result	NOUN	NNS	9	O
in	in	ADP	IN	5	O
microglial	microglial	ADJ	JJ	3	O
activation	activation	NOUN	NN	3	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
innate	innate	ADJ	JJ	5	O
neuroinflammatory	neuroinflammatory	ADJ	JJ	3	O
pathways	pathway	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
behavioral	behavioral	ADJ	JJ	5	B-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
,	,	PUNCT	,	9	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
described	describe	VERB	VBN	9	O
in	in	ADP	IN	5	O
autism	autism	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
provides	provide	VERB	VBZ	5	O
a	a	DET	DT	5	O
useful	useful	ADJ	JJ	5	O
animal	animal	NOUN	NN	5	O
model	model	NOUN	NN	5	O
for	for	ADP	IN	5	O
understanding	understand	VERB	VBG	5	O
the	the	DET	DT	5	O
neuropathological	neuropathological	ADJ	JJ	5	O
processes	process	NOUN	NNS	5	O
underlying	underlie	VERB	VBG	5	O
autism	autism	NOUN	NN	5	B-Disease
spectrum	spectrum	NOUN	NN	9	I-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Upregulation	upregulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
P	p	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
glycoprotein	glycoprotein	NOUN	NN	3	O
in	in	ADP	IN	5	O
MRP2	MRP2	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
deficient	deficient	ADJ	JJ	3	O
TR	TR	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
resembles	resemble	VERB	VBZ	9	O
seizure	seizure	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
up	up	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
efflux	efflux	NOUN	NN	0	O
transporter	transporter	NOUN	NN	1	O
in	in	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
multidrug	multidrug	NOUN	NN	9	O
resistance	resistance	NOUN	NN	9	O
protein	protein	NOUN	NN	1	O
2	2	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
MRP2	MRP2	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
drug	drug	NOUN	NN	5	O
efflux	efflux	NOUN	NN	0	O
transporter	transporter	NOUN	NN	1	O
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
expressed	express	VERB	VBN	3	O
predominantly	predominantly	ADV	RB	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
apical	apical	ADJ	JJ	9	O
domain	domain	NOUN	NN	1	O
of	of	ADP	IN	5	O
hepatocytes	hepatocyte	NOUN	NNS	3	O
but	but	CCONJ	CC	9	O
seems	seem	VERB	VBZ	5	O
also	also	ADV	RB	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
expressed	express	VERB	VBN	3	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
apical	apical	ADJ	JJ	9	O
membrane	membrane	NOUN	NN	9	O
of	of	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
capillary	capillary	ADJ	JJ	0	O
endothelial	endothelial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
that	that	DET	WDT	5	O
form	form	VERB	VBP	9	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
brain	brain	NOUN	NN	5	O
barrier	barrier	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
BBB	BBB	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

MRP2	MRP2	PROPN	NNP	3	O
is	be	VERB	VBZ	5	O
absent	absent	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
transport	transport	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
deficient	deficient	ADJ	JJ	3	O
(	(	PUNCT	-LRB-	9	O
TR	TR	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
Wistar	wistar	NOUN	NN	9	O
rat	rat	NOUN	NN	3	O
mutant	mutant	NOUN	NN	1	O
,	,	PUNCT	,	9	O
so	so	ADP	IN	5	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
rat	rat	NOUN	NN	3	O
strain	strain	NOUN	NN	1	O
was	be	VERB	VBD	9	O
very	very	ADV	RB	5	O
helpful	helpful	ADJ	JJ	6	O
in	in	ADP	IN	5	O
defining	define	VERB	VBG	5	O
substrates	substrate	NOUN	NNS	0	O
of	of	ADP	IN	5	O
MRP2	MRP2	PROPN	NNP	3	O
by	by	ADP	IN	9	O
comparing	compare	VERB	VBG	9	O
tissue	tissue	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
or	or	CCONJ	CC	5	O
functional	functional	ADJ	JJ	9	O
activities	activity	NOUN	NNS	9	O
of	of	ADP	IN	5	O
compounds	compound	NOUN	NNS	0	O
in	in	ADP	IN	5	O
MRP2	MRP2	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
deficient	deficient	ADJ	JJ	3	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
in	in	ADP	IN	5	O
transport	transport	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
competent	competent	ADJ	JJ	9	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
using	use	VERB	VBG	9	O
this	this	DET	DT	5	O
strategy	strategy	NOUN	NN	5	O
to	to	PART	TO	5	O
study	study	VERB	VB	9	O
the	the	DET	DT	5	O
involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
MRP2	MRP2	PROPN	NNP	3	O
in	in	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
access	access	NOUN	NN	5	O
of	of	ADP	IN	5	O
antiepileptic	antiepileptic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
AEDs	AEDs	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
recently	recently	ADV	RB	9	O
reported	report	VERB	VBD	9	O
that	that	ADP	IN	5	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
substrate	substrate	NOUN	NN	0	O
for	for	ADP	IN	5	O
MRP2	MRP2	PROPN	NNP	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
BBB	BBB	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
drawback	drawback	NOUN	NN	5	O
of	of	ADP	IN	5	O
such	such	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
in	in	ADP	IN	5	O
genetically	genetically	ADV	RB	9	O
deficient	deficient	ADJ	JJ	3	O
rats	rat	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
fact	fact	NOUN	NN	9	O
that	that	ADP	IN	5	O
compensatory	compensatory	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
with	with	ADP	IN	5	O
upregulation	upregulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
other	other	ADJ	JJ	5	O
transporters	transporter	NOUN	NNS	1	O
can	can	VERB	MD	5	O
occur	occur	VERB	VB	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
prompted	prompt	VERB	VBD	9	O
us	-PRON-	PRON	PRP	5	O
to	to	PART	TO	5	O
study	study	VERB	VB	9	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
P	p	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
glycoprotein	glycoprotein	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
Pgp	Pgp	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
efflux	efflux	NOUN	NN	0	O
transporter	transporter	NOUN	NN	1	O
in	in	ADP	IN	5	O
many	many	ADJ	JJ	5	O
tissues	tissue	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
the	the	DET	DT	5	O
BBB	BBB	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
TR	TR	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
nonmutant	nonmutant	ADJ	JJ	1	O
(	(	PUNCT	-LRB-	9	O
wild	wild	ADJ	JJ	1	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
Wistar	wistar	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
MRP2	MRP2	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
Pgp	Pgp	PROPN	NNP	3	O
in	in	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
liver	liver	NOUN	NN	9	O
sections	section	NOUN	NNS	9	O
of	of	ADP	IN	5	O
TR	TR	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
normal	normal	ADJ	JJ	9	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
with	with	ADP	IN	5	O
immunohistochemistry	immunohistochemistry	NOUN	NN	3	O
,	,	PUNCT	,	9	O
by	by	ADP	IN	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
novel	novel	NOUN	NN	9	O
,	,	PUNCT	,	9	O
highly	highly	ADV	RB	9	O
selective	selective	ADJ	JJ	9	O
monoclonal	monoclonal	ADJ	JJ	3	O
MRP2	MRP2	PROPN	NNP	3	O
antibody	antibody	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
monoclonal	monoclonal	ADJ	JJ	3	O
Pgp	Pgp	PROPN	NNP	3	O
antibody	antibody	NOUN	NN	3	O
C219	C219	PROPN	NNP	8	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Immunofluorescence	immunofluorescence	NOUN	NN	3	O
staining	staining	NOUN	NN	3	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
MRP2	MRP2	PROPN	NNP	3	O
antibody	antibody	NOUN	NN	3	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
label	label	VERB	VB	9	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
microvessels	microvessel	NOUN	NNS	3	O
throughout	throughout	ADP	IN	9	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
in	in	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
such	such	ADJ	JJ	5	O
labeling	labeling	NOUN	NN	3	O
was	be	VERB	VBD	9	O
absent	absent	ADJ	JJ	9	O
in	in	ADP	IN	5	O
TR	TR	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

TR	TR	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
exhibited	exhibit	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
up	up	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
Pgp	Pgp	PROPN	NNP	3	O
in	in	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
capillary	capillary	ADJ	JJ	0	O
endothelial	endothelial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
wild	wild	ADJ	JJ	1	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
such	such	ADJ	JJ	5	O
obvious	obvious	ADJ	JJ	9	O
upregulation	upregulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
Pgp	Pgp	PROPN	NNP	3	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
sections	section	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
comparable	comparable	ADJ	JJ	9	O
overexpression	overexpression	NOUN	NN	3	O
of	of	ADP	IN	5	O
Pgp	Pgp	PROPN	NNP	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
BBB	BBB	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
after	after	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
wild	wild	ADJ	JJ	1	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
Wistar	wistar	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Experiments	experiment	NOUN	NNS	9	O
with	with	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Pgp	Pgp	PROPN	NNP	3	O
substrate	substrate	NOUN	NN	0	O
phenobarbital	phenobarbital	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
Pgp	Pgp	PROPN	NNP	3	O
inhibitor	inhibitor	NOUN	NN	3	O
tariquidar	tariquidar	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
TR	TR	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
substantiated	substantiate	VERB	VBD	9	O
that	that	ADP	IN	5	O
Pgp	Pgp	PROPN	NNP	3	O
is	be	VERB	VBZ	5	O
functional	functional	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
compensates	compensate	NOUN	NNS	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
lack	lack	NOUN	NN	9	O
of	of	ADP	IN	5	O
MRP2	MRP2	PROPN	NNP	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
BBB	BBB	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
on	on	ADP	IN	5	O
TR	TR	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
Pgp	Pgp	PROPN	NNP	3	O
plays	play	VERB	VBZ	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
compensation	compensation	NOUN	NN	5	O
of	of	ADP	IN	5	O
MRP2	MRP2	PROPN	NNP	3	O
deficiency	deficiency	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
BBB	BBB	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
such	such	DET	PDT	5	O
a	a	DET	DT	5	O
compensatory	compensatory	ADJ	JJ	5	O
mechanism	mechanism	NOUN	NN	9	O
most	most	ADV	RBS	9	O
likely	likely	ADJ	JJ	5	O
occurs	occur	VERB	VBZ	9	O
to	to	PART	TO	5	O
reduce	reduce	VERB	VB	5	O
injury	injury	NOUN	NN	9	B-Disease
to	to	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
brain	brain	NOUN	NN	5	I-Disease
from	from	ADP	IN	9	O
cytotoxic	cytotoxic	NOUN	NN	3	O
compounds	compound	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
data	datum	NOUN	NNS	5	O
substantiate	substantiate	VERB	VBP	9	O
the	the	DET	DT	5	O
concept	concept	NOUN	NN	5	O
that	that	ADP	IN	5	O
MRP2	MRP2	PROPN	NNP	3	O
performs	perform	VERB	VBZ	5	O
a	a	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
BBB	BBB	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
our	-PRON-	DET	PRP$	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
TR	TR	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
an	an	DET	DT	5	O
interesting	interesting	ADJ	JJ	9	O
tool	tool	NOUN	NN	5	O
to	to	PART	TO	5	O
study	study	VERB	VB	9	O
consequences	consequence	NOUN	NNS	5	O
of	of	ADP	IN	5	O
overexpression	overexpression	NOUN	NN	3	O
of	of	ADP	IN	5	O
Pgp	Pgp	PROPN	NNP	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
BBB	BBB	PROPN	NNP	9	O
on	on	ADP	IN	5	O
access	access	NOUN	NN	5	O
of	of	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
,	,	PUNCT	,	9	O
without	without	ADP	IN	9	O
the	the	DET	DT	5	O
need	need	NOUN	NN	5	O
of	of	ADP	IN	5	O
inducing	induce	VERB	VBG	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
or	or	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
Pgp	Pgp	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
enhancing	enhance	VERB	VBG	9	O
events	event	NOUN	NNS	5	O
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
xanthine	xanthine	NOUN	NN	0	B-Chemical
oxidase	oxidase	NOUN	NN	0	O
in	in	ADP	IN	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

1	1	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

Glucocorticoid	Glucocorticoid	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
GC	GC	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
HT	HT	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
redox	redox	NOUN	NN	0	O
imbalance	imbalance	NOUN	NN	9	O
.	.	PUNCT	.	9	O

2	2	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
studied	study	VERB	VBD	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
xanthine	xanthine	NOUN	NN	0	B-Chemical
oxidase	oxidase	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
XO	XO	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
production	production	NOUN	NN	9	O
of	of	ADP	IN	5	O
reactive	reactive	ADJ	JJ	9	O
oxygen	oxygen	NOUN	NN	0	O
species	specie	NOUN	NNS	4	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
dex	dex	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
HT	HT	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

3	3	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
male	male	NOUN	NN	9	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
divided	divide	VERB	VBN	5	O
randomly	randomly	ADV	RB	5	O
into	into	ADP	IN	9	O
four	four	NUM	CD	9	O
treatment	treatment	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
saline	saline	NOUN	NN	0	O
,	,	PUNCT	,	9	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
dex	dex	NOUN	NN	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
allopurinol	allopurinol	VERB	VB	0	B-Chemical
plus	plus	CCONJ	CC	9	O
saline	saline	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
allopurinol	allopurinol	VERB	VB	0	B-Chemical
plus	plus	CCONJ	CC	9	O
dex	dex	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

4	4	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

Systolic	systolic	ADJ	JJ	7	O
blood	blood	NOUN	NN	9	O
pressures	pressure	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
SBP	SBP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
bodyweights	bodyweight	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
each	each	DET	DT	5	O
alternate	alternate	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Thymus	thymus	ADJ	JJ	9	O
weight	weight	NOUN	NN	9	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
marker	marker	NOUN	NN	3	O
of	of	ADP	IN	5	O
glucocorticoid	glucocorticoid	NOUN	NN	9	O
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
serum	serum	ADV	RB	9	O
urate	urate	ADJ	JJ	0	B-Chemical
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
XO	XO	PROPN	NNP	0	O
inhibition	inhibition	NOUN	NN	3	O
.	.	PUNCT	.	9	O

5	5	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

Dex	dex	NOUN	NN	3	B-Chemical
increased	increase	VERB	VBD	9	B-Disease
SBP	SBP	PROPN	NNP	9	I-Disease
(	(	PUNCT	-LRB-	9	O
110	110	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
126	126	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
mmHg	mmhg	SYM	SYM	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	B-Disease
thymus	thymus	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	I-Disease
P	p	NOUN	NN	9	I-Disease
<	<	X	XX	0	I-Disease
0	0	NUM	CD	7	I-Disease
.	.	PUNCT	.	9	I-Disease
001	001	NUM	CD	9	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
and	and	CCONJ	CC	5	I-Disease
bodyweights	bodyweight	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
"	"	PUNCT	``	5	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Allopurinol	Allopurinol	PROPN	NNP	0	B-Chemical
decreased	decrease	VERB	VBD	9	O
serum	serum	NOUN	NN	9	O
urate	urate	ADJ	JJ	0	B-Chemical
from	from	ADP	IN	9	O
76	76	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
to	to	PART	TO	5	O
30	30	NUM	CD	9	O
+	+	NOUN	NN	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
micromol	micromol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
from	from	ADP	IN	9	O
84	84	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
13	13	NUM	CD	7	O
to	to	PART	TO	5	O
28	28	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
micromol	micromol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
in	in	ADP	IN	5	O
dex	dex	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

6	6	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

Allopurinol	Allopurinol	PROPN	NNP	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
prevent	prevent	VERB	VB	5	O
dex	dex	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
HT	HT	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
,	,	PUNCT	,	9	O
together	together	ADV	RB	9	O
with	with	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
previous	previous	ADJ	JJ	9	O
findings	finding	NOUN	NNS	9	O
that	that	DET	WDT	5	O
allopurinol	allopurinol	NOUN	NN	0	B-Chemical
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
adrenocorticotrophic	adrenocorticotrophic	ADJ	JJ	0	O
hormone	hormone	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
XO	XO	PROPN	NNP	0	O
activity	activity	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
determinant	determinant	NOUN	NN	9	O
of	of	ADP	IN	5	O
GC	GC	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
HT	HT	PROPN	NNP	9	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
methylprednisolone	methylprednisolone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
posterior	posterior	ADJ	JJ	5	O
sub	sub	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
Tenon	tenon	NOUN	NN	2	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
space	space	NOUN	NN	5	O
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	O
emetic	emetic	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
methylprednisolone	methylprednisolone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
posterior	posterior	ADJ	JJ	5	O
sub	sub	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
Tenon	tenon	NOUN	NN	2	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
space	space	NOUN	NN	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
routine	routine	ADJ	JJ	5	O
cataract	cataract	NOUN	NN	5	B-Disease
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

SETTING	setting	NOUN	NN	2	O
:	:	PUNCT	:	9	O
St	st	INTJ	UH	2	O
.	.	PUNCT	.	9	O

Luke	Luke	PROPN	NNP	6	O
'	'	PUNCT	''	9	O
s	s	PROPN	NNP	9	O
Hospital	Hospital	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Gwardamangia	Gwardamangia	PROPN	NNP	_	O
,	,	PUNCT	,	9	O
Malta	Malta	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	NOUN	NN	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
armed	armed	ADJ	JJ	5	O
prospective	prospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
comprised	comprise	VERB	VBD	9	O
40	40	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
uneventful	uneventful	ADJ	JJ	5	O
sutureless	sutureless	NOUN	NN	5	O
phacoemulsification	phacoemulsification	NOUN	NN	5	O
under	under	ADP	IN	9	O
sub	sub	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
Tenon	tenon	NOUN	NN	2	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
local	local	ADJ	JJ	5	O
infiltration	infiltration	NOUN	NN	3	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	O
mL	ml	NOUN	NN	0	O
of	of	ADP	IN	5	O
plain	plain	ADJ	JJ	5	O
lignocaine	lignocaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
procedure	procedure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
Group	Group	PROPN	NNP	9	O
A	A	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
20	20	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mL	ml	NOUN	NN	0	O
of	of	ADP	IN	5	O
methylprednisolone	methylprednisolone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mL	ml	NOUN	NN	0	O
of	of	ADP	IN	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
injected	inject	VERB	VBD	3	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
posterior	posterior	ADJ	JJ	5	O
sub	sub	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
Tenon	tenon	NOUN	NN	2	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
space	space	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
Group	Group	PROPN	NNP	9	O
B	B	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
20	20	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
combination	combination	NOUN	NN	9	O
injected	inject	VERB	VBD	3	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
anterior	anterior	ADJ	JJ	5	O
sub	sub	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
Tenon	tenon	NOUN	NN	2	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
space	space	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Postoperatively	postoperatively	ADV	RB	5	O
,	,	PUNCT	,	9	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
for	for	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
nausea	nausea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	I-Disease
vomiting	vomiting	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
headache	headache	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
chi	chi	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
square	square	ADJ	JJ	5	O
test	test	NOUN	NN	5	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
statistical	statistical	ADJ	JJ	5	O
significance	significance	NOUN	NN	9	O
of	of	ADP	IN	5	O
results	result	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Sixty	sixty	NUM	CD	5	O
percent	percent	NOUN	NN	5	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
A	A	PROPN	NNP	9	O
developed	developed	ADJ	JJ	5	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
emetic	emetic	ADJ	JJ	5	I-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
headache	headache	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
both	both	DET	DT	9	O
;	;	PUNCT	:	9	O
1	1	NUM	CD	9	O
patient	patient	NOUN	NN	5	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
B	B	PROPN	NNP	9	O
developed	develop	VERB	VBD	5	O
symptoms	symptom	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
methylprednisolone	methylprednisolone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
posterior	posterior	ADJ	JJ	5	O
sub	sub	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
Tenon	tenon	NOUN	NN	2	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
space	space	NOUN	NN	5	O
was	be	VERB	VBD	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
including	include	VERB	VBG	9	O
nausea	nausea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	I-Disease
vomiting	vomiting	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
headache	headache	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
self	self	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
limiting	limit	VERB	VBG	9	O
.	.	PUNCT	.	9	O

Assessment	assessment	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
invasive	invasive	ADJ	JJ	5	O
index	index	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
performance	performance	NOUN	NN	5	O
for	for	ADP	IN	5	O
detection	detection	NOUN	NN	9	O
of	of	ADP	IN	5	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Electrocardiography	Electrocardiography	PROPN	NNP	5	O
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
very	very	ADV	RB	5	O
low	low	ADJ	JJ	9	O
sensitivity	sensitivity	NOUN	NN	9	O
in	in	ADP	IN	5	O
detecting	detect	VERB	VBG	9	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
added	add	VERB	VBN	0	O
diagnostic	diagnostic	ADJ	JJ	5	O
value	value	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
cardiac	cardiac	ADJ	JJ	5	O
performance	performance	NOUN	NN	5	O
index	index	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
dP	dP	PROPN	NNP	5	O
/	/	SYM	SYM	9	O
dtejc	dtejc	NOUN	NN	_	O
)	)	PUNCT	-RRB-	9	O
measurement	measurement	NOUN	NN	5	O
,	,	PUNCT	,	9	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
brachial	brachial	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
flow	flow	NOUN	NN	5	O
changes	change	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
standard	standard	ADJ	JJ	5	O
12	12	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
lead	lead	NOUN	NN	5	O
ECG	ECG	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
detecting	detect	VERB	VBG	9	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
using	use	VERB	VBG	9	O
Tc99m	Tc99m	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
Sestamibi	Sestamibi	PROPN	NNP	0	I-Chemical
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
photon	photon	NOUN	NN	5	O
emission	emission	NOUN	NN	0	O
computed	compute	VERB	VBD	5	O
tomography	tomography	NOUN	NN	5	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
gold	gold	ADJ	JJ	0	O
standard	standard	NOUN	NN	5	O
of	of	ADP	IN	5	O
comparison	comparison	NOUN	NN	9	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
ischemia	ischemia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
study	study	NOUN	NN	9	O
group	group	NOUN	NN	9	O
comprised	comprise	VERB	VBD	9	O
40	40	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
Sestamibi	Sestamibi	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
SPECT	SPECT	PROPN	NNP	5	O
/	/	SYM	SYM	9	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
stress	stress	NOUN	NN	9	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Simultaneous	simultaneous	ADJ	JJ	9	O
measurements	measurement	NOUN	NNS	5	O
of	of	ADP	IN	5	O
ECG	ECG	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
brachial	brachial	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
dP	dP	PROPN	NNP	5	O
/	/	SYM	SYM	9	O
dtejc	dtejc	NOUN	NN	_	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
at	at	ADP	IN	9	O
each	each	DET	DT	5	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
level	level	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
19	19	NUM	CD	7	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
40	40	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
perfusion	perfusion	NOUN	NN	5	O
defects	defect	NOUN	NNS	9	O
compatible	compatible	ADJ	JJ	5	O
with	with	ADP	IN	5	O
ischemia	ischemia	NOUN	NN	9	B-Disease
were	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
on	on	ADP	IN	5	O
SPECT	SPECT	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
dP	dP	PROPN	NNP	5	O
/	/	SYM	SYM	9	O
dtejc	dtejc	NOUN	NN	_	O
during	during	ADP	IN	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
dobutamine	dobutamine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
severely	severely	ADV	RB	9	O
impaired	impair	VERB	VBN	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
ischemic	ischemic	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

dP	dP	PROPN	NNP	5	O
/	/	SYM	SYM	9	O
dtejc	dtejc	NOUN	NN	_	O
outcome	outcome	NOUN	NN	5	O
was	be	VERB	VBD	9	O
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
ECG	ECG	PROPN	NNP	5	O
results	result	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
giving	give	VERB	VBG	5	O
an	an	DET	DT	5	O
ECG	ECG	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
enhanced	enhance	VERB	VBN	3	O
value	value	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
ECG	ECG	PROPN	NNP	5	O
alone	alone	ADV	RB	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
sensitivity	sensitivity	NOUN	NN	9	O
improved	improve	VERB	VBD	5	O
dramatically	dramatically	ADV	RB	9	O
from	from	ADP	IN	9	O
16	16	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	ADP	IN	5	O
79	79	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
positive	positive	ADJ	JJ	9	O
predictive	predictive	ADJ	JJ	5	O
value	value	NOUN	NN	9	O
increased	increase	VERB	VBD	9	O
from	from	ADP	IN	9	O
60	60	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
68	68	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
negative	negative	ADJ	JJ	9	O
predictive	predictive	ADJ	JJ	5	O
value	value	NOUN	NN	9	O
from	from	ADP	IN	9	O
54	54	NUM	CD	7	O
%	%	NOUN	NN	9	O
to	to	ADP	IN	5	O
78	78	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
specificity	specificity	NOUN	NN	9	O
decreased	decrease	VERB	VBD	9	O
from	from	ADP	IN	9	O
90	90	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
67	67	NUM	CD	7	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
If	if	ADP	IN	5	O
ECG	ECG	PROPN	NNP	5	O
alone	alone	ADV	RB	9	O
is	be	VERB	VBZ	5	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
specificity	specificity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
dP	dP	PROPN	NNP	5	O
/	/	SYM	SYM	9	O
dtejc	dtejc	NOUN	NN	_	O
improved	improve	VERB	VBD	5	O
the	the	DET	DT	5	O
sensitivity	sensitivity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
test	test	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
cost	cost	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
savings	saving	NOUN	NNS	5	O
alternative	alternative	NOUN	NN	5	O
to	to	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
imaging	imaging	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
perfusion	perfusion	NOUN	NN	5	O
studies	study	NOUN	NNS	9	O
to	to	PART	TO	5	O
detect	detect	VERB	VB	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
unable	unable	ADJ	JJ	9	O
to	to	PART	TO	5	O
exercise	exercise	VERB	VB	5	O
.	.	PUNCT	.	9	O

Cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
clinical	clinical	ADJ	JJ	5	O
observations	observation	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
pathogenetic	pathogenetic	ADJ	JJ	5	O
considerations	consideration	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
experimental	experimental	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
published	publish	VERB	VBN	9	O
to	to	ADP	IN	5	O
date	date	NOUN	NN	5	O
suggest	suggest	VERB	VB	9	O
several	several	ADJ	JJ	9	O
possible	possible	ADJ	JJ	5	O
mechanisms	mechanism	NOUN	NNS	9	O
by	by	ADP	IN	9	O
which	which	DET	WDT	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
may	may	VERB	MD	5	O
result	result	VERB	VB	9	O
in	in	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
myocardial	myocardial	ADJ	JJ	9	I-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
individuals	individual	NOUN	NNS	5	O
with	with	ADP	IN	5	O
preexisting	preexist	VERB	VBG	9	O
,	,	PUNCT	,	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
grade	grade	NOUN	NN	9	O
coronary	coronary	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
narrowing	narrowing	NOUN	NN	5	O
,	,	PUNCT	,	9	O
acute	acute	ADJ	JJ	9	B-Disease
myocardial	myocardial	ADJ	JJ	9	I-Disease
infarction	infarction	NOUN	NN	5	I-Disease
may	may	VERB	MD	5	O
result	result	VERB	VB	9	O
from	from	ADP	IN	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
demand	demand	NOUN	NN	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
rate	rate	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
pressure	pressure	NOUN	NN	5	O
product	product	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
other	other	ADJ	JJ	5	O
individuals	individual	NOUN	NNS	5	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
underlying	underlying	ADJ	JJ	5	O
atherosclerotic	atherosclerotic	ADJ	JJ	3	B-Disease
obstruction	obstruction	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
occlusion	occlusion	NOUN	NN	5	I-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
spasm	spasm	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
thrombus	thrombus	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
both	both	DET	DT	9	O
.	.	PUNCT	.	9	O

With	with	ADP	IN	5	O
regard	regard	NOUN	NN	5	O
to	to	ADP	IN	5	O
spasm	spasm	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
largely	largely	ADV	RB	9	O
circumstantial	circumstantial	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
locus	locus	NOUN	NN	1	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
vasoconstriction	vasoconstriction	NOUN	NN	9	O
remains	remain	VERB	VBZ	9	O
speculative	speculative	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
certain	certain	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
experimental	experimental	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
support	support	VERB	VBP	5	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	DET	WDT	5	O
spasm	spasm	VERB	VBZ	5	B-Disease
involves	involve	VERB	VBZ	5	O
the	the	DET	DT	5	O
epicardial	epicardial	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
medium	medium	ADJ	JJ	0	O
-	-	PUNCT	HYPH	7	O
size	size	NOUN	NN	9	O
vessels	vessel	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
other	other	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
intramural	intramural	ADJ	JJ	5	O
vasoconstriction	vasoconstriction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Diffuse	diffuse	VERB	VB	9	O
intramural	intramural	ADJ	JJ	5	O
vasoconstriction	vasoconstriction	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
reports	report	NOUN	NNS	9	O
of	of	ADP	IN	5	O
segmental	segmental	NOUN	NN	5	O
,	,	PUNCT	,	9	O
discrete	discrete	ADJ	JJ	5	O
infarction	infarction	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Whereas	whereas	ADP	IN	9	O
certain	certain	ADJ	JJ	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
these	these	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
,	,	PUNCT	,	9	O
other	other	ADJ	JJ	5	O
in	in	ADP	IN	5	O
vitro	vitro	X	FW	3	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
the	the	DET	DT	5	O
opposite	opposite	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
finding	finding	NOUN	NN	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
vasoconstriction	vasoconstriction	NOUN	NN	9	O
in	in	ADP	IN	5	O
segments	segment	NOUN	NNS	9	O
of	of	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
noninnervated	noninnervated	ADJ	JJ	3	O
)	)	PUNCT	-RRB-	9	O
human	human	ADJ	JJ	3	O
umbilical	umbilical	ADJ	JJ	3	O
artery	artery	NOUN	NN	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
intact	intact	ADJ	JJ	9	O
innervation	innervation	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
sufficient	sufficient	ADJ	JJ	9	O
to	to	PART	TO	5	O
explain	explain	VERB	VB	9	O
the	the	DET	DT	5	O
discrepant	discrepant	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
involving	involve	VERB	VBG	5	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Finally	finally	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
contribution	contribution	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
excluded	exclude	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Proteomic	proteomic	NOUN	NN	9	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
striatal	striatal	ADJ	JJ	3	O
proteins	protein	NOUN	NNS	1	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
DOPA	DOPA	PROPN	NNP	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
DOPA	dopa	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
LID	LID	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
motor	motor	NOUN	NN	5	O
complications	complication	NOUN	NNS	5	O
that	that	DET	WDT	5	O
arise	arise	VERB	VBP	5	O
in	in	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
PD	pd	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
prolonged	prolonged	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
DOPA	DOPA	PROPN	NNP	0	I-Chemical
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
this	this	DET	DT	5	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
transcriptome	transcriptome	NOUN	NN	9	O
analysis	analysis	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
performed	perform	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
LID	LID	PROPN	NNP	5	B-Disease
[	[	PUNCT	-LRB-	9	O
Neurobiol	Neurobiol	PROPN	NNP	2	O
.	.	PUNCT	.	9	O
Dis	Dis	PROPN	NNP	2	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
17	17	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
2004	2004	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
219	219	NUM	CD	7	O
]	]	PUNCT	-RRB-	9	O
but	but	CCONJ	CC	9	O
information	information	NOUN	NN	5	O
regarding	regard	VERB	VBG	5	O
the	the	DET	DT	5	O
proteome	proteome	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
still	still	ADV	RB	5	O
lacking	lack	VERB	VBG	1	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
changes	change	NOUN	NNS	9	O
occurring	occur	VERB	VBG	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
protein	protein	NOUN	NN	1	O
level	level	NOUN	NN	9	O
in	in	ADP	IN	5	O
striatal	striatal	ADJ	JJ	3	O
samples	sample	NOUN	NNS	9	O
obtained	obtain	VERB	VBN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
unilaterally	unilaterally	ADJ	JJ	5	O
6	6	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxydopamine	hydroxydopamine	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
lesion	lesion	NOUN	NN	5	O
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
PD	pd	NOUN	NN	9	B-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
,	,	PUNCT	,	9	O
L	L	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
DOPA	DOPA	PROPN	NNP	0	I-Chemical
or	or	CCONJ	CC	5	O
bromocriptine	bromocriptine	NOUN	NN	0	B-Chemical
using	use	VERB	VBG	9	O
two	two	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
dimensional	dimensional	ADJ	JJ	5	O
difference	difference	NOUN	NN	9	O
gel	gel	NOUN	NN	0	O
electrophoresis	electrophoresis	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
mass	mass	NOUN	NN	9	O
spectrometry	spectrometry	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
MS	MS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
DOPA	DOPA	PROPN	NNP	0	I-Chemical
were	be	VERB	VBD	9	O
allocated	allocate	VERB	VBN	5	O
to	to	ADP	IN	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
LID	LID	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
the	the	DET	DT	5	O
2000	2000	NUM	CD	9	O
spots	spot	NOUN	NNS	9	O
compared	compare	VERB	VBN	9	O
for	for	ADP	IN	5	O
statistical	statistical	ADJ	JJ	5	O
difference	difference	NOUN	NN	9	O
,	,	PUNCT	,	9	O
67	67	NUM	CD	7	O
spots	spot	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
changed	change	VERB	VBN	9	O
in	in	ADP	IN	5	O
abundance	abundance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
identified	identify	VERB	VBD	9	O
using	use	VERB	VBG	9	O
matrix	matrix	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
assisted	assist	VERB	VBN	5	O
laser	laser	NOUN	NN	5	O
desorption	desorption	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ionization	ionization	NOUN	NN	0	O
time	time	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
of	of	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
flight	flight	NOUN	NN	5	O
MS	MS	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
atmospheric	atmospheric	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
matrix	matrix	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
assisted	assist	VERB	VBN	5	O
laser	laser	NOUN	NN	5	O
desorption	desorption	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ionization	ionization	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
HPLC	HPLC	PROPN	NNP	0	O
coupled	couple	VERB	VBD	9	O
tandem	tandem	NOUN	NN	1	O
MS	MS	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
LC	LC	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
MS	MS	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
MS	MS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Out	out	ADP	IN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
67	67	NUM	CD	7	O
proteins	protein	NOUN	NNS	1	O
,	,	PUNCT	,	9	O
LID	LID	PROPN	NNP	5	B-Disease
significantly	significantly	ADV	RB	9	O
changed	change	VERB	VBD	9	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
five	five	NUM	CD	9	O
proteins	protein	NOUN	NNS	1	O
:	:	PUNCT	:	9	O
alphabeta	alphabeta	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
crystalin	crystalin	NOUN	NN	9	O
,	,	PUNCT	,	9	O
gamma	gamma	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
enolase	enolase	NOUN	NN	1	O
,	,	PUNCT	,	9	O
guanidoacetate	guanidoacetate	NOUN	NN	0	O
methyltransferase	methyltransferase	NOUN	NN	1	O
,	,	PUNCT	,	9	O
vinculin	vinculin	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
proteasome	proteasome	VERB	VB	3	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
subunit	subunit	NOUN	NN	1	O
.	.	PUNCT	.	9	O

Complementary	complementary	ADJ	JJ	5	O
techniques	technique	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
western	western	ADJ	JJ	3	O
immunoblotting	immunoblotting	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
immunohistochemistry	immunohistochemistry	NOUN	NN	3	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
validity	validity	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
obtained	obtain	VERB	VBN	9	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
proteomic	proteomic	ADJ	JJ	9	O
approach	approach	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
provides	provide	VERB	VBZ	5	O
new	new	ADJ	JJ	5	O
insights	insight	NOUN	NNS	5	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
protein	protein	NOUN	NN	1	O
changes	change	NOUN	NNS	9	O
occurring	occur	VERB	VBG	9	O
in	in	ADP	IN	5	O
LID	LID	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

Cardiac	Cardiac	PROPN	NNP	9	O
Angiography	Angiography	PROPN	NNP	5	O
in	in	ADP	IN	5	O
Renally	Renally	PROPN	NNP	9	O
Impaired	impaired	ADJ	JJ	9	O
Patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
CARE	CARE	PROPN	NNP	2	O
)	)	PUNCT	-RRB-	9	O
study	study	NOUN	NN	9	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
randomized	randomize	VERB	VBN	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
contrast	contrast	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
kidney	kidney	NOUN	NN	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
No	no	DET	DT	9	O
direct	direct	ADJ	JJ	9	O
comparisons	comparison	NOUN	NNS	5	O
exist	exist	VERB	VBP	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
tolerability	tolerability	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
osmolality	osmolality	NOUN	NN	0	O
contrast	contrast	NOUN	NN	9	B-Chemical
medium	medium	NOUN	NN	0	I-Chemical
iopamidol	iopamidol	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
iso	iso	ADJ	JJ	0	O
-	-	PUNCT	HYPH	7	O
osmolality	osmolality	NOUN	NN	0	O
contrast	contrast	NOUN	NN	9	B-Chemical
medium	medium	NOUN	NN	0	I-Chemical
iodixanol	iodixanol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
risk	risk	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
multicenter	multicenter	NOUN	NN	5	O
,	,	PUNCT	,	9	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
comparison	comparison	NOUN	NN	9	O
of	of	ADP	IN	5	O
iopamidol	iopamidol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
iodixanol	iodixanol	VERB	VBP	0	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
kidney	kidney	NOUN	NN	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
estimated	estimate	VERB	VBN	5	O
glomerular	glomerular	ADJ	JJ	5	O
filtration	filtration	NOUN	NN	0	O
rate	rate	NOUN	NN	9	O
,	,	PUNCT	,	9	O
20	20	NUM	CD	9	O
to	to	PART	TO	5	O
59	59	NUM	CD	7	O
mL	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
who	who	PRON	WP	5	O
underwent	undergo	VERB	VBD	5	O
cardiac	cardiac	ADJ	JJ	5	O
angiography	angiography	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
percutaneous	percutaneous	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
interventions	intervention	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Serum	Serum	PROPN	NNP	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
SCr	SCr	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
levels	level	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
estimated	estimate	VERB	VBN	5	O
glomerular	glomerular	ADJ	JJ	5	O
filtration	filtration	NOUN	NN	0	O
rate	rate	NOUN	NN	9	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
to	to	PART	TO	5	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
medications	medication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
outcome	outcome	NOUN	NN	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
postdose	postdose	NOUN	NN	5	O
SCr	SCr	NOUN	NNS	5	O
increase	increase	VERB	VBP	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
44	44	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
micromol	micromol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
over	over	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Secondary	secondary	ADJ	JJ	9	O
outcomes	outcome	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
a	a	DET	DT	5	O
postdose	postdose	NOUN	NN	5	O
SCr	SCr	NOUN	NNS	5	O
increase	increase	VERB	VBP	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
postdose	postdose	ADV	RB	5	O
estimated	estimate	VERB	VBN	5	O
glomerular	glomerular	ADJ	JJ	5	O
filtration	filtration	NOUN	NN	0	O
rate	rate	NOUN	NN	9	O
decrease	decrease	NOUN	NN	9	O
of	of	ADP	IN	5	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
peak	peak	NOUN	NN	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
SCr	SCr	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
414	414	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
contrast	contrast	NOUN	NN	9	O
volume	volume	NOUN	NN	9	O
,	,	PUNCT	,	9	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
diabetes	diabetes	NOUN	NN	5	B-Disease
mellitus	mellitus	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
acetylcysteine	acetylcysteine	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
mean	mean	VERB	VB	5	O
baseline	baseline	NOUN	NN	5	O
SCr	SCr	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
estimated	estimate	VERB	VBN	5	O
glomerular	glomerular	ADJ	JJ	5	O
filtration	filtration	NOUN	NN	0	O
rate	rate	NOUN	NN	9	O
were	be	VERB	VBD	9	O
comparable	comparable	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
2	2	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

SCr	SCr	NOUN	NNS	5	O
increases	increase	VERB	VBZ	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dL	PROPN	NNP	7	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
of	of	ADP	IN	5	O
204	204	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
iopamidol	iopamidol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
14	14	NUM	CD	7	O
of	of	ADP	IN	5	O
210	210	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
iodixanol	iodixanol	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
39	39	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
rates	rate	NOUN	NNS	5	O
of	of	ADP	IN	5	O
SCr	SCr	NOUN	NNS	5	O
increases	increase	VERB	VBZ	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
were	be	VERB	VBD	9	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
44	44	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
diabetes	diabete	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
SCr	SCr	NOUN	NNS	5	O
increases	increase	VERB	VBZ	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dL	NOUN	NNS	7	O
were	be	VERB	VBD	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
of	of	ADP	IN	5	O
78	78	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
iopamidol	iopamidol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
of	of	ADP	IN	5	O
92	92	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
iodixanol	iodixanol	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
11	11	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
SCr	SCr	NOUN	NNS	5	O
increases	increase	VERB	VBZ	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
were	be	VERB	VBD	9	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
37	37	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Mean	mean	VERB	VB	9	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
SCr	SCr	NOUN	NNS	5	O
increases	increase	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
less	less	ADV	RBR	5	O
with	with	ADP	IN	5	O
iopamidol	iopamidol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
0	0	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
07	07	NUM	CD	7	O
versus	versus	ADJ	JJ	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
12	12	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dL	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
versus	versus	ADP	IN	9	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
micromol	micromol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
;	;	PUNCT	:	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
diabetes	diabete	NOUN	NNS	5	B-Disease
:	:	PUNCT	:	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
07	07	NUM	CD	7	O
versus	versus	ADJ	JJ	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
16	16	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dL	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
versus	versus	ADP	IN	9	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
micromol	micromol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
contrast	contrast	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
defined	define	VERB	VBN	5	O
by	by	ADP	IN	9	O
multiple	multiple	ADJ	JJ	5	O
end	end	NOUN	NN	9	O
points	point	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
statistically	statistically	ADV	RB	9	O
different	different	ADJ	JJ	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
intraarterial	intraarterial	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
iopamidol	iopamidol	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
iodixanol	iodixanol	ADJ	JJ	0	B-Chemical
to	to	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
risk	risk	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
diabetes	diabetes	NOUN	NN	5	B-Disease
mellitus	mellitus	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Any	any	DET	DT	5	O
true	true	ADJ	JJ	5	O
difference	difference	NOUN	NN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
agents	agent	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
small	small	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
not	not	ADV	RB	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
clinically	clinically	ADV	RB	5	O
significant	significant	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
novel	novel	NOUN	NN	9	O
compound	compound	NOUN	NN	0	O
,	,	PUNCT	,	9	O
maltolyl	maltolyl	NOUN	NN	_	B-Chemical
p	p	NOUN	NN	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
coumarate	coumarate	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
attenuates	attenuate	VERB	VBZ	3	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
shows	show	VERB	VBZ	9	O
neuroprotective	neuroprotective	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
dementia	dementia	NOUN	NN	5	B-Disease
models	model	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
develop	develop	VERB	VB	5	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
effective	effective	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
that	that	DET	WDT	5	O
could	could	VERB	MD	9	O
enhance	enhance	VERB	VB	9	O
cognitive	cognitive	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
neuroprotection	neuroprotection	NOUN	NN	3	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
newly	newly	ADV	RB	9	O
synthesized	synthesize	VERB	VBD	0	O
maltolyl	maltolyl	NOUN	NN	_	B-Chemical
p	p	NOUN	NN	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
coumarate	coumarate	NOUN	NN	0	I-Chemical
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
esterification	esterification	NOUN	NN	0	O
of	of	ADP	IN	5	O
maltol	maltol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
p	p	NOUN	NN	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
coumaric	coumaric	NOUN	NN	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
investigated	investigate	VERB	VBD	9	O
whether	whether	ADP	IN	9	O
maltolyl	maltolyl	NOUN	NN	_	B-Chemical
p	p	NOUN	NN	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
coumarate	coumarate	NOUN	NN	0	I-Chemical
could	could	VERB	MD	9	O
improve	improve	VERB	VB	5	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
decline	decline	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
injected	inject	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
amyloid	amyloid	NOUN	NN	3	B-Chemical
beta	beta	NOUN	NN	9	I-Chemical
peptide	peptide	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
1	1	NUM	CD	9	I-Chemical
-	-	SYM	SYM	7	I-Chemical
42	42	NUM	CD	7	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	O
infused	infuse	VERB	VBN	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Maltolyl	Maltolyl	PROPN	NNP	_	B-Chemical
p	p	NOUN	NN	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
coumarate	coumarate	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
attenuate	attenuate	VERB	VB	9	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
rat	rat	NOUN	NN	3	O
models	model	NOUN	NNS	5	O
using	use	VERB	VBG	9	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
test	test	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
reduce	reduce	VERB	VB	5	O
apoptotic	apoptotic	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
death	death	NOUN	NN	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
amyloid	amyloid	NOUN	NN	3	B-Chemical
beta	beta	NOUN	NN	9	I-Chemical
peptide	peptide	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
1	1	NUM	CD	9	I-Chemical
-	-	SYM	SYM	7	I-Chemical
42	42	NUM	CD	7	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	O
infused	infuse	VERB	VBN	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
also	also	ADV	RB	9	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
neuroprotective	neuroprotective	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
maltolyl	maltolyl	NOUN	NN	_	B-Chemical
p	p	NOUN	NN	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
coumarate	coumarate	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
using	use	VERB	VBG	9	O
SH	SH	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
SY5Y	sy5y	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Cells	cell	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
pretreated	pretreate	VERB	VBN	3	O
with	with	ADP	IN	5	O
maltolyl	maltolyl	NOUN	NN	_	B-Chemical
p	p	NOUN	NN	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
coumarate	coumarate	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
before	before	ADP	IN	9	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
amyloid	amyloid	VERB	VB	3	B-Chemical
beta	beta	NOUN	NN	9	I-Chemical
peptide	peptide	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
1	1	NUM	CD	9	I-Chemical
-	-	SYM	SYM	7	I-Chemical
42	42	NUM	CD	7	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
,	,	PUNCT	,	9	O
glutamate	glutamate	VERB	VB	0	B-Chemical
or	or	CCONJ	CC	5	O
H2O2	h2o2	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
found	find	VERB	VBD	9	O
that	that	ADP	IN	5	O
maltolyl	maltolyl	NOUN	NN	_	B-Chemical
p	p	NOUN	NN	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
coumarate	coumarate	NOUN	NN	0	I-Chemical
significantly	significantly	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	O
apoptotic	apoptotic	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
death	death	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
reduced	reduce	VERB	VBN	9	O
reactive	reactive	ADJ	JJ	9	O
oxygen	oxygen	NOUN	NN	0	O
species	specie	NOUN	NNS	4	O
,	,	PUNCT	,	9	O
cytochrome	cytochrome	ADJ	JJ	0	O
c	c	DET	DT	9	O
release	release	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
caspase	caspase	NOUN	NN	3	O
3	3	NUM	CD	9	O
activation	activation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Taking	take	VERB	VBG	5	O
these	these	DET	DT	5	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
results	result	VERB	VBZ	9	O
together	together	ADV	RB	9	O
,	,	PUNCT	,	9	O
our	-PRON-	DET	PRP$	5	O
study	study	NOUN	NN	9	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
maltolyl	maltolyl	NOUN	NN	_	B-Chemical
p	p	NOUN	NN	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
coumarate	coumarate	NOUN	NN	0	I-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
potentially	potentially	ADV	RB	5	O
effective	effective	ADJ	JJ	5	O
candidate	candidate	NOUN	NN	9	O
against	against	ADP	IN	9	O
Alzheimer	Alzheimer	PROPN	NNP	5	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
wide	wide	ADJ	JJ	5	O
spread	spread	VERB	VBN	5	O
neuronal	neuronal	ADJ	JJ	3	B-Disease
death	death	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
progressive	progressive	ADJ	JJ	5	O
decline	decline	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
cognitive	cognitive	ADJ	JJ	5	I-Disease
function	function	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Attenuation	attenuation	NOUN	NN	9	O
of	of	ADP	IN	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nigrostriatal	nigrostriatal	ADJ	JJ	3	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
by	by	ADP	IN	9	O
lipopolysaccharide	lipopolysaccharide	NOUN	NN	3	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Immunological	immunological	ADJ	JJ	9	O
activation	activation	NOUN	NN	3	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
proposed	propose	VERB	VBN	5	O
to	to	PART	TO	5	O
play	play	VERB	VB	9	O
a	a	DET	DT	5	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
dopaminergic	dopaminergic	ADJ	JJ	5	B-Disease
terminal	terminal	NOUN	NN	9	I-Disease
damage	damage	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
roles	role	NOUN	NNS	9	O
of	of	ADP	IN	5	O
lipopolysaccharide	lipopolysaccharide	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
pro	pro	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
factor	factor	NOUN	NN	9	O
,	,	PUNCT	,	9	O
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
modulating	modulate	VERB	VBG	9	O
the	the	DET	DT	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nigrostriatal	nigrostriatal	ADJ	JJ	3	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Lipopolysaccharide	lipopolysaccharide	VERB	VB	0	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
affect	affect	VERB	VB	9	O
the	the	DET	DT	5	O
basal	basal	NOUN	NN	3	O
body	body	NOUN	NN	5	O
temperature	temperature	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
elicited	elicit	VERB	VBN	9	O
hyperthermia	hyperthermia	ADJ	JJ	5	B-Disease
three	three	NUM	CD	9	O
days	day	NOUN	NNS	9	O
later	later	ADV	RB	9	O
.	.	PUNCT	.	9	O

Such	such	ADJ	JJ	5	O
systemic	systemic	ADJ	JJ	9	O
lipopolysaccharide	lipopolysaccharide	NOUN	NN	3	B-Chemical
treatment	treatment	NOUN	NN	9	O
mitigated	mitigate	VERB	VBN	9	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
striatal	striatal	ADJ	JJ	3	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dihydroxyphenylacetic	dihydroxyphenylacetic	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
depletions	depletion	NOUN	NNS	3	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
manner	manner	NOUN	NN	9	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
potent	potent	ADJ	JJ	3	O
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
lipopolysaccharide	lipopolysaccharide	NOUN	NN	3	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
two	two	NUM	CD	5	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
day	day	NOUN	NN	9	O
before	before	ADV	RB	9	O
or	or	CCONJ	CC	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
dosing	dose	VERB	VBG	9	O
regimen	regiman	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
striatal	striatal	ADJ	JJ	3	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dihydroxyphenylacetic	dihydroxyphenylacetic	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
depletions	depletion	NOUN	NNS	3	O
remained	remain	VERB	VBD	9	O
unaltered	unaltered	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
systemic	systemic	ADJ	JJ	9	O
lipopolysaccharide	lipopolysaccharide	NOUN	NN	3	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
attenuated	attenuate	VERB	VBD	3	O
local	local	ADJ	JJ	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
infusion	infusion	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
produced	produce	VERB	VBN	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dihydroxyphenylacetic	dihydroxyphenylacetic	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
depletions	depletion	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
lipopolysaccharide	lipopolysaccharide	NOUN	NN	3	B-Chemical
is	be	VERB	VBZ	5	O
less	less	ADV	RBR	5	O
likely	likely	ADV	RB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
interrupted	interrupt	VERB	VBN	5	O
peripheral	peripheral	ADJ	JJ	9	O
distribution	distribution	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
metabolism	metabolism	NOUN	NN	9	O
of	of	ADP	IN	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
concluded	conclude	VERB	VBD	9	O
a	a	DET	DT	5	O
critical	critical	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
window	window	NOUN	NN	5	O
for	for	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	O
lipopolysaccharide	lipopolysaccharide	NOUN	NN	3	B-Chemical
pretreatment	pretreatment	NOUN	NN	0	O
in	in	ADP	IN	5	O
exerting	exert	VERB	VBG	9	O
effective	effective	ADJ	JJ	5	O
protection	protection	NOUN	NN	9	O
against	against	ADP	IN	9	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nigrostriatal	nigrostriatal	ADJ	JJ	3	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
myocarditis	myocarditis	NOUN	NN	9	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
myocarditis	myocarditis	NOUN	NN	9	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
commencement	commencement	NOUN	NN	5	O
of	of	ADP	IN	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
is	be	VERB	VBZ	5	O
described	describe	VERB	VBN	9	O
,	,	PUNCT	,	9	O
highlighting	highlight	VERB	VBG	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
,	,	PUNCT	,	9	O
course	course	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
possible	possible	ADJ	JJ	5	O
contributing	contributing	NOUN	NN	9	O
factors	factor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
urgent	urgent	ADJ	JJ	5	O
need	need	NOUN	NN	5	O
to	to	PART	TO	5	O
raise	raise	VERB	VB	9	O
awareness	awareness	NOUN	NN	5	O
about	about	ADP	IN	5	O
this	this	DET	DT	5	O
potentially	potentially	ADV	RB	5	O
fatal	fatal	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
20	20	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
male	male	NOUN	NN	9	O
with	with	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
sudden	sudden	ADJ	JJ	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
myocarditis	myocarditis	NOUN	NN	9	B-Disease
after	after	ADP	IN	9	O
commencement	commencement	NOUN	NN	5	O
of	of	ADP	IN	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
recovered	recover	VERB	VBD	9	O
with	with	ADP	IN	5	O
intensive	intensive	ADJ	JJ	5	O
medical	medical	ADJ	JJ	5	O
support	support	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
occurred	occur	VERB	VBD	9	O
around	around	ADV	RB	5	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
starting	start	VERB	VBG	9	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
inpatient	inpatient	NOUN	NN	5	O
setting	setting	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Possible	possible	ADJ	JJ	9	O
contributing	contributing	NOUN	NN	9	O
factors	factor	NOUN	NNS	9	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
been	be	VERB	VBN	9	O
concomitant	concomitant	ADJ	JJ	9	O
antidepressant	antidepressant	ADJ	JJ	5	B-Chemical
use	use	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
unaccustomed	unaccustomed	ADJ	JJ	5	O
physical	physical	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Myocarditis	Myocarditis	PROPN	NNP	7	B-Disease
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
increasingly	increasingly	ADV	RB	5	O
recognized	recognize	VERB	VBN	9	O
complication	complication	NOUN	NN	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
fatal	fatal	ADJ	JJ	5	O
if	if	ADP	IN	5	O
not	not	ADV	RB	5	O
recognized	recognize	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
treated	treat	VERB	VBN	3	O
early	early	ADV	RB	9	O
.	.	PUNCT	.	9	O

Considering	consider	VERB	VBG	9	O
that	that	DET	DT	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
remains	remain	VERB	VBZ	9	O
the	the	DET	DT	5	O
gold	gold	NOUN	NN	0	O
standard	standard	NOUN	NN	5	O
in	in	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
resistant	resistant	ADJ	JJ	9	O
psychosis	psychosis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
urgent	urgent	ADJ	JJ	5	O
need	need	NOUN	NN	5	O
to	to	PART	TO	5	O
raise	raise	VERB	VB	9	O
awareness	awareness	NOUN	NN	5	O
among	among	ADP	IN	5	O
medical	medical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
paramedical	paramedical	ADJ	JJ	5	O
staff	staff	NOUN	NN	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
care	care	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
are	be	VERB	VBP	5	O
also	also	ADV	RB	9	O
implications	implication	NOUN	NNS	5	O
for	for	ADP	IN	5	O
recommendations	recommendation	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
regulations	regulation	NOUN	NNS	5	O
regarding	regard	VERB	VBG	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Severe	severe	ADJ	JJ	9	O
rhabdomyolysis	rhabdomyolysis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
concomitant	concomitant	ADJ	JJ	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
amiodarone	amiodarone	ADV	RB	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
atazanavir	atazanavir	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
report	report	VERB	VB	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
severe	severe	ADJ	JJ	5	O
interaction	interaction	NOUN	NN	9	O
between	between	ADP	IN	5	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
amiodarone	amiodarone	ADV	RB	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
atazanavir	atazanavir	NOUN	NN	0	B-Chemical
resulting	resulting	NOUN	NN	9	O
in	in	ADP	IN	5	O
rhabdomyolysis	rhabdomyolysis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
72	72	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
white	white	ADJ	JJ	9	O
man	man	NOUN	NN	5	O
with	with	ADP	IN	5	O
underlying	underlie	VERB	VBG	5	O
human	human	ADJ	JJ	3	B-Disease
immunodeficiency	immunodeficiency	NOUN	NN	9	I-Disease
virus	virus	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
hyperlipidemia	hyperlipidemia	NOUN	NN	9	B-Disease
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
generalized	generalized	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
fatigue	fatigue	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
dark	dark	ADJ	JJ	9	O
orange	orange	NOUN	NN	9	O
urine	urine	NOUN	NN	9	O
for	for	ADP	IN	5	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
taking	take	VERB	VBG	5	O
80	80	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
bedtime	bedtime	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
initiated	initiate	VERB	VBN	9	O
27	27	NUM	CD	7	O
days	day	NOUN	NNS	9	O
earlier	earlier	ADV	RBR	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
amiodarone	amiodarone	ADV	RB	0	B-Chemical
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
400	400	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
daily	daily	ADV	RB	5	O
for	for	ADP	IN	5	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
then	then	ADV	RB	9	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
daily	daily	ADV	RB	5	O
(	(	PUNCT	-LRB-	9	O
initiated	initiate	VERB	VBN	9	O
19	19	NUM	CD	7	O
days	day	NOUN	NNS	9	O
earlier	earlier	ADV	RBR	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
400	400	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
atazanavir	atazanavir	ADJ	JJ	0	B-Chemical
daily	daily	ADV	RB	5	O
(	(	PUNCT	-LRB-	9	O
initiated	initiate	VERB	VBN	9	O
at	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
2	2	NUM	CD	9	O
years	year	NOUN	NNS	5	O
previously	previously	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Laboratory	laboratory	NOUN	NN	2	O
evaluation	evaluation	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
66	66	NUM	CD	7	O
,	,	PUNCT	,	9	O
680	680	NUM	CD	9	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
creatine	creatine	NOUN	NN	0	B-Chemical
kinase	kinase	NOUN	NN	3	O
,	,	PUNCT	,	9	O
93	93	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
blood	blood	NOUN	NN	9	B-Chemical
urea	urea	ADJ	JJ	0	I-Chemical
nitrogen	nitrogen	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dL	PROPN	NNP	7	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
1579	1579	NUM	CD	7	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
aspartate	aspartate	NOUN	NN	1	B-Chemical
aminotransferase	aminotransferase	NOUN	NN	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
738	738	NUM	CD	7	O
U	U	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
alanine	alanine	NOUN	NN	1	B-Chemical
aminotransferase	aminotransferase	NOUN	NN	7	O
.	.	PUNCT	.	9	O

Simvastatin	Simvastatin	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
amiodarone	amiodarone	ADV	RB	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
human	human	ADJ	JJ	3	B-Disease
immunodeficiency	immunodeficiency	NOUN	NN	9	I-Disease
virus	virus	NOUN	NN	9	I-Disease
medications	medication	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
all	all	ADV	RB	5	O
temporarily	temporarily	ADV	RB	5	O
discontinued	discontinue	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
forced	force	VERB	VBN	5	O
alkaline	alkaline	NOUN	NN	0	O
diuresis	diuresis	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
started	start	VERB	VBD	5	O
on	on	ADP	IN	5	O
dialysis	dialysis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Nine	nine	NUM	CD	9	O
days	day	NOUN	NNS	9	O
later	later	ADV	RB	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
creatine	creatine	NOUN	NN	0	B-Chemical
kinase	kinase	NOUN	NN	3	O
had	have	VERB	VBD	9	O
dropped	drop	VERB	VBN	9	O
to	to	ADP	IN	5	O
1695	1695	NUM	CD	7	O
U	U	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
discharged	discharge	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
continued	continue	VERB	VBN	9	O
outpatient	outpatient	NOUN	NN	5	O
dialysis	dialysis	NOUN	NN	5	O
for	for	ADP	IN	5	O
1	1	NUM	CD	9	O
month	month	NOUN	NN	5	O
until	until	ADP	IN	5	O
his	-PRON-	DET	PRP$	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
recovered	recover	VERB	VBD	9	O
.	.	PUNCT	.	9	O

DISCUSSION	discussion	NOUN	NN	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
rhabdomyolysis	rhabdomyolysis	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
increased	increase	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
concomitant	concomitant	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
that	that	DET	WDT	5	O
inhibit	inhibit	VERB	VBP	3	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
metabolism	metabolism	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Simvastatin	Simvastatin	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
metabolized	metabolize	VERB	VBN	0	O
by	by	ADP	IN	9	O
CYP3A4	CYP3A4	PROPN	NNP	3	O
.	.	PUNCT	.	9	O

Amiodarone	amiodarone	ADJ	JJ	7	B-Chemical
and	and	CCONJ	CC	5	O
atazanavir	atazanavir	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
recognized	recognize	VERB	VBN	9	O
CYP3A4	cyp3a4	NOUN	NN	3	O
inhibitors	inhibitor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Pharmacokinetic	pharmacokinetic	ADJ	JJ	0	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
statins	statin	NOUN	NNS	5	B-Chemical
are	be	VERB	VBP	5	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
consideration	consideration	NOUN	NN	5	O
for	for	ADP	IN	5	O
assessing	assess	VERB	VBG	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
potential	potential	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
interactions	interaction	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
requiring	require	VERB	VBG	5	O
the	the	DET	DT	5	O
concurrent	concurrent	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
statins	statin	NOUN	NNS	5	B-Chemical
and	and	CCONJ	CC	5	O
CYP3A4	cyp3a4	NOUN	NN	3	O
inhibitors	inhibitor	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
pravastatin	pravastatin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
fluvastatin	fluvastatin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
rosuvastatin	rosuvastatin	NOUN	NN	0	B-Chemical
carry	carry	VERB	VBP	9	O
the	the	DET	DT	5	O
lowest	low	ADJ	JJS	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
interactions	interaction	NOUN	NNS	9	O
;	;	PUNCT	,	9	O
atorvastatin	atorvastatin	ADV	RB	0	B-Chemical
carries	carry	VERB	VBZ	9	O
moderate	moderate	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
lovastatin	lovastatin	NOUN	NN	0	B-Chemical
have	have	VERB	VB	5	O
the	the	DET	DT	5	O
highest	high	ADJ	JJS	9	O
risk	risk	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
avoided	avoid	VERB	VBN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
taking	take	VERB	VBG	5	O
concomitant	concomitant	ADJ	JJ	9	O
CYP3A4	cyp3a4	NOUN	NN	3	O
inhibitors	inhibitor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Interaction	interaction	NOUN	NN	9	O
between	between	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
levofloxacin	levofloxacin	ADJ	JJ	0	B-Chemical
:	:	PUNCT	:	9	O
case	case	NOUN	NN	5	O
series	series	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Warfarin	Warfarin	PROPN	NNP	5	B-Chemical
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
oral	oral	ADJ	JJ	9	O
anticoagulant	anticoagulant	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
is	be	VERB	VBZ	5	O
indicated	indicate	VERB	VBN	9	O
for	for	ADP	IN	5	O
many	many	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
conditions	condition	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Levofloxacin	Levofloxacin	PROPN	NNP	7	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
fluoroquinolone	fluoroquinolone	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
commonly	commonly	ADV	RB	5	O
prescribed	prescribe	VERB	VBN	5	O
antibiotics	antibiotic	NOUN	NNS	5	O
in	in	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
practice	practice	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
is	be	VERB	VBZ	5	O
effective	effective	ADJ	JJ	5	O
against	against	ADP	IN	9	O
Gram	Gram	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
Gram	Gram	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
negative	negative	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
atypical	atypical	ADJ	JJ	5	O
bacteria	bacteria	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

While	while	ADP	IN	9	O
small	small	ADJ	JJ	9	O
prospective	prospective	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
not	not	ADV	RB	5	O
revealed	reveal	VERB	VBN	9	O
any	any	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
drug	drug	NOUN	NN	5	O
interaction	interaction	NOUN	NN	9	O
between	between	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
levofloxacin	levofloxacin	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
several	several	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
reports	report	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
indicated	indicate	VERB	VBN	9	O
that	that	ADP	IN	5	O
levofloxacin	levofloxacin	ADJ	JJ	0	B-Chemical
may	may	VERB	MD	5	O
significantly	significantly	ADV	RB	9	O
potentiate	potentiate	VERB	VB	3	O
the	the	DET	DT	5	O
anticoagulation	anticoagulation	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
3	3	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
serious	serious	ADJ	JJ	5	O
bleeding	bleeding	NOUN	NN	5	B-Disease
complications	complication	NOUN	NNS	5	O
that	that	DET	WDT	5	O
appear	appear	VERB	VBP	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
interaction	interaction	NOUN	NN	9	O
between	between	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
levofloxacin	levofloxacin	ADJ	JJ	0	B-Chemical
.	.	PUNCT	.	9	O

Physicians	physician	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
interaction	interaction	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
use	use	VERB	VB	5	O
caution	caution	NOUN	NN	5	O
when	when	ADV	WRB	5	O
prescribing	prescribe	VERB	VBG	5	O
levofloxacin	levofloxacin	ADJ	JJ	0	B-Chemical
to	to	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
taking	take	VERB	VBG	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Mutations	mutation	NOUN	NNS	1	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
lamivudine	lamivudine	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
resistance	resistance	NOUN	NN	9	O
in	in	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
na	na	NOUN	NN	7	B-Chemical
ve	ve	X	FW	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
virus	virus	PROPN	NNP	9	I-Disease
(	(	PUNCT	-LRB-	9	I-Disease
HBV	HBV	PROPN	NNP	9	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
infected	infect	VERB	VBD	3	I-Disease
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
and	and	CCONJ	CC	5	O
without	without	ADP	IN	9	O
HIV	HIV	PROPN	NNP	5	B-Disease
co	co	NOUN	NN	9	I-Disease
-	-	NOUN	NN	7	I-Disease
infection	infection	NOUN	NN	9	I-Disease
:	:	PUNCT	:	9	O
implications	implication	NOUN	NNS	5	O
for	for	ADP	IN	5	O
antiretroviral	antiretroviral	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
HBV	HBV	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	I-Disease
HIV	HIV	PROPN	NNP	5	I-Disease
co	co	VERB	VBD	9	I-Disease
-	-	ADJ	JJ	7	I-Disease
infected	infect	VERB	VBN	3	I-Disease
South	south	ADJ	JJ	4	O
African	african	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
an	an	DET	DT	5	O
exploratory	exploratory	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
resistant	resistant	ADJ	JJ	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
virus	virus	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
HBV	HBV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
strains	strain	VERB	VBZ	1	O
in	in	ADP	IN	5	O
selected	select	VERB	VBN	9	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
na	na	X	FW	7	B-Chemical
ve	ve	ADP	IN	9	O
HBV	HBV	PROPN	NNP	9	O
carriers	carrier	NOUN	NNS	9	O
with	with	ADP	IN	5	O
and	and	CCONJ	CC	5	O
without	without	ADP	IN	9	O
human	human	ADJ	JJ	3	B-Disease
immunodeficiency	immunodeficiency	NOUN	NN	9	I-Disease
virus	virus	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	I-Disease
HIV	HIV	PROPN	NNP	5	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
co	co	ADJ	JJ	9	I-Disease
-	-	NOUN	NN	7	I-Disease
infection	infection	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
South	south	ADJ	JJ	4	O
African	african	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
five	five	NUM	CD	9	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
na	na	NOUN	NN	7	B-Chemical
ve	ve	ADP	IN	9	O
HBV	HBV	PROPN	NNP	9	B-Disease
infected	infect	VERB	VBD	3	I-Disease
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
HIV	HIV	PROPN	NNP	5	B-Disease
co	co	NOUN	NN	9	I-Disease
-	-	NOUN	NN	7	I-Disease
infection	infection	NOUN	NN	9	I-Disease
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
:	:	PUNCT	:	9	O
15	15	NUM	CD	9	O
chronic	chronic	ADJ	JJ	5	O
HBV	HBV	PROPN	NNP	9	B-Disease
mono	mono	NOUN	NNS	0	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
infected	infect	VERB	VBN	3	I-Disease
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
20	20	NUM	CD	9	O
HBV	HBV	PROPN	NNP	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
HIV	HIV	PROPN	NNP	5	I-Disease
co	co	VERB	VBD	9	I-Disease
-	-	ADJ	JJ	7	I-Disease
infected	infected	ADJ	JJ	3	I-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
latter	latter	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
further	further	ADJ	JJ	9	O
sub	sub	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
divided	divide	VERB	VBN	5	O
into	into	ADP	IN	9	O
13	13	NUM	CD	7	O
occult	occult	NOUN	NN	5	O
HBV	HBV	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
HBsAg	HBsAg	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
negative	negative	ADJ	JJ	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
7	7	NUM	CD	9	O
overt	overt	ADJ	JJ	5	O
HBV	HBV	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
HBsAg	HBsAg	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

HBsAg	HBsAg	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
HBs	hbs	ADJ	JJ	3	O
,	,	PUNCT	,	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
HBc	HBc	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
HIV	hiv	ADJ	JJ	5	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
as	as	ADP	IN	5	O
part	part	NOUN	NN	9	O
of	of	ADP	IN	5	O
routine	routine	ADJ	JJ	5	O
diagnosis	diagnosis	NOUN	NN	5	O
using	use	VERB	VBG	9	O
Axsym	Axsym	PROPN	NNP	0	O
assays	assay	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
Abbott	Abbott	PROPN	NNP	2	O
Laboratories	Laboratories	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
North	North	PROPN	NNP	4	O
Chicago	Chicago	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
IL	IL	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Serum	serum	ADJ	JJ	9	O
samples	sample	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
PCR	PCR	PROPN	NNP	9	O
amplified	amplify	VERB	VBN	1	O
with	with	ADP	IN	5	O
HBV	HBV	PROPN	NNP	9	O
reverse	reverse	NOUN	NN	9	O
transcriptase	transcriptase	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
RT	RT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
primers	primer	NOUN	NNS	1	O
,	,	PUNCT	,	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
direct	direct	ADJ	JJ	9	O
sequencing	sequencing	NOUN	NN	9	O
across	across	ADP	IN	5	O
the	the	DET	DT	5	O
tyrosine	tyrosine	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
methionine	methionine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
aspartate	aspartate	NOUN	NN	1	B-Chemical
-	-	PUNCT	HYPH	7	O
aspartate	aspartate	NOUN	NN	1	B-Chemical
(	(	PUNCT	-LRB-	9	O
YMDD	YMDD	PROPN	NNP	1	O
)	)	PUNCT	-RRB-	9	O
motif	motif	NOUN	NN	1	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
major	major	ADJ	JJ	9	O
catalytic	catalytic	ADJ	JJ	1	O
region	region	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
C	C	PROPN	NNP	9	O
domain	domain	NOUN	NN	1	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
HBV	HBV	PROPN	NNP	9	O
RT	RT	PROPN	NNP	9	O
enzyme	enzyme	NOUN	NN	0	O
.	.	PUNCT	.	9	O

HBV	HBV	PROPN	NNP	9	O
viral	viral	ADJ	JJ	9	O
load	load	NOUN	NN	5	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
with	with	ADP	IN	5	O
Amplicor	Amplicor	PROPN	NNP	5	O
HBV	HBV	PROPN	NNP	9	O
Monitor	Monitor	PROPN	NNP	5	O
test	test	NOUN	NN	5	O
v2	v2	PROPN	NNP	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
(	(	PUNCT	-LRB-	9	O
Roche	Roche	PROPN	NNP	0	O
Diagnostics	Diagnostics	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Penzberg	Penzberg	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
Germany	Germany	PROPN	NNP	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

HBV	HBV	PROPN	NNP	9	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
resistant	resistant	ADJ	JJ	9	O
strains	strain	NOUN	NNS	1	O
were	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
of	of	ADP	IN	5	O
15	15	NUM	CD	9	O
mono	mono	NOUN	NNS	0	O
-	-	PUNCT	HYPH	7	O
infected	infect	VERB	VBN	3	O
chronic	chronic	ADJ	JJ	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
of	of	ADP	IN	5	O
20	20	NUM	CD	9	O
HBV	HBV	PROPN	NNP	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
HIV	HIV	PROPN	NNP	5	I-Disease
co	co	VERB	VBD	9	I-Disease
-	-	ADJ	JJ	7	I-Disease
infected	infected	ADJ	JJ	3	I-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
the	the	DET	DT	5	O
best	good	ADJ	JJS	5	O
of	of	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
knowledge	knowledge	NOUN	NN	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
constitutes	constitute	VERB	VBZ	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
HBV	HBV	PROPN	NNP	9	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
resistant	resistant	ADJ	JJ	9	O
strains	strain	NOUN	NNS	1	O
in	in	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
na	na	NOUN	NN	7	B-Chemical
ve	ve	ADP	IN	9	O
HBV	HBV	PROPN	NNP	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
HIV	HIV	PROPN	NNP	5	I-Disease
co	co	VERB	VBD	9	I-Disease
-	-	ADJ	JJ	7	I-Disease
infected	infected	ADJ	JJ	3	I-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
HBV	HBV	PROPN	NNP	9	O
viral	viral	NOUN	NN	9	O
loads	load	NOUN	NNS	9	O
for	for	ADP	IN	5	O
mono	mono	NOUN	NNS	0	O
-	-	PUNCT	HYPH	7	O
infected	infect	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
co	co	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
infected	infected	ADJ	JJ	3	O
patients	patient	NOUN	NNS	5	O
ranged	range	VERB	VBD	9	O
from	from	ADP	IN	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
32	32	NUM	CD	7	O
x	x	SYM	SYM	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
82	82	NUM	CD	7	O
x	x	SYM	SYM	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
<	<	X	XX	0	O
200	200	NUM	CD	0	O
to	to	ADP	IN	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
40	40	NUM	CD	9	O
x	x	SYM	SYM	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
copies	copy	NOUN	NNS	9	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
remains	remain	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
seen	see	VERB	VBN	9	O
whether	whether	ADP	IN	9	O
such	such	ADJ	JJ	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
existing	existing	ADJ	JJ	5	O
antiviral	antiviral	ADJ	JJ	9	O
mutations	mutation	NOUN	NNS	1	O
could	could	VERB	MD	9	O
result	result	VERB	VB	9	O
in	in	ADP	IN	5	O
widespread	widespread	ADJ	JJ	5	O
emergence	emergence	NOUN	NN	9	O
of	of	ADP	IN	5	O
HBV	HBV	PROPN	NNP	9	O
resistant	resistant	ADJ	JJ	9	O
strains	strain	NOUN	NNS	1	O
when	when	ADV	WRB	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
highly	highly	ADV	RB	9	O
active	active	ADJ	JJ	9	O
antiretroviral	antiretroviral	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ARV	ARV	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
treatment	treatment	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
HAART	HAART	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
regimens	regimen	NOUN	NNS	5	O
become	become	VERB	VBP	5	O
widely	widely	ADV	RB	5	O
applied	apply	VERB	VBN	5	O
in	in	ADP	IN	5	O
South	South	PROPN	NNP	4	O
Africa	Africa	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
this	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
potential	potential	ADJ	JJ	9	O
implications	implication	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
HBV	HBV	PROPN	NNP	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
HIV	HIV	PROPN	NNP	5	I-Disease
co	co	VERB	VBD	9	I-Disease
-	-	ADJ	JJ	7	I-Disease
infected	infected	ADJ	JJ	3	I-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Rabbit	rabbit	NOUN	NN	3	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
antidepressant	antidepressant	ADJ	JJ	5	B-Chemical
use	use	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cerebral	cerebral	ADJ	JJ	5	O
perfusion	perfusion	NOUN	NN	5	O
SPECT	SPECT	NOUN	NNS	5	O
scan	scan	NOUN	NN	5	O
findings	finding	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rabbit	rabbit	NOUN	NN	3	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Its	-PRON-	DET	PRP$	5	O
occurrence	occurrence	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
being	be	VERB	VBG	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
imipramine	imipramine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
described	describe	VERB	VBN	9	O
,	,	PUNCT	,	9	O
representing	represent	VERB	VBG	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
reported	report	VERB	VBN	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
in	in	ADP	IN	5	O
conjunction	conjunction	NOUN	NN	9	O
with	with	ADP	IN	5	O
antidepressants	antidepressant	NOUN	NNS	5	B-Chemical
.	.	PUNCT	.	9	O

Repeated	repeat	VERB	VBN	5	O
cerebral	cerebral	ADJ	JJ	5	O
perfusion	perfusion	NOUN	NN	5	O
SPECT	SPECT	PROPN	NNP	5	O
scans	scan	NOUN	NNS	5	O
revealed	reveal	VERB	VBD	9	O
decreased	decrease	VERB	VBD	9	B-Disease
basal	basal	NOUN	NN	3	I-Disease
ganglia	ganglion	NOUN	NNS	5	I-Disease
perfusion	perfusion	NOUN	NN	5	I-Disease
while	while	ADP	IN	9	O
the	the	DET	DT	5	O
movement	movement	NOUN	NN	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
present	present	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
return	return	NOUN	NN	5	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
perfusion	perfusion	NOUN	NN	5	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
rabbit	rabbit	NOUN	NN	3	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
resolved	resolve	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Estrogen	Estrogen	PROPN	NNP	9	O
prevents	prevent	VERB	VBZ	9	O
cholesteryl	cholesteryl	NOUN	NN	0	B-Chemical
ester	ester	NOUN	NN	0	I-Chemical
accumulation	accumulation	NOUN	NN	9	O
in	in	ADP	IN	5	O
macrophages	macrophage	NOUN	NNS	3	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
HIV	HIV	PROPN	NNP	5	O
protease	protease	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
ritonavir	ritonavir	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Individuals	individual	NOUN	NNS	5	O
with	with	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	O
can	can	VERB	MD	5	O
now	now	ADV	RB	5	O
live	live	VERB	VB	9	O
long	long	ADJ	JJ	5	O
lives	life	NOUN	NNS	5	O
with	with	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
that	that	DET	WDT	5	O
often	often	ADV	RB	5	O
includes	include	VERB	VBZ	5	O
protease	protease	NOUN	NN	0	O
inhibitors	inhibitor	NOUN	NNS	3	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
ritonavir	ritonavir	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Many	many	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
develop	develop	VERB	VB	5	O
negative	negative	ADJ	JJ	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
premature	premature	ADJ	JJ	9	B-Disease
atherosclerosis	atherosclerosis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
previously	previously	ADV	RB	9	O
demonstrated	demonstrate	VERB	VBN	9	O
that	that	ADP	IN	5	O
ritonavir	ritonavir	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
increases	increase	NOUN	NNS	9	O
atherosclerotic	atherosclerotic	ADJ	JJ	3	B-Disease
lesion	lesion	NOUN	NN	5	I-Disease
formation	formation	NOUN	NN	9	O
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
mice	mouse	NOUN	NNS	3	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
greater	great	ADJ	JJR	5	O
extent	extent	NOUN	NN	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
female	female	ADJ	JJ	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
peripheral	peripheral	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
monocytes	monocyte	NOUN	NNS	3	O
isolated	isolate	VERB	VBN	9	O
from	from	ADP	IN	9	O
ritonavir	ritonavir	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
females	female	NOUN	NNS	9	O
had	have	VERB	VBD	9	O
less	less	ADJ	JJR	5	O
cholesteryl	cholesteryl	NOUN	NN	0	B-Chemical
ester	ester	NOUN	NN	0	I-Chemical
accumulation	accumulation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
have	have	VERB	VBP	5	O
investigated	investigate	VERB	VBN	9	O
the	the	DET	DT	5	O
molecular	molecular	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
by	by	ADP	IN	9	O
which	which	DET	WDT	5	O
female	female	ADJ	JJ	9	O
hormones	hormone	NOUN	NNS	9	O
influence	influence	VERB	VBP	5	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
metabolism	metabolism	NOUN	NN	9	O
in	in	ADP	IN	5	O
macrophages	macrophage	NOUN	NNS	3	O
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
HIV	HIV	PROPN	NNP	5	O
protease	protease	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
ritonavir	ritonavir	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
utilized	utilize	VERB	VBN	9	O
the	the	DET	DT	5	O
human	human	ADJ	JJ	3	O
monocyte	monocyte	NOUN	NN	3	O
cell	cell	NOUN	NN	3	O
line	line	NOUN	NN	9	O
,	,	PUNCT	,	9	O
THP	THP	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
model	model	NOUN	NN	5	O
to	to	PART	TO	5	O
address	address	VERB	VB	5	O
this	this	DET	DT	5	O
question	question	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Briefly	Briefly	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
cells	cell	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
differentiated	differentiate	VERB	VBN	3	O
for	for	ADP	IN	5	O
72	72	NUM	CD	9	O
h	h	NOUN	NN	0	O
with	with	ADP	IN	5	O
100	100	NUM	CD	0	O
nM	nM	PROPN	NNP	0	O
PMA	PMA	PROPN	NNP	3	O
to	to	PART	TO	5	O
obtain	obtain	VERB	VB	5	O
a	a	DET	DT	5	O
macrophage	macrophage	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
phenotype	phenotype	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
nM	nm	NOUN	NN	0	O
17beta	17beta	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
estradiol	estradiol	NOUN	NNS	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
E2	E2	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
100	100	NUM	CD	0	O
nM	nm	NOUN	NN	0	O
progesterone	progesterone	NOUN	NN	3	B-Chemical
or	or	CCONJ	CC	5	O
vehicle	vehicle	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
%	%	NOUN	NN	9	O
ethanol	ethanol	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Cells	cell	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
then	then	ADV	RB	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
30	30	NUM	CD	9	O
ng	ng	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
ritonavir	ritonavir	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
vehicle	vehicle	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
aggregated	aggregate	VERB	VBN	5	O
LDL	LDL	PROPN	NNP	0	O
for	for	ADP	IN	5	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Cell	cell	NOUN	NN	3	O
extracts	extract	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
harvested	harvest	VERB	VBN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
lipid	lipid	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
total	total	ADJ	JJ	9	O
RNA	RNA	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
isolated	isolate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

E2	E2	PROPN	NNP	3	B-Chemical
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
accumulation	accumulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
cholesteryl	cholesteryl	NOUN	NN	0	B-Chemical
esters	ester	NOUN	NNS	0	I-Chemical
in	in	ADP	IN	5	O
macrophages	macrophage	NOUN	NNS	3	O
following	follow	VERB	VBG	9	O
ritonavir	ritonavir	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Ritonavir	Ritonavir	PROPN	NNP	0	B-Chemical
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
scavenger	scavenger	NOUN	NN	0	O
receptor	receptor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
CD36	CD36	PROPN	NNP	3	O
mRNA	mRNA	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
uptake	uptake	NOUN	NN	0	O
of	of	ADP	IN	5	O
LDL	LDL	PROPN	NNP	0	O
.	.	PUNCT	.	9	O

Additionally	additionally	ADV	RB	9	O
,	,	PUNCT	,	9	O
ritonavir	ritonavir	VERB	VB	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
selectively	selectively	ADV	RB	3	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
relative	relative	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
PPARgamma	PPARgamma	PROPN	NNP	3	O
mRNA	mRNA	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
transcription	transcription	NOUN	NN	1	O
factor	factor	NOUN	NN	9	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
CD36	CD36	PROPN	NNP	3	O
mRNA	mRNA	PROPN	NNP	3	O
expression	expression	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
E2	E2	PROPN	NNP	3	B-Chemical
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
these	these	DET	DT	5	O
increases	increase	NOUN	NNS	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
mRNA	mRNA	PROPN	NNP	3	O
level	level	NOUN	NN	9	O
.	.	PUNCT	.	9	O

E2	E2	PROPN	NNP	3	B-Chemical
did	do	VERB	VBD	9	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
significantly	significantly	ADV	RB	9	O
suppress	suppress	VERB	VB	3	O
CD36	CD36	PROPN	NNP	3	O
protein	protein	NOUN	NN	1	O
levels	level	NOUN	NNS	3	O
as	as	ADP	IN	5	O
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
fluorescent	fluorescent	ADJ	JJ	3	O
immunocytochemistry	immunocytochemistry	NOUN	NN	3	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
data	data	NOUN	NN	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
E2	E2	PROPN	NNP	3	B-Chemical
modifies	modify	VERB	VBZ	9	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
CD36	CD36	PROPN	NNP	3	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
protein	protein	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
monocyte	monocyte	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
derived	derive	VERB	VBN	9	O
macrophages	macrophage	NOUN	NNS	3	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
reduced	reduce	VERB	VBN	9	O
cholesteryl	cholesteryl	NOUN	NN	0	B-Chemical
ester	ester	NOUN	NN	0	I-Chemical
accumulation	accumulation	NOUN	NN	9	O
following	follow	VERB	VBG	9	O
ritonavir	ritonavir	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
attack	attack	NOUN	NN	5	O
after	after	ADP	IN	9	O
exposure	exposure	NOUN	NN	9	O
to	to	PART	TO	5	O
telithromycin	telithromycin	VERB	VB	0	B-Chemical
.	.	PUNCT	.	9	O

INTRODUCTION	INTRODUCTION	PROPN	NNP	5	O
:	:	PUNCT	:	9	O
Antibiotic	Antibiotic	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
rare	rare	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

With	with	ADP	IN	5	O
widespread	widespread	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
antimicrobial	antimicrobial	ADJ	JJ	9	O
agents	agent	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
occurs	occur	VERB	VBZ	9	O
frequently	frequently	ADV	RB	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
among	among	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	B-Disease
drug	drug	NOUN	NN	5	I-Disease
reactions	reaction	NOUN	NNS	9	I-Disease
,	,	PUNCT	,	9	O
idiosyncratic	idiosyncratic	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
serious	serious	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
SUMMARY	summary	NOUN	NN	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
25	25	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
male	male	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
height	height	NOUN	NN	5	O
of	of	ADP	IN	5	O
175	175	NUM	CD	7	O
cm	cm	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
weight	weight	NOUN	NN	9	O
of	of	ADP	IN	5	O
72	72	NUM	CD	9	O
kg	kg	NOUN	NNS	0	O
presented	present	VERB	VBN	5	O
to	to	ADP	IN	5	O
Marmara	Marmara	PROPN	NNP	2	O
University	University	PROPN	NNP	2	O
Hospital	Hospital	PROPN	NNP	2	O
Emergency	Emergency	PROPN	NNP	2	O
Department	Department	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Istanbul	Istanbul	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Turkey	Turkey	PROPN	NNP	4	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
'	'	PART	POS	9	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
jaundice	jaundice	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
malaise	malaise	NOUN	NN	4	O
,	,	PUNCT	,	9	O
nausea	nausea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
vomiting	vomiting	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
prescribed	prescribe	VERB	VBN	5	O
telithromycin	telithromycin	VERB	VBD	0	B-Chemical
400	400	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
PO	po	NOUN	NN	9	O
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
an	an	DET	DT	5	O
upper	upper	ADJ	JJ	9	B-Disease
respiratory	respiratory	ADJ	JJ	5	I-Disease
tract	tract	NOUN	NN	9	I-Disease
infection	infection	NOUN	NN	9	I-Disease
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
prior	prior	ADV	RB	9	O
.	.	PUNCT	.	9	O

Admission	admission	NOUN	NN	7	O
laboratory	laboratory	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
as	as	ADP	IN	5	O
follows	follow	VERB	VBZ	9	O
:	:	PUNCT	:	9	O
alanine	alanine	NOUN	NN	1	B-Chemical
aminotransferase	aminotransferase	NOUN	NN	7	O
,	,	PUNCT	,	9	O
67	67	NUM	CD	7	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
reference	reference	NOUN	NN	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
37	37	NUM	CD	9	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
aspartate	aspartate	VERB	VB	1	B-Chemical
aminotransferase	aminotransferase	NOUN	NN	7	O
,	,	PUNCT	,	9	O
98	98	NUM	CD	7	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
40	40	NUM	CD	9	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
L	L	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	,	9	O
alkaline	alkaline	NOUN	NN	0	O
phosphatase	phosphatase	NOUN	NN	0	O
,	,	PUNCT	,	9	O
513	513	NUM	CD	7	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
270	270	NUM	CD	9	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
L	L	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
gamma	gamma	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
glutamyltransferase	glutamyltransferase	NOUN	NN	7	O
,	,	PUNCT	,	9	O
32	32	NUM	CD	7	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
-	-	SYM	SYM	7	O
49	49	NUM	CD	7	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
amylase	amylase	NOUN	NN	9	O
,	,	PUNCT	,	9	O
46	46	NUM	CD	7	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
220	220	NUM	CD	9	O
U	u	NOUN	NN	9	O
/	/	SYM	SYM	9	O
L	L	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	,	9	O
total	total	ADJ	JJ	9	O
bilirubin	bilirubin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dL	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
direct	direct	ADJ	JJ	9	O
bilirubin	bilirubin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	NOUN	NN	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dL	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
albumin	albumin	NOUN	NN	0	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dl	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dL	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
toxin	toxin	NOUN	NN	1	O
,	,	PUNCT	,	9	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
suffered	suffer	VERB	VBN	5	O
a	a	DET	DT	5	O
previous	previous	ADJ	JJ	9	O
episode	episode	NOUN	NN	5	O
of	of	ADP	IN	5	O
"	"	PUNCT	``	5	O
acute	acute	ADJ	JJ	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
unknown	unknown	ADJ	JJ	9	O
origin	origin	NOUN	NN	9	O
,	,	PUNCT	,	9	O
"	"	PUNCT	''	5	O
that	that	DET	WDT	5	O
occurred	occur	VERB	VBD	9	O
after	after	ADP	IN	9	O
telithromycin	telithromycin	NOUN	NN	0	B-Chemical
usage	usage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
incidents	incident	NOUN	NNS	5	O
occurred	occur	VERB	VBD	9	O
within	within	ADP	IN	9	O
a	a	DET	DT	5	O
year	year	NOUN	NN	5	O
.	.	PUNCT	.	9	O

DISCUSSION	discussion	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Telithromycin	Telithromycin	PROPN	NNP	7	B-Chemical
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ketolide	ketolide	NOUN	NN	5	O
antibacterials	antibacterial	NOUN	NNS	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
US	US	PROPN	NNP	5	O
Food	Food	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
Drug	Drug	PROPN	NNP	5	O
Administration	Administration	PROPN	NNP	2	O
approval	approval	NOUN	NN	5	O
for	for	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
infrequent	infrequent	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
usually	usually	ADV	RB	5	O
reversible	reversible	ADJ	JJ	9	O
severe	severe	ADJ	JJ	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Based	base	VERB	VBN	9	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
score	score	NOUN	NN	5	O
of	of	ADP	IN	5	O
8	8	NUM	CD	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
Naranjo	Naranjo	PROPN	NNP	6	O
adverse	adverse	ADJ	JJ	5	B-Disease
drug	drug	NOUN	NN	5	I-Disease
reaction	reaction	NOUN	NN	9	I-Disease
probability	probability	NOUN	NN	5	O
scale	scale	NOUN	NN	5	O
,	,	PUNCT	,	9	O
telithromycin	telithromycin	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
probable	probable	ADJ	JJ	9	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
pathological	pathological	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
suggested	suggest	VERB	VBD	9	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
toxic	toxic	ADJ	JJ	0	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Recurrence	recurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
attack	attack	NOUN	NN	5	O
might	may	VERB	MD	9	O
have	have	VERB	VB	5	O
been	be	VERB	VBN	9	O
avoided	avoid	VERB	VBN	5	O
if	if	ADP	IN	5	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
incident	incident	NOUN	NN	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
communicated	communicate	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
attending	attend	VERB	VBG	5	O
physician	physician	NOUN	NN	5	O
who	who	PRON	WP	5	O
prescribed	prescribe	VERB	VBD	5	O
telithromycin	telithromycin	VERB	VBD	0	B-Chemical
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Here	here	ADV	RB	9	O
we	-PRON-	PRON	PRP	5	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
probably	probably	ADV	RB	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
telithromycin	telithromycin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
study	study	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
heparin	heparin	ADJ	JJ	0	B-Chemical
injection	injection	NOUN	NN	9	O
on	on	ADP	IN	5	O
bruising	bruising	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
pain	pain	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

AIM	AIM	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
carried	carry	VERB	VBN	9	O
out	out	PART	RP	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
injection	injection	NOUN	NN	9	O
duration	duration	NOUN	NN	5	O
on	on	ADP	IN	5	O
bruising	bruising	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
pain	pain	NOUN	NN	5	B-Disease
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Although	although	ADP	IN	9	O
different	different	ADJ	JJ	9	O
methods	method	NOUN	NNS	5	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
bruising	bruising	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
pain	pain	NOUN	NN	5	B-Disease
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
widely	widely	ADV	RB	5	O
studied	study	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
described	describe	VERB	VBN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
injection	injection	NOUN	NN	9	O
duration	duration	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
bruising	bruising	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
pain	pain	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
little	little	ADV	RB	9	O
documented	documented	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
as	as	ADP	IN	5	O
within	within	ADP	IN	9	O
-	-	PUNCT	HYPH	7	O
subject	subject	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
quasi	quasi	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
experimental	experimental	ADJ	JJ	5	O
research	research	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
sample	sample	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
consisted	consist	VERB	VBN	5	O
of	of	ADP	IN	5	O
50	50	NUM	CD	0	O
patients	patient	NOUN	NNS	5	O
to	to	PART	TO	5	O
whom	whom	PRON	WP	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
heparin	heparin	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Heparin	Heparin	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
over	over	ADP	IN	5	O
10	10	NUM	CD	9	O
seconds	second	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	ADJ	JJ	5	O
abdominal	abdominal	ADJ	JJ	5	O
site	site	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
seconds	second	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
left	left	ADJ	JJ	5	O
abdominal	abdominal	ADJ	JJ	5	O
site	site	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Injections	injection	NOUN	NNS	9	O
areas	area	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
bruising	bruise	VERB	VBG	5	B-Disease
at	at	ADP	IN	9	O
48	48	NUM	CD	9	O
and	and	CCONJ	CC	5	O
72	72	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
each	each	DET	DT	5	O
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Dimensions	dimension	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
bruising	bruising	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
applied	apply	VERB	VBN	5	O
areas	area	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
using	use	VERB	VBG	9	O
transparent	transparent	ADJ	JJ	5	O
millimetric	millimetric	ADJ	JJ	5	O
measuring	measuring	NOUN	NN	9	O
paper	paper	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
visual	visual	ADJ	JJ	5	O
analog	analog	NOUN	NN	0	O
scale	scale	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
VAS	VAS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
measure	measure	VERB	VB	5	O
pain	pain	NOUN	NN	5	B-Disease
intensity	intensity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
stop	stop	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
watch	watch	NOUN	NN	5	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
time	time	VERB	VB	5	O
the	the	DET	DT	5	O
pain	pain	NOUN	NN	5	B-Disease
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Data	datum	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
analysed	analyse	VERB	VBN	9	O
using	use	VERB	VBG	9	O
chi	chi	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
square	square	ADJ	JJ	5	O
test	test	NOUN	NN	5	O
,	,	PUNCT	,	9	O
Mann	Mann	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Whitney	Whitney	PROPN	NNP	9	O
U	u	NOUN	NN	9	O
,	,	PUNCT	,	9	O
Wilcoxon	Wilcoxon	PROPN	NNP	5	O
signed	sign	VERB	VBD	5	O
ranks	rank	NOUN	NNS	5	O
tests	test	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
correlation	correlation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
percentage	percentage	NOUN	NN	9	O
of	of	ADP	IN	5	O
bruising	bruise	VERB	VBG	5	B-Disease
occurrence	occurrence	NOUN	NN	5	O
was	be	VERB	VBD	9	O
64	64	NUM	CD	7	O
%	%	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
seconds	second	NOUN	NNS	5	O
duration	duration	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
42	42	NUM	CD	7	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
30	30	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
second	second	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
size	size	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
bruising	bruising	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
smaller	small	ADJ	JJR	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
30	30	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
second	second	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Pain	pain	NOUN	NN	5	B-Disease
intensity	intensity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
pain	pain	NOUN	NN	5	B-Disease
period	period	NOUN	NN	5	O
were	be	VERB	VBD	9	O
statistically	statistically	ADV	RB	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
30	30	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
second	second	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
than	than	ADP	IN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
10	10	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
second	second	NOUN	NN	9	O
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
that	that	ADP	IN	5	O
injection	injection	NOUN	NN	9	O
duration	duration	NOUN	NN	5	O
had	have	VERB	VBD	9	O
an	an	DET	DT	5	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
bruising	bruising	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
pain	pain	NOUN	NN	5	B-Disease
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
repeated	repeat	VERB	VBN	5	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
larger	large	ADJ	JJR	5	O
sample	sample	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RELEVANCE	RELEVANCE	NOUN	NNS	2	O
TO	to	ADP	IN	2	O
CLINICAL	CLINICAL	PROPN	NNP	2	O
PRACTICE	practice	NOUN	NN	2	O
:	:	PUNCT	:	9	O
When	when	ADV	WRB	9	O
administering	administer	VERB	VBG	9	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
heparin	heparin	ADJ	JJ	0	B-Chemical
injections	injection	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
important	important	ADJ	JJ	9	O
to	to	PART	TO	5	O
extend	extend	VERB	VB	9	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
regular	regular	ADJ	JJ	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
consumption	consumption	NOUN	NN	5	O
ingesting	ingest	VERB	VBG	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
dosage	dosage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
currently	currently	ADV	RB	5	O
debated	debate	VERB	VBN	5	O
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
REPORT	REPORT	PROPN	NNP	5	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
2	2	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
regular	regular	ADJ	JJ	5	O
consumers	consumer	NOUN	NNS	5	O
of	of	ADP	IN	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
liver	liver	NOUN	NN	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
within	within	ADP	IN	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
hospitalization	hospitalization	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
stopping	stop	VERB	VBG	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
consumption	consumption	NOUN	NN	5	O
while	while	ADP	IN	9	O
being	be	VERB	VBG	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
4	4	NUM	CD	9	O
g	g	NOUN	NN	0	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
serum	serum	ADJ	JJ	9	O
level	level	NOUN	NN	9	O
obtained	obtain	VERB	VBN	9	O
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
toxic	toxic	ADJ	JJ	0	O
range	range	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Possible	possible	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
e	e	NOUN	NN	9	O
.	.	PUNCT	.	9	O
g	g	NOUN	NN	0	O
.	.	PUNCT	.	9	O
regular	regular	ADJ	JJ	5	O
consumption	consumption	NOUN	NN	5	O
of	of	ADP	IN	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
liver	liver	NOUN	NN	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
possible	possible	ADJ	JJ	5	O
when	when	ADV	WRB	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
are	be	VERB	VBP	5	O
ingested	ingest	VERB	VBN	0	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
propose	propose	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
dose	dose	NOUN	NN	9	O
should	should	VERB	MD	5	O
not	not	ADV	RB	5	O
exceed	exceed	VERB	VB	5	O
2	2	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
in	in	ADP	IN	5	O
such	such	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
liver	liver	NOUN	NN	9	O
function	function	NOUN	NN	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
monitored	monitor	VERB	VBN	9	O
closely	closely	ADV	RB	9	O
while	while	ADP	IN	9	O
being	be	VERB	VBG	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Associations	association	NOUN	NNS	5	O
between	between	ADP	IN	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
benzodiazepines	benzodiazepine	NOUN	NNS	5	B-Chemical
or	or	CCONJ	CC	5	O
related	relate	VERB	VBN	9	O
drugs	drug	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
health	health	NOUN	NN	5	O
,	,	PUNCT	,	9	O
physical	physical	ADJ	JJ	5	O
abilities	ability	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
cognitive	cognitive	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
randomised	randomise	VERB	VBN	5	O
clinical	clinical	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
elderly	elderly	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
describe	describe	VERB	VB	5	O
associations	association	NOUN	NNS	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
benzodiazepines	benzodiazepine	NOUN	NNS	5	B-Chemical
or	or	CCONJ	CC	5	O
related	relate	VERB	VBN	9	O
drugs	drug	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
BZDs	bzd	NOUN	NNS	5	B-Chemical
/	/	SYM	SYM	9	O
RDs	RDs	PROPN	NNPS	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
health	health	NOUN	NN	5	O
,	,	PUNCT	,	9	O
functional	functional	ADJ	JJ	9	O
abilities	ability	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
cognitive	cognitive	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
elderly	elderly	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
randomised	randomise	VERB	VBN	5	O
clinical	clinical	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
aged	age	VERB	VBN	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	NOUN	NNS	7	O
65	65	NUM	CD	7	O
years	year	NOUN	NNS	5	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
hospital	hospital	NOUN	NN	5	O
wards	ward	NOUN	NNS	5	O
during	during	ADP	IN	5	O
1	1	NUM	CD	9	O
month	month	NOUN	NN	5	O
.	.	PUNCT	.	9	O

164	164	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
age	age	NOUN	NN	5	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
standard	standard	ADJ	JJ	5	O
deviation	deviation	NOUN	NN	5	O
[	[	PUNCT	-LRB-	9	O
SD	sd	NOUN	NN	7	O
]	]	PUNCT	-RRB-	9	O
81	81	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
admitted	admit	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
these	these	DET	DT	5	O
,	,	PUNCT	,	9	O
nearly	nearly	ADV	RB	9	O
half	half	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
78	78	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
used	use	VERB	VBN	5	O
BZDs	bzd	NOUN	NNS	5	B-Chemical
/	/	SYM	SYM	9	O
RDs	rd	NOUN	NNS	5	O
before	before	ADP	IN	9	O
admission	admission	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
remainder	remainder	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
86	86	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
users	user	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Cognitive	cognitive	ADJ	JJ	5	O
ability	ability	NOUN	NN	9	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
Mini	Mini	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
Mental	Mental	PROPN	NNP	5	O
State	State	PROPN	NNP	2	O
Examination	Examination	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
MMSE	MMSE	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
scoring	score	VERB	VBG	5	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
20	20	NUM	CD	9	O
MMSE	mmse	NUM	CD	5	O
sum	sum	NOUN	NN	5	O
points	point	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
interviewed	interview	VERB	VBN	5	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
79	79	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
questioned	question	VERB	VBD	5	O
regarding	regard	VERB	VBG	5	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
functional	functional	ADJ	JJ	9	O
abilities	ability	NOUN	NNS	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
week	week	NOUN	NN	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
admission	admission	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Data	datum	NOUN	NNS	5	O
on	on	ADP	IN	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
BZDs	bzd	NOUN	NNS	5	B-Chemical
/	/	SYM	SYM	9	O
RDs	rd	NOUN	NNS	5	O
before	before	ADP	IN	9	O
admission	admission	NOUN	NN	5	O
,	,	PUNCT	,	9	O
current	current	ADJ	JJ	5	O
medications	medication	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
discharge	discharge	NOUN	NN	5	O
diagnoses	diagnosis	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
collected	collect	VERB	VBN	9	O
from	from	ADP	IN	9	O
medical	medical	ADJ	JJ	5	O
records	record	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Health	Health	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
physical	physical	ADJ	JJ	5	O
abilities	ability	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
cognitive	cognitive	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
between	between	ADP	IN	5	O
BZD	BZD	PROPN	NNP	5	O
/	/	SYM	SYM	9	O
RD	RD	PROPN	NNP	9	O
users	user	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
users	user	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
adjustments	adjustment	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
made	make	VERB	VBN	5	O
for	for	ADP	IN	5	O
confounding	confound	VERB	VBG	5	O
variables	variable	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
residual	residual	ADJ	JJ	9	O
serum	serum	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
oxazepam	oxazepam	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
temazepam	temazepam	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
zopiclone	zopiclone	NOUN	NN	5	B-Chemical
were	be	VERB	VBD	9	O
analysed	analyse	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SD	sd	NOUN	NN	7	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
BZD	BZD	PROPN	NNP	5	O
/	/	SYM	SYM	9	O
RD	RD	PROPN	NNP	9	O
use	use	NOUN	NN	5	O
was	be	VERB	VBD	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
7	7	NUM	CD	9	O
years	year	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
range	range	VERB	VB	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
31	31	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
or	or	CCONJ	CC	5	O
three	three	NUM	CD	9	O
BZDs	bzd	NOUN	NNS	5	B-Chemical
/	/	SYM	SYM	9	O
RDs	rd	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
concomitantly	concomitantly	ADV	RB	9	O
taken	take	VERB	VBN	5	O
by	by	ADP	IN	9	O
26	26	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
users	user	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
20	20	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Long	long	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
female	female	ADJ	JJ	9	O
sex	sex	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
with	with	ADP	IN	5	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
CNS	CNS	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
tended	tend	VERB	VBD	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
diagnosed	diagnose	VERB	VBN	5	O
dementia	dementia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
adjustment	adjustment	NOUN	NN	5	O
for	for	ADP	IN	5	O
these	these	DET	DT	5	O
variables	variable	NOUN	NNS	5	O
as	as	ADP	IN	5	O
confounders	confounder	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
BZDs	bzd	NOUN	NNS	5	B-Chemical
/	/	SYM	SYM	9	O
RDs	rd	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
cognitive	cognitive	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
as	as	ADP	IN	5	O
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
MMSE	MMSE	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
BZDs	bzd	NOUN	NNS	5	B-Chemical
/	/	SYM	SYM	9	O
RDs	rd	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
dizziness	dizziness	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
inability	inability	NOUN	NN	9	B-Disease
to	to	PART	TO	5	I-Disease
sleep	sleep	VERB	VB	5	I-Disease
after	after	ADP	IN	9	O
awaking	awake	VERB	VBG	5	O
at	at	ADP	IN	9	O
night	night	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
tiredness	tiredness	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mornings	morning	NOUN	NNS	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
week	week	NOUN	NN	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
admission	admission	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
with	with	ADP	IN	5	O
stronger	strong	ADJ	JJR	9	O
depressive	depressive	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
measured	measure	VERB	VBN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
beginning	beginning	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hospital	hospital	NOUN	NN	5	O
stay	stay	VERB	VB	5	O
.	.	PUNCT	.	9	O

Use	Use	PROPN	NNP	5	O
of	of	ADP	IN	5	O
BZDs	bzd	NOUN	NNS	5	B-Chemical
/	/	SYM	SYM	9	O
RDs	rd	NOUN	NNS	5	O
tended	tend	VERB	VBD	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
reduced	reduced	ADJ	JJ	9	O
ability	ability	NOUN	NN	9	O
to	to	PART	TO	5	O
walk	walk	VERB	VB	5	O
and	and	CCONJ	CC	5	O
shorter	short	ADJ	JJR	9	O
night	night	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
time	time	NOUN	NN	5	O
sleep	sleep	NOUN	NN	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
week	week	NOUN	NN	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
admission	admission	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
higher	high	ADJ	JJR	9	O
residual	residual	ADJ	JJ	9	O
serum	serum	ADJ	JJ	9	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
temazepam	temazepam	NOUN	NN	0	B-Chemical
correlated	correlate	VERB	VBD	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
lower	low	ADJ	JJR	9	O
MMSE	MMSE	PROPN	NNP	5	O
sum	sum	NOUN	NN	5	O
score	score	NOUN	NN	5	O
after	after	ADP	IN	9	O
adjustment	adjustment	NOUN	NN	5	O
for	for	ADP	IN	5	O
confounding	confound	VERB	VBG	5	O
variables	variable	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Long	long	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
use	use	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
concomitant	concomitant	ADJ	JJ	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
one	one	NUM	CD	5	O
BZD	BZD	PROPN	NNP	5	O
/	/	SYM	SYM	9	O
RD	RD	PROPN	NNP	9	O
were	be	VERB	VBD	9	O
common	common	ADJ	JJ	5	O
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
hospitalised	hospitalise	VERB	VBN	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
illnesses	illness	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Long	long	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
use	use	NOUN	NN	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
daytime	daytime	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
night	night	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
time	time	NOUN	NN	5	O
symptoms	symptom	NOUN	NNS	5	O
indicative	indicative	ADJ	JJ	9	O
of	of	ADP	IN	5	O
poorer	poor	ADJ	JJR	5	O
health	health	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
potentially	potentially	ADV	RB	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
vocal	vocal	ADJ	JJ	5	B-Disease
fold	fold	VERB	VBP	9	I-Disease
palsy	palsy	ADJ	JJ	5	I-Disease
after	after	ADP	IN	9	O
acute	acute	ADJ	JJ	9	O
disulfiram	disulfiram	NOUN	NN	0	B-Chemical
intoxication	intoxication	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
peripheral	peripheral	NOUN	NN	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
disulfiram	disulfiram	NOUN	NN	0	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
is	be	VERB	VBZ	5	O
very	very	ADV	RB	5	O
rare	rare	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
no	no	DET	DT	9	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
vocal	vocal	ADJ	JJ	5	B-Disease
fold	fold	VERB	VB	9	I-Disease
palsy	palsy	ADJ	JJ	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
49	49	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
was	be	VERB	VBD	9	O
transferred	transfer	VERB	VBN	9	O
to	to	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
department	department	NOUN	NN	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
quadriparesis	quadriparesis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
lancinating	lancinate	VERB	VBG	5	O
pain	pain	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
sensory	sensory	ADJ	JJ	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
paresthesia	paresthesia	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
distal	distal	ADJ	JJ	9	O
limbs	limb	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
month	month	NOUN	NN	5	O
previously	previously	ADV	RB	9	O
,	,	PUNCT	,	9	O
she	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
taken	take	VERB	VBN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
disulfiram	disulfiram	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
130	130	NUM	CD	9	O
tablets	tablet	NOUN	NNS	0	O
of	of	ADP	IN	5	O
ALCOHOL	ALCOHOL	PROPN	NNP	2	B-Chemical
STOP	STOP	PROPN	NNP	1	O
TAB	TAB	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Shin	Shin	PROPN	NNP	6	O
-	-	PUNCT	HYPH	7	O
Poong	Poong	PROPN	NNP	2	O
Pharm	Pharm	PROPN	NNP	2	O
.	.	PUNCT	.	9	O
Co	co	INTJ	UH	0	O
.	.	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
Ansan	Ansan	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Korea	Korea	PROPN	NNP	2	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
suicide	suicide	NOUN	NN	5	O
attempt	attempt	NOUN	NN	5	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
an	an	DET	DT	5	O
alcoholic	alcoholic	NOUN	NN	5	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
few	few	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
ingestion	ingestion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
she	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
confused	confused	ADJ	JJ	4	O
state	state	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
mild	mild	ADJ	JJ	9	O
to	to	PART	TO	5	O
moderate	moderate	VERB	VB	9	O
ataxia	ataxia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
giddiness	giddiness	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
noticed	notice	VERB	VBD	9	O
hoarseness	hoarseness	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
distally	distally	ADV	RB	5	O
accentuated	accentuate	VERB	VBN	5	O
motor	motor	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
sensory	sensory	ADJ	JJ	5	O
dysfunction	dysfunction	NOUN	NN	9	O
after	after	ADP	IN	9	O
she	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
recovered	recover	VERB	VBN	9	O
from	from	ADP	IN	9	O
this	this	DET	DT	5	O
state	state	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
nerve	nerve	NOUN	NN	5	O
conduction	conduction	NOUN	NN	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
sensorimotor	sensorimotor	NOUN	NN	5	O
axonal	axonal	ADJ	JJ	3	O
polyneuropathy	polyneuropathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Laryngeal	laryngeal	ADJ	JJ	5	O
electromyography	electromyography	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
thyroarytenoid	thyroarytenoid	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
showed	show	VERB	VBD	9	O
ample	ample	ADJ	JJ	5	O
denervation	denervation	NOUN	NN	5	O
potentials	potential	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Laryngoscopy	Laryngoscopy	PROPN	NNP	5	O
revealed	reveal	VERB	VBD	9	O
asymmetric	asymmetric	ADJ	JJ	9	O
vocal	vocal	ADJ	JJ	5	O
fold	fold	VERB	VBP	9	O
movements	movement	NOUN	NNS	5	O
during	during	ADP	IN	5	O
phonation	phonation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Her	-PRON-	DET	PRP$	5	O
vocal	vocal	ADJ	JJ	5	O
change	change	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
weakness	weakness	NOUN	NN	5	O
began	begin	VERB	VBD	5	O
to	to	PART	TO	5	O
improve	improve	VERB	VB	5	O
spontaneously	spontaneously	ADV	RB	5	O
about	about	ADV	RB	5	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
transfer	transfer	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
palsy	palsy	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
recurrent	recurrent	ADJ	JJ	5	O
laryngeal	laryngeal	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
superimposed	superimpose	VERB	VBD	5	O
severe	severe	ADJ	JJ	5	O
acute	acute	ADJ	JJ	9	O
sensorimotor	sensorimotor	NOUN	NN	5	O
axonal	axonal	ADJ	JJ	3	O
polyneuropathy	polyneuropathy	NOUN	NN	5	B-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
disulfiram	disulfiram	NOUN	NN	0	B-Chemical
intoxication	intoxication	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Encephalopathy	Encephalopathy	PROPN	NNP	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
levetiracetam	levetiracetam	NOUN	NN	5	B-Chemical
added	add	VERB	VBN	0	O
to	to	PART	TO	5	O
valproate	valproate	VERB	VB	0	B-Chemical
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
manifestation	manifestation	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
levetiracetam	levetiracetam	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
LEV	LEV	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	:	7	O
induced	induce	VERB	VBN	3	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
.	.	PUNCT	.	9	O

FINDINGS	finding	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
28	28	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
suffering	suffer	VERB	VBG	5	O
from	from	ADP	IN	9	O
idiopathic	idiopathic	ADJ	JJ	5	B-Disease
epilepsy	epilepsy	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
generalized	generalized	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
LEV	LEV	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
3000	3000	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
added	add	VERB	VBD	0	O
to	to	PART	TO	5	O
valproate	valproate	VERB	VB	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
VPA	VPA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
2000	2000	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
generalized	generalized	ADJ	JJ	5	O
tonic	tonic	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
clonic	clonic	NOUN	NN	5	I-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
increased	increase	VERB	VBD	9	O
from	from	ADP	IN	9	O
one	one	NUM	CD	5	O
per	per	ADP	IN	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
to	to	ADP	IN	5	O
two	two	NUM	CD	5	O
per	per	ADP	IN	9	O
month	month	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Neuropsychological	neuropsychological	ADJ	JJ	5	O
testing	testing	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
impaired	impaired	ADJ	JJ	9	B-Disease
word	word	NOUN	NN	5	I-Disease
fluency	fluency	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	I-Disease
psychomotor	psychomotor	NOUN	NN	5	I-Disease
speed	speed	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
working	work	VERB	VBG	5	I-Disease
memory	memory	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
interictal	interictal	ADJ	JJ	5	O
electroencephalogram	electroencephalogram	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
EEG	EEG	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
generalized	generalize	VERB	VBN	5	O
slowing	slowing	NOUN	NN	5	O
to	to	ADP	IN	5	O
5	5	NUM	CD	9	O
per	per	ADP	IN	9	O
second	second	ADJ	JJ	9	O
theta	theta	NOUN	NN	5	O
rhythms	rhythm	NOUN	NNS	5	O
with	with	ADP	IN	5	O
bilateral	bilateral	ADJ	JJ	5	O
generalized	generalize	VERB	VBN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
amplitude	amplitude	NOUN	NN	5	O
discharges	discharge	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

OUTCOME	outcome	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Following	follow	VERB	VBG	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
LEV	LEV	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
EEG	EEG	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
neuropsychological	neuropsychological	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
improved	improve	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
seizure	seizure	VERB	VB	5	B-Disease
frequency	frequency	NOUN	NN	5	O
decreased	decrease	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Norepinephrine	norepinephrine	NOUN	NN	0	B-Chemical
signaling	signal	VERB	VBG	3	O
through	through	ADP	IN	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	NOUN	NN	9	O
receptors	receptor	NOUN	NNS	3	O
is	be	VERB	VBZ	5	O
critical	critical	ADJ	JJ	9	O
for	for	ADP	IN	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
anxiety	anxiety	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Cocaine	cocaine	NOUN	NN	5	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
widely	widely	ADV	RB	5	O
abused	abused	ADJ	JJ	5	O
psychostimulant	psychostimulant	NOUN	NN	5	O
that	that	DET	WDT	5	O
has	have	VERB	VBZ	9	O
both	both	CCONJ	CC	9	O
rewarding	rewarding	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
aversive	aversive	ADJ	JJ	5	O
properties	property	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

While	while	ADP	IN	9	O
the	the	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
underlying	underlie	VERB	VBG	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
rewarding	rewarding	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
studied	study	VERB	VBN	9	O
extensively	extensively	ADV	RB	9	O
,	,	PUNCT	,	9	O
less	less	ADJ	JJR	5	O
attention	attention	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
paid	pay	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
unpleasant	unpleasant	ADJ	JJ	5	O
behavioral	behavioral	ADJ	JJ	5	O
states	state	NOUN	NNS	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
anxiety	anxiety	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
evaluated	evaluate	VERB	VBD	9	O
the	the	DET	DT	5	O
performance	performance	NOUN	NN	5	O
of	of	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
hydroxylase	hydroxylase	NOUN	NN	1	O
knockout	knockout	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
Dbh	Dbh	PROPN	NNP	1	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
lack	lack	VERB	VBP	9	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
NE	NE	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
elevated	elevated	ADJ	JJ	9	O
plus	plus	CCONJ	CC	9	O
maze	maze	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
EPM	EPM	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
the	the	DET	DT	5	O
contribution	contribution	NOUN	NN	9	O
of	of	ADP	IN	5	O
noradrenergic	noradrenergic	ADV	RB	5	O
signaling	signal	VERB	VBG	3	O
to	to	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
anxiety	anxiety	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
found	find	VERB	VBD	9	O
that	that	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependently	dependently	ADV	RB	3	O
increased	increase	VERB	VBN	9	O
anxiety	anxiety	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
behavior	behavior	NOUN	NN	5	O
in	in	ADP	IN	5	O
control	control	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
Dbh	Dbh	PROPN	NNP	1	O
+	+	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
open	open	ADJ	JJ	5	O
arm	arm	NOUN	NN	5	O
exploration	exploration	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
Dbh	Dbh	PROPN	NNP	1	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
mice	mouse	NOUN	NNS	3	O
had	have	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
baseline	baseline	NOUN	NN	5	O
performance	performance	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
EPM	EPM	PROPN	NNP	9	O
but	but	CCONJ	CC	9	O
were	be	VERB	VBD	9	O
completely	completely	ADV	RB	9	O
resistant	resistant	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
anxiogenic	anxiogenic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
anxiety	anxiety	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
attenuated	attenuate	VERB	VBN	3	O
in	in	ADP	IN	5	O
Dbh	Dbh	PROPN	NNP	1	O
+	+	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
mice	mouse	NOUN	NNS	3	O
following	follow	VERB	VBG	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
disulfiram	disulfiram	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
hydroxylase	hydroxylase	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
DBH	DBH	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
inhibitor	inhibitor	NOUN	NN	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
experiments	experiment	NOUN	NNS	9	O
using	use	VERB	VBG	9	O
specific	specific	ADJ	JJ	9	O
adrenergic	adrenergic	NOUN	NN	9	O
antagonists	antagonist	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
found	find	VERB	VBD	9	O
that	that	DET	DT	5	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
blocked	block	VERB	VBN	3	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
anxiety	anxiety	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
behavior	behavior	NOUN	NN	5	O
in	in	ADP	IN	5	O
Dbh	Dbh	PROPN	NNP	1	O
+	+	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
wild	wild	ADJ	JJ	1	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
C57BL6	c57bl6	NOUN	NN	3	O
/	/	SYM	SYM	9	O
J	J	PROPN	NNP	9	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
the	the	DET	DT	5	O
alpha	alpha	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
antagonist	antagonist	NOUN	NN	3	O
prazosin	prazosin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
alpha	alpha	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
antagonist	antagonist	NOUN	NN	3	O
yohimbine	yohimbine	NOUN	NN	0	B-Chemical
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
noradrenergic	noradrenergic	ADP	IN	5	O
signaling	signal	VERB	VBG	3	O
via	via	ADP	IN	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	NOUN	NN	9	O
receptors	receptor	NOUN	NNS	3	O
is	be	VERB	VBZ	5	O
required	require	VERB	VBN	9	O
for	for	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
anxiety	anxiety	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Hypothalamic	hypothalamic	ADJ	JJ	3	O
prolactin	prolactin	NOUN	NN	3	O
receptor	receptor	NOUN	NN	3	O
messenger	messenger	NOUN	NN	9	O
ribonucleic	ribonucleic	NOUN	NN	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
prolactin	prolactin	NOUN	NN	3	O
signaling	signaling	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
hyperprolactinemic	hyperprolactinemic	ADJ	JJ	3	B-Disease
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
pulsatile	pulsatile	NOUN	NN	5	O
luteinizing	luteinize	VERB	VBG	0	O
hormone	hormone	NOUN	NN	9	O
secretion	secretion	NOUN	NN	3	O
are	be	VERB	VBP	5	O
dependent	dependent	ADJ	JJ	9	O
on	on	ADP	IN	5	O
estradiol	estradiol	NOUN	NNS	0	B-Chemical
.	.	PUNCT	.	9	O

Hyperprolactinemia	Hyperprolactinemia	PROPN	NNP	5	B-Disease
can	can	VERB	MD	5	O
reduce	reduce	VERB	VB	5	O
fertility	fertility	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
libido	libido	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
central	central	ADJ	JJ	5	O
prolactin	prolactin	NOUN	NN	3	O
actions	action	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
thought	think	VERB	VBN	5	O
to	to	PART	TO	5	O
contribute	contribute	VERB	VB	9	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
poorly	poorly	ADV	RB	9	O
understood	understand	VERB	VBN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
first	first	ADV	RB	9	O
tested	test	VERB	VBD	9	O
whether	whether	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
inhibited	inhibit	VERB	VBD	3	O
two	two	NUM	CD	5	O
neuroendocrine	neuroendocrine	NOUN	NN	5	O
parameters	parameter	NOUN	NNS	5	O
necessary	necessary	ADJ	JJ	5	O
for	for	ADP	IN	5	O
female	female	ADJ	JJ	9	O
fertility	fertility	NOUN	NN	5	O
:	:	PUNCT	:	9	O
pulsatile	pulsatile	NOUN	NN	5	O
LH	LH	PROPN	NNP	9	O
secretion	secretion	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
LH	LH	PROPN	NNP	9	O
surge	surge	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Chronic	chronic	ADJ	JJ	9	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
antagonist	antagonist	NOUN	NN	3	O
sulpiride	sulpiride	NOUN	NN	0	B-Chemical
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
LH	LH	PROPN	NNP	9	O
pulse	pulse	NOUN	NN	5	O
frequency	frequency	NOUN	NN	5	O
in	in	ADP	IN	5	O
ovariectomized	ovariectomize	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
low	low	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
estradiol	estradiol	NOUN	NNS	0	B-Chemical
.	.	PUNCT	.	9	O

Sulpiride	sulpiride	NOUN	NN	7	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
affect	affect	VERB	VB	9	O
the	the	DET	DT	5	O
magnitude	magnitude	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
steroid	steroid	ADV	RB	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
LH	LH	PROPN	NNP	9	O
surge	surge	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
percentage	percentage	NOUN	NN	9	O
of	of	ADP	IN	5	O
GnRH	GnRH	PROPN	NNP	3	O
neurons	neuron	NOUN	NNS	3	O
activated	activate	VERB	VBN	3	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
surge	surge	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Estradiol	Estradiol	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
influence	influence	VERB	VB	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
form	form	NOUN	NN	9	O
of	of	ADP	IN	5	O
prolactin	prolactin	NOUN	NN	3	O
receptors	receptor	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
PRL	PRL	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
R	R	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
components	component	NOUN	NNS	5	O
of	of	ADP	IN	5	O
prolactin	prolactin	NOUN	NN	3	O
'	'	PUNCT	''	9	O
s	s	NOUN	NNS	9	O
signaling	signal	VERB	VBG	3	O
pathway	pathway	NOUN	NN	3	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
test	test	VERB	VB	5	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	ADP	IN	5	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
increases	increase	VERB	VBZ	9	O
PRL	PRL	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
R	r	NOUN	NN	9	O
expression	expression	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
sensitivity	sensitivity	NOUN	NN	9	O
to	to	ADP	IN	5	O
prolactin	prolactin	NOUN	NN	3	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
next	next	ADV	RB	9	O
demonstrated	demonstrate	VERB	VBD	9	O
that	that	ADP	IN	5	O
estradiol	estradiol	NOUN	NNS	0	B-Chemical
greatly	greatly	ADV	RB	9	O
augments	augment	VERB	VBZ	3	O
prolactin	prolactin	ADJ	JJ	3	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
STAT5	stat5	ADJ	JJ	3	O
activation	activation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Lastly	lastly	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
measured	measure	VERB	VBD	9	O
PRL	PRL	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
R	R	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
suppressor	suppressor	NOUN	NN	3	O
of	of	ADP	IN	5	O
cytokine	cytokine	NOUN	NN	3	O
signaling	signal	VERB	VBG	3	O
(	(	PUNCT	-LRB-	9	O
SOCS	SOCS	PROPN	NNP	1	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
CIS	CIS	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
reflect	reflect	VERB	VBP	5	O
the	the	DET	DT	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
prolactin	prolactin	NOUN	NN	3	O
signaling	signaling	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
mRNAs	mRNAs	PROPN	NNP	3	O
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
sulpiride	sulpiride	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
estradiol	estradiol	NOUN	NNS	0	B-Chemical
.	.	PUNCT	.	9	O

Sulpiride	sulpiride	NOUN	NN	7	B-Chemical
induced	induce	VERB	VBD	3	O
only	only	ADJ	JJ	9	O
SOCS	SOCS	PROPN	NNP	1	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
medial	medial	ADJ	JJ	5	O
preoptic	preoptic	ADJ	JJ	5	O
area	area	NOUN	NN	5	O
,	,	PUNCT	,	9	O
where	where	ADV	WRB	5	O
GnRH	GnRH	PROPN	NNP	3	O
neurons	neuron	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
regulated	regulate	VERB	VBN	3	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
arcuate	arcuate	ADJ	JJ	5	O
nucleus	nucleus	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
choroid	choroid	ADJ	JJ	9	O
plexus	plexus	NOUN	NN	9	O
,	,	PUNCT	,	9	O
PRL	PRL	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
R	R	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
SOCS	socs	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
CIS	CIS	PROPN	NNP	9	O
mRNA	mRNA	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
induced	induce	VERB	VBN	3	O
.	.	PUNCT	.	9	O

Estradiol	Estradiol	PROPN	NNP	0	B-Chemical
enhanced	enhance	VERB	VBD	3	O
these	these	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
SOCS	SOCS	PROPN	NNP	1	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
CIS	CIS	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Interestingly	interestingly	ADV	RB	9	O
,	,	PUNCT	,	9	O
estradiol	estradiol	NOUN	NNS	0	B-Chemical
also	also	ADV	RB	9	O
induced	induce	VERB	VBD	3	O
PRL	PRL	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
R	R	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
SOCS	socs	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
CIS	CIS	PROPN	NNP	9	O
mRNA	mRNA	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
independently	independently	ADV	RB	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
GnRH	GnRH	PROPN	NNP	3	O
pulse	pulse	NOUN	NN	5	O
frequency	frequency	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
inhibited	inhibit	VERB	VBN	3	O
by	by	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
steroid	steroid	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
manner	manner	NOUN	NN	9	O
.	.	PUNCT	.	9	O

They	-PRON-	PRON	PRP	5	O
also	also	ADV	RB	9	O
provide	provide	VERB	VBP	5	O
evidence	evidence	NOUN	NN	9	O
for	for	ADP	IN	5	O
estradiol	estradiol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
brain	brain	NOUN	NN	5	O
region	region	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
specific	specific	ADJ	JJ	9	O
regulation	regulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
PRL	PRL	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
R	r	NOUN	NN	9	O
expression	expression	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
signaling	signal	VERB	VBG	3	O
responses	response	NOUN	NNS	5	O
by	by	ADP	IN	9	O
prolactin	prolactin	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Clonidine	clonidine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
attention	attention	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
deficit	deficit	NOUN	NN	5	I-Disease
/	/	SYM	SYM	9	I-Disease
hyperactivity	hyperactivity	NOUN	NN	5	I-Disease
disorder	disorder	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
II	ii	INTJ	UH	9	O
.	.	PUNCT	.	9	O

ECG	ECG	PROPN	NNP	5	O
changes	change	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
analysis	analysis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
examine	examine	VERB	VB	9	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
tolerability	tolerability	NOUN	NN	5	O
of	of	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
used	use	VERB	VBD	5	O
alone	alone	ADV	RB	9	O
or	or	CCONJ	CC	5	O
with	with	ADP	IN	5	O
methylphenidate	methylphenidate	ADJ	JJ	5	B-Chemical
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
attention	attention	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
deficit	deficit	NOUN	NN	5	I-Disease
/	/	SYM	SYM	9	I-Disease
hyperactivity	hyperactivity	NOUN	NN	5	I-Disease
disorder	disorder	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
ADHD	ADHD	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
a	a	DET	DT	5	O
16	16	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
multicenter	multicenter	NOUN	NN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
,	,	PUNCT	,	9	O
122	122	NUM	CD	7	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
ADHD	ADHD	PROPN	NNP	5	B-Disease
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
assigned	assign	VERB	VBN	5	O
to	to	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
31	31	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
methylphenidate	methylphenidate	ADJ	JJ	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
29	29	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
methylphenidate	methylphenidate	ADJ	JJ	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
32	32	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
30	30	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Doses	dose	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
flexibly	flexibly	ADV	RB	5	O
titrated	titrate	VERB	VBN	0	O
up	up	PART	RP	5	O
to	to	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
60	60	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
methylphenidate	methylphenidate	ADJ	JJ	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
both	both	DET	DT	9	O
with	with	ADP	IN	5	O
divided	divide	VERB	VBN	5	O
dosing	dosing	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
regarding	regard	VERB	VBG	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
changes	change	NOUN	NNS	9	O
from	from	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
to	to	ADP	IN	5	O
week	week	NOUN	NN	9	O
16	16	NUM	CD	9	O
in	in	ADP	IN	5	O
electrocardiograms	electrocardiogram	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
vital	vital	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
more	more	ADJ	JJR	5	O
incidents	incident	NOUN	NNS	5	O
of	of	ADP	IN	5	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
subjects	subject	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
not	not	ADV	RB	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
versus	versus	ADP	IN	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
;	;	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
no	no	DET	DT	9	O
other	other	ADJ	JJ	5	O
significant	significant	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
differences	difference	NOUN	NNS	9	O
regarding	regard	VERB	VBG	5	O
electrocardiogram	electrocardiogram	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
outcomes	outcome	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
suggestions	suggestion	NOUN	NNS	6	O
of	of	ADP	IN	5	O
interactions	interaction	NOUN	NNS	9	O
between	between	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
methylphenidate	methylphenidate	ADJ	JJ	5	B-Chemical
regarding	regard	VERB	VBG	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
outcomes	outcome	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Moderate	moderate	ADJ	JJ	7	O
or	or	CCONJ	CC	5	O
severe	severe	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
common	common	ADJ	JJ	5	O
in	in	ADP	IN	5	O
subjects	subject	NOUN	NNS	5	O
on	on	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
79	79	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
versus	versus	ADP	IN	9	O
49	49	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
;	;	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
=	=	X	XX	7	O
.	.	PUNCT	.	9	O
0006	0006	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
higher	high	ADJ	JJR	9	O
rates	rate	NOUN	NNS	5	O
of	of	ADP	IN	5	O
early	early	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
withdrawal	withdrawal	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Drowsiness	Drowsiness	PROPN	NNP	7	B-Disease
was	be	VERB	VBD	9	O
common	common	ADJ	JJ	5	O
on	on	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
generally	generally	ADV	RB	5	O
resolved	resolve	VERB	VBN	9	O
by	by	ADP	IN	9	O
6	6	NUM	CD	9	O
to	to	PART	TO	5	O
8	8	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Clonidine	Clonidine	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
used	use	VERB	VBD	5	O
alone	alone	ADV	RB	9	O
or	or	CCONJ	CC	5	O
with	with	ADP	IN	5	O
methylphenidate	methylphenidate	ADJ	JJ	5	B-Chemical
,	,	PUNCT	,	9	O
appears	appear	VERB	VBZ	9	O
safe	safe	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
in	in	ADP	IN	5	O
childhood	childhood	NOUN	NN	5	O
ADHD	adhd	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Physicians	physician	NOUN	NNS	5	O
prescribing	prescribe	VERB	VBG	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
should	should	VERB	MD	5	O
monitor	monitor	VERB	VB	5	O
for	for	ADP	IN	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
advise	advise	VERB	VB	5	O
patients	patient	NOUN	NNS	5	O
about	about	ADP	IN	5	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
likelihood	likelihood	NOUN	NN	5	O
of	of	ADP	IN	5	O
initial	initial	ADJ	JJ	9	O
drowsiness	drowsiness	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Renal	Renal	PROPN	NNP	9	B-Disease
Fanconi	Fanconi	PROPN	NNP	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
myopathy	myopathy	NOUN	NN	9	B-Disease
after	after	ADP	IN	9	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
:	:	PUNCT	:	9	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
cytopathy	cytopathy	NOUN	NN	9	I-Disease
?	?	PUNCT	.	5	O

Advances	advance	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
field	field	NOUN	NN	5	O
of	of	ADP	IN	5	O
transplantation	transplantation	NOUN	NN	9	O
provide	provide	VERB	VBP	5	O
a	a	DET	DT	5	O
better	well	ADJ	JJR	5	O
quality	quality	NOUN	NN	5	O
of	of	ADP	IN	5	O
life	life	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
allow	allow	VERB	VB	5	O
more	more	ADV	RBR	5	O
favorable	favorable	ADJ	JJ	5	O
conditions	condition	NOUN	NNS	9	O
for	for	ADP	IN	5	O
growth	growth	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
development	development	NOUN	NN	9	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
combinations	combination	NOUN	NNS	9	O
of	of	ADP	IN	5	O
different	different	ADJ	JJ	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
regimens	regimen	NOUN	NNS	5	O
require	require	VERB	VBP	5	O
consideration	consideration	NOUN	NN	5	O
of	of	ADP	IN	5	O
potential	potential	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
a	a	DET	DT	5	O
15	15	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
yr	yr	NOUN	NN	7	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
girl	girl	NOUN	NN	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
orthotopic	orthotopic	ADJ	JJ	3	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
Wilson	Wilson	PROPN	NNP	6	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Tacrolimus	Tacrolimus	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
MMF	MMF	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
steroids	steroid	NOUN	NNS	9	B-Chemical
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
as	as	ADP	IN	5	O
immunosuppressant	immunosuppressant	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Lamivudine	Lamivudine	PROPN	NNP	7	B-Chemical
was	be	VERB	VBD	9	O
added	add	VERB	VBN	0	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
de	de	X	FW	2	O
nova	nova	NOUN	NN	4	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
infection	infection	NOUN	NN	9	I-Disease
during	during	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
yr	yr	NOUN	NN	7	O
after	after	ADP	IN	9	O
transplantation	transplantation	NOUN	NN	9	O
she	-PRON-	PRON	PRP	5	O
developed	develop	VERB	VBD	5	O
renal	renal	ADJ	JJ	9	B-Disease
Fanconi	Fanconi	PROPN	NNP	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
metabolic	metabolic	ADJ	JJ	9	B-Disease
acidosis	acidosis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
hypophosphatemia	hypophosphatemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
glycosuria	glycosuria	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
aminoaciduria	aminoaciduria	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
suspected	suspect	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
late	late	ADJ	JJ	9	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
transplant	transplant	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	O
acidosis	acidosis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
replaced	replace	VERB	VBN	9	O
by	by	ADP	IN	9	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
acidosis	acidosis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
electrolyte	electrolyte	NOUN	NN	0	O
imbalance	imbalance	NOUN	NN	9	O
got	get	VERB	VBD	5	O
worse	bad	ADJ	JJR	5	O
.	.	PUNCT	.	9	O

Proximal	proximal	ADJ	JJ	9	O
muscle	muscle	NOUN	NN	9	B-Disease
weakness	weakness	NOUN	NN	5	I-Disease
has	have	VERB	VBZ	9	O
developed	develop	VERB	VBN	5	O
during	during	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Fanconi	fanconi	ADJ	JJ	9	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
myopathy	myopathy	ADJ	JJ	9	B-Disease
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
well	well	ADV	RB	9	O
recognized	recognize	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
depletion	depletion	NOUN	NN	3	O
of	of	ADP	IN	5	O
mtDNA	mtDNA	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
tubular	tubular	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
myopathy	myopathy	NOUN	NN	9	B-Disease
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
resulted	result	VERB	VBN	9	O
from	from	ADP	IN	9	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
triggered	trigger	VERB	VBN	9	O
by	by	ADP	IN	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
augmented	augment	VERB	VBN	9	O
by	by	ADP	IN	9	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Higher	high	ADJ	JJR	9	O
optical	optical	ADJ	JJ	5	O
density	density	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
antigen	antigen	NOUN	NN	3	O
assay	assay	ADJ	JJ	3	O
predicts	predict	VERB	VBZ	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
correlate	correlate	VERB	VB	9	O
optical	optical	ADJ	JJ	5	O
density	density	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
percent	percent	NOUN	NN	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
two	two	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
step	step	NOUN	NN	9	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
HIT	HIT	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
antigen	antigen	NOUN	NN	3	O
assay	assay	ADJ	JJ	3	O
with	with	ADP	IN	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
assay	assay	ADJ	JJ	3	O
utilizes	utilize	VERB	VBZ	9	O
reaction	reaction	NOUN	NN	9	O
inhibition	inhibition	NOUN	NN	3	O
characteristics	characteristic	NOUN	NNS	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
heparin	heparin	ADJ	JJ	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
platelet	platelet	NOUN	NN	9	O
count	count	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
<	<	X	XX	0	O
150	150	NUM	CD	0	O
x	x	SYM	SYM	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
positive	positive	ADJ	JJ	9	O
two	two	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
step	step	NOUN	NN	9	O
antigen	antigen	NOUN	NN	3	O
assay	assay	NOUN	NN	3	O
[	[	PUNCT	-LRB-	9	O
optical	optical	ADJ	JJ	5	O
density	density	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
OD	OD	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
>	>	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
and	and	CCONJ	CC	5	O
>	>	X	XX	0	O
50	50	NUM	CD	0	O
inhibition	inhibition	NOUN	NN	3	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
]	]	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Forty	forty	NUM	CD	9	O
of	of	ADP	IN	5	O
94	94	NUM	CD	7	O
HIT	HIT	PROPN	NNP	5	B-Disease
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
at	at	ADP	IN	9	O
diagnosis	diagnosis	NOUN	NN	5	O
;	;	PUNCT	:	9	O
54	54	NUM	CD	7	O
/	/	SYM	SYM	9	O
94	94	NUM	CD	7	O
had	have	VERB	VBD	9	O
isolated	isolate	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
HIT	hit	VERB	VB	5	B-Disease
without	without	ADP	IN	9	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Eight	eight	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
isolated	isolate	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
HIT	HIT	VERB	VBN	5	B-Disease
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
next	next	ADJ	JJ	9	O
30	30	NUM	CD	9	O
d	d	NOUN	NN	9	O
;	;	PUNCT	:	9	O
thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
48	48	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
at	at	ADP	IN	9	O
day	day	NOUN	NN	9	O
30	30	NUM	CD	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
diagnosis	diagnosis	NOUN	NN	5	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
OD	OD	PROPN	NNP	9	O
between	between	ADP	IN	5	O
HIT	HIT	PROPN	NNP	5	B-Disease
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
those	those	DET	DT	5	O
with	with	ADP	IN	5	O
isolated	isolate	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
HIT	HIT	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
OD	OD	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
48	48	NUM	CD	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
34	34	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
89	89	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
isolated	isolate	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
HIT	HIT	VERB	VBN	5	B-Disease
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
later	later	ADV	RB	9	O
developed	develop	VERB	VBD	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
within	within	ADP	IN	9	O
30	30	NUM	CD	9	O
d	d	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
84	84	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
64	64	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
isolated	isolate	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
HIT	HIT	PROPN	NNP	5	B-Disease
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
develop	develop	VERB	VB	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
96	96	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
75	75	NUM	CD	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
011	011	NUM	CD	2	O
and	and	CCONJ	CC	5	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
008	008	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
Receiver	Receiver	PROPN	NNP	5	O
Operative	Operative	PROPN	NNP	5	O
Characteristic	Characteristic	PROPN	NNP	9	O
Curve	Curve	PROPN	NNP	5	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
OD	OD	PROPN	NNP	9	O
>	>	X	XX	0	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
27	27	NUM	CD	7	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
isolated	isolate	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
HIT	HIT	PROPN	NNP	5	B-Disease
group	group	NOUN	NN	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
chance	chance	NOUN	NN	5	O
of	of	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
by	by	ADP	IN	9	O
day	day	NOUN	NN	9	O
30	30	NUM	CD	9	O
.	.	PUNCT	.	9	O

None	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
groups	group	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
percent	percent	NOUN	NN	5	O
inhibition	inhibition	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Multivariate	Multivariate	PROPN	NNP	5	O
analysis	analysis	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
-	-	ADV	RB	7	O
fold	fold	VERB	VB	9	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
females	female	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Similarly	similarly	ADV	RB	9	O
,	,	PUNCT	,	9	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
risk	risk	NOUN	NN	5	O
increased	increase	VERB	VBD	9	O
with	with	ADP	IN	5	O
age	age	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
OD	OD	PROPN	NNP	9	O
values	value	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Higher	high	ADJ	JJR	9	O
OD	OD	PROPN	NNP	9	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
subsequent	subsequent	ADJ	JJ	9	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
isolated	isolate	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
HIT	HIT	PROPN	NNP	5	B-Disease
;	;	PUNCT	:	9	O
percent	percent	NOUN	NN	5	O
inhibition	inhibition	NOUN	NN	3	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
predictive	predictive	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Thalidomide	Thalidomide	PROPN	NNP	0	B-Chemical
has	have	VERB	VBZ	9	O
limited	limit	VERB	VBN	5	O
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
agent	agent	NOUN	NN	9	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
relapsed	relapse	VERB	VBN	5	O
or	or	CCONJ	CC	5	O
refractory	refractory	ADJ	JJ	9	O
indolent	indolent	ADJ	JJ	5	O
non	non	ADJ	JJ	9	B-Disease
-	-	ADJ	JJ	7	I-Disease
Hodgkin	hodgkin	ADJ	JJ	5	I-Disease
lymphomas	lymphoma	NOUN	NNS	3	I-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
phase	phase	NOUN	NN	5	O
II	II	PROPN	NNP	9	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Cancer	Cancer	PROPN	NNP	2	B-Disease
and	and	CCONJ	CC	5	O
Leukemia	Leukemia	PROPN	NNP	2	B-Disease
Group	Group	PROPN	NNP	9	O
B	B	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Thalidomide	Thalidomide	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
immunomodulatory	immunomodulatory	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
with	with	ADP	IN	5	O
demonstrated	demonstrate	VERB	VBN	9	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
multiple	multiple	ADJ	JJ	5	B-Disease
myeloma	myeloma	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
mantle	mantle	NOUN	NN	5	B-Disease
cell	cell	NOUN	NN	3	I-Disease
lymphoma	lymphoma	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
lymphoplasmacytic	lymphoplasmacytic	ADJ	JJ	5	B-Disease
lymphoma	lymphoma	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Its	-PRON-	DET	PRP$	5	O
activity	activity	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
believed	believe	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
due	due	ADJ	JJ	5	O
modulation	modulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
tumour	tumour	NOUN	NN	3	B-Disease
milieu	milieu	NOUN	NN	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
downregulation	downregulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
angiogenesis	angiogenesis	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
inflammatory	inflammatory	ADJ	JJ	3	O
cytokines	cytokine	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Between	between	ADP	IN	9	O
July	July	PROPN	NNP	2	O
2001	2001	NUM	CD	2	O
and	and	CCONJ	CC	5	O
April	April	PROPN	NNP	2	O
2004	2004	NUM	CD	2	O
,	,	PUNCT	,	9	O
24	24	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
relapsed	relapsed	ADJ	JJ	5	O
/	/	SYM	SYM	9	O
refractory	refractory	ADJ	JJ	9	O
indolent	indolent	ADJ	JJ	5	O
lymphomas	lymphoma	NOUN	NNS	3	B-Disease
received	receive	VERB	VBD	9	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
daily	daily	ADV	RB	5	O
with	with	ADP	IN	5	O
escalation	escalation	NOUN	NN	5	O
by	by	ADP	IN	9	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
daily	daily	ADV	RB	5	O
every	every	DET	DT	5	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
as	as	ADP	IN	5	O
tolerated	tolerate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
up	up	ADP	IN	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
maximum	maximum	NOUN	NN	5	O
of	of	ADP	IN	5	O
800	800	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
daily	daily	ADV	RB	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
received	receive	VERB	VBN	9	O
a	a	DET	DT	5	O
median	median	NOUN	NN	9	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
prior	prior	ADV	RB	9	O
regimens	regimen	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
24	24	NUM	CD	9	O
evaluable	evaluable	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
two	two	NUM	CD	5	O
achieved	achieve	VERB	VBD	5	O
a	a	DET	DT	5	O
complete	complete	ADJ	JJ	9	O
remission	remission	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
one	one	NUM	CD	5	O
achieved	achieve	VERB	VBD	5	O
a	a	DET	DT	5	O
partial	partial	ADJ	JJ	9	O
remission	remission	NOUN	NN	5	O
for	for	ADP	IN	5	O
an	an	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
:	:	PUNCT	:	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
-	-	SYM	SYM	7	O
32	32	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Eleven	eleven	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
progressed	progress	VERB	VBN	9	O
during	during	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Grade	Grade	PROPN	NNP	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
included	include	VERB	VBD	5	O
myelosuppression	myelosuppression	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
fatigue	fatigue	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
somnolence	somnolence	NOUN	NN	5	B-Disease
/	/	SYM	SYM	9	O
depressed	depressed	ADJ	JJ	5	B-Disease
mood	mood	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
neuropathy	neuropathy	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
dyspnea	dyspnea	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
concern	concern	NOUN	NN	5	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
four	four	NUM	CD	9	O
thromboembolic	thromboembolic	ADJ	JJ	5	B-Disease
events	event	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
demonstrate	demonstrate	VERB	VB	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
to	to	ADP	IN	5	O
single	single	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
thalidomide	thalidomide	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
indolent	indolent	ADJ	JJ	5	O
lymphomas	lymphoma	NOUN	NNS	3	B-Disease
and	and	CCONJ	CC	5	O
contrast	contrast	VERB	VB	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
higher	high	ADJ	JJR	9	O
activity	activity	NOUN	NN	9	O
level	level	NOUN	NN	9	O
reported	report	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
generation	generation	NOUN	NN	9	O
immunomodulatory	immunomodulatory	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
,	,	PUNCT	,	9	O
lenalidomide	lenalidomide	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Sex	sex	NOUN	NN	7	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
antagonist	antagonist	NOUN	NN	3	O
enhancement	enhancement	NOUN	NN	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
antihyperalgesia	antihyperalgesia	NOUN	NN	3	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
capsaicin	capsaicin	ADJ	JJ	0	B-Chemical
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
persistent	persistent	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
comparisons	comparison	NOUN	NNS	5	O
to	to	ADP	IN	5	O
two	two	NUM	CD	5	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
acute	acute	ADJ	JJ	9	B-Disease
pain	pain	NOUN	NN	5	I-Disease
models	model	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
D	d	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aspartate	aspartate	NOUN	NN	1	I-Chemical
(	(	PUNCT	-LRB-	9	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
antagonists	antagonist	NOUN	NNS	3	O
enhance	enhance	VERB	VB	9	O
the	the	DET	DT	5	O
antinociceptive	antinociceptive	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
greater	great	ADJ	JJR	5	O
extent	extent	NOUN	NN	9	O
in	in	ADP	IN	5	O
males	male	NOUN	NNS	9	O
than	than	ADP	IN	5	O
females	female	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
investigation	investigation	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
extend	extend	VERB	VB	9	O
these	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
persistent	persistent	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
model	model	NOUN	NN	5	O
which	which	DET	WDT	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
distinguished	distinguish	VERB	VBN	9	O
from	from	ADP	IN	9	O
acute	acute	ADJ	JJ	9	B-Disease
pain	pain	NOUN	NN	5	I-Disease
models	model	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
basis	basis	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
nociceptive	nociceptive	ADJ	JJ	5	O
fibers	fiber	NOUN	NNS	9	O
activated	activate	VERB	VBN	3	O
,	,	PUNCT	,	9	O
neurochemical	neurochemical	ADJ	JJ	5	O
substrates	substrate	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
nociceptive	nociceptive	ADJ	JJ	5	O
stimulus	stimulus	NOUN	NN	5	O
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
this	this	DET	DT	5	O
end	end	NOUN	NN	9	O
,	,	PUNCT	,	9	O
persistent	persistent	ADJ	JJ	5	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
tail	tail	NOUN	NN	9	O
of	of	ADP	IN	5	O
gonadally	gonadally	ADV	RB	3	O
intact	intact	ADJ	JJ	9	O
F344	f344	NOUN	NN	3	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
following	follow	VERB	VBG	9	O
which	which	DET	WDT	5	O
the	the	DET	DT	5	O
tail	tail	NOUN	NN	9	O
was	be	VERB	VBD	9	O
immersed	immerse	VERB	VBN	0	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
mildly	mildly	ADV	RB	9	O
noxious	noxious	ADJ	JJ	5	O
thermal	thermal	ADJ	JJ	9	O
stimulus	stimulus	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
tail	tail	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
withdrawal	withdrawal	NOUN	NN	5	O
latencies	latency	NOUN	NNS	5	O
measured	measure	VERB	VBN	9	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
comparison	comparison	NOUN	NN	9	O
,	,	PUNCT	,	9	O
tests	test	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
acute	acute	ADJ	JJ	9	B-Disease
pain	pain	NOUN	NN	5	I-Disease
models	model	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
hotplate	hotplate	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
warm	warm	ADJ	JJ	5	O
water	water	NOUN	NN	0	O
tail	tail	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
withdrawal	withdrawal	NOUN	NN	5	O
procedures	procedure	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
males	male	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
competitive	competitive	ADJ	JJ	9	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
antagonist	antagonist	NOUN	NN	3	O
dextromethorphan	dextromethorphan	NOUN	NN	0	B-Chemical
enhanced	enhance	VERB	VBD	3	O
the	the	DET	DT	5	O
antihyperalgesic	antihyperalgesic	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
low	low	ADJ	JJ	9	O
to	to	PART	TO	5	O
moderate	moderate	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
time	time	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
manner	manner	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Across	across	ADP	IN	5	O
the	the	DET	DT	5	O
doses	dose	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
pretreatment	pretreatment	NOUN	NN	0	O
times	time	NOUN	NNS	5	O
examined	examine	VERB	VBN	9	O
,	,	PUNCT	,	9	O
enhancement	enhancement	NOUN	NN	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
females	female	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Enhancement	enhancement	NOUN	NN	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
antinociception	antinociception	NOUN	NN	3	O
by	by	ADP	IN	9	O
dextromethorphan	dextromethorphan	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
males	male	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
females	female	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	B-Disease
pain	pain	NOUN	NN	5	I-Disease
models	model	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
magnitude	magnitude	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
being	be	VERB	VBG	5	O
greater	great	ADJ	JJR	5	O
in	in	ADP	IN	5	O
males	male	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
demonstrate	demonstrate	VERB	VBP	9	O
a	a	DET	DT	5	O
sexually	sexually	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
dimorphic	dimorphic	ADJ	JJ	4	O
interaction	interaction	NOUN	NN	9	O
between	between	ADP	IN	5	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
antagonists	antagonist	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
persistent	persistent	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
model	model	NOUN	NN	5	O
that	that	DET	WDT	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
distinguished	distinguish	VERB	VBN	9	O
from	from	ADP	IN	9	O
those	those	DET	DT	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
pain	pain	NOUN	NN	5	I-Disease
models	model	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Development	development	NOUN	NN	2	O
of	of	ADP	IN	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
after	after	ADP	IN	9	O
switch	switch	NOUN	NN	9	O
to	to	ADP	IN	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
immunosuppression	immunosuppression	NOUN	NN	5	O
in	in	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
cardiac	cardiac	ADJ	JJ	5	O
transplant	transplant	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Calcineurin	calcineurin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
inhibitor	inhibitor	NOUN	NN	3	O
therapy	therapy	NOUN	NN	5	O
can	can	VERB	MD	5	O
lead	lead	VERB	VB	5	O
to	to	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
transplantation	transplantation	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
IS	be	VERB	VBZ	9	O
)	)	PUNCT	-RRB-	9	O
drug	drug	NOUN	NN	5	O
sirolmus	sirolmus	NOUN	NN	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
Srl	Srl	PROPN	NNP	2	B-Chemical
)	)	PUNCT	-RRB-	9	O
lacks	lack	VERB	VBZ	1	O
nephrotoxic	nephrotoxic	ADJ	JJ	5	B-Disease
effects	effect	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
proteinuria	proteinuria	VERB	VB	9	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
Srl	Srl	PROPN	NNP	2	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
following	follow	VERB	VBG	9	O
renal	renal	ADJ	JJ	9	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
cardiac	cardiac	ADJ	JJ	5	O
transplantation	transplantation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
Srl	Srl	PROPN	NNP	2	B-Chemical
is	be	VERB	VBZ	5	O
unknown	unknown	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
cardiac	cardiac	ADJ	JJ	5	O
transplant	transplant	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
switched	switch	VERB	VBN	9	O
from	from	ADP	IN	9	O
cyclosporine	cyclosporine	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
Srl	Srl	PROPN	NNP	2	B-Chemical
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
IS	be	VERB	VBZ	9	O
.	.	PUNCT	.	9	O

Concomitant	Concomitant	PROPN	NNP	9	O
IS	be	VERB	VBZ	9	O
consisted	consist	VERB	VBN	5	O
of	of	ADP	IN	5	O
mycophenolate	mycophenolate	NOUN	NN	0	B-Chemical
mofetil	mofetil	X	FW	0	I-Chemical
+	+	X	XX	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
steroids	steroid	NOUN	NNS	9	B-Chemical
.	.	PUNCT	.	9	O

Proteinuria	Proteinuria	PROPN	NNP	7	O
increased	increase	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
median	median	NOUN	NN	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
13	13	NUM	CD	7	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
range	range	VERB	VBP	9	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
preswitch	preswitch	NOUN	NN	5	O
to	to	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
23	23	NUM	CD	7	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
88	88	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
24	24	NUM	CD	9	O
months	month	NOUN	NNS	5	O
postswitch	postswitch	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0024	0024	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Before	before	ADP	IN	9	O
the	the	DET	DT	5	O
switch	switch	NOUN	NN	9	O
,	,	PUNCT	,	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
grade	grade	NOUN	NN	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
this	this	DET	DT	5	O
increased	increase	VERB	VBD	9	O
to	to	ADP	IN	5	O
22	22	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
postswitch	postswitch	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
006	006	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

ACE	ACE	PROPN	NNP	9	B-Chemical
inhibitor	inhibitor	NOUN	NN	3	I-Chemical
and	and	CCONJ	CC	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
releasing	release	VERB	VBG	9	I-Chemical
blocker	blocker	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
ARB	ARB	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
therapy	therapy	NOUN	NN	5	O
reduced	reduce	VERB	VBD	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
development	development	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
without	without	ADP	IN	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
had	have	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
median	median	NOUN	NN	9	O
42	42	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
64	64	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
grade	grade	NOUN	NN	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
showed	show	VERB	VBD	9	O
decreased	decrease	VERB	VBD	9	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
median	median	NOUN	NN	9	O
39	39	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
29	29	NUM	CD	7	O
.	.	NOUN	NN	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
125	125	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
may	may	VERB	MD	5	O
develop	develop	VERB	VB	5	O
in	in	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
transplant	transplant	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
after	after	ADP	IN	9	O
switch	switch	NOUN	NN	9	O
to	to	ADP	IN	5	O
Srl	Srl	PROPN	NNP	2	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
an	an	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Srl	Srl	PROPN	NNP	2	B-Chemical
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
with	with	ADP	IN	5	O
ACEi	ACEi	NOUN	NNS	5	B-Chemical
/	/	SYM	SYM	9	O
ARB	ARB	PROPN	NNP	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
patients	patient	NOUN	NNS	5	O
monitored	monitor	VERB	VBN	9	O
for	for	ADP	IN	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
renal	renal	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Ginsenoside	Ginsenoside	PROPN	NNP	0	B-Chemical
Rg1	Rg1	PROPN	NNP	0	I-Chemical
restores	restore	VERB	VBZ	3	O
the	the	DET	DT	5	O
impairment	impairment	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
learning	learning	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Rg1	Rg1	NOUN	NNS	0	B-Chemical
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
ginsenoside	ginsenoside	NOUN	NN	0	B-Chemical
extracted	extract	VERB	VBN	9	O
from	from	ADP	IN	9	O
Panax	Panax	PROPN	NNP	4	O
ginseng	ginseng	NOUN	NN	4	O
,	,	PUNCT	,	9	O
could	could	VERB	MD	9	O
ameliorate	ameliorate	VERB	VB	9	O
spatial	spatial	ADJ	JJ	5	O
learning	learning	NOUN	NN	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Previous	previous	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
demonstrated	demonstrate	VERB	VBN	9	O
that	that	ADP	IN	5	O
Rg1	rg1	PRON	PRP	0	B-Chemical
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
useful	useful	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
prevention	prevention	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
Rg1	rg1	PRON	PRP	0	B-Chemical
on	on	ADP	IN	5	O
learning	learn	VERB	VBG	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
by	by	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Male	male	ADJ	JJ	7	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
subcutaneously	subcutaneously	ADV	RB	3	O
injected	inject	VERB	VBN	3	O
with	with	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
twice	twice	ADV	RB	9	O
a	a	DET	DT	5	O
day	day	NOUN	NN	9	O
at	at	ADP	IN	9	O
12	12	NUM	CD	9	O
hour	hour	NOUN	NN	0	O
intervals	interval	NOUN	NNS	5	O
for	for	ADP	IN	5	O
10	10	NUM	CD	9	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
Rg1	Rg1	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
intraperitoneally	intraperitoneally	ADV	RB	0	O
injected	inject	VERB	VBN	3	O
2	2	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
once	once	ADV	RB	5	O
a	a	DET	DT	5	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
10	10	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Spatial	spatial	ADJ	JJ	5	O
learning	learning	NOUN	NN	5	O
capacity	capacity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Morris	Morris	PROPN	NNP	6	O
water	water	NOUN	NN	0	O
maze	maze	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
Morphine	Morphine	PROPN	NNP	0	B-Chemical
/	/	SYM	SYM	9	O
Rg1	Rg1	PROPN	NNP	0	B-Chemical
decreased	decrease	VERB	VBD	9	O
escape	escape	NOUN	NN	5	O
latency	latency	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
spent	spend	VERB	VBN	5	O
in	in	ADP	IN	5	O
platform	platform	NOUN	NN	5	O
quadrant	quadrant	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
entering	enter	VERB	VBG	5	O
frequency	frequency	NOUN	NN	5	O
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
implantation	implantation	NOUN	NN	5	O
of	of	ADP	IN	5	O
electrodes	electrode	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
electrophysiological	electrophysiological	ADJ	JJ	5	O
recording	recording	NOUN	NN	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
Rg1	rg1	PRON	PRP	0	B-Chemical
restored	restore	VERB	VBD	3	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
potentiation	potentiation	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
LTP	LTP	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
impaired	impair	VERB	VBN	9	O
by	by	ADP	IN	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
both	both	CCONJ	CC	9	O
freely	freely	ADV	RB	5	O
moving	move	VERB	VBG	5	O
and	and	CCONJ	CC	5	O
anaesthetised	anaesthetise	VERB	VBD	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
electrophysiological	electrophysiological	ADJ	JJ	5	O
recording	recording	NOUN	NN	5	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
Rg1	rg1	PRON	PRP	0	B-Chemical
restored	restore	VERB	VBD	3	O
the	the	DET	DT	5	O
LTP	LTP	PROPN	NNP	3	O
in	in	ADP	IN	5	O
slices	slice	NOUN	NNS	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
changed	change	VERB	VBN	9	O
LTP	LTP	PROPN	NNP	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
slices	slice	NOUN	NNS	9	O
from	from	ADP	IN	9	O
normal	normal	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
or	or	CCONJ	CC	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
Rg1	rg1	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
this	this	DET	DT	5	O
restoration	restoration	NOUN	NN	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
inhibited	inhibit	VERB	VBN	3	O
by	by	ADP	IN	9	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
D	d	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aspartate	aspartate	NOUN	NN	1	I-Chemical
(	(	PUNCT	-LRB-	9	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
MK801	mk801	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
Rg1	rg1	PRON	PRP	0	B-Chemical
may	may	VERB	MD	5	O
significantly	significantly	ADV	RB	9	O
improve	improve	VERB	VB	5	O
the	the	DET	DT	5	O
spatial	spatial	ADJ	JJ	5	O
learning	learning	NOUN	NN	5	O
capacity	capacity	NOUN	NN	9	O
impaired	impair	VERB	VBN	9	O
by	by	ADP	IN	9	O
chonic	chonic	NOUN	NN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
restore	restore	VERB	VB	9	O
the	the	DET	DT	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
inhibited	inhibit	VERB	VBN	3	O
LTP	LTP	PROPN	NNP	3	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
NMDA	nmda	ADJ	JJ	3	B-Chemical
receptor	receptor	NOUN	NN	3	O
dependent	dependent	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Synthesis	Synthesis	PROPN	NNP	0	O
of	of	ADP	IN	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
pyrimidinyl	pyrimidinyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
phenoxyacetamides	phenoxyacetamide	NOUN	NNS	_	I-Chemical
as	as	ADP	IN	5	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
A2A	A2A	PROPN	NNP	3	O
receptor	receptor	NOUN	NN	3	O
antagonists	antagonist	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
series	series	NOUN	NN	5	O
of	of	ADP	IN	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
pyrimidinyl	pyrimidinyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
phenoxyacetamide	phenoxyacetamide	NOUN	NN	9	I-Chemical
adenosine	adenosine	NOUN	NN	0	B-Chemical
A	a	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2A	2a	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
antagonists	antagonist	NOUN	NNS	3	O
is	be	VERB	VBZ	5	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

SAR	SAR	PROPN	NNP	9	O
studies	study	NOUN	NNS	9	O
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
compound	compound	VERB	VB	0	O
14	14	NUM	CD	7	O
with	with	ADP	IN	5	O
excellent	excellent	ADJ	JJ	5	O
potency	potency	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
K	K	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
=	=	VERB	VBZ	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
nM	nm	X	XX	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
selectivity	selectivity	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
A	a	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
/	/	SYM	SYM	9	O
A	a	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2A	2a	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
>	>	X	XX	0	O
100	100	NUM	CD	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
efficacy	efficacy	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
MED	MED	PROPN	NNP	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
haloperidol	haloperidol	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
model	model	NOUN	NN	5	O
for	for	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Evidence	evidence	NOUN	NN	9	O
for	for	ADP	IN	5	O
an	an	DET	DT	5	O
involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
D1	d1	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
D2	d2	NOUN	NN	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
receptors	receptor	NOUN	NNS	3	O
in	in	ADP	IN	5	O
mediating	mediate	VERB	VBG	9	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Previous	previous	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
repeated	repeat	VERB	VBN	5	O
exposure	exposure	NOUN	NN	9	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
environment	environment	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
necessary	necessary	ADJ	JJ	5	O
to	to	PART	TO	5	O
observe	observe	VERB	VB	9	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
locomotor	locomotor	NOUN	NN	5	O
stimulation	stimulation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
habituation	habituation	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
environment	environment	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
stimulant	stimulant	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
receptors	receptor	NOUN	NNS	3	O
in	in	ADP	IN	5	O
mediating	mediate	VERB	VBG	9	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
locomotor	locomotor	NOUN	NN	5	O
stimulation	stimulation	NOUN	NN	3	O
was	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
by	by	ADP	IN	9	O
examining	examine	VERB	VBG	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
selective	selective	ADJ	JJ	9	O
D1	d1	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
D2	d2	NOUN	NN	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
receptor	receptor	NOUN	NN	3	O
antagonists	antagonist	NOUN	NNS	3	O
on	on	ADP	IN	5	O
activity	activity	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
tested	test	VERB	VBN	9	O
in	in	ADP	IN	5	O
photocell	photocell	NOUN	NN	5	O
cages	cage	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Nicotine	Nicotine	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	NOUN	NN	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
locomotor	locomotor	NOUN	NN	5	I-Disease
activity	activity	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
that	that	DET	WDT	5	O
were	be	VERB	VBD	9	O
habituated	habituate	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
test	test	NOUN	NN	5	O
environment	environment	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
had	have	VERB	VBD	9	O
only	only	ADV	RB	9	O
a	a	DET	DT	5	O
weak	weak	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
delayed	delayed	ADJ	JJ	9	O
stimulant	stimulant	ADJ	JJ	5	O
action	action	NOUN	NN	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
that	that	DET	WDT	5	O
were	be	VERB	VBD	9	O
unfamiliar	unfamiliar	ADJ	JJ	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
test	test	NOUN	NN	5	O
environment	environment	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
stimulant	stimulant	ADJ	JJ	5	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
blocked	block	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
nicotinic	nicotinic	ADJ	JJ	0	O
antagonist	antagonist	NOUN	NN	3	O
mecamylamine	mecamylamine	NOUN	NN	0	B-Chemical
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
peripheral	peripheral	ADJ	JJ	9	O
nicotinic	nicotinic	ADJ	JJ	0	O
blocker	blocker	NOUN	NN	0	O
hexamethonium	hexamethonium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
response	response	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
probably	probably	ADV	RB	9	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
central	central	ADJ	JJ	5	O
nicotinic	nicotinic	ADJ	JJ	0	O
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Nicotine	nicotine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
blocked	block	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
D1	d1	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
SCH	SCH	PROPN	NNP	9	B-Chemical
23390	23390	NUM	CD	0	I-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
D2	d2	NOUN	NN	9	O
antagonist	antagonist	NOUN	NN	3	O
raclopride	raclopride	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
D1	D1	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
D2	d2	NOUN	NN	9	O
antagonist	antagonist	NOUN	NN	3	O
fluphenazine	fluphenazine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Pretreatment	pretreatment	NOUN	NN	3	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
D2	d2	NOUN	NN	9	O
agonist	agonist	NOUN	NN	3	O
PHNO	PHNO	PROPN	NNP	0	B-Chemical
enhanced	enhance	VERB	VBD	3	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
the	the	DET	DT	5	O
D1	d1	NOUN	NN	3	O
agonist	agonist	NOUN	NN	3	O
SKF	SKF	PROPN	NNP	3	B-Chemical
38393	38393	NUM	CD	3	I-Chemical
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
injection	injection	NOUN	NN	9	O
induces	induce	VERB	VBZ	3	O
a	a	DET	DT	5	O
pronounced	pronounced	ADJ	JJ	9	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
habituated	habituate	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
test	test	NOUN	NN	5	O
environment	environment	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
central	central	ADJ	JJ	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
receptors	receptor	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
possibly	possibly	ADV	RB	9	O
located	locate	VERB	VBN	9	O
on	on	ADP	IN	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
neurons	neuron	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
also	also	ADV	RB	9	O
requires	require	VERB	VBZ	5	O
the	the	DET	DT	5	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
D1	d1	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
D2	d2	NOUN	NN	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Central	central	ADJ	JJ	4	O
retinal	retinal	ADJ	JJ	5	B-Disease
vein	vein	NOUN	NN	5	I-Disease
occlusion	occlusion	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
clomiphene	clomiphene	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
ovulation	ovulation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
report	report	VERB	VB	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
central	central	ADJ	JJ	5	O
retinal	retinal	ADJ	JJ	5	B-Disease
vein	vein	NOUN	NN	5	I-Disease
occlusion	occlusion	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
clomiphene	clomiphene	NOUN	NN	5	B-Chemical
citrate	citrate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
CC	CC	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

DESIGN	design	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Case	case	NOUN	NN	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

SETTING	setting	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Ophthalmology	ophthalmology	NOUN	NN	2	O
clinic	clinic	NOUN	NN	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
academic	academic	ADJ	JJ	5	O
hospital	hospital	NOUN	NN	5	O
.	.	PUNCT	.	9	O

PATIENT	PATIENT	PROPN	NNP	2	O
(	(	PUNCT	-LRB-	9	O
S	S	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
36	36	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
referred	refer	VERB	VBD	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
infertility	infertility	NOUN	NN	5	B-Disease
clinic	clinic	NOUN	NN	5	O
for	for	ADP	IN	5	O
blurred	blur	VERB	VBN	5	B-Disease
vision	vision	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

INTERVENTION	INTERVENTION	PROPN	NNP	2	O
(	(	PUNCT	-LRB-	9	O
S	S	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
:	:	PUNCT	:	9	O
Ophthalmic	ophthalmic	ADJ	JJ	2	O
examination	examination	NOUN	NN	5	O
after	after	ADP	IN	9	O
CC	CC	PROPN	NNP	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

MAIN	MAIN	PROPN	NNP	2	O
OUTCOME	OUTCOME	PROPN	NNP	2	O
MEASURE	MEASURE	PROPN	NNP	2	O
(	(	PUNCT	-LRB-	9	O
S	S	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
:	:	PUNCT	:	9	O
Central	central	ADJ	JJ	4	O
retinal	retinal	ADJ	JJ	5	B-Disease
vein	vein	NOUN	NN	5	I-Disease
occlusion	occlusion	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
ovulation	ovulation	ADJ	JJ	5	O
induction	induction	NOUN	NN	3	O
with	with	ADP	IN	5	O
CC	CC	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

RESULT	RESULT	PROPN	NNP	2	O
(	(	PUNCT	-LRB-	9	O
S	S	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
36	36	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
Chinese	chinese	ADJ	JJ	9	O
woman	woman	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
central	central	ADJ	JJ	5	O
retinal	retinal	ADJ	JJ	5	B-Disease
vein	vein	NOUN	NN	5	I-Disease
occlusion	occlusion	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
eight	eight	NUM	CD	9	O
courses	course	NOUN	NNS	5	O
of	of	ADP	IN	5	O
CC	CC	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
search	search	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
thromboembolic	thromboembolic	ADJ	JJ	5	B-Disease
complications	complication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
CC	CC	PROPN	NNP	9	B-Chemical
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
include	include	VERB	VB	5	O
this	this	DET	DT	5	O
severe	severe	ADJ	JJ	5	O
ophthalmic	ophthalmic	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
mild	mild	ADJ	JJ	9	O
visual	visual	ADJ	JJ	5	B-Disease
disturbance	disturbance	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
CC	cc	NOUN	NN	9	B-Chemical
intake	intake	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
uncommon	uncommon	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

CONCLUSION	CONCLUSION	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
S	S	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
reported	report	VERB	VBN	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
central	central	ADJ	JJ	5	O
retinal	retinal	ADJ	JJ	5	B-Disease
vein	vein	NOUN	NN	5	I-Disease
occlusion	occlusion	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
CC	CC	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

Extra	extra	ADJ	JJ	9	O
caution	caution	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
warranted	warrant	VERB	VBN	9	O
in	in	ADP	IN	5	O
treating	treat	VERB	VBG	5	O
infertility	infertility	NOUN	NN	5	B-Disease
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
CC	CC	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
patients	patient	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
well	well	ADV	RB	9	O
informed	informed	ADJ	JJ	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
before	before	ADP	IN	9	O
commencement	commencement	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
bronchodilating	bronchodilating	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
ipratropium	ipratropium	NOUN	NN	5	B-Chemical
bromide	bromide	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
theophylline	theophylline	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
obstructive	obstructive	ADJ	JJ	5	I-Disease
pulmonary	pulmonary	ADJ	JJ	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
bronchodilator	bronchodilator	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
ipratropium	ipratropium	NOUN	NN	5	B-Chemical
bromide	bromide	NOUN	NN	0	I-Chemical
aerosol	aerosol	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
36	36	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
short	short	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
acting	act	VERB	VBG	9	O
theophylline	theophylline	NOUN	NN	0	B-Chemical
tablets	tablet	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
dose	dose	NOUN	NN	9	O
titrated	titrate	VERB	VBN	0	O
to	to	PART	TO	5	O
produce	produce	VERB	VB	9	O
serum	serum	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
20	20	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
crossover	crossover	NOUN	NN	5	O
study	study	NOUN	NN	9	O
in	in	ADP	IN	5	O
21	21	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
stable	stable	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
chronic	chronic	ADJ	JJ	5	B-Disease
obstructive	obstructive	ADJ	JJ	5	I-Disease
pulmonary	pulmonary	ADJ	JJ	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Mean	mean	ADJ	JJ	9	O
peak	peak	NOUN	NN	9	O
forced	force	VERB	VBN	5	O
expiratory	expiratory	NOUN	NN	5	O
volume	volume	NOUN	NN	9	O
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
second	second	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
FEV1	FEV1	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
increases	increase	VERB	VBZ	9	O
over	over	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
proportion	proportion	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
attaining	attain	VERB	VBG	5	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
a	a	DET	DT	5	O
15	15	NUM	CD	9	O
%	%	NOUN	NN	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
FEV1	FEV1	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
responders	responder	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
31	31	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
90	90	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
ipratropium	ipratropium	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
17	17	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
theophylline	theophylline	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
average	average	ADJ	JJ	5	O
FEV1	FEV1	PROPN	NNP	5	O
increases	increase	NOUN	NNS	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
observation	observation	NOUN	NN	9	O
period	period	NOUN	NN	5	O
were	be	VERB	VBD	9	O
18	18	NUM	CD	7	O
%	%	NOUN	NN	9	O
for	for	ADP	IN	5	O
ipratropium	ipratropium	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
for	for	ADP	IN	5	O
theophylline	theophylline	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
was	be	VERB	VBD	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
with	with	ADP	IN	5	O
ipratropium	ipratropium	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
with	with	ADP	IN	5	O
theophylline	theophylline	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

While	while	ADP	IN	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
rare	rare	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
those	those	DET	DT	5	O
experienced	experience	VERB	VBN	5	O
after	after	ADP	IN	9	O
theophylline	theophylline	NOUN	NN	0	B-Chemical
use	use	NOUN	NN	5	O
did	do	VERB	VBD	9	O
involve	involve	VERB	VB	5	O
the	the	DET	DT	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
gastrointestinal	gastrointestinal	ADJ	JJ	9	I-Disease
systems	system	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
ipratropium	ipratropium	NOUN	NN	5	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
more	more	ADV	RBR	5	O
potent	potent	ADJ	JJ	3	O
bronchodilator	bronchodilator	NOUN	NN	5	O
than	than	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
theophylline	theophylline	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
airflow	airflow	ADJ	JJ	5	I-Disease
obstruction	obstruction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Methamphetamine	Methamphetamine	PROPN	NNP	7	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
microglial	microglial	ADJ	JJ	3	O
activation	activation	NOUN	NN	3	O
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
fractalkine	fractalkine	ADJ	JJ	3	O
receptor	receptor	NOUN	NN	3	O
signaling	signal	VERB	VBG	3	O
.	.	PUNCT	.	9	O

Methamphetamine	Methamphetamine	PROPN	NNP	7	B-Chemical
(	(	PUNCT	-LRB-	9	O
METH	METH	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
damages	damage	NOUN	NNS	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
DA	DA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
nerve	nerve	NOUN	NN	5	O
endings	ending	NOUN	NNS	5	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
process	process	NOUN	NN	5	O
that	that	DET	WDT	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
linked	link	VERB	VBN	9	O
to	to	ADP	IN	5	O
microglial	microglial	ADJ	JJ	3	O
activation	activation	NOUN	NN	3	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
signaling	signaling	NOUN	NN	3	O
pathways	pathway	NOUN	NNS	9	O
that	that	DET	WDT	5	O
mediate	mediate	VERB	VBP	3	O
this	this	DET	DT	5	O
response	response	NOUN	NN	9	O
have	have	VERB	VBP	5	O
not	not	ADV	RB	5	O
yet	yet	ADV	RB	9	O
been	be	VERB	VBN	9	O
delineated	delineate	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Cardona	Cardona	PROPN	NNP	6	O
et	et	PROPN	NNP	6	O
al	al	PROPN	NNP	6	O
.	.	PUNCT	.	9	O

[	[	PUNCT	-LRB-	9	O
Nat	Nat	PROPN	NNP	2	O
.	.	PUNCT	.	9	O
Neurosci	neurosci	INTJ	UH	2	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
2006	2006	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
917	917	NUM	CD	7	O
]	]	PUNCT	-RRB-	9	O
recently	recently	ADV	RB	9	O
identified	identify	VERB	VBD	9	O
the	the	DET	DT	5	O
microglial	microglial	ADJ	JJ	3	O
-	-	PUNCT	HYPH	7	O
specific	specific	ADJ	JJ	9	O
fractalkine	fractalkine	ADJ	JJ	3	O
receptor	receptor	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
CX3CR1	cx3cr1	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
mediator	mediator	NOUN	NN	9	O
of	of	ADP	IN	5	O
MPTP	MPTP	PROPN	NNP	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
neurodegeneration	neurodegeneration	NOUN	NN	3	B-Disease
of	of	ADP	IN	5	O
DA	DA	PROPN	NNP	9	B-Chemical
neurons	neuron	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
the	the	DET	DT	5	O
CNS	CNS	PROPN	NNP	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
METH	METH	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
MPTP	MPTP	PROPN	NNP	3	B-Chemical
is	be	VERB	VBZ	5	O
highly	highly	ADV	RB	9	O
selective	selective	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
DA	DA	PROPN	NNP	9	B-Chemical
neuronal	neuronal	ADJ	JJ	3	O
system	system	NOUN	NN	5	O
in	in	ADP	IN	5	O
mouse	mouse	NOUN	NN	3	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
hypothesized	hypothesize	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
CX3CR1	cx3cr1	NOUN	NN	3	O
plays	play	VERB	VBZ	9	O
a	a	DET	DT	5	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
METH	METH	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
microglial	microglial	ADJ	JJ	3	O
activation	activation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Mice	mouse	NOUN	NNS	3	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
the	the	DET	DT	5	O
CX3CR1	cx3cr1	ADJ	JJ	3	O
gene	gene	NOUN	NN	1	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
deleted	delete	VERB	VBN	1	O
and	and	CCONJ	CC	5	O
replaced	replace	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
cDNA	cDNA	PROPN	NNP	1	O
encoding	encode	VERB	VBG	1	O
enhanced	enhance	VERB	VBD	3	O
green	green	ADJ	JJ	9	O
fluorescent	fluorescent	NOUN	NN	3	O
protein	protein	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
eGFP	eGFP	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
METH	METH	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
examined	examine	VERB	VBN	9	O
for	for	ADP	IN	5	O
striatal	striatal	ADJ	JJ	3	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

METH	METH	PROPN	NNP	9	B-Chemical
depleted	deplete	VERB	VBD	3	O
DA	DA	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
caused	cause	VERB	VBD	9	O
microglial	microglial	ADJ	JJ	3	O
activation	activation	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
body	body	NOUN	NN	5	O
temperature	temperature	NOUN	NN	0	O
in	in	ADP	IN	5	O
CX3CR1	cx3cr1	NOUN	NN	3	O
knockout	knockout	ADJ	JJ	3	O
mice	mouse	NOUN	NNS	3	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
extent	extent	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
course	course	NOUN	NN	5	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
wild	wild	ADJ	JJ	1	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
METH	METH	PROPN	NNP	9	B-Chemical
in	in	ADP	IN	5	O
CX3CR1	cx3cr1	ADJ	JJ	3	O
knockout	knockout	NOUN	NN	3	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
gender	gender	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
extend	extend	VERB	VB	9	O
beyond	beyond	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Striatal	striatal	ADJ	JJ	3	O
microglia	microglia	NOUN	NNS	3	O
expressing	express	VERB	VBG	3	O
eGFP	egfp	ADJ	JJ	3	O
constitutively	constitutively	ADV	RB	3	O
show	show	VERB	VBP	9	O
morphological	morphological	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
after	after	ADP	IN	9	O
METH	METH	PROPN	NNP	9	B-Chemical
that	that	DET	WDT	5	O
are	be	VERB	VBP	5	O
characteristic	characteristic	ADJ	JJ	9	O
of	of	ADP	IN	5	O
activation	activation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
response	response	NOUN	NN	9	O
was	be	VERB	VBD	9	O
restricted	restrict	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
contrasted	contrast	VERB	VBD	5	O
sharply	sharply	ADV	RB	9	O
with	with	ADP	IN	5	O
unresponsive	unresponsive	ADJ	JJ	9	O
eGFP	egfp	ADJ	JJ	3	O
-	-	PUNCT	HYPH	7	O
microglia	microglia	NOUN	NNS	3	O
in	in	ADP	IN	5	O
surrounding	surround	VERB	VBG	9	O
brain	brain	NOUN	NN	5	O
areas	area	NOUN	NNS	5	O
that	that	DET	WDT	5	O
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
damaged	damage	VERB	VBN	9	O
by	by	ADP	IN	9	O
METH	METH	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
from	from	ADP	IN	9	O
these	these	DET	DT	5	O
studies	study	NOUN	NNS	9	O
that	that	DET	WDT	5	O
CX3CR1	cx3cr1	NOUN	NN	3	O
signaling	signaling	NOUN	NN	3	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
modulate	modulate	VERB	VB	9	O
METH	METH	PROPN	NNP	9	B-Chemical
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
or	or	CCONJ	CC	5	O
microglial	microglial	ADJ	JJ	3	O
activation	activation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
appears	appear	VERB	VBZ	9	O
that	that	ADP	IN	5	O
striatal	striatal	ADJ	JJ	3	O
-	-	PUNCT	HYPH	7	O
resident	resident	NOUN	NN	9	O
microglia	microglia	NOUN	NN	3	O
respond	respond	NOUN	NN	5	O
to	to	ADP	IN	5	O
METH	METH	PROPN	NNP	9	B-Chemical
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
activation	activation	NOUN	NN	3	O
cascade	cascade	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
then	then	ADV	RB	9	O
return	return	VERB	VB	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
surveying	surveying	NOUN	NN	5	O
state	state	NOUN	NN	5	O
without	without	ADP	IN	9	O
undergoing	undergo	VERB	VBG	9	O
apoptosis	apoptosis	NOUN	NN	3	O
or	or	CCONJ	CC	5	O
migration	migration	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Nicotine	nicotine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nystagmus	nystagmus	NOUN	NN	5	B-Disease
correlates	correlate	NOUN	NNS	9	O
with	with	ADP	IN	5	O
midpontine	midpontine	ADJ	JJ	5	O
activation	activation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pathomechanism	pathomechanism	NOUN	NN	5	O
of	of	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nystagmus	nystagmus	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
NIN	NIN	PROPN	NNP	1	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
unknown	unknown	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
delineate	delineate	VERB	VB	9	O
brain	brain	NOUN	NN	5	O
structures	structure	NOUN	NNS	9	O
that	that	DET	WDT	5	O
are	be	VERB	VBP	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
NIN	NIN	PROPN	NNP	1	B-Disease
generation	generation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Eight	eight	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
volunteers	volunteer	NOUN	NNS	5	O
inhaled	inhale	VERB	VBD	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
darkness	darkness	NOUN	NN	9	O
during	during	ADP	IN	5	O
a	a	DET	DT	5	O
functional	functional	ADJ	JJ	9	O
magnetic	magnetic	ADJ	JJ	0	O
resonance	resonance	NOUN	NN	5	O
imaging	imaging	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
fMRI	fMRI	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
experiment	experiment	NOUN	NN	9	O
;	;	PUNCT	:	9	O
eye	eye	NOUN	NN	5	O
movements	movement	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
registered	register	VERB	VBN	5	O
using	use	VERB	VBG	9	O
video	video	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
oculography	oculography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

NIN	NIN	PROPN	NNP	1	B-Disease
correlated	correlate	VERB	VBD	9	O
with	with	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
BOLD	BOLD	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
activity	activity	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
midpontine	midpontine	ADJ	JJ	5	O
site	site	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
posterior	posterior	ADJ	JJ	5	O
basis	basis	NOUN	NN	5	O
pontis	pontis	NOUN	NN	4	O
.	.	PUNCT	.	9	O

NIN	NIN	PROPN	NNP	1	B-Disease
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
midpontine	midpontine	ADJ	JJ	5	O
activation	activation	NOUN	NN	3	O
may	may	VERB	MD	5	O
correspond	correspond	VERB	VB	9	O
to	to	ADP	IN	5	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
dorsomedial	dorsomedial	ADJ	JJ	5	O
pontine	pontine	NOUN	NN	5	O
nuclei	nucleus	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
nucleus	nucleus	NOUN	NN	9	O
reticularis	reticularis	NOUN	NN	5	O
tegmenti	tegmenti	NOUN	NN	2	O
pontis	pontis	NOUN	NN	4	O
,	,	PUNCT	,	9	O
structures	structure	NOUN	NNS	9	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
participate	participate	VERB	VB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
generation	generation	NOUN	NN	9	O
of	of	ADP	IN	5	O
multidirectional	multidirectional	ADJ	JJ	5	O
saccades	saccade	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
smooth	smooth	ADJ	JJ	5	O
pursuit	pursuit	NOUN	NN	5	O
eye	eye	NOUN	NN	5	O
movements	movement	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
propylpentanoyl	propylpentanoyl	NOUN	NN	_	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
urea	urea	ADJ	JJ	0	I-Chemical
on	on	ADP	IN	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
amino	amino	NOUN	NN	1	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
neurotransmitters	neurotransmitter	NOUN	NNS	9	O
in	in	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
seizure	seizure	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
aimed	aim	VERB	VBN	5	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
anticonvulsant	anticonvulsant	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
amino	amino	NOUN	NN	1	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
neurotransmitters	neurotransmitter	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
glutamate	glutamate	VERB	VB	0	B-Chemical
,	,	PUNCT	,	9	O
aspartate	aspartate	VERB	VB	1	B-Chemical
,	,	PUNCT	,	9	O
glycine	glycine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
propylpentanoyl	propylpentanoyl	NOUN	NN	_	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
urea	urea	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
VPU	VPU	PROPN	NNP	1	B-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
comparison	comparison	NOUN	NN	9	O
to	to	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
parent	parent	NOUN	NN	9	O
compound	compound	NOUN	NN	0	O
,	,	PUNCT	,	9	O
valproic	valproic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
VPA	VPA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

VPU	VPU	PROPN	NNP	1	B-Chemical
was	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
potent	potent	ADJ	JJ	3	O
than	than	ADP	IN	5	O
VPA	VPA	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
exhibiting	exhibit	VERB	VBG	9	O
the	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
effective	effective	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
ED	ED	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
49	49	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
in	in	ADP	IN	5	O
protecting	protect	VERB	VBG	9	O
rats	rat	NOUN	NNS	9	O
against	against	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
seizure	seizure	NOUN	NN	5	B-Disease
whereas	whereas	ADP	IN	9	O
the	the	DET	DT	5	O
corresponding	correspond	VERB	VBG	9	O
value	value	NOUN	NN	9	O
for	for	ADP	IN	5	O
VPA	VPA	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
322	322	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
vivo	vivo	NOUN	NNS	3	O
microdialysis	microdialysis	NOUN	NN	5	O
demonstrated	demonstrate	VERB	VBD	9	O
that	that	ADP	IN	5	O
an	an	DET	DT	5	O
intraperitoneal	intraperitoneal	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
induced	induce	VERB	VBD	3	O
a	a	DET	DT	5	O
pronounced	pronounced	ADJ	JJ	9	O
increment	increment	NOUN	NN	9	O
of	of	ADP	IN	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
glutamate	glutamate	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
aspartate	aspartate	VERB	VB	1	B-Chemical
whereas	whereas	ADP	IN	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
change	change	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
glycine	glycine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Pretreatment	pretreatment	NOUN	NN	3	O
with	with	ADP	IN	5	O
either	either	DET	DT	9	O
VPU	VPU	PROPN	NNP	1	B-Chemical
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
and	and	CCONJ	CC	5	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
VPA	VPA	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
300	300	NUM	CD	0	O
and	and	CCONJ	CC	5	O
600	600	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
completely	completely	ADV	RB	9	O
abolished	abolish	VERB	VBD	3	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
evoked	evoke	VERB	VBN	5	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
extracellular	extracellular	ADJ	JJ	9	O
glutamate	glutamate	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
aspartate	aspartate	VERB	VB	1	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
observed	observe	VERB	VBN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
glycine	glycine	NOUN	NN	0	B-Chemical
but	but	CCONJ	CC	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
a	a	DET	DT	5	O
drastic	drastic	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
glutamate	glutamate	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
aspartate	aspartate	VERB	VB	1	B-Chemical
level	level	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Based	base	VERB	VBN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
finding	finding	NOUN	NN	9	O
that	that	ADP	IN	5	O
VPU	VPU	PROPN	NNP	1	B-Chemical
and	and	CCONJ	CC	5	O
VPA	VPA	PROPN	NNP	9	B-Chemical
could	could	VERB	MD	9	O
protect	protect	VERB	VB	9	O
the	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
against	against	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
seizure	seizure	NOUN	NN	5	B-Disease
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
inhibitory	inhibitory	ADJ	JJ	3	O
amino	amino	NOUN	NN	1	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
neurotransmitters	neurotransmitter	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
comparatively	comparatively	ADV	RB	9	O
minor	minor	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
offset	offset	VERB	VBN	5	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
pronounced	pronounced	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
glutamate	glutamate	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
aspartate	aspartate	VERB	VB	1	B-Chemical
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
like	like	ADP	IN	9	O
VPA	VPA	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
finding	finding	NOUN	NN	9	O
that	that	ADP	IN	5	O
VPU	VPU	PROPN	NNP	1	B-Chemical
could	could	VERB	MD	9	O
drastically	drastically	ADV	RB	9	O
reduce	reduce	VERB	VB	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
glutamate	glutamate	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
aspartate	aspartate	VERB	VB	1	B-Chemical
should	should	VERB	MD	5	O
account	account	VERB	VB	5	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
partly	partly	ADV	RB	9	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
anticonvulsant	anticonvulsant	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
seizure	seizure	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Some	some	DET	DT	5	O
other	other	ADJ	JJ	5	O
mechanism	mechanism	NOUN	NN	9	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
being	be	VERB	VBG	5	O
reported	report	VERB	VBN	9	O
herein	herein	NOUN	NN	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
further	further	ADV	RB	9	O
investigated	investigate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
gastric	gastric	ADJ	JJ	9	B-Disease
hemorrhagic	hemorrhagic	NOUN	NN	5	I-Disease
ulcers	ulcer	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
atherosclerotic	atherosclerotic	ADJ	JJ	3	B-Disease
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Studies	study	NOUN	NNS	9	O
concerning	concern	VERB	VBG	5	O
with	with	ADP	IN	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
gastric	gastric	ADJ	JJ	9	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
mucosal	mucosal	NOUN	NN	9	O
ulceration	ulceration	NOUN	NN	5	O
produced	produce	VERB	VBN	9	O
in	in	ADP	IN	5	O
atherosclerotic	atherosclerotic	ADJ	JJ	3	B-Disease
rats	rat	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
lacking	lack	VERB	VBG	1	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
gastric	gastric	ADJ	JJ	9	O
acid	acid	NOUN	NN	0	O
back	back	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
diffusion	diffusion	NOUN	NN	5	O
,	,	PUNCT	,	9	O
mast	mast	NOUN	NN	3	O
cell	cell	NOUN	NN	3	O
histamine	histamine	NOUN	NN	0	B-Chemical
release	release	NOUN	NN	9	O
,	,	PUNCT	,	9	O
lipid	lipid	NOUN	NN	0	O
peroxide	peroxide	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
LPO	LPO	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
generation	generation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
mucosal	mucosal	NOUN	NN	9	O
microvascular	microvascular	ADJ	JJ	5	O
permeability	permeability	NOUN	NN	0	O
in	in	ADP	IN	5	O
modulating	modulate	VERB	VBG	9	O
gastric	gastric	ADJ	JJ	9	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
ulcer	ulcer	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
atherosclerosis	atherosclerosis	NOUN	NN	9	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
coadministration	coadministration	NOUN	NN	0	O
of	of	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D2	d2	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Additionally	additionally	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
this	this	DET	DT	5	O
ulcer	ulcer	NOUN	NN	5	B-Disease
model	model	NOUN	NN	5	O
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Male	Male	PROPN	NNP	7	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
challenged	challenge	VERB	VBN	3	O
intragastrically	intragastrically	ADV	RB	0	O
once	once	ADV	RB	5	O
daily	daily	ADJ	JJ	5	O
for	for	ADP	IN	5	O
9	9	NUM	CD	7	O
days	day	NOUN	NNS	9	O
with	with	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
ml	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
of	of	ADP	IN	5	O
corn	corn	NOUN	NN	4	O
oil	oil	NOUN	NN	0	O
containing	contain	VERB	VBG	0	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D2	d2	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
atherosclerosis	atherosclerosis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
received	receive	VERB	VBD	9	O
corn	corn	NOUN	NN	4	O
oil	oil	NOUN	NN	0	O
only	only	ADV	RB	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
gastric	gastric	ADJ	JJ	9	O
surgery	surgery	NOUN	NN	5	O
,	,	PUNCT	,	9	O
rat	rat	NOUN	NN	3	O
stomachs	stomach	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
irrigated	irrigate	VERB	VBN	5	O
for	for	ADP	IN	5	O
3	3	NUM	CD	9	O
h	h	NOUN	NN	0	O
with	with	ADP	IN	5	O
either	either	DET	DT	9	O
simulated	simulate	VERB	VBN	5	O
gastric	gastric	ADJ	JJ	9	O
juice	juice	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
normal	normal	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Gastric	Gastric	PROPN	NNP	9	O
acid	acid	NOUN	NN	0	O
back	back	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
diffusion	diffusion	NOUN	NN	5	O
,	,	PUNCT	,	9	O
mucosal	mucosal	NOUN	NN	9	O
LPO	LPO	PROPN	NNP	0	O
generation	generation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
histamine	histamine	ADJ	JJ	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
,	,	PUNCT	,	9	O
microvascular	microvascular	ADJ	JJ	5	O
permeability	permeability	NOUN	NN	0	O
,	,	PUNCT	,	9	O
luminal	luminal	ADJ	JJ	3	B-Chemical
hemoglobin	hemoglobin	NOUN	NN	0	O
content	content	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
ulcer	ulcer	NOUN	NN	5	B-Disease
areas	area	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Elevated	elevated	ADJ	JJ	9	O
atherosclerotic	atherosclerotic	ADJ	JJ	3	B-Disease
parameters	parameter	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
total	total	ADJ	JJ	9	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
density	density	NOUN	NN	9	O
lipoprotein	lipoprotein	NOUN	NN	9	O
concentration	concentration	NOUN	NN	0	O
were	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
in	in	ADP	IN	5	O
atherosclerotic	atherosclerotic	ADJ	JJ	3	B-Disease
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Severe	severe	ADJ	JJ	9	O
gastric	gastric	ADJ	JJ	9	O
ulcers	ulcer	NOUN	NNS	5	B-Disease
accompanied	accompany	VERB	VBN	9	O
with	with	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
ulcerogenic	ulcerogenic	ADJ	JJ	0	O
factors	factor	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
gastric	gastric	ADJ	JJ	9	O
acid	acid	NOUN	NN	0	O
back	back	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
diffusion	diffusion	NOUN	NN	5	O
,	,	PUNCT	,	9	O
histamine	histamine	NOUN	NN	0	B-Chemical
release	release	NOUN	NN	9	O
,	,	PUNCT	,	9	O
LPO	LPO	PROPN	NNP	0	O
generation	generation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
luminal	luminal	ADJ	JJ	3	B-Chemical
hemoglobin	hemoglobin	NOUN	NN	0	O
content	content	NOUN	NN	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
positive	positive	ADJ	JJ	9	O
correlation	correlation	NOUN	NN	9	O
of	of	ADP	IN	5	O
histamine	histamine	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
gastric	gastric	ADJ	JJ	9	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
to	to	ADP	IN	5	O
ulcer	ulcer	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
those	those	DET	DT	5	O
atherosclerotic	atherosclerotic	ADJ	JJ	3	B-Disease
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
ulcer	ulcer	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
various	various	ADJ	JJ	9	O
ulcerogenic	ulcerogenic	ADJ	JJ	0	O
parameters	parameter	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
dose	dose	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
dependently	dependently	ADV	RB	3	O
ameliorated	ameliorate	VERB	VBN	9	O
by	by	ADP	IN	9	O
daily	daily	ADJ	JJ	5	O
intragastric	intragastric	ADJ	JJ	0	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Atherosclerosis	atherosclerosis	NOUN	NN	5	B-Disease
could	could	VERB	MD	9	O
produce	produce	VERB	VB	9	O
gastric	gastric	ADJ	JJ	9	B-Disease
hemorrhagic	hemorrhagic	NOUN	NN	5	I-Disease
ulcer	ulcer	NOUN	NN	5	B-Disease
via	via	ADP	IN	9	O
aggravation	aggravation	NOUN	NN	5	O
of	of	ADP	IN	5	O
gastric	gastric	ADJ	JJ	9	O
acid	acid	NOUN	NN	0	O
back	back	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
diffusion	diffusion	NOUN	NN	5	O
,	,	PUNCT	,	9	O
LPO	LPO	PROPN	NNP	0	O
generation	generation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
histamine	histamine	NOUN	NN	0	B-Chemical
release	release	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
microvascular	microvascular	ADJ	JJ	5	O
permeability	permeability	NOUN	NN	0	O
that	that	DET	WDT	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
ameliorated	ameliorate	VERB	VBN	9	O
by	by	ADP	IN	9	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Lamivudine	lamivudine	NOUN	NN	7	B-Chemical
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
hepatitis	hepatitis	PROPN	NNP	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
virus	virus	NOUN	NN	9	O
reactivation	reactivation	NOUN	NN	9	O
in	in	ADP	IN	5	O
hepatitis	hepatitis	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
B	B	PROPN	NNP	9	I-Chemical
surface	surface	NOUN	NN	9	I-Chemical
antigen	antigen	NOUN	NN	3	I-Chemical
(	(	PUNCT	-LRB-	9	O
HBSAG	HBSAG	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
seropositive	seropositive	ADJ	JJ	9	O
cancer	cancer	NOUN	NN	3	B-Disease
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
cytotoxic	cytotoxic	NOUN	NN	3	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Hepatitis	Hepatitis	PROPN	NNP	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
virus	virus	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
HBV	HBV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
major	major	ADJ	JJ	9	O
causes	cause	NOUN	NNS	9	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
liver	liver	NOUN	NN	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
worldwide	worldwide	ADV	RB	5	O
.	.	PUNCT	.	9	O

Cancer	cancer	NOUN	NN	2	B-Disease
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
are	be	VERB	VBP	5	O
chronic	chronic	ADJ	JJ	5	O
carriers	carrier	NOUN	NNS	9	O
of	of	ADP	IN	5	O
HBV	HBV	PROPN	NNP	9	O
have	have	VERB	VBP	5	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
complication	complication	NOUN	NN	5	I-Disease
rate	rate	NOUN	NN	9	O
while	while	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
cytotoxic	cytotoxic	NOUN	NN	3	O
chemotherapy	chemotherapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CT	CT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
this	this	DET	DT	5	O
has	have	VERB	VBZ	9	O
mainly	mainly	ADV	RB	9	O
been	be	VERB	VBN	9	O
attributed	attribute	VERB	VBN	9	O
to	to	ADP	IN	5	O
HBV	HBV	PROPN	NNP	9	O
reactivation	reactivation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
cancer	cancer	NOUN	NN	3	B-Disease
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
have	have	VERB	VBP	5	O
solid	solid	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
hematological	hematological	ADJ	JJ	9	B-Disease
malignancies	malignancy	NOUN	NNS	5	I-Disease
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
HBV	HBV	PROPN	NNP	9	B-Disease
infection	infection	NOUN	NN	9	I-Disease
received	receive	VERB	VBD	9	O
the	the	DET	DT	5	O
antiviral	antiviral	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
prior	prior	ADV	RB	9	O
and	and	CCONJ	CC	5	O
during	during	ADP	IN	5	O
CT	CT	PROPN	NNP	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
historical	historical	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
who	who	PRON	WP	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
receive	receive	VERB	VB	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
objectives	objective	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
reducing	reduce	VERB	VBG	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
HBV	HBV	PROPN	NNP	9	O
reactivation	reactivation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
diminishing	diminish	VERB	VBG	5	O
morbidity	morbidity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
mortality	mortality	NOUN	NN	5	O
during	during	ADP	IN	5	O
CT	CT	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
prophylactic	prophylactic	ADJ	JJ	5	O
lamivudin	lamivudin	NOUN	NN	9	B-Chemical
group	group	NOUN	NN	9	O
consisted	consist	VERB	VBD	5	O
of	of	ADP	IN	5	O
37	37	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
prophylactic	prophylactic	ADJ	JJ	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
historical	historical	ADJ	JJ	5	O
controls	control	NOUN	NNS	9	O
consisted	consist	VERB	VBD	5	O
of	of	ADP	IN	5	O
50	50	NUM	CD	0	O
consecutive	consecutive	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
underwent	undergo	VERB	VBD	5	O
CT	CT	PROPN	NNP	9	O
without	without	ADP	IN	9	O
prophylactic	prophylactic	ADJ	JJ	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

They	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
followed	follow	VERB	VBN	9	O
up	up	PART	RP	5	O
during	during	ADP	IN	5	O
and	and	CCONJ	CC	5	O
for	for	ADP	IN	5	O
8	8	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
CT	CT	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
outcomes	outcome	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
for	for	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
50	50	NUM	CD	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
21	21	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
42	42	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
established	establish	VERB	VBN	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Twelve	twelve	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
24	24	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
as	as	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
prophylactic	prophylactic	ADJ	JJ	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
group	group	NOUN	NN	9	O
severe	severe	ADJ	JJ	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
patient	patient	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
37	37	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
006	006	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Comparison	Comparison	PROPN	NNP	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
ALT	ALT	PROPN	NNP	9	O
values	value	NOUN	NNS	5	O
revealed	reveal	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
mean	mean	ADJ	JJ	5	O
alanine	alanine	NOUN	NN	1	B-Chemical
aminotransferase	aminotransferase	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
ALT	ALT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
values	value	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
prophylactic	prophylactic	ADJ	JJ	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
group	group	NOUN	NN	9	O
;	;	PUNCT	:	9	O
154	154	NUM	CD	7	O
:	:	SYM	SYM	9	O
64	64	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
32	32	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
study	study	NOUN	NN	9	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
prophylactic	prophylactic	ADJ	JJ	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
significantly	significantly	ADV	RB	9	O
decreases	decrease	VERB	VBZ	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
HBV	HBV	PROPN	NNP	9	O
reactivation	reactivation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
overall	overall	ADJ	JJ	5	O
morbidity	morbidity	NOUN	NN	5	O
in	in	ADP	IN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
patients	patient	NOUN	NNS	5	O
during	during	ADP	IN	5	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
needed	need	VERB	VBN	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
appropriate	appropriate	ADJ	JJ	5	O
nucleoside	nucleoside	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
nucleotide	nucleotide	NOUN	NN	1	B-Chemical
analogue	analogue	NOUN	NN	0	O
for	for	ADP	IN	5	O
antiviral	antiviral	ADJ	JJ	9	O
prophylaxis	prophylaxis	NOUN	NN	5	O
during	during	ADP	IN	5	O
CT	CT	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
optimal	optimal	ADJ	JJ	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
administration	administration	NOUN	NN	9	O
after	after	ADP	IN	9	O
completion	completion	NOUN	NN	5	O
of	of	ADP	IN	5	O
CT	CT	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
brachial	brachial	ADJ	JJ	5	B-Disease
neuritis	neuritis	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
conversion	conversion	NOUN	NN	9	O
to	to	PART	TO	5	O
everolimus	everolimus	VERB	VB	0	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
pediatric	pediatric	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	O
transplant	transplant	NOUN	NN	9	O
recipient	recipient	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

TAC	TAC	PROPN	NNP	9	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
potent	potent	ADJ	JJ	3	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
for	for	ADP	IN	5	O
solid	solid	ADJ	JJ	9	O
organ	organ	NOUN	NN	5	O
transplantation	transplantation	NOUN	NN	9	O
in	in	ADP	IN	5	O
pediatrics	pediatric	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Neurotoxicity	neurotoxicity	NOUN	NN	0	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
potentially	potentially	ADV	RB	5	O
serious	serious	ADJ	JJ	5	O
toxic	toxic	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	O
headaches	headache	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
neurological	neurological	ADJ	JJ	5	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
describe	describe	VERB	VBP	5	O
an	an	DET	DT	5	O
eight	eight	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
-	-	PUNCT	HYPH	7	O
a	a	DET	DT	5	O
-	-	PUNCT	HYPH	7	O
half	half	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
yr	yr	NOUN	NN	7	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
male	male	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	O
transplant	transplant	NOUN	NN	9	O
recipient	recipient	NOUN	NN	9	O
with	with	ADP	IN	5	O
right	right	ADJ	JJ	5	O
BN	BN	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

MRI	MRI	PROPN	NNP	5	O
demonstrated	demonstrate	VERB	VBD	9	O
hyperintense	hyperintense	NOUN	NN	5	O
T2	T2	PROPN	NNP	9	O
signals	signal	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cervical	cervical	ADJ	JJ	5	O
cord	cord	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
right	right	ADJ	JJ	5	O
brachial	brachial	ADJ	JJ	5	O
plexus	plexus	NOUN	NN	9	O
roots	root	NOUN	NNS	4	O
indicative	indicative	ADJ	JJ	9	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
myelitis	myelitis	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	O
right	right	ADJ	JJ	5	O
brachial	brachial	ADJ	JJ	5	B-Disease
plexitis	plexitis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Symptoms	symptom	NOUN	NNS	5	O
persisted	persist	VERB	VBD	9	O
for	for	ADP	IN	5	O
three	three	NUM	CD	9	O
months	month	NOUN	NNS	5	O
despite	despite	ADP	IN	9	O
TAC	TAC	PROPN	NNP	9	B-Chemical
dose	dose	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
,	,	PUNCT	,	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
IVIG	ivig	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
four	four	NUM	CD	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
methylprednisolone	methylprednisolone	ADJ	JJ	0	B-Chemical
pulse	pulse	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Improvement	improvement	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
eventually	eventually	ADV	RB	5	O
full	full	ADJ	JJ	5	O
recovery	recovery	NOUN	NN	9	O
only	only	ADV	RB	9	O
occurred	occur	VERB	VBD	9	O
after	after	ADP	IN	9	O
TAC	TAC	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
completely	completely	ADV	RB	9	O
discontinued	discontinue	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
successfully	successfully	ADV	RB	5	O
replaced	replace	VERB	VBN	9	O
by	by	ADP	IN	9	O
everolimus	everolimus	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Omitting	omit	VERB	VBG	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
reduces	reduce	VERB	VBZ	9	O
nausea	nausea	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
vomiting	vomiting	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
without	without	ADP	IN	9	O
increasing	increase	VERB	VBG	9	O
pain	pain	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
after	after	ADP	IN	9	O
sevoflurane	sevoflurane	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
day	day	NOUN	NN	9	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
OBJECTIVE	OBJECTIVE	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Despite	despite	ADP	IN	5	O
advantages	advantage	NOUN	NNS	5	O
of	of	ADP	IN	5	O
induction	induction	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
maintenance	maintenance	NOUN	NN	9	O
of	of	ADP	IN	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
with	with	ADP	IN	5	O
sevoflurane	sevoflurane	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
nausea	nausea	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
vomiting	vomiting	NOUN	NN	5	I-Disease
occurs	occur	VERB	VBZ	9	O
frequently	frequently	ADV	RB	5	O
.	.	PUNCT	.	9	O

Fentanyl	Fentanyl	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
commonly	commonly	ADV	RB	5	O
used	use	VERB	VBN	5	O
supplement	supplement	NOUN	NN	9	O
that	that	DET	WDT	5	O
may	may	VERB	MD	5	O
contribute	contribute	VERB	VB	9	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
also	also	ADV	RB	9	O
improve	improve	VERB	VB	5	O
analgesia	analgesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
nausea	nausea	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
vomiting	vomiting	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
pain	pain	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
sevoflurane	sevoflurane	NOUN	NN	0	B-Chemical
anaesthesia	anaesthesia	NOUN	NN	5	O
in	in	ADP	IN	5	O
216	216	NUM	CD	7	O
adult	adult	NOUN	NN	9	O
day	day	NOUN	NN	9	O
surgery	surgery	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
allocated	allocate	VERB	VBN	5	O
to	to	ADP	IN	5	O
either	either	CCONJ	CC	9	O
receive	receive	VERB	VB	5	O
or	or	CCONJ	CC	5	O
not	not	ADV	RB	5	O
receive	receive	VERB	VB	5	O
1	1	NUM	CD	9	O
1	1	NUM	CD	9	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
a	a	DET	DT	5	O
third	third	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
received	receive	VERB	VBD	9	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Omission	omission	NOUN	NN	9	O
of	of	ADP	IN	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
reduce	reduce	VERB	VB	5	O
the	the	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
nausea	nausea	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
vomiting	vomiting	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
did	do	VERB	VBD	9	O
reduce	reduce	VERB	VB	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
vomiting	vomiting	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
moderate	moderate	ADJ	JJ	9	O
to	to	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
nausea	nausea	NOUN	NN	5	B-Disease
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
discharge	discharge	NOUN	NN	5	O
from	from	ADP	IN	9	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
17	17	NUM	CD	7	O
%	%	NOUN	NN	9	O
with	with	ADP	IN	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
to	to	ADP	IN	5	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
013	013	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Antiemetic	antiemetic	ADJ	JJ	5	O
requirements	requirement	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
from	from	ADP	IN	9	O
24	24	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
31	31	NUM	CD	7	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0012	0012	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Dexamethasone	Dexamethasone	PROPN	NNP	0	B-Chemical
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
nausea	nausea	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
vomiting	vomiting	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Combining	combine	VERB	VBG	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
groups	group	NOUN	NNS	9	O
revealed	reveal	VERB	VBD	9	O
further	further	ADJ	JJ	9	O
significant	significant	ADJ	JJ	9	O
benefits	benefit	NOUN	NNS	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
avoidance	avoidance	NOUN	NN	5	O
of	of	ADP	IN	5	O
opioids	opioid	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
reducing	reduce	VERB	VBG	9	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
nausea	nausea	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
vomiting	vomiting	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
nausea	nausea	NOUN	NN	5	B-Disease
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
discharge	discharge	NOUN	NN	5	O
from	from	ADP	IN	9	O
35	35	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
33	33	NUM	CD	7	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
22	22	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
19	19	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
049	049	NUM	CD	7	O
and	and	CCONJ	CC	5	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
035	035	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
nausea	nausea	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
was	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
from	from	ADP	IN	9	O
42	42	NUM	CD	7	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
27	27	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
034	034	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Pain	pain	NOUN	NN	5	B-Disease
severity	severity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
analgesic	analgesic	ADJ	JJ	5	O
requirements	requirement	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
unaffected	unaffected	ADJ	JJ	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
omission	omission	NOUN	NN	5	O
of	of	ADP	IN	5	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Fentanyl	Fentanyl	PROPN	NNP	0	B-Chemical
did	do	VERB	VBD	9	O
reduce	reduce	VERB	VB	5	O
minor	minor	ADJ	JJ	9	O
intraoperative	intraoperative	ADJ	JJ	5	O
movement	movement	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
sevoflurane	sevoflurane	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
sparing	sparing	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
depression	depression	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
As	as	ADP	IN	9	O
fentanyl	fentanyl	ADJ	JJ	0	B-Chemical
exacerbated	exacerbate	VERB	VBD	9	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
nausea	nausea	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
vomiting	vomiting	NOUN	NN	5	I-Disease
without	without	ADP	IN	9	O
an	an	DET	DT	5	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
also	also	ADV	RB	9	O
had	have	VERB	VBD	9	O
adverse	adverse	ADJ	JJ	5	O
cardiorespiratory	cardiorespiratory	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
unnecessary	unnecessary	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
possibly	possibly	ADV	RB	9	O
detrimental	detrimental	ADJ	JJ	9	O
supplement	supplement	NOUN	NN	9	O
to	to	PART	TO	5	O
sevoflurane	sevoflurane	VERB	VB	0	B-Chemical
in	in	ADP	IN	5	O
day	day	NOUN	NN	9	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Valvular	valvular	ADJ	JJ	7	B-Disease
heart	heart	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
pergolide	pergolide	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Course	course	ADJ	JJ	5	O
following	follow	VERB	VBG	9	O
treatment	treatment	NOUN	NN	9	O
modifications	modification	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Valvular	valvular	ADJ	JJ	7	B-Disease
heart	heart	NOUN	NN	5	I-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
PD	PD	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
pergolide	pergolide	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
abnormalities	abnormality	NOUN	NNS	9	O
vary	vary	VERB	VBP	5	O
from	from	ADP	IN	9	O
study	study	NOUN	NN	9	O
to	to	PART	TO	5	O
study	study	VERB	VB	9	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
course	course	NOUN	NN	5	O
after	after	ADP	IN	9	O
drug	drug	NOUN	NN	5	O
withdrawal	withdrawal	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
systematically	systematically	ADV	RB	5	O
assessed	assess	VERB	VBN	9	O
.	.	PUNCT	.	9	O

OBJECTIVES	objectives	NOUN	NN	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
estimate	estimate	VERB	VB	5	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
valvular	valvular	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
abnormality	abnormality	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
possible	possible	ADJ	JJ	5	O
reversibility	reversibility	NOUN	NN	9	O
after	after	ADP	IN	9	O
drug	drug	NOUN	NN	5	O
withdrawal	withdrawal	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
All	all	DET	DT	9	O
PD	pd	NOUN	NN	9	B-Disease
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Amiens	Amiens	PROPN	NNP	2	O
area	area	NOUN	NN	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
pergolide	pergolide	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
invited	invite	VERB	VBN	5	O
to	to	PART	TO	5	O
attend	attend	VERB	VB	5	O
a	a	DET	DT	5	O
cardiologic	cardiologic	ADJ	JJ	5	O
assessment	assessment	NOUN	NN	5	O
including	include	VERB	VBG	9	O
transthoracic	transthoracic	NOUN	NN	5	O
echocardiography	echocardiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
PD	pd	NOUN	NN	9	B-Disease
patients	patient	NOUN	NNS	5	O
participated	participate	VERB	VBD	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
second	second	ADJ	JJ	9	O
echocardiography	echocardiography	NOUN	NN	5	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
median	median	ADJ	JJ	9	O
interval	interval	NOUN	NN	5	O
:	:	PUNCT	:	9	O
13	13	NUM	CD	7	O
months	month	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
pergolide	pergolide	ADJ	JJ	0	B-Chemical
withdrawal	withdrawal	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
10	10	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Controls	control	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
age	age	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
sex	sex	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
matched	match	VERB	VBN	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
PD	pd	ADJ	JJ	9	B-Disease
patients	patient	NOUN	NNS	5	O
referred	refer	VERB	VBD	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
cardiology	cardiology	NOUN	NN	5	O
department	department	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
aortic	aortic	ADJ	JJ	9	B-Disease
regurgitation	regurgitation	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
:	:	SYM	SYM	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
IC	ic	NOUN	NN	9	O
:	:	PUNCT	:	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
mitral	mitral	ADJ	JJ	5	B-Disease
regurgitation	regurgitation	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
OR	or	CCONJ	CC	9	O
:	:	PUNCT	:	9	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
;	;	SYM	SYM	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
IC	ic	NOUN	NN	9	O
:	:	PUNCT	:	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
53	53	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
frequent	frequent	ADJ	JJ	5	O
in	in	ADP	IN	5	O
PD	pd	NOUN	NN	9	B-Disease
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
tricuspid	tricuspid	ADJ	JJ	5	O
:	:	PUNCT	:	9	O
NS	NS	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
affected	affect	VERB	VBN	9	O
valves	valve	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
sum	sum	NOUN	NN	5	O
of	of	ADP	IN	5	O
regurgitation	regurgitation	NOUN	NN	5	O
grades	grade	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
09	09	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
008	008	NUM	CD	7	O
and	and	CCONJ	CC	5	O
p	p	NOUN	NNS	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
006	006	NUM	CD	7	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pergolide	pergolide	ADJ	JJ	0	B-Chemical
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
regurgitation	regurgitation	NOUN	NN	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
pergolide	pergolide	ADJ	JJ	0	B-Chemical
cumulative	cumulative	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
restrictive	restrictive	ADJ	JJ	5	O
pattern	pattern	NOUN	NN	9	O
of	of	ADP	IN	5	O
valvular	valvular	ADJ	JJ	5	B-Disease
regurgitation	regurgitation	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
suggestive	suggestive	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
pergolide	pergolide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
12	12	NUM	CD	9	O
/	/	SYM	SYM	9	O
30	30	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
including	include	VERB	VBG	9	O
two	two	NUM	CD	5	O
with	with	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Pergolide	Pergolide	PROPN	NNP	7	B-Chemical
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
in	in	ADP	IN	5	O
10	10	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
valvular	valvular	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
lower	low	ADJ	JJR	9	O
regurgitation	regurgitation	NOUN	NN	5	O
grade	grade	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
transthoracic	transthoracic	NOUN	NN	5	O
echocardiography	echocardiography	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
nearly	nearly	ADV	RB	9	O
normal	normal	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
supports	support	VERB	VBZ	9	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
restrictive	restrictive	ADJ	JJ	5	O
valve	valve	NOUN	NN	5	B-Disease
regurgitation	regurgitation	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
PD	pd	NOUN	NN	9	B-Disease
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
pergolide	pergolide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
reveals	reveal	VERB	VBZ	9	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
improvement	improvement	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
usual	usual	ADJ	JJ	5	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
converted	convert	VERB	VBN	9	O
to	to	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
ergot	ergot	ADJ	JJ	0	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
agonists	agonist	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Adriamycin	Adriamycin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
autophagic	autophagic	ADJ	JJ	3	O
cardiomyocyte	cardiomyocyte	NOUN	NN	3	O
death	death	NOUN	NN	9	B-Disease
plays	play	VERB	VBZ	9	O
a	a	DET	DT	5	O
pathogenic	pathogenic	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
underlying	underlie	VERB	VBG	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
adriamycin	adriamycin	NOUN	NN	3	B-Chemical
are	be	VERB	VBP	5	O
very	very	ADV	RB	5	O
complicated	complicated	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
still	still	ADV	RB	5	O
unclear	unclear	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
whether	whether	ADP	IN	9	O
autophagy	autophagy	NOUN	NN	3	O
was	be	VERB	VBD	9	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
progression	progression	NOUN	NN	9	O
of	of	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
adriamycin	adriamycin	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
so	so	ADP	IN	5	O
that	that	ADP	IN	5	O
we	-PRON-	PRON	PRP	5	O
can	can	VERB	MD	5	O
develop	develop	VERB	VB	5	O
a	a	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
strategy	strategy	NOUN	NN	5	O
for	for	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
3	3	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyladenine	methyladenine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
3MA	3ma	NUM	CD	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
specific	specific	ADJ	JJ	9	O
inhibitor	inhibitor	NOUN	NN	3	O
on	on	ADP	IN	5	O
autophagy	autophagy	NOUN	NN	3	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
adriamycin	adriamycin	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

Neonatal	neonatal	ADJ	JJ	9	O
cardiomyocytes	cardiomyocyte	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
isolated	isolate	VERB	VBN	9	O
from	from	ADP	IN	9	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
rat	rat	NOUN	NN	3	O
hearts	heart	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
randomly	randomly	ADV	RB	5	O
divided	divide	VERB	VBN	5	O
into	into	ADP	IN	9	O
controls	control	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
adriamycin	adriamycin	ADV	RB	3	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
3MA	3ma	NUM	CD	3	B-Chemical
plus	plus	CCONJ	CC	9	O
adriamycin	adriamycin	ADV	RB	3	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
then	then	ADV	RB	9	O
examined	examine	VERB	VBD	9	O
the	the	DET	DT	5	O
morphology	morphology	NOUN	NN	9	O
,	,	PUNCT	,	9	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
beclin	beclin	NOUN	NN	3	O
1	1	NUM	CD	9	O
gene	gene	NOUN	NN	1	O
,	,	PUNCT	,	9	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
permeability	permeability	NOUN	NN	0	O
transition	transition	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
MPT	MPT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
Na	Na	PROPN	NNP	0	O
+	+	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
K	K	PROPN	NNP	9	B-Chemical
+	+	CCONJ	CC	9	O
ATPase	ATPase	PROPN	NNP	1	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
also	also	ADV	RB	9	O
assessed	assess	VERB	VBD	9	O
cell	cell	NOUN	NN	3	O
viability	viability	NOUN	NN	3	O
,	,	PUNCT	,	9	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
membrane	membrane	NOUN	NN	9	O
potential	potential	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
counted	count	VERB	VBD	9	O
autophagic	autophagic	ADJ	JJ	3	O
vacuoles	vacuole	NOUN	NNS	9	O
in	in	ADP	IN	5	O
cultured	culture	VERB	VBN	3	O
cardiomyocytes	cardiomyocyte	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
analyzed	analyze	VERB	VBD	9	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
autophagy	autophagy	NOUN	NN	3	O
associated	associate	VERB	VBN	9	O
gene	gene	NOUN	NN	1	O
,	,	PUNCT	,	9	O
beclin	beclin	NOUN	NN	3	O
1	1	NUM	CD	9	O
using	use	VERB	VBG	9	O
RT	RT	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
PCR	PCR	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
Western	Western	PROPN	NNP	3	O
blotting	blotting	NOUN	NN	3	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
animal	animal	NOUN	NN	5	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
3MA	3ma	NUM	CD	3	B-Chemical
significantly	significantly	ADV	RB	9	O
improved	improve	VERB	VBN	5	O
cardiac	cardiac	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
reduced	reduce	VERB	VBN	9	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
injury	injury	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
adriamycin	adriamycin	PROPN	NNP	3	B-Chemical
induced	induce	VERB	VBD	3	O
the	the	DET	DT	5	O
formation	formation	NOUN	NN	9	O
of	of	ADP	IN	5	O
autophagic	autophagic	ADJ	JJ	3	O
vacuoles	vacuole	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
3MA	3ma	NUM	CD	3	B-Chemical
strongly	strongly	ADV	RB	9	O
downregulated	downregulate	VERB	VBD	3	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
beclin	beclin	NOUN	NN	3	O
1	1	NUM	CD	9	O
in	in	ADP	IN	5	O
adriamycin	adriamycin	ADV	RB	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
failing	fail	VERB	VBG	5	O
heart	heart	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
inhibited	inhibit	VERB	VBD	3	O
the	the	DET	DT	5	O
formation	formation	NOUN	NN	9	O
of	of	ADP	IN	5	O
autophagic	autophagic	ADJ	JJ	3	O
vacuoles	vacuole	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Autophagic	autophagic	ADJ	JJ	3	O
cardiomyocyte	cardiomyocyte	NOUN	NN	3	O
death	death	NOUN	NN	9	B-Disease
plays	play	VERB	VBZ	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
adriamycin	adriamycin	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

Mitochondrial	mitochondrial	ADJ	JJ	9	O
injury	injury	NOUN	NN	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
progression	progression	NOUN	NN	9	O
of	of	ADP	IN	5	O
heart	heart	NOUN	NN	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
adriamycin	adriamycin	NOUN	NN	3	B-Chemical
via	via	ADP	IN	9	O
the	the	DET	DT	5	O
autophagy	autophagy	ADJ	JJ	3	O
pathway	pathway	NOUN	NN	3	O
.	.	PUNCT	.	9	O

mToR	mToR	NOUN	NNS	3	O
inhibitors	inhibitor	NOUN	NNS	3	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
:	:	PUNCT	:	9	O
mechanisms	mechanism	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
significance	significance	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
management	management	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Massive	massive	ADJ	JJ	5	O
urinary	urinary	ADJ	JJ	9	O
protein	protein	NOUN	NN	1	O
excretion	excretion	NOUN	NN	0	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
observed	observe	VERB	VBN	9	O
after	after	ADP	IN	9	O
conversion	conversion	NOUN	NN	9	O
from	from	ADP	IN	9	O
calcineurin	calcineurin	NOUN	NN	3	O
inhibitors	inhibitor	NOUN	NNS	3	O
to	to	ADP	IN	5	O
mammalian	mammalian	ADJ	JJ	9	O
target	target	NOUN	NN	9	O
of	of	ADP	IN	5	O
rapamycin	rapamycin	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
mToR	mToR	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O
inhibitors	inhibitor	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
sirolimus	sirolimus	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
transplant	transplant	NOUN	NN	9	O
recipients	recipient	NOUN	NNS	9	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
allograft	allograft	NOUN	NN	5	I-Disease
nephropathy	nephropathy	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
predictive	predictive	ADJ	JJ	5	O
factor	factor	NOUN	NN	9	O
of	of	ADP	IN	5	O
poor	poor	ADJ	JJ	5	O
transplantation	transplantation	NOUN	NN	9	O
outcome	outcome	NOUN	NN	5	O
,	,	PUNCT	,	9	O
many	many	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
focused	focus	VERB	VBD	5	O
on	on	ADP	IN	5	O
this	this	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
event	event	NOUN	NN	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
past	past	ADJ	JJ	5	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Whether	whether	ADP	IN	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
only	only	ADV	RB	9	O
a	a	DET	DT	5	O
consequence	consequence	NOUN	NN	5	O
of	of	ADP	IN	5	O
calcineurin	calcineurin	NOUN	NN	3	O
inhibitors	inhibitor	NOUN	NNS	3	O
withdrawal	withdrawal	NOUN	NN	5	O
remained	remain	VERB	VBD	9	O
unsolved	unsolved	ADJ	JJ	9	O
until	until	ADP	IN	5	O
high	high	ADJ	JJ	9	O
range	range	NOUN	NN	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
observed	observe	VERB	VBN	9	O
during	during	ADP	IN	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
islet	islet	NOUN	NN	3	O
transplantation	transplantation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
sirolimus	sirolimus	ADJ	JJ	0	B-Chemical
de	de	X	FW	2	O
novo	novo	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Podocyte	podocyte	NOUN	NN	3	O
injury	injury	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
focal	focal	ADJ	JJ	5	O
segmental	segmental	ADJ	JJ	5	O
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	B-Disease
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
mToR	mToR	NOUN	NNS	3	O
inhibition	inhibition	NOUN	NN	3	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
pathways	pathway	NOUN	NNS	9	O
underlying	underlie	VERB	VBG	5	O
these	these	DET	DT	5	O
lesions	lesion	NOUN	NNS	5	O
remain	remain	VERB	VBP	9	O
hypothetic	hypothetic	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
discuss	discuss	VERB	VBP	5	O
herein	herein	VERB	VB	9	O
the	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
mechanisms	mechanism	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
significance	significance	NOUN	NN	9	O
of	of	ADP	IN	5	O
mToR	mToR	NOUN	NNS	3	O
blockade	blockade	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Neuropsychiatric	neuropsychiatric	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
mefloquine	mefloquine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
describes	describe	VERB	VBZ	5	O
neuropsychiatric	neuropsychiatric	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
mefloquine	mefloquine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Reactions	reaction	NOUN	NNS	0	O
consisted	consist	VERB	VBD	5	O
mainly	mainly	ADV	RB	9	O
of	of	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
acute	acute	ADJ	JJ	9	O
psychoses	psychosis	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
anxiety	anxiety	NOUN	NN	5	B-Disease
neurosis	neurosis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
major	major	ADJ	JJ	9	O
disturbances	disturbance	NOUN	NNS	5	B-Disease
of	of	ADP	IN	5	I-Disease
sleep	sleep	NOUN	NN	5	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
wake	wake	NOUN	NN	5	I-Disease
rhythm	rhythm	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
occurred	occur	VERB	VBD	9	O
after	after	ADP	IN	9	O
both	both	CCONJ	CC	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
prophylactic	prophylactic	ADJ	JJ	5	O
intake	intake	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
graded	grade	VERB	VBN	5	O
from	from	ADP	IN	9	O
moderate	moderate	ADJ	JJ	9	O
to	to	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
risk	risk	NOUN	NN	5	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
neuropsychiatric	neuropsychiatric	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
Germany	Germany	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
estimated	estimate	VERB	VBN	5	O
that	that	ADP	IN	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
mefloquine	mefloquine	NOUN	NN	0	B-Chemical
users	user	NOUN	NNS	5	O
suffers	suffer	VERB	VBZ	5	O
from	from	ADP	IN	9	O
such	such	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
calculation	calculation	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
that	that	ADP	IN	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
215	215	NUM	CD	7	O
therapeutic	therapeutic	ADJ	JJ	5	O
users	user	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
reactions	reaction	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
13	13	NUM	CD	7	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
prophylaxis	prophylaxis	NOUN	NN	5	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
making	make	VERB	VBG	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
neuropsychiatric	neuropsychiatric	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
after	after	ADP	IN	9	O
mefloquine	mefloquine	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
60	60	NUM	CD	9	O
times	time	NOUN	NNS	5	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
after	after	ADP	IN	9	O
prophylaxis	prophylaxis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
certain	certain	ADJ	JJ	5	O
limitations	limitation	NOUN	NNS	5	O
for	for	ADP	IN	5	O
malaria	malaria	NOUN	NN	5	B-Disease
prophylaxis	prophylaxis	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
mefloquine	mefloquine	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
recommended	recommend	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Prenatal	prenatal	ADJ	JJ	5	O
protein	protein	NOUN	NN	1	O
deprivation	deprivation	NOUN	NN	9	O
alters	alter	NOUN	NNS	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
behaviors	behavior	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
glutamatergic	glutamatergic	ADJ	JJ	3	O
receptor	receptor	NOUN	NN	3	O
binding	bind	VERB	VBG	1	O
.	.	PUNCT	.	9	O

Epidemiological	epidemiological	ADJ	JJ	5	O
evidence	evidence	NOUN	NN	9	O
indicates	indicate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
prenatal	prenatal	ADJ	JJ	5	O
nutritional	nutritional	ADJ	JJ	5	O
deprivation	deprivation	NOUN	NN	9	O
may	may	VERB	MD	5	O
increase	increase	VERB	VB	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
goal	goal	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
studies	study	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
use	use	VERB	VB	5	O
an	an	DET	DT	5	O
animal	animal	NOUN	NN	5	O
model	model	NOUN	NN	5	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
prenatal	prenatal	ADJ	JJ	5	O
protein	protein	NOUN	NN	1	O
deprivation	deprivation	NOUN	NN	9	O
on	on	ADP	IN	5	O
behaviors	behavior	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
receptor	receptor	NOUN	NN	3	O
binding	bind	VERB	VBG	1	O
with	with	ADP	IN	5	O
relevance	relevance	NOUN	NN	9	O
to	to	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
that	that	ADP	IN	5	O
prenatally	prenatally	ADV	RB	5	O
protein	protein	NOUN	NN	1	O
deprived	deprive	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
PD	PD	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
female	female	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
stereotypic	stereotypic	NOUN	NN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
locomotor	locomotor	NOUN	NN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
adulthood	adulthood	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
differences	difference	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
observed	observe	VERB	VBN	9	O
during	during	ADP	IN	5	O
puberty	puberty	NOUN	NN	5	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
locomotion	locomotion	NOUN	NN	5	O
were	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
following	follow	VERB	VBG	9	O
PD	pd	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
PD	pd	NOUN	NN	9	O
female	female	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
H	H	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	PROPN	NNP	7	I-Chemical
binding	bind	VERB	VBG	1	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
hippocampus	hippocampus	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cortex	cortex	NOUN	NN	5	O
.	.	PUNCT	.	9	O

PD	pd	NOUN	NN	9	O
female	female	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
also	also	ADV	RB	9	O
showed	show	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
H	h	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
binding	binding	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
transporter	transporter	NOUN	NN	1	O
binding	bind	VERB	VBG	1	O
in	in	ADP	IN	5	O
striatum	striatum	NOUN	NN	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
behavior	behavior	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
receptor	receptor	NOUN	NN	3	O
binding	bind	VERB	VBG	1	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
PD	pd	NOUN	NN	9	O
males	male	NOUN	NNS	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
exception	exception	NOUN	NN	9	O
of	of	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
H	H	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	PROPN	NNP	7	I-Chemical
binding	bind	VERB	VBG	1	O
in	in	ADP	IN	5	O
cortex	cortex	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
animal	animal	NOUN	NN	5	O
model	model	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
useful	useful	ADJ	JJ	5	O
to	to	PART	TO	5	O
explore	explore	VERB	VB	5	O
the	the	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
by	by	ADP	IN	9	O
which	which	DET	WDT	5	O
prenatal	prenatal	ADJ	JJ	5	O
nutritional	nutritional	ADJ	JJ	5	B-Disease
deficiency	deficiency	NOUN	NN	9	I-Disease
enhances	enhance	NOUN	NNS	3	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
also	also	ADV	RB	9	O
have	have	VERB	VB	5	O
implications	implication	NOUN	NNS	5	O
for	for	ADP	IN	5	O
developmental	developmental	ADJ	JJ	9	O
processes	process	NOUN	NNS	5	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
differential	differential	ADJ	JJ	9	O
sensitivity	sensitivity	NOUN	NN	9	O
to	to	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
of	of	ADP	IN	5	O
abuse	abuse	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
topical	topical	ADJ	JJ	0	O
papaverine	papaverine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
auditory	auditory	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Papaverine	papaverine	ADJ	JJ	0	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
direct	direct	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
acting	act	VERB	VBG	9	O
vasodilator	vasodilator	NOUN	NN	0	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
manage	manage	VERB	VB	5	O
vasospasm	vasospasm	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
various	various	ADJ	JJ	9	O
neurosurgical	neurosurgical	ADJ	JJ	5	O
operations	operation	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Transient	transient	ADJ	JJ	9	O
cranial	cranial	ADJ	JJ	5	B-Disease
nerve	nerve	NOUN	NN	5	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
described	describe	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
few	few	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
with	with	ADP	IN	5	O
topical	topical	ADJ	JJ	0	O
papaverine	papaverine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
supports	support	VERB	VBZ	9	O
previous	previous	ADJ	JJ	9	O
reports	report	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
provides	provide	VERB	VBZ	5	O
neurophysiological	neurophysiological	ADJ	JJ	5	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
auditory	auditory	NOUN	NN	5	O
nerve	nerve	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
conducted	conduct	VERB	VBD	9	O
a	a	DET	DT	5	O
retrospective	retrospective	ADJ	JJ	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
70	70	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
microvascular	microvascular	ADJ	JJ	5	O
decompression	decompression	NOUN	NN	5	O
operations	operation	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
studied	study	VERB	VBD	9	O
those	those	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
topical	topical	ADJ	JJ	0	O
papaverine	papaverine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
vasospasm	vasospasm	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Topical	topical	ADJ	JJ	0	O
papaverine	papaverine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
action	action	NOUN	NN	5	O
to	to	PART	TO	5	O
manage	manage	VERB	VB	5	O
vasospasm	vasospasm	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
11	11	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
timing	timing	NOUN	NN	5	O
of	of	ADP	IN	5	O
papaverine	papaverine	ADJ	JJ	0	B-Chemical
application	application	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
ongoing	ongoing	ADJ	JJ	5	O
operative	operative	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
reviewed	review	VERB	VBN	9	O
relative	relative	ADJ	JJ	9	O
to	to	ADP	IN	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
neurophysiological	neurophysiological	ADJ	JJ	5	O
recordings	recording	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Brainstem	Brainstem	PROPN	NNP	5	O
auditory	auditory	NOUN	NN	5	O
evoked	evoke	VERB	VBD	5	O
potentials	potential	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
BAEPs	baep	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
routinely	routinely	ADV	RB	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
monitor	monitor	VERB	VB	5	O
cochlear	cochlear	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
function	function	NOUN	NN	9	O
during	during	ADP	IN	5	O
these	these	DET	DT	5	O
operations	operation	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

FINDINGS	finding	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
temporal	temporal	ADJ	JJ	5	O
relationship	relationship	NOUN	NN	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
between	between	ADP	IN	5	O
topical	topical	ADJ	JJ	0	O
papaverine	papaverine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
BAEP	BAEP	PROPN	NNP	5	O
changes	change	NOUN	NNS	9	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
complete	complete	ADJ	JJ	9	O
waveform	waveform	NOUN	NN	5	O
loss	loss	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
average	average	ADJ	JJ	5	O
temporal	temporal	ADJ	JJ	5	O
delay	delay	NOUN	NN	5	O
between	between	ADP	IN	5	O
papaverine	papaverine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
BAEP	BAEP	PROPN	NNP	5	O
change	change	NOUN	NN	9	O
was	be	VERB	VBD	9	O
5	5	NUM	CD	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
10	10	NUM	CD	9	O
of	of	ADP	IN	5	O
11	11	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
BAEP	BAEP	PROPN	NNP	5	O
waves	wave	VERB	VBZ	5	O
II	II	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
III	iii	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
V	v	NOUN	NN	9	O
completely	completely	ADV	RB	9	O
disappeared	disappear	VERB	VBD	9	O
within	within	ADP	IN	9	O
2	2	NUM	CD	9	O
to	to	ADP	IN	5	O
25	25	NUM	CD	9	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
papaverine	papaverine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Eight	eight	NUM	CD	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
10	10	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
complete	complete	ADJ	JJ	9	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
BAEP	BAEP	PROPN	NNP	5	O
waveforms	waveform	NOUN	NNS	5	O
within	within	ADP	IN	9	O
10	10	NUM	CD	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
no	no	DET	DT	9	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
later	later	ADJ	JJ	9	O
waves	wave	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
delayed	delay	VERB	VBN	9	O
profound	profound	ADJ	JJ	9	O
sensorineural	sensorineural	ADJ	JJ	5	B-Disease
hearing	hearing	NOUN	NN	5	I-Disease
loss	loss	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
average	average	ADJ	JJ	5	O
recovery	recovery	NOUN	NN	9	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
BAEP	BAEP	PROPN	NNP	5	O
waveforms	waveform	NOUN	NNS	5	O
to	to	PART	TO	5	O
pre	pre	VERB	VB	9	O
-	-	VERB	VB	7	O
papaverine	papaverine	ADJ	JJ	0	B-Chemical
baseline	baseline	NOUN	NN	5	O
values	value	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
39	39	NUM	CD	7	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Topical	topical	ADJ	JJ	0	O
papaverine	papaverine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
vasospasm	vasospasm	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
transient	transient	ADJ	JJ	9	O
disturbance	disturbance	NOUN	NN	5	O
in	in	ADP	IN	5	O
neurophysiological	neurophysiological	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ascending	ascend	VERB	VBG	5	O
auditory	auditory	NOUN	NN	5	O
brainstem	brainstem	NOUN	NN	5	O
pathway	pathway	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
complete	complete	ADJ	JJ	9	O
disappearance	disappearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
BAEP	BAEP	PROPN	NNP	5	O
waveforms	waveform	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
consistent	consistent	ADJ	JJ	9	O
temporal	temporal	ADJ	JJ	5	O
delay	delay	NOUN	NN	5	O
suggests	suggest	VERB	VBZ	9	O
a	a	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	B-Disease
effect	effect	NOUN	NN	9	I-Disease
on	on	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
proximal	proximal	ADJ	JJ	9	I-Disease
eighth	eighth	ADJ	JJ	5	I-Disease
nerve	nerve	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Recommendations	recommendation	NOUN	NNS	5	O
to	to	PART	TO	5	O
avoid	avoid	VERB	VB	5	O
potential	potential	ADJ	JJ	9	O
cranial	cranial	ADJ	JJ	5	B-Disease
nerve	nerve	NOUN	NN	5	I-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
from	from	ADP	IN	9	O
papaverine	papaverine	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
provided	provide	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Simvastatin	simvastatin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ezetimibe	ezetimibe	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
necessitating	necessitate	VERB	VBG	5	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Abstract	Abstract	PROPN	NNP	2	O
Serum	Serum	PROPN	NNP	9	O
aminotransferase	aminotransferase	NOUN	NN	7	O
elevations	elevation	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
a	a	DET	DT	5	O
commonly	commonly	ADV	RB	5	O
known	know	VERB	VBN	9	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hydroxy	hydroxy	NUM	CD	0	O
-	-	PUNCT	HYPH	7	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
methylglutaryl	methylglutaryl	NOUN	NN	1	O
coenzyme	coenzyme	NOUN	NN	0	O
A	a	DET	DT	9	O
reductase	reductase	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
statin	statin	NOUN	NN	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
hepatotoxic	hepatotoxic	ADJ	JJ	0	B-Disease
events	event	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
widely	widely	ADV	RB	5	O
published	publish	VERB	VBN	9	O
with	with	ADP	IN	5	O
ezetimibe	ezetimibe	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
agent	agent	NOUN	NN	9	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ezetimibe	ezetimibe	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
a	a	DET	DT	5	O
70	70	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
Hispanic	hispanic	ADJ	JJ	7	O
woman	woman	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
fulminant	fulminant	ADJ	JJ	5	B-Disease
hepatic	hepatic	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
necessitating	necessitate	VERB	VBG	5	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
10	10	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
conversion	conversion	NOUN	NN	9	O
from	from	ADP	IN	9	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
to	to	PART	TO	5	O
simvastatin	simvastatin	VERB	VB	0	B-Chemical
10	10	NUM	CD	9	I-Chemical
mg	mg	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ezetimibe	ezetimibe	VERB	VB	0	I-Chemical
40	40	NUM	CD	9	I-Chemical
mg	mg	NOUN	NN	0	I-Chemical
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
lipid	lipid	NOUN	NN	0	O
panel	panel	NOUN	NN	3	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
maintained	maintain	VERB	VBN	9	O
with	with	ADP	IN	5	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
18	18	NUM	CD	7	O
months	month	NOUN	NNS	5	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
conversion	conversion	NOUN	NN	9	O
without	without	ADP	IN	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
routine	routine	ADJ	JJ	5	O
laboratory	laboratory	NOUN	NN	9	O
work	work	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
10	10	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
conversion	conversion	NOUN	NN	9	O
revealed	reveal	VERB	VBD	9	O
elevated	elevate	VERB	VBD	9	O
serum	serum	NOUN	NN	9	O
aminotransferase	aminotransferase	NOUN	NN	7	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Simvastatinezetimibe	Simvastatinezetimibe	PROPN	NNP	_	B-Chemical
and	and	CCONJ	CC	5	O
escitalopram	escitalopram	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
which	which	DET	WDT	5	O
she	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
taking	take	VERB	VBG	5	O
for	for	ADP	IN	5	O
depression	depression	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
potential	potential	ADJ	JJ	9	O
causes	cause	NOUN	NNS	9	O
of	of	ADP	IN	5	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
were	be	VERB	VBD	9	O
excluded	exclude	VERB	VBN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
repeat	repeat	NOUN	NN	9	O
work	work	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
further	further	ADJ	JJ	9	O
elevations	elevation	NOUN	NNS	9	O
in	in	ADP	IN	5	O
aminotransferase	aminotransferase	NOUN	NN	7	O
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
liver	liver	NOUN	NN	9	O
biopsy	biopsy	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
moderate	moderate	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
severe	severe	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
underwent	undergo	VERB	VBD	5	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
uneventful	uneventful	ADJ	JJ	5	O
postoperative	postoperative	ADJ	JJ	5	O
course	course	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Her	-PRON-	DET	PRP$	5	O
aminotransferase	aminotransferase	NOUN	NN	7	O
levels	level	NOUN	NNS	3	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
by	by	ADP	IN	9	O
postoperative	postoperative	ADJ	JJ	5	O
day	day	NOUN	NN	9	O
23	23	NUM	CD	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
her	-PRON-	DET	PRP$	5	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
no	no	DET	DT	9	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Ezetimibe	ezetimibe	NOUN	NN	0	B-Chemical
undergoes	undergoe	NOUN	NNS	9	O
extensive	extensive	ADJ	JJ	5	O
glucuronidation	glucuronidation	NOUN	NN	0	O
by	by	ADP	IN	9	O
uridine	uridine	ADJ	JJ	0	B-Chemical
diphosphate	diphosphate	NOUN	NN	0	I-Chemical
glucoronosyltransferases	glucoronosyltransferase	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
UGT	UGT	PROPN	NNP	1	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
intestine	intestine	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
liver	liver	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
inhibited	inhibit	VERB	VBN	3	O
the	the	DET	DT	5	O
glucuronidation	glucuronidation	NOUN	NN	0	O
of	of	ADP	IN	5	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
hydroxy	hydroxy	NOUN	NN	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
subsequent	subsequent	ADJ	JJ	9	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
knowledge	knowledge	NOUN	NN	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ezetimibe	ezetimibe	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
liver	liver	NOUN	NN	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
that	that	DET	WDT	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
postulate	postulate	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
simvastatinezetimibe	simvastatinezetimibe	NOUN	NN	_	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
increased	increased	ADJ	JJ	9	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
exposure	exposure	NOUN	NN	9	O
by	by	ADP	IN	9	O
ezetimibe	ezetimibe	NOUN	NN	0	B-Chemical
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
UGT	UGT	PROPN	NNP	1	O
enzymes	enzyme	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

Clinicians	clinician	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
potential	potential	ADJ	JJ	9	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
with	with	ADP	IN	5	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ezetimibe	ezetimibe	NOUN	NN	0	I-Chemical
especially	especially	ADV	RB	5	O
in	in	ADP	IN	5	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
should	should	VERB	MD	5	O
carefully	carefully	ADV	RB	5	O
monitor	monitor	VERB	VB	5	O
serum	serum	NOUN	NN	9	O
aminotransferase	aminotransferase	NOUN	NN	7	O
levels	level	NOUN	NNS	3	O
when	when	ADV	WRB	5	O
starting	start	VERB	VBG	9	O
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
titrating	titrate	VERB	VBG	0	O
the	the	DET	DT	5	O
dosage	dosage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Massive	massive	ADJ	JJ	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
oral	oral	ADJ	JJ	9	O
bisphosphonate	bisphosphonate	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
alendronate	alendronate	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
administration	administration	NOUN	NN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
focal	focal	ADJ	JJ	5	B-Disease
segmental	segmental	ADJ	JJ	5	I-Disease
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
61	61	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
Japanese	japanese	ADJ	JJ	9	O
man	man	NOUN	NN	5	O
with	with	ADP	IN	5	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
focal	focal	ADJ	JJ	5	B-Disease
segmental	segmental	ADJ	JJ	5	I-Disease
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	I-Disease
was	be	VERB	VBD	9	O
initially	initially	ADV	RB	9	O
responding	respond	VERB	VBG	5	O
well	well	ADV	RB	9	O
to	to	PART	TO	5	O
steroid	steroid	VERB	VB	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
amount	amount	NOUN	NN	9	O
of	of	ADP	IN	5	O
daily	daily	ADJ	JJ	5	O
urinary	urinary	ADJ	JJ	9	O
protein	protein	NOUN	NN	1	O
decreased	decrease	VERB	VBD	9	O
from	from	ADP	IN	9	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
g	g	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Within	within	ADP	IN	9	O
14	14	NUM	CD	7	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
oral	oral	ADJ	JJ	9	O
bisphosphonate	bisphosphonate	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
alendronate	alendronate	NOUN	NN	0	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
amount	amount	NOUN	NN	9	O
of	of	ADP	IN	5	O
daily	daily	ADJ	JJ	5	O
urinary	urinary	ADJ	JJ	9	O
protein	protein	NOUN	NN	1	O
increased	increase	VERB	VBD	9	O
rapidly	rapidly	ADV	RB	9	O
up	up	ADP	IN	5	O
to	to	ADP	IN	5	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
g	g	NOUN	NN	0	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
discontinuing	discontinue	VERB	VBG	5	O
the	the	DET	DT	5	O
oral	oral	ADJ	JJ	9	O
alendronate	alendronate	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
underwent	undergo	VERB	VBD	5	O
six	six	NUM	CD	9	O
cycles	cycle	NOUN	NNS	9	O
of	of	ADP	IN	5	O
hemodialysis	hemodialysis	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
four	four	NUM	CD	9	O
cycles	cycle	NOUN	NNS	9	O
of	of	ADP	IN	5	O
LDL	LDL	PROPN	NNP	0	O
apheresis	apheresis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Urinary	urinary	ADJ	JJ	9	O
volume	volume	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
recovered	recover	VERB	VBD	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
urinary	urinary	ADJ	JJ	9	O
protein	protein	NOUN	NN	1	O
disappearing	disappear	VERB	VBG	5	O
completely	completely	ADV	RB	9	O
within	within	ADP	IN	9	O
40	40	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
report	report	NOUN	NN	5	O
demonstrates	demonstrate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
not	not	ADV	RB	5	O
only	only	ADV	RB	9	O
intravenous	intravenous	ADJ	JJ	0	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
also	also	ADV	RB	9	O
oral	oral	ADJ	JJ	9	O
bisphosphonates	bisphosphonate	NOUN	NNS	5	B-Chemical
can	can	VERB	MD	5	O
aggravate	aggravate	VERB	VB	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Serum	Serum	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
glucocorticoid	glucocorticoid	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
inducible	inducible	ADJ	JJ	3	O
kinase	kinase	NUM	CD	3	O
1	1	NUM	CD	9	O
in	in	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Doxorubicin	Doxorubicin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
leads	lead	VERB	VBZ	9	O
to	to	ADP	IN	5	O
epithelial	epithelial	ADJ	JJ	3	O
sodium	sodium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
ENaC	ENaC	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
volume	volume	NOUN	NN	9	B-Disease
retention	retention	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aldosterone	aldosterone	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
sensitive	sensitive	ADJ	JJ	9	O
serum	serum	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
glucocorticoid	glucocorticoid	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
inducible	inducible	ADJ	JJ	3	O
kinase	kinase	NOUN	NN	3	O
SGK1	SGK1	PROPN	NNP	3	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
participate	participate	VERB	VB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
ENaC	ENaC	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
mediate	mediate	VERB	VB	3	O
renal	renal	ADJ	JJ	9	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
following	follow	VERB	VBG	9	O
mineralocorticoid	mineralocorticoid	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
salt	salt	NOUN	NN	0	O
excess	excess	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
to	to	PART	TO	5	O
elucidate	elucidate	VERB	VB	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
SGK1	SGK1	PROPN	NNP	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
volume	volume	NOUN	NN	9	B-Disease
retention	retention	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
during	during	ADP	IN	5	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
this	this	DET	DT	5	O
end	end	NOUN	NN	9	O
,	,	PUNCT	,	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
mug	mug	NOUN	NN	5	O
/	/	SYM	SYM	9	O
g	g	NOUN	NN	0	O
body	body	NOUN	NN	5	O
wt	wt	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
intravenously	intravenously	ADV	RB	0	O
into	into	ADP	IN	9	O
gene	gene	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
targeted	target	VERB	VBN	9	O
mice	mouse	NOUN	NNS	3	O
lacking	lack	VERB	VBG	1	O
SGK1	SGK1	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
sgk1	sgk1	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
wild	wild	ADJ	JJ	1	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
littermates	littermate	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
sgk1	sgk1	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
+	+	X	XX	9	O
/	/	SYM	SYM	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Doxorubicin	Doxorubicin	PROPN	NNP	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
heavy	heavy	ADJ	JJ	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
protein	protein	NOUN	NN	1	O
/	/	SYM	SYM	9	O
mg	mg	NOUN	NN	0	O
crea	crea	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
15	15	NUM	CD	9	O
/	/	SYM	SYM	9	O
44	44	NUM	CD	7	O
of	of	ADP	IN	5	O
sgk1	sgk1	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
+	+	X	XX	9	O
/	/	SYM	SYM	9	O
+	+	X	XX	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
15	15	NUM	CD	9	O
/	/	SYM	SYM	9	O
44	44	NUM	CD	7	O
of	of	ADP	IN	5	O
sgk1	sgk1	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
ascites	ascite	NOUN	NNS	3	B-Disease
,	,	PUNCT	,	9	O
lipidemia	lipidemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
hypoalbuminemia	hypoalbuminemia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
genotypes	genotype	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Plasma	plasma	NOUN	NN	0	O
aldosterone	aldosterone	NOUN	NN	9	B-Chemical
levels	level	NOUN	NNS	3	O
increased	increase	VERB	VBD	9	O
in	in	ADP	IN	5	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
mice	mouse	NOUN	NNS	3	O
of	of	ADP	IN	5	O
both	both	CCONJ	CC	9	O
genotypes	genotype	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
increased	increase	VERB	VBN	9	O
SGK1	SGK1	PROPN	NNP	3	O
protein	protein	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
sgk1	sgk1	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
+	+	X	XX	9	O
/	/	SYM	SYM	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Urinary	urinary	ADJ	JJ	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
excretion	excretion	NOUN	NN	0	O
reached	reach	VERB	VBD	9	O
signficantly	signficantly	ADV	RB	3	O
lower	low	ADJ	JJR	9	O
values	value	NOUN	NNS	5	O
in	in	ADP	IN	5	O
sgk1	sgk1	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
+	+	X	XX	9	O
/	/	SYM	SYM	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
mumol	mumol	NOUN	NN	7	O
/	/	SYM	SYM	9	O
mg	mg	NOUN	NN	0	O
crea	crea	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
sgk1	sgk1	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
35	35	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
mumol	mumol	NOUN	NN	7	O
/	/	SYM	SYM	9	O
mg	mg	NOUN	NN	0	O
crea	crea	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	B-Disease
gain	gain	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
sgk1	sgk1	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
+	+	X	XX	9	O
/	/	SYM	SYM	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
sgk1	sgk1	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
+	+	CCONJ	CC	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
g	g	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
the	the	DET	DT	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
serum	serum	ADV	RB	9	O
urea	urea	ADJ	JJ	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
increased	increase	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
faster	faster	ADV	RBR	5	O
in	in	ADP	IN	5	O
sgk1	sgk1	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
sgk1	sgk1	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
+	+	X	XX	9	O
/	/	SYM	SYM	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
uremia	uremia	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
reduced	reduced	ADJ	JJ	9	O
median	median	ADJ	JJ	9	O
survival	survival	NOUN	NN	9	O
in	in	ADP	IN	5	O
sgk1	sgk1	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
29	29	NUM	CD	7	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
40	40	NUM	CD	9	O
days	day	NOUN	NNS	9	O
in	in	ADP	IN	5	O
sgk1	sgk1	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
+	+	X	XX	9	O
/	/	SYM	SYM	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
gene	gene	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
targeted	target	VERB	VBN	9	O
mice	mouse	NOUN	NNS	3	O
lacking	lack	VERB	VBG	1	O
SGK1	SGK1	PROPN	NNP	3	O
showed	show	VERB	VBD	9	O
blunted	blunted	ADJ	JJ	9	O
volume	volume	NOUN	NN	9	B-Disease
retention	retention	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
yet	yet	CCONJ	CC	9	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
protected	protect	VERB	VBN	9	O
against	against	ADP	IN	9	O
renal	renal	ADJ	JJ	9	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
during	during	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Severe	severe	ADJ	JJ	9	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
haemolytic	haemolytic	ADJ	JJ	9	B-Disease
anaemia	anaemia	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
ciprofloxacin	ciprofloxacin	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
with	with	ADP	IN	5	O
fatal	fatal	ADJ	JJ	5	O
outcome	outcome	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Haematological	haematological	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
fatal	fatal	ADJ	JJ	5	O
outcome	outcome	NOUN	NN	5	O
are	be	VERB	VBP	5	O
rare	rare	ADJ	JJ	5	O
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
ciprofloxacin	ciprofloxacin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
30	30	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
old	old	ADJ	JJ	5	O
Caucasian	caucasian	ADJ	JJ	9	O
man	man	NOUN	NN	5	O
reported	report	VERB	VBD	9	O
with	with	ADP	IN	5	O
abdominal	abdominal	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
jaundice	jaundice	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
ciprofloxacin	ciprofloxacin	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
suspect	suspect	NOUN	NN	5	O
of	of	ADP	IN	5	O
urinary	urinary	ADJ	JJ	9	B-Disease
tract	tract	NOUN	NN	9	I-Disease
infection	infection	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
evaluations	evaluation	NOUN	NNS	5	O
suggested	suggest	VERB	VBD	9	O
an	an	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
haemolysis	haemolysis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
progressively	progressively	ADV	RB	9	O
developed	develop	VERB	VBD	5	O
petechiae	petechiae	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
purpura	purpura	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
thorax	thorax	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
lower	low	ADJ	JJR	9	O
limbs	limb	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
pharmacological	pharmacological	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
supportive	supportive	ADJ	JJ	5	O
interventions	intervention	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
laboratory	laboratory	NOUN	NN	9	O
parameters	parameter	NOUN	NNS	5	O
worsened	worsen	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
died	die	VERB	VBD	9	O
17	17	NUM	CD	7	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
admission	admission	NOUN	NN	5	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
accurate	accurate	ADJ	JJ	5	O
autopsy	autopsy	ADV	RB	5	O
revealed	reveal	VERB	VBD	9	O
most	most	ADJ	JJS	9	O
organs	organ	NOUN	NNS	9	O
with	with	ADP	IN	5	O
diffuse	diffuse	NOUN	NN	5	O
petechial	petechial	ADJ	JJ	5	O
haemorrhages	haemorrhage	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
bone	bone	NOUN	NN	5	B-Disease
marrow	marrow	NOUN	NN	3	I-Disease
depression	depression	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
thrombi	thrombi	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
microangiopathies	microangiopathie	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
arterial	arterial	ADJ	JJ	5	O
vessels	vessel	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Blood	blood	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
urine	urine	NOUN	NN	9	O
cultures	culture	NOUN	NNS	3	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
show	show	VERB	VB	9	O
any	any	DET	DT	5	O
bacterial	bacterial	ADJ	JJ	9	O
growth	growth	NOUN	NN	3	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
shows	show	VERB	VBZ	9	O
that	that	ADP	IN	5	O
ciprofloxacin	ciprofloxacin	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
precipitate	precipitate	VERB	VB	0	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
threatening	threaten	VERB	VBG	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
haemolytic	haemolytic	ADJ	JJ	9	B-Disease
anaemia	anaemia	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
even	even	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
early	early	ADJ	JJ	9	O
phases	phase	NOUN	NNS	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
without	without	ADP	IN	9	O
apparent	apparent	ADJ	JJ	9	O
previous	previous	ADJ	JJ	9	O
exposures	exposure	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
lipoic	lipoic	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
prevents	prevent	VERB	VBZ	9	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
neuropathy	neuropathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
study	study	NOUN	NN	9	O
investigates	investigate	VERB	VBZ	5	O
if	if	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
lipoic	lipoic	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
is	be	VERB	VBZ	5	O
neuroprotective	neuroprotective	ADJ	JJ	9	O
against	against	ADP	IN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
induced	induce	VERB	VBD	3	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
if	if	ADP	IN	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
plays	play	VERB	VBZ	9	O
a	a	DET	DT	5	O
critical	critical	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
toxic	toxic	ADJ	JJ	0	B-Disease
neurodegenerative	neurodegenerative	ADJ	JJ	9	I-Disease
cascade	cascade	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
if	if	ADP	IN	5	O
neuroprotective	neuroprotective	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
lipoic	lipoic	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
depend	depend	VERB	VBP	5	O
on	on	ADP	IN	5	O
mitochondria	mitochondria	ADJ	JJ	3	O
protection	protection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
used	use	VERB	VBD	5	O
an	an	DET	DT	5	O
in	in	ADP	IN	5	O
vitro	vitro	X	FW	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
induced	induce	VERB	VBD	3	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
that	that	DET	WDT	5	O
closely	closely	ADV	RB	9	O
mimic	mimic	VERB	VB	9	O
the	the	DET	DT	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
condition	condition	NOUN	NN	5	O
by	by	ADP	IN	9	O
exposing	expose	VERB	VBG	9	O
primary	primary	ADJ	JJ	9	O
cultures	culture	NOUN	NNS	3	O
of	of	ADP	IN	5	O
dorsal	dorsal	ADJ	JJ	5	O
root	root	NOUN	NN	5	O
ganglion	ganglion	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
DRG	DRG	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
sensory	sensory	ADJ	JJ	5	O
neurons	neuron	NOUN	NNS	3	O
to	to	PART	TO	5	O
paclitaxel	paclitaxel	VERB	VB	0	B-Chemical
and	and	CCONJ	CC	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
two	two	NUM	CD	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
highly	highly	ADV	RB	9	O
effective	effective	ADJ	JJ	5	O
chemotherapeutic	chemotherapeutic	ADJ	JJ	3	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
approach	approach	NOUN	NN	5	O
allowed	allow	VERB	VBD	9	O
investigating	investigate	VERB	VBG	5	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
lipoic	lipoic	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
preventing	prevent	VERB	VBG	9	O
axonal	axonal	ADJ	JJ	3	B-Disease
damage	damage	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
apoptosis	apoptosis	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
ultrastructural	ultrastructural	ADJ	JJ	9	O
morphology	morphology	NOUN	NN	9	O
of	of	ADP	IN	5	O
mitochondria	mitochondria	NOUN	NN	3	O
after	after	ADP	IN	9	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
toxic	toxic	ADJ	JJ	0	O
agents	agent	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
lipoic	lipoic	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
demonstrate	demonstrate	VERB	VBP	9	O
that	that	ADP	IN	5	O
both	both	CCONJ	CC	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
paclitaxel	paclitaxel	ADJ	JJ	0	B-Chemical
cause	cause	NOUN	NN	5	O
early	early	ADJ	JJ	9	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
membrane	membrane	NOUN	NN	9	O
potential	potential	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
autophagic	autophagic	ADJ	JJ	3	O
vacuoles	vacuole	NOUN	NNS	9	O
in	in	ADP	IN	5	O
neurons	neuron	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
lipoic	lipoic	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
exerts	exert	VERB	VBZ	9	O
neuroprotective	neuroprotective	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
against	against	ADP	IN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
induced	induce	VERB	VBD	3	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
sensory	sensory	ADJ	JJ	5	O
neurons	neuron	NOUN	NNS	3	O
:	:	PUNCT	:	9	O
it	-PRON-	PRON	PRP	5	O
rescues	rescue	VERB	VBZ	3	O
the	the	DET	DT	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
induces	induce	VERB	VBZ	3	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
frataxin	frataxin	NOUN	NN	1	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
essential	essential	ADJ	JJ	9	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
protein	protein	NOUN	NN	1	O
with	with	ADP	IN	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
oxidant	oxidant	ADJ	JJ	0	O
and	and	CCONJ	CC	5	O
chaperone	chaperone	NOUN	NN	1	O
properties	property	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
mitochondrial	mitochondrial	ADJ	JJ	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
early	early	ADJ	JJ	9	O
common	common	ADJ	JJ	5	O
event	event	NOUN	NN	5	O
both	both	CCONJ	CC	9	O
in	in	ADP	IN	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
induced	induced	ADJ	JJ	3	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
lipoic	lipoic	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
protects	protect	VERB	VBZ	3	O
sensory	sensory	ADJ	JJ	5	O
neurons	neuron	NOUN	NNS	3	O
through	through	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
oxidant	oxidant	ADJ	JJ	0	O
and	and	CCONJ	CC	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
regulatory	regulatory	ADJ	JJ	1	O
functions	function	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
possibly	possibly	ADV	RB	9	O
inducing	induce	VERB	VBG	3	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
frataxin	frataxin	NOUN	NN	1	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
lipoic	lipoic	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
might	may	VERB	MD	9	O
reduce	reduce	VERB	VB	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
nerve	nerve	NOUN	NN	5	I-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
encourage	encourage	VERB	VB	5	O
further	further	ADJ	JJ	9	O
confirmatory	confirmatory	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Toxicity	toxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
rhesus	rhesus	ADJ	JJ	9	O
monkeys	monkey	NOUN	NNS	5	O
following	follow	VERB	VBG	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
8	8	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminoquinoline	aminoquinoline	NOUN	NN	0	I-Chemical
8	8	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
amino	amino	NOUN	NN	1	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
l	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methylbutyl	methylbutyl	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
amino	amino	NOUN	NN	1	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5	5	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
l	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hexyloxy	hexyloxy	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
6	6	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methoxy	methoxy	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methylquinoline	methylquinoline	NOUN	NN	_	I-Chemical
(	(	PUNCT	-LRB-	9	O
WR242511	WR242511	PROPN	NNP	_	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

INTRODUCTION	introduction	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Many	many	ADJ	JJ	5	O
substances	substance	NOUN	NNS	0	O
that	that	DET	WDT	5	O
form	form	VERB	VBP	9	O
methemoglobin	methemoglobin	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
MHb	MHb	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
effectively	effectively	ADV	RB	5	O
counter	counter	VERB	VBP	5	O
cyanide	cyanide	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
CN	CN	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
MHb	MHb	PROPN	NNP	3	O
formers	former	NOUN	NNS	0	O
are	be	VERB	VBP	5	O
generally	generally	ADV	RB	5	O
applied	apply	VERB	VBN	5	O
as	as	ADP	IN	5	O
treatments	treatment	NOUN	NNS	9	O
for	for	ADP	IN	5	O
CN	CN	PROPN	NNP	9	O
poisoning	poisoning	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
proposed	propose	VERB	VBN	5	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
stable	stable	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
long	long	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
acting	act	VERB	VBG	9	O
MHb	MHb	NOUN	NNS	3	O
former	former	ADJ	JJ	5	O
could	could	VERB	MD	9	O
serve	serve	VERB	VB	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
CN	CN	PROPN	NNP	9	O
pretreatment	pretreatment	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Using	use	VERB	VBG	9	O
this	this	DET	DT	5	O
rationale	rationale	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
8	8	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminoquinoline	aminoquinoline	NOUN	NN	0	I-Chemical
WR242511	wr242511	NOUN	NN	_	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
potent	potent	ADJ	JJ	3	O
long	long	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
lasting	last	VERB	VBG	5	O
MHb	MHb	NOUN	NNS	3	O
former	former	ADJ	JJ	5	O
in	in	ADP	IN	5	O
rodents	rodent	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
beagle	beagle	VERB	VB	0	O
dogs	dog	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rhesus	rhesus	ADJ	JJ	9	O
monkey	monkey	NOUN	NN	9	O
for	for	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
development	development	NOUN	NN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
CN	CN	PROPN	NNP	9	O
pretreatment	pretreatment	NOUN	NN	0	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
WR242511	WR242511	PROPN	NNP	_	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
intravenously	intravenously	ADV	RB	0	O
(	(	PUNCT	-LRB-	9	O
IV	IV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
female	female	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
male	male	NOUN	NN	9	O
rhesus	rhesus	NOUN	NN	9	O
monkeys	monkey	NOUN	NNS	5	O
in	in	ADP	IN	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
7	7	NUM	CD	9	O
.	.	NOUN	NN	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
;	;	PUNCT	:	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
male	male	NOUN	NN	9	O
also	also	ADV	RB	9	O
received	receive	VERB	VBD	9	O
WR242511	wr242511	NOUN	NN	_	B-Chemical
orally	orally	ADV	RB	0	O
(	(	PUNCT	-LRB-	9	O
PO	PO	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
7	7	NUM	CD	9	O
.	.	NOUN	NN	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Health	health	NOUN	NN	2	O
status	status	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
MHb	MHb	PROPN	NNP	3	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
monitored	monitor	VERB	VBN	9	O
following	follow	VERB	VBG	9	O
exposure	exposure	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
selected	select	VERB	VBN	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
WR242511	wr242511	NOUN	NN	_	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
produced	produce	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
methemoglobinemia	methemoglobinemia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
beagle	beagle	NOUN	NN	0	O
dogs	dog	NOUN	NNS	5	O
in	in	ADP	IN	5	O
earlier	early	ADJ	JJR	9	O
studies	study	NOUN	NNS	9	O
conducted	conduct	VERB	VBN	9	O
elsewhere	elsewhere	ADV	RB	9	O
,	,	PUNCT	,	9	O
produced	produce	VERB	VBD	9	O
very	very	ADV	RB	5	O
little	little	ADJ	JJ	9	O
MHb	MHb	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
<	<	X	XX	0	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rhesus	rhesus	ADJ	JJ	9	O
monkey	monkey	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
transient	transient	ADJ	JJ	9	O
hemoglobinuria	hemoglobinuria	NOUN	NN	3	B-Disease
was	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
approximately	approximately	ADV	RB	9	O
60	60	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
postinjection	postinjection	NOUN	NN	0	O
of	of	ADP	IN	5	O
WR242511	WR242511	PROPN	NNP	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
or	or	CCONJ	CC	5	O
7	7	NUM	CD	9	O
.	.	NOUN	NN	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
lethalities	lethality	NOUN	NNS	3	O
occurred	occur	VERB	VBD	9	O
(	(	PUNCT	-LRB-	9	O
one	one	NUM	CD	5	O
IV	iv	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
one	one	NUM	CD	5	O
PO	po	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
7	7	NUM	CD	9	O
.	.	NOUN	NN	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Myoglobinuria	Myoglobinuria	PROPN	NNP	7	B-Disease
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
observed	observe	VERB	VBN	9	O
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
7	7	NUM	CD	9	O
.	.	NOUN	NN	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Histopathology	histopathology	NOUN	NN	9	O
analyses	analyse	VERB	VBZ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
2	2	NUM	CD	9	O
animals	animal	NOUN	NNS	9	O
that	that	DET	WDT	5	O
died	die	VERB	VBD	9	O
revealed	reveal	VERB	VBN	9	O
liver	liver	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	I-Disease
kidney	kidney	NOUN	NN	9	I-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
greater	great	ADJ	JJR	5	O
severity	severity	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
orally	orally	ADV	RB	0	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
animal	animal	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
demonstrate	demonstrate	VERB	VBP	9	O
direct	direct	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
indirect	indirect	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
WR242511	wr242511	NOUN	NN	_	B-Chemical
should	should	VERB	MD	5	O
not	not	ADV	RB	5	O
be	be	VERB	VB	5	O
pursued	pursue	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
pretreatment	pretreatment	NOUN	NN	0	O
for	for	ADP	IN	5	O
CN	CN	PROPN	NNP	9	O
poisoning	poisoning	NOUN	NN	5	B-Disease
unless	unless	ADP	IN	9	O
the	the	DET	DT	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
CN	cn	ADJ	JJ	9	O
characteristics	characteristic	NOUN	NNS	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
compound	compound	NOUN	NN	0	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
successfully	successfully	ADV	RB	5	O
dissociated	dissociate	VERB	VBN	3	O
from	from	ADP	IN	9	O
those	those	DET	DT	5	O
producing	produce	VERB	VBG	9	O
undesirable	undesirable	ADJ	JJ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Repetitive	repetitive	ADJ	JJ	5	O
transcranial	transcranial	ADJ	JJ	5	O
magnetic	magnetic	ADJ	JJ	0	O
stimulation	stimulation	NOUN	NN	3	O
for	for	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
,	,	PUNCT	,	9	O
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blinded	blinded	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
crossover	crossover	NOUN	NN	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
assessed	assess	VERB	VBD	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
"	"	PUNCT	``	5	O
real	real	ADJ	JJ	5	O
"	"	PUNCT	``	5	O
repetitive	repetitive	ADJ	JJ	5	O
transcranial	transcranial	ADJ	JJ	5	O
magnetic	magnetic	ADJ	JJ	0	O
stimulation	stimulation	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
rTMS	rTMS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
versus	versus	ADP	IN	9	O
"	"	PUNCT	``	5	O
sham	sham	ADJ	JJ	9	O
"	"	PUNCT	''	5	O
rTMS	rtms	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
placebo	placebo	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
peak	peak	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
PD	PD	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Ten	ten	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
PD	pd	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
prominent	prominent	ADJ	JJ	9	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
had	have	VERB	VBD	9	O
rTMS	rTMS	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
800	800	NUM	CD	0	O
pulses	pulse	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
1	1	NUM	CD	9	O
Hz	Hz	PROPN	NNP	5	O
rate	rate	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
delivered	deliver	VERB	VBN	5	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
motor	motor	NOUN	NN	5	O
cortex	cortex	NOUN	NN	5	O
for	for	ADP	IN	5	O
4	4	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
twice	twice	ADV	RB	9	O
,	,	PUNCT	,	9	O
once	once	ADP	IN	5	O
real	real	ADJ	JJ	5	O
stimuli	stimulus	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
once	once	ADV	RB	5	O
sham	sham	ADJ	JJ	9	O
stimulation	stimulation	NOUN	NN	3	O
were	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
;	;	PUNCT	:	9	O
evaluations	evaluation	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
done	do	VERB	VBN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
baseline	baseline	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
day	day	NOUN	NN	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
each	each	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
series	series	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Direct	direct	ADJ	JJ	9	O
comparison	comparison	NOUN	NN	9	O
between	between	ADP	IN	5	O
sham	sham	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
real	real	ADJ	JJ	5	O
rTMS	rtms	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
clinician	clinician	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
assessed	assess	VERB	VBN	9	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
severity	severity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
comparison	comparison	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
baseline	baseline	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
small	small	ADJ	JJ	9	O
but	but	CCONJ	CC	9	O
significant	significant	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
severity	severity	NOUN	NN	5	O
following	follow	VERB	VBG	9	O
real	real	ADJ	JJ	5	O
rTMS	rtms	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
placebo	placebo	VERB	VB	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
major	major	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
on	on	ADP	IN	5	O
dystonia	dystonia	NOUN	NN	5	B-Disease
subscore	subscore	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Similarly	similarly	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
patient	patient	ADJ	JJ	5	O
diaries	diary	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
both	both	DET	DT	9	O
treatments	treatment	NOUN	NNS	9	O
caused	cause	VERB	VBD	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
subjective	subjective	ADJ	JJ	5	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
scores	score	NOUN	NNS	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
intervention	intervention	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
sustained	sustain	VERB	VBN	5	O
for	for	ADP	IN	5	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
intervention	intervention	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
real	real	ADJ	JJ	5	O
rTMS	rTMS	PROPN	NNP	5	O
only	only	ADV	RB	9	O
.	.	PUNCT	.	9	O

Following	follow	VERB	VBG	9	O
rTMS	rtms	NOUN	NN	5	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
motor	motor	NOUN	NN	5	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
PD	pd	NOUN	NN	9	B-Disease
symptoms	symptom	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
the	the	DET	DT	5	O
existence	existence	NOUN	NN	9	O
of	of	ADP	IN	5	O
residual	residual	ADJ	JJ	9	O
beneficial	beneficial	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
aftereffects	aftereffect	NOUN	NNS	5	O
of	of	ADP	IN	5	O
consecutive	consecutive	ADJ	JJ	5	O
daily	daily	ADJ	JJ	5	O
applications	application	NOUN	NNS	5	O
of	of	ADP	IN	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
frequency	frequency	NOUN	NN	5	O
rTMS	rtms	NOUN	NN	5	O
on	on	ADP	IN	5	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
PD	PD	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
further	further	ADV	RBR	9	O
exploited	exploit	VERB	VBN	5	O
for	for	ADP	IN	5	O
potential	potential	ADJ	JJ	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
uses	use	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Intracavernous	intracavernous	ADJ	JJ	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
minimally	minimally	ADV	RB	5	O
invasive	invasive	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
priapism	priapism	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
emergency	emergency	NOUN	NN	5	O
department	department	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Priapism	priapism	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
prolonged	prolonged	ADJ	JJ	9	O
erection	erection	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
penis	penis	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
sexual	sexual	ADJ	JJ	5	O
arousal	arousal	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
45	45	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
admitted	admit	VERB	VBN	5	O
frequent	frequent	ADJ	JJ	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
user	user	NOUN	NN	5	O
,	,	PUNCT	,	9	O
presented	present	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
Emergency	Emergency	PROPN	NNP	2	O
Department	Department	PROPN	NNP	2	O
(	(	PUNCT	-LRB-	9	O
ED	ED	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
two	two	NUM	CD	5	O
separate	separate	ADJ	JJ	9	O
occasions	occasion	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
priapism	priapism	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
management	management	NOUN	NN	5	O
options	option	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ED	ED	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
exemplified	exemplify	VERB	VBN	9	O
by	by	ADP	IN	9	O
four	four	NUM	CD	9	O
individual	individual	ADJ	JJ	5	O
case	case	NOUN	NN	5	O
reports	report	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
particular	particular	ADJ	JJ	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
minimally	minimally	ADV	RB	5	O
invasive	invasive	ADJ	JJ	5	O
method	method	NOUN	NN	5	O
of	of	ADP	IN	5	O
intracorporal	intracorporal	ADJ	JJ	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
instillation	instillation	NOUN	NN	0	O
,	,	PUNCT	,	9	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Prophylactic	prophylactic	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
rheumatologic	rheumatologic	NOUN	NN	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
objective	objective	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
report	report	VERB	VB	5	O
our	-PRON-	DET	PRP$	5	O
experience	experience	NOUN	NN	5	O
concerning	concern	VERB	VBG	5	O
the	the	DET	DT	5	O
effectiveness	effectiveness	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
prophylactic	prophylactic	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
hepatitis	hepatitis	PROPN	NNP	9	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
virus	virus	NOUN	NN	9	I-Chemical
surface	surface	NOUN	NN	9	I-Chemical
antigen	antigen	NOUN	NN	3	I-Chemical
(	(	PUNCT	-LRB-	9	O
HBs	HBs	PROPN	NNP	3	B-Chemical
Ag	Ag	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
positive	positive	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
rheumatologic	rheumatologic	NOUN	NN	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

From	from	ADP	IN	5	O
June	June	PROPN	NNP	2	O
2004	2004	NUM	CD	2	O
to	to	ADP	IN	5	O
October	October	PROPN	NNP	2	O
2006	2006	NUM	CD	2	O
,	,	PUNCT	,	9	O
11	11	NUM	CD	7	O
HBs	hb	NOUN	NNS	3	B-Chemical
Ag	Ag	PROPN	NNP	0	I-Chemical
positive	positive	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
rheumatologic	rheumatologic	NOUN	NN	5	B-Disease
diseases	disease	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
on	on	ADP	IN	5	O
both	both	CCONJ	CC	9	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
prophylactic	prophylactic	ADJ	JJ	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
therapies	therapy	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
retrospectively	retrospectively	ADV	RB	5	O
assessed	assessed	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Liver	liver	NOUN	NN	9	O
function	function	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
hepatitis	hepatitis	PROPN	NNP	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
virus	virus	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
HBV	HBV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
serologic	serologic	ADJ	JJ	9	O
markers	marker	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
HBV	HBV	PROPN	NNP	9	O
DNA	DNA	PROPN	NNP	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
during	during	ADP	IN	5	O
follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
were	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
from	from	ADP	IN	9	O
hospital	hospital	NOUN	NN	5	O
file	file	NOUN	NN	9	O
records	record	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Eleven	eleven	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
six	six	NUM	CD	9	O
male	male	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
median	median	ADJ	JJ	9	O
age	age	NOUN	NN	5	O
47	47	NUM	CD	7	O
years	year	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
range	range	VERB	VB	9	O
27	27	NUM	CD	7	O
-	-	SYM	SYM	7	O
73	73	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
median	median	ADJ	JJ	9	O
disease	disease	NOUN	NN	5	O
duration	duration	NOUN	NN	5	O
50	50	NUM	CD	0	O
months	month	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
range	range	VERB	VB	9	O
9	9	NUM	CD	7	O
-	-	SYM	SYM	7	O
178	178	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
median	median	ADJ	JJ	9	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
months	month	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
range	range	VERB	VB	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
27	27	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
enrolled	enrol	VERB	VBN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Lamivudine	Lamivudine	PROPN	NNP	7	B-Chemical
therapy	therapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
started	start	VERB	VBN	5	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Baseline	Baseline	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
liver	liver	NOUN	NN	9	O
function	function	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
elevated	elevate	VERB	VBN	9	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
fourth	fourth	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
:	:	PUNCT	:	9	O
ALT	ALT	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
122	122	NUM	CD	7	O
IU	IU	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
l	l	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
AST	AST	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
111	111	NUM	CD	7	O
IU	IU	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
l	l	NOUN	NN	0	O
,	,	PUNCT	,	9	O
tenth	tenth	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
:	:	PUNCT	:	9	O
ALT	ALT	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
294	294	NUM	CD	7	O
IU	IU	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
l	l	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
AST	AST	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
274	274	NUM	CD	7	O
IU	IU	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
l	l	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
minimal	minimal	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
biopsy	biopsy	NOUN	NN	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Shortly	shortly	ADV	RB	9	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
their	-PRON-	DET	PRP$	5	O
tests	test	NOUN	NNS	5	O
normalized	normalize	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
during	during	ADP	IN	5	O
follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
period	period	NOUN	NN	5	O
none	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
abnormal	abnormal	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
function	function	NOUN	NN	9	I-Disease
tests	test	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
HBV	HBV	PROPN	NNP	9	O
DNA	DNA	PROPN	NNP	9	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
normalized	normalize	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
others	other	NOUN	NNS	5	O
increased	increase	VERB	VBD	9	O
later	later	ADV	RB	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
three	three	NUM	CD	9	O
additional	additional	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
HBV	HBV	PROPN	NNP	9	O
DNA	DNA	PROPN	NNP	9	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
during	during	ADP	IN	5	O
follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
.	.	PUNCT	.	9	O

None	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
sings	sing	NOUN	NNS	5	O
of	of	ADP	IN	5	O
HBV	HBV	PROPN	NNP	9	O
activation	activation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Lamivudine	Lamivudine	PROPN	NNP	7	B-Chemical
was	be	VERB	VBD	9	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
continued	continue	VERB	VBN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Prophylactic	prophylactic	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
required	require	VERB	VBD	9	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
safe	safe	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
well	well	INTJ	UH	9	O
tolerated	tolerated	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
preventing	prevent	VERB	VBG	9	O
HBV	HBV	PROPN	NNP	9	O
reactivation	reactivation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
green	green	ADJ	JJ	9	B-Chemical
tea	tea	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
E	e	NOUN	NN	9	I-Chemical
combination	combination	NOUN	NN	9	O
in	in	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
aimed	aim	VERB	VBN	5	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
combined	combined	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
green	green	ADJ	JJ	9	B-Chemical
tea	tea	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
E	e	NOUN	NN	9	I-Chemical
on	on	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
,	,	PUNCT	,	9	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
,	,	PUNCT	,	9	O
serum	serum	ADJ	JJ	9	O
marker	marker	NOUN	NN	3	O
enzymes	enzyme	NOUN	NNS	1	O
,	,	PUNCT	,	9	O
lipid	lipid	NOUN	NN	0	O
peroxidation	peroxidation	NOUN	NN	0	O
,	,	PUNCT	,	9	O
endogenous	endogenous	ADJ	JJ	3	O
antioxidants	antioxidant	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
membrane	membrane	NOUN	NN	9	O
bound	bound	ADJ	JJ	9	O
ATPases	atpase	NOUN	NNS	1	O
in	in	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
ISO	ISO	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Adult	adult	ADJ	JJ	9	O
male	male	ADJ	JJ	9	O
albino	albino	NOUN	NN	3	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
ISO	ISO	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
s	s	X	XX	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
days	day	NOUN	NNS	9	O
at	at	ADP	IN	9	O
an	an	DET	DT	5	O
interval	interval	NOUN	NN	5	O
of	of	ADP	IN	5	O
24	24	NUM	CD	9	O
h	h	NOUN	NNS	0	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
,	,	PUNCT	,	9	O
serum	serum	ADJ	JJ	9	O
marker	marker	NOUN	NN	3	O
enzymes	enzyme	NOUN	NNS	1	O
,	,	PUNCT	,	9	O
lipid	lipid	NOUN	NN	0	O
peroxidation	peroxidation	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
Ca	ca	NOUN	NN	0	B-Chemical
+	+	CCONJ	CC	9	O
2	2	NUM	CD	9	O
ATPase	ATPase	PROPN	NNP	1	O
level	level	NOUN	NN	9	O
whereas	whereas	ADP	IN	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
,	,	PUNCT	,	9	O
endogenous	endogenous	ADJ	JJ	3	O
antioxidants	antioxidant	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
Na	Na	PROPN	NNP	0	B-Chemical
+	+	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
K	K	PROPN	NNP	9	B-Chemical
+	+	SYM	SYM	9	O
ATPase	ATPase	PROPN	NNP	1	O
and	and	CCONJ	CC	5	O
Mg	Mg	PROPN	NNP	0	B-Chemical
+	+	CCONJ	CC	9	O
2	2	NUM	CD	9	O
ATPase	ATPase	PROPN	NNP	1	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
green	green	ADJ	JJ	9	B-Chemical
tea	tea	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
E	e	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
together	together	ADV	RB	9	O
for	for	ADP	IN	5	O
30	30	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
challenged	challenge	VERB	VBN	3	O
with	with	ADP	IN	5	O
ISO	ISO	PROPN	NNP	0	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
day	day	NOUN	NN	9	O
29th	29th	NOUN	NN	2	O
and	and	CCONJ	CC	5	O
30th	30th	NOUN	NN	9	O
,	,	PUNCT	,	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
,	,	PUNCT	,	9	O
serum	serum	ADJ	JJ	9	O
marker	marker	NOUN	NN	3	O
enzymes	enzyme	NOUN	NNS	1	O
,	,	PUNCT	,	9	O
lipid	lipid	NOUN	NN	0	O
peroxidation	peroxidation	NOUN	NN	0	O
,	,	PUNCT	,	9	O
Ca	Ca	PROPN	NNP	0	B-Chemical
+	+	CCONJ	CC	9	O
2	2	NUM	CD	9	O
ATPase	ATPase	PROPN	NNP	1	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
,	,	PUNCT	,	9	O
endogenous	endogenous	ADJ	JJ	3	O
antioxidants	antioxidant	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
Na	Na	PROPN	NNP	0	B-Chemical
+	+	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
K	K	PROPN	NNP	9	B-Chemical
+	+	SYM	SYM	9	O
ATPase	ATPase	PROPN	NNP	1	O
and	and	CCONJ	CC	5	O
Mg	Mg	PROPN	NNP	0	B-Chemical
+	+	CCONJ	CC	9	O
2	2	NUM	CD	9	O
ATPase	ATPase	PROPN	NNP	1	O
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
ISO	ISO	PROPN	NNP	0	B-Chemical
treated	treat	VERB	VBN	3	O
group	group	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
green	green	ADJ	JJ	9	B-Chemical
tea	tea	NOUN	NN	0	I-Chemical
or	or	CCONJ	CC	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
E	E	NOUN	NNS	9	I-Chemical
alone	alone	ADV	RB	9	O
treated	treated	ADJ	JJ	3	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
the	the	DET	DT	5	O
synergistic	synergistic	ADJ	JJ	9	O
protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
green	green	ADJ	JJ	9	B-Chemical
tea	tea	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
E	e	NOUN	NN	9	I-Chemical
during	during	ADP	IN	5	O
ISO	ISO	PROPN	NNP	0	B-Chemical
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Irreversible	irreversible	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
medullary	medullary	ADJ	JJ	5	O
interstitium	interstitium	NOUN	NN	9	O
in	in	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
analgesic	analgesic	ADJ	JJ	5	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
F344	f344	NOUN	NN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	B-Disease
papillary	papillary	ADJ	JJ	5	I-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
RPN	RPN	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
decreased	decrease	VERB	VBN	9	O
urinary	urinary	ADJ	JJ	9	O
concentrating	concentrating	NOUN	NN	5	O
ability	ability	NOUN	NN	9	O
developed	develop	VERB	VBN	5	O
during	during	ADP	IN	5	O
continuous	continuous	ADJ	JJ	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
female	female	ADJ	JJ	9	O
Fischer	Fischer	PROPN	NNP	6	O
344	344	NUM	CD	7	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	O
structure	structure	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
concentrating	concentrating	NOUN	NN	5	O
ability	ability	NOUN	NN	9	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
recovery	recovery	NOUN	NN	9	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
18	18	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
no	no	DET	DT	9	O
analgesics	analgesic	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
,	,	PUNCT	,	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
whether	whether	ADP	IN	9	O
the	the	DET	DT	5	O
analgesic	analgesic	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
changes	change	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
reversible	reversible	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
repair	repair	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
damaged	damage	VERB	VBN	9	O
medullary	medullary	ADJ	JJ	5	O
interstitial	interstitial	ADJ	JJ	9	O
matrix	matrix	NOUN	NN	5	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
proliferation	proliferation	NOUN	NN	3	O
of	of	ADP	IN	5	O
remaining	remain	VERB	VBG	9	O
undamaged	undamaged	ADJ	JJ	9	O
type	type	NOUN	NN	9	O
1	1	NUM	CD	9	O
medullary	medullary	ADJ	JJ	5	O
interstitial	interstitial	ADJ	JJ	9	O
cells	cell	NOUN	NNS	3	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
recovery	recovery	NOUN	NN	9	O
period	period	NOUN	NN	5	O
following	follow	VERB	VBG	9	O
analgesic	analgesic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
urinary	urinary	ADJ	JJ	9	O
concentrating	concentrating	NOUN	NN	5	O
ability	ability	NOUN	NN	9	O
was	be	VERB	VBD	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
length	length	NOUN	NN	9	O
of	of	ADP	IN	5	O
analgesic	analgesic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
resulting	result	VERB	VBG	9	O
inner	inner	ADJ	JJ	9	O
medullary	medullary	ADJ	JJ	5	O
structural	structural	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
the	the	DET	DT	5	O
early	early	ADJ	JJ	9	O
stages	stage	NOUN	NNS	9	O
of	of	ADP	IN	5	O
analgesic	analgesic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
urinary	urinary	ADJ	JJ	9	O
concentrating	concentrating	NOUN	NN	5	O
ability	ability	NOUN	NN	9	O
were	be	VERB	VBD	9	O
reversible	reversible	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
after	after	ADP	IN	9	O
prolonged	prolong	VERB	VBN	9	O
analgesic	analgesic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
maximum	maximum	ADJ	JJ	5	O
urinary	urinary	ADJ	JJ	9	O
concentrating	concentrating	NOUN	NN	5	O
ability	ability	NOUN	NN	9	O
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
recover	recover	VERB	VB	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
shows	show	VERB	VBZ	9	O
that	that	ADP	IN	5	O
prolonged	prolong	VERB	VBN	9	O
analgesic	analgesic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
Fischer	Fischer	PROPN	NNP	6	O
344	344	NUM	CD	7	O
rats	rat	NOUN	NNS	9	O
causes	cause	VERB	VBZ	9	O
progressive	progressive	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
irreversible	irreversible	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
interstitial	interstitial	ADJ	JJ	9	O
matrix	matrix	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
type	type	NOUN	NN	9	O
1	1	NUM	CD	9	O
interstitial	interstitial	ADJ	JJ	9	O
cells	cell	NOUN	NNS	3	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
RPN	RPN	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
associated	associated	ADJ	JJ	9	O
urinary	urinary	ADJ	JJ	9	O
concentrating	concentrating	NOUN	NN	5	O
defect	defect	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
reversible	reversible	ADJ	JJ	9	O
only	only	ADV	RB	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
early	early	ADJ	JJ	9	O
stages	stage	NOUN	NNS	9	O
of	of	ADP	IN	5	O
structural	structural	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
inner	inner	ADJ	JJ	9	O
medulla	medulla	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Testosterone	testosterone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
upregulation	upregulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
intrarenal	intrarenal	ADJ	JJ	5	O
angiotensinogen	angiotensinogen	NOUN	NN	3	O
in	in	ADP	IN	5	O
Dahl	Dahl	PROPN	NNP	6	O
salt	salt	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
sensitive	sensitive	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
BP	BP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
more	more	ADJ	JJR	5	O
salt	salt	NOUN	NN	0	B-Chemical
sensitive	sensitive	ADJ	JJ	9	O
in	in	ADP	IN	5	O
men	man	NOUN	NNS	5	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
premenopausal	premenopausal	NOUN	NN	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
Dahl	Dahl	PROPN	NNP	6	O
salt	salt	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
sensitive	sensitive	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
DS	DS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
salt	salt	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
HS	HS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
diet	diet	NOUN	NN	9	O
increases	increase	VERB	VBZ	9	O
BP	BP	PROPN	NNP	9	O
more	more	ADV	RBR	5	O
in	in	ADP	IN	5	O
males	male	NOUN	NNS	9	O
than	than	ADP	IN	5	O
females	female	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
systemic	systemic	ADJ	JJ	9	O
renin	renin	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
system	system	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
suppressed	suppress	VERB	VBN	3	O
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
HS	h	NOUN	NNS	9	O
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
DS	DS	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
intrarenal	intrarenal	ADJ	JJ	5	O
angiotensinogen	angiotensinogen	NOUN	NN	3	O
expression	expression	NOUN	NN	3	O
is	be	VERB	VBZ	5	O
increased	increase	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
intrarenal	intrarenal	ADJ	JJ	5	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
ANG	ANG	PROPN	NNP	3	O
II	II	PROPN	NNP	9	O
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
suppressed	suppress	VERB	VBN	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
was	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
that	that	ADP	IN	5	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
sexual	sexual	ADJ	JJ	5	O
dimorphism	dimorphism	NOUN	NN	4	O
in	in	ADP	IN	5	O
HS	HS	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
upregulation	upregulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
intrarenal	intrarenal	ADJ	JJ	5	O
angiotensinogen	angiotensinogen	NOUN	NN	3	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
that	that	DET	WDT	5	O
also	also	ADV	RB	9	O
causes	cause	VERB	VBZ	9	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
BP	BP	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
a	a	DET	DT	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
salt	salt	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
LS	LS	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
diet	diet	NOUN	NN	9	O
,	,	PUNCT	,	9	O
male	male	ADJ	JJ	9	O
DS	DS	PROPN	NNP	9	O
had	have	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
intrarenal	intrarenal	ADJ	JJ	5	O
angiotensinogen	angiotensinogen	NOUN	NN	3	O
mRNA	mRNA	NOUN	NNS	3	O
than	than	ADP	IN	5	O
females	female	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

HS	HS	PROPN	NNP	9	O
diet	diet	NOUN	NN	9	O
for	for	ADP	IN	5	O
4	4	NUM	CD	9	O
wk	wk	ADP	IN	9	O
increased	increase	VERB	VBN	9	O
renal	renal	ADJ	JJ	9	O
cortical	cortical	ADJ	JJ	5	O
angiotensinogen	angiotensinogen	NOUN	NN	3	O
mRNA	mRNA	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
protein	protein	NOUN	NN	1	O
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
DS	DS	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
prevented	prevent	VERB	VBN	9	O
by	by	ADP	IN	9	O
castration	castration	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Ovariectomy	ovariectomy	NOUN	NN	3	O
of	of	ADP	IN	5	O
female	female	ADJ	JJ	9	O
DS	DS	PROPN	NNP	9	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
intrarenal	intrarenal	ADJ	JJ	5	O
angiotensinogen	angiotensinogen	NOUN	NN	3	O
expression	expression	NOUN	NN	3	O
on	on	ADP	IN	5	O
either	either	DET	DT	9	O
diet	diet	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Radiotelemetric	Radiotelemetric	PROPN	NNP	9	O
BP	BP	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
between	between	ADP	IN	5	O
males	male	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
castrated	castrate	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
on	on	ADP	IN	5	O
LS	LS	PROPN	NNP	9	O
diet	diet	NOUN	NN	9	O
.	.	PUNCT	.	9	O

HS	HS	PROPN	NNP	9	O
diet	diet	NOUN	NN	9	O
for	for	ADP	IN	5	O
4	4	NUM	CD	9	O
wk	wk	ADP	IN	9	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
progressive	progressive	ADJ	JJ	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
BP	BP	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
protein	protein	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
albumin	albumin	NOUN	NN	0	O
excretion	excretion	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
glomerular	glomerular	ADJ	JJ	5	B-Disease
sclerosis	sclerosis	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
DS	DS	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
attenuated	attenuate	VERB	VBN	3	O
by	by	ADP	IN	9	O
castration	castration	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Testosterone	testosterone	NOUN	NN	0	B-Chemical
replacement	replacement	NOUN	NN	9	O
in	in	ADP	IN	5	O
castrated	castrate	VERB	VBN	3	O
DS	DS	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
increased	increase	VERB	VBD	9	O
BP	BP	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
renal	renal	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
upregulation	upregulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
angiotensinogen	angiotensinogen	NOUN	NN	3	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
HS	HS	PROPN	NNP	9	O
diet	diet	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Testosterone	Testosterone	PROPN	NNP	0	B-Chemical
contributes	contribute	VERB	VBZ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
male	male	ADJ	JJ	9	O
DS	DS	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
on	on	ADP	IN	5	O
HS	HS	PROPN	NNP	9	O
diet	diet	NOUN	NN	9	O
possibly	possibly	ADV	RB	9	O
through	through	ADP	IN	9	O
upregulation	upregulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
intrarenal	intrarenal	ADJ	JJ	5	O
renin	renin	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Explicit	explicit	ADJ	JJ	5	O
episodic	episodic	ADJ	JJ	5	O
memory	memory	NOUN	NN	5	O
for	for	ADP	IN	5	O
sensory	sensory	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
discriminative	discriminative	ADJ	JJ	5	O
components	component	NOUN	NNS	5	O
of	of	ADP	IN	5	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
pain	pain	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
immediate	immediate	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
delayed	delay	VERB	VBN	9	O
ratings	rating	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Pain	Pain	PROPN	NNP	5	B-Disease
memory	memory	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
thought	think	VERB	VBN	5	O
to	to	PART	TO	5	O
affect	affect	VERB	VB	9	O
future	future	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
sensitivity	sensitivity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
thus	thus	ADV	RB	9	O
contribute	contribute	VERB	VB	9	O
to	to	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
conditions	condition	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Systematic	systematic	ADJ	JJ	5	O
investigations	investigation	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
human	human	ADJ	JJ	3	O
capacity	capacity	NOUN	NN	9	O
to	to	PART	TO	5	O
remember	remember	VERB	VB	5	O
sensory	sensory	ADJ	JJ	5	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
are	be	VERB	VBP	5	O
sparse	sparse	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
address	address	VERB	VB	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
pain	pain	NOUN	NN	5	B-Disease
memory	memory	NOUN	NN	5	O
,	,	PUNCT	,	9	O
nine	nine	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
male	male	ADJ	JJ	9	O
volunteers	volunteer	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
intradermal	intradermal	ADJ	JJ	9	O
injections	injection	NOUN	NNS	9	O
of	of	ADP	IN	5	O
three	three	NUM	CD	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
20	20	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
separated	separate	VERB	VBN	9	O
by	by	ADP	IN	9	O
15	15	NUM	CD	9	O
min	min	NOUN	NN	0	O
breaks	break	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
each	each	DET	DT	5	O
given	give	VERB	VBN	5	O
three	three	NUM	CD	9	O
times	time	NOUN	NNS	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
balanced	balanced	ADJ	JJ	5	O
design	design	NOUN	NN	5	O
across	across	ADP	IN	5	O
three	three	NUM	CD	9	O
sessions	session	NOUN	NNS	5	O
at	at	ADP	IN	9	O
one	one	NUM	CD	5	O
week	week	NOUN	NN	9	O
intervals	interval	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Pain	pain	NOUN	NN	5	B-Disease
rating	rating	NOUN	NN	5	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
computerized	computerized	ADJ	JJ	5	O
visual	visual	ADJ	JJ	5	O
analogue	analogue	NOUN	NN	0	O
scale	scale	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
100	100	NUM	CD	0	O
)	)	PUNCT	-RRB-	9	O
digitized	digitize	VERB	VBN	5	O
at	at	ADP	IN	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
s	s	NOUN	NN	9	O
,	,	PUNCT	,	9	O
either	either	CCONJ	CC	9	O
immediately	immediately	ADV	RB	9	O
online	online	ADV	RB	5	O
or	or	CCONJ	CC	5	O
one	one	NUM	CD	5	O
hour	hour	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
one	one	NUM	CD	5	O
day	day	NOUN	NN	9	O
after	after	ADP	IN	9	O
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Subjects	subject	NOUN	NNS	5	O
also	also	ADV	RB	9	O
recalled	recall	VERB	VBD	5	O
their	-PRON-	DET	PRP$	5	O
pains	pain	NOUN	NNS	5	B-Disease
one	one	NUM	CD	5	O
week	week	NOUN	NN	9	O
later	later	ADV	RB	9	O
.	.	PUNCT	.	9	O

Capsaicin	capsaicin	NOUN	NN	0	B-Chemical
injection	injection	NOUN	NN	9	O
reliably	reliably	ADV	RB	5	O
induced	induce	VERB	VBD	3	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
flare	flare	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
without	without	ADP	IN	9	O
any	any	DET	DT	5	O
difference	difference	NOUN	NN	9	O
within	within	ADP	IN	9	O
or	or	CCONJ	CC	5	O
across	across	ADP	IN	5	O
sessions	session	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
strong	strong	ADJ	JJ	9	O
burning	burn	VERB	VBG	5	O
pain	pain	NOUN	NN	5	B-Disease
decayed	decay	VERB	VBD	5	O
exponentially	exponentially	ADV	RB	9	O
within	within	ADP	IN	9	O
a	a	DET	DT	5	O
few	few	ADJ	JJ	5	O
minutes	minute	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Subjects	subject	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
able	able	ADJ	JJ	9	O
to	to	PART	TO	5	O
reliably	reliably	ADV	RB	5	O
discriminate	discriminate	VERB	VB	5	O
pain	pain	NOUN	NN	5	B-Disease
magnitude	magnitude	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
duration	duration	NOUN	NN	5	O
across	across	ADP	IN	5	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
doses	dose	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
both	both	CCONJ	CC	9	O
p	p	NOUN	NNS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
regardless	regardless	ADV	RB	9	O
of	of	ADP	IN	5	O
whether	whether	ADP	IN	9	O
first	first	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
time	time	NOUN	NN	5	O
ratings	rating	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
requested	request	VERB	VBN	5	O
immediately	immediately	ADV	RB	9	O
,	,	PUNCT	,	9	O
after	after	ADP	IN	9	O
one	one	NUM	CD	5	O
hour	hour	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
after	after	ADP	IN	9	O
one	one	NUM	CD	5	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Pain	pain	NOUN	NN	5	B-Disease
recall	recall	NOUN	NN	5	O
after	after	ADP	IN	9	O
one	one	NUM	CD	5	O
week	week	NOUN	NN	9	O
was	be	VERB	VBD	9	O
similarly	similarly	ADV	RB	9	O
precise	precise	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
magnitude	magnitude	NOUN	NN	5	O
:	:	PUNCT	:	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
,	,	PUNCT	,	9	O
duration	duration	NOUN	NN	5	O
:	:	PUNCT	:	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Correlation	correlation	NOUN	NN	9	O
with	with	ADP	IN	5	O
rating	rate	VERB	VBG	5	O
recall	recall	NOUN	NN	5	O
after	after	ADP	IN	9	O
one	one	NUM	CD	5	O
week	week	NOUN	NN	9	O
was	be	VERB	VBD	9	O
best	good	ADJ	JJS	5	O
when	when	ADV	WRB	5	O
first	first	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
time	time	NOUN	NN	5	O
ratings	rating	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
requested	request	VERB	VBN	5	O
as	as	ADV	RB	5	O
late	late	ADV	RB	9	O
as	as	ADP	IN	5	O
one	one	NUM	CD	5	O
day	day	NOUN	NN	9	O
after	after	ADP	IN	9	O
injection	injection	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
R	r	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
=	=	VERB	VBZ	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
79	79	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
indicating	indicate	VERB	VBG	9	O
that	that	ADP	IN	5	O
both	both	DET	DT	9	O
rating	rating	NOUN	NN	5	O
retrievals	retrieval	NOUN	NNS	5	O
utilized	utilize	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
memory	memory	NOUN	NN	5	O
traces	trace	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
a	a	DET	DT	5	O
reliable	reliable	ADJ	JJ	5	O
memory	memory	NOUN	NN	5	O
for	for	ADP	IN	5	O
magnitude	magnitude	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
experimentally	experimentally	ADV	RB	9	O
induced	induce	VERB	VBN	3	O
pain	pain	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
further	further	ADV	RB	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
consolidation	consolidation	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
memory	memory	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
interim	interim	ADJ	JJ	5	O
stage	stage	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
take	take	VERB	VB	5	O
up	up	ADV	RB	5	O
to	to	PART	TO	5	O
one	one	NUM	CD	5	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Severe	severe	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
long	long	ADJ	JJ	5	O
lasting	lasting	ADJ	JJ	5	O
cholestasis	cholestasis	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
co	co	NOUN	NN	9	B-Chemical
-	-	NOUN	NN	7	I-Chemical
trimoxazole	trimoxazole	ADJ	JJ	0	I-Chemical
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
Pneumocystis	Pneumocystis	PROPN	NNP	9	B-Disease
pneumonia	pneumonia	PROPN	NNP	5	I-Disease
in	in	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
infected	infect	VERB	VBN	3	I-Disease
patients	patient	NOUN	NNS	5	O
-	-	PUNCT	:	7	O
-	-	PUNCT	:	7	O
a	a	DET	DT	5	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Pneumocystis	Pneumocystis	PROPN	NNP	9	B-Disease
pneumonia	pneumonia	PROPN	NNP	5	I-Disease
(	(	PUNCT	-LRB-	9	O
PCP	PCP	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
common	common	ADJ	JJ	5	O
opportunistic	opportunistic	ADJ	JJ	5	B-Disease
infection	infection	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
infected	infect	VERB	VBN	3	I-Disease
individuals	individual	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
generally	generally	ADV	RB	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
co	co	NOUN	NN	9	B-Chemical
-	-	NOUN	NN	7	I-Chemical
trimoxazole	trimoxazole	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
treatment	treatment	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
often	often	ADV	RB	5	O
limited	limit	VERB	VBN	5	O
by	by	ADP	IN	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
report	report	VERB	VBP	5	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
severely	severely	ADV	RB	9	O
immunocompromised	immunocompromise	VERB	VBN	5	O
HIV	HIV	PROPN	NNP	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
infected	infect	VERB	VBN	3	I-Disease
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
severe	severe	ADJ	JJ	5	O
intrahepatic	intrahepatic	ADJ	JJ	9	B-Disease
cholestasis	cholestasis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
patient	patient	ADJ	JJ	5	O
lesions	lesion	NOUN	NNS	5	O
mimicking	mimic	VERB	VBG	9	O
liver	liver	NOUN	NN	9	B-Disease
abscess	abscess	NOUN	NN	5	I-Disease
formation	formation	NOUN	NN	9	O
on	on	ADP	IN	5	O
radiologic	radiologic	NOUN	NN	5	O
exams	exam	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
during	during	ADP	IN	5	O
co	co	NOUN	NN	9	B-Chemical
-	-	NOUN	NN	7	I-Chemical
trimoxazole	trimoxazole	ADJ	JJ	0	I-Chemical
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
PCP	PCP	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

Whereas	whereas	ADP	IN	9	O
patient	patient	NOUN	NN	5	O
1	1	NUM	CD	9	O
showed	show	VERB	VBD	9	O
lesions	lesion	NOUN	NNS	5	O
of	of	ADP	IN	5	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
1	1	NUM	CD	9	O
cm	cm	NOUN	NNS	9	O
readily	readily	ADV	RB	9	O
detectable	detectable	VERB	VB	9	O
on	on	ADP	IN	5	O
magnetic	magnetic	ADJ	JJ	0	O
resonance	resonance	NOUN	NN	5	O
imaging	image	VERB	VBG	5	O
under	under	ADP	IN	9	O
prolonged	prolonged	ADJ	JJ	9	O
co	co	NOUN	NN	9	B-Chemical
-	-	ADJ	JJ	7	I-Chemical
trimoxazole	trimoxazole	ADJ	JJ	0	I-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
therapy	therapy	NOUN	NN	5	O
of	of	ADP	IN	5	O
patient	patient	NOUN	NN	5	O
2	2	NUM	CD	9	O
was	be	VERB	VBD	9	O
switched	switch	VERB	VBN	9	O
early	early	ADV	RB	9	O
.	.	PUNCT	.	9	O

Bradykinin	bradykinin	NOUN	NN	0	B-Chemical
receptors	receptor	NOUN	NNS	3	O
antagonists	antagonist	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
synthase	synthase	NOUN	NN	1	O
inhibitors	inhibitor	NOUN	NNS	3	O
in	in	ADP	IN	5	O
vincristine	vincristine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
streptozotocin	streptozotocin	NOUN	NN	0	B-Chemical
induced	induced	ADJ	JJ	3	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
irreversible	irreversible	ADJ	JJ	9	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
constitutive	constitutive	ADJ	JJ	3	O
NO	no	DET	DT	9	B-Chemical
synthase	synthase	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
L	L	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
NOArg	NOArg	PROPN	NNP	_	O
;	;	PUNCT	:	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
ip	ip	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
relatively	relatively	ADV	RB	5	O
selective	selective	ADJ	JJ	9	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
inducible	inducible	ADJ	JJ	3	O
NO	no	DET	DT	9	B-Chemical
synthase	synthase	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
L	L	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
NIL	NIL	PROPN	NNP	9	O
;	;	PUNCT	:	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
ip	ip	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
relatively	relatively	ADV	RB	5	O
specific	specific	ADJ	JJ	9	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
neuronal	neuronal	ADJ	JJ	3	O
NO	no	NOUN	NN	9	B-Chemical
synthase	synthase	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
NI	NI	PROPN	NNP	9	O
;	;	PUNCT	:	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
ip	ip	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
antihyperalgesic	antihyperalgesic	ADJ	JJ	0	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
selective	selective	ADJ	JJ	9	O
antagonists	antagonist	NOUN	NNS	3	O
of	of	ADP	IN	5	O
B2	b2	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
B1	B1	PROPN	NNP	9	O
receptors	receptor	NOUN	NNS	3	O
:	:	PUNCT	:	9	O
D	D	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Arg	arg	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
[	[	PUNCT	-LRB-	9	O
Hyp3	hyp3	DET	DT	1	O
,	,	PUNCT	,	9	O
Thi5	Thi5	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
D	D	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Tic7	Tic7	PROPN	NNP	_	O
,	,	PUNCT	,	9	O
Oic8	Oic8	PROPN	NNP	0	O
]	]	PUNCT	-RRB-	9	O
bradykinin	bradykinin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
HOE	HOE	PROPN	NNP	0	B-Chemical
140	140	NUM	CD	9	I-Chemical
;	;	PUNCT	:	9	O
70	70	NUM	CD	9	O
nmol	nmol	NOUN	NN	0	O
/	/	PUNCT	,	9	O
kg	kg	ADV	RB	0	O
ip	ip	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
des	des	X	XX	2	B-Chemical
Arg10	Arg10	PROPN	NNP	1	I-Chemical
HOE	HOE	PROPN	NNP	0	I-Chemical
140	140	NUM	CD	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
70	70	NUM	CD	9	O
nmol	nmol	NOUN	NN	0	O
/	/	PUNCT	,	9	O
kg	kg	ADV	RB	0	O
ip	ip	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
(	(	PUNCT	-LRB-	9	I-Disease
streptozotocin	streptozotocin	ADV	RB	0	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
induced	induce	VERB	VBN	3	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
and	and	CCONJ	CC	5	I-Disease
toxic	toxic	ADJ	JJ	0	I-Disease
(	(	PUNCT	-LRB-	9	I-Disease
vincristine	vincristine	ADV	RB	0	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
induced	induced	ADJ	JJ	3	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
thresholds	threshold	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
using	use	VERB	VBG	9	O
mechanical	mechanical	ADJ	JJ	5	O
stimuli	stimulus	NOUN	NNS	5	O
-	-	PUNCT	,	7	O
-	-	PUNCT	:	7	O
the	the	DET	DT	5	O
modification	modification	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
classic	classic	ADJ	JJ	5	O
paw	paw	DET	PRP$	5	O
withdrawal	withdrawal	NOUN	NN	5	O
test	test	NOUN	NN	5	O
described	describe	VERB	VBN	9	O
by	by	ADP	IN	9	O
Randall	Randall	PROPN	NNP	6	O
-	-	PUNCT	HYPH	7	O
Selitto	Selitto	PROPN	NNP	6	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
paper	paper	NOUN	NN	5	O
confirm	confirm	VERB	VBP	9	O
that	that	ADP	IN	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
bradykinin	bradykinin	NOUN	NN	0	B-Chemical
receptors	receptor	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
inducible	inducible	ADJ	JJ	3	O
NO	no	DET	DT	9	B-Chemical
synthase	synthase	NOUN	NN	1	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
neuronal	neuronal	ADJ	JJ	3	O
NO	no	DET	DT	9	B-Chemical
synthase	synthase	NOUN	NN	1	O
activity	activity	NOUN	NN	9	O
reduces	reduce	VERB	VBZ	9	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
hyperalgesia	hyperalgesia	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Pretreatment	pretreatment	NOUN	NN	3	O
with	with	ADP	IN	5	O
L	L	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
NOArg	NOArg	PROPN	NNP	_	O
and	and	CCONJ	CC	5	O
L	L	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
NIL	NIL	PROPN	NNP	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
7	7	NUM	CD	9	O
-	-	SYM	SYM	7	O
NI	NI	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
significantly	significantly	ADV	RB	9	O
increases	increase	VERB	VBZ	9	O
antihyperalgesic	antihyperalgesic	ADJ	JJ	0	O
activity	activity	NOUN	NN	9	O
both	both	CCONJ	CC	9	O
HOE	HOE	PROPN	NNP	0	B-Chemical
140	140	NUM	CD	9	I-Chemical
and	and	CCONJ	CC	5	O
des	des	PROPN	NNP	2	B-Chemical
Arg10	Arg10	PROPN	NNP	1	I-Chemical
HOE	HOE	PROPN	NNP	0	I-Chemical
140	140	NUM	CD	9	I-Chemical
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
shown	show	VERB	VBN	9	O
that	that	ADP	IN	5	O
both	both	DET	DT	9	O
products	product	NOUN	NNS	9	O
of	of	ADP	IN	5	O
inducible	inducible	ADJ	JJ	3	O
NO	no	DET	DT	9	B-Chemical
synthase	synthase	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
neuronal	neuronal	ADJ	JJ	3	O
NO	no	DET	DT	9	B-Chemical
synthase	synthase	NOUN	NN	1	O
activation	activation	NOUN	NN	3	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
bradykinin	bradykinin	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
vincristine	vincristine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
L	L	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
NOArg	NOArg	PROPN	NNP	_	O
and	and	CCONJ	CC	5	O
7	7	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
NI	NI	PROPN	NNP	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
L	l	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
NIL	NIL	PROPN	NNP	9	O
intensify	intensify	NOUN	NN	5	O
antihyperalgesic	antihyperalgesic	ADJ	JJ	0	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
HOE	HOE	PROPN	NNP	0	B-Chemical
140	140	NUM	CD	9	I-Chemical
or	or	CCONJ	CC	5	O
des	des	NOUN	NN	2	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
Arg10HOE	Arg10HOE	PROPN	NNP	_	I-Chemical
140	140	NUM	CD	9	I-Chemical
in	in	ADP	IN	5	O
toxic	toxic	ADJ	JJ	0	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
studies	study	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
B1	b1	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
B2	b2	NOUN	NN	9	O
receptors	receptor	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
engaged	engage	VERB	VBN	5	O
in	in	ADP	IN	5	O
transmission	transmission	NOUN	NN	5	O
of	of	ADP	IN	5	O
nociceptive	nociceptive	ADJ	JJ	5	O
stimuli	stimulus	NOUN	NNS	5	O
in	in	ADP	IN	5	O
both	both	CCONJ	CC	9	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
and	and	CCONJ	CC	5	I-Disease
toxic	toxic	ADJ	JJ	0	I-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
streptozotocin	streptozotocin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
,	,	PUNCT	,	9	O
inducible	inducible	ADJ	JJ	3	O
NO	no	DET	DT	9	B-Chemical
synthase	synthase	NOUN	NN	1	O
participates	participate	VERB	VBZ	9	O
in	in	ADP	IN	5	O
pronociceptive	pronociceptive	ADJ	JJ	3	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
bradykinin	bradykinin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
in	in	ADP	IN	5	O
vincristine	vincristine	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
bradykinin	bradykinin	NOUN	NN	0	B-Chemical
seemed	seem	VERB	VBD	9	O
to	to	PART	TO	5	O
activate	activate	VERB	VB	3	O
neuronal	neuronal	ADJ	JJ	3	O
NO	no	NOUN	NN	9	B-Chemical
synthase	synthase	NOUN	NN	1	O
pathway	pathway	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
concomitant	concomitant	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
small	small	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
bradykinin	bradykinin	NOUN	NN	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
antagonists	antagonist	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
NO	no	DET	DT	9	B-Chemical
synthase	synthase	NOUN	NN	1	O
inhibitors	inhibitor	NOUN	NNS	3	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
alleviation	alleviation	NOUN	NN	5	O
of	of	ADP	IN	5	O
neuropathic	neuropathic	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
even	even	ADV	RB	5	O
in	in	ADP	IN	5	O
hospital	hospital	NOUN	NN	5	O
care	care	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Confusion	confusion	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
rather	rather	ADV	RB	5	O
serious	serious	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
reaction	reaction	NOUN	NN	9	O
with	with	ADP	IN	5	O
valproic	valproic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
French	french	ADJ	JJ	2	O
Pharmacovigilance	Pharmacovigilance	PROPN	NNP	5	O
database	database	NOUN	NN	5	O
.	.	PUNCT	.	9	O

INTRODUCTION	INTRODUCTION	PROPN	NNP	5	O
:	:	PUNCT	:	9	O
Confusion	confusion	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
reaction	reaction	NOUN	NN	9	O
frequently	frequently	ADV	RB	5	O
observed	observe	VERB	VBD	9	O
with	with	ADP	IN	5	O
valproic	valproic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Some	some	DET	DT	5	O
case	case	NOUN	NN	5	O
reports	report	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
published	publish	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
no	no	DET	DT	9	O
systematic	systematic	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
sample	sample	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
published	publish	VERB	VBN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
performed	perform	VERB	VBD	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
describe	describe	VERB	VB	5	O
the	the	DET	DT	5	O
main	main	ADJ	JJ	5	O
characteristics	characteristic	NOUN	NNS	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
reaction	reaction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
French	french	ADJ	JJ	2	O
Pharmacovigilance	Pharmacovigilance	PROPN	NNP	5	O
database	database	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
selected	select	VERB	VBD	9	O
the	the	DET	DT	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
confusion	confusion	NOUN	NN	5	B-Disease
reported	report	VERB	VBN	9	O
since	since	ADP	IN	9	O
1985	1985	NUM	CD	2	O
with	with	ADP	IN	5	O
valproic	valproic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
272	272	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
confusion	confusion	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
with	with	ADP	IN	5	O
valproic	valproic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
:	:	PUNCT	:	9	O
153	153	NUM	CD	7	O
women	woman	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
119	119	NUM	CD	7	O
men	man	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Confusion	confusion	NOUN	NN	5	B-Disease
mostly	mostly	ADV	RB	9	O
occurred	occur	VERB	VBD	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
first	first	ADJ	JJ	9	O
weeks	week	NOUN	NNS	9	O
following	follow	VERB	VBG	9	O
valproic	valproic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
exposure	exposure	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
39	39	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
"	"	PUNCT	``	5	O
serious	serious	ADJ	JJ	5	O
"	"	PUNCT	''	5	O
for	for	ADP	IN	5	O
almost	almost	ADV	RB	9	O
2	2	NUM	CD	9	O
/	/	SYM	SYM	9	O
3	3	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
62	62	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
outcome	outcome	NOUN	NN	5	O
favourable	favourable	ADJ	JJ	5	O
in	in	ADP	IN	5	O
most	most	ADJ	JJS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cases	case	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
82	82	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
ADR	ADR	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
frequent	frequent	ADJ	JJ	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
aged	age	VERB	VBN	9	O
between	between	ADP	IN	5	O
61	61	NUM	CD	7	O
and	and	CCONJ	CC	5	O
80	80	NUM	CD	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
work	work	NOUN	NN	5	O
shows	show	VERB	VBZ	9	O
that	that	ADP	IN	5	O
confusion	confusion	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
valproic	valproic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
serious	serious	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
rather	rather	ADV	RB	5	O
frequent	frequent	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
reversible	reversible	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
reaction	reaction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
occurs	occur	VERB	VBZ	9	O
especially	especially	ADV	RB	5	O
in	in	ADP	IN	5	O
older	old	ADJ	JJR	5	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
two	two	NUM	CD	5	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Reversible	reversible	ADJ	JJ	0	O
inferior	inferior	ADJ	JJ	5	B-Disease
colliculus	colliculus	NOUN	NN	5	I-Disease
lesion	lesion	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
metronidazole	metronidazole	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
:	:	PUNCT	:	9	O
magnetic	magnetic	ADJ	JJ	0	O
resonance	resonance	NOUN	NN	5	O
findings	finding	NOUN	NNS	9	O
on	on	ADP	IN	5	O
diffusion	diffusion	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
weighted	weight	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
fluid	fluid	ADJ	JJ	5	O
attenuated	attenuate	VERB	VBN	3	O
inversion	inversion	NOUN	NN	5	O
recovery	recovery	NOUN	NN	9	O
imaging	imaging	NOUN	NN	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
to	to	PART	TO	5	O
present	present	VERB	VB	9	O
reversible	reversible	ADJ	JJ	9	O
inferior	inferior	ADJ	JJ	5	B-Disease
colliculus	colliculus	NOUN	NN	5	I-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
metronidazole	metronidazole	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	O
to	to	PART	TO	5	O
focus	focus	VERB	VB	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
diffusion	diffusion	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
weighted	weight	VERB	VBN	5	O
imaging	imaging	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
DWI	DWI	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
fluid	fluid	ADJ	JJ	5	O
attenuated	attenuate	VERB	VBN	3	O
inversion	inversion	NOUN	NN	5	O
recovery	recovery	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
FLAIR	FLAIR	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
imaging	imaging	NOUN	NN	5	O
.	.	PUNCT	.	9	O

MATERIALS	material	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
From	from	ADP	IN	5	O
November	November	PROPN	NNP	2	O
2005	2005	NUM	CD	2	O
to	to	ADP	IN	5	O
September	September	PROPN	NNP	2	O
2007	2007	NUM	CD	2	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
men	man	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
diagnosed	diagnose	VERB	VBN	5	O
as	as	ADP	IN	5	O
having	have	VERB	VBG	5	O
metronidazole	metronidazole	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
(	(	PUNCT	-LRB-	9	O
age	age	NOUN	NN	5	O
range	range	NOUN	NN	9	O
;	;	PUNCT	:	9	O
43	43	NUM	CD	7	O
-	-	SYM	SYM	7	O
78	78	NUM	CD	7	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

They	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
taking	take	VERB	VBG	5	O
metronidazole	metronidazole	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
total	total	ADJ	JJ	9	O
dosage	dosage	NOUN	NN	9	O
,	,	PUNCT	,	9	O
45	45	NUM	CD	9	O
-	-	SYM	SYM	7	O
120	120	NUM	CD	9	O
g	g	NOUN	NN	0	O
;	;	PUNCT	:	9	O
duration	duration	NOUN	NN	5	O
,	,	PUNCT	,	9	O
30	30	NUM	CD	9	O
days	day	NOUN	NNS	9	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
months	month	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
the	the	DET	DT	5	O
infection	infection	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
various	various	ADJ	JJ	9	O
organs	organ	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Initial	initial	ADJ	JJ	9	O
brain	brain	NOUN	NN	5	O
magnetic	magnetic	ADJ	JJ	0	O
resonance	resonance	NOUN	NN	5	O
imaging	imaging	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MRI	MRI	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
hospitalization	hospitalization	NOUN	NN	5	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
DWI	DWI	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
/	/	SYM	SYM	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
apparent	apparent	ADJ	JJ	9	O
diffusion	diffusion	NOUN	NN	5	O
coefficient	coefficient	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ADC	ADC	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
map	map	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
/	/	SYM	SYM	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
FLAIR	FLAIR	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
/	/	SYM	SYM	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
T2	t2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
weighted	weighted	ADJ	JJ	5	O
image	image	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
/	/	SYM	SYM	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
MRIs	mri	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
on	on	ADP	IN	5	O
5	5	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
from	from	ADP	IN	9	O
third	third	ADJ	JJ	9	O
to	to	ADP	IN	5	O
14th	14th	ADJ	JJ	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
metronidazole	metronidazole	ADJ	JJ	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Findings	finding	NOUN	NNS	5	O
of	of	ADP	IN	5	O
initial	initial	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
MRIs	mri	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
retrospectively	retrospectively	ADV	RB	5	O
evaluated	evaluate	VERB	VBN	9	O
by	by	ADP	IN	9	O
2	2	NUM	CD	9	O
neuroradiologists	neuroradiologist	NOUN	NNS	5	O
by	by	ADP	IN	9	O
consensus	consensus	NOUN	NN	9	O
,	,	PUNCT	,	9	O
to	to	PART	TO	5	O
analyze	analyze	VERB	VB	9	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
abnormal	abnormal	ADJ	JJ	9	O
signal	signal	NOUN	NN	9	O
intensities	intensity	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
their	-PRON-	DET	PRP$	5	O
locations	location	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
signal	signal	VERB	VB	9	O
changes	change	NOUN	NNS	9	O
on	on	ADP	IN	5	O
follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
images	image	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Initial	Initial	PROPN	NNP	9	O
MRIs	MRIs	PROPN	NNPS	5	O
showed	show	VERB	VBD	9	O
abnormal	abnormal	ADJ	JJ	9	O
high	high	ADJ	JJ	9	O
signal	signal	NOUN	NN	9	O
intensities	intensity	NOUN	NNS	9	O
on	on	ADP	IN	5	O
DWI	DWI	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
FLAIR	FLAIR	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
or	or	CCONJ	CC	5	O
T2	t2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
weighted	weighted	ADJ	JJ	5	O
image	image	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
dentate	dentate	ADJ	JJ	3	O
nucleus	nucleus	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
/	/	SYM	SYM	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
inferior	inferior	ADJ	JJ	5	O
colliculus	colliculus	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
/	/	SYM	SYM	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
corpus	corpus	NOUN	NN	5	O
callosum	callosum	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
/	/	SYM	SYM	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
pons	pon	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
/	/	SYM	SYM	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
medulla	medulla	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
bilateral	bilateral	ADJ	JJ	5	O
cerebral	cerebral	ADJ	JJ	5	O
white	white	ADJ	JJ	9	O
matter	matter	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
signal	signal	NOUN	NN	9	O
intensity	intensity	NOUN	NN	5	O
lesions	lesion	NOUN	NNS	5	O
on	on	ADP	IN	5	O
DWI	DWI	PROPN	NNP	5	O
tended	tend	VERB	VBD	5	O
to	to	PART	TO	5	O
show	show	VERB	VB	9	O
low	low	ADJ	JJ	9	O
signal	signal	NOUN	NN	9	O
intensity	intensity	NOUN	NN	5	O
on	on	ADP	IN	5	O
ADC	adc	NOUN	NN	5	O
map	map	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
/	/	SYM	SYM	9	O
4	4	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
high	high	ADJ	JJ	9	O
signal	signal	NOUN	NN	9	O
intensity	intensity	NOUN	NN	5	O
was	be	VERB	VBD	9	O
shown	show	VERB	VBN	9	O
at	at	ADP	IN	9	O
bilateral	bilateral	ADJ	JJ	5	O
dentate	dentate	NOUN	NN	3	O
nuclei	nucleus	NOUN	NNS	3	O
on	on	ADP	IN	5	O
not	not	ADV	RB	5	O
only	only	ADV	RB	9	O
DWI	DWI	PROPN	NNP	5	O
but	but	CCONJ	CC	9	O
also	also	ADV	RB	9	O
ADC	adc	DET	DT	5	O
map	map	NOUN	NN	5	O
.	.	PUNCT	.	9	O

All	all	DET	PDT	9	O
the	the	DET	DT	5	O
lesions	lesion	NOUN	NNS	5	O
in	in	ADP	IN	5	O
dentate	dentate	ADJ	JJ	3	O
,	,	PUNCT	,	9	O
inferior	inferior	ADJ	JJ	5	O
colliculus	colliculus	NOUN	NN	5	O
,	,	PUNCT	,	9	O
pons	pon	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
medullas	medulla	NOUN	NNS	3	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
resolved	resolve	VERB	VBN	9	O
completely	completely	ADV	RB	9	O
on	on	ADP	IN	5	O
follow	follow	VERB	VB	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
MRIs	mri	NOUN	NNS	5	O
in	in	ADP	IN	5	O
5	5	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
patient	patient	NOUN	NN	5	O
of	of	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
,	,	PUNCT	,	9	O
corpus	corpus	NOUN	NN	5	O
callosal	callosal	NOUN	NN	5	B-Disease
lesion	lesion	NOUN	NN	5	I-Disease
persisted	persist	VERB	VBD	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Reversible	reversible	ADJ	JJ	0	O
inferior	inferior	ADJ	JJ	5	B-Disease
colliculus	colliculus	NOUN	NN	5	I-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
characteristic	characteristic	NOUN	NN	9	O
for	for	ADP	IN	5	O
metronidazole	metronidazole	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	O
next	next	ADV	RB	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
dentate	dentate	ADJ	JJ	3	O
nucleus	nucleus	NOUN	NN	9	O
involvement	involvement	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Clinically	clinically	ADV	RB	5	O
significant	significant	ADJ	JJ	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
transplant	transplant	NOUN	NN	9	O
recipients	recipient	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Sirolimus	sirolimus	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
latest	late	ADJ	JJS	5	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
rejection	rejection	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
less	less	ADJ	JJR	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
than	than	ADP	IN	5	O
calcineurin	calcineurin	NOUN	NN	3	O
inhibitor	inhibitor	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
CNI	CNI	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
regimens	regimen	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
date	date	NOUN	NN	5	O
there	there	ADV	EX	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
little	little	ADJ	JJ	9	O
documentation	documentation	NOUN	NN	5	O
of	of	ADP	IN	5	O
clinically	clinically	ADV	RB	5	O
significant	significant	ADJ	JJ	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
linked	link	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
encountered	encounter	VERB	VBN	5	O
several	several	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
substantial	substantial	ADJ	JJ	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
each	each	DET	DT	5	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
close	close	ADJ	JJ	5	O
temporal	temporal	ADJ	JJ	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
commencement	commencement	NOUN	NN	5	O
of	of	ADP	IN	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
proteinuria	proteinuria	VERB	VB	9	B-Disease
implicated	implicate	VERB	VBN	9	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
likely	likely	ADJ	JJ	5	O
etiology	etiology	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
analyzed	analyze	VERB	VBD	9	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
laboratory	laboratory	NOUN	NN	9	O
information	information	NOUN	NN	5	O
available	available	ADJ	JJ	5	O
for	for	ADP	IN	5	O
all	all	DET	DT	5	O
119	119	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
transplanted	transplant	VERB	VBN	3	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
Washington	Washington	PROPN	NNP	2	O
Hospital	Hospital	PROPN	NNP	2	O
Center	Center	PROPN	NNP	2	O
between	between	ADP	IN	5	O
1999	1999	NUM	CD	2	O
-	-	SYM	SYM	7	O
2003	2003	NUM	CD	2	O
for	for	ADP	IN	5	O
whom	whom	PRON	WP	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
component	component	NOUN	NN	9	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
immunosuppressant	immunosuppressant	ADJ	JJ	9	O
regimen	regimen	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
magnitude	magnitude	NOUN	NN	5	O
of	of	ADP	IN	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
on	on	ADP	IN	5	O
morning	morning	NOUN	NN	5	O
urine	urine	NOUN	NN	9	O
samples	sample	NOUN	NNS	9	O
by	by	ADP	IN	9	O
turbidometric	turbidometric	ADJ	JJ	0	O
measurement	measurement	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
random	random	ADJ	JJ	5	O
urine	urine	ADJ	JJ	9	O
protein	protein	NOUN	NN	1	O
:	:	PUNCT	:	9	O
creatinine	creatinine	VERB	VB	0	B-Chemical
ratios	ratio	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
estimate	estimate	NOUN	NN	5	O
of	of	ADP	IN	5	O
grams	gram	NOUN	NNS	0	O
of	of	ADP	IN	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Laboratory	laboratory	NOUN	NN	2	O
results	result	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
between	between	ADP	IN	5	O
prior	prior	ADV	RB	9	O
,	,	PUNCT	,	9	O
during	during	ADP	IN	5	O
and	and	CCONJ	CC	5	O
following	follow	VERB	VBG	9	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
eight	eight	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
24	24	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
developed	develop	VERB	VBD	5	O
increased	increase	VERB	VBN	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
from	from	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
during	during	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
transplantation	transplantation	NOUN	NN	9	O
course	course	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
21	21	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
an	an	DET	DT	5	O
alternative	alternative	ADJ	JJ	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
either	either	CCONJ	CC	9	O
obvious	obvious	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
insufficient	insufficient	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
available	available	ADJ	JJ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
conclusive	conclusive	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
7	7	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
28	28	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
striking	striking	ADJ	JJ	9	O
temporal	temporal	ADJ	JJ	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	O
range	range	NOUN	NN	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Proteinuria	Proteinuria	PROPN	NNP	7	B-Disease
correlated	correlate	VERB	VBD	9	O
most	most	ADV	RBS	9	O
strongly	strongly	ADV	RB	9	O
with	with	ADP	IN	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
other	other	ADJ	JJ	5	O
demographic	demographic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
variables	variable	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
most	most	ADJ	JJS	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
resolution	resolution	NOUN	NN	5	O
,	,	PUNCT	,	9	O
of	of	ADP	IN	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Sirolimus	sirolimus	NOUN	NN	0	B-Chemical
induces	induce	NOUN	NNS	3	O
or	or	CCONJ	CC	5	O
aggravates	aggravate	VERB	VBZ	9	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
existing	existing	ADJ	JJ	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
unpredictable	unpredictable	ADJ	JJ	5	O
subset	subset	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
allograft	allograft	NOUN	NN	5	O
recipients	recipient	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Proteinuria	Proteinuria	PROPN	NNP	7	B-Disease
may	may	VERB	MD	5	O
improve	improve	VERB	VB	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
resolve	resolve	VERB	VB	5	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
sirolimus	sirolimus	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
withdrawn	withdraw	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Components	component	NOUN	NNS	5	O
of	of	ADP	IN	5	O
lemon	lemon	NOUN	NN	4	O
essential	essential	ADJ	JJ	9	O
oil	oil	NOUN	NN	0	O
attenuate	attenuate	NOUN	NN	9	O
dementia	dementia	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
dementia	dementia	ADJ	JJ	5	B-Disease
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
s	s	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
limonene	limonene	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
s	s	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
perillyl	perillyl	NOUN	NN	0	I-Chemical
alcohol	alcohol	NOUN	NN	5	I-Chemical
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
test	test	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
PA	PA	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
open	open	ADJ	JJ	5	O
field	field	NOUN	NN	5	O
habituation	habituation	NOUN	NN	5	O
test	test	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
OFH	OFH	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
lemon	lemon	ADJ	JJ	4	O
essential	essential	ADJ	JJ	9	O
oils	oil	NOUN	NNS	4	O
showed	show	VERB	VBD	9	O
strong	strong	ADJ	JJ	9	O
ability	ability	NOUN	NN	9	O
to	to	PART	TO	5	O
improve	improve	VERB	VB	5	O
memory	memory	NOUN	NN	5	B-Disease
impaired	impair	VERB	VBN	9	I-Disease
by	by	ADP	IN	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
s	s	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
perillyl	perillyl	NOUN	NN	0	I-Chemical
alcohol	alcohol	NOUN	NN	5	I-Chemical
relieved	relieve	VERB	VBD	5	O
the	the	DET	DT	5	O
deficit	deficit	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
associative	associative	ADJ	JJ	5	I-Disease
memory	memory	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
PA	PA	PROPN	NNP	9	O
only	only	ADV	RB	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
improve	improve	VERB	VB	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
associative	associative	ADJ	JJ	5	O
memory	memory	NOUN	NN	5	O
significantly	significantly	ADV	RB	9	O
in	in	ADP	IN	5	O
OFH	OFH	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
neurotransmitter	neurotransmitter	ADJ	JJ	9	O
concentration	concentration	NOUN	NN	0	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
brain	brain	NOUN	NN	5	O
regions	region	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
test	test	NOUN	NN	5	O
day	day	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
vehicle	vehicle	NOUN	NN	3	O
/	/	SYM	SYM	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
vehicle	vehicle	NOUN	NN	3	O
/	/	SYM	SYM	9	O
vehicle	vehicle	NOUN	NN	3	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
this	this	DET	DT	5	O
phenomenon	phenomenon	NOUN	NN	5	O
was	be	VERB	VBD	9	O
reversed	reverse	VERB	VBN	9	O
when	when	ADV	WRB	5	O
s	s	NOUN	NN	9	B-Chemical
-	-	PUNCT	:	7	I-Chemical
limonene	limonene	NOUN	NN	0	I-Chemical
or	or	CCONJ	CC	5	O
s	s	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
perillyl	perillyl	NOUN	NN	0	I-Chemical
alcohol	alcohol	NOUN	NN	5	I-Chemical
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Simultaneously	simultaneously	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
found	find	VERB	VBD	9	O
that	that	ADP	IN	5	O
these	these	DET	DT	5	O
two	two	NUM	CD	5	O
lemon	lemon	NOUN	NN	4	O
essential	essential	ADJ	JJ	9	O
oil	oil	NOUN	NN	0	O
components	component	NOUN	NNS	5	O
could	could	VERB	MD	9	O
inhibit	inhibit	VERB	VB	3	O
acetylcholinesterase	acetylcholinesterase	NOUN	NN	0	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
Ellman	Ellman	PROPN	NNP	0	O
method	method	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Attentional	attentional	ADJ	JJ	5	O
modulation	modulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
perceived	perceive	VERB	VBN	5	O
pain	pain	NOUN	NN	5	B-Disease
intensity	intensity	NOUN	NN	5	O
in	in	ADP	IN	5	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
secondary	secondary	ADJ	JJ	9	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

Perceived	perceive	VERB	VBN	5	O
pain	pain	NOUN	NN	5	B-Disease
intensity	intensity	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
modulated	modulate	VERB	VBN	9	O
by	by	ADP	IN	9	O
attention	attention	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
known	know	VERB	VBN	9	O
that	that	ADP	IN	5	O
how	how	ADV	WRB	5	O
pain	pain	NOUN	NN	5	B-Disease
intensity	intensity	NOUN	NN	5	O
ratings	rating	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
attention	attention	NOUN	NN	5	O
in	in	ADP	IN	5	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
secondary	secondary	ADJ	JJ	9	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
we	-PRON-	PRON	PRP	5	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
perceived	perceive	VERB	VBD	5	O
pain	pain	NOUN	NN	5	B-Disease
intensity	intensity	NOUN	NN	5	O
in	in	ADP	IN	5	O
secondary	secondary	ADJ	JJ	9	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
is	be	VERB	VBZ	5	O
decreased	decrease	VERB	VBN	9	O
when	when	ADV	WRB	5	O
attention	attention	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
distracted	distract	VERB	VBN	5	O
away	away	ADV	RB	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
painful	painful	ADJ	JJ	5	O
pinprick	pinprick	NOUN	NN	5	O
stimulus	stimulus	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
visual	visual	ADJ	JJ	5	O
task	task	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
magnitude	magnitude	NOUN	NN	5	O
of	of	ADP	IN	5	O
attentional	attentional	ADJ	JJ	5	O
modulation	modulation	NOUN	NN	9	O
in	in	ADP	IN	5	O
secondary	secondary	ADJ	JJ	9	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
is	be	VERB	VBZ	5	O
very	very	ADV	RB	5	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
untreated	untreated	ADJ	JJ	3	O
,	,	PUNCT	,	9	O
control	control	NOUN	NN	9	O
condition	condition	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
findings	finding	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
showing	show	VERB	VBG	9	O
no	no	DET	DT	9	O
interaction	interaction	NOUN	NN	9	O
between	between	ADP	IN	5	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
attentional	attentional	ADJ	JJ	5	O
modulation	modulation	NOUN	NN	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
capsaicin	capsaicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
secondary	secondary	ADJ	JJ	9	O
hyperalgesia	hyperalgesia	NOUN	NN	3	B-Disease
and	and	CCONJ	CC	5	O
attention	attention	NOUN	NN	5	O
might	may	VERB	MD	9	O
affect	affect	VERB	VB	9	O
mechanical	mechanical	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
through	through	ADP	IN	9	O
independent	independent	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Cardioprotective	cardioprotective	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
salvianolic	salvianolic	NOUN	NN	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
A	a	NOUN	NN	9	I-Chemical
on	on	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
cardioprotective	cardioprotective	ADJ	JJ	9	O
potential	potential	NOUN	NN	9	O
of	of	ADP	IN	5	O
salvianolic	salvianolic	NOUN	NN	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
A	a	NOUN	NN	9	I-Chemical
on	on	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Hemodynamic	hemodynamic	ADJ	JJ	5	O
parameters	parameter	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
lead	lead	VERB	VBP	5	O
II	II	PROPN	NNP	9	O
electrocardiograph	electrocardiograph	NOUN	NN	5	O
were	be	VERB	VBD	9	O
monitored	monitor	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
recorded	record	VERB	VBN	5	O
continuously	continuously	ADV	RB	5	O
.	.	PUNCT	.	9	O

Cardiac	cardiac	ADJ	JJ	9	O
marker	marker	NOUN	NN	3	O
enzymes	enzyme	NOUN	NNS	1	O
and	and	CCONJ	CC	5	O
antioxidative	antioxidative	ADJ	JJ	0	O
parameters	parameter	NOUN	NNS	5	O
in	in	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
tissues	tissue	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Assay	assay	ADJ	JJ	0	O
for	for	ADP	IN	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
respiratory	respiratory	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
histopathological	histopathological	ADJ	JJ	9	O
examination	examination	NOUN	NN	5	O
of	of	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
tissues	tissue	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
lactate	lactate	NOUN	NN	0	B-Chemical
dehydrogenase	dehydrogenase	NOUN	NN	1	O
,	,	PUNCT	,	9	O
aspartate	aspartate	VERB	VB	1	B-Chemical
transaminase	transaminase	NOUN	NN	0	O
,	,	PUNCT	,	9	O
creatine	creatine	NOUN	NN	0	B-Chemical
kinase	kinase	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
malondialdehyde	malondialdehyde	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
significant	significant	ADJ	JJ	9	O
decreases	decrease	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
activities	activity	NOUN	NNS	9	O
of	of	ADP	IN	5	O
superoxide	superoxide	NOUN	NN	0	B-Chemical
dismutase	dismutase	NOUN	NN	0	O
,	,	PUNCT	,	9	O
catalase	catalase	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
glutathione	glutathione	ADJ	JJ	0	B-Chemical
peroxidase	peroxidase	NOUN	NN	0	O
in	in	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
also	also	ADV	RB	9	O
showed	show	VERB	VBD	9	O
declines	decline	NOUN	NNS	9	O
in	in	ADP	IN	5	O
left	leave	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	O
systolic	systolic	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
maximum	maximum	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
minimum	minimum	ADJ	JJ	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
developed	develop	VERB	VBN	5	O
left	leave	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
left	left	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	O
end	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
diastolic	diastolic	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
ST	st	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
segment	segment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
decreased	decrease	VERB	VBN	9	O
respiratory	respiratory	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
ratio	ratio	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
ADP	ADP	PROPN	NNP	0	B-Chemical
/	/	SYM	SYM	9	O
O	O	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
salvianolic	salvianolic	NOUN	NN	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
A	a	NOUN	NN	9	I-Chemical
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
8	8	NUM	CD	9	O
days	day	NOUN	NNS	9	O
significantly	significantly	ADV	RB	9	O
attenuated	attenuate	VERB	VBD	3	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
improved	improve	VERB	VBD	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
respiratory	respiratory	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
protective	protective	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
salvianolic	salvianolic	NOUN	NN	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
A	a	DET	DT	9	I-Chemical
against	against	ADP	IN	9	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
further	further	ADV	RB	9	O
confirmed	confirm	VERB	VBN	9	O
by	by	ADP	IN	9	O
histopathological	histopathological	ADJ	JJ	9	O
examination	examination	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
study	study	NOUN	NN	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
salvianolic	salvianolic	NOUN	NN	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
A	a	DET	DT	9	I-Chemical
possessing	possess	VERB	VBG	9	O
antioxidant	antioxidant	ADJ	JJ	0	O
activity	activity	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
against	against	ADP	IN	9	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Long	long	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
glutamate	glutamate	ADJ	JJ	0	B-Chemical
supplementation	supplementation	NOUN	NN	0	O
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
protect	protect	VERB	VB	9	O
against	against	ADP	IN	9	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
neurotoxicity	neurotoxicity	NOUN	NN	9	I-Disease
of	of	ADP	IN	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Toxic	toxic	ADJ	JJ	0	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
still	still	ADV	RB	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
limiting	limit	VERB	VBG	9	O
factor	factor	NOUN	NN	9	O
for	for	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
PAC	PAC	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
glutamate	glutamate	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
closely	closely	ADV	RB	9	O
related	related	ADJ	JJ	9	O
amino	amino	NOUN	NN	1	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
glutamine	glutamine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
claimed	claim	VERB	VBN	5	O
to	to	PART	TO	5	O
ameliorate	ameliorate	VERB	VB	9	O
PAC	PAC	PROPN	NNP	9	B-Chemical
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
pilot	pilot	NOUN	NN	5	O
trial	trial	NOUN	NN	5	O
aimed	aim	VERB	VBN	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
glutamate	glutamate	ADJ	JJ	0	B-Chemical
supplementation	supplementation	NOUN	NN	0	O
for	for	ADP	IN	5	O
preventing	prevent	VERB	VBG	9	O
PAC	PAC	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
randomized	randomized	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blinded	blind	VERB	VBN	5	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
electro	electro	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
diagnostic	diagnostic	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Forty	forty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
three	three	NUM	CD	9	O
ovarian	ovarian	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
available	available	ADJ	JJ	5	O
for	for	ADP	IN	5	O
analysis	analysis	NOUN	NN	9	O
following	follow	VERB	VBG	9	O
six	six	NUM	CD	9	O
cycles	cycle	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
PAC	PAC	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
regimen	regimen	NOUN	NN	5	O
:	:	PUNCT	:	9	O
23	23	NUM	CD	7	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
supplemented	supplement	VERB	VBN	0	O
by	by	ADP	IN	9	O
glutamate	glutamate	NOUN	NN	0	B-Chemical
all	all	ADV	RB	5	O
along	along	ADP	IN	9	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
daily	daily	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
three	three	NUM	CD	9	O
times	time	NOUN	NNS	5	O
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
group	group	NOUN	NN	9	O
G	G	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
20	20	NUM	CD	9	O
had	have	VERB	VBD	9	O
received	receive	VERB	VBN	9	O
a	a	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
group	group	NOUN	NN	9	O
P	P	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
by	by	ADP	IN	9	O
neurological	neurological	ADJ	JJ	5	O
examinations	examination	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
questionnaires	questionnaire	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
sensory	sensory	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
motor	motor	NOUN	NN	5	O
nerve	nerve	NOUN	NN	5	O
conduction	conduction	NOUN	NN	5	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
signs	sign	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
symptoms	symptom	NOUN	NNS	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
although	although	ADP	IN	9	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
symptoms	symptom	NOUN	NNS	5	O
presented	present	VERB	VBD	5	O
mostly	mostly	ADV	RB	9	O
with	with	ADP	IN	5	O
lower	low	ADJ	JJR	9	O
scores	score	NOUN	NNS	5	O
of	of	ADP	IN	5	O
severity	severity	NOUN	NN	5	O
in	in	ADP	IN	5	O
group	group	NOUN	NN	9	O
G	g	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
difference	difference	NOUN	NN	9	O
reached	reach	VERB	VBD	9	O
statistical	statistical	ADJ	JJ	5	O
significance	significance	NOUN	NN	9	O
only	only	ADV	RB	9	O
with	with	ADP	IN	5	O
regard	regard	NOUN	NN	5	O
to	to	ADP	IN	5	O
reported	report	VERB	VBN	9	O
pain	pain	NOUN	NN	5	B-Disease
sensation	sensation	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
011	011	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Also	also	ADV	RB	9	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
abnormal	abnormal	ADJ	JJ	9	O
electro	electro	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
diagnostic	diagnostic	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
similarity	similarity	NOUN	NN	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
G	g	NOUN	NN	9	O
:	:	PUNCT	:	9	O
7	7	NUM	CD	9	O
/	/	SYM	SYM	9	O
23	23	NUM	CD	7	O
=	=	SYM	SYM	7	O
30	30	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
:	:	PUNCT	:	9	O
6	6	NUM	CD	9	O
/	/	SYM	SYM	9	O
20	20	NUM	CD	9	O
=	=	SYM	SYM	7	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
pilot	pilot	NOUN	NN	5	O
study	study	NOUN	NN	9	O
leads	lead	VERB	VBZ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
conclusion	conclusion	NOUN	NN	9	O
that	that	DET	WDT	5	O
glutamate	glutamate	VERB	VBP	0	B-Chemical
supplementation	supplementation	NOUN	NN	0	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
chosen	choose	VERB	VBN	5	O
regimen	regimen	NOUN	NN	5	O
fails	fail	VERB	VBZ	9	O
to	to	PART	TO	5	O
protect	protect	VERB	VB	9	O
against	against	ADP	IN	9	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
neurotoxicity	neurotoxicity	NOUN	NN	9	I-Disease
of	of	ADP	IN	5	O
PAC	PAC	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

Development	development	NOUN	NN	2	O
of	of	ADP	IN	5	O
ocular	ocular	ADJ	JJ	5	B-Disease
myasthenia	myasthenia	NOUN	NN	9	I-Disease
during	during	ADP	IN	5	O
pegylated	pegylate	VERB	VBN	0	B-Chemical
interferon	interferon	NOUN	NN	3	I-Chemical
and	and	CCONJ	CC	5	O
ribavirin	ribavirin	ADJ	JJ	9	B-Chemical
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
C	C	PROPN	NNP	9	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
63	63	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
male	male	NOUN	NN	9	O
experienced	experience	VERB	VBD	5	O
sudden	sudden	ADJ	JJ	5	O
diplopia	diplopia	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
9	9	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
pegylated	pegylate	VERB	VBN	0	B-Chemical
interferon	interferon	NOUN	NN	3	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
IFN	IFN	PROPN	NNP	3	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
alpha	alpha	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2b	2b	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
for	for	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
C	C	PROPN	NNP	9	I-Disease
(	(	PUNCT	-LRB-	9	O
CHC	CHC	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Ophthalmologic	ophthalmologic	ADJ	JJ	2	O
examinations	examination	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
ptosis	ptosis	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
right	right	ADJ	JJ	5	I-Disease
upper	upper	ADJ	JJ	9	I-Disease
lid	lid	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
restricted	restrict	VERB	VBD	9	B-Disease
right	right	ADJ	JJ	5	I-Disease
eye	eye	NOUN	NN	5	I-Disease
movement	movement	NOUN	NN	5	I-Disease
without	without	ADP	IN	9	O
any	any	DET	DT	5	O
other	other	ADJ	JJ	5	O
neurological	neurological	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
brain	brain	NOUN	NN	5	O
imaging	image	VERB	VBG	5	O
study	study	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
repetitive	repetitive	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
stimulation	stimulation	NOUN	NN	3	O
test	test	NOUN	NN	5	O
indicated	indicate	VERB	VBD	9	O
no	no	DET	DT	9	O
abnormality	abnormality	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
antibody	antibody	NOUN	NN	3	O
titer	titer	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
response	response	NOUN	NN	9	O
to	to	PART	TO	5	O
acetylcholinesterase	acetylcholinesterase	VERB	VB	0	O
inhibitors	inhibitor	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
negative	negative	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
thyroid	thyroid	NOUN	NN	9	O
function	function	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
ophthalmological	ophthalmological	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
improved	improve	VERB	VBD	5	O
rapidly	rapidly	ADV	RB	9	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
pegylated	pegylate	VERB	VBN	0	B-Chemical
IFN	IFN	PROPN	NNP	3	I-Chemical
alpha	alpha	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2b	2b	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
ocular	ocular	ADJ	JJ	5	B-Disease
myasthenia	myasthenia	NOUN	NN	9	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
of	of	ADP	IN	5	O
pegylated	pegylate	VERB	VBN	0	B-Chemical
IFN	IFN	PROPN	NNP	3	I-Chemical
alpha	alpha	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2b	2b	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
for	for	ADP	IN	5	O
CHC	CHC	PROPN	NNP	9	B-Disease
is	be	VERB	VBZ	5	O
very	very	ADV	RB	5	O
rarely	rarely	ADV	RB	5	O
reported	report	VERB	VBN	9	O
;	;	PUNCT	:	9	O
therefore	therefore	ADV	RB	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
present	present	VERB	VBP	9	O
this	this	DET	DT	5	O
case	case	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
various	various	ADJ	JJ	9	O
eye	eye	NOUN	NN	5	O
complications	complication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
IFN	IFN	PROPN	NNP	3	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Learning	learning	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
memory	memory	NOUN	NN	5	I-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
neural	neural	ADJ	JJ	5	O
correlates	correlate	NOUN	NNS	9	O
during	during	ADP	IN	5	O
a	a	DET	DT	5	O
face	face	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
learning	learn	VERB	VBG	5	O
task	task	NOUN	NN	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
consistently	consistently	ADV	RB	9	O
shown	show	VERB	VBN	9	O
that	that	ADP	IN	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
display	display	VERB	VBP	9	O
impairments	impairment	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	I-Disease
learning	learning	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
memory	memory	NOUN	NN	5	I-Disease
performance	performance	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
working	work	VERB	VBG	5	O
memory	memory	NOUN	NN	5	O
processing	processing	NOUN	NN	5	O
in	in	ADP	IN	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
neural	neural	ADJ	JJ	5	O
alterations	alteration	NOUN	NNS	9	O
in	in	ADP	IN	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
cortical	cortical	ADJ	JJ	5	O
regions	region	NOUN	NNS	9	O
as	as	ADP	IN	5	O
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
functional	functional	ADJ	JJ	9	O
magnetic	magnetic	ADJ	JJ	0	O
resonance	resonance	NOUN	NN	5	O
imaging	imaging	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
fMRI	fMRI	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Using	use	VERB	VBG	9	O
functional	functional	ADJ	JJ	9	O
imaging	imaging	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
face	face	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
learning	learn	VERB	VBG	5	O
task	task	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
investigated	investigate	VERB	VBD	9	O
neural	neural	ADJ	JJ	5	O
correlates	correlate	NOUN	NNS	9	O
of	of	ADP	IN	5	O
encoding	encoding	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
recalling	recall	VERB	VBG	5	O
face	face	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
name	name	NOUN	NN	5	O
associations	association	NOUN	NNS	5	O
in	in	ADP	IN	5	O
20	20	NUM	CD	9	O
recreational	recreational	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
users	user	NOUN	NNS	5	O
whose	whose	DET	WP$	9	O
predominant	predominant	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
use	use	NOUN	NN	5	O
was	be	VERB	VBD	9	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
20	20	NUM	CD	9	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
address	address	VERB	VB	5	O
the	the	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
confounding	confound	VERB	VBG	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cannabis	cannabis	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
using	use	VERB	VBG	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
second	second	ADJ	JJ	9	O
analysis	analysis	NOUN	NN	9	O
included	include	VERB	VBD	5	O
14	14	NUM	CD	7	O
previously	previously	ADV	RB	9	O
tested	test	VERB	VBN	9	O
cannabis	cannabis	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
Nestor	Nestor	PROPN	NNP	6	O
,	,	PUNCT	,	9	O
L	L	PROPN	NNP	0	O
.	.	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
Roberts	Roberts	PROPN	NNP	6	O
,	,	PUNCT	,	9	O
G	G	PROPN	NNP	9	O
.	.	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
Garavan	Garavan	PROPN	NNP	6	O
,	,	PUNCT	,	9	O
H	H	PROPN	NNP	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
Hester	Hester	PROPN	NNP	6	O
,	,	PUNCT	,	9	O
R	R	PROPN	NNP	9	O
.	.	NOUN	NN	9	O
,	,	PUNCT	,	9	O
2008	2008	NUM	CD	2	O
.	.	PUNCT	.	9	O
Deficits	deficit	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	I-Disease
learning	learning	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
memory	memory	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
parahippocampal	parahippocampal	ADJ	JJ	5	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
frontocortical	frontocortical	ADJ	JJ	5	O
hypoactivity	hypoactivity	NOUN	NN	5	O
in	in	ADP	IN	5	O
cannabis	cannabis	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
.	.	PUNCT	.	9	O
Neuroimage	neuroimage	NOUN	NN	2	O
40	40	NUM	CD	9	O
,	,	PUNCT	,	9	O
1328	1328	NUM	CD	7	O
-	-	SYM	SYM	7	O
1339	1339	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Ecstasy	Ecstasy	PROPN	NNP	7	B-Chemical
users	user	NOUN	NNS	5	O
performed	perform	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
worse	worse	ADV	RBR	5	O
in	in	ADP	IN	5	O
learning	learning	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
memory	memory	NOUN	NN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
cannabis	cannabis	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
conjunction	conjunction	NOUN	NN	9	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
encode	encode	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
recall	recall	VERB	VB	5	O
phases	phase	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
task	task	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
specific	specific	ADJ	JJ	9	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
bilateral	bilateral	ADJ	JJ	5	O
frontal	frontal	ADJ	JJ	5	O
regions	region	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
left	leave	VERB	VBD	5	O
temporal	temporal	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
right	right	ADJ	JJ	5	O
parietal	parietal	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
bilateral	bilateral	ADJ	JJ	5	O
temporal	temporal	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
bilateral	bilateral	ADJ	JJ	5	O
occipital	occipital	ADJ	JJ	5	O
brain	brain	NOUN	NN	5	O
regions	region	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Ecstasy	ecstasy	NOUN	NN	7	B-Chemical
-	-	PUNCT	HYPH	7	O
specific	specific	ADJ	JJ	9	O
hypoactivity	hypoactivity	NOUN	NN	5	O
was	be	VERB	VBD	9	O
evident	evident	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	ADJ	JJ	5	O
dorsal	dorsal	ADJ	JJ	5	O
anterior	anterior	NOUN	NN	5	O
cingulated	cingulate	VERB	VBN	5	O
cortex	cortex	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ACC	ACC	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
left	leave	VERB	VBD	5	O
posterior	posterior	ADJ	JJ	5	O
cingulated	cingulated	ADJ	JJ	5	O
cortex	cortex	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
both	both	CCONJ	CC	9	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
cannabis	cannabis	NOUN	NN	5	B-Chemical
groups	group	NOUN	NNS	9	O
brain	brain	NOUN	NN	5	O
activation	activation	NOUN	NN	3	O
was	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	ADJ	JJ	5	O
medial	medial	ADJ	JJ	5	O
frontal	frontal	ADJ	JJ	5	O
gyrus	gyrus	NOUN	NN	5	O
,	,	PUNCT	,	9	O
left	leave	VERB	VBD	5	O
parahippocampal	parahippocampal	ADJ	JJ	5	O
gyrus	gyrus	NOUN	NN	5	O
,	,	PUNCT	,	9	O
left	leave	VERB	VBD	5	O
dorsal	dorsal	ADJ	JJ	5	O
cingulate	cingulate	NOUN	NN	5	O
gyrus	gyrus	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
left	leave	VERB	VBD	5	O
caudate	caudate	ADV	RB	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
elucidated	elucidate	VERB	VBD	9	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
deficits	deficit	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
only	only	ADV	RB	9	O
some	some	DET	DT	5	O
of	of	ADP	IN	5	O
which	which	DET	WDT	5	O
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
attributed	attribute	VERB	VBN	9	O
to	to	ADP	IN	5	O
cannabis	cannabis	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
specific	specific	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
vulnerability	vulnerability	NOUN	NN	5	O
of	of	ADP	IN	5	O
isocortical	isocortical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
allocortical	allocortical	ADJ	JJ	5	O
regions	region	NOUN	NNS	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
ecstasy	ecstasy	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Disulfiram	Disulfiram	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
syndrome	syndrome	NOUN	NN	5	O
after	after	ADP	IN	9	O
hydrogen	hydrogen	NOUN	NN	0	B-Chemical
cyanamide	cyanamide	NOUN	NN	0	I-Chemical
professional	professional	ADJ	JJ	5	O
skin	skin	NOUN	NN	5	O
exposure	exposure	NOUN	NN	9	O
:	:	PUNCT	:	9	O
two	two	NUM	CD	5	O
case	case	NOUN	NN	5	O
reports	report	NOUN	NNS	9	O
in	in	ADP	IN	5	O
France	France	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

Hydrogen	Hydrogen	PROPN	NNP	0	B-Chemical
cyanamide	cyanamide	NOUN	NN	0	I-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
plant	plant	NOUN	NN	4	O
growth	growth	NOUN	NN	3	O
regulator	regulator	NOUN	NN	1	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
agriculture	agriculture	NOUN	NN	5	O
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
bud	bud	NOUN	NN	9	O
break	break	NOUN	NN	5	O
in	in	ADP	IN	5	O
fruit	fruit	NOUN	NN	4	O
trees	tree	NOUN	NNS	4	O
.	.	PUNCT	.	9	O

Contact	contact	NOUN	NN	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
skin	skin	NOUN	NN	5	O
can	can	VERB	MD	5	O
result	result	VERB	VB	9	O
in	in	ADP	IN	5	O
percutaneous	percutaneous	ADJ	JJ	5	O
absorption	absorption	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
substance	substance	NOUN	NN	5	O
that	that	DET	WDT	5	O
inhibits	inhibit	VERB	VBZ	3	O
aldehyde	aldehyde	NOUN	NN	0	B-Chemical
dehydrogenase	dehydrogenase	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
can	can	VERB	MD	5	O
induce	induce	VERB	VB	3	O
acetaldehyde	acetaldehyde	NOUN	NN	0	B-Chemical
syndrome	syndrome	NOUN	NN	5	O
in	in	ADP	IN	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
report	report	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
to	to	PART	TO	5	O
describe	describe	VERB	VB	5	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
disulfiram	disulfiram	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
syndrome	syndrome	NOUN	NN	5	O
following	follow	VERB	VBG	9	O
occupational	occupational	ADJ	JJ	5	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
hydrogen	hydrogen	NOUN	NN	0	B-Chemical
cyanamide	cyanamide	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
involved	involve	VERB	VBD	9	O
a	a	DET	DT	5	O
59	59	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
who	who	PRON	WP	5	O
used	use	VERB	VBD	5	O
Dormex	Dormex	PROPN	NNP	_	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
contains	contain	VERB	VBZ	9	O
hydrogen	hydrogen	NOUN	NN	0	B-Chemical
cyanamide	cyanamide	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
without	without	ADP	IN	9	O
protection	protection	NOUN	NN	9	O
after	after	ADP	IN	9	O
consuming	consume	VERB	VBG	5	O
a	a	DET	DT	5	O
large	large	ADJ	JJ	5	O
amount	amount	NOUN	NN	9	O
of	of	ADP	IN	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
during	during	ADP	IN	5	O
a	a	DET	DT	5	O
meal	meal	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
1	1	NUM	CD	9	O
hour	hour	NOUN	NN	0	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
ingestion	ingestion	NOUN	NN	9	O
of	of	ADP	IN	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
he	-PRON-	PRON	PRP	5	O
developed	develop	VERB	VBD	5	O
malaise	malaise	NOUN	NN	4	O
with	with	ADP	IN	5	O
flushing	flush	VERB	VBG	5	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
face	face	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
dyspnea	dyspnea	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Manifestations	manifestation	NOUN	NNS	5	O
regressed	regress	VERB	VBD	5	O
spontaneously	spontaneously	ADV	RB	5	O
under	under	ADP	IN	9	O
surveillance	surveillance	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hospital	hospital	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
55	55	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
farmer	farmer	NOUN	NN	5	O
following	follow	VERB	VBG	9	O
cutaneous	cutaneous	ADJ	JJ	5	O
contact	contact	NOUN	NN	5	O
with	with	ADP	IN	5	O
Dormex	Dormex	PROPN	NNP	_	B-Chemical
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
exposure	exposure	NOUN	NN	9	O
,	,	PUNCT	,	9	O
he	-PRON-	PRON	PRP	5	O
developed	develop	VERB	VBD	5	O
disulfiram	disulfiram	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
syndrome	syndrome	NOUN	NN	5	O
with	with	ADP	IN	5	O
flushing	flushing	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
arterial	arterial	ADJ	JJ	5	B-Disease
hypotension	hypotension	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
consuming	consume	VERB	VBG	5	O
three	three	NUM	CD	9	O
glasses	glass	NOUN	NNS	5	O
of	of	ADP	IN	5	O
wine	wine	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
recovered	recover	VERB	VBD	9	O
spontaneously	spontaneously	ADV	RB	5	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
under	under	ADP	IN	9	O
surveillance	surveillance	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hospital	hospital	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
cases	case	NOUN	NNS	5	O
confirm	confirm	VERB	VBP	9	O
the	the	DET	DT	5	O
necessity	necessity	NOUN	NN	5	O
of	of	ADP	IN	5	O
avoiding	avoid	VERB	VBG	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
consumption	consumption	NOUN	NN	5	O
as	as	ADP	IN	5	O
recommended	recommend	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
instructions	instruction	NOUN	NNS	5	O
for	for	ADP	IN	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
Dormex	Dormex	PROPN	NNP	_	B-Chemical
and	and	CCONJ	CC	5	O
of	of	ADP	IN	5	O
preventing	prevent	VERB	VBG	9	O
cutaneous	cutaneous	ADJ	JJ	5	O
contact	contact	NOUN	NN	5	O
during	during	ADP	IN	5	O
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Sulpiride	sulpiride	NOUN	NN	7	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
tardive	tardive	ADJ	JJ	5	B-Disease
dystonia	dystonia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Sulpiride	sulpiride	NOUN	NN	7	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
D2	d2	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
with	with	ADP	IN	5	O
antipsychotic	antipsychotic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
antidepressant	antidepressant	ADJ	JJ	5	B-Chemical
properties	property	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
initially	initially	ADV	RB	9	O
thought	think	VERB	VBD	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
free	free	ADJ	JJ	9	O
of	of	ADP	IN	5	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
sulpiride	sulpiride	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
tardive	tardive	ADJ	JJ	5	B-Disease
dyskinesia	dyskinesia	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
parkinsonism	parkinsonism	NOUN	NN	5	B-Disease
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
occasionally	occasionally	ADV	RB	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
studied	study	VERB	VBD	9	O
a	a	DET	DT	5	O
37	37	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
persistent	persistent	ADJ	JJ	5	O
segmental	segmental	NOUN	NN	5	O
dystonia	dystonia	NOUN	NN	5	B-Disease
within	within	ADP	IN	9	O
2	2	NUM	CD	9	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
starting	start	VERB	VBG	9	O
sulpiride	sulpiride	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
could	could	VERB	MD	9	O
not	not	ADV	RB	5	O
find	find	VERB	VB	5	O
any	any	DET	DT	5	O
previous	previous	ADJ	JJ	9	O
reports	report	NOUN	NNS	9	O
of	of	ADP	IN	5	O
sulpiride	sulpiride	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
tardive	tardive	ADJ	JJ	5	B-Disease
dystonia	dystonia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Comparative	comparative	ADJ	JJ	9	O
cognitive	cognitive	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
subjective	subjective	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
immediate	immediate	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
release	release	NOUN	NN	9	O
oxycodone	oxycodone	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
middle	middle	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
aged	aged	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
older	old	ADJ	JJR	5	O
adults	adult	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
measured	measure	VERB	VBD	9	O
the	the	DET	DT	5	O
objective	objective	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
subjective	subjective	ADJ	JJ	5	O
neurocognitive	neurocognitive	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
10	10	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
mg	mg	NOUN	NN	0	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
immediate	immediate	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
release	release	NOUN	NN	9	O
oxycodone	oxycodone	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
older	old	ADJ	JJR	5	O
(	(	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
65	65	NUM	CD	7	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
middle	middle	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
aged	aged	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
35	35	NUM	CD	9	O
to	to	PART	TO	5	O
55	55	NUM	CD	7	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
adults	adult	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
suffering	suffer	VERB	VBG	5	O
from	from	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
significant	significant	ADJ	JJ	9	O
daily	daily	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Seventy	seventy	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
one	one	NUM	CD	5	O
participants	participant	NOUN	NNS	5	O
completed	complete	VERB	VBD	5	O
2	2	NUM	CD	9	O
separate	separate	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
days	day	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
blind	blind	ADJ	JJ	5	O
to	to	ADP	IN	5	O
medication	medication	NOUN	NN	5	O
condition	condition	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
placebo	placebo	NOUN	NN	9	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
mg	mg	NOUN	NN	0	O
oxycodone	oxycodone	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Plasma	plasma	ADJ	JJ	0	O
oxycodone	oxycodone	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
peaked	peak	VERB	VBD	9	O
between	between	ADP	IN	5	O
60	60	NUM	CD	9	O
and	and	CCONJ	CC	5	O
90	90	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
postdose	postdose	ADV	RB	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
pupil	pupil	NOUN	NN	5	O
size	size	NOUN	NN	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
indication	indication	NOUN	NN	5	O
of	of	ADP	IN	5	O
physiological	physiological	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
medication	medication	NOUN	NN	5	O
,	,	PUNCT	,	9	O
peaked	peak	VERB	VBD	9	O
at	at	ADP	IN	9	O
approximately	approximately	ADV	RB	9	O
90	90	NUM	CD	9	O
to	to	PART	TO	5	O
120	120	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
postdose	postdose	ADV	RB	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Significant	significant	ADJ	JJ	9	O
declines	decline	NOUN	NNS	9	B-Disease
in	in	ADP	IN	5	I-Disease
simple	simple	ADJ	JJ	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
sustained	sustained	ADJ	JJ	5	I-Disease
attention	attention	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	I-Disease
working	work	VERB	VBG	5	I-Disease
memory	memory	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	I-Disease
and	and	CCONJ	CC	5	I-Disease
verbal	verbal	ADJ	JJ	5	I-Disease
memory	memory	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
at	at	ADP	IN	9	O
1	1	NUM	CD	9	O
hour	hour	NOUN	NN	0	O
postdose	postdose	ADV	RB	5	O
compared	compare	VERB	VBN	9	O
to	to	PART	TO	5	O
baseline	baseline	VERB	VB	5	O
for	for	ADP	IN	5	O
both	both	DET	DT	9	O
age	age	NOUN	NN	5	O
groups	group	NOUN	NNS	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
trend	trend	NOUN	NN	9	O
toward	toward	ADP	IN	5	O
return	return	NOUN	NN	5	O
to	to	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
by	by	ADP	IN	9	O
5	5	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
postdose	postdose	ADV	RB	5	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
almost	almost	ADV	RB	9	O
all	all	DET	DT	5	O
cognitive	cognitive	ADJ	JJ	5	O
measures	measure	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
medication	medication	NOUN	NN	5	O
by	by	ADP	IN	9	O
age	age	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
interaction	interaction	NOUN	NN	9	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
indicates	indicate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
2	2	NUM	CD	9	O
age	age	NOUN	NN	5	O
groups	group	NOUN	NNS	9	O
exhibited	exhibit	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
responses	response	NOUN	NNS	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
medication	medication	NOUN	NN	5	O
challenge	challenge	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
for	for	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
older	old	ADJ	JJR	5	O
adults	adult	NOUN	NNS	5	O
who	who	PRON	WP	5	O
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
suffering	suffer	VERB	VBG	5	O
from	from	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
neurocognitive	neurocognitive	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
pharmacodynamic	pharmacodynamic	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
10	10	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
mg	mg	NOUN	NN	0	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
immediate	immediate	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
release	release	NOUN	NN	9	O
oxycodone	oxycodone	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
observed	observe	VERB	VBN	9	O
for	for	ADP	IN	5	O
middle	middle	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
aged	aged	ADJ	JJ	9	O
adults	adult	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

PERSPECTIVE	perspective	VERB	VB	2	O
:	:	PUNCT	:	9	O
Study	study	NOUN	NN	5	O
findings	finding	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
metabolism	metabolism	NOUN	NN	9	O
,	,	PUNCT	,	9	O
neurocognitive	neurocognitive	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
physical	physical	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
oxycodone	oxycodone	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
similar	similar	ADJ	JJ	9	O
for	for	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
middle	middle	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
aged	aged	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
older	old	ADJ	JJR	5	O
adults	adult	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
clinicians	clinician	NOUN	NNS	5	O
should	should	VERB	MD	5	O
not	not	ADV	RB	5	O
avoid	avoid	VERB	VB	5	O
prescribing	prescribe	VERB	VBG	5	O
oral	oral	ADJ	JJ	9	O
opioids	opioid	NOUN	NNS	5	O
to	to	ADP	IN	5	O
older	old	ADJ	JJR	5	O
adults	adult	NOUN	NNS	5	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
belief	belief	NOUN	NN	5	O
that	that	ADP	IN	5	O
older	old	ADJ	JJR	5	O
adults	adult	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
at	at	ADP	IN	9	O
higher	high	ADJ	JJR	9	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
than	than	ADP	IN	5	O
younger	young	ADJ	JJR	5	O
adults	adult	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
glycine	glycine	NOUN	NN	0	B-Chemical
transporter	transporter	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
inhibitor	inhibitor	NOUN	NN	3	O
SSR103800	SSR103800	PROPN	NNP	9	B-Chemical
displays	display	VERB	VBZ	9	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
specific	specific	ADJ	JJ	9	O
antipsychotic	antipsychotic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
profile	profile	NOUN	NN	9	O
in	in	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
transgenic	transgenic	ADJ	JJ	3	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Schizophrenia	Schizophrenia	PROPN	NNP	5	B-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
initially	initially	ADV	RB	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
dysfunction	dysfunction	NOUN	NN	9	O
in	in	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
neurotransmission	neurotransmission	NOUN	NN	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
observation	observation	NOUN	NN	9	O
that	that	DET	WDT	5	O
antagonists	antagonist	VERB	VBZ	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
glutamate	glutamate	ADJ	JJ	0	B-Chemical
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
D	d	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aspartate	aspartate	NOUN	NN	1	I-Chemical
(	(	PUNCT	-LRB-	9	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
receptor	receptor	NOUN	NN	3	O
produce	produce	VERB	VBP	9	O
schizophrenic	schizophrenic	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
symptoms	symptom	NOUN	NNS	5	O
in	in	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
has	have	VERB	VBZ	9	O
led	lead	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
idea	idea	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
dysfunctioning	dysfunctioning	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
glutamatergic	glutamatergic	ADJ	JJ	3	O
system	system	NOUN	NN	5	O
via	via	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
receptor	receptor	NOUN	NN	3	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
a	a	DET	DT	5	O
result	result	NOUN	NN	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
growing	grow	VERB	VBG	9	O
interest	interest	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
pharmacological	pharmacological	ADJ	JJ	9	O
agents	agent	NOUN	NNS	5	O
with	with	ADP	IN	5	O
potential	potential	ADJ	JJ	9	O
antipsychotic	antipsychotic	ADJ	JJ	5	O
properties	property	NOUN	NNS	9	O
that	that	DET	WDT	5	O
enhance	enhance	VERB	VBP	9	O
the	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
glutamatergic	glutamatergic	ADJ	JJ	3	O
system	system	NOUN	NN	5	O
via	via	ADP	IN	9	O
a	a	DET	DT	5	O
modulation	modulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
receptor	receptor	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
them	-PRON-	PRON	PRP	5	O
are	be	VERB	VBP	5	O
glycine	glycine	ADJ	JJ	0	B-Chemical
transporter	transporter	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
GlyT1	GlyT1	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
inhibitors	inhibitor	NOUN	NNS	3	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
SSR103800	SSR103800	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
indirectly	indirectly	ADV	RB	9	O
enhance	enhance	VERB	VBP	9	O
NMDA	nmda	ADJ	JJ	3	B-Chemical
receptor	receptor	NOUN	NN	3	O
function	function	NOUN	NN	9	O
by	by	ADP	IN	9	O
increasing	increase	VERB	VBG	9	O
the	the	DET	DT	5	O
glycine	glycine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
a	a	DET	DT	5	O
co	co	NOUN	NN	9	O
-	-	NOUN	NN	7	O
agonist	agonist	NOUN	NN	3	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
receptor	receptor	NOUN	NN	3	O
)	)	PUNCT	-RRB-	9	O
levels	level	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
synapse	synapse	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
aimed	aim	VERB	VBN	5	O
at	at	ADP	IN	9	O
investigating	investigate	VERB	VBG	5	O
the	the	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
antipsychotic	antipsychotic	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
properties	property	NOUN	NNS	9	O
of	of	ADP	IN	5	O
SSR103800	SSR103800	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
particular	particular	ADJ	JJ	5	O
focus	focus	NOUN	NN	5	O
on	on	ADP	IN	5	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
involving	involve	VERB	VBG	5	O
either	either	CCONJ	CC	9	O
drug	drug	NOUN	NN	5	O
challenge	challenge	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
ie	ie	X	FW	5	O
,	,	PUNCT	,	9	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	PROPN	NNP	7	I-Chemical
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
transgenic	transgenic	ADJ	JJ	3	O
mice	mouse	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
ie	ie	X	FW	5	O
,	,	PUNCT	,	9	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
Nr1	nr1	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
neo	neo	PROPN	NNP	1	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
DAT	DAT	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Results	result	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
SSR103800	SSR103800	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
blocked	block	VERB	VBD	3	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
competitive	competitive	ADJ	JJ	9	O
NMDA	nmda	ADJ	JJ	3	B-Chemical
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
801	801	PROPN	NNP	7	I-Chemical
and	and	CCONJ	CC	5	O
partially	partially	ADV	RB	9	O
reversed	reverse	VERB	VBD	9	O
spontaneous	spontaneous	ADJ	JJ	5	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
NMDA	NMDA	PROPN	NNP	3	B-Chemical
Nr1	nr1	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
neo	neo	PROPN	NNP	1	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
SSR103800	SSR103800	PROPN	NNP	9	B-Chemical
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
affect	affect	VERB	VB	9	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
or	or	CCONJ	CC	5	O
naturally	naturally	ADV	RB	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
transporter	transporter	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
DAT	DAT	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
knockout	knockout	ADJ	JJ	3	O
mice	mouse	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Importantly	importantly	ADV	RB	9	O
,	,	PUNCT	,	9	O
both	both	DET	DT	9	O
classical	classical	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
atypical	atypical	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
olanzapine	olanzapine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
aripiprazole	aripiprazole	NOUN	NN	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
antipsychotics	antipsychotic	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
all	all	DET	PDT	5	O
these	these	DET	DT	5	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
unlike	unlike	ADP	IN	9	O
these	these	DET	DT	5	O
latter	latter	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
SSR103800	SSR103800	PROPN	NNP	9	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
produce	produce	VERB	VB	9	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
retention	retention	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
bar	bar	NOUN	NN	9	O
test	test	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O

Together	together	ADV	RB	9	O
these	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
GlyT1	GlyT1	PROPN	NNP	3	O
inhibitor	inhibitor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
SSR103800	SSR103800	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
produces	produce	VERB	VBZ	9	O
antipsychotic	antipsychotic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
differ	differ	VERB	VBP	9	O
from	from	ADP	IN	9	O
those	those	DET	DT	5	O
observed	observe	VERB	VBN	9	O
with	with	ADP	IN	5	O
compounds	compound	NOUN	NNS	0	O
primarily	primarily	ADV	RB	9	O
targeting	target	VERB	VBG	3	O
the	the	DET	DT	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
reduced	reduce	VERB	VBN	9	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effect	effect	NOUN	NN	9	O
potential	potential	NOUN	NN	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
these	these	DET	DT	5	O
latter	latter	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Pyrrolidine	Pyrrolidine	PROPN	NNP	0	B-Chemical
dithiocarbamate	dithiocarbamate	NOUN	NN	0	I-Chemical
protects	protect	VERB	VBZ	3	O
the	the	DET	DT	5	O
piriform	piriform	NOUN	NN	5	O
cortex	cortex	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Pyrrolidine	Pyrrolidine	PROPN	NNP	0	B-Chemical
dithiocarbamate	dithiocarbamate	VERB	VBP	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
PDTC	PDTC	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
dual	dual	ADJ	JJ	9	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
antioxidant	antioxidant	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
transcription	transcription	NOUN	NN	1	O
factor	factor	NOUN	NN	9	O
kappa	kappa	NOUN	NNS	9	O
-	-	PUNCT	HYPH	7	O
beta	beta	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
,	,	PUNCT	,	9	O
production	production	NOUN	NN	9	O
of	of	ADP	IN	5	O
reactive	reactive	ADJ	JJ	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
species	specie	NOUN	NNS	4	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
NF	NF	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
kappaB	kappaB	PROPN	NNP	3	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
neuronal	neuronal	ADJ	JJ	3	B-Disease
damage	damage	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
different	different	ADJ	JJ	9	O
sub	sub	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
regions	region	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
surrounding	surround	VERB	VBG	9	O
cortices	cortex	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
PDTC	PDTC	PROPN	NNP	3	B-Chemical
on	on	ADP	IN	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
cell	cell	NOUN	NN	3	O
loss	loss	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
piriform	piriform	NOUN	NN	5	O
cortex	cortex	NOUN	NN	5	O
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
fractionated	fractionate	VERB	VBN	0	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
150	150	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
PDTC	PDTC	NOUN	NNS	3	B-Chemical
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
following	follow	VERB	VBG	9	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
mortality	mortality	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
to	to	ADP	IN	5	O
100	100	NUM	CD	0	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
PDTC	PDTC	PROPN	NNP	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
exert	exert	VERB	VB	9	O
major	major	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
mortality	mortality	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
vehicle	vehicle	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
caused	cause	VERB	VBD	9	O
pronounced	pronounced	ADJ	JJ	9	O
neuronal	neuronal	ADJ	JJ	3	B-Disease
damage	damage	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
piriform	piriform	NOUN	NN	5	O
cortex	cortex	NOUN	NN	5	O
comprising	comprise	VERB	VBG	9	O
both	both	DET	DT	9	O
pyramidal	pyramidal	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
interneurons	interneuron	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
PDTC	pdtc	NOUN	NN	3	B-Chemical
treatment	treatment	NOUN	NN	9	O
almost	almost	ADV	RB	9	O
completely	completely	ADV	RB	9	O
protected	protect	VERB	VBN	9	O
from	from	ADP	IN	9	O
lesions	lesion	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
piriform	piriform	NOUN	NN	5	O
cortex	cortex	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
neuronal	neuronal	ADJ	JJ	3	O
density	density	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
hilar	hilar	ADJ	JJ	5	O
formation	formation	NOUN	NN	9	O
was	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
in	in	ADP	IN	5	O
vehicle	vehicle	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
PDTC	pdtc	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
following	follow	VERB	VBG	9	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
NF	NF	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
kappaB	kappaB	PROPN	NNP	3	O
inhibitor	inhibitor	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
antioxidant	antioxidant	ADJ	JJ	0	O
PDTC	PDTC	PROPN	NNP	3	B-Chemical
protected	protect	VERB	VBD	9	O
the	the	DET	DT	5	O
piriform	piriform	NOUN	NN	5	O
cortex	cortex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
affect	affect	VERB	VB	9	O
hilar	hilar	ADJ	JJ	5	O
neuronal	neuronal	ADJ	JJ	3	B-Disease
loss	loss	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
might	may	VERB	MD	9	O
indicate	indicate	VERB	VB	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
generation	generation	NOUN	NN	9	O
of	of	ADP	IN	5	O
reactive	reactive	ADJ	JJ	9	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
species	specie	NOUN	NNS	4	O
and	and	CCONJ	CC	5	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
NF	NF	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
kappaB	kappaB	PROPN	NNP	3	O
plays	play	VERB	VBZ	9	O
a	a	DET	DT	5	O
more	more	ADV	RBR	5	O
central	central	ADJ	JJ	5	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
neuronal	neuronal	ADJ	JJ	3	B-Disease
damage	damage	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
temporal	temporal	ADJ	JJ	5	O
cortex	cortex	NOUN	NN	5	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
hilus	hilus	NOUN	NN	3	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
future	future	ADJ	JJ	5	O
investigations	investigation	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
necessary	necessary	ADJ	JJ	5	O
to	to	PART	TO	5	O
exactly	exactly	ADV	RB	5	O
analyze	analyze	VERB	VB	9	O
the	the	DET	DT	5	O
biochemical	biochemical	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
by	by	ADP	IN	9	O
which	which	DET	WDT	5	O
PDTC	PDTC	NOUN	NNS	3	B-Chemical
exerted	exert	VERB	VBD	9	O
its	-PRON-	DET	PRP$	9	O
beneficial	beneficial	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
piriform	piriform	NOUN	NN	5	O
cortex	cortex	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Anaesthetists	anaesthetist	NOUN	NNS	2	O
'	'	PART	POS	9	O
nightmare	nightmare	NOUN	NN	5	O
:	:	PUNCT	:	9	O
masseter	masseter	NOUN	NN	5	B-Disease
spasm	spasm	NOUN	NNS	5	I-Disease
after	after	ADP	IN	9	O
induction	induction	NOUN	NN	3	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
undiagnosed	undiagnosed	ADJ	JJ	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
myotonia	myotonia	NOUN	NN	5	B-Disease
congenita	congenita	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
an	an	DET	DT	5	O
undiagnosed	undiagnosed	ADJ	JJ	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
myotonia	myotonia	NOUN	NN	5	B-Disease
congenita	congenita	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
previously	previously	ADV	RB	9	O
healthy	healthy	ADJ	JJ	5	O
primigravida	primigravida	NOUN	NN	5	O
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
life	life	NOUN	NN	5	O
threatening	threaten	VERB	VBG	5	O
masseter	masseter	NOUN	NN	5	B-Disease
spasm	spasm	NOUN	NNS	5	I-Disease
following	follow	VERB	VBG	9	O
a	a	DET	DT	5	O
standard	standard	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
suxamethonium	suxamethonium	NOUN	NN	5	B-Chemical
for	for	ADP	IN	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Neither	neither	CCONJ	CC	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
nor	nor	CCONJ	CC	9	O
the	the	DET	DT	5	O
anaesthetist	anaesthetist	NOUN	NN	5	O
was	be	VERB	VBD	9	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
before	before	ADP	IN	9	O
this	this	DET	DT	5	O
potentially	potentially	ADV	RB	5	O
lethal	lethal	ADJ	JJ	9	O
complication	complication	NOUN	NN	5	O
occurred	occur	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Twin	twin	ADJ	JJ	5	O
preterm	preterm	ADJ	JJ	5	O
neonates	neonate	NOUN	NNS	9	O
with	with	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
lopinavir	lopinavir	ADJ	JJ	0	B-Chemical
/	/	SYM	SYM	9	I-Chemical
ritonavir	ritonavir	NOUN	NN	0	I-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
twin	twin	ADJ	JJ	5	O
neonates	neonate	NOUN	NNS	9	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
born	bear	VERB	VBN	5	O
prematurely	prematurely	ADV	RB	5	O
at	at	ADP	IN	9	O
32	32	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
gestation	gestation	NOUN	NN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
mother	mother	NOUN	NN	5	O
with	with	ADP	IN	5	O
human	human	ADJ	JJ	3	B-Disease
immunodeficiency	immunodeficiency	NOUN	NN	9	I-Disease
virus	virus	NOUN	NN	9	I-Disease
infection	infection	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
twins	twin	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
complete	complete	ADJ	JJ	9	O
heart	heart	NOUN	NN	5	B-Disease
block	block	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
dilated	dilate	VERB	VBD	5	B-Disease
cardiomyopathy	cardiomyopathy	NOUN	NN	5	I-Disease
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
lopinavir	lopinavir	ADJ	JJ	0	B-Chemical
/	/	SYM	SYM	9	I-Chemical
ritonavir	ritonavir	NOUN	NN	0	I-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
boosted	boost	VERB	VBN	9	O
protease	protease	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
inhibitor	inhibitor	NOUN	NN	3	O
agent	agent	NOUN	NN	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
twin	twin	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
mild	mild	ADJ	JJ	9	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
recommend	recommend	VERB	VBP	5	O
caution	caution	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
lopinavir	lopinavir	ADJ	JJ	0	B-Chemical
/	/	SYM	SYM	9	I-Chemical
ritonavir	ritonavir	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
immediate	immediate	ADJ	JJ	5	O
neonatal	neonatal	ADJ	JJ	9	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
drugs	drug	NOUN	NNS	5	O
disappear	disappear	VERB	VBP	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
:	:	PUNCT	:	9	O
elimination	elimination	NOUN	NN	9	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
medication	medication	NOUN	NN	5	O
by	by	ADP	IN	9	O
hemodiafiltration	hemodiafiltration	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
three	three	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
heart	heart	NOUN	NN	5	O
transplantation	transplantation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
threatening	threaten	VERB	VBG	5	O
acute	acute	ADJ	JJ	9	O
right	right	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
failure	failure	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
diagnosed	diagnose	VERB	VBN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
requiring	require	VERB	VBG	5	O
continuous	continuous	ADJ	JJ	5	O
venovenous	venovenous	ADJ	JJ	5	O
hemodiafiltration	hemodiafiltration	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CVVHDF	CVVHDF	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Increasing	increase	VERB	VBG	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
catecholamines	catecholamine	NOUN	NNS	9	B-Chemical
,	,	PUNCT	,	9	O
sedatives	sedative	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
muscle	muscle	NOUN	NN	9	O
relaxants	relaxant	NOUN	NNS	5	O
administered	administer	VERB	VBD	9	O
through	through	ADP	IN	9	O
a	a	DET	DT	5	O
central	central	ADJ	JJ	5	O
venous	venous	ADJ	JJ	5	O
catheter	catheter	NOUN	NN	5	O
were	be	VERB	VBD	9	O
ineffective	ineffective	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
bolus	bolus	NOUN	NN	0	O
of	of	ADP	IN	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
injected	inject	VERB	VBN	3	O
through	through	ADP	IN	9	O
an	an	DET	DT	5	O
alternative	alternative	ADJ	JJ	5	O
catheter	catheter	NOUN	NN	5	O
provoked	provoke	VERB	VBD	9	O
a	a	DET	DT	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
crisis	crisis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
interference	interference	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
venous	venous	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
dialysis	dialysis	NOUN	NN	5	O
catheter	catheter	NOUN	NN	5	O
was	be	VERB	VBD	9	O
suspected	suspect	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
catheters	catheter	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
changed	change	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
hemodynamics	hemodynamic	NOUN	NNS	5	O
stabilized	stabilize	VERB	VBD	9	O
at	at	ADP	IN	9	O
lower	low	ADJ	JJR	9	O
catecholamine	catecholamine	NOUN	NN	9	B-Chemical
doses	dose	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
IV	IV	PROPN	NNP	9	O
drugs	drug	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
inadequate	inadequate	ADJ	JJ	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
CVVHDF	CVVHDF	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
interference	interference	NOUN	NN	9	O
with	with	ADP	IN	5	O
adjacent	adjacent	ADJ	JJ	9	O
catheters	catheter	NOUN	NNS	5	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
elimination	elimination	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
by	by	ADP	IN	9	O
CVVHDF	CVVHDF	PROPN	NNP	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
suspected	suspect	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Less	less	ADV	RBR	5	O
frequent	frequent	ADJ	JJ	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
lower	lower	VERB	VB	9	O
urine	urine	ADJ	JJ	9	O
volume	volume	NOUN	NN	9	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
maintained	maintain	VERB	VBN	9	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
regimen	regimen	NOUN	NN	5	O
of	of	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
once	once	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
per	per	ADP	IN	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
schedule	schedule	NOUN	NN	5	O
have	have	VERB	VBP	5	O
lower	low	ADJ	JJR	9	O
urine	urine	NOUN	NN	9	O
volumes	volume	NOUN	NNS	5	O
than	than	ADP	IN	5	O
do	do	VERB	VBP	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
multiple	multiple	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
cross	cross	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
sectional	sectional	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
85	85	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
clinic	clinic	NOUN	NN	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
different	different	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
schedules	schedule	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
hospital	hospital	NOUN	NN	5	O
for	for	ADP	IN	5	O
measurement	measurement	NOUN	NN	5	O
of	of	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
,	,	PUNCT	,	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
clearance	clearance	NOUN	NN	9	O
,	,	PUNCT	,	9	O
urine	urine	NOUN	NN	9	O
volume	volume	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
maximum	maximum	ADJ	JJ	5	O
osmolality	osmolality	NOUN	NN	0	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Multiple	Multiple	PROPN	NNP	5	O
daily	daily	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
higher	high	ADJ	JJR	9	O
urine	urine	NOUN	NN	9	O
volumes	volume	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
dosing	dosing	ADJ	JJ	9	O
schedule	schedule	NOUN	NN	5	O
,	,	PUNCT	,	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
daily	daily	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
affect	affect	VERB	VB	9	O
maximum	maximum	ADJ	JJ	5	O
osmolality	osmolality	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
clearance	clearance	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Urine	urine	NOUN	NN	9	O
volume	volume	NOUN	NN	9	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
giving	give	VERB	VBG	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
once	once	ADV	RB	5	O
daily	daily	ADV	RB	5	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
by	by	ADP	IN	9	O
lowering	lower	VERB	VBG	9	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
daily	daily	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Lithium	Lithium	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
polyuria	polyuria	NOUN	NN	5	B-Disease
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
extrarenal	extrarenal	ADJ	JJ	5	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
to	to	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Antibacterial	antibacterial	ADJ	JJ	0	O
medication	medication	NOUN	NN	5	O
use	use	NOUN	NN	5	O
during	during	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
birth	birth	NOUN	NN	5	B-Disease
defects	defect	NOUN	NNS	9	I-Disease
:	:	PUNCT	:	9	O
National	National	PROPN	NNP	2	O
Birth	Birth	PROPN	NNP	7	B-Disease
Defects	Defects	PROPN	NNPS	9	I-Disease
Prevention	Prevention	PROPN	NNP	2	O
Study	Study	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
estimate	estimate	VERB	VB	5	O
the	the	DET	DT	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
antibacterial	antibacterial	ADJ	JJ	0	O
medications	medication	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
selected	select	VERB	VBN	9	O
birth	birth	NOUN	NN	5	B-Disease
defects	defect	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

DESIGN	DESIGN	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
SETTING	setting	NOUN	NN	2	O
,	,	PUNCT	,	9	O
AND	and	CCONJ	CC	2	O
PARTICIPANTS	participant	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Population	population	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
,	,	PUNCT	,	9	O
multisite	multisite	NOUN	NN	5	O
,	,	PUNCT	,	9	O
case	case	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
control	control	NOUN	NN	9	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
pregnancies	pregnancy	NOUN	NNS	5	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
1	1	NUM	CD	9	O
of	of	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
30	30	NUM	CD	9	O
eligible	eligible	ADJ	JJ	5	O
major	major	ADJ	JJ	9	O
birth	birth	NOUN	NN	5	B-Disease
defects	defect	NOUN	NNS	9	I-Disease
identified	identify	VERB	VBN	9	O
via	via	ADP	IN	9	O
birth	birth	NOUN	NN	5	B-Disease
defect	defect	VERB	VBP	9	I-Disease
surveillance	surveillance	NOUN	NN	5	O
programs	program	NOUN	NNS	5	O
in	in	ADP	IN	5	O
10	10	NUM	CD	9	O
states	state	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
13	13	NUM	CD	7	O
155	155	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
control	control	NOUN	NN	9	O
women	woman	NOUN	NNS	5	O
randomly	randomly	ADV	RB	5	O
selected	select	VERB	VBD	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
geographical	geographical	ADJ	JJ	5	O
regions	region	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
4941	4941	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

MAIN	MAIN	PROPN	NNP	2	O
EXPOSURE	EXPOSURE	VERB	VBN	2	O
:	:	PUNCT	:	9	O
Reported	report	VERB	VBN	5	O
maternal	maternal	ADJ	JJ	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
antibacterials	antibacterial	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
month	month	NOUN	NN	5	O
before	before	ADP	IN	9	O
pregnancy	pregnancy	NOUN	NN	5	O
through	through	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
trimester	trimester	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

MAIN	MAIN	PROPN	NNP	2	O
OUTCOME	OUTCOME	PROPN	NNP	2	O
MEASURE	MEASURE	VERB	VBD	2	O
:	:	PUNCT	:	9	O
Odds	odd	NOUN	NNS	5	O
ratios	ratio	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
ORs	or	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
measuring	measure	VERB	VBG	9	O
the	the	DET	DT	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
antibacterial	antibacterial	ADJ	JJ	0	O
use	use	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
selected	select	VERB	VBN	9	O
birth	birth	NOUN	NN	5	B-Disease
defects	defect	NOUN	NNS	9	I-Disease
adjusted	adjust	VERB	VBN	9	O
for	for	ADP	IN	5	O
potential	potential	ADJ	JJ	9	O
confounders	confounder	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
reported	report	VERB	VBN	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
antibacterials	antibacterial	NOUN	NNS	5	O
increased	increase	VERB	VBD	9	O
during	during	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
peaking	peak	VERB	VBG	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
third	third	ADJ	JJ	9	O
month	month	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Sulfonamides	sulfonamide	NOUN	NNS	0	B-Chemical
were	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
anencephaly	anencephaly	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
adjusted	adjust	VERB	VBN	9	O
OR	or	CCONJ	CC	9	O
[	[	PUNCT	-LRB-	9	O
AOR	AOR	PROPN	NNP	5	O
]	]	PUNCT	-RRB-	9	O
=	=	VERB	VBZ	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
[	[	PUNCT	-LRB-	9	O
CI	CI	PROPN	NNP	7	O
]	]	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
hypoplastic	hypoplastic	ADJ	JJ	5	B-Disease
left	left	ADJ	JJ	5	I-Disease
heart	heart	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
AOR	AOR	PROPN	NNP	5	O
=	=	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
coarctation	coarctation	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
aorta	aorta	NOUN	NNS	9	I-Disease
(	(	PUNCT	-LRB-	9	O
AOR	AOR	PROPN	NNP	5	O
=	=	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
;	;	SYM	SYM	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
choanal	choanal	ADJ	JJ	5	B-Disease
atresia	atresia	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
AOR	AOR	PROPN	NNP	5	O
=	=	SYM	SYM	7	O
8	8	NUM	CD	9	O
.	.	NOUN	NN	9	O
0	0	NUM	CD	7	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
-	-	SYM	SYM	7	O
23	23	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
transverse	transverse	ADJ	JJ	5	B-Disease
limb	limb	NOUN	NN	5	I-Disease
deficiency	deficiency	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
AOR	AOR	PROPN	NNP	5	O
=	=	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
diaphragmatic	diaphragmatic	ADJ	JJ	5	B-Disease
hernia	hernia	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
AOR	AOR	PROPN	NNP	5	O
=	=	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Nitrofurantoins	nitrofurantoin	NOUN	NNS	_	B-Chemical
were	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
anophthalmia	anophthalmia	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
microphthalmos	microphthalmo	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
AOR	AOR	PROPN	NNP	5	O
=	=	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
;	;	SYM	SYM	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
hypoplastic	hypoplastic	ADJ	JJ	5	B-Disease
left	left	ADJ	JJ	5	I-Disease
heart	heart	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
AOR	AOR	PROPN	NNP	5	O
=	=	SYM	SYM	7	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
-	-	SYM	SYM	7	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
atrial	atrial	ADJ	JJ	5	B-Disease
septal	septal	ADJ	JJ	5	I-Disease
defects	defect	NOUN	NNS	9	I-Disease
(	(	PUNCT	-LRB-	9	O
AOR	AOR	PROPN	NNP	5	O
=	=	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
;	;	SYM	SYM	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cleft	cleft	VERB	VB	5	B-Disease
lip	lip	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
cleft	cleft	NOUN	NN	5	B-Disease
palate	palate	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
AOR	AOR	PROPN	NNP	5	O
=	=	SYM	SYM	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Other	other	ADJ	JJ	9	O
antibacterial	antibacterial	ADJ	JJ	0	O
agents	agent	NOUN	NNS	5	O
that	that	DET	WDT	5	O
showed	show	VERB	VBD	9	O
associations	association	NOUN	NNS	5	O
included	include	VERB	VBD	5	O
erythromycins	erythromycin	NOUN	NNS	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
defects	defect	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
penicillins	penicillin	NOUN	NNS	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
defect	defect	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
cephalosporins	cephalosporin	VERB	VBZ	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
defect	defect	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
quinolones	quinolone	NOUN	NNS	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
defect	defect	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Reassuringly	reassuringly	ADV	RB	5	O
,	,	PUNCT	,	9	O
penicillins	penicillin	NOUN	NNS	0	B-Chemical
,	,	PUNCT	,	9	O
erythromycins	erythromycin	NOUN	NNS	9	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cephalosporins	cephalosporin	VERB	VBZ	5	B-Chemical
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
used	use	VERB	VBN	5	O
commonly	commonly	ADV	RB	5	O
by	by	ADP	IN	9	O
pregnant	pregnant	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
many	many	ADJ	JJ	5	O
birth	birth	NOUN	NN	5	B-Disease
defects	defect	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

Sulfonamides	sulfonamide	NOUN	NNS	0	B-Chemical
and	and	CCONJ	CC	5	O
nitrofurantoins	nitrofurantoin	NOUN	NNS	9	B-Chemical
were	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
several	several	ADJ	JJ	9	O
birth	birth	NOUN	NN	5	B-Disease
defects	defect	NOUN	NNS	9	I-Disease
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
a	a	DET	DT	5	O
need	need	NOUN	NN	5	O
for	for	ADP	IN	5	O
additional	additional	ADJ	JJ	9	O
scrutiny	scrutiny	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Differential	differential	ADJ	JJ	9	O
impact	impact	NOUN	NN	5	O
of	of	ADP	IN	5	O
immune	immune	ADJ	JJ	3	O
escape	escape	NOUN	NN	5	O
mutations	mutation	NOUN	NNS	1	O
G145R	g145r	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
P120T	p120t	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
replication	replication	NOUN	NN	9	O
of	of	ADP	IN	5	O
lamivudine	lamivudine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
resistant	resistant	ADJ	JJ	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
virus	virus	NOUN	NN	9	I-Chemical
e	e	NOUN	NN	9	I-Chemical
antigen	antigen	NOUN	NN	3	I-Chemical
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
-	-	PUNCT	HYPH	7	O
negative	negative	ADJ	JJ	9	O
strains	strain	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

Immune	Immune	PROPN	NNP	9	O
escape	escape	VERB	VBP	5	O
variants	variant	NOUN	NNS	1	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hepatitis	hepatitis	PROPN	NNP	9	B-Disease
B	B	PROPN	NNP	9	I-Disease
virus	virus	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
HBV	HBV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
represent	represent	VERB	VBP	9	O
an	an	DET	DT	5	O
emerging	emerge	VERB	VBG	5	O
clinical	clinical	ADJ	JJ	5	O
challenge	challenge	NOUN	NN	9	O
,	,	PUNCT	,	9	O
because	because	ADP	IN	5	O
they	-PRON-	PRON	PRP	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
vaccine	vaccine	NOUN	NN	5	O
escape	escape	NOUN	NN	5	O
,	,	PUNCT	,	9	O
HBV	HBV	PROPN	NNP	9	O
reactivation	reactivation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
failure	failure	NOUN	NN	5	O
of	of	ADP	IN	5	O
diagnostic	diagnostic	ADJ	JJ	5	O
tests	test	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Recent	recent	ADJ	JJ	9	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
a	a	DET	DT	5	O
preferential	preferential	ADJ	JJ	9	O
selection	selection	NOUN	NN	5	O
of	of	ADP	IN	5	O
immune	immune	ADJ	JJ	3	O
escape	escape	NOUN	NN	5	O
mutants	mutant	NOUN	NNS	1	O
in	in	ADP	IN	5	O
distinct	distinct	ADJ	JJ	9	O
peripheral	peripheral	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
leukocyte	leukocyte	NOUN	NN	3	O
compartments	compartment	NOUN	NNS	9	O
of	of	ADP	IN	5	O
infected	infected	ADJ	JJ	3	O
individuals	individual	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
therefore	therefore	ADV	RB	5	O
systematically	systematically	ADV	RB	5	O
analyzed	analyze	VERB	VBD	9	O
the	the	DET	DT	5	O
functional	functional	ADJ	JJ	9	O
impact	impact	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
prevalent	prevalent	ADJ	JJ	9	O
immune	immune	ADJ	JJ	3	O
escape	escape	NOUN	NN	5	O
variants	variant	NOUN	NNS	1	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
sG145R	sG145R	NOUN	NNS	1	O
and	and	CCONJ	CC	5	O
sP120T	sP120T	PROPN	NNP	9	O
mutants	mutant	NOUN	NNS	1	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
viral	viral	ADJ	JJ	9	O
replication	replication	NOUN	NN	9	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
antiviral	antiviral	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
susceptibility	susceptibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
common	common	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
mutants	mutant	NOUN	NNS	1	O
with	with	ADP	IN	5	O
resistance	resistance	NOUN	NN	9	O
to	to	PART	TO	5	O
lamivudine	lamivudine	VERB	VB	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
LAM	LAM	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
HBeAg	HBeAg	PROPN	NNP	9	B-Chemical
negativity	negativity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Replication	replication	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
competent	competent	ADJ	JJ	9	O
HBV	HBV	PROPN	NNP	9	O
strains	strain	VERB	VBZ	1	O
with	with	ADP	IN	5	O
sG145R	sG145R	PROPN	NNP	1	O
or	or	CCONJ	CC	5	O
sP120T	sP120T	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
LAM	LAM	PROPN	NNP	9	B-Chemical
resistance	resistance	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
rtM204I	rtM204I	NOUN	NNS	1	O
or	or	CCONJ	CC	5	O
rtL180M	rtL180M	PROPN	NNP	7	O
/	/	SYM	SYM	9	O
rtM204V	rtm204v	NOUN	NN	1	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
generated	generate	VERB	VBN	9	O
on	on	ADP	IN	5	O
an	an	DET	DT	5	O
HBeAg	HBeAg	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
HBeAg	HBeAg	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
negative	negative	ADJ	JJ	9	O
background	background	NOUN	NN	9	O
with	with	ADP	IN	5	O
precore	precore	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
PC	pc	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
basal	basal	NOUN	NN	3	O
core	core	NOUN	NN	9	O
promoter	promoter	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
BCP	BCP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
mutants	mutant	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
sG145R	sG145R	PROPN	NNP	1	O
mutation	mutation	NOUN	NN	1	O
strongly	strongly	ADV	RB	9	O
reduced	reduce	VERB	VBD	9	O
HBsAg	HBsAg	PROPN	NNP	9	B-Chemical
levels	level	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
able	able	ADJ	JJ	9	O
to	to	PART	TO	5	O
fully	fully	ADV	RB	9	O
restore	restore	VERB	VB	9	O
the	the	DET	DT	5	O
impaired	impaired	ADJ	JJ	9	O
replication	replication	NOUN	NN	9	O
of	of	ADP	IN	5	O
LAM	LAM	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
resistant	resistant	ADJ	JJ	9	O
HBV	HBV	PROPN	NNP	9	O
mutants	mutant	NOUN	NNS	1	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
wild	wild	ADJ	JJ	1	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
HBV	HBV	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
PC	pc	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
BCP	BCP	PROPN	NNP	9	O
mutations	mutation	NOUN	NNS	1	O
further	further	ADV	RB	9	O
enhanced	enhance	VERB	VBD	3	O
viral	viral	ADJ	JJ	9	O
replication	replication	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
the	the	DET	DT	5	O
sP120T	sP120T	PROPN	NNP	9	O
substitution	substitution	NOUN	NN	9	O
also	also	ADV	RB	9	O
impaired	impair	VERB	VBD	9	O
HBsAg	HBsAg	PROPN	NNP	9	B-Chemical
secretion	secretion	NOUN	NN	3	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
enhance	enhance	VERB	VB	9	O
the	the	DET	DT	5	O
replication	replication	NOUN	NN	9	O
of	of	ADP	IN	5	O
LAM	LAM	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
resistant	resistant	ADJ	JJ	9	O
clones	clone	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
concomitant	concomitant	ADJ	JJ	9	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
HBeAg	HBeAg	PROPN	NNP	9	B-Chemical
negativity	negativity	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
PC	PC	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
BCP	BCP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
sP120T	sp120t	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
LAM	LAM	PROPN	NNP	9	B-Chemical
resistance	resistance	NOUN	NN	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
restoration	restoration	NOUN	NN	5	O
of	of	ADP	IN	5	O
replication	replication	NOUN	NN	9	O
to	to	ADP	IN	5	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
wild	wild	ADJ	JJ	1	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
HBV	HBV	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
all	all	DET	DT	5	O
clones	clone	NOUN	NNS	3	O
with	with	ADP	IN	5	O
combined	combine	VERB	VBN	9	O
immune	immune	ADJ	JJ	3	O
escape	escape	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
LAM	LAM	PROPN	NNP	9	B-Chemical
resistance	resistance	NOUN	NN	9	O
mutations	mutation	NOUN	NNS	1	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
nucleotide	nucleotide	NOUN	NN	1	B-Chemical
analogues	analogue	VERB	VBZ	0	O
adefovir	adefovir	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
tenofovir	tenofovir	DET	DT	0	B-Chemical
remained	remain	VERB	VBD	9	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
suppressing	suppress	VERB	VBG	3	O
viral	viral	ADJ	JJ	9	O
replication	replication	NOUN	NN	9	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
reveal	reveal	VERB	VBP	9	O
the	the	DET	DT	5	O
differential	differential	ADJ	JJ	9	O
impact	impact	NOUN	NN	5	O
of	of	ADP	IN	5	O
immune	immune	ADJ	JJ	3	O
escape	escape	NOUN	NN	5	O
variants	variant	NOUN	NNS	1	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
replication	replication	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
drug	drug	NOUN	NN	5	O
susceptibility	susceptibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
complex	complex	ADJ	JJ	9	O
HBV	HBV	PROPN	NNP	9	O
mutants	mutant	NOUN	NNS	1	O
,	,	PUNCT	,	9	O
supporting	support	VERB	VBG	9	O
the	the	DET	DT	5	O
need	need	NOUN	NN	5	O
of	of	ADP	IN	5	O
close	close	ADJ	JJ	5	O
surveillance	surveillance	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
adjustment	adjustment	NOUN	NN	5	O
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
selection	selection	NOUN	NN	5	O
of	of	ADP	IN	5	O
distinct	distinct	ADJ	JJ	9	O
mutational	mutational	ADJ	JJ	9	O
patterns	pattern	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
omeprazole	omeprazole	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Omeprazole	Omeprazole	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
block	block	VERB	VB	9	O
the	the	DET	DT	5	O
final	final	ADJ	JJ	9	O
step	step	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
acid	acid	NOUN	NN	0	O
secretory	secretory	ADJ	JJ	3	O
process	process	NOUN	NN	5	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
parietal	parietal	ADJ	JJ	5	O
cell	cell	NOUN	NN	3	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
extremely	extremely	ADV	RB	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
peptic	peptic	ADJ	JJ	5	B-Disease
ulcer	ulcer	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
reflux	reflux	NOUN	NN	5	B-Disease
esophagitis	esophagitis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
Zollinger	Zollinger	PROPN	NNP	6	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
Ellison	Ellison	PROPN	NNP	6	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
clinical	clinical	ADJ	JJ	5	O
experience	experience	NOUN	NN	5	O
with	with	ADP	IN	5	O
omeprazole	omeprazole	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
still	still	ADV	RB	5	O
limited	limited	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
many	many	ADJ	JJ	5	O
controlled	control	VERB	VBN	5	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
established	establish	VERB	VBN	9	O
the	the	DET	DT	5	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
serious	serious	ADJ	JJ	5	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
adverse	adverse	ADJ	JJ	5	O
reaction	reaction	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
omeprazole	omeprazole	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
weakness	weakness	NOUN	NN	5	O
,	,	PUNCT	,	9	O
lethargy	lethargy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
shortness	shortness	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
breath	breath	NOUN	NN	5	I-Disease
2	2	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
starting	start	VERB	VBG	9	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
omeprazole	omeprazole	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
her	-PRON-	DET	PRP$	5	O
hematocrit	hematocrit	NOUN	NN	9	O
had	have	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
from	from	ADP	IN	9	O
44	44	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	ADP	IN	5	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
she	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
positive	positive	ADJ	JJ	9	O
direct	direct	ADJ	JJ	9	O
Coombs	Coombs	PROPN	NNP	6	O
antiglobulin	antiglobulin	NOUN	NN	3	O
test	test	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
elevated	elevated	ADJ	JJ	9	O
indirect	indirect	ADJ	JJ	5	O
bilirubin	bilirubin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
she	-PRON-	PRON	PRP	5	O
discontinued	discontinue	VERB	VBD	5	O
the	the	DET	DT	5	O
omeprazole	omeprazole	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
her	-PRON-	DET	PRP$	5	O
hemoglobin	hemoglobin	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
hematocrit	hematocrit	NOUN	NN	9	O
gradually	gradually	ADV	RB	9	O
returned	return	VERB	VBN	5	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
by	by	ADP	IN	9	O
which	which	DET	WDT	5	O
omeprazole	omeprazole	NOUN	NN	0	B-Chemical
caused	cause	VERB	VBD	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
uncertain	uncertain	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
physicians	physician	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
alerted	alert	VERB	VBN	5	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Phenylephrine	phenylephrine	NOUN	NN	0	B-Chemical
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
ephedrine	ephedrine	NOUN	NN	0	B-Chemical
reduces	reduce	VERB	VBZ	9	B-Disease
frontal	frontal	ADJ	JJ	5	I-Disease
lobe	lobe	ADJ	JJ	5	I-Disease
oxygenation	oxygenation	NOUN	NN	5	I-Disease
following	follow	VERB	VBG	9	O
anesthesia	anesthesia	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Vasopressor	Vasopressor	PROPN	NNP	7	O
agents	agent	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
correct	correct	VERB	VB	5	O
anesthesia	anesthesia	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
phenylephrine	phenylephrine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
ephedrine	ephedrine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
frontal	frontal	ADJ	JJ	5	O
lobe	lobe	NOUN	NN	5	O
oxygenation	oxygenation	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
S	S	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
c	c	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
O	o	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
following	follow	VERB	VBG	9	O
anesthesia	anesthesia	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Following	follow	VERB	VBG	9	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
anesthesia	anesthesia	NOUN	NN	5	O
by	by	ADP	IN	9	O
fentanyl	fentanyl	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
15	15	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
kg	kg	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
propofol	propofol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
kg	kg	X	FW	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
13	13	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
phenylephrine	phenylephrine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	NOUN	NN	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
iv	iv	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
12	12	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
ephedrine	ephedrine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
iv	iv	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
to	to	PART	TO	5	O
restore	restore	VERB	VB	9	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MAP	MAP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Heart	heart	NOUN	NN	2	O
rate	rate	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
HR	HR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
MAP	MAP	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
stroke	stroke	NOUN	NN	5	B-Disease
volume	volume	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
SV	SV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
cardiac	cardiac	ADJ	JJ	5	O
output	output	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CO	CO	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
frontal	frontal	ADJ	JJ	5	O
lobe	lobe	NOUN	NN	5	O
oxygenation	oxygenation	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
S	S	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
c	c	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
O	o	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
registered	register	VERB	VBN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
anesthesia	anesthesia	NOUN	NN	5	O
was	be	VERB	VBD	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	B-Disease
decrease	decrease	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	I-Disease
MAP	MAP	PROPN	NNP	9	I-Disease
,	,	PUNCT	,	9	I-Disease
HR	hr	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	I-Disease
SV	SV	PROPN	NNP	9	I-Disease
,	,	PUNCT	,	9	I-Disease
and	and	CCONJ	CC	5	I-Disease
CO	CO	PROPN	NNP	0	I-Disease
concomitant	concomitant	ADJ	JJ	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
elevation	elevation	NOUN	NN	9	O
in	in	ADP	IN	5	O
S	S	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
c	c	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
O	o	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
phenylephrine	phenylephrine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
MAP	MAP	PROPN	NNP	9	O
increased	increase	VERB	VBD	9	O
(	(	PUNCT	-LRB-	9	O
51	51	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
12	12	NUM	CD	9	O
to	to	PART	TO	5	O
81	81	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
13	13	NUM	CD	7	O
mmHg	mmhg	SYM	SYM	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
;	;	PUNCT	:	9	O
mean	mean	VERB	VB	5	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SD	sd	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
14	14	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
from	from	ADP	IN	9	O
70	70	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	ADP	IN	5	O
60	60	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
S	S	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
c	c	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
O	o	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
followed	follow	VERB	VBD	9	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
CO	CO	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
l	l	NOUN	NN	0	O
min	min	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
ephedrine	ephedrine	NOUN	NN	0	B-Chemical
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
MAP	MAP	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
53	53	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
9	9	NUM	CD	7	O
to	to	ADP	IN	5	O
79	79	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
8	8	NUM	CD	9	O
mmHg	mmhg	NOUN	NN	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
restored	restore	VERB	VBN	3	O
CO	CO	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
to	to	ADP	IN	5	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
l	l	NOUN	NN	0	O
min	min	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
preserved	preserve	VERB	VBN	9	O
S	S	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
c	c	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
O	o	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
utilization	utilization	NOUN	NN	9	O
of	of	ADP	IN	5	O
phenylephrine	phenylephrine	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
correct	correct	VERB	VB	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
anesthesia	anesthesia	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
negative	negative	ADJ	JJ	9	O
impact	impact	NOUN	NN	5	O
on	on	ADP	IN	5	O
S	S	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
c	c	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
O	o	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
while	while	ADP	IN	9	O
ephedrine	ephedrine	NOUN	NN	0	B-Chemical
maintains	maintain	VERB	VBZ	9	O
frontal	frontal	ADJ	JJ	5	O
lobe	lobe	NOUN	NN	5	O
oxygenation	oxygenation	NOUN	NN	5	O
potentially	potentially	ADV	RB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
CO	CO	PROPN	NNP	0	O
.	.	PUNCT	.	9	O

Prolonged	prolonged	ADJ	JJ	9	O
elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
argatroban	argatroban	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	O
transplant	transplant	NOUN	NN	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
suspected	suspect	VERB	VBN	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
with	with	ADP	IN	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Direct	direct	ADJ	JJ	9	O
thrombin	thrombin	NOUN	NN	0	O
inhibitors	inhibitor	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
DTIs	dti	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
provide	provide	VERB	VBP	5	O
an	an	DET	DT	5	O
alternative	alternative	ADJ	JJ	5	O
method	method	NOUN	NN	5	O
of	of	ADP	IN	5	O
anticoagulation	anticoagulation	NOUN	NN	5	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
heparin	heparin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
HIT	HIT	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
HIT	hit	VERB	VB	5	B-Disease
with	with	ADP	IN	5	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
HITT	HITT	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
undergoing	undergo	VERB	VBG	9	O
cardiopulmonary	cardiopulmonary	ADJ	JJ	5	O
bypass	bypass	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CPB	CPB	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
following	follow	VERB	VBG	9	O
report	report	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
65	65	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
critically	critically	ADV	RB	9	B-Disease
ill	ill	ADJ	JJ	5	I-Disease
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
suspected	suspect	VERB	VBN	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
HITT	HITT	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
argatroban	argatroban	ADV	RB	5	B-Chemical
for	for	ADP	IN	5	O
anticoagulation	anticoagulation	NOUN	NN	5	O
on	on	ADP	IN	5	O
bypass	bypass	NOUN	NN	5	O
during	during	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
transplantation	transplantation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
required	require	VERB	VBN	9	O
massive	massive	ADJ	JJ	9	O
transfusion	transfusion	NOUN	NN	5	O
support	support	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
55	55	NUM	CD	7	O
units	unit	NOUN	NNS	9	O
of	of	ADP	IN	5	O
red	red	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
cells	cell	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
42	42	NUM	CD	7	O
units	unit	NOUN	NNS	9	O
of	of	ADP	IN	5	O
fresh	fresh	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
frozen	frozen	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
,	,	PUNCT	,	9	O
40	40	NUM	CD	9	O
units	unit	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cryoprecipitate	cryoprecipitate	NOUN	NN	5	O
,	,	PUNCT	,	9	O
40	40	NUM	CD	9	O
units	unit	NOUN	NNS	9	O
of	of	ADP	IN	5	O
platelets	platelet	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
three	three	NUM	CD	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
recombinant	recombinant	ADJ	JJ	3	O
Factor	Factor	PROPN	NNP	9	O
VIIa	VIIa	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
intraoperative	intraoperative	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
postoperative	postoperative	ADJ	JJ	5	I-Disease
bleeding	bleeding	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

STUDY	STUDY	PROPN	NNP	2	O
DESIGN	DESIGN	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Plasma	plasma	NOUN	NN	0	O
samples	sample	NOUN	NNS	9	O
from	from	ADP	IN	9	O
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
CPB	CPB	PROPN	NNP	5	O
were	be	VERB	VBD	9	O
analyzed	analyze	VERB	VBN	9	O
postoperatively	postoperatively	ADV	RB	5	O
for	for	ADP	IN	5	O
argatroban	argatroban	ADJ	JJ	5	B-Chemical
concentration	concentration	NOUN	NN	0	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
modified	modify	VERB	VBN	9	O
ecarin	ecarin	ADJ	JJ	0	O
clotting	clotting	NOUN	NN	5	O
time	time	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ECT	ECT	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
assay	assay	VERB	VBP	3	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Unexpectedly	unexpectedly	ADV	RB	9	O
high	high	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
argatroban	argatroban	NOUN	NN	5	B-Chemical
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
samples	sample	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
32	32	NUM	CD	7	O
microg	microg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
prolonged	prolonged	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
argatroban	argatroban	VERB	VBP	5	B-Chemical
half	half	NOUN	NN	5	O
life	life	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
t	t	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
514	514	NUM	CD	7	O
minutes	minute	NOUN	NNS	0	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
published	publish	VERB	VBN	9	O
elimination	elimination	NOUN	NN	9	O
t	t	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
39	39	NUM	CD	7	O
-	-	SYM	SYM	7	O
51	51	NUM	CD	7	O
minutes	minute	NOUN	NNS	0	O
[	[	PUNCT	-LRB-	9	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
181	181	NUM	CD	7	O
minutes	minute	NOUN	NNS	0	O
with	with	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
]	]	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Correlation	correlation	NOUN	NN	9	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
argatroban	argatroban	ADJ	JJ	5	B-Chemical
concentration	concentration	NOUN	NN	0	O
versus	versus	ADP	IN	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	VERB	VBZ	9	O
coagulation	coagulation	NOUN	NN	5	O
variables	variable	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
course	course	NOUN	NN	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
prolonged	prolong	VERB	VBN	9	O
elevated	elevated	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
argatroban	argatroban	NOUN	NN	5	B-Chemical
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
contributed	contribute	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
extended	extend	VERB	VBN	5	O
coagulopathy	coagulopathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
DTIs	dti	NOUN	NNS	5	O
do	do	VERB	VBP	5	O
not	not	ADV	RB	5	O
have	have	VERB	VB	5	O
reversal	reversal	NOUN	NN	9	O
agents	agent	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
surgical	surgical	ADJ	JJ	5	O
teams	team	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
transfusion	transfusion	NOUN	NN	5	O
services	service	NOUN	NNS	5	O
should	should	VERB	MD	5	O
remain	remain	VERB	VB	9	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
massive	massive	ADJ	JJ	9	O
transfusion	transfusion	NOUN	NN	5	O
events	event	NOUN	NNS	5	O
during	during	ADP	IN	5	O
anticoagulation	anticoagulation	NOUN	NN	5	O
with	with	ADP	IN	5	O
these	these	DET	DT	5	O
agents	agent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
report	report	NOUN	NN	5	O
to	to	PART	TO	5	O
measure	measure	VERB	VB	5	O
plasma	plasma	NOUN	NN	9	O
argatroban	argatroban	ADJ	JJ	5	B-Chemical
concentration	concentration	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
context	context	NOUN	NN	5	O
of	of	ADP	IN	5	O
CPB	CPB	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
extended	extend	VERB	VBN	5	O
coagulopathy	coagulopathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
adjunctive	adjunctive	ADJ	JJ	5	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
male	male	ADJ	JJ	9	O
sexual	sexual	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	B-Chemical
serotonin	serotonin	NOUN	NN	9	I-Chemical
reuptake	reuptake	NOUN	NN	0	I-Chemical
inhibitor	inhibitor	NOUN	NN	3	I-Chemical
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
randomized	randomized	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
adjunctive	adjunctive	ADJ	JJ	5	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
sustained	sustain	VERB	VBN	5	O
-	-	PUNCT	HYPH	7	O
release	release	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
SR	SR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
male	male	ADJ	JJ	9	O
sexual	sexual	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
SD	SD	PROPN	NNP	7	B-Disease
)	)	PUNCT	-RRB-	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	B-Chemical
serotonin	serotonin	NOUN	NN	9	I-Chemical
reuptake	reuptake	NOUN	NN	0	I-Chemical
inhibitor	inhibitor	NOUN	NN	3	I-Chemical
(	(	PUNCT	-LRB-	9	O
SSRI	SSRI	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
SD	SD	PROPN	NNP	7	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
common	common	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
SSRIs	ssri	NOUN	NNS	5	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
effective	effective	ADJ	JJ	5	O
treatments	treatment	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
yet	yet	ADV	RB	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
determined	determine	VERB	VBN	9	O
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
randomized	randomized	ADJ	JJ	5	O
sample	sample	NOUN	NN	9	O
consisted	consist	VERB	VBN	5	O
of	of	ADP	IN	5	O
234	234	NUM	CD	7	O
euthymic	euthymic	ADJ	JJ	3	O
men	man	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
receiving	receive	VERB	VBG	9	O
some	some	DET	DT	5	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
SSRI	SSRI	PROPN	NNP	5	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
men	man	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
assigned	assign	VERB	VBN	5	O
to	to	ADP	IN	5	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
SR	SR	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
150	150	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
twice	twice	ADV	RB	9	O
daily	daily	ADV	RB	5	O
,	,	PUNCT	,	9	O
117	117	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
twice	twice	ADV	RB	9	O
daily	daily	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
117	117	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
12	12	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Efficacy	Efficacy	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
Clinical	Clinical	PROPN	NNP	5	O
Global	Global	PROPN	NNP	5	O
Impression	Impression	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
Sexual	Sexual	PROPN	NNP	5	O
Function	Function	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
CGI	CGI	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
SF	SF	PROPN	NNP	9	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
outcome	outcome	NOUN	NN	5	O
measure	measure	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
International	International	PROPN	NNP	2	O
Index	Index	PROPN	NNP	5	O
of	of	ADP	IN	5	O
Erectile	Erectile	PROPN	NNP	5	O
Function	Function	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
IIEF	IIEF	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
Arizona	Arizona	PROPN	NNP	4	O
Sexual	Sexual	PROPN	NNP	5	O
Experience	experience	NOUN	NN	5	O
Scale	Scale	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
ASEX	ASEX	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
Erectile	Erectile	PROPN	NNP	5	B-Disease
Dysfunction	Dysfunction	PROPN	NNP	5	I-Disease
Inventory	Inventory	PROPN	NNP	5	O
of	of	ADP	IN	5	O
Treatment	Treatment	PROPN	NNP	9	O
Satisfaction	Satisfaction	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
EDITS	EDITS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
secondary	secondary	ADJ	JJ	9	O
outcome	outcome	NOUN	NN	5	O
measures	measure	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Participants	participant	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
followed	follow	VERB	VBN	9	O
biweekly	biweekly	ADV	RB	5	O
during	during	ADP	IN	5	O
study	study	NOUN	NN	9	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
After	after	ADP	IN	9	O
12	12	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
mean	mean	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
sd	sd	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
scores	score	NOUN	NNS	5	O
for	for	ADP	IN	5	O
CGI	CGI	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
SF	SF	PROPN	NNP	9	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
e	e	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
better	well	ADJ	JJR	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
on	on	ADP	IN	5	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
SR	SR	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Men	man	NOUN	NNS	7	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
IIEF	iief	ADJ	JJ	5	O
score	score	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
54	54	NUM	CD	7	O
.	.	NOUN	NN	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
003	003	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
five	five	NUM	CD	9	O
different	different	ADJ	JJ	9	O
domains	domain	NOUN	NNS	1	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
IIEF	IIEF	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Total	total	ADJ	JJ	7	O
ASEX	ASEX	PROPN	NNP	5	O
scores	score	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
e	e	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
better	well	ADJ	JJR	5	O
,	,	PUNCT	,	9	O
among	among	ADP	IN	5	O
men	man	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
than	than	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
vs	vs	ADP	IN	7	O
21	21	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
002	002	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
EDITS	EDITS	PROPN	NNP	5	O
scores	score	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
67	67	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
36	36	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
ASEX	ASEX	PROPN	NNP	5	O
score	score	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
CGI	cgi	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
SF	SF	PROPN	NNP	9	O
score	score	NOUN	NN	5	O
were	be	VERB	VBD	9	O
correlated	correlate	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
003	003	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
linear	linear	ADJ	JJ	5	O
regression	regression	NOUN	NN	5	O
analyses	analyse	VERB	VBZ	9	O
the	the	DET	DT	5	O
CGI	CGI	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
SF	SF	PROPN	NNP	9	O
score	score	NOUN	NN	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
affected	affect	VERB	VBN	9	O
significantly	significantly	ADV	RB	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
SD	SD	PROPN	NNP	7	B-Disease
,	,	PUNCT	,	9	O
type	type	NOUN	NN	9	O
of	of	ADP	IN	5	O
SSRI	SSRI	PROPN	NNP	5	B-Chemical
used	use	VERB	VBD	5	O
and	and	CCONJ	CC	5	O
age	age	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Bupropion	bupropion	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
male	male	ADJ	JJ	9	O
SD	sd	NOUN	NN	7	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
SSRIs	ssri	NOUN	NNS	5	B-Chemical
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
provide	provide	VERB	VBP	5	O
empirical	empirical	ADJ	JJ	5	O
support	support	NOUN	NN	5	O
for	for	ADP	IN	5	O
conducting	conduct	VERB	VBG	5	O
a	a	DET	DT	5	O
further	further	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
bupropion	bupropion	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Prevention	prevention	NOUN	NN	2	O
of	of	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
reorganization	reorganization	NOUN	NN	9	O
of	of	ADP	IN	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
functions	function	NOUN	NNS	9	O
by	by	ADP	IN	9	O
transplantation	transplantation	NOUN	NN	9	O
of	of	ADP	IN	5	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
phase	phase	NOUN	NN	5	O
of	of	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
investigated	investigate	VERB	VBD	9	O
the	the	DET	DT	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
potential	potential	NOUN	NN	9	O
of	of	ADP	IN	5	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
mononuclear	mononuclear	NOUN	NN	3	O
cells	cell	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
BMCs	BMCs	PROPN	NNPS	3	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

BMCs	bmc	NOUN	NNS	3	O
obtained	obtain	VERB	VBD	9	O
from	from	ADP	IN	9	O
green	green	ADJ	JJ	9	O
fluorescent	fluorescent	ADJ	JJ	3	O
protein	protein	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
GFP	GFP	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
transgenic	transgenic	ADJ	JJ	3	O
mice	mouse	NOUN	NNS	3	O
or	or	CCONJ	CC	5	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
transplanted	transplant	VERB	VBN	3	O
intravenously	intravenously	ADV	RB	0	O
after	after	ADP	IN	9	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
SE	se	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Spontaneous	spontaneous	ADJ	JJ	9	B-Disease
recurrent	recurrent	NOUN	NN	5	I-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
SRS	SRS	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
monitored	monitor	VERB	VBN	9	O
using	use	VERB	VBG	9	O
Racine	Racine	PROPN	NNP	6	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
seizure	seizure	VERB	VB	5	B-Disease
severity	severity	NOUN	NN	5	O
scale	scale	NOUN	NN	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
saline	saline	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
developed	develop	VERB	VBD	5	O
SRS	SRS	PROPN	NNP	5	B-Disease
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
none	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
BMC	BMC	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
animals	animal	NOUN	NNS	9	O
had	have	VERB	VBD	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
short	short	ADJ	JJ	5	O
term	term	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
transplantation	transplantation	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
regardless	regardless	ADV	RB	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
BMC	BMC	PROPN	NNP	9	O
source	source	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Over	over	ADP	IN	5	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
chronic	chronic	ADJ	JJ	5	O
phase	phase	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
120	120	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
transplantation	transplantation	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
only	only	ADV	RB	9	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
BMC	bmc	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
animals	animal	NOUN	NNS	9	O
had	have	VERB	VBD	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
lower	low	ADJ	JJR	9	O
frequency	frequency	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
duration	duration	NOUN	NN	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
density	density	NOUN	NN	9	O
of	of	ADP	IN	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
neurons	neuron	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
brains	brain	NOUN	NNS	9	O
of	of	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
BMCs	bmc	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
markedly	markedly	ADV	RB	9	O
preserved	preserve	VERB	VBN	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
hippocampal	hippocampal	ADJ	JJ	3	O
Schaeffer	Schaeffer	PROPN	NNP	6	O
collateral	collateral	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
CA1	CA1	PROPN	NNP	3	O
synapses	synapsis	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
potentiation	potentiation	NOUN	NN	3	O
was	be	VERB	VBD	9	O
preserved	preserve	VERB	VBN	9	O
in	in	ADP	IN	5	O
BMC	BMC	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
transplanted	transplant	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
donor	donor	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
derived	derive	VERB	VBN	9	O
GFP	GFP	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
cells	cell	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
rarely	rarely	ADV	RB	5	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
brains	brain	NOUN	NNS	9	O
of	of	ADP	IN	5	O
transplanted	transplanted	ADJ	JJ	3	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
BMCs	bmc	NOUN	NNS	3	O
can	can	VERB	MD	5	O
prevent	prevent	VERB	VB	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
reduce	reduce	VERB	VB	5	O
neuronal	neuronal	ADJ	JJ	3	B-Disease
loss	loss	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
influence	influence	VERB	VB	5	O
the	the	DET	DT	5	O
reorganization	reorganization	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampal	hippocampal	ADJ	JJ	3	O
neuronal	neuronal	ADJ	JJ	3	O
network	network	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Normalizing	normalizing	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
modafinil	modafinil	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
sleep	sleep	NOUN	NN	5	O
in	in	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
morning	morning	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
dosed	dose	VERB	VBN	0	O
modafinil	modafinil	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
sleep	sleep	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
daytime	daytime	ADJ	JJ	5	B-Disease
sleepiness	sleepiness	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Twenty	twenty	NUM	CD	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
participants	participant	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
assigned	assign	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
modafinil	modafinil	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
400	400	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
N	n	NOUN	NN	9	O
=	=	SYM	SYM	7	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
N	n	NOUN	NN	9	O
=	=	SYM	SYM	7	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
every	every	DET	DT	5	O
morning	morning	NOUN	NN	5	O
at	at	ADP	IN	9	O
7	7	NUM	CD	9	O
:	:	SYM	SYM	9	O
30	30	NUM	CD	9	O
a	a	DET	DT	5	O
.	.	PUNCT	.	9	O
m	m	NOUN	NN	9	O
.	.	PUNCT	.	9	O
for	for	ADP	IN	5	O
16	16	NUM	CD	9	O
days	day	NOUN	NNS	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
inpatient	inpatient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
randomized	randomize	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Participants	participant	NOUN	NNS	5	O
underwent	undergo	VERB	VBD	5	O
polysomnographic	polysomnographic	ADJ	JJ	5	O
sleep	sleep	NOUN	NN	5	O
recordings	recording	NOUN	NNS	5	O
on	on	ADP	IN	5	O
days	day	NOUN	NNS	9	O
1	1	NUM	CD	9	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
7	7	NUM	CD	9	O
to	to	ADP	IN	5	O
9	9	NUM	CD	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
14	14	NUM	CD	7	O
to	to	PART	TO	5	O
16	16	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
first	first	ADV	RB	9	O
,	,	PUNCT	,	9	O
second	second	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
third	third	ADJ	JJ	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
abstinence	abstinence	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
Multiple	Multiple	PROPN	NNP	5	O
Sleep	Sleep	PROPN	NNP	5	O
Latency	Latency	PROPN	NNP	5	O
Test	Test	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
at	at	ADP	IN	9	O
11	11	NUM	CD	7	O
:	:	SYM	SYM	9	O
30	30	NUM	CD	9	O
a	a	DET	DT	5	O
.	.	PUNCT	.	9	O
m	m	NOUN	NN	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
:	:	SYM	SYM	9	O
00	00	PUNCT	NFP	7	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
m	m	NOUN	NN	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
:	:	SYM	SYM	9	O
30	30	NUM	CD	9	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
m	m	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
on	on	ADP	IN	5	O
days	day	NOUN	NNS	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
comparison	comparison	NOUN	NN	9	O
of	of	ADP	IN	5	O
sleep	sleep	NOUN	NN	5	O
architecture	architecture	NOUN	NN	5	O
variables	variable	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
12	12	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
comparison	comparison	NOUN	NN	9	O
participants	participant	NOUN	NNS	5	O
underwent	undergo	VERB	VBD	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
night	night	NOUN	NN	5	O
of	of	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
polysomnography	polysomnography	NOUN	NN	5	O
that	that	DET	WDT	5	O
followed	follow	VERB	VBD	9	O
1	1	NUM	CD	9	O
night	night	NOUN	NN	5	O
of	of	ADP	IN	5	O
accommodation	accommodation	NOUN	NN	5	O
polysomnography	polysomnography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Progressive	progressive	ADJ	JJ	5	O
abstinence	abstinence	NOUN	NN	5	O
from	from	ADP	IN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
worsening	worsen	VERB	VBG	5	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
measured	measure	VERB	VBN	9	O
polysomnographic	polysomnographic	ADJ	JJ	5	O
sleep	sleep	NOUN	NN	5	O
outcomes	outcome	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
,	,	PUNCT	,	9	O
modafinil	modafinil	NOUN	NN	5	B-Chemical
decreased	decrease	VERB	VBD	9	O
nighttime	nighttime	ADJ	JJ	5	O
sleep	sleep	NOUN	NN	5	O
latency	latency	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBD	9	O
slow	slow	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
wave	wave	NOUN	NN	5	O
sleep	sleep	NOUN	NN	5	O
time	time	NOUN	NN	5	O
in	in	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
participants	participant	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
modafinil	modafinil	NOUN	NN	5	B-Chemical
interacted	interact	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
abstinence	abstinence	NOUN	NN	5	O
week	week	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
longer	long	ADJ	JJR	5	O
total	total	ADJ	JJ	9	O
sleep	sleep	NOUN	NN	5	O
time	time	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
shorter	short	ADJ	JJR	9	O
REM	rem	NOUN	NN	5	O
sleep	sleep	NOUN	NN	5	O
latency	latency	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
third	third	ADJ	JJ	9	O
week	week	NOUN	NN	9	O
of	of	ADP	IN	5	O
abstinence	abstinence	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Comparison	comparison	NOUN	NN	9	O
of	of	ADP	IN	5	O
slow	slow	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
wave	wave	NOUN	NN	5	O
sleep	sleep	NOUN	NN	5	O
time	time	NOUN	NN	5	O
,	,	PUNCT	,	9	O
total	total	ADJ	JJ	9	O
sleep	sleep	NOUN	NN	5	O
time	time	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
sleep	sleep	VERB	VB	5	O
latency	latency	NOUN	NN	5	O
in	in	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
healthy	healthy	ADJ	JJ	5	O
participants	participant	NOUN	NNS	5	O
revealed	reveal	VERB	VBD	9	O
a	a	DET	DT	5	O
normalizing	normalizing	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
modafinil	modafinil	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
participants	participant	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Modafinil	Modafinil	PROPN	NNP	5	B-Chemical
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
daytime	daytime	ADJ	JJ	5	O
sleep	sleep	NOUN	NN	5	O
latency	latency	NOUN	NN	5	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
Multiple	Multiple	PROPN	NNP	5	O
Sleep	Sleep	PROPN	NNP	5	O
Latency	Latency	PROPN	NNP	5	O
Test	Test	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
nearly	nearly	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
subjective	subjective	ADJ	JJ	5	O
daytime	daytime	ADJ	JJ	5	B-Disease
sleepiness	sleepiness	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Morning	morning	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
dosed	dose	VERB	VBN	0	O
modafinil	modafinil	NOUN	NN	5	B-Chemical
promotes	promote	VERB	VBZ	3	O
nocturnal	nocturnal	ADJ	JJ	5	O
sleep	sleep	NOUN	NN	5	O
,	,	PUNCT	,	9	O
normalizes	normalize	NOUN	NNS	9	O
sleep	sleep	NOUN	NN	5	O
architecture	architecture	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
decreases	decrease	VERB	VBZ	9	O
daytime	daytime	ADJ	JJ	5	B-Disease
sleepiness	sleepiness	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
abstinent	abstinent	ADJ	JJ	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
users	user	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
relevant	relevant	ADJ	JJ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
dependence	dependence	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
transesophageal	transesophageal	NOUN	NN	5	O
echocardiography	echocardiography	NOUN	NN	5	O
in	in	ADP	IN	5	O
adults	adult	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
study	study	VERB	VB	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
multidisciplinary	multidisciplinary	ADJ	JJ	5	O
hospital	hospital	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
TEE	TEE	PROPN	NNP	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
semi	semi	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
invasive	invasive	ADJ	JJ	5	O
tool	tool	NOUN	NN	5	O
broadly	broadly	ADV	RB	5	O
used	use	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
utilization	utilization	NOUN	NN	9	O
associated	associate	VERB	VBN	9	O
to	to	ADP	IN	5	O
sedatives	sedative	NOUN	NNS	5	O
drugs	drug	NOUN	NNS	5	O
might	may	VERB	MD	9	O
to	to	PART	TO	5	O
affect	affect	VERB	VB	9	O
the	the	DET	DT	5	O
procedure	procedure	NOUN	NN	5	O
safety	safety	NOUN	NN	5	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
to	to	PART	TO	5	O
analyze	analyze	VERB	VB	9	O
aspects	aspect	NOUN	NNS	5	O
of	of	ADP	IN	5	O
TEE	TEE	PROPN	NNP	5	O
safety	safety	NOUN	NN	5	O
associated	associate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
Midazolan	Midazolan	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
MZ	MZ	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
Flumazenil	Flumazenil	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
FL	FL	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
variables	variable	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
event	event	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
prospective	prospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
with	with	ADP	IN	5	O
137	137	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
that	that	DET	WDT	5	O
underwent	undergo	VERB	VBD	5	O
TEE	TEE	PROPN	NNP	5	O
with	with	ADP	IN	5	O
MZ	MZ	PROPN	NNP	9	B-Chemical
associated	associate	VERB	VBN	9	O
to	to	ADP	IN	5	O
moderate	moderate	ADJ	JJ	9	O
sedation	sedation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
analyzed	analyze	VERB	VBD	9	O
the	the	DET	DT	5	O
following	follow	VERB	VBG	9	O
events	event	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
complications	complication	NOUN	NNS	5	O
related	relate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
topical	topical	ADJ	JJ	0	O
anesthesia	anesthesia	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
MZ	MZ	PROPN	NNP	9	B-Chemical
use	use	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
procedure	procedure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Uni	Uni	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
multivariate	multivariate	NOUN	NN	5	O
analyses	analysis	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
test	test	VERB	VB	5	O
the	the	DET	DT	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
variables	variable	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
sex	sex	NOUN	NN	5	O
,	,	PUNCT	,	9	O
stroke	stroke	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
myocardiopathy	myocardiopathy	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
MP	MP	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
test	test	NOUN	NN	5	O
,	,	PUNCT	,	9	O
mitral	mitral	ADJ	JJ	5	B-Disease
regurgitation	regurgitation	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
MR	MR	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
MZ	MZ	PROPN	NNP	9	B-Chemical
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
65	65	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
16	16	NUM	CD	9	O
yrs	yrs	NOUN	NN	7	O
;	;	PUNCT	:	9	O
58	58	NUM	CD	7	O
%	%	NOUN	NN	9	O
males	male	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
finished	finish	VERB	VBD	5	O
the	the	DET	DT	5	O
examination	examination	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
MZ	MZ	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
FL	FL	PROPN	NNP	9	B-Chemical
were	be	VERB	VBD	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
28	28	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
examination	examination	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
ejection	ejection	NOUN	NN	5	O
fraction	fraction	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
EF	EF	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
16	16	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
60	60	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Mild	mild	ADJ	JJ	9	O
hypoxia	hypoxia	NOUN	NN	3	B-Disease
(	(	PUNCT	-LRB-	9	O
SO2	SO2	PROPN	NNP	0	O
<	<	X	XX	0	O
90	90	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
event	event	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
presented	present	VERB	VBN	5	O
transient	transient	ADJ	JJ	9	O
hypoxia	hypoxia	NOUN	NN	3	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
upper	upper	ADJ	JJ	9	O
airway	airway	NOUN	NN	5	B-Disease
obstruction	obstruction	NOUN	NN	5	I-Disease
by	by	ADP	IN	9	O
probe	probe	NOUN	NN	9	O
introduction	introduction	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
8	8	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
hypoxia	hypoxia	NOUN	NN	3	B-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
MZ	MZ	PROPN	NNP	9	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Transient	transient	ADJ	JJ	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
SAP	SAP	PROPN	NNP	9	O
<	<	X	XX	0	O
90mmHg	90mmhg	NUM	CD	5	O
)	)	PUNCT	-RRB-	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
patient	patient	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
multivariate	multivariate	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
MR	MR	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
MP	MP	PROPN	NNP	9	B-Disease
(	(	PUNCT	-LRB-	9	O
EF	EF	PROPN	NNP	9	O
<	<	X	XX	0	O
45	45	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
MZ	MZ	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
5mg	5mg	ADJ	JJ	0	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
events	event	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
EF	EF	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
group	group	NOUN	NN	9	O
with	with	ADP	IN	5	O
MP	MP	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
44	44	NUM	CD	7	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
group	group	NOUN	NN	9	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
MR	MR	PROPN	NNP	9	B-Disease
and	and	CCONJ	CC	5	O
it	-PRON-	PRON	PRP	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
factor	factor	NOUN	NN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
TEE	tee	NOUN	NN	5	O
with	with	ADP	IN	5	O
sedation	sedation	NOUN	NN	5	O
presents	present	VERB	VBZ	5	O
a	a	DET	DT	5	O
low	low	ADJ	JJ	9	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
events	event	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
severe	severe	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
need	need	NOUN	NN	5	O
to	to	PART	TO	5	O
interrupt	interrupt	VERB	VB	9	O
the	the	DET	DT	5	O
examinations	examination	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
direct	direct	ADJ	JJ	9	O
intracoronary	intracoronary	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
methylergonovine	methylergonovine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
and	and	CCONJ	CC	5	O
without	without	ADP	IN	9	O
variant	variant	ADJ	JJ	1	B-Disease
angina	angina	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
intracoronary	intracoronary	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
methylergonovine	methylergonovine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
21	21	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
variant	variant	ADJ	JJ	1	B-Disease
angina	angina	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
22	22	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
atypical	atypical	ADJ	JJ	5	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
others	other	NOUN	NNS	5	O
without	without	ADP	IN	9	O
angina	angina	NOUN	NN	5	B-Disease
pectoris	pectori	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Methylergonovine	Methylergonovine	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
continuously	continuously	ADV	RB	5	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
min	min	VERB	VB	0	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
50	50	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
variant	variant	ADJ	JJ	1	B-Disease
angina	angina	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
spasm	spasm	NOUN	NNS	5	I-Disease
was	be	VERB	VBD	9	O
provoked	provoke	VERB	VBN	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
28	28	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
13	13	NUM	CD	7	O
micrograms	microgram	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SD	sd	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
neither	neither	CCONJ	CC	9	O
ischemic	ischemic	ADJ	JJ	9	O
ST	ST	PROPN	NNP	9	O
change	change	NOUN	NN	9	O
nor	nor	CCONJ	CC	9	O
localized	localize	VERB	VBN	9	O
spasm	spasm	NOUN	NNS	5	B-Disease
occurred	occur	VERB	VBD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
basal	basal	NOUN	NN	3	O
tone	tone	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
left	left	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
percentage	percentage	NOUN	NN	9	O
of	of	ADP	IN	5	O
vasoconstriction	vasoconstriction	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
left	left	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
spasm	spasm	ADJ	JJ	5	B-Disease
provocation	provocation	NOUN	NN	5	O
tests	test	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
use	use	VERB	VBP	5	O
an	an	DET	DT	5	O
intracoronary	intracoronary	ADJ	JJ	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
relatively	relatively	ADV	RB	5	O
low	low	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
methylergonovine	methylergonovine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
have	have	VERB	VBP	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
sensitivity	sensitivity	NOUN	NN	9	O
in	in	ADP	IN	5	O
variant	variant	ADJ	JJ	1	B-Disease
angina	angina	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
vasoreactivity	vasoreactivity	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
arteries	artery	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Oral	oral	ADJ	JJ	9	O
manifestations	manifestation	NOUN	NNS	5	O
of	of	ADP	IN	5	O
"	"	PUNCT	``	5	O
meth	meth	ADJ	JJ	0	B-Disease
mouth	mouth	NOUN	NN	5	I-Disease
"	"	PUNCT	''	5	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

AIM	AIM	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
documentation	documentation	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
case	case	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
to	to	PART	TO	5	O
make	make	VERB	VB	5	O
clinicians	clinician	NOUN	NNS	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
"	"	PUNCT	``	5	O
meth	meth	ADJ	JJ	0	B-Disease
mouth	mouth	NOUN	NN	5	I-Disease
"	"	PUNCT	''	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
medical	medical	ADJ	JJ	5	O
risks	risk	NOUN	NNS	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
this	this	DET	DT	5	O
serious	serious	ADJ	JJ	5	O
condition	condition	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Methamphetamine	Methamphetamine	PROPN	NNP	7	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
very	very	ADV	RB	5	O
addictive	addictive	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
powerful	powerful	ADJ	JJ	5	O
stimulant	stimulant	NOUN	NN	5	O
that	that	DET	WDT	5	O
increases	increase	VERB	VBZ	9	O
wakefulness	wakefulness	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
physical	physical	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
can	can	VERB	MD	5	O
produce	produce	VERB	VB	9	O
other	other	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
dysrhythmias	dysrhythmia	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
hallucinations	hallucination	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
violent	violent	ADJ	JJ	5	B-Disease
behavior	behavior	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Dental	dental	ADJ	JJ	2	O
patients	patient	NOUN	NNS	5	O
abusing	abuse	VERB	VBG	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
can	can	VERB	MD	5	O
present	present	VERB	VB	9	O
with	with	ADP	IN	5	O
poor	poor	ADJ	JJ	5	O
oral	oral	ADJ	JJ	9	O
hygiene	hygiene	NOUN	NN	5	O
,	,	PUNCT	,	9	O
xerostomia	xerostomia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
rampant	rampant	ADJ	JJ	5	O
caries	carie	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
"	"	PUNCT	``	5	O
meth	meth	ADJ	JJ	0	B-Disease
mouth	mouth	NOUN	NN	5	I-Disease
"	"	PUNCT	''	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
excessive	excessive	ADJ	JJ	5	O
tooth	tooth	NOUN	NN	5	B-Disease
wear	wear	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Oral	oral	ADJ	JJ	9	O
rehabilitation	rehabilitation	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
using	use	VERB	VBG	9	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
challenging	challenge	VERB	VBG	5	O
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
DESCRIPTION	description	NOUN	NN	2	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
30	30	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
Caucasian	caucasian	ADJ	JJ	9	O
woman	woman	NOUN	NN	5	O
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
dental	dental	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
bad	bad	ADJ	JJ	5	B-Disease
breath	breath	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
self	self	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
reported	report	VERB	VBN	9	O
poor	poor	ADJ	JJ	5	O
esthetics	esthetic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
comprehensive	comprehensive	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
including	include	VERB	VBG	9	O
her	-PRON-	DET	PRP$	5	O
medical	medical	ADJ	JJ	5	O
history	history	NOUN	NN	5	O
,	,	PUNCT	,	9	O
panoramic	panoramic	ADJ	JJ	5	O
radiograph	radiograph	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
intraoral	intraoral	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
19	19	NUM	CD	7	O
carious	carious	ADJ	JJ	5	B-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
very	very	ADV	RB	5	O
common	common	ADJ	JJ	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
healthy	healthy	ADJ	JJ	5	O
adult	adult	NOUN	NN	9	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
reported	report	VERB	VBD	9	O
her	-PRON-	DET	PRP$	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
methamphetamine	methamphetamine	NOUN	NN	5	B-Chemical
for	for	ADP	IN	5	O
five	five	NUM	CD	9	O
years	year	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
not	not	ADV	RB	5	O
experienced	experience	VERB	VBN	5	O
any	any	DET	DT	5	O
major	major	ADJ	JJ	9	O
carious	carious	ADJ	JJ	5	B-Disease
episodes	episode	NOUN	NNS	5	I-Disease
before	before	ADP	IN	9	O
she	-PRON-	PRON	PRP	5	O
started	start	VERB	VBD	5	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

SUMMARY	summary	NOUN	NN	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	VERB	VBZ	9	O
medical	medical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
dental	dental	ADJ	JJ	5	O
histories	history	NOUN	NNS	5	O
along	along	ADP	IN	9	O
with	with	ADP	IN	5	O
radiographic	radiographic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
lead	lead	VERB	VBP	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
"	"	PUNCT	``	5	O
meth	meth	ADJ	JJ	0	B-Disease
mouth	mouth	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O
"	"	PUNCT	''	5	O
Although	although	ADP	IN	9	O
three	three	NUM	CD	9	O
different	different	ADJ	JJ	9	O
dental	dental	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
modalities	modality	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
either	either	CCONJ	CC	9	O
conventional	conventional	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
implant	implant	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
supported	support	VERB	VBN	9	O
)	)	PUNCT	-RRB-	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
offered	offer	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
since	since	ADP	IN	9	O
August	August	PROPN	NNP	2	O
2007	2007	NUM	CD	2	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
yet	yet	ADV	RB	9	O
to	to	PART	TO	5	O
initiate	initiate	VERB	VB	9	O
any	any	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CLINICAL	CLINICAL	PROPN	NNP	2	O
SIGNIFICANCE	SIGNIFICANCE	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
case	case	NOUN	NN	5	O
showing	show	VERB	VBG	9	O
oral	oral	ADJ	JJ	9	O
manifestations	manifestation	NOUN	NNS	5	O
of	of	ADP	IN	5	O
meth	meth	ADJ	JJ	0	B-Disease
mouth	mouth	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
presented	present	VERB	VBN	5	O
to	to	PART	TO	5	O
help	help	VERB	VB	5	O
dental	dental	ADJ	JJ	5	O
practitioners	practitioner	NOUN	NNS	5	O
recognize	recognize	VERB	VB	9	O
and	and	CCONJ	CC	5	O
manage	manage	VERB	VB	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
abusing	abuse	VERB	VBG	5	O
methamphetamines	methamphetamine	NOUN	NNS	5	B-Chemical
.	.	PUNCT	.	9	O

Dental	dental	ADJ	JJ	2	O
practitioners	practitioner	NOUN	NNS	5	O
also	also	ADV	RB	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
skeptical	skeptical	ADJ	JJ	5	O
about	about	ADP	IN	5	O
the	the	DET	DT	5	O
reliability	reliability	NOUN	NN	5	O
of	of	ADP	IN	5	O
appointment	appointment	NOUN	NN	5	O
keeping	keeping	NOUN	NN	5	O
by	by	ADP	IN	9	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
they	-PRON-	PRON	PRP	5	O
frequently	frequently	ADV	RB	5	O
miss	miss	VERB	VBP	5	O
their	-PRON-	DET	PRP$	5	O
appointments	appointment	NOUN	NNS	5	O
without	without	ADP	IN	9	O
reasonable	reasonable	ADJ	JJ	5	O
justification	justification	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Antituberculosis	antituberculosis	NOUN	NN	2	B-Chemical
therapy	therapy	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
magnitude	magnitude	NOUN	NN	5	O
,	,	PUNCT	,	9	O
profile	profile	NOUN	NN	9	O
,	,	PUNCT	,	9	O
prognosis	prognosis	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
predictors	predictor	NOUN	NNS	5	O
of	of	ADP	IN	5	O
outcome	outcome	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Antituberculosis	antituberculosis	NOUN	NN	2	B-Chemical
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ATT	ATT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
acute	acute	ADJ	JJ	9	B-Disease
liver	liver	NOUN	NN	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
ATT	ATT	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
ALF	ALF	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
commonest	common	ADJ	JJS	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
ALF	ALF	PROPN	NNP	9	B-Disease
in	in	ADP	IN	5	O
South	South	PROPN	NNP	4	O
Asia	Asia	PROPN	NNP	4	O
.	.	PUNCT	.	9	O

Prospective	prospective	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
on	on	ADP	IN	5	O
ATT	ATT	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
ALF	ALF	PROPN	NNP	9	B-Disease
are	be	VERB	VBP	5	O
lacking	lack	VERB	VBG	1	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
prospectively	prospectively	ADV	RB	5	O
evaluated	evaluate	VERB	VBD	9	O
the	the	DET	DT	5	O
magnitude	magnitude	NOUN	NN	5	O
,	,	PUNCT	,	9	O
clinical	clinical	ADJ	JJ	5	O
course	course	NOUN	NN	5	O
,	,	PUNCT	,	9	O
outcome	outcome	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
prognostic	prognostic	ADJ	JJ	5	O
factors	factor	NOUN	NNS	9	O
in	in	ADP	IN	5	O
ATT	ATT	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
ALF	ALF	PROPN	NNP	9	B-Disease
.	.	PUNCT	.	9	O

From	from	ADP	IN	5	O
January	January	PROPN	NNP	2	O
1986	1986	NUM	CD	2	O
to	to	ADP	IN	5	O
January	January	PROPN	NNP	2	O
2009	2009	NUM	CD	2	O
,	,	PUNCT	,	9	O
1223	1223	NUM	CD	7	O
consecutive	consecutive	ADJ	JJ	5	O
ALF	ALF	PROPN	NNP	9	B-Disease
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
:	:	PUNCT	:	9	O
ATT	ATT	PROPN	NNP	9	O
alone	alone	ADV	RB	9	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
cause	cause	NOUN	NN	5	O
in	in	ADP	IN	5	O
70	70	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Another	another	DET	DT	5	O
15	15	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
ATT	ATT	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
simultaneous	simultaneous	ADJ	JJ	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
virus	virus	NOUN	NN	9	I-Disease
infection	infection	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
44	44	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
62	62	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
ATT	ATT	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
prescribed	prescribe	VERB	VBN	5	O
empirically	empirically	ADV	RB	5	O
without	without	ADP	IN	9	O
definitive	definitive	ADJ	JJ	5	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
tuberculosis	tuberculosis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

ATT	ATT	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
ALF	ALF	PROPN	NNP	9	B-Disease
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
younger	young	ADJ	JJR	5	O
(	(	PUNCT	-LRB-	9	O
32	32	NUM	CD	7	O
.	.	PUNCT	.	9	O
87	87	NUM	CD	7	O
[	[	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
]	]	PUNCT	-RRB-	9	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
49	49	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
70	70	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Most	most	ADV	RBS	5	O
had	have	VERB	VBD	9	O
hyperacute	hyperacute	ADJ	JJ	5	O
presentation	presentation	NOUN	NN	5	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
icterus	icterus	NOUN	NN	5	B-Disease
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
interval	interval	NOUN	NN	5	O
was	be	VERB	VBD	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
-	-	SYM	SYM	7	O
30	30	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
ATT	ATT	PROPN	NNP	9	O
before	before	ADP	IN	9	O
ALF	ALF	PROPN	NNP	9	B-Disease
was	be	VERB	VBD	9	O
30	30	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
-	-	SYM	SYM	7	O
350	350	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
presentation	presentation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
advanced	advanced	ADJ	JJ	5	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
51	51	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
76	76	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
29	29	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
41	41	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Gastrointestinal	gastrointestinal	ADJ	JJ	9	B-Disease
bleed	bleed	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
infection	infection	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
documented	document	VERB	VBN	9	O
in	in	ADP	IN	5	O
seven	seven	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
five	five	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
26	26	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
37	37	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
seven	seven	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
E	E	PROPN	NNP	9	I-Disease
virus	virus	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
HEV	HEV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
A	a	ADJ	JJ	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
E	e	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
ALF	ALF	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
ATT	ATT	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
ALF	ALF	PROPN	NNP	9	B-Disease
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
nearly	nearly	ADV	RB	9	O
similar	similar	ADJ	JJ	9	O
presentations	presentation	NOUN	NNS	5	O
except	except	ADP	IN	9	O
for	for	ADP	IN	5	O
older	old	ADJ	JJR	5	O
age	age	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
less	less	ADJ	JJR	5	O
elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
enzymes	enzyme	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mortality	mortality	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
among	among	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
ATT	ATT	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
ALF	ALF	PROPN	NNP	9	B-Disease
was	be	VERB	VBD	9	O
high	high	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
67	67	NUM	CD	7	O
.	.	NOUN	NN	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
47	47	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
only	only	ADV	RB	9	O
23	23	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
32	32	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
recovered	recover	VERB	VBN	9	O
with	with	ADP	IN	5	O
medical	medical	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
multivariate	multivariate	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
three	three	NUM	CD	9	O
factors	factor	NOUN	NNS	9	O
independently	independently	ADV	RB	9	O
predicted	predict	VERB	VBD	9	O
mortality	mortality	NOUN	NN	5	O
:	:	PUNCT	:	9	O
serum	serum	NOUN	NN	9	O
bilirubin	bilirubin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dL	dL	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
prothrombin	prothrombin	NOUN	NN	9	O
time	time	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
PT	PT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
prolongation	prolongation	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
>	>	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	VERB	VBZ	7	O
26	26	NUM	CD	7	O
seconds	second	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
grade	grade	NOUN	NN	9	O
III	III	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
IV	IV	PROPN	NNP	9	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
at	at	ADP	IN	9	O
presentation	presentation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
ATT	ATT	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
ALF	ALF	PROPN	NNP	9	B-Disease
constituted	constitute	VERB	VBD	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
ALF	ALF	PROPN	NNP	9	B-Disease
at	at	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
center	center	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
mortality	mortality	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
the	the	DET	DT	5	O
mortality	mortality	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
so	so	ADV	RB	5	O
high	high	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
determining	determine	VERB	VBG	9	O
which	which	DET	WDT	5	O
factors	factor	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
predictors	predictor	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
less	less	ADV	RBR	5	O
important	important	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
high	high	ADJ	JJ	9	O
proportion	proportion	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
consumed	consume	VERB	VBN	5	O
ATT	ATT	PROPN	NNP	9	O
empirically	empirically	ADV	RB	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
could	could	VERB	MD	9	O
have	have	VERB	VB	5	O
been	be	VERB	VBN	9	O
prevented	prevent	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Design	design	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
HYPREN	HYPREN	PROPN	NNP	_	O
-	-	PUNCT	HYPH	7	O
trial	trial	PROPN	NNP	5	O
:	:	PUNCT	:	9	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
enalapril	enalapril	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
prazosin	prazosin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
phase	phase	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
congestive	congestive	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
the	the	DET	DT	5	O
introduction	introduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
converting	convert	VERB	VBG	9	I-Chemical
enzyme	enzyme	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
ACE	ACE	PROPN	NNP	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
inhibitors	inhibitor	NOUN	NNS	3	I-Chemical
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
adjunctive	adjunctive	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
congestive	congestive	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
have	have	VERB	VBP	5	O
occasionally	occasionally	ADV	RB	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ACE	ACE	PROPN	NNP	9	B-Chemical
inhibitor	inhibitor	NOUN	NN	3	I-Chemical
enalapril	enalapril	VERB	VBP	0	B-Chemical
a	a	DET	DT	5	O
multicenter	multicenter	NOUN	NN	5	O
,	,	PUNCT	,	9	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
prazosin	prazosin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
that	that	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
symptomatic	symptomatic	ADJ	JJ	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Trial	trial	NOUN	NN	5	O
medication	medication	NOUN	NN	5	O
was	be	VERB	VBD	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
enalapril	enalapril	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
prazosin	prazosin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Subjects	subject	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
1210	1210	NUM	CD	7	O
inpatients	inpatient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
New	New	PROPN	NNP	2	O
York	York	PROPN	NNP	2	O
Heart	Heart	PROPN	NNP	2	O
Association	Association	PROPN	NNP	2	O
(	(	PUNCT	-LRB-	9	O
NYHA	NYHA	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
functional	functional	ADJ	JJ	9	O
class	class	NOUN	NN	9	O
II	II	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
III	III	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
enalapril	enalapril	NOUN	NN	0	B-Chemical
experienced	experience	VERB	VBD	5	O
clinically	clinically	ADV	RB	5	O
and	and	CCONJ	CC	5	O
statistically	statistically	ADV	RB	9	O
significantly	significantly	ADV	RB	9	O
less	less	ADV	RBR	5	O
symptomatic	symptomatic	ADJ	JJ	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
prazosin	prazosin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
recovered	recover	VERB	VBD	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
concluded	conclude	VERB	VBN	9	O
that	that	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
enalapril	enalapril	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
,	,	PUNCT	,	9	O
therefore	therefore	ADV	RB	5	O
,	,	PUNCT	,	9	O
unreasonable	unreasonable	ADJ	JJ	5	O
to	to	PART	TO	5	O
restrict	restrict	VERB	VB	5	O
the	the	DET	DT	5	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
enalapril	enalapril	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
inpatients	inpatient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Central	central	ADJ	JJ	4	B-Disease
nervous	nervous	ADJ	JJ	5	I-Disease
system	system	NOUN	NN	5	I-Disease
complications	complication	NOUN	NNS	5	I-Disease
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
lymphoblastic	lymphoblastic	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
pediatric	pediatric	ADJ	JJ	5	O
institution	institution	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Central	central	ADJ	JJ	4	B-Disease
nervous	nervous	ADJ	JJ	5	I-Disease
system	system	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	I-Disease
CNS	CNS	PROPN	NNP	9	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
complications	complication	NOUN	NNS	5	I-Disease
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
childhood	childhood	NOUN	NN	5	O
acute	acute	ADJ	JJ	9	B-Disease
lymphoblastic	lymphoblastic	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
ALL	all	DET	DT	9	B-Disease
)	)	PUNCT	-RRB-	9	O
remain	remain	VERB	VBP	9	O
a	a	DET	DT	5	O
challenging	challenging	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
problem	problem	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Outcome	outcome	NOUN	NN	5	O
improvement	improvement	NOUN	NN	5	O
with	with	ADP	IN	5	O
more	more	ADV	RBR	5	O
intensive	intensive	ADJ	JJ	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
analyzed	analyze	VERB	VBD	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
neurological	neurological	ADJ	JJ	5	B-Disease
complications	complication	NOUN	NNS	5	I-Disease
during	during	ADP	IN	5	O
ALL	all	DET	DT	9	B-Disease
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
pediatric	pediatric	ADJ	JJ	5	O
institution	institution	NOUN	NN	5	O
,	,	PUNCT	,	9	O
focusing	focus	VERB	VBG	5	O
on	on	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
radiological	radiological	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
electrophysiological	electrophysiological	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Exclusion	exclusion	NOUN	NN	5	O
criteria	criterion	NOUN	NNS	5	O
included	include	VERB	VBD	5	O
CNS	CNS	PROPN	NNP	9	O
leukemic	leukemic	NOUN	NN	3	B-Disease
infiltration	infiltration	NOUN	NN	3	I-Disease
at	at	ADP	IN	9	O
diagnosis	diagnosis	NOUN	NN	5	O
,	,	PUNCT	,	9	O
therapy	therapy	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
late	late	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
onset	onset	NOUN	NN	5	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
neurocognitive	neurocognitive	ADJ	JJ	5	B-Disease
defects	defect	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
a	a	DET	DT	5	O
9	9	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
retrospectively	retrospectively	ADV	RB	5	O
collected	collect	VERB	VBD	9	O
27	27	NUM	CD	7	O
neurological	neurological	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
as	as	ADV	RB	5	O
many	many	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
from	from	ADP	IN	9	O
253	253	NUM	CD	7	O
children	child	NOUN	NNS	5	O
enrolled	enrol	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
ALL	all	DET	DT	9	B-Disease
front	front	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
line	line	NOUN	NN	9	O
protocol	protocol	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CNS	CNS	PROPN	NNP	9	O
complications	complication	NOUN	NNS	5	O
included	include	VERB	VBD	5	O
posterior	posterior	ADJ	JJ	5	O
reversible	reversible	ADJ	JJ	9	O
leukoencephalopathy	leukoencephalopathy	ADJ	JJ	5	B-Disease
syndrome	syndrome	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
stroke	stroke	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
temporal	temporal	ADJ	JJ	5	B-Disease
lobe	lobe	NOUN	NN	5	I-Disease
epilepsy	epilepsy	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
syndrome	syndrome	NOUN	NN	5	O
of	of	ADP	IN	5	O
inappropriate	inappropriate	ADJ	JJ	5	B-Disease
antidiuretic	antidiuretic	ADJ	JJ	5	I-Disease
hormone	hormone	NOUN	NN	9	I-Disease
secretion	secretion	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
unclassified	unclassified	ADJ	JJ	9	O
events	event	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
CNS	CNS	PROPN	NNP	9	O
complications	complication	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
frequent	frequent	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
during	during	ADP	IN	5	O
ALL	all	DET	DT	9	B-Disease
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
require	require	VERB	VB	5	O
rapid	rapid	ADJ	JJ	5	O
detection	detection	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
prompt	prompt	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
to	to	PART	TO	5	O
limit	limit	VERB	VB	5	O
permanent	permanent	ADJ	JJ	5	O
damage	damage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Cocaine	cocaine	NOUN	NN	5	B-Chemical
causes	cause	VERB	VBZ	9	O
memory	memory	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
learning	learning	NOUN	NN	5	I-Disease
impairments	impairment	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
:	:	PUNCT	:	9	O
involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
nuclear	nuclear	ADJ	JJ	3	O
factor	factor	NOUN	NN	9	O
kappa	kappa	NOUN	NNS	9	O
B	B	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
prevention	prevention	NOUN	NN	5	O
by	by	ADP	IN	9	O
topiramate	topiramate	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Different	different	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
suggested	suggest	VERB	VBN	9	O
for	for	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
including	include	VERB	VBG	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
status	status	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
induced	induce	VERB	VBN	3	O
-	-	PUNCT	HYPH	7	O
behaviour	behaviour	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
poorly	poorly	ADV	RB	9	O
understood	understand	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Nuclear	nuclear	ADJ	JJ	9	O
factor	factor	NOUN	NN	9	O
kappa	kappa	NOUN	NNS	9	O
B	B	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
NFkappaB	NFkappaB	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
sensor	sensor	NOUN	NN	5	O
of	of	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
participates	participate	NOUN	NNS	9	O
in	in	ADP	IN	5	O
memory	memory	NOUN	NN	5	O
formation	formation	NOUN	NN	9	O
that	that	DET	WDT	5	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
addiction	addiction	NOUN	NN	5	O
mechanisms	mechanism	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
NFkappaB	NFkappaB	PROPN	NNP	3	O
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
,	,	PUNCT	,	9	O
neuronal	neuronal	ADJ	JJ	3	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
synthase	synthase	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
nNOS	nNOS	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
spatial	spatial	ADJ	JJ	5	O
learning	learning	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
memory	memory	NOUN	NN	5	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
topiramate	topiramate	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
previously	previously	ADV	RB	9	O
proposed	propose	VERB	VBN	5	O
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Disease
addiction	addiction	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
administration	administration	NOUN	NN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

NFkappaB	NFkappaB	PROPN	NNP	3	O
activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
frontal	frontal	ADJ	JJ	5	O
cortex	cortex	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
GSH	GSH	PROPN	NNP	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
glutathione	glutathione	NOUN	NN	0	B-Chemical
peroxidase	peroxidase	NOUN	NN	0	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
nNOS	nNOS	PROPN	NNP	3	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hippocampus	hippocampus	NOUN	NN	9	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Memory	memory	NOUN	NN	5	O
retrieval	retrieval	NOUN	NN	5	O
of	of	ADP	IN	5	O
experiences	experience	NOUN	NNS	5	O
acquired	acquire	VERB	VBN	5	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
administration	administration	NOUN	NN	9	O
was	be	VERB	VBD	9	O
impaired	impair	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
negatively	negatively	ADV	RB	9	O
correlated	correlate	VERB	VBD	9	O
with	with	ADP	IN	5	O
NFkappaB	NFkappaB	PROPN	NNP	3	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
frontal	frontal	ADJ	JJ	5	O
cortex	cortex	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
learning	learn	VERB	VBG	5	O
of	of	ADP	IN	5	O
new	new	ADJ	JJ	5	O
tasks	task	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
enhanced	enhance	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
nNOS	nNOS	PROPN	NNP	3	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
of	of	ADP	IN	5	O
glutathione	glutathione	ADJ	JJ	0	B-Chemical
peroxidase	peroxidase	NOUN	NN	0	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
provide	provide	VERB	VBP	5	O
evidence	evidence	NOUN	NN	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
mechanistic	mechanistic	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
nitrosative	nitrosative	ADJ	JJ	3	O
stress	stress	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
NFkappaB	NFkappaB	PROPN	NNP	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
alterations	alteration	NOUN	NNS	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Topiramate	topiramate	NOUN	NN	0	B-Chemical
prevented	prevent	VERB	VBD	9	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
alterations	alteration	NOUN	NNS	9	O
observed	observe	VERB	VBD	9	O
,	,	PUNCT	,	9	O
showing	show	VERB	VBG	9	O
novel	novel	ADJ	JJ	9	O
neuroprotective	neuroprotective	ADJ	JJ	9	O
properties	property	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Efficacy	efficacy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
asenapine	asenapine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
haloperidol	haloperidol	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
exacerbation	exacerbation	NOUN	NN	5	O
of	of	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Asenapine	Asenapine	PROPN	NNP	7	B-Chemical
is	be	VERB	VBZ	5	O
approved	approve	VERB	VBN	2	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
Food	Food	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
Drugs	Drugs	PROPN	NNPS	0	O
Administration	Administration	PROPN	NNP	2	O
in	in	ADP	IN	5	O
adults	adult	NOUN	NNS	5	O
for	for	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
of	of	ADP	IN	5	O
manic	manic	ADJ	JJ	5	B-Disease
or	or	CCONJ	CC	5	O
mixed	mixed	ADJ	JJ	9	O
episodes	episode	NOUN	NNS	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
bipolar	bipolar	NOUN	NNS	5	B-Disease
I	-PRON-	PRON	PRP	9	I-Disease
disorder	disorder	VERB	VBP	5	I-Disease
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
psychotic	psychotic	ADJ	JJ	5	B-Disease
features	feature	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
trial	trial	NOUN	NN	5	O
,	,	PUNCT	,	9	O
458	458	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
schizophrenia	schizophrenia	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
assigned	assign	VERB	VBN	5	O
to	to	ADP	IN	5	O
fixed	fix	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
asenapine	asenapine	NOUN	NN	5	B-Chemical
at	at	ADP	IN	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
twice	twice	ADV	RB	9	O
daily	daily	ADV	RB	5	O
(	(	PUNCT	-LRB-	9	O
BID	BID	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
asenapine	asenapine	NOUN	NN	5	B-Chemical
at	at	ADP	IN	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
BID	BID	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
at	at	ADP	IN	9	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
BID	BID	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
to	to	PART	TO	5	O
verify	verify	VERB	VB	9	O
assay	assay	ADJ	JJ	3	O
sensitivity	sensitivity	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

With	with	ADP	IN	5	O
last	last	ADJ	JJ	5	O
observations	observation	NOUN	NNS	9	O
carried	carry	VERB	VBN	9	O
forward	forward	PART	RP	9	O
(	(	PUNCT	-LRB-	9	O
LOCF	LOCF	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
mean	mean	VERB	VB	5	O
Positive	positive	ADJ	JJ	7	O
and	and	CCONJ	CC	5	O
Negative	Negative	PROPN	NNP	7	O
Syndrome	Syndrome	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
total	total	ADJ	JJ	9	O
score	score	NOUN	NN	5	O
reductions	reduction	NOUN	NNS	9	O
from	from	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
to	to	ADP	IN	5	O
endpoint	endpoint	NOUN	NN	5	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
greater	great	ADJ	JJR	5	O
with	with	ADP	IN	5	O
asenapine	asenapine	NOUN	NN	5	B-Chemical
at	at	ADP	IN	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
BID	BID	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
16	16	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
;	;	PUNCT	:	9	O
both	both	DET	DT	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	,	9	O
using	use	VERB	VBG	9	O
mixed	mixed	ADJ	JJ	9	O
model	model	NOUN	NN	5	O
for	for	ADP	IN	5	O
repeated	repeat	VERB	VBN	5	O
measures	measure	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
MMRM	MMRM	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
changes	change	VERB	VBZ	9	O
at	at	ADP	IN	9	O
day	day	NOUN	NN	9	O
42	42	NUM	CD	7	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
greater	great	ADJ	JJR	5	O
with	with	ADP	IN	5	O
asenapine	asenapine	NOUN	NN	5	B-Chemical
at	at	ADP	IN	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
BID	BID	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
21	21	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
-	-	PUNCT	HYPH	7	O
19	19	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
-	-	SYM	SYM	7	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
14	14	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
;	;	PUNCT	:	9	O
all	all	DET	DT	5	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
Positive	Positive	PROPN	NNP	7	O
and	and	CCONJ	CC	5	O
Negative	Negative	PROPN	NNP	7	O
Syndrome	Syndrome	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
positive	positive	ADJ	JJ	9	O
subscale	subscale	NOUN	NN	5	O
,	,	PUNCT	,	9	O
all	all	DET	DT	5	O
treatments	treatment	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
superior	superior	ADJ	JJ	5	O
to	to	PART	TO	5	O
placebo	placebo	VERB	VB	9	O
with	with	ADP	IN	5	O
LOCF	LOCF	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
MMRM	MMRM	PROPN	NNP	5	O
;	;	PUNCT	:	9	O
asenapine	asenapine	NOUN	NN	5	B-Chemical
at	at	ADP	IN	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
BID	BID	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
superior	superior	ADJ	JJ	5	O
to	to	PART	TO	5	O
placebo	placebo	VERB	VB	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
negative	negative	ADJ	JJ	9	O
subscale	subscale	NOUN	NN	5	O
with	with	ADP	IN	5	O
MMRM	MMRM	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
general	general	ADJ	JJ	5	O
psychopathology	psychopathology	NOUN	NN	5	O
subscale	subscale	NOUN	NN	5	O
with	with	ADP	IN	5	O
LOCF	LOCF	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
MMRM	MMRM	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
adverse	adverse	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
AEs	ae	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
44	44	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
52	52	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
57	57	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
41	41	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
asenapine	asenapine	NOUN	NN	5	B-Chemical
at	at	ADP	IN	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
BID	BID	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Extrapyramidal	Extrapyramidal	PROPN	NNP	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
reported	report	VERB	VBD	9	O
as	as	ADP	IN	5	O
AEs	ae	NOUN	NNS	5	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
15	15	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
18	18	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
34	34	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
asenapine	asenapine	NOUN	NN	5	B-Chemical
at	at	ADP	IN	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
BID	BID	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Across	across	ADP	IN	5	O
all	all	DET	DT	5	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
clinically	clinically	ADV	RB	5	O
significant	significant	ADJ	JJ	9	O
weight	weight	NOUN	NN	9	O
change	change	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Post	Post	PROPN	NNP	9	O
hoc	hoc	X	FW	5	O
analyses	analyse	VERB	VBZ	9	O
indicated	indicate	VERB	VBD	9	O
that	that	ADP	IN	5	O
efficacy	efficacy	NOUN	NN	9	O
was	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
with	with	ADP	IN	5	O
asenapine	asenapine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
;	;	PUNCT	:	9	O
greater	great	ADJ	JJR	5	O
contrasts	contrast	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
AEs	ae	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Salvage	salvage	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
nelarabine	nelarabine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
etoposide	etoposide	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
relapsed	relapsed	ADJ	JJ	5	O
/	/	SYM	SYM	9	O
refractory	refractory	NOUN	NN	9	O
paediatric	paediatric	ADJ	JJ	5	O
T	T	PROPN	NNP	3	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
cell	cell	NOUN	NN	3	I-Disease
lymphoblastic	lymphoblastic	ADJ	JJ	3	I-Disease
leukaemia	leukaemia	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	I-Disease
lymphoma	lymphoma	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
d	d	NOUN	NN	9	O
of	of	ADP	IN	5	O
nelarabine	nelarabine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
AraG	AraG	PROPN	NNP	1	B-Chemical
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
5	5	NUM	CD	9	O
d	d	NOUN	NNS	9	O
of	of	ADP	IN	5	O
etoposide	etoposide	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
VP	VP	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CPM	CPM	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
prophylactic	prophylactic	ADJ	JJ	5	O
intrathecal	intrathecal	ADJ	JJ	3	O
chemotherapy	chemotherapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
as	as	ADP	IN	5	O
salvage	salvage	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
seven	seven	NUM	CD	9	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
refractory	refractory	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
relapsed	relapse	VERB	VBN	5	O
T	T	PROPN	NNP	3	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
cell	cell	NOUN	NN	3	I-Disease
leukaemia	leukaemia	NOUN	NN	3	I-Disease
or	or	CCONJ	CC	5	I-Disease
lymphoma	lymphoma	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
attributable	attributable	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
AraG	AraG	PROPN	NNP	1	B-Chemical
included	include	VERB	VBD	5	O
Grade	Grade	PROPN	NNP	9	O
2	2	NUM	CD	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
sensory	sensory	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
motor	motor	NOUN	NN	5	O
neuropathy	neuropathy	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
musculoskeletal	musculoskeletal	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Haematological	haematological	ADJ	JJ	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
greater	great	ADJ	JJR	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
combination	combination	NOUN	NN	9	O
than	than	ADP	IN	5	O
AraG	AraG	PROPN	NNP	1	B-Chemical
alone	alone	ADV	RB	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
median	median	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
to	to	ADP	IN	5	O
neutrophil	neutrophil	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
platelet	platelet	NOUN	NN	9	O
recovery	recovery	NOUN	NN	9	O
was	be	VERB	VBD	9	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
salvage	salvage	NOUN	NN	5	O
therapies	therapy	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
some	some	DET	DT	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
combined	combine	VERB	VBN	9	O
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
five	five	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
seven	seven	NUM	CD	9	O
went	go	VERB	VBD	5	O
into	into	ADP	IN	9	O
complete	complete	ADJ	JJ	9	O
remission	remission	NOUN	NN	5	O
after	after	ADP	IN	9	O
one	one	NUM	CD	5	O
or	or	CCONJ	CC	5	O
two	two	NUM	CD	5	O
courses	course	NOUN	NNS	5	O
of	of	ADP	IN	5	O
AraG	AraG	PROPN	NNP	1	B-Chemical
/	/	SYM	SYM	9	O
VP	VP	PROPN	NNP	9	B-Chemical
/	/	SYM	SYM	9	O
CPM	cpm	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
experience	experience	NOUN	NN	5	O
supports	support	VERB	VBZ	9	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
giving	give	VERB	VBG	5	O
AraG	AraG	PROPN	NNP	1	B-Chemical
as	as	ADP	IN	5	O
salvage	salvage	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
synchrony	synchrony	NOUN	NN	5	O
with	with	ADP	IN	5	O
etoposide	etoposide	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
neurological	neurological	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
must	must	VERB	MD	5	O
be	be	VERB	VB	5	O
closely	closely	ADV	RB	9	O
monitored	monitor	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
adriamycin	adriamycin	NOUN	NN	3	B-Chemical
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
whole	whole	ADJ	JJ	9	O
body	body	NOUN	NN	5	O
hyperthermia	hyperthermia	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
tumor	tumor	NOUN	NN	3	B-Disease
and	and	CCONJ	CC	5	O
normal	normal	ADJ	JJ	9	O
tissues	tissue	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Thermal	thermal	ADJ	JJ	0	O
enhancement	enhancement	NOUN	NN	9	O
of	of	ADP	IN	5	O
Adriamycin	Adriamycin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
antitumor	antitumor	CCONJ	CC	3	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
normal	normal	ADJ	JJ	9	O
tissue	tissue	NOUN	NN	9	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
by	by	ADP	IN	9	O
whole	whole	ADJ	JJ	9	O
body	body	NOUN	NN	5	O
hyperthermia	hyperthermia	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
F344	f344	NOUN	NN	3	O
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Antitumor	Antitumor	PROPN	NNP	0	O
activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
tumor	tumor	NOUN	NN	3	B-Disease
growth	growth	NOUN	NN	3	O
delay	delay	NOUN	NN	5	O
assay	assay	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
normal	normal	ADJ	JJ	9	O
tissue	tissue	NOUN	NN	9	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
e	e	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
leukopenia	leukopenia	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
late	late	ADJ	JJ	9	O
normal	normal	ADJ	JJ	9	O
tissue	tissue	NOUN	NN	9	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
e	e	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
myocardial	myocardial	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	I-Disease
kidney	kidney	NOUN	NN	9	I-Disease
injury	injury	NOUN	NN	9	I-Disease
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
by	by	ADP	IN	9	O
functional	functional	ADJ	JJ	9	O
/	/	SYM	SYM	9	O
physiological	physiological	ADJ	JJ	9	O
assays	assay	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
by	by	ADP	IN	9	O
morphological	morphological	ADJ	JJ	9	O
techniques	technique	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Whole	whole	ADJ	JJ	9	O
body	body	NOUN	NN	5	O
hyperthermia	hyperthermia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
120	120	NUM	CD	9	O
min	min	NOUN	NN	0	O
at	at	ADP	IN	9	O
41	41	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
degrees	degree	NOUN	NNS	5	O
C	C	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
enhanced	enhance	VERB	VBD	3	O
both	both	DET	DT	9	O
Adriamycin	Adriamycin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
antitumor	antitumor	CCONJ	CC	3	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
toxic	toxic	ADJ	JJ	0	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
thermal	thermal	ADJ	JJ	9	O
enhancement	enhancement	NOUN	NN	9	O
ratio	ratio	NOUN	NN	9	O
calculated	calculate	VERB	VBN	5	O
for	for	ADP	IN	5	O
antitumor	antitumor	ADJ	JJ	3	O
activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O

Thermal	thermal	ADJ	JJ	0	O
enhancement	enhancement	NOUN	NN	9	O
ratios	ratio	NOUN	NNS	9	O
estimated	estimate	VERB	VBN	5	O
for	for	ADP	IN	5	O
"	"	PUNCT	``	5	O
acute	acute	ADJ	JJ	9	O
"	"	PUNCT	''	5	O
hematological	hematological	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
those	those	DET	DT	5	O
estimated	estimate	VERB	VBN	5	O
for	for	ADP	IN	5	O
"	"	PUNCT	``	5	O
late	late	ADJ	JJ	9	O
"	"	PUNCT	''	5	O
damage	damage	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
morphological	morphological	ADJ	JJ	9	O
cardiac	cardiac	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
)	)	PUNCT	-RRB-	9	O
varied	vary	VERB	VBD	9	O
between	between	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
whole	whole	ADJ	JJ	9	O
body	body	NOUN	NN	5	O
hyperthermia	hyperthermia	NOUN	NN	5	B-Disease
enhances	enhance	NOUN	NNS	3	O
Adriamycin	Adriamycin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
antitumor	antitumor	CCONJ	CC	3	O
effect	effect	NOUN	NN	9	O
,	,	PUNCT	,	9	O
normal	normal	ADJ	JJ	9	O
tissue	tissue	NOUN	NN	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
also	also	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
therapeutic	therapeutic	ADJ	JJ	5	O
gain	gain	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
combined	combined	ADJ	JJ	9	O
modality	modality	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
eroded	erode	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Permeability	permeability	NOUN	NN	0	O
,	,	PUNCT	,	9	O
ultrastructural	ultrastructural	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
distribution	distribution	NOUN	NN	9	O
of	of	ADP	IN	5	O
novel	novel	ADJ	JJ	9	O
proteins	protein	NOUN	NNS	1	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
glomerular	glomerular	ADJ	JJ	5	O
barrier	barrier	NOUN	NN	5	O
in	in	ADP	IN	5	O
early	early	ADJ	JJ	9	O
puromycin	puromycin	NOUN	NN	3	B-Chemical
aminonucleoside	aminonucleoside	ADP	IN	0	I-Chemical
nephrosis	nephrosis	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	PROPN	NNP	2	O
/	/	SYM	SYM	9	O
AIMS	aims	NOUN	NN	5	O
:	:	PUNCT	:	9	O
It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
still	still	ADV	RB	5	O
unclear	unclear	ADJ	JJ	9	O
what	what	PRON	WP	5	O
happens	happen	VERB	VBZ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
glomerulus	glomerulus	NOUN	NN	9	O
when	when	ADV	WRB	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
starts	start	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Using	use	VERB	VBG	9	O
puromycin	puromycin	NOUN	NN	3	B-Chemical
aminonucleoside	aminonucleoside	ADP	IN	0	I-Chemical
nephrosis	nephrosis	NOUN	NN	0	B-Disease
(	(	PUNCT	-LRB-	9	O
PAN	PAN	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
studied	study	VERB	VBD	9	O
early	early	ADJ	JJ	9	O
ultrastructural	ultrastructural	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
permeability	permeability	NOUN	NN	0	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
relation	relation	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
podocyte	podocyte	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
molecules	molecule	NOUN	NNS	3	O
nephrin	nephrin	NOUN	NN	3	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
-	-	PUNCT	HYPH	7	O
actinin	actinin	NOUN	NN	3	O
,	,	PUNCT	,	9	O
dendrin	dendrin	ADJ	JJ	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
plekhh2	plekhh2	NOUN	NN	_	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
two	two	NUM	CD	5	O
of	of	ADP	IN	5	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
only	only	ADV	RB	9	O
recently	recently	ADV	RB	9	O
discovered	discover	VERB	VBN	9	O
in	in	ADP	IN	5	O
podocytes	podocyte	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Using	use	VERB	VBG	9	O
immune	immune	ADJ	JJ	3	O
stainings	staining	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
semiquantitative	semiquantitative	ADJ	JJ	9	O
measurement	measurement	NOUN	NN	5	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
under	under	ADP	IN	9	O
the	the	DET	DT	5	O
electron	electron	NOUN	NN	0	O
microscope	microscope	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Permeability	permeability	NOUN	NN	0	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
using	use	VERB	VBG	9	O
isolated	isolate	VERB	VBN	9	O
kidney	kidney	NOUN	NN	9	O
perfusion	perfusion	NOUN	NN	5	O
with	with	ADP	IN	5	O
tracers	tracer	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Possible	possible	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
ACE	ACE	PROPN	NNP	9	O
inhibition	inhibition	NOUN	NN	3	O
were	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
By	by	ADP	IN	5	O
day	day	NOUN	NN	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
some	some	DET	DT	5	O
patchy	patchy	ADJ	JJ	5	O
foot	foot	NOUN	NN	5	O
process	process	NOUN	NN	5	O
effacement	effacement	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
no	no	DET	DT	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
appeared	appear	VERB	VBD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
amount	amount	NOUN	NN	9	O
of	of	ADP	IN	5	O
nephrin	nephrin	NOUN	NN	3	O
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
diseased	diseased	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
normal	normal	ADJ	JJ	9	O
areas	area	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
proteins	protein	NOUN	NNS	1	O
showed	show	VERB	VBD	9	O
few	few	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
limited	limit	VERB	VBN	5	O
to	to	ADP	IN	5	O
diseased	disease	VERB	VBN	5	O
areas	area	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
day	day	NOUN	NN	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
foot	foot	NOUN	NN	5	O
process	process	NOUN	NN	5	O
effacement	effacement	NOUN	NN	5	O
was	be	VERB	VBD	9	O
complete	complete	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
appeared	appear	VERB	VBD	9	O
in	in	ADP	IN	5	O
parallel	parallel	NOUN	NN	5	O
with	with	ADP	IN	5	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
size	size	NOUN	NN	9	O
barrier	barrier	NOUN	NN	5	O
damage	damage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Nephrin	Nephrin	PROPN	NNP	3	O
decreased	decrease	VERB	VBD	9	O
further	further	ADV	RBR	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
dendrin	dendrin	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
plekhh2	plekhh2	NOUN	NN	_	O
also	also	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	O
but	but	CCONJ	CC	9	O
a	a	DET	DT	5	O
-	-	PUNCT	HYPH	7	O
actinin	actinin	NOUN	NN	3	O
remained	remain	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

ACE	ACE	PROPN	NNP	9	O
inhibition	inhibition	NOUN	NN	3	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
protective	protective	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
PAN	PAN	PROPN	NNP	0	O
glomeruli	glomerulus	NOUN	NNS	9	O
already	already	ADV	RB	5	O
showed	show	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
pathology	pathology	NOUN	NN	5	O
by	by	ADP	IN	9	O
day	day	NOUN	NN	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
despite	despite	ADP	IN	9	O
relatively	relatively	ADV	RB	5	O
mild	mild	ADJ	JJ	9	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
preceded	precede	VERB	VBN	9	O
by	by	ADP	IN	9	O
altered	altered	ADJ	JJ	9	O
nephrin	nephrin	NOUN	NN	3	O
expression	expression	NOUN	NN	3	O
,	,	PUNCT	,	9	O
supporting	support	VERB	VBG	9	O
its	-PRON-	DET	PRP$	9	O
pivotal	pivotal	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
podocyte	podocyte	NOUN	NN	3	O
morphology	morphology	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
proteins	protein	NOUN	NNS	1	O
dendrin	dendrin	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
plekhh2	plekhh2	NOUN	NN	_	O
were	be	VERB	VBD	9	O
both	both	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
roles	role	NOUN	NNS	9	O
in	in	ADP	IN	5	O
PAN	PAN	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
a	a	DET	DT	5	O
-	-	PUNCT	HYPH	7	O
actinin	actinin	NOUN	NN	3	O
was	be	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
novel	novel	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
multiple	multiple	ADJ	JJ	5	O
symptom	symptom	NOUN	NN	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
obsessive	obsessive	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
compulsive	compulsive	NOUN	NN	5	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
like	like	ADJ	JJ	9	I-Disease
behaviors	behavior	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Current	current	ADJ	JJ	9	O
animal	animal	NOUN	NN	5	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
obsessive	obsessive	ADJ	JJ	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
compulsive	compulsive	NOUN	NN	5	I-Disease
disorder	disorder	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
OCD	OCD	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
typically	typically	ADV	RB	5	O
involve	involve	VERB	VBP	5	O
acute	acute	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
symptom	symptom	NOUN	NN	5	O
provocation	provocation	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
a	a	DET	DT	5	O
genetic	genetic	ADJ	JJ	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
stereotypies	stereotypie	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
anxiety	anxiety	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

None	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
current	current	ADJ	JJ	5	O
models	model	NOUN	NNS	5	O
demonstrate	demonstrate	VERB	VBP	9	O
multiple	multiple	ADJ	JJ	5	O
OCD	ocd	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
behaviors	behavior	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Neonatal	neonatal	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
tricyclic	tricyclic	ADJ	JJ	0	O
antidepressant	antidepressant	ADJ	JJ	5	B-Chemical
clomipramine	clomipramine	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
vehicle	vehicle	NOUN	NN	3	O
between	between	ADP	IN	5	O
days	day	NOUN	NNS	9	O
9	9	NUM	CD	7	O
and	and	CCONJ	CC	5	O
16	16	NUM	CD	9	O
twice	twice	ADV	RB	9	O
daily	daily	ADV	RB	5	O
and	and	CCONJ	CC	5	O
behaviorally	behaviorally	ADV	RB	5	O
tested	test	VERB	VBN	9	O
in	in	ADP	IN	5	O
adulthood	adulthood	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Clomipramine	clomipramine	NOUN	NN	7	B-Chemical
exposure	exposure	NOUN	NN	9	O
in	in	ADP	IN	5	O
immature	immature	ADJ	JJ	3	O
rats	rat	NOUN	NNS	9	O
produced	produce	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
behavioral	behavioral	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
biochemical	biochemical	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
that	that	DET	WDT	5	O
include	include	VERB	VBP	5	O
enhanced	enhance	VERB	VBN	3	O
anxiety	anxiety	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
elevated	elevate	VERB	VBN	9	O
plus	plus	CCONJ	CC	9	O
maze	maze	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
marble	marble	NOUN	NN	5	O
burying	burying	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
behavioral	behavioral	ADJ	JJ	5	B-Disease
inflexibility	inflexibility	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
perseveration	perseveration	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
alternation	alternation	NOUN	NN	5	O
task	task	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
impaired	impaired	ADJ	JJ	9	O
reversal	reversal	NOUN	NN	9	O
learning	learning	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
working	work	VERB	VBG	5	O
memory	memory	NOUN	NN	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
e	e	NOUN	NN	9	O
.	.	PUNCT	.	9	O
g	g	NOUN	NN	0	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
win	win	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
shift	shift	NOUN	NN	9	O
paradigm	paradigm	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
hoarding	hoarding	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
corticostriatal	corticostriatal	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Dopamine	dopamine	NOUN	NN	0	B-Chemical
D2	D2	PROPN	NNP	9	O
receptors	receptor	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
elevated	elevate	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
2C	2c	NUM	CD	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
serotonin	serotonin	ADP	IN	9	B-Chemical
1A	1a	NOUN	NN	9	O
,	,	PUNCT	,	9	O
receptors	receptor	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
elevated	elevate	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
orbital	orbital	ADJ	JJ	5	O
frontal	frontal	ADJ	JJ	5	O
cortex	cortex	NOUN	NN	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
demonstration	demonstration	NOUN	NN	9	O
of	of	ADP	IN	5	O
multiple	multiple	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
OCD	ocd	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
profile	profile	NOUN	NN	9	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
behaviors	behavior	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
biochemical	biochemical	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
regions	region	NOUN	NNS	9	O
previously	previously	ADV	RB	9	O
identified	identify	VERB	VBN	9	O
as	as	ADP	IN	5	O
relevant	relevant	ADJ	JJ	5	O
to	to	ADP	IN	5	O
OCD	OCD	PROPN	NNP	5	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
novel	novel	ADJ	JJ	9	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
OCD	OCD	PROPN	NNP	5	B-Disease
demonstrates	demonstrate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
exposure	exposure	NOUN	NN	9	O
during	during	ADP	IN	5	O
a	a	DET	DT	5	O
sensitive	sensitive	ADJ	JJ	9	O
period	period	NOUN	NN	5	O
can	can	VERB	MD	5	O
program	program	NOUN	NN	5	O
disease	disease	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
like	like	ADJ	JJ	9	O
systems	system	NOUN	NNS	5	O
permanently	permanently	ADV	RB	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
could	could	VERB	MD	9	O
have	have	VERB	VB	5	O
implications	implication	NOUN	NNS	5	O
for	for	ADP	IN	5	O
current	current	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
future	future	ADJ	JJ	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
strategies	strategy	NOUN	NNS	5	O
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
psychiatric	psychiatric	ADJ	JJ	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
ADAM10	adam10	NOUN	NN	3	O
,	,	PUNCT	,	9	O
ADAM17	adam17	NOUN	NN	3	O
,	,	PUNCT	,	9	O
MMP	MMP	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
2	2	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
MMP	MMP	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
9	9	NUM	CD	7	O
expression	expression	NOUN	NN	3	O
with	with	ADP	IN	5	O
media	medium	NOUN	NNS	9	O
degeneration	degeneration	NOUN	NN	9	O
features	feature	VERB	VBZ	5	O
CaCl2	CaCl2	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
thoracic	thoracic	NOUN	NN	5	B-Disease
aortic	aortic	ADJ	JJ	9	I-Disease
aneurysm	aneurysm	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
establish	establish	VERB	VB	5	O
a	a	DET	DT	5	O
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
thoracic	thoracic	NOUN	NN	5	B-Disease
aortic	aortic	ADJ	JJ	9	I-Disease
aneurysm	aneurysm	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
TAA	TAA	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
by	by	ADP	IN	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
CaCl	CaCl	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	PUNCT	LS	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
arterial	arterial	ADJ	JJ	5	B-Disease
injury	injury	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
explore	explore	VERB	VB	5	O
the	the	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
disintegrin	disintegrin	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
metalloproteinase	metalloproteinase	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
ADAM	ADAM	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
matrix	matrix	NOUN	NN	5	O
metalloproteinases	metalloproteinase	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
MMPs	MMPs	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
endogenous	endogenous	ADJ	JJ	3	O
inhibitors	inhibitor	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
TIMPs	timp	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
TAA	TAA	PROPN	NNP	9	B-Disease
formation	formation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

METHODS	METHODS	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Thoracic	Thoracic	PROPN	NNP	5	O
aorta	aorta	NOUN	NNS	9	O
of	of	ADP	IN	5	O
male	male	ADJ	JJ	9	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5M	5M	PROPN	NNP	0	O
CaCl	CaCl	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
or	or	CCONJ	CC	5	O
normal	normal	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
NaCl	NaCl	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
12weeks	12weeks	NUM	CD	7	O
,	,	PUNCT	,	9	O
animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
euthanized	euthanize	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
CaCl	CaCl	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
,	,	PUNCT	,	9	O
CaCl	CaCl	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	O
untreated	untreated	ADJ	JJ	3	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
12	12	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
NaCl	NaCl	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
aortic	aortic	ADJ	JJ	9	O
segments	segment	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
12	12	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
collected	collect	VERB	VBN	9	O
for	for	ADP	IN	5	O
histological	histological	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
molecular	molecular	ADJ	JJ	9	O
assessments	assessment	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

MMP	MMP	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
TIMP	TIMP	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
ADAM	ADAM	PROPN	NNP	3	O
mRNAs	mRNAs	PROPN	NNP	3	O
were	be	VERB	VBD	9	O
semi	semi	ADV	RB	5	O
-	-	ADJ	JJ	7	O
quantitatively	quantitatively	ADV	RB	9	O
analyzed	analyzed	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
protein	protein	NOUN	NN	1	O
expressions	expression	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
immunohistochemistry	immunohistochemistry	NOUN	NN	3	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Despite	despite	ADP	IN	5	O
similar	similar	ADJ	JJ	9	O
external	external	ADJ	JJ	5	O
diameters	diameter	NOUN	NNS	5	O
among	among	ADP	IN	5	O
CaCl	CaCl	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
,	,	PUNCT	,	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
CaCl	cacl	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
NaCl	NaCl	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
segments	segment	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
aneurymal	aneurymal	ADJ	JJ	9	O
alteration	alteration	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
6	6	NUM	CD	9	O
,	,	PUNCT	,	9	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
media	medium	NOUN	NNS	9	O
degeneration	degeneration	NOUN	NN	9	O
with	with	ADP	IN	5	O
regional	regional	ADJ	JJ	5	O
disruption	disruption	NOUN	NN	9	O
,	,	PUNCT	,	9	O
fragmentation	fragmentation	NOUN	NN	9	O
of	of	ADP	IN	5	O
elastic	elastic	ADJ	JJ	5	O
fiber	fiber	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBN	9	O
collagen	collagen	NOUN	NN	3	O
deposition	deposition	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
12	12	NUM	CD	9	O
,	,	PUNCT	,	9	O
100	100	NUM	CD	0	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
demonstrated	demonstrate	VERB	VBN	9	O
in	in	ADP	IN	5	O
CaCl	CaCl	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
segments	segment	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

MMP	MMP	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
MMP	MMP	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
9	9	NUM	CD	7	O
,	,	PUNCT	,	9	O
ADAM	ADAM	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
10	10	NUM	CD	9	O
and	and	CCONJ	CC	5	O
ADAM	ADAM	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
17	17	NUM	CD	7	O
mRNA	mRNA	NOUN	NNS	3	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
in	in	ADP	IN	5	O
CaCl	CaCl	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
segments	segment	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
all	all	DET	DT	5	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
trends	trend	NOUN	NNS	5	O
of	of	ADP	IN	5	O
elevation	elevation	NOUN	NN	9	O
in	in	ADP	IN	5	O
CaCl	CaCl	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	O
untreated	untreated	ADJ	JJ	3	O
segments	segment	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
NaCl	NaCl	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
segments	segment	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Immunohistochemistry	immunohistochemistry	NOUN	NN	3	O
displayed	display	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
expressions	expression	NOUN	NNS	9	O
of	of	ADP	IN	5	O
MMP	MMP	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
2	2	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
MMP	MMP	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
9	9	NUM	CD	7	O
,	,	PUNCT	,	9	O
ADAM	ADAM	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
10	10	NUM	CD	9	O
and	and	CCONJ	CC	5	O
ADAM	ADAM	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
17	17	PROPN	NNP	7	O
(	(	PUNCT	-LRB-	9	O
all	all	DET	DT	5	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
intima	intima	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
media	medium	NOUN	NNS	9	O
for	for	ADP	IN	5	O
CaCl	CaCl	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
segments	segment	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

TIMP	timp	NOUN	NN	3	O
mRNA	mRNA	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
tissue	tissue	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
differ	differ	VERB	VB	9	O
obviously	obviously	ADV	RB	9	O
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
three	three	NUM	CD	9	O
aortic	aortic	ADJ	JJ	9	O
segments	segment	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
establishes	establish	VERB	VBZ	9	O
a	a	DET	DT	5	O
TAA	TAA	PROPN	NNP	9	B-Disease
model	model	NOUN	NN	5	O
by	by	ADP	IN	9	O
periarterial	periarterial	ADJ	JJ	5	O
CaCl	CaCl	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	PUNCT	LS	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
exposure	exposure	NOUN	NN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
demonstrates	demonstrate	VERB	VBZ	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
MMP	MMP	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
2	2	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
MMP	MMP	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
9	9	NUM	CD	7	O
,	,	PUNCT	,	9	O
ADAM10	adam10	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
ADAM17	adam17	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
vascular	vascular	ADJ	JJ	5	O
remodeling	remodeling	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Suxamethonium	Suxamethonium	PROPN	NNP	0	B-Chemical
induced	induce	VERB	VBD	3	O
prolonged	prolong	VERB	VBN	9	O
apnea	apnea	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
receiving	receive	VERB	VBG	9	O
electroconvulsive	electroconvulsive	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Suxamethonium	suxamethonium	NOUN	NN	0	B-Chemical
causes	cause	NOUN	NNS	9	O
prolonged	prolong	VERB	VBD	9	O
apnea	apnea	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
whom	whom	PRON	WP	5	O
pseudocholinesterase	pseudocholinesterase	NOUN	NN	0	O
enzyme	enzyme	NOUN	NN	0	O
gets	get	VERB	VBZ	5	O
deactivated	deactivate	VERB	VBN	5	O
by	by	ADP	IN	9	O
organophosphorus	organophosphorus	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
OP	op	NOUN	NN	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
poisons	poison	NOUN	NNS	5	I-Chemical
.	.	PUNCT	.	9	O

Here	here	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
present	present	VERB	VBP	9	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
incident	incident	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
severely	severely	ADV	RB	9	O
depressed	depressed	ADJ	JJ	5	B-Disease
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
electroconvulsive	electroconvulsive	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ECT	ECT	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Prolonged	prolong	VERB	VBN	9	O
apnea	apnea	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
case	case	NOUN	NN	5	O
ensued	ensue	VERB	VBN	5	O
because	because	ADP	IN	5	O
the	the	DET	DT	5	O
information	information	NOUN	NN	5	O
about	about	ADP	IN	5	O
suicidal	suicidal	ADJ	JJ	5	O
attempt	attempt	NOUN	NN	5	O
by	by	ADP	IN	9	O
OP	op	NOUN	NN	9	B-Chemical
compound	compound	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
concealed	conceal	VERB	VBN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
treating	treating	NOUN	NN	5	O
team	team	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Curcumin	curcumin	NOUN	NN	0	B-Chemical
ameliorates	ameliorate	VERB	VBZ	3	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
oxidative	oxidative	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
in	in	ADP	IN	5	O
phenobarbitone	phenobarbitone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
administered	administer	VERB	VBN	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
antiepileptic	antiepileptic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
phenobarbitone	phenobarbitone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
well	well	ADV	RB	9	O
known	known	ADJ	JJ	9	O
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
on	on	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
free	free	ADJ	JJ	9	O
radical	radical	ADJ	JJ	0	O
generation	generation	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
implicated	implicate	VERB	VBN	9	O
as	as	ADP	IN	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
important	important	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
by	by	ADP	IN	9	O
antiepileptic	antiepileptic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Curcumin	Curcumin	PROPN	NNP	0	B-Chemical
has	have	VERB	VBZ	9	O
shown	show	VERB	VBN	9	O
antioxidant	antioxidant	ADJ	JJ	0	O
,	,	PUNCT	,	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
neuro	neuro	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
protective	protective	ADJ	JJ	9	O
properties	property	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
carried	carry	VERB	VBN	9	O
out	out	PART	RP	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
curcumin	curcumin	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
on	on	ADP	IN	5	O
phenobarbitone	phenobarbitone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Pharmacokinetic	pharmacokinetic	ADJ	JJ	0	O
interactions	interaction	NOUN	NNS	9	O
of	of	ADP	IN	5	O
curcumin	curcumin	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
phenobarbitone	phenobarbitone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
studied	study	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Vehicle	Vehicle	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
drugs	drug	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
daily	daily	ADV	RB	5	O
for	for	ADP	IN	5	O
21days	21days	NUM	CD	0	O
to	to	ADP	IN	5	O
male	male	ADJ	JJ	9	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
paradigm	paradigm	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
elevated	elevated	ADJ	JJ	9	O
plus	plus	CCONJ	CC	9	O
maze	maze	NOUN	NN	5	O
test	test	NOUN	NN	5	O
were	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
cognitive	cognitive	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
study	study	NOUN	NN	9	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
serum	serum	ADJ	JJ	9	O
phenobarbitone	phenobarbitone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
whole	whole	ADJ	JJ	9	O
brain	brain	NOUN	NN	5	O
malondialdehyde	malondialdehyde	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
reduced	reduce	VERB	VBD	9	O
glutathione	glutathione	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
estimated	estimate	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
phenobarbitone	phenobarbitone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
21days	21days	NUM	CD	0	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
impairment	impairment	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
learning	learning	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
memory	memory	NOUN	NN	5	I-Disease
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Concomitant	concomitant	ADJ	JJ	9	O
curcumin	curcumin	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
prevented	prevent	VERB	VBD	9	O
the	the	DET	DT	5	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
oxidative	oxidative	ADJ	JJ	9	O
stress	stress	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
these	these	DET	DT	5	O
antiepileptic	antiepileptic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Curcumin	curcumin	NOUN	NN	0	B-Chemical
co	co	NOUN	NN	9	O
-	-	NOUN	NN	7	O
administration	administration	NOUN	NN	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
cause	cause	VERB	VB	5	O
any	any	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
alteration	alteration	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
phenobarbitone	phenobarbitone	NOUN	NN	0	B-Chemical
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
curcumin	curcumin	NOUN	NN	0	B-Chemical
has	have	VERB	VBZ	9	O
beneficial	beneficial	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
in	in	ADP	IN	5	O
mitigating	mitigate	VERB	VBG	5	O
the	the	DET	DT	5	O
deterioration	deterioration	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
cognitive	cognitive	ADJ	JJ	5	I-Disease
functions	function	NOUN	NNS	9	I-Disease
and	and	CCONJ	CC	5	O
oxidative	oxidative	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
phenobarbitone	phenobarbitone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
without	without	ADP	IN	9	O
significantly	significantly	ADV	RB	9	O
altering	alter	VERB	VBG	9	O
their	-PRON-	DET	PRP$	5	O
serum	serum	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
curcumin	curcumin	NOUN	NN	0	B-Chemical
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
safe	safe	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
effective	effective	ADJ	JJ	5	O
adjuvant	adjuvant	NOUN	NN	9	O
to	to	PART	TO	5	O
phenobarbitone	phenobarbitone	VERB	VB	0	B-Chemical
and	and	CCONJ	CC	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
preventing	prevent	VERB	VBG	9	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
these	these	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Can	Can	VERB	MD	5	O
angiogenesis	angiogenesis	NOUN	NN	3	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
target	target	NOUN	NN	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
associated	associate	VERB	VBN	9	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
?	?	PUNCT	.	5	O

BACKGROUND	BACKGROUND	PROPN	NNP	2	O
/	/	SYM	SYM	9	O
AIMS	AIMS	PROPN	NNP	5	O
:	:	PUNCT	:	9	O
Recently	recently	ADV	RB	9	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
inhibit	inhibit	VERB	VB	3	O
angiogenesis	angiogenesis	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
angiogenesis	angiogenesis	NOUN	NN	3	O
inhibitors	inhibitor	NOUN	NNS	3	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
sunitinib	sunitinib	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
sorafenib	sorafenib	NOUN	NN	3	B-Chemical
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
acute	acute	ADJ	JJ	9	O
hemolysis	hemolysis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
aimed	aim	VERB	VBD	5	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
whether	whether	ADP	IN	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
relation	relation	NOUN	NN	5	O
between	between	ADP	IN	5	O
hemoglobin	hemoglobin	NOUN	NN	0	O
,	,	PUNCT	,	9	O
haptoglobin	haptoglobin	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
angiogenesis	angiogenesis	NOUN	NN	3	O
soluble	soluble	ADJ	JJ	0	O
markers	marker	NOUN	NNS	3	O
which	which	DET	WDT	5	O
are	be	VERB	VBP	5	O
modifiable	modifiable	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
can	can	VERB	MD	5	O
help	help	VERB	VB	5	O
in	in	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
strategies	strategy	NOUN	NNS	5	O
against	against	ADP	IN	9	O
anemia	anemia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Fourteen	fourteen	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
chronically	chronically	ADV	RB	9	B-Disease
infected	infect	VERB	VBN	3	I-Disease
with	with	ADP	IN	5	I-Disease
hepatitis	hepatitis	PROPN	NNP	9	I-Disease
C	C	PROPN	NNP	9	I-Disease
virus	virus	NOUN	NN	9	I-Disease
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
by	by	ADP	IN	9	O
pegylated	pegylate	VERB	VBN	0	B-Chemical
interferon	interferon	NOUN	NN	3	I-Chemical
alpha	alpha	NOUN	NN	9	I-Chemical
2a	2a	NUM	CD	9	I-Chemical
and	and	CCONJ	CC	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

Serum	serum	ADJ	JJ	9	O
hemoglobin	hemoglobin	NOUN	NN	0	O
,	,	PUNCT	,	9	O
haptoglobin	haptoglobin	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
angiogenesis	angiogenesis	NOUN	NN	3	O
markers	marker	NOUN	NNS	3	O
of	of	ADP	IN	5	O
vascular	vascular	ADJ	JJ	5	O
endothelial	endothelial	ADJ	JJ	3	O
growth	growth	NOUN	NN	3	O
factor	factor	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
angiopoetin	angiopoetin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
were	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
before	before	ADP	IN	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
observed	observe	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
haptoglobin	haptoglobin	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Hemoglobin	hemoglobin	NOUN	NN	7	O
levels	level	NOUN	NNS	3	O
also	also	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	O
but	but	CCONJ	CC	9	O
insignificantly	insignificantly	ADV	RB	9	O
by	by	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
,	,	PUNCT	,	9	O
serum	serum	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
angiogenesis	angiogenesis	NOUN	NN	3	O
factors	factor	NOUN	NNS	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
change	change	VERB	VB	9	O
significantly	significantly	ADV	RB	9	O
by	by	ADP	IN	9	O
pegylated	pegylate	VERB	VBN	0	B-Chemical
interferon	interferon	NOUN	NN	3	I-Chemical
and	and	CCONJ	CC	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
found	find	VERB	VBD	9	O
no	no	DET	DT	9	O
correlation	correlation	NOUN	NN	9	O
of	of	ADP	IN	5	O
angiogenesis	angiogenesis	NOUN	NN	3	O
soluble	soluble	ADJ	JJ	0	O
markers	marker	NOUN	NNS	3	O
with	with	ADP	IN	5	O
either	either	DET	DT	9	O
hemoglobin	hemoglobin	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
haptoglobin	haptoglobin	NOUN	NN	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
investigating	investigate	VERB	VBG	5	O
a	a	DET	DT	5	O
link	link	NOUN	NN	5	O
between	between	ADP	IN	5	O
angiogenesis	angiogenesis	NOUN	NN	3	O
soluble	soluble	ADJ	JJ	0	O
markers	marker	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
induced	induce	VERB	VBN	3	O
anemia	anemia	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hepatitis	hepatitis	PROPN	NNP	9	B-Disease
C	C	PROPN	NNP	9	I-Disease
and	and	CCONJ	CC	5	O
we	-PRON-	PRON	PRP	5	O
could	could	VERB	MD	9	O
not	not	ADV	RB	5	O
find	find	VERB	VB	5	O
any	any	DET	DT	5	O
relation	relation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Future	future	ADJ	JJ	5	O
research	research	NOUN	NN	5	O
with	with	ADP	IN	5	O
larger	large	ADJ	JJR	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
needed	need	VERB	VBN	5	O
to	to	PART	TO	5	O
find	find	VERB	VB	5	O
out	out	PART	RP	9	O
modifiable	modifiable	ADJ	JJ	5	O
factors	factor	NOUN	NNS	9	O
that	that	DET	WDT	5	O
will	will	VERB	MD	5	O
improve	improve	VERB	VB	5	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
injection	injection	NOUN	NN	9	O
pain	pain	NOUN	NN	5	B-Disease
using	use	VERB	VBG	9	O
buffered	buffer	VERB	VBN	0	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
local	local	ADJ	JJ	5	O
anesthetic	anesthetic	NOUN	NN	5	O
before	before	ADP	IN	9	O
cardiac	cardiac	ADJ	JJ	5	O
catheterization	catheterization	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Previous	previous	ADJ	JJ	9	O
reports	report	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
acidic	acidic	ADJ	JJ	0	O
pH	pH	NOUN	NNS	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
solution	solution	NOUN	NN	0	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
determine	determine	VERB	VB	9	O
if	if	ADP	IN	5	O
the	the	DET	DT	5	O
addition	addition	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
buffering	buffer	VERB	VBG	5	O
solution	solution	NOUN	NN	0	O
to	to	PART	TO	5	O
adjust	adjust	VERB	VB	5	O
the	the	DET	DT	5	O
pH	pH	NOUN	NNS	0	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
physiologic	physiologic	NOUN	NN	9	O
range	range	NOUN	NN	9	O
would	would	VERB	MD	5	O
reduce	reduce	VERB	VB	5	O
pain	pain	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
injection	injection	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
performed	perform	VERB	VBD	9	O
a	a	DET	DT	5	O
blinded	blind	VERB	VBN	5	O
randomized	randomize	VERB	VBN	5	O
study	study	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
cardiac	cardiac	ADJ	JJ	5	O
catheterization	catheterization	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
asked	ask	VERB	VBN	5	O
to	to	PART	TO	5	O
quantify	quantify	VERB	VB	9	O
the	the	DET	DT	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
standard	standard	ADJ	JJ	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
femoral	femoral	ADJ	JJ	5	O
area	area	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
buffered	buffer	VERB	VBD	0	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
opposite	opposite	ADJ	JJ	9	O
femoral	femoral	ADJ	JJ	5	O
area	area	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
score	score	NOUN	NN	5	O
for	for	ADP	IN	5	O
buffered	buffered	ADJ	JJ	0	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
score	score	NOUN	NN	5	O
for	for	ADP	IN	5	O
standard	standard	ADJ	JJ	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
3	3	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pH	pH	PROPN	NNP	0	O
adjustment	adjustment	NOUN	NN	5	O
of	of	ADP	IN	5	O
standard	standard	ADJ	JJ	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
accomplished	accomplish	VERB	VBN	5	O
easily	easily	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
catheterization	catheterization	NOUN	NN	5	O
laboratory	laboratory	NOUN	NN	9	O
before	before	ADP	IN	9	O
injection	injection	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
results	result	NOUN	NNS	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
pain	pain	NOUN	NN	5	B-Disease
occurring	occur	VERB	VBG	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
infiltration	infiltration	NOUN	NN	3	O
of	of	ADP	IN	5	O
tissues	tissue	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
alpha	alpha	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
glyceryl	glyceryl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
phosphorylcholine	phosphorylcholine	NOUN	NN	0	I-Chemical
on	on	ADP	IN	5	O
amnesia	amnesia	NOUN	NN	5	B-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
carried	carry	VERB	VBN	9	O
out	out	PART	RP	9	O
to	to	PART	TO	5	O
test	test	VERB	VB	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
alpha	alpha	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
glycerylphosphorylcholine	glycerylphosphorylcholine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
alpha	alpha	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
GFC	gfc	NOUN	NN	5	I-Chemical
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
memory	memory	NOUN	NN	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
man	man	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
two	two	NUM	CD	5	O
healthy	healthy	ADJ	JJ	5	O
young	young	ADJ	JJ	5	O
volunteers	volunteer	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
allocated	allocate	VERB	VBN	5	O
to	to	ADP	IN	5	O
four	four	NUM	CD	9	O
different	different	ADJ	JJ	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

They	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
a	a	DET	DT	5	O
ten	ten	NUM	CD	9	O
day	day	NOUN	NN	9	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
either	either	CCONJ	CC	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
alpha	alpha	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
GFC	gfc	NOUN	NN	5	I-Chemical
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
,	,	PUNCT	,	9	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
eleventh	eleventh	ADJ	JJ	5	O
day	day	NOUN	NN	9	O
either	either	CCONJ	CC	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
m	m	PUNCT	LS	9	O
.	.	PUNCT	.	9	O

Before	before	ADP	IN	9	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
injection	injection	NOUN	NN	9	O
the	the	DET	DT	5	O
subjects	subject	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
attention	attention	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
mnemonic	mnemonic	NOUN	NN	5	O
tests	test	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
able	able	ADJ	JJ	9	O
to	to	PART	TO	5	O
antagonize	antagonize	VERB	VB	3	O
impairment	impairment	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
attention	attention	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
memory	memory	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
capecitabine	capecitabine	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
review	review	NOUN	NN	5	O
.	.	PUNCT	.	9	O

IMPORTANCE	importance	NOUN	NN	2	O
OF	of	ADP	IN	2	O
THE	the	DET	DT	2	O
FIELD	FIELD	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Fluoropyrimidines	fluoropyrimidine	NOUN	NNS	0	B-Chemical
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
particular	particular	ADJ	JJ	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
the	the	DET	DT	5	O
mainstay	mainstay	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
several	several	ADJ	JJ	9	O
solid	solid	ADJ	JJ	9	O
tumors	tumor	NOUN	NNS	3	B-Disease
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
colorectal	colorectal	ADJ	JJ	9	B-Disease
,	,	PUNCT	,	9	I-Disease
breast	breast	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	I-Disease
head	head	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
neck	neck	NOUN	NN	5	I-Disease
cancers	cancer	NOUN	NNS	9	I-Disease
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
>	>	X	XX	0	O
40	40	NUM	CD	9	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

AREAS	AREAS	PROPN	NNP	2	O
COVERED	covered	VERB	VB	2	O
IN	in	ADP	IN	2	O
THIS	this	DET	DT	2	O
REVIEW	review	NOUN	NN	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
article	article	NOUN	NN	6	O
reviews	review	VERB	VBZ	5	O
the	the	DET	DT	5	O
pharmacology	pharmacology	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
capecitabine	capecitabine	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
special	special	ADJ	JJ	5	O
emphasis	emphasis	NOUN	NN	5	O
on	on	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
safety	safety	NOUN	NN	5	O
.	.	PUNCT	.	9	O

WHAT	what	DET	WDT	2	O
THE	the	DET	DT	2	O
READER	READER	NOUN	NNS	2	O
WILL	WILL	VERB	MD	2	O
GAIN	gain	VERB	VB	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
reader	reader	NOUN	NN	5	O
will	will	VERB	MD	5	O
gain	gain	VERB	VB	5	O
better	well	ADJ	JJR	5	O
insight	insight	NOUN	NN	5	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
capecitabine	capecitabine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
special	special	ADJ	JJ	5	O
populations	population	NOUN	NNS	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
renal	renal	ADJ	JJ	9	B-Disease
and	and	CCONJ	CC	5	I-Disease
kidney	kidney	NOUN	NN	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
also	also	ADV	RB	9	O
explore	explore	VERB	VBP	5	O
different	different	ADJ	JJ	9	O
dosing	dosing	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
schedules	schedule	NOUN	NNS	5	O
of	of	ADP	IN	5	O
capecitabine	capecitabine	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

TAKE	TAKE	PROPN	NNP	2	O
HOME	HOME	PROPN	NNP	5	O
MESSAGE	message	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Capecitabine	Capecitabine	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
oral	oral	ADJ	JJ	9	O
prodrug	prodrug	NOUN	NN	0	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
developed	develop	VERB	VBN	5	O
to	to	PART	TO	5	O
fulfill	fulfill	VERB	VB	5	O
the	the	DET	DT	5	O
need	need	NOUN	NN	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
more	more	ADV	RBR	5	O
convenient	convenient	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
provide	provide	VERB	VB	5	O
an	an	DET	DT	5	O
improved	improved	ADJ	JJ	5	O
safety	safety	NOUN	NN	5	O
/	/	SYM	SYM	9	O
efficacy	efficacy	NOUN	NN	9	O
profile	profile	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
shown	show	VERB	VBN	9	O
promising	promising	ADJ	JJ	5	O
results	result	NOUN	NNS	9	O
alone	alone	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
chemotherapeutic	chemotherapeutic	ADJ	JJ	3	O
agents	agent	NOUN	NNS	5	O
in	in	ADP	IN	5	O
colorectal	colorectal	ADJ	JJ	9	B-Disease
,	,	PUNCT	,	9	I-Disease
breast	breast	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	I-Disease
pancreaticobiliary	pancreaticobiliary	ADJ	JJ	5	I-Disease
,	,	PUNCT	,	9	I-Disease
gastric	gastric	ADJ	JJ	9	I-Disease
,	,	PUNCT	,	9	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
cell	cell	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	I-Disease
head	head	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
neck	neck	NOUN	NN	5	I-Disease
cancers	cancer	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
commonly	commonly	ADV	RB	5	O
reported	report	VERB	VBD	9	O
toxic	toxic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
capecitabine	capecitabine	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
diarrhea	diarrhea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
nausea	nausea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
vomiting	vomiting	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
stomatitis	stomatitis	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
hand	hand	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
foot	foot	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Capecitabine	Capecitabine	PROPN	NNP	0	B-Chemical
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
established	establish	VERB	VBN	9	O
safety	safety	NOUN	NN	5	O
profile	profile	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
given	give	VERB	VBN	5	O
safely	safely	ADV	RB	5	O
to	to	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
and	and	CCONJ	CC	5	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
dysfunctions	dysfunction	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Levodopa	Levodopa	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
filling	fill	VERB	VBG	5	O
the	the	DET	DT	5	O
bench	bench	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
bedside	bedside	NOUN	NN	5	O
gap	gap	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Levodopa	Levodopa	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
effective	effective	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
precursor	precursor	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
complicated	complicate	VERB	VBN	5	O
by	by	ADP	IN	9	O
highly	highly	ADV	RB	9	O
disabling	disable	VERB	VBG	5	O
fluctuations	fluctuation	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
preclinical	preclinical	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
pulsatile	pulsatile	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
striatal	striatal	ADJ	JJ	3	O
postsynaptic	postsynaptic	ADJ	JJ	3	O
receptors	receptor	NOUN	NNS	3	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
key	key	ADJ	JJ	9	O
mechanism	mechanism	NOUN	NN	9	O
underlying	underlie	VERB	VBG	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
their	-PRON-	DET	PRP$	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
still	still	ADV	RB	5	O
unclear	unclear	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
recent	recent	ADJ	JJ	5	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
evidence	evidence	NOUN	NN	9	O
from	from	ADP	IN	9	O
animal	animal	NOUN	NN	5	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
has	have	VERB	VBZ	9	O
provided	provide	VERB	VBN	9	O
important	important	ADJ	JJ	9	O
information	information	NOUN	NN	5	O
to	to	PART	TO	5	O
understand	understand	VERB	VB	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
specific	specific	ADJ	JJ	9	O
receptor	receptor	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
receptor	receptor	ADJ	JJ	3	O
molecular	molecular	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
underlying	underlie	VERB	VBG	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
dyskinetic	dyskinetic	ADJ	JJ	5	B-Disease
movements	movement	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Recent	recent	ADJ	JJ	9	O
preclinical	preclinical	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
from	from	ADP	IN	9	O
promising	promise	VERB	VBG	5	O
lines	line	NOUN	NNS	3	O
of	of	ADP	IN	5	O
research	research	NOUN	NN	5	O
focus	focus	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
differential	differential	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
presynaptic	presynaptic	ADJ	JJ	3	O
versus	versus	ADP	IN	9	O
postsynaptic	postsynaptic	ADJ	JJ	3	O
mechanisms	mechanism	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
receptor	receptor	NOUN	NN	3	O
subtypes	subtype	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
ionotropic	ionotropic	ADJ	JJ	3	O
and	and	CCONJ	CC	5	O
metabotropic	metabotropic	ADJ	JJ	3	O
glutamate	glutamate	ADJ	JJ	0	B-Chemical
receptors	receptor	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
neurotransmitter	neurotransmitter	NOUN	NN	9	O
systems	system	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathophysiology	pathophysiology	NOUN	NN	9	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
pallidal	pallidal	ADJ	JJ	5	O
neurotensin	neurotensin	NOUN	NN	3	B-Chemical
on	on	ADP	IN	5	O
haloperidol	haloperidol	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
catalepsy	catalepsy	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
behavioral	behavioral	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
electrophysiological	electrophysiological	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
globus	globus	NOUN	NN	5	O
pallidus	pallidus	NOUN	NN	4	O
plays	play	VERB	VBZ	9	O
a	a	DET	DT	5	O
critical	critical	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
movement	movement	NOUN	NN	5	O
regulation	regulation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Previous	previous	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
indicated	indicate	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
globus	globus	NOUN	NN	5	O
pallidus	pallidus	NOUN	NN	4	O
receives	receive	VERB	VBZ	5	O
neurotensinergic	neurotensinergic	ADJ	JJ	3	O
innervation	innervation	NOUN	NN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
systemic	systemic	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
neurotensin	neurotensin	NOUN	NN	3	B-Chemical
analog	analog	NOUN	NN	0	O
could	could	VERB	MD	9	O
produce	produce	VERB	VB	9	O
antiparkinsonian	antiparkinsonian	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
aimed	aim	VERB	VBN	5	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
pallidal	pallidal	ADJ	JJ	5	O
neurotensin	neurotensin	NOUN	NN	3	B-Chemical
on	on	ADP	IN	5	O
haloperidol	haloperidol	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Behavioral	behavioral	ADJ	JJ	5	O
experiments	experiment	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
electrophysiological	electrophysiological	ADJ	JJ	5	O
recordings	recording	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Bilateral	bilateral	ADJ	JJ	5	O
infusions	infusion	NOUN	NNS	9	O
of	of	ADP	IN	5	O
neurotensin	neurotensin	NOUN	NN	3	B-Chemical
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
globus	globus	NOUN	NN	5	O
pallidus	pallidus	NOUN	NN	4	O
reversed	reverse	VERB	VBD	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
catalepsy	catalepsy	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Electrophysiological	electrophysiological	ADJ	JJ	5	O
recordings	recording	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
microinjection	microinjection	NOUN	NN	3	O
of	of	ADP	IN	5	O
neurotensin	neurotensin	NOUN	NN	3	B-Chemical
induced	induce	VERB	VBN	3	O
excitation	excitation	NOUN	NN	0	O
of	of	ADP	IN	5	O
pallidal	pallidal	ADJ	JJ	5	O
neurons	neuron	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
neurotensin	neurotensin	NOUN	NN	3	B-Chemical
type	type	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
receptor	receptor	NOUN	NN	3	I-Chemical
antagonist	antagonist	NOUN	NN	3	I-Chemical
SR48692	SR48692	PROPN	NNP	3	B-Chemical
blocked	block	VERB	VBN	3	O
both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
behavioral	behavioral	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
electrophysiological	electrophysiological	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
neurotensin	neurotensin	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
pallidal	pallidal	ADJ	JJ	5	O
neurotensin	neurotensin	NOUN	NN	3	B-Chemical
receptors	receptor	NOUN	NNS	3	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
neurotensin	neurotensin	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
antiparkinsonian	antiparkinsonian	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Carmofur	Carmofur	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
organic	organic	ADJ	JJ	0	B-Disease
mental	mental	ADJ	JJ	5	I-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Organic	organic	ADJ	JJ	0	B-Disease
mental	mental	ADJ	JJ	5	I-Disease
disorder	disorder	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
29	29	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
female	female	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
prognostic	prognostic	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
carmofur	carmofur	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
leukoencephalopathy	leukoencephalopathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Symptoms	symptom	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
euphoria	euphoria	NOUN	NN	5	O
,	,	PUNCT	,	9	O
emotional	emotional	ADJ	JJ	5	O
lability	lability	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
puerile	puerile	ADJ	JJ	5	O
attitude	attitude	NOUN	NN	5	O
noted	note	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
were	be	VERB	VBD	9	O
diagnosed	diagnose	VERB	VBN	5	O
as	as	ADP	IN	5	O
organic	organic	ADJ	JJ	0	B-Disease
personality	personality	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
criteria	criterion	NOUN	NNS	5	O
defined	define	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
DSM	DSM	PROPN	NNP	4	O
-	-	PUNCT	HYPH	7	O
III	III	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
R	r	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
referred	refer	VERB	VBN	5	O
to	to	ADP	IN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
frontal	frontal	ADJ	JJ	5	B-Disease
lobe	lobe	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Brain	Brain	PROPN	NNP	9	O
CT	CT	PROPN	NNP	9	O
revealed	reveal	VERB	VBD	9	O
a	a	DET	DT	5	O
periventricular	periventricular	ADJ	JJ	5	O
low	low	ADJ	JJ	9	O
density	density	NOUN	NN	9	O
area	area	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
frontal	frontal	ADJ	JJ	5	O
white	white	ADJ	JJ	9	O
matter	matter	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
moderate	moderate	ADJ	JJ	9	O
dilatation	dilatation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
lateral	lateral	ADJ	JJ	5	O
ventricles	ventricle	NOUN	NNS	5	O
especially	especially	ADV	RB	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
bilateral	bilateral	ADJ	JJ	5	O
anterior	anterior	ADJ	JJ	5	O
horns	horn	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Consequently	consequently	ADV	RB	9	O
,	,	PUNCT	,	9	O
carmofur	carmofur	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
leukoencephalopathy	leukoencephalopathy	NOUN	NN	5	B-Disease
may	may	VERB	MD	5	O
uncommonly	uncommonly	ADV	RB	5	O
result	result	VERB	VB	9	O
in	in	ADP	IN	5	O
organic	organic	ADJ	JJ	0	B-Disease
personality	personality	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
residual	residual	ADJ	JJ	9	O
state	state	NOUN	NN	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
attributed	attribute	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
structural	structural	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
to	to	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
frontal	frontal	ADJ	JJ	5	I-Disease
lobe	lobe	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Butyrylcholinesterase	butyrylcholinesterase	ADJ	JJ	7	O
gene	gene	NOUN	NN	1	O
mutations	mutation	NOUN	NNS	1	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
prolonged	prolong	VERB	VBN	9	O
apnea	apnea	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
for	for	ADP	IN	5	O
electroconvulsive	electroconvulsive	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
electroconvulsive	electroconvulsive	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ECT	ECT	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
often	often	ADV	RB	5	O
receive	receive	VERB	VBP	5	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
as	as	ADP	IN	5	O
part	part	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
procedure	procedure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
prolonged	prolong	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
genetic	genetic	ADJ	JJ	5	O
variants	variant	NOUN	NNS	1	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
butyrylcholinesterase	butyrylcholinesterase	ADJ	JJ	0	O
enzyme	enzyme	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
BChE	BChE	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
being	be	VERB	VBG	5	O
the	the	DET	DT	5	O
K	K	PROPN	NNP	9	O
-	-	PUNCT	:	7	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
A	a	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
variants	variant	NOUN	NNS	1	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
significance	significance	NOUN	NN	9	O
of	of	ADP	IN	5	O
genetic	genetic	ADJ	JJ	5	O
variants	variant	NOUN	NNS	1	O
in	in	ADP	IN	5	O
butyrylcholinesterase	butyrylcholinesterase	ADJ	JJ	0	O
gene	gene	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
BCHE	BCHE	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
suspected	suspect	VERB	VBN	5	O
prolonged	prolonged	ADJ	JJ	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
after	after	ADP	IN	9	O
ECT	ECT	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
13	13	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
referred	refer	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
Danish	Danish	PROPN	NNP	5	O
Cholinesterase	Cholinesterase	PROPN	NNP	0	O
Research	Research	PROPN	NNP	2	O
Unit	Unit	PROPN	NNP	2	O
after	after	ADP	IN	9	O
ECT	ECT	PROPN	NNP	5	O
during	during	ADP	IN	5	O
38	38	NUM	CD	7	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
determined	determine	VERB	VBD	9	O
the	the	DET	DT	5	O
BChE	BChE	PROPN	NNP	0	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
BCHE	BCHE	PROPN	NNP	7	O
genotype	genotype	NOUN	NN	9	O
using	use	VERB	VBG	9	O
molecular	molecular	ADJ	JJ	9	O
genetic	genetic	ADJ	JJ	5	O
methods	method	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
apnea	apnea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
time	time	NOUN	NN	5	O
to	to	ADP	IN	5	O
sufficient	sufficient	ADJ	JJ	9	O
spontaneous	spontaneous	ADJ	JJ	5	O
ventilation	ventilation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
whether	whether	ADP	IN	9	O
neuromuscular	neuromuscular	ADJ	JJ	5	O
monitoring	monitoring	NOUN	NN	5	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
apnea	apnea	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
published	publish	VERB	VBN	9	O
data	datum	NOUN	NNS	5	O
on	on	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
in	in	ADP	IN	5	O
11	11	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
mutations	mutation	NOUN	NNS	1	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
BCHE	BCHE	PROPN	NNP	7	O
gene	gene	NOUN	NN	1	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
K	K	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
variant	variant	PROPN	NNP	1	O
being	be	VERB	VBG	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
frequent	frequent	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
apnea	apnea	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
15	15	NUM	CD	9	O
min	min	NOUN	NN	0	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
min	min	NOUN	NN	0	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Severe	severe	ADJ	JJ	9	O
distress	distress	NOUN	NN	5	O
was	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
recovery	recovery	NOUN	NN	9	O
phase	phase	NOUN	NN	5	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Neuromuscular	neuromuscular	ADJ	JJ	2	O
monitoring	monitoring	NOUN	NN	5	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
eleven	eleven	NUM	CD	9	O
of	of	ADP	IN	5	O
13	13	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
prolonged	prolonged	ADJ	JJ	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
succinylcholine	succinylcholine	NOUN	NN	5	B-Chemical
had	have	VERB	VBD	9	O
mutations	mutation	NOUN	NNS	1	O
in	in	ADP	IN	5	O
BCHE	BCHE	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
reason	reason	NOUN	NN	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
prolonged	prolonged	ADJ	JJ	9	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
apnea	apnea	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
recommend	recommend	VERB	VBP	5	O
objective	objective	ADJ	JJ	5	O
neuromuscular	neuromuscular	ADJ	JJ	5	O
monitoring	monitoring	NOUN	NN	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
ECT	ECT	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Perhexiline	perhexiline	ADJ	JJ	0	B-Chemical
maleate	maleate	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
noted	note	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
perhexiline	perhexiline	NOUN	NN	0	B-Chemical
maleate	maleate	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
drug	drug	NOUN	NN	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
France	France	PROPN	NNP	2	O
(	(	PUNCT	-LRB-	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
trials	trial	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
United	United	PROPN	NNP	9	O
States	States	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
prophylactic	prophylactic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
angina	angina	NOUN	NN	5	B-Disease
pectoris	pectori	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
24	24	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
this	this	DET	DT	5	O
complication	complication	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
marked	mark	VERB	VBN	9	O
slowing	slowing	NOUN	NN	5	O
of	of	ADP	IN	5	O
motor	motor	NOUN	NN	5	O
nerve	nerve	NOUN	NN	5	O
conduction	conduction	NOUN	NN	5	O
velocity	velocity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
electromyographic	electromyographic	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
imply	imply	VERB	VBP	9	O
mainly	mainly	ADV	RB	9	O
a	a	DET	DT	5	O
demyelinating	demyelinate	VERB	VBG	9	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Improvement	improvement	NOUN	NN	5	O
was	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
with	with	ADP	IN	5	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
few	few	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
active	active	ADJ	JJ	9	O
denervation	denervation	NOUN	NN	5	O
signified	signify	VERB	VBD	5	O
a	a	DET	DT	5	O
poor	poor	ADJ	JJ	5	O
prognosis	prognosis	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
only	only	ADJ	JJ	9	O
slight	slight	ADJ	JJ	9	O
improvement	improvement	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
underlying	underlie	VERB	VBG	5	O
mechanism	mechanism	NOUN	NN	9	O
causing	cause	VERB	VBG	9	O
the	the	DET	DT	5	O
neuropathy	neuropathy	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
yet	yet	ADV	RB	9	O
fully	fully	ADV	RB	9	O
known	know	VERB	VBN	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
some	some	DET	DT	5	O
evidence	evidence	NOUN	NN	9	O
indicates	indicate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
lipid	lipid	NOUN	NN	0	O
storage	storage	NOUN	NN	9	O
process	process	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
phase	phase	NOUN	NN	5	O
I	-PRON-	PRON	PRP	9	O
study	study	VERB	VBP	9	O
of	of	ADP	IN	5	O
4	4	NUM	CD	9	B-Chemical
'	'	PART	POS	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
0	0	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tetrahydropyranyladriamycin	tetrahydropyranyladriamycin	NOUN	NN	_	I-Chemical
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
pharmacology	pharmacology	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
pharmacokinetics	pharmacokinetic	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
Phase	Phase	PROPN	NNP	9	O
I	-PRON-	PRON	PRP	9	O
study	study	VERB	VBP	9	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
(	(	PUNCT	-LRB-	9	O
IV	IV	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
bolus	bolus	NOUN	NN	0	O
4	4	NUM	CD	9	B-Chemical
'	'	PART	POS	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
0	0	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tetrahydropyranyladriamycin	tetrahydropyranyladriamycin	NOUN	NN	_	I-Chemical
(	(	PUNCT	-LRB-	9	O
Pirarubicin	Pirarubicin	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
done	do	VERB	VBN	9	O
in	in	ADP	IN	5	O
55	55	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
good	good	ADJ	JJ	5	O
performance	performance	NOUN	NN	5	O
status	status	NOUN	NN	9	O
with	with	ADP	IN	5	O
refractory	refractory	ADJ	JJ	9	O
tumors	tumor	NOUN	NNS	3	B-Disease
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
six	six	NUM	CD	9	O
had	have	VERB	VBD	9	O
minimal	minimal	ADJ	JJ	9	O
prior	prior	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
good	good	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
23	23	NUM	CD	7	O
had	have	VERB	VBD	9	O
extensive	extensive	ADJ	JJ	5	O
prior	prior	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
poor	poor	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
six	six	NUM	CD	9	O
had	have	VERB	VBD	9	O
renal	renal	ADJ	JJ	9	B-Disease
and	and	CCONJ	CC	5	I-Disease
/	/	SYM	SYM	9	I-Disease
or	or	CCONJ	CC	5	I-Disease
hepatic	hepatic	ADJ	JJ	9	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
167	167	NUM	CD	7	O
courses	course	NOUN	NNS	5	O
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
15	15	NUM	CD	9	O
to	to	PART	TO	5	O
70	70	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NNS	7	O
were	be	VERB	VBD	9	O
evaluable	evaluable	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Maximum	maximum	ADJ	JJ	9	O
tolerated	tolerate	VERB	VBN	9	O
dose	dose	NOUN	NN	9	O
in	in	ADP	IN	5	O
good	good	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
risk	risk	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
70	70	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
poor	poor	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
risk	risk	NOUN	NN	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
60	60	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
limiting	limit	VERB	VBG	9	O
toxic	toxic	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
transient	transient	ADJ	JJ	9	O
noncumulative	noncumulative	ADJ	JJ	5	O
granulocytopenia	granulocytopenia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Granulocyte	Granulocyte	PROPN	NNP	3	O
nadir	nadir	NOUN	NN	9	O
was	be	VERB	VBD	9	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
14	14	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
4	4	NUM	CD	9	O
-	-	SYM	SYM	7	O
22	22	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Less	less	ADV	RBR	5	O
frequent	frequent	ADJ	JJ	5	O
toxic	toxic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
included	include	VERB	VBD	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
anemia	anemia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
nausea	nausea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
mild	mild	ADJ	JJ	9	O
alopecia	alopecia	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
phlebitis	phlebitis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
mucositis	mucositis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Myelosuppression	myelosuppression	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
more	more	ADJ	JJR	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Pharmacokinetic	pharmacokinetic	ADJ	JJ	0	O
analyses	analysis	NOUN	NNS	9	O
in	in	ADP	IN	5	O
21	21	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
revealed	reveal	VERB	VBD	9	O
Pirarubicin	Pirarubicin	PROPN	NNP	0	B-Chemical
plasma	plasma	NOUN	NN	9	O
T	T	PROPN	NNP	3	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
alpha	alpha	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SE	se	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
85	85	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
T	T	PROPN	NNP	3	O
beta	beta	NOUN	NN	9	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
of	of	ADP	IN	5	O
25	25	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
T	t	NOUN	NN	3	O
1	1	NUM	CD	9	O
/	/	SYM	SYM	9	O
2	2	NUM	CD	9	O
gamma	gamma	NOUN	NN	9	O
of	of	ADP	IN	5	O
23	23	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
area	area	NOUN	NN	5	O
under	under	ADP	IN	9	O
the	the	DET	DT	5	O
curve	curve	NOUN	NN	9	O
was	be	VERB	VBD	9	O
537	537	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
149	149	NUM	CD	7	O
ng	ng	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
x	x	SYM	SYM	9	O
hours	hour	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
volume	volume	NOUN	NN	9	O
of	of	ADP	IN	5	O
distribution	distribution	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
Vd	vd	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
3504	3504	NUM	CD	7	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
644	644	NUM	CD	7	O
l	l	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
total	total	ADJ	JJ	9	O
clearance	clearance	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
ClT	ClT	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
204	204	NUM	CD	7	O
+	+	SYM	SYM	9	O
39	39	NUM	CD	7	O
.	.	NOUN	NN	9	O
3	3	NUM	CD	9	O
l	l	NOUN	NN	0	O
/	/	SYM	SYM	9	O
hour	hour	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
.	.	PUNCT	.	9	O

Adriamycinol	adriamycinol	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
adriamycinone	adriamycinone	ADJ	JJ	9	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
tetrahydropyranyladriamycinol	tetrahydropyranyladriamycinol	NOUN	NN	_	B-Chemical
were	be	VERB	VBD	9	O
the	the	DET	DT	5	O
metabolites	metabolite	NOUN	NNS	0	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
amount	amount	NOUN	NN	9	O
of	of	ADP	IN	5	O
doxorubicin	doxorubicin	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
or	or	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
metabolites	metabolite	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Urinary	urinary	ADJ	JJ	9	O
excretion	excretion	NOUN	NN	0	O
of	of	ADP	IN	5	O
Pirarubicin	Pirarubicin	PROPN	NNP	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
24	24	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
or	or	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
in	in	ADP	IN	5	O
mesothelioma	mesothelioma	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
leiomyosarcoma	leiomyosarcoma	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
basal	basal	NOUN	NN	3	B-Disease
cell	cell	NOUN	NN	3	I-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
recommended	recommend	VERB	VBN	5	O
starting	start	VERB	VBG	9	O
dose	dose	NOUN	NN	9	O
for	for	ADP	IN	5	O
Phase	Phase	PROPN	NNP	9	O
II	II	PROPN	NNP	9	O
trials	trial	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
60	60	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
IV	IV	PROPN	NNP	9	O
bolus	bolus	NOUN	NN	0	O
every	every	DET	DT	5	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Ocular	ocular	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
auditory	auditory	NOUN	NN	5	I-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
hemodialyzed	hemodialyzed	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
desferrioxamine	desferrioxamine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
an	an	DET	DT	5	O
18	18	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
month	month	NOUN	NN	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
study	study	NOUN	NN	9	O
41	41	NUM	CD	7	O
hemodialyzed	hemodialyzed	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
desferrioxamine	desferrioxamine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
BW	BW	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
3	3	NUM	CD	9	O
times	time	NOUN	NNS	5	O
weekly	weekly	ADJ	JJ	5	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
were	be	VERB	VBD	9	O
monitored	monitor	VERB	VBN	9	O
for	for	ADP	IN	5	O
detection	detection	NOUN	NN	9	O
of	of	ADP	IN	5	O
audiovisual	audiovisual	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

6	6	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
presented	present	VERB	VBD	5	O
clinical	clinical	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
visual	visual	ADJ	JJ	5	B-Disease
or	or	CCONJ	CC	5	I-Disease
auditory	auditory	NOUN	NN	5	I-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
detailed	detailed	ADJ	JJ	5	O
ophthalmologic	ophthalmologic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
audiologic	audiologic	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
disclosed	disclose	VERB	VBD	9	O
abnormalities	abnormality	NOUN	NNS	9	O
in	in	ADP	IN	5	O
7	7	NUM	CD	9	O
more	more	ADV	RBR	5	O
asymptomatic	asymptomatic	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Visual	visual	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
of	of	ADP	IN	5	O
retinal	retinal	ADJ	JJ	5	O
origin	origin	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
tritan	tritan	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
dyschromatopsy	dyschromatopsy	NOUN	NN	_	B-Disease
,	,	PUNCT	,	9	O
sometimes	sometimes	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
of	of	ADP	IN	5	I-Disease
visual	visual	ADJ	JJ	5	I-Disease
acuity	acuity	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
pigmentary	pigmentary	ADJ	JJ	5	B-Disease
retinal	retinal	ADJ	JJ	5	I-Disease
deposits	deposit	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

Auditory	auditory	NOUN	NN	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
mid	mid	NOUN	NN	9	O
-	-	NOUN	NN	7	O
to	to	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
frequency	frequency	NOUN	NN	5	O
neurosensorial	neurosensorial	ADJ	JJ	5	B-Disease
hearing	hearing	NOUN	NN	5	I-Disease
loss	loss	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
lesion	lesion	NOUN	NN	5	O
was	be	VERB	VBD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cochlear	cochlear	NOUN	NN	5	O
type	type	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Desferrioxamine	desferrioxamine	NOUN	NN	0	B-Chemical
withdrawal	withdrawal	NOUN	NN	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
complete	complete	ADJ	JJ	9	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
visual	visual	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
patient	patient	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
partial	partial	ADJ	JJ	9	O
recovery	recovery	NOUN	NN	9	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
complete	complete	ADJ	JJ	9	O
reversal	reversal	NOUN	NN	9	O
of	of	ADP	IN	5	O
hearing	hear	VERB	VBG	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
partial	partial	ADJ	JJ	9	O
recovery	recovery	NOUN	NN	9	O
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
appeared	appear	VERB	VBD	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
the	the	DET	DT	5	O
higher	high	ADJ	JJR	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
desferrioxamine	desferrioxamine	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
coincided	coincide	VERB	VBD	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
normalization	normalization	NOUN	NN	5	O
of	of	ADP	IN	5	O
ferritin	ferritin	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
aluminium	aluminium	ADJ	JJ	0	B-Chemical
serum	serum	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
audiovisual	audiovisual	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
an	an	DET	DT	5	O
infrequent	infrequent	NOUN	NN	5	O
complication	complication	NOUN	NN	5	O
in	in	ADP	IN	5	O
hemodialyzed	hemodialyzed	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
desferrioxamine	desferrioxamine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Periodical	periodical	ADJ	JJ	2	O
audiovisual	audiovisual	ADJ	JJ	5	O
monitoring	monitoring	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
performed	perform	VERB	VBN	9	O
on	on	ADP	IN	5	O
hemodialyzed	hemodialyzed	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
detect	detect	VERB	VB	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
as	as	ADV	RB	5	O
early	early	ADV	RB	9	O
as	as	ADP	IN	5	O
possible	possible	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Serial	serial	ADJ	JJ	9	O
epilepsy	epilepsy	NOUN	NN	5	B-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
/	/	SYM	SYM	9	I-Chemical
carbidopa	carbidopa	ADJ	JJ	0	I-Chemical
administration	administration	NOUN	NN	9	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
on	on	ADP	IN	5	O
hemodialysis	hemodialysis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
similar	similar	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
features	feature	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
presented	present	VERB	VBN	5	O
:	:	PUNCT	:	9	O
both	both	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
chronic	chronic	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
hemodialysis	hemodialysis	NOUN	NN	5	O
for	for	ADP	IN	5	O
many	many	ADJ	JJ	5	O
years	year	NOUN	NNS	5	O
but	but	CCONJ	CC	9	O
recently	recently	ADV	RB	9	O
begun	begin	VERB	VBN	5	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
flux	flux	NOUN	NN	9	O
dialyzer	dialyzer	NOUN	NN	0	O
;	;	PUNCT	,	9	O
both	both	DET	DT	9	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
receiving	receive	VERB	VBG	9	O
a	a	DET	DT	5	O
carbidopa	carbidopa	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	I-Chemical
levodopa	levodopa	ADJ	JJ	5	I-Chemical
preparation	preparation	NOUN	NN	9	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
both	both	DET	DT	9	O
had	have	VERB	VBD	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
hallucinosis	hallucinosis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
recurrent	recurrent	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
refractory	refractory	ADJ	JJ	9	O
to	to	ADP	IN	5	O
anticonvulsants	anticonvulsant	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
died	die	VERB	VBD	9	O
without	without	ADP	IN	9	O
a	a	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
dramatic	dramatic	ADJ	JJ	9	O
recovery	recovery	NOUN	NN	9	O
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
B6	b6	NOUN	NN	3	I-Chemical
.	.	PUNCT	.	9	O

Neither	neither	DET	DT	9	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
considered	consider	VERB	VBN	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
state	state	NOUN	NN	5	O
sufficiently	sufficiently	ADV	RB	5	O
severe	severe	ADJ	JJ	5	O
enough	enough	ADV	RB	5	O
to	to	PART	TO	5	O
explain	explain	VERB	VB	9	O
their	-PRON-	DET	PRP$	5	O
presentation	presentation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
mazindol	mazindol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
Duchenne	Duchenne	PROPN	NNP	5	B-Disease
dystrophy	dystrophy	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
evidence	evidence	NOUN	NN	9	O
that	that	ADP	IN	5	O
growth	growth	NOUN	NN	3	O
hormone	hormone	NOUN	NN	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
progression	progression	NOUN	NN	9	O
of	of	ADP	IN	5	O
weakness	weakness	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
Duchenne	Duchenne	PROPN	NNP	5	B-Disease
dystrophy	dystrophy	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conducted	conduct	VERB	VBD	9	O
a	a	DET	DT	5	O
12	12	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
month	month	NOUN	NN	5	O
controlled	control	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
mazindol	mazindol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
putative	putative	ADJ	JJ	1	O
growth	growth	NOUN	NN	3	O
hormone	hormone	NOUN	NN	9	O
secretion	secretion	NOUN	NN	3	O
inhibitor	inhibitor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
83	83	NUM	CD	7	O
boys	boy	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Duchenne	Duchenne	PROPN	NNP	5	B-Disease
dystrophy	dystrophy	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Muscle	muscle	NOUN	NN	9	O
strength	strength	NOUN	NN	5	O
,	,	PUNCT	,	9	O
contractures	contracture	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
functional	functional	ADJ	JJ	9	O
ability	ability	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
pulmonary	pulmonary	ADJ	JJ	5	O
function	function	NOUN	NN	9	O
were	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
at	at	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
and	and	CCONJ	CC	5	O
12	12	NUM	CD	9	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
mazindol	mazindol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
power	power	NOUN	NN	5	O
of	of	ADP	IN	5	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
90	90	NUM	CD	9	O
to	to	PART	TO	5	O
detect	detect	VERB	VB	9	O
a	a	DET	DT	5	O
slowing	slowing	NOUN	NN	5	O
to	to	ADP	IN	5	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
expected	expect	VERB	VBN	9	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
progression	progression	NOUN	NN	9	O
of	of	ADP	IN	5	O
weakness	weakness	NOUN	NN	5	B-Disease
at	at	ADP	IN	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
.	.	PUNCT	.	9	O

Mazindol	mazindol	NOUN	NN	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
benefit	benefit	VERB	VB	5	O
strength	strength	NOUN	NN	5	O
at	at	ADP	IN	9	O
any	any	DET	DT	5	O
point	point	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
attributable	attributable	ADJ	JJ	9	O
to	to	ADP	IN	5	O
mazindol	mazindol	NOUN	NN	0	B-Chemical
included	include	VERB	VBN	5	O
decreased	decrease	VERB	VBD	9	B-Disease
appetite	appetite	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
36	36	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
dry	dry	ADJ	JJ	0	B-Disease
mouth	mouth	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
behavioral	behavioral	ADJ	JJ	5	O
change	change	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
22	22	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
gastrointestinal	gastrointestinal	ADJ	JJ	9	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
18	18	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
mazindol	mazindol	NOUN	NN	0	B-Chemical
dosage	dosage	NOUN	NN	9	O
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
43	43	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
mazindol	mazindol	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
GH	GH	PROPN	NNP	9	O
secretion	secretion	NOUN	NN	3	O
was	be	VERB	VBD	9	O
estimated	estimate	VERB	VBN	5	O
indirectly	indirectly	ADV	RB	9	O
by	by	ADP	IN	9	O
comparing	compare	VERB	VBG	9	O
the	the	DET	DT	5	O
postabsorptive	postabsorptive	ADJ	JJ	5	O
IGF	IGF	PROPN	NNP	3	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
levels	level	NOUN	NNS	3	O
obtained	obtain	VERB	VBD	9	O
following	follow	VERB	VBG	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
6	6	NUM	CD	9	O
,	,	PUNCT	,	9	O
9	9	NUM	CD	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
12	12	NUM	CD	9	O
months	month	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mazindol	mazindol	NOUN	NN	0	B-Chemical
treated	treat	VERB	VBN	3	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
mazindol	mazindol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
gained	gain	VERB	VBD	5	O
less	less	ADJ	JJR	5	O
weight	weight	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
height	height	NOUN	NN	5	O
than	than	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
IGF	IGF	PROPN	NNP	3	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
levels	level	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Mazindol	mazindol	NOUN	NN	0	B-Chemical
doses	dose	VERB	VBZ	0	O
not	not	ADV	RB	5	O
slow	slow	VERB	VB	5	O
the	the	DET	DT	5	O
progression	progression	NOUN	NN	9	O
of	of	ADP	IN	5	O
weakness	weakness	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
Duchenne	Duchenne	PROPN	NNP	5	B-Disease
dystrophy	dystrophy	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Facilitation	facilitation	NOUN	NN	5	O
of	of	ADP	IN	5	O
memory	memory	NOUN	NN	5	O
retrieval	retrieval	NOUN	NN	5	O
by	by	ADP	IN	9	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
test	test	NOUN	NN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
state	state	NOUN	NN	5	O
dependency	dependency	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
step	step	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
through	through	PART	RP	9	O
type	type	NOUN	NN	9	O
passive	passive	ADJ	JJ	5	O
avoidance	avoidance	NOUN	NN	5	O
learning	learn	VERB	VBG	5	O
test	test	NOUN	NN	5	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Amnesia	Amnesia	PROPN	NNP	5	B-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
cycloheximide	cycloheximide	NOUN	NN	3	B-Chemical
were	be	VERB	VBD	9	O
reversed	reverse	VERB	VBN	9	O
by	by	ADP	IN	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
given	give	VERB	VBN	5	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
test	test	NOUN	NN	5	O
trial	trial	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
pre	pre	ADJ	JJ	9	O
-	-	NOUN	NN	7	O
test	test	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
test	test	ADJ	JJ	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
also	also	ADV	RB	9	O
facilitated	facilitate	VERB	VBD	5	O
the	the	DET	DT	5	O
memory	memory	NOUN	NN	5	O
retrieval	retrieval	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
administered	administer	VERB	VBD	9	O
naloxone	naloxone	ADV	RB	0	B-Chemical
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
training	training	NOUN	NN	5	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Similarly	similarly	ADV	RB	9	O
,	,	PUNCT	,	9	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
test	test	NOUN	NN	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
partially	partially	ADV	RB	9	O
reversed	reverse	VERB	VBD	9	O
the	the	DET	DT	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
amnesia	amnesia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
test	test	ADJ	JJ	5	O
cycloheximide	cycloheximide	NOUN	NN	3	B-Chemical
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
reverse	reverse	VERB	VB	9	O
the	the	DET	DT	5	O
cycloheximide	cycloheximide	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
amnesia	amnesia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
facilitation	facilitation	NOUN	NN	5	O
of	of	ADP	IN	5	O
memory	memory	NOUN	NN	5	O
retrieval	retrieval	NOUN	NN	5	O
by	by	ADP	IN	9	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
test	test	ADJ	JJ	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
rather	rather	ADV	RB	5	O
than	than	ADP	IN	5	O
a	a	DET	DT	5	O
state	state	NOUN	NN	5	O
dependent	dependent	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Naloxone	naloxone	NOUN	NN	0	B-Chemical
reverses	reverse	VERB	VBZ	3	O
the	the	DET	DT	5	O
antihypertensive	antihypertensive	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
unanesthetized	unanesthetize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
spontaneously	spontaneously	ADV	RB	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
the	the	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
intravenous	intravenous	ADJ	JJ	0	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
to	to	PART	TO	5	O
20	20	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
inhibited	inhibit	VERB	VBN	3	O
or	or	CCONJ	CC	5	O
reversed	reverse	VERB	VBN	9	O
by	by	ADP	IN	9	O
nalozone	nalozone	ADV	RB	_	B-Chemical
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyldopa	methyldopa	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
partially	partially	ADV	RB	9	O
reversed	reverse	VERB	VBN	9	O
by	by	ADP	IN	9	O
naloxone	naloxone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Naloxone	naloxone	NOUN	NN	0	B-Chemical
alone	alone	ADV	RB	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
affect	affect	VERB	VB	9	O
either	either	CCONJ	CC	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
brain	brain	NOUN	NN	5	O
membranes	membrane	NOUN	NNS	0	O
from	from	ADP	IN	9	O
spontaneously	spontaneously	ADV	RB	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
M	M	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
influence	influence	VERB	VB	5	O
stereoselective	stereoselective	ADJ	JJ	0	O
binding	binding	NOUN	NN	1	O
of	of	ADP	IN	5	O
[	[	PUNCT	-LRB-	9	B-Chemical
3H	3h	NOUN	NN	0	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	:	7	I-Chemical
naloxone	naloxone	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
nM	nM	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
naloxone	naloxone	ADV	RB	0	B-Chemical
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
8	8	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
4	4	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
M	M	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
influence	influence	VERB	VB	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
suppressible	suppressible	ADJ	JJ	3	O
binding	binding	NOUN	NN	1	O
of	of	ADP	IN	5	O
[	[	PUNCT	-LRB-	9	B-Chemical
3H	3h	NOUN	NN	0	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dihydroergocryptine	dihydroergocryptine	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
nM	nm	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
in	in	ADP	IN	5	O
spontaneously	spontaneously	ADV	RB	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
rats	rat	NOUN	NNS	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
central	central	ADJ	JJ	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenoceptor	adrenoceptor	NOUN	NN	5	O
stimulation	stimulation	NOUN	NN	3	O
involve	involve	VERB	VBP	5	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
opiate	opiate	ADJ	JJ	5	O
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
naloxone	naloxone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
do	do	VERB	VBP	5	O
not	not	ADV	RB	5	O
appear	appear	VERB	VB	9	O
to	to	PART	TO	5	O
interact	interact	VERB	VB	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
receptor	receptor	NOUN	NN	3	O
site	site	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
observed	observed	ADJ	JJ	9	O
functional	functional	ADJ	JJ	9	O
antagonism	antagonism	NOUN	NN	9	O
suggests	suggest	VERB	VBZ	9	O
the	the	DET	DT	5	O
release	release	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
endogenous	endogenous	ADJ	JJ	3	O
opiate	opiate	NOUN	NN	5	O
by	by	ADP	IN	9	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
alpha	alpha	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyldopa	methyldopa	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
opiate	opiate	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
of	of	ADP	IN	5	O
sympathetic	sympathetic	ADJ	JJ	5	O
tone	tone	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Neurotoxicity	neurotoxicity	NOUN	NN	0	B-Disease
of	of	ADP	IN	5	O
halogenated	halogenate	VERB	VBN	0	B-Chemical
hydroxyquinolines	hydroxyquinoline	NOUN	NNS	_	I-Chemical
:	:	PUNCT	:	9	O
clinical	clinical	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
cases	case	NOUN	NNS	5	O
reported	report	VERB	VBN	9	O
outside	outside	ADP	IN	5	O
Japan	Japan	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
analysis	analysis	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
presented	present	VERB	VBN	5	O
of	of	ADP	IN	5	O
220	220	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
possible	possible	ADJ	JJ	5	O
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
reactions	reaction	NOUN	NNS	9	O
to	to	ADP	IN	5	O
halogenated	halogenate	VERB	VBN	0	B-Chemical
hydroxyquinolines	hydroxyquinoline	NOUN	NNS	_	I-Chemical
reported	report	VERB	VBN	9	O
from	from	ADP	IN	9	O
outside	outside	ADP	IN	5	O
Japan	Japan	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
80	80	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
insufficient	insufficient	ADJ	JJ	5	O
information	information	NOUN	NN	5	O
was	be	VERB	VBD	9	O
available	available	ADJ	JJ	5	O
for	for	ADP	IN	5	O
adequate	adequate	ADJ	JJ	5	O
comment	comment	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
29	29	NUM	CD	7	O
a	a	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
clioquinol	clioquinol	NOUN	NN	0	B-Chemical
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
excluded	exclude	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
remainder	remainder	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
to	to	ADP	IN	5	O
clioquinol	clioquinol	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
considered	consider	VERB	VBN	5	O
probable	probable	ADJ	JJ	9	O
in	in	ADP	IN	5	O
42	42	NUM	CD	7	O
and	and	CCONJ	CC	5	O
possible	possible	ADJ	JJ	5	O
in	in	ADP	IN	5	O
69	69	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
six	six	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
probable	probable	ADJ	JJ	9	O
cases	case	NOUN	NNS	5	O
the	the	DET	DT	5	O
neurological	neurological	ADJ	JJ	5	B-Disease
disturbance	disturbance	NOUN	NN	5	I-Disease
consisted	consist	VERB	VBD	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
reversible	reversible	ADJ	JJ	9	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
usually	usually	ADV	RB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
ingestion	ingestion	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
clioquinol	clioquinol	NOUN	NN	0	B-Chemical
over	over	ADP	IN	5	O
a	a	DET	DT	5	O
short	short	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
manifestation	manifestation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
15	15	NUM	CD	9	O
further	further	ADJ	JJ	9	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
isolated	isolate	VERB	VBN	9	O
optic	optic	ADJ	JJ	5	B-Disease
atrophy	atrophy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
most	most	ADV	RBS	9	O
frequently	frequently	ADV	RB	5	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
many	many	DET	DT	5	O
of	of	ADP	IN	5	O
whom	whom	PRON	WP	5	O
had	have	VERB	VBD	9	O
received	receive	VERB	VBN	9	O
clioquinol	clioquinol	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
acrodermatitis	acrodermatitis	NOUN	NN	4	B-Disease
enteropathica	enteropathica	ADV	RB	4	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
remaining	remain	VERB	VBG	9	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
myelopathy	myelopathy	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	O
visual	visual	ADJ	JJ	5	B-Disease
disturbance	disturbance	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
manifestation	manifestation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Isolated	isolated	ADJ	JJ	9	O
myelopathy	myelopathy	ADJ	JJ	5	B-Disease
or	or	CCONJ	CC	5	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
these	these	DET	DT	5	O
manifestations	manifestation	NOUN	NNS	5	O
occurring	occur	VERB	VBG	9	O
together	together	ADV	RB	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
infrequent	infrequent	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
manifestations	manifestation	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
except	except	ADP	IN	9	O
toxic	toxic	ADJ	JJ	0	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
usually	usually	ADV	RB	5	O
subacute	subacute	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
subsequent	subsequent	ADJ	JJ	9	O
partial	partial	ADJ	JJ	9	O
recovery	recovery	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Older	old	ADJ	JJR	5	O
subjects	subject	NOUN	NNS	5	O
tended	tend	VERB	VBD	5	O
to	to	PART	TO	5	O
display	display	VERB	VB	9	O
more	more	ADJ	JJR	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
full	full	ADJ	JJ	5	O
syndrome	syndrome	NOUN	NN	5	O
of	of	ADP	IN	5	O
subacute	subacute	ADJ	JJ	5	O
myelo	myelo	NOUN	NN	3	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
optic	optic	ADJ	JJ	5	I-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
frequent	frequent	ADJ	JJ	5	O
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
they	-PRON-	PRON	PRP	5	O
tended	tend	VERB	VBD	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
taken	take	VERB	VBN	5	O
greater	great	ADJ	JJR	5	O
quantities	quantity	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Prazosin	Prazosin	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
stress	stress	NOUN	NN	9	B-Disease
incontinence	incontinence	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
genuine	genuine	ADJ	JJ	5	O
stress	stress	NOUN	NN	9	B-Disease
incontinence	incontinence	NOUN	NN	5	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
prazosin	prazosin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
common	common	ADJ	JJ	5	O
antihypertensive	antihypertensive	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
presented	present	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Prazosin	Prazosin	PROPN	NNP	0	B-Chemical
exerts	exert	VERB	VBZ	9	O
its	-PRON-	DET	PRP$	9	O
antihypertensive	antihypertensive	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
through	through	ADP	IN	9	O
vasodilatation	vasodilatation	NOUN	NN	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
selective	selective	ADJ	JJ	9	O
blockade	blockade	NOUN	NN	3	O
of	of	ADP	IN	5	O
postsynaptic	postsynaptic	ADJ	JJ	3	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
adrenergic	adrenergic	NOUN	NN	9	O
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
an	an	DET	DT	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blocker	blocker	NOUN	NN	0	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
also	also	ADV	RB	9	O
exerts	exert	VERB	VBZ	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
relaxant	relaxant	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
bladder	bladder	NOUN	NN	9	O
neck	neck	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
urethra	urethra	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
clinical	clinical	ADJ	JJ	5	O
course	course	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
described	describe	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
initial	initial	ADJ	JJ	9	O
urodynamic	urodynamic	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
while	while	ADP	IN	9	O
on	on	ADP	IN	5	O
prazosin	prazosin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
subsequent	subsequent	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
while	while	ADP	IN	9	O
taking	take	VERB	VBG	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Her	-PRON-	DET	PRP$	5	O
incontinence	incontinence	NOUN	NN	5	B-Disease
resolved	resolve	VERB	VBD	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
change	change	NOUN	NN	9	O
of	of	ADP	IN	5	O
medication	medication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
restoration	restoration	NOUN	NN	5	O
of	of	ADP	IN	5	O
continence	continence	NOUN	NN	5	O
was	be	VERB	VBD	9	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
substantial	substantial	ADJ	JJ	9	O
rise	rise	NOUN	NN	9	O
in	in	ADP	IN	5	O
maximum	maximum	ADJ	JJ	5	O
urethral	urethral	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
maximum	maximum	ADJ	JJ	5	O
urethral	urethral	ADJ	JJ	5	O
closure	closure	NOUN	NN	5	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
functional	functional	ADJ	JJ	9	O
urethral	urethral	ADJ	JJ	5	O
length	length	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
present	present	VERB	VBP	9	O
with	with	ADP	IN	5	O
stress	stress	NOUN	NN	9	B-Disease
incontinence	incontinence	NOUN	NN	5	I-Disease
while	while	ADP	IN	9	O
taking	take	VERB	VBG	5	O
prazosin	prazosin	NOUN	NN	0	B-Chemical
should	should	VERB	MD	5	O
change	change	VERB	VB	9	O
their	-PRON-	DET	PRP$	5	O
antihypertensive	antihypertensive	ADJ	JJ	5	O
medication	medication	NOUN	NN	5	O
before	before	ADP	IN	9	O
considering	consider	VERB	VBG	5	O
surgery	surgery	NOUN	NN	5	O
,	,	PUNCT	,	9	O
because	because	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
incontinence	incontinence	NOUN	NN	5	B-Disease
may	may	VERB	MD	5	O
resolve	resolve	VERB	VB	5	O
spontaneously	spontaneously	ADV	RB	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
following	follow	VERB	VBG	9	O
sublingual	sublingual	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
isosorbide	isosorbide	NOUN	NN	0	B-Chemical
dinitrate	dinitrate	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
78	78	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
with	with	ADP	IN	5	O
healed	heal	VERB	VBN	5	O
septal	septal	ADJ	JJ	5	O
necrosis	necrosis	NOUN	NN	9	B-Disease
suffered	suffer	VERB	VBD	5	O
a	a	DET	DT	5	O
recurrent	recurrent	ADJ	JJ	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
anterior	anterior	ADJ	JJ	5	O
wall	wall	NOUN	NN	5	O
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
isosorbide	isosorbide	NOUN	NN	0	B-Chemical
dinitrate	dinitrate	NOUN	NN	0	I-Chemical
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
sublingually	sublingually	ADV	RB	0	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
detailing	detail	VERB	VBG	5	O
the	the	DET	DT	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
events	event	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
discuss	discuss	VERB	VBP	5	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
paradoxical	paradoxical	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
spasm	spasm	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
occurring	occur	VERB	VBG	9	O
downstream	downstream	ADJ	JJ	1	O
to	to	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
arterial	arterial	ADJ	JJ	5	I-Disease
stenosis	stenosis	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathophysiology	pathophysiology	NOUN	NN	9	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
coronary	coronary	ADJ	JJ	5	I-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Comparison	Comparison	PROPN	NNP	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
respiratory	respiratory	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
infusions	infusion	NOUN	NNS	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
regional	regional	ADJ	JJ	5	O
analgesia	analgesia	NOUN	NN	5	O
by	by	ADP	IN	9	O
extradural	extradural	ADJ	JJ	5	O
block	block	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	O
respiratory	respiratory	ADJ	JJ	5	O
apnoea	apnoea	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
between	between	ADP	IN	5	O
five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
a	a	DET	DT	5	O
continuous	continuous	ADJ	JJ	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
73	73	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
a	a	DET	DT	5	O
continuous	continuous	ADJ	JJ	5	O
extradural	extradural	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VBP	5	O
192	192	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
24	24	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
h	h	NOUN	NN	0	O
period	period	NOUN	NN	5	O
following	follow	VERB	VBG	9	O
upper	upper	ADJ	JJ	9	O
abdominal	abdominal	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Monitoring	monitoring	NOUN	NN	5	O
consisted	consist	VERB	VBD	5	O
of	of	ADP	IN	5	O
airflow	airflow	ADJ	JJ	5	O
detection	detection	NOUN	NN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
carbon	carbon	NOUN	NN	0	B-Chemical
dioxide	dioxide	NOUN	NN	0	I-Chemical
analyser	analyser	NOUN	NN	0	O
,	,	PUNCT	,	9	O
chest	chest	NOUN	NN	5	O
wall	wall	NOUN	NN	5	O
movement	movement	NOUN	NN	5	O
detected	detect	VERB	VBN	9	O
by	by	ADP	IN	9	O
pneumatic	pneumatic	ADJ	JJ	5	O
capsules	capsule	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
continuous	continuous	ADJ	JJ	5	O
electrocardiograph	electrocardiograph	NOUN	NN	5	O
recorded	record	VERB	VBN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
Holter	holter	NOUN	NN	5	O
ambulatory	ambulatory	ADJ	JJ	5	O
monitor	monitor	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
obstructive	obstructive	VERB	VBP	5	B-Disease
(	(	PUNCT	-LRB-	9	I-Disease
P	p	NOUN	NN	9	I-Disease
less	less	ADJ	JJR	5	I-Disease
than	than	ADP	IN	5	I-Disease
0	0	NUM	CD	7	I-Disease
.	.	PUNCT	.	9	I-Disease
05	05	NUM	CD	7	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
and	and	CCONJ	CC	5	I-Disease
central	central	ADJ	JJ	5	I-Disease
apnoea	apnoea	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
occurred	occur	VERB	VBD	9	O
more	more	ADV	RBR	5	O
frequently	frequently	ADV	RB	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
tachyarrhythmias	tachyarrhythmia	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
ectopic	ectopic	NOUN	NN	3	I-Disease
beats	beat	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
aminophylline	aminophylline	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
threshold	threshold	NOUN	NN	5	O
for	for	ADP	IN	5	O
initiating	initiate	VERB	VBG	9	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Cardiac	cardiac	ADJ	JJ	9	B-Disease
arrhythmias	arrhythmia	NOUN	NNS	5	I-Disease
have	have	VERB	VBP	5	O
frequently	frequently	ADV	RB	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
additive	additive	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
pharmacologic	pharmacologic	ADJ	JJ	9	O
agents	agent	NOUN	NNS	5	O
in	in	ADP	IN	5	O
precipitating	precipitate	VERB	VBG	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
disturbances	disturbance	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
has	have	VERB	VBZ	9	O
only	only	ADV	RB	9	O
recently	recently	ADV	RB	9	O
been	be	VERB	VBN	9	O
emphasized	emphasize	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
aminophylline	aminophylline	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
threshold	threshold	NOUN	NN	5	O
during	during	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
acid	acid	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
base	base	NOUN	NN	5	O
conditions	condition	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
during	during	ADP	IN	5	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
anesthetized	anesthetized	ADJ	JJ	0	O
open	open	ADJ	JJ	5	O
chest	chest	NOUN	NN	5	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
threshold	threshold	NOUN	NN	5	O
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
passing	pass	VERB	VBG	5	O
a	a	DET	DT	5	O
gated	gate	VERB	VBN	3	O
train	train	NOUN	NN	5	O
of	of	ADP	IN	5	O
12	12	NUM	CD	9	O
constant	constant	ADJ	JJ	9	O
current	current	ADJ	JJ	5	O
pulses	pulse	NOUN	NNS	5	O
through	through	ADP	IN	9	O
the	the	DET	DT	5	O
ventricular	ventricular	ADJ	JJ	5	O
myocardium	myocardium	NOUN	NN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
vulnerable	vulnerable	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	O
cycle	cycle	NOUN	NN	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
the	the	DET	DT	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
aminophylline	aminophylline	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
threshold	threshold	NOUN	NN	5	O
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
30	30	NUM	CD	9	O
to	to	PART	TO	5	O
40	40	NUM	CD	9	O
percent	percent	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
when	when	ADV	WRB	5	O
pH	pH	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
partial	partial	ADJ	JJ	9	O
pressures	pressure	NOUN	NNS	5	O
of	of	ADP	IN	5	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
PO2	PO2	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
carbon	carbon	NOUN	NN	0	B-Chemical
dioxide	dioxide	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
CO2	CO2	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
kept	keep	VERB	VBN	9	O
within	within	ADP	IN	9	O
normal	normal	ADJ	JJ	9	O
limits	limit	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
hypoventilation	hypoventilation	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
pH	ph	X	XX	0	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
to	to	ADP	IN	5	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
;	;	PUNCT	:	9	O
PC02	PC02	PROPN	NNP	0	O
70	70	NUM	CD	9	O
to	to	PART	TO	5	O
100	100	NUM	CD	0	O
mm	mm	NOUN	NN	9	O
Hg	Hg	PROPN	NNP	0	O
:	:	PUNCT	:	9	O
P02	P02	PROPN	NNP	9	O
20	20	NUM	CD	9	O
to	to	PART	TO	5	O
40	40	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
aminophylline	aminophylline	NOUN	NN	0	B-Chemical
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
even	even	ADV	RB	5	O
greater	great	ADJ	JJR	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
threshold	threshold	NOUN	NN	5	O
to	to	ADP	IN	5	O
60	60	NUM	CD	9	O
percent	percent	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
level	level	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
experiments	experiment	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
although	although	ADP	IN	9	O
many	many	ADJ	JJ	5	O
factors	factor	NOUN	NNS	9	O
may	may	VERB	MD	5	O
contribute	contribute	VERB	VB	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
arrhythmias	arrhythmia	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
pharmacologic	pharmacologic	ADJ	JJ	9	O
agents	agent	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
aminophylline	aminophylline	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
play	play	VERB	VB	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Pentoxifylline	Pentoxifylline	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Trental	Trental	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
inhibit	inhibit	VERB	VB	3	O
dipyridamole	dipyridamole	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
coronary	coronary	ADJ	JJ	5	O
hyperemia	hyperemia	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
implications	implication	NOUN	NNS	5	O
for	for	ADP	IN	5	O
dipyridamole	dipyridamole	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
thallium	thallium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
201	201	NUM	CD	7	O
myocardial	myocardial	ADJ	JJ	9	O
imaging	imaging	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Dipyridamole	dipyridamole	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
thallium	thallium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
201	201	NUM	CD	7	O
imaging	imaging	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
often	often	ADV	RB	5	O
performed	perform	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
unable	unable	ADJ	JJ	9	O
to	to	PART	TO	5	O
exercise	exercise	VERB	VB	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
vascular	vascular	ADJ	JJ	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Many	many	ADJ	JJ	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
taking	take	VERB	VBG	5	O
pentoxifylline	pentoxifylline	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Trental	Trental	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
methylxanthine	methylxanthine	NOUN	NN	0	B-Chemical
derivative	derivative	NOUN	NN	0	O
which	which	DET	WDT	5	O
may	may	VERB	MD	5	O
improve	improve	VERB	VB	5	O
intermittent	intermittent	ADJ	JJ	5	B-Disease
claudication	claudication	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Whether	whether	ADP	IN	9	O
pentoxifylline	pentoxifylline	NOUN	NN	0	B-Chemical
inhibits	inhibit	VERB	VBZ	3	O
dipyridamole	dipyridamole	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
coronary	coronary	ADJ	JJ	5	O
hyperemia	hyperemia	NOUN	NN	5	B-Disease
like	like	ADP	IN	9	O
other	other	ADJ	JJ	5	O
methylxanthines	methylxanthine	NOUN	NNS	0	B-Chemical
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
theophylline	theophylline	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
stopped	stop	VERB	VBN	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
dipyridamole	dipyridamole	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
thallium	thallium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
201	201	NUM	CD	7	O
imaging	imaging	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
unknown	unknown	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
studied	study	VERB	VBD	9	O
the	the	DET	DT	5	O
hyperemic	hyperemic	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
to	to	PART	TO	5	O
dipyridamole	dipyridamole	VERB	VB	0	B-Chemical
in	in	ADP	IN	5	O
seven	seven	NUM	CD	9	O
open	open	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
chest	chest	NOUN	NN	5	O
anesthetized	anesthetize	VERB	VBN	0	O
dogs	dog	NOUN	NNS	5	O
after	after	ADP	IN	9	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
either	either	DET	DT	9	O
pentoxifylline	pentoxifylline	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
,	,	PUNCT	,	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
15	15	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
theophylline	theophylline	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Baseline	baseline	NOUN	NN	9	O
circumflex	circumflex	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
flows	flow	NOUN	NNS	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
differ	differ	VERB	VB	9	O
significantly	significantly	ADV	RB	9	O
among	among	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Dipyridamole	Dipyridamole	PROPN	NNP	0	B-Chemical
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
coronary	coronary	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
or	or	CCONJ	CC	5	O
15	15	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
pentoxifylline	pentoxifylline	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
002	002	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Neither	neither	DET	DT	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
pentoxifylline	pentoxifylline	NOUN	NN	0	B-Chemical
significantly	significantly	ADV	RB	9	O
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
dipyridamole	dipyridamole	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hyperemia	hyperemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
peak	peak	NOUN	NN	9	O
coronary	coronary	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
after	after	ADP	IN	9	O
theophylline	theophylline	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	DET	DT	5	O
pentoxyifylline	pentoxyifylline	NOUN	NN	_	B-Chemical
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
inhibit	inhibit	VERB	VB	3	O
dipyridamole	dipyridamole	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
coronary	coronary	ADJ	JJ	5	O
hyperemia	hyperemia	NOUN	NN	5	B-Disease
even	even	ADV	RB	5	O
at	at	ADP	IN	9	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
death	death	NOUN	NN	9	B-Disease
among	among	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
mortality	mortality	NOUN	NN	5	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
haemorrhage	haemorrhage	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Causes	cause	NOUN	NNS	5	O
of	of	ADP	IN	5	O
death	death	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
special	special	ADJ	JJ	5	O
reference	reference	NOUN	NN	9	O
to	to	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
haemorrhage	haemorrhage	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
among	among	ADP	IN	5	O
240	240	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
pathologically	pathologically	ADV	RB	5	O
verified	verify	VERB	VBN	9	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
Annuals	Annuals	PROPN	NNPS	2	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Pathological	Pathological	PROPN	NNP	9	O
Autopsy	Autopsy	PROPN	NNP	5	O
Cases	case	NOUN	NNS	9	O
in	in	ADP	IN	5	O
Japan	Japan	PROPN	NNP	2	O
from	from	ADP	IN	9	O
1981	1981	NUM	CD	2	O
to	to	ADP	IN	5	O
1985	1985	NUM	CD	2	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
leading	lead	VERB	VBG	9	O
causes	cause	NOUN	NNS	9	O
of	of	ADP	IN	5	O
death	death	NOUN	NN	9	B-Disease
were	be	VERB	VBD	9	O
pneumonia	pneumonia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
bronchitis	bronchitis	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
44	44	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
malignant	malignant	ADJ	JJ	3	O
neoplasms	neoplasm	NOUN	NNS	5	B-Disease
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
heart	heart	NOUN	NN	5	B-Disease
diseases	disease	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
septicaemia	septicaemia	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Cerebral	cerebral	ADJ	JJ	5	B-Disease
haemorrhage	haemorrhage	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
11th	11th	ADJ	JJ	9	O
most	most	ADV	RBS	9	O
frequent	frequent	ADJ	JJ	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
death	death	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
accounting	account	VERB	VBG	5	O
for	for	ADP	IN	5	O
only	only	ADV	RB	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
deaths	death	NOUN	NNS	5	B-Disease
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
5th	5th	ADJ	JJ	9	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
death	death	NOUN	NN	9	B-Disease
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
Japanese	japanese	ADJ	JJ	9	O
general	general	ADJ	JJ	5	O
population	population	NOUN	NN	5	O
in	in	ADP	IN	5	O
1985	1985	NUM	CD	2	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
low	low	ADJ	JJ	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
haemorrhage	haemorrhage	NOUN	NN	5	I-Disease
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
death	death	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
may	may	VERB	MD	5	O
reflect	reflect	VERB	VB	5	O
the	the	DET	DT	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
mechanism	mechanism	NOUN	NN	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
reduced	reduce	VERB	VBN	9	O
noradrenaline	noradrenaline	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
brain	brain	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Possible	possible	ADJ	JJ	9	O
intramuscular	intramuscular	ADJ	JJ	9	O
midazolam	midazolam	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
cardiorespiratory	cardiorespiratory	NOUN	NN	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
death	death	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Midazolam	midazolam	NOUN	NN	0	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
is	be	VERB	VBZ	5	O
commonly	commonly	ADV	RB	5	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
dental	dental	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
endoscopic	endoscopic	ADJ	JJ	5	O
procedures	procedure	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
generally	generally	ADV	RB	5	O
consisted	consist	VERB	VBN	5	O
safe	safe	ADJ	JJ	5	O
when	when	ADV	WRB	5	O
given	give	VERB	VBN	5	O
intramuscularly	intramuscularly	ADV	RB	0	O
,	,	PUNCT	,	9	O
intravenous	intravenous	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
cause	cause	VERB	VB	5	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
cardiovascular	cardiovascular	ADJ	JJ	5	I-Disease
depression	depression	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
report	report	NOUN	NN	5	O
describes	describe	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
published	publish	VERB	VBN	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiorespiratory	cardiorespiratory	NOUN	NN	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
death	death	NOUN	NN	9	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
intramuscular	intramuscular	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
midazolam	midazolam	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Information	information	NOUN	NN	5	O
regarding	regard	VERB	VBG	5	O
midazolam	midazolam	NOUN	NN	0	B-Chemical
use	use	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
reviewed	review	VERB	VBN	9	O
to	to	PART	TO	5	O
provide	provide	VERB	VB	5	O
recommendation	recommendation	NOUN	NN	5	O
for	for	ADP	IN	5	O
safe	safe	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Myasthenia	Myasthenia	PROPN	NNP	2	B-Disease
gravis	gravi	NOUN	NNS	2	I-Disease
presenting	present	VERB	VBG	5	O
as	as	ADP	IN	5	O
weakness	weakness	NOUN	NN	5	O
after	after	ADP	IN	9	O
magnesium	magnesium	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
studied	study	VERB	VBD	9	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
prior	prior	ADJ	JJ	9	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
neuromuscular	neuromuscular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
who	who	PRON	WP	5	O
became	become	VERB	VBD	9	O
virtually	virtually	ADV	RB	9	O
quadriplegic	quadriplegic	ADJ	JJ	5	B-Disease
after	after	ADP	IN	9	O
parenteral	parenteral	ADJ	JJ	5	O
magnesium	magnesium	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
for	for	ADP	IN	5	O
preeclampsia	preeclampsia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
magnesium	magnesium	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
was	be	VERB	VBD	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
mEq	mEq	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
usually	usually	ADV	RB	5	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
magnesium	magnesium	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
stopped	stop	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
she	-PRON-	PRON	PRP	5	O
recovered	recover	VERB	VBD	9	O
over	over	ADP	IN	5	O
a	a	DET	DT	5	O
few	few	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

While	while	ADP	IN	9	O
she	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
weak	weak	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	:	7	O
Hz	hz	DET	PRP$	5	O
repetitive	repetitive	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
revealed	reveal	VERB	VBD	9	O
a	a	DET	DT	5	O
decrement	decrement	NOUN	NN	5	O
without	without	ADP	IN	9	O
significant	significant	ADJ	JJ	9	O
facilitation	facilitation	NOUN	NN	5	O
at	at	ADP	IN	9	O
rapid	rapid	ADJ	JJ	5	O
rates	rate	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
after	after	ADP	IN	9	O
exercise	exercise	NOUN	NN	5	O
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
postsynaptic	postsynaptic	ADJ	JJ	3	B-Disease
neuromuscular	neuromuscular	ADJ	JJ	5	I-Disease
blockade	blockade	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
her	-PRON-	DET	PRP$	5	O
strength	strength	NOUN	NN	5	O
returned	return	VERB	VBD	5	O
,	,	PUNCT	,	9	O
repetitive	repetitive	ADJ	JJ	5	O
stimulation	stimulation	NOUN	NN	3	O
was	be	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
single	single	ADJ	JJ	9	O
fiber	fiber	NOUN	NN	5	O
EMG	EMG	PROPN	NNP	5	O
revealed	reveal	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
jitter	jitter	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
blocking	blocking	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Her	-PRON-	DET	PRP$	5	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
antibody	antibody	NOUN	NN	3	O
level	level	NOUN	NN	9	O
was	be	VERB	VBD	9	O
markedly	markedly	ADV	RB	9	O
elevated	elevated	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
paralysis	paralysis	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
magnesium	magnesium	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
described	describe	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
known	know	VERB	VBN	9	O
myasthenia	myasthenia	ADJ	JJ	9	B-Disease
gravis	gravi	NOUN	NNS	2	I-Disease
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
previously	previously	ADV	RB	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
only	only	ADJ	JJ	9	O
manifestation	manifestation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
are	be	VERB	VBP	5	O
unusually	unusually	ADV	RB	9	O
sensitive	sensitive	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
neuromuscular	neuromuscular	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
magnesium	magnesium	NOUN	NN	0	B-Chemical
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
suspected	suspect	VERB	VBN	5	O
of	of	ADP	IN	5	O
having	have	VERB	VBG	5	O
an	an	DET	DT	5	O
underlying	underlying	ADJ	JJ	5	O
disorder	disorder	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
neuromuscular	neuromuscular	ADJ	JJ	5	I-Disease
transmission	transmission	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
enhancement	enhancement	NOUN	NN	9	O
by	by	ADP	IN	9	O
phenobarbital	phenobarbital	NOUN	NN	0	B-Chemical
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hepatocarcinogenicity	hepatocarcinogenicity	NOUN	NN	0	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
choline	choline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
devoid	devoid	ADJ	JJ	9	O
diet	diet	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
experiment	experiment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
to	to	PART	TO	5	O
test	test	VERB	VB	5	O
whether	whether	ADP	IN	9	O
inclusion	inclusion	NOUN	NN	5	O
of	of	ADP	IN	5	O
phenobarbital	phenobarbital	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
choline	choline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
devoid	devoid	ADJ	JJ	9	O
diet	diet	NOUN	NN	9	O
would	would	VERB	MD	5	O
increase	increase	VERB	VB	9	O
the	the	DET	DT	5	O
hepatocarcinogenicity	hepatocarcinogenicity	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
diet	diet	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
old	old	ADJ	JJ	5	O
male	male	ADJ	JJ	9	O
Fischer	Fischer	PROPN	NNP	6	O
-	-	PUNCT	HYPH	7	O
344	344	NUM	CD	7	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
fed	feed	VERB	VBN	9	O
for	for	ADP	IN	5	O
7	7	NUM	CD	9	O
-	-	SYM	SYM	7	O
25	25	NUM	CD	9	O
months	month	NOUN	NNS	5	O
semipurified	semipurifie	VERB	VBD	0	O
choline	choline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
devoid	devoid	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
choline	choline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
supplemented	supplement	VERB	VBN	0	O
diets	diet	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
containing	contain	VERB	VBG	0	O
or	or	CCONJ	CC	5	O
not	not	ADV	RB	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
06	06	NUM	CD	7	O
%	%	NOUN	NN	9	O
phenobarbital	phenobarbital	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
hepatic	hepatic	ADJ	JJ	9	O
preneoplastic	preneoplastic	ADJ	JJ	3	O
nodules	nodule	NOUN	NNS	9	O
or	or	CCONJ	CC	5	O
hepatocellular	hepatocellular	ADJ	JJ	9	B-Disease
carcinomas	carcinoma	NOUN	NNS	3	I-Disease
developed	develop	VERB	VBN	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
fed	feed	VERB	VBD	9	O
the	the	DET	DT	5	O
plain	plain	ADJ	JJ	5	O
choline	choline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
supplemented	supplement	VERB	VBN	0	O
diet	diet	NOUN	NN	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
one	one	NUM	CD	5	O
preneoplastic	preneoplastic	ADJ	JJ	3	O
nodule	nodule	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
one	one	NUM	CD	5	O
hepatocellular	hepatocellular	ADJ	JJ	9	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
developed	develop	VERB	VBD	5	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
rats	rat	NOUN	NNS	9	O
fed	feed	VERB	VBD	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
diet	diet	NOUN	NN	9	O
containing	contain	VERB	VBG	0	O
phenobarbital	phenobarbital	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
preneoplastic	preneoplastic	ADJ	JJ	3	O
nodules	nodule	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
of	of	ADP	IN	5	O
hepatocellular	hepatocellular	ADJ	JJ	9	B-Disease
carcinomas	carcinoma	NOUN	NNS	3	I-Disease
was	be	VERB	VBD	9	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
37	37	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
fed	feed	VERB	VBD	9	O
the	the	DET	DT	5	O
plain	plain	ADJ	JJ	5	O
choline	choline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
devoid	devoid	ADJ	JJ	9	O
diet	diet	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
17	17	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
fed	feed	VERB	VBD	9	O
the	the	DET	DT	5	O
phenobarbital	phenobarbital	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
containing	contain	VERB	VBG	0	O
choline	choline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
devoid	devoid	ADJ	JJ	9	O
diet	diet	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
evinced	evince	VERB	VBD	5	O
no	no	DET	DT	9	O
enhancement	enhancement	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hepatocarcinogenicity	hepatocarcinogenicity	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
choline	choline	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
devoid	devoid	ADJ	JJ	9	O
diet	diet	NOUN	NN	9	O
by	by	ADP	IN	9	O
phenobarbital	phenobarbital	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Sporadic	sporadic	ADJ	JJ	9	O
neoplastic	neoplastic	ADJ	JJ	3	O
lesions	lesion	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
organs	organ	NOUN	NNS	9	O
other	other	ADJ	JJ	5	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
of	of	ADP	IN	5	O
some	some	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
irrespective	irrespective	ADV	RB	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
diet	diet	NOUN	NN	9	O
fed	feed	VERB	VBN	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
two	two	NUM	CD	5	O
paradoxical	paradoxical	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
prednisolone	prednisolone	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
ribosomal	ribosomal	ADJ	JJ	1	O
RNA	RNA	PROPN	NNP	9	O
biosyntheses	biosynthese	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Liver	liver	NOUN	NN	9	B-Disease
enlargement	enlargement	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
muscle	muscle	NOUN	NN	9	B-Disease
wastage	wastage	NOUN	NN	5	I-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
prednisolone	prednisolone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
content	content	NOUN	NN	9	O
of	of	ADP	IN	5	O
RNA	RNA	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
biosynthesis	biosynthesis	NOUN	NN	0	O
of	of	ADP	IN	5	O
ribosomal	ribosomal	ADJ	JJ	1	O
RNA	RNA	PROPN	NNP	9	O
increased	increase	VERB	VBD	9	O
while	while	ADP	IN	9	O
both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
RNA	RNA	PROPN	NNP	9	O
content	content	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
ribosomal	ribosomal	ADJ	JJ	1	O
RNA	RNA	PROPN	NNP	9	O
biosynthesis	biosynthesis	NOUN	NN	0	O
were	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
gastrocnemius	gastrocnemius	NOUN	NN	9	O
muscle	muscle	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
acted	act	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
tissue	tissue	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
specific	specific	ADJ	JJ	9	O
manner	manner	NOUN	NN	9	O
to	to	PART	TO	5	O
enhance	enhance	VERB	VB	9	O
ribosomal	ribosomal	ADJ	JJ	1	O
RNA	rna	NOUN	NN	9	O
synthesis	synthesis	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
depress	depress	NOUN	NN	5	O
such	such	ADJ	JJ	5	O
synthesis	synthesis	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
muscle	muscle	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
view	view	NOUN	NN	5	O
supports	support	VERB	VBZ	9	O
the	the	DET	DT	5	O
contention	contention	NOUN	NN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
muscle	muscle	NOUN	NN	9	O
are	be	VERB	VBP	5	O
independent	independent	ADJ	JJ	9	O
sites	site	NOUN	NNS	9	O
of	of	ADP	IN	5	O
prednisolone	prednisolone	ADJ	JJ	0	B-Chemical
action	action	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Differential	differential	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hexachlorocyclohexane	hexachlorocyclohexane	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
lindane	lindane	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
pharmacologically	pharmacologically	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Gamma	Gamma	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hexachlorocyclohexane	hexachlorocyclohexane	PROPN	NNP	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
gamma	gamma	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HCH	HCH	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
active	active	ADJ	JJ	9	O
ingredient	ingredient	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
insecticide	insecticide	ADJ	JJ	5	O
lindane	lindane	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
decrease	decrease	VERB	VB	9	O
seizure	seizure	NOUN	NN	5	B-Disease
threshold	threshold	NOUN	NN	5	O
to	to	ADP	IN	5	O
pentylenetrazol	pentylenetrazol	NOUN	NN	_	O
(	(	PUNCT	-LRB-	9	O
PTZ	PTZ	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
3	3	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HCH	HCH	PROPN	NNP	0	I-Chemical
and	and	CCONJ	CC	5	O
conversely	conversely	ADV	RB	9	O
increase	increase	VERB	VB	9	O
threshold	threshold	NOUN	NN	5	O
to	to	ADP	IN	5	O
PTZ	ptz	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HCH	HCH	PROPN	NNP	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
Vohland	Vohland	PROPN	NNP	_	O
et	et	PROPN	NNP	6	O
al	al	PROPN	NNP	6	O
.	.	PUNCT	.	9	O
1981	1981	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
other	other	ADJ	JJ	5	O
seizure	seizure	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
inducing	induce	VERB	VBG	3	O
agents	agent	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
intraperitoneal	intraperitoneal	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
80	80	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HCH	HCH	PROPN	NNP	0	I-Chemical
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
hour	hour	NOUN	NN	0	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HCH	HCH	PROPN	NNP	0	I-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
inducing	induce	VERB	VBG	3	O
agents	agent	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
,	,	PUNCT	,	9	O
regardless	regardless	ADV	RB	9	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
mechanism	mechanism	NOUN	NN	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
24	24	NUM	CD	9	O
h	h	DET	DT	0	O
after	after	ADP	IN	9	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HCH	hch	NOUN	NN	0	I-Chemical
a	a	DET	DT	5	O
differential	differential	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Seizure	seizure	VERB	VB	5	B-Disease
activity	activity	NOUN	NN	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
PTZ	PTZ	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
picrotoxin	picrotoxin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
PTX	PTX	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
decreased	decrease	VERB	VBN	9	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
seizure	seizure	VERB	VB	5	B-Disease
activity	activity	NOUN	NN	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
mercaptopropionic	mercaptopropionic	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
MPA	MPA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
bicuculline	bicuculline	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
BCC	BCC	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
methyl	methyl	NOUN	NN	0	B-Chemical
6	6	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
7	7	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dimethoxy	dimethoxy	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ethyl	ethyl	ADV	RB	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
B	b	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
carboline	carboline	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
carboxylate	carboxylate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
DMCM	DMCM	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
strychnine	strychnine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
STR	STR	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
different	different	ADJ	JJ	9	O
from	from	ADP	IN	9	O
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
vitro	vitro	NOUN	NN	3	O
,	,	PUNCT	,	9	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HCH	HCH	PROPN	NNP	0	I-Chemical
,	,	PUNCT	,	9	O
pentylenetetrazol	pentylenetetrazol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
picrotoxin	picrotoxin	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
inhibit	inhibit	VERB	VB	3	O
3H	3h	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
TBOB	tbob	NOUN	NN	_	I-Chemical
binding	bind	VERB	VBG	1	O
in	in	ADP	IN	5	O
mouse	mouse	NOUN	NN	3	O
whole	whole	ADJ	JJ	9	O
brain	brain	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
IC50	ic50	ADJ	JJ	0	O
values	value	NOUN	NNS	5	O
of	of	ADP	IN	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
,	,	PUNCT	,	9	O
404	404	NUM	CD	7	O
and	and	CCONJ	CC	5	O
9	9	NUM	CD	7	O
.	.	NOUN	NN	9	O
4	4	NUM	CD	9	O
microM	microM	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

MPA	MPA	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
BCC	BCC	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
DMCM	DMCM	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
STR	STR	PROPN	NNP	9	B-Chemical
showed	show	VERB	VBD	9	O
no	no	DET	DT	9	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
3H	3h	NUM	CD	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
TBOB	tbob	NOUN	NN	_	I-Chemical
(	(	PUNCT	-LRB-	9	O
t	t	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
butyl	butyl	NOUN	NN	0	I-Chemical
bicyclo	bicyclo	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
orthobenzoate	orthobenzoate	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
binding	bind	VERB	VBG	1	O
at	at	ADP	IN	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
100	100	NUM	CD	0	O
micron	micron	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pharmacological	pharmacological	ADJ	JJ	9	O
challenge	challenge	NOUN	NN	9	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
tolerance	tolerance	NOUN	NN	9	O
may	may	VERB	MD	5	O
occur	occur	VERB	VB	5	O
to	to	PART	TO	5	O
seizure	seizure	VERB	VB	5	B-Disease
activity	activity	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
PTZ	PTZ	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
PTX	PTX	PROPN	NNP	3	B-Chemical
24	24	NUM	CD	9	O
h	h	DET	DT	0	O
after	after	ADP	IN	9	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HCH	HCH	PROPN	NNP	0	I-Chemical
,	,	PUNCT	,	9	O
since	since	ADP	IN	9	O
the	the	DET	DT	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
only	only	ADV	RB	9	O
these	these	DET	DT	5	O
two	two	NUM	CD	5	O
seizure	seizure	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
inducing	induce	VERB	VBG	3	O
agents	agent	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
decreased	decrease	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
in	in	ADP	IN	5	O
vitro	vitro	X	FW	3	O
data	datum	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
site	site	NOUN	NN	9	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
activity	activity	NOUN	NN	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HCH	HCH	PROPN	NNP	0	I-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
GABA	GABA	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
A	A	PROPN	NNP	9	O
receptor	receptor	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
linked	link	VERB	VBN	9	O
chloride	chloride	NOUN	NN	0	O
channel	channel	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Tolerance	tolerance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
antiviral	antiviral	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Argentine	argentine	ADJ	JJ	4	B-Disease
hemorrhagic	hemorrhagic	ADJ	JJ	5	I-Disease
fever	fever	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Tolerance	tolerance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
antiviral	antiviral	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
6	6	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Argentine	argentine	ADJ	JJ	4	B-Disease
hemorrhagic	hemorrhagic	ADJ	JJ	5	I-Disease
fever	fever	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
AHF	AHF	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
8	8	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
evolution	evolution	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
neutralization	neutralization	NOUN	NN	3	O
of	of	ADP	IN	5	O
viremia	viremia	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
drop	drop	NOUN	NN	9	O
of	of	ADP	IN	5	O
endogenous	endogenous	ADJ	JJ	3	O
interferon	interferon	ADJ	JJ	3	O
titers	titer	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
average	average	ADJ	JJ	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
death	death	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
delayed	delay	VERB	VBN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
reversible	reversible	ADJ	JJ	9	O
anemia	anemia	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
only	only	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

From	from	ADP	IN	5	O
these	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
has	have	VERB	VBZ	9	O
an	an	DET	DT	5	O
antiviral	antiviral	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
in	in	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
AHF	AHF	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
that	that	DET	DT	5	O
anemia	anemia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
only	only	ADJ	JJ	9	O
secondary	secondary	ADJ	JJ	9	O
reaction	reaction	NOUN	NN	9	O
observed	observe	VERB	VBN	9	O
,	,	PUNCT	,	9	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
easily	easily	ADV	RB	5	O
managed	manage	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
beneficial	beneficial	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
ribavirin	ribavirin	NOUN	NN	9	B-Chemical
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
AHF	AHF	PROPN	NNP	9	B-Disease
is	be	VERB	VBZ	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Is	be	VERB	VBZ	9	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
scabies	scabie	NOUN	NNS	5	B-Disease
hazardous	hazardous	ADJ	JJ	5	O
?	?	PUNCT	.	5	O

Treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
scabies	scabie	NOUN	NNS	5	B-Disease
is	be	VERB	VBZ	5	O
usually	usually	ADV	RB	5	O
initiated	initiate	VERB	VBN	9	O
by	by	ADP	IN	9	O
general	general	ADJ	JJ	5	O
practitioners	practitioner	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
most	most	ADJ	JJS	9	O
consider	consider	VERB	VBP	5	O
lindane	lindane	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
gamma	gamma	NOUN	NN	9	B-Chemical
benzene	benzene	NOUN	NN	0	I-Chemical
hexachloride	hexachloride	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
choice	choice	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Lindane	Lindane	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
also	also	ADV	RB	9	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
agricultural	agricultural	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
industrial	industrial	ADJ	JJ	5	O
pesticide	pesticide	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
result	result	NOUN	NN	9	O
the	the	DET	DT	5	O
toxic	toxic	ADJ	JJ	0	O
profile	profile	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
insecticide	insecticide	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
well	well	ADV	RB	9	O
understood	understand	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Evidence	evidence	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
accumulating	accumulate	VERB	VBG	9	O
that	that	ADP	IN	5	O
lindane	lindane	NOUN	NN	0	B-Chemical
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
toxic	toxic	ADJ	JJ	0	B-Disease
to	to	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
central	central	ADJ	JJ	5	I-Disease
nervous	nervous	ADJ	JJ	5	I-Disease
system	system	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anaemia	anaemia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Preparations	preparation	NOUN	NNS	0	O
containing	contain	VERB	VBG	0	O
lindane	lindane	NOUN	NN	0	B-Chemical
continue	continue	VERB	VBP	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
sold	sell	VERB	VBN	5	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
counter	counter	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
represent	represent	VERB	VB	9	O
a	a	DET	DT	5	O
hazard	hazard	NOUN	NN	5	O
to	to	PART	TO	5	O
poorly	poorly	ADV	RB	9	O
informed	inform	VERB	VBN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
literature	literature	NOUN	NN	5	O
review	review	NOUN	NN	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
general	general	ADJ	JJ	5	O
practitioners	practitioner	NOUN	NNS	5	O
should	should	VERB	MD	5	O
prescribe	prescribe	VERB	VB	5	O
scabicides	scabicide	NOUN	NNS	9	O
with	with	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
caution	caution	NOUN	NN	5	O
for	for	ADP	IN	5	O
certain	certain	ADJ	JJ	5	O
at	at	ADP	IN	9	O
-	-	PUNCT	HYPH	7	O
risk	risk	NOUN	NN	5	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
give	give	VERB	VB	5	O
adequate	adequate	ADJ	JJ	5	O
warnings	warning	NOUN	NNS	5	O
regarding	regard	VERB	VBG	5	O
potential	potential	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Mouse	mouse	NOUN	NN	3	O
strain	strain	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
amantadine	amantadine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
motility	motility	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
brain	brain	NOUN	NN	5	O
biogenic	biogenic	ADJ	JJ	0	O
amines	amine	NOUN	NNS	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
amantadine	amantadine	NOUN	NN	0	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
injected	inject	VERB	VBD	3	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
in	in	ADP	IN	5	O
6	6	NUM	CD	9	O
increments	increment	NOUN	NNS	9	O
of	of	ADP	IN	5	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
each	each	DET	DT	5	O
over	over	ADP	IN	5	O
30	30	NUM	CD	9	O
hr	hr	INTJ	UH	0	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
mouse	mouse	NOUN	NN	3	O
motility	motility	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
whole	whole	ADJ	JJ	9	O
brain	brain	NOUN	NN	5	O
content	content	NOUN	NN	9	O
of	of	ADP	IN	5	O
selected	select	VERB	VBN	9	O
biogenic	biogenic	ADJ	JJ	0	O
amines	amine	NOUN	NNS	0	B-Chemical
and	and	CCONJ	CC	5	O
major	major	ADJ	JJ	9	O
metabolites	metabolite	NOUN	NNS	0	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
4	4	NUM	CD	9	O
strains	strain	NOUN	NNS	1	O
of	of	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
were	be	VERB	VBD	9	O
the	the	DET	DT	5	O
albino	albino	ADJ	JJ	3	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
ICR	icr	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
BALB	BALB	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
C	C	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
black	black	ADJ	JJ	9	O
C57BL	C57BL	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
6	6	NUM	CD	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
brown	brown	ADJ	JJ	4	O
CDF	CDF	PROPN	NNP	5	O
-	-	PUNCT	:	7	O
I	-PRON-	PRON	PRP	9	O
mouse	mouse	VERB	VBP	3	O
strains	strain	VERB	VBZ	1	O
.	.	PUNCT	.	9	O

Amantadine	amantadine	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
produced	produce	VERB	VBD	9	O
a	a	DET	DT	5	O
biphasic	biphasic	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
mouse	mouse	NOUN	NN	3	O
motility	motility	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
amantadine	amantadine	NOUN	NN	0	B-Chemical
depressed	depressed	ADJ	JJ	5	B-Disease
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
mouse	mouse	NOUN	NN	3	O
strains	strain	NOUN	NNS	1	O
studied	study	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
BALB	BALB	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
C	C	PROPN	NNP	9	O
mice	mouse	NOUN	NNS	3	O
being	be	VERB	VBG	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
sensitive	sensitive	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Subsequent	subsequent	ADJ	JJ	9	O
amantadine	amantadine	NOUN	NN	0	B-Chemical
treatments	treatment	NOUN	NNS	9	O
produced	produce	VERB	VBD	9	O
enhancement	enhancement	NOUN	NN	9	O
of	of	ADP	IN	5	O
motility	motility	NOUN	NN	9	O
from	from	ADP	IN	9	O
corresponding	correspond	VERB	VBG	9	O
control	control	NOUN	NN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
mouse	mouse	NOUN	NN	3	O
strains	strain	VERB	VBZ	1	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
BALB	BALB	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
C	C	PROPN	NNP	9	O
mice	mouse	NOUN	NNS	3	O
being	be	VERB	VBG	5	O
the	the	DET	DT	5	O
least	least	ADJ	JJS	9	O
sensitive	sensitive	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
from	from	ADP	IN	9	O
corresponding	correspond	VERB	VBG	9	O
controls	control	NOUN	NNS	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
strains	strain	NOUN	NNS	1	O
studied	study	VERB	VBN	9	O
,	,	PUNCT	,	9	O
except	except	ADP	IN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
ICR	ICR	PROPN	NNP	9	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
during	during	ADP	IN	5	O
an	an	DET	DT	5	O
overnight	overnight	ADJ	JJ	0	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
period	period	NOUN	NN	5	O
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
fourth	fourth	ADJ	JJ	9	O
amantadine	amantadine	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Readministration	readministration	NOUN	NN	9	O
of	of	ADP	IN	5	O
amantadine	amantadine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
overnight	overnight	ADJ	JJ	0	O
period	period	NOUN	NN	5	O
,	,	PUNCT	,	9	O
increased	increase	VERB	VBN	9	O
motility	motility	NOUN	NN	9	O
from	from	ADP	IN	9	O
respective	respective	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
control	control	NOUN	NN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
strains	strain	NOUN	NNS	1	O
with	with	ADP	IN	5	O
exception	exception	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
BALB	BALB	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
C	C	PROPN	NNP	9	O
mice	mouse	NOUN	NNS	3	O
where	where	ADV	WRB	5	O
suppression	suppression	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
motility	motility	NOUN	NN	9	I-Disease
occurred	occur	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
amantadine	amantadine	NOUN	NN	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
alter	alter	VERB	VB	9	O
whole	whole	ADJ	JJ	9	O
brain	brain	NOUN	NN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
levels	level	NOUN	NNS	3	O
but	but	CCONJ	CC	9	O
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
amounts	amount	NOUN	NNS	9	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dihydroxyphenylacetic	dihydroxyphenylacetic	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
BALB	BALB	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
C	C	PROPN	NNP	9	O
mice	mouse	NOUN	NNS	3	O
compared	compare	VERB	VBN	9	O
to	to	PART	TO	5	O
saline	saline	VERB	VB	0	O
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Conversely	conversely	ADV	RB	9	O
,	,	PUNCT	,	9	O
brain	brain	NOUN	NN	5	O
normetanephrine	normetanephrine	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
from	from	ADP	IN	9	O
saline	saline	NOUN	NN	0	O
control	control	NOUN	NN	9	O
by	by	ADP	IN	9	O
amantadine	amantadine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
BALB	BALB	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
C	C	PROPN	NNP	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
a	a	DET	DT	5	O
strain	strain	NOUN	NN	1	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
amantadine	amantadine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
motility	motility	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
indicate	indicate	VERB	VBP	9	O
a	a	DET	DT	5	O
differential	differential	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
multiple	multiple	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
regimens	regimen	NOUN	NNS	5	O
used	use	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
BALB	BALB	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
C	C	PROPN	NNP	9	O
mouse	mouse	NOUN	NN	3	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
sensitive	sensitive	ADJ	JJ	9	O
strain	strain	NOUN	NN	1	O
and	and	CCONJ	CC	5	O
could	could	VERB	MD	9	O
serve	serve	VERB	VB	5	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
strain	strain	NOUN	NN	1	O
of	of	ADP	IN	5	O
choice	choice	NOUN	NN	5	O
for	for	ADP	IN	5	O
evaluating	evaluate	VERB	VBG	5	O
the	the	DET	DT	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
amantadine	amantadine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
biochemical	biochemical	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
biogenic	biogenic	ADJ	JJ	0	O
amines	amine	NOUN	NNS	0	B-Chemical
of	of	ADP	IN	5	O
BALB	BALB	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
C	c	NOUN	NN	9	O
mouse	mouse	NOUN	NN	3	O
strain	strain	NOUN	NN	1	O
suggest	suggest	VERB	VBP	9	O
a	a	DET	DT	5	O
probable	probable	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
of	of	ADP	IN	5	O
catecholamine	catecholamine	NOUN	NN	9	B-Chemical
turnover	turnover	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
metabolism	metabolism	NOUN	NN	9	O
by	by	ADP	IN	9	O
monoamine	monoamine	NOUN	NN	0	O
oxidase	oxidase	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
resulting	result	VERB	VBG	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
O	o	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
methylation	methylation	NOUN	NN	9	O
of	of	ADP	IN	5	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
which	which	DET	WDT	5	O
may	may	VERB	MD	5	O
account	account	VERB	VB	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
behavioral	behavioral	ADJ	JJ	5	B-Disease
depression	depression	NOUN	NN	5	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
amantadine	amantadine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
BALB	BALB	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
C	C	PROPN	NNP	9	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Chloroacetaldehyde	Chloroacetaldehyde	PROPN	NNP	7	B-Chemical
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
contribution	contribution	NOUN	NN	9	O
to	to	ADP	IN	5	O
urotoxicity	urotoxicity	NOUN	NN	5	O
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
ifosfamide	ifosfamide	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
/	/	SYM	SYM	9	O
short	short	ADJ	JJ	5	O
communication	communication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Based	base	VERB	VBN	9	O
on	on	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
that	that	DET	DT	5	O
chloroacetaldehyde	chloroacetaldehyde	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CAA	CAA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
metabolite	metabolite	NOUN	NN	0	O
of	of	ADP	IN	5	O
oxazaphosphorine	oxazaphosphorine	NOUN	NN	0	O
cytostatics	cytostatic	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
carried	carry	VERB	VBN	9	O
out	out	PART	RP	9	O
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
elucidate	elucidate	VERB	VB	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
CAA	caa	NOUN	NN	9	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
demonstrate	demonstrate	VERB	VBP	9	O
that	that	DET	DT	5	O
CAA	caa	NOUN	NN	9	B-Chemical
after	after	ADP	IN	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
administration	administration	NOUN	NN	9	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
contribute	contribute	VERB	VB	9	O
to	to	ADP	IN	5	O
bladder	bladder	NOUN	NN	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
instilled	instill	VERB	VBN	9	O
directly	directly	ADV	RB	9	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
bladder	bladder	NOUN	NN	9	O
,	,	PUNCT	,	9	O
CAA	CAA	PROPN	NNP	9	B-Chemical
exerts	exert	VERB	VBZ	9	O
urotoxic	urotoxic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
susceptible	susceptible	ADJ	JJ	9	O
to	to	ADP	IN	5	O
detoxification	detoxification	NOUN	NN	9	O
with	with	ADP	IN	5	O
mesna	mesna	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Source	source	NOUN	NN	9	O
of	of	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
primitive	primitive	ADJ	JJ	5	O
dysfunction	dysfunction	NOUN	NN	9	O
in	in	ADP	IN	5	O
migraine	migraine	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
an	an	DET	DT	5	O
identical	identical	ADJ	JJ	9	O
site	site	NOUN	NN	9	O
?	?	PUNCT	.	5	O

Twenty	twenty	NUM	CD	9	O
common	common	ADJ	JJ	5	O
migraine	migraine	NOUN	NN	5	B-Disease
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
a	a	DET	DT	5	O
one	one	NUM	CD	5	O
sided	sided	ADJ	JJ	5	O
frontotemporal	frontotemporal	ADJ	JJ	5	O
application	application	NOUN	NN	5	O
of	of	ADP	IN	5	O
nitroglycerin	nitroglycerin	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
ointment	ointment	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
blind	blind	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Early	early	ADJ	JJ	9	O
onset	onset	NOUN	NN	5	O
migraine	migraine	NOUN	NN	5	B-Disease
attacks	attack	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
nitroglycerin	nitroglycerin	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
seven	seven	NUM	CD	9	O
out	out	ADP	IN	9	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
versus	versus	ADP	IN	9	O
no	no	DET	DT	9	O
patient	patient	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Subsequently	subsequently	ADV	RB	9	O
20	20	NUM	CD	9	O
migraine	migraine	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
an	an	DET	DT	5	O
early	early	ADJ	JJ	9	O
onset	onset	NOUN	NN	5	O
attack	attack	NOUN	NN	5	O
with	with	ADP	IN	5	O
frontotemporal	frontotemporal	ADJ	JJ	5	O
nitroglycerin	nitroglycerin	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
received	receive	VERB	VBD	9	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
second	second	ADJ	JJ	9	O
induction	induction	NOUN	NN	3	O
test	test	NOUN	NN	5	O
at	at	ADP	IN	9	O
other	other	ADJ	JJ	5	O
body	body	NOUN	NN	5	O
areas	area	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
early	early	ADJ	JJ	9	O
onset	onset	NOUN	NN	5	O
migraine	migraine	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
the	the	DET	DT	5	O
migraine	migraine	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	O
inducing	induce	VERB	VBG	3	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
nitroglycerin	nitroglycerin	NOUN	NN	5	B-Chemical
seems	seem	VERB	VBZ	5	O
to	to	PART	TO	5	O
depend	depend	VERB	VB	5	O
on	on	ADP	IN	5	O
direct	direct	ADJ	JJ	9	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
habitual	habitual	ADJ	JJ	5	O
site	site	NOUN	NN	9	O
of	of	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
frontotemporal	frontotemporal	ADJ	JJ	5	O
region	region	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
of	of	ADP	IN	5	O
crucial	crucial	ADJ	JJ	9	O
importance	importance	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
migraine	migraine	ADJ	JJ	5	B-Disease
crisis	crisis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
CNS	CNS	PROPN	NNP	9	O
origin	origin	NOUN	NN	9	O
of	of	ADP	IN	5	O
migraine	migraine	ADJ	JJ	5	B-Disease
attack	attack	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
to	to	PART	TO	5	O
carbamazepine	carbamazepine	VERB	VB	0	B-Chemical
presenting	present	VERB	VBG	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
leukemoid	leukemoid	ADJ	JJ	5	B-Disease
reaction	reaction	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
eosinophilia	eosinophilia	NOUN	NNS	3	B-Disease
,	,	PUNCT	,	9	O
erythroderma	erythroderma	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
in	in	ADP	IN	5	O
whom	whom	PRON	WP	5	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
to	to	PART	TO	5	O
carbamazepine	carbamazepine	VERB	VB	0	B-Chemical
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
generalized	generalized	ADJ	JJ	5	O
erythroderma	erythroderma	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
severe	severe	ADJ	JJ	5	O
leukemoid	leukemoid	NOUN	NN	5	B-Disease
reaction	reaction	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
eosinophilia	eosinophilia	NOUN	NNS	3	B-Disease
,	,	PUNCT	,	9	O
hyponatremia	hyponatremia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
such	such	DET	PDT	5	O
an	an	DET	DT	5	O
unusual	unusual	ADJ	JJ	9	O
reaction	reaction	NOUN	NN	9	O
to	to	PART	TO	5	O
carbamazepine	carbamazepine	VERB	VB	0	B-Chemical
.	.	PUNCT	.	9	O

Fluoxetine	Fluoxetine	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
akathisia	akathisia	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
theoretical	theoretical	ADJ	JJ	5	O
implications	implication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
obsessive	obsessive	ADJ	JJ	5	B-Disease
compulsive	compulsive	ADJ	JJ	5	I-Disease
disorder	disorder	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
major	major	ADJ	JJ	9	B-Disease
depression	depression	NOUN	NN	5	I-Disease
developed	develop	VERB	VBD	5	O
akathisia	akathisia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
typical	typical	ADJ	JJ	9	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
restlessness	restlessness	NOUN	NN	5	O
,	,	PUNCT	,	9	O
constant	constant	ADJ	JJ	9	O
pacing	pacing	NOUN	NN	5	O
,	,	PUNCT	,	9	O
purposeless	purposeless	NOUN	NN	5	O
movements	movement	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
feet	foot	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
legs	leg	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
marked	marked	ADJ	JJ	9	O
anxiety	anxiety	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
indistinguishable	indistinguishable	ADJ	JJ	9	O
from	from	ADP	IN	9	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
akathisia	akathisia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
experienced	experience	VERB	VBN	5	O
neuroleptic	neuroleptic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
akathisia	akathisia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
past	past	NOUN	NN	5	O
reported	report	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
akathisia	akathisia	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
identical	identical	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
somewhat	somewhat	ADV	RB	5	O
milder	milder	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Akathisia	Akathisia	PROPN	NNP	5	B-Disease
appeared	appear	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
common	common	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
generally	generally	ADV	RB	5	O
responded	respond	VERB	VBD	9	O
well	well	ADV	RB	9	O
to	to	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	NOUN	NN	9	O
antagonist	antagonist	NOUN	NN	3	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
dose	dose	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
both	both	DET	DT	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
authors	author	NOUN	NNS	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
akathisia	akathisia	NOUN	NN	5	B-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
serotonergically	serotonergically	ADV	RB	9	O
mediated	mediate	VERB	VBN	3	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
neurotransmission	neurotransmission	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
pathophysiology	pathophysiology	NOUN	NN	9	O
of	of	ADP	IN	5	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
akathisia	akathisia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
tricyclic	tricyclic	ADJ	JJ	0	O
antidepressant	antidepressant	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
"	"	PUNCT	``	5	O
jitteriness	jitteriness	NOUN	NN	5	O
"	"	PUNCT	''	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
identical	identical	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
converting	convert	VERB	VBG	9	O
enzyme	enzyme	ADJ	JJ	0	O
inhibition	inhibition	NOUN	NN	3	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
adriamycin	adriamycin	ADV	RB	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
converting	convert	VERB	VBG	9	O
enzyme	enzyme	ADJ	JJ	0	O
inhibitor	inhibitor	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
CEI	CEI	PROPN	NNP	2	O
)	)	PUNCT	-RRB-	9	O
enalapril	enalapril	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
in	in	ADP	IN	5	O
Munich	Munich	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
established	establish	VERB	VBN	9	O
adriamycin	adriamycin	ADJ	JJ	3	B-Chemical
nephrosis	nephrosis	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

Rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
adriamycin	adriamycin	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
one	one	NUM	CD	5	O
month	month	NOUN	NN	5	O
later	later	ADV	RB	9	O
divided	divide	VERB	VBD	5	O
into	into	ADP	IN	9	O
four	four	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
matched	match	VERB	VBN	9	O
for	for	ADP	IN	5	O
albuminuria	albuminuria	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
plasma	plasma	VERB	VB	9	O
albumin	albumin	NOUN	NN	0	O
concentration	concentration	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Groups	group	NOUN	NNS	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
remained	remain	VERB	VBD	9	O
untreated	untreated	ADJ	JJ	3	O
while	while	ADP	IN	9	O
groups	group	NOUN	NNS	9	O
2	2	NUM	CD	9	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
received	receive	VERB	VBN	9	O
enalapril	enalapril	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Groups	group	NOUN	NNS	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
underwent	undergo	VERB	VBD	5	O
micropuncture	micropuncture	NOUN	NN	5	O
studies	study	NOUN	NNS	9	O
after	after	ADP	IN	9	O
10	10	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
short	short	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
studies	study	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
enalapril	enalapril	ADJ	JJ	0	B-Chemical
reduced	reduce	VERB	VBN	9	O
arterial	arterial	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
101	101	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
124	124	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
group	group	NOUN	NN	9	O
2	2	NUM	CD	9	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
glomerular	glomerular	ADJ	JJ	5	O
capillary	capillary	ADJ	JJ	0	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
54	54	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
61	61	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
without	without	ADP	IN	9	O
reducing	reduce	VERB	VBG	9	O
albuminuria	albuminuria	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
617	617	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
50	50	NUM	CD	0	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
570	570	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
47	47	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
GFR	GFR	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
04	04	NUM	CD	7	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
04	04	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
11	11	NUM	CD	7	O
ml	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Groups	group	NOUN	NNS	9	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
at	at	ADP	IN	9	O
four	four	NUM	CD	9	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
six	six	NUM	CD	9	O
months	month	NOUN	NNS	5	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
enalapril	enalapril	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
progression	progression	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
adriamycin	adriamycin	ADJ	JJ	3	B-Chemical
nephrosis	nephrosis	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

Chronic	chronic	ADJ	JJ	9	O
enalapril	enalapril	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
reduced	reduce	VERB	VBN	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
without	without	ADP	IN	9	O
reducing	reduce	VERB	VBG	9	O
albuminuria	albuminuria	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
group	group	NOUN	NN	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O

Untreated	untreated	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
3	3	NUM	CD	9	O
rats	rat	NOUN	NNS	9	O
exhibited	exhibit	VERB	VBD	9	O
a	a	DET	DT	5	O
progressive	progressive	ADJ	JJ	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
GFR	GFR	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
35	35	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
08	08	NUM	CD	7	O
ml	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
at	at	ADP	IN	9	O
4	4	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
27	27	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
07	07	NUM	CD	7	O
ml	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
at	at	ADP	IN	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Enalapril	enalapril	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
blunted	blunt	VERB	VBN	9	O
but	but	CCONJ	CC	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
prevent	prevent	VERB	VB	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
GFR	GFR	PROPN	NNP	5	O
in	in	ADP	IN	5	O
group	group	NOUN	NN	9	O
4	4	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
86	86	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
15	15	NUM	CD	9	O
ml	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
at	at	ADP	IN	9	O
4	4	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
69	69	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
13	13	NUM	CD	7	O
ml	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
at	at	ADP	IN	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
both	both	CCONJ	CC	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
group	group	NOUN	NN	9	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
GFR	GFR	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
glomerular	glomerular	ADJ	JJ	5	B-Disease
sclerosis	sclerosis	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
both	both	CCONJ	CC	9	O
treated	treat	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
untreated	untreated	ADJ	JJ	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
250	250	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

Clotiazepam	Clotiazepam	PROPN	NNP	_	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
acute	acute	ADJ	JJ	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
with	with	ADP	IN	5	O
extensive	extensive	ADJ	JJ	5	B-Disease
hepatocellular	hepatocellular	ADJ	JJ	9	I-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
7	7	NUM	CD	9	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
clotiazepam	clotiazepam	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
thienodiazepine	thienodiazepine	NOUN	NN	9	B-Chemical
derivative	derivative	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Clotiazepam	Clotiazepam	PROPN	NNP	_	B-Chemical
withdrawal	withdrawal	NOUN	NN	5	O
was	be	VERB	VBD	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
prompt	prompt	ADJ	JJ	5	O
recovery	recovery	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
several	several	ADJ	JJ	9	O
benzodiazepines	benzodiazepine	NOUN	NNS	5	B-Chemical
,	,	PUNCT	,	9	O
chemically	chemically	ADV	RB	0	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
clotiazepam	clotiazepam	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
interfere	interfere	VERB	VB	9	O
with	with	ADP	IN	5	O
recovery	recovery	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
induce	induce	VERB	VB	3	O
any	any	DET	DT	5	O
relapse	relapse	NOUN	NN	5	O
of	of	ADP	IN	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
observation	observation	NOUN	NN	9	O
shows	show	VERB	VBZ	9	O
that	that	ADP	IN	5	O
clotiazepam	clotiazepam	NOUN	NN	0	B-Chemical
can	can	VERB	MD	5	O
induce	induce	VERB	VB	3	O
acute	acute	ADJ	JJ	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
no	no	DET	DT	9	O
cross	cross	ADJ	JJ	5	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
between	between	ADP	IN	5	O
clotiazepam	clotiazepam	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
several	several	ADJ	JJ	9	O
benzodiazepines	benzodiazepine	NOUN	NNS	5	B-Chemical
.	.	PUNCT	.	9	O

5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
azacytidine	azacytidine	NOUN	NN	3	I-Chemical
potentiates	potentiate	NOUN	NNS	3	O
initiation	initiation	NOUN	NN	9	B-Disease
induced	induce	VERB	VBN	3	I-Disease
by	by	ADP	IN	9	I-Disease
carcinogens	carcinogen	NOUN	NNS	0	I-Disease
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
liver	liver	NOUN	NN	9	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
test	test	VERB	VB	5	O
the	the	DET	DT	5	O
validity	validity	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	DET	DT	5	O
hypomethylation	hypomethylation	NOUN	NN	9	O
of	of	ADP	IN	5	O
DNA	dna	NOUN	NN	9	O
plays	play	VERB	VBZ	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
initiation	initiation	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
carcinogenic	carcinogenic	ADJ	JJ	0	I-Disease
process	process	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
azacytidine	azacytidine	NOUN	NN	3	I-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
AzC	AzC	PROPN	NNP	1	I-Chemical
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
DNA	dna	NOUN	NN	9	O
methylation	methylation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
to	to	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
phase	phase	NOUN	NN	5	O
of	of	ADP	IN	5	O
repair	repair	NOUN	NN	9	O
synthesis	synthesis	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
three	three	NUM	CD	9	O
carcinogens	carcinogen	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
benzo	benzo	NOUN	NN	0	B-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
a	a	DET	DT	5	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
pyrene	pyrene	ADJ	JJ	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
N	n	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
nitrosourea	nitrosourea	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
60	60	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dimethylhydrazine	dimethylhydrazine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
DMH	DMH	PROPN	NNP	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
initiated	initiate	VERB	VBN	9	O
hepatocytes	hepatocyte	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
were	be	VERB	VBD	9	O
assayed	assay	VERB	VBN	3	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
gamma	gamma	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
glutamyltransferase	glutamyltransferase	NOUN	NN	7	O
(	(	PUNCT	-LRB-	9	O
gamma	gamma	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
GT	GT	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
positive	positive	ADJ	JJ	9	O
foci	foci	NOUN	NN	9	O
formed	form	VERB	VBD	9	O
following	follow	VERB	VBG	9	O
a	a	DET	DT	5	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
selection	selection	NOUN	NN	5	O
regimen	regiman	NOUN	NNS	5	O
consisting	consist	VERB	VBG	9	O
of	of	ADP	IN	5	O
dietary	dietary	ADJ	JJ	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
%	%	NOUN	NN	9	O
2	2	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
acetylaminofluorene	acetylaminofluorene	NOUN	NN	0	I-Chemical
coupled	couple	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
necrogenic	necrogenic	ADJ	JJ	0	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
CCl4	CCl4	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
obtained	obtain	VERB	VBN	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
with	with	ADP	IN	5	O
all	all	DET	DT	5	O
three	three	NUM	CD	9	O
carcinogens	carcinogen	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
AzC	azc	NOUN	NN	1	I-Chemical
during	during	ADP	IN	5	O
repair	repair	NOUN	NN	9	O
synthesis	synthesis	NOUN	NN	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
initiated	initiate	VERB	VBN	9	O
hepatocytes	hepatocyte	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
example	example	NOUN	NN	5	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
20	20	NUM	CD	9	O
foci	foci	NOUN	NN	9	O
/	/	SYM	SYM	9	O
cm2	cm2	NOUN	NN	0	O
in	in	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
AzC	AzC	PROPN	NNP	1	I-Chemical
and	and	CCONJ	CC	5	O
carcinogen	carcinogen	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
5	5	NUM	CD	9	O
foci	foci	NOUN	NN	9	O
/	/	SYM	SYM	9	O
cm2	cm2	NOUN	NN	0	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
carcinogen	carcinogen	NOUN	NN	0	O
only	only	ADV	RB	9	O
.	.	PUNCT	.	9	O

Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
[	[	PUNCT	-LRB-	9	B-Chemical
3H	3h	NOUN	NN	0	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5	5	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
azadeoxycytidine	azadeoxycytidine	NOUN	NN	9	I-Chemical
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
repair	repair	NOUN	NN	9	O
synthesis	synthesis	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
1	1	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
DMH	dmh	NOUN	NN	9	I-Chemical
further	further	ADV	RB	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
019	019	NUM	CD	7	O
mol	mol	NOUN	NN	0	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
cytosine	cytosine	ADJ	JJ	1	B-Chemical
residues	residue	NOUN	NNS	1	O
in	in	ADP	IN	5	O
DNA	dna	NOUN	NN	9	O
were	be	VERB	VBD	9	O
substituted	substitute	VERB	VBN	0	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
analogue	analogue	NOUN	NN	0	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
that	that	ADP	IN	5	O
incorporation	incorporation	NOUN	NN	0	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
AzC	AzC	PROPN	NNP	1	I-Chemical
occurs	occur	VERB	VBZ	9	O
during	during	ADP	IN	5	O
repair	repair	NOUN	NN	9	O
synthesis	synthesis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
carcinogen	carcinogen	NOUN	NN	0	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
AzC	AzC	PROPN	NNP	1	I-Chemical
given	give	VERB	VBN	5	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
two	two	NUM	CD	5	O
thirds	third	NOUN	NNS	5	O
partial	partial	ADJ	JJ	9	O
hepatectomy	hepatectomy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
its	-PRON-	DET	PRP$	9	O
incorporation	incorporation	NOUN	NN	0	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
maximum	maximum	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
any	any	DET	DT	5	O
gamma	gamma	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
GT	gt	ADJ	JJ	9	O
positive	positive	ADJ	JJ	9	O
foci	foci	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
hypomethylation	hypomethylation	NOUN	NN	9	O
of	of	ADP	IN	5	O
DNA	dna	NOUN	NN	9	O
per	per	X	FW	9	O
se	se	X	FW	9	O
may	may	VERB	MD	5	O
not	not	ADV	RB	5	O
be	be	VERB	VB	5	O
sufficient	sufficient	ADJ	JJ	9	O
for	for	ADP	IN	5	O
initiation	initiation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Perhaps	perhaps	ADV	RB	5	O
two	two	NUM	CD	5	O
events	event	NOUN	NNS	5	O
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
necessary	necessary	ADJ	JJ	5	O
for	for	ADP	IN	5	O
initiation	initiation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
carcinogen	carcinogen	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
second	second	ADJ	JJ	9	O
involving	involve	VERB	VBG	5	O
hypomethylation	hypomethylation	NOUN	NN	9	O
of	of	ADP	IN	5	O
DNA	dna	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Antihypertensive	antihypertensive	ADJ	JJ	7	O
drugs	drug	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
depression	depression	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
reappraisal	reappraisal	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Eighty	eighty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
nine	nine	NUM	CD	9	O
new	new	ADJ	JJ	5	O
referral	referral	NOUN	NN	5	O
hypertensive	hypertensive	NOUN	NN	5	B-Disease
out	out	PART	RP	9	O
-	-	PUNCT	HYPH	7	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
46	46	NUM	CD	7	O
new	new	ADJ	JJ	5	O
referral	referral	ADJ	JJ	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
chronically	chronically	ADV	RB	9	O
physically	physically	ADV	RB	5	O
ill	ill	ADJ	JJ	5	O
out	out	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
patients	patient	NOUN	NNS	5	O
completed	complete	VERB	VBD	5	O
a	a	DET	DT	5	O
mood	mood	NOUN	NN	5	O
rating	rating	NOUN	NN	5	O
scale	scale	NOUN	NN	5	O
at	at	ADP	IN	9	O
regular	regular	ADJ	JJ	5	O
intervals	interval	NOUN	NNS	5	O
for	for	ADP	IN	5	O
one	one	NUM	CD	5	O
year	year	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
depression	depression	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
preponderance	preponderance	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Hypertensive	hypertensive	ADJ	JJ	7	B-Disease
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
psychiatric	psychiatric	ADJ	JJ	5	B-Disease
histories	history	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
depression	depression	NOUN	NN	5	B-Disease
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
comparison	comparison	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
accounted	account	VERB	VBN	5	O
for	for	ADP	IN	5	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
depressions	depression	NOUN	NNS	5	B-Disease
occurring	occur	VERB	VBG	9	O
in	in	ADP	IN	5	O
methyl	methyl	NOUN	NN	0	B-Chemical
dopa	dopa	ADJ	JJ	0	I-Chemical
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
psychiatric	psychiatric	ADJ	JJ	5	B-Disease
histories	history	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Chronic	chronic	ADJ	JJ	9	B-Disease
active	active	ADJ	JJ	9	I-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
diclofenac	diclofenac	NOUN	NN	0	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Diclofenac	diclofenac	NOUN	NN	0	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
Voltarol	Voltarol	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
Geigy	Geigy	PROPN	NNP	2	O
Pharmaceuticals	Pharmaceuticals	PROPN	NNPS	2	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
steroidal	steroidal	ADJ	JJ	0	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
derivative	derivative	NOUN	NN	0	O
of	of	ADP	IN	5	O
phenylacetic	phenylacetic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
generally	generally	ADV	RB	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
tolerated	tolerate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
asymptomatic	asymptomatic	ADJ	JJ	5	O
abnormalities	abnormality	NOUN	NNS	9	B-Disease
of	of	ADP	IN	5	I-Disease
liver	liver	NOUN	NN	9	I-Disease
function	function	NOUN	NN	9	I-Disease
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
recorded	record	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
less	less	ADV	RBR	5	O
commonly	commonly	ADV	RB	5	O
,	,	PUNCT	,	9	O
severe	severe	ADJ	JJ	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
diclofenac	diclofenac	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
described	describe	VERB	VBD	9	O
developed	develop	VERB	VBD	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
active	active	ADJ	JJ	9	I-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
after	after	ADP	IN	9	O
six	six	NUM	CD	9	O
months	month	NOUN	NNS	5	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
diclofenac	diclofenac	NOUN	NN	0	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
which	which	DET	WDT	5	O
progressed	progress	VERB	VBD	9	O
despite	despite	ADP	IN	9	O
the	the	DET	DT	5	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
finding	finding	NOUN	NN	9	O
not	not	ADV	RB	5	O
previously	previously	ADV	RB	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Arterial	arterial	ADJ	JJ	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
prolonged	prolong	VERB	VBN	9	O
ketoconazole	ketoconazole	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
of	of	ADP	IN	5	O
14	14	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Cushing	cushe	VERB	VBG	5	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	NOUN	NN	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
treated	treat	VERB	VBN	3	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
basis	basis	NOUN	NN	5	O
with	with	ADP	IN	5	O
ketoconazole	ketoconazole	NOUN	NN	0	B-Chemical
developed	develop	VERB	VBD	5	O
sustained	sustained	ADJ	JJ	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
both	both	DET	DT	9	O
cases	case	NOUN	NNS	5	O
normal	normal	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
urinary	urinary	ADJ	JJ	9	O
free	free	ADJ	JJ	9	O
cortisol	cortisol	NOUN	NN	5	B-Chemical
levels	level	NOUN	NNS	3	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
achieved	achieve	VERB	VBN	5	O
following	follow	VERB	VBG	9	O
ketoconazole	ketoconazole	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
yet	yet	CCONJ	CC	9	O
continuous	continuous	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
monitoring	monitoring	NOUN	NN	5	O
demonstrated	demonstrate	VERB	VBD	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
31	31	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
patient	patient	ADJ	JJ	5	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
52	52	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
patient	patient	ADJ	JJ	5	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
patient	patient	NOUN	NN	5	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
plasma	plasma	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
deoxycorticosterone	deoxycorticosterone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
11	11	NUM	CD	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
deoxycortisol	deoxycortisol	NOUN	NN	0	I-Chemical
were	be	VERB	VBD	9	O
elevated	elevate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
patient	patient	NOUN	NN	5	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
both	both	CCONJ	CC	9	O
deoxycorticosterone	deoxycorticosterone	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
11	11	NUM	CD	7	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
deoxycortisol	deoxycortisol	NOUN	NN	0	I-Chemical
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
plasma	plasma	NOUN	NN	9	O
aldosterone	aldosterone	NOUN	NN	9	B-Chemical
values	value	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
raised	raise	VERB	VBN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
concomitant	concomitant	ADJ	JJ	9	O
suppression	suppression	NOUN	NN	9	O
of	of	ADP	IN	5	O
renin	renin	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
findings	finding	NOUN	NNS	9	O
show	show	VERB	VBP	9	O
that	that	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
ketoconazole	ketoconazole	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
induce	induce	VERB	VB	3	O
enzyme	enzyme	ADJ	JJ	0	O
blockade	blockade	NOUN	NN	3	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
mineralocorticoid	mineralocorticoid	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
converting	convert	VERB	VBG	9	O
enzyme	enzyme	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
Captopril	Captopril	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
intravascular	intravascular	ADJ	JJ	5	B-Disease
coagulation	coagulation	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
intravascular	intravascular	ADJ	JJ	5	B-Disease
coagulation	coagulation	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
fibrinolysis	fibrinolysis	NOUN	NN	5	O
by	by	ADP	IN	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
thrombin	thrombin	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
tranexamic	tranexamic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
AMCA	AMCA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
gives	give	VERB	VBZ	5	O
rise	rise	NOUN	NN	9	O
to	to	ADP	IN	5	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
resembling	resemble	VERB	VBG	9	O
that	that	ADP	IN	5	O
occurring	occur	VERB	VBG	9	O
after	after	ADP	IN	9	O
trauma	trauma	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
sepsis	sepsis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
man	man	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
Captopril	Captopril	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
converting	convert	VERB	VBG	9	O
enzyme	enzyme	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
ACE	ACE	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
reduced	reduce	VERB	VBD	9	O
both	both	CCONJ	CC	9	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
lung	lung	NOUN	NN	9	O
weights	weight	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
lower	low	ADJ	JJR	9	O
and	and	CCONJ	CC	5	O
PaO2	pao2	NOUN	NN	5	O
was	be	VERB	VBD	9	O
improved	improve	VERB	VBN	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
given	give	VERB	VBN	5	O
this	this	DET	DT	5	O
enzyme	enzyme	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
blocking	block	VERB	VBG	3	O
agent	agent	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
contents	content	NOUN	NNS	9	O
of	of	ADP	IN	5	O
albumin	albumin	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
lungs	lung	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
changed	change	VERB	VBN	9	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
that	that	ADP	IN	5	O
Captopril	Captopril	PROPN	NNP	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
influence	influence	VERB	VB	5	O
the	the	DET	DT	5	O
extravasation	extravasation	NOUN	NN	3	O
of	of	ADP	IN	5	O
protein	protein	NOUN	NN	1	O
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
as	as	ADP	IN	5	O
reflected	reflect	VERB	VBN	5	O
by	by	ADP	IN	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
urea	urea	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
kidney	kidney	NOUN	NN	9	O
weight	weight	NOUN	NN	9	O
was	be	VERB	VBD	9	O
prevented	prevent	VERB	VBN	9	O
by	by	ADP	IN	9	O
Captopril	Captopril	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
amount	amount	NOUN	NN	9	O
of	of	ADP	IN	5	O
fibrin	fibrin	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
kidneys	kidney	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
considerably	considerably	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
which	which	DET	WDT	5	O
received	receive	VERB	VBD	9	O
thrombin	thrombin	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
AMCA	amca	NOUN	NN	0	B-Chemical
alone	alone	ADV	RB	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
Captopril	Captopril	PROPN	NNP	0	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
lungs	lung	NOUN	NNS	3	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
attributable	attributable	ADJ	JJ	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
vasodilatory	vasodilatory	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
circulating	circulating	ADJ	JJ	9	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
Angiotension	Angiotension	PROPN	NNP	9	B-Chemical
II	II	PROPN	NNP	9	I-Chemical
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
prostacyclin	prostacyclin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
bradykinin	bradykinin	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Captopril	Captopril	PROPN	NNP	0	B-Chemical
may	may	VERB	MD	5	O
,	,	PUNCT	,	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
mechanism	mechanism	NOUN	NN	9	O
,	,	PUNCT	,	9	O
reduce	reduce	VERB	VB	5	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
glomerular	glomerular	ADJ	JJ	5	O
filtration	filtration	NOUN	NN	0	O
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
occur	occur	VERB	VB	5	O
after	after	ADP	IN	9	O
an	an	DET	DT	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
thrombin	thrombin	NOUN	NN	0	O
,	,	PUNCT	,	9	O
thereby	thereby	ADV	RB	9	O
diminishing	diminish	VERB	VBG	5	O
the	the	DET	DT	5	O
aggregation	aggregation	NOUN	NN	9	O
of	of	ADP	IN	5	O
fibrin	fibrin	ADJ	JJ	0	O
monomers	monomer	NOUN	NNS	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
glomeruli	glomeruli	NOUN	NN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
result	result	NOUN	NN	9	O
that	that	ADP	IN	5	O
less	less	ADJ	JJR	5	O
fibrin	fibrin	NOUN	NN	0	O
will	will	VERB	MD	5	O
be	be	VERB	VB	5	O
deposited	deposit	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
thus	thus	ADV	RB	9	O
less	less	ADJ	JJR	5	O
kidney	kidney	NOUN	NN	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
will	will	VERB	MD	5	O
be	be	VERB	VB	5	O
produced	produce	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Stroke	stroke	NOUN	NN	5	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
eight	eight	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
whom	whom	PRON	WP	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
was	be	VERB	VBD	9	O
related	relate	VERB	VBN	9	O
to	to	PART	TO	5	O
stroke	stroke	VERB	VB	5	B-Disease
and	and	CCONJ	CC	5	O
review	review	VERB	VB	5	O
39	39	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
these	these	DET	DT	5	O
47	47	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SD	sd	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
age	age	NOUN	NN	5	O
was	be	VERB	VBD	9	O
32	32	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
years	year	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
76	76	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
34	34	NUM	CD	7	O
/	/	SYM	SYM	9	O
45	45	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
men	man	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Stroke	stroke	NOUN	NN	5	B-Disease
followed	follow	VERB	VBD	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
by	by	ADP	IN	9	O
inhalation	inhalation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
intranasal	intranasal	NOUN	NN	9	O
,	,	PUNCT	,	9	O
intravenous	intravenous	ADJ	JJ	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
intramuscular	intramuscular	ADJ	JJ	9	O
routes	route	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Intracranial	intracranial	ADJ	JJ	5	B-Disease
aneurysms	aneurysm	NOUN	NNS	5	I-Disease
or	or	CCONJ	CC	5	O
arteriovenous	arteriovenous	ADJ	JJ	5	B-Disease
malformations	malformation	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
17	17	NUM	CD	7	O
of	of	ADP	IN	5	O
32	32	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
studied	study	VERB	VBN	9	O
angiographically	angiographically	ADV	RB	5	O
or	or	CCONJ	CC	5	O
at	at	ADP	IN	9	O
autopsy	autopsy	ADJ	JJ	5	O
;	;	PUNCT	:	9	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
vasculitis	vasculitis	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Cerebral	cerebral	ADJ	JJ	5	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
10	10	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
22	22	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
intracerebral	intracerebral	ADJ	JJ	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
22	22	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
49	49	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
subarachnoid	subarachnoid	ADJ	JJ	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
13	13	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
29	29	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
the	the	DET	DT	5	O
apparent	apparent	ADJ	JJ	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
stroke	stroke	NOUN	NN	5	B-Disease
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
increasing	increase	VERB	VBG	9	O
;	;	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
stroke	stroke	NOUN	NN	5	B-Disease
occurs	occur	VERB	VBZ	9	O
primarily	primarily	ADV	RB	9	O
in	in	ADP	IN	5	O
young	young	ADJ	JJ	5	O
adults	adult	NOUN	NNS	5	O
;	;	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
stroke	stroke	NOUN	NN	5	B-Disease
may	may	VERB	MD	5	O
follow	follow	VERB	VB	5	O
any	any	DET	DT	5	O
route	route	NOUN	NN	5	O
of	of	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
administration	administration	NOUN	NN	9	O
;	;	PUNCT	:	9	O
(	(	PUNCT	-LRB-	9	O
4	4	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
stroke	stroke	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
use	use	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
frequently	frequently	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
intracranial	intracranial	ADJ	JJ	5	B-Disease
aneurysms	aneurysm	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
arteriovenous	arteriovenous	ADJ	JJ	5	B-Disease
malformations	malformation	NOUN	NNS	5	I-Disease
;	;	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
(	(	PUNCT	-LRB-	9	O
5	5	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
stroke	stroke	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
intracranial	intracranial	ADJ	JJ	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
exceeds	exceed	VERB	VBZ	5	O
that	that	ADP	IN	5	O
of	of	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
randomized	randomize	VERB	VBN	5	O
comparison	comparison	NOUN	NN	9	O
of	of	ADP	IN	5	O
labetalol	labetalol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
nitroprusside	nitroprusside	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
induced	induced	ADJ	JJ	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
randomized	randomize	VERB	VBN	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
labetalol	labetalol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
nitroprusside	nitroprusside	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
in	in	ADP	IN	5	O
20	20	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
in	in	ADP	IN	5	O
each	each	DET	DT	5	O
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
scheduled	schedule	VERB	VBN	5	O
for	for	ADP	IN	5	O
major	major	ADJ	JJ	9	O
orthopedic	orthopedic	ADJ	JJ	5	O
procedures	procedure	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Each	each	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
subjected	subject	VERB	VBN	9	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
identical	identical	ADJ	JJ	9	O
anesthetic	anesthetic	ADJ	JJ	5	O
protocol	protocol	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
similar	similar	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
reductions	reduction	NOUN	NNS	9	B-Disease
in	in	ADP	IN	5	I-Disease
mean	mean	ADJ	JJ	5	I-Disease
arterial	arterial	ADJ	JJ	5	I-Disease
blood	blood	NOUN	NN	9	I-Disease
pressure	pressure	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
BP	BP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
to	to	PART	TO	5	O
55	55	NUM	CD	7	O
mmHg	mmHg	PROPN	NNPS	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Nitroprusside	nitroprusside	ADJ	JJ	0	O
infusion	infusion	NOUN	NN	0	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
increase	increase	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
heart	heart	NOUN	NN	5	I-Disease
rate	rate	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	I-Disease
cardiac	cardiac	ADJ	JJ	5	I-Disease
output	output	NOUN	NN	5	I-Disease
;	;	PUNCT	:	9	O
rebound	rebound	NOUN	NN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
after	after	ADP	IN	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
nitroprusside	nitroprusside	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Labetalol	labetalol	ADJ	JJ	0	B-Chemical
administration	administration	NOUN	NN	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
any	any	DET	DT	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Arterial	Arterial	PROPN	NNP	5	O
PO2	PO2	PROPN	NNP	0	B-Chemical
decreased	decrease	VERB	VBD	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
labetalol	labetalol	NOUN	NN	0	B-Chemical
offers	offer	VERB	VBZ	5	O
advantages	advantage	NOUN	NNS	5	O
over	over	ADP	IN	5	O
nitroprusside	nitroprusside	ADV	RB	0	B-Chemical
.	.	PUNCT	.	9	O

Sodium	sodium	NOUN	NN	0	B-Chemical
status	status	NOUN	NN	9	O
influences	influence	NOUN	NNS	5	O
chronic	chronic	VERB	VBP	5	O
amphotericin	amphotericin	ADV	RB	0	B-Chemical
B	b	ADP	IN	9	I-Chemical
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
nephrotoxic	nephrotoxic	ADJ	JJ	5	B-Disease
potential	potential	NOUN	NN	9	O
of	of	ADP	IN	5	O
amphotericin	amphotericin	NOUN	NN	0	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
intraperitoneally	intraperitoneally	ADV	RB	0	O
for	for	ADP	IN	5	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
investigated	investigate	VERB	VBN	9	O
in	in	ADP	IN	5	O
salt	salt	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
depleted	deplete	VERB	VBN	3	O
,	,	PUNCT	,	9	O
normal	normal	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
salt	salt	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
salt	salt	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
loaded	load	VERB	VBN	0	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
salt	salt	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
depleted	deplete	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
amphotericin	amphotericin	ADV	RB	0	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
decreased	decrease	VERB	VBD	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
clearance	clearance	NOUN	NN	9	O
linearly	linearly	ADV	RB	5	O
with	with	ADP	IN	5	O
time	time	NOUN	NN	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
85	85	NUM	CD	9	O
%	%	NOUN	NN	9	O
reduction	reduction	NOUN	NN	9	O
by	by	ADP	IN	9	O
week	week	NOUN	NN	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
salt	salt	NOUN	NN	0	O
rats	rat	NOUN	NNS	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
clearance	clearance	NOUN	NN	9	O
was	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
but	but	CCONJ	CC	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
lesser	less	ADJ	JJR	9	O
extent	extent	NOUN	NN	9	O
at	at	ADP	IN	9	O
week	week	NOUN	NN	9	O
2	2	NUM	CD	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
salt	salt	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
loaded	load	VERB	VBN	0	O
rats	rat	NOUN	NNS	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
clearance	clearance	NOUN	NN	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
change	change	VERB	VB	9	O
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
by	by	ADP	IN	9	O
43	43	NUM	CD	7	O
%	%	NOUN	NN	9	O
at	at	ADP	IN	9	O
week	week	NOUN	NN	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
rats	rat	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
depleted	deplete	VERB	VBN	3	O
group	group	NOUN	NN	9	O
had	have	VERB	VBD	9	O
histopathological	histopathological	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
patchy	patchy	NOUN	NN	5	O
tubular	tubular	ADJ	JJ	9	O
cytoplasmic	cytoplasmic	ADJ	JJ	3	O
degeneration	degeneration	NOUN	NN	9	O
in	in	ADP	IN	5	O
tubules	tubule	NOUN	NNS	9	O
that	that	DET	WDT	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
any	any	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
salt	salt	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
salt	salt	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
loaded	load	VERB	VBN	0	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
amphotericin	amphotericin	PROPN	NNP	0	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
in	in	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
different	different	ADJ	JJ	9	O
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
three	three	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
at	at	ADP	IN	9	O
any	any	DET	DT	5	O
time	time	NOUN	NN	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
amphotericin	amphotericin	ADV	RB	0	B-Chemical
B	b	NOUN	NN	9	I-Chemical
levels	level	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
kidneys	kidney	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
liver	liver	NOUN	NN	9	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
salt	salt	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
depleted	deplete	VERB	VBN	3	O
and	and	CCONJ	CC	5	O
normal	normal	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
salt	salt	NOUN	NN	0	O
rats	rat	NOUN	NNS	9	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
in	in	ADP	IN	5	O
salt	salt	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
loaded	load	VERB	VBN	0	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
/	/	SYM	SYM	9	O
kidney	kidney	NOUN	NN	9	O
ratios	ratio	NOUN	NNS	9	O
of	of	ADP	IN	5	O
21	21	NUM	CD	7	O
,	,	PUNCT	,	9	O
14	14	NUM	CD	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
8	8	NUM	CD	9	O
in	in	ADP	IN	5	O
salt	salt	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
depleted	deplete	VERB	VBN	3	O
,	,	PUNCT	,	9	O
normal	normal	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
salt	salt	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
salt	salt	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
loaded	load	VERB	VBN	0	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
reductions	reduction	NOUN	NNS	9	O
in	in	ADP	IN	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
clearance	clearance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	O
amphotericin	amphotericin	NOUN	NN	0	B-Chemical
B	b	NOUN	NN	9	I-Chemical
accumulation	accumulation	NOUN	NN	9	O
after	after	ADP	IN	9	O
chronic	chronic	NOUN	NN	5	O
amphotericin	amphotericin	NOUN	NN	0	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
administration	administration	NOUN	NN	9	O
were	be	VERB	VBD	9	O
enhanced	enhance	VERB	VBN	3	O
by	by	ADP	IN	9	O
salt	salt	NOUN	NN	0	O
depletion	depletion	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
attenuated	attenuate	VERB	VBN	3	O
by	by	ADP	IN	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
loading	loading	NOUN	NN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Flestolol	Flestolol	PROPN	NNP	_	B-Chemical
:	:	PUNCT	:	9	O
an	an	DET	DT	5	O
ultra	ultra	ADJ	JJ	0	O
-	-	ADJ	JJ	7	O
short	short	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
acting	act	VERB	VBG	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	NOUN	NN	9	O
blocking	block	VERB	VBG	3	O
agent	agent	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Flestolol	Flestolol	PROPN	NNP	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
ACC	ACC	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9089	9089	PROPN	NNP	7	I-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
nonselective	nonselective	ADJ	JJ	0	O
,	,	PUNCT	,	9	O
competitive	competitive	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
ultra	ultra	ADJ	JJ	0	O
-	-	ADJ	JJ	7	O
short	short	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
acting	act	VERB	VBG	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	NOUN	NN	9	O
blocking	block	VERB	VBG	3	O
agent	agent	NOUN	NN	9	O
,	,	PUNCT	,	9	O
without	without	ADP	IN	9	O
any	any	DET	DT	5	O
intrinsic	intrinsic	ADJ	JJ	9	O
sympathomimetic	sympathomimetic	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Flestolol	Flestolol	PROPN	NNP	_	B-Chemical
is	be	VERB	VBZ	5	O
metabolized	metabolize	VERB	VBN	0	O
by	by	ADP	IN	9	O
plasma	plasma	NOUN	NN	9	O
esterases	esterase	VERB	VBZ	0	O
and	and	CCONJ	CC	5	O
has	have	VERB	VBZ	9	O
an	an	DET	DT	5	O
elimination	elimination	NOUN	NN	9	O
half	half	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
life	life	NOUN	NN	5	O
of	of	ADP	IN	5	O
approximately	approximately	ADV	RB	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
agent	agent	NOUN	NN	9	O
was	be	VERB	VBD	9	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
in	in	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
volunteers	volunteer	NOUN	NNS	5	O
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
100	100	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
infusion	infusion	NOUN	NN	0	O
studies	study	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
flestolol	flestolol	NOUN	NN	_	B-Chemical
was	be	VERB	VBD	9	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blocking	block	VERB	VBG	3	O
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
seven	seven	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Flestolol	flestolol	NOUN	NN	_	B-Chemical
blood	blood	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
increased	increase	VERB	VBD	9	O
linearly	linearly	ADV	RB	5	O
with	with	ADP	IN	5	O
increasing	increase	VERB	VBG	9	O
dose	dose	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
good	good	ADJ	JJ	5	O
correlation	correlation	NOUN	NN	9	O
exists	exist	VERB	VBZ	9	O
between	between	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
flestolol	flestolol	NOUN	NN	_	B-Chemical
and	and	CCONJ	CC	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	NOUN	NN	9	O
blockade	blockade	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Flestolol	Flestolol	PROPN	NNP	_	B-Chemical
produced	produce	VERB	VBD	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
attenuation	attenuation	NOUN	NN	9	O
of	of	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Electrophysiologic	electrophysiologic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
hemodynamic	hemodynamic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
flestolol	flestolol	NOUN	NN	_	B-Chemical
are	be	VERB	VBP	5	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
other	other	ADJ	JJ	5	O
beta	beta	NOUN	NN	9	O
blockers	blocker	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
beta	beta	NOUN	NN	9	O
blockers	blocker	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
flestolol	flestolol	NOUN	NN	_	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
effects	effect	NOUN	NNS	9	O
reverse	reverse	VERB	VBP	9	O
rapidly	rapidly	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
within	within	ADP	IN	9	O
30	30	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
following	follow	VERB	VBG	9	O
discontinuation	discontinuation	NOUN	NN	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
short	short	ADJ	JJ	5	O
half	half	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
life	life	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Flestolol	Flestolol	PROPN	NNP	_	B-Chemical
effectively	effectively	ADV	RB	5	O
reduced	reduce	VERB	VBD	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
supraventricular	supraventricular	ADJ	JJ	5	B-Disease
tachyarrhythmia	tachyarrhythmia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
unstable	unstable	ADJ	JJ	5	B-Disease
angina	angina	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
flestolol	flestolol	NOUN	NN	_	B-Chemical
infusion	infusion	NOUN	NN	0	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
safe	safe	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
controlling	control	VERB	VBG	9	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
flestolol	flestolol	NOUN	NN	_	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
potent	potent	ADJ	JJ	3	O
,	,	PUNCT	,	9	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
tolerated	tolerate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
ultra	ultra	ADJ	JJ	0	O
-	-	ADJ	JJ	7	O
short	short	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
acting	act	VERB	VBG	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	NOUN	NN	9	O
blocking	block	VERB	VBG	3	O
agent	agent	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
flestolol	flestolol	NOUN	NN	_	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
critical	critical	ADJ	JJ	9	O
care	care	NOUN	NN	5	O
setting	setting	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
currently	currently	ADV	RB	5	O
undergoing	undergo	VERB	VBG	9	O
investigation	investigation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Immunohistochemical	immunohistochemical	ADV	RB	3	O
,	,	PUNCT	,	9	O
electron	electron	NOUN	NN	0	O
microscopic	microscopic	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
morphometric	morphometric	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
rat	rat	NOUN	NN	3	O
prolactinomas	prolactinoma	NOUN	NNS	5	B-Disease
after	after	ADP	IN	9	O
bromocriptine	bromocriptine	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
clarify	clarify	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
bromocriptine	bromocriptine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
prolactinoma	prolactinoma	ADJ	JJ	5	B-Disease
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
immunohistochemical	immunohistochemical	ADJ	JJ	3	O
,	,	PUNCT	,	9	O
ultrastructural	ultrastructural	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
morphometrical	morphometrical	ADJ	JJ	5	O
analyses	analysis	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
applied	apply	VERB	VBN	5	O
to	to	ADP	IN	5	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
rat	rat	NOUN	NN	3	O
prolactinoma	prolactinoma	NOUN	NN	5	B-Disease
cells	cell	NOUN	NNS	3	O
1	1	NUM	CD	9	O
h	h	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
bromocriptine	bromocriptine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
of	of	ADP	IN	5	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
serum	serum	ADJ	JJ	9	O
prolactin	prolactin	NOUN	NN	3	O
levels	level	NOUN	NNS	3	O
decreased	decrease	VERB	VBD	9	O
markedly	markedly	ADV	RB	9	O
.	.	PUNCT	.	9	O

Electron	Electron	PROPN	NNP	0	O
microscopy	microscopy	NOUN	NN	9	O
disclosed	disclose	VERB	VBD	9	O
many	many	ADJ	JJ	5	O
secretory	secretory	ADJ	JJ	3	O
granules	granule	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
slightly	slightly	ADV	RB	9	O
distorted	distort	VERB	VBD	5	O
rough	rough	ADJ	JJ	5	O
endoplasmic	endoplasmic	ADJ	JJ	3	O
reticulum	reticulum	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
partially	partially	ADV	RB	9	O
dilated	dilate	VERB	VBD	5	O
Golgi	Golgi	PROPN	NNP	9	O
cisternae	cisterna	NOUN	NNS	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
prolactinoma	prolactinoma	ADJ	JJ	5	B-Disease
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Morphometric	morphometric	ADJ	JJ	9	O
analysis	analysis	NOUN	NN	9	O
revealed	reveal	VERB	VBD	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
volume	volume	NOUN	NN	9	O
density	density	NOUN	NN	9	O
of	of	ADP	IN	5	O
secretory	secretory	ADJ	JJ	3	O
granules	granule	NOUN	NNS	9	O
increased	increase	VERB	VBD	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
the	the	DET	DT	5	O
volume	volume	NOUN	NN	9	O
density	density	NOUN	NN	9	O
of	of	ADP	IN	5	O
cytoplasmic	cytoplasmic	ADJ	JJ	3	O
microtubules	microtubule	NOUN	NNS	9	O
decreased	decrease	VERB	VBD	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
lowered	lower	VERB	VBD	9	O
serum	serum	ADJ	JJ	9	O
prolactin	prolactin	NOUN	NN	3	O
levels	level	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
early	early	ADJ	JJ	9	O
phase	phase	NOUN	NN	5	O
of	of	ADP	IN	5	O
bromocriptine	bromocriptine	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
may	may	VERB	MD	5	O
result	result	VERB	VB	9	O
from	from	ADP	IN	9	O
an	an	DET	DT	5	O
impaired	impaired	ADJ	JJ	9	O
secretion	secretion	NOUN	NN	3	O
of	of	ADP	IN	5	O
prolactin	prolactin	NOUN	NN	3	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
decreasing	decrease	VERB	VBG	9	O
numbers	number	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cytoplasmic	cytoplasmic	ADJ	JJ	3	O
microtubules	microtubule	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
6	6	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
injection	injection	NOUN	NN	9	O
,	,	PUNCT	,	9	O
serum	serum	ADJ	JJ	9	O
prolactin	prolactin	NOUN	NN	3	O
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
still	still	ADV	RB	5	O
considerably	considerably	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
prolactinoma	prolactinoma	ADJ	JJ	5	B-Disease
cells	cell	NOUN	NNS	3	O
at	at	ADP	IN	9	O
this	this	DET	DT	5	O
time	time	NOUN	NN	5	O
were	be	VERB	VBD	9	O
well	well	ADV	RB	9	O
granulated	granulate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
vesiculated	vesiculated	ADJ	JJ	5	O
rough	rough	ADJ	JJ	5	O
endoplasmic	endoplasmic	ADJ	JJ	3	O
reticulum	reticulum	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
markedly	markedly	ADV	RB	9	O
dilated	dilate	VERB	VBN	5	O
Golgi	Golgi	PROPN	NNP	9	O
cisternae	cisterna	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Electron	Electron	PROPN	NNP	0	O
microscopical	microscopical	ADJ	JJ	9	O
immunohistochemistry	immunohistochemistry	NOUN	NN	3	O
revealed	reveal	VERB	VBD	9	O
positive	positive	ADJ	JJ	9	O
reaction	reaction	NOUN	NN	9	O
products	product	NOUN	NNS	9	O
noted	note	VERB	VBN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
secretory	secretory	ADJ	JJ	3	O
granules	granule	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
Golgi	Golgi	PROPN	NNP	9	O
cisternae	cisterna	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
endoplasmic	endoplasmic	ADJ	JJ	3	O
reticulum	reticulum	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
untreated	untreated	ADJ	JJ	3	O
rat	rat	NOUN	NN	3	O
prolactinoma	prolactinoma	ADJ	JJ	5	B-Disease
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
only	only	ADV	RB	9	O
secretory	secretory	ADJ	JJ	3	O
granules	granule	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
the	the	DET	DT	5	O
positive	positive	ADJ	JJ	9	O
reaction	reaction	NOUN	NN	9	O
products	product	NOUN	NNS	9	O
for	for	ADP	IN	5	O
prolactin	prolactin	NOUN	NN	3	O
6	6	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
bromocriptine	bromocriptine	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
adenoma	adenoma	NOUN	NN	9	B-Disease
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
volume	volume	NOUN	NN	9	O
density	density	NOUN	NN	9	O
of	of	ADP	IN	5	O
secretory	secretory	ADJ	JJ	3	O
granules	granule	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
volume	volume	NOUN	NN	9	O
densities	density	NOUN	NNS	9	O
of	of	ADP	IN	5	O
rough	rough	ADJ	JJ	5	O
endoplasmic	endoplasmic	ADJ	JJ	3	O
reticulum	reticulum	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
microtubules	microtubule	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
morphometric	morphometric	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
that	that	ADP	IN	5	O
bromocriptine	bromocriptine	NOUN	NN	0	B-Chemical
inhibits	inhibit	VERB	VBZ	3	O
protein	protein	NOUN	NN	1	O
synthesis	synthesis	NOUN	NN	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
bringing	bring	VERB	VBG	5	O
about	about	PART	RP	5	O
a	a	DET	DT	5	O
disturbance	disturbance	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
prolactin	prolactin	NOUN	NN	3	O
secretion	secretion	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Sulfasalazine	Sulfasalazine	PROPN	NNP	7	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
lupus	lupus	NOUN	NN	9	B-Disease
erythematosus	erythematosus	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Pneumonitis	Pneumonitis	PROPN	NNP	7	B-Disease
,	,	PUNCT	,	9	O
bilateral	bilateral	ADJ	JJ	5	O
pleural	pleural	ADJ	JJ	5	B-Disease
effusions	effusion	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
echocardiographic	echocardiographic	ADJ	JJ	5	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
tamponade	tamponade	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
positive	positive	ADJ	JJ	9	O
autoantibodies	autoantibody	NOUN	NNS	3	O
developed	develop	VERB	VBD	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
43	43	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
was	be	VERB	VBD	9	O
receiving	receive	VERB	VBG	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
sulfasalazine	sulfasalazine	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
ulcerative	ulcerative	ADJ	JJ	5	B-Disease
colitis	colitis	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
sulfasalazine	sulfasalazine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
completion	completion	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
six	six	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
corticosteroids	corticosteroid	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
these	these	DET	DT	5	O
problems	problem	NOUN	NNS	5	O
resolved	resolve	VERB	VBD	9	O
over	over	ADP	IN	5	O
a	a	DET	DT	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
four	four	NUM	CD	9	O
to	to	PART	TO	5	O
six	six	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
sulfasalazine	sulfasalazine	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
lupus	lupus	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
manifested	manifest	VERB	VBD	9	O
with	with	ADP	IN	5	O
serositis	serositis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
pulmonary	pulmonary	ADJ	JJ	5	O
parenchymal	parenchymal	ADJ	JJ	5	O
involvement	involvement	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
joint	joint	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Physicians	physician	NOUN	NNS	5	O
who	who	PRON	WP	5	O
use	use	VERB	VBP	5	O
sulfasalazine	sulfasalazine	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
inflammatory	inflammatory	ADJ	JJ	3	B-Disease
bowel	bowel	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
sulfasalazine	sulfasalazine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
lupus	lupus	NOUN	NN	9	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Chronic	chronic	ADJ	JJ	9	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
:	:	PUNCT	:	9	O
efficacy	efficacy	NOUN	NN	9	O
,	,	PUNCT	,	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
tissue	tissue	VERB	VB	9	O
folate	folate	ADJ	JJ	9	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Folate	folate	ADJ	JJ	7	B-Chemical
depletion	depletion	NOUN	NN	3	O
has	have	VERB	VBZ	9	O
often	often	ADV	RB	5	O
been	be	VERB	VBN	9	O
a	a	DET	DT	5	O
problem	problem	NOUN	NN	5	O
in	in	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
antiepileptic	antiepileptic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
AED	AED	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Carbamazepine	Carbamazepine	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CBZ	CBZ	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
commonly	commonly	ADV	RB	5	O
used	use	VERB	VBN	5	O
AED	aed	NOUN	NN	5	O
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
rat	rat	NOUN	NN	3	O
model	model	NOUN	NN	5	O
was	be	VERB	VBD	9	O
developed	develop	VERB	VBN	5	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
CBZ	cbz	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
on	on	ADP	IN	5	O
folate	folate	ADJ	JJ	9	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
this	this	DET	DT	5	O
model	model	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
common	common	ADJ	JJ	5	O
vehicle	vehicle	NOUN	NN	3	O
,	,	PUNCT	,	9	O
propylene	propylene	NOUN	NN	0	B-Chemical
glycol	glycol	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
by	by	ADP	IN	9	O
itself	-PRON-	PRON	PRP	9	O
in	in	ADP	IN	5	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
exhibit	exhibit	VERB	VB	9	O
protective	protective	ADJ	JJ	9	O
properties	property	NOUN	NNS	9	O
against	against	ADP	IN	9	O
induced	induced	ADJ	JJ	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
inhibited	inhibited	ADJ	JJ	3	O
weight	weight	NOUN	NN	9	B-Disease
gain	gain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Seizures	seizure	NOUN	NNS	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
hexafluorodiethyl	hexafluorodiethyl	NOUN	NN	_	B-Chemical
ether	ether	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
HFDE	HFDE	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
more	more	ADV	RBR	5	O
sensitive	sensitive	ADJ	JJ	9	O
measure	measure	NOUN	NN	5	O
of	of	ADP	IN	5	O
protection	protection	NOUN	NN	9	O
by	by	ADP	IN	9	O
CBZ	CBZ	PROPN	NNP	0	B-Chemical
than	than	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
maximal	maximal	ADJ	JJ	9	O
electroshock	electroshock	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MES	MES	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Oral	oral	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
CBZ	CBZ	PROPN	NNP	0	B-Chemical
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
aqueous	aqueous	ADJ	JJ	0	O
suspension	suspension	NOUN	NN	0	O
every	every	DET	DT	5	O
8	8	NUM	CD	9	O
h	h	NOUN	NN	0	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
250	250	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
was	be	VERB	VBD	9	O
continuously	continuously	ADV	RB	5	O
protective	protective	ADJ	JJ	9	O
against	against	ADP	IN	9	O
HFDE	hfde	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
minimally	minimally	ADV	RB	5	O
toxic	toxic	ADJ	JJ	0	O
as	as	ADP	IN	5	O
measured	measure	VERB	VBN	9	O
by	by	ADP	IN	9	O
weight	weight	NOUN	NN	9	B-Disease
gain	gain	NOUN	NN	5	I-Disease
over	over	ADP	IN	5	O
8	8	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
CBZ	CBZ	PROPN	NNP	0	B-Chemical
levels	level	NOUN	NNS	3	O
measured	measure	VERB	VBN	9	O
in	in	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
brain	brain	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
below	below	ADP	IN	9	O
those	those	DET	DT	5	O
normally	normally	ADV	RB	9	O
considered	consider	VERB	VBN	5	O
protective	protective	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
CBZ	CBZ	PROPN	NNP	0	B-Chemical
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
apparent	apparent	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
folate	folate	ADJ	JJ	9	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
indeed	indeed	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
folate	folate	ADJ	JJ	9	B-Chemical
concentration	concentration	NOUN	NN	0	O
increased	increase	VERB	VBD	9	O
in	in	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
after	after	ADP	IN	9	O
6	6	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
at	at	ADP	IN	9	O
8	8	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Dipyridamole	Dipyridamole	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Angina	angina	ADJ	JJ	7	B-Disease
and	and	CCONJ	CC	5	O
ischemic	ischemic	ADJ	JJ	9	O
electrocardiographic	electrocardiographic	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
occurred	occur	VERB	VBD	9	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
dipyridamole	dipyridamole	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
awaiting	await	VERB	VBG	5	O
urgent	urgent	ADJ	JJ	5	O
myocardial	myocardial	ADJ	JJ	9	O
revascularization	revascularization	NOUN	NN	5	O
procedures	procedure	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
knowledge	knowledge	NOUN	NN	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
previously	previously	ADV	RB	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
preoperative	preoperative	ADJ	JJ	5	O
dipyridamole	dipyridamole	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
dipyridamole	dipyridamole	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
ischemia	ischemia	NOUN	NN	9	I-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
demonstrated	demonstrate	VERB	VBN	9	O
to	to	PART	TO	5	O
occur	occur	VERB	VB	5	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
humans	human	NOUN	NNS	9	O
with	with	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Epicardial	epicardial	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
collateral	collateral	NOUN	NN	5	O
vessels	vessel	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
demonstrated	demonstrate	VERB	VBN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
a	a	DET	DT	5	O
coronary	coronary	ADJ	JJ	5	O
"	"	PUNCT	``	5	O
steal	steal	ADJ	JJ	5	O
"	"	PUNCT	''	5	O
phenomenon	phenomenon	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
dipyridamole	dipyridamole	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
ischemia	ischemia	NOUN	NN	9	B-Disease
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
sympathoadrenal	sympathoadrenal	ADJ	JJ	3	O
activity	activity	NOUN	NN	9	O
by	by	ADP	IN	9	O
atrial	atrial	ADJ	JJ	5	O
natriuretic	natriuretic	ADJ	JJ	9	O
factor	factor	NOUN	NN	9	O
in	in	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
six	six	NUM	CD	9	O
conscious	conscious	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
trained	train	VERB	VBN	5	O
dogs	dog	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
maintained	maintain	VERB	VBD	9	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
intake	intake	NOUN	NN	5	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
to	to	PART	TO	5	O
4	4	NUM	CD	9	O
mEq	mEq	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
sympathetic	sympathetic	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
release	release	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
during	during	ADP	IN	5	O
15	15	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
minute	minute	NOUN	NN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
infusions	infusion	NOUN	NNS	9	O
of	of	ADP	IN	5	O
human	human	ADJ	JJ	3	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
atrial	atrial	ADJ	JJ	5	O
natriuretic	natriuretic	ADJ	JJ	9	O
factor	factor	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Mean	mean	VERB	VB	9	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
percentage	percentage	NOUN	NN	9	O
of	of	ADP	IN	5	O
control	control	NOUN	NN	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SEM	SEM	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
during	during	ADP	IN	5	O
randomized	randomize	VERB	VBN	5	O
infusions	infusion	NOUN	NNS	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	NOUN	NN	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
microgram	microgram	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
was	be	VERB	VBD	9	O
99	99	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
95	95	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
93	93	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
79	79	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
no	no	DET	DT	9	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
augmentation	augmentation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
release	release	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
up	up	ADP	IN	5	O
to	to	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
microgram	microgram	NOUN	NN	0	O
/	/	PUNCT	,	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
in	in	ADP	IN	5	O
contrast	contrast	NOUN	NN	9	O
to	to	ADP	IN	5	O
comparable	comparable	ADJ	JJ	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
hydralazine	hydralazine	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
nitroglycerin	nitroglycerin	ADJ	JJ	5	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
release	release	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
control	control	NOUN	NN	9	O
,	,	PUNCT	,	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
ng	ng	ADP	IN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
declined	decline	VERB	VBD	9	O
immediately	immediately	ADV	RB	9	O
during	during	ADP	IN	5	O
infusions	infusion	NOUN	NNS	9	O
of	of	ADP	IN	5	O
atrial	atrial	ADJ	JJ	5	O
natriuretic	natriuretic	ADJ	JJ	9	O
factor	factor	NOUN	NN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
minimum	minimum	NOUN	NN	5	O
of	of	ADP	IN	5	O
49	49	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
control	control	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	X	XX	7	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
during	during	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
microgram	microgram	NOUN	NN	0	O
/	/	PUNCT	,	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
to	to	ADP	IN	5	O
63	63	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
p	p	X	XX	7	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
95	95	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
13	13	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
not	not	ADV	RB	5	O
significant	significant	ADJ	JJ	9	O
)	)	PUNCT	-RRB-	9	O
during	during	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
or	or	CCONJ	CC	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
microgram	microgram	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Steady	steady	ADJ	JJ	9	O
state	state	NOUN	NN	5	O
arterial	arterial	ADJ	JJ	5	O
plasma	plasma	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
atrial	atrial	ADJ	JJ	5	O
natriuretic	natriuretic	ADJ	JJ	9	O
factor	factor	NOUN	NN	9	O
were	be	VERB	VBD	9	O
39	39	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
10	10	NUM	CD	9	O
pg	pg	NOUN	NN	7	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
during	during	ADP	IN	5	O
infusions	infusion	NOUN	NNS	9	O
of	of	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
284	284	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
24	24	NUM	CD	9	O
pg	pg	NOUN	NN	7	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
1520	1520	NUM	CD	7	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
300	300	NUM	CD	0	O
pg	pg	NOUN	NN	7	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
during	during	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
and	and	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
microgram	microgram	NOUN	NN	0	O
/	/	PUNCT	,	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
infusions	infusion	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
factor	factor	NOUN	NN	9	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
250	250	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

Inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
immunoreactive	immunoreactive	ADJ	JJ	3	O
corticotropin	corticotropin	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
releasing	release	VERB	VBG	9	O
factor	factor	NOUN	NN	9	O
secretion	secretion	NOUN	NN	3	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
hypophysial	hypophysial	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
portal	portal	ADJ	JJ	5	O
circulation	circulation	NOUN	NN	9	O
by	by	ADP	IN	9	O
delayed	delay	VERB	VBN	9	O
glucocorticoid	glucocorticoid	NOUN	NN	9	O
feedback	feedback	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Nitroprusside	nitroprusside	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
evokes	evoke	VERB	VBZ	5	O
ACTH	ACTH	PROPN	NNP	0	O
secretion	secretion	NOUN	NN	3	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
primarily	primarily	ADV	RB	9	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
enhanced	enhance	VERB	VBN	3	O
secretion	secretion	NOUN	NN	3	O
of	of	ADP	IN	5	O
immunoreactive	immunoreactive	ADJ	JJ	3	O
corticotropin	corticotropin	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
releasing	release	VERB	VBG	9	O
factor	factor	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
irCRF	ircrf	NOUN	NN	_	O
)	)	PUNCT	-RRB-	9	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
hypophysial	hypophysial	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
portal	portal	ADJ	JJ	5	O
circulation	circulation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Portal	portal	ADJ	JJ	2	O
plasma	plasma	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
neither	neither	DET	DT	9	O
arginine	arginine	NOUN	NN	0	B-Chemical
vasopressin	vasopressin	NOUN	NN	9	I-Chemical
nor	nor	CCONJ	CC	9	O
oxytocin	oxytocin	NOUN	NN	5	B-Chemical
are	be	VERB	VBP	5	O
significantly	significantly	ADV	RB	9	O
altered	alter	VERB	VBN	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
paradigm	paradigm	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Application	application	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
delayed	delay	VERB	VBN	9	O
feedback	feedback	NOUN	NN	5	O
signal	signal	NOUN	NN	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
form	form	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
h	h	DET	DT	0	O
systemic	systemic	ADJ	JJ	9	O
corticosterone	corticosterone	NOUN	NN	3	B-Chemical
infusion	infusion	NOUN	NN	0	O
in	in	ADP	IN	5	O
urethane	urethane	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
anesthetized	anesthetized	ADJ	JJ	0	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
pharmacological	pharmacological	ADJ	JJ	9	O
blockade	blockade	NOUN	NN	3	O
of	of	ADP	IN	5	O
glucocorticoid	glucocorticoid	ADJ	JJ	9	O
synthesis	synthesis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
without	without	ADP	IN	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
resting	rest	VERB	VBG	5	O
secretion	secretion	NOUN	NN	3	O
of	of	ADP	IN	5	O
arginine	arginine	NOUN	NN	0	B-Chemical
vasopressin	vasopressin	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
oxytocin	oxytocin	NOUN	NN	5	B-Chemical
at	at	ADP	IN	9	O
any	any	DET	DT	5	O
corticosterone	corticosterone	NOUN	NN	3	B-Chemical
feedback	feedback	NOUN	NN	5	O
dose	dose	NOUN	NN	9	O
tested	test	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Resting	rest	VERB	VBG	9	O
irCRF	ircrf	NUM	CD	_	O
levels	level	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
suppressed	suppress	VERB	VBN	3	O
only	only	ADV	RB	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
highest	high	ADJ	JJS	9	O
corticosterone	corticosterone	ADJ	JJ	3	B-Chemical
infusion	infusion	NOUN	NN	0	O
rate	rate	NOUN	NN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	O
corticosterone	corticosterone	NOUN	NN	3	B-Chemical
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
40	40	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
.	.	PUNCT	.	9	O

Suppression	suppression	NOUN	NN	9	O
of	of	ADP	IN	5	O
irCRF	irCRF	PROPN	NNP	_	O
secretion	secretion	NOUN	NN	3	O
in	in	ADP	IN	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
nitroprusside	nitroprusside	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
observed	observe	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
occurs	occur	VERB	VBZ	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
corticosterone	corticosterone	NOUN	NN	3	B-Chemical
level	level	NOUN	NN	9	O
between	between	ADP	IN	5	O
8	8	NUM	CD	9	O
-	-	SYM	SYM	7	O
12	12	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
studies	study	NOUN	NNS	9	O
provide	provide	VERB	VBP	5	O
further	further	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
strong	strong	ADJ	JJ	9	O
central	central	ADJ	JJ	5	O
component	component	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
delayed	delay	VERB	VBN	9	O
feedback	feedback	NOUN	NN	5	O
process	process	NOUN	NN	5	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
modulation	modulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
irCRF	ircrf	NOUN	NN	_	O
release	release	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Noradrenergic	noradrenergic	ADJ	JJ	5	O
involvement	involvement	NOUN	NN	9	O
in	in	ADP	IN	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
delta	delta	NOUN	NN	9	B-Chemical
9	9	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tetrahydrocannabinol	tetrahydrocannabinol	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
elucidate	elucidate	VERB	VB	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
catecholaminergic	catecholaminergic	ADJ	JJ	3	O
system	system	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cataleptogenic	cataleptogenic	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
delta	delta	NOUN	NN	9	B-Chemical
9	9	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tetrahydrocannabinol	tetrahydrocannabinol	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
THC	THC	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
6	6	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxydopamine	hydroxydopamine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
OHDA	ohda	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
with	with	ADP	IN	5	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
OHDA	ohda	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
lesions	lesion	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
locus	locus	NOUN	NN	1	O
coeruleus	coeruleus	NOUN	NN	4	O
were	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cataleptogenic	cataleptogenic	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
THC	THC	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
6	6	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
OHDA	ohda	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
lesions	lesion	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
locus	locus	NOUN	NN	1	O
coeruleus	coeruleus	NOUN	NN	4	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
OHDA	ohda	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
contrary	contrary	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
cataleptogenic	cataleptogenic	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
OHDA	ohda	NOUN	NN	0	I-Chemical
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
6	6	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
OHDA	ohda	NOUN	NN	0	I-Chemical
or	or	CCONJ	CC	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
lesions	lesion	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
locus	locus	NOUN	NN	1	O
coeruleus	coeruleus	NOUN	NN	4	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
noradrenergic	noradrenergic	ADJ	JJ	5	O
neurons	neuron	NOUN	NNS	3	O
have	have	VERB	VBP	5	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
manifestation	manifestation	NOUN	NN	5	O
of	of	ADP	IN	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
THC	THC	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
neurons	neuron	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
important	important	ADJ	JJ	9	O
in	in	ADP	IN	5	O
catalepsy	catalepsy	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Reversibility	reversibility	NOUN	NN	0	O
of	of	ADP	IN	5	O
captopril	captopril	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
renal	renal	ADJ	JJ	9	B-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
after	after	ADP	IN	9	O
prolonged	prolong	VERB	VBN	9	O
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
unusual	unusual	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
renovascular	renovascular	ADJ	JJ	5	B-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
occluded	occluded	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	O
artery	artery	NOUN	NN	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
solitary	solitary	ADJ	JJ	5	O
kidney	kidney	NOUN	NN	9	O
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
sudden	sudden	ADJ	JJ	5	B-Disease
deterioration	deterioration	NOUN	NN	5	I-Disease
of	of	ADP	IN	5	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
function	function	NOUN	NN	9	I-Disease
following	follow	VERB	VBG	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
captopril	captopril	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

His	-PRON-	DET	PRP$	9	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
remained	remain	VERB	VBD	9	O
impaired	impaired	ADJ	JJ	9	O
but	but	CCONJ	CC	9	O
stable	stable	ADJ	JJ	9	O
during	during	ADP	IN	5	O
2	2	NUM	CD	9	O
years	year	NOUN	NNS	5	O
'	'	PART	POS	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
captopril	captopril	NOUN	NN	0	B-Chemical
but	but	CCONJ	CC	9	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
treatment	treatment	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
soon	soon	ADV	RB	5	O
after	after	ADP	IN	9	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
indicates	indicate	VERB	VBZ	9	O
reversibility	reversibility	NOUN	NN	9	O
in	in	ADP	IN	5	O
captopril	captopril	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
even	even	ADV	RB	5	O
after	after	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
prolonged	prolonged	ADJ	JJ	9	O
use	use	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
no	no	DET	DT	9	O
organic	organic	ADJ	JJ	0	O
damage	damage	NOUN	NN	9	O
occurs	occur	VERB	VBZ	9	O
to	to	PART	TO	5	O
glomerular	glomerular	VERB	VB	5	O
arterioles	arteriole	NOUN	NNS	9	O
following	follow	VERB	VBG	9	O
chronic	chronic	ADJ	JJ	5	O
ACE	ACE	PROPN	NNP	9	O
inhibition	inhibition	NOUN	NN	3	O
.	.	PUNCT	.	9	O

HMG	HMG	PROPN	NNP	1	O
CoA	CoA	PROPN	NNP	0	O
reductase	reductase	NOUN	NN	0	O
inhibitors	inhibitor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Current	current	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
experience	experience	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Lovastatin	Lovastatin	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
the	the	DET	DT	5	O
2	2	NUM	CD	9	O
best	best	ADV	RBS	5	O
-	-	PUNCT	HYPH	7	O
known	know	VERB	VBN	9	O
members	member	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
class	class	NOUN	NN	9	O
of	of	ADP	IN	5	O
hypolipidaemic	hypolipidaemic	ADJ	JJ	0	O
agents	agent	NOUN	NNS	5	O
known	know	VERB	VBN	9	O
as	as	ADP	IN	5	O
HMG	HMG	PROPN	NNP	1	O
CoA	CoA	PROPN	NNP	0	O
reductase	reductase	NOUN	NN	0	O
inhibitors	inhibitor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
experience	experience	NOUN	NN	5	O
with	with	ADP	IN	5	O
lovastatin	lovastatin	NOUN	NN	0	B-Chemical
includes	include	VERB	VBZ	5	O
over	over	ADP	IN	5	O
5000	5000	NUM	CD	0	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
700	700	NUM	CD	9	O
of	of	ADP	IN	5	O
whom	whom	PRON	WP	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
treated	treat	VERB	VBN	3	O
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
years	year	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
experience	experience	NOUN	NN	5	O
with	with	ADP	IN	5	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
includes	include	VERB	VBZ	5	O
over	over	ADP	IN	5	O
3500	3500	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
of	of	ADP	IN	5	O
whom	whom	PRON	WP	5	O
350	350	NUM	CD	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
treated	treat	VERB	VBN	3	O
for	for	ADP	IN	5	O
18	18	NUM	CD	7	O
months	month	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
.	.	PUNCT	.	9	O

Lovastatin	Lovastatin	PROPN	NNP	0	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
marketed	market	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
United	United	PROPN	NNP	9	O
States	States	PROPN	NNP	9	O
for	for	ADP	IN	5	O
over	over	ADP	IN	5	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
agents	agent	NOUN	NNS	5	O
show	show	VERB	VBP	9	O
substantial	substantial	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
efficacy	efficacy	NOUN	NN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
reductions	reduction	NOUN	NNS	9	O
in	in	ADP	IN	5	O
total	total	ADJ	JJ	9	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
of	of	ADP	IN	5	O
over	over	ADP	IN	5	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
LDL	LDL	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
of	of	ADP	IN	5	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Modest	modest	ADJ	JJ	9	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
HDL	HDL	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
about	about	ADV	RB	5	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
are	be	VERB	VBP	5	O
also	also	ADV	RB	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
tolerability	tolerability	NOUN	NN	5	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
agents	agent	NOUN	NNS	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
good	good	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
fewer	few	ADJ	JJR	5	O
than	than	ADP	IN	5	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
withdrawn	withdraw	VERB	VBN	9	O
from	from	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
experiences	experience	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Ophthalmological	ophthalmological	ADJ	JJ	2	O
examinations	examination	NOUN	NNS	5	O
in	in	ADP	IN	5	O
over	over	ADP	IN	5	O
1100	1100	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
one	one	NUM	CD	5	O
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
have	have	VERB	VBP	5	O
revealed	reveal	VERB	VBN	9	O
no	no	DET	DT	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
short	short	ADJ	JJ	5	O
term	term	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
2	2	NUM	CD	9	O
years	year	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
cataractogenic	cataractogenic	NOUN	NN	3	O
potential	potential	NOUN	NN	9	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
elevations	elevation	NOUN	NNS	9	O
of	of	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
transaminases	transaminase	NOUN	NNS	9	O
to	to	ADP	IN	5	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
3	3	NUM	CD	9	O
times	time	NOUN	NNS	5	O
the	the	DET	DT	5	O
upper	upper	ADJ	JJ	9	O
limit	limit	NOUN	NN	5	O
of	of	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
episodes	episode	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
asymptomatic	asymptomatic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
reversible	reversible	ADJ	JJ	9	O
when	when	ADV	WRB	5	O
therapy	therapy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
discontinued	discontinue	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Minor	minor	ADJ	JJ	9	O
elevations	elevation	NOUN	NNS	9	O
of	of	ADP	IN	5	O
creatine	creatine	NOUN	NN	0	B-Chemical
kinase	kinase	NOUN	NN	3	O
levels	level	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
about	about	ADV	RB	5	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Myopathy	Myopathy	PROPN	NNP	7	B-Disease
,	,	PUNCT	,	9	O
associated	associate	VERB	VBN	9	O
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
cases	case	NOUN	NNS	5	O
with	with	ADP	IN	5	O
myoglobinuria	myoglobinuria	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
with	with	ADP	IN	5	O
transient	transient	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
rarely	rarely	ADV	RB	5	O
reported	report	VERB	VBN	9	O
with	with	ADP	IN	5	O
lovastatin	lovastatin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
concomitantly	concomitantly	ADV	RB	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
cyclosporin	cyclosporin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
gemfibrozil	gemfibrozil	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
niacin	niacin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Lovastatin	Lovastatin	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
simvastatin	simvastatin	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
both	both	DET	DT	9	O
effective	effective	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
tolerated	tolerate	VERB	VBN	9	O
agents	agent	NOUN	NNS	5	O
for	for	ADP	IN	5	O
lowering	lower	VERB	VBG	9	O
elevated	elevated	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
wider	wide	ADJ	JJR	5	O
use	use	NOUN	NN	5	O
confirms	confirm	VERB	VBZ	9	O
their	-PRON-	DET	PRP$	5	O
safety	safety	NOUN	NN	5	O
profile	profile	NOUN	NN	9	O
,	,	PUNCT	,	9	O
they	-PRON-	PRON	PRP	5	O
will	will	VERB	MD	5	O
gain	gain	VERB	VB	5	O
increasing	increase	VERB	VBG	9	O
importance	importance	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
approach	approach	NOUN	NN	5	O
to	to	ADP	IN	5	O
hypercholesterolaemia	hypercholesterolaemia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
consequences	consequence	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Hepatic	hepatic	ADJ	JJ	9	O
reactions	reaction	NOUN	NNS	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
ketoconazole	ketoconazole	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
United	United	PROPN	NNP	9	O
Kingdom	Kingdom	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

Ketoconazole	Ketoconazole	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
introduced	introduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
United	United	PROPN	NNP	9	O
Kingdom	Kingdom	PROPN	NNP	2	O
in	in	ADP	IN	5	O
1981	1981	NUM	CD	2	O
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
November	November	PROPN	NNP	2	O
1984	1984	NUM	CD	2	O
the	the	DET	DT	5	O
Committee	Committee	PROPN	NNP	2	O
on	on	ADP	IN	5	O
Safety	Safety	PROPN	NNP	5	O
of	of	ADP	IN	5	O
Medicines	Medicines	PROPN	NNPS	5	O
had	have	VERB	VBD	9	O
received	receive	VERB	VBN	9	O
82	82	NUM	CD	7	O
reports	report	NOUN	NNS	9	O
of	of	ADP	IN	5	O
possible	possible	ADJ	JJ	5	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
five	five	NUM	CD	9	O
deaths	death	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
75	75	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
that	that	DET	WDT	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
adequately	adequately	ADV	RB	5	O
followed	follow	VERB	VBN	9	O
up	up	PART	RP	5	O
suggested	suggest	VERB	VBD	9	O
that	that	ADP	IN	5	O
16	16	NUM	CD	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
three	three	NUM	CD	9	O
deaths	death	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
probably	probably	ADV	RB	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
remainder	remainder	NOUN	NN	9	O
,	,	PUNCT	,	9	O
48	48	NUM	CD	9	O
were	be	VERB	VBD	9	O
possibly	possibly	ADV	RB	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
five	five	NUM	CD	9	O
were	be	VERB	VBD	9	O
unlikely	unlikely	ADJ	JJ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
so	so	ADV	RB	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
six	six	NUM	CD	9	O
were	be	VERB	VBD	9	O
unclassifiable	unclassifiable	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
16	16	NUM	CD	9	O
probable	probable	ADJ	JJ	9	O
cases	case	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
57	57	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
being	be	VERB	VBG	5	O
more	more	ADV	RBR	5	O
common	common	ADJ	JJ	5	O
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
average	average	ADJ	JJ	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
jaundice	jaundice	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
61	61	NUM	CD	7	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

None	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
well	well	ADV	RB	9	O
validated	validate	VERB	VBN	5	O
cases	case	NOUN	NNS	5	O
occurred	occur	VERB	VBD	9	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
10	10	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
liver	liver	NOUN	NN	9	O
function	function	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
suggested	suggest	VERB	VBD	9	O
hepatocellular	hepatocellular	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
63	63	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
rest	rest	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
mixed	mixed	ADJ	JJ	9	O
pattern	pattern	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
histological	histological	ADJ	JJ	9	O
examination	examination	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
often	often	ADV	RB	5	O
showed	show	VERB	VBD	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
cholestasis	cholestasis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
characteristics	characteristic	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
48	48	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
cases	case	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Allergic	allergic	ADJ	JJ	9	O
manifestations	manifestation	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
rash	rash	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
eosinophilia	eosinophilia	NOUN	NNS	3	B-Disease
were	be	VERB	VBD	9	O
rare	rare	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Hepatitis	Hepatitis	PROPN	NNP	9	B-Disease
was	be	VERB	VBD	9	O
usually	usually	ADV	RB	5	O
reversible	reversible	ADJ	JJ	9	O
when	when	ADV	WRB	5	O
treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
stopped	stop	VERB	VBN	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
function	function	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
returning	return	VERB	VBG	5	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
after	after	ADP	IN	9	O
an	an	DET	DT	5	O
average	average	NOUN	NN	5	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
two	two	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
three	three	NUM	CD	9	O
deaths	death	NOUN	NNS	5	B-Disease
probably	probably	ADV	RB	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
ketoconazole	ketoconazole	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
continued	continue	VERB	VBN	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
jaundice	jaundice	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
biochemical	biochemical	NOUN	NN	9	O
monitoring	monitoring	NOUN	NN	5	O
at	at	ADP	IN	9	O
regular	regular	ADJ	JJ	5	O
intervals	interval	NOUN	NNS	5	O
for	for	ADP	IN	5	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
advised	advise	VERB	VBN	5	O
during	during	ADP	IN	5	O
long	long	ADJ	JJ	5	O
term	term	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
ketoconazole	ketoconazole	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
possible	possible	ADJ	JJ	5	O
serious	serious	ADJ	JJ	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Glyburide	glyburide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
common	common	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
only	only	ADV	RB	9	O
infrequently	infrequently	ADV	RB	5	O
with	with	ADP	IN	5	O
sulfonylureas	sulfonylurea	NOUN	NNS	5	B-Chemical
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
glyburide	glyburide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
second	second	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
generation	generation	NOUN	NN	9	O
sulfonylurea	sulfonylurea	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
only	only	ADV	RB	9	O
two	two	NUM	CD	5	O
brief	brief	ADJ	JJ	5	O
reports	report	NOUN	NNS	9	O
of	of	ADP	IN	5	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
exist	exist	VERB	VBP	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
type	type	NOUN	NN	9	B-Disease
II	II	PROPN	NNP	9	I-Disease
diabetes	diabetes	NOUN	NN	5	I-Disease
mellitus	mellitus	NOUN	NN	9	I-Disease
developed	develop	VERB	VBD	5	O
an	an	DET	DT	5	O
acute	acute	ADJ	JJ	9	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
like	like	ADJ	JJ	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
soon	soon	ADV	RB	5	O
after	after	ADP	IN	9	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
glyburide	glyburide	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
serologic	serologic	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
viral	viral	ADJ	JJ	9	B-Disease
infection	infection	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
liver	liver	NOUN	NN	9	O
biopsy	biopsy	NOUN	NN	5	O
sample	sample	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
histologic	histologic	ADJ	JJ	9	O
pattern	pattern	NOUN	NN	9	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
drug	drug	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
induced	induce	VERB	VBN	3	I-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
recovered	recover	VERB	VBD	9	O
quickly	quickly	ADV	RB	5	O
after	after	ADP	IN	9	O
stopping	stop	VERB	VBG	5	O
glyburide	glyburide	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
have	have	VERB	VBP	5	O
remained	remain	VERB	VBN	9	O
well	well	ADV	RB	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Glyburide	Glyburide	PROPN	NNP	0	B-Chemical
can	can	VERB	MD	5	O
produce	produce	VERB	VB	9	O
an	an	DET	DT	5	O
acute	acute	ADJ	JJ	9	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
like	like	ADJ	JJ	9	I-Disease
illness	illness	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
some	some	DET	DT	5	O
persons	person	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Intracranial	intracranial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
increases	increase	VERB	VBZ	9	O
during	during	ADP	IN	5	O
alfentanil	alfentanil	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
rigidity	rigidity	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Intracranial	intracranial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
ICP	ICP	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
during	during	ADP	IN	5	O
alfentanil	alfentanil	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
rigidity	rigidity	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Ten	ten	NUM	CD	9	O
rats	rat	NOUN	NNS	9	O
had	have	VERB	VBD	9	O
arterial	arterial	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
central	central	ADJ	JJ	5	O
venous	venous	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
CVP	CVP	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
subdural	subdural	ADJ	JJ	5	O
cannulae	cannulae	NOUN	NN	5	O
inserted	insert	VERB	VBN	9	O
under	under	ADP	IN	9	O
halothane	halothane	NOUN	NN	0	B-Chemical
anesthesia	anesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
mechanically	mechanically	ADV	RB	5	O
ventilated	ventilate	VERB	VBN	5	O
to	to	PART	TO	5	O
achieve	achieve	VERB	VB	5	O
normocarbia	normocarbia	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
PCO2	PCO2	PROPN	NNP	9	O
=	=	SYM	SYM	7	O
42	42	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
mmHg	mmhg	SYM	SYM	7	O
,	,	PUNCT	,	9	O
mean	mean	ADJ	JJ	5	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SE	se	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Following	follow	VERB	VBG	9	O
instrumentation	instrumentation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
halothane	halothane	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
alfentanil	alfentanil	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
125	125	NUM	CD	9	O
mu	mu	NOUN	NNS	9	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
administered	administer	VERB	VBD	9	O
iv	iv	PRON	PRP	9	O
during	during	ADP	IN	5	O
emergence	emergence	NOUN	NN	9	O
from	from	ADP	IN	9	O
halothane	halothane	NOUN	NN	0	B-Chemical
anesthesia	anesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
five	five	NUM	CD	9	O
rats	rat	NOUN	NNS	9	O
that	that	DET	WDT	5	O
developed	develop	VERB	VBD	5	O
somatic	somatic	ADJ	JJ	9	B-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
ICP	ICP	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
CVP	CVP	PROPN	NNP	5	O
increased	increase	VERB	VBN	9	O
significantly	significantly	ADV	RB	9	O
above	above	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
delta	delta	NOUN	NN	9	O
ICP	ICP	PROPN	NNP	5	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mmHg	mmhg	SYM	SYM	7	O
,	,	PUNCT	,	9	O
delta	delta	NOUN	NN	9	O
CVP	cvp	ADP	IN	5	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
mmHg	mmHg	PROPN	NNP	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
variables	variable	NOUN	NNS	5	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
when	when	ADV	WRB	5	O
rigidity	rigidity	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
abolished	abolish	VERB	VBN	3	O
with	with	ADP	IN	5	O
metocurine	metocurine	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
five	five	NUM	CD	9	O
rats	rat	NOUN	NNS	9	O
that	that	DET	WDT	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
become	become	VERB	VB	5	O
rigid	rigid	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
ICP	ICP	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
CVP	CVP	PROPN	NNP	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
change	change	VERB	VB	9	O
following	follow	VERB	VBG	9	O
alfentanil	alfentanil	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
observations	observation	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
rigidity	rigidity	NOUN	NN	5	B-Disease
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
prevented	prevent	VERB	VBN	9	O
when	when	ADV	WRB	5	O
alfentanil	alfentanil	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
presumably	presumably	ADV	RB	9	O
,	,	PUNCT	,	9	O
other	other	ADJ	JJ	5	O
opiates	opiate	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
are	be	VERB	VBP	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
ICP	ICP	PROPN	NNP	5	O
problems	problem	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Verapamil	Verapamil	PROPN	NNP	0	B-Chemical
withdrawal	withdrawal	NOUN	NN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
coronary	coronary	ADJ	JJ	5	O
angiogram	angiogram	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Verapamil	Verapamil	PROPN	NNP	0	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
relatively	relatively	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
safe	safe	ADJ	JJ	5	O
antihypertensive	antihypertensive	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Serious	serious	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
uncommon	uncommon	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
mainly	mainly	ADV	RB	9	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
depression	depression	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
contractility	contractility	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
conduction	conduction	NOUN	NN	5	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blocking	block	VERB	VBG	3	O
agents	agent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
coincided	coincide	VERB	VBD	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
introduction	introduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
captopril	captopril	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
previously	previously	ADV	RB	9	O
asymptomatic	asymptomatic	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Possible	possible	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
that	that	DET	WDT	5	O
involve	involve	VERB	VBP	5	O
a	a	DET	DT	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
platelet	platelet	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
vascular	vascular	ADJ	JJ	5	O
alpha	alpha	NOUN	NN	9	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
adrenoreceptor	adrenoreceptor	NOUN	NN	0	O
affinity	affinity	NOUN	NN	0	O
for	for	ADP	IN	5	O
catecholamines	catecholamine	NOUN	NNS	9	B-Chemical
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Haemolytic	haemolytic	ADJ	JJ	0	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
uraemic	uraemic	ADJ	JJ	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
metronidazole	metronidazole	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
paper	paper	NOUN	NN	5	O
describes	describe	VERB	VBZ	5	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
six	six	NUM	CD	9	O
children	child	NOUN	NNS	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
the	the	DET	DT	5	O
haemolytic	haemolytic	ADJ	JJ	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
uraemic	uraemic	ADJ	JJ	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
metronidazole	metronidazole	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
children	child	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
older	old	ADJ	JJR	5	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
undergone	undergo	VERB	VBN	5	O
recent	recent	ADJ	JJ	5	O
bowel	bowel	NOUN	NN	5	O
surgery	surgery	NOUN	NN	5	O
than	than	ADP	IN	5	O
are	be	VERB	VBP	5	O
other	other	ADJ	JJ	5	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
this	this	DET	DT	5	O
condition	condition	NOUN	NN	5	O
.	.	PUNCT	.	9	O

While	while	ADP	IN	9	O
the	the	DET	DT	5	O
involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
metronidazole	metronidazole	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
aetiology	aetiology	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
haemolytic	haemolytic	ADJ	JJ	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
uraemic	uraemic	ADJ	JJ	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
established	establish	VERB	VBN	9	O
firmly	firmly	ADV	RB	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
in	in	ADP	IN	5	O
sensitizing	sensitize	VERB	VBG	3	O
tissues	tissue	NOUN	NNS	9	O
to	to	ADP	IN	5	O
oxidation	oxidation	NOUN	NN	0	O
injury	injury	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
reported	report	VERB	VBN	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
oxidation	oxidation	NOUN	NN	0	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
haemolytic	haemolytic	ADJ	JJ	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
uraemic	uraemic	ADJ	JJ	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
suggest	suggest	VERB	VBP	9	O
a	a	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
link	link	NOUN	NN	5	O
between	between	ADP	IN	5	O
metronidazole	metronidazole	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
some	some	DET	DT	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
haemolytic	haemolytic	ADJ	JJ	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
uraemic	uraemic	ADJ	JJ	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Adverse	adverse	ADJ	JJ	5	O
cardiac	cardiac	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
during	during	ADP	IN	5	O
induction	induction	NOUN	NN	3	O
chemotherapy	chemotherapy	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
cis	cis	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
platin	platin	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Survival	survival	NOUN	NN	9	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
advanced	advanced	ADJ	JJ	5	O
head	head	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
neck	neck	NOUN	NN	5	I-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
esophageal	esophageal	ADJ	JJ	5	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
is	be	VERB	VBZ	5	O
poor	poor	ADJ	JJ	5	O
with	with	ADP	IN	5	O
radiotherapy	radiotherapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Obviously	obviously	ADV	RB	5	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
need	need	NOUN	NN	5	O
for	for	ADP	IN	5	O
effective	effective	ADJ	JJ	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
cis	cis	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
platin	platin	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
80	80	NUM	CD	9	O
-	-	SYM	SYM	7	O
120	120	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2BSA	m2BSA	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
1000	1000	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2BSA	m2BSA	PROPN	NNP	9	O
daily	daily	ADV	RB	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
continuous	continuous	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
during	during	ADP	IN	5	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
to	to	ADP	IN	5	O
76	76	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
before	before	ADP	IN	9	O
radiotherapy	radiotherapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
clarify	clarify	VERB	VB	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
cardiac	cardiac	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Before	before	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
serial	serial	ADJ	JJ	9	O
ECG	ECG	PROPN	NNP	5	O
recordings	recording	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
treatment	treatment	ADJ	JJ	9	O
evaluation	evaluation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
33	33	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
43	43	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
adverse	adverse	ADJ	JJ	5	O
cardiac	cardiac	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
14	14	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
18	18	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
as	as	ADP	IN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
entire	entire	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
64	64	NUM	CD	7	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
those	those	DET	DT	5	O
without	without	ADP	IN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
treatment	treatment	ADJ	JJ	9	O
evaluation	evaluation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
were	be	VERB	VBD	9	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
ST	ST	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
T	T	PROPN	NNP	3	O
wave	wave	NOUN	NN	5	O
changes	change	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
was	be	VERB	VBD	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
sudden	sudden	ADJ	JJ	5	B-Disease
death	death	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
another	another	DET	DT	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
on	on	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
treatment	treatment	NOUN	NN	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
under	under	ADP	IN	9	O
close	close	ADJ	JJ	5	O
supervision	supervision	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
discontinued	discontinue	VERB	VBN	5	O
if	if	ADP	IN	5	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
tachyarrhythmia	tachyarrhythmia	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Death	death	NOUN	NN	9	B-Disease
from	from	ADP	IN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
gestational	gestational	ADJ	JJ	5	B-Disease
trophoblastic	trophoblastic	ADJ	JJ	3	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Multiple	Multiple	PROPN	NNP	5	O
cytotoxic	cytotoxic	NOUN	NN	3	O
drug	drug	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
generally	generally	ADV	RB	5	O
accepted	accept	VERB	VBN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
risk	risk	NOUN	NN	5	O
stage	stage	NOUN	NN	9	O
of	of	ADP	IN	5	O
choriocarcinoma	choriocarcinoma	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

Based	base	VERB	VBN	9	O
on	on	ADP	IN	5	O
this	this	DET	DT	5	O
principle	principle	NOUN	NN	5	O
a	a	DET	DT	5	O
27	27	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
,	,	PUNCT	,	9	O
classified	classify	VERB	VBN	5	O
as	as	ADP	IN	5	O
being	be	VERB	VBG	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
risk	risk	NOUN	NN	5	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
Goldstein	Goldstein	PROPN	NNP	6	O
and	and	CCONJ	CC	5	O
Berkowitz	Berkowitz	PROPN	NNP	6	O
score	score	NOUN	NN	5	O
:	:	PUNCT	:	9	O
11	11	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
multiple	multiple	ADJ	JJ	5	O
cytotoxic	cytotoxic	NOUN	NN	3	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
multiple	multiple	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
schema	schema	NOUN	NN	5	O
consisted	consist	VERB	VBN	5	O
of	of	ADP	IN	5	O
:	:	PUNCT	:	9	O
Etoposide	Etoposide	PROPN	NNP	3	B-Chemical
16	16	NUM	CD	9	O
.	.	PUNCT	.	9	O
213	213	NUM	CD	7	O
,	,	PUNCT	,	9	O
Methotrexate	Methotrexate	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
Cyclophosphamide	Cyclophosphamide	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
Actomycin	Actomycin	PROPN	NNP	_	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
D	D	PROPN	NNP	9	I-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
Cisplatin	Cisplatin	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
schedule	schedule	NOUN	NN	5	O
,	,	PUNCT	,	9	O
moderate	moderate	ADJ	JJ	9	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
Methotrexate	Methotrexate	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
Etoposide	Etoposide	PROPN	NNP	3	B-Chemical
and	and	CCONJ	CC	5	O
Cyclophosphamide	Cyclophosphamide	PROPN	NNP	0	B-Chemical
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Within	within	ADP	IN	9	O
8	8	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
died	die	VERB	VBD	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
picture	picture	NOUN	NN	5	O
resembling	resemble	VERB	VBG	9	O
massive	massive	ADJ	JJ	9	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
obstruction	obstruction	NOUN	NN	5	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
choriocarcinomic	choriocarcinomic	ADJ	JJ	_	O
tissue	tissue	NOUN	NN	9	O
plugs	plug	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
probably	probably	ADV	RB	9	O
originating	originate	VERB	VBG	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
uterus	uterus	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Formation	formation	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
plugs	plug	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
probably	probably	ADV	RB	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
extensive	extensive	ADJ	JJ	5	O
tumor	tumor	NOUN	NN	3	B-Disease
necrosis	necrosis	NOUN	NN	9	B-Disease
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
walls	wall	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
major	major	ADJ	JJ	9	O
uterine	uterine	ADJ	JJ	5	O
veins	vein	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
open	open	ADJ	JJ	5	O
exchange	exchange	NOUN	NN	9	O
of	of	ADP	IN	5	O
tumor	tumor	NOUN	NN	3	B-Disease
plugs	plug	NOUN	NNS	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
vascular	vascular	ADJ	JJ	5	O
spaces	space	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
tumor	tumor	NOUN	NN	3	B-Disease
tissue	tissue	NOUN	NN	9	O
coherence	coherence	NOUN	NN	5	O
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
further	further	ADV	RB	9	O
contributed	contribute	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
formation	formation	NOUN	NN	9	O
of	of	ADP	IN	5	O
tumor	tumor	NOUN	NN	3	B-Disease
emboli	emboli	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
view	view	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
close	close	ADJ	JJ	5	O
time	time	NOUN	NN	5	O
association	association	NOUN	NN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
start	start	NOUN	NN	9	O
of	of	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
massive	massive	ADJ	JJ	9	O
embolism	embolism	NOUN	NN	5	B-Disease
other	other	ADJ	JJ	5	O
explanations	explanation	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
necrosis	necrosis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
must	must	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
less	less	ADV	RBR	5	O
likely	likely	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
large	large	ADJ	JJ	5	O
pelvic	pelvic	ADJ	JJ	5	B-Disease
tumor	tumor	NOUN	NN	3	I-Disease
loads	load	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
,	,	PUNCT	,	9	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
existing	exist	VERB	VBG	5	O
classifications	classification	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
high	high	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
to	to	PART	TO	5	O
die	die	VERB	VB	5	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
develop	develop	VERB	VB	5	O
drug	drug	NOUN	NN	5	O
resistance	resistance	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Notwithstanding	notwithstanding	ADP	IN	5	O
these	these	DET	DT	5	O
facts	fact	NOUN	NNS	5	O
our	-PRON-	DET	PRP$	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
might	may	VERB	MD	9	O
benefit	benefit	VERB	VB	5	O
from	from	ADP	IN	9	O
relatively	relatively	ADV	RB	5	O
mild	mild	ADJ	JJ	9	O
initial	initial	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
true	true	ADJ	JJ	5	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
not	not	ADV	RB	5	O
previously	previously	ADV	RB	9	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Close	close	ADJ	JJ	9	O
observation	observation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
response	response	NOUN	NN	9	O
status	status	NOUN	NN	9	O
both	both	CCONJ	CC	9	O
clinically	clinically	ADV	RB	5	O
and	and	CCONJ	CC	5	O
with	with	ADP	IN	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
hCG	hcg	NUM	CD	9	O
values	value	NOUN	NNS	5	O
may	may	VERB	MD	5	O
indicate	indicate	VERB	VB	9	O
whether	whether	ADP	IN	9	O
and	and	CCONJ	CC	5	O
when	when	ADV	WRB	5	O
more	more	ADV	RBR	5	O
agressive	agressive	ADJ	JJ	5	O
combination	combination	NOUN	NN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
started	start	VERB	VBN	5	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
250	250	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

Pulmonary	pulmonary	ADJ	JJ	9	O
shunt	shunt	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
responses	response	NOUN	NNS	5	O
to	to	ADP	IN	5	O
CPAP	CPAP	PROPN	NNP	5	O
during	during	ADP	IN	5	O
nitroprusside	nitroprusside	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
continuous	continuous	ADJ	JJ	5	O
positive	positive	ADJ	JJ	9	O
airway	airway	NOUN	NN	5	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CPAP	CPAP	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
dynamics	dynamic	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
pulmonary	pulmonary	ADJ	JJ	5	O
shunt	shunt	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
QS	QS	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
QT	QT	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
in	in	ADP	IN	5	O
12	12	NUM	CD	9	O
dogs	dog	NOUN	NNS	5	O
before	before	ADV	RB	9	O
and	and	CCONJ	CC	5	O
during	during	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
nitroprusside	nitroprusside	NOUN	NN	0	I-Chemical
infusion	infusion	NOUN	NN	0	O
that	that	DET	WDT	5	O
decreased	decrease	VERB	VBD	9	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
40	40	NUM	CD	9	O
-	-	SYM	SYM	7	O
50	50	NUM	CD	0	O
per	per	ADP	IN	9	O
cent	cent	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Before	before	ADP	IN	9	O
nitroprusside	nitroprusside	ADJ	JJ	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
cm	cm	NOUN	NNS	9	O
H2O	H2O	PROPN	NNP	0	B-Chemical
CPAP	CPAP	PROPN	NNP	5	O
significantly	significantly	ADV	RB	9	O
,	,	PUNCT	,	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
,	,	PUNCT	,	9	O
decreased	decrease	VERB	VBD	9	O
arterial	arterial	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
alter	alter	VERB	VB	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
,	,	PUNCT	,	9	O
cardiac	cardiac	ADJ	JJ	5	O
output	output	NOUN	NN	5	O
,	,	PUNCT	,	9	O
systemic	systemic	ADJ	JJ	9	O
vascular	vascular	ADJ	JJ	5	O
resistance	resistance	NOUN	NN	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
QS	QS	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
QT	QT	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Ten	ten	NUM	CD	9	O
cm	cm	NOUN	NNS	9	O
H2O	H2O	PROPN	NNP	0	B-Chemical
CPAP	CPAP	PROPN	NNP	5	O
before	before	ADP	IN	9	O
nitroprusside	nitroprusside	ADJ	JJ	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
produced	produce	VERB	VBD	9	O
a	a	DET	DT	5	O
further	further	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
arterial	arterial	ADJ	JJ	5	I-Disease
blood	blood	NOUN	NN	9	I-Disease
pressure	pressure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	B-Disease
cardiac	cardiac	ADJ	JJ	5	I-Disease
output	output	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
QS	QS	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
QT	QT	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Nitroprusside	Nitroprusside	PROPN	NNP	0	B-Chemical
caused	cause	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
decreases	decrease	NOUN	NNS	9	B-Disease
in	in	ADP	IN	5	I-Disease
arterial	arterial	ADJ	JJ	5	I-Disease
blood	blood	NOUN	NN	9	I-Disease
pressure	pressure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
systemic	systemic	ADJ	JJ	9	O
vascular	vascular	ADJ	JJ	5	O
resistance	resistance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
change	change	VERB	VB	9	O
cardiac	cardiac	ADJ	JJ	5	O
output	output	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
QS	QS	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
QT	QT	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
cm	cm	NOUN	NNS	9	O
H2O	H2O	PROPN	NNP	0	B-Chemical
CPAP	CPAP	PROPN	NNP	5	O
during	during	ADP	IN	5	O
nitroprusside	nitroprusside	NOUN	NN	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
further	further	ADV	RB	9	O
alter	alter	VERB	VB	9	O
any	any	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
above	above	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
mentioned	mention	VERB	VBN	5	O
variables	variable	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
cm	cm	NOUN	NNS	9	O
H2O	H2O	PROPN	NNP	0	B-Chemical
CPAP	CPAP	PROPN	NNP	5	O
decreased	decrease	VERB	VBD	9	O
arterial	arterial	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
cardiac	cardiac	ADJ	JJ	5	O
output	output	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
QS	QS	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
QT	QT	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
nitroprusside	nitroprusside	ADJ	JJ	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
rates	rate	NOUN	NNS	5	O
that	that	DET	WDT	5	O
decrease	decrease	VERB	VBP	9	O
mean	mean	VERB	VBP	5	O
arterial	arterial	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
by	by	ADP	IN	9	O
40	40	NUM	CD	9	O
-	-	SYM	SYM	7	O
50	50	NUM	CD	0	O
per	per	ADP	IN	9	O
cent	cent	NOUN	NN	5	O
do	do	VERB	VBP	5	O
not	not	ADV	RB	5	O
change	change	VERB	VB	9	O
cardiac	cardiac	ADJ	JJ	5	O
output	output	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
QS	QS	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
QT	QT	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
nitroprusside	nitroprusside	ADJ	JJ	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
low	low	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
CPAP	CPAP	PROPN	NNP	5	O
do	do	VERB	VBP	5	O
not	not	ADV	RB	5	O
markedly	markedly	ADV	RB	9	O
alter	alter	VERB	VB	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
dynamics	dynamic	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
high	high	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
CPAP	CPAP	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
cm	cm	NOUN	NNS	9	O
H2O	H2O	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
decreasing	decrease	VERB	VBG	9	O
QS	QS	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
QT	QT	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
produce	produce	VERB	VB	9	O
marked	mark	VERB	VBN	9	O
decreases	decrease	NOUN	NNS	9	B-Disease
in	in	ADP	IN	5	I-Disease
arterial	arterial	ADJ	JJ	5	I-Disease
blood	blood	NOUN	NN	9	I-Disease
pressure	pressure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
cardiac	cardiac	ADJ	JJ	5	I-Disease
output	output	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Systolic	systolic	ADJ	JJ	7	O
pressure	pressure	NOUN	NN	5	O
variation	variation	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
greater	great	ADJ	JJR	5	O
during	during	ADP	IN	5	O
hemorrhage	hemorrhage	NOUN	NN	5	B-Disease
than	than	ADP	IN	5	O
during	during	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
nitroprusside	nitroprusside	ADV	RB	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
ventilated	ventilate	VERB	VBN	5	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
systolic	systolic	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
variation	variation	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
SPV	SPV	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
difference	difference	NOUN	NN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
maximal	maximal	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
minimal	minimal	ADJ	JJ	9	O
values	value	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
systolic	systolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
SBP	SBP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
one	one	NUM	CD	5	O
positive	positive	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
pressure	pressure	NOUN	NN	5	O
breath	breath	NOUN	NN	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
ventilated	ventilate	VERB	VBN	5	O
dogs	dog	NOUN	NNS	5	O
subjected	subject	VERB	VBN	9	O
to	to	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Mean	mean	VERB	VB	9	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
to	to	ADP	IN	5	O
50	50	NUM	CD	0	O
mm	mm	NOUN	NNS	9	O
Hg	Hg	PROPN	NNP	0	O
for	for	ADP	IN	5	O
30	30	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
either	either	ADV	RB	9	O
by	by	ADP	IN	9	O
hemorrhage	hemorrhage	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
HEM	HEM	PROPN	NNP	0	B-Disease
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
by	by	ADP	IN	9	O
continuous	continuous	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
nitroprusside	nitroprusside	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
SNP	SNP	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
HEM	HEM	PROPN	NNP	0	B-Disease
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
the	the	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	O
output	output	NOUN	NN	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
and	and	CCONJ	CC	5	O
systemic	systemic	ADJ	JJ	9	O
vascular	vascular	ADJ	JJ	5	O
resistance	resistance	NOUN	NN	9	O
higher	higher	ADV	RBR	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
that	that	DET	DT	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
SNP	SNP	PROPN	NNP	9	B-Chemical
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
systemic	systemic	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
central	central	ADJ	JJ	5	O
venous	venous	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
pulmonary	pulmonary	ADJ	JJ	5	O
capillary	capillary	ADJ	JJ	0	O
wedge	wedge	NOUN	NN	5	O
pressures	pressure	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
respiratory	respiratory	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
waveform	waveform	NOUN	NN	5	O
enabled	enable	VERB	VBD	5	O
differentiation	differentiation	NOUN	NN	3	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
SPV	SPV	PROPN	NNP	5	O
during	during	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
Hg	Hg	PROPN	NNP	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
HEM	HEM	PROPN	NNP	0	B-Disease
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
SNP	SNP	PROPN	NNP	9	B-Chemical
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
delta	delta	NOUN	NN	9	O
down	down	ADV	RB	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
measure	measure	NOUN	NN	5	O
of	of	ADP	IN	5	O
decrease	decrease	NOUN	NN	9	O
of	of	ADP	IN	5	O
SBP	SBP	PROPN	NNP	9	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
mechanical	mechanical	ADJ	JJ	5	O
breath	breath	NOUN	NN	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
20	20	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
Hg	Hg	PROPN	NNP	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
HEM	HEM	PROPN	NNP	0	B-Disease
and	and	CCONJ	CC	5	O
SNP	SNP	PROPN	NNP	9	B-Chemical
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
during	during	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
SPV	SPV	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
delta	delta	NOUN	NN	9	O
down	down	ADV	RB	9	O
are	be	VERB	VBP	5	O
characteristic	characteristic	ADJ	JJ	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
state	state	NOUN	NN	5	O
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
predominant	predominant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
preload	preload	NOUN	NN	5	O
.	.	PUNCT	.	9	O

They	-PRON-	PRON	PRP	5	O
are	be	VERB	VBP	5	O
thus	thus	ADV	RB	9	O
more	more	ADV	RBR	5	O
important	important	ADJ	JJ	9	O
during	during	ADP	IN	5	O
absolute	absolute	ADJ	JJ	5	O
hypovolemia	hypovolemia	NOUN	NN	5	B-Disease
than	than	ADP	IN	5	O
during	during	ADP	IN	5	O
deliberate	deliberate	ADJ	JJ	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Ventricular	ventricular	ADJ	JJ	5	B-Disease
tachyarrhythmias	tachyarrhythmia	NOUN	NNS	5	I-Disease
during	during	ADP	IN	5	O
cesarean	cesarean	ADJ	JJ	5	O
section	section	NOUN	NN	5	O
after	after	ADP	IN	9	O
ritodrine	ritodrine	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
:	:	PUNCT	:	9	O
interaction	interaction	NOUN	NN	9	O
with	with	ADP	IN	5	O
anesthetics	anesthetic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
illustrates	illustrate	VERB	VBZ	5	O
that	that	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
ritodrine	ritodrine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
preterm	preterm	ADJ	JJ	5	B-Disease
labor	labor	NOUN	NN	5	I-Disease
may	may	VERB	MD	5	O
risk	risk	VERB	VB	5	O
interactions	interaction	NOUN	NNS	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
residual	residual	ADJ	JJ	9	O
betamimetic	betamimetic	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
ritodrine	ritodrine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
anesthetics	anesthetic	NOUN	NNS	5	O
during	during	ADP	IN	5	O
cesarean	cesarean	ADJ	JJ	5	O
section	section	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Such	such	ADJ	JJ	5	O
interactions	interaction	NOUN	NNS	9	O
may	may	VERB	MD	5	O
result	result	VERB	VB	9	O
in	in	ADP	IN	5	O
serious	serious	ADJ	JJ	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
complications	complication	NOUN	NNS	5	I-Disease
even	even	ADV	RB	5	O
after	after	ADP	IN	9	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
ritodrine	ritodrine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Preoperative	preoperative	ADJ	JJ	5	O
assessment	assessment	NOUN	NN	5	O
should	should	VERB	MD	5	O
focus	focus	VERB	VB	5	O
on	on	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
status	status	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
serum	serum	ADJ	JJ	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Delaying	delay	VERB	VBG	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
anesthesia	anesthesia	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
whenever	whenever	ADV	WRB	5	O
possible	possible	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Careful	careful	ADJ	JJ	5	O
fluid	fluid	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
cautious	cautious	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
titrated	titrate	VERB	VBN	0	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
ephedrine	ephedrine	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
advised	advise	VERB	VBN	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
delivery	delivery	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
infant	infant	NOUN	NN	5	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
no	no	DET	DT	9	O
contraindication	contraindication	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	NOUN	NN	9	O
vasopressor	vasopressor	NOUN	NN	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
phenylephrine	phenylephrine	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
tachycardia	tachycardia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Verapamil	Verapamil	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
after	after	ADP	IN	9	O
combined	combine	VERB	VBN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
showed	show	VERB	VBD	9	O
complete	complete	ADJ	JJ	9	O
recovery	recovery	NOUN	NN	9	O
after	after	ADP	IN	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
entry	entry	NOUN	NN	9	O
blocker	blocker	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Use	Use	PROPN	NNP	5	O
of	of	ADP	IN	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
should	should	VERB	MD	5	O
either	either	CCONJ	CC	9	O
be	be	VERB	VB	5	O
avoided	avoid	VERB	VBN	5	O
or	or	CCONJ	CC	5	O
prescribed	prescribe	VERB	VBN	5	O
only	only	ADV	RB	9	O
with	with	ADP	IN	5	O
appropriate	appropriate	ADJ	JJ	5	O
adjustment	adjustment	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
usually	usually	ADV	RB	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
dose	dose	NOUN	NN	9	O
by	by	ADP	IN	9	O
one	one	NUM	CD	5	O
half	half	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Paracetamol	paracetamol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
coma	coma	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
metabolic	metabolic	ADJ	JJ	9	B-Disease
acidosis	acidosis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
renal	renal	ADJ	JJ	9	B-Disease
and	and	CCONJ	CC	5	I-Disease
hepatic	hepatic	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
metabolic	metabolic	ADJ	JJ	9	B-Disease
acidosis	acidosis	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
hepatic	hepatic	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
following	follow	VERB	VBG	9	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
ingestion	ingestion	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
presented	present	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
diagnostic	diagnostic	ADJ	JJ	5	O
difficulty	difficulty	NOUN	NN	5	O
at	at	ADP	IN	9	O
presentation	presentation	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
highlighted	highlight	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Continuous	continuous	ADJ	JJ	5	O
arteriovenous	arteriovenous	ADJ	JJ	5	O
haemofiltration	haemofiltration	NOUN	NN	5	O
proved	prove	VERB	VBD	9	O
a	a	DET	DT	5	O
valuable	valuable	ADJ	JJ	5	O
means	mean	NOUN	NNS	5	O
of	of	ADP	IN	5	O
maintaining	maintain	VERB	VBG	9	O
fluid	fluid	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
electrolyte	electrolyte	NOUN	NN	0	O
balance	balance	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
recovered	recover	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Sexual	sexual	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
among	among	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
arthritis	arthritis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
of	of	ADP	IN	5	O
arthritis	arthritis	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
sexual	sexual	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
among	among	ADP	IN	5	O
169	169	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
rheumatoid	rheumatoid	ADJ	JJ	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
osteoarthritis	osteoarthritis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
spondyloarthropathy	spondyloarthropathy	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
130	130	NUM	CD	9	O
of	of	ADP	IN	5	O
whom	whom	PRON	WP	5	O
were	be	VERB	VBD	9	O
pair	pair	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
matched	match	VERB	VBN	9	O
to	to	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Assessments	assessment	NOUN	NNS	5	O
of	of	ADP	IN	5	O
marital	marital	ADJ	JJ	5	O
happiness	happiness	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
depressed	depressed	ADJ	JJ	5	B-Disease
mood	mood	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
made	make	VERB	VBN	5	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
CES	CES	PROPN	NNP	5	O
-	-	PUNCT	HYPH	7	O
D	D	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
Azrin	Azrin	PROPN	NNP	6	O
Marital	Marital	PROPN	NNP	7	O
Happiness	Happiness	PROPN	NNP	5	O
Scale	scale	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
AMHS	AMHS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Sexual	sexual	ADJ	JJ	5	B-Disease
dysfunctions	dysfunction	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
common	common	ADJ	JJ	5	O
among	among	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
controls	control	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
majority	majority	NOUN	NN	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
reporting	report	VERB	VBG	5	O
one	one	NUM	CD	5	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
dysfunctions	dysfunction	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Impotence	impotence	NOUN	NN	2	B-Disease
was	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
common	common	ADJ	JJ	5	O
among	among	ADP	IN	5	O
male	male	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
than	than	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
co	co	NOUN	NN	9	O
-	-	NOUN	NN	7	O
morbidity	morbidity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
taking	taking	NOUN	NN	5	O
of	of	ADP	IN	5	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

Depressed	depressed	ADJ	JJ	5	B-Disease
mood	mood	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
common	common	ADJ	JJ	5	O
among	among	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
certain	certain	ADJ	JJ	5	O
sexual	sexual	ADJ	JJ	5	O
difficulties	difficulty	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
with	with	ADP	IN	5	O
impotence	impotence	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Marital	marital	ADJ	JJ	7	O
unhappiness	unhappiness	NOUN	NN	5	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
indicated	indicate	VERB	VBN	9	O
by	by	ADP	IN	9	O
AMHS	AMHS	PROPN	NNP	5	O
scores	score	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
arthritis	arthritis	NOUN	NN	9	B-Disease
but	but	CCONJ	CC	9	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
sexual	sexual	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
sexual	sexual	ADJ	JJ	5	O
dissatisfaction	dissatisfaction	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
being	be	VERB	VBG	5	O
female	female	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Does	do	VERB	VBZ	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
cause	cause	VERB	VB	5	O
urothelial	urothelial	ADJ	JJ	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
or	or	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
papillary	papillary	ADJ	JJ	5	I-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
?	?	PUNCT	.	5	O

The	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
renal	renal	ADJ	JJ	9	B-Disease
papillary	papillary	ADJ	JJ	5	I-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
or	or	CCONJ	CC	5	O
cancer	cancer	NOUN	NN	3	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
pelvis	pelvi	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	I-Disease
ureter	ureter	ADJ	JJ	5	I-Disease
or	or	CCONJ	CC	5	I-Disease
bladder	bladder	NOUN	NN	9	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
consumption	consumption	NOUN	NN	5	O
of	of	ADP	IN	5	O
either	either	DET	DT	9	O
phenacetin	phenacetin	ADJ	JJ	0	B-Chemical
or	or	CCONJ	CC	5	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
calculated	calculate	VERB	VBN	5	O
from	from	ADP	IN	9	O
data	datum	NOUN	NNS	5	O
acquired	acquire	VERB	VBN	5	O
by	by	ADP	IN	9	O
questionnaire	questionnaire	NOUN	NN	5	O
from	from	ADP	IN	9	O
381	381	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
808	808	NUM	CD	7	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
papillary	papillary	ADJ	JJ	5	I-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
nearly	nearly	ADV	RB	9	O
20	20	NUM	CD	9	O
-	-	NOUN	NN	7	O
fold	fold	VERB	VB	9	O
by	by	ADP	IN	9	O
consumption	consumption	NOUN	NN	5	O
of	of	ADP	IN	5	O
phenacetin	phenacetin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
also	also	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
pelvis	pelvi	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	I-Disease
bladder	bladder	NOUN	NN	9	I-Disease
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
for	for	ADP	IN	5	O
ureteric	ureteric	ADJ	JJ	5	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

By	by	ADP	IN	5	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
unable	unable	ADJ	JJ	9	O
to	to	PART	TO	5	O
substantiate	substantiate	VERB	VB	9	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
from	from	ADP	IN	9	O
paracetamol	paracetamol	NOUN	NN	0	B-Chemical
consumption	consumption	NOUN	NN	5	O
for	for	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
papillary	papillary	ADJ	JJ	5	I-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
or	or	CCONJ	CC	5	O
any	any	DET	DT	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
cancers	cancer	NOUN	NNS	9	B-Disease
although	although	ADP	IN	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
suggestion	suggestion	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
cancer	cancer	NOUN	NN	3	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
ureter	ureter	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Dapsone	dapsone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
Heinz	Heinz	PROPN	NNP	6	O
body	body	NOUN	NN	5	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
Cambodian	cambodian	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
hemoglobin	hemoglobin	NOUN	NN	0	O
E	e	NOUN	NN	9	O
trait	trait	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
Cambodian	cambodian	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
hemoglobin	hemoglobin	NOUN	NN	0	O
E	e	NOUN	NN	9	O
trait	trait	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
AE	AE	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
leprosy	leprosy	NOUN	NN	5	B-Disease
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
Heinz	Heinz	PROPN	NNP	6	O
body	body	NOUN	NN	5	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
while	while	ADP	IN	9	O
taking	take	VERB	VBG	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
dapsone	dapsone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
not	not	ADV	RB	5	O
usually	usually	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
hemolysis	hemolysis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Her	-PRON-	DET	PRP$	5	O
red	red	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
cells	cell	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
RBCs	rbc	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
incubated	incubate	VERB	VBN	0	O
Heinz	Heinz	PROPN	NNP	6	O
body	body	NOUN	NN	5	O
formation	formation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
decreased	decrease	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
glutathione	glutathione	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
GSH	GSH	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
GSH	GSH	PROPN	NNP	0	B-Chemical
stability	stability	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pentose	pentose	ADJ	JJ	0	B-Chemical
phosphate	phosphate	NOUN	NN	0	I-Chemical
shunt	shunt	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
dapsone	dapsone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
exposed	expose	VERB	VBN	9	O
AE	AE	PROPN	NNP	9	O
RBCs	rbc	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
RBCs	rbc	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
the	the	DET	DT	5	O
AE	AE	PROPN	NNP	9	O
RBCs	rbc	NOUN	NNS	9	O
from	from	ADP	IN	9	O
an	an	DET	DT	5	O
individual	individual	NOUN	NN	5	O
not	not	ADV	RB	5	O
taking	take	VERB	VBG	5	O
dapsone	dapsone	NOUN	NN	0	B-Chemical
had	have	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
incubated	incubate	VERB	VBN	0	O
Heinz	Heinz	PROPN	NNP	6	O
body	body	NOUN	NN	5	O
formation	formation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
GSH	GSH	PROPN	NNP	0	B-Chemical
content	content	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
GSH	GSH	PROPN	NNP	0	B-Chemical
stability	stability	NOUN	NN	9	O
were	be	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pentose	pentose	ADJ	JJ	0	B-Chemical
phosphate	phosphate	NOUN	NN	0	I-Chemical
shunt	shunt	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
dapsone	dapsone	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
exposed	expose	VERB	VBN	9	O
AE	AE	PROPN	NNP	9	O
RBCs	rbc	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
RBCs	rbc	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
AE	AE	PROPN	NNP	9	O
RBCs	rbc	NOUN	NNS	9	O
appear	appear	VERB	VBP	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
sensitivity	sensitivity	NOUN	NN	9	O
to	to	ADP	IN	5	O
oxidant	oxidant	ADJ	JJ	0	O
stress	stress	NOUN	NN	9	O
both	both	CCONJ	CC	9	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
vivo	vivo	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
since	since	ADP	IN	9	O
dapsone	dapsone	NOUN	NN	0	B-Chemical
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
cause	cause	VERB	VB	5	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
at	at	ADP	IN	9	O
this	this	DET	DT	5	O
dose	dose	NOUN	NN	9	O
in	in	ADP	IN	5	O
hematologically	hematologically	ADV	RB	5	O
normal	normal	ADJ	JJ	9	O
individuals	individual	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Given	give	VERB	VBN	9	O
the	the	DET	DT	5	O
influx	influx	NOUN	NN	9	O
of	of	ADP	IN	5	O
Southeast	Southeast	PROPN	NNP	4	O
Asians	Asians	PROPN	NNPS	5	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
United	United	PROPN	NNP	9	O
States	States	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
oxidant	oxidant	ADJ	JJ	0	O
medications	medication	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
with	with	ADP	IN	5	O
caution	caution	NOUN	NN	5	O
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
if	if	ADP	IN	5	O
an	an	DET	DT	5	O
infection	infection	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
present	present	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
individuals	individual	NOUN	NNS	5	O
of	of	ADP	IN	5	O
ethnic	ethnic	ADJ	JJ	5	O
backgrounds	background	NOUN	NNS	9	O
that	that	DET	WDT	5	O
have	have	VERB	VBP	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
hemoglobin	hemoglobin	NOUN	NN	0	O
E	e	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Severe	severe	ADJ	JJ	9	O
complications	complication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
antianginal	antianginal	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
identified	identify	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
poor	poor	ADJ	JJ	5	O
metabolizer	metabolizer	NOUN	NN	5	O
of	of	ADP	IN	5	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
propafenone	propafenone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
diltiazem	diltiazem	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
sparteine	sparteine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
47	47	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
suffering	suffering	NOUN	NN	5	O
from	from	ADP	IN	9	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
CCU	CCU	PROPN	NNP	5	O
in	in	ADP	IN	5	O
shock	shock	NOUN	NN	9	B-Disease
with	with	ADP	IN	5	O
III	III	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

AV	av	NOUN	NN	9	B-Disease
block	block	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
severe	severe	ADJ	JJ	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
impairment	impairment	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
ventricular	ventricular	ADJ	JJ	5	I-Disease
function	function	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
week	week	NOUN	NN	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
admission	admission	NOUN	NN	5	O
a	a	DET	DT	5	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
standard	standard	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
t	t	NOUN	NN	5	O
.	.	PUNCT	.	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
d	d	X	XX	9	O
.	.	PUNCT	.	9	O
and	and	CCONJ	CC	5	O
then	then	ADV	RB	9	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
b	b	NOUN	NN	9	O
.	.	PUNCT	.	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
d	d	X	XX	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
initiated	initiate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
days	day	NOUN	NNS	9	O
before	before	ADP	IN	9	O
admission	admission	NOUN	NN	5	O
diltiazem	diltiazem	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
60	60	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
b	b	NOUN	NN	9	O
.	.	PUNCT	.	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
d	d	X	XX	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
prescribed	prescribe	VERB	VBN	5	O
in	in	ADP	IN	5	O
addition	addition	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Analyses	analysis	NOUN	NNS	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
blood	blood	NOUN	NN	9	O
sample	sample	NOUN	NN	9	O
revealed	reveal	VERB	VBD	9	O
unusually	unusually	ADV	RB	9	O
high	high	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
3000	3000	NUM	CD	0	O
ng	ng	ADP	IN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
diltiazem	diltiazem	ADJ	JJ	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
526	526	NUM	CD	7	O
ng	ng	ADP	IN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
recovered	recover	VERB	VBD	9	O
within	within	ADP	IN	9	O
1	1	NUM	CD	9	O
week	week	NOUN	NN	9	O
following	follow	VERB	VBG	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
antianginal	antianginal	ADJ	JJ	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
months	month	NOUN	NNS	5	O
later	later	ADV	RB	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
diltiazem	diltiazem	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
propafenone	propafenone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
since	since	ADP	IN	9	O
he	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
received	receive	VERB	VBN	9	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
past	past	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
sparteine	sparteine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
probe	probe	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
debrisoquine	debrisoquine	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
sparteine	sparteine	NOUN	NN	0	B-Chemical
type	type	NOUN	NN	9	O
polymorphism	polymorphism	NOUN	NN	9	O
of	of	ADP	IN	5	O
oxidative	oxidative	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
metabolism	metabolism	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
that	that	ADP	IN	5	O
he	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
poor	poor	ADJ	JJ	5	O
metabolizer	metabolizer	NOUN	NN	5	O
of	of	ADP	IN	5	O
all	all	DET	DT	5	O
four	four	NUM	CD	9	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
that	that	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
metabolism	metabolism	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
under	under	ADP	IN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
genetic	genetic	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
patients	patient	NOUN	NNS	5	O
belonging	belong	VERB	VBG	4	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
poor	poor	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
metabolizer	metabolizer	NOUN	NN	5	O
phenotype	phenotype	NOUN	NN	3	O
of	of	ADP	IN	5	O
sparteine	sparteine	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
debrisoquine	debrisoquine	NOUN	NN	0	B-Chemical
polymorphism	polymorphism	NOUN	NN	9	O
in	in	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
metabolism	metabolism	NOUN	NN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
constitutes	constitute	VERB	VBZ	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
German	german	ADJ	JJ	5	O
population	population	NOUN	NN	5	O
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
experience	experience	VERB	VB	5	O
adverse	adverse	ADJ	JJ	5	B-Disease
drug	drug	NOUN	NN	5	I-Disease
reactions	reaction	NOUN	NNS	9	I-Disease
when	when	ADV	WRB	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
standard	standard	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
alone	alone	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
coadministration	coadministration	NOUN	NN	0	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
frequently	frequently	ADV	RB	5	O
used	use	VERB	VBN	5	O
drugs	drug	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
expected	expect	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
especially	especially	ADV	RB	5	O
harmful	harmful	ADJ	JJ	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
subgroup	subgroup	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
experiences	experience	NOUN	NNS	5	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
open	open	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
sixty	sixty	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
trated	trate	VERB	VBN	0	O
with	with	ADP	IN	5	O
bromperidol	bromperidol	NOUN	NN	7	B-Chemical
first	first	ADV	RB	9	O
in	in	ADP	IN	5	O
open	open	ADJ	JJ	5	O
conditions	condition	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
then	then	ADV	RB	9	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
blind	blind	ADJ	JJ	5	O
basis	basis	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
40	40	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
reference	reference	NOUN	NN	9	O
substance	substance	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
open	open	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
lasted	last	VERB	VBD	5	O
for	for	ADP	IN	5	O
four	four	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
was	be	VERB	VBD	9	O
administrated	administrate	VERB	VBN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
form	form	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
tablets	tablet	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
daily	daily	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
initial	initial	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
:	:	PUNCT	:	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
;	;	PUNCT	:	9	O
mean	mean	VERB	VB	5	O
dose	dose	NOUN	NN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
trial	trial	NOUN	NN	5	O
:	:	PUNCT	:	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
47	47	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
always	always	ADV	RB	5	O
administered	administer	VERB	VBN	9	O
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Nineteen	nineteen	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
finished	finish	VERB	VBD	5	O
the	the	DET	DT	5	O
trial	trial	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
18	18	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
the	the	DET	DT	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
result	result	NOUN	NN	9	O
was	be	VERB	VBD	9	O
considered	consider	VERB	VBN	5	O
very	very	ADV	RB	5	O
good	good	ADJ	JJ	5	O
to	to	ADP	IN	5	O
good	good	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
confirmed	confirm	VERB	VBN	9	O
by	by	ADP	IN	9	O
statistical	statistical	ADJ	JJ	5	O
analysis	analysis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Nine	nine	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
exhibited	exhibit	VERB	VBD	9	O
mild	mild	ADJ	JJ	9	O
to	to	PART	TO	5	O
moderate	moderate	VERB	VB	9	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	B-Disease
concomitant	concomitant	ADJ	JJ	9	I-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
;	;	PUNCT	:	9	O
no	no	DET	DT	9	O
other	other	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
detailed	detailed	ADJ	JJ	5	O
laboratory	laboratory	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
evaluations	evaluation	NOUN	NNS	5	O
of	of	ADP	IN	5	O
various	various	ADJ	JJ	9	O
quantitative	quantitative	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
qualitative	qualitative	ADJ	JJ	5	O
tolerability	tolerability	NOUN	NN	5	O
parameters	parameter	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
indicative	indicative	ADJ	JJ	9	O
of	of	ADP	IN	5	O
toxic	toxic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
double	double	ADJ	JJ	9	O
blind	blind	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
with	with	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
both	both	DET	DT	9	O
substances	substance	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
highly	highly	ADV	RB	9	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
psychotic	psychotic	ADJ	JJ	5	B-Disease
syndromes	syndrome	NOUN	NNS	5	I-Disease
belonging	belong	VERB	VBG	4	I-Disease
predominantly	predominantly	ADV	RB	9	I-Disease
to	to	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
schizophrenia	schizophrenia	NOUN	NN	5	I-Disease
group	group	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Certain	certain	ADJ	JJ	9	O
clues	clue	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
,	,	PUNCT	,	9	O
seem	seem	VERB	VBP	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
indicative	indicative	ADJ	JJ	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
superiority	superiority	NOUN	NN	5	O
of	of	ADP	IN	5	O
bromperidol	bromperidol	NOUN	NN	7	B-Chemical
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
differences	difference	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
with	with	ADP	IN	5	O
respect	respect	NOUN	NN	9	O
to	to	ADP	IN	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
general	general	ADJ	JJ	5	O
tolerability	tolerability	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Prolonged	prolonged	ADJ	JJ	9	O
cholestasis	cholestasis	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
troleandomycin	troleandomycin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
in	in	ADP	IN	5	O
whom	whom	PRON	WP	5	O
troleandomycin	troleandomycin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
prolonged	prolong	VERB	VBN	9	O
anicteric	anicteric	ADJ	JJ	5	O
cholestasis	cholestasis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Jaundice	Jaundice	PROPN	NNP	7	B-Disease
occurred	occur	VERB	VBD	9	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
troleandomycin	troleandomycin	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
7	7	NUM	CD	9	O
days	day	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
hypereosinophilia	hypereosinophilia	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Jaundice	Jaundice	PROPN	NNP	7	B-Disease
disappeared	disappear	VERB	VBD	9	O
within	within	ADP	IN	9	O
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
but	but	CCONJ	CC	9	O
was	be	VERB	VBD	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
prolonged	prolong	VERB	VBN	9	O
anicteric	anicteric	ADJ	JJ	5	O
cholestasis	cholestasis	NOUN	NN	5	B-Disease
marked	mark	VERB	VBN	9	O
by	by	ADP	IN	9	O
pruritus	pruritus	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
high	high	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
alkaline	alkaline	NOUN	NN	0	O
phosphatase	phosphatase	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
gammaglutamyltransferase	gammaglutamyltransferase	ADJ	JJ	9	O
activities	activity	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Finally	finally	ADV	RB	9	O
,	,	PUNCT	,	9	O
pruritus	pruritus	NOUN	NN	5	B-Disease
disappeared	disappear	VERB	VBD	9	O
within	within	ADP	IN	9	O
19	19	NUM	CD	7	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
liver	liver	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
27	27	NUM	CD	7	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
observation	observation	NOUN	NN	9	O
demonstrates	demonstrate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
prolonged	prolong	VERB	VBN	9	O
cholestasis	cholestasis	NOUN	NN	5	B-Disease
can	can	VERB	MD	5	O
follow	follow	VERB	VB	5	O
troleandomycin	troleandomycin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Serial	serial	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
auditory	auditory	NOUN	NN	5	B-Disease
neurotoxicity	neurotoxicity	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
deferoxamine	deferoxamine	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Visual	visual	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
auditory	auditory	NOUN	NN	5	I-Disease
neurotoxicity	neurotoxicity	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
previously	previously	ADV	RB	9	O
documented	document	VERB	VBN	9	O
in	in	ADP	IN	5	O
42	42	NUM	CD	7	O
of	of	ADP	IN	5	O
89	89	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
transfusion	transfusion	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
anemia	anemia	NOUN	NN	9	B-Disease
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
receiving	receive	VERB	VBG	9	O
iron	iron	NOUN	NN	0	B-Chemical
chelation	chelation	NOUN	NN	0	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
daily	daily	ADJ	JJ	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
deferoxamine	deferoxamine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
affected	affected	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
had	have	VERB	VBD	9	O
abnormal	abnormal	ADJ	JJ	9	B-Disease
audiograms	audiogram	NOUN	NNS	5	I-Disease
with	with	ADP	IN	5	I-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
mostly	mostly	ADV	RB	9	I-Disease
in	in	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
high	high	ADJ	JJ	9	I-Disease
frequency	frequency	NOUN	NN	5	I-Disease
range	range	NOUN	NN	9	I-Disease
of	of	ADP	IN	5	I-Disease
4	4	NUM	CD	9	I-Disease
,	,	PUNCT	,	9	I-Disease
000	000	NUM	CD	9	I-Disease
to	to	PART	TO	5	I-Disease
8	8	NUM	CD	9	I-Disease
,	,	PUNCT	,	9	I-Disease
000	000	NUM	CD	9	I-Disease
Hz	Hz	PROPN	NNP	5	I-Disease
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hearing	hearing	NOUN	NN	5	O
threshold	threshold	NOUN	NN	5	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
30	30	NUM	CD	9	O
to	to	PART	TO	5	O
100	100	NUM	CD	0	O
decibels	decibel	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
deferoxamine	deferoxamine	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
serial	serial	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
,	,	PUNCT	,	9	O
audiograms	audiogram	NOUN	NNS	5	O
in	in	ADP	IN	5	O
seven	seven	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
reverted	revert	VERB	VBN	9	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
near	near	ADP	IN	9	O
normal	normal	ADJ	JJ	9	O
within	within	ADP	IN	9	O
two	two	NUM	CD	5	O
to	to	PART	TO	5	O
three	three	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
nine	nine	NUM	CD	9	O
of	of	ADP	IN	5	O
13	13	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
became	become	VERB	VBD	9	O
asymptomatic	asymptomatic	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Audiograms	audiogram	NOUN	NNS	5	O
from	from	ADP	IN	9	O
15	15	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
remained	remain	VERB	VBD	9	O
abnormal	abnormal	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
required	require	VERB	VBN	9	O
hearing	hearing	NOUN	NN	5	O
aids	aid	NOUN	NNS	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
permanent	permanent	ADJ	JJ	5	B-Disease
disability	disability	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
18	18	NUM	CD	7	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
22	22	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
initially	initially	ADV	RB	9	O
receiving	receive	VERB	VBG	9	O
deferoxamine	deferoxamine	NOUN	NN	0	B-Chemical
doses	dose	NOUN	NNS	0	O
in	in	ADP	IN	5	O
excess	excess	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
commonly	commonly	ADV	RB	5	O
recommended	recommend	VERB	VBN	5	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
per	per	ADP	IN	9	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
therapy	therapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
restarted	restart	VERB	VBN	5	O
with	with	ADP	IN	5	O
lower	low	ADJ	JJR	9	O
doses	dose	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
usually	usually	ADV	RB	5	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
per	per	ADP	IN	9	O
dose	dose	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
less	less	ADV	RBR	5	O
depending	depend	VERB	VBG	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
auditory	auditory	NOUN	NN	5	B-Disease
abnormality	abnormality	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
exception	exception	NOUN	NN	9	O
of	of	ADP	IN	5	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
no	no	DET	DT	9	O
further	further	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
demonstrated	demonstrate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Auditory	auditory	NOUN	NN	5	O
deterioration	deterioration	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
improvement	improvement	NOUN	NN	5	O
,	,	PUNCT	,	9	O
demonstrated	demonstrate	VERB	VBD	9	O
serially	serially	ADV	RB	9	O
in	in	ADP	IN	5	O
individual	individual	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
and	and	CCONJ	CC	5	O
not	not	ADV	RB	5	O
receiving	receive	VERB	VBG	9	O
deferoxamine	deferoxamine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
provided	provide	VERB	VBN	9	O
convincing	convincing	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
cause	cause	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
-	-	PUNCT	HYPH	7	O
effect	effect	NOUN	NN	9	O
relation	relation	NOUN	NN	5	O
between	between	ADP	IN	5	O
deferoxamine	deferoxamine	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
ototoxicity	ototoxicity	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Based	base	VERB	VBN	9	O
on	on	ADP	IN	5	O
these	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
plan	plan	NOUN	NN	5	O
of	of	ADP	IN	5	O
management	management	NOUN	NN	5	O
was	be	VERB	VBD	9	O
developed	develop	VERB	VBN	5	O
that	that	ADP	IN	5	O
allows	allow	VERB	VBZ	5	O
effective	effective	ADJ	JJ	5	O
yet	yet	CCONJ	CC	9	O
safe	safe	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
deferoxamine	deferoxamine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
is	be	VERB	VBZ	5	O
recommended	recommend	VERB	VBN	5	O
in	in	ADP	IN	5	O
those	those	DET	DT	5	O
without	without	ADP	IN	9	O
audiogram	audiogram	NOUN	NN	5	O
abnormalities	abnormality	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

With	with	ADP	IN	5	O
mild	mild	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
to	to	ADP	IN	5	O
30	30	NUM	CD	9	O
or	or	CCONJ	CC	5	O
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
per	per	ADP	IN	9	O
dose	dose	NOUN	NN	9	O
should	should	VERB	MD	5	O
result	result	VERB	VB	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
reversal	reversal	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
abnormal	abnormal	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
within	within	ADP	IN	9	O
four	four	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Moderate	moderate	ADJ	JJ	7	O
abnormalities	abnormality	NOUN	NNS	9	O
require	require	VERB	VBP	5	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
deferoxamine	deferoxamine	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	VERB	VB	0	O
per	per	ADP	IN	9	O
dose	dose	NOUN	NN	9	O
with	with	ADP	IN	5	O
careful	careful	ADJ	JJ	5	O
monitoring	monitoring	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
those	those	DET	DT	5	O
with	with	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hearing	hear	VERB	VBG	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
stopped	stop	VERB	VBN	9	O
for	for	ADP	IN	5	O
four	four	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
audiogram	audiogram	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
stable	stable	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
improved	improve	VERB	VBN	5	O
,	,	PUNCT	,	9	O
therapy	therapy	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
restarted	restart	VERB	VBN	5	O
at	at	ADP	IN	9	O
10	10	NUM	CD	9	O
to	to	PART	TO	5	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
per	per	ADP	IN	9	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Serial	serial	ADJ	JJ	9	O
audiograms	audiogram	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
performed	perform	VERB	VBN	9	O
every	every	DET	DT	5	O
six	six	NUM	CD	9	O
months	month	NOUN	NNS	5	O
in	in	ADP	IN	5	O
those	those	DET	DT	5	O
without	without	ADP	IN	9	O
problems	problem	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
more	more	ADV	RBR	5	O
frequently	frequently	ADV	RB	5	O
in	in	ADP	IN	5	O
young	young	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
serum	serum	NOUN	NN	9	O
ferritin	ferritin	ADJ	JJ	9	O
values	value	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
those	those	DET	DT	5	O
with	with	ADP	IN	5	O
auditory	auditory	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Lidocaine	lidocaine	ADV	RBR	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
asystole	asystole	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Intravenous	intravenous	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
50	50	NUM	CD	0	O
-	-	PUNCT	HYPH	7	O
mg	mg	NOUN	NN	0	O
bolus	bolus	NOUN	NN	0	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
67	67	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
profound	profound	ADJ	JJ	9	O
depression	depression	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
sinoatrial	sinoatrial	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
atrioventricular	atrioventricular	ADJ	JJ	5	O
nodal	nodal	ADJ	JJ	5	O
pacemakers	pacemaker	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
apparent	apparent	ADJ	JJ	9	O
associated	associated	ADJ	JJ	9	O
conditions	condition	NOUN	NNS	9	O
which	which	DET	WDT	5	O
might	may	VERB	MD	9	O
have	have	VERB	VB	5	O
predisposed	predispose	VERB	VBN	5	O
him	-PRON-	PRON	PRP	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
bradyarrhythmias	bradyarrhythmia	NOUN	NNS	5	B-Disease
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
probably	probably	ADV	RB	9	O
represented	represent	VERB	VBD	9	O
a	a	DET	DT	5	O
true	true	ADJ	JJ	5	O
idiosyncrasy	idiosyncrasy	NOUN	NN	5	O
to	to	PART	TO	5	O
lidocaine	lidocaine	VERB	VB	0	B-Chemical
.	.	PUNCT	.	9	O

Flurbiprofen	Flurbiprofen	PROPN	NNP	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
juvenile	juvenile	NOUN	NN	4	B-Disease
rheumatoid	rheumatoid	ADJ	JJ	9	I-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
juvenile	juvenile	ADJ	JJ	4	B-Disease
rheumatoid	rheumatoid	ADJ	JJ	9	I-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
flurbiprofen	flurbiprofen	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
maximum	maximum	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
4	4	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
had	have	VERB	VBD	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
decreases	decrease	NOUN	NNS	9	O
from	from	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
in	in	ADP	IN	5	O
6	6	NUM	CD	9	O
arthritis	arthritis	NOUN	NN	9	B-Disease
indices	index	NOUN	NNS	5	O
after	after	ADP	IN	9	O
12	12	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Improvements	improvement	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
tender	tender	ADJ	JJ	5	B-Disease
joints	joint	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
swelling	swell	VERB	VBG	5	B-Disease
and	and	CCONJ	CC	5	O
tenderness	tenderness	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
walk	walk	NOUN	NN	5	O
50	50	NUM	CD	0	O
feet	foot	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
morning	morning	NOUN	NN	5	B-Disease
stiffness	stiffness	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
circumference	circumference	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
left	left	ADJ	JJ	5	O
knee	knee	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
frequently	frequently	ADV	RB	5	O
observed	observe	VERB	VBN	9	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
fecal	fecal	ADJ	JJ	9	B-Disease
occult	occult	NOUN	NN	5	I-Disease
blood	blood	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
other	other	ADJ	JJ	5	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
gastrointestinal	gastrointestinal	ADJ	JJ	9	B-Disease
(	(	PUNCT	-LRB-	9	I-Disease
GI	GI	PROPN	NNP	9	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
bleeding	bleed	VERB	VBG	5	I-Disease
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
prematurely	prematurely	ADV	RB	5	O
discontinued	discontinue	VERB	VBN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
for	for	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
headache	headache	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
abdominal	abdominal	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Most	Most	ADJ	JJS	5	O
side	side	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
mild	mild	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
GI	GI	PROPN	NNP	9	O
tract	tract	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Hyperkalemia	Hyperkalemia	PROPN	NNP	7	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
sulindac	sulindac	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Hyperkalemia	Hyperkalemia	PROPN	NNP	7	B-Disease
has	have	VERB	VBZ	9	O
recently	recently	ADV	RB	9	O
been	be	VERB	VBN	9	O
recognized	recognize	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
nonsteroidal	nonsteroidal	ADJ	JJ	5	O
antiinflammatory	antiinflammatory	ADJ	JJ	9	O
agents	agent	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
NSAID	NSAID	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
indomethacin	indomethacin	ADV	RB	0	B-Chemical
.	.	PUNCT	.	9	O

Several	several	ADJ	JJ	9	O
recent	recent	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
stressed	stress	VERB	VBN	9	O
the	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
sparing	sparing	NOUN	NN	5	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
sulindac	sulindac	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
owing	owe	VERB	VBG	5	O
to	to	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
lack	lack	NOUN	NN	9	O
of	of	ADP	IN	5	O
interference	interference	NOUN	NN	9	O
with	with	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
prostacyclin	prostacyclin	NOUN	NN	0	B-Chemical
synthesis	synthesis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
4	4	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
whom	whom	PRON	WP	5	O
hyperkalemia	hyperkalemia	NOUN	NN	5	B-Disease
ranging	range	VERB	VBG	9	O
from	from	ADP	IN	9	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
to	to	ADP	IN	5	O
6	6	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
mEq	meq	NOUN	NN	0	O
/	/	SYM	SYM	9	O
l	l	NOUN	NN	0	O
developed	develop	VERB	VBN	5	O
within	within	ADP	IN	9	O
3	3	NUM	CD	9	O
to	to	PART	TO	5	O
8	8	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
sulindac	sulindac	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
all	all	DET	DT	5	O
of	of	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
normal	normal	ADJ	JJ	9	O
serum	serum	ADJ	JJ	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
reached	reach	VERB	VBD	9	O
within	within	ADP	IN	9	O
2	2	NUM	CD	9	O
to	to	PART	TO	5	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
stopping	stop	VERB	VBG	5	O
sulindac	sulindac	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
no	no	DET	DT	9	O
other	other	ADJ	JJ	5	O
medications	medication	NOUN	NNS	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
effect	effect	VERB	VB	9	O
serum	serum	ADJ	JJ	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
given	give	VERB	VBN	5	O
concomitantly	concomitantly	ADV	RB	9	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
events	event	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
suggestive	suggestive	ADJ	JJ	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
cause	cause	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
-	-	PUNCT	HYPH	7	O
effect	effect	NOUN	NN	9	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
sulindac	sulindac	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
hyperkalemia	hyperkalemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
observations	observation	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
initial	initial	ADJ	JJ	9	O
hopes	hope	NOUN	NNS	5	O
that	that	DET	WDT	5	O
sulindac	sulindac	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
not	not	ADV	RB	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
other	other	ADJ	JJ	5	O
NSAID	NSAID	PROPN	NNP	5	O
are	be	VERB	VBP	5	O
probably	probably	ADV	RB	9	O
not	not	ADV	RB	5	O
justified	justified	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
arterial	arterial	ADJ	JJ	5	O
spasm	spasm	NOUN	NNS	5	B-Disease
relieved	relieve	VERB	VBN	5	O
by	by	ADP	IN	9	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Following	follow	VERB	VBG	9	O
major	major	ADJ	JJ	9	O
intracranial	intracranial	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
35	35	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
,	,	PUNCT	,	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
pentothal	pentothal	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
intravenously	intravenously	ADV	RB	0	O
infused	infuse	VERB	VBN	9	O
to	to	PART	TO	5	O
minimize	minimize	VERB	VB	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
ischaemia	ischaemia	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Intense	intense	ADJ	JJ	9	O
vasospasm	vasospasm	VERB	VBZ	5	B-Disease
with	with	ADP	IN	5	O
threatened	threaten	VERB	VBN	5	O
gangrene	gangrene	NOUN	NNS	5	B-Disease
arose	arise	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
arm	arm	NOUN	NN	5	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
the	the	DET	DT	5	O
cranial	cranial	ADJ	JJ	5	O
condition	condition	NOUN	NN	5	O
precluded	preclude	VERB	VBD	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
more	more	ADJ	JJR	5	O
usual	usual	ADJ	JJ	5	O
methods	method	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
intra	intra	ADJ	JJ	5	O
-	-	NOUN	NN	7	O
arterially	arterially	ADV	RB	0	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
careful	careful	ADJ	JJ	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
monitoring	monitoring	NOUN	NN	5	O
,	,	PUNCT	,	9	O
to	to	PART	TO	5	O
counteract	counteract	VERB	VB	9	O
the	the	DET	DT	5	O
vasospasm	vasospasm	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
rapidly	rapidly	ADV	RB	9	O
successful	successful	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Regional	regional	ADJ	JJ	2	O
localization	localization	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
antagonism	antagonism	NOUN	NN	9	O
of	of	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
by	by	ADP	IN	9	O
intracerebral	intracerebral	ADJ	JJ	5	O
calcitonin	calcitonin	ADJ	JJ	3	B-Chemical
injections	injection	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Calcitonin	calcitonin	ADJ	JJ	0	B-Chemical
receptors	receptor	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
intracerebral	intracerebral	ADJ	JJ	5	O
infusions	infusion	NOUN	NNS	9	O
of	of	ADP	IN	5	O
calcitonin	calcitonin	NOUN	NN	3	B-Chemical
can	can	VERB	MD	5	O
produce	produce	VERB	VB	9	O
behavioral	behavioral	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
these	these	DET	DT	5	O
behavioral	behavioral	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
decreases	decrease	NOUN	NNS	9	O
in	in	ADP	IN	5	O
food	food	NOUN	NN	5	O
intake	intake	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
decreases	decrease	VERB	VBZ	9	O
in	in	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
previous	previous	ADJ	JJ	9	O
experiments	experiment	NOUN	NNS	9	O
we	-PRON-	PRON	PRP	5	O
found	find	VERB	VBD	9	O
that	that	ADP	IN	5	O
decreases	decrease	NOUN	NNS	9	O
in	in	ADP	IN	5	O
food	food	NOUN	NN	5	O
intake	intake	NOUN	NN	5	O
were	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
local	local	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
calcitonin	calcitonin	NOUN	NN	3	B-Chemical
into	into	ADP	IN	9	O
several	several	ADJ	JJ	9	O
hypothalamic	hypothalamic	ADJ	JJ	3	O
sites	site	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
nucleus	nucleus	NOUN	NN	9	O
accumbens	accumben	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
experiment	experiment	NOUN	NN	9	O
calcitonin	calcitonin	NOUN	NN	3	B-Chemical
decreased	decrease	VERB	VBD	9	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
when	when	ADV	WRB	5	O
locally	locally	ADV	RB	5	O
injected	inject	VERB	VBN	3	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
sites	site	NOUN	NNS	9	O
where	where	ADV	WRB	5	O
it	-PRON-	PRON	PRP	5	O
decreases	decrease	VERB	VBZ	9	O
food	food	NOUN	NN	5	O
intake	intake	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
areas	area	NOUN	NNS	5	O
where	where	ADV	WRB	5	O
calcitonin	calcitonin	NOUN	NN	3	B-Chemical
is	be	VERB	VBZ	5	O
most	most	ADV	RBS	9	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
decreasing	decrease	VERB	VBG	9	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
are	be	VERB	VBP	5	O
located	locate	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hypothalamus	hypothalamus	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
nucleus	nucleus	NOUN	NN	9	O
accumbens	accumben	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
that	that	ADP	IN	5	O
these	these	DET	DT	5	O
areas	area	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
the	the	DET	DT	5	O
major	major	ADJ	JJ	9	O
sites	site	NOUN	NNS	9	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
calcitonin	calcitonin	NOUN	NN	3	B-Chemical
in	in	ADP	IN	5	O
inhibiting	inhibit	VERB	VBG	3	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hematologic	hematologic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cefonicid	cefonicid	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
cefazedone	cefazedone	NOUN	NN	9	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
dog	dog	NOUN	NN	5	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
cephalosporin	cephalosporin	ADJ	JJ	0	B-Chemical
hematotoxicity	hematotoxicity	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
man	man	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cephalosporin	Cephalosporin	PROPN	NNP	7	B-Chemical
antibiotics	antibiotic	NOUN	NNS	5	O
cause	cause	VERB	VBP	5	O
a	a	DET	DT	5	O
variety	variety	NOUN	NN	5	O
of	of	ADP	IN	5	O
hematologic	hematologic	NOUN	NN	5	B-Disease
disturbances	disturbance	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
man	man	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
pathogeneses	pathogenese	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
hematopathology	hematopathology	NOUN	NN	5	O
of	of	ADP	IN	5	O
which	which	DET	WDT	5	O
remain	remain	VERB	VBP	9	O
poorly	poorly	ADV	RB	9	O
characterized	characterize	VERB	VBN	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
need	need	NOUN	NN	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
defined	define	VERB	VBN	5	O
animal	animal	NOUN	NN	5	O
model	model	NOUN	NN	5	O
in	in	ADP	IN	5	O
which	which	DET	WDT	5	O
these	these	DET	DT	5	O
blood	blood	NOUN	NN	9	B-Disease
dyscrasias	dyscrasia	NOUN	NNS	5	I-Disease
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
studied	study	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
four	four	NUM	CD	9	O
subacute	subacute	NOUN	NN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
studies	study	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
intravenous	intravenous	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
cefonicid	cefonicid	NOUN	NN	9	B-Chemical
or	or	CCONJ	CC	5	O
cefazedone	cefazedone	NOUN	NN	9	B-Chemical
to	to	PART	TO	5	O
beagle	beagle	VERB	VB	0	O
dogs	dog	NOUN	NNS	5	O
caused	cause	VERB	VBD	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
anemia	anemia	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
after	after	ADP	IN	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
nonregenerative	nonregenerative	ADJ	JJ	5	O
anemia	anemia	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
compromising	compromising	ADJ	JJ	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cytopenias	cytopenia	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
approximately	approximately	ADV	RB	9	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
400	400	NUM	CD	0	O
-	-	SYM	SYM	7	O
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
cefonicid	cefonicid	ADJ	JJ	9	B-Chemical
or	or	CCONJ	CC	5	O
540	540	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
840	840	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
cefazedone	cefazedone	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
three	three	NUM	CD	9	O
cytopenias	cytopenia	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
completely	completely	ADV	RB	9	O
reversible	reversible	ADJ	JJ	9	O
following	following	ADJ	JJ	9	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
required	require	VERB	VBN	9	O
for	for	ADP	IN	5	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
erythron	erythron	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
approximately	approximately	ADV	RB	9	O
1	1	NUM	CD	9	O
month	month	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
considerably	considerably	ADV	RB	9	O
longer	long	ADJ	JJR	5	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
granulocytes	granulocyte	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
platelets	platelet	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
hours	hour	NOUN	NNS	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
few	few	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Upon	upon	ADP	IN	9	O
rechallenge	rechallenge	NOUN	NN	3	O
with	with	ADP	IN	5	O
either	either	DET	DT	9	O
cephalosporin	cephalosporin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
hematologic	hematologic	NOUN	NN	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
reproduced	reproduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
most	most	ADJ	JJS	9	O
dogs	dog	NOUN	NNS	5	O
tested	test	VERB	VBN	9	O
;	;	PUNCT	:	9	O
cefonicid	cefonicid	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
cefazedone	cefazedone	NOUN	NN	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
dogs	dog	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
substantially	substantially	ADV	RB	9	O
reduced	reduce	VERB	VBN	9	O
induction	induction	NOUN	NN	3	O
period	period	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
61	61	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
24	24	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
observation	observation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
along	along	ADP	IN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
rapid	rapid	ADJ	JJ	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
decline	decline	NOUN	NN	9	O
in	in	ADP	IN	5	O
red	red	ADJ	JJ	9	O
cell	cell	NOUN	NN	3	O
mass	mass	NOUN	NN	9	O
parameters	parameter	NOUN	NNS	5	O
of	of	ADP	IN	5	O
affected	affected	ADJ	JJ	9	O
dogs	dog	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
component	component	NOUN	NN	9	O
complicated	complicate	VERB	VBD	5	O
the	the	DET	DT	5	O
red	red	ADJ	JJ	9	O
cell	cell	NOUN	NN	3	O
production	production	NOUN	NN	9	O
problem	problem	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
multiple	multiple	ADJ	JJ	5	O
toxicologic	toxicologic	ADJ	JJ	5	O
mechanisms	mechanism	NOUN	NNS	9	O
contributed	contribute	VERB	VBD	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
cytopenia	cytopenia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
cefonicid	cefonicid	NOUN	NN	9	B-Chemical
or	or	CCONJ	CC	5	O
cefazedone	cefazedone	NOUN	NN	9	B-Chemical
to	to	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
can	can	VERB	MD	5	O
induce	induce	VERB	VB	3	O
hematotoxicity	hematotoxicity	NOUN	NN	5	B-Disease
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
cephalosporin	cephalosporin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
blood	blood	NOUN	NN	9	B-Disease
dyscrasias	dyscrasia	NOUN	NNS	5	I-Disease
described	describe	VERB	VBN	9	O
in	in	ADP	IN	5	O
man	man	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
thus	thus	ADV	RB	9	O
provides	provide	VERB	VBZ	5	O
a	a	DET	DT	5	O
useful	useful	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
for	for	ADP	IN	5	O
studying	study	VERB	VBG	5	O
the	the	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
disorders	disorder	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Cerebral	cerebral	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
metabolism	metabolism	NOUN	NN	9	O
during	during	ADP	IN	5	O
isoflurane	isoflurane	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
subjected	subject	VERB	VBN	9	O
to	to	ADP	IN	5	O
surgery	surgery	NOUN	NN	5	O
for	for	ADP	IN	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
aneurysms	aneurysm	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Cerebral	cerebral	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
cerebral	cerebral	ADJ	JJ	5	O
metabolic	metabolic	ADJ	JJ	9	O
rate	rate	NOUN	NN	9	O
for	for	ADP	IN	5	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
during	during	ADP	IN	5	O
isoflurane	isoflurane	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
10	10	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
subjected	subject	VERB	VBN	9	O
to	to	ADP	IN	5	O
craniotomy	craniotomy	NOUN	NN	5	O
for	for	ADP	IN	5	O
clipping	clipping	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
aneurysm	aneurysm	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Flow	flow	VERB	VB	3	O
and	and	CCONJ	CC	5	O
metabolism	metabolism	NOUN	NN	9	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
13	13	NUM	CD	7	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
subarachnoid	subarachnoid	NOUN	NN	5	B-Disease
haemorrhage	haemorrhage	NOUN	NN	5	I-Disease
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
modification	modification	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
classical	classical	ADJ	JJ	9	O
Kety	Kety	PROPN	NNP	6	O
-	-	PUNCT	HYPH	7	O
Schmidt	Schmidt	PROPN	NNP	6	O
technique	technique	NOUN	NN	5	O
using	use	VERB	VBG	9	O
xenon	xenon	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
133	133	NUM	CD	7	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
Anaesthesia	Anaesthesia	PROPN	NNP	2	O
was	be	VERB	VBD	9	O
maintained	maintain	VERB	VBN	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
inspired	inspire	VERB	VBN	5	O
isoflurane	isoflurane	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
75	75	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
plus	plus	CCONJ	CC	9	O
67	67	NUM	CD	7	O
%	%	NOUN	NN	9	O
nitrous	nitrous	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
during	during	ADP	IN	5	O
which	which	DET	WDT	5	O
CBF	CBF	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
CMRO2	CMRO2	PROPN	NNP	5	O
were	be	VERB	VBD	9	O
34	34	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
ml	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
100	100	NUM	CD	0	O
g	g	NOUN	NN	0	O
min	min	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
32	32	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
16	16	NUM	CD	9	O
ml	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
100	100	NUM	CD	0	O
g	g	NOUN	NN	0	O
min	min	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
at	at	ADP	IN	9	O
PaCO2	paco2	NOUN	NN	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
kPa	kpa	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SEM	SEM	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Controlled	control	VERB	VBN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
average	average	ADJ	JJ	5	O
MAP	MAP	PROPN	NNP	9	O
of	of	ADP	IN	5	O
50	50	NUM	CD	0	O
-	-	SYM	SYM	7	O
55	55	NUM	CD	7	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
increasing	increase	VERB	VBG	9	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
isoflurane	isoflurane	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
maintained	maintain	VERB	VBD	9	O
at	at	ADP	IN	9	O
an	an	DET	DT	5	O
inspired	inspire	VERB	VBN	5	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
CMRO2	CMRO2	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
to	to	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
73	73	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
16	16	NUM	CD	9	O
ml	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
100	100	NUM	CD	0	O
g	g	NOUN	NN	0	O
min	min	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
CBF	CBF	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
the	the	DET	DT	5	O
clipping	clipping	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
aneurysm	aneurysm	NOUN	NNS	5	B-Disease
the	the	DET	DT	5	O
isoflurane	isoflurane	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
to	to	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
75	75	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
CBF	CBF	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
CMRO2	CMRO2	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
values	value	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
changes	change	NOUN	NNS	9	O
might	may	VERB	MD	9	O
offer	offer	VERB	VB	5	O
protection	protection	NOUN	NN	9	O
to	to	PART	TO	5	O
brain	brain	VERB	VB	5	O
tissue	tissue	NOUN	NN	9	O
during	during	ADP	IN	5	O
periods	period	NOUN	NNS	5	O
of	of	ADP	IN	5	O
induced	induced	ADJ	JJ	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Triazolam	Triazolam	PROPN	NNP	7	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
brief	brief	NOUN	NN	5	O
episodes	episode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
secondary	secondary	ADJ	JJ	9	O
mania	mania	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
depressed	depressed	ADJ	JJ	5	B-Disease
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Large	large	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
triazolam	triazolam	NOUN	NN	0	B-Chemical
repeatedly	repeatedly	ADV	RB	5	O
induced	induce	VERB	VBD	3	O
brief	brief	ADJ	JJ	5	O
episodes	episode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
mania	mania	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
depressed	depressed	ADJ	JJ	5	B-Disease
elderly	elderly	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
organic	organic	ADJ	JJ	0	B-Disease
mental	mental	ADJ	JJ	5	I-Disease
disorder	disorder	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
delirium	delirium	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
present	present	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Manic	manic	ADJ	JJ	2	B-Disease
excitement	excitement	NOUN	NN	5	O
was	be	VERB	VBD	9	O
coincident	coincident	ADJ	JJ	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
triazolam	triazolam	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
contribution	contribution	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
triazolo	triazolo	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
to	to	ADP	IN	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
affective	affective	ADJ	JJ	5	O
status	status	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
correlation	correlation	NOUN	NN	9	O
between	between	ADP	IN	5	O
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
esterase	esterase	NOUN	NN	0	O
inhibition	inhibition	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
mipafox	mipafox	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
neuropathic	neuropathic	ADJ	JJ	5	B-Disease
damage	damage	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
correlation	correlation	NOUN	NN	9	O
between	between	ADP	IN	5	O
neuropathic	neuropathic	ADJ	JJ	5	B-Disease
damage	damage	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
esterase	esterase	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
neuropathy	neuropathy	ADJ	JJ	5	B-Disease
target	target	NOUN	NN	9	O
enzyme	enzyme	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
NTE	NTE	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
acutely	acutely	ADV	RB	9	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
Mipafox	Mipafox	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
N	N	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
N	N	PROPN	NNP	9	I-Chemical
'	'	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
diisopropylphosphorodiamidofluoridate	diisopropylphosphorodiamidofluoridate	NOUN	NN	_	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
organophosphate	organophosphate	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Brain	brain	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
spinal	spinal	ADJ	JJ	5	O
cord	cord	NOUN	NN	9	O
NTE	NTE	PROPN	NNP	0	O
activities	activity	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
in	in	ADP	IN	5	O
Long	Long	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Evans	Evans	PROPN	NNP	6	O
male	male	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
1	1	NUM	CD	9	O
hr	hr	NOUN	NN	0	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
various	various	ADJ	JJ	9	O
dosages	dosage	NOUN	NNS	9	O
of	of	ADP	IN	5	O
Mipafox	Mipafox	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
ip	ip	NOUN	NN	0	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
15	15	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
histologically	histologically	ADV	RB	9	O
scored	score	VERB	VBN	5	O
cervical	cervical	ADJ	JJ	5	O
cord	cord	NOUN	NN	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
separate	separate	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
similarly	similarly	ADV	RB	9	O
dosed	dose	VERB	VBN	0	O
rats	rat	NOUN	NNS	9	O
sampled	sample	VERB	VBD	5	O
14	14	NUM	CD	7	O
-	-	SYM	SYM	7	O
21	21	NUM	CD	7	O
days	day	NOUN	NNS	9	O
post	post	NOUN	NN	9	O
-	-	NOUN	NN	7	O
exposure	exposure	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Those	those	DET	DT	5	O
dosages	dosage	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
or	or	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
that	that	DET	WDT	5	O
inhibited	inhibit	VERB	VBD	3	O
mean	mean	ADJ	JJ	5	O
NTE	NTE	PROPN	NNP	0	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
spinal	spinal	ADJ	JJ	5	O
cord	cord	NOUN	NN	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
or	or	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
73	73	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
brain	brain	NOUN	NN	5	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
or	or	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
67	67	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
control	control	NOUN	NN	9	O
values	value	NOUN	NNS	5	O
produced	produce	VERB	VBN	9	O
severe	severe	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
or	or	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
cervical	cervical	ADJ	JJ	5	O
cord	cord	NOUN	NN	9	O
pathology	pathology	NOUN	NN	5	O
in	in	ADP	IN	5	O
85	85	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
dosages	dosage	NOUN	NNS	9	O
of	of	ADP	IN	5	O
Mipafox	Mipafox	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
or	or	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
which	which	DET	WDT	5	O
inhibited	inhibit	VERB	VBD	3	O
mean	mean	ADJ	JJ	5	O
NTE	NTE	PROPN	NNP	0	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
spinal	spinal	ADJ	JJ	5	O
cord	cord	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
or	or	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
61	61	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
brain	brain	NOUN	NN	5	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
or	or	CCONJ	CC	5	O
equal	equal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
60	60	NUM	CD	9	O
%	%	NOUN	NN	9	O
produced	produce	VERB	VBD	9	O
this	this	DET	DT	5	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
cord	cord	NOUN	NN	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
only	only	ADV	RB	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
critical	critical	ADJ	JJ	9	O
percentage	percentage	NOUN	NN	9	O
of	of	ADP	IN	5	O
NTE	NTE	PROPN	NNP	0	O
inhibition	inhibition	NOUN	NN	3	O
in	in	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
spinal	spinal	ADJ	JJ	5	O
cord	cord	NOUN	NN	9	O
sampled	sample	VERB	VBN	5	O
shortly	shortly	ADV	RB	9	O
after	after	ADP	IN	9	O
Mipafox	Mipafox	PROPN	NNP	9	B-Chemical
exposure	exposure	NOUN	NN	9	O
can	can	VERB	MD	5	O
predict	predict	VERB	VB	5	O
neuropathic	neuropathic	ADJ	JJ	5	B-Disease
damage	damage	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
several	several	ADJ	JJ	9	O
weeks	week	NOUN	NNS	9	O
later	later	ADV	RB	9	O
.	.	PUNCT	.	9	O

Allergic	allergic	ADJ	JJ	9	B-Disease
reaction	reaction	NOUN	NN	9	I-Disease
to	to	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
allergic	allergic	ADJ	JJ	9	B-Disease
reaction	reaction	NOUN	NN	9	I-Disease
consisting	consist	VERB	VBG	9	O
of	of	ADP	IN	5	O
angioneurotic	angioneurotic	ADJ	JJ	2	B-Disease
edema	edema	NOUN	NN	5	I-Disease
secondary	secondary	ADJ	JJ	9	O
to	to	PART	TO	5	O
continuous	continuous	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
recurrent	recurrent	ADJ	JJ	5	O
carcinoma	carcinoma	NOUN	NN	3	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
oral	oral	ADJ	JJ	9	I-Disease
cavity	cavity	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
cirrhosis	cirrhosis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
impaired	impaired	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
function	function	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
reaction	reaction	NOUN	NN	9	O
occurred	occur	VERB	VBD	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
sixth	sixth	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
seventh	seventh	ADJ	JJ	9	O
courses	course	NOUN	NNS	5	O
of	of	ADP	IN	5	O
infusional	infusional	ADJ	JJ	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Oral	oral	ADJ	JJ	9	O
diphenhydramine	diphenhydramine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
prednisone	prednisone	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
ineffective	ineffective	ADJ	JJ	9	O
in	in	ADP	IN	5	O
preventing	prevent	VERB	VBG	9	O
the	the	DET	DT	5	O
recurrence	recurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
allergic	allergic	ADJ	JJ	9	B-Disease
reaction	reaction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Discontinuance	discontinuance	NOUN	NN	5	O
of	of	ADP	IN	5	O
effective	effective	ADJ	JJ	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
during	during	ADP	IN	5	O
partial	partial	ADJ	JJ	9	O
remission	remission	NOUN	NN	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
fatal	fatal	ADJ	JJ	5	O
disease	disease	NOUN	NN	5	O
progression	progression	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Myasthenia	Myasthenia	PROPN	NNP	2	B-Disease
gravis	gravi	NOUN	NNS	2	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
penicillamine	penicillamine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
chloroquine	chloroquine	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
rheumatoid	rheumatoid	ADJ	JJ	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
described	describe	VERB	VBN	9	O
a	a	DET	DT	5	O
unique	unique	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
reversible	reversible	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
myasthenia	myasthenia	ADJ	JJ	9	B-Disease
gravis	gravi	NOUN	NNS	2	I-Disease
after	after	ADP	IN	9	O
penicillamine	penicillamine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
chloroquine	chloroquine	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
rheumatoid	rheumatoid	ADJ	JJ	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
receptor	receptor	NOUN	NN	3	O
antibodies	antibody	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
detectable	detectable	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
course	course	NOUN	NN	5	O
was	be	VERB	VBD	9	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
autoimmune	autoimmune	ADJ	JJ	3	O
process	process	NOUN	NN	5	O
.	.	PUNCT	.	9	O

On	on	ADP	IN	5	O
the	the	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
tolerance	tolerance	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
muscular	muscular	ADJ	JJ	5	B-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
tolerance	tolerance	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
muscular	muscular	ADJ	JJ	5	B-Disease
rigidity	rigidity	NOUN	NN	5	I-Disease
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
morphine	morphine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Saline	Saline	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
pretreated	pretreate	VERB	VBN	3	O
controls	control	NOUN	NNS	9	O
given	give	VERB	VBN	5	O
a	a	DET	DT	5	O
test	test	NOUN	NN	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
pronounced	pronounced	ADJ	JJ	9	O
rigidity	rigidity	NOUN	NN	5	B-Disease
recorded	record	VERB	VBN	5	O
as	as	ADP	IN	5	O
tonic	tonic	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
electromyogram	electromyogram	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBD	3	O
for	for	ADP	IN	5	O
11	11	NUM	CD	7	O
days	day	NOUN	NNS	9	O
with	with	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
withdrawn	withdraw	VERB	VBN	9	O
for	for	ADP	IN	5	O
36	36	NUM	CD	9	O
-	-	SYM	SYM	7	O
40	40	NUM	CD	9	O
h	h	NOUN	NN	0	O
showed	show	VERB	VBD	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
tolerance	tolerance	NOUN	NN	9	O
:	:	PUNCT	:	9	O
about	about	ADP	IN	5	O
half	half	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
rigidity	rigidity	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
test	test	NOUN	NN	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
that	that	DET	WDT	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
controls	control	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
akinetic	akinetic	ADJ	JJ	5	B-Disease
(	(	PUNCT	-LRB-	9	O
A	a	DET	DT	9	O
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
strong	strong	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rigidity	rigidity	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
stereotyped	stereotyped	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
S	S	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
licking	licking	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
gnawing	gnaw	VERB	VBG	5	O
in	in	ADP	IN	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
akinetic	akinetic	ADJ	JJ	5	B-Disease
or	or	CCONJ	CC	5	O
hyperkinetic	hyperkinetic	ADJ	JJ	5	B-Disease
(	(	PUNCT	-LRB-	9	O
K	K	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
behaviour	behaviour	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
AS	AS	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
KS	KS	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
activation	activation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rigidity	rigidity	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
considerably	considerably	ADV	RB	9	O
decreased	decrease	VERB	VBN	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
after	after	ADP	IN	9	O
20	20	NUM	CD	9	O
days	day	NOUN	NNS	9	O
'	'	PART	POS	9	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
further	further	ADJ	JJ	9	O
series	series	NOUN	NN	5	O
of	of	ADP	IN	5	O
experiments	experiment	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
block	block	VERB	VB	9	O
the	the	DET	DT	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
activation	activation	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
estimate	estimate	VERB	VB	5	O
the	the	DET	DT	5	O
real	real	ADJ	JJ	5	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
tolerance	tolerance	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
rigidity	rigidity	NOUN	NN	5	B-Disease
without	without	ADP	IN	9	O
any	any	DET	DT	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
interference	interference	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Haloperidol	Haloperidol	PROPN	NNP	7	B-Chemical
enhanced	enhance	VERB	VBD	3	O
the	the	DET	DT	5	O
rigidity	rigidity	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
A	a	DET	DT	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
level	level	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
AS	AS	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
KS	KS	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
remained	remain	VERB	VBD	9	O
considerably	considerably	ADV	RB	9	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
A	a	DET	DT	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	DET	DT	5	O
rigidity	rigidity	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
is	be	VERB	VBZ	5	O
assumed	assume	VERB	VBN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
morphine	morphine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
,	,	PUNCT	,	9	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
antagonized	antagonize	VERB	VBN	3	O
by	by	ADP	IN	9	O
another	another	DET	DT	9	O
process	process	NOUN	NN	5	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
activation	activation	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
striatum	striatum	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Nevertheless	nevertheless	ADV	RB	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
occurs	occur	VERB	VBZ	9	O
some	some	DET	DT	5	O
real	real	ADJ	JJ	5	O
tolerance	tolerance	NOUN	NN	9	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rapid	rapid	ADJ	JJ	5	O
alternations	alternation	NOUN	NNS	5	O
of	of	ADP	IN	5	O
rigidity	rigidity	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
activation	activation	NOUN	NN	3	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
AS	AS	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
KS	KS	PROPN	NNP	9	O
group	group	NOUN	NN	9	O
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
rapid	rapid	ADJ	JJ	5	O
shifts	shift	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
predominance	predominance	NOUN	NN	9	O
of	of	ADP	IN	5	O
various	various	ADJ	JJ	9	O
DA	da	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
innervated	innervate	VERB	VBN	5	O
structures	structure	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
massive	massive	ADJ	JJ	9	O
rhabdomyolysis	rhabdomyolysis	NOUN	NN	5	B-Disease
following	follow	VERB	VBG	9	O
molindone	molindone	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Rhabdomyolysis	rhabdomyolysis	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
potentially	potentially	ADV	RB	5	O
lethal	lethal	ADJ	JJ	9	O
syndrome	syndrome	NOUN	NN	5	O
that	that	ADP	IN	5	O
psychiatric	psychiatric	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
seem	seem	VERB	VBP	5	O
predisposed	predispose	VERB	VBN	5	O
to	to	PART	TO	5	O
develop	develop	VERB	VB	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
symptoms	symptom	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
typical	typical	ADJ	JJ	9	O
laboratory	laboratory	NOUN	NN	9	O
features	feature	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
complications	complication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
rhabdomyolysis	rhabdomyolysis	NOUN	NN	5	B-Disease
are	be	VERB	VBP	5	O
presented	present	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
schizophrenic	schizophrenic	ADJ	JJ	5	B-Disease
patient	patient	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
reported	report	VERB	VBN	9	O
to	to	PART	TO	5	O
illustrate	illustrate	VERB	VB	5	O
massive	massive	ADJ	JJ	9	O
rhabdomyolysis	rhabdomyolysis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
subsequent	subsequent	ADJ	JJ	9	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
following	follow	VERB	VBG	9	O
molindone	molindone	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Physicians	physician	NOUN	NNS	5	O
who	who	PRON	WP	5	O
prescribe	prescribe	VERB	VBP	5	O
molindone	molindone	PRON	PRP	0	B-Chemical
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
reaction	reaction	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Compression	compression	NOUN	NN	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
radial	radial	ADJ	JJ	5	I-Disease
nerve	nerve	NOUN	NN	5	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
pentazocine	pentazocine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
fibrous	fibrous	ADJ	JJ	5	B-Disease
myopathy	myopathy	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Fibrous	fibrous	ADJ	JJ	5	B-Disease
myopathy	myopathy	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
common	common	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
known	know	VERB	VBN	9	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
repeated	repeat	VERB	VBN	5	O
pentazocine	pentazocine	NOUN	NN	0	B-Chemical
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
compression	compression	NOUN	NN	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
fibrotic	fibrotic	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
pentazocine	pentazocine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myopathy	myopathy	NOUN	NN	9	B-Disease
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
previously	previously	ADV	RB	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
37	37	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
documented	document	VERB	VBN	9	O
pentazocine	pentazocine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
fibrous	fibrous	ADJ	JJ	5	B-Disease
myopathy	myopathy	NOUN	NN	9	I-Disease
of	of	ADP	IN	5	O
triceps	tricep	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
deltoid	deltoid	ADJ	JJ	5	O
muscles	muscle	NOUN	NNS	5	O
bilaterally	bilaterally	ADV	RB	5	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
three	three	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
right	right	ADJ	JJ	5	O
wrist	wrist	NOUN	NN	5	O
drop	drop	NOUN	NN	9	O
,	,	PUNCT	,	9	O
electrodiagnostic	electrodiagnostic	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
severe	severe	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
partial	partial	ADJ	JJ	9	O
lesion	lesion	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	ADJ	JJ	5	O
radial	radial	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
distal	distal	ADJ	JJ	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
branches	branch	NOUN	NNS	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
triceps	tricep	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
fibrous	fibrous	ADJ	JJ	5	B-Disease
myopathy	myopathy	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Surgery	Surgery	PROPN	NNP	2	O
revealed	reveal	VERB	VBD	9	O
the	the	DET	DT	5	O
right	right	ADJ	JJ	5	O
radial	radial	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
severely	severely	ADV	RB	9	O
compressed	compress	VERB	VBN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
densely	densely	ADV	RB	5	O
fibrotic	fibrotic	ADJ	JJ	5	O
lateral	lateral	ADJ	JJ	5	O
head	head	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
triceps	tricep	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Decompression	decompression	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
neurolysis	neurolysis	NOUN	NN	5	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
with	with	ADP	IN	5	O
good	good	ADJ	JJ	5	O
subsequent	subsequent	ADJ	JJ	9	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Recurrent	recurrent	ADJ	JJ	5	O
reversible	reversible	ADJ	JJ	9	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
from	from	ADP	IN	9	O
amphotericin	amphotericin	ADV	RB	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
cryptogenic	cryptogenic	ADJ	JJ	5	O
cirrhosis	cirrhosis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
disseminated	disseminate	VERB	VBN	5	O
sporotrichosis	sporotrichosis	NOUN	NN	4	B-Disease
developed	develop	VERB	VBD	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
immediately	immediately	ADV	RB	9	O
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
amphotericin	amphotericin	PROPN	NNP	0	B-Chemical
B	B	PROPN	NNP	9	I-Chemical
on	on	ADP	IN	5	O
four	four	NUM	CD	9	O
separate	separate	ADJ	JJ	9	O
occasions	occasion	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
abruptness	abruptness	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
reversibility	reversibility	NOUN	NN	9	O
within	within	ADP	IN	9	O
days	day	NOUN	NNS	9	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
functional	functional	ADJ	JJ	9	O
component	component	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
propose	propose	VERB	VBP	9	O
that	that	DET	DT	5	O
amphotericin	amphotericin	ADV	RB	0	B-Chemical
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
setting	setting	NOUN	NN	5	O
of	of	ADP	IN	5	O
reduced	reduce	VERB	VBN	9	O
effective	effective	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
volume	volume	NOUN	NN	9	O
,	,	PUNCT	,	9	O
may	may	VERB	MD	5	O
activate	activate	VERB	VB	3	O
tubuloglomerular	tubuloglomerular	ADJ	JJ	5	O
feedback	feedback	NOUN	NN	5	O
,	,	PUNCT	,	9	O
thereby	thereby	ADV	RB	9	O
contributing	contribute	VERB	VBG	9	O
to	to	PART	TO	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Cerebral	cerebral	ADJ	JJ	5	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
oral	oral	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
phenylpropanolamine	phenylpropanolamine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Phenylpropanolamine	Phenylpropanolamine	PROPN	NNP	7	B-Chemical
(	(	PUNCT	-LRB-	9	O
PPA	PPA	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
synthetic	synthetic	ADJ	JJ	0	O
sympathomimetic	sympathomimetic	NOUN	NN	5	O
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
structurally	structurally	ADV	RB	9	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
amphetamine	amphetamine	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
available	available	ADJ	JJ	5	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
counter	counter	NOUN	NN	5	O
in	in	ADP	IN	5	O
anorectics	anorectic	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
nasal	nasal	NOUN	NN	5	O
congestants	congestant	NOUN	NNS	_	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cold	cold	ADJ	JJ	9	O
preparations	preparation	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Its	-PRON-	DET	PRP$	5	O
prolonged	prolong	VERB	VBN	9	O
use	use	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
overuse	overuse	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
intracerebral	intracerebral	ADJ	JJ	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
neuropsychiatric	neuropsychiatric	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
nonhemorrhagic	nonhemorrhagic	ADJ	JJ	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
young	young	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
who	who	PRON	WP	5	O
suffered	suffer	VERB	VBD	5	O
a	a	DET	DT	5	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
taking	take	VERB	VBG	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
oral	oral	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
PPA	PPA	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

Remission	remission	NOUN	NN	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
meningeal	meningeal	ADJ	JJ	5	B-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
intravenous	intravenous	ADJ	JJ	0	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
lymphoblastic	lymphoblastic	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
meningeal	meningeal	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
intravenous	intravenous	ADJ	JJ	0	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
regimen	regiman	NOUN	NNS	5	O
that	that	DET	WDT	5	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
achieve	achieve	VERB	VB	5	O
and	and	CCONJ	CC	5	O
maintain	maintain	VERB	VB	5	O
CSF	csf	NOUN	NN	9	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
mol	mol	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
without	without	ADP	IN	9	O
the	the	DET	DT	5	O
need	need	NOUN	NN	5	O
for	for	ADP	IN	5	O
concomitant	concomitant	ADJ	JJ	9	O
intrathecal	intrathecal	ADJ	JJ	3	O
dosing	dosing	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
loading	loading	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
6	6	NUM	CD	9	O
,	,	PUNCT	,	9	O
000	000	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
one	one	NUM	CD	5	O
hour	hour	NOUN	NN	0	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
an	an	DET	DT	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
/	/	SYM	SYM	9	O
h	h	NOUN	NN	0	O
for	for	ADP	IN	5	O
23	23	NUM	CD	7	O
hours	hour	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Leucovorin	Leucovorin	PROPN	NNP	0	B-Chemical
rescue	rescue	NOUN	NN	3	O
was	be	VERB	VBD	9	O
initiated	initiate	VERB	VBN	9	O
12	12	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
end	end	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
infusion	infusion	NOUN	NN	0	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
loading	loading	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
12	12	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
every	every	DET	DT	5	O
three	three	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
for	for	ADP	IN	5	O
six	six	NUM	CD	9	O
doses	dose	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
then	then	ADV	RB	9	O
every	every	DET	DT	5	O
six	six	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
until	until	ADP	IN	5	O
the	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
level	level	NOUN	NN	9	O
decreased	decrease	VERB	VBD	9	O
to	to	ADP	IN	5	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
1	1	NUM	CD	9	O
X	x	NOUN	NN	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
mol	mol	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
steady	steady	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
state	state	NOUN	NN	5	O
plasma	plasma	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
CSF	csf	NOUN	NN	9	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
achieved	achieve	VERB	VBN	5	O
were	be	VERB	VBD	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
X	x	NOUN	NN	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
3	3	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
mol	mol	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
X	x	NOUN	NN	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
mol	mol	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
L	l	NOUN	NN	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
20	20	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
responded	respond	VERB	VBD	9	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
regimen	regimen	NOUN	NN	5	O
,	,	PUNCT	,	9	O
16	16	NUM	CD	9	O
/	/	SYM	SYM	9	O
20	20	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
80	80	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
achieved	achieve	VERB	VBD	5	O
a	a	DET	DT	5	O
complete	complete	ADJ	JJ	9	O
remission	remission	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
obtained	obtain	VERB	VBD	9	O
a	a	DET	DT	5	O
partial	partial	ADJ	JJ	9	O
remission	remission	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
encountered	encounter	VERB	VBN	5	O
were	be	VERB	VBD	9	O
transient	transient	ADJ	JJ	9	O
serum	serum	NOUN	NN	9	O
transaminase	transaminase	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
bilirubin	bilirubin	NOUN	NN	0	B-Chemical
elevations	elevation	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
mucositis	mucositis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
focal	focal	ADJ	JJ	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
transient	transient	ADJ	JJ	9	B-Disease
hemiparesis	hemiparesis	NOUN	NN	5	I-Disease
but	but	CCONJ	CC	9	O
recovered	recover	VERB	VBD	9	O
completely	completely	ADV	RB	9	O
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
intravenous	intravenous	ADJ	JJ	0	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
remission	remission	NOUN	NN	5	O
after	after	ADP	IN	9	O
meningeal	meningeal	ADJ	JJ	5	O
relapse	relapse	NOUN	NN	5	O
in	in	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
lymphoblastic	lymphoblastic	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Interaction	interaction	NOUN	NN	9	O
of	of	ADP	IN	5	O
cyclosporin	cyclosporin	NOUN	NN	0	B-Chemical
A	A	PROPN	NNP	9	I-Chemical
with	with	ADP	IN	5	O
antineoplastic	antineoplastic	ADJ	JJ	9	O
agents	agent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
synergistic	synergistic	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
etoposide	etoposide	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
cyclosporin	cyclosporin	VERB	VB	0	B-Chemical
A	A	PROPN	NNP	9	I-Chemical
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
T	T	PROPN	NNP	3	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
lymphocytic	lymphocytic	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
in	in	ADP	IN	5	O
relapse	relapse	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
concomitant	concomitant	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
etoposide	etoposide	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
cyclosporin	cyclosporin	VERB	VB	0	B-Chemical
A	A	PROPN	NNP	9	I-Chemical
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
eradication	eradication	NOUN	NN	5	O
of	of	ADP	IN	5	O
hitherto	hitherto	ADJ	JJ	9	O
refractory	refractory	NOUN	NN	9	O
leukemic	leukemic	NOUN	NN	3	B-Disease
infiltration	infiltration	NOUN	NN	3	I-Disease
of	of	ADP	IN	5	O
bone	bone	NOUN	NN	5	O
marrow	marrow	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Severe	severe	ADJ	JJ	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
in	in	ADP	IN	5	O
terms	term	NOUN	NNS	5	O
of	of	ADP	IN	5	O
mental	mental	ADJ	JJ	5	O
confusion	confusion	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
progressive	progressive	ADJ	JJ	5	O
hyperbilirubinemia	hyperbilirubinemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
point	point	VERB	VBP	5	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
enhancement	enhancement	NOUN	NN	9	O
not	not	ADV	RB	5	O
only	only	ADV	RB	9	O
of	of	ADP	IN	5	O
antineoplastic	antineoplastic	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
but	but	CCONJ	CC	9	O
also	also	ADV	RB	9	O
of	of	ADP	IN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
tissues	tissue	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
report	report	NOUN	NN	5	O
demonstrates	demonstrate	VERB	VBZ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
that	that	DET	WDT	5	O
the	the	DET	DT	5	O
pharmacodynamic	pharmacodynamic	ADJ	JJ	5	O
properties	property	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cyclosporin	cyclosporin	NOUN	NN	0	B-Chemical
A	A	PROPN	NNP	9	I-Chemical
may	may	VERB	MD	5	O
not	not	ADV	RB	5	O
be	be	VERB	VB	5	O
confined	confine	VERB	VBN	9	O
strictly	strictly	ADV	RB	9	O
to	to	ADP	IN	5	O
suppression	suppression	NOUN	NN	9	O
of	of	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
T	T	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
cell	cell	NOUN	NN	3	O
functions	function	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Incidence	incidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
neoplasms	neoplasm	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
rheumatoid	rheumatoid	ADJ	JJ	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
different	different	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
regimens	regimen	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Immunosuppressive	immunosuppressive	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
used	use	VERB	VBN	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
30	30	NUM	CD	9	O
years	year	NOUN	NNS	5	O
in	in	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
rheumatoid	rheumatoid	ADJ	JJ	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
commonly	commonly	ADV	RB	5	O
used	use	VERB	VBN	5	O
are	be	VERB	VBP	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
chlorambucil	chlorambucil	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
alkylating	alkylate	VERB	VBG	0	B-Chemical
agents	agent	NOUN	NNS	5	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
azathioprine	azathioprine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
purine	purine	ADJ	JJ	0	B-Chemical
analogue	analogue	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
folic	folic	ADJ	JJ	0	B-Chemical
acid	acid	ADJ	JJ	0	I-Chemical
analogue	analogue	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
evidence	evidence	NOUN	NN	9	O
that	that	ADP	IN	5	O
all	all	DET	DT	5	O
four	four	NUM	CD	9	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
can	can	VERB	MD	5	O
reduce	reduce	VERB	VB	5	O
synovitis	synovitis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
disease	disease	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
almost	almost	ADV	RB	9	O
always	always	ADV	RB	5	O
recurs	recur	VERB	VBZ	5	O
after	after	ADP	IN	9	O
therapy	therapy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
stopped	stop	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
frequent	frequent	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
50	50	NUM	CD	0	O
percent	percent	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
able	able	ADJ	JJ	9	O
to	to	PART	TO	5	O
continue	continue	VERB	VB	5	O
a	a	DET	DT	5	O
particular	particular	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
for	for	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
one	one	NUM	CD	5	O
year	year	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
takes	take	VERB	VBZ	5	O
three	three	NUM	CD	9	O
to	to	PART	TO	5	O
12	12	NUM	CD	9	O
months	month	NOUN	NNS	5	O
to	to	PART	TO	5	O
achieve	achieve	VERB	VB	5	O
maximal	maximal	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
those	those	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
are	be	VERB	VBP	5	O
unable	unable	ADJ	JJ	9	O
to	to	PART	TO	5	O
continue	continue	VERB	VB	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
receive	receive	VERB	VBP	5	O
little	little	ADJ	JJ	9	O
benefit	benefit	NOUN	NN	5	O
from	from	ADP	IN	9	O
it	-PRON-	PRON	PRP	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBD	3	O
with	with	ADP	IN	5	O
alkylating	alkylate	VERB	VBG	0	B-Chemical
agents	agent	NOUN	NNS	5	I-Chemical
have	have	VERB	VBP	5	O
an	an	DET	DT	5	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
nonlymphocytic	nonlymphocytic	ADJ	JJ	3	I-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
both	both	DET	DT	9	O
alkylating	alkylate	VERB	VBG	0	B-Chemical
agents	agent	NOUN	NNS	5	I-Chemical
and	and	CCONJ	CC	5	O
azathioprine	azathioprine	NOUN	NN	5	B-Chemical
are	be	VERB	VBP	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
non	non	ADJ	JJ	9	B-Disease
-	-	PROPN	NNP	7	I-Disease
Hodgkin	Hodgkin	PROPN	NNP	5	I-Disease
'	'	PUNCT	''	9	I-Disease
s	s	NOUN	NN	9	I-Disease
lymphoma	lymphoma	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Cyclophosphamide	Cyclophosphamide	PROPN	NNP	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
increases	increase	VERB	VBZ	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
carcinoma	carcinoma	NOUN	NN	3	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
bladder	bladder	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
several	several	ADJ	JJ	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
rheumatoid	rheumatoid	ADJ	JJ	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
azathioprine	azathioprine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
most	most	ADJ	JJS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
common	common	ADJ	JJ	5	O
cancers	cancer	NOUN	NNS	9	B-Disease
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
increased	increase	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Data	datum	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
increased	increase	VERB	VBN	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
malignancy	malignancy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rheumatoid	rheumatoid	ADJ	JJ	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
are	be	VERB	VBP	5	O
still	still	ADV	RB	5	O
being	be	VERB	VBG	5	O
collected	collect	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
until	until	ADP	IN	5	O
further	further	ADJ	JJ	9	O
information	information	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
available	available	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
immunosuppressive	immunosuppressive	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
alkylating	alkylate	VERB	VBG	0	B-Chemical
agents	agent	NOUN	NNS	5	I-Chemical
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
rheumatoid	rheumatoid	ADJ	JJ	9	B-Disease
arthritis	arthritis	NOUN	NN	9	I-Disease
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
reserved	reserve	VERB	VBN	5	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
progressive	progressive	ADJ	JJ	5	O
disease	disease	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
life	life	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
threatening	threaten	VERB	VBG	5	O
complications	complication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Warfarin	warfarin	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
iliopsoas	iliopsoas	ADJ	JJ	5	O
hemorrhage	hemorrhage	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
subsequent	subsequent	ADJ	JJ	9	O
femoral	femoral	ADJ	JJ	5	B-Disease
nerve	nerve	NOUN	NN	5	I-Disease
palsy	palsy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
present	present	VERB	VBP	9	O
the	the	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
28	28	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
on	on	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
who	who	PRON	WP	5	O
sustained	sustain	VERB	VBD	5	O
a	a	DET	DT	5	O
minor	minor	ADJ	JJ	9	O
muscle	muscle	NOUN	NN	9	B-Disease
tear	tear	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
developed	develop	VERB	VBD	5	O
increasing	increase	VERB	VBG	9	O
pain	pain	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
flexure	flexure	NOUN	NN	5	O
contracture	contracture	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
right	right	ADJ	JJ	5	O
hip	hip	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Surgical	surgical	ADJ	JJ	5	O
exploration	exploration	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
an	an	DET	DT	5	O
iliopsoas	iliopsoas	ADJ	JJ	5	O
hematoma	hematoma	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
femoral	femoral	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	B-Disease
entrapment	entrapment	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
femoral	femoral	ADJ	JJ	5	B-Disease
nerve	nerve	NOUN	NN	5	I-Disease
palsy	palsy	ADJ	JJ	5	I-Disease
and	and	CCONJ	CC	5	O
partial	partial	ADJ	JJ	9	B-Disease
loss	loss	NOUN	NN	9	I-Disease
of	of	ADP	IN	5	I-Disease
quadriceps	quadricep	NOUN	NNS	5	I-Disease
functions	function	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

Anticoagulant	Anticoagulant	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
femoral	femoral	ADJ	JJ	5	B-Disease
nerve	nerve	NOUN	NN	5	I-Disease
palsy	palsy	NOUN	NN	5	I-Disease
represents	represent	VERB	VBZ	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
form	form	NOUN	NN	9	O
of	of	ADP	IN	5	O
warfarin	warfarin	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
;	;	PUNCT	:	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
severe	severe	ADJ	JJ	5	O
pain	pain	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
inguinal	inguinal	ADJ	JJ	5	O
region	region	NOUN	NN	9	O
,	,	PUNCT	,	9	O
varying	vary	VERB	VBG	5	O
degrees	degree	NOUN	NNS	5	O
of	of	ADP	IN	5	O
motor	motor	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
sensory	sensory	ADJ	JJ	5	I-Disease
impairment	impairment	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
flexure	flexure	NOUN	NN	5	O
contracture	contracture	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
involved	involved	ADJ	JJ	9	O
extremity	extremity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Pneumonitis	pneumoniti	NOUN	NNS	7	O
with	with	ADP	IN	5	O
pleural	pleural	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
pericardial	pericardial	ADJ	JJ	5	I-Disease
effusion	effusion	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
neuropathy	neuropathy	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
amiodarone	amiodarone	ADJ	JJ	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
sinuatrial	sinuatrial	ADJ	JJ	3	B-Disease
disease	disease	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
implanted	implanted	ADJ	JJ	9	O
pacemaker	pacemaker	NOUN	NN	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
maximum	maximum	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
1000	1000	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
maintenance	maintenance	NOUN	NN	9	O
dose	dose	NOUN	NN	9	O
800	800	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
daily	daily	ADV	RB	5	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
10	10	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
control	control	NOUN	NN	9	O
of	of	ADP	IN	5	O
supraventricular	supraventricular	ADJ	JJ	5	B-Disease
tachyarrhythmias	tachyarrhythmia	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
developed	develop	VERB	VBD	5	O
pneumonitis	pneumonitis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
pleural	pleural	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
pericardial	pericardial	ADJ	JJ	5	I-Disease
effusions	effusion	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
predominantly	predominantly	ADV	RB	9	O
proximal	proximal	ADJ	JJ	9	B-Disease
motor	motor	NOUN	NN	5	I-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Immediate	immediate	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
gradual	gradual	ADJ	JJ	9	O
improvement	improvement	NOUN	NN	5	O
followed	follow	VERB	VBD	9	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
prednisolone	prednisolone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Review	review	NOUN	NN	2	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
and	and	CCONJ	CC	5	O
previously	previously	ADV	RB	9	O
reported	report	VERB	VBN	9	O
cases	case	NOUN	NNS	5	O
indicates	indicate	VERB	VBZ	9	O
the	the	DET	DT	5	O
need	need	NOUN	NN	5	O
for	for	ADP	IN	5	O
early	early	ADJ	JJ	9	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	ADJ	JJ	0	B-Chemical
pneumonitis	pneumonitis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
immediate	immediate	ADJ	JJ	5	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
prompt	prompt	VERB	VB	5	O
but	but	CCONJ	CC	9	O
continued	continued	ADJ	JJ	9	O
steroid	steroid	NOUN	NN	9	B-Chemical
therapy	therapy	NOUN	NN	5	O
to	to	PART	TO	5	O
ensure	ensure	VERB	VB	5	O
full	full	ADJ	JJ	5	O
recovery	recovery	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Amiodarone	amiodarone	ADV	RB	7	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
sinoatrial	sinoatrial	ADJ	JJ	5	B-Disease
block	block	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
observed	observe	VERB	VBD	9	O
sinoatrial	sinoatrial	ADJ	JJ	5	B-Disease
block	block	NOUN	NN	9	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
chronic	chronic	VERB	VB	5	O
amiodarone	amiodarone	ADJ	JJ	0	B-Chemical
administration	administration	NOUN	NN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
boy	boy	NOUN	NN	5	O
with	with	ADP	IN	5	O
primary	primary	ADJ	JJ	9	B-Disease
cardiomyopathy	cardiomyopathy	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
Wolff	Wolff	PROPN	NNP	6	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
Parkinson	Parkinson	PROPN	NNP	5	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
White	White	PROPN	NNP	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
supraventricular	supraventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
dosage	dosage	NOUN	NN	9	O
of	of	ADP	IN	5	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
disappearance	disappearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
sinoatrial	sinoatrial	ADJ	JJ	5	B-Disease
block	block	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
persistence	persistence	NOUN	NN	9	O
of	of	ADP	IN	5	O
asymptomatic	asymptomatic	ADJ	JJ	5	O
sinus	sinus	NOUN	NN	5	B-Disease
bradycardia	bradycardia	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Desipramine	desipramine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
delirium	delirium	NOUN	NN	5	B-Disease
at	at	ADP	IN	9	O
"	"	PUNCT	``	5	O
subtherapeutic	subtherapeutic	ADJ	JJ	5	O
"	"	PUNCT	''	5	O
concentrations	concentration	NOUN	NNS	0	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
elderly	elderly	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
low	low	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
Desipramine	Desipramine	PROPN	NNP	0	B-Chemical
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
delirium	delirium	NOUN	NN	5	B-Disease
while	while	ADP	IN	9	O
her	-PRON-	DET	PRP$	5	O
plasma	plasma	NOUN	NN	9	O
level	level	NOUN	NN	9	O
was	be	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
"	"	PUNCT	``	5	O
subtherapeutic	subtherapeutic	ADJ	JJ	5	O
"	"	PUNCT	''	5	O
range	range	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Delirium	Delirium	PROPN	NNP	5	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
tricyclic	tricyclic	ADJ	JJ	0	O
drug	drug	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
elderly	elderly	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
tricyclics	tricyclic	NOUN	NNS	5	O
with	with	ADP	IN	5	O
low	low	ADJ	JJ	9	O
anticholinergic	anticholinergic	ADJ	JJ	5	O
potency	potency	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Therapeutic	therapeutic	ADJ	JJ	5	O
ranges	range	NOUN	NNS	5	O
for	for	ADP	IN	5	O
antidepressants	antidepressant	NOUN	NNS	5	B-Chemical
that	that	DET	WDT	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
derived	derive	VERB	VBN	9	O
from	from	ADP	IN	9	O
general	general	ADJ	JJ	5	O
adult	adult	NOUN	NN	9	O
population	population	NOUN	NN	5	O
studies	study	NOUN	NNS	9	O
may	may	VERB	MD	5	O
not	not	ADV	RB	5	O
be	be	VERB	VB	5	O
appropriate	appropriate	ADJ	JJ	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
elderly	elderly	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
specifically	specifically	ADV	RB	9	O
elderly	elderly	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
now	now	ADV	RB	5	O
required	require	VERB	VBN	9	O
to	to	PART	TO	5	O
establish	establish	VERB	VB	5	O
safer	safe	ADJ	JJR	5	O
and	and	CCONJ	CC	5	O
more	more	ADV	RBR	5	O
appropriate	appropriate	ADJ	JJ	5	O
guidelines	guideline	NOUN	NNS	5	O
for	for	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Indomethacin	indomethacin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
renal	renal	ADJ	JJ	9	B-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
:	:	PUNCT	:	9	O
recurrence	recurrence	NOUN	NN	5	O
on	on	ADP	IN	5	O
rechallenge	rechallenge	NOUN	NN	3	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
have	have	VERB	VBP	5	O
reported	report	VERB	VBN	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
oliguric	oliguric	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
hyperkalemia	hyperkalemia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
cirrhosis	cirrhosis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
ascites	ascite	NOUN	NNS	3	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cor	cor	ADJ	JJ	5	B-Disease
pulmonale	pulmonale	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
indomethacin	indomethacin	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Prompt	prompt	ADJ	JJ	5	O
restoration	restoration	NOUN	NN	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
followed	follow	VERB	VBD	9	O
drug	drug	NOUN	NN	5	O
withdrawal	withdrawal	NOUN	NN	5	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
re	re	NOUN	NN	5	O
-	-	NOUN	NN	7	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
indomethacin	indomethacin	ADV	RB	0	B-Chemical
caused	cause	VERB	VBN	9	O
recurrence	recurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
reversible	reversible	ADJ	JJ	9	O
oliguria	oliguria	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
case	case	NOUN	NN	5	O
supports	support	VERB	VBZ	9	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	ADP	IN	5	O
endogenous	endogenous	ADJ	JJ	3	O
renal	renal	ADJ	JJ	9	O
prostaglandins	prostaglandin	NOUN	NNS	0	B-Chemical
play	play	VERB	VBP	9	O
a	a	DET	DT	5	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
maintenance	maintenance	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
when	when	ADV	WRB	5	O
circulating	circulate	VERB	VBG	9	O
plasma	plasma	NOUN	NN	9	O
volume	volume	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
diminished	diminish	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
nonsteroidal	nonsteroidal	ADJ	JJ	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
inflammatory	inflammatory	ADJ	JJ	3	O
agents	agent	NOUN	NNS	5	O
interfere	interfere	VERB	VBP	9	O
with	with	ADP	IN	5	O
this	this	DET	DT	5	O
compensatory	compensatory	ADJ	JJ	5	O
mechanism	mechanism	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
may	may	VERB	MD	5	O
cause	cause	VERB	VB	5	O
acute	acute	ADJ	JJ	9	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
they	-PRON-	PRON	PRP	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
with	with	ADP	IN	5	O
caution	caution	NOUN	NN	5	O
in	in	ADP	IN	5	O
such	such	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Patterns	pattern	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
methyldopa	methyldopa	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Twelve	twelve	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
liver	liver	NOUN	NN	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
methyldopa	methyldopa	ADJ	JJ	0	B-Chemical
were	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
between	between	ADP	IN	5	O
1967	1967	NUM	CD	2	O
and	and	CCONJ	CC	5	O
1977	1977	NUM	CD	2	O
.	.	PUNCT	.	9	O

Illness	illness	NOUN	NN	5	O
occurred	occur	VERB	VBD	9	O
within	within	ADP	IN	9	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
9	9	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
commencement	commencement	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
9	9	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
remaining	remain	VERB	VBG	9	O
3	3	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
having	have	VERB	VBG	5	O
received	receive	VERB	VBN	9	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
for	for	ADP	IN	5	O
13	13	NUM	CD	7	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
15	15	NUM	CD	9	O
months	month	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
7	7	NUM	CD	9	O
years	year	NOUN	NNS	5	O
before	before	ADP	IN	9	O
experiencing	experience	VERB	VBG	5	O
symptoms	symptom	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Jaundice	jaundice	NOUN	NN	7	B-Disease
with	with	ADP	IN	5	O
tender	tender	NOUN	NN	5	O
hepatomegaly	hepatomegaly	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
usually	usually	ADV	RB	5	O
preceded	precede	VERB	VBN	9	O
by	by	ADP	IN	9	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
malaise	malaise	NOUN	NN	4	O
,	,	PUNCT	,	9	O
anorexia	anorexia	INTJ	UH	5	B-Disease
,	,	PUNCT	,	9	O
nausea	nausea	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
vomiting	vomiting	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
upper	upper	ADJ	JJ	9	O
abdominal	abdominal	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
an	an	DET	DT	5	O
invariable	invariable	ADJ	JJ	9	O
finding	finding	NOUN	NN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Biochemical	biochemical	ADJ	JJ	9	O
liver	liver	NOUN	NN	9	O
function	function	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
indicated	indicate	VERB	VBD	9	O
hepatocellular	hepatocellular	ADJ	JJ	9	O
necrosis	necrosis	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
correlated	correlate	VERB	VBD	9	O
with	with	ADP	IN	5	O
histopathological	histopathological	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
spectrum	spectrum	NOUN	NN	9	O
of	of	ADP	IN	5	O
which	which	DET	WDT	5	O
ranged	range	VERB	VBD	9	O
from	from	ADP	IN	9	O
fatty	fatty	ADJ	JJ	0	B-Disease
change	change	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
focal	focal	ADJ	JJ	5	O
hepatocellular	hepatocellular	ADJ	JJ	9	O
necrosis	necrosis	NOUN	NN	9	B-Disease
to	to	PART	TO	5	O
massive	massive	ADJ	JJ	9	B-Disease
hepatic	hepatic	ADJ	JJ	9	I-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Most	Most	ADJ	JJS	5	O
patients	patient	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
moderate	moderate	ADJ	JJ	9	O
to	to	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
acute	acute	ADJ	JJ	9	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
or	or	CCONJ	CC	5	O
chronic	chronic	VERB	VB	5	B-Disease
active	active	ADJ	JJ	9	I-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
with	with	ADP	IN	5	O
associated	associated	ADJ	JJ	9	O
cholestasis	cholestasis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
was	be	VERB	VBD	9	O
withdrawn	withdraw	VERB	VBN	9	O
on	on	ADP	IN	5	O
presentation	presentation	NOUN	NN	5	O
to	to	ADP	IN	5	O
hospital	hospital	NOUN	NN	5	O
in	in	ADP	IN	5	O
11	11	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
rapid	rapid	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
died	die	VERB	VBD	9	O
,	,	PUNCT	,	9	O
having	have	VERB	VBG	5	O
presented	present	VERB	VBN	5	O
in	in	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
another	another	DET	DT	9	O
,	,	PUNCT	,	9	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
taking	take	VERB	VBG	5	O
methyldopa	methyldopa	ADJ	JJ	0	B-Chemical
for	for	ADP	IN	5	O
7	7	NUM	CD	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
showed	show	VERB	VBD	9	O
slower	slow	ADJ	JJR	9	O
clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
biochemical	biochemical	ADJ	JJ	9	O
resolution	resolution	NOUN	NN	5	O
over	over	ADP	IN	5	O
a	a	DET	DT	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
several	several	ADJ	JJ	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
remaining	remain	VERB	VBG	9	O
patient	patient	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
series	series	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
fulminant	fulminant	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
was	be	VERB	VBD	9	O
accidentally	accidentally	ADV	RB	5	O
recommenced	recommence	VERB	VBN	5	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
prior	prior	ADJ	JJ	9	O
episode	episode	NOUN	NN	5	O
of	of	ADP	IN	5	O
methyldopa	methyldopa	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
latter	latter	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
others	other	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
causal	causal	ADJ	JJ	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
methyldopa	methyldopa	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
proved	prove	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
recurrence	recurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
within	within	ADP	IN	9	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
re	re	NOUN	NN	5	O
-	-	NOUN	NN	7	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Suxamethonium	suxamethonium	ADJ	JJ	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
observed	observed	ADJ	JJ	9	O
fasciculations	fasciculation	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
response	response	NOUN	NN	9	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Suxamethonium	suxamethonium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
Sch	Sch	PROPN	NNP	2	B-Chemical
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
to	to	ADP	IN	5	O
36	36	NUM	CD	9	O
adult	adult	NOUN	NN	9	O
males	male	NOUN	NNS	9	O
at	at	ADP	IN	9	O
six	six	NUM	CD	9	O
rates	rate	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
s	s	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
to	to	PART	TO	5	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
s	s	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
infusion	infusion	NOUN	NN	0	O
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
either	either	CCONJ	CC	9	O
when	when	ADV	WRB	5	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
muscular	muscular	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
tetanic	tetanic	ADJ	JJ	5	B-Disease
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ulnar	ulnar	ADJ	JJ	5	O
nerve	nerve	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
when	when	ADV	WRB	5	O
Sch	Sch	PROPN	NNP	2	B-Chemical
120	120	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
was	be	VERB	VBD	9	O
exceeded	exceed	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Six	six	NUM	CD	9	O
additional	additional	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
a	a	DET	DT	5	O
30	30	NUM	CD	9	O
-	-	SYM	SYM	7	O
mg	mg	NOUN	NN	0	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
bolus	bolus	NOUN	NN	0	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Fasciculations	fasciculation	NOUN	NNS	7	B-Disease
in	in	ADP	IN	5	O
six	six	NUM	CD	9	O
areas	area	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
body	body	NOUN	NN	5	O
were	be	VERB	VBD	9	O
scored	score	VERB	VBN	5	O
from	from	ADP	IN	9	O
0	0	NUM	CD	7	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
summated	summate	VERB	VBD	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
total	total	ADJ	JJ	9	O
fasciculation	fasciculation	NOUN	NN	5	B-Disease
score	score	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
times	time	NOUN	NNS	5	O
to	to	ADP	IN	5	O
first	first	ADJ	JJ	9	O
fasciculation	fasciculation	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
twitch	twitch	NOUN	NN	5	B-Disease
suppression	suppression	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
tetanus	tetanus	NOUN	NN	9	B-Disease
suppression	suppression	NOUN	NN	9	O
were	be	VERB	VBD	9	O
inversely	inversely	ADV	RB	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
infusion	infusion	NOUN	NN	0	O
rates	rate	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Fasciculations	fasciculation	NOUN	NNS	7	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
six	six	NUM	CD	9	O
areas	area	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
fasciculation	fasciculation	NOUN	NN	5	B-Disease
score	score	NOUN	NN	5	O
were	be	VERB	VBD	9	O
related	relate	VERB	VBN	9	O
directly	directly	ADV	RB	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Total	total	ADJ	JJ	7	O
fasciculation	fasciculation	NOUN	NN	5	B-Disease
scores	score	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
30	30	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
mg	mg	NOUN	NN	0	O
bolus	bolus	NOUN	NN	0	O
group	group	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
mg	mg	NOUN	NN	0	O
s	s	PROPN	NNPS	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
20	20	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
mg	mg	NOUN	NN	0	O
s	s	PROPN	NNPS	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
infusion	infusion	NOUN	NN	0	O
groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
different	different	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
psoriasis	psoriasis	NOUN	NN	9	B-Disease
with	with	ADP	IN	5	O
azathioprine	azathioprine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Azathioprine	azathioprine	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
benefited	benefit	VERB	VBD	5	O
19	19	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
66	66	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
out	out	ADP	IN	9	O
of	of	ADP	IN	5	O
29	29	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
suffering	suffer	VERB	VBG	5	O
from	from	ADP	IN	9	O
severe	severe	ADJ	JJ	5	O
psoriasis	psoriasis	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Haematological	haematological	ADJ	JJ	9	O
complications	complication	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
troublesome	troublesome	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
biochemical	biochemical	ADJ	JJ	9	O
liver	liver	NOUN	NN	9	O
function	function	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
remained	remain	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Minimal	minimal	ADJ	JJ	9	O
cholestasis	cholestasis	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
portal	portal	ADJ	JJ	5	O
fibrosis	fibrosis	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
reversible	reversible	ADJ	JJ	9	O
degree	degree	NOUN	NN	5	O
in	in	ADP	IN	5	O
eight	eight	NUM	CD	9	O
.	.	PUNCT	.	9	O

Liver	liver	NOUN	NN	9	O
biopsies	biopsy	NOUN	NNS	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
undertaken	undertake	VERB	VBN	5	O
at	at	ADP	IN	9	O
regular	regular	ADJ	JJ	5	O
intervals	interval	NOUN	NNS	5	O
if	if	ADP	IN	5	O
azathioprine	azathioprine	NOUN	NN	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
continued	continue	VERB	VBN	9	O
so	so	ADP	IN	5	O
that	that	ADP	IN	5	O
structural	structural	ADJ	JJ	9	O
liver	liver	NOUN	NN	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
detected	detect	VERB	VBN	9	O
at	at	ADP	IN	9	O
an	an	DET	DT	5	O
early	early	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
reversible	reversible	ADJ	JJ	9	O
stage	stage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Angiosarcoma	Angiosarcoma	PROPN	NNP	7	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
liver	liver	NOUN	NN	9	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
diethylstilbestrol	diethylstilbestrol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Angiosarcoma	Angiosarcoma	PROPN	NNP	7	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
liver	liver	NOUN	NN	9	I-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
76	76	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
treated	treat	VERB	VBN	3	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
differentiated	differentiate	VERB	VBN	3	O
adenocarcinoma	adenocarcinoma	NOUN	NN	3	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
liver	liver	NOUN	NN	9	I-Disease
with	with	ADP	IN	5	O
diethylstilbestrol	diethylstilbestrol	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
13	13	NUM	CD	7	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Angiosarcoma	Angiosarcoma	PROPN	NNP	7	B-Disease
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
present	present	ADJ	JJ	9	O
within	within	ADP	IN	9	O
pulmonary	pulmonary	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	O
arteries	artery	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
intraarterial	intraarterial	ADJ	JJ	5	B-Disease
lesions	lesion	NOUN	NNS	5	I-Disease
might	may	VERB	MD	9	O
represent	represent	VERB	VB	9	O
independent	independent	ADJ	JJ	9	O
primary	primary	ADJ	JJ	9	O
tumors	tumor	NOUN	NNS	3	B-Disease
is	be	VERB	VBZ	5	O
considered	consider	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Galanthamine	galanthamine	NOUN	NN	0	B-Chemical
hydrobromide	hydrobromide	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
longer	longer	ADV	RBR	5	O
acting	act	VERB	VBG	9	O
anticholinesterase	anticholinesterase	NOUN	NN	0	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Hyoscine	Hyoscine	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Galanthamine	galanthamine	NOUN	NN	0	B-Chemical
hydrobromide	hydrobromide	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
anticholinesterase	anticholinesterase	NOUN	NN	0	O
drug	drug	NOUN	NN	5	O
capable	capable	ADJ	JJ	9	O
of	of	ADP	IN	5	O
penetrating	penetrate	VERB	VBG	5	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
brain	brain	NOUN	NN	5	O
barrier	barrier	NOUN	NN	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
demonstrating	demonstrate	VERB	VBG	9	O
central	central	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
hyoscine	hyoscine	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
overdosage	overdosage	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
longer	longer	ADV	RBR	5	O
acting	act	VERB	VBG	9	O
than	than	ADP	IN	5	O
physostigmine	physostigmine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
is	be	VERB	VBZ	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
to	to	PART	TO	5	O
reverse	reverse	VERB	VB	9	O
the	the	DET	DT	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
depolarizing	depolarizing	ADJ	JJ	5	O
neuromuscular	neuromuscular	ADJ	JJ	5	O
block	block	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
studies	study	NOUN	NNS	9	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
necessary	necessary	ADJ	JJ	5	O
to	to	ADP	IN	5	O
combating	combat	VERB	VBG	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
intoxication	intoxication	NOUN	NN	9	O
are	be	VERB	VBP	5	O
indicated	indicate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Comparison	Comparison	PROPN	NNP	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
subjective	subjective	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
plasma	plasma	NOUN	NN	9	O
concentrations	concentration	NOUN	NNS	0	O
following	follow	VERB	VBG	9	O
oral	oral	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
m	m	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
flunitrazepam	flunitrazepam	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
volunteers	volunteer	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Flunitrazepam	Flunitrazepam	PROPN	NNP	7	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	NUM	CD	7	O
or	or	CCONJ	CC	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
oral	oral	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
m	m	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
routes	route	NOUN	NNS	5	O
to	to	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
volunteers	volunteer	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
effects	effect	NOUN	NNS	9	O
compared	compare	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Plasma	plasma	ADJ	JJ	0	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
were	be	VERB	VBD	9	O
estimated	estimate	VERB	VBN	5	O
by	by	ADP	IN	9	O
gas	gas	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
liquid	liquid	NOUN	NN	0	O
chromatography	chromatography	NOUN	NN	0	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
smaller	small	ADJ	JJR	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
striking	striking	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
sedation	sedation	NOUN	NN	5	O
which	which	DET	WDT	5	O
increased	increase	VERB	VBD	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
producing	produce	VERB	VBG	9	O
deep	deep	ADJ	JJ	5	O
sleep	sleep	NOUN	NN	5	O
although	although	ADP	IN	9	O
the	the	DET	DT	5	O
subjects	subject	NOUN	NNS	5	O
could	could	VERB	MD	9	O
still	still	ADV	RB	5	O
be	be	VERB	VB	5	O
aroused	arouse	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
m	m	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
administration	administration	NOUN	NN	9	O
were	be	VERB	VBD	9	O
apparent	apparent	ADJ	JJ	9	O
earlier	earlier	ADV	RBR	9	O
and	and	CCONJ	CC	5	O
sometimes	sometimes	ADV	RB	5	O
lasted	last	VERB	VBD	5	O
longer	longer	ADV	RBR	5	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
following	follow	VERB	VBG	9	O
oral	oral	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Dizziness	dizziness	NOUN	NN	7	B-Disease
was	be	VERB	VBD	9	O
less	less	ADV	RBR	5	O
marked	marked	ADJ	JJ	9	O
than	than	ADP	IN	5	O
sedation	sedation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
increased	increase	VERB	VBD	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
pain	pain	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
m	m	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
flunitrazepam	flunitrazepam	NOUN	NN	0	B-Chemical
significantly	significantly	ADV	RB	9	O
more	more	ADV	RBR	5	O
often	often	ADV	RB	5	O
than	than	ADP	IN	5	O
with	with	ADP	IN	5	O
isotonic	isotonic	ADJ	JJ	0	O
saline	saline	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Plasma	plasma	ADJ	JJ	0	O
concentrations	concentration	NOUN	NNS	0	O
varied	vary	VERB	VBN	9	O
with	with	ADP	IN	5	O
dose	dose	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
route	route	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
corresponded	correspond	VERB	VBD	9	O
qualitatively	qualitatively	ADV	RB	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
subjective	subjective	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
was	be	VERB	VBD	9	O
still	still	ADV	RB	5	O
present	present	ADJ	JJ	9	O
in	in	ADP	IN	5	O
measurable	measurable	ADJ	JJ	9	O
quantities	quantity	NOUN	NNS	9	O
after	after	ADP	IN	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
even	even	ADV	RB	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
smallest	small	ADJ	JJS	5	O
dose	dose	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Possible	possible	ADJ	JJ	9	O
teratogenicity	teratogenicity	NOUN	NN	5	O
of	of	ADP	IN	5	O
sulphasalazine	sulphasalazine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
infants	infant	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
born	bear	VERB	VBN	5	O
of	of	ADP	IN	5	O
two	two	NUM	CD	5	O
mothers	mother	NOUN	NNS	5	O
with	with	ADP	IN	5	O
inflammatory	inflammatory	ADJ	JJ	3	B-Disease
bowel	bowel	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
sulphasalazine	sulphasalazine	NOUN	NN	0	B-Chemical
throughout	throughout	ADP	IN	9	O
pregnancy	pregnancy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
major	major	ADJ	JJ	9	O
congenital	congenital	ADJ	JJ	5	B-Disease
anomalies	anomaly	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
singleton	singleton	NOUN	NN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
mother	mother	NOUN	NN	5	O
had	have	VERB	VBD	9	O
ulcerative	ulcerative	ADJ	JJ	5	B-Disease
colitis	colitis	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
infant	infant	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
male	male	NOUN	NN	9	O
,	,	PUNCT	,	9	O
had	have	VERB	VBD	9	O
coarctation	coarctation	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
aorta	aorta	NOUN	NNS	9	I-Disease
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
septal	septal	ADJ	JJ	5	I-Disease
defect	defect	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
twin	twin	ADJ	JJ	5	O
pregnancy	pregnancy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
mother	mother	NOUN	NN	5	O
had	have	VERB	VBD	9	O
Crohn	Crohn	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
twin	twin	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
female	female	NOUN	NN	9	O
,	,	PUNCT	,	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
left	left	ADJ	JJ	5	O
Potter	potter	NOUN	NN	6	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
type	type	NOUN	NN	9	I-Disease
IIa	IIa	NOUN	NNS	9	I-Disease
polycystic	polycystic	ADJ	JJ	5	I-Disease
kidney	kidney	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
rudimentary	rudimentary	ADJ	JJ	5	B-Disease
left	leave	VERB	VBD	5	I-Disease
uterine	uterine	ADJ	JJ	5	I-Disease
cornu	cornu	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
twin	twin	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
male	male	NOUN	NN	9	O
,	,	PUNCT	,	9	O
had	have	VERB	VBD	9	O
some	some	DET	DT	5	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
Potter	Potter	PROPN	NNP	6	B-Disease
'	'	PART	POS	9	I-Disease
s	s	NOUN	NN	9	I-Disease
facies	facie	NOUN	NNS	4	I-Disease
,	,	PUNCT	,	9	O
hypoplastic	hypoplastic	ADJ	JJ	5	B-Disease
lungs	lung	NOUN	NNS	3	I-Disease
,	,	PUNCT	,	9	O
absent	absent	ADJ	JJ	9	B-Disease
kidneys	kidney	NOUN	NNS	9	I-Disease
and	and	CCONJ	CC	5	I-Disease
ureters	ureter	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
talipes	talipe	VERB	VBZ	5	B-Disease
equinovarus	equinovarus	ADJ	JJ	5	I-Disease
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
reports	report	NOUN	NNS	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
contrary	contrary	NOUN	NN	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
sulphasalazine	sulphasalazine	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
teratogenic	teratogenic	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Thrombotic	thrombotic	ADJ	JJ	5	B-Disease
microangiopathy	microangiopathy	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
antineoplastic	antineoplastic	ADJ	JJ	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
carcinoma	carcinoma	NOUN	NN	3	B-Disease
developed	develop	VERB	VBN	5	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
microangiopathy	microangiopathy	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
characterized	characterize	VERB	VBN	9	O
by	by	ADP	IN	9	O
renal	renal	ADJ	JJ	9	B-Disease
insufficiency	insufficiency	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
microangiopathic	microangiopathic	ADJ	JJ	5	B-Disease
hemolytic	hemolytic	ADJ	JJ	0	I-Disease
anemia	anemia	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
usually	usually	ADV	RB	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
bleomycin	bleomycin	VERB	VBD	3	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
vinca	vinca	NOUN	NN	0	B-Chemical
alkaloid	alkaloid	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
thrombocytopenic	thrombocytopenic	NOUN	NN	5	I-Disease
purpura	purpura	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
three	three	NUM	CD	9	O
the	the	DET	DT	5	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
uremic	uremic	ADJ	JJ	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
one	one	NUM	CD	5	O
an	an	DET	DT	5	O
apparent	apparent	ADJ	JJ	9	O
forme	forme	ADJ	JJ	2	O
fruste	fruste	NOUN	NN	5	O
of	of	ADP	IN	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
disorders	disorder	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Histologic	histologic	ADJ	JJ	9	O
examination	examination	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
tissue	tissue	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
intravascular	intravascular	ADJ	JJ	5	B-Disease
coagulation	coagulation	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
primarily	primarily	ADV	RB	9	O
affecting	affect	VERB	VBG	9	O
the	the	DET	DT	5	O
small	small	ADJ	JJ	9	O
arteries	artery	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
arterioles	arteriole	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
glomeruli	glomeruli	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
each	each	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
tumor	tumor	NOUN	NN	3	B-Disease
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
had	have	VERB	VBD	9	O
only	only	ADV	RB	9	O
a	a	DET	DT	5	O
small	small	ADJ	JJ	9	O
tumor	tumor	NOUN	NN	3	B-Disease
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
thrombotic	thrombotic	ADJ	JJ	5	B-Disease
microangiopathy	microangiopathy	NOUN	NN	5	I-Disease
may	may	VERB	MD	5	O
have	have	VERB	VB	5	O
been	be	VERB	VBN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Diagnosis	diagnosis	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
potentially	potentially	ADV	RB	5	O
fatal	fatal	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
delayed	delay	VERB	VBN	9	O
or	or	CCONJ	CC	5	O
missed	miss	VERB	VBN	5	O
if	if	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
tissue	tissue	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
peripheral	peripheral	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
smear	smear	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
examined	examine	VERB	VBN	9	O
,	,	PUNCT	,	9	O
because	because	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
ascribed	ascribe	VERB	VBN	9	O
to	to	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
anemia	anemia	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
thrombocytopenia	thrombocytopenia	NOUN	NN	9	B-Disease
to	to	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
bone	bone	NOUN	NN	5	B-Disease
marrow	marrow	NOUN	NN	3	I-Disease
suppression	suppression	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

International	international	ADJ	JJ	2	O
mexiletine	mexiletine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
antiarrhythmic	antiarrhythmic	ADJ	JJ	5	O
coronary	coronary	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
:	:	PUNCT	:	9	O
I	-PRON-	PRON	PRP	9	O
.	.	PUNCT	.	9	O

Report	report	VERB	VB	5	O
on	on	ADP	IN	5	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
findings	finding	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Impact	Impact	PROPN	NNP	5	O
Research	Research	PROPN	NNP	2	O
Group	Group	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
antiarrhythmic	antiarrhythmic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
sustained	sustained	ADJ	JJ	5	O
release	release	NOUN	NN	9	O
form	form	NOUN	NN	9	O
of	of	ADP	IN	5	O
mexiletine	mexiletine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Mexitil	Mexitil	PROPN	NNP	_	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
Perlongets	Perlongets	PROPN	NNP	_	I-Chemical
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
placebo	placebo	NOUN	NN	9	O
trial	trial	NOUN	NN	5	O
in	in	ADP	IN	5	O
630	630	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
recent	recent	ADJ	JJ	5	O
documented	document	VERB	VBN	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
variable	variable	NOUN	NN	5	O
was	be	VERB	VBD	9	O
based	base	VERB	VBN	5	O
on	on	ADP	IN	5	O
central	central	ADJ	JJ	5	O
reading	reading	NOUN	NN	5	O
of	of	ADP	IN	5	O
24	24	NUM	CD	9	O
hour	hour	NOUN	NN	0	O
ambulatory	ambulatory	ADJ	JJ	5	O
electrocardiographic	electrocardiographic	ADJ	JJ	5	O
recordings	recording	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
defined	define	VERB	VBN	5	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
30	30	NUM	CD	9	O
or	or	CCONJ	CC	5	O
more	more	ADV	RBR	5	O
single	single	ADJ	JJ	9	O
premature	premature	ADJ	JJ	9	O
ventricular	ventricular	ADJ	JJ	5	O
complexes	complex	NOUN	NNS	9	O
in	in	ADP	IN	5	O
any	any	DET	DT	5	O
two	two	NUM	CD	5	O
consecutive	consecutive	ADJ	JJ	5	O
30	30	NUM	CD	9	O
minute	minute	NOUN	NN	5	O
blocks	block	NOUN	NNS	9	O
or	or	CCONJ	CC	5	O
one	one	NUM	CD	5	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
runs	run	NOUN	NNS	5	O
of	of	ADP	IN	5	O
two	two	NUM	CD	5	O
or	or	CCONJ	CC	5	O
more	more	ADV	RBR	5	O
premature	premature	ADJ	JJ	9	O
ventricular	ventricular	ADJ	JJ	5	O
complexes	complex	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
entire	entire	ADJ	JJ	9	O
24	24	NUM	CD	9	O
hour	hour	NOUN	NN	0	O
electrocardiographic	electrocardiographic	ADJ	JJ	5	O
recording	recording	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Large	large	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
regarded	regard	VERB	VBN	5	O
as	as	ADP	IN	5	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
mexiletine	mexiletine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
in	in	ADP	IN	5	O
that	that	DET	DT	5	O
end	end	NOUN	NN	9	O
point	point	NOUN	NN	5	O
at	at	ADP	IN	9	O
months	month	NOUN	NNS	5	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
only	only	ADV	RB	9	O
trends	trend	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
at	at	ADP	IN	9	O
month	month	NOUN	NN	5	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
differences	difference	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
even	even	ADV	RB	5	O
though	though	ADP	IN	9	O
the	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
mexiletine	mexiletine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
obtained	obtain	VERB	VBN	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
were	be	VERB	VBD	9	O
generally	generally	ADV	RB	5	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
studies	study	NOUN	NNS	9	O
that	that	DET	WDT	5	O
have	have	VERB	VBP	5	O
used	use	VERB	VBN	5	O
the	the	DET	DT	5	O
regular	regular	ADJ	JJ	5	O
form	form	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
more	more	ADJ	JJR	5	O
deaths	death	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mexiletine	mexiletine	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
difference	difference	NOUN	NN	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
coronary	coronary	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Previously	previously	ADV	RB	9	O
recognized	recognize	VERB	VBN	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
tremor	tremor	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
gastrointestinal	gastrointestinal	ADJ	JJ	9	B-Disease
problems	problem	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
frequent	frequent	ADJ	JJ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mexiletine	mexiletine	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
size	size	NOUN	NN	9	O
during	during	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
timolol	timolol	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
after	after	ADP	IN	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
timolol	timolol	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
on	on	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
size	size	NOUN	NN	9	O
after	after	ADP	IN	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
by	by	ADP	IN	9	O
X	x	NOUN	NN	9	O
-	-	NOUN	NN	7	O
ray	ray	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
including	include	VERB	VBG	9	O
241	241	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
placebo	placebo	VERB	VB	9	O
126	126	NUM	CD	7	O
,	,	PUNCT	,	9	O
timolol	timolol	NOUN	NN	0	B-Chemical
115	115	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
period	period	NOUN	NN	5	O
was	be	VERB	VBD	9	O
12	12	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
timolol	timolol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
small	small	ADJ	JJ	9	O
but	but	CCONJ	CC	9	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
size	size	NOUN	NN	9	O
from	from	ADP	IN	9	O
baseline	baseline	NOUN	NN	5	O
in	in	ADP	IN	5	O
contrast	contrast	NOUN	NN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
differences	difference	NOUN	NNS	9	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
timolol	timolol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
compensatory	compensatory	ADJ	JJ	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
end	end	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
diastolic	diastolic	ADJ	JJ	5	O
volume	volume	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
timolol	timolol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
size	size	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
borderline	borderline	NOUN	NN	9	O
heart	heart	NOUN	NN	5	O
size	size	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cardiomegaly	cardiomegaly	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
size	size	NOUN	NN	9	O
was	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
re	re	NOUN	NN	5	O
-	-	NOUN	NN	7	O
infarction	infarction	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
heart	heart	NOUN	NN	5	O
size	size	NOUN	NN	9	O
increased	increase	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
placebo	placebo	NOUN	NN	9	O
group	group	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
remained	remain	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
timolol	timolol	NOUN	NN	0	B-Chemical
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Vitamin	vitamin	NOUN	NN	0	B-Chemical
D3	d3	NOUN	NN	9	I-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
dairy	dairy	NOUN	NN	5	O
cows	cow	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Large	large	ADJ	JJ	9	O
parenteral	parenteral	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D3	d3	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
to	to	ADP	IN	5	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
x	x	SYM	SYM	9	O
10	10	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
IU	IU	PROPN	NNP	0	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D3	d3	NOUN	NN	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
prolonged	prolonged	ADJ	JJ	9	O
hypercalcemia	hypercalcemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
hyperphosphatemia	hyperphosphatemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
large	large	ADJ	JJ	5	O
increases	increase	NOUN	NNS	9	O
of	of	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D3	d3	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
metabolites	metabolite	NOUN	NNS	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
plasma	plasma	NOUN	NN	9	O
of	of	ADP	IN	5	O
nonlactating	nonlactate	VERB	VBG	5	O
nonpregnant	nonpregnant	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
pregnant	pregnant	ADJ	JJ	5	O
Jersey	Jersey	PROPN	NNP	2	O
cows	cow	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Calcium	calcium	NOUN	NN	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
1	1	NUM	CD	9	O
day	day	NOUN	NN	9	O
postpartum	postpartum	NOUN	NN	5	O
were	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
cows	cow	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D3	D3	PROPN	NNP	9	I-Chemical
about	about	ADV	RB	5	O
32	32	NUM	CD	7	O
days	day	NOUN	NNS	9	O
prepartum	prepartum	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
.	.	NOUN	NN	9	O
8	8	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
100	100	NUM	CD	0	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
control	control	NOUN	NN	9	O
cows	cow	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
100	100	NUM	CD	0	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

None	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cows	cow	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D3	d3	NOUN	NN	9	I-Chemical
showed	show	VERB	VBD	9	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
milk	milk	NOUN	NN	9	B-Disease
fever	fever	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
peripartal	peripartal	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
22	22	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
cows	cow	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
clinical	clinical	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
milk	milk	NOUN	NN	9	B-Disease
fever	fever	NOUN	NN	5	I-Disease
during	during	ADP	IN	5	O
this	this	DET	DT	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D3	d3	NOUN	NN	9	I-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
nonlactating	nonlactate	VERB	VBG	5	O
nonpregnant	nonpregnant	ADJ	JJ	5	O
cows	cow	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
pregnant	pregnant	ADJ	JJ	5	O
cows	cow	NOUN	NNS	5	O
commonly	commonly	ADV	RB	5	O
developed	develop	VERB	VBD	5	O
severe	severe	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D3	d3	NOUN	NN	9	I-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
of	of	ADP	IN	5	O
17	17	NUM	CD	7	O
cows	cow	NOUN	NNS	5	O
died	die	VERB	VBD	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
widespread	widespread	ADJ	JJ	5	O
metastatic	metastatic	ADJ	JJ	3	O
calcification	calcification	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cows	cow	NOUN	NNS	5	O
that	that	DET	WDT	5	O
died	die	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
extreme	extreme	ADJ	JJ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D3	d3	NOUN	NN	9	I-Chemical
in	in	ADP	IN	5	O
pregnant	pregnant	ADJ	JJ	5	O
Jersey	Jersey	PROPN	NNP	2	O
cows	cow	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
low	low	ADJ	JJ	9	O
margin	margin	NOUN	NN	5	O
of	of	ADP	IN	5	O
safety	safety	NOUN	NN	5	O
between	between	ADP	IN	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D3	d3	NOUN	NN	9	I-Chemical
that	that	DET	WDT	5	O
prevent	prevent	VERB	VBP	5	O
milk	milk	NOUN	NN	9	B-Disease
fever	fever	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
doses	dose	VERB	VBZ	0	O
that	that	DET	WDT	5	O
induce	induce	VERB	VBP	3	O
milk	milk	NOUN	NN	9	B-Disease
fever	fever	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
concluded	conclude	VERB	VBD	9	O
that	that	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
D3	d3	NOUN	NN	9	I-Chemical
cannot	cannot	NOUN	NN	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
practically	practically	ADV	RB	5	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
milk	milk	NOUN	NN	9	B-Disease
fever	fever	NOUN	NN	5	I-Disease
when	when	ADV	WRB	5	O
injected	inject	VERB	VBD	3	O
several	several	ADJ	JJ	9	O
weeks	week	NOUN	NNS	9	O
prepartum	prepartum	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Diseases	disease	NOUN	NNS	2	B-Disease
of	of	ADP	IN	5	I-Disease
peripheral	peripheral	ADJ	JJ	9	I-Disease
nerves	nerve	NOUN	NNS	5	I-Disease
as	as	ADP	IN	5	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Nigerian	nigerian	ADJ	JJ	5	O
African	African	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
anatomical	anatomical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
aetiological	aetiological	ADJ	JJ	5	O
diagnoses	diagnosis	NOUN	NNS	5	O
of	of	ADP	IN	5	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
nerve	nerve	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
excluding	exclude	VERB	VBG	9	O
its	-PRON-	DET	PRP$	9	O
primary	primary	ADJ	JJ	9	O
benign	benign	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
malignant	malignant	ADJ	JJ	3	O
disorders	disorder	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
358	358	NUM	CD	7	O
Nigerians	Nigerians	PROPN	NNPS	5	O
are	be	VERB	VBP	5	O
presented	present	VERB	VBN	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
male	male	ADJ	JJ	9	O
preponderance	preponderance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
peak	peak	NOUN	NN	9	O
incidence	incidence	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
fourth	fourth	ADJ	JJ	9	O
decade	decade	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Sensori	Sensori	NOUN	NNS	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
motor	motor	NOUN	NN	5	I-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
commonest	common	ADJ	JJS	5	O
presentation	presentation	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Guillain	Guillain	PROPN	NNP	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
Barr	Barr	PROPN	NNP	6	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
commonest	common	ADJ	JJS	5	O
identifiable	identifiable	ADJ	JJ	5	O
cause	cause	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
accounting	account	VERB	VBG	5	O
for	for	ADP	IN	5	O
half	half	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cases	case	NOUN	NNS	5	O
with	with	ADP	IN	5	O
motor	motor	NOUN	NN	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
nutritional	nutritional	ADJ	JJ	5	B-Disease
deficiency	deficiency	NOUN	NN	9	I-Disease
of	of	ADP	IN	5	O
thiamine	thiamine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
riboflavin	riboflavin	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
common	common	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
presented	present	VERB	VBN	5	O
mainly	mainly	ADV	RB	9	O
as	as	ADP	IN	5	O
sensory	sensory	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
sensori	sensori	NOUN	NNS	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
motor	motor	NOUN	NN	5	I-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Diabetes	diabetes	NOUN	NN	7	B-Disease
mellitus	mellitus	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
major	major	ADJ	JJ	9	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
autonomic	autonomic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Isoniazid	Isoniazid	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
frequent	frequent	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
in	in	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
neuropathy	neuropathy	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Migraine	Migraine	PROPN	NNP	5	B-Disease
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
an	an	DET	DT	5	O
uncommon	uncommon	ADJ	JJ	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
cranial	cranial	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
although	although	ADP	IN	9	O
malignancies	malignancy	NOUN	NNS	5	B-Disease
arising	arise	VERB	VBG	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
reticuloendothelial	reticuloendothelial	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
related	related	ADJ	JJ	9	O
structures	structure	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
head	head	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
neck	neck	NOUN	NN	5	O
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
frequent	frequent	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
26	26	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
26	26	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
aetiology	aetiology	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
neuropathy	neuropathy	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
undetermined	undetermined	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Heredofamilial	heredofamilial	ADJ	JJ	7	O
and	and	CCONJ	CC	5	O
connective	connective	ADJ	JJ	5	B-Disease
tissue	tissue	NOUN	NN	9	I-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
were	be	VERB	VBD	9	O
rare	rare	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Some	some	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
factors	factor	NOUN	NNS	9	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
presentation	presentation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
neuropathies	neuropathy	NOUN	NNS	5	B-Disease
are	be	VERB	VBP	5	O
briefly	briefly	ADV	RB	9	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
by	by	ADP	IN	9	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
allegedly	allegedly	ADV	RB	5	O
consumed	consume	VERB	VBD	5	O
100	100	NUM	CD	0	O
tablets	tablet	NOUN	NNS	0	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
over	over	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
the	the	DET	DT	5	O
-	-	PUNCT	HYPH	7	O
counter	counter	NOUN	NN	5	O
analgesic	analgesic	NOUN	NN	5	O
containing	contain	VERB	VBG	0	O
sodium	sodium	NOUN	NN	0	B-Chemical
acetylsalicylate	acetylsalicylate	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
displayed	display	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
CNS	CNS	PROPN	NNP	9	O
stimulation	stimulation	NOUN	NN	3	O
despite	despite	ADP	IN	9	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
175	175	NUM	CD	7	O
micrograms	microgram	NOUN	NNS	0	O
of	of	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
per	per	ADP	IN	9	O
mL	ml	NOUN	NN	0	O
of	of	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
salicylates	salicylate	NOUN	NNS	0	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
to	to	PART	TO	5	O
augment	augment	VERB	VB	9	O
the	the	DET	DT	5	O
stimulatory	stimulatory	ADJ	JJ	3	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
CNS	CNS	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
attention	attention	NOUN	NN	5	O
was	be	VERB	VBD	9	O
focused	focus	VERB	VBN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
52	52	NUM	CD	7	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
CNS	CNS	PROPN	NNP	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Studies	study	NOUN	NNS	9	O
in	in	ADP	IN	5	O
DBA	DBA	PROPN	NNP	3	O
/	/	SYM	SYM	9	O
2J	2j	NOUN	NN	3	O
mice	mouse	NOUN	NNS	3	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
:	:	PUNCT	:	9	O
1	1	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
interval	interval	NOUN	NN	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
300	300	NUM	CD	0	O
to	to	ADP	IN	5	O
450	450	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
IP	IP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
fatal	fatal	ADJ	JJ	5	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
factor	factor	NOUN	NN	9	O
of	of	ADP	IN	5	O
about	about	ADP	IN	5	O
two	two	NUM	CD	5	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
pretreatment	pretreatment	NOUN	NN	0	O
with	with	ADP	IN	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
75	75	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
audiogenic	audiogenic	ADJ	JJ	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
produced	produce	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
to	to	PART	TO	5	O
75	75	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
IP	IP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
sound	sound	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
seizures	seizure	NOUN	NNS	5	B-Disease
after	after	ADP	IN	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
or	or	CCONJ	CC	5	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
from	from	ADP	IN	9	O
50	50	NUM	CD	0	O
to	to	PART	TO	5	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
by	by	ADP	IN	9	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
300	300	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
modify	modify	VERB	VB	9	O
the	the	DET	DT	5	O
seizures	seizure	NOUN	NNS	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
maximal	maximal	ADJ	JJ	9	O
electroshock	electroshock	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
alter	alter	VERB	VB	9	O
the	the	DET	DT	5	O
convulsant	convulsant	NOUN	NN	0	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
pentylenetetrezol	pentylenetetrezol	NOUN	NN	_	B-Chemical
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
tests	test	NOUN	NNS	5	O
performed	perform	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
Anticonvulsant	Anticonvulsant	PROPN	NNP	0	O
Screening	Screening	PROPN	NNP	9	O
Project	Project	PROPN	NNP	2	O
of	of	ADP	IN	5	O
NINCDS	NINCDS	PROPN	NNP	2	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Acetaminophen	Acetaminophen	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
150	150	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
/	/	SYM	SYM	9	O
mL	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
retard	retard	VERB	VB	9	O
the	the	DET	DT	5	O
incorporation	incorporation	NOUN	NN	0	O
of	of	ADP	IN	5	O
radioactive	radioactive	ADJ	JJ	0	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
into	into	ADP	IN	9	O
ATP	ATP	PROPN	NNP	0	B-Chemical
in	in	ADP	IN	5	O
slices	slice	NOUN	NNS	9	O
of	of	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
cerebral	cerebral	ADJ	JJ	5	O
cortex	cortex	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
the	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
by	by	ADP	IN	9	O
which	which	DET	WDT	5	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
antagonizes	antagonize	VERB	VBZ	3	O
the	the	DET	DT	5	O
actions	action	NOUN	NNS	5	O
of	of	ADP	IN	5	O
caffeine	caffeine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
CNS	CNS	PROPN	NNP	9	O
remains	remain	VERB	VBZ	9	O
unknown	unknown	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
dothiepin	dothiepin	ADJ	JJ	5	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
major	major	ADJ	JJ	9	O
depressive	depressive	ADJ	JJ	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
parallel	parallel	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
dothiepin	dothiepin	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
amitriptyline	amitriptyline	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
to	to	PART	TO	5	O
placebo	placebo	VERB	VB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
33	33	NUM	CD	7	O
depressed	depressed	ADJ	JJ	5	B-Disease
outpatients	outpatient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Dothiepin	Dothiepin	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
amitriptyline	amitriptyline	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
equally	equally	ADV	RB	9	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
alleviating	alleviate	VERB	VBG	5	O
the	the	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
depressive	depressive	ADJ	JJ	5	B-Disease
illness	illness	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
both	both	DET	DT	9	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
superior	superior	ADJ	JJ	5	O
to	to	ADP	IN	5	O
placebo	placebo	VERB	VB	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
blurred	blur	VERB	VBN	5	B-Disease
vision	vision	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
dry	dry	ADJ	JJ	0	B-Disease
mouth	mouth	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
drowsiness	drowsiness	NOUN	NN	5	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
less	less	ADJ	JJR	5	O
with	with	ADP	IN	5	O
dothiepin	dothiepin	NOUN	NN	5	B-Chemical
than	than	ADP	IN	5	O
with	with	ADP	IN	5	O
amitriptyline	amitriptyline	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Dothiepin	Dothiepin	PROPN	NNP	0	B-Chemical
also	also	ADV	RB	9	O
produced	produce	VERB	VBD	9	O
fewer	few	ADJ	JJR	5	O
CNS	CNS	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
clinically	clinically	ADV	RB	5	O
important	important	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
laboratory	laboratory	NOUN	NN	9	O
parameters	parameter	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Dothiepin	Dothiepin	PROPN	NNP	0	B-Chemical
thus	thus	ADV	RB	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
antidepressant	antidepressant	ADJ	JJ	5	B-Chemical
drug	drug	NOUN	NN	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
fewer	few	ADJ	JJR	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
than	than	ADP	IN	5	O
amitriptyline	amitriptyline	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
depressed	depressed	ADJ	JJ	5	B-Disease
outpatients	outpatient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Behavioral	behavioral	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
panic	panic	NOUN	NN	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
agoraphobia	agoraphobia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
median	median	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
single	single	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
80	80	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
median	median	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
240	240	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
psychological	psychological	ADJ	JJ	5	O
performance	performance	NOUN	NN	5	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
panic	panic	NOUN	NN	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
agoraphobia	agoraphobia	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
randomized	randomize	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
crossover	crossover	NOUN	NN	5	O
design	design	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
drugs	drug	NOUN	NNS	5	O
impaired	impair	VERB	VBD	9	B-Disease
immediate	immediate	ADJ	JJ	5	I-Disease
free	free	ADJ	JJ	9	I-Disease
recall	recall	NOUN	NN	5	I-Disease
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
was	be	VERB	VBD	9	O
greater	great	ADJ	JJR	5	O
for	for	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
than	than	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Delayed	delay	VERB	VBN	5	B-Disease
free	free	ADJ	JJ	9	I-Disease
recall	recall	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	I-Disease
also	also	ADV	RB	9	I-Disease
impaired	impair	VERB	VBN	9	I-Disease
but	but	CCONJ	CC	9	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
drugs	drug	NOUN	NNS	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
differ	differ	VERB	VB	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
tapped	tap	VERB	VBD	5	O
faster	faster	ADV	RBR	5	O
after	after	ADP	IN	9	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
than	than	ADP	IN	5	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
they	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
sedated	sedated	ADJ	JJ	5	O
after	after	ADP	IN	9	O
diazepam	diazepam	NOUN	NN	0	B-Chemical
than	than	ADP	IN	5	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
patients	patient	NOUN	NNS	5	O
tested	test	VERB	VBD	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
8	8	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
medication	medication	NOUN	NN	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
show	show	VERB	VB	9	O
any	any	DET	DT	5	O
decrement	decrement	NOUN	NN	5	O
of	of	ADP	IN	5	O
performance	performance	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
previously	previously	ADV	RB	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
healthy	healthy	ADJ	JJ	5	O
subjects	subject	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Accumulation	accumulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
drugs	drug	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
reflected	reflect	VERB	VBN	5	O
in	in	ADP	IN	5	O
prolonged	prolong	VERB	VBN	9	O
behavioral	behavioral	ADJ	JJ	5	B-Disease
impairment	impairment	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Comparison	Comparison	PROPN	NNP	9	O
of	of	ADP	IN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
glycopyrrolate	glycopyrrolate	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
atropine	atropine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
prevention	prevention	NOUN	NN	5	O
of	of	ADP	IN	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
arrhythmias	arrhythmia	NOUN	NNS	5	B-Disease
following	follow	VERB	VBG	9	O
repeated	repeat	VERB	VBN	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
suxamethonium	suxamethonium	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effectiveness	effectiveness	NOUN	NN	5	O
of	of	ADP	IN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
glycopyrrolate	glycopyrrolate	NOUN	NN	0	B-Chemical
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
atropine	atropine	NOUN	NN	0	B-Chemical
10	10	NUM	CD	9	O
and	and	CCONJ	CC	5	O
20	20	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
immediately	immediately	ADV	RB	9	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
,	,	PUNCT	,	9	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
following	follow	VERB	VBG	9	O
repeated	repeat	VERB	VBN	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
suxamethonium	suxamethonium	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
was	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
for	for	ADP	IN	5	O
comparison	comparison	NOUN	NN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
lower	low	ADJ	JJR	9	O
dose	dose	NOUN	NN	9	O
range	range	NOUN	NN	9	O
of	of	ADP	IN	5	O
glycopyrrolate	glycopyrrolate	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
atropine	atropine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
of	of	ADP	IN	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
was	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
this	this	DET	DT	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
different	different	ADJ	JJ	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
active	active	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Bradycardia	Bradycardia	PROPN	NNP	7	B-Disease
(	(	PUNCT	-LRB-	9	O
defined	define	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
to	to	ADP	IN	5	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
50	50	NUM	CD	0	O
beat	beat	VERB	VBN	5	O
min	min	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
prevented	prevent	VERB	VBN	9	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
larger	large	ADJ	JJR	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
either	either	DET	DT	9	O
active	active	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
recommended	recommend	VERB	VBN	5	O
that	that	ADP	IN	5	O
either	either	DET	DT	9	O
glycopyrrolate	glycopyrrolate	NOUN	NN	0	B-Chemical
10	10	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
or	or	CCONJ	CC	5	O
atropine	atropine	NOUN	NN	0	B-Chemical
20	20	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
should	should	VERB	MD	5	O
immediately	immediately	ADV	RB	9	O
precede	precede	VERB	VB	9	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
if	if	ADP	IN	5	O
the	the	DET	DT	5	O
repeated	repeat	VERB	VBN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
suxamethonium	suxamethonium	NOUN	NN	5	B-Chemical
is	be	VERB	VBZ	5	O
anticipated	anticipate	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Veno	veno	ADJ	JJ	6	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
occlusive	occlusive	ADJ	JJ	5	I-Disease
liver	liver	NOUN	NN	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
dacarbazine	dacarbazine	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
DTIC	DTIC	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
melanoma	melanoma	NOUN	NN	3	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
veno	veno	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
occlusive	occlusive	ADJ	JJ	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
liver	liver	NOUN	NN	9	I-Disease
with	with	ADP	IN	5	O
fatal	fatal	ADJ	JJ	5	O
outcome	outcome	NOUN	NN	5	O
after	after	ADP	IN	9	O
dacarbazine	dacarbazine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DTIC	DTIC	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
melanoma	melanoma	NOUN	NN	3	B-Disease
is	be	VERB	VBZ	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
fulminant	fulminant	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
course	course	NOUN	NN	5	O
from	from	ADP	IN	9	O
start	start	NOUN	NN	9	O
of	of	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
until	until	ADP	IN	5	O
death	death	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
autopsy	autopsy	ADV	RB	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
was	be	VERB	VBD	9	O
enlarged	enlarge	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
firm	firm	ADJ	JJ	5	O
with	with	ADP	IN	5	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
venous	venous	ADJ	JJ	5	B-Disease
congestion	congestion	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Small	small	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
medium	medium	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
sized	sized	ADJ	JJ	5	O
hepatic	hepatic	ADJ	JJ	9	O
veins	vein	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
blocked	block	VERB	VBN	3	O
by	by	ADP	IN	9	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Eosinophilic	eosinophilic	ADJ	JJ	2	O
infiltrations	infiltration	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
around	around	ADP	IN	5	O
the	the	DET	DT	5	O
vessels	vessel	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Published	publish	VERB	VBN	9	O
cases	case	NOUN	NNS	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
are	be	VERB	VBP	5	O
reviewed	review	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
pertinent	pertinent	ADJ	JJ	5	O
features	feature	NOUN	NNS	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Maternal	maternal	ADJ	JJ	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
neonatal	neonatal	ADJ	JJ	9	O
Ebstein	Ebstein	PROPN	NNP	5	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	NOUN	NNS	9	I-Disease
anomaly	anomaly	ADJ	JJ	5	I-Disease
:	:	PUNCT	:	9	O
evaluation	evaluation	NOUN	NN	5	O
with	with	ADP	IN	5	O
cross	cross	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
sectional	sectional	ADJ	JJ	5	O
echocardiography	echocardiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Cross	cross	ADJ	JJ	2	O
-	-	PUNCT	HYPH	7	O
sectional	sectional	ADJ	JJ	5	O
echocardiography	echocardiography	NOUN	NN	5	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
two	two	NUM	CD	5	O
neonates	neonate	NOUN	NNS	9	O
whose	whose	DET	WP$	9	O
mothers	mother	NOUN	NNS	5	O
ingested	ingest	VERB	VBD	0	O
lithium	lithium	NOUN	NN	0	B-Chemical
during	during	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
one	one	NUM	CD	5	O
infant	infant	NOUN	NN	5	O
,	,	PUNCT	,	9	O
Ebstein	Ebstein	PROPN	NNP	5	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	VERB	VBZ	9	I-Disease
anomaly	anomaly	NOUN	NN	5	I-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
tricuspid	tricuspid	ADJ	JJ	5	O
valve	valve	NOUN	NN	5	O
was	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
infant	infant	NOUN	NN	5	O
cross	cross	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
sectional	sectional	ADJ	JJ	5	O
echocardiography	echocardiography	NOUN	NN	5	O
provided	provide	VERB	VBN	9	O
reassurance	reassurance	NOUN	NN	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
infant	infant	NOUN	NN	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
have	have	VERB	VB	5	O
Ebstein	Ebstein	PROPN	NNP	5	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	NOUN	NNS	9	I-Disease
anomaly	anomaly	ADJ	JJ	5	I-Disease
.	.	PUNCT	.	9	O

Cross	cross	ADJ	JJ	2	O
-	-	PUNCT	HYPH	7	O
sectional	sectional	ADJ	JJ	5	O
echocardiographic	echocardiographic	ADJ	JJ	5	O
screening	screening	NOUN	NN	5	O
of	of	ADP	IN	5	O
newborns	newborn	NOUN	NNS	5	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
during	during	ADP	IN	5	O
gestation	gestation	NOUN	NN	9	O
can	can	VERB	MD	5	O
provide	provide	VERB	VB	5	O
highly	highly	ADV	RB	9	O
accurate	accurate	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
noninvasive	noninvasive	ADJ	JJ	5	O
assessment	assessment	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
malformations	malformation	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
training	training	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
aging	age	VERB	VBG	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
exercise	exercise	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
isoproterenol	isoproterenol	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
female	female	ADJ	JJ	9	O
albino	albino	ADJ	JJ	3	O
rats	rat	NOUN	NNS	9	O
of	of	ADP	IN	5	O
20	20	NUM	CD	9	O
,	,	PUNCT	,	9	O
40	40	NUM	CD	9	O
,	,	PUNCT	,	9	O
60	60	NUM	CD	9	O
and	and	CCONJ	CC	5	O
80	80	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
trained	train	VERB	VBN	5	O
to	to	PART	TO	5	O
swim	swim	VERB	VB	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
specific	specific	ADJ	JJ	9	O
duration	duration	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
particular	particular	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
infarcts	infarct	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
confirmed	confirm	VERB	VBN	9	O
by	by	ADP	IN	9	O
histological	histological	ADJ	JJ	9	O
methods	method	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Elevations	elevation	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
GOT	GOT	PROPN	NNP	0	O
and	and	CCONJ	CC	5	O
GPT	GPT	PROPN	NNP	0	O
were	be	VERB	VBD	9	O
maximum	maximum	ADJ	JJ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
sedentary	sedentary	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
isoproterenols	isoproterenol	NOUN	NNS	_	B-Chemical
and	and	CCONJ	CC	5	O
minimum	minimum	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
exercise	exercise	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
transaminases	transaminase	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
corresponding	correspond	VERB	VBG	9	O
depletions	depletion	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cardiac	cardiac	ADJ	JJ	5	O
GOT	GOT	PROPN	NNP	0	O
and	and	CCONJ	CC	5	O
GPT	GPT	PROPN	NNP	0	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
age	age	NOUN	NN	5	O
was	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
to	to	PART	TO	5	O
interfere	interfere	VERB	VB	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
responses	response	NOUN	NNS	5	O
exhibited	exhibit	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
young	young	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
old	old	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Studies	study	NOUN	NNS	9	O
dealing	deal	VERB	VBG	5	O
with	with	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
are	be	VERB	VBP	5	O
more	more	ADV	RBR	5	O
informative	informative	ADJ	JJ	5	O
when	when	ADV	WRB	5	O
dealt	deal	VERB	VBN	5	O
with	with	ADP	IN	5	O
age	age	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
polyethylene	polyethylene	NOUN	NN	0	B-Chemical
glycol	glycol	VERB	VBD	0	I-Chemical
400	400	NUM	CD	0	I-Chemical
on	on	ADP	IN	5	O
adriamycin	adriamycin	ADJ	JJ	3	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
organic	organic	ADJ	JJ	0	O
solvent	solvent	NOUN	NN	0	O
,	,	PUNCT	,	9	O
polyethylene	polyethylene	NOUN	NN	0	B-Chemical
glycol	glycol	VERB	VBD	0	I-Chemical
400	400	NUM	CD	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
PEG	PEG	PROPN	NNP	0	B-Chemical
400	400	NUM	CD	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
toxic	toxic	ADJ	JJ	0	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
chronic	chronic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
adriamycin	adriamycin	PROPN	NNP	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
ADR	ADR	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

PEG	PEG	PROPN	NNP	0	B-Chemical
400	400	NUM	CD	0	I-Chemical
impressively	impressively	ADV	RB	5	O
decreased	decrease	VERB	VBD	9	O
both	both	DET	DT	9	O
acute	acute	ADJ	JJ	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
chronic	chronic	ADJ	JJ	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
ADR	adr	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
lethality	lethality	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Light	light	ADJ	JJ	9	O
microscopic	microscopic	ADJ	JJ	9	O
analysis	analysis	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
protection	protection	NOUN	NN	9	O
against	against	ADP	IN	9	O
ADR	ADR	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
morphological	morphological	ADJ	JJ	9	I-Disease
alterations	alteration	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

Such	such	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
diminish	diminish	VERB	VB	9	O
the	the	DET	DT	5	O
ADR	ADR	PROPN	NNP	9	B-Chemical
antitumor	antitumor	CCONJ	CC	3	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
L1210	L1210	PROPN	NNP	3	B-Disease
leukemia	leukemia	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
Ehrlich	Ehrlich	PROPN	NNP	9	B-Disease
ascites	ascite	VERB	VBZ	3	I-Disease
tumor	tumor	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Sublingual	sublingual	ADJ	JJ	5	O
absorption	absorption	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
quaternary	quaternary	ADJ	JJ	0	B-Chemical
ammonium	ammonium	NOUN	NN	0	I-Chemical
antiarrhythmic	antiarrhythmic	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
,	,	PUNCT	,	9	O
UM	UM	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
272	272	NUM	CD	7	I-Chemical
.	.	PUNCT	.	9	O

UM	UM	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
272	272	NUM	CD	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
N	n	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
N	n	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dimethylpropranolol	dimethylpropranolol	NOUN	NN	_	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
quaternary	quaternary	ADJ	JJ	0	O
antiarrhythmic	antiarrhythmic	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
sublingually	sublingually	ADV	RB	0	O
to	to	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
with	with	ADP	IN	5	O
ouabain	ouabain	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardias	tachycardias	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
arrhythmic	arrhythmic	ADJ	JJ	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
bioavailability	bioavailability	NOUN	NN	0	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Sublingual	sublingual	ADJ	JJ	5	O
UM	UM	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
272	272	NUM	CD	7	I-Chemical
converted	convert	VERB	VBD	9	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
to	to	PART	TO	5	O
sinus	sinus	VERB	VB	5	O
rhythm	rhythm	NOUN	NN	5	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
5	5	NUM	CD	9	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
area	area	NOUN	NN	5	O
under	under	ADP	IN	9	O
the	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
concentration	concentration	NOUN	NN	0	O
time	time	NOUN	NN	5	O
curve	curve	NOUN	NN	9	O
at	at	ADP	IN	9	O
90	90	NUM	CD	9	O
min	min	NOUN	NN	0	O
was	be	VERB	VBD	9	O
4	4	NUM	CD	9	O
-	-	SYM	SYM	7	O
12	12	NUM	CD	9	O
times	time	NOUN	NNS	5	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
for	for	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
the	the	DET	DT	5	O
existence	existence	NOUN	NN	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
absorption	absorption	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
limiting	limit	VERB	VBG	9	O
process	process	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
intestine	intestine	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
providing	provide	VERB	VBG	9	O
an	an	DET	DT	5	O
alternate	alternate	ADJ	JJ	9	O
form	form	NOUN	NN	9	O
of	of	ADP	IN	5	O
administration	administration	NOUN	NN	9	O
for	for	ADP	IN	5	O
quaternary	quaternary	ADJ	JJ	0	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Early	early	ADJ	JJ	9	O
adjuvant	adjuvant	ADJ	JJ	9	O
adriamycin	adriamycin	NOUN	NN	3	B-Chemical
in	in	ADP	IN	5	O
superficial	superficial	ADJ	JJ	5	O
bladder	bladder	NOUN	NN	9	B-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
multicenter	multicenter	NOUN	NN	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
in	in	ADP	IN	5	O
110	110	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
superficial	superficial	ADJ	JJ	5	O
transitional	transitional	ADJ	JJ	9	O
cell	cell	NOUN	NN	3	O
carcinoma	carcinoma	NOUN	NN	3	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
bladder	bladder	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Adriamycin	Adriamycin	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
50	50	NUM	CD	0	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
intravesically	intravesically	ADV	RB	0	O
within	within	ADP	IN	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
transurethral	transurethral	ADJ	JJ	5	O
resection	resection	NOUN	NN	5	O
of	of	ADP	IN	5	O
TA	TA	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
T1	T1	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
O	o	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
A	a	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
bladder	bladder	NOUN	NN	9	B-Disease
tumors	tumor	NOUN	NNS	3	I-Disease
.	.	PUNCT	.	9	O

Instillation	instillation	NOUN	NN	0	O
was	be	VERB	VBD	9	O
repeated	repeat	VERB	VBN	5	O
twice	twice	ADV	RB	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
week	week	NOUN	NN	9	O
,	,	PUNCT	,	9	O
then	then	ADV	RB	9	O
weekly	weekly	ADV	RB	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
month	month	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
afterwards	afterwards	ADV	RB	5	O
monthly	monthly	ADJ	JJ	5	O
for	for	ADP	IN	5	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
tolerance	tolerance	NOUN	NN	9	O
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
110	110	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
29	29	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
local	local	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
24	24	NUM	CD	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
chemical	chemical	NOUN	NN	0	O
cystitis	cystitis	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
severe	severe	ADJ	JJ	5	O
enough	enough	ADV	RB	5	O
for	for	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
to	to	PART	TO	5	O
drop	drop	VERB	VB	9	O
out	out	ADP	IN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
systemic	systemic	ADJ	JJ	9	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Recurrence	Recurrence	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
82	82	NUM	CD	7	O
evaluable	evaluable	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
after	after	ADP	IN	9	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
of	of	ADP	IN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
72	72	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
followed	follow	VERB	VBD	9	O
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
years	year	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
32	32	NUM	CD	7	O
months	month	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
82	82	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
studied	study	VERB	VBN	9	O
after	after	ADP	IN	9	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
,	,	PUNCT	,	9	O
23	23	NUM	CD	7	O
had	have	VERB	VBD	9	O
primary	primary	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
59	59	NUM	CD	7	O
recurrent	recurrent	ADJ	JJ	5	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
82	82	NUM	CD	7	O
evaluable	evaluable	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
50	50	NUM	CD	0	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
show	show	VERB	VB	9	O
any	any	DET	DT	5	O
recurrence	recurrence	NOUN	NN	5	O
after	after	ADP	IN	9	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
61	61	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
32	32	NUM	CD	7	O
presented	present	VERB	VBD	5	O
with	with	ADP	IN	5	O
one	one	NUM	CD	5	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
recurrences	recurrence	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
39	39	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
these	these	DET	DT	5	O
recurrences	recurrence	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
27	27	NUM	CD	7	O
were	be	VERB	VBD	9	O
T1	t1	NUM	CD	9	O
tumors	tumor	NOUN	NNS	3	B-Disease
while	while	ADP	IN	9	O
five	five	NUM	CD	9	O
progressed	progress	VERB	VBD	9	O
to	to	ADP	IN	5	O
more	more	ADV	RBR	5	O
highly	highly	ADV	RB	9	O
invasive	invasive	ADJ	JJ	5	O
lesions	lesion	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
that	that	DET	WDT	5	O
were	be	VERB	VBD	9	O
free	free	ADJ	JJ	9	O
of	of	ADP	IN	5	O
recurrence	recurrence	NOUN	NN	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
year	year	NOUN	NN	5	O
,	,	PUNCT	,	9	O
80	80	NUM	CD	9	O
%	%	NOUN	NN	9	O
remained	remain	VERB	VBD	9	O
tumor	tumor	NOUN	NN	3	B-Disease
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
2	2	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
developing	develop	VERB	VBG	5	O
one	one	NUM	CD	5	O
or	or	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
recurrences	recurrence	NOUN	NNS	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
year	year	NOUN	NN	5	O
,	,	PUNCT	,	9	O
only	only	ADV	RB	9	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
further	further	ADJ	JJ	9	O
recurrence	recurrence	NOUN	NN	5	O
once	once	ADP	IN	5	O
the	the	DET	DT	5	O
instillations	instillation	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
stopped	stop	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
beneficial	beneficial	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
Adriamycin	Adriamycin	PROPN	NNP	0	B-Chemical
appears	appear	VERB	VBZ	9	O
obvious	obvious	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
itself	-PRON-	PRON	PRP	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
early	early	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
repeated	repeat	VERB	VBN	5	O
instillations	instillation	NOUN	NNS	0	O
after	after	ADP	IN	9	O
TUR	TUR	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
both	both	DET	DT	9	O
.	.	PUNCT	.	9	O

D	d	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
penicillamine	penicillamine	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
angiopathy	angiopathy	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
D	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
penicillamine	penicillamine	NOUN	NN	0	I-Chemical
treatment	treatment	NOUN	NN	9	O
on	on	ADP	IN	5	O
aortic	aortic	ADJ	JJ	9	O
permeability	permeability	NOUN	NN	0	O
to	to	ADP	IN	5	O
albumin	albumin	VERB	VB	0	O
and	and	CCONJ	CC	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
ultrastructure	ultrastructure	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
vessel	vessel	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Male	Male	PROPN	NNP	7	O
Sprague	Sprague	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
Dawley	Dawley	PROPN	NNP	0	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
D	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
penicillamine	penicillamine	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
pen	pen	NOUN	NN	5	I-Chemical
)	)	PUNCT	-RRB-	9	O
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
10	10	NUM	CD	9	O
or	or	CCONJ	CC	5	O
42	42	NUM	CD	7	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Pair	pair	VERB	VB	5	O
fed	feed	VERB	VBN	9	O
rats	rat	NOUN	NNS	9	O
served	serve	VERB	VBD	9	O
as	as	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
aortic	aortic	ADJ	JJ	9	O
morphology	morphology	NOUN	NN	9	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
by	by	ADP	IN	9	O
light	light	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
and	and	CCONJ	CC	5	O
transmission	transmission	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
electron	electron	NOUN	NN	0	O
microscopy	microscopy	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
TEM	TEM	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
endothelial	endothelial	ADJ	JJ	3	O
permeability	permeability	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
penetration	penetration	NOUN	NN	5	O
through	through	ADP	IN	9	O
the	the	DET	DT	5	O
aortic	aortic	ADJ	JJ	9	O
wall	wall	NOUN	NN	5	O
of	of	ADP	IN	5	O
albumin	albumin	NOUN	NN	0	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
10	10	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
24	24	NUM	CD	9	O
and	and	CCONJ	CC	5	O
48	48	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
human	human	ADJ	JJ	3	O
serum	serum	ADJ	JJ	9	O
131I	131i	NUM	CD	0	O
-	-	PUNCT	HYPH	7	O
albumin	albumin	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
131I	131i	NUM	CD	0	O
-	-	PUNCT	HYPH	7	O
HSA	HSA	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

TEM	TEM	PROPN	NNP	9	O
revealed	reveal	VERB	VBD	9	O
extensive	extensive	ADJ	JJ	5	O
elastolysis	elastolysis	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
arterial	arterial	ADJ	JJ	5	O
wall	wall	NOUN	NN	5	O
of	of	ADP	IN	5	O
D	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
pen	pen	NOUN	NN	5	I-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
inhibitory	inhibitory	ADJ	JJ	3	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
crosslink	crosslink	NOUN	NN	0	O
formation	formation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
experimental	experimental	ADJ	JJ	5	O
animals	animal	NOUN	NNS	9	O
excess	excess	ADJ	JJ	9	O
deposition	deposition	NOUN	NN	9	O
of	of	ADP	IN	5	O
collagen	collagen	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
glycoaminoglycans	glycoaminoglycan	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
subendothelial	subendothelial	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
medial	medial	ADJ	JJ	5	O
layer	layer	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
aortic	aortic	ADJ	JJ	9	O
wall	wall	NOUN	NN	5	O
,	,	PUNCT	,	9	O
together	together	ADV	RB	9	O
with	with	ADP	IN	5	O
prominent	prominent	ADJ	JJ	9	O
basal	basal	NOUN	NN	3	O
membrane	membrane	NOUN	NN	9	O
substance	substance	NOUN	NN	5	O
around	around	ADP	IN	5	O
aortic	aortic	ADJ	JJ	9	O
smooth	smooth	ADJ	JJ	5	O
muscle	muscle	NOUN	NN	9	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aorta	aorta	NOUN	NNS	9	O
/	/	SYM	SYM	9	O
serum	serum	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
ratio	ratio	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
radioactive	radioactive	ADJ	JJ	0	O
build	build	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
24	24	NUM	CD	9	O
and	and	CCONJ	CC	5	O
48	48	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
131I	131i	NUM	CD	0	O
-	-	PUNCT	HYPH	7	O
HSA	HSA	PROPN	NNP	0	O
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
D	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
pen	pen	NOUN	NN	5	I-Chemical
for	for	ADP	IN	5	O
42	42	NUM	CD	7	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
an	an	DET	DT	5	O
impeded	impeded	ADJ	JJ	9	O
transmural	transmural	ADJ	JJ	5	O
transport	transport	NOUN	NN	9	O
of	of	ADP	IN	5	O
tracer	tracer	NOUN	NN	0	O
which	which	DET	WDT	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
steric	steric	ADJ	JJ	0	O
exclusion	exclusion	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
abundant	abundant	ADJ	JJ	9	O
hyaluronate	hyaluronate	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
endothelial	endothelial	ADJ	JJ	3	O
ultrastructure	ultrastructure	NOUN	NN	9	O
was	be	VERB	VBD	9	O
unaffected	unaffected	ADJ	JJ	9	O
by	by	ADP	IN	9	O
D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
pen	pen	NOUN	NN	5	I-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
aortic	aortic	ADJ	JJ	9	O
131I	131i	NUM	CD	0	O
-	-	PUNCT	HYPH	7	O
HSA	HSA	PROPN	NNP	0	O
radioactivity	radioactivity	NOUN	NN	0	O
or	or	CCONJ	CC	5	O
aorta	aorta	NOUN	NNS	9	O
/	/	SYM	SYM	9	O
serum	serum	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
ratio	ratio	NOUN	NN	9	O
were	be	VERB	VBD	9	O
recorded	record	VERB	VBN	5	O
between	between	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
control	control	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
10	10	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
tracer	tracer	NOUN	NN	0	O
injection	injection	NOUN	NN	9	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
permeability	permeability	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
endothelial	endothelial	ADJ	JJ	3	O
barrier	barrier	NOUN	NN	5	O
to	to	PART	TO	5	O
albumin	albumin	NOUN	NN	0	O
remained	remain	VERB	VBD	9	O
unaffected	unaffected	ADJ	JJ	9	O
by	by	ADP	IN	9	O
D	D	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
pen	pen	NOUN	NN	5	I-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
observations	observation	NOUN	NNS	9	O
support	support	VERB	VBP	5	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
D	d	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
pen	pen	NOUN	NN	5	I-Chemical
may	may	VERB	MD	5	O
induce	induce	VERB	VB	3	O
a	a	DET	DT	5	O
fibroproliferative	fibroproliferative	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
aorta	aorta	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
possibly	possibly	ADV	RB	9	O
by	by	ADP	IN	9	O
an	an	DET	DT	5	O
inhibitory	inhibitory	ADJ	JJ	3	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
cross	cross	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
linking	linking	NOUN	NN	9	O
of	of	ADP	IN	5	O
collagen	collagen	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
elastin	elastin	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
on	on	ADP	IN	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	:	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
5	5	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
nitro	nitro	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
furyl	furyl	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
thiazolyl	thiazolyl	NOUN	NN	0	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
formamide	formamide	ADV	RB	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
epithelial	epithelial	ADJ	JJ	3	O
proliferation	proliferation	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
urinary	urinary	ADJ	JJ	9	O
bladder	bladder	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
forestomach	forestomach	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
co	co	NOUN	NN	9	O
-	-	NOUN	NN	7	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
with	with	ADP	IN	5	O
N	n	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	:	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
5	5	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
nitro	nitro	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
furyl	furyl	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
thiazolyl	thiazolyl	NOUN	NN	0	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
formamide	formamide	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
FANFT	FANFT	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
reduced	reduced	ADJ	JJ	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
FANFT	FANFT	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
bladder	bladder	NOUN	NN	9	B-Disease
carcinomas	carcinoma	NOUN	NNS	3	I-Disease
but	but	CCONJ	CC	9	O
a	a	DET	DT	5	O
concomitant	concomitant	ADJ	JJ	9	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
forestomach	forestomach	ADJ	JJ	3	B-Disease
tumors	tumor	NOUN	NNS	3	I-Disease
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
autoradiographic	autoradiographic	ADJ	JJ	0	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
on	on	ADP	IN	5	O
male	male	ADJ	JJ	9	O
F	F	PROPN	NNP	7	O
-	-	PUNCT	HYPH	7	O
344	344	NUM	CD	7	O
rats	rat	NOUN	NNS	9	O
fed	feed	VERB	VBN	9	O
diet	diet	NOUN	NN	9	O
containing	contain	VERB	VBG	0	O
FANFT	FANFT	PROPN	NNP	0	B-Chemical
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
aspirin	aspirin	VERB	VB	9	B-Chemical
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
cell	cell	NOUN	NN	3	O
proliferation	proliferation	NOUN	NN	3	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
FANFT	FANFT	PROPN	NNP	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
forestomach	forestomach	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
bladder	bladder	NOUN	NN	9	O
.	.	PUNCT	.	9	O

FANFT	FANFT	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cell	cell	NOUN	NN	3	O
proliferation	proliferation	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
bladder	bladder	NOUN	NN	9	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
suppressed	suppress	VERB	VBN	3	O
by	by	ADP	IN	9	O
aspirin	aspirin	ADJ	JJ	9	B-Chemical
co	co	NOUN	NN	9	O
-	-	NOUN	NN	7	O
administration	administration	NOUN	NN	9	O
after	after	ADP	IN	9	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
after	after	ADP	IN	9	O
12	12	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
forestomach	forestomach	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
also	also	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
,	,	PUNCT	,	9	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
affect	affect	VERB	VB	9	O
the	the	DET	DT	5	O
FANFT	FANFT	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
labeling	labeling	NOUN	NN	3	O
index	index	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
consistent	consistent	ADJ	JJ	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
carcinogenicity	carcinogenicity	NOUN	NN	5	O
experiment	experiment	NOUN	NN	9	O
suggesting	suggest	VERB	VBG	9	O
that	that	ADP	IN	5	O
different	different	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
involved	involve	VERB	VBN	9	O
in	in	ADP	IN	5	O
FANFT	FANFT	PROPN	NNP	0	B-Chemical
carcinogenesis	carcinogenesis	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
bladder	bladder	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
forestomach	forestomach	NOUN	NN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
that	that	DET	DT	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
'	'	PUNCT	''	9	O
s	s	VERB	VBZ	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
FANFT	FANFT	PROPN	NNP	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
forestomach	forestomach	NOUN	NN	3	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
an	an	DET	DT	5	O
irritant	irritant	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
cell	cell	NOUN	NN	3	O
proliferation	proliferation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Also	also	ADV	RB	9	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
adaptation	adaptation	NOUN	NN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
chronic	chronic	ADJ	JJ	5	O
ingestion	ingestion	NOUN	NN	9	O
of	of	ADP	IN	5	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
tardive	tardive	ADJ	JJ	5	B-Disease
dyskinesia	dyskinesia	NOUN	NN	5	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
metoclopramide	metoclopramide	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Abnormal	abnormal	ADJ	JJ	9	B-Disease
involuntary	involuntary	ADJ	JJ	5	I-Disease
movements	movement	NOUN	NNS	5	I-Disease
appeared	appear	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mouth	mouth	NOUN	NN	5	O
,	,	PUNCT	,	9	O
tongue	tongue	NOUN	NN	5	O
,	,	PUNCT	,	9	O
neck	neck	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
abdomen	abdoman	NOUN	NNS	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
64	64	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
male	male	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
after	after	ADP	IN	9	O
he	-PRON-	PRON	PRP	5	O
took	take	VERB	VBD	5	O
metoclopramide	metoclopramide	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
gastrointestinal	gastrointestinal	ADJ	JJ	9	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
regimen	regimen	NOUN	NN	5	O
of	of	ADP	IN	5	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
about	about	ADP	IN	5	O
260	260	NUM	CD	9	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
exacerbated	exacerbate	VERB	VBD	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
maximum	maximum	NOUN	NN	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
month	month	NOUN	NN	5	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
the	the	DET	DT	5	O
metoclopramide	metoclopramide	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
abnormal	abnormal	ADJ	JJ	9	B-Disease
movements	movement	NOUN	NNS	5	I-Disease
gradually	gradually	ADV	RB	9	O
improved	improve	VERB	VBD	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
considerable	considerable	ADJ	JJ	5	O
extent	extent	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Attention	attention	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
specific	specific	ADJ	JJ	9	O
tardive	tardive	ADJ	JJ	5	B-Disease
dyskinesia	dyskinesia	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
called	call	VERB	VBN	5	O
for	for	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Intra	intra	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
arterial	arterial	ADJ	JJ	5	O
BCNU	BCNU	PROPN	NNP	0	B-Chemical
chemotherapy	chemotherapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
malignant	malignant	ADJ	JJ	3	B-Disease
gliomas	glioma	NOUN	NNS	3	I-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rapid	rapid	ADJ	JJ	5	O
systemic	systemic	ADJ	JJ	9	O
clearance	clearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
BCNU	BCNU	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
3	3	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
bis	bis	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
chloroethyl	chloroethyl	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
nitrosourea	nitrosourea	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
intra	intra	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
arterial	arterial	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
should	should	VERB	MD	5	O
provide	provide	VERB	VB	5	O
a	a	DET	DT	5	O
substantial	substantial	ADJ	JJ	9	O
advantage	advantage	NOUN	NN	5	O
over	over	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
malignant	malignant	ADJ	JJ	3	B-Disease
gliomas	glioma	NOUN	NNS	3	I-Disease
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
six	six	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
BCNU	BCNU	PROPN	NNP	0	B-Chemical
every	every	DET	DT	5	O
6	6	NUM	CD	9	O
to	to	PART	TO	5	O
8	8	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
either	either	CCONJ	CC	9	O
by	by	ADP	IN	9	O
transfemoral	transfemoral	ADJ	JJ	5	O
catheterization	catheterization	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
internal	internal	ADJ	JJ	5	O
carotid	carotid	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
vertebral	vertebral	ADJ	JJ	5	O
artery	artery	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
through	through	ADP	IN	9	O
a	a	DET	DT	5	O
fully	fully	ADV	RB	9	O
implantable	implantable	ADJ	JJ	5	O
intracarotid	intracarotid	ADJ	JJ	0	O
drug	drug	NOUN	NN	5	O
delivery	delivery	NOUN	NN	5	O
system	system	NOUN	NN	5	O
,	,	PUNCT	,	9	O
beginning	begin	VERB	VBG	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
sq	sq	NOUN	NN	9	O
m	m	NUM	CD	9	O
body	body	NOUN	NN	5	O
surface	surface	NOUN	NN	9	O
area	area	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Twelve	twelve	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Grade	Grade	PROPN	NNP	9	O
III	III	PROPN	NNP	9	O
or	or	CCONJ	CC	5	O
IV	IV	PROPN	NNP	9	O
astrocytomas	astrocytoma	NOUN	NNS	3	B-Disease
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
after	after	ADP	IN	9	O
partial	partial	ADJ	JJ	9	O
resection	resection	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
tumor	tumor	NOUN	NN	3	B-Disease
without	without	ADP	IN	9	O
prior	prior	ADJ	JJ	9	O
radiation	radiation	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
two	two	NUM	CD	5	O
to	to	PART	TO	5	O
seven	seven	NUM	CD	9	O
cycles	cycle	NOUN	NNS	9	O
of	of	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
nine	nine	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
tumor	tumor	NOUN	NN	3	B-Disease
size	size	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
surrounding	surround	VERB	VBG	9	O
edema	edema	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
contrast	contrast	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
enhanced	enhance	VERB	VBN	3	O
computerized	computerized	ADJ	JJ	5	O
tomography	tomography	NOUN	NN	5	O
scans	scan	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
nine	nine	NUM	CD	9	O
responders	responder	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
median	median	ADJ	JJ	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
response	response	NOUN	NN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
operation	operation	NOUN	NN	5	O
was	be	VERB	VBD	9	O
25	25	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
range	range	VERB	VBP	9	O
12	12	NUM	CD	9	O
to	to	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
91	91	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
survival	survival	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
12	12	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
54	54	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
range	range	VERB	VBP	9	O
21	21	NUM	CD	7	O
to	to	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
156	156	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
18	18	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
month	month	NOUN	NN	5	O
survival	survival	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
42	42	NUM	CD	7	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
recurrent	recurrent	NOUN	NN	5	O
Grade	Grade	PROPN	NNP	9	O
I	-PRON-	PRON	PRP	9	O
to	to	ADP	IN	5	O
IV	IV	PROPN	NNP	9	O
astrocytomas	astrocytoma	NOUN	NNS	3	B-Disease
,	,	PUNCT	,	9	O
whose	whose	DET	WP$	9	O
resection	resection	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
irradiation	irradiation	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
had	have	VERB	VBD	9	O
failed	fail	VERB	VBN	9	O
,	,	PUNCT	,	9	O
received	receive	VERB	VBD	9	O
two	two	NUM	CD	5	O
to	to	PART	TO	5	O
eight	eight	NUM	CD	9	O
courses	course	NOUN	NNS	5	O
of	of	ADP	IN	5	O
intra	intra	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
arterial	arterial	ADJ	JJ	5	O
BCNU	BCNU	PROPN	NNP	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Seventeen	seventeen	NUM	CD	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
response	response	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
stable	stable	ADJ	JJ	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
median	median	NOUN	NN	9	O
of	of	ADP	IN	5	O
20	20	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
range	range	VERB	VBP	9	O
6	6	NUM	CD	9	O
to	to	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
66	66	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
catheterization	catheterization	NOUN	NN	5	O
procedure	procedure	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
safe	safe	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
no	no	DET	DT	9	O
immediate	immediate	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
in	in	ADP	IN	5	O
111	111	NUM	CD	7	O
infusions	infusion	NOUN	NNS	9	O
of	of	ADP	IN	5	O
BCNU	BCNU	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
delayed	delay	VERB	VBN	9	O
complication	complication	NOUN	NN	5	O
in	in	ADP	IN	5	O
nine	nine	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
unilateral	unilateral	ADJ	JJ	5	O
loss	loss	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
vision	vision	NOUN	NN	5	I-Disease
secondary	secondary	ADJ	JJ	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
retinal	retinal	ADJ	JJ	5	B-Disease
vasculitis	vasculitis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
visual	visual	ADJ	JJ	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
decreased	decrease	VERB	VBD	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ethanol	ethanol	NOUN	NN	0	B-Chemical
diluent	diluent	NOUN	NN	0	O
was	be	VERB	VBD	9	O
lowered	lower	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Provocation	provocation	NOUN	NN	5	O
of	of	ADP	IN	5	O
postural	postural	ADJ	JJ	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
by	by	ADP	IN	9	O
nitroglycerin	nitroglycerin	ADJ	JJ	5	B-Chemical
in	in	ADP	IN	5	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
autonomic	autonomic	ADJ	JJ	5	I-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
?	?	PUNCT	.	5	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
nitroglycerin	nitroglycerin	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
systolic	systolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
was	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
in	in	ADP	IN	5	O
5	5	NUM	CD	9	O
normal	normal	ADJ	JJ	9	O
subjects	subject	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
12	12	NUM	CD	9	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
subjects	subject	NOUN	NNS	5	O
without	without	ADP	IN	9	O
autonomic	autonomic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
subjects	subject	NOUN	NNS	5	O
with	with	ADP	IN	5	O
autonomic	autonomic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
magnitude	magnitude	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
time	time	NOUN	NN	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
systolic	systolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
after	after	ADP	IN	9	O
nitroglycerin	nitroglycerin	NOUN	NN	5	B-Chemical
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
normal	normal	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
subjects	subject	NOUN	NNS	5	O
without	without	ADP	IN	9	O
autonomic	autonomic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
a	a	DET	DT	5	O
lesser	less	ADJ	JJR	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
greater	great	ADJ	JJR	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
systolic	systolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
subjects	subject	NOUN	NNS	5	O
with	with	ADP	IN	5	O
autonomic	autonomic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
therefore	therefore	ADV	RB	5	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
caution	caution	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
exercised	exercise	VERB	VBN	5	O
when	when	ADV	WRB	5	O
prescribing	prescribe	VERB	VBG	5	O
vasodilator	vasodilator	NOUN	NN	0	O
drugs	drug	NOUN	NNS	5	O
in	in	ADP	IN	5	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
those	those	DET	DT	5	O
with	with	ADP	IN	5	O
autonomic	autonomic	ADJ	JJ	5	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
response	response	NOUN	NN	9	O
to	to	PART	TO	5	O
chronic	chronic	VERB	VB	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
intrarenal	intrarenal	ADJ	JJ	5	O
noradrenaline	noradrenaline	NOUN	NN	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
in	in	ADP	IN	5	O
conscious	conscious	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Sodium	sodium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
solution	solution	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
noradrenaline	noradrenaline	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
12	12	NUM	CD	9	O
and	and	CCONJ	CC	5	O
36	36	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
h	h	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
was	be	VERB	VBD	9	O
infused	infuse	VERB	VBN	9	O
for	for	ADP	IN	5	O
five	five	NUM	CD	9	O
consecutive	consecutive	ADJ	JJ	5	O
days	day	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
either	either	CCONJ	CC	9	O
intrarenally	intrarenally	ADV	RB	3	O
(	(	PUNCT	-LRB-	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
technique	technique	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
intravenously	intravenously	ADV	RB	0	O
into	into	ADP	IN	9	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
one	one	NUM	CD	5	O
kidney	kidney	NOUN	NN	9	O
removed	remove	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Intrarenal	intrarenal	ADJ	JJ	3	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
noradrenaline	noradrenaline	NOUN	NN	0	B-Chemical
caused	cause	VERB	VBN	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
at	at	ADP	IN	9	O
doses	dose	NOUN	NNS	0	O
which	which	DET	WDT	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
do	do	VERB	VB	5	O
so	so	ADV	RB	5	O
when	when	ADV	WRB	5	O
infused	infuse	VERB	VBN	9	O
intravenously	intravenously	ADV	RB	0	O
.	.	PUNCT	.	9	O

Intrarenal	intrarenal	ADJ	JJ	3	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
noradrenaline	noradrenaline	NOUN	NN	0	B-Chemical
caused	cause	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
plasma	plasma	NOUN	NN	9	O
noradrenaline	noradrenaline	NOUN	NN	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
shift	shift	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
noradrenaline	noradrenaline	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
curve	curve	NOUN	NN	9	O
towards	towards	ADP	IN	5	O
lower	low	ADJ	JJR	9	O
plasma	plasma	NOUN	NN	9	O
noradrenaline	noradrenaline	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	DET	DT	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
intrarenal	intrarenal	ADJ	JJ	5	O
noradrenaline	noradrenaline	NOUN	NN	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
is	be	VERB	VBZ	5	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
relatively	relatively	ADV	RB	5	O
higher	high	ADJ	JJR	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
circulating	circulate	VERB	VBG	9	O
noradrenaline	noradrenaline	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
by	by	ADP	IN	9	O
triggering	trigger	VERB	VBG	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
additional	additional	ADJ	JJ	9	O
intrarenal	intrarenal	ADJ	JJ	5	O
pressor	pressor	NOUN	NN	5	O
mechanism	mechanism	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Characterization	characterization	NOUN	NN	9	O
of	of	ADP	IN	5	O
estrogen	estrogen	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
adenohypophyseal	adenohypophyseal	ADJ	JJ	3	B-Disease
tumors	tumor	NOUN	NNS	3	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Fischer	Fischer	PROPN	NNP	6	O
344	344	NUM	CD	7	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Pituitary	pituitary	ADJ	JJ	2	B-Disease
tumors	tumor	NOUN	NNS	3	I-Disease
were	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
in	in	ADP	IN	5	O
F344	f344	NOUN	NN	3	O
female	female	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
by	by	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
diethylstilbestrol	diethylstilbestrol	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
DES	DES	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
implanted	implant	VERB	VBN	9	O
subcutaneously	subcutaneously	ADV	RB	3	O
in	in	ADP	IN	5	O
silastic	silastic	ADJ	JJ	5	O
capsules	capsule	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Over	over	ADP	IN	5	O
a	a	DET	DT	5	O
range	range	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
150	150	NUM	CD	0	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
DES	DES	PROPN	NNP	9	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
pairs	pair	NOUN	NNS	9	O
of	of	ADP	IN	5	O
control	control	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
DES	DES	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
sacrificed	sacrifice	VERB	VBN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
their	-PRON-	DET	PRP$	5	O
pituitaries	pituitary	NOUN	NNS	3	O
dissociated	dissociate	VERB	VBD	3	O
enzymatically	enzymatically	ADV	RB	0	O
into	into	ADP	IN	9	O
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
cell	cell	NOUN	NN	3	O
preparations	preparation	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cell	cell	NOUN	NN	3	O
populations	population	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
regarding	regard	VERB	VBG	5	O
total	total	ADJ	JJ	9	O
cell	cell	NOUN	NN	3	O
recovery	recovery	NOUN	NN	9	O
correlated	correlate	VERB	VBD	9	O
with	with	ADP	IN	5	O
gland	gland	NOUN	NN	9	O
weight	weight	NOUN	NN	9	O
,	,	PUNCT	,	9	O
intracellular	intracellular	ADJ	JJ	3	O
prolactin	prolactin	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
PRL	PRL	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
content	content	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
subsequent	subsequent	ADJ	JJ	9	O
release	release	NOUN	NN	9	O
in	in	ADP	IN	5	O
primary	primary	ADJ	JJ	9	O
culture	culture	NOUN	NN	9	O
,	,	PUNCT	,	9	O
immunocytochemical	immunocytochemical	ADJ	JJ	3	O
PRL	PRL	PROPN	NNP	3	O
staining	staining	NOUN	NN	3	O
,	,	PUNCT	,	9	O
density	density	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
size	size	NOUN	NN	9	O
alterations	alteration	NOUN	NNS	9	O
via	via	ADP	IN	9	O
separation	separation	NOUN	NN	5	O
on	on	ADP	IN	5	O
Ficoll	Ficoll	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
Hypaque	Hypaque	PROPN	NNP	0	O
and	and	CCONJ	CC	5	O
by	by	ADP	IN	9	O
unit	unit	NOUN	NN	5	O
gravity	gravity	NOUN	NN	5	O
sedimentation	sedimentation	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cell	cell	NOUN	NN	3	O
cycle	cycle	NOUN	NN	9	O
analysis	analysis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
after	after	ADP	IN	9	O
acriflavine	acriflavine	NOUN	NN	0	B-Chemical
DNA	dna	NOUN	NN	9	O
staining	staining	NOUN	NN	3	O
,	,	PUNCT	,	9	O
by	by	ADP	IN	9	O
laser	laser	NOUN	NN	5	O
flow	flow	NOUN	NN	5	O
cytometry	cytometry	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Total	total	ADJ	JJ	7	O
cell	cell	NOUN	NN	3	O
yields	yield	NOUN	NNS	9	O
from	from	ADP	IN	9	O
DES	DES	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
pituitaries	pituitary	NOUN	NNS	3	O
increased	increase	VERB	VBD	9	O
from	from	ADP	IN	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
times	time	NOUN	NNS	5	O
control	control	VERB	VBP	9	O
yields	yield	NOUN	NNS	9	O
at	at	ADP	IN	9	O
8	8	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
to	to	ADP	IN	5	O
58	58	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
times	time	NOUN	NNS	5	O
control	control	NOUN	NN	9	O
values	value	NOUN	NNS	5	O
by	by	ADP	IN	9	O
day	day	NOUN	NN	9	O
150	150	NUM	CD	0	O
.	.	PUNCT	.	9	O

Intracellular	Intracellular	PROPN	NNP	3	O
PRL	PRL	PROPN	NNP	3	O
content	content	NOUN	NN	9	O
ranged	range	VERB	VBD	9	O
from	from	ADP	IN	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
to	to	ADP	IN	5	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
times	time	NOUN	NNS	5	O
control	control	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
PRL	PRL	PROPN	NNP	3	O
release	release	NOUN	NN	9	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
and	and	CCONJ	CC	5	O
consistently	consistently	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
after	after	ADP	IN	9	O
at	at	ADV	RB	9	O
least	least	ADJ	JJS	9	O
8	8	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
DES	DES	PROPN	NNP	9	B-Chemical
exposure	exposure	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Beyond	beyond	ADP	IN	5	O
8	8	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
DES	DES	PROPN	NNP	9	B-Chemical
exposure	exposure	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
immunochemically	immunochemically	ADV	RB	3	O
PRL	PRL	PROPN	NNP	3	O
-	-	PUNCT	HYPH	7	O
positive	positive	ADJ	JJ	9	O
proportion	proportion	NOUN	NN	9	O
of	of	ADP	IN	5	O
cells	cell	NOUN	NNS	3	O
increased	increase	VERB	VBD	9	O
to	to	ADP	IN	5	O
over	over	ADP	IN	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
population	population	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Increased	increase	VERB	VBN	9	O
density	density	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
size	size	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
PRL	PRL	PROPN	NNP	3	O
content	content	NOUN	NN	9	O
were	be	VERB	VBD	9	O
indicated	indicate	VERB	VBN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
majority	majority	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
PRL	PRL	PROPN	NNP	3	O
cell	cell	NOUN	NN	3	O
population	population	NOUN	NN	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
types	type	NOUN	NNS	9	O
of	of	ADP	IN	5	O
separation	separation	NOUN	NN	5	O
protocols	protocol	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

All	all	DET	PDT	9	O
these	these	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
DES	DES	PROPN	NNP	9	B-Chemical
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
pronounced	pronounce	VERB	VBN	9	O
among	among	ADP	IN	5	O
previously	previously	ADV	RB	9	O
ovariectomized	ovariectomize	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
extend	extend	VERB	VBP	9	O
the	the	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
of	of	ADP	IN	5	O
other	other	ADJ	JJ	5	O
investigators	investigator	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
further	further	ADV	RB	9	O
establishing	establish	VERB	VBG	5	O
the	the	DET	DT	5	O
DES	DES	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
tumor	tumor	NOUN	NN	3	B-Disease
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
model	model	NOUN	NN	5	O
for	for	ADP	IN	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
PRL	PRL	PROPN	NNP	3	O
cellular	cellular	ADJ	JJ	3	O
control	control	NOUN	NN	9	O
mechanisms	mechanism	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Age	age	NOUN	NN	7	O
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	O
clearance	clearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
35	35	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
ages	age	NOUN	NNS	5	O
20	20	NUM	CD	9	O
to	to	PART	TO	5	O
86	86	NUM	CD	7	O
yr	yr	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
receiving	receive	VERB	VBG	9	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
therapeutically	therapeutically	ADV	RB	9	O
two	two	NUM	CD	5	O
serum	serum	ADJ	JJ	9	O
samples	sample	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
all	all	DET	DT	5	O
urine	urine	NOUN	NN	9	O
formed	form	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
interim	interim	NOUN	NN	5	O
were	be	VERB	VBD	9	O
collected	collect	VERB	VBN	9	O
for	for	ADP	IN	5	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
by	by	ADP	IN	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
pressure	pressure	NOUN	NN	5	O
liquid	liquid	ADJ	JJ	0	O
chromatography	chromatography	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
for	for	ADP	IN	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Cimetidine	cimetidine	ADJ	JJ	0	B-Chemical
clearance	clearance	NOUN	NN	9	O
decreased	decrease	VERB	VBD	9	O
with	with	ADP	IN	5	O
age	age	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
extrapolated	extrapolated	ADJ	JJ	5	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hr	hr	NOUN	NN	0	O
serum	serum	ADJ	JJ	9	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
per	per	ADP	IN	9	O
unit	unit	NOUN	NN	5	O
dose	dose	NOUN	NN	9	O
,	,	PUNCT	,	9	O
after	after	ADP	IN	9	O
intravenous	intravenous	ADJ	JJ	0	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
increased	increase	VERB	VBD	9	O
with	with	ADP	IN	5	O
age	age	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
ratio	ratio	NOUN	NN	9	O
of	of	ADP	IN	5	O
cimetidine	cimetidine	ADJ	JJ	0	B-Chemical
clearance	clearance	NOUN	NN	9	O
to	to	PART	TO	5	O
creatinine	creatinine	VERB	VB	0	B-Chemical
clearance	clearance	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
Rc	Rc	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
averaged	average	VERB	VBD	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
net	net	ADJ	JJ	5	O
tubular	tubular	ADJ	JJ	9	O
secretion	secretion	NOUN	NN	3	O
for	for	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Rc	Rc	PROPN	NNP	0	O
seemed	seem	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
independent	independent	ADJ	JJ	9	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
with	with	ADP	IN	5	O
increasing	increase	VERB	VBG	9	O
serum	serum	ADJ	JJ	9	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
that	that	ADP	IN	5	O
secretion	secretion	NOUN	NN	3	O
of	of	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
saturable	saturable	ADJ	JJ	0	O
process	process	NOUN	NN	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
only	only	ADV	RB	9	O
one	one	NUM	CD	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
dementia	dementia	NOUN	NN	5	B-Disease
possibly	possibly	ADV	RB	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
drug	drug	NOUN	NN	5	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
microgram	microgram	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
6	6	NUM	CD	9	O
hr	hr	NOUN	NNS	0	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
13	13	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
without	without	ADP	IN	9	O
liver	liver	NOUN	NN	9	B-Disease
or	or	CCONJ	CC	5	I-Disease
kidney	kidney	NOUN	NN	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
above	above	ADP	IN	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
microgram	microgram	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
high	high	ADJ	JJ	9	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
alone	alone	ADV	RB	9	O
do	do	VERB	VBP	5	O
not	not	ADV	RB	5	O
always	always	ADV	RB	5	O
induce	induce	VERB	VB	3	O
dementia	dementia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
observations	observation	NOUN	NNS	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
electrophysiologic	electrophysiologic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
amiodarone	amiodarone	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
presented	present	VERB	VBN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
reversible	reversible	ADJ	JJ	9	O
intra	intra	ADJ	JJ	5	B-Disease
-	-	ADJ	JJ	7	I-Disease
Hisian	hisian	ADJ	JJ	5	I-Disease
block	block	NOUN	NN	9	I-Disease
occurring	occur	VERB	VBG	9	O
under	under	ADP	IN	9	O
amiodarone	amiodarone	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
without	without	ADP	IN	9	O
clear	clear	ADJ	JJ	9	O
intraventricular	intraventricular	ADJ	JJ	5	B-Disease
conduction	conduction	NOUN	NN	5	I-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
.	.	PUNCT	.	9	O

His	-PRON-	DET	PRP$	9	O
bundle	bundle	NOUN	NN	5	O
recordings	recording	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
an	an	DET	DT	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
intermittent	intermittent	ADJ	JJ	5	O
exit	exit	NOUN	NN	9	O
block	block	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
greatly	greatly	ADV	RB	9	O
prolonged	prolong	VERB	VBN	9	O
BH	BH	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
HV	HV	PROPN	NNP	9	O
intervals	interval	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
40	40	NUM	CD	9	O
and	and	CCONJ	CC	5	O
100	100	NUM	CD	0	O
msec	msec	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
amiodarone	amiodarone	ADJ	JJ	0	B-Chemical
discontinuation	discontinuation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
His	-PRON-	DET	PRP$	9	O
bundle	bundle	NOUN	NN	5	O
electrograms	electrogram	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
atrial	atrial	ADJ	JJ	5	B-Disease
flutter	flutter	ADV	RB	5	I-Disease
without	without	ADP	IN	9	O
intra	intra	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
Hisian	hisian	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
infra	infra	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
Hisian	hisian	ADJ	JJ	5	O
delay	delay	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Amiodarone	amiodarone	NOUN	NN	7	B-Chemical
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
used	use	VERB	VBN	5	O
with	with	ADP	IN	5	O
caution	caution	NOUN	NN	5	O
during	during	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
oral	oral	ADJ	JJ	9	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
clear	clear	ADJ	JJ	9	O
intraventricular	intraventricular	ADJ	JJ	5	O
conduction	conduction	NOUN	NN	5	O
defects	defect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Development	development	NOUN	NN	2	O
of	of	ADP	IN	5	O
clear	clear	ADJ	JJ	9	B-Disease
cell	cell	NOUN	NN	3	I-Disease
adenocarcinoma	adenocarcinoma	NOUN	NN	3	I-Disease
in	in	ADP	IN	5	O
DES	DES	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
exposed	expose	VERB	VBN	9	O
offspring	offspring	NOUN	NN	9	O
under	under	ADP	IN	9	O
observation	observation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
clear	clear	ADJ	JJ	9	B-Disease
cell	cell	NOUN	NN	3	I-Disease
adenocarcinoma	adenocarcinoma	NOUN	NN	3	I-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
vagina	vagina	NOUN	NN	5	I-Disease
detected	detect	VERB	VBN	9	O
at	at	ADP	IN	9	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
in	in	ADP	IN	5	O
young	young	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
exposed	expose	VERB	VBN	9	O
in	in	ADP	IN	5	O
utero	utero	NOUN	NN	9	O
to	to	ADP	IN	5	O
diethylstilbestrol	diethylstilbestrol	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
aged	age	VERB	VBD	9	O
23	23	NUM	CD	7	O
,	,	PUNCT	,	9	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
followed	follow	VERB	VBN	9	O
for	for	ADP	IN	5	O
2	2	NUM	CD	9	O
years	year	NOUN	NNS	5	O
before	before	ADP	IN	9	O
carcinoma	carcinoma	NOUN	NN	3	B-Disease
was	be	VERB	VBD	9	O
diagnosed	diagnose	VERB	VBN	5	O
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
aged	aged	ADJ	JJ	9	O
22	22	NUM	CD	7	O
,	,	PUNCT	,	9	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
seen	see	VERB	VBN	9	O
on	on	ADP	IN	5	O
a	a	DET	DT	5	O
regular	regular	ADJ	JJ	5	O
basis	basis	NOUN	NN	5	O
for	for	ADP	IN	5	O
5	5	NUM	CD	9	O
years	year	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
both	both	DET	DT	9	O
instances	instance	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
suspicion	suspicion	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
carcinoma	carcinoma	NOUN	NN	3	B-Disease
was	be	VERB	VBD	9	O
aroused	arouse	VERB	VBN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
palpation	palpation	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
small	small	ADJ	JJ	9	O
nodule	nodule	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
vaginal	vaginal	ADJ	JJ	9	O
fornix	fornix	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Hysterosalpingography	Hysterosalpingography	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
on	on	ADP	IN	5	O
both	both	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
instance	instance	NOUN	NN	5	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
abnormal	abnormal	ADJ	JJ	9	O
x	x	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
ray	ray	NOUN	NN	5	O
film	film	NOUN	NN	0	O
was	be	VERB	VBD	9	O
reflected	reflect	VERB	VBN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
gross	gross	ADJ	JJ	5	O
appearance	appearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
uterine	uterine	ADJ	JJ	5	O
cavity	cavity	NOUN	NN	5	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
surgical	surgical	ADJ	JJ	5	O
specimen	speciman	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Neurologic	neurologic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
subarachnoid	subarachnoid	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
chloroprocaine	chloroprocaine	NOUN	NN	5	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
CE	CE	PROPN	NNP	9	I-Chemical
,	,	PUNCT	,	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
low	low	ADJ	JJ	9	O
pH	pH	NOUN	NNS	0	O
normal	normal	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
in	in	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
neurologic	neurologic	ADJ	JJ	5	O
consequences	consequence	NOUN	NNS	5	O
of	of	ADP	IN	5	O
deliberate	deliberate	ADJ	JJ	5	O
subarachnoid	subarachnoid	NOUN	NN	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
large	large	ADJ	JJ	5	O
volumes	volume	NOUN	NNS	5	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
chloroprocaine	chloroprocaine	NOUN	NN	5	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
CE	CE	PROPN	NNP	9	I-Chemical
in	in	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
animals	animal	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
low	low	ADJ	JJ	9	O
pH	pH	NOUN	NNS	0	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
total	total	ADJ	JJ	9	O
volume	volume	NOUN	NN	9	O
as	as	ADP	IN	5	O
potential	potential	ADJ	JJ	9	O
factors	factor	NOUN	NNS	9	O
in	in	ADP	IN	5	O
causing	cause	VERB	VBG	9	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
65	65	NUM	CD	7	O
dogs	dog	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
received	receive	VERB	VBD	9	O
injections	injection	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
subarachnoid	subarachnoid	ADJ	JJ	5	O
space	space	NOUN	NN	5	O
as	as	ADP	IN	5	O
follows	follow	VERB	VBZ	9	O
:	:	PUNCT	:	9	O
6	6	NUM	CD	9	O
to	to	PART	TO	5	O
8	8	NUM	CD	9	O
ml	ml	NOUN	NNS	0	O
of	of	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
N	n	NOUN	NN	9	O
=	=	SYM	SYM	7	O
15	15	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
chloroprocaine	chloroprocaine	NOUN	NN	5	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
CE	CE	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
N	n	NOUN	NN	9	O
=	=	SYM	SYM	7	O
20	20	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
low	low	ADJ	JJ	9	O
pH	ph	X	XX	0	O
normal	normal	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
pH	pH	NOUN	NNS	0	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
N	n	NOUN	NN	9	O
=	=	SYM	SYM	7	O
20	20	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
normal	normal	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
N	n	NOUN	NN	9	O
=	=	SYM	SYM	7	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
20	20	NUM	CD	9	O
animals	animal	NOUN	NNS	9	O
that	that	DET	WDT	5	O
received	receive	VERB	VBD	9	O
subarachnoid	subarachnoid	ADJ	JJ	5	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
chloroprocaine	chloroprocaine	NOUN	NN	5	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
CE	ce	NOUN	NN	9	I-Chemical
seven	seven	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
35	35	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
developed	develop	VERB	VBD	5	O
hind	hind	NOUN	NN	4	O
-	-	PUNCT	HYPH	7	O
limb	limb	NOUN	NN	5	O
paralysis	paralysis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

None	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
that	that	DET	WDT	5	O
received	receive	VERB	VBD	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
normal	normal	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
normal	normal	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
titrated	titrate	VERB	VBN	0	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
pH	ph	NOUN	NN	0	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
developed	develop	VERB	VBN	5	O
hind	hind	NOUN	NN	4	O
-	-	PUNCT	HYPH	7	O
limb	limb	NOUN	NN	5	O
paralysis	paralysis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
15	15	NUM	CD	9	O
spinal	spinal	ADJ	JJ	5	O
cords	cord	NOUN	NNS	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
that	that	DET	WDT	5	O
received	receive	VERB	VBD	9	O
2	2	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
chloroprocaine	chloroprocaine	NOUN	NN	5	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
CE	CE	PROPN	NNP	9	I-Chemical
,	,	PUNCT	,	9	O
13	13	NUM	CD	7	O
showed	show	VERB	VBD	9	O
subpial	subpial	ADJ	JJ	5	B-Disease
necrosis	necrosis	NOUN	NN	9	I-Disease
;	;	PUNCT	:	9	O
the	the	DET	DT	5	O
nerve	nerve	NOUN	NN	5	O
roots	root	NOUN	NNS	4	O
and	and	CCONJ	CC	5	O
subarachnoid	subarachnoid	NOUN	NN	5	O
vessels	vessel	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
spinal	spinal	ADJ	JJ	5	O
cords	cord	NOUN	NNS	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
that	that	DET	WDT	5	O
received	receive	VERB	VBD	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
low	low	ADJ	JJ	9	O
pH	pH	NOUN	NNS	0	O
normal	normal	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
pH	pH	NOUN	NNS	0	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
normal	normal	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
show	show	VERB	VB	9	O
abnormal	abnormal	ADJ	JJ	9	O
findings	finding	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Procainamide	procainamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
polymorphous	polymorphous	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Seven	seven	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
procainamide	procainamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
polymorphous	polymorphous	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
are	be	VERB	VBP	5	O
presented	present	VERB	VBN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
polymorphous	polymorphous	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
appeared	appear	VERB	VBD	9	O
after	after	ADP	IN	9	O
intravenous	intravenous	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
200	200	NUM	CD	0	O
to	to	ADP	IN	5	O
400	400	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
of	of	ADP	IN	5	O
procainamide	procainamide	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
sustained	sustain	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
remaining	remain	VERB	VBG	9	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
procainamide	procainamide	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
orally	orally	ADV	RB	0	O
for	for	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
premature	premature	ADJ	JJ	9	B-Disease
ventricular	ventricular	ADJ	JJ	5	I-Disease
contractions	contraction	NOUN	NNS	5	I-Disease
or	or	CCONJ	CC	5	O
atrial	atrial	ADJ	JJ	5	B-Disease
flutter	flutter	ADV	RB	5	I-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
Q	Q	PROPN	NNP	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
T	t	NOUN	NN	3	I-Disease
prolongation	prolongation	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
recurrent	recurrent	NOUN	NN	5	O
syncope	syncope	NOUN	NN	5	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
polymorphous	polymorphous	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
rapidly	rapidly	ADV	RB	9	O
diagnosed	diagnose	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
disappearance	disappearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
further	further	ADJ	JJ	9	O
episodes	episode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
degenerated	degenerate	VERB	VBD	9	O
into	into	ADP	IN	9	O
irreversible	irreversible	ADJ	JJ	9	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
both	both	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
died	die	VERB	VBD	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
seventh	seventh	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
permanent	permanent	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	O
pacemaker	pacemaker	NOUN	NN	5	O
was	be	VERB	VBD	9	O
inserted	insert	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
despite	despite	ADP	IN	9	O
continuation	continuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
procainamide	procainamide	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
polymorphous	polymorphous	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
reoccur	reoccur	VERB	VB	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
seven	seven	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
demonstrate	demonstrate	VERB	VBP	9	O
that	that	DET	DT	5	O
procainamide	procainamide	NOUN	NN	0	B-Chemical
can	can	VERB	MD	5	O
produce	produce	VERB	VB	9	O
an	an	DET	DT	5	O
acquired	acquire	VERB	VBN	5	O
prolonged	prolong	VERB	VBN	9	B-Disease
Q	Q	PROPN	NNP	9	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
T	t	NOUN	NN	3	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
polymorphous	polymorphous	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Phenobarbitone	Phenobarbitone	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
enlargement	enlargement	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
liver	liver	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
:	:	PUNCT	:	9	O
its	-PRON-	DET	PRP$	9	O
relationship	relationship	NOUN	NN	5	O
to	to	ADP	IN	5	O
carbon	carbon	NOUN	NN	0	B-Chemical
tetrachloride	tetrachloride	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cirrhosis	cirrhosis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
yield	yield	NOUN	NN	9	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
cirrhosis	cirrhosis	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
liver	liver	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
defined	define	VERB	VBN	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
shrunken	shrunken	NOUN	NN	5	O
finely	finely	ADV	RB	4	O
nodular	nodular	ADJ	JJ	5	O
liver	liver	NOUN	NN	9	O
with	with	ADP	IN	5	O
micronodular	micronodular	ADJ	JJ	5	O
histology	histology	NOUN	NN	9	O
,	,	PUNCT	,	9	O
ascites	ascite	VERB	VBZ	3	B-Disease
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
30	30	NUM	CD	9	O
ml	ml	NOUN	NN	0	O
,	,	PUNCT	,	9	O
plasma	plasma	NOUN	NN	9	O
albumin	albumin	NOUN	NN	0	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
,	,	PUNCT	,	9	O
splenomegaly	splenomegaly	ADJ	JJ	9	B-Disease
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
times	time	NOUN	NNS	5	O
normal	normal	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
testicular	testicular	ADJ	JJ	9	O
atrophy	atrophy	NOUN	NN	5	B-Disease
approximately	approximately	ADV	RB	9	O
half	half	DET	PDT	5	O
normal	normal	ADJ	JJ	9	O
weight	weight	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
12	12	NUM	CD	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
carbon	carbon	NOUN	NN	0	B-Chemical
tetrachloride	tetrachloride	NOUN	NN	0	I-Chemical
given	give	VERB	VBN	5	O
intragastrically	intragastrically	ADV	RB	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
phenobarbitone	phenobarbitone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
primed	prime	VERB	VBN	3	O
rat	rat	NOUN	NN	3	O
was	be	VERB	VBD	9	O
increased	increase	VERB	VBN	9	O
from	from	ADP	IN	9	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
56	56	NUM	CD	7	O
%	%	NOUN	NN	9	O
by	by	ADP	IN	9	O
giving	give	VERB	VBG	5	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
"	"	PUNCT	``	5	O
calibrating	calibrating	NOUN	NN	5	O
"	"	PUNCT	''	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
carbon	carbon	NOUN	NN	0	B-Chemical
tetrachloride	tetrachloride	NOUN	NN	0	I-Chemical
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
peak	peak	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
phenobarbitone	phenobarbitone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
enlargement	enlargement	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
liver	liver	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
this	this	DET	DT	5	O
point	point	NOUN	NN	5	O
it	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
assumed	assume	VERB	VBN	5	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
cytochrome	cytochrome	ADJ	JJ	0	O
P450	P450	PROPN	NNP	1	O
/	/	SYM	SYM	9	O
CCl4	CCl4	PROPN	NNP	0	B-Chemical
toxic	toxic	ADJ	JJ	0	O
state	state	NOUN	NN	5	O
was	be	VERB	VBD	9	O
both	both	DET	DT	9	O
maximal	maximal	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
stable	stable	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
optimal	optimal	ADJ	JJ	5	O
rat	rat	NOUN	NN	3	O
size	size	NOUN	NN	9	O
to	to	PART	TO	5	O
begin	begin	VERB	VB	5	O
phenobarbitone	phenobarbitone	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
as	as	ADP	IN	5	O
100	100	NUM	CD	0	O
g	g	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
this	this	DET	DT	5	O
size	size	NOUN	NN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
group	group	NOUN	NN	9	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
maximum	maximum	ADJ	JJ	5	O
relative	relative	ADJ	JJ	9	O
liver	liver	NOUN	NN	9	O
weight	weight	NOUN	NN	9	O
increase	increase	NOUN	NN	9	O
47	47	NUM	CD	7	O
%	%	NOUN	NN	9	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
rats	rat	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
body	body	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
optimal	optimal	ADJ	JJ	5	O
time	time	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
carbon	carbon	NOUN	NN	0	B-Chemical
tetrachloride	tetrachloride	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
after	after	ADP	IN	9	O
14	14	NUM	CD	7	O
days	day	NOUN	NNS	9	O
on	on	ADP	IN	5	O
phenobarbitone	phenobarbitone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Triamterene	triamterene	NOUN	NN	7	B-Chemical
nephrolithiasis	nephrolithiasis	NOUN	NN	5	B-Disease
complicating	complicate	VERB	VBG	5	O
dyazide	dyazide	NOUN	NN	_	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
triamterene	triamterene	NOUN	NN	0	B-Chemical
nephrolithiasis	nephrolithiasis	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
man	man	NOUN	NN	5	O
after	after	ADP	IN	9	O
4	4	NUM	CD	9	O
years	year	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hydrochlorothiazide	hydrochlorothiazide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
triamterene	triamterene	NOUN	NN	0	I-Chemical
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
stone	stone	NOUN	NN	5	O
passed	pass	VERB	VBD	5	O
spontaneously	spontaneously	ADV	RB	5	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
contain	contain	VERB	VB	9	O
a	a	DET	DT	5	O
triamterene	triamterene	NOUN	NN	0	B-Chemical
metabolite	metabolite	NOUN	NN	0	O
admixed	admix	VERB	VBN	9	O
with	with	ADP	IN	5	O
uric	uric	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
salts	salt	NOUN	NNS	0	I-Chemical
.	.	PUNCT	.	9	O

Factors	factor	NOUN	NNS	5	O
affecting	affect	VERB	VBG	9	O
triamterene	triamterene	NOUN	NN	0	B-Chemical
nephrolithiasis	nephrolithiasis	NOUN	NN	5	B-Disease
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
previously	previously	ADV	RB	9	O
reported	report	VERB	VBN	9	O
cases	case	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
reviewed	review	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Busulfan	Busulfan	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
busulfan	busulfan	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hemorrhage	hemorrhage	NOUN	NN	5	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Spontaneous	spontaneous	ADJ	JJ	9	O
resolution	resolution	NOUN	NN	5	O
occurred	occur	VERB	VBD	9	O
following	follow	VERB	VBG	9	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
similarity	similarity	NOUN	NN	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
histologic	histologic	ADJ	JJ	9	O
appearances	appearance	NOUN	NNS	5	O
of	of	ADP	IN	5	O
busulfan	busulfan	ADJ	JJ	0	B-Chemical
cystitis	cystitis	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
both	both	CCONJ	CC	9	O
radiation	radiation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cystitis	cystitis	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
discussed	discuss	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
world	world	NOUN	NN	5	O
literature	literature	NOUN	NN	5	O
reviewed	review	VERB	VBD	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
view	view	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
known	know	VERB	VBN	9	O
tendency	tendency	NOUN	NN	5	O
of	of	ADP	IN	5	O
busulfan	busulfan	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
cellular	cellular	ADJ	JJ	3	O
atypia	atypia	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
carcinoma	carcinoma	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
other	other	ADJ	JJ	5	O
sites	site	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
periodic	periodic	ADJ	JJ	5	O
urinary	urinary	ADJ	JJ	9	O
cytology	cytology	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
suggested	suggest	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
on	on	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Variant	variant	ADJ	JJ	9	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
variant	variant	ADJ	JJ	1	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
desipramine	desipramine	NOUN	NN	0	B-Chemical
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Unusual	unusual	ADJ	JJ	9	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
arrhythmia	arrhythmia	NOUN	NN	5	B-Disease
are	be	VERB	VBP	5	O
repetitive	repetitive	ADJ	JJ	5	O
group	group	NOUN	NN	9	O
beating	beating	NOUN	NN	5	O
,	,	PUNCT	,	9	O
progressive	progressive	ADJ	JJ	5	O
shortening	shortening	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
R	r	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
R	r	NOUN	NN	9	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
progressive	progressive	ADJ	JJ	5	O
widening	widening	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
QRS	QRS	PROPN	NNP	5	O
complex	complex	NOUN	NN	9	O
with	with	ADP	IN	5	O
eventual	eventual	ADJ	JJ	5	O
failure	failure	NOUN	NN	5	O
of	of	ADP	IN	5	O
intraventricular	intraventricular	ADJ	JJ	5	O
conduction	conduction	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
direction	direction	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
QRS	QRS	PROPN	NNP	5	O
axis	axis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Recognition	recognition	NOUN	NN	5	O
of	of	ADP	IN	5	O
variant	variant	ADJ	JJ	1	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
important	important	ADJ	JJ	9	O
because	because	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
differs	differ	NOUN	NNS	9	O
from	from	ADP	IN	9	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
classic	classic	ADJ	JJ	5	O
ventricular	ventricular	ADJ	JJ	5	B-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Rebound	Rebound	PROPN	NNP	5	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
after	after	ADP	IN	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
nitroprusside	nitroprusside	ADV	RB	0	I-Chemical
prevented	prevent	VERB	VBN	9	O
by	by	ADP	IN	9	O
saralasin	saralasin	NOUN	NN	3	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
renin	renin	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
system	system	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
maintenance	maintenance	NOUN	NN	9	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
during	during	ADP	IN	5	O
halothane	halothane	NOUN	NN	0	B-Chemical
anesthesia	anesthesia	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
nitroprusside	nitroprusside	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
SNP	SNP	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
received	receive	VERB	VBD	9	O
halothane	halothane	NOUN	NN	0	B-Chemical
anesthesia	anesthesia	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
MAC	MAC	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
one	one	NUM	CD	5	O
hour	hour	NOUN	NN	0	O
,	,	PUNCT	,	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
SNP	SNP	PROPN	NNP	9	B-Chemical
infusion	infusion	NOUN	NN	0	O
,	,	PUNCT	,	9	O
40	40	NUM	CD	9	O
microgram	microgram	NOUN	NN	0	O
/	/	PUNCT	,	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
,	,	PUNCT	,	9	O
followed	follow	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
30	30	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
min	min	NOUN	NN	0	O
recovery	recovery	NOUN	NN	9	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
second	second	ADJ	JJ	9	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
identically	identically	ADV	RB	9	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
received	receive	VERB	VBD	9	O
an	an	DET	DT	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
saralasin	saralasin	PROPN	NNP	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
a	a	DET	DT	5	O
competitive	competitive	ADJ	JJ	9	O
inhibitor	inhibitor	NOUN	NN	3	O
of	of	ADP	IN	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
II	II	PROPN	NNP	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
throughout	throughout	ADP	IN	9	O
the	the	DET	DT	5	O
experimental	experimental	ADJ	JJ	5	O
period	period	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
each	each	DET	DT	5	O
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
SNP	SNP	PROPN	NNP	9	B-Chemical
infusion	infusion	NOUN	NN	0	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
from	from	ADP	IN	9	O
86	86	NUM	CD	7	O
torr	torr	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
83	83	NUM	CD	7	O
torr	torr	NOUN	NN	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
to	to	ADP	IN	5	O
48	48	NUM	CD	9	O
torr	torr	NOUN	NN	0	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
the	the	DET	DT	5	O
SNP	SNP	PROPN	NNP	9	B-Chemical
infusion	infusion	NOUN	NN	0	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
animals	animal	NOUN	NNS	9	O
demonstrated	demonstrate	VERB	VBD	9	O
a	a	DET	DT	5	O
progressive	progressive	ADJ	JJ	5	O
increase	increase	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
blood	blood	NOUN	NN	9	I-Disease
pressure	pressure	NOUN	NN	5	I-Disease
to	to	ADP	IN	5	O
61	61	NUM	CD	7	O
torr	torr	NOUN	NN	0	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
the	the	DET	DT	5	O
saralasin	saralasin	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
animals	animal	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
no	no	DET	DT	9	O
change	change	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Following	follow	VERB	VBG	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
SNP	SNP	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
animals	animal	NOUN	NNS	9	O
rebounded	rebound	VERB	VBD	9	O
to	to	ADP	IN	5	O
94	94	NUM	CD	7	O
torr	torr	NOUN	NN	0	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
78	78	NUM	CD	7	O
torr	torr	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
saralasin	saralasin	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
indicates	indicate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
with	with	ADP	IN	5	O
stable	stable	ADJ	JJ	9	O
halothane	halothane	NOUN	NN	0	B-Chemical
anesthesia	anesthesia	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
partial	partial	ADJ	JJ	9	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
during	during	ADP	IN	5	O
SNP	SNP	PROPN	NNP	9	B-Chemical
infusion	infusion	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
post	post	NOUN	NN	9	O
-	-	ADJ	JJ	7	O
SNP	SNP	PROPN	NNP	9	B-Chemical
rebound	rebound	NOUN	NN	5	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
completely	completely	ADV	RB	9	O
blocked	block	VERB	VBN	3	O
by	by	ADP	IN	9	O
saralasin	saralasin	NOUN	NN	3	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
demonstrates	demonstrate	VERB	VBZ	9	O
the	the	DET	DT	5	O
participation	participation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
renin	renin	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
-	-	PUNCT	HYPH	7	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
system	system	NOUN	NN	5	O
in	in	ADP	IN	5	O
antagonizing	antagonize	VERB	VBG	3	O
the	the	DET	DT	5	O
combined	combine	VERB	VBN	9	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
halothane	halothane	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
SNP	SNP	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
tobramycin	tobramycin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
prospective	prospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Nearly	nearly	ADV	RB	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
million	million	NUM	CD	5	O
people	people	NOUN	NNS	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
country	country	NOUN	NN	5	O
receive	receive	VERB	VBP	5	O
aminoglycoside	aminoglycoside	ADJ	JJ	9	B-Chemical
antibiotics	antibiotic	NOUN	NNS	5	O
annually	annually	ADV	RB	5	O
.	.	PUNCT	.	9	O

Gentamicin	gentamicin	NOUN	NN	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
tobramycin	tobramycin	ADJ	JJ	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	I-Chemical
continue	continue	VERB	VBP	5	O
to	to	PART	TO	5	O
demonstrate	demonstrate	VERB	VB	9	O
ototoxicity	ototoxicity	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
animal	animal	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
62	62	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
confirmed	confirm	VERB	VBN	9	O
initial	initial	ADJ	JJ	9	O
normal	normal	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
2	2	NUM	CD	9	O
to	to	PART	TO	5	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
of	of	ADP	IN	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	I-Chemical
or	or	CCONJ	CC	5	O
tobramycin	tobramycin	ADJ	JJ	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	I-Chemical
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
minimum	minimum	NOUN	NN	5	O
of	of	ADP	IN	5	O
seven	seven	NUM	CD	9	O
days	day	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
followed	follow	VERB	VBN	9	O
up	up	PART	RP	5	O
prospectively	prospectively	ADV	RB	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
aminoglycoside	aminoglycoside	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
defined	define	VERB	VBN	5	O
as	as	ADP	IN	5	O
at	at	ADP	IN	9	O
least	least	ADJ	JJS	9	O
a	a	DET	DT	5	O
one	one	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
third	third	ADJ	JJ	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
these	these	DET	DT	5	O
62	62	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
other	other	ADJ	JJ	5	O
causes	cause	NOUN	NNS	9	O
for	for	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
identified	identify	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
of	of	ADP	IN	5	O
33	33	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
tobramycin	tobramycin	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
16	16	NUM	CD	9	O
of	of	ADP	IN	5	O
29	29	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
55	55	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
three	three	NUM	CD	9	O
times	time	NOUN	NNS	5	O
as	as	ADV	RB	5	O
often	often	ADV	RB	5	O
as	as	ADP	IN	5	O
was	be	VERB	VBD	9	O
tobramycin	tobramycin	ADJ	JJ	0	B-Chemical
.	.	PUNCT	.	9	O

Metabolic	metabolic	ADJ	JJ	9	O
involvement	involvement	NOUN	NN	9	O
in	in	ADP	IN	5	O
adriamycin	adriamycin	ADJ	JJ	3	B-Chemical
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cardiotoxic	cardiotoxic	ADJ	JJ	5	B-Disease
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
adriamycin	adriamycin	NOUN	NN	3	B-Chemical
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
mammalian	mammalian	ADJ	JJ	9	O
myocardial	myocardial	ADJ	JJ	9	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
culture	culture	NOUN	NN	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
model	model	NOUN	NN	5	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Adriamycin	Adriamycin	PROPN	NNP	0	B-Chemical
inhibited	inhibited	ADJ	JJ	3	O
cell	cell	NOUN	NN	3	O
growth	growth	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
rhythmic	rhythmic	ADJ	JJ	5	O
contractions	contraction	NOUN	NNS	5	O
characteristic	characteristic	ADJ	JJ	9	O
of	of	ADP	IN	5	O
myocardial	myocardial	ADJ	JJ	9	O
cells	cell	NOUN	NNS	3	O
in	in	ADP	IN	5	O
culture	culture	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
possible	possible	ADJ	JJ	5	O
involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
energy	energy	NOUN	NN	5	O
metabolism	metabolism	NOUN	NN	9	O
was	be	VERB	VBD	9	O
suggested	suggest	VERB	VBN	9	O
previously	previously	ADV	RB	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
the	the	DET	DT	5	O
adenylate	adenylate	ADJ	JJ	0	O
energy	energy	NOUN	NN	5	O
charge	charge	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
phosphorylcreatine	phosphorylcreatine	NOUN	NN	0	B-Chemical
mole	mole	NOUN	NN	0	O
fraction	fraction	NOUN	NN	9	O
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
adriamycin	adriamycin	ADV	RB	3	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
adenylate	adenylate	ADJ	JJ	0	O
energy	energy	NOUN	NN	5	O
charge	charge	NOUN	NN	5	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
significantly	significantly	ADV	RB	9	O
decreased	decrease	VERB	VBN	9	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
the	the	DET	DT	5	O
phophorylcreatine	phophorylcreatine	NOUN	NN	_	B-Chemical
mole	mole	NOUN	NN	0	O
fraction	fraction	NOUN	NN	9	O
was	be	VERB	VBD	9	O
unchanged	unchanged	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Such	such	ADJ	JJ	5	O
disparity	disparity	NOUN	NN	5	O
suggests	suggest	VERB	VBZ	9	O
an	an	DET	DT	5	O
inhibition	inhibition	NOUN	NN	3	O
of	of	ADP	IN	5	O
creatine	creatine	NOUN	NN	0	B-Chemical
phosphokinase	phosphokinase	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
addition	addition	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
mM	mM	PROPN	NNP	0	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
myocardial	myocardial	ADJ	JJ	9	O
cell	cell	NOUN	NN	3	O
cultures	culture	NOUN	NNS	3	O
markedly	markedly	ADV	RB	9	O
increases	increase	VERB	VBZ	9	O
the	the	DET	DT	5	O
ATP	ATP	PROPN	NNP	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
through	through	ADP	IN	9	O
a	a	DET	DT	5	O
pathway	pathway	NOUN	NN	3	O
reportedly	reportedly	ADV	RB	9	O
leading	lead	VERB	VBG	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
compartmentalized	compartmentalize	VERB	VBN	9	O
ATP	ATP	PROPN	NNP	0	B-Chemical
pool	pool	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
adriamycin	adriamycin	ADV	RB	3	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
cells	cell	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
addition	addition	NOUN	NN	9	O
of	of	ADP	IN	5	O
adenosine	adenosine	NOUN	NN	0	B-Chemical
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
adenylate	adenylate	ADJ	JJ	0	O
charge	charge	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
,	,	PUNCT	,	9	O
concomitant	concomitant	ADJ	JJ	9	O
with	with	ADP	IN	5	O
this	this	DET	DT	5	O
inrcease	inrcease	NOUN	NN	_	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
cells	cell	NOUN	NNS	3	O
'	'	PART	POS	9	O
functional	functional	ADJ	JJ	9	O
integrity	integrity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
terms	term	NOUN	NNS	5	O
of	of	ADP	IN	5	O
percentage	percentage	NOUN	NN	9	O
of	of	ADP	IN	5	O
beating	beat	VERB	VBG	5	O
cells	cell	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
contractions	contraction	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
maintained	maintain	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Age	age	NOUN	NN	7	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
sensitivity	sensitivity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
to	to	ADP	IN	5	O
neurotoxic	neurotoxic	ADJ	JJ	9	B-Disease
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
streptomycin	streptomycin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Streptomycin	Streptomycin	PROPN	NNP	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
300	300	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
s	s	PROPN	NNPS	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
for	for	ADP	IN	5	O
various	various	ADJ	JJ	9	O
periods	period	NOUN	NNS	5	O
into	into	ADP	IN	9	O
preweanling	preweanle	VERB	VBG	3	O
rats	rat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
for	for	ADP	IN	5	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
into	into	ADP	IN	9	O
weanling	weanle	VERB	VBG	3	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Beginning	begin	VERB	VBG	5	O
at	at	ADP	IN	9	O
8	8	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
body	body	NOUN	NN	5	O
movement	movement	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
hearing	hearing	NOUN	NN	5	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
for	for	ADP	IN	5	O
6	6	NUM	CD	9	O
and	and	CCONJ	CC	5	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
17	17	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Abnormal	abnormal	ADJ	JJ	9	B-Disease
movements	movement	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
deafness	deafness	NOUN	NN	5	B-Disease
occurred	occur	VERB	VBD	9	O
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
preweaning	preweaning	NOUN	NN	5	O
period	period	NOUN	NN	5	O
;	;	PUNCT	:	9	O
within	within	ADP	IN	9	O
this	this	DET	DT	5	O
period	period	NOUN	NN	5	O
the	the	DET	DT	5	O
greatest	great	ADJ	JJS	9	O
sensitivities	sensitivity	NOUN	NNS	9	O
for	for	ADP	IN	5	O
these	these	DET	DT	5	O
abnormalities	abnormality	NOUN	NNS	9	O
occurred	occur	VERB	VBD	9	O
from	from	ADP	IN	9	O
2	2	NUM	CD	9	O
to	to	ADP	IN	5	O
11	11	NUM	CD	7	O
-	-	SYM	SYM	7	O
17	17	NUM	CD	7	O
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	O
to	to	PART	TO	5	O
11	11	NUM	CD	7	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
,	,	PUNCT	,	9	O
indicating	indicate	VERB	VBG	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
cochlea	cochlea	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
more	more	ADV	RBR	5	O
sensitive	sensitive	ADJ	JJ	9	O
to	to	PART	TO	5	O
streptomycin	streptomycin	VERB	VB	0	B-Chemical
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
site	site	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
vestibular	vestibular	ADJ	JJ	5	O
or	or	CCONJ	CC	5	O
central	central	ADJ	JJ	5	O
)	)	PUNCT	-RRB-	9	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
dyskinesias	dyskinesia	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Late	late	ADV	RB	9	O
,	,	PUNCT	,	9	O
late	late	ADJ	JJ	9	O
doxorubicin	doxorubicin	ADJ	JJ	0	B-Chemical
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Cardiac	cardiac	ADJ	JJ	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
complication	complication	NOUN	NN	5	O
which	which	DET	WDT	5	O
limits	limit	VERB	VBZ	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
adriamycin	adriamycin	NOUN	NN	3	B-Chemical
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
chemotherapeutic	chemotherapeutic	ADJ	JJ	3	O
agent	agent	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Cardiomyopathy	Cardiomyopathy	PROPN	NNP	7	B-Disease
is	be	VERB	VBZ	5	O
frequent	frequent	ADJ	JJ	5	O
when	when	ADV	WRB	5	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
exceeds	exceed	VERB	VBZ	5	O
600	600	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
and	and	CCONJ	CC	5	O
occurs	occur	VERB	VBZ	9	O
within	within	ADP	IN	9	O
one	one	NUM	CD	5	O
to	to	PART	TO	5	O
six	six	NUM	CD	9	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
patient	patient	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
reported	report	VERB	VBN	9	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
progressive	progressive	ADJ	JJ	5	O
cardiomyopathy	cardiomyopathy	NOUN	NN	5	B-Disease
two	two	NUM	CD	5	O
and	and	CCONJ	CC	5	O
one	one	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
half	half	NOUN	NN	5	O
years	year	NOUN	NNS	5	O
after	after	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
580	580	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NNS	7	O
which	which	DET	WDT	5	O
apparently	apparently	ADV	RB	9	O
represents	represent	VERB	VBZ	9	O
late	late	ADV	RB	9	O
,	,	PUNCT	,	9	O
late	late	ADJ	JJ	9	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Attenuation	attenuation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
diabetes	diabetes	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
insipidus	insipidus	NOUN	NN	5	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
like	like	ADJ	JJ	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
by	by	ADP	IN	9	O
amiloride	amiloride	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
amiloride	amiloride	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
polydipsia	polydipsia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
polyuria	polyuria	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
,	,	PUNCT	,	9	O
brain	brain	NOUN	NN	5	O
,	,	PUNCT	,	9	O
kidney	kidney	NOUN	NN	9	O
,	,	PUNCT	,	9	O
thyroid	thyroid	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
red	red	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
cells	cell	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
chronically	chronically	ADV	RB	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
LiCl	LiCl	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Amiloride	Amiloride	PROPN	NNP	0	B-Chemical
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
drinking	drinking	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
urine	urine	NOUN	NN	9	O
volume	volume	NOUN	NN	9	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
acute	acute	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
or	or	CCONJ	CC	5	O
12	12	NUM	CD	9	O
h	h	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
subacute	subacute	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
experiment	experiment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

6	6	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
amiloride	amiloride	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
content	content	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
medulla	medulla	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
organs	organ	NOUN	NNS	9	O
studied	study	VERB	VBN	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
12	12	NUM	CD	9	O
h	h	NOUN	NN	0	O
,	,	PUNCT	,	9	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
tissues	tissue	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
slight	slight	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
combined	combined	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
marked	marked	ADJ	JJ	9	O
elevation	elevation	NOUN	NN	9	O
in	in	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
tissue	tissue	NOUN	NN	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
accompanied	accompany	VERB	VBD	9	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
water	water	NOUN	NN	0	O
intake	intake	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
experiments	experiment	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
attenuation	attenuation	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
diabetes	diabetes	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
insipidus	insipidus	NOUN	NN	5	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
like	like	ADJ	JJ	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
by	by	ADP	IN	9	O
amiloride	amiloride	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ratio	ratio	NOUN	NN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
renal	renal	ADJ	JJ	9	O
medulla	medulla	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
its	-PRON-	DET	PRP$	9	O
levels	level	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
an	an	DET	DT	5	O
elevation	elevation	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
potassium	potassium	NOUN	NN	0	B-Chemical
level	level	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
amiloride	amiloride	ADP	IN	0	B-Chemical
administration	administration	NOUN	NN	9	O
to	to	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
patients	patient	NOUN	NNS	5	O
suffering	suffer	VERB	VBG	5	O
from	from	ADP	IN	9	O
polydipsia	polydipsia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
polyuria	polyuria	NOUN	NN	5	B-Disease
might	may	VERB	MD	9	O
relieve	relieve	VERB	VB	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
but	but	CCONJ	CC	9	O
prolonged	prolong	VERB	VBN	9	O
amiloride	amiloride	ADJ	JJ	0	B-Chemical
supplementation	supplementation	NOUN	NN	0	O
would	would	VERB	MD	5	O
result	result	VERB	VB	9	O
in	in	ADP	IN	5	O
elevated	elevated	ADJ	JJ	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
hazardous	hazardous	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Cardiovascular	cardiovascular	ADJ	JJ	2	B-Disease
complications	complication	NOUN	NNS	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
terbutaline	terbutaline	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
preterm	preterm	ADJ	JJ	5	B-Disease
labor	labor	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Severe	severe	ADJ	JJ	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
complications	complication	NOUN	NNS	5	I-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
eight	eight	NUM	CD	9	O
of	of	ADP	IN	5	O
160	160	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
terbutaline	terbutaline	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
preterm	preterm	ADJ	JJ	5	B-Disease
labor	labor	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Associated	associated	ADJ	JJ	9	O
corticosteroid	corticosteroid	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
twin	twin	ADJ	JJ	5	O
gestations	gestation	NOUN	NNS	5	O
appear	appear	VERB	VBP	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
predisposing	predispose	VERB	VBG	5	O
factors	factor	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Potential	potential	ADJ	JJ	5	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
pathophysiology	pathophysiology	NOUN	NN	9	O
are	be	VERB	VBP	5	O
briefly	briefly	ADV	RB	9	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Toxic	Toxic	PROPN	NNP	0	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
antithyroid	antithyroid	ADJ	JJ	0	O
drugs	drug	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
four	four	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
including	include	VERB	VBG	9	O
one	one	NUM	CD	5	O
with	with	ADP	IN	5	O
cross	cross	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
reactivity	reactivity	NOUN	NN	9	O
between	between	ADP	IN	5	O
carbimazole	carbimazole	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
benzylthiouracil	benzylthiouracil	NOUN	NN	_	B-Chemical
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
to	to	PART	TO	5	O
assess	assess	VERB	VB	5	O
the	the	DET	DT	5	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
adverse	adverse	ADJ	JJ	5	I-Disease
effects	effect	NOUN	NNS	9	I-Disease
encountered	encounter	VERB	VBN	5	O
with	with	ADP	IN	5	O
antithyroid	antithyroid	ADJ	JJ	0	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Retrospective	retrospective	ADJ	JJ	9	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
medical	medical	ADJ	JJ	5	O
records	record	NOUN	NNS	5	O
of	of	ADP	IN	5	O
236	236	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hyperthyroidism	hyperthyroidism	NOUN	NN	5	B-Disease
admitted	admit	VERB	VBN	5	O
in	in	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
department	department	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
in	in	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
or	or	CCONJ	CC	5	O
out	out	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
from	from	ADP	IN	9	O
1986	1986	NUM	CD	2	O
to	to	ADP	IN	5	O
1992	1992	NUM	CD	2	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
with	with	ADP	IN	5	O
toxic	toxic	ADJ	JJ	0	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
which	which	DET	WDT	5	O
could	could	VERB	MD	9	O
reasonably	reasonably	ADV	RB	5	O
be	be	VERB	VB	5	O
attributed	attribute	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
antithyroid	antithyroid	ADJ	JJ	0	O
agent	agent	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
cholestatic	cholestatic	ADJ	JJ	5	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
carbimazole	carbimazole	ADJ	JJ	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
N	n	NOUN	NN	9	B-Chemical
omercazole	omercazole	NOUN	NN	_	I-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
others	other	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
mixed	mixed	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
cholestatic	cholestatic	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	O
cytolytic	cytolytic	ADJ	JJ	3	O
)	)	PUNCT	-RRB-	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
following	follow	VERB	VBG	9	O
carbimazole	carbimazole	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
latter	latter	ADJ	JJ	9	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
further	further	ADV	RB	9	O
experienced	experience	VERB	VBD	5	O
a	a	DET	DT	5	O
cytolytic	cytolytic	ADJ	JJ	3	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
which	which	DET	WDT	5	O
appeared	appear	VERB	VBD	9	O
after	after	ADP	IN	9	O
Benzylthiouracil	Benzylthiouracil	PROPN	NNP	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
Basd	Basd	PROPN	NNP	_	B-Chemical
ne	ne	INTJ	UH	2	I-Chemical
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
replaced	replace	VERB	VBN	9	O
carbimazole	carbimazole	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Biological	biological	ADJ	JJ	2	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
disappeared	disappear	VERB	VBD	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
cases	case	NOUN	NNS	5	O
after	after	ADP	IN	9	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
incriminated	incriminate	VERB	VBN	5	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
biliary	biliary	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
viral	viral	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
immunological	immunological	ADJ	JJ	9	O
searches	search	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
negative	negative	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Only	only	ADV	RB	9	O
2	2	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
of	of	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
retrospective	retrospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
experienced	experience	VERB	VBD	5	O
a	a	DET	DT	5	O
mild	mild	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
severe	severe	ADJ	JJ	5	O
neutropenia	neutropenia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
Toxic	Toxic	PROPN	NNP	0	B-Disease
hepatitis	hepatitis	PROPN	NNP	9	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
antithyroid	antithyroid	ADJ	JJ	0	O
drugs	drug	NOUN	NNS	5	O
which	which	DET	WDT	5	O
warrants	warrant	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
for	for	ADP	IN	5	O
haematological	haematological	ADJ	JJ	5	O
disturbances	disturbance	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
pre	pre	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
therapeutic	therapeutic	ADJ	JJ	5	O
determination	determination	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
careful	careful	ADJ	JJ	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
of	of	ADP	IN	5	O
relevant	relevant	ADJ	JJ	5	O
biological	biological	ADJ	JJ	5	O
markers	marker	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
may	may	VERB	MD	5	O
not	not	ADV	RB	5	O
be	be	VERB	VB	5	O
restricted	restrict	VERB	VBN	9	O
to	to	ADP	IN	5	O
one	one	NUM	CD	5	O
class	class	NOUN	NN	9	O
of	of	ADP	IN	5	O
antithyroid	antithyroid	ADJ	JJ	0	O
agents	agent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Interactive	interactive	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
variations	variation	NOUN	NNS	5	O
in	in	ADP	IN	5	O
[	[	PUNCT	-LRB-	9	O
Na	Na	PROPN	NNP	0	B-Chemical
]	]	PUNCT	-RRB-	9	O
o	o	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
[	[	PUNCT	-LRB-	9	O
Ca	Ca	VERB	MD	0	B-Chemical
]	]	PUNCT	-RRB-	9	O
o	o	X	XX	9	O
on	on	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
atrial	atrial	ADJ	JJ	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
frequency	frequency	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
varying	vary	VERB	VBG	5	O
the	the	DET	DT	5	O
extracellular	extracellular	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
Na	Na	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
Ca	Ca	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
[	[	PUNCT	-LRB-	9	O
Na	na	ADV	RB	0	B-Chemical
]	]	PUNCT	-RRB-	9	O
o	o	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
[	[	PUNCT	-LRB-	9	O
Ca	Ca	VERB	MD	0	B-Chemical
]	]	PUNCT	-RRB-	9	O
o	o	X	XX	9	O
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
both	both	DET	DT	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
beating	beating	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
negative	negative	ADJ	JJ	9	O
chronotropic	chronotropic	ADJ	JJ	5	O
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
isolated	isolated	ADJ	JJ	9	O
rat	rat	NOUN	NN	3	O
atria	atria	ADV	RB	9	O
.	.	PUNCT	.	9	O

Basal	basal	NOUN	NN	9	O
frequency	frequency	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
BF	BF	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
evaluated	evaluate	VERB	VBN	9	O
by	by	ADP	IN	9	O
surface	surface	NOUN	NN	9	O
electrogram	electrogram	NOUN	NN	5	O
was	be	VERB	VBD	9	O
223	223	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
4	4	NUM	CD	9	O
beats	beat	NOUN	NNS	5	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O
in	in	ADP	IN	5	O
control	control	NOUN	NN	9	O
Krebs	Krebs	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
Ringer	Ringer	PROPN	NNP	0	O
containing	contain	VERB	VBG	0	O
137	137	NUM	CD	7	O
mM	mM	PROPN	NNP	0	O
Na	Na	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
35	35	NUM	CD	9	O
mM	mm	NOUN	NN	0	O
Ca	Ca	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
N	N	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
decreased	decrease	VERB	VBD	9	O
by	by	ADP	IN	9	O
16	16	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
by	by	ADP	IN	9	O
lowering	lower	VERB	VBG	9	O
[	[	PUNCT	-LRB-	9	O
Na	Na	PROPN	NNP	0	B-Chemical
]	]	PUNCT	-RRB-	9	O
o	o	NOUN	NN	9	O
to	to	ADP	IN	5	O
78	78	NUM	CD	7	O
mM	mM	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
LNa	LNa	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
23	23	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
by	by	ADP	IN	9	O
lowering	lower	VERB	VBG	9	O
simultaneously	simultaneously	ADV	RB	5	O
[	[	PUNCT	-LRB-	9	O
Na	na	ADV	RB	0	B-Chemical
]	]	PUNCT	-RRB-	9	O
o	o	NOUN	NN	9	O
to	to	ADP	IN	5	O
78	78	NUM	CD	7	O
mM	mM	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
[	[	PUNCT	-LRB-	9	O
Ca	Ca	VERB	MD	0	B-Chemical
]	]	PUNCT	-RRB-	9	O
o	o	NOUN	NN	9	O
to	to	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
675	675	NUM	CD	7	O
mM	mM	NOUN	NNS	0	O
(	(	PUNCT	-LRB-	9	O
LNa	LNa	NOUN	NNS	9	O
+	+	SYM	SYM	9	O
LCa	LCa	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
31	31	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
by	by	ADP	IN	9	O
lowering	lower	VERB	VBG	9	O
[	[	PUNCT	-LRB-	9	O
Na	Na	PROPN	NNP	0	B-Chemical
]	]	PUNCT	-RRB-	9	O
o	o	NOUN	NN	9	O
to	to	ADP	IN	5	O
78	78	NUM	CD	7	O
mM	mM	NOUN	NNS	0	O
plus	plus	CCONJ	CC	9	O
increasing	increase	VERB	VBG	9	O
[	[	PUNCT	-LRB-	9	O
Ca	Ca	VERB	MD	0	B-Chemical
]	]	PUNCT	-RRB-	9	O
o	o	NOUN	NN	9	O
to	to	ADP	IN	5	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
mM	mM	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
LNa	LNa	PROPN	NNP	9	O
+	+	SYM	SYM	9	O
HCa	HCa	NOUN	NNS	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
normal	normal	ADJ	JJ	9	O
[	[	PUNCT	-LRB-	9	O
Na	Na	PROPN	NNP	0	B-Chemical
]	]	PUNCT	-RRB-	9	O
o	o	NOUN	NN	9	O
,	,	PUNCT	,	9	O
decrease	decrease	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
675	675	NUM	CD	7	O
mM	mM	NOUN	NNS	0	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
increase	increase	VERB	VB	9	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
mM	mM	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
[	[	PUNCT	-LRB-	9	O
Ca	Ca	VERB	MD	0	B-Chemical
]	]	PUNCT	-RRB-	9	O
o	o	NOUN	NN	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
modify	modify	VERB	VB	9	O
BF	BF	PROPN	NNP	9	O
;	;	PUNCT	:	9	O
a	a	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
ten	ten	NUM	CD	9	O
times	time	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
135	135	NUM	CD	7	O
mM	mM	NOUN	NNS	0	O
of	of	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
[	[	PUNCT	-LRB-	9	O
Ca	Ca	VERB	MD	0	B-Chemical
]	]	PUNCT	-RRB-	9	O
o	o	NOUN	NN	9	O
was	be	VERB	VBD	9	O
effective	effective	ADJ	JJ	5	O
to	to	PART	TO	5	O
reduce	reduce	VERB	VB	5	O
BF	bf	NOUN	NN	9	O
by	by	ADP	IN	9	O
40	40	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
13	13	NUM	CD	7	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
negative	negative	ADJ	JJ	9	O
chronotropic	chronotropic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
BF	BF	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Dose	dose	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
potentiated	potentiate	VERB	VBN	3	O
by	by	ADP	IN	9	O
LNa	LNa	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
LCa	LCa	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
HCa	HCa	NOUN	NNS	7	O
.	.	PUNCT	.	9	O

Independent	independent	ADJ	JJ	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
additive	additive	VERB	VB	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
Na	Na	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
Ca	ca	PRON	PRP	0	B-Chemical
are	be	VERB	VBP	5	O
shown	show	VERB	VBN	9	O
by	by	ADP	IN	9	O
decreases	decrease	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
values	value	NOUN	NNS	5	O
of	of	ADP	IN	5	O
[	[	PUNCT	-LRB-	9	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
]	]	PUNCT	-RRB-	9	O
o	o	NOUN	NN	9	O
needed	need	VERB	VBN	5	O
to	to	PART	TO	5	O
reduce	reduce	VERB	VB	5	O
BF	bf	NOUN	NN	9	O
by	by	ADP	IN	9	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
IC30	IC30	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
following	follow	VERB	VBG	9	O
order	order	NOUN	NN	5	O
of	of	ADP	IN	5	O
inhibitory	inhibitory	ADJ	JJ	3	O
potency	potency	NOUN	NN	9	O
:	:	PUNCT	:	9	O
LNa	LNa	NOUN	NNS	9	O
>	>	X	XX	0	O
LCa	LCa	NOUN	NNS	3	O
>	>	X	XX	0	O
HCa	HCa	NOUN	NNS	7	O
>	>	X	XX	0	O
N	n	NOUN	NN	9	O
,	,	PUNCT	,	9	O
resulting	result	VERB	VBG	9	O
LNa	LNa	NOUN	NNS	9	O
+	+	SYM	SYM	9	O
HCa	HCa	NOUN	NNS	7	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
LNa	LNa	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
[	[	PUNCT	-LRB-	9	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
]	]	PUNCT	-RRB-	9	O
o	o	NOUN	NN	9	O
that	that	DET	WDT	5	O
arrested	arrest	VERB	VBD	3	O
atrial	atrial	ADJ	JJ	5	O
beating	beating	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
AC	AC	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
potentiated	potentiate	VERB	VBN	3	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
order	order	NOUN	NN	5	O
LNa	LNa	NOUN	NNS	9	O
=	=	SYM	SYM	7	O
LNa	LNa	NOUN	NNS	9	O
+	+	SYM	SYM	9	O
LCa	LCa	NOUN	NNS	3	O
=	=	SYM	SYM	7	O
LNa	LNa	NOUN	NNS	9	O
+	+	CCONJ	CC	9	O
HCa	HCa	NOUN	NNS	7	O
=	=	SYM	SYM	7	O
LCa	LCa	NOUN	NNS	3	O
>	>	X	XX	0	O
HCa	HCa	NOUN	NNS	7	O
=	=	SYM	SYM	7	O
N	n	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
rat	rat	VERB	VBP	3	O
atrial	atrial	ADJ	JJ	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
beating	beating	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
more	more	ADV	RBR	5	O
dependent	dependent	ADJ	JJ	9	O
on	on	ADP	IN	5	O
[	[	PUNCT	-LRB-	9	O
Na	Na	PROPN	NNP	0	B-Chemical
]	]	PUNCT	-RRB-	9	O
o	o	X	XX	9	O
than	than	ADP	IN	5	O
on	on	ADP	IN	5	O
[	[	PUNCT	-LRB-	9	O
Ca	Ca	PROPN	NNP	0	B-Chemical
]	]	PUNCT	-RRB-	9	O
o	o	X	XX	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
range	range	NOUN	NN	9	O
of	of	ADP	IN	5	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
normal	normal	ADJ	JJ	9	O
concentration	concentration	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Also	also	ADV	RB	9	O
the	the	DET	DT	5	O
enhancement	enhancement	NOUN	NN	9	O
of	of	ADP	IN	5	O
verapamil	verapamil	ADJ	JJ	0	B-Chemical
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
atrial	atrial	ADJ	JJ	5	O
beating	beating	NOUN	NN	5	O
was	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
pronounced	pronounce	VERB	VBN	9	O
at	at	ADP	IN	9	O
LNa	LNa	NOUN	NNS	9	O
than	than	ADP	IN	5	O
at	at	ADP	IN	9	O
LCa	LCa	NOUN	NNS	3	O
.	.	PUNCT	.	9	O
(	(	PUNCT	-LRB-	9	O
ABSTRACT	ABSTRACT	PROPN	NNP	2	O
TRUNCATED	truncated	NUM	CD	2	O
AT	at	ADP	IN	9	O
250	250	NUM	CD	0	O
WORDS	word	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O

Pseudo	pseudo	NOUN	NN	7	O
-	-	PUNCT	HYPH	7	O
allergic	allergic	ADJ	JJ	9	B-Disease
reactions	reaction	NOUN	NNS	9	I-Disease
to	to	ADP	IN	5	O
corticosteroids	corticosteroid	NOUN	NNS	5	B-Chemical
:	:	PUNCT	:	9	O
diagnosis	diagnosis	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
alternatives	alternative	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
parenteral	parenteral	ADJ	JJ	5	O
paramethasone	paramethasone	NOUN	NN	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
Triniol	Triniol	PROPN	NNP	_	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
dexamethasone	dexamethasone	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Sedionbel	Sedionbel	PROPN	NNP	_	O
)	)	PUNCT	-RRB-	9	O
are	be	VERB	VBP	5	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
few	few	ADJ	JJ	5	O
minutes	minute	NOUN	NNS	0	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
they	-PRON-	PRON	PRP	5	O
presented	present	VERB	VBD	5	O
urticaria	urticaria	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
patients	patient	NOUN	NNS	5	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
conjunctivitis	conjunctivitis	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
patient	patient	ADJ	JJ	5	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
'	'	PART	POS	9	O
reactions	reaction	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
immunological	immunological	ADJ	JJ	9	O
mechanisms	mechanism	NOUN	NNS	9	O
involved	involve	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
whether	whether	ADP	IN	9	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
would	would	VERB	MD	5	O
be	be	VERB	VB	5	O
able	able	ADJ	JJ	9	O
to	to	PART	TO	5	O
tolerate	tolerate	VERB	VB	5	O
any	any	DET	DT	5	O
kind	kind	NOUN	NN	5	O
of	of	ADP	IN	5	O
corticoid	corticoid	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
examinations	examination	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
skin	skin	NOUN	NN	5	O
,	,	PUNCT	,	9	O
oral	oral	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
parenteral	parenteral	ADJ	JJ	5	O
challenges	challenge	NOUN	NNS	5	O
with	with	ADP	IN	5	O
different	different	ADJ	JJ	9	O
corticosteroids	corticosteroid	NOUN	NNS	5	B-Chemical
and	and	CCONJ	CC	5	O
ELISA	ELISA	PROPN	NNP	3	O
tests	test	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
skin	skin	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
ELISA	ELISA	PROPN	NNP	3	O
tests	test	NOUN	NNS	5	O
with	with	ADP	IN	5	O
paramethasone	paramethasone	NOUN	NN	_	B-Chemical
were	be	VERB	VBD	9	O
negative	negative	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
prick	prick	NOUN	NN	5	O
test	test	NOUN	NN	5	O
with	with	ADP	IN	5	O
each	each	DET	DT	5	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
excipients	excipient	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
parenteral	parenteral	ADJ	JJ	5	O
challenge	challenge	NOUN	NN	9	O
with	with	ADP	IN	5	O
Triniol	Triniol	PROPN	NNP	_	O
was	be	VERB	VBD	9	O
positive	positive	ADJ	JJ	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
patients	patient	NOUN	NNS	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
ml	ml	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
negative	negative	ADJ	JJ	9	O
with	with	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
excipients	excipient	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
also	also	ADV	RB	9	O
carried	carry	VERB	VBD	9	O
out	out	PART	RP	9	O
oral	oral	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
parenteral	parenteral	ADJ	JJ	5	O
challenges	challenge	NOUN	NNS	5	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
corticosteroids	corticosteroid	NOUN	NNS	5	B-Chemical
and	and	CCONJ	CC	5	O
found	find	VERB	VBD	9	O
intolerance	intolerance	NOUN	NN	5	O
to	to	ADP	IN	5	O
some	some	DET	DT	5	O
of	of	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
paramethasone	paramethasone	NOUN	NN	_	B-Chemical
caused	cause	VERB	VBD	9	O
pseudoallergic	pseudoallergic	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
in	in	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Corticosteroids	corticosteroid	NOUN	NNS	9	O
different	different	ADJ	JJ	9	O
from	from	ADP	IN	9	O
paramethasone	paramethasone	NOUN	NN	_	B-Chemical
also	also	ADV	RB	9	O
produced	produce	VERB	VBD	9	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
reactions	reaction	NOUN	NNS	9	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
few	few	ADJ	JJ	5	O
of	of	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
were	be	VERB	VBD	9	O
tolerated	tolerate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
basic	basic	ADJ	JJ	5	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
those	those	DET	DT	5	O
reactions	reaction	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
yet	yet	ADV	RB	9	O
fully	fully	ADV	RB	9	O
understood	understand	VERB	VBN	5	O
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
knowledge	knowledge	NOUN	NN	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
pseudo	pseudo	NOUN	NN	5	O
-	-	NOUN	NN	7	O
allergy	allergy	NOUN	NN	9	B-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
paramethasone	paramethasone	NOUN	NN	_	B-Chemical
.	.	PUNCT	.	9	O

Study	study	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
B12	B12	PROPN	NNP	9	I-Chemical
and	and	CCONJ	CC	5	O
folinic	folinic	VERB	VB	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
supplementation	supplementation	NOUN	NN	0	O
in	in	ADP	IN	5	O
preventing	prevent	VERB	VBG	9	O
hematologic	hematologic	NOUN	NN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
zidovudine	zidovudine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
prospective	prospective	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
randomized	randomized	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
B12	B12	PROPN	NNP	9	I-Chemical
and	and	CCONJ	CC	5	O
folinic	folinic	VERB	VB	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
supplementation	supplementation	NOUN	NN	0	O
in	in	ADP	IN	5	O
preventing	prevent	VERB	VBG	9	O
zidovudine	zidovudine	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
ZDV	ZDV	PROPN	NNP	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
bone	bone	NOUN	NN	5	B-Disease
marrow	marrow	NOUN	NN	3	I-Disease
suppression	suppression	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Seventy	seventy	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
five	five	NUM	CD	9	O
human	human	ADJ	JJ	3	B-Disease
immunodeficiency	immunodeficiency	NOUN	NN	9	I-Disease
virus	virus	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	I-Disease
HIV	HIV	PROPN	NNP	5	I-Disease
)	)	PUNCT	-RRB-	9	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
infected	infect	VERB	VBN	3	I-Disease
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
CD4	CD4	PROPN	NNP	3	O
+	+	SYM	SYM	9	O
cell	cell	NOUN	NN	3	O
counts	count	VERB	VBZ	9	O
<	<	X	XX	0	O
500	500	NUM	CD	0	O
/	/	SYM	SYM	9	O
mm3	mm3	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
randomized	randomize	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
either	either	DET	DT	9	O
ZDV	ZDV	PROPN	NNP	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
500	500	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
daily	daily	ADV	RB	5	O
)	)	PUNCT	-RRB-	9	O
alone	alone	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
group	group	NOUN	NN	9	O
I	-PRON-	PRON	PRP	9	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
38	38	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
folinic	folinic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
daily	daily	ADV	RB	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
intramascular	intramascular	ADJ	JJ	0	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
B12	B12	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
1000	1000	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
monthly	monthly	ADJ	JJ	5	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
group	group	NOUN	NN	9	O
II	II	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
37	37	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Finally	finally	ADV	RB	9	O
,	,	PUNCT	,	9	O
15	15	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
excluded	exclude	VERB	VBN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
noncompliance	noncompliance	NOUN	NN	5	O
14	14	NUM	CD	7	O
,	,	PUNCT	,	9	O
death	death	NOUN	NN	9	B-Disease
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
60	60	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
31	31	NUM	CD	7	O
in	in	ADP	IN	5	O
group	group	NOUN	NN	9	O
I	I	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
29	29	NUM	CD	7	O
in	in	ADP	IN	5	O
group	group	NOUN	NN	9	O
II	II	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
eligible	eligible	ADJ	JJ	5	O
for	for	ADP	IN	5	O
analysis	analysis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
differences	difference	NOUN	NNS	9	O
between	between	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
at	at	ADP	IN	9	O
enrollment	enrollment	NOUN	NN	5	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
B12	B12	PROPN	NNP	9	I-Chemical
and	and	CCONJ	CC	5	O
folate	folate	ADJ	JJ	9	B-Chemical
levels	level	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
in	in	ADP	IN	5	O
group	group	NOUN	NN	9	O
II	II	PROPN	NNP	9	O
patients	patient	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
hemoglobin	hemoglobin	NOUN	NN	0	O
,	,	PUNCT	,	9	O
hematocrit	hematocrit	NOUN	NN	9	O
,	,	PUNCT	,	9	O
mean	mean	ADJ	JJ	5	O
corpuscular	corpuscular	ADJ	JJ	0	O
volume	volume	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
white	white	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
cell	cell	NOUN	NN	3	O
,	,	PUNCT	,	9	O
neutrophil	neutrophil	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
platelet	platelet	NOUN	NN	9	O
counts	count	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
between	between	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
at	at	ADP	IN	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
6	6	NUM	CD	9	O
,	,	PUNCT	,	9	O
9	9	NUM	CD	7	O
and	and	CCONJ	CC	5	O
12	12	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Severe	severe	ADJ	JJ	9	O
hematologic	hematologic	NOUN	NN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
neutrophil	neutrophil	NOUN	NN	3	O
count	count	NOUN	NN	9	O
<	<	X	XX	0	O
1000	1000	NUM	CD	9	O
/	/	SYM	SYM	9	O
mm3	mm3	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
hemoglobin	hemoglobin	NOUN	NN	0	O
<	<	X	XX	0	O
8	8	NUM	CD	9	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
dl	dl	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
4	4	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
assigned	assign	VERB	VBN	5	O
to	to	ADP	IN	5	O
group	group	NOUN	NN	9	O
I	I	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
7	7	NUM	CD	9	O
assigned	assign	VERB	VBN	5	O
to	to	ADP	IN	5	O
group	group	NOUN	NN	9	O
II	II	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
correlation	correlation	NOUN	NN	9	O
between	between	ADP	IN	5	O
vitamin	vitamin	NOUN	NN	0	B-Chemical
B12	B12	PROPN	NNP	9	I-Chemical
or	or	CCONJ	CC	5	O
folate	folate	ADJ	JJ	9	B-Chemical
levels	level	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
myelosuppression	myelosuppression	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Vitamin	Vitamin	PROPN	NNP	0	B-Chemical
B12	B12	PROPN	NNP	9	I-Chemical
and	and	CCONJ	CC	5	O
folinic	folinic	VERB	VB	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
supplementation	supplementation	NOUN	NN	0	O
of	of	ADP	IN	5	O
ZDV	ZDV	PROPN	NNP	5	B-Chemical
therapy	therapy	NOUN	NN	5	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
seem	seem	VERB	VB	5	O
useful	useful	ADJ	JJ	5	O
in	in	ADP	IN	5	O
preventing	prevent	VERB	VBG	9	O
or	or	CCONJ	CC	5	O
reducing	reduce	VERB	VBG	9	O
ZDV	ZDV	PROPN	NNP	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myelotoxicity	myelotoxicity	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
treated	treat	VERB	VBN	3	O
population	population	NOUN	NN	5	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
a	a	DET	DT	5	O
beneficial	beneficial	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
in	in	ADP	IN	5	O
certain	certain	ADJ	JJ	5	O
subgroups	subgroup	NOUN	NNS	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
cannot	cannot	NOUN	NN	5	O
be	be	VERB	VB	5	O
excluded	exclude	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Safety	safety	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
alprazolam	alprazolam	NOUN	NNS	0	B-Chemical
.	.	PUNCT	.	9	O

Controlled	control	VERB	VBN	5	O
study	study	NOUN	NN	9	O
in	in	ADP	IN	5	O
agoraphobia	agoraphobia	NOUN	NN	5	B-Disease
with	with	ADP	IN	5	O
panic	panic	NOUN	NN	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
widespread	widespread	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
benzodiazepines	benzodiazepine	NOUN	NNS	5	B-Chemical
has	have	VERB	VBZ	9	O
led	lead	VERB	VBN	9	O
to	to	ADP	IN	5	O
increasing	increase	VERB	VBG	9	O
recognition	recognition	NOUN	NN	5	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
unwanted	unwanted	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
alprazolam	alprazolam	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
in	in	ADP	IN	5	O
panic	panic	NOUN	NN	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
agoraphobia	agoraphobia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effect	effect	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
adverse	adverse	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
profiles	profile	NOUN	NNS	9	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
drug	drug	NOUN	NN	5	O
groups	group	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
London	London	PROPN	NNP	2	O
and	and	CCONJ	CC	5	O
Toronto	Toronto	PROPN	NNP	2	O
154	154	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
met	meet	VERB	VBD	5	O
DSM	DSM	PROPN	NNP	4	O
-	-	PUNCT	HYPH	7	O
III	III	PROPN	NNP	9	O
criteria	criterion	NOUN	NNS	5	O
for	for	ADP	IN	5	O
panic	panic	NOUN	NN	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
agoraphobia	agoraphobia	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
randomised	randomise	VERB	VBN	5	O
to	to	PART	TO	5	O
alprazolam	alprazolam	VERB	VB	0	B-Chemical
or	or	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Subjects	subject	NOUN	NNS	5	O
in	in	ADP	IN	5	O
each	each	DET	DT	5	O
drug	drug	NOUN	NN	5	O
group	group	NOUN	NN	9	O
also	also	ADV	RB	9	O
received	receive	VERB	VBD	9	O
either	either	CCONJ	CC	9	O
exposure	exposure	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
relaxation	relaxation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
from	from	ADP	IN	9	O
weeks	week	NOUN	NNS	9	O
0	0	NUM	CD	7	O
to	to	ADP	IN	5	O
8	8	NUM	CD	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
then	then	ADV	RB	9	O
tapered	taper	VERB	VBN	5	O
from	from	ADP	IN	9	O
weeks	week	NOUN	NNS	9	O
8	8	NUM	CD	9	O
to	to	ADP	IN	5	O
16	16	NUM	CD	9	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Mean	mean	VERB	VB	9	O
alprazolam	alprazolam	NOUN	NN	0	B-Chemical
dose	dose	NOUN	NN	9	O
was	be	VERB	VBD	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
daily	daily	ADV	RB	5	O
.	.	PUNCT	.	9	O

Compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
subjects	subject	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
alprazolam	alprazolam	NOUN	NN	0	B-Chemical
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
more	more	ADV	RBR	5	O
adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
21	21	NUM	CD	7	O
%	%	NOUN	NN	9	O
v	v	NOUN	NN	0	O
.	.	NOUN	NN	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
depression	depression	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
enuresis	enuresis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
disinhibition	disinhibition	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
aggression	aggression	NOUN	NN	5	B-Disease
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
more	more	ADJ	JJR	5	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
sedation	sedation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
irritability	irritability	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
impaired	impaired	ADJ	JJ	9	B-Disease
memory	memory	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
weight	weight	NOUN	NN	9	B-Disease
loss	loss	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
ataxia	ataxia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effects	effect	NOUN	NNS	9	O
tended	tend	VERB	VBD	5	O
to	to	PART	TO	5	O
diminish	diminish	VERB	VB	9	O
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
remained	remain	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
at	at	ADP	IN	9	O
week	week	NOUN	NN	9	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
this	this	DET	DT	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
drop	drop	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
out	out	PART	RP	9	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
low	low	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Alprazolam	Alprazolam	PROPN	NNP	0	B-Chemical
caused	cause	VERB	VBD	9	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effects	effect	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
many	many	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
willing	willing	ADJ	JJ	5	O
to	to	PART	TO	5	O
accept	accept	VERB	VB	5	O
these	these	DET	DT	5	O
.	.	PUNCT	.	9	O

Crescentic	crescentic	ADJ	JJ	7	O
fibrillary	fibrillary	NOUN	NN	3	O
glomerulonephritis	glomerulonephritis	NOUN	NN	3	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
intermittent	intermittent	ADJ	JJ	5	O
rifampin	rifampin	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
tuberculosis	tuberculosis	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
study	study	NOUN	NN	9	O
reveals	reveal	VERB	VBZ	9	O
an	an	DET	DT	5	O
unusual	unusual	ADJ	JJ	9	O
finding	finding	NOUN	NN	9	O
of	of	ADP	IN	5	O
rapidly	rapidly	ADV	RB	9	O
proliferative	proliferative	ADJ	JJ	3	O
crescentic	crescentic	ADJ	JJ	5	O
glomerulonephritis	glomerulonephritis	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
rifampin	rifampin	NOUN	NN	0	B-Chemical
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
other	other	ADJ	JJ	5	O
identifiable	identifiable	ADJ	JJ	5	O
causes	cause	NOUN	NNS	9	O
for	for	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
this	this	DET	DT	5	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
patient	patient	NOUN	NN	5	O
underwent	undergo	VERB	VBD	5	O
a	a	DET	DT	5	O
10	10	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
month	month	NOUN	NN	5	O
regimen	regiman	NOUN	NNS	5	O
of	of	ADP	IN	5	O
rifampin	rifampin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
isoniazid	isoniazid	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
tuberculosis	tuberculosis	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
discovered	discover	VERB	VBN	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
developed	develop	VERB	VBN	5	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	B-Disease
failure	failure	NOUN	NN	5	I-Disease
five	five	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
completion	completion	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	O
biopsy	biopsy	NOUN	NN	5	O
revealed	reveal	VERB	VBD	9	O
severe	severe	ADJ	JJ	5	O
glomerulonephritis	glomerulonephritis	NOUN	NN	3	B-Disease
with	with	ADP	IN	5	O
crescents	crescent	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
electron	electron	VERB	VB	0	O
dense	dense	ADJ	JJ	5	O
fibrillar	fibrillar	ADJ	JJ	3	O
deposits	deposit	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
moderate	moderate	ADJ	JJ	9	O
lymphocytic	lymphocytic	ADJ	JJ	3	O
interstitial	interstitial	ADJ	JJ	9	O
infiltrate	infiltrate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Other	other	ADJ	JJ	9	O
possible	possible	ADJ	JJ	5	O
causes	cause	NOUN	NNS	9	O
of	of	ADP	IN	5	O
rapidly	rapidly	ADV	RB	9	O
progressive	progressive	ADJ	JJ	5	O
glomerulonephritis	glomerulonephritis	NOUN	NN	3	B-Disease
were	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
ruled	rule	VERB	VBN	9	O
out	out	PART	RP	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
report	report	NOUN	NN	5	O
documents	document	VERB	VBZ	5	O
the	the	DET	DT	5	O
unusual	unusual	ADJ	JJ	9	O
occurrence	occurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
rapidly	rapidly	ADV	RB	9	O
progressive	progressive	ADJ	JJ	5	O
glomerulonephritis	glomerulonephritis	NOUN	NN	3	B-Disease
with	with	ADP	IN	5	O
crescents	crescent	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
fibrillar	fibrillar	ADJ	JJ	3	O
glomerulonephritis	glomerulonephritis	NOUN	NN	3	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
rifampin	rifampin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
confusion	confusion	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
folinic	folinic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
61	61	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
incorporating	incorporate	VERB	VBG	5	O
cisplatinum	cisplatinum	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
etoposide	etoposide	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
250	250	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
/	/	SYM	SYM	9	O
24	24	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
folinic	folinic	VERB	VB	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
for	for	ADP	IN	5	O
an	an	DET	DT	5	O
inoperable	inoperable	ADJ	JJ	5	O
gastric	gastric	ADJ	JJ	9	B-Disease
adenocarcinoma	adenocarcinoma	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

He	-PRON-	PRON	PRP	5	O
developed	develop	VERB	VBD	5	O
acute	acute	ADJ	JJ	9	O
neurologic	neurologic	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
mental	mental	ADJ	JJ	5	O
confusion	confusion	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
disorientation	disorientation	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
irritability	irritability	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
then	then	ADV	RB	9	O
lapsed	lapse	VERB	VBD	5	O
into	into	ADP	IN	9	O
a	a	DET	DT	5	O
deep	deep	ADJ	JJ	5	O
coma	coma	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
lasting	last	VERB	VBG	5	O
for	for	ADP	IN	5	O
approximately	approximately	ADV	RB	9	O
40	40	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
day	day	NOUN	NN	9	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
folinic	folinic	VERB	VB	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
complication	complication	NOUN	NN	5	O
reappeared	reappear	VERB	VBD	9	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
25	25	NUM	CD	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
second	second	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
and	and	CCONJ	CC	5	O
folinic	folinic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
then	then	ADV	RB	9	O
the	the	DET	DT	5	O
only	only	ADJ	JJ	9	O
drugs	drug	NOUN	NNS	5	O
given	give	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
folinic	folinic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
unlikely	unlikely	ADJ	JJ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
this	this	DET	DT	5	O
condition	condition	NOUN	NN	5	O
,	,	PUNCT	,	9	O
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
highly	highly	ADV	RB	9	O
suspected	suspect	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
neurotoxicity	neurotoxicity	NOUN	NN	9	B-Disease
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
Krebs	Krebs	PROPN	NNP	0	O
cycle	cycle	NOUN	NN	9	O
blockade	blockade	NOUN	NN	3	O
by	by	ADP	IN	9	O
fluoroacetate	fluoroacetate	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
fluorocitrate	fluorocitrate	ADJ	JJ	3	B-Chemical
,	,	PUNCT	,	9	O
thiamine	thiamine	NOUN	NN	0	B-Chemical
deficiency	deficiency	NOUN	NN	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
dihydrouracil	dihydrouracil	NOUN	NN	0	B-Chemical
dehydrogenase	dehydrogenase	NOUN	NN	1	O
deficiency	deficiency	NOUN	NN	9	O
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
/	/	SYM	SYM	9	O
folinic	folinic	NOUN	NN	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
infusion	infusion	NOUN	NN	0	O
therapy	therapy	NOUN	NN	5	O
has	have	VERB	VBZ	9	O
recently	recently	ADV	RB	9	O
become	become	VERB	VBN	5	O
a	a	DET	DT	5	O
popular	popular	ADJ	JJ	5	O
regimen	regimen	NOUN	NN	5	O
for	for	ADP	IN	5	O
various	various	ADJ	JJ	9	O
cancers	cancer	NOUN	NNS	9	B-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
necessary	necessary	ADJ	JJ	5	O
that	that	ADP	IN	5	O
both	both	DET	DT	9	O
oncologists	oncologist	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
neurologists	neurologist	NOUN	NNS	5	O
be	be	VERB	VB	5	O
fully	fully	ADV	RB	9	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
unusual	unusual	ADJ	JJ	9	O
complication	complication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
switching	switch	VERB	VBG	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
oxcarbazepine	oxcarbazepine	VERB	VB	0	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
neuroleptics	neuroleptic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Carbamazepine	Carbamazepine	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
switched	switch	VERB	VBN	9	O
to	to	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
10	10	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
keto	keto	NOUN	NN	0	O
analogue	analogue	NOUN	NN	0	O
oxcarbazepine	oxcarbazepine	NOUN	NN	0	B-Chemical
among	among	ADP	IN	5	O
six	six	NUM	CD	9	O
difficult	difficult	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
to	to	PART	TO	5	O
-	-	PUNCT	HYPH	7	O
treat	treat	VERB	VB	5	O
schizophrenic	schizophrenic	ADJ	JJ	5	B-Disease
or	or	CCONJ	CC	5	O
organic	organic	ADJ	JJ	0	B-Disease
psychotic	psychotic	ADJ	JJ	5	I-Disease
patients	patient	NOUN	NNS	5	O
using	use	VERB	VBG	9	O
concomitantly	concomitantly	ADV	RB	9	O
haloperidol	haloperidol	ADJ	JJ	5	B-Chemical
,	,	PUNCT	,	9	O
chlorpromazine	chlorpromazine	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
clozapine	clozapine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
change	change	NOUN	NN	9	O
resulted	result	VERB	VBD	9	O
within	within	ADP	IN	9	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
50	50	NUM	CD	0	O
-	-	SYM	SYM	7	O
200	200	NUM	CD	0	O
%	%	NOUN	NN	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
neuroleptics	neuroleptic	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
appearance	appearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

None	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
any	any	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
deteriotation	deteriotation	NOUN	NN	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
following	following	ADJ	JJ	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
support	support	VERB	VBP	5	O
the	the	DET	DT	5	O
idea	idea	NOUN	NN	5	O
that	that	ADP	IN	5	O
in	in	ADP	IN	5	O
contrast	contrast	NOUN	NN	9	O
with	with	ADP	IN	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
oxcarbazepine	oxcarbazepine	NOUN	NN	0	B-Chemical
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
induce	induce	VERB	VB	3	O
the	the	DET	DT	5	O
hepatic	hepatic	ADJ	JJ	9	O
microsomal	microsomal	ADJ	JJ	0	O
enzyme	enzyme	ADJ	JJ	0	O
systems	system	NOUN	NNS	5	O
regulating	regulate	VERB	VBG	9	O
the	the	DET	DT	5	O
inactivation	inactivation	NOUN	NN	9	O
of	of	ADP	IN	5	O
antipsychotic	antipsychotic	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Time	time	NOUN	NN	9	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
lipid	lipid	NOUN	NN	0	O
peroxidation	peroxidation	NOUN	NN	0	O
in	in	ADP	IN	5	O
puromycin	puromycin	ADJ	JJ	3	B-Chemical
aminonucleoside	aminonucleoside	ADV	RB	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Reactive	reactive	ADJ	JJ	0	O
oxygen	oxygen	NOUN	NN	0	B-Chemical
species	specie	NOUN	NNS	4	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
puromycin	puromycin	NOUN	NN	3	B-Chemical
aminonucleoside	aminonucleoside	ADP	IN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
PAN	PAN	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
antioxidants	antioxidant	NOUN	NNS	0	O
significantly	significantly	ADV	RB	9	O
reducing	reduce	VERB	VBG	9	O
the	the	DET	DT	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
temporal	temporal	ADJ	JJ	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
lipid	lipid	NOUN	NN	0	O
peroxidation	peroxidation	NOUN	NN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
kidney	kidney	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
IV	iv	NOUN	NN	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
puromycin	puromycin	NOUN	NN	3	B-Chemical
aminonucleoside	aminonucleoside	ADV	RB	0	I-Chemical
,	,	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
PAN	PAN	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
24	24	NUM	CD	9	O
hour	hour	NOUN	NN	0	O
urine	urine	NOUN	NN	9	O
samples	sample	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
sacrifice	sacrifice	VERB	VB	9	O
on	on	ADP	IN	5	O
days	day	NOUN	NNS	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
7	7	NUM	CD	9	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
,	,	PUNCT	,	9	O
17	17	NUM	CD	7	O
,	,	PUNCT	,	9	O
27	27	NUM	CD	7	O
,	,	PUNCT	,	9	O
41	41	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
N	n	NOUN	NN	9	O
=	=	SYM	SYM	7	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
10	10	NUM	CD	9	O
per	per	ADP	IN	9	O
group	group	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
kidneys	kidney	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
removed	remove	VERB	VBN	9	O
,	,	PUNCT	,	9	O
flushed	flush	VERB	VBN	9	O
with	with	ADP	IN	5	O
ice	ice	NOUN	NN	0	O
cold	cold	ADJ	JJ	9	O
TRIS	tris	NOUN	NN	0	O
buffer	buffer	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Kidney	Kidney	PROPN	NNP	9	O
cortices	cortice	VERB	VBZ	5	O
from	from	ADP	IN	9	O
each	each	DET	DT	5	O
animal	animal	NOUN	NN	5	O
were	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
prepare	prepare	VERB	VB	9	O
homogenates	homogenate	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Tissue	tissue	NOUN	NN	9	O
lipid	lipid	NOUN	NN	0	O
peroxidation	peroxidation	NOUN	NN	0	O
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
in	in	ADP	IN	5	O
whole	whole	ADJ	JJ	9	O
homogenates	homogenate	NOUN	NNS	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
in	in	ADP	IN	5	O
lipid	lipid	NOUN	NN	0	O
extracts	extract	NOUN	NNS	0	O
from	from	ADP	IN	9	O
homogenates	homogenate	NOUN	NNS	9	O
as	as	ADP	IN	5	O
thiobarbituric	thiobarbituric	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
reactive	reactive	ADJ	JJ	9	O
substances	substance	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Proteinuria	Proteinuria	PROPN	NNP	7	B-Disease
was	be	VERB	VBD	9	O
evident	evident	ADJ	JJ	9	O
at	at	ADP	IN	9	O
day	day	NOUN	NN	9	O
5	5	NUM	CD	9	O
,	,	PUNCT	,	9	O
peaked	peak	VERB	VBD	9	O
at	at	ADP	IN	9	O
day	day	NOUN	NN	9	O
7	7	NUM	CD	9	O
and	and	CCONJ	CC	5	O
persisted	persist	VERB	VBD	9	O
to	to	ADP	IN	5	O
day	day	NOUN	NN	9	O
27	27	NUM	CD	7	O
.	.	PUNCT	.	9	O

Lipid	Lipid	PROPN	NNP	0	O
peroxidation	peroxidation	NOUN	NN	0	O
in	in	ADP	IN	5	O
homogenates	homogenate	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
maximal	maximal	ADJ	JJ	9	O
at	at	ADP	IN	9	O
day	day	NOUN	NN	9	O
3	3	NUM	CD	9	O
and	and	CCONJ	CC	5	O
declined	decline	VERB	VBD	9	O
rapidly	rapidly	ADV	RB	9	O
to	to	PART	TO	5	O
control	control	VERB	VB	9	O
levels	level	NOUN	NNS	3	O
by	by	ADP	IN	9	O
day	day	NOUN	NN	9	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
supports	support	VERB	VBZ	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
lipid	lipid	NOUN	NN	0	O
peroxidation	peroxidation	NOUN	NN	0	O
in	in	ADP	IN	5	O
mediating	mediate	VERB	VBG	9	O
the	the	DET	DT	5	O
proteinuric	proteinuric	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
PAN	PAN	PROPN	NNP	0	B-Chemical
nephropathy	nephropathy	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Composition	composition	NOUN	NN	0	O
of	of	ADP	IN	5	O
gall	gall	NOUN	NN	4	B-Disease
bladder	bladder	NOUN	NN	9	I-Disease
stones	stone	NOUN	NNS	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
octreotide	octreotide	NOUN	NN	0	B-Chemical
:	:	PUNCT	:	9	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
ursodeoxycholic	ursodeoxycholic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Octreotide	octreotide	ADV	RB	0	B-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
acromegaly	acromegaly	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
induces	induce	VERB	VBZ	3	O
gall	gall	NOUN	NN	4	B-Disease
bladder	bladder	NOUN	NN	9	I-Disease
stones	stone	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
13	13	NUM	CD	7	O
-	-	SYM	SYM	7	O
60	60	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Because	because	ADP	IN	9	O
knowledge	knowledge	NOUN	NN	5	O
of	of	ADP	IN	5	O
stone	stone	NOUN	NN	5	O
composition	composition	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
essential	essential	ADJ	JJ	9	O
for	for	ADP	IN	5	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
prevention	prevention	NOUN	NN	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
was	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
by	by	ADP	IN	9	O
direct	direct	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
indirect	indirect	ADJ	JJ	5	O
methods	method	NOUN	NNS	5	O
in	in	ADP	IN	5	O
14	14	NUM	CD	7	O
octreotide	octreotide	NOUN	NN	0	B-Chemical
treated	treat	VERB	VBD	3	O
acromegalic	acromegalic	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
gall	gall	NOUN	NN	4	B-Disease
stones	stone	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Chemical	chemical	NOUN	NN	0	O
analysis	analysis	NOUN	NN	9	O
of	of	ADP	IN	5	O
gall	gall	NOUN	NN	4	B-Disease
stones	stone	NOUN	NNS	5	I-Disease
retrieved	retrieve	VERB	VBN	9	O
at	at	ADP	IN	9	O
cholecystectomy	cholecystectomy	NOUN	NN	5	O
from	from	ADP	IN	9	O
two	two	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
they	-PRON-	PRON	PRP	5	O
contained	contain	VERB	VBD	9	O
71	71	NUM	CD	7	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
87	87	NUM	CD	7	O
%	%	NOUN	NN	9	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
by	by	ADP	IN	9	O
weight	weight	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
remaining	remain	VERB	VBG	9	O
12	12	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
localised	localise	VERB	VBD	9	O
computed	compute	VERB	VBN	5	O
tomography	tomography	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
gall	gall	NOUN	NN	4	O
bladder	bladder	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
eight	eight	NUM	CD	9	O
had	have	VERB	VBD	9	O
stones	stone	NOUN	NNS	5	O
with	with	ADP	IN	5	O
maximum	maximum	ADJ	JJ	5	O
attenuation	attenuation	NOUN	NN	9	O
scores	score	NOUN	NNS	5	O
of	of	ADP	IN	5	O
<	<	X	XX	0	O
100	100	NUM	CD	0	O
Hounsfield	Hounsfield	PROPN	NNP	5	O
units	unit	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
values	value	NOUN	NNS	5	O
of	of	ADP	IN	5	O
<	<	X	XX	0	O
100	100	NUM	CD	0	O
HU	HU	PROPN	NNP	9	O
predict	predict	VERB	VB	5	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
rich	rich	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
dissolvable	dissolvable	ADJ	JJ	0	O
stones	stone	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Gall	gall	NOUN	NN	6	O
bladder	bladder	NOUN	NN	9	O
bile	bile	NOUN	NN	0	O
was	be	VERB	VBD	9	O
obtained	obtain	VERB	VBN	9	O
by	by	ADP	IN	9	O
ultrasound	ultrasound	NOUN	NN	5	O
guided	guide	VERB	VBN	5	O
,	,	PUNCT	,	9	O
fine	fine	ADJ	JJ	5	O
needle	needle	NOUN	NN	5	O
puncture	puncture	NOUN	NN	5	O
from	from	ADP	IN	9	O
six	six	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
six	six	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
supersaturated	supersaturate	VERB	VBN	0	O
bile	bile	ADJ	JJ	0	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
(	(	PUNCT	-LRB-	9	O
SEM	SEM	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
saturation	saturation	NOUN	NN	9	O
index	index	NOUN	NN	5	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
19	19	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
08	08	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
range	range	VERB	VBP	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
-	-	SYM	SYM	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
53	53	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
all	all	DET	DT	5	O
had	have	VERB	VBD	9	O
abnormally	abnormally	ADV	RB	9	O
rapid	rapid	ADJ	JJ	5	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
microcrystal	microcrystal	NOUN	NN	0	O
nucleation	nucleation	NOUN	NN	9	O
times	time	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
<	<	X	XX	0	O
4	4	NUM	CD	9	O
days	day	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
range	range	VERB	VB	9	O
1	1	NUM	CD	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
whilst	whilst	ADP	IN	9	O
in	in	ADP	IN	5	O
four	four	NUM	CD	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
bile	bile	NOUN	NN	0	O
contained	contain	VERB	VBD	9	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
microcrystals	microcrystal	NOUN	NNS	0	O
immediately	immediately	ADV	RB	9	O
after	after	ADP	IN	9	O
sampling	sample	VERB	VBG	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
12	12	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
considered	consider	VERB	VBN	5	O
for	for	ADP	IN	5	O
oral	oral	ADJ	JJ	9	O
ursodeoxycholic	ursodeoxycholic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
UDCA	UDCA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
two	two	NUM	CD	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
blocked	block	VERB	VBN	3	O
cystic	cystic	ADJ	JJ	5	O
duct	duct	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
started	start	VERB	VBN	5	O
on	on	ADP	IN	5	O
UDCA	UDCA	PROPN	NNP	0	B-Chemical
while	while	ADP	IN	9	O
one	one	PRON	PRP	5	O
was	be	VERB	VBD	9	O
lost	lose	VERB	VBN	9	O
to	to	PART	TO	5	O
follow	follow	VERB	VB	5	O
up	up	PART	RP	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
one	one	NUM	CD	5	O
year	year	NOUN	NN	5	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
five	five	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
remaining	remain	VERB	VBG	9	O
nine	nine	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
either	either	CCONJ	CC	9	O
partial	partial	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
complete	complete	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
2	2	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
gall	gall	NOUN	NN	4	B-Disease
stone	stone	NOUN	NN	5	I-Disease
dissolution	dissolution	NOUN	NN	0	O
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
that	that	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
stones	stone	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
rich	rich	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
corresponds	correspond	VERB	VBZ	9	O
,	,	PUNCT	,	9	O
by	by	ADP	IN	9	O
actuarial	actuarial	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
life	life	NOUN	NN	5	O
table	table	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
analysis	analysis	NOUN	NN	9	O
,	,	PUNCT	,	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
combined	combine	VERB	VBN	9	O
gall	gall	NOUN	NN	4	B-Disease
stone	stone	NOUN	NN	5	I-Disease
dissolution	dissolution	NOUN	NN	0	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
58	58	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
conclusion	conclusion	NOUN	NN	9	O
,	,	PUNCT	,	9	O
octreotide	octreotide	ADP	IN	0	B-Chemical
induced	induced	ADJ	JJ	3	O
gall	gall	NOUN	NN	4	B-Disease
stones	stone	NOUN	NNS	5	I-Disease
are	be	VERB	VBP	5	O
generally	generally	ADV	RB	5	O
small	small	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
multiple	multiple	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cholesterol	cholesterol	NOUN	NN	0	B-Chemical
rich	rich	ADJ	JJ	9	O
although	although	ADP	IN	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
common	common	ADJ	JJ	5	O
with	with	ADP	IN	5	O
spontaneous	spontaneous	ADJ	JJ	5	O
gall	gall	NOUN	NN	4	B-Disease
stone	stone	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
presentation	presentation	NOUN	NN	5	O
some	some	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
will	will	VERB	MD	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
blocked	block	VERB	VBN	3	O
cystic	cystic	ADJ	JJ	5	O
duct	duct	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
some	some	DET	DT	5	O
gall	gall	NOUN	NN	4	B-Disease
stones	stone	NOUN	NNS	5	I-Disease
containing	contain	VERB	VBG	0	O
calcium	calcium	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Erythema	Erythema	PROPN	NNP	2	B-Disease
multiforme	multiforme	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
myocarditis	myocarditis	NOUN	NN	9	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
ampicillin	ampicillin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
report	report	VERB	VB	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
erythema	erythema	NOUN	NN	5	B-Disease
multiforme	multiforme	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
myocarditis	myocarditis	NOUN	NN	9	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
ampicillin	ampicillin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
SUMMARY	summary	NOUN	NN	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
13	13	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
boy	boy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
ampicillin	ampicillin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
gentamicin	gentamicin	NOUN	NN	0	B-Chemical
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
suspected	suspect	VERB	VBN	5	O
septicemia	septicemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Medications	medication	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
when	when	ADV	WRB	5	O
erythema	erythema	NOUN	NN	5	B-Disease
multiforme	multiforme	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
congestive	congestive	ADJ	JJ	5	B-Disease
heart	heart	NOUN	NN	5	I-Disease
failure	failure	NOUN	NN	5	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
myocarditis	myocarditis	NOUN	NN	9	B-Disease
occurred	occur	VERB	VBD	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
methylprednisolone	methylprednisolone	ADJ	JJ	0	B-Chemical
and	and	CCONJ	CC	5	O
gradually	gradually	ADV	RB	9	O
improved	improve	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Macrophage	macrophage	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
migration	migration	NOUN	NN	3	O
inhibition	inhibition	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
MIF	MIF	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
test	test	NOUN	NN	5	O
with	with	ADP	IN	5	O
ampicillin	ampicillin	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
positive	positive	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

DISCUSSION	discussion	NOUN	NN	9	O
:	:	PUNCT	:	9	O
After	after	ADP	IN	9	O
most	most	ADJ	JJS	9	O
infections	infection	NOUN	NNS	5	B-Disease
causing	cause	VERB	VBG	9	O
erythema	erythema	NOUN	NN	5	B-Disease
multiforme	multiforme	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
myocarditis	myocarditis	NOUN	NN	9	B-Disease
were	be	VERB	VBD	9	O
ruled	rule	VERB	VBN	9	O
out	out	PART	RP	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
drug	drug	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
induced	induce	VERB	VBN	3	I-Disease
allergic	allergic	ADJ	JJ	9	I-Disease
reaction	reaction	NOUN	NN	9	I-Disease
was	be	VERB	VBD	9	O
suspected	suspect	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Positive	Positive	PROPN	NNP	7	O
MIF	MIF	PROPN	NNP	3	O
test	test	NOUN	NN	5	O
for	for	ADP	IN	5	O
ampicillin	ampicillin	NOUN	NN	0	B-Chemical
showed	show	VERB	VBD	9	O
sensitization	sensitization	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
lymphocytes	lymphocyte	NOUN	NNS	3	O
to	to	PART	TO	5	O
ampicillin	ampicillin	VERB	VB	0	B-Chemical
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
myocarditis	myocarditis	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
dangerous	dangerous	ADJ	JJ	5	O
manifestation	manifestation	NOUN	NN	5	O
of	of	ADP	IN	5	O
allergy	allergy	NOUN	NN	9	B-Disease
to	to	ADP	IN	5	O
penicillins	penicillin	NOUN	NNS	0	B-Chemical
.	.	PUNCT	.	9	O

Clomipramine	clomipramine	NOUN	NN	7	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
sleep	sleep	NOUN	NN	5	B-Disease
disturbance	disturbance	NOUN	NN	5	I-Disease
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
impair	impair	VERB	VB	9	O
its	-PRON-	DET	PRP$	9	O
prolactin	prolactin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
releasing	release	VERB	VBG	9	O
action	action	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
undertaken	undertake	VERB	VBN	5	O
to	to	PART	TO	5	O
examine	examine	VERB	VB	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
sleep	sleep	NOUN	NN	5	B-Disease
disturbance	disturbance	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
clomipramine	clomipramine	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
secretory	secretory	ADJ	JJ	3	O
rate	rate	NOUN	NN	9	O
of	of	ADP	IN	5	O
prolactin	prolactin	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
PRL	PRL	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
direct	direct	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
supine	supine	NOUN	NN	5	O
subjects	subject	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
under	under	ADP	IN	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
conditions	condition	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
night	night	NOUN	NN	5	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
sleeping	sleep	VERB	VBG	5	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
at	at	ADP	IN	9	O
daytime	daytime	NOUN	NN	5	O
,	,	PUNCT	,	9	O
when	when	ADV	WRB	5	O
awake	awake	ADJ	JJ	5	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
6	6	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Each	each	DET	DT	5	O
subject	subject	NOUN	NN	5	O
received	receive	VERB	VBD	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
clomipramine	clomipramine	NOUN	NN	0	B-Chemical
given	give	VERB	VBN	5	O
orally	orally	ADV	RB	0	O
2	2	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
before	before	ADP	IN	9	O
blood	blood	NOUN	NN	9	O
collection	collection	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Plasma	plasma	ADJ	JJ	0	O
PRL	PRL	PROPN	NNP	3	O
concentrations	concentration	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
analysed	analyse	VERB	VBN	9	O
at	at	ADP	IN	9	O
10	10	NUM	CD	9	O
min	min	NOUN	NN	0	O
intervals	interval	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
underlying	underlie	VERB	VBG	5	O
secretory	secretory	ADJ	JJ	3	O
rates	rate	NOUN	NNS	5	O
calculated	calculate	VERB	VBN	5	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
deconvolution	deconvolution	NOUN	NN	5	O
procedure	procedure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
both	both	DET	DT	9	O
experiments	experiment	NOUN	NNS	9	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
intake	intake	NOUN	NN	5	O
led	lead	VERB	VBN	9	O
to	to	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
increases	increase	NOUN	NNS	9	O
in	in	ADP	IN	5	O
PRL	PRL	PROPN	NNP	3	O
secretion	secretion	NOUN	NN	3	O
,	,	PUNCT	,	9	O
acting	act	VERB	VBG	9	O
preferentially	preferentially	ADV	RB	9	O
on	on	ADP	IN	5	O
tonic	tonic	NOUN	NN	5	O
secretion	secretion	NOUN	NN	3	O
as	as	ADP	IN	5	O
pulse	pulse	NOUN	NN	5	O
amplitude	amplitude	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
frequency	frequency	NOUN	NN	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
differ	differ	VERB	VB	9	O
significantly	significantly	ADV	RB	9	O
from	from	ADP	IN	9	O
corresponding	correspond	VERB	VBG	9	O
control	control	NOUN	NN	9	O
values	value	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
the	the	DET	DT	5	O
night	night	NOUN	NN	5	O
clomipramine	clomipramine	NOUN	NN	0	B-Chemical
ingestion	ingestion	NOUN	NN	9	O
altered	alter	VERB	VBD	9	O
the	the	DET	DT	5	O
complete	complete	ADJ	JJ	9	O
sleep	sleep	NOUN	NN	5	O
architecture	architecture	NOUN	NN	5	O
in	in	ADP	IN	5	O
that	that	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
suppressed	suppress	VERB	VBD	3	O
REM	rem	NOUN	NN	5	O
sleep	sleep	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
sleep	sleep	NOUN	NN	5	O
cycles	cycle	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
induced	induce	VERB	VBD	3	O
increased	increase	VERB	VBN	9	O
wakefulness	wakefulness	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
the	the	DET	DT	5	O
relative	relative	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
PRL	PRL	PROPN	NNP	3	O
secretion	secretion	NOUN	NN	3	O
expressed	express	VERB	VBD	3	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
percentage	percentage	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
mean	mean	NOUN	NN	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
differ	differ	VERB	VB	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
night	night	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
day	day	NOUN	NN	9	O
time	time	NOUN	NN	5	O
studies	study	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
46	46	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
19	19	NUM	CD	7	O
%	%	NOUN	NN	9	O
vs	vs	ADP	IN	7	O
34	34	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
observed	observed	ADJ	JJ	9	O
sleep	sleep	NOUN	NN	5	B-Disease
disturbance	disturbance	NOUN	NN	5	I-Disease
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
interfere	interfere	VERB	VB	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
action	action	NOUN	NN	5	O
per	per	ADP	IN	9	O
se	se	X	FW	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
REM	rem	NOUN	NN	5	O
sleep	sleep	NOUN	NN	5	O
was	be	VERB	VBD	9	O
shown	show	VERB	VBN	9	O
not	not	ADV	RB	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
determining	determine	VERB	VBG	9	O
factor	factor	NOUN	NN	9	O
either	either	CCONJ	CC	9	O
for	for	ADP	IN	5	O
secretory	secretory	ADJ	JJ	3	O
pulse	pulse	NOUN	NN	5	O
amplitude	amplitude	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
frequency	frequency	NOUN	NN	5	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
both	both	DET	DT	9	O
,	,	PUNCT	,	9	O
mean	mean	VERB	VB	5	O
nocturnal	nocturnal	ADJ	JJ	5	O
values	value	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
with	with	ADP	IN	5	O
and	and	CCONJ	CC	5	O
without	without	ADP	IN	9	O
prior	prior	ADJ	JJ	9	O
clomipramine	clomipramine	NOUN	NN	0	B-Chemical
ingestion	ingestion	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Survey	survey	NOUN	NN	5	O
of	of	ADP	IN	5	O
complications	complication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
indocyanine	indocyanine	ADJ	JJ	0	B-Chemical
green	green	ADJ	JJ	9	I-Chemical
angiography	angiography	NOUN	NN	5	O
in	in	ADP	IN	5	O
Japan	Japan	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
evaluated	evaluate	VERB	VBD	9	O
the	the	DET	DT	5	O
safety	safety	NOUN	NN	5	O
of	of	ADP	IN	5	O
indocyanine	indocyanine	ADJ	JJ	0	B-Chemical
green	green	NOUN	NN	9	I-Chemical
for	for	ADP	IN	5	O
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
fundus	fundus	NOUN	NN	5	O
angiography	angiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
sent	send	VERB	VBD	5	O
a	a	DET	DT	5	O
questionnaire	questionnaire	NOUN	NN	5	O
concerning	concern	VERB	VBG	5	O
complications	complication	NOUN	NNS	5	O
of	of	ADP	IN	5	O
indocyanine	indocyanine	ADJ	JJ	0	B-Chemical
green	green	ADJ	JJ	9	I-Chemical
to	to	ADP	IN	5	O
32	32	NUM	CD	7	O
institutions	institution	NOUN	NNS	5	O
in	in	ADP	IN	5	O
Japan	Japan	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
selected	select	VERB	VBN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
basis	basis	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
client	client	NOUN	NN	5	O
list	list	NOUN	NN	5	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
Topcon	Topcon	PROPN	NNP	5	O
Company	Company	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
manufactures	manufacture	VERB	VBZ	5	O
the	the	DET	DT	5	O
indocyanine	indocyanine	ADJ	JJ	0	B-Chemical
green	green	ADJ	JJ	9	I-Chemical
fundus	fundus	NOUN	NN	5	O
camera	camera	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Ophthalmologists	ophthalmologist	NOUN	NNS	2	O
at	at	ADP	IN	9	O
15	15	NUM	CD	9	O
institutions	institution	NOUN	NNS	5	O
responded	respond	VERB	VBD	9	O
,	,	PUNCT	,	9	O
reporting	report	VERB	VBG	5	O
a	a	DET	DT	5	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
774	774	NUM	CD	7	O
indocyanine	indocyanine	ADJ	JJ	0	B-Chemical
green	green	ADJ	JJ	9	I-Chemical
angiograms	angiogram	NOUN	NNS	5	O
performed	perform	VERB	VBN	9	O
on	on	ADP	IN	5	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
820	820	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
between	between	ADP	IN	5	O
June	June	PROPN	NNP	2	O
1984	1984	NUM	CD	2	O
and	and	CCONJ	CC	5	O
September	September	PROPN	NNP	2	O
1992	1992	NUM	CD	2	O
.	.	PUNCT	.	9	O

Before	before	ADP	IN	9	O
angiography	angiography	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
intradermal	intradermal	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
intravenous	intravenous	ADJ	JJ	0	O
indocyanine	indocyanine	ADJ	JJ	0	B-Chemical
green	green	ADJ	JJ	9	I-Chemical
testing	testing	NOUN	NN	5	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
both	both	DET	DT	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
at	at	ADP	IN	9	O
13	13	NUM	CD	7	O
of	of	ADP	IN	5	O
15	15	NUM	CD	9	O
institutions	institution	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
decision	decision	NOUN	NN	5	O
was	be	VERB	VBD	9	O
made	make	VERB	VBN	5	O
not	not	ADV	RB	5	O
to	to	PART	TO	5	O
proceed	proceed	VERB	VB	9	O
with	with	ADP	IN	5	O
angiography	angiography	NOUN	NN	5	O
after	after	ADP	IN	9	O
positive	positive	ADJ	JJ	9	O
preangiographic	preangiographic	ADJ	JJ	_	O
testing	testing	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
dosage	dosage	NOUN	NN	9	O
of	of	ADP	IN	5	O
indocyanine	indocyanine	ADJ	JJ	0	B-Chemical
green	green	NOUN	NN	9	I-Chemical
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
angiography	angiography	NOUN	NN	5	O
varied	varied	ADJ	JJ	9	O
from	from	ADP	IN	9	O
25	25	NUM	CD	9	O
to	to	PART	TO	5	O
75	75	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
depending	depend	VERB	VBG	5	O
upon	upon	ADP	IN	9	O
the	the	DET	DT	5	O
institution	institution	NOUN	NN	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
13	13	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
34	34	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
ten	ten	NUM	CD	9	O
of	of	ADP	IN	5	O
which	which	DET	WDT	5	O
were	be	VERB	VBD	9	O
mild	mild	ADJ	JJ	9	O
reactions	reaction	NOUN	NNS	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
nausea	nausea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
exanthema	exanthema	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
urtication	urtication	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
itchiness	itchiness	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
urgency	urgency	NOUN	NN	5	O
to	to	PART	TO	5	O
defecate	defecate	VERB	VB	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
require	require	VERB	VB	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Also	also	ADV	RB	9	O
recorded	record	VERB	VBN	5	O
were	be	VERB	VBD	9	O
one	one	NUM	CD	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
vein	vein	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
required	require	VERB	VBD	9	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
two	two	NUM	CD	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
two	two	NUM	CD	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
required	require	VERB	VBD	9	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
shock	shock	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
comparison	comparison	NOUN	NN	9	O
of	of	ADP	IN	5	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
to	to	PART	TO	5	O
indocyanine	indocyanine	VERB	VB	0	B-Chemical
green	green	ADJ	JJ	9	I-Chemical
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
previously	previously	ADV	RB	9	O
reported	report	VERB	VBN	9	O
frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
such	such	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
to	to	PART	TO	5	O
fluorescein	fluorescein	VERB	VB	0	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
indicated	indicate	VERB	VBD	9	O
that	that	ADP	IN	5	O
indocyanine	indocyanine	ADJ	JJ	0	B-Chemical
green	green	NOUN	NN	9	I-Chemical
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
safe	safe	ADJ	JJ	5	O
as	as	ADP	IN	5	O
fluorescein	fluorescein	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
use	use	NOUN	NN	5	O
in	in	ADP	IN	5	O
angiography	angiography	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Angioedema	Angioedema	PROPN	NNP	5	B-Disease
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
intravenous	intravenous	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
72	72	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
was	be	VERB	VBD	9	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
hospital	hospital	NOUN	NN	5	O
with	with	ADP	IN	5	O
"	"	PUNCT	``	5	O
flash	flash	NOUN	NN	5	O
"	"	PUNCT	''	5	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
preceded	precede	VERB	VBN	9	O
by	by	ADP	IN	9	O
chest	chest	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
requiring	require	VERB	VBG	5	O
intubation	intubation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Her	-PRON-	DET	PRP$	5	O
medical	medical	ADJ	JJ	5	O
history	history	NOUN	NN	5	O
included	include	VERB	VBD	5	O
coronary	coronary	ADJ	JJ	5	B-Disease
artery	artery	NOUN	NN	5	I-Disease
disease	disease	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
previous	previous	ADJ	JJ	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarctions	infarction	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
diabetes	diabetes	NOUN	NN	5	B-Disease
mellitus	mellitus	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
angioedema	angioedema	NOUN	NN	5	B-Disease
secondary	secondary	ADJ	JJ	9	O
to	to	PART	TO	5	O
lisinopril	lisinopril	ADJ	JJ	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
elicited	elicit	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Current	current	ADJ	JJ	9	O
medications	medication	NOUN	NNS	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
include	include	VERB	VB	5	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
converting	convert	VERB	VBG	9	O
enzyme	enzyme	ADJ	JJ	0	O
inhibitors	inhibitor	NOUN	NNS	3	O
or	or	CCONJ	CC	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blockers	blocker	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
previous	previous	ADJ	JJ	9	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blocking	block	VERB	VBG	3	O
drug	drug	NOUN	NN	5	O
exposure	exposure	NOUN	NN	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
of	of	ADP	IN	5	O
hospitalization	hospitalization	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
while	while	ADP	IN	9	O
intubated	intubate	VERB	VBN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
intravenous	intravenous	ADJ	JJ	0	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
,	,	PUNCT	,	9	O
resulting	result	VERB	VBG	9	O
in	in	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
angioedema	angioedema	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
angioedema	angioedema	NOUN	NN	5	B-Disease
resolved	resolve	VERB	VBD	9	O
after	after	ADP	IN	9	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
steroids	steroid	NOUN	NNS	9	B-Chemical
and	and	CCONJ	CC	5	O
diphenhydramine	diphenhydramine	ADJ	JJ	0	B-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
coniine	coniine	NOUN	NN	5	B-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
developing	develop	VERB	VBG	5	O
chick	chick	NOUN	NN	9	O
embryo	embryo	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Coniine	Coniine	PROPN	NNP	_	B-Chemical
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
alkaloid	alkaloid	NOUN	NN	0	O
from	from	ADP	IN	9	O
Conium	Conium	PROPN	NNP	4	O
maculatum	maculatum	NOUN	NN	4	O
(	(	PUNCT	-LRB-	9	O
poison	poison	NOUN	NN	9	O
hemlock	hemlock	NOUN	NN	4	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
teratogenic	teratogenic	ADJ	JJ	5	O
in	in	ADP	IN	5	O
livestock	livestock	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
major	major	ADJ	JJ	9	O
teratogenic	teratogenic	NOUN	NN	5	O
outcome	outcome	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
arthrogryposis	arthrogryposis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
presumably	presumably	ADV	RB	9	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
nicotinic	nicotinic	ADJ	JJ	0	O
receptor	receptor	NOUN	NN	3	O
blockade	blockade	NOUN	NN	3	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
coniine	coniine	NOUN	NN	5	B-Chemical
has	have	VERB	VBZ	9	O
failed	fail	VERB	VBN	9	O
to	to	PART	TO	5	O
produce	produce	VERB	VB	9	O
arthrogryposis	arthrogryposis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
or	or	CCONJ	CC	5	O
mice	mouse	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
is	be	VERB	VBZ	5	O
only	only	ADV	RB	9	O
weakly	weakly	ADJ	JJ	9	O
teratogenic	teratogenic	NOUN	NN	5	O
in	in	ADP	IN	5	O
rabbits	rabbit	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
and	and	CCONJ	CC	5	O
compare	compare	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
coniine	coniine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
developing	develop	VERB	VBG	5	O
chick	chick	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
coniine	coniine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	O
were	be	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
015	015	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
075	075	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
15	15	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
75	75	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
compounds	compound	NOUN	NNS	0	O
caused	cause	VERB	VBD	9	O
deformations	deformation	NOUN	NNS	5	B-Disease
and	and	CCONJ	CC	5	O
lethality	lethality	NOUN	NN	3	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
manner	manner	NOUN	NN	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	O
caused	cause	VERB	VBD	9	O
some	some	DET	DT	5	O
lethality	lethality	NOUN	NN	3	O
but	but	CCONJ	CC	9	O
a	a	DET	DT	5	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
level	level	NOUN	NN	9	O
for	for	ADP	IN	5	O
coniine	coniine	NOUN	NN	5	B-Chemical
lethality	lethality	NOUN	NN	3	O
was	be	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
75	75	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
deformations	deformation	NOUN	NNS	5	B-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
both	both	DET	DT	9	O
coniine	coniine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	O
were	be	VERB	VBD	9	O
excessive	excessive	ADJ	JJ	5	B-Disease
flexion	flexion	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	I-Disease
extension	extension	NOUN	NN	9	I-Disease
of	of	ADP	IN	5	I-Disease
one	one	NUM	CD	5	I-Disease
or	or	CCONJ	CC	5	I-Disease
more	more	ADJ	JJR	5	I-Disease
toes	toe	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
histopathological	histopathological	ADJ	JJ	9	O
alterations	alteration	NOUN	NNS	9	O
or	or	CCONJ	CC	5	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
bone	bone	NOUN	NN	5	O
formation	formation	NOUN	NN	9	O
were	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
limbs	limb	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
toes	toe	NOUN	NNS	5	O
of	of	ADP	IN	5	O
any	any	DET	DT	5	O
chicks	chick	NOUN	NNS	5	O
from	from	ADP	IN	9	O
any	any	DET	DT	5	O
group	group	NOUN	NN	9	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
extensive	extensive	ADJ	JJ	5	O
cranial	cranial	ADJ	JJ	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
chicks	chick	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
movement	movement	NOUN	NN	5	O
in	in	ADP	IN	5	O
coniine	coniine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	O
treated	treat	VERB	VBN	3	O
chicks	chick	NOUN	NNS	5	O
as	as	ADP	IN	5	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
ultrasound	ultrasound	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Control	control	NOUN	NN	9	O
chicks	chick	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
in	in	ADP	IN	5	O
motion	motion	NOUN	NN	5	O
an	an	DET	DT	5	O
average	average	NOUN	NN	5	O
of	of	ADP	IN	5	O
33	33	NUM	CD	7	O
.	.	PUNCT	.	9	O
67	67	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
coniine	coniine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
chicks	chick	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
only	only	ADV	RB	9	O
moving	move	VERB	VBG	5	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
min	min	NOUN	NN	0	O
interval	interval	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
movement	movement	NOUN	NN	5	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
for	for	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
sulfate	sulfate	NOUN	NN	0	O
treated	treat	VERB	VBN	3	O
chicks	chick	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
summary	summary	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
chick	chick	NOUN	NN	9	O
embryo	embryo	NOUN	NN	9	O
provides	provide	VERB	VBZ	5	O
a	a	DET	DT	5	O
reliable	reliable	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
simple	simple	ADJ	JJ	5	O
experimental	experimental	ADJ	JJ	5	O
animal	animal	NOUN	NN	5	O
model	model	NOUN	NN	5	O
of	of	ADP	IN	5	O
coniine	coniine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
arthrogryposis	arthrogryposis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Data	datum	NOUN	NNS	5	O
from	from	ADP	IN	9	O
this	this	DET	DT	5	O
model	model	NOUN	NN	5	O
support	support	NOUN	NN	5	O
a	a	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
involving	involve	VERB	VBG	5	O
nicotinic	nicotinic	ADJ	JJ	0	O
receptor	receptor	NOUN	NN	3	O
blockade	blockade	NOUN	NN	3	O
with	with	ADP	IN	5	O
subsequent	subsequent	ADJ	JJ	9	O
decreased	decrease	VERB	VBN	9	O
fetal	fetal	ADJ	JJ	9	O
movement	movement	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Immediate	immediate	ADJ	JJ	5	O
allergic	allergic	ADJ	JJ	9	B-Disease
reactions	reaction	NOUN	NNS	9	I-Disease
to	to	PART	TO	5	O
amoxicillin	amoxicillin	VERB	VB	0	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
large	large	ADJ	JJ	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
suspected	suspect	VERB	VBN	5	O
allergic	allergic	ADJ	JJ	9	B-Disease
reactions	reaction	NOUN	NNS	9	I-Disease
to	to	ADP	IN	5	O
beta	beta	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
lactam	lactam	NOUN	NN	0	I-Chemical
antibiotics	antibiotic	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
detailed	detailed	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
history	history	NOUN	NN	5	O
,	,	PUNCT	,	9	O
together	together	ADV	RB	9	O
with	with	ADP	IN	5	O
skin	skin	NOUN	NN	5	O
tests	test	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
RAST	RAST	PROPN	NNP	5	O
(	(	PUNCT	-LRB-	9	O
radioallergosorbent	radioallergosorbent	NOUN	NN	0	O
test	test	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
controlled	control	VERB	VBN	5	O
challenge	challenge	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
establish	establish	VERB	VB	5	O
whether	whether	ADP	IN	9	O
patients	patient	NOUN	NNS	5	O
allergic	allergic	ADJ	JJ	9	B-Disease
to	to	ADP	IN	5	O
beta	beta	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
lactam	lactam	NOUN	NN	0	I-Chemical
antibiotics	antibiotic	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
selective	selective	ADJ	JJ	9	O
immediate	immediate	ADJ	JJ	5	O
allergic	allergic	NOUN	NN	9	B-Disease
responses	response	NOUN	NNS	5	O
to	to	PART	TO	5	O
amoxicillin	amoxicillin	VERB	VB	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
AX	AX	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
cross	cross	ADJ	JJ	5	O
-	-	ADJ	JJ	7	O
reacting	react	VERB	VBG	0	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
penicillin	penicillin	NOUN	NN	0	B-Chemical
derivatives	derivative	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Skin	skin	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
with	with	ADP	IN	5	O
benzylpenicilloyl	benzylpenicilloyl	ADJ	JJ	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
poly	poly	ADJ	JJ	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
L	l	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
lysine	lysine	PROPN	NNP	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
BPO	BPO	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
PLL	PLL	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
benzylpenicilloate	benzylpenicilloate	NOUN	NN	_	B-Chemical
,	,	PUNCT	,	9	O
benzylpenicillin	benzylpenicillin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
PG	PG	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
ampicillin	ampicillin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
AMP	AMP	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
AX	ax	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

RAST	RAST	VERB	VBN	5	O
for	for	ADP	IN	5	O
BPO	BPO	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
PLL	PLL	PROPN	NNP	0	I-Chemical
and	and	CCONJ	CC	5	O
AX	AX	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	O
PLL	PLL	PROPN	NNP	0	O
was	be	VERB	VBD	9	O
done	do	VERB	VBN	9	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
both	both	DET	DT	9	O
skin	skin	NOUN	NN	5	O
test	test	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
RAST	RAST	PROPN	NNP	5	O
for	for	ADP	IN	5	O
BPO	BPO	PROPN	NNP	0	B-Chemical
were	be	VERB	VBD	9	O
negative	negative	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
challenge	challenge	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
done	do	VERB	VBN	9	O
to	to	PART	TO	5	O
ensure	ensure	VERB	VB	5	O
tolerance	tolerance	NOUN	NN	9	O
of	of	ADP	IN	5	O
PG	PG	PROPN	NNP	9	B-Chemical
or	or	CCONJ	CC	5	O
sensitivity	sensitivity	NOUN	NN	9	O
to	to	ADP	IN	5	O
AX	AX	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
177	177	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
diagnosed	diagnose	VERB	VBN	5	O
as	as	ADP	IN	5	O
allergic	allergic	ADJ	JJ	9	B-Disease
to	to	ADP	IN	5	O
beta	beta	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
lactam	lactam	NOUN	NN	0	I-Chemical
antibiotics	antibiotic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
selected	select	VERB	VBD	9	O
the	the	DET	DT	5	O
54	54	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
30	30	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
immediate	immediate	ADJ	JJ	5	O
AX	ax	NOUN	NN	9	B-Chemical
allergy	allergy	NOUN	NN	9	B-Disease
with	with	ADP	IN	5	O
good	good	ADJ	JJ	5	O
tolerance	tolerance	NOUN	NN	9	O
of	of	ADP	IN	5	O
PG	PG	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

Anaphylaxis	Anaphylaxis	PROPN	NNP	5	B-Disease
was	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
37	37	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
69	69	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
17	17	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
31	31	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
having	have	VERB	VBG	5	O
urticaria	urticaria	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
angioedema	angioedema	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

All	all	DET	PDT	9	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
skin	skin	NOUN	NN	5	O
test	test	NOUN	NN	5	O
negative	negative	ADJ	JJ	9	O
to	to	ADP	IN	5	O
BPO	BPO	PROPN	NNP	0	B-Chemical
;	;	PUNCT	:	9	O
49	49	NUM	CD	7	O
of	of	ADP	IN	5	O
51	51	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
96	96	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
negative	negative	ADJ	JJ	9	O
to	to	ADP	IN	5	O
MDM	MDM	PROPN	NNP	3	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
44	44	NUM	CD	7	O
of	of	ADP	IN	5	O
46	46	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
96	96	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
PG	PG	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

Skin	skin	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
with	with	ADP	IN	5	O
AX	AX	PROPN	NNP	9	B-Chemical
were	be	VERB	VBD	9	O
positive	positive	ADJ	JJ	9	O
in	in	ADP	IN	5	O
34	34	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
63	63	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

RAST	RAST	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
positive	positive	ADJ	JJ	9	O
for	for	ADP	IN	5	O
AX	ax	NOUN	NN	9	B-Chemical
in	in	ADP	IN	5	O
22	22	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
41	41	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
to	to	ADP	IN	5	O
BPO	BPO	PROPN	NNP	0	B-Chemical
in	in	ADP	IN	5	O
just	just	ADV	RB	5	O
5	5	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

None	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
sera	sera	NOUN	NN	3	O
with	with	ADP	IN	5	O
negative	negative	ADJ	JJ	9	O
RAST	RAST	PROPN	NNP	5	O
for	for	ADP	IN	5	O
AX	AX	PROPN	NNP	9	B-Chemical
were	be	VERB	VBD	9	O
positive	positive	ADJ	JJ	9	O
to	to	ADP	IN	5	O
BPO	BPO	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Challenge	challenge	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
with	with	ADP	IN	5	O
AX	AX	PROPN	NNP	9	B-Chemical
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
in	in	ADP	IN	5	O
23	23	NUM	CD	7	O
subjects	subject	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
43	43	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
to	to	PART	TO	5	O
establish	establish	VERB	VB	5	O
the	the	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
immediate	immediate	ADJ	JJ	5	O
allergic	allergic	ADJ	JJ	9	B-Disease
reaction	reaction	NOUN	NN	9	I-Disease
to	to	ADP	IN	5	O
AX	AX	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
15	15	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
28	28	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
both	both	DET	DT	9	O
skin	skin	NOUN	NN	5	O
test	test	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
RAST	RAST	PROPN	NNP	5	O
for	for	ADP	IN	5	O
AX	AX	PROPN	NNP	9	B-Chemical
were	be	VERB	VBD	9	O
negative	negative	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

PG	PG	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
by	by	ADP	IN	9	O
all	all	DET	DT	5	O
54	54	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
the	the	DET	DT	5	O
largest	large	ADJ	JJS	5	O
group	group	NOUN	NN	9	O
of	of	ADP	IN	5	O
AX	ax	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
allergic	allergic	ADJ	JJ	9	B-Disease
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
have	have	VERB	VBP	5	O
tolerated	tolerate	VERB	VBN	9	O
PG	PG	PROPN	NNP	9	B-Chemical
reported	report	VERB	VBN	9	O
so	so	ADV	RB	5	O
far	far	ADV	RB	5	O
.	.	PUNCT	.	9	O

Diagnosis	diagnosis	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
achieved	achieve	VERB	VBN	5	O
only	only	ADV	RB	9	O
if	if	ADP	IN	5	O
specific	specific	ADJ	JJ	9	O
AX	ax	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
reagents	reagent	NOUN	NNS	0	O
are	be	VERB	VBP	5	O
employed	employ	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Further	further	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
necessary	necessary	ADJ	JJ	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
exact	exact	ADJ	JJ	5	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
problem	problem	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
improve	improve	VERB	VB	5	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
of	of	ADP	IN	5	O
diagnostic	diagnostic	ADJ	JJ	5	O
methods	method	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Reversal	reversal	NOUN	NN	9	O
by	by	ADP	IN	9	O
phenylephrine	phenylephrine	NOUN	NN	0	B-Chemical
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
beneficial	beneficial	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
nitroglycerin	nitroglycerin	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
myocardial	myocardial	ADJ	JJ	9	I-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Nitroglycerin	Nitroglycerin	PROPN	NNP	0	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
reduce	reduce	VERB	VB	5	O
ST	st	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
segment	segment	NOUN	NN	9	O
elevation	elevation	NOUN	NN	9	O
during	during	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
myocardial	myocardial	ADJ	JJ	9	I-Disease
infarction	infarction	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
effect	effect	NOUN	NN	9	O
potentiated	potentiate	VERB	VBN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
dog	dog	NOUN	NN	5	O
by	by	ADP	IN	9	O
agents	agent	NOUN	NNS	5	O
that	that	DET	WDT	5	O
reverse	reverse	VERB	VBP	9	O
nitroglycerin	nitroglycerin	ADV	RB	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
combined	combine	VERB	VBN	9	O
nitroglycerin	nitroglycerin	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
phenylephrine	phenylephrine	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Ten	ten	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
transmural	transmural	ADJ	JJ	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarctions	infarction	NOUN	NNS	5	I-Disease
received	receive	VERB	VBD	9	O
intravenous	intravenous	ADJ	JJ	0	O
nitroglycerin	nitroglycerin	ADV	RB	5	B-Chemical
,	,	PUNCT	,	9	O
sufficient	sufficient	ADJ	JJ	9	O
to	to	PART	TO	5	O
reduce	reduce	VERB	VB	5	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
from	from	ADP	IN	9	O
107	107	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
to	to	PART	TO	5	O
85	85	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
6	6	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
Hg	Hg	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
60	60	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Left	leave	VERB	VBN	9	O
ventricular	ventricular	ADJ	JJ	5	O
filling	filling	NOUN	NN	5	O
pressure	pressure	NOUN	NN	5	O
decreased	decrease	VERB	VBD	9	O
from	from	ADP	IN	9	O
19	19	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
to	to	ADP	IN	5	O
11	11	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
Hg	Hg	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

SigmaST	SigmaST	PROPN	NNP	_	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
sum	sum	NOUN	NN	5	O
of	of	ADP	IN	5	O
ST	ST	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
segment	segment	NOUN	NN	9	O
elevations	elevation	NOUN	NNS	9	O
in	in	ADP	IN	5	O
16	16	NUM	CD	9	O
precordial	precordial	NOUN	NN	5	O
leads	lead	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
decreased	decrease	VERB	VBD	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
intravenous	intravenous	ADJ	JJ	0	O
nitroglycerin	nitroglycerin	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Subsequent	subsequent	ADJ	JJ	9	O
addition	addition	NOUN	NN	9	O
of	of	ADP	IN	5	O
phenylephrine	phenylephrine	NOUN	NN	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
,	,	PUNCT	,	9	O
sufficient	sufficient	ADJ	JJ	9	O
to	to	PART	TO	5	O
re	re	VERB	VB	5	O
-	-	VERB	VB	7	O
elevate	elevate	ADJ	JJ	9	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
to	to	ADP	IN	5	O
106	106	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
4	4	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
Hg	Hg	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
30	30	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
increased	increase	VERB	VBD	9	O
left	leave	VERB	VBN	5	O
ventricular	ventricular	ADJ	JJ	5	O
filling	fill	VERB	VBG	5	O
pressure	pressure	NOUN	NN	5	O
to	to	ADP	IN	5	O
17	17	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
mm	mm	NOUN	NN	9	O
Hg	Hg	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
also	also	ADV	RB	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
sigmaST	sigmaST	PROPN	NNP	_	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
addition	addition	NOUN	NN	9	O
of	of	ADP	IN	5	O
phenylephrine	phenylephrine	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
nitroglycerin	nitroglycerin	NOUN	NN	5	B-Chemical
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
beneficial	beneficial	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
acute	acute	ADJ	JJ	9	B-Disease
myocardial	myocardial	ADJ	JJ	9	I-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Acetazolamide	acetazolamide	ADV	RB	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrolithiasis	nephrolithiasis	NOUN	NN	5	B-Disease
:	:	PUNCT	:	9	O
implications	implication	NOUN	NNS	5	O
for	for	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
neuromuscular	neuromuscular	ADJ	JJ	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Carbonic	carbonic	ADJ	JJ	7	O
anhydrase	anhydrase	NOUN	NN	0	O
inhibitors	inhibitor	NOUN	NNS	3	O
can	can	VERB	MD	5	O
cause	cause	VERB	VB	5	O
nephrolithiasis	nephrolithiasis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
studied	study	VERB	VBD	9	O
20	20	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
carbonic	carbonic	ADJ	JJ	0	O
anhydrase	anhydrase	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
periodic	periodic	ADJ	JJ	5	O
paralysis	paralysis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
myotonia	myotonia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
on	on	ADP	IN	5	O
acetazolamide	acetazolamide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
developed	develop	VERB	VBN	5	O
renal	renal	ADJ	JJ	9	B-Disease
calculi	calculi	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Extracorporeal	extracorporeal	ADJ	JJ	5	O
lithotripsy	lithotripsy	NOUN	NN	5	O
successfully	successfully	ADV	RB	5	O
removed	remove	VERB	VBD	9	O
a	a	DET	DT	5	O
renal	renal	ADJ	JJ	9	B-Disease
calculus	calculus	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
surgery	surgery	NOUN	NN	5	O
removed	remove	VERB	VBD	9	O
a	a	DET	DT	5	O
staghorn	staghorn	ADJ	JJ	5	O
calculus	calculus	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
another	another	DET	DT	9	O
,	,	PUNCT	,	9	O
permitting	permit	VERB	VBG	5	O
continued	continued	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
remained	remain	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Nephrolithiasis	nephrolithiasis	NOUN	NN	7	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
complication	complication	NOUN	NN	5	O
of	of	ADP	IN	5	O
acetazolamide	acetazolamide	ADV	RB	0	B-Chemical
but	but	CCONJ	CC	9	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
preclude	preclude	VERB	VB	5	O
its	-PRON-	DET	PRP$	9	O
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blockers	blocker	NOUN	NNS	9	O
on	on	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blockers	blocker	NOUN	NNS	9	O
on	on	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
each	each	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
three	three	NUM	CD	9	O
tested	test	VERB	VBN	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blockers	blocker	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
diltiazem	diltiazem	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
bepridil	bepridil	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
6	6	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
by	by	ADP	IN	9	O
two	two	NUM	CD	5	O
different	different	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
e	e	PUNCT	LS	9	O
.	.	NOUN	NN	9	O
2	2	NUM	CD	9	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
an	an	DET	DT	5	O
equal	equal	ADJ	JJ	9	O
volume	volume	NOUN	NN	9	O
of	of	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
20	20	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
15	15	NUM	CD	9	O
minutes	minute	NOUN	NNS	0	O
later	later	ADV	RB	9	O
,	,	PUNCT	,	9	O
all	all	DET	PDT	5	O
the	the	DET	DT	5	O
animals	animal	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
injected	inject	VERB	VBN	3	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
convulsant	convulsant	ADJ	JJ	0	O
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
latency	latency	NOUN	NN	5	O
to	to	ADP	IN	5	O
convulse	convulse	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
mortality	mortality	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
in	in	ADP	IN	5	O
each	each	DET	DT	5	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
local	local	ADJ	JJ	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
mortality	mortality	NOUN	NN	5	O
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
three	three	NUM	CD	9	O
different	different	ADJ	JJ	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blockers	blocker	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
convulsant	convulsant	ADJ	JJ	0	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
modified	modify	VERB	VBN	9	O
but	but	CCONJ	CC	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blockers	blocker	NOUN	NNS	9	O
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
latency	latency	NOUN	NN	5	O
to	to	PART	TO	5	O
obtain	obtain	VERB	VB	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
convulsions	convulsion	NOUN	NNS	5	B-Disease
;	;	PUNCT	:	9	O
this	this	DET	DT	5	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
less	less	ADV	RBR	5	O
pronounced	pronounce	VERB	VBN	9	O
with	with	ADP	IN	5	O
bepridil	bepridil	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Epidural	epidural	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
during	during	ADP	IN	5	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
E1	E1	PROPN	NNP	9	I-Chemical
or	or	CCONJ	CC	5	O
trimethaphan	trimethaphan	ADP	IN	9	B-Chemical
induced	induced	ADJ	JJ	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
E1	E1	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
PGE1	PGE1	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
trimethaphan	trimethaphan	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
TMP	TMP	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
induced	induce	VERB	VBD	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
epidural	epidural	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
flow	flow	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
EBF	EBF	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
during	during	ADP	IN	5	O
spinal	spinal	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
,	,	PUNCT	,	9	O
EBF	EBF	PROPN	NNP	5	O
was	be	VERB	VBD	9	O
measured	measure	VERB	VBN	9	O
using	use	VERB	VBG	9	O
the	the	DET	DT	5	O
heat	heat	NOUN	NN	9	O
clearance	clearance	NOUN	NN	9	O
method	method	NOUN	NN	5	O
in	in	ADP	IN	5	O
30	30	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
underwent	undergo	VERB	VBD	5	O
postero	postero	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
lateral	lateral	ADJ	JJ	5	O
interbody	interbody	ADJ	JJ	5	O
fusion	fusion	NOUN	NN	1	O
under	under	ADP	IN	9	O
isoflurane	isoflurane	NOUN	NN	0	B-Chemical
anaesthesia	anaesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
initial	initial	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
microgram	microgram	NOUN	NN	0	O
.	.	PUNCT	.	9	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
min	min	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
of	of	ADP	IN	5	O
PGE1	PGE1	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
10	10	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
.	.	PUNCT	.	9	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
min	min	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
of	of	ADP	IN	5	O
TMP	TMP	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
15	15	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
intravenously	intravenously	ADV	RB	0	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
dural	dural	ADJ	JJ	5	O
opening	opening	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
was	be	VERB	VBD	9	O
adjusted	adjust	VERB	VBN	9	O
to	to	PART	TO	5	O
maintain	maintain	VERB	VB	5	O
the	the	DET	DT	5	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
MAP	MAP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
about	about	ADV	RB	5	O
60	60	NUM	CD	9	O
mmHg	mmHg	NOUN	NNS	7	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
drug	drug	NOUN	NN	5	O
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
completion	completion	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
operative	operative	ADJ	JJ	5	O
procedure	procedure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
starting	start	VERB	VBG	9	O
PGE1	PGE1	PROPN	NNP	0	B-Chemical
or	or	CCONJ	CC	5	O
TMP	TMP	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
MAP	MAP	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
rate	rate	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
product	product	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
RPP	RPP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
decreased	decrease	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
preinfusion	preinfusion	NOUN	NN	0	O
values	value	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
PGE1	PGE1	PROPN	NNP	0	B-Chemical
remained	remain	VERB	VBD	9	O
constant	constant	ADJ	JJ	9	O
until	until	ADP	IN	5	O
60	60	NUM	CD	9	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
discontinuation	discontinuation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Heart	heart	NOUN	NN	2	O
rate	rate	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
HR	hr	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
change	change	VERB	VB	9	O
in	in	ADP	IN	5	O
either	either	DET	DT	9	O
group	group	NOUN	NN	9	O
.	.	PUNCT	.	9	O

EBFF	EBFF	PROPN	NNP	_	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
change	change	VERB	VB	9	O
during	during	ADP	IN	5	O
PGE1	PGE1	PROPN	NNP	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
whereas	whereas	ADP	IN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
TMP	TMP	PROPN	NNP	0	B-Chemical
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
EBF	EBF	PROPN	NNP	5	O
decreased	decrease	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
at	at	ADP	IN	9	O
30	30	NUM	CD	9	O
and	and	CCONJ	CC	5	O
60	60	NUM	CD	9	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
start	start	NOUN	NN	9	O
of	of	ADP	IN	5	O
TMP	TMP	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
preinfusion	preinfusion	NOUN	NN	0	O
:	:	PUNCT	:	9	O
45	45	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
ml	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
100g	100g	PROPN	NNP	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O
30	30	NUM	CD	9	O
min	min	NOUN	NN	0	O
:	:	PUNCT	:	9	O
32	32	NUM	CD	7	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
9	9	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
ml	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
100	100	NUM	CD	0	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O
60	60	NUM	CD	9	O
min	min	NOUN	NN	0	O
:	:	PUNCT	:	9	O
30	30	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
ml	ml	NOUN	NN	0	O
/	/	SYM	SYM	9	O
100	100	NUM	CD	0	O
g	g	NOUN	NN	0	O
/	/	SYM	SYM	9	O
min	min	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
PGE1	PGE1	PROPN	NNP	0	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
preferable	preferable	ADJ	JJ	5	O
to	to	ADP	IN	5	O
TMP	TMP	PROPN	NNP	0	B-Chemical
for	for	ADP	IN	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
anaesthesia	anaesthesia	NOUN	NN	5	O
in	in	ADP	IN	5	O
spinal	spinal	ADJ	JJ	5	O
surgery	surgery	NOUN	NN	5	O
because	because	ADP	IN	5	O
TMP	TMP	PROPN	NNP	0	B-Chemical
decreased	decrease	VERB	VBD	9	O
EBF	EBF	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

Dup	Dup	PROPN	NNP	7	B-Chemical
753	753	NUM	CD	7	I-Chemical
prevents	prevent	VERB	VBZ	9	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
puromycin	puromycin	ADJ	JJ	3	B-Chemical
aminonucleoside	aminonucleoside	ADP	IN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrosis	nephrosis	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
appearance	appearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
nephrotic	nephrotic	ADJ	JJ	5	B-Disease
syndromes	syndrome	NOUN	NNS	5	I-Disease
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
proteinuria	proteinuria	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
hypoalbuminemia	hypoalbuminemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
hypercholesterolemia	hypercholesterolemia	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
increase	increase	VERB	VB	9	O
in	in	ADP	IN	5	O
blood	blood	NOUN	NN	9	B-Chemical
nitrogen	nitrogen	NOUN	NN	0	I-Chemical
urea	urea	ADJ	JJ	0	I-Chemical
,	,	PUNCT	,	9	O
induced	induce	VERB	VBN	3	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
by	by	ADP	IN	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
puromycin	puromycin	NOUN	NN	3	B-Chemical
aminonucleoside	aminonucleoside	ADV	RB	0	I-Chemical
was	be	VERB	VBD	9	O
markedly	markedly	ADV	RB	9	O
inhibited	inhibit	VERB	VBN	3	O
by	by	ADP	IN	9	O
oral	oral	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
Dup	Dup	PROPN	NNP	7	B-Chemical
753	753	NUM	CD	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
losartan	losartan	ADJ	JJ	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
novel	novel	NOUN	NN	9	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
II	II	PROPN	NNP	9	I-Chemical
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
,	,	PUNCT	,	9	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
or	or	CCONJ	CC	5	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
per	per	ADP	IN	9	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
a	a	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
involvement	involvement	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
renin	renin	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
angiotensin	angiotensin	NOUN	NN	9	B-Chemical
system	system	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
puromycin	puromycin	ADJ	JJ	3	B-Chemical
aminonucleoside	aminonucleoside	ADP	IN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
nephrosis	nephrosis	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

Neuroplasticity	neuroplasticity	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
adult	adult	NOUN	NN	9	O
primate	primate	NOUN	NN	9	O
auditory	auditory	NOUN	NN	5	O
cortex	cortex	NOUN	NN	5	O
following	follow	VERB	VBG	9	O
cochlear	cochlear	NOUN	NN	5	O
hearing	hearing	NOUN	NN	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Tonotopic	tonotopic	ADJ	JJ	5	O
organization	organization	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
essential	essential	ADJ	JJ	9	O
feature	feature	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
primary	primary	ADJ	JJ	9	O
auditory	auditory	NOUN	NN	5	O
area	area	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
A1	A1	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
primate	primate	ADJ	JJ	9	O
cortex	cortex	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
A1	A1	PROPN	NNP	9	O
of	of	ADP	IN	5	O
macaque	macaque	NOUN	NN	9	O
monkeys	monkey	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
low	low	ADJ	JJ	9	O
frequencies	frequency	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
represented	represent	VERB	VBN	9	O
rostrolaterally	rostrolaterally	ADV	RB	5	O
and	and	CCONJ	CC	5	O
high	high	ADJ	JJ	9	O
frequencies	frequency	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
represented	represent	VERB	VBN	9	O
caudomedially	caudomedially	ADV	RB	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
purpose	purpose	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
if	if	ADP	IN	5	O
changes	change	NOUN	NNS	9	O
occur	occur	VERB	VBP	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
tonotopic	tonotopic	ADJ	JJ	5	O
organization	organization	NOUN	NN	5	O
following	follow	VERB	VBG	9	O
cochlear	cochlear	NOUN	NN	5	O
hearing	hearing	NOUN	NN	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Under	under	ADP	IN	9	O
anesthesia	anesthesia	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
superior	superior	ADJ	JJ	5	O
temporal	temporal	ADJ	JJ	5	O
gyrus	gyrus	NOUN	NN	5	O
of	of	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
macaque	macaque	NOUN	NN	9	O
monkeys	monkey	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
exposed	expose	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
tonotopic	tonotopic	ADJ	JJ	5	O
organization	organization	NOUN	NN	5	O
of	of	ADP	IN	5	O
A1	A1	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
mapped	map	VERB	VBN	9	O
using	use	VERB	VBG	9	O
conventional	conventional	ADJ	JJ	5	O
microelectrode	microelectrode	NOUN	NN	5	O
recording	recording	NOUN	NN	5	O
techniques	technique	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Following	follow	VERB	VBG	9	O
recovery	recovery	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
monkeys	monkey	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
selectively	selectively	ADV	RB	3	O
deafened	deafen	VERB	VBN	5	O
for	for	ADP	IN	5	O
high	high	ADJ	JJ	9	O
frequencies	frequency	NOUN	NNS	9	O
using	use	VERB	VBG	9	O
kanamycin	kanamycin	NOUN	NN	1	B-Chemical
and	and	CCONJ	CC	5	O
furosemide	furosemide	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
actual	actual	ADJ	JJ	5	O
frequencies	frequency	NOUN	NNS	9	O
deafened	deafen	VERB	VBD	5	O
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
loss	loss	NOUN	NN	9	O
of	of	ADP	IN	5	O
tone	tone	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
burst	burst	NOUN	NN	5	O
elicited	elicit	VERB	VBN	9	O
auditory	auditory	NOUN	NN	5	O
brainstem	brainstem	NOUN	NN	5	O
responses	response	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
deafening	deafen	VERB	VBG	5	O
,	,	PUNCT	,	9	O
A1	A1	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
remapped	remappe	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Postmortem	postmortem	VERB	VB	5	O
cytoarchitectural	cytoarchitectural	ADJ	JJ	5	O
features	feature	NOUN	NNS	5	O
identifying	identify	VERB	VBG	5	O
A1	A1	PROPN	NNP	9	O
were	be	VERB	VBD	9	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
electrophysiologic	electrophysiologic	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
deprived	deprived	ADJ	JJ	9	O
area	area	NOUN	NN	5	O
of	of	ADP	IN	5	O
A1	A1	PROPN	NNP	9	O
undergoes	undergoe	NOUN	NNS	9	O
extensive	extensive	ADJ	JJ	5	O
reorganization	reorganization	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
becomes	become	VERB	VBZ	5	O
responsive	responsive	ADJ	JJ	9	O
to	to	ADP	IN	5	O
intact	intact	ADJ	JJ	9	O
cochlear	cochlear	ADJ	JJ	5	O
frequencies	frequency	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
region	region	NOUN	NN	9	O
of	of	ADP	IN	5	O
cortex	cortex	NOUN	NN	5	O
that	that	DET	WDT	5	O
represents	represent	VERB	VBZ	9	O
the	the	DET	DT	5	O
low	low	ADJ	JJ	9	O
frequencies	frequency	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
obviously	obviously	ADV	RB	9	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
cochlear	cochlear	NOUN	NN	5	O
hearing	hearing	NOUN	NN	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Sodium	sodium	NOUN	NN	0	B-Chemical
bicarbonate	bicarbonate	NOUN	NN	0	I-Chemical
alleviates	alleviate	NOUN	NNS	9	O
penile	penile	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
intracavernous	intracavernous	ADJ	JJ	5	O
injections	injection	NOUN	NNS	9	O
for	for	ADP	IN	5	O
erectile	erectile	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
an	an	DET	DT	5	O
attempt	attempt	NOUN	NN	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
whether	whether	ADP	IN	9	O
penile	penile	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
intracorporeal	intracorporeal	ADJ	JJ	5	O
injections	injection	NOUN	NNS	9	O
could	could	VERB	MD	9	O
be	be	VERB	VB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
acidity	acidity	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
medication	medication	NOUN	NN	5	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
performed	perform	VERB	VBD	9	O
a	a	DET	DT	5	O
randomized	randomize	VERB	VBN	5	O
study	study	NOUN	NN	9	O
comparing	compare	VERB	VBG	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
penile	penile	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
following	follow	VERB	VBG	9	O
intracorporeal	intracorporeal	ADJ	JJ	5	O
injections	injection	NOUN	NNS	9	O
with	with	ADP	IN	5	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
the	the	DET	DT	5	O
addition	addition	NOUN	NN	9	O
of	of	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
bicarbonate	bicarbonate	NOUN	NN	0	I-Chemical
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
intracorporeal	intracorporeal	ADJ	JJ	5	O
medications	medication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
total	total	NOUN	NN	9	O
of	of	ADP	IN	5	O
38	38	NUM	CD	7	O
consecutive	consecutive	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
presented	present	VERB	VBD	5	O
to	to	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
clinic	clinic	NOUN	NN	5	O
with	with	ADP	IN	5	O
impotence	impotence	NOUN	NN	5	B-Disease
received	receive	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
ml	ml	NOUN	NN	0	O
.	.	PUNCT	.	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	O
drugs	drug	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
6	6	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
papaverine	papaverine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
100	100	NUM	CD	0	O
micrograms	microgram	NOUN	NNS	0	O
.	.	PUNCT	.	9	O
phentolamine	phentolamine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
.	.	PUNCT	.	9	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
E1	E1	PROPN	NNP	9	I-Chemical
with	with	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
pH	pH	PROPN	NNP	0	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
without	without	ADP	IN	9	O
(	(	PUNCT	-LRB-	9	O
pH	ph	X	XX	0	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
17	17	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
the	the	DET	DT	5	O
addition	addition	NOUN	NN	9	O
of	of	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
bicarbonate	bicarbonate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
mEq	meq	NOUN	NN	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
19	19	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
without	without	ADP	IN	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
bicarbonate	bicarbonate	NOUN	NN	0	I-Chemical
added	add	VERB	VBN	0	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
medication	medication	NOUN	NN	5	O
11	11	NUM	CD	7	O
(	(	PUNCT	-LRB-	9	O
58	58	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
complained	complain	VERB	VBD	5	O
of	of	ADP	IN	5	O
penile	penile	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
due	due	ADP	IN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
medication	medication	NOUN	NN	5	O
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
only	only	ADV	RB	9	O
1	1	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
19	19	NUM	CD	7	O
men	man	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
sodium	sodium	NOUN	NN	0	B-Chemical
bicarbonate	bicarbonate	NOUN	NN	0	I-Chemical
complained	complain	VERB	VBD	5	O
of	of	ADP	IN	5	O
penile	penile	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

From	from	ADP	IN	5	O
these	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
we	-PRON-	PRON	PRP	5	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
penile	penile	NOUN	NN	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
following	follow	VERB	VBG	9	O
intracorporeal	intracorporeal	ADJ	JJ	5	O
injections	injection	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
most	most	ADV	RBS	9	O
likely	likely	ADV	RB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
acidity	acidity	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
medication	medication	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
overcome	overcome	VERB	VBN	5	O
by	by	ADP	IN	9	O
elevating	elevate	VERB	VBG	9	O
the	the	DET	DT	5	O
pH	pH	NOUN	NNS	0	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
neutral	neutral	ADJ	JJ	5	O
level	level	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
use	use	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
didanosine	didanosine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
ddI	ddI	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
HIV	HIV	PROPN	NNP	5	B-Disease
antibody	antibody	NOUN	NN	3	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
positive	positive	ADJ	JJ	9	I-Disease
individuals	individual	NOUN	NNS	5	O
intolerant	intolerant	ADJ	JJ	9	O
to	to	ADP	IN	5	O
zidovudine	zidovudine	PROPN	NNP	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
AZT	AZT	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O

One	one	NUM	CD	5	O
hundred	hundred	NUM	CD	5	O
and	and	CCONJ	CC	5	O
fifty	fifty	NUM	CD	5	O
-	-	PUNCT	HYPH	7	O
one	one	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
intolerant	intolerant	ADJ	JJ	9	O
to	to	ADP	IN	5	O
zidovudine	zidovudine	PROPN	NNP	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
AZT	AZT	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
received	receive	VERB	VBD	9	O
didanosine	didanosine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
ddI	ddI	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
maximum	maximum	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Patient	patient	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
using	use	VERB	VBG	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
CD4	CD4	PROPN	NNP	3	O
+	+	CCONJ	CC	9	O
lymphocyte	lymphocyte	NOUN	NN	3	O
subset	subset	NOUN	NN	9	O
count	count	NOUN	NN	9	O
,	,	PUNCT	,	9	O
HIV	HIV	PROPN	NNP	5	O
p24	p24	DET	DT	3	O
antigen	antigen	NOUN	NN	3	O
,	,	PUNCT	,	9	O
weight	weight	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
quality	quality	NOUN	NN	5	O
of	of	ADP	IN	5	O
life	life	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Seventy	seventy	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
major	major	ADJ	JJ	9	O
opportunistic	opportunistic	ADJ	JJ	5	B-Disease
infections	infection	NOUN	NNS	5	I-Disease
whilst	whilst	ADP	IN	9	O
on	on	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
;	;	PUNCT	:	9	O
this	this	DET	DT	5	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
AIDS	AIDS	PROPN	NNP	5	B-Disease
diagnosis	diagnosis	NOUN	NN	5	O
in	in	ADP	IN	5	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O

Only	only	ADJ	JJ	9	O
minor	minor	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
CD4	CD4	PROPN	NNP	3	O
+	+	CCONJ	CC	9	O
lymphocyte	lymphocyte	NOUN	NN	3	O
subset	subset	NOUN	NN	9	O
count	count	NOUN	NN	9	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
AIDS	AIDS	PROPN	NNP	5	B-Disease
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
a	a	DET	DT	5	O
more	more	ADV	RBR	5	O
significant	significant	ADJ	JJ	9	O
rise	rise	NOUN	NN	9	O
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
those	those	DET	DT	5	O
with	with	ADP	IN	5	O
earlier	early	ADJ	JJR	9	O
stages	stage	NOUN	NNS	9	O
of	of	ADP	IN	5	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
those	those	DET	DT	5	O
positive	positive	ADJ	JJ	9	O
for	for	ADP	IN	5	O
p24	p24	NOUN	NN	3	O
antigen	antigen	NOUN	NN	3	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
commencement	commencement	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
67	67	NUM	CD	7	O
%	%	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
positive	positive	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
this	this	DET	DT	5	O
was	be	VERB	VBD	9	O
most	most	ADV	RBS	9	O
likely	likely	ADJ	JJ	5	O
in	in	ADP	IN	5	O
those	those	DET	DT	5	O
with	with	ADP	IN	5	O
CD4	CD4	PROPN	NNP	3	O
+	+	CCONJ	CC	9	O
lymphocyte	lymphocyte	X	FW	3	O
subset	subset	NOUN	NN	9	O
counts	count	VERB	VBZ	9	O
above	above	ADP	IN	9	O
100	100	NUM	CD	0	O
mm3	mm3	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
positive	positive	ADJ	JJ	9	O
weight	weight	NOUN	NN	9	O
response	response	NOUN	NN	9	O
was	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
16	16	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Most	Most	ADJ	JJS	5	O
patients	patient	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
individual	individual	ADJ	JJ	5	O
parameters	parameter	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
global	global	ADJ	JJ	5	O
score	score	NOUN	NN	5	O
of	of	ADP	IN	5	O
quality	quality	NOUN	NN	5	O
of	of	ADP	IN	5	O
life	life	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
possibly	possibly	ADV	RB	9	O
attributable	attributable	ADJ	JJ	9	O
to	to	PART	TO	5	O
didanosine	didanosine	VERB	VB	0	B-Chemical
were	be	VERB	VBD	9	O
common	common	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
most	most	ADV	RBS	9	O
common	common	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effect	effect	NOUN	NN	9	O
was	be	VERB	VBD	9	O
diarrhoea	diarrhoea	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
cessation	cessation	NOUN	NN	5	O
of	of	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
19	19	NUM	CD	7	O
individuals	individual	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Peripheral	peripheral	ADJ	JJ	9	B-Disease
neuropathy	neuropathy	NOUN	NN	5	I-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
12	12	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
pancreatitis	pancreatitis	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
six	six	NUM	CD	9	O
.	.	PUNCT	.	9	O

Thirteen	thirteen	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
raised	raise	VERB	VBN	9	O
serum	serum	ADJ	JJ	9	O
amylase	amylase	NOUN	NN	9	O
without	without	ADP	IN	9	O
abdominal	abdominal	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Seven	seven	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
glucose	glucose	NOUN	NN	0	B-Disease
tolerance	tolerance	NOUN	NN	9	I-Disease
curves	curve	NOUN	NNS	5	I-Disease
characteristic	characteristic	ADJ	JJ	9	O
of	of	ADP	IN	5	O
diabetes	diabete	NOUN	NNS	5	B-Disease
but	but	CCONJ	CC	9	O
these	these	DET	DT	5	O
were	be	VERB	VBD	9	O
mild	mild	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
require	require	VERB	VB	5	O
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
on	on	ADP	IN	5	O
ceasing	ceasing	NOUN	NN	5	O
didanosine	didanosine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Immunohistochemical	immunohistochemical	ADJ	JJ	3	O
studies	study	NOUN	NNS	9	O
with	with	ADP	IN	5	O
antibodies	antibody	NOUN	NNS	3	O
to	to	ADP	IN	5	O
neurofilament	neurofilament	NOUN	NN	3	O
proteins	protein	NOUN	NNS	1	O
on	on	ADP	IN	5	O
axonal	axonal	ADJ	JJ	3	B-Disease
damage	damage	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
experimental	experimental	ADJ	JJ	5	O
focal	focal	ADJ	JJ	5	O
lesions	lesion	NOUN	NNS	5	O
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Immunohistochemistry	immunohistochemistry	NOUN	NN	3	O
with	with	ADP	IN	5	O
monoclonal	monoclonal	ADJ	JJ	3	O
antibodies	antibody	NOUN	NNS	3	O
against	against	ADP	IN	9	O
neurofilament	neurofilament	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
NF	NF	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
proteins	protein	NOUN	NNS	1	O
of	of	ADP	IN	5	O
middle	middle	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
high	high	ADJ	JJ	9	O
molecular	molecular	ADJ	JJ	9	O
weight	weight	NOUN	NN	9	O
class	class	NOUN	NN	9	O
,	,	PUNCT	,	9	O
NF	NF	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
M	M	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
NF	NF	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
H	H	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
study	study	VERB	VB	9	O
axonal	axonal	ADJ	JJ	3	B-Disease
injury	injury	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
borderzone	borderzone	NOUN	NN	5	O
of	of	ADP	IN	5	O
focal	focal	ADJ	JJ	5	O
lesions	lesion	NOUN	NNS	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Focal	focal	ADJ	JJ	9	O
injury	injury	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
the	the	DET	DT	5	I-Disease
cortex	cortex	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
lactate	lactate	NOUN	NN	0	B-Chemical
at	at	ADP	IN	9	O
acid	acid	NOUN	NN	0	O
pH	pH	NOUN	NNS	0	O
or	or	CCONJ	CC	5	O
by	by	ADP	IN	9	O
stab	stab	NOUN	NN	5	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
needle	needle	NOUN	NN	5	O
insertion	insertion	NOUN	NN	1	O
.	.	PUNCT	.	9	O

Infarcts	infarct	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	I-Disease
substantia	substantia	NOUN	NN	9	I-Disease
nigra	nigra	NOUN	NN	4	I-Disease
pars	par	NOUN	NNS	4	I-Disease
reticulata	reticulata	NOUN	NN	4	I-Disease
were	be	VERB	VBD	9	O
evoked	evoke	VERB	VBN	5	O
by	by	ADP	IN	9	O
prolonged	prolong	VERB	VBN	9	O
pilocarpine	pilocarpine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
status	status	NOUN	NN	9	B-Disease
epilepticus	epilepticus	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Immunohistochemical	immunohistochemical	ADJ	JJ	3	O
staining	staining	NOUN	NN	3	O
for	for	ADP	IN	5	O
NFs	nf	NOUN	NNS	3	O
showed	show	VERB	VBD	9	O
characteristic	characteristic	ADJ	JJ	9	O
terminal	terminal	NOUN	NN	9	O
clubs	club	NOUN	NNS	5	O
of	of	ADP	IN	5	O
axons	axon	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
borderzone	borderzone	NOUN	NN	5	O
of	of	ADP	IN	5	O
lesions	lesion	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
labelling	labelling	NOUN	NN	9	O
pattern	pattern	NOUN	NN	9	O
occurred	occur	VERB	VBD	9	O
with	with	ADP	IN	5	O
different	different	ADJ	JJ	9	O
antibodies	antibody	NOUN	NNS	3	O
which	which	DET	WDT	5	O
apparently	apparently	ADV	RB	9	O
depended	depend	VERB	VBD	9	O
on	on	ADP	IN	5	O
molecular	molecular	ADJ	JJ	9	O
weight	weight	NOUN	NN	9	O
class	class	NOUN	NN	9	O
of	of	ADP	IN	5	O
NFs	nf	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
phosphorylation	phosphorylation	NOUN	NN	3	O
state	state	NOUN	NN	5	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
immunohistochemical	immunohistochemical	ADJ	JJ	3	O
changes	change	NOUN	NNS	9	O
of	of	ADP	IN	5	O
NFs	nf	NOUN	NNS	3	O
can	can	VERB	MD	5	O
serve	serve	VERB	VB	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
marker	marker	NOUN	NN	3	O
for	for	ADP	IN	5	O
axonal	axonal	ADJ	JJ	3	B-Disease
damage	damage	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
various	various	ADJ	JJ	9	O
experimental	experimental	ADJ	JJ	5	O
traumatic	traumatic	ADJ	JJ	5	B-Disease
or	or	CCONJ	CC	5	O
ischemic	ischemic	ADJ	JJ	9	O
lesions	lesion	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Pharmacokinetic	pharmacokinetic	ADJ	JJ	0	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
mental	mental	ADJ	JJ	5	O
confusion	confusion	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

15	15	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
mental	mental	ADJ	JJ	5	O
confusion	confusion	NOUN	NN	5	B-Disease
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
order	order	NOUN	NN	5	O
that	that	ADP	IN	5	O
this	this	DET	DT	5	O
syndrome	syndrome	NOUN	NN	5	O
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
investigated	investigate	VERB	VBN	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
mental	mental	ADJ	JJ	5	O
status	status	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
M	M	PROPN	NNP	9	O
.	.	PUNCT	.	9	O
S	S	PROPN	NNP	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
renal	renal	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
hepatic	hepatic	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
36	36	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
30	30	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
M	m	NOUN	NN	9	O
.	.	PUNCT	.	9	O
S	S	PROPN	NNP	9	O
.	.	PUNCT	.	9	O
change	change	NOUN	NN	9	O
on	on	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
had	have	VERB	VBD	9	O
moderate	moderate	ADJ	JJ	9	O
to	to	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
6	6	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
both	both	CCONJ	CC	9	O
renal	renal	ADJ	JJ	9	B-Disease
and	and	CCONJ	CC	5	I-Disease
liver	liver	NOUN	NN	9	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
cimetidine	cimetidine	ADJ	JJ	0	B-Chemical
trough	trough	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
microgram	microgram	NOUN	NN	0	O
/	/	SYM	SYM	9	O
ml	ml	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
M	M	PROPN	NNP	9	O
.	.	PUNCT	.	9	O
S	S	PROPN	NNP	9	O
.	.	PUNCT	.	9	O
changes	change	NOUN	NNS	9	O
increased	increase	VERB	VBD	9	O
as	as	ADP	IN	5	O
trough	trough	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
concentrations	concentration	NOUN	NNS	0	O
rose	rise	VERB	VBD	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
lumbar	lumbar	ADJ	JJ	5	O
puncture	puncture	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cerebrospinal	cerebrospinal	ADJ	JJ	9	O
fluid	fluid	NOUN	NN	5	O
:	:	PUNCT	:	9	O
serum	serum	ADJ	JJ	9	O
ratio	ratio	NOUN	NN	9	O
of	of	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
was	be	VERB	VBD	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
24	24	NUM	CD	9	O
:	:	SYM	SYM	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
indicates	indicate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
passes	pass	VERB	VBZ	5	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
brain	brain	NOUN	NN	5	O
barrier	barrier	NOUN	NN	5	O
;	;	PUNCT	:	9	O
it	-PRON-	PRON	PRP	5	O
also	also	ADV	RB	9	O
raises	raise	VERB	VBZ	9	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
that	that	ADP	IN	5	O
M	M	PROPN	NNP	9	O
.	.	PUNCT	.	9	O
S	S	PROPN	NNP	9	O
.	.	PUNCT	.	9	O
changes	change	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
blockade	blockade	NOUN	NN	3	O
of	of	ADP	IN	5	O
histamine	histamine	ADJ	JJ	0	B-Chemical
H2	H2	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
receptors	receptor	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
both	both	DET	DT	9	O
raised	raise	VERB	VBN	9	O
trough	trough	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
concentrations	concentration	NOUN	NNS	0	O
and	and	CCONJ	CC	5	O
mental	mental	ADJ	JJ	5	O
confusion	confusion	NOUN	NN	5	B-Disease
are	be	VERB	VBP	5	O
those	those	DET	DT	5	O
with	with	ADP	IN	5	O
both	both	CCONJ	CC	9	O
severe	severe	ADJ	JJ	5	O
renal	renal	ADJ	JJ	9	B-Disease
and	and	CCONJ	CC	5	I-Disease
hepatic	hepatic	ADJ	JJ	9	I-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

They	-PRON-	PRON	PRP	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
closely	closely	ADV	RB	9	O
observed	observed	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
given	give	VERB	VBN	5	O
reduced	reduced	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Prospective	prospective	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
somatostatin	somatostatin	NOUN	NN	3	O
analog	analog	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
octreotide	octreotide	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
on	on	ADP	IN	5	O
gallbladder	gallbladder	NOUN	NN	5	O
function	function	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
gallstone	gallstone	NOUN	NN	5	B-Disease
formation	formation	NOUN	NN	9	O
in	in	ADP	IN	5	O
Chinese	chinese	ADJ	JJ	9	O
acromegalic	acromegalic	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
article	article	NOUN	NN	6	O
reports	report	VERB	VBZ	9	O
the	the	DET	DT	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
gallbladder	gallbladder	NOUN	NN	5	O
function	function	NOUN	NN	9	O
examined	examine	VERB	VBN	9	O
by	by	ADP	IN	9	O
ultrasonography	ultrasonography	NOUN	NN	5	O
in	in	ADP	IN	5	O
20	20	NUM	CD	9	O
Chinese	chinese	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
active	active	ADJ	JJ	9	O
acromegaly	acromegaly	NOUN	NN	5	B-Disease
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
sc	sc	NOUN	NN	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
somatostatin	somatostatin	ADJ	JJ	3	O
analog	analog	NOUN	NN	0	O
octreotide	octreotide	ADV	RB	0	B-Chemical
in	in	ADP	IN	5	O
dosages	dosage	NOUN	NNS	9	O
of	of	ADP	IN	5	O
300	300	NUM	CD	0	O
-	-	SYM	SYM	7	O
1500	1500	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
mean	mean	NOUN	NN	5	O
of	of	ADP	IN	5	O
24	24	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
13	13	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
octreotide	octreotide	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
17	17	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
developed	develop	VERB	VBD	5	O
sludge	sludge	NOUN	NN	0	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
had	have	VERB	VBD	9	O
gallstones	gallstone	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	O
developed	develop	VERB	VBD	5	O
acute	acute	ADJ	JJ	9	B-Disease
cholecystitis	cholecystitis	NOUN	NN	5	I-Disease
requiring	require	VERB	VBG	5	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
all	all	DET	DT	5	O
of	of	ADP	IN	5	O
7	7	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
examined	examine	VERB	VBN	9	O
acutely	acutely	ADV	RB	9	O
,	,	PUNCT	,	9	O
gallbladder	gallbladder	NOUN	NN	5	O
contractility	contractility	NOUN	NN	9	O
was	be	VERB	VBD	9	O
inhibited	inhibit	VERB	VBN	3	O
after	after	ADP	IN	9	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
100	100	NUM	CD	0	O
-	-	PUNCT	HYPH	7	O
micrograms	micrograms	NOUN	NN	0	O
injection	injection	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
8	8	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
followed	follow	VERB	VBD	9	O
for	for	ADP	IN	5	O
24	24	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
gallbladder	gallbladder	NOUN	NN	5	O
contractility	contractility	NOUN	NN	9	O
remained	remain	VERB	VBD	9	O
depressed	depressed	ADJ	JJ	5	B-Disease
throughout	throughout	ADP	IN	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
octreotide	octreotide	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
10	10	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
without	without	ADP	IN	9	O
gallstones	gallstone	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
assessed	assess	VERB	VBN	9	O
had	have	VERB	VBD	9	O
return	return	NOUN	NN	5	O
of	of	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
gallbladder	gallbladder	NOUN	NN	5	O
contractility	contractility	NOUN	NN	9	O
within	within	ADP	IN	9	O
1	1	NUM	CD	9	O
month	month	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
8	8	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
remaining	remain	VERB	VBG	9	O
10	10	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
gallstones	gallstone	NOUN	NNS	5	B-Disease
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
gallbladder	gallbladder	NOUN	NN	5	O
contractility	contractility	NOUN	NN	9	O
normalized	normalize	VERB	VBN	9	O
in	in	ADP	IN	5	O
5	5	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
of	of	ADP	IN	5	O
whom	whom	PRON	WP	5	O
has	have	VERB	VBZ	9	O
disappearance	disappearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
stones	stone	NOUN	NNS	5	O
within	within	ADP	IN	9	O
3	3	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
remained	remain	VERB	VBD	9	O
depressed	depressed	ADJ	JJ	5	B-Disease
in	in	ADP	IN	5	O
3	3	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
of	of	ADP	IN	5	O
whom	whom	PRON	WP	5	O
had	have	VERB	VBD	9	O
stones	stone	NOUN	NNS	5	O
present	present	ADJ	JJ	9	O
at	at	ADP	IN	9	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
suppression	suppression	NOUN	NN	9	O
of	of	ADP	IN	5	O
gallbladder	gallbladder	NOUN	NN	5	O
contractility	contractility	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
successive	successive	ADJ	JJ	5	O
formation	formation	NOUN	NN	9	O
of	of	ADP	IN	5	O
bile	bile	ADJ	JJ	0	O
sludge	sludge	NOUN	NN	0	O
,	,	PUNCT	,	9	O
gallstones	gallstone	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
cholecystitis	cholecystitis	NOUN	NN	5	B-Disease
during	during	ADP	IN	5	O
octreotide	octreotide	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
in	in	ADP	IN	5	O
Chinese	chinese	ADJ	JJ	9	O
acromegalic	acromegalic	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
therefore	therefore	ADV	RB	5	O
very	very	ADV	RB	5	O
important	important	ADJ	JJ	9	O
to	to	PART	TO	5	O
follow	follow	VERB	VB	5	O
the	the	DET	DT	5	O
changes	change	NOUN	NNS	9	O
of	of	ADP	IN	5	O
gallbladder	gallbladder	NOUN	NN	5	O
function	function	NOUN	NN	9	O
during	during	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
octreotide	octreotide	NOUN	NN	0	B-Chemical
therapy	therapy	NOUN	NN	5	O
of	of	ADP	IN	5	O
acromegalic	acromegalic	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
disability	disability	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
medication	medication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Depression	depression	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
major	major	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
feature	feature	NOUN	NN	5	O
of	of	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
the	the	DET	DT	5	O
increased	increase	VERB	VBN	9	O
amount	amount	NOUN	NN	9	O
of	of	ADP	IN	5	O
motor	motor	NOUN	NN	5	B-Disease
disability	disability	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
idiopathic	idiopathic	ADJ	JJ	5	B-Disease
Parkinson	Parkinson	PROPN	NNP	5	I-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
antidepressant	antidepressant	ADJ	JJ	5	B-Chemical
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
clinically	clinically	ADV	RB	5	O
relevant	relevant	ADJ	JJ	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
antagonistic	antagonistic	ADJ	JJ	9	O
capacity	capacity	NOUN	NN	9	O
of	of	ADP	IN	5	O
fluoxetine	fluoxetine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
patients	patient	NOUN	NNS	5	O
must	must	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Sinus	sinus	NOUN	NN	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
continuous	continuous	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
infusion	infusion	NOUN	NN	0	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
intermittent	intermittent	ADJ	JJ	5	O
intravenous	intravenous	ADJ	JJ	0	O
infusions	infusion	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
infrequently	infrequently	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
bradyarrhythmias	bradyarrhythmia	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
40	40	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
with	with	ADP	IN	5	O
leukemia	leukemia	NOUN	NN	3	B-Disease
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
developed	develop	VERB	VBD	5	O
recurrent	recurrent	NOUN	NN	5	O
,	,	PUNCT	,	9	O
brief	brief	ADJ	JJ	5	O
episodes	episode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
apparent	apparent	ADJ	JJ	9	O
sinus	sinus	NOUN	NN	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
while	while	ADP	IN	9	O
receiving	receive	VERB	VBG	9	O
continuous	continuous	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
infusion	infusion	NOUN	NN	0	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
hour	hour	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
arrhythmias	arrhythmia	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
temporally	temporally	ADV	RB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
disappeared	disappear	VERB	VBD	9	O
after	after	ADP	IN	9	O
dechallenge	dechallenge	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
recur	recur	VERB	VB	5	O
during	during	ADP	IN	5	O
ranitidine	ranitidine	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
reported	report	VERB	VBN	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
sinus	sinus	NOUN	NN	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
continuous	continuous	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
infusion	infusion	NOUN	NN	0	O
cimetidine	cimetidine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Phase	phase	VERB	VB	9	O
II	II	PROPN	NNP	9	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
vinorelbine	vinorelbine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
squamous	squamous	ADJ	JJ	5	B-Disease
cell	cell	NOUN	NN	3	I-Disease
esophageal	esophageal	NOUN	NN	5	I-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

European	European	PROPN	NNP	5	O
Organization	Organization	PROPN	NNP	2	O
for	for	ADP	IN	5	O
Research	Research	PROPN	NNP	2	O
and	and	CCONJ	CC	5	O
Treatment	Treatment	PROPN	NNP	9	O
of	of	ADP	IN	5	O
Cancer	Cancer	PROPN	NNP	2	B-Disease
Gastrointestinal	Gastrointestinal	PROPN	NNP	9	O
Treat	Treat	PROPN	NNP	9	O
Cancer	Cancer	PROPN	NNP	2	B-Disease
Cooperative	Cooperative	PROPN	NNP	2	O
Group	Group	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
response	response	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
toxic	toxic	ADJ	JJ	0	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
vinorelbine	vinorelbine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
VNB	VNB	PROPN	NNP	4	B-Chemical
)	)	PUNCT	-RRB-	9	O
administered	administer	VERB	VBD	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
in	in	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
squamous	squamous	ADJ	JJ	5	B-Disease
cell	cell	NOUN	NN	3	I-Disease
esophageal	esophageal	NOUN	NN	5	I-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

PATIENTS	PATIENTS	PROPN	NNP	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Forty	forty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
six	six	NUM	CD	9	O
eligible	eligible	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
measurable	measurable	ADJ	JJ	9	O
lesions	lesion	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
included	include	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
stratified	stratify	VERB	VBN	5	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
previous	previous	ADJ	JJ	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
without	without	ADP	IN	9	O
prior	prior	ADJ	JJ	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
16	16	NUM	CD	9	O
pretreated	pretreate	VERB	VBD	3	O
with	with	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
were	be	VERB	VBD	9	O
assessable	assessable	ADJ	JJ	5	O
for	for	ADP	IN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
response	response	NOUN	NN	9	O
.	.	PUNCT	.	9	O

VNB	VNB	PROPN	NNP	4	B-Chemical
was	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
weekly	weekly	ADV	RB	5	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
25	25	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NNS	7	O
short	short	ADV	RB	5	O
intravenous	intravenous	ADJ	JJ	0	O
(	(	PUNCT	-LRB-	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
infusion	infusion	NOUN	NN	0	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Six	six	NUM	CD	9	O
of	of	ADP	IN	5	O
30	30	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
without	without	ADP	IN	9	O
prior	prior	ADJ	JJ	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
achieved	achieve	VERB	VBD	5	O
a	a	DET	DT	5	O
partial	partial	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
PR	PR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
confidence	confidence	NOUN	NN	5	O
interval	interval	NOUN	NN	5	O
[	[	PUNCT	-LRB-	9	O
CI	CI	PROPN	NNP	7	O
]	]	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
39	39	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
response	response	NOUN	NN	9	O
was	be	VERB	VBD	9	O
21	21	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
17	17	NUM	CD	7	O
to	to	PART	TO	5	O
28	28	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
of	of	ADP	IN	5	O
16	16	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
prior	prior	ADJ	JJ	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
had	have	VERB	VBD	9	O
a	a	DET	DT	5	O
complete	complete	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
CR	CR	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
of	of	ADP	IN	5	O
31	31	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
'	'	PART	POS	9	O
duration	duration	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
World	World	PROPN	NNP	5	O
Health	Health	PROPN	NNP	2	O
Organization	Organization	PROPN	NNP	2	O
[	[	PUNCT	-LRB-	9	O
WHO	who	PRON	WP	5	O
]	]	PUNCT	-RRB-	9	O
criteria	criterion	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
15	15	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
CR	CR	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
;	;	PUNCT	:	9	O
PR	pr	NOUN	NN	9	O
13	13	NUM	CD	7	O
%	%	NOUN	NN	9	O
;	;	PUNCT	:	9	O
95	95	NUM	CD	7	O
%	%	NOUN	NN	9	O
CI	CI	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
to	to	PART	TO	5	O
29	29	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
intensity	intensity	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
DI	DI	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
20	20	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
/	/	SYM	SYM	9	O
wk	wk	NOUN	NN	9	O
.	.	PUNCT	.	9	O

VNB	VNB	PROPN	NNP	4	B-Chemical
was	be	VERB	VBD	9	O
well	well	ADV	RB	9	O
tolerated	tolerate	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
zero	zero	NUM	CD	5	O
instances	instance	NOUN	NNS	5	O
of	of	ADP	IN	5	O
WHO	who	PRON	WP	5	O
grade	grade	NOUN	NN	9	O
4	4	NUM	CD	9	O
nonhematologic	nonhematologic	ADJ	JJ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
occurred	occur	VERB	VBD	9	O
.	.	PUNCT	.	9	O

At	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
one	one	NUM	CD	5	O
episode	episode	NOUN	NN	5	O
of	of	ADP	IN	5	O
grade	grade	NOUN	NN	9	O
3	3	NUM	CD	9	O
or	or	CCONJ	CC	5	O
4	4	NUM	CD	9	O
granulocytopenia	granulocytopenia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
59	59	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
grade	grade	NOUN	NN	9	O
2	2	NUM	CD	9	O
or	or	CCONJ	CC	5	O
3	3	NUM	CD	9	O
infection	infection	NOUN	NN	9	B-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
16	16	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
no	no	DET	DT	9	O
toxic	toxic	ADJ	JJ	0	O
deaths	death	NOUN	NNS	5	B-Disease
occurred	occur	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Other	other	ADJ	JJ	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
rare	rare	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
peripheral	peripheral	ADJ	JJ	9	B-Disease
neurotoxicity	neurotoxicity	NOUN	NN	9	I-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
minor	minor	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
26	26	NUM	CD	7	O
%	%	NOUN	NN	9	O
grade	grade	NOUN	NN	9	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
VNB	VNB	PROPN	NNP	4	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
active	active	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
in	in	ADP	IN	5	O
metastatic	metastatic	ADJ	JJ	3	O
esophageal	esophageal	ADJ	JJ	5	B-Disease
squamous	squamous	ADJ	JJ	5	I-Disease
cell	cell	NOUN	NN	3	I-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Given	give	VERB	VBN	9	O
its	-PRON-	DET	PRP$	9	O
excellent	excellent	ADJ	JJ	5	O
tolerance	tolerance	NOUN	NN	9	O
profile	profile	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
low	low	ADJ	JJ	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
further	further	ADJ	JJ	9	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
VNB	VNB	PROPN	NNP	4	B-Chemical
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
warranted	warrant	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
of	of	ADP	IN	5	O
aponidine	aponidine	ADJ	JJ	_	B-Chemical
hydrochloride	hydrochloride	VERB	VB	0	I-Chemical
ophthalmic	ophthalmic	ADJ	JJ	5	O
solution	solution	NOUN	NN	0	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
prospectively	prospectively	ADV	RB	5	O
evaluated	evaluate	VERB	VBD	9	O
the	the	DET	DT	5	O
adverse	adverse	ADJ	JJ	5	O
reactions	reaction	NOUN	NNS	9	O
of	of	ADP	IN	5	O
apraclonidine	apraclonidine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
20	20	NUM	CD	9	O
normal	normal	ADJ	JJ	9	O
volunteers	volunteer	NOUN	NNS	5	O
by	by	ADP	IN	9	O
instilling	instill	VERB	VBG	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
drop	drop	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
apraclonidine	apraclonidine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
right	right	ADJ	JJ	5	O
eyes	eye	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Examinations	examination	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
pulse	pulse	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
,	,	PUNCT	,	9	O
conjunctiva	conjunctiva	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
cornea	cornea	NOUN	NN	5	O
,	,	PUNCT	,	9	O
intraocular	intraocular	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
IOP	IOP	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
pupil	pupil	NOUN	NN	5	O
diameter	diameter	NOUN	NN	9	O
,	,	PUNCT	,	9	O
basal	basal	NOUN	NN	3	O
tear	tear	NOUN	NN	5	O
secretion	secretion	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
margin	margin	NOUN	NN	5	O
reflex	reflex	ADJ	JJ	5	O
distance	distance	NOUN	NN	5	O
of	of	ADP	IN	5	O
both	both	CCONJ	CC	9	O
upper	upper	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
lower	low	ADJ	JJR	9	O
eyelids	eyelid	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
entry	entry	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
and	and	CCONJ	CC	5	O
7	7	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
instillation	instillation	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
ocular	ocular	ADJ	JJ	5	B-Disease
hypotensive	hypotensive	ADJ	JJ	5	I-Disease
effects	effect	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
for	for	ADP	IN	5	O
apraclonidine	apraclonidine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
eyes	eye	NOUN	NNS	5	O
throughout	throughout	ADP	IN	9	O
the	the	DET	DT	5	O
study	study	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
also	also	ADV	RB	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
for	for	ADP	IN	5	O
contralateral	contralateral	ADJ	JJ	5	O
eyes	eye	NOUN	NNS	5	O
from	from	ADP	IN	9	O
three	three	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
topical	topical	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
apraclonidine	apraclonidine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Decreases	decrease	NOUN	NNS	9	B-Disease
in	in	ADP	IN	5	I-Disease
systolic	systolic	ADJ	JJ	5	I-Disease
blood	blood	NOUN	NN	9	I-Disease
pressure	pressure	NOUN	NN	5	I-Disease
were	be	VERB	VBD	9	O
statistically	statistically	ADV	RB	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
clinically	clinically	ADV	RB	5	O
,	,	PUNCT	,	9	O
significant	significant	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
diastolic	diastolic	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
pulse	pulse	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
basal	basal	NOUN	NN	3	O
tear	tear	NOUN	NN	5	O
secretion	secretion	NOUN	NN	3	O
were	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Conjunctival	conjunctival	NOUN	NN	5	B-Disease
blanching	blanching	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
mydriasis	mydriasis	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
commonly	commonly	ADV	RB	5	O
found	find	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Upper	upper	ADJ	JJ	9	O
lid	lid	NOUN	NN	5	O
retraction	retraction	NOUN	NN	5	O
was	be	VERB	VBD	9	O
frequently	frequently	ADV	RB	5	O
noted	note	VERB	VBN	9	O
.	.	PUNCT	.	9	O

While	while	ADP	IN	9	O
the	the	DET	DT	5	O
elevations	elevation	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
upper	upper	ADJ	JJ	9	O
lid	lid	NOUN	NN	5	O
margin	margin	NOUN	NN	5	O
in	in	ADP	IN	5	O
most	most	ADJ	JJS	9	O
subjects	subject	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
2	2	NUM	CD	9	O
mm	mm	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
cause	cause	VERB	VB	5	O
noticeable	noticeable	ADJ	JJ	9	O
change	change	NOUN	NN	9	O
in	in	ADP	IN	5	O
appearance	appearance	NOUN	NN	9	O
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
subject	subject	NOUN	NN	5	O
suffered	suffer	VERB	VBN	5	O
from	from	ADP	IN	9	O
mechanical	mechanical	ADJ	JJ	5	O
entropion	entropion	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
marked	mark	VERB	VBN	9	O
corneal	corneal	ADJ	JJ	5	B-Disease
abrasion	abrasion	NOUN	NN	5	I-Disease
3	3	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
after	after	ADP	IN	9	O
instillation	instillation	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
medication	medication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
may	may	VERB	MD	5	O
well	well	ADV	RB	9	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
particularly	particularly	ADV	RB	5	O
notable	notable	ADJ	JJ	9	O
finding	finding	NOUN	NN	9	O
in	in	ADP	IN	5	O
Asian	asian	ADJ	JJ	4	O
people	people	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Thiopentone	thiopentone	NOUN	NN	0	B-Chemical
pretreatment	pretreatment	ADJ	JJ	0	O
for	for	ADP	IN	5	O
propofol	propofol	ADJ	JJ	0	B-Chemical
injection	injection	NOUN	NN	9	O
pain	pain	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
ambulatory	ambulatory	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
investigated	investigate	VERB	VBD	9	O
propofol	propofol	ADJ	JJ	0	B-Chemical
injection	injection	NOUN	NN	9	O
pain	pain	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
ambulatory	ambulatory	ADJ	JJ	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
randomized	randomize	VERB	VBN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
trial	trial	NOUN	NN	5	O
,	,	PUNCT	,	9	O
90	90	NUM	CD	9	O
women	woman	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
allocated	allocate	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
three	three	NUM	CD	9	O
treatments	treatment	NOUN	NNS	9	O
prior	prior	ADV	RB	9	O
to	to	ADP	IN	5	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
with	with	ADP	IN	5	O
propofol	propofol	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Patients	Patients	PROPN	NNP	5	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
C	C	PROPN	NNP	9	O
received	receive	VERB	VBD	9	O
2	2	NUM	CD	9	O
ml	ml	NOUN	NN	0	O
normal	normal	ADJ	JJ	9	O
saline	saline	NOUN	NN	0	O
,	,	PUNCT	,	9	O
Group	Group	PROPN	NNP	9	O
L	L	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
ml	ml	NOUN	NN	0	O
,	,	PUNCT	,	9	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
Group	Group	PROPN	NNP	9	O
T	T	PROPN	NNP	3	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
ml	ml	NOUN	NN	0	O
thiopentone	thiopentone	NOUN	NN	0	B-Chemical
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
50	50	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Venous	venous	ADJ	JJ	5	O
discomfort	discomfort	NOUN	NN	5	O
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
visual	visual	ADJ	JJ	5	O
analogue	analogue	NOUN	NN	0	O
scale	scale	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
VAS	VAS	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
15	15	NUM	CD	9	O
sec	sec	NOUN	NN	9	O
after	after	ADP	IN	9	O
commencing	commence	VERB	VBG	5	O
propofol	propofol	ADJ	JJ	0	B-Chemical
administration	administration	NOUN	NN	9	O
using	use	VERB	VBG	9	O
an	an	DET	DT	5	O
infusion	infusion	NOUN	NN	0	O
pump	pump	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
rate	rate	NOUN	NN	9	O
1000	1000	NUM	CD	9	O
micrograms	microgram	NOUN	NNS	0	O
.	.	PUNCT	.	9	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
min	min	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Loss	loss	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
consciousness	consciousness	NOUN	NN	5	I-Disease
occurred	occur	VERB	VBD	9	O
in	in	ADP	IN	5	O
60	60	NUM	CD	9	O
-	-	SYM	SYM	7	O
90	90	NUM	CD	9	O
sec	sec	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Visual	visual	ADJ	JJ	5	O
analogue	analogue	NOUN	NN	0	O
scores	score	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
SD	sd	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
during	during	ADP	IN	5	O
induction	induction	NOUN	NN	3	O
were	be	VERB	VBD	9	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
Groups	Groups	PROPN	NNP	9	O
L	L	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
3	3	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
T	T	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
7	7	PUNCT	LS	9	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
C	C	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0031	0031	NUM	CD	7	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
venous	venous	ADJ	JJ	5	O
discomfort	discomfort	NOUN	NN	5	O
was	be	VERB	VBD	9	O
lower	low	ADJ	JJR	9	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
L	L	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
76	76	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
Group	Group	PROPN	NNP	9	O
C	C	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
100	100	NUM	CD	0	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
different	different	ADJ	JJ	9	O
from	from	ADP	IN	9	O
Group	Group	PROPN	NNP	9	O
T	T	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
90	90	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
VAS	VAS	PROPN	NNP	5	O
scores	score	NOUN	NNS	5	O
for	for	ADP	IN	5	O
recall	recall	NOUN	NN	5	O
of	of	ADP	IN	5	O
pain	pain	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
recovery	recovery	NOUN	NN	9	O
room	room	NOUN	NN	9	O
were	be	VERB	VBD	9	O
correlated	correlate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
VAS	VAS	PROPN	NNP	5	O
scores	score	NOUN	NNS	5	O
during	during	ADP	IN	5	O
induction	induction	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
r	r	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
7045	7045	NUM	CD	7	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Recovery	recovery	NOUN	NN	9	O
room	room	NOUN	NN	9	O
discharge	discharge	NOUN	NN	5	O
times	time	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
:	:	PUNCT	:	9	O
C	C	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
75	75	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
19	19	NUM	CD	7	O
.	.	PUNCT	.	9	O
4	4	NUM	CD	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
L	l	NOUN	NN	0	O
73	73	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
21	21	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
;	;	PUNCT	:	9	O
T	T	PROPN	NNP	3	O
(	(	PUNCT	-LRB-	9	O
77	77	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
18	18	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Assessing	assess	VERB	VBG	5	O
their	-PRON-	DET	PRP$	5	O
overall	overall	ADJ	JJ	5	O
satisfaction	satisfaction	NOUN	NN	5	O
,	,	PUNCT	,	9	O
89	89	NUM	CD	7	O
.	.	PUNCT	.	9	O
7	7	NUM	CD	9	O
%	%	NOUN	NN	9	O
would	would	VERB	MD	5	O
choose	choose	VERB	VB	5	O
propofol	propofol	ADJ	JJ	0	B-Chemical
anaesthesia	anaesthesia	NOUN	NN	5	O
again	again	ADV	RB	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
reduces	reduce	VERB	VBZ	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
propofol	propofol	ADJ	JJ	0	B-Chemical
injection	injection	NOUN	NN	9	O
pain	pain	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
ambulatory	ambulatory	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
whereas	whereas	ADP	IN	9	O
thiopentone	thiopentone	NOUN	NN	0	B-Chemical
only	only	ADV	RB	9	O
reduces	reduce	VERB	VBZ	9	O
its	-PRON-	DET	PRP$	9	O
severity	severity	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Persistent	persistent	ADJ	JJ	9	O
paralysis	paralysis	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
prolonged	prolong	VERB	VBN	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
atracurium	atracurium	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
corticosteroids	corticosteroid	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Neuromuscular	neuromuscular	ADJ	JJ	2	O
blocking	block	VERB	VBG	3	O
agents	agent	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
NMBAs	nmba	NOUN	NNS	5	O
)	)	PUNCT	-RRB-	9	O
are	be	VERB	VBP	5	O
often	often	ADV	RB	5	O
used	use	VERB	VBN	5	O
for	for	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
requiring	require	VERB	VBG	5	O
prolonged	prolong	VERB	VBN	9	O
mechanical	mechanical	ADJ	JJ	5	O
ventilation	ventilation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Reports	report	NOUN	NNS	5	O
of	of	ADP	IN	5	O
persistent	persistent	ADJ	JJ	5	O
paralysis	paralysis	NOUN	NN	5	B-Disease
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
discontinuance	discontinuance	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
most	most	ADV	RBS	9	O
often	often	ADV	RB	5	O
involved	involve	VERB	VBN	9	O
aminosteroid	aminosteroid	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
based	base	VERB	VBN	5	O
NMBAs	nmba	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
vecuronium	vecuronium	NOUN	NN	0	B-Chemical
bromide	bromide	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
especially	especially	ADV	RB	5	O
when	when	ADV	WRB	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
conjunction	conjunction	NOUN	NN	9	O
with	with	ADP	IN	5	O
corticosteroids	corticosteroid	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Atracurium	atracurium	ADJ	JJ	0	B-Chemical
besylate	besylate	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
short	short	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
acting	act	VERB	VBG	9	O
benzylisoquinolinium	benzylisoquinolinium	NOUN	NN	5	B-Chemical
NMBA	NMBA	PROPN	NNP	0	O
that	that	DET	WDT	5	O
is	be	VERB	VBZ	5	O
eliminated	eliminate	VERB	VBN	9	O
independently	independently	ADV	RB	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
or	or	CCONJ	CC	5	O
hepatic	hepatic	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
,	,	PUNCT	,	9	O
has	have	VERB	VBZ	9	O
also	also	ADV	RB	9	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
persistent	persistent	ADJ	JJ	5	O
paralysis	paralysis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
only	only	ADV	RB	9	O
when	when	ADV	WRB	5	O
used	use	VERB	VBN	5	O
with	with	ADP	IN	5	O
corticosteroids	corticosteroid	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
atracurium	atracurium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
paralysis	paralysis	NOUN	NN	5	B-Disease
persisting	persist	VERB	VBG	9	O
for	for	ADP	IN	5	O
approximately	approximately	ADV	RB	9	O
50	50	NUM	CD	0	O
hours	hour	NOUN	NNS	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
corticosteroids	corticosteroid	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
phase	phase	NOUN	NN	5	O
I	I	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
II	II	PROPN	NNP	9	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
plus	plus	CCONJ	CC	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
as	as	ADP	IN	5	O
first	first	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
line	line	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
for	for	ADP	IN	5	O
head	head	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
neck	neck	NOUN	NN	5	I-Disease
cancers	cancer	NOUN	NNS	9	I-Disease
:	:	PUNCT	:	9	O
preliminary	preliminary	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Improved	improved	ADJ	JJ	9	O
outcomes	outcome	NOUN	NNS	5	O
among	among	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
head	head	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
neck	neck	NOUN	NN	5	I-Disease
carcinomas	carcinoma	NOUN	NNS	3	I-Disease
require	require	VERB	VBP	5	O
investigations	investigation	NOUN	NNS	9	O
of	of	ADP	IN	5	O
new	new	ADJ	JJ	5	O
drugs	drug	NOUN	NNS	5	O
for	for	ADP	IN	5	O
induction	induction	NOUN	NN	3	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Preliminary	preliminary	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
an	an	DET	DT	5	O
Eastern	Eastern	PROPN	NNP	4	O
Cooperative	Cooperative	PROPN	NNP	2	O
Oncology	Oncology	PROPN	NNP	2	O
Group	Group	PROPN	NNP	9	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
single	single	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
agent	agent	NOUN	NN	9	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Taxol	Taxol	PROPN	NNP	0	B-Chemical
;	;	PUNCT	:	9	O
Bristol	Bristol	PROPN	NNP	2	O
-	-	PUNCT	HYPH	7	O
Myers	Myers	PROPN	NNP	6	O
Squibb	Squibb	PROPN	NNP	2	O
Company	Company	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Princeton	Princeton	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
NJ	NJ	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
reported	report	VERB	VBD	9	O
a	a	DET	DT	5	O
37	37	NUM	CD	9	O
%	%	NOUN	NN	9	O
response	response	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
head	head	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
neck	neck	NOUN	NN	5	I-Disease
cancer	cancer	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
/	/	SYM	SYM	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
combination	combination	NOUN	NN	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
used	use	VERB	VBN	5	O
successfully	successfully	ADV	RB	5	O
and	and	CCONJ	CC	5	O
has	have	VERB	VBZ	9	O
significantly	significantly	ADV	RB	9	O
improved	improve	VERB	VBN	5	O
median	median	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
duration	duration	NOUN	NN	5	O
in	in	ADP	IN	5	O
ovarian	ovarian	ADJ	JJ	9	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
initiated	initiate	VERB	VBD	9	O
a	a	DET	DT	5	O
phase	phase	NOUN	NN	5	O
I	I	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
II	II	PROPN	NNP	9	O
trial	trial	NOUN	NN	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
response	response	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
escalating	escalate	VERB	VBG	5	O
paclitaxel	paclitaxel	ADJ	JJ	0	B-Chemical
doses	dose	NOUN	NNS	0	O
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
fixed	fix	VERB	VBN	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
with	with	ADP	IN	5	O
granulocyte	granulocyte	NOUN	NN	3	O
colony	colony	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
stimulating	stimulate	VERB	VBG	9	O
factor	factor	NOUN	NN	9	O
support	support	NOUN	NN	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
untreated	untreated	ADJ	JJ	3	O
locally	locally	ADV	RB	5	O
advanced	advanced	ADJ	JJ	5	O
inoperable	inoperable	ADJ	JJ	5	O
head	head	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
neck	neck	NOUN	NN	5	I-Disease
carcinoma	carcinoma	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

To	to	ADP	IN	9	O
date	date	NOUN	NN	5	O
,	,	PUNCT	,	9	O
23	23	NUM	CD	7	O
men	man	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
median	median	ADJ	JJ	9	O
age	age	NOUN	NN	5	O
of	of	ADP	IN	5	O
50	50	NUM	CD	0	O
years	year	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
good	good	ADJ	JJ	5	O
performance	performance	NOUN	NN	5	O
status	status	NOUN	NN	9	O
have	have	VERB	VBP	5	O
entered	enter	VERB	VBN	5	O
the	the	DET	DT	5	O
trial	trial	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Primary	primary	ADJ	JJ	9	O
tumor	tumor	NOUN	NN	3	B-Disease
sites	site	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
oropharynx	oropharynx	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
10	10	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
;	;	PUNCT	:	9	O
hypopharynx	hypopharynx	NOUN	NN	5	O
,	,	PUNCT	,	9	O
four	four	NUM	CD	9	O
;	;	PUNCT	:	9	O
larynx	larynx	NOUN	NN	5	O
,	,	PUNCT	,	9	O
two	two	NUM	CD	5	O
;	;	PUNCT	:	9	O
oral	oral	ADJ	JJ	9	O
cavity	cavity	NOUN	NN	5	O
,	,	PUNCT	,	9	O
three	three	NUM	CD	9	O
;	;	PUNCT	:	9	O
unknown	unknown	ADJ	JJ	9	O
primary	primary	NOUN	NN	9	O
,	,	PUNCT	,	9	O
two	two	NUM	CD	5	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
nasal	nasal	NOUN	NN	5	O
cavity	cavity	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
parotid	parotid	VERB	VB	5	O
gland	gland	NOUN	NN	9	O
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
each	each	DET	DT	5	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
20	20	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
evaluable	evaluable	ADJ	JJ	9	O
for	for	ADP	IN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
four	four	NUM	CD	9	O
had	have	VERB	VBD	9	O
stage	stage	NOUN	NN	9	O
III	iii	NUM	CD	9	O
and	and	CCONJ	CC	5	O
16	16	NUM	CD	9	O
had	have	VERB	VBD	9	O
stage	stage	NOUN	NN	9	O
IV	iv	NOUN	NN	9	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
given	give	VERB	VBN	5	O
every	every	DET	DT	5	O
21	21	NUM	CD	7	O
days	day	NOUN	NNS	9	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
maximum	maximum	NOUN	NN	5	O
of	of	ADP	IN	5	O
three	three	NUM	CD	9	O
cycles	cycle	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
consisted	consist	VERB	VBN	5	O
of	of	ADP	IN	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
by	by	ADP	IN	9	O
3	3	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
infusion	infusion	NOUN	NN	0	O
followed	follow	VERB	VBD	9	O
the	the	DET	DT	5	O
next	next	ADJ	JJ	9	O
day	day	NOUN	NN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
fixed	fix	VERB	VBN	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
75	75	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
incorporate	incorporate	VERB	VBP	5	O
escalating	escalate	VERB	VBG	5	O
paclitaxel	paclitaxel	NOUN	NN	0	B-Chemical
doses	dose	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
intrapatient	intrapatient	ADJ	JJ	5	O
escalations	escalation	NOUN	NNS	5	O
within	within	ADP	IN	9	O
a	a	DET	DT	5	O
given	give	VERB	VBN	5	O
dose	dose	NOUN	NN	9	O
level	level	NOUN	NN	9	O
are	be	VERB	VBP	5	O
permitted	permit	VERB	VBN	5	O
if	if	ADP	IN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
permits	permit	VERB	VBZ	5	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
writing	writing	NOUN	NN	5	O
,	,	PUNCT	,	9	O
dose	dose	NOUN	NN	9	O
level	level	NOUN	NN	9	O
4	4	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
260	260	NUM	CD	9	O
,	,	PUNCT	,	9	O
270	270	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
280	280	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
being	be	VERB	VBG	5	O
evaluated	evaluate	VERB	VBN	9	O
;	;	PUNCT	:	9	O
three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
from	from	ADP	IN	9	O
this	this	DET	DT	5	O
level	level	NOUN	NN	9	O
are	be	VERB	VBP	5	O
evaluable	evaluable	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

With	with	ADP	IN	5	O
paclitaxel	paclitaxel	ADJ	JJ	0	B-Chemical
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
and	and	CCONJ	CC	5	O
higher	high	ADJ	JJR	9	O
,	,	PUNCT	,	9	O
granulocyte	granulocyte	NOUN	NN	3	O
colony	colony	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
stimulating	stimulate	VERB	VBG	9	O
factor	factor	NOUN	NN	9	O
5	5	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
d	d	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
given	give	VERB	VBN	5	O
(	(	PUNCT	-LRB-	9	O
days	day	NOUN	NNS	9	O
4	4	NUM	CD	9	O
through	through	ADP	IN	9	O
12	12	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
18	18	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
evaluable	evaluable	ADJ	JJ	9	O
for	for	ADP	IN	5	O
response	response	NOUN	NN	9	O
,	,	PUNCT	,	9	O
seven	seven	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
39	39	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
achieved	achieve	VERB	VBD	5	O
a	a	DET	DT	5	O
complete	complete	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
six	six	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
33	33	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
achieved	achieve	VERB	VBD	5	O
a	a	DET	DT	5	O
partial	partial	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
change	change	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
disease	disease	NOUN	NN	5	O
progressed	progress	VERB	VBD	9	O
in	in	ADP	IN	5	O
two	two	NUM	CD	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
72	72	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Eleven	eleven	NUM	CD	9	O
responding	respond	VERB	VBG	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
subsequent	subsequent	ADJ	JJ	9	O
surgery	surgery	NOUN	NN	5	O
/	/	SYM	SYM	9	O
radiotherapy	radiotherapy	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
radical	radical	ADJ	JJ	0	O
radiotherapy	radiotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
pathologic	pathologic	NOUN	NN	5	O
complete	complete	ADJ	JJ	9	O
responses	response	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
achieved	achieve	VERB	VBN	5	O
clinical	clinical	ADJ	JJ	5	O
complete	complete	ADJ	JJ	9	O
responses	response	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Alopecia	Alopecia	PROPN	NNP	2	B-Disease
,	,	PUNCT	,	9	O
paresthesias	paresthesia	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
arthralgias	arthralgia	NOUN	NNS	5	B-Disease
/	/	SYM	SYM	9	O
myalgias	myalgia	NOUN	NNS	5	B-Disease
have	have	VERB	VBP	5	O
occurred	occur	VERB	VBN	9	O
frequently	frequently	ADV	RB	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
with	with	ADP	IN	5	O
one	one	NUM	CD	5	O
exception	exception	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
a	a	DET	DT	5	O
grade	grade	NOUN	NN	9	O
3	3	NUM	CD	9	O
myalgia	myalgia	NOUN	NN	5	B-Disease
)	)	PUNCT	-RRB-	9	O
they	-PRON-	PRON	PRP	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
grade	grade	NOUN	NN	9	O
1	1	NUM	CD	9	O
or	or	CCONJ	CC	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
limiting	limit	VERB	VBG	9	O
hematologic	hematologic	NOUN	NN	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
seen	see	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Paclitaxel	Paclitaxel	PROPN	NNP	0	B-Chemical
/	/	SYM	SYM	9	O
cisplatin	cisplatin	NOUN	NN	3	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
first	first	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
line	line	NOUN	NN	9	O
regimen	regiman	NOUN	NNS	5	O
for	for	ADP	IN	5	O
locoregionally	locoregionally	ADV	RB	5	O
advanced	advanced	ADJ	JJ	5	O
head	head	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
neck	neck	NOUN	NN	5	I-Disease
cancer	cancer	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
continued	continued	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
warranted	warrant	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Results	result	NOUN	NNS	9	O
thus	thus	ADV	RB	9	O
far	far	ADV	RB	5	O
suggest	suggest	VERB	VBP	9	O
no	no	DET	DT	9	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
response	response	NOUN	NN	9	O
effect	effect	NOUN	NN	9	O
for	for	ADP	IN	5	O
paclitaxel	paclitaxel	ADJ	JJ	0	B-Chemical
doses	dose	NOUN	NNS	0	O
above	above	ADP	IN	9	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
.	.	PUNCT	.	9	O

Improvement	improvement	NOUN	NN	5	O
of	of	ADP	IN	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
by	by	ADP	IN	9	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Seven	seven	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
suffering	suffer	VERB	VBG	5	O
from	from	ADP	IN	9	O
Parkinson	Parkinson	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
PD	PD	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
with	with	ADP	IN	5	O
severely	severely	ADV	RB	9	O
disabling	disable	VERB	VBG	5	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
received	receive	VERB	VBN	9	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
propranolol	propranolol	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
adjunct	adjunct	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
currently	currently	ADV	RB	5	O
used	use	VERB	VBN	5	O
medical	medical	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
dyskinesia	dyskinesia	ADJ	JJ	5	B-Disease
score	score	NOUN	NN	5	O
without	without	ADP	IN	9	O
increase	increase	NOUN	NN	9	O
of	of	ADP	IN	5	O
parkinsonian	parkinsonian	ADJ	JJ	5	B-Disease
motor	motor	NOUN	NN	5	B-Disease
disability	disability	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Ballistic	ballistic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
choreic	choreic	NOUN	NN	5	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
were	be	VERB	VBD	9	O
markedly	markedly	ADV	RB	9	O
ameliorated	ameliorate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
dystonia	dystonia	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
low	low	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
blockers	blocker	NOUN	NNS	9	O
may	may	VERB	MD	5	O
improve	improve	VERB	VB	5	O
levodopa	levodopa	ADJ	JJ	5	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induced	ADJ	JJ	3	O
ballistic	ballistic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
choreic	choreic	ADJ	JJ	5	O
dyskinesia	dyskinesia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
PD	pd	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Habitual	habitual	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
risk	risk	NOUN	NN	5	O
factor	factor	NOUN	NN	9	O
for	for	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
comparison	comparison	NOUN	NN	9	O
with	with	ADP	IN	5	O
phenacetin	phenacetin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Six	six	NUM	CD	9	O
epidemiologic	epidemiologic	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
United	United	PROPN	NNP	9	O
States	States	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
Europe	Europe	PROPN	NNP	4	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
habitual	habitual	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
phenacetin	phenacetin	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
end	end	NOUN	NN	9	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
stage	stage	NOUN	NN	9	I-Disease
renal	renal	ADJ	JJ	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
relative	relative	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
range	range	NOUN	NN	9	O
of	of	ADP	IN	5	O
4	4	NUM	CD	9	O
to	to	ADP	IN	5	O
19	19	NUM	CD	7	O
.	.	PUNCT	.	9	O

As	as	ADP	IN	9	O
a	a	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
and	and	CCONJ	CC	5	O
other	other	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
phenacetin	phenacetin	NOUN	NN	0	B-Chemical
has	have	VERB	VBZ	9	O
now	now	ADV	RB	5	O
been	be	VERB	VBN	9	O
withdrawn	withdraw	VERB	VBN	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
market	market	NOUN	NN	5	O
in	in	ADP	IN	5	O
most	most	ADJ	JJS	9	O
countries	country	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
three	three	NUM	CD	9	O
case	case	NOUN	NN	5	O
control	control	NOUN	NN	9	O
studies	study	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
each	each	DET	DT	5	O
in	in	ADP	IN	5	O
North	North	PROPN	NNP	4	O
Carolina	Carolina	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
northern	northern	ADJ	JJ	4	O
Maryland	Maryland	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
West	West	PROPN	NNP	4	O
Berlin	Berlin	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
Germany	Germany	PROPN	NNP	2	O
,	,	PUNCT	,	9	O
showed	show	VERB	VBD	9	O
that	that	ADP	IN	5	O
habitual	habitual	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
also	also	ADV	RB	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	B-Disease
renal	renal	ADJ	JJ	9	I-Disease
failure	failure	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
ESRD	esrd	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
relative	relative	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
range	range	NOUN	NN	9	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
to	to	ADP	IN	5	O
4	4	NUM	CD	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
studies	study	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
both	both	DET	DT	9	O
phenacetin	phenacetin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
contribute	contribute	VERB	VB	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
burden	burden	NOUN	NN	5	O
of	of	ADP	IN	5	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
latter	latter	ADJ	JJ	9	O
being	be	VERB	VBG	5	O
somewhat	somewhat	ADV	RB	5	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
former	former	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
apparent	apparent	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
in	in	ADP	IN	5	O
risk	risk	NOUN	NN	5	O
may	may	VERB	MD	5	O
not	not	ADV	RB	5	O
be	be	VERB	VB	5	O
due	due	ADJ	JJ	5	O
to	to	ADP	IN	5	O
differences	difference	NOUN	NNS	9	O
in	in	ADP	IN	5	O
nephrotoxic	nephrotoxic	ADJ	JJ	5	B-Disease
potential	potential	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
themselves	-PRON-	PRON	PRP	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
lower	lower	ADV	RBR	9	O
relative	relative	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
would	would	VERB	MD	5	O
be	be	VERB	VB	5	O
expected	expect	VERB	VBN	9	O
for	for	ADP	IN	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
if	if	ADP	IN	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
drugs	drug	NOUN	NNS	5	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
analgesics	analgesic	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
either	either	DET	DT	9	O
agent	agent	NOUN	NN	9	O
alone	alone	ADV	RB	9	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
used	use	VERB	VBN	5	O
both	both	DET	DT	9	O
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
agent	agent	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
with	with	ADP	IN	5	O
other	other	ADJ	JJ	5	O
analgesics	analgesic	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
whereas	whereas	ADP	IN	9	O
phenacetin	phenacetin	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
available	available	ADJ	JJ	5	O
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
combinations	combination	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
that	that	ADP	IN	5	O
habitual	habitual	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
alone	alone	ADV	RB	9	O
increases	increase	VERB	VBZ	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
ESRD	ESRD	PROPN	NNP	5	B-Disease
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
clearly	clearly	ADV	RB	9	O
demonstrated	demonstrate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
cannot	cannot	NOUN	NN	5	O
be	be	VERB	VB	5	O
dismissed	dismiss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Acetaminophen	Acetaminophen	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Through	through	ADP	IN	5	O
30	30	NUM	CD	9	O
years	year	NOUN	NNS	5	O
of	of	ADP	IN	5	O
widespread	widespread	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
,	,	PUNCT	,	9	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
shown	show	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
remarkably	remarkably	ADV	RB	9	O
safe	safe	ADJ	JJ	5	O
medication	medication	NOUN	NN	5	O
in	in	ADP	IN	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
dosages	dosage	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
potential	potential	NOUN	NN	9	O
for	for	ADP	IN	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
produce	produce	VERB	VB	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
toxicities	toxicity	NOUN	NNS	5	I-Disease
is	be	VERB	VBZ	5	O
very	very	ADV	RB	5	O
low	low	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
demonstrated	demonstrate	VERB	VBN	9	O
to	to	PART	TO	5	O
produce	produce	VERB	VB	9	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
anaphylaxis	anaphylaxis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
hypotension	hypotension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
sensitive	sensitive	ADJ	JJ	9	O
individuals	individual	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
article	article	NOUN	NN	6	O
describes	describe	VERB	VBZ	5	O
two	two	NUM	CD	5	O
critically	critically	ADV	RB	9	B-Disease
ill	ill	ADJ	JJ	5	I-Disease
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
whom	whom	PRON	WP	5	O
transient	transient	ADJ	JJ	9	O
episodes	episode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
reproducibly	reproducibly	ADV	RB	9	O
developed	develop	VERB	VBD	5	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
acetaminophen	acetaminophen	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Other	other	ADJ	JJ	9	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
allergic	allergic	ADJ	JJ	9	B-Disease
reactions	reaction	NOUN	NNS	9	I-Disease
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
clinically	clinically	ADV	RB	5	O
detectable	detectable	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
hypotensive	hypotensive	ADJ	JJ	5	B-Disease
episodes	episode	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
severe	severe	ADJ	JJ	5	O
enough	enough	ADV	RB	5	O
to	to	PART	TO	5	O
require	require	VERB	VB	5	O
vasopressor	vasopressor	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
reports	report	NOUN	NNS	9	O
illustrate	illustrate	VERB	VBP	5	O
the	the	DET	DT	5	O
need	need	NOUN	NN	5	O
for	for	ADP	IN	5	O
clinicians	clinician	NOUN	NNS	5	O
to	to	PART	TO	5	O
consider	consider	VERB	VB	5	O
acetaminophen	acetaminophen	ADV	RB	0	B-Chemical
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
unknown	unknown	ADJ	JJ	9	O
origin	origin	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Reduction	reduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
heparan	heparan	NOUN	NN	3	B-Chemical
sulphate	sulphate	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
anionic	anionic	ADJ	JJ	0	O
sites	site	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
glomerular	glomerular	ADJ	JJ	5	O
basement	basement	NOUN	NN	3	O
membrane	membrane	NOUN	NN	9	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
streptozotocin	streptozotocin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
nephropathy	nephropathy	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Heparan	Heparan	PROPN	NNP	0	B-Chemical
sulphate	sulphate	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
anionic	anionic	ADJ	JJ	0	O
sites	site	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
glomerular	glomerular	ADJ	JJ	5	O
basement	basement	NOUN	NN	3	O
membrane	membrane	NOUN	NN	9	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
8	8	NUM	CD	9	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
induction	induction	NOUN	NN	3	O
of	of	ADP	IN	5	O
diabetes	diabete	NOUN	NNS	5	B-Disease
by	by	ADP	IN	9	O
streptozotocin	streptozotocin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
age	age	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
adn	adn	NOUN	NN	2	O
sex	sex	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
matched	match	VERB	VBN	9	O
control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
employing	employ	VERB	VBG	9	O
the	the	DET	DT	5	O
cationic	cationic	ADJ	JJ	0	O
dye	dye	NOUN	NN	0	O
cuprolinic	cuprolinic	NOUN	NN	0	B-Chemical
blue	blue	NOUN	NN	9	I-Chemical
.	.	PUNCT	.	9	O

Morphometric	morphometric	ADJ	JJ	9	O
analysis	analysis	NOUN	NN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
ultrastructural	ultrastructural	ADJ	JJ	9	O
level	level	NOUN	NN	9	O
was	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
computerized	computerized	ADJ	JJ	5	O
image	image	NOUN	NN	5	O
processor	processor	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
heparan	heparan	NOUN	NN	3	B-Chemical
sulphate	sulphate	NOUN	NN	0	I-Chemical
specificity	specificity	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cuprolinic	cuprolinic	NOUN	NN	0	B-Chemical
blue	blue	ADJ	JJ	9	I-Chemical
staining	staining	NOUN	NN	3	O
was	be	VERB	VBD	9	O
demonstrated	demonstrate	VERB	VBN	9	O
by	by	ADP	IN	9	O
glycosaminoglycan	glycosaminoglycan	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
degrading	degrading	NOUN	NN	9	O
enzymes	enzyme	NOUN	NNS	1	O
,	,	PUNCT	,	9	O
showing	show	VERB	VBG	9	O
that	that	DET	DT	5	O
pretreatment	pretreatment	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
sections	section	NOUN	NNS	9	O
with	with	ADP	IN	5	O
heparitinase	heparitinase	NOUN	NN	3	O
abolished	abolish	VERB	VBD	3	O
all	all	DET	DT	5	O
staining	staining	NOUN	NN	3	O
,	,	PUNCT	,	9	O
whereas	whereas	DET	WDT	9	O
chondroitinase	chondroitinase	VERB	VBP	0	O
ABC	ABC	PROPN	NNP	9	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
majority	majority	NOUN	NN	9	O
of	of	ADP	IN	5	O
anionic	anionic	ADJ	JJ	0	O
sites	site	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
74	74	NUM	CD	7	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
and	and	CCONJ	CC	5	O
81	81	NUM	CD	7	O
%	%	NOUN	NN	9	O
in	in	ADP	IN	5	O
control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
within	within	ADP	IN	9	O
the	the	DET	DT	5	O
lamina	lamina	NOUN	NN	9	O
rara	rara	NOUN	NN	2	O
externa	externa	NOUN	NN	4	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
glomerular	glomerular	ADJ	JJ	5	O
basement	basement	NOUN	NN	3	O
membrane	membrane	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
minority	minority	NOUN	NN	5	O
of	of	ADP	IN	5	O
anionic	anionic	ADJ	JJ	0	O
sites	site	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
scattered	scatter	VERB	VBN	5	O
throughout	throughout	ADP	IN	9	O
the	the	DET	DT	5	O
lamina	lamina	NOUN	NN	9	O
densa	densa	ADJ	JJ	4	O
and	and	CCONJ	CC	5	O
lamina	lamina	NOUN	NN	9	O
rara	rara	NOUN	NN	2	O
interna	interna	NOUN	NN	2	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
smaller	small	ADJ	JJR	5	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
lamina	lamina	NOUN	NN	9	O
rara	rara	NOUN	NN	2	O
externa	externa	NOUN	NN	4	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
glomerular	glomerular	ADJ	JJ	5	O
basement	basement	NOUN	NN	3	O
membrane	membrane	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
and	and	CCONJ	CC	5	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
01	01	NUM	CD	7	O
for	for	ADP	IN	5	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
and	and	CCONJ	CC	5	O
control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Diabetic	diabetic	ADJ	JJ	9	B-Disease
rats	rat	NOUN	NNS	9	O
progressively	progressively	ADV	RB	9	O
developed	develop	VERB	VBD	5	O
albuminuria	albuminuria	NOUN	NN	9	B-Disease
reaching	reach	VERB	VBG	5	O
40	40	NUM	CD	9	O
.	.	PUNCT	.	9	O
3	3	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
32	32	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
62	62	NUM	CD	7	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
)	)	PUNCT	-RRB-	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
after	after	ADP	IN	9	O
8	8	NUM	CD	9	O
months	month	NOUN	NNS	5	O
in	in	ADP	IN	5	O
contrast	contrast	NOUN	NN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
animals	animal	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
8	8	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
24	24	NUM	CD	9	O
h	h	NOUN	NN	0	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
002	002	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
time	time	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
heparan	heparan	NOUN	NN	3	B-Chemical
sulphate	sulphate	NOUN	NN	0	I-Chemical
anionic	anionic	ADJ	JJ	0	O
sites	site	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
total	total	ADJ	JJ	9	O
anionic	anionic	ADJ	JJ	0	O
site	site	NOUN	NN	9	O
surface	surface	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
anionic	anionic	ADJ	JJ	0	O
sites	site	NOUN	NNS	9	O
x	x	SYM	SYM	9	O
mean	mean	VERB	VBP	5	O
anionic	anionic	ADJ	JJ	0	O
site	site	NOUN	NN	9	O
surface	surface	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
lamina	lamina	NOUN	NN	9	O
rara	rara	NOUN	NN	2	O
externa	externa	NOUN	NN	4	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
glomerular	glomerular	ADJ	JJ	5	O
basement	basement	NOUN	NN	3	O
membrane	membrane	NOUN	NN	9	O
was	be	VERB	VBD	9	O
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
19	19	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
021	021	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
by	by	ADP	IN	9	O
26	26	NUM	CD	7	O
%	%	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
02	02	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Number	number	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
total	total	ADJ	JJ	9	O
anionic	anionic	ADJ	JJ	0	O
site	site	NOUN	NN	9	O
surface	surface	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
remaining	remain	VERB	VBG	9	O
part	part	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
glomerular	glomerular	ADJ	JJ	5	O
basement	basement	NOUN	NN	3	O
membrane	membrane	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
lamina	lamina	NOUN	NN	9	O
densa	densa	ADJ	JJ	4	O
and	and	CCONJ	CC	5	O
lamina	lamina	NOUN	NN	9	O
rara	rara	NOUN	NN	2	O
interna	interna	NOUN	NN	2	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
significantly	significantly	ADV	RB	9	O
changed	change	VERB	VBN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
in	in	ADP	IN	5	O
streptozotocin	streptozotocin	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
diabetic	diabetic	ADJ	JJ	9	B-Disease
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
an	an	DET	DT	5	O
increased	increased	ADJ	JJ	9	O
urinary	urinary	ADJ	JJ	9	O
albumin	albumin	NOUN	NN	0	O
excretion	excretion	NOUN	NN	0	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
reduced	reduced	ADJ	JJ	9	O
heparan	heparan	NOUN	NN	3	B-Chemical
sulphate	sulphate	NOUN	NN	0	I-Chemical
charge	charge	NOUN	NN	5	O
barrier	barrier	NOUN	NN	5	O
/	/	SYM	SYM	9	O
density	density	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
found	find	VERB	VBN	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
lamina	lamina	NOUN	NN	9	O
rara	rara	NOUN	NN	2	O
externa	externa	NOUN	NN	4	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
glomerular	glomerular	ADJ	JJ	5	O
basement	basement	NOUN	NN	3	O
membrane	membrane	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Mediation	mediation	NOUN	NN	5	O
of	of	ADP	IN	5	O
enhanced	enhance	VERB	VBN	3	O
reflex	reflex	ADJ	JJ	5	O
vagal	vagal	ADJ	JJ	5	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
by	by	ADP	IN	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	NOUN	NN	0	I-Chemical
via	via	ADP	IN	9	O
central	central	ADJ	JJ	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
formation	formation	NOUN	NN	9	O
in	in	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

L	L	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
Dopa	Dopa	PROPN	NNP	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
decreased	decrease	VERB	VBD	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
after	after	ADP	IN	9	O
extracerebral	extracerebral	ADJ	JJ	5	O
decarboxylase	decarboxylase	NOUN	NN	1	O
inhibition	inhibition	NOUN	NN	3	O
with	with	ADP	IN	5	O
MK	MK	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
486	486	NUM	CD	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
25	25	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
anesthetize	anesthetize	NOUN	NN	5	O
MAO	MAO	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
inhibited	inhibit	VERB	VBN	3	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
reflex	reflex	ADJ	JJ	5	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
injected	injected	ADJ	JJ	3	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
was	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
enhanced	enhance	VERB	VBN	3	O
by	by	ADP	IN	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	PROPN	NNP	0	I-Chemical
,	,	PUNCT	,	9	O
DL	DL	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
Threo	Threo	PROPN	NNP	1	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dihydroxyphenylserine	dihydroxyphenylserine	PROPN	NNP	_	I-Chemical
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
reflex	reflex	VERB	VB	5	O
responses	response	NOUN	NNS	5	O
to	to	ADP	IN	5	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

FLA	FLA	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
63	63	NUM	CD	7	I-Chemical
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
oxidase	oxidase	NOUN	NN	0	O
inhibitor	inhibitor	NOUN	NN	3	O
,	,	PUNCT	,	9	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
have	have	VERB	VB	5	O
any	any	DET	DT	5	O
effect	effect	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
reflex	reflex	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
enhancing	enhance	VERB	VBG	9	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Pimozide	Pimozide	PROPN	NNP	0	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
affect	affect	VERB	VB	9	O
the	the	DET	DT	5	O
actions	action	NOUN	NNS	5	O
of	of	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	NOUN	NN	0	I-Chemical
on	on	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
completely	completely	ADV	RB	9	O
blocked	block	VERB	VBD	3	O
the	the	DET	DT	5	O
enhancement	enhancement	NOUN	NN	9	O
of	of	ADP	IN	5	O
reflexes	reflex	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Removal	Removal	PROPN	NNP	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
carotid	carotid	ADJ	JJ	5	O
sinuses	sinus	NOUN	NNS	5	O
caused	cause	VERB	VBD	9	O
an	an	DET	DT	5	O
elevation	elevation	NOUN	NN	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
abolished	abolish	VERB	VBD	3	O
the	the	DET	DT	5	O
negative	negative	ADJ	JJ	9	O
chronotropic	chronotropic	ADJ	JJ	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	NOUN	NN	0	I-Chemical
restored	restore	VERB	VBD	3	O
the	the	DET	DT	5	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
in	in	ADP	IN	5	O
addition	addition	NOUN	NN	9	O
to	to	ADP	IN	5	O
decreasing	decrease	VERB	VBG	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

5	5	PUNCT	LS	9	B-Chemical
-	-	PUNCT	:	7	I-Chemical
HTP	HTP	PROPN	NNP	5	I-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
decreased	decrease	VERB	VBD	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
heart	heart	NOUN	NN	5	O
rate	rate	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
the	the	DET	DT	5	O
reflex	reflex	ADJ	JJ	5	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
to	to	ADP	IN	5	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
L	l	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dopa	dopa	ADJ	JJ	0	I-Chemical
enhances	enhance	NOUN	NNS	3	O
reflex	reflex	VERB	VBP	5	O
bradycardia	bradycardia	NOUN	NNS	5	B-Disease
through	through	ADP	IN	9	O
central	central	ADJ	JJ	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
receptor	receptor	NOUN	NN	3	O
stimulation	stimulation	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Furthermore	furthermore	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
mediated	mediate	VERB	VBN	3	O
through	through	ADP	IN	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
rather	rather	ADV	RB	5	O
than	than	ADP	IN	5	O
norepinephrine	norepinephrine	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
do	do	VERB	VBP	5	O
not	not	ADV	RB	5	O
require	require	VERB	VB	5	O
the	the	DET	DT	5	O
carotid	carotid	ADJ	JJ	5	O
sinus	sinus	NOUN	NN	5	O
baroreceptors	baroreceptor	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Microangiopathic	microangiopathic	ADJ	JJ	2	B-Disease
hemolytic	hemolytic	ADJ	JJ	0	I-Disease
anemia	anemia	NOUN	NN	9	I-Disease
complicating	complicate	VERB	VBG	5	O
FK506	FK506	PROPN	NNP	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
3	3	NUM	CD	9	O
episodes	episode	NOUN	NNS	5	O
of	of	ADP	IN	5	O
microangiopathic	microangiopathic	ADJ	JJ	5	B-Disease
hemolytic	hemolytic	ADJ	JJ	0	I-Disease
anemia	anemia	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
MAHA	MAHA	PROPN	NNP	0	B-Disease
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
solid	solid	ADJ	JJ	9	O
organ	organ	NOUN	NN	5	O
recipients	recipient	NOUN	NNS	9	O
under	under	ADP	IN	9	O
FK506	FK506	PROPN	NNP	3	B-Chemical
(	(	PUNCT	-LRB-	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
both	both	DET	DT	9	O
cases	case	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
discontinuation	discontinuation	NOUN	NN	5	O
of	of	ADP	IN	5	O
FK506	fk506	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
exchange	exchange	NOUN	NN	9	O
,	,	PUNCT	,	9	O
fresh	fresh	ADJ	JJ	9	O
frozen	frozen	ADJ	JJ	9	O
plasma	plasma	NOUN	NN	9	O
replacement	replacement	NOUN	NN	9	O
,	,	PUNCT	,	9	O
corticosteroids	corticosteroid	NOUN	NNS	5	B-Chemical
,	,	PUNCT	,	9	O
aspirin	aspirin	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
dipyridamole	dipyridamole	NOUN	NN	0	B-Chemical
led	lead	VERB	VBN	9	O
to	to	ADP	IN	5	O
resolution	resolution	NOUN	NN	5	O
of	of	ADP	IN	5	O
MAHA	MAHA	PROPN	NNP	0	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
one	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
,	,	PUNCT	,	9	O
reintroduction	reintroduction	NOUN	NN	9	O
of	of	ADP	IN	5	O
FK506	FK506	PROPN	NNP	3	B-Chemical
led	lead	VERB	VBD	9	O
to	to	ADP	IN	5	O
rapid	rapid	ADJ	JJ	5	O
recurrence	recurrence	NOUN	NN	5	O
of	of	ADP	IN	5	O
MAHA	MAHA	PROPN	NNP	0	B-Disease
.	.	PUNCT	.	9	O

FK506	fk506	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
MAHA	MAHA	PROPN	NNP	0	B-Disease
is	be	VERB	VBZ	5	O
probably	probably	ADV	RB	9	O
rare	rare	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
physicians	physician	NOUN	NNS	5	O
must	must	VERB	MD	5	O
be	be	VERB	VB	5	O
aware	aware	ADJ	JJ	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
severe	severe	ADJ	JJ	5	O
complication	complication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
experience	experience	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
,	,	PUNCT	,	9	O
FK506	FK506	PROPN	NNP	3	B-Chemical
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
seem	seem	VERB	VB	5	O
to	to	PART	TO	5	O
cross	cross	VERB	VB	5	O
-	-	ADJ	JJ	7	O
react	react	NOUN	NN	9	O
with	with	ADP	IN	5	O
cyclosporin	cyclosporin	NOUN	NN	0	B-Chemical
A	A	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
CyA	CyA	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
an	an	DET	DT	5	O
immuno	immuno	NOUN	NNS	3	O
-	-	PUNCT	HYPH	7	O
suppressive	suppressive	ADJ	JJ	3	O
drug	drug	NOUN	NN	5	O
already	already	ADV	RB	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
MAHA	MAHA	PROPN	NNP	0	B-Disease
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
some	some	DET	DT	5	O
anticancer	anticancer	NOUN	NN	0	O
drugs	drug	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
combined	combined	ADJ	JJ	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
on	on	ADP	IN	5	O
renal	renal	ADJ	JJ	9	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
nephrotoxic	nephrotoxic	ADJ	JJ	5	B-Disease
action	action	NOUN	NN	5	O
of	of	ADP	IN	5	O
anticancer	anticancer	NOUN	NN	0	O
drugs	drug	NOUN	NNS	5	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
nitrogranulogen	nitrogranulogen	NOUN	NN	_	B-Chemical
(	(	PUNCT	-LRB-	9	O
NG	NG	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
methotrexate	methotrexate	NOUN	NN	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
MTX	MTX	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
cyclophosphamide	cyclophosphamide	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CY	CY	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
administered	administer	VERB	VBD	9	O
alone	alone	ADV	RB	9	O
or	or	CCONJ	CC	5	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
[	[	PUNCT	-LRB-	9	O
MTX	MTX	PROPN	NNP	0	B-Chemical
+	+	CCONJ	CC	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
+	+	SYM	SYM	9	O
CY	CY	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
CMF	CMF	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
]	]	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
in	in	ADP	IN	5	O
experiments	experiment	NOUN	NNS	9	O
on	on	ADP	IN	5	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
drug	drug	NOUN	NN	5	O
administration	administration	NOUN	NN	9	O
,	,	PUNCT	,	9	O
creatinine	creatinine	VERB	VB	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
urine	urine	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
clearance	clearance	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Histopathologic	histopathologic	ADJ	JJ	5	O
evaluation	evaluation	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
kidneys	kidney	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
performed	perform	VERB	VBN	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
MTX	MTX	PROPN	NNP	0	B-Chemical
administration	administration	NOUN	NN	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0228	0228	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
plasma	plasma	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
clearance	clearance	NOUN	NN	9	O
was	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
NG	NG	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
CY	CY	PROPN	NNP	9	B-Chemical
neither	neither	CCONJ	CC	9	O
a	a	DET	DT	5	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
nor	nor	CCONJ	CC	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
clearance	clearance	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
group	group	NOUN	NN	9	O
receiving	receive	VERB	VBG	9	O
no	no	DET	DT	9	O
cytostatics	cytostatic	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Following	follow	VERB	VBG	9	O
polytherapy	polytherapy	NOUN	NN	5	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
CMF	CMF	PROPN	NNP	9	O
regimen	regimen	NOUN	NN	5	O
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
=	=	X	XX	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0343	0343	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
clearance	clearance	NOUN	NN	9	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
creatinine	creatinine	VERB	VB	0	B-Chemical
concentration	concentration	NOUN	NN	0	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
increase	increase	VERB	VB	9	O
significantly	significantly	ADV	RB	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CY	CY	PROPN	NNP	9	B-Chemical
caused	cause	VERB	VBD	9	O
hemorrhagic	hemorrhagic	ADJ	JJ	5	B-Disease
cystitis	cystitis	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
it	-PRON-	PRON	PRP	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
cause	cause	VERB	VB	5	O
this	this	DET	DT	5	O
complication	complication	NOUN	NN	5	O
when	when	ADV	WRB	5	O
combined	combine	VERB	VBN	9	O
with	with	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
MTX	MTX	PROPN	NNP	0	B-Chemical
.	.	PUNCT	.	9	O

Histologic	histologic	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
kidneys	kidney	NOUN	NNS	9	O
after	after	ADP	IN	9	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
MTX	MTX	PROPN	NNP	0	B-Chemical
,	,	PUNCT	,	9	O
CY	CY	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
NG	NG	PROPN	NNP	9	B-Chemical
,	,	PUNCT	,	9	O
while	while	ADP	IN	9	O
no	no	DET	DT	9	O
such	such	ADJ	JJ	5	O
change	change	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
after	after	ADP	IN	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
joint	joint	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
MTX	MTX	PROPN	NNP	0	B-Chemical
+	+	CCONJ	CC	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
+	+	SYM	SYM	9	O
CY	CY	PROPN	NNP	9	B-Chemical
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
studies	study	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
MTX	MTX	PROPN	NNP	0	B-Chemical
+	+	CCONJ	CC	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
+	+	SYM	SYM	9	O
CY	CY	PROPN	NNP	9	B-Chemical
administered	administer	VERB	VBD	9	O
jointly	jointly	ADV	RB	5	O
is	be	VERB	VBZ	5	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
monotherapy	monotherapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
interpeduncular	interpeduncular	ADJ	JJ	5	O
nucleus	nucleus	NOUN	NN	9	O
regulates	regulate	VERB	VBZ	3	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
'	'	PUNCT	''	9	O
s	s	VERB	VBZ	9	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
free	free	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
field	field	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Partial	partial	ADJ	JJ	9	O
lesions	lesion	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
made	make	VERB	VBN	5	O
with	with	ADP	IN	5	O
kainic	kainic	NOUN	NN	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
interpeduncular	interpeduncular	ADJ	JJ	5	O
nucleus	nucleus	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
ventral	ventral	ADJ	JJ	5	O
midbrain	midbrain	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
sham	sham	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
operated	operate	VERB	VBN	5	O
controls	control	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
lesions	lesion	NOUN	NNS	5	O
significantly	significantly	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
25	25	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
blunted	blunt	VERB	VBD	9	O
the	the	DET	DT	5	O
early	early	ADJ	JJ	9	O
(	(	PUNCT	-LRB-	9	O
<	<	X	XX	0	O
60	60	NUM	CD	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
free	free	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
field	field	NOUN	NN	5	O
locomotor	locomotor	NOUN	NN	5	B-Disease
hypoactivity	hypoactivity	NOUN	NN	5	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
kg	kg	PROPN	NNP	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
m	m	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
enhanced	enhance	VERB	VBD	3	O
the	the	DET	DT	5	O
later	later	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
60	60	NUM	CD	9	O
-	-	SYM	SYM	7	O
120	120	NUM	CD	9	O
min	min	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
raised	raise	VERB	VBD	9	O
spontaneous	spontaneous	ADJ	JJ	5	O
nocturnal	nocturnal	ADJ	JJ	5	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Lesions	lesion	NOUN	NNS	5	O
reduced	reduce	VERB	VBD	9	O
the	the	DET	DT	5	O
extent	extent	NOUN	NN	9	O
of	of	ADP	IN	5	O
immunohistological	immunohistological	ADJ	JJ	3	O
staining	staining	NOUN	NN	3	O
for	for	ADP	IN	5	O
choline	choline	NOUN	NN	0	B-Chemical
acetyltransferase	acetyltransferase	NOUN	NN	1	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
interpeduncular	interpeduncular	ADJ	JJ	5	O
nucleus	nucleus	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
p	p	NOUN	NN	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
025	025	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
for	for	ADP	IN	5	O
tyrosine	tyrosine	NOUN	NN	3	B-Chemical
hydroxylase	hydroxylase	NOUN	NN	1	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
surrounding	surround	VERB	VBG	9	O
catecholaminergic	catecholaminergic	ADJ	JJ	3	O
A10	A10	PROPN	NNP	9	O
region	region	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
interpeduncular	interpeduncular	ADJ	JJ	5	O
nucleus	nucleus	NOUN	NN	9	O
mediates	mediate	VERB	VBZ	3	O
nicotinic	nicotinic	ADJ	JJ	0	O
depression	depression	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
dampens	dampen	VERB	VBZ	3	O
nicotinic	nicotinic	ADJ	JJ	0	O
arousal	arousal	NOUN	NN	5	O
mechanisms	mechanism	NOUN	NNS	9	O
located	locate	VERB	VBN	9	O
elsewhere	elsewhere	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Lithium	Lithium	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
functional	functional	ADJ	JJ	9	I-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
reduced	reduce	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
switch	switch	NOUN	NN	9	O
to	to	ADP	IN	5	O
divalproex	divalproex	VERB	VBN	5	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
series	series	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Lithium	Lithium	PROPN	NNP	0	B-Chemical
remains	remain	VERB	VBZ	9	O
a	a	DET	DT	5	O
first	first	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
line	line	NOUN	NN	9	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
acute	acute	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
maintenance	maintenance	NOUN	NN	9	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
disorder	disorder	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
much	much	ADJ	JJ	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
written	write	VERB	VBN	5	O
about	about	ADP	IN	5	O
the	the	DET	DT	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
more	more	ADV	RBR	5	O
common	common	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
polyuria	polyuria	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
tremor	tremor	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
more	more	ADV	RBR	5	O
subtle	subtle	ADJ	JJ	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
such	such	ADJ	JJ	5	O
as	as	ADP	IN	5	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
loss	loss	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
creativity	creativity	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
functional	functional	ADJ	JJ	9	B-Disease
impairments	impairment	NOUN	NNS	5	I-Disease
remain	remain	VERB	VBP	9	O
understudied	understudied	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
report	report	NOUN	NN	5	O
summarizes	summarize	VERB	VBZ	5	O
our	-PRON-	DET	PRP$	5	O
experience	experience	NOUN	NN	5	O
in	in	ADP	IN	5	O
switching	switch	VERB	VBG	5	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
from	from	ADP	IN	9	O
lithium	lithium	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
divalproex	divalproex	ADJ	JJ	5	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
to	to	PART	TO	5	O
alleviate	alleviate	VERB	VB	5	O
such	such	ADJ	JJ	5	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
and	and	CCONJ	CC	5	I-Disease
functional	functional	ADJ	JJ	9	I-Disease
impairments	impairment	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
Open	open	VERB	VB	5	O
,	,	PUNCT	,	9	O
case	case	NOUN	NN	5	O
series	series	NOUN	NN	5	O
design	design	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
seven	seven	NUM	CD	9	O
cases	case	NOUN	NNS	5	O
where	where	ADV	WRB	5	O
substitution	substitution	NOUN	NN	9	O
of	of	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
either	either	CCONJ	CC	9	O
fully	fully	ADV	RB	9	O
or	or	CCONJ	CC	5	O
partially	partially	ADV	RB	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
divalproex	divalproex	ADJ	JJ	5	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
extremely	extremely	ADV	RB	5	O
helpful	helpful	ADJ	JJ	6	O
in	in	ADP	IN	5	O
reducing	reduce	VERB	VBG	9	O
the	the	DET	DT	5	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
,	,	PUNCT	,	9	I-Disease
motivational	motivational	ADJ	JJ	5	I-Disease
,	,	PUNCT	,	9	I-Disease
or	or	CCONJ	CC	5	I-Disease
creative	creative	ADJ	JJ	5	I-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
attributed	attribute	VERB	VBN	9	O
to	to	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

CONCLUSION	conclusion	NOUN	NN	5	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
this	this	DET	DT	5	O
preliminary	preliminary	ADJ	JJ	9	O
report	report	NOUN	NN	5	O
,	,	PUNCT	,	9	O
divalproex	divalproex	ADJ	JJ	5	B-Chemical
sodium	sodium	NOUN	NN	0	I-Chemical
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
superior	superior	ADJ	JJ	5	O
alternative	alternative	NOUN	NN	5	O
to	to	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
bipolar	bipolar	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
experiencing	experience	VERB	VBG	5	O
cognitive	cognitive	ADJ	JJ	5	B-Disease
deficits	deficit	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
loss	loss	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
creativity	creativity	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
functional	functional	ADJ	JJ	9	B-Disease
impairments	impairment	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Effect	effect	NOUN	NN	0	O
of	of	ADP	IN	5	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
transplant	transplant	NOUN	NN	9	O
recipients	recipient	NOUN	NNS	9	O
receiving	receive	VERB	VBG	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
transplant	transplant	NOUN	NN	9	O
recipients	recipient	NOUN	NNS	9	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
receiving	receive	VERB	VBG	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
between	between	ADP	IN	5	O
January	January	PROPN	NNP	2	O
1992	1992	NUM	CD	2	O
and	and	CCONJ	CC	5	O
January	January	PROPN	NNP	2	O
1996	1996	NUM	CD	2	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
over	over	ADP	IN	5	O
a	a	DET	DT	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
,	,	PUNCT	,	9	O
one	one	NUM	CD	5	O
group	group	NOUN	NN	9	O
comprising	comprise	VERB	VBG	9	O
hypertensive	hypertensive	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
receiving	receive	VERB	VBG	9	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
comprising	comprise	VERB	VBG	9	O
nonhypertensive	nonhypertensive	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
not	not	ADV	RB	5	O
receiving	receive	VERB	VBG	9	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
time	time	NOUN	NN	5	O
from	from	ADP	IN	9	O
transplant	transplant	NOUN	NN	9	O
to	to	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
was	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Nifedipine	nifedipine	NOUN	NN	0	B-Chemical
significantly	significantly	ADV	RB	9	O
improved	improve	VERB	VBD	5	O
kidney	kidney	NOUN	NN	9	O
function	function	NOUN	NN	9	O
as	as	ADP	IN	5	O
indicated	indicate	VERB	VBN	9	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
lowering	lowering	NOUN	NN	9	O
of	of	ADP	IN	5	O
serum	serum	NOUN	NN	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
at	at	ADP	IN	9	O
6	6	NUM	CD	9	O
and	and	CCONJ	CC	5	O
12	12	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
observed	observed	ADJ	JJ	9	O
positive	positive	ADJ	JJ	9	O
impact	impact	NOUN	NN	5	O
of	of	ADP	IN	5	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
on	on	ADP	IN	5	O
reducing	reduce	VERB	VBG	9	O
the	the	DET	DT	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
liver	liver	NOUN	NN	9	O
transplant	transplant	NOUN	NN	9	O
recipients	recipient	NOUN	NNS	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
factor	factor	NOUN	NN	9	O
in	in	ADP	IN	5	O
selecting	select	VERB	VBG	5	O
an	an	DET	DT	5	O
agent	agent	NOUN	NN	9	O
to	to	PART	TO	5	O
treat	treat	VERB	VB	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
population	population	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Alpha	alpha	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
beta	beta	NOUN	NN	9	O
coma	coma	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
intoxication	intoxication	NOUN	NN	9	O
uncomplicated	uncomplicate	VERB	VBN	5	O
by	by	ADP	IN	9	O
cerebral	cerebral	ADJ	JJ	5	B-Disease
hypoxia	hypoxia	NOUN	NN	3	I-Disease
.	.	PUNCT	.	9	O

Four	four	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
rendered	render	VERB	VBN	9	O
comatose	comatose	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
stuporous	stuporous	ADJ	JJ	5	B-Disease
by	by	ADP	IN	9	O
drug	drug	NOUN	NN	5	O
intoxication	intoxication	NOUN	NN	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
hypoxic	hypoxic	ADJ	JJ	3	O
,	,	PUNCT	,	9	O
are	be	VERB	VBP	5	O
described	describe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Three	three	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
received	receive	VERB	VBD	9	O
high	high	ADJ	JJ	9	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
chlormethiazole	chlormethiazole	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
alcohol	alcohol	NOUN	NN	5	B-Chemical
withdrawal	withdrawal	NOUN	NN	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
one	one	NUM	CD	5	O
took	take	VERB	VBD	5	O
a	a	DET	DT	5	O
suicidal	suicidal	ADJ	JJ	5	O
overdose	overdose	NOUN	NN	0	B-Disease
of	of	ADP	IN	5	O
nitrazepam	nitrazepam	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
nitrazepam	nitrazepam	NOUN	NN	0	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
and	and	CCONJ	CC	5	O
two	two	NUM	CD	5	O
of	of	ADP	IN	5	O
those	those	DET	DT	5	O
with	with	ADP	IN	5	O
chlormethiazole	chlormethiazole	ADJ	JJ	0	B-Chemical
intoxication	intoxication	NOUN	NN	9	O
conformed	conform	VERB	VBD	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
criteria	criterion	NOUN	NNS	5	O
of	of	ADP	IN	5	O
'	'	PUNCT	``	9	O
alpha	alpha	NOUN	NN	9	O
coma	coma	NOUN	NN	5	B-Disease
'	'	PUNCT	''	9	O
,	,	PUNCT	,	9	O
showing	show	VERB	VBG	9	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
reactive	reactive	ADJ	JJ	9	O
generalized	generalize	VERB	VBN	5	O
or	or	CCONJ	CC	5	O
frontally	frontally	ADV	RB	5	O
predominant	predominant	ADJ	JJ	9	O
alpha	alpha	NOUN	NN	9	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
EEG	EEG	PROPN	NNP	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
fourth	fourth	ADJ	JJ	9	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
was	be	VERB	VBD	9	O
unconscious	unconscious	ADJ	JJ	5	O
after	after	ADP	IN	9	O
chlormethiazole	chlormethiazole	NOUN	NN	0	B-Chemical
administration	administration	NOUN	NN	9	O
exhibite	exhibite	NOUN	NN	9	O
generalized	generalize	VERB	VBN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
reactive	reactive	ADJ	JJ	9	O
activity	activity	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
slow	slow	ADJ	JJ	5	O
beta	beta	NOUN	NN	9	O
range	range	NOUN	NN	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
four	four	NUM	CD	9	O
recovered	recover	VERB	VBN	9	O
completely	completely	ADV	RB	9	O
without	without	ADP	IN	9	O
neurological	neurological	ADJ	JJ	5	B-Disease
sequelae	sequelae	NOUN	NN	5	I-Disease
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
offending	offend	VERB	VBG	5	O
agents	agent	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
similarities	similarity	NOUN	NNS	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
structural	structural	ADJ	JJ	9	O
lesions	lesion	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
pharmacological	pharmacological	ADJ	JJ	9	O
depression	depression	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
brain	brain	NOUN	NN	5	O
stem	stem	NOUN	NN	3	O
reticular	reticular	ADJ	JJ	5	O
formation	formation	NOUN	NN	9	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
suggested	suggest	VERB	VBN	9	O
that	that	ADP	IN	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
situations	situation	NOUN	NNS	5	O
disturbed	disturb	VERB	VBD	5	O
reticulo	reticulo	ADJ	JJ	3	O
-	-	PUNCT	HYPH	7	O
thalamic	thalamic	ADJ	JJ	5	O
interactions	interaction	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
important	important	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	O
coma	coma	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
when	when	ADV	WRB	5	O
this	this	DET	DT	5	O
electroencephalographic	electroencephalographic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
behavioural	behavioural	ADJ	JJ	5	O
picture	picture	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
drug	drug	NOUN	NN	5	O
intoxication	intoxication	NOUN	NN	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
absence	absence	NOUN	NN	3	O
of	of	ADP	IN	5	O
significant	significant	ADJ	JJ	9	O
hypoxaemia	hypoxaemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
a	a	DET	DT	5	O
favourable	favourable	ADJ	JJ	5	O
outcome	outcome	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
anticipated	anticipate	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Magnetic	magnetic	ADJ	JJ	5	O
resonance	resonance	NOUN	NN	5	O
volumetry	volumetry	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cerebellum	cerebellum	NOUN	NN	9	O
in	in	ADP	IN	5	O
epileptic	epileptic	ADJ	JJ	5	B-Disease
patients	patient	NOUN	NNS	5	O
after	after	ADP	IN	9	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
overdosages	overdosage	NOUN	NNS	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
relationship	relationship	NOUN	NN	5	O
between	between	ADP	IN	5	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
medication	medication	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
cerebellar	cerebellar	ADJ	JJ	5	B-Disease
atrophy	atrophy	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
experienced	experience	VERB	VBN	5	O
clinical	clinical	ADJ	JJ	5	O
intoxication	intoxication	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
females	female	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
6	6	NUM	CD	9	O
males	male	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
21	21	NUM	CD	7	O
-	-	SYM	SYM	7	O
59	59	NUM	CD	7	O
years	year	NOUN	NNS	5	O
of	of	ADP	IN	5	O
age	age	NOUN	NN	5	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
-	-	PUNCT	:	7	O
T	t	NOUN	NN	3	O
whole	whole	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
body	body	NOUN	NN	5	O
system	system	NOUN	NN	5	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
circular	circular	ADJ	JJ	5	O
polarized	polarize	VERB	VBN	3	O
head	head	NOUN	NN	5	O
coil	coil	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Conventional	conventional	ADJ	JJ	5	O
spin	spin	NOUN	NN	0	O
echo	echo	NOUN	NN	5	O
images	image	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
acquired	acquire	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
sagittal	sagittal	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
transverse	transverse	ADJ	JJ	5	O
orientation	orientation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
performed	perform	VERB	VBD	9	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
resolution	resolution	NOUN	NN	5	O
3D	3d	NOUN	NN	5	O
gradient	gradient	NOUN	NN	9	O
echo	echo	VERB	VBP	5	O
,	,	PUNCT	,	9	O
T1	T1	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
weighted	weight	VERB	VBN	5	O
sequences	sequence	NOUN	NNS	1	O
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
1	1	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
mm	mm	NOUN	NN	9	O
slice	slice	NOUN	NN	5	O
thickness	thickness	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
images	image	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
subsequently	subsequently	ADV	RB	9	O
processed	process	VERB	VBN	9	O
to	to	PART	TO	5	O
obtain	obtain	VERB	VB	5	O
volumetric	volumetric	ADJ	JJ	5	O
data	datum	NOUN	NNS	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
cerebellum	cerebellum	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Cerebellar	cerebellar	ADJ	JJ	9	O
volume	volume	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
group	group	NOUN	NN	9	O
ranged	range	VERB	VBD	9	O
between	between	ADP	IN	5	O
67	67	NUM	CD	7	O
.	.	PUNCT	.	9	O
66	66	NUM	CD	7	O
and	and	CCONJ	CC	5	O
131	131	NUM	CD	7	O
.	.	PUNCT	.	9	O
08	08	NUM	CD	7	O
ml	ml	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
mean	mean	VERB	VB	5	O
108	108	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
ml	ml	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
3D	3d	NOUN	NN	5	O
gradient	gradient	NOUN	NN	9	O
echo	echo	NOUN	NN	5	O
data	data	NOUN	NN	5	O
sets	set	NOUN	NNS	5	O
from	from	ADP	IN	9	O
10	10	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
male	male	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
10	10	NUM	CD	9	O
healthy	healthy	ADJ	JJ	5	O
female	female	ADJ	JJ	9	O
age	age	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
matched	match	VERB	VBN	9	O
volunteers	volunteer	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
used	use	VERB	VBN	5	O
to	to	PART	TO	5	O
compare	compare	VERB	VB	9	O
cerebellar	cerebellar	ADJ	JJ	5	O
volumes	volume	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Using	use	VERB	VBG	9	O
linear	linear	ADJ	JJ	5	O
regression	regression	NOUN	NN	5	O
we	-PRON-	PRON	PRP	5	O
found	find	VERB	VBD	9	O
that	that	ADP	IN	5	O
no	no	DET	DT	9	O
correlation	correlation	NOUN	NN	9	O
exists	exist	VERB	VBZ	9	O
between	between	ADP	IN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
duration	duration	NOUN	NN	5	O
,	,	PUNCT	,	9	O
elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
serum	serum	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
cerebellar	cerebellar	ADJ	JJ	5	O
volume	volume	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
multiple	multiple	ADJ	JJ	5	O
regression	regression	NOUN	NN	5	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
daily	daily	ADJ	JJ	5	O
dosage	dosage	NOUN	NN	9	O
,	,	PUNCT	,	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
cerebellar	cerebellar	ADJ	JJ	5	O
volume	volume	NOUN	NN	9	O
revealed	reveal	VERB	VBD	9	O
a	a	DET	DT	5	O
correlation	correlation	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
parameters	parameter	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
conclude	conclude	VERB	VBP	9	O
that	that	ADP	IN	5	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
overdosage	overdosage	NOUN	NN	5	B-Disease
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
necessarily	necessarily	ADV	RB	5	O
result	result	VERB	VB	9	O
in	in	ADP	IN	5	O
cerebellar	cerebellar	ADJ	JJ	5	B-Disease
atrophy	atrophy	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
unlikely	unlikely	ADJ	JJ	9	O
that	that	ADP	IN	5	O
phenytoin	phenytoin	NOUN	NN	0	B-Chemical
medication	medication	NOUN	NN	5	O
was	be	VERB	VBD	9	O
the	the	DET	DT	5	O
only	only	ADJ	JJ	9	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
cerebellar	cerebellar	ADJ	JJ	5	B-Disease
atrophy	atrophy	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
remaining	remain	VERB	VBG	9	O
patients	patient	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Quantitative	quantitative	ADJ	JJ	9	O
morphometric	morphometric	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cerebellum	cerebellum	NOUN	NN	9	O
provide	provide	VERB	VBP	5	O
valuable	valuable	ADJ	JJ	5	O
insights	insight	NOUN	NNS	5	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
cerebellar	cerebellar	ADJ	JJ	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Late	late	ADJ	JJ	9	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
uremic	uremic	ADJ	JJ	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
case	case	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
reported	report	VERB	VBN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hemolytic	hemolytic	ADJ	JJ	0	B-Disease
uremic	uremic	ADJ	JJ	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
HUS	HUS	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
woman	woman	NOUN	NN	5	O
taking	take	VERB	VBG	5	O
oral	oral	ADJ	JJ	9	B-Chemical
contraceptives	contraceptive	NOUN	NNS	5	I-Chemical
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
heparin	heparin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
dipyridamole	dipyridamole	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
hemodialysis	hemodialysis	NOUN	NN	5	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
after	after	ADP	IN	9	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
three	three	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
her	-PRON-	DET	PRP$	5	O
urinary	urinary	ADJ	JJ	9	O
output	output	NOUN	NN	5	O
rose	rise	VERB	VBD	9	O
above	above	ADP	IN	9	O
500	500	NUM	CD	0	O
ml	ml	NOUN	NNS	0	O
;	;	PUNCT	:	9	O
and	and	CCONJ	CC	5	O
six	six	NUM	CD	9	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
anuria	anuria	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
dialysis	dialysis	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
was	be	VERB	VBD	9	O
stopped	stop	VERB	VBN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
emphasizes	emphasize	VERB	VBZ	5	O
the	the	DET	DT	5	O
possibility	possibility	NOUN	NN	9	O
that	that	ADP	IN	5	O
HUS	HUS	PROPN	NNP	9	B-Disease
in	in	ADP	IN	5	O
adults	adult	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
invariably	invariably	ADV	RB	9	O
irreversible	irreversible	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
that	that	ADP	IN	5	O
,	,	PUNCT	,	9	O
despite	despite	ADP	IN	9	O
prolonged	prolonged	ADJ	JJ	9	O
oliguria	oliguria	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
obtained	obtain	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
adult	adult	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
affected	affect	VERB	VBN	9	O
by	by	ADP	IN	9	O
HUS	HUS	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
dialysis	dialysis	NOUN	NN	5	O
should	should	VERB	MD	5	O
not	not	ADV	RB	5	O
be	be	VERB	VB	5	O
discontinued	discontinue	VERB	VBN	5	O
prematurely	prematurely	ADV	RB	5	O
;	;	PUNCT	:	9	O
moreover	moreover	ADV	RB	9	O
,	,	PUNCT	,	9	O
bilateral	bilateral	ADJ	JJ	5	O
nephrectomy	nephrectomy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
microangiopathic	microangiopathic	ADJ	JJ	5	B-Disease
hemolytic	hemolytic	ADJ	JJ	0	I-Disease
anemia	anemia	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
performed	perform	VERB	VBN	9	O
with	with	ADP	IN	5	O
caution	caution	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Morphological	morphological	ADJ	JJ	9	O
features	feature	NOUN	NNS	5	O
of	of	ADP	IN	5	O
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
after	after	ADP	IN	9	O
chronic	chronic	ADJ	JJ	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
antiepileptic	antiepileptic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
valproate	valproate	NOUN	NN	0	B-Chemical
to	to	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
transmission	transmission	NOUN	NN	5	O
electron	electron	NOUN	NN	0	O
microscopic	microscopic	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
of	of	ADP	IN	5	O
capillaries	capillary	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cerebellar	cerebellar	ADJ	JJ	5	O
cortex	cortex	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Long	long	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
intragastric	intragastric	ADJ	JJ	0	O
application	application	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
antiepileptic	antiepileptic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
valproate	valproate	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
Vupral	vupral	ADJ	JJ	_	O
"	"	PUNCT	``	5	O
Polfa	Polfa	PROPN	NNP	0	O
"	"	PUNCT	''	5	O
)	)	PUNCT	-RRB-	9	O
at	at	ADP	IN	9	O
the	the	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
200	200	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	ADP	IN	0	O
b	b	NOUN	NN	9	O
.	.	PUNCT	.	9	O

w	w	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
once	once	ADV	RB	5	O
daily	daily	ADV	RB	5	O
to	to	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
for	for	ADP	IN	5	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
6	6	NUM	CD	9	O
,	,	PUNCT	,	9	O
9	9	NUM	CD	7	O
and	and	CCONJ	CC	5	O
12	12	NUM	CD	9	O
months	month	NOUN	NNS	5	O
revealed	reveal	VERB	VBD	9	O
neurological	neurological	ADJ	JJ	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
indicating	indicate	VERB	VBG	9	O
cerebellum	cerebellum	NOUN	NN	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
"	"	PUNCT	``	5	O
valproate	valproate	NOUN	NN	0	B-Chemical
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
"	"	PUNCT	''	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
ultrastructural	ultrastructural	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
structural	structural	ADJ	JJ	9	O
elements	element	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
brain	brain	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
barrier	barrier	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
BBB	BBB	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
cerebellar	cerebellar	ADJ	JJ	5	O
cortex	cortex	NOUN	NN	5	O
were	be	VERB	VBD	9	O
detectable	detectable	ADJ	JJ	9	O
after	after	ADP	IN	9	O
3	3	NUM	CD	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
experiment	experiment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

They	-PRON-	PRON	PRP	5	O
became	become	VERB	VBD	9	O
more	more	ADV	RBR	5	O
severe	severe	ADJ	JJ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
later	later	ADJ	JJ	9	O
months	month	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
experiment	experiment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
were	be	VERB	VBD	9	O
most	most	ADV	RBS	9	O
severe	severe	ADJ	JJ	5	O
after	after	ADP	IN	9	O
12	12	NUM	CD	9	O
months	month	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
located	locate	VERB	VBN	9	O
mainly	mainly	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
molecular	molecular	ADJ	JJ	9	O
layer	layer	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cerebellar	cerebellar	ADJ	JJ	5	O
cortex	cortex	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Lesions	lesion	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
capillary	capillary	ADJ	JJ	0	O
included	include	VERB	VBN	5	O
necrosis	necrosis	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
endothelial	endothelial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Organelles	organelle	NOUN	NNS	2	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
cells	cell	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
particular	particular	ADJ	JJ	5	O
the	the	DET	DT	5	O
mitochondria	mitochondria	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
increased	increase	VERB	VBN	9	O
number	number	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
size	size	NOUN	NN	9	O
,	,	PUNCT	,	9	O
distinct	distinct	ADJ	JJ	9	O
degeneration	degeneration	NOUN	NN	9	O
of	of	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
matrix	matrix	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
cristae	cristae	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
Golgi	Golgi	PROPN	NNP	9	O
apparatus	apparatus	NOUN	NN	9	O
were	be	VERB	VBD	9	O
altered	alter	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Reduced	reduced	ADJ	JJ	9	O
size	size	NOUN	NN	9	O
of	of	ADP	IN	5	O
capillary	capillary	ADJ	JJ	0	O
lumen	luman	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
occlusion	occlusion	NOUN	NN	5	O
were	be	VERB	VBD	9	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
swollen	swollen	ADJ	JJ	9	O
endothelial	endothelial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
which	which	DET	WDT	5	O
had	have	VERB	VBD	9	O
luminal	luminal	ADJ	JJ	3	B-Chemical
protrusions	protrusion	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
swollen	swollen	ADJ	JJ	9	O
microvilli	microvilli	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Pressure	pressure	NOUN	NN	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
vessel	vessel	NOUN	NN	5	O
wall	wall	NOUN	NN	5	O
was	be	VERB	VBD	9	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
enlarged	enlarge	VERB	VBN	9	O
perivascular	perivascular	ADJ	JJ	3	O
astrocytic	astrocytic	ADJ	JJ	3	O
processes	process	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Fragments	fragment	NOUN	NNS	9	O
of	of	ADP	IN	5	O
necrotic	necrotic	ADJ	JJ	3	B-Disease
endothelial	endothelial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
vascular	vascular	ADJ	JJ	5	O
lumens	lumen	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
these	these	DET	DT	5	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
loosening	loosen	VERB	VBG	5	O
and	and	CCONJ	CC	5	O
breaking	breaking	NOUN	NN	5	O
of	of	ADP	IN	5	O
tight	tight	ADJ	JJ	9	O
cellular	cellular	ADJ	JJ	3	O
junctions	junction	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Damage	damage	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
vascular	vascular	ADJ	JJ	5	O
basement	basement	NOUN	NN	3	O
lamina	lamina	NOUN	NN	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
observed	observe	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Damage	damage	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
capillary	capillary	NOUN	NN	0	O
was	be	VERB	VBD	9	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
marked	marked	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
to	to	ADP	IN	5	O
neuroglial	neuroglial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
mainly	mainly	ADV	RB	9	O
to	to	ADP	IN	5	O
perivascular	perivascular	ADJ	JJ	3	O
processes	process	NOUN	NNS	5	O
of	of	ADP	IN	5	O
astrocytes	astrocyte	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
proliferation	proliferation	NOUN	NN	3	O
of	of	ADP	IN	5	O
astrocytes	astrocyte	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
Bergmann	Bergmann	PROPN	NNP	6	O
'	'	PART	POS	9	O
s	s	NOUN	NN	9	O
in	in	ADP	IN	5	O
particular	particular	ADJ	JJ	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
occasionally	occasionally	ADV	RB	5	O
of	of	ADP	IN	5	O
oligodendrocytes	oligodendrocyte	NOUN	NNS	3	O
was	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Alterations	alteration	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
structural	structural	ADJ	JJ	9	O
elements	element	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
BBB	BBB	PROPN	NNP	9	O
coexisted	coexist	VERB	VBN	9	O
with	with	ADP	IN	5	O
marked	marked	ADJ	JJ	9	O
lesions	lesion	NOUN	NNS	5	O
of	of	ADP	IN	5	O
neurons	neuron	NOUN	NNS	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cerebellum	cerebellum	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
Purkinje	Purkinje	PROPN	NNP	3	O
cells	cell	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
earliest	early	ADJ	JJS	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
electron	electron	NOUN	NN	0	O
micrographs	micrograph	NOUN	NNS	9	O
both	both	CCONJ	CC	9	O
luminal	luminal	ADJ	JJ	3	B-Chemical
and	and	CCONJ	CC	5	O
antiluminal	antiluminal	ADJ	JJ	9	O
sides	side	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
BBB	BBB	PROPN	NNP	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cerebellar	cerebellar	ADJ	JJ	5	O
cortex	cortex	NOUN	NN	5	O
had	have	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
lesions	lesion	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
possible	possible	ADJ	JJ	5	O
influence	influence	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hepatic	hepatic	ADJ	JJ	9	B-Disease
damage	damage	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
mainly	mainly	ADV	RB	9	O
hyperammonemia	hyperammonemia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
upon	upon	ADP	IN	9	O
the	the	DET	DT	5	O
development	development	NOUN	NN	9	O
of	of	ADP	IN	5	O
valproate	valproate	NOUN	NN	0	B-Chemical
encephalopathy	encephalopathy	ADJ	JJ	5	B-Disease
is	be	VERB	VBZ	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Fatal	fatal	ADJ	JJ	5	O
intracranial	intracranial	ADJ	JJ	5	B-Disease
bleeding	bleeding	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
prehospital	prehospital	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
present	present	VERB	VBP	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
paramedic	paramedic	ADJ	JJ	5	O
misjudgment	misjudgment	NOUN	NN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
execution	execution	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
protocol	protocol	NOUN	NN	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
allergic	allergic	ADJ	JJ	9	B-Disease
reaction	reaction	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
pulmonary	pulmonary	ADJ	JJ	5	B-Disease
edema	edema	NOUN	NN	5	I-Disease
with	with	ADP	IN	5	O
wheezing	wheeze	VERB	VBG	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
sudden	sudden	ADJ	JJ	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
respiratory	respiratory	ADJ	JJ	5	B-Disease
distress	distress	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
rash	rash	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
history	history	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
medicine	medicine	NOUN	NN	5	O
led	lead	VERB	VBD	9	O
the	the	DET	DT	5	O
two	two	NUM	CD	5	O
paramedics	paramedic	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
scene	scene	NOUN	NN	5	O
to	to	PART	TO	5	O
administer	administer	VERB	VB	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Subsequently	subsequently	ADV	RB	9	O
,	,	PUNCT	,	9	O
acute	acute	ADJ	JJ	9	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
fatal	fatal	ADJ	JJ	5	O
subarachnoid	subarachnoid	NOUN	NN	5	B-Disease
hemorrhage	hemorrhage	NOUN	NN	5	I-Disease
occurred	occur	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Epinephrine	Epinephrine	PROPN	NNP	0	B-Chemical
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
proven	prove	VERB	VBN	5	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
in	in	ADP	IN	5	O
prehospital	prehospital	ADJ	JJ	5	O
care	care	NOUN	NN	5	O
;	;	PUNCT	:	9	O
however	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
use	use	NOUN	NN	5	O
by	by	ADP	IN	9	O
paramedics	paramedic	NOUN	NNS	5	O
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
suspected	suspect	VERB	VBN	5	O
allergic	allergic	ADJ	JJ	9	B-Disease
reaction	reaction	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
severe	severe	ADJ	JJ	5	O
hypertension	hypertension	NOUN	NN	5	B-Disease
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
viewed	view	VERB	VBN	5	O
with	with	ADP	IN	5	O
caution	caution	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
bradykinin	bradykinin	NOUN	NN	0	B-Chemical
B2	b2	NOUN	NN	9	O
receptors	receptor	NOUN	NNS	3	O
in	in	ADP	IN	5	O
disruption	disruption	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
brain	brain	NOUN	NN	5	O
barrier	barrier	NOUN	NN	5	O
during	during	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Cellular	Cellular	PROPN	NNP	9	O
mechanisms	mechanism	NOUN	NNS	9	O
which	which	DET	WDT	5	O
account	account	VERB	VBP	5	O
for	for	ADP	IN	5	O
disruption	disruption	NOUN	NN	9	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
brain	brain	NOUN	NN	5	O
barrier	barrier	NOUN	NN	5	O
during	during	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
clear	clear	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
goal	goal	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
synthesis	synthesis	NOUN	NN	9	O
/	/	SYM	SYM	9	O
release	release	NOUN	NN	9	O
of	of	ADP	IN	5	O
bradykinin	bradykinin	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
activate	activate	VERB	VB	3	O
B2	b2	NOUN	NN	9	O
receptors	receptor	NOUN	NNS	3	O
in	in	ADP	IN	5	O
disruption	disruption	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
brain	brain	NOUN	NN	5	O
barrier	barrier	NOUN	NN	5	O
during	during	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Permeability	permeability	NOUN	NN	0	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
brain	brain	NOUN	NN	5	O
barrier	barrier	NOUN	NN	5	O
was	be	VERB	VBD	9	O
quantitated	quantitate	VERB	VBN	9	O
by	by	ADP	IN	9	O
clearance	clearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
fluorescent	fluorescent	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
labeled	label	VERB	VBN	3	O
dextran	dextran	NOUN	NN	0	B-Chemical
before	before	ADP	IN	9	O
and	and	CCONJ	CC	5	O
during	during	ADP	IN	5	O
phenylephrine	phenylephrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
acute	acute	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
vehicle	vehicle	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
Hoe	Hoe	PROPN	NNP	6	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
140	140	NUM	CD	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
1	1	NUM	CD	9	O
microM	microM	PROPN	NNP	0	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Phenylephrine	phenylephrine	ADJ	JJ	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
increased	increase	VERB	VBD	9	O
arterial	arterial	ADJ	JJ	5	O
pressure	pressure	NOUN	NN	5	O
,	,	PUNCT	,	9	O
arteriolar	arteriolar	ADJ	JJ	5	O
diameter	diameter	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
clearance	clearance	NOUN	NN	9	O
of	of	ADP	IN	5	O
fluorescent	fluorescent	ADJ	JJ	3	O
dextran	dextran	NOUN	NN	0	B-Chemical
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
magnitude	magnitude	NOUN	NN	5	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
findings	finding	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
disruption	disruption	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
blood	blood	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
brain	brain	NOUN	NN	5	O
barrier	barrier	NOUN	NN	5	O
during	during	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
related	relate	VERB	VBN	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
synthesis	synthesis	NOUN	NN	9	O
/	/	SYM	SYM	9	O
release	release	NOUN	NN	9	O
of	of	ADP	IN	5	O
bradykinin	bradykinin	NOUN	NN	0	B-Chemical
to	to	PART	TO	5	O
activate	activate	VERB	VB	3	O
B2	b2	NOUN	NN	9	O
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
of	of	ADP	IN	5	O
sensorineural	sensorineural	ADJ	JJ	5	B-Disease
hearing	hearing	NOUN	NN	5	I-Disease
loss	loss	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
preterm	preterm	ADJ	JJ	5	O
infants	infant	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Among	among	ADP	IN	9	O
547	547	NUM	CD	7	O
preterm	preterm	ADJ	JJ	5	O
infants	infant	NOUN	NNS	5	O
of	of	ADP	IN	5	O
<	<	X	XX	0	O
or	or	CCONJ	CC	5	O
=	=	SYM	SYM	7	O
34	34	NUM	CD	7	O
weeks	week	NOUN	NNS	9	O
gestation	gestation	NOUN	NN	9	O
born	bear	VERB	VBN	5	O
between	between	ADP	IN	5	O
1987	1987	NUM	CD	2	O
and	and	CCONJ	CC	5	O
1991	1991	NUM	CD	2	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
children	child	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
46	46	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
developed	develop	VERB	VBD	5	O
severe	severe	ADJ	JJ	5	O
progressive	progressive	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
bilateral	bilateral	ADJ	JJ	5	O
sensorineural	sensorineural	ADJ	JJ	5	B-Disease
hearing	hearing	NOUN	NN	5	I-Disease
loss	loss	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Perinatal	perinatal	ADJ	JJ	2	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
of	of	ADP	IN	5	O
infants	infant	NOUN	NNS	5	O
with	with	ADP	IN	5	O
hearing	hear	VERB	VBG	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
two	two	NUM	CD	5	O
control	control	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
matched	match	VERB	VBN	9	O
for	for	ADP	IN	5	O
gestation	gestation	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
birth	birth	NOUN	NN	5	O
weight	weight	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
for	for	ADP	IN	5	O
perinatal	perinatal	ADJ	JJ	5	O
complications	complication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Our	-PRON-	DET	PRP$	9	O
observations	observation	NOUN	NNS	9	O
demonstrated	demonstrate	VERB	VBD	9	O
an	an	DET	DT	5	O
association	association	NOUN	NN	9	O
of	of	ADP	IN	5	O
hearing	hear	VERB	VBG	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
higher	high	ADJ	JJR	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
perinatal	perinatal	ADJ	JJ	5	O
complications	complication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Ototoxicity	ototoxicity	NOUN	NN	7	B-Disease
appeared	appear	VERB	VBD	9	O
closely	closely	ADV	RB	9	O
related	related	ADJ	JJ	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
prolonged	prolonged	ADJ	JJ	9	O
administration	administration	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
higher	high	ADJ	JJR	9	O
total	total	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
ototoxic	ototoxic	ADJ	JJ	5	B-Disease
drugs	drug	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
particularly	particularly	ADV	RB	5	O
aminoglycosides	aminoglycoside	NOUN	NNS	9	B-Chemical
and	and	CCONJ	CC	5	O
furosemide	furosemide	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Finally	finally	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
strongly	strongly	ADV	RB	9	O
recommend	recommend	VERB	VBP	5	O
to	to	PART	TO	5	O
prospectively	prospectively	ADV	RB	5	O
and	and	CCONJ	CC	5	O
regularly	regularly	ADV	RB	5	O
perform	perform	VERB	VB	5	O
audiologic	audiologic	NOUN	NN	5	O
assessment	assessment	NOUN	NN	5	O
in	in	ADP	IN	5	O
sick	sick	ADJ	JJ	5	O
preterm	preterm	ADJ	JJ	5	O
children	child	NOUN	NNS	5	O
as	as	ADP	IN	5	O
hearing	hear	VERB	VBG	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
is	be	VERB	VBZ	5	O
of	of	ADP	IN	5	O
delayed	delayed	ADJ	JJ	9	O
onset	onset	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
most	most	ADJ	JJS	9	O
cases	case	NOUN	NNS	5	O
bilateral	bilateral	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
severe	severe	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

Seizure	seizure	VERB	VB	5	B-Disease
resulting	result	VERB	VBG	9	O
from	from	ADP	IN	9	O
a	a	DET	DT	5	O
venlafaxine	venlafaxine	NOUN	NN	5	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
To	to	PART	TO	9	O
report	report	VERB	VB	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
venlafaxine	venlafaxine	NOUN	NN	5	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
.	.	PUNCT	.	9	O

CASE	case	NOUN	NN	2	O
SUMMARY	summary	NOUN	NN	9	O
:	:	PUNCT	:	9	O
A	a	DET	DT	9	O
40	40	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
with	with	ADP	IN	5	O
major	major	ADJ	JJ	9	B-Disease
depression	depression	NOUN	NN	5	I-Disease
took	take	VERB	VBD	5	O
an	an	DET	DT	5	O
overdose	overdose	NOUN	NN	0	B-Disease
of	of	ADP	IN	5	O
venlafaxine	venlafaxine	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
apparent	apparent	ADJ	JJ	9	O
suicide	suicide	NOUN	NN	5	O
attempt	attempt	NOUN	NN	5	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
the	the	DET	DT	5	O
ingestion	ingestion	NOUN	NN	9	O
of	of	ADP	IN	5	O
26	26	NUM	CD	7	O
venlafaxine	venlafaxine	NOUN	NN	5	B-Chemical
50	50	NUM	CD	0	O
-	-	PUNCT	HYPH	7	O
mg	mg	NOUN	NN	0	O
tablets	tablet	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
experienced	experience	VERB	VBD	5	O
a	a	DET	DT	5	O
witnessed	witness	VERB	VBN	5	O
generalized	generalized	ADJ	JJ	5	O
seizure	seizure	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

She	-PRON-	PRON	PRP	5	O
was	be	VERB	VBD	9	O
admitted	admit	VERB	VBN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
medical	medical	ADJ	JJ	5	O
intensive	intensive	ADJ	JJ	5	O
care	care	NOUN	NN	5	O
unit	unit	NOUN	NN	5	O
,	,	PUNCT	,	9	O
venlafaxine	venlafaxine	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
discontinued	discontinue	VERB	VBN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
no	no	DET	DT	9	O
further	further	ADV	RB	9	O
sequelae	sequelae	ADV	RB	5	O
were	be	VERB	VBD	9	O
seen	see	VERB	VBN	9	O
.	.	PUNCT	.	9	O

DISCUSSION	discussion	NOUN	NN	9	O
:	:	PUNCT	:	9	O
To	to	ADP	IN	9	O
our	-PRON-	DET	PRP$	5	O
knowledge	knowledge	NOUN	NN	5	O
,	,	PUNCT	,	9	O
this	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
reported	report	VERB	VBN	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
venlafaxine	venlafaxine	NOUN	NN	5	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
that	that	DET	WDT	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
generalized	generalized	ADJ	JJ	5	O
seizure	seizure	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Based	base	VERB	VBN	9	O
on	on	ADP	IN	5	O
nonoverdose	nonoverdose	ADJ	JJ	_	O
pharmacokinetics	pharmacokinetic	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
pharmacodynamics	pharmacodynamic	NOUN	NNS	5	O
of	of	ADP	IN	5	O
venlafaxine	venlafaxine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
risks	risk	NOUN	NNS	5	O
of	of	ADP	IN	5	O
available	available	ADJ	JJ	5	O
interventions	intervention	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
emergent	emergent	NOUN	NN	5	O
therapy	therapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
instituted	institute	VERB	VBN	5	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
venlafaxine	venlafaxine	NOUN	NN	5	B-Chemical
overdose	overdose	NOUN	NN	0	B-Disease
in	in	ADP	IN	5	O
our	-PRON-	DET	PRP$	5	O
patient	patient	NOUN	NN	5	O
resulted	result	VERB	VBD	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
single	single	ADJ	JJ	9	O
episode	episode	NOUN	NN	5	O
of	of	ADP	IN	5	O
generalized	generalized	ADJ	JJ	5	O
seizure	seizure	NOUN	NN	5	B-Disease
but	but	CCONJ	CC	9	O
elicited	elicit	VERB	VBD	9	O
no	no	DET	DT	9	O
further	further	ADV	RB	9	O
sequelae	sequelae	ADV	RB	5	O
.	.	PUNCT	.	9	O

Combined	combined	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
prolonged	prolonged	ADJ	JJ	9	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
E1	e1	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
haemodilution	haemodilution	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
human	human	ADJ	JJ	3	O
hepatic	hepatic	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Combined	combined	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
prolonged	prolonged	ADJ	JJ	9	O
prostaglandin	prostaglandin	NOUN	NN	0	B-Chemical
E1	E1	PROPN	NNP	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
PGE1	PGE1	PROPN	NNP	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
haemodilution	haemodilution	NOUN	NN	5	B-Disease
on	on	ADP	IN	5	O
hepatic	hepatic	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
in	in	ADP	IN	5	O
30	30	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
undergoing	undergo	VERB	VBG	9	O
hip	hip	NOUN	NN	5	O
surgery	surgery	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
allocated	allocate	VERB	VBN	5	O
to	to	ADP	IN	5	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
three	three	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
those	those	DET	DT	5	O
in	in	ADP	IN	5	O
group	group	NOUN	NN	9	O
A	A	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
subjected	subject	VERB	VBN	9	O
to	to	ADP	IN	5	O
controlled	control	VERB	VBN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
alone	alone	ADV	RB	9	O
,	,	PUNCT	,	9	O
those	those	DET	DT	5	O
in	in	ADP	IN	5	O
group	group	NOUN	NN	9	O
B	B	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
to	to	PART	TO	5	O
haemodilution	haemodilution	VERB	VB	5	B-Disease
alone	alone	ADV	RB	9	O
and	and	CCONJ	CC	5	O
those	those	DET	DT	5	O
in	in	ADP	IN	5	O
group	group	NOUN	NN	9	O
C	C	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
10	10	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
to	to	ADP	IN	5	O
both	both	DET	DT	9	O
controlled	control	VERB	VBN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
haemodilution	haemodilution	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Haemodilution	haemodilution	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
B	B	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
C	C	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
withdrawing	withdraw	VERB	VBG	5	O
approximately	approximately	ADV	RB	9	O
1000	1000	NUM	CD	9	O
mL	ml	NOUN	NN	0	O
of	of	ADP	IN	5	O
blood	blood	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
replacing	replace	VERB	VBG	9	O
it	-PRON-	PRON	PRP	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
amount	amount	NOUN	NN	9	O
of	of	ADP	IN	5	O
dextran	dextran	NOUN	NN	0	B-Chemical
solution	solution	NOUN	NN	0	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
final	final	ADJ	JJ	9	O
haematocrit	haematocrit	NOUN	NN	5	O
values	value	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
21	21	NUM	CD	7	O
or	or	CCONJ	CC	5	O
22	22	NUM	CD	7	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Controlled	control	VERB	VBN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
A	A	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
C	C	PROPN	NNP	9	O
was	be	VERB	VBD	9	O
induced	induce	VERB	VBN	3	O
with	with	ADP	IN	5	O
PGE1	PGE1	PROPN	NNP	0	B-Chemical
to	to	PART	TO	5	O
maintain	maintain	VERB	VB	5	O
mean	mean	ADJ	JJ	5	O
arterial	arterial	ADJ	JJ	5	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
at	at	ADP	IN	9	O
55	55	NUM	CD	7	O
mmHg	mmHg	NOUN	NNS	7	O
for	for	ADP	IN	5	O
180	180	NUM	CD	9	O
min	min	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Measurements	measurement	NOUN	NNS	9	O
included	include	VERB	VBD	5	O
arterial	arterial	ADJ	JJ	5	O
ketone	ketone	NOUN	NN	0	O
body	body	NOUN	NN	5	O
ratio	ratio	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
AKBR	AKBR	PROPN	NNP	5	O
,	,	PUNCT	,	9	O
aceto	aceto	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
acetate	acetate	ADJ	JJ	0	I-Chemical
/	/	SYM	SYM	9	O
3	3	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxybutyrate	hydroxybutyrate	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
clinical	clinical	ADJ	JJ	5	O
hepatic	hepatic	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
parameters	parameter	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

AKBR	AKBR	PROPN	NNP	5	O
and	and	CCONJ	CC	5	O
biological	biological	ADJ	JJ	5	O
hepatic	hepatic	ADJ	JJ	9	O
function	function	NOUN	NN	9	O
tests	test	NOUN	NNS	5	O
showed	show	VERB	VBD	9	O
no	no	DET	DT	9	O
change	change	NOUN	NN	9	O
throughout	throughout	ADP	IN	9	O
the	the	DET	DT	5	O
time	time	NOUN	NN	5	O
course	course	NOUN	NN	5	O
in	in	ADP	IN	5	O
groups	group	NOUN	NNS	9	O
A	a	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
B	b	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
group	group	NOUN	NN	9	O
C	C	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
AKBR	AKBR	PROPN	NNP	5	O
showed	show	VERB	VBD	9	O
a	a	DET	DT	5	O
significant	significant	ADJ	JJ	9	O
decrease	decrease	NOUN	NN	9	O
at	at	ADP	IN	9	O
120	120	NUM	CD	9	O
min	min	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
180	180	NUM	CD	9	O
min	min	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
49	49	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
start	start	NOUN	NN	9	O
of	of	ADP	IN	5	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
at	at	ADP	IN	9	O
60	60	NUM	CD	9	O
min	min	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
-	-	PUNCT	HYPH	7	O
32	32	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
recovery	recovery	NOUN	NN	9	O
of	of	ADP	IN	5	O
normotension	normotension	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
SGOT	SGOT	PROPN	NNP	0	O
,	,	PUNCT	,	9	O
SGPT	SGPT	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
LDH	LDH	PROPN	NNP	0	O
and	and	CCONJ	CC	5	O
total	total	ADJ	JJ	9	O
bilirubin	bilirubin	NOUN	NN	0	B-Chemical
showed	show	VERB	VBD	9	O
significant	significant	ADJ	JJ	9	O
increases	increase	NOUN	NNS	9	O
after	after	ADP	IN	9	O
operation	operation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
prolonged	prolonged	ADJ	JJ	9	O
combination	combination	NOUN	NN	9	O
of	of	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
120	120	NUM	CD	9	O
min	min	NOUN	NN	0	O
of	of	ADP	IN	5	O
PGE1	PGE1	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypotension	hypotension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
moderate	moderate	ADJ	JJ	9	O
haemodilution	haemodilution	NOUN	NN	5	B-Disease
would	would	VERB	MD	5	O
cause	cause	VERB	VB	5	O
impairment	impairment	NOUN	NN	5	B-Disease
of	of	ADP	IN	5	I-Disease
hepatic	hepatic	ADJ	JJ	9	I-Disease
function	function	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Cardiovascular	cardiovascular	ADJ	JJ	2	B-Disease
alterations	alteration	NOUN	NNS	9	I-Disease
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
fetuses	fetus	NOUN	NNS	9	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blockers	blocker	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Preclinical	preclinical	ADJ	JJ	9	O
toxicologic	toxicologic	NOUN	NN	5	O
investigation	investigation	NOUN	NN	9	O
suggested	suggest	VERB	VBD	9	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
new	new	ADJ	JJ	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blocker	blocker	NOUN	NN	0	O
,	,	PUNCT	,	9	O
Ro	Ro	PROPN	NNP	0	B-Chemical
40	40	NUM	CD	9	I-Chemical
-	-	SYM	SYM	7	I-Chemical
5967	5967	NUM	CD	7	I-Chemical
,	,	PUNCT	,	9	O
induced	induce	VERB	VBD	3	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
alterations	alteration	NOUN	NNS	9	I-Disease
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
fetuses	fetus	NOUN	NNS	9	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
this	this	DET	DT	5	O
agent	agent	NOUN	NN	9	O
during	during	ADP	IN	5	O
organogenesis	organogenesis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
designed	design	VERB	VBN	9	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
the	the	DET	DT	5	O
hypothesis	hypothesis	NOUN	NN	9	O
that	that	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blockers	blocker	NOUN	NNS	9	O
in	in	ADP	IN	5	O
general	general	ADJ	JJ	5	O
induce	induce	NOUN	NN	3	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
malformations	malformation	NOUN	NNS	5	I-Disease
indicating	indicate	VERB	VBG	9	O
a	a	DET	DT	5	O
pharmacologic	pharmacologic	ADJ	JJ	9	O
class	class	NOUN	NN	9	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
studied	study	VERB	VBD	9	O
three	three	NUM	CD	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blockers	blocker	NOUN	NNS	9	O
of	of	ADP	IN	5	O
different	different	ADJ	JJ	9	O
structure	structure	NOUN	NN	9	O
,	,	PUNCT	,	9	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
diltiazem	diltiazem	ADJ	JJ	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
along	along	ADP	IN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
new	new	ADJ	JJ	5	O
agent	agent	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Pregnant	pregnant	ADJ	JJ	5	O
rats	rat	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
administered	administer	VERB	VBN	9	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blockers	blocker	NOUN	NNS	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
period	period	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
morphogenesis	morphogenesis	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
offspring	offspring	NOUN	NN	9	O
examined	examine	VERB	VBD	9	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
20	20	NUM	CD	9	O
of	of	ADP	IN	5	O
gestation	gestation	NOUN	NN	9	O
for	for	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
malformations	malformation	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
low	low	ADJ	JJ	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
malformations	malformation	NOUN	NNS	5	I-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
after	after	ADP	IN	9	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
each	each	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
four	four	NUM	CD	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blockers	blocker	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
this	this	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
was	be	VERB	VBD	9	O
statistically	statistically	ADV	RB	9	O
significant	significant	ADJ	JJ	9	O
only	only	ADV	RB	9	O
for	for	ADP	IN	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
nifedipine	nifedipine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
four	four	NUM	CD	9	O
agents	agent	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
aortic	aortic	ADJ	JJ	9	O
arch	arch	NOUN	NN	5	O
branching	branch	VERB	VBG	9	O
variants	variant	NOUN	NNS	1	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
only	only	ADV	RB	9	O
for	for	ADP	IN	5	O
Ro	Ro	PROPN	NNP	0	B-Chemical
40	40	NUM	CD	9	I-Chemical
-	-	SYM	SYM	7	I-Chemical
5967	5967	NUM	CD	7	I-Chemical
and	and	CCONJ	CC	5	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
site	site	NOUN	NN	9	O
of	of	ADP	IN	5	O
common	common	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
sumatriptan	sumatriptan	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Atypical	atypical	ADJ	JJ	9	B-Disease
sensations	sensation	NOUN	NNS	5	I-Disease
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
subcutaneous	subcutaneous	ADJ	JJ	9	O
sumatriptan	sumatriptan	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
common	common	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
of	of	ADP	IN	5	O
uncertain	uncertain	ADJ	JJ	5	O
origin	origin	NOUN	NN	9	O
.	.	PUNCT	.	9	O

They	-PRON-	PRON	PRP	5	O
are	be	VERB	VBP	5	O
almost	almost	ADV	RB	9	O
always	always	ADV	RB	5	O
benign	benign	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
mistaken	mistake	VERB	VBN	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
serious	serious	ADJ	JJ	5	O
adverse	adverse	ADJ	JJ	5	O
event	event	NOUN	NN	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
presented	present	VERB	VBN	5	O
with	with	ADP	IN	5	O
tingling	tingle	VERB	VBG	5	B-Disease
or	or	CCONJ	CC	5	I-Disease
burning	burn	VERB	VBG	5	I-Disease
sensations	sensation	NOUN	NNS	5	I-Disease
limited	limit	VERB	VBN	5	O
to	to	ADP	IN	5	O
areas	area	NOUN	NNS	5	O
of	of	ADP	IN	5	O
heat	heat	NOUN	NN	9	O
exposure	exposure	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
sunburn	sunburn	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
these	these	DET	DT	5	O
individuals	individual	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
most	most	ADV	RBS	9	O
likely	likely	ADV	RB	5	O
generated	generate	VERB	VBN	9	O
superficially	superficially	ADV	RB	4	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
skin	skin	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Macula	macula	NOUN	NN	2	O
toxicity	toxicity	NOUN	NN	9	B-Disease
after	after	ADP	IN	9	O
intravitreal	intravitreal	ADJ	JJ	0	O
amikacin	amikacin	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Although	although	ADP	IN	9	O
intravitreal	intravitreal	ADJ	JJ	0	O
aminoglycosides	aminoglycoside	NOUN	NNS	9	B-Chemical
have	have	VERB	VBP	5	O
substantially	substantially	ADV	RB	9	O
improved	improve	VERB	VBN	5	O
visual	visual	ADJ	JJ	5	O
prognosis	prognosis	NOUN	NN	5	O
in	in	ADP	IN	5	O
endophthalmitis	endophthalmitis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
macular	macular	ADJ	JJ	5	O
infarction	infarction	NOUN	NN	5	B-Disease
may	may	VERB	MD	5	O
impair	impair	VERB	VB	9	O
full	full	ADJ	JJ	5	O
visual	visual	ADJ	JJ	5	O
recovery	recovery	NOUN	NN	9	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
present	present	VERB	VBP	9	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
presumed	presume	VERB	VBN	9	O
amikacin	amikacin	ADJ	JJ	0	B-Chemical
retinal	retinal	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
following	follow	VERB	VBG	9	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
amikacin	amikacin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
vancomycin	vancomycin	PROPN	NNP	9	B-Chemical
for	for	ADP	IN	5	O
alpha	alpha	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
haemolytic	haemolytic	ADJ	JJ	9	O
streptococcal	streptococcal	ADJ	JJ	9	B-Disease
endophthalmitis	endophthalmitis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
Endophthalmitis	Endophthalmitis	PROPN	NNP	5	B-Disease
resolved	resolve	VERB	VBD	9	O
with	with	ADP	IN	5	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
visual	visual	ADJ	JJ	5	O
acuity	acuity	NOUN	NN	5	O
to	to	ADP	IN	5	O
6	6	NUM	CD	9	O
/	/	SYM	SYM	9	O
24	24	NUM	CD	9	O
at	at	ADP	IN	9	O
three	three	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Fundus	fundus	NOUN	NN	0	O
fluorescein	fluorescein	NOUN	NN	0	B-Chemical
angiography	angiography	ADV	RB	5	O
confirmed	confirm	VERB	VBD	9	O
macular	macular	ADJ	JJ	5	O
capillary	capillary	ADJ	JJ	0	O
closure	closure	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
telangiectasis	telangiectasis	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Currently	currently	ADV	RB	9	O
accepted	accept	VERB	VBN	5	O
intravitreal	intravitreal	ADJ	JJ	0	O
antibiotic	antibiotic	ADJ	JJ	5	O
regimens	regimen	NOUN	NNS	5	O
may	may	VERB	MD	5	O
cause	cause	VERB	VB	5	O
retinal	retinal	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
macular	macular	ADJ	JJ	5	O
ischaemia	ischaemia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
strategies	strategy	NOUN	NNS	5	O
aimed	aim	VERB	VBN	5	O
at	at	ADP	IN	9	O
avoiding	avoid	VERB	VBG	5	O
retinal	retinal	ADJ	JJ	5	B-Disease
toxicity	toxicity	NOUN	NN	9	I-Disease
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
role	role	NOUN	NN	9	O
of	of	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
smoking	smoking	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Nicotine	nicotine	NOUN	NN	0	B-Chemical
activates	activate	VERB	VBZ	3	O
the	the	DET	DT	5	O
sympathetic	sympathetic	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
way	way	NOUN	NN	5	O
could	could	VERB	MD	9	O
contribute	contribute	VERB	VB	9	O
to	to	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Animal	animal	NOUN	NN	2	O
studies	study	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
mechanistic	mechanistic	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
could	could	VERB	MD	9	O
play	play	VERB	VB	9	O
a	a	DET	DT	5	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
accelerating	accelerate	VERB	VBG	9	O
atherosclerosis	atherosclerosis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
evidence	evidence	NOUN	NN	9	O
among	among	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
is	be	VERB	VBZ	5	O
too	too	ADV	RB	5	O
inadequate	inadequate	ADJ	JJ	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
definitive	definitive	ADJ	JJ	5	O
about	about	ADP	IN	5	O
such	such	DET	PDT	5	O
an	an	DET	DT	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Almost	almost	ADV	RB	5	O
certainly	certainly	ADV	RB	5	O
,	,	PUNCT	,	9	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
via	via	ADP	IN	9	O
its	-PRON-	DET	PRP$	9	O
hemodynamic	hemodynamic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
contributes	contribute	NOUN	NNS	9	O
to	to	PART	TO	5	O
acute	acute	VERB	VB	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
current	current	ADJ	JJ	5	O
evidence	evidence	NOUN	NN	9	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
much	much	ADV	RB	5	O
less	less	ADV	RBR	5	O
important	important	ADJ	JJ	9	O
than	than	ADP	IN	5	O
are	be	VERB	VBP	5	O
the	the	DET	DT	5	O
prothrombotic	prothrombotic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
cigarette	cigarette	NOUN	NN	5	O
smoking	smoking	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
carbon	carbon	NOUN	NN	0	B-Chemical
monoxide	monoxide	NOUN	NN	0	I-Chemical
.	.	PUNCT	.	9	O

Nicotine	nicotine	NOUN	NN	0	B-Chemical
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
appear	appear	VERB	VB	9	O
to	to	PART	TO	5	O
enhance	enhance	VERB	VB	9	O
thrombosis	thrombosis	NOUN	NN	5	B-Disease
among	among	ADP	IN	5	O
humans	human	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
of	of	ADP	IN	5	O
pipe	pipe	NOUN	NN	5	O
smokers	smoker	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
people	people	NOUN	NNS	5	O
using	use	VERB	VBG	9	O
transdermal	transdermal	ADJ	JJ	0	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
support	support	VERB	VBP	5	O
the	the	DET	DT	5	O
idea	idea	NOUN	NN	5	O
that	that	DET	WDT	5	O
toxins	toxin	VERB	VBZ	9	O
other	other	ADJ	JJ	5	O
than	than	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
important	important	ADJ	JJ	9	O
causes	cause	NOUN	NNS	9	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Finally	finally	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
response	response	NOUN	NN	9	O
for	for	ADP	IN	5	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
events	event	NOUN	NNS	5	O
of	of	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
flat	flat	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
suggesting	suggest	VERB	VBG	9	O
that	that	ADP	IN	5	O
if	if	ADP	IN	5	O
nicotine	nicotine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
involved	involve	VERB	VBN	9	O
,	,	PUNCT	,	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
seen	see	VERB	VBN	9	O
with	with	ADP	IN	5	O
relatively	relatively	ADV	RB	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
level	level	NOUN	NN	9	O
cigarette	cigarette	NOUN	NN	5	O
exposures	exposure	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Iatrogenically	iatrogenically	ADV	RB	5	O
induced	induce	VERB	VBD	3	O
intractable	intractable	ADJ	JJ	5	O
atrioventricular	atrioventricular	ADJ	JJ	5	B-Disease
reentrant	reentrant	NOUN	NN	5	I-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
after	after	ADP	IN	9	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
catheter	catheter	VERB	VB	5	O
ablation	ablation	NOUN	NN	9	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
Wolff	Wolff	PROPN	NNP	6	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
Parkinson	Parkinson	PROPN	NNP	5	I-Disease
-	-	PUNCT	HYPH	7	I-Disease
White	White	PROPN	NNP	9	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
idiopathic	idiopathic	ADJ	JJ	5	B-Disease
dilated	dilate	VERB	VBN	5	I-Disease
cardiomyopathy	cardiomyopathy	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
with	with	ADP	IN	5	O
WPW	WPW	PROPN	NNP	5	B-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
idiopathic	idiopathic	ADJ	JJ	5	B-Disease
dilated	dilate	VERB	VBN	5	I-Disease
cardiomyopathy	cardiomyopathy	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
intractable	intractable	ADJ	JJ	5	O
atrioventricular	atrioventricular	ADJ	JJ	5	B-Disease
reentrant	reentrant	NOUN	NN	5	I-Disease
tachycardia	tachycardia	NOUN	NN	5	I-Disease
(	(	PUNCT	-LRB-	9	O
AVRT	AVRT	PROPN	NNP	5	B-Disease
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
iatrogenically	iatrogenically	ADV	RB	5	O
induced	induce	VERB	VBN	3	O
.	.	PUNCT	.	9	O

QRS	QRS	PROPN	NNP	5	O
without	without	ADP	IN	9	O
preexcitation	preexcitation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
junctional	junctional	ADJ	JJ	9	O
escape	escape	NOUN	NN	5	O
beats	beat	NOUN	NNS	5	O
after	after	ADP	IN	9	O
verapamil	verapamil	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
unidirectional	unidirectional	ADJ	JJ	5	O
antegrade	antegrade	ADJ	JJ	5	O
block	block	NOUN	NN	9	O
of	of	ADP	IN	5	O
accessory	accessory	NOUN	NN	9	O
pathway	pathway	NOUN	NN	3	O
after	after	ADP	IN	9	O
catheter	catheter	NOUN	NN	5	O
ablation	ablation	NOUN	NN	9	O
,	,	PUNCT	,	9	O
established	establish	VERB	VBN	9	O
frequent	frequent	ADJ	JJ	5	O
AVRT	AVRT	PROPN	NNP	5	B-Disease
attack	attack	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Epidemic	Epidemic	PROPN	NNP	5	O
of	of	ADP	IN	5	O
liver	liver	NOUN	NN	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
hydrochlorofluorocarbons	hydrochlorofluorocarbon	NOUN	NNS	0	B-Chemical
used	use	VERB	VBN	5	O
as	as	ADP	IN	5	O
ozone	ozone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
sparing	sparing	NOUN	NN	5	O
substitutes	substitute	NOUN	NNS	5	O
of	of	ADP	IN	5	O
chlorofluorocarbons	chlorofluorocarbon	NOUN	NNS	0	B-Chemical
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Hydrochlorofluorocarbons	hydrochlorofluorocarbon	NOUN	NNS	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
HCFCs	hcfc	NOUN	NNS	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
are	be	VERB	VBP	5	O
used	use	VERB	VBN	5	O
increasingly	increasingly	ADV	RB	5	O
in	in	ADP	IN	5	O
industry	industry	NOUN	NN	5	O
as	as	ADP	IN	5	O
substitutes	substitute	NOUN	NNS	5	O
for	for	ADP	IN	5	O
ozone	ozone	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
depleting	deplete	VERB	VBG	3	O
chlorofluorocarbons	chlorofluorocarbon	NOUN	NNS	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
CFCs	CFCs	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Limited	limited	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
potential	potential	ADJ	JJ	9	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
some	some	DET	DT	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
compounds	compound	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
investigated	investigate	VERB	VBD	9	O
an	an	DET	DT	5	O
epidemic	epidemic	NOUN	NN	5	O
of	of	ADP	IN	5	O
liver	liver	NOUN	NN	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
nine	nine	NUM	CD	9	O
industrial	industrial	ADJ	JJ	5	O
workers	worker	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
had	have	VERB	VBN	9	O
repeated	repeat	VERB	VBN	5	O
accidental	accidental	ADJ	JJ	5	O
exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
mixture	mixture	NOUN	NN	0	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	B-Chemical
,	,	PUNCT	,	9	I-Chemical
1	1	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
dichloro	dichloro	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
trifluoroethane	trifluoroethane	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
HCFC	HCFC	PROPN	NNP	0	B-Chemical
123	123	NUM	CD	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
1	1	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
chloro	chloro	PROPN	NNP	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tetrafluoroethane	tetrafluoroethane	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
HCFC	HCFC	PROPN	NNP	0	B-Chemical
124	124	NUM	CD	7	I-Chemical
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
nine	nine	NUM	CD	9	O
exposed	expose	VERB	VBN	9	O
workers	worker	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
affected	affect	VERB	VBN	9	O
to	to	ADP	IN	5	O
various	various	ADJ	JJ	9	O
degrees	degree	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
compounds	compound	NOUN	NNS	0	O
are	be	VERB	VBP	5	O
metabolised	metabolise	VERB	VBN	0	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
way	way	NOUN	NN	5	O
as	as	ADP	IN	5	O
1	1	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
bromo	bromo	NOUN	NNS	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
1	1	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
chloro	chloro	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
2	2	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
trifluoroethane	trifluoroethane	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
halothane	halothane	NOUN	NN	0	B-Chemical
)	)	PUNCT	-RRB-	9	O
to	to	PART	TO	5	O
form	form	VERB	VB	9	O
reactive	reactive	ADJ	JJ	9	O
trifluoroacetyl	trifluoroacetyl	NOUN	NN	0	B-Chemical
halide	halide	NOUN	NN	0	O
intermediates	intermediate	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
implicated	implicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
halothane	halothane	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
aimed	aim	VERB	VBD	5	O
to	to	PART	TO	5	O
test	test	VERB	VB	5	O
whether	whether	ADP	IN	9	O
HCFCs	hcfc	NOUN	NNS	5	B-Chemical
123	123	NUM	CD	9	I-Chemical
and	and	CCONJ	CC	5	I-Chemical
124	124	NUM	CD	7	I-Chemical
can	can	VERB	MD	5	O
result	result	VERB	VB	9	O
in	in	ADP	IN	5	O
serious	serious	ADJ	JJ	5	O
liver	liver	NOUN	NN	9	B-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
For	for	ADP	IN	9	O
one	one	NUM	CD	5	O
severely	severely	ADV	RB	9	O
affected	affected	ADJ	JJ	9	O
worker	worker	NOUN	NN	5	O
liver	liver	NOUN	NN	9	O
biopsy	biopsy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
immunohistochemical	immunohistochemical	ADJ	JJ	3	O
stainings	staining	NOUN	NNS	3	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
presence	presence	NOUN	NN	9	O
of	of	ADP	IN	5	O
trifluoroacetyl	trifluoroacetyl	NOUN	NN	0	B-Chemical
protein	protein	NOUN	NN	1	O
adducts	adduct	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
done	do	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
serum	serum	NOUN	NN	9	O
of	of	ADP	IN	5	O
six	six	NUM	CD	9	O
affected	affected	ADJ	JJ	9	O
workers	worker	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
five	five	NUM	CD	9	O
controls	control	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
tested	test	VERB	VBN	9	O
for	for	ADP	IN	5	O
autoantibodies	autoantibody	NOUN	NNS	3	O
that	that	DET	WDT	5	O
react	react	VERB	VBP	9	O
with	with	ADP	IN	5	O
human	human	ADJ	JJ	3	O
liver	liver	NOUN	NN	9	O
cytochrome	cytochrome	ADJ	JJ	0	O
-	-	PUNCT	HYPH	7	O
P450	p450	NOUN	NN	1	O
2E1	2e1	NUM	CD	0	O
(	(	PUNCT	-LRB-	9	O
P450	P450	PROPN	NNP	1	O
2E1	2e1	NUM	CD	0	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
P58	P58	PROPN	NNP	1	O
protein	protein	NOUN	NN	1	O
disulphide	disulphide	VERB	VBP	1	O
isomerase	isomerase	NOUN	NN	1	O
isoform	isoform	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
P58	P58	PROPN	NNP	1	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

FINDINGS	finding	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
biopsy	biopsy	NOUN	NN	5	O
sample	sample	NOUN	NN	9	O
showed	show	VERB	VBD	9	O
hepatocellular	hepatocellular	ADJ	JJ	9	O
necrosis	necrosis	NOUN	NN	9	B-Disease
which	which	DET	WDT	5	O
was	be	VERB	VBD	9	O
prominent	prominent	ADJ	JJ	9	O
in	in	ADP	IN	5	O
perivenular	perivenular	ADJ	JJ	3	O
zone	zone	NOUN	NN	9	O
three	three	NUM	CD	9	O
and	and	CCONJ	CC	5	O
extended	extend	VERB	VBD	5	O
focally	focally	ADV	RB	3	O
from	from	ADP	IN	9	O
portal	portal	ADJ	JJ	5	O
tracts	tract	NOUN	NNS	5	O
to	to	ADP	IN	5	O
portal	portal	ADJ	JJ	5	O
tracts	tract	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
centrilobular	centrilobular	NOUN	NN	5	O
areas	area	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
bridging	bridge	VERB	VBG	5	O
necrosis	necrosis	NOUN	NN	9	B-Disease
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Trifluoroacetyl	trifluoroacetyl	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
adducted	adduct	VERB	VBN	0	O
proteins	protein	NOUN	NNS	1	O
were	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
surviving	survive	VERB	VBG	9	O
hepatocytes	hepatocyte	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Autoantibodies	autoantibody	NOUN	NNS	3	O
against	against	ADP	IN	9	O
P450	P450	PROPN	NNP	1	O
2E1	2e1	NUM	CD	0	O
or	or	CCONJ	CC	5	O
P58	P58	PROPN	NNP	1	O
,	,	PUNCT	,	9	O
previously	previously	ADV	RB	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
halothane	halothane	NOUN	NN	0	B-Disease
hepatitis	hepatitis	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
detected	detect	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
serum	serum	NOUN	NN	9	O
of	of	ADP	IN	5	O
five	five	NUM	CD	9	O
affected	affected	ADJ	JJ	9	O
workers	worker	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

INTERPRETATION	INTERPRETATION	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
Repeated	repeat	VERB	VBN	5	O
exposure	exposure	NOUN	NN	9	O
of	of	ADP	IN	5	O
human	human	ADJ	JJ	3	O
beings	being	NOUN	NNS	5	O
to	to	ADP	IN	5	O
HCFCs	hcfc	NOUN	NNS	5	B-Chemical
123	123	NUM	CD	9	I-Chemical
and	and	CCONJ	CC	5	I-Chemical
124	124	NUM	CD	7	I-Chemical
can	can	VERB	MD	5	O
result	result	VERB	VB	9	O
in	in	ADP	IN	5	O
serious	serious	ADJ	JJ	5	O
liver	liver	NOUN	NN	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
large	large	ADJ	JJ	5	O
proportion	proportion	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
exposed	expose	VERB	VBN	9	O
population	population	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
the	the	DET	DT	5	O
exact	exact	ADJ	JJ	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
hepatotoxicity	hepatotoxicity	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
agents	agent	NOUN	NNS	5	O
is	be	VERB	VBZ	5	O
not	not	ADV	RB	5	O
known	know	VERB	VBN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
trifluoroacetyl	trifluoroacetyl	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
altered	alter	VERB	VBN	9	O
liver	liver	NOUN	NN	9	O
proteins	protein	NOUN	NNS	1	O
are	be	VERB	VBP	5	O
involved	involve	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
view	view	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
potentially	potentially	ADV	RB	5	O
widespread	widespread	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
compounds	compound	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
urgent	urgent	ADJ	JJ	5	O
need	need	NOUN	NN	5	O
to	to	PART	TO	5	O
develop	develop	VERB	VB	5	O
safer	safe	ADJ	JJR	5	O
alternatives	alternative	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Bile	bile	ADJ	JJ	0	B-Disease
duct	duct	NOUN	NN	5	I-Disease
hamartoma	hamartoma	NOUN	NN	5	I-Disease
occurring	occur	VERB	VBG	9	O
in	in	ADP	IN	5	O
association	association	NOUN	NN	9	O
with	with	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
treatment	treatment	NOUN	NN	9	O
with	with	ADP	IN	5	O
danazol	danazol	NOUN	NNS	0	B-Chemical
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
report	report	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
bile	bile	ADJ	JJ	0	B-Disease
duct	duct	NOUN	NN	5	I-Disease
hamartoma	hamartoma	NOUN	NN	5	I-Disease
which	which	DET	WDT	5	O
developed	develop	VERB	VBD	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
on	on	ADP	IN	5	O
long	long	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
danazol	danazol	ADJ	JJ	0	B-Chemical
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Such	such	ADJ	JJ	5	O
patients	patient	NOUN	NNS	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
under	under	ADP	IN	9	O
close	close	ADJ	JJ	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
,	,	PUNCT	,	9	O
preferably	preferably	ADV	RB	5	O
with	with	ADP	IN	5	O
periodic	periodic	ADJ	JJ	5	O
ultrasound	ultrasound	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
.	.	PUNCT	.	9	O

If	if	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
develops	develop	VERB	VBZ	5	O
a	a	DET	DT	5	O
liver	liver	NOUN	NN	9	B-Disease
mass	mass	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
non	non	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
specific	specific	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
features	feature	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
imaging	image	VERB	VBG	5	O
appearances	appearance	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
biopsy	biopsy	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
the	the	DET	DT	5	O
only	only	ADJ	JJ	9	O
way	way	NOUN	NN	5	O
to	to	PART	TO	5	O
achieve	achieve	VERB	VB	5	O
a	a	DET	DT	5	O
definitive	definitive	ADJ	JJ	5	O
diagnosis	diagnosis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Endocrine	endocrine	NOUN	NN	2	O
screening	screening	NOUN	NN	5	O
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
022	022	NUM	CD	7	O
men	man	NOUN	NNS	5	O
with	with	ADP	IN	5	O
erectile	erectile	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
:	:	PUNCT	:	9	O
clinical	clinical	ADJ	JJ	5	O
significance	significance	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
cost	cost	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effective	effective	ADJ	JJ	5	O
strategy	strategy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

PURPOSE	PURPOSE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
reviewed	review	VERB	VBD	9	O
the	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
prolactin	prolactin	NOUN	NN	3	O
determination	determination	NOUN	NN	9	O
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
022	022	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
referred	refer	VERB	VBD	5	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
erectile	erectile	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
compared	compare	VERB	VBD	9	O
the	the	DET	DT	5	O
data	datum	NOUN	NNS	5	O
with	with	ADP	IN	5	O
history	history	NOUN	NN	5	O
,	,	PUNCT	,	9	O
results	result	NOUN	NNS	9	O
of	of	ADP	IN	5	O
physical	physical	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
,	,	PUNCT	,	9	O
other	other	ADJ	JJ	5	O
etiological	etiological	ADJ	JJ	5	O
investigations	investigation	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
endocrine	endocrine	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
to	to	PART	TO	5	O
refine	refine	VERB	VB	5	O
the	the	DET	DT	5	O
rules	rule	NOUN	NNS	5	O
of	of	ADP	IN	5	O
cost	cost	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effective	effective	ADJ	JJ	5	O
endocrine	endocrine	NOUN	NN	9	O
screening	screening	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
pinpoint	pinpoint	VERB	VB	5	O
actual	actual	ADJ	JJ	5	O
responsibility	responsibility	NOUN	NN	5	O
for	for	ADP	IN	5	O
hormonal	hormonal	ADJ	JJ	9	O
abnormalities	abnormality	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

MATERIALS	material	NOUN	NNS	2	O
AND	and	CCONJ	CC	2	O
METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Testosterone	Testosterone	PROPN	NNP	0	B-Chemical
and	and	CCONJ	CC	5	O
prolactin	prolactin	NOUN	NN	3	O
were	be	VERB	VBD	9	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
radioimmunoassay	radioimmunoassay	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Every	every	DET	DT	5	O
patient	patient	NOUN	NN	5	O
was	be	VERB	VBD	9	O
screened	screen	VERB	VBN	9	O
for	for	ADP	IN	5	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
451	451	NUM	CD	7	O
were	be	VERB	VBD	9	O
screened	screen	VERB	VBN	9	O
for	for	ADP	IN	5	O
prolactin	prolactin	NOUN	NN	3	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
basis	basis	NOUN	NN	5	O
of	of	ADP	IN	5	O
low	low	ADJ	JJ	9	B-Disease
sexual	sexual	ADJ	JJ	5	I-Disease
desire	desire	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
gynecomastia	gynecomastia	NOUN	NN	5	B-Disease
or	or	CCONJ	CC	5	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
4	4	NUM	CD	9	O
ng	ng	ADP	IN	0	O
.	.	PUNCT	.	9	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Determination	determination	NOUN	NN	0	O
was	be	VERB	VBD	9	O
repeated	repeat	VERB	VBN	5	O
in	in	ADP	IN	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
abnormal	abnormal	ADJ	JJ	9	O
first	first	ADJ	JJ	9	O
results	result	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Prolactin	prolactin	NOUN	NN	9	O
results	result	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
previous	previous	ADJ	JJ	9	O
personal	personal	ADJ	JJ	5	O
cohort	cohort	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
340	340	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
erectile	erectile	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
systematic	systematic	ADJ	JJ	5	O
prolactin	prolactin	NOUN	NN	3	O
determination	determination	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Main	main	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
criteria	criterion	NOUN	NNS	5	O
tested	test	VERB	VBD	9	O
regarding	regard	VERB	VBG	5	O
efficiency	efficiency	NOUN	NN	9	O
in	in	ADP	IN	5	O
hormone	hormone	NOUN	NN	9	O
determination	determination	NOUN	NN	9	O
were	be	VERB	VBD	9	O
low	low	ADJ	JJ	9	B-Disease
sexual	sexual	ADJ	JJ	5	I-Disease
desire	desire	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
small	small	ADJ	JJ	9	O
testes	testis	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
gynecomastia	gynecomastia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Endocrine	endocrine	NOUN	NN	2	O
therapy	therapy	NOUN	NN	5	O
consisted	consist	VERB	VBD	5	O
of	of	ADP	IN	5	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
heptylate	heptylate	NOUN	NN	9	I-Chemical
or	or	CCONJ	CC	5	O
human	human	ADJ	JJ	3	O
chorionic	chorionic	ADJ	JJ	9	O
gonadotropin	gonadotropin	NOUN	NN	9	O
for	for	ADP	IN	5	O
hypogonadism	hypogonadism	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
bromocriptine	bromocriptine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
hyperprolactinemia	hyperprolactinemia	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Testosterone	Testosterone	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
3	3	NUM	CD	9	O
ng	ng	ADP	IN	0	O
.	.	PUNCT	.	9	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
.	.	PUNCT	.	9	O
in	in	ADP	IN	5	O
107	107	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
but	but	CCONJ	CC	9	O
normal	normal	ADJ	JJ	9	O
in	in	ADP	IN	5	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
at	at	ADP	IN	9	O
repeat	repeat	NOUN	NN	9	O
determination	determination	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
prevalence	prevalence	NOUN	NN	5	O
of	of	ADP	IN	5	O
repeatedly	repeatedly	ADV	RB	5	O
low	low	ADJ	JJ	9	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
increased	increase	VERB	VBD	9	O
with	with	ADP	IN	5	O
age	age	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
%	%	NOUN	NN	9	O
before	before	ADP	IN	9	O
age	age	NOUN	NN	5	O
50	50	NUM	CD	0	O
years	year	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
9	9	NUM	CD	7	O
%	%	NOUN	NN	9	O
50	50	NUM	CD	0	O
years	year	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
older	old	ADJ	JJR	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
pituitary	pituitary	ADJ	JJ	3	B-Disease
tumors	tumor	NOUN	NNS	3	I-Disease
were	be	VERB	VBD	9	O
discovered	discover	VERB	VBN	9	O
after	after	ADP	IN	9	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
determination	determination	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Most	Most	ADJ	JJS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
low	low	ADJ	JJ	9	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
levels	level	NOUN	NNS	3	O
seemed	seem	VERB	VBD	9	O
to	to	PART	TO	5	O
result	result	VERB	VB	9	O
from	from	ADP	IN	9	O
nonorganic	nonorganic	ADJ	JJ	5	O
hypothalamic	hypothalamic	ADJ	JJ	3	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
serum	serum	NOUN	NN	9	O
luteinizing	luteinize	VERB	VBG	0	O
hormone	hormone	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
prolactin	prolactin	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
only	only	ADV	RB	9	O
a	a	DET	DT	5	O
small	small	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
erectile	erectile	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
definite	definite	ADJ	JJ	5	O
improvement	improvement	NOUN	NN	5	O
in	in	ADP	IN	5	O
only	only	ADV	RB	9	O
16	16	NUM	CD	9	O
of	of	ADP	IN	5	O
44	44	NUM	CD	7	O
[	[	PUNCT	-LRB-	9	O
36	36	NUM	CD	9	O
%	%	NOUN	NN	9	O
]	]	PUNCT	-RRB-	9	O
after	after	ADP	IN	9	O
androgen	androgen	NOUN	NN	3	O
therapy	therapy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
normal	normal	ADJ	JJ	9	O
morning	morning	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
nocturnal	nocturnal	ADJ	JJ	5	O
erections	erection	NOUN	NNS	5	O
in	in	ADP	IN	5	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
definite	definite	ADJ	JJ	5	O
vasculogenic	vasculogenic	ADJ	JJ	3	O
contributions	contribution	NOUN	NNS	5	O
in	in	ADP	IN	5	O
42	42	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Determining	determine	VERB	VBG	5	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
low	low	ADJ	JJ	9	B-Disease
sexual	sexual	ADJ	JJ	5	I-Disease
desire	desire	NOUN	NN	5	I-Disease
or	or	CCONJ	CC	5	O
abnormal	abnormal	ADJ	JJ	9	O
physical	physical	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
would	would	VERB	MD	5	O
have	have	VERB	VB	5	O
missed	miss	VERB	VBN	5	O
40	40	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
cases	case	NOUN	NNS	5	O
with	with	ADP	IN	5	O
low	low	ADJ	JJ	9	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
37	37	NUM	CD	9	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
those	those	DET	DT	5	O
subsequently	subsequently	ADV	RB	9	O
improved	improve	VERB	VBN	5	O
by	by	ADP	IN	9	O
androgen	androgen	NOUN	NN	3	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Prolactin	Prolactin	PROPN	NNP	9	O
exceeded	exceed	VERB	VBD	9	O
20	20	NUM	CD	9	O
ng	ng	NOUN	NNS	0	O
.	.	PUNCT	.	9	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
.	.	PUNCT	.	9	O
in	in	ADP	IN	5	O
5	5	NUM	CD	9	O
men	man	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
normal	normal	ADJ	JJ	9	O
in	in	ADP	IN	5	O
2	2	NUM	CD	9	O
at	at	ADP	IN	9	O
repeat	repeat	NOUN	NN	9	O
determination	determination	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Only	only	ADV	RB	9	O
1	1	NUM	CD	9	O
prolactinoma	prolactinoma	NOUN	NN	5	B-Disease
was	be	VERB	VBD	9	O
discovered	discover	VERB	VBN	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
lower	low	ADJ	JJR	9	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
we	-PRON-	PRON	PRP	5	O
found	find	VERB	VBD	9	O
during	during	ADP	IN	5	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
2	2	NUM	CD	9	O
decades	decade	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
overall	overall	ADV	RB	5	O
prolactin	prolactin	NOUN	NN	3	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
20	20	NUM	CD	9	O
ng	ng	NOUN	NNS	0	O
.	.	PUNCT	.	9	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
.	.	PUNCT	.	9	O
in	in	ADP	IN	5	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
86	86	NUM	CD	7	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
821	821	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
prolactinomas	prolactinoma	NOUN	NNS	5	B-Disease
in	in	ADP	IN	5	O
7	7	NUM	CD	9	O
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
38	38	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Bromocriptine	Bromocriptine	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
definitely	definitely	ADV	RB	5	O
effective	effective	ADJ	JJ	5	O
in	in	ADP	IN	5	O
cases	case	NOUN	NNS	5	O
with	with	ADP	IN	5	O
prolactin	prolactin	NOUN	NN	3	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
35	35	NUM	CD	9	O
ng	ng	NOUN	NN	0	O
.	.	PUNCT	.	9	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
.	.	PUNCT	.	9	O

(	(	PUNCT	-LRB-	9	O
8	8	NUM	CD	9	O
of	of	ADP	IN	5	O
12	12	NUM	CD	9	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
only	only	ADV	RB	9	O
9	9	NUM	CD	7	O
of	of	ADP	IN	5	O
22	22	NUM	CD	7	O
cases	case	NOUN	NNS	5	O
with	with	ADP	IN	5	O
prolactin	prolactin	NOUN	NN	3	O
between	between	ADP	IN	5	O
20	20	NUM	CD	9	O
and	and	CCONJ	CC	5	O
35	35	NUM	CD	9	O
ng	ng	NOUN	NN	0	O
.	.	PUNCT	.	9	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Testosterone	Testosterone	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
low	low	ADJ	JJ	9	O
in	in	ADP	IN	5	O
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
cases	case	NOUN	NNS	5	O
with	with	ADP	IN	5	O
prolactin	prolactin	NOUN	NN	3	O
greater	great	ADJ	JJR	5	O
than	than	ADP	IN	5	O
35	35	NUM	CD	9	O
ng	ng	NOUN	NN	0	O
.	.	PUNCT	.	9	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Low	low	ADJ	JJ	9	O
prevalences	prevalence	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
low	low	ADJ	JJ	9	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
and	and	CCONJ	CC	5	O
high	high	ADJ	JJ	9	O
prolactin	prolactin	NOUN	NN	3	O
in	in	ADP	IN	5	O
erectile	erectile	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
cannot	cannot	NOUN	NN	5	O
justify	justify	VERB	VB	5	O
their	-PRON-	DET	PRP$	5	O
routine	routine	ADJ	JJ	5	O
determination	determination	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
cost	cost	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
effective	effective	ADJ	JJ	5	O
screening	screening	NOUN	NN	5	O
strategies	strategy	NOUN	NNS	5	O
recommended	recommend	VERB	VBN	5	O
so	so	ADV	RB	5	O
far	far	ADV	RB	5	O
missed	miss	VERB	VBD	5	O
40	40	NUM	CD	9	O
to	to	PART	TO	5	O
50	50	NUM	CD	0	O
%	%	NOUN	NN	9	O
of	of	ADP	IN	5	O
cases	case	NOUN	NNS	5	O
improved	improve	VERB	VBN	5	O
with	with	ADP	IN	5	O
endocrine	endocrine	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
pituitary	pituitary	ADJ	JJ	3	B-Disease
tumors	tumor	NOUN	NNS	3	I-Disease
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
now	now	ADV	RB	5	O
advocate	advocate	VERB	VBP	5	O
that	that	ADP	IN	5	O
before	before	ADP	IN	9	O
age	age	NOUN	NN	5	O
50	50	NUM	CD	0	O
years	year	NOUN	NNS	5	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
be	be	VERB	VB	5	O
determined	determine	VERB	VBN	9	O
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
low	low	ADJ	JJ	9	B-Disease
sexual	sexual	ADJ	JJ	5	I-Disease
desire	desire	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
abnormal	abnormal	ADJ	JJ	9	O
physical	physical	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
that	that	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
be	be	VERB	VB	5	O
measured	measure	VERB	VBN	9	O
in	in	ADP	IN	5	O
all	all	DET	DT	5	O
men	man	NOUN	NNS	5	O
older	old	ADJ	JJR	5	O
than	than	ADP	IN	5	O
50	50	NUM	CD	0	O
years	year	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Prolactin	prolactin	NOUN	NN	9	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
determined	determine	VERB	VBN	9	O
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
cases	case	NOUN	NNS	5	O
of	of	ADP	IN	5	O
low	low	ADJ	JJ	9	B-Disease
sexual	sexual	ADJ	JJ	5	I-Disease
desire	desire	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
gynecomastia	gynecomastia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
testosterone	testosterone	NOUN	NN	9	B-Chemical
less	less	ADJ	JJR	5	O
than	than	ADP	IN	5	O
4	4	NUM	CD	9	O
ng	ng	ADP	IN	0	O
.	.	PUNCT	.	9	O
/	/	SYM	SYM	9	O
ml	ml	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Extrapyramidal	extrapyramidal	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
with	with	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
at	at	ADP	IN	9	O
comparable	comparable	ADJ	JJ	9	O
D2	d2	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
occupancy	occupancy	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Risperidone	risperidone	NOUN	NN	7	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
antipsychotic	antipsychotic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
with	with	ADP	IN	5	O
high	high	ADJ	JJ	9	O
affinity	affinity	NOUN	NN	0	O
at	at	ADP	IN	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
D2	d2	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
serotonin	serotonin	NOUN	NN	9	B-Chemical
5	5	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
HT2	ht2	NOUN	NN	3	I-Chemical
receptors	receptor	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Previous	previous	ADJ	JJ	9	O
clinical	clinical	ADJ	JJ	5	O
studies	study	NOUN	NNS	9	O
have	have	VERB	VBP	5	O
proposed	propose	VERB	VBN	5	O
that	that	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
pharmacologic	pharmacologic	NOUN	NN	9	O
profile	profile	NOUN	NN	9	O
may	may	VERB	MD	5	O
produce	produce	VERB	VB	9	O
improved	improve	VERB	VBN	5	O
efficacy	efficacy	NOUN	NN	9	O
for	for	ADP	IN	5	O
negative	negative	ADJ	JJ	9	O
psychotic	psychotic	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
decreased	decrease	VERB	VBD	9	O
propensity	propensity	NOUN	NN	5	O
for	for	ADP	IN	5	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
;	;	PUNCT	:	9	O
features	feature	NOUN	NNS	5	O
shared	share	VERB	VBN	5	O
by	by	ADP	IN	9	O
so	so	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
called	call	VERB	VBN	5	O
'	'	PUNCT	``	9	O
atypical	atypical	ADJ	JJ	5	O
'	'	PUNCT	''	9	O
neuroleptics	neuroleptic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
determine	determine	VERB	VB	9	O
if	if	ADP	IN	5	O
routine	routine	ADJ	JJ	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
treatment	treatment	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
unique	unique	ADJ	JJ	9	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
D2	d2	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
occupancy	occupancy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
pattern	pattern	NOUN	NN	9	O
of	of	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
used	use	VERB	VBD	5	O
[	[	PUNCT	-LRB-	9	O
123I	123i	NUM	CD	0	O
]	]	PUNCT	-RRB-	9	O
IBZM	ibzm	NOUN	NN	0	O
SPECT	spect	VERB	VBP	5	O
to	to	PART	TO	5	O
determine	determine	VERB	VB	9	O
D2	d2	NOUN	NN	9	O
occupancy	occupancy	NOUN	NN	9	O
in	in	ADP	IN	5	O
subjects	subject	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
routine	routine	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
12	12	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
or	or	CCONJ	CC	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
7	7	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
produced	produce	VERB	VBN	9	O
D2	d2	NOUN	NN	9	O
occupancy	occupancy	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
between	between	ADP	IN	5	O
approximately	approximately	ADV	RB	9	O
60	60	NUM	CD	9	O
and	and	CCONJ	CC	5	O
90	90	NUM	CD	9	O
%	%	NOUN	NN	9	O
at	at	ADP	IN	9	O
standard	standard	ADJ	JJ	5	O
clinical	clinical	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
no	no	DET	DT	9	O
significant	significant	ADJ	JJ	9	O
difference	difference	NOUN	NN	9	O
between	between	ADP	IN	5	O
occupancy	occupancy	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
obtained	obtain	VERB	VBN	9	O
with	with	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
or	or	CCONJ	CC	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Drug	drug	NOUN	NN	5	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
induced	induce	VERB	VBN	3	I-Disease
parkinsonism	parkinsonism	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
subjects	subject	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
42	42	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
(	(	PUNCT	-LRB-	9	O
29	29	NUM	CD	7	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
at	at	ADP	IN	9	O
occupancy	occupancy	NOUN	NN	9	O
levels	level	NOUN	NNS	3	O
above	above	ADP	IN	9	O
60	60	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Based	base	VERB	VBN	9	O
on	on	ADP	IN	5	O
these	these	DET	DT	5	O
observations	observation	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
HT2	ht2	NOUN	NN	3	O
blockade	blockade	NOUN	NN	3	O
obtained	obtain	VERB	VBN	9	O
with	with	ADP	IN	5	O
risperidone	risperidone	NOUN	NN	5	B-Chemical
at	at	ADP	IN	9	O
D2	d2	NOUN	NN	9	O
occupancy	occupancy	NOUN	NN	9	O
rates	rate	NOUN	NNS	5	O
of	of	ADP	IN	5	O
60	60	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
above	above	ADV	RB	9	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
appear	appear	VERB	VB	9	O
to	to	PART	TO	5	O
protect	protect	VERB	VB	9	O
against	against	ADP	IN	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
for	for	ADP	IN	5	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
previously	previously	ADV	RB	9	O
treated	treat	VERB	VBN	3	O
metastatic	metastatic	ADJ	JJ	3	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
by	by	ADP	IN	9	O
mitoxantrone	mitoxantrone	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
48	48	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hour	hour	NOUN	NN	0	O
continuous	continuous	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
and	and	CCONJ	CC	5	O
leucovorin	leucovorin	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
MFL	MFL	PROPN	NNP	7	B-Chemical
)	)	PUNCT	-RRB-	9	O
:	:	PUNCT	:	9	O
low	low	ADJ	JJ	9	O
palliative	palliative	ADJ	JJ	5	O
benefit	benefit	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
high	high	ADJ	JJ	9	O
treatment	treatment	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
previously	previously	ADV	RB	9	O
treated	treat	VERB	VBN	3	O
advanced	advanced	ADJ	JJ	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
is	be	VERB	VBZ	5	O
no	no	DET	DT	9	O
standard	standard	ADJ	JJ	5	O
second	second	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
line	line	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Combination	combination	NOUN	NN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
mitoxantrone	mitoxantrone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
high	high	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
fluorouracil	fluorouracil	NOUN	NN	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
leucovorin	leucovorin	VERB	VB	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
MFL	MFL	PROPN	NNP	7	B-Chemical
regimen	regiman	NOUN	NNS	5	I-Chemical
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
effective	effective	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
well	well	ADV	RB	9	O
tolerated	tolerated	ADJ	JJ	9	O
regimen	regiman	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

From	from	ADP	IN	5	O
October	October	PROPN	NNP	2	O
1993	1993	NUM	CD	2	O
to	to	ADP	IN	5	O
November	November	PROPN	NNP	2	O
1995	1995	NUM	CD	2	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
treated	treat	VERB	VBD	3	O
13	13	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
previously	previously	ADV	RB	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
metastatic	metastatic	ADJ	JJ	3	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
by	by	ADP	IN	9	O
mitoxantrone	mitoxantrone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
12	12	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
day	day	NOUN	NN	9	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
continuous	continuous	ADJ	JJ	5	O
infusion	infusion	NOUN	NN	0	O
of	of	ADP	IN	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
FU	fu	NOUN	NN	9	I-Chemical
,	,	PUNCT	,	9	O
3000	3000	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	INTJ	UH	7	O
,	,	PUNCT	,	9	O
together	together	ADV	RB	9	O
with	with	ADP	IN	5	O
leucovorin	leucovorin	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
300	300	NUM	CD	0	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	PROPN	NNP	7	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
48	48	NUM	CD	9	O
h	h	NOUN	NN	0	O
from	from	ADP	IN	9	O
day	day	NOUN	NN	9	O
1	1	NUM	CD	9	O
to	to	ADP	IN	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O

Each	each	DET	DT	5	O
course	course	NOUN	NN	5	O
of	of	ADP	IN	5	O
chemotherapy	chemotherapy	NOUN	NN	5	O
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
every	every	DET	DT	5	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Most	Most	ADJ	JJS	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
two	two	NUM	CD	5	O
metastatic	metastatic	ADJ	JJ	3	O
sites	site	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
lung	lung	NOUN	NN	9	O
metastasis	metastasis	NOUN	NN	3	O
predominant	predominant	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Seven	seven	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
anthracycline	anthracycline	NOUN	NN	9	B-Chemical
.	.	PUNCT	.	9	O

Seven	seven	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
previously	previously	ADV	RB	9	O
received	receive	VERB	VBN	9	O
radiotherapy	radiotherapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
seven	seven	NUM	CD	9	O
had	have	VERB	VBD	9	O
received	receive	VERB	VBN	9	O
hormone	hormone	NOUN	NN	9	O
therapy	therapy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Median	median	ADJ	JJ	7	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
courses	course	NOUN	NNS	5	O
of	of	ADP	IN	5	O
MFL	MFL	PROPN	NNP	7	B-Chemical
regimen	regiman	NOUN	NNS	5	I-Chemical
given	give	VERB	VBN	5	O
was	be	VERB	VBD	9	O
six	six	NUM	CD	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
cumulative	cumulative	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
mitoxantrone	mitoxantrone	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
68	68	NUM	CD	7	O
.	.	PUNCT	.	9	O
35	35	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
m2	m2	NOUN	NN	7	O
.	.	PUNCT	.	9	O

One	one	NUM	CD	5	O
patient	patient	NOUN	NN	5	O
had	have	VERB	VBD	9	O
complete	complete	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
,	,	PUNCT	,	9	O
seven	seven	NUM	CD	9	O
had	have	VERB	VBD	9	O
stable	stable	ADJ	JJ	9	O
disease	disease	NOUN	NN	5	O
,	,	PUNCT	,	9	O
none	none	NOUN	NN	9	O
had	have	VERB	VBD	9	O
partial	partial	ADJ	JJ	9	O
response	response	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
five	five	NUM	CD	9	O
had	have	VERB	VBD	9	O
progressive	progressive	ADJ	JJ	5	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
overall	overall	ADJ	JJ	5	O
objective	objective	ADJ	JJ	5	O
response	response	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
was	be	VERB	VBD	9	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
median	median	ADJ	JJ	9	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	PART	RP	5	O
period	period	NOUN	NN	5	O
was	be	VERB	VBD	9	O
14	14	NUM	CD	7	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Median	median	ADJ	JJ	7	O
survival	survival	NOUN	NN	9	O
was	be	VERB	VBD	9	O
16	16	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Median	median	ADJ	JJ	7	O
progression	progression	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
survival	survival	NOUN	NN	9	O
was	be	VERB	VBD	9	O
5	5	NUM	CD	9	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
complete	complete	ADJ	JJ	9	O
responder	responder	NOUN	NN	9	O
had	have	VERB	VBD	9	O
relapse	relapse	VERB	VBN	5	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
survival	survival	NOUN	NN	9	O
up	up	ADP	IN	5	O
to	to	PART	TO	5	O
17	17	NUM	CD	7	O
months	month	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Major	major	ADJ	JJ	9	O
toxicities	toxicity	NOUN	NNS	5	B-Disease
were	be	VERB	VBD	9	O
cardiotoxicity	cardiotoxicity	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
leukopenia	leukopenia	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

Eight	eight	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
dead	dead	ADJ	JJ	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
;	;	PUNCT	:	9	O
two	two	NUM	CD	5	O
of	of	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
died	die	VERB	VBD	9	O
of	of	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
MFL	MFL	PROPN	NNP	7	B-Chemical
regimen	regimen	NOUN	NN	5	I-Chemical
achieves	achieve	VERB	VBZ	5	O
little	little	ADJ	JJ	9	O
palliative	palliative	ADJ	JJ	5	O
benefit	benefit	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
induces	induce	VERB	VBZ	3	O
severe	severe	ADJ	JJ	5	O
toxicity	toxicity	NOUN	NN	9	B-Disease
at	at	ADP	IN	9	O
a	a	DET	DT	5	O
fairly	fairly	ADV	RB	5	O
high	high	ADJ	JJ	9	O
rate	rate	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Administration	administration	NOUN	NN	2	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
regimen	regimen	NOUN	NN	5	O
to	to	ADP	IN	5	O
breast	breast	NOUN	NN	3	B-Disease
cancer	cancer	NOUN	NN	3	I-Disease
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
treated	treat	VERB	VBN	3	O
by	by	ADP	IN	9	O
chemotherapy	chemotherapy	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
those	those	DET	DT	5	O
with	with	ADP	IN	5	O
impaired	impaired	ADJ	JJ	9	B-Disease
heart	heart	NOUN	NN	5	I-Disease
function	function	NOUN	NN	9	I-Disease
requires	require	VERB	VBZ	5	O
careful	careful	ADJ	JJ	5	O
attention	attention	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Ticlopidine	ticlopidine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
:	:	PUNCT	:	9	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
three	three	NUM	CD	9	O
Chinese	chinese	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
review	review	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
literature	literature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
,	,	PUNCT	,	9	O
three	three	NUM	CD	9	O
Chinese	chinese	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
ticlopidine	ticlopidine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
were	be	VERB	VBD	9	O
reported	report	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
another	another	DET	DT	9	O
13	13	NUM	CD	7	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
English	English	PROPN	NNP	5	O
literature	literature	NOUN	NN	5	O
were	be	VERB	VBD	9	O
reviewed	review	VERB	VBN	9	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
attempted	attempt	VERB	VBD	5	O
to	to	PART	TO	5	O
find	find	VERB	VB	5	O
underlying	underlying	ADJ	JJ	5	O
similarities	similarity	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
identify	identify	VERB	VB	9	O
appropriate	appropriate	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
this	this	DET	DT	5	O
complication	complication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
but	but	ADP	IN	9	O
one	one	NUM	CD	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
over	over	ADP	IN	5	O
60	60	NUM	CD	9	O
years	year	NOUN	NNS	5	O
old	old	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
6	6	NUM	CD	9	O
who	who	PRON	WP	5	O
died	die	VERB	VBD	9	O
were	be	VERB	VBD	9	O
all	all	ADV	RB	5	O
older	old	ADJ	JJR	5	O
than	than	ADP	IN	5	O
65	65	NUM	CD	7	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
old	old	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
a	a	DET	DT	5	O
risk	risk	NOUN	NN	5	O
factor	factor	NOUN	NN	9	O
for	for	ADP	IN	5	O
developing	develop	VERB	VBG	5	O
this	this	DET	DT	5	O
complication	complication	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Agranulocytosis	Agranulocytosis	PROPN	NNP	5	B-Disease
occurred	occur	VERB	VBD	9	O
3	3	NUM	CD	9	O
-	-	SYM	SYM	7	O
20	20	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
after	after	ADP	IN	9	O
initiation	initiation	NOUN	NN	9	O
of	of	ADP	IN	5	O
ticlopidine	ticlopidine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
so	so	ADV	RB	5	O
frequent	frequent	ADJ	JJ	5	O
examination	examination	NOUN	NN	5	O
of	of	ADP	IN	5	O
white	white	ADJ	JJ	9	O
cell	cell	NOUN	NN	3	O
count	count	NOUN	NN	9	O
during	during	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
recommended	recommend	VERB	VBN	5	O
.	.	PUNCT	.	9	O

There	there	ADV	EX	5	O
seemed	seem	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
no	no	DET	DT	9	O
direct	direct	ADJ	JJ	9	O
correlation	correlation	NOUN	NN	9	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
dose	dose	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
duration	duration	NOUN	NN	5	O
used	use	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
bone	bone	NOUN	NN	5	B-Disease
marrow	marrow	NOUN	NN	3	I-Disease
suppression	suppression	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Treatment	treatment	NOUN	NN	9	O
for	for	ADP	IN	5	O
ticlopidine	ticlopidine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
aplastic	aplastic	ADJ	JJ	5	B-Disease
anemia	anemia	NOUN	NN	9	I-Disease
with	with	ADP	IN	5	O
colony	colony	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
stimulating	stimulate	VERB	VBG	9	O
factors	factor	NOUN	NNS	9	O
seemed	seem	VERB	VBD	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
little	little	ADJ	JJ	9	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
fact	fact	NOUN	NN	9	O
that	that	ADP	IN	5	O
5	5	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
6	6	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
received	receive	VERB	VBD	9	O
concurrent	concurrent	ADJ	JJ	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
channel	channel	NOUN	NN	9	O
blockers	blocker	NOUN	NNS	9	O
died	die	VERB	VBD	9	O
,	,	PUNCT	,	9	O
should	should	VERB	MD	5	O
alert	alert	VERB	VB	5	O
clinicians	clinician	NOUN	NNS	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
more	more	ADV	RBR	5	O
cautious	cautious	ADJ	JJ	5	O
when	when	ADV	WRB	5	O
using	use	VERB	VBG	9	O
these	these	DET	DT	5	O
two	two	NUM	CD	5	O
drugs	drug	NOUN	NNS	5	O
simultaneously	simultaneously	ADV	RB	5	O
.	.	PUNCT	.	9	O

Upregulation	upregulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
vasopressin	vasopressin	NOUN	NN	9	B-Chemical
gene	gene	NOUN	NN	1	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
paraventricular	paraventricular	ADJ	JJ	9	O
and	and	CCONJ	CC	5	O
supraoptic	supraoptic	ADJ	JJ	9	O
nuclei	nucleus	NOUN	NNS	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
diabetes	diabetes	NOUN	NN	5	B-Disease
insipidus	insipidus	NOUN	NN	5	I-Disease
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
arginine	arginine	NOUN	NN	0	B-Chemical
vasopressin	vasopressin	NOUN	NN	9	I-Chemical
(	(	PUNCT	-LRB-	9	O
AVP	AVP	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
gene	gene	NOUN	NN	1	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
paraventricular	paraventricular	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
PVN	PVN	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
supraoptic	supraoptic	ADJ	JJ	9	O
nuclei	nucleus	NOUN	NNS	3	O
(	(	PUNCT	-LRB-	9	O
SON	SON	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
investigated	investigate	VERB	VBN	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
with	with	ADP	IN	5	O
lithium	lithium	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
Li	Li	PROPN	NNP	6	B-Chemical
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
polyuria	polyuria	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
using	use	VERB	VBG	9	O
in	in	ADP	IN	5	O
situ	situ	ADJ	JJ	9	O
hybridization	hybridization	NOUN	NN	9	O
histochemistry	histochemistry	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
radioimmunoassay	radioimmunoassay	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
male	male	ADJ	JJ	9	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
consuming	consume	VERB	VBG	5	O
a	a	DET	DT	5	O
diet	diet	NOUN	NN	9	O
that	that	DET	WDT	5	O
contained	contain	VERB	VBD	9	O
LiCl	LiCl	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
60	60	NUM	CD	9	O
mmol	mmol	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
developed	develop	VERB	VBD	5	O
marked	mark	VERB	VBN	9	O
polyuria	polyuria	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
Li	Li	PROPN	NNP	6	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
produced	produce	VERB	VBD	9	O
a	a	DET	DT	5	O
large	large	ADJ	JJ	5	O
volume	volume	NOUN	NN	9	O
of	of	ADP	IN	5	O
hypotonic	hypotonic	ADJ	JJ	0	O
urine	urine	NOUN	NN	9	O
with	with	ADP	IN	5	O
low	low	ADJ	JJ	9	O
ionic	ionic	ADJ	JJ	0	O
concentrations	concentration	NOUN	NNS	0	O
.	.	PUNCT	.	9	O

Plasma	plasma	ADJ	JJ	0	O
sodium	sodium	NOUN	NN	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
slightly	slightly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Li	Li	PROPN	NNP	6	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
those	those	DET	DT	5	O
in	in	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Plasma	plasma	ADJ	JJ	0	O
concentration	concentration	NOUN	NN	0	O
of	of	ADP	IN	5	O
AVP	AVP	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
transcripts	transcript	NOUN	NNS	1	O
of	of	ADP	IN	5	O
AVP	AVP	PROPN	NNP	9	B-Chemical
gene	gene	NOUN	NN	1	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
PVN	PVN	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
SON	SON	PROPN	NNP	9	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
increased	increase	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
Li	Li	PROPN	NNP	6	B-Chemical
-	-	PUNCT	HYPH	7	O
treated	treat	VERB	VBN	3	O
rats	rat	NOUN	NNS	9	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
controls	control	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
dehydration	dehydration	NOUN	NN	9	B-Disease
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
the	the	DET	DT	5	O
activation	activation	NOUN	NN	3	O
of	of	ADP	IN	5	O
visceral	visceral	ADJ	JJ	9	O
afferent	afferent	NOUN	NN	5	O
inputs	input	NOUN	NNS	5	O
may	may	VERB	MD	5	O
contribute	contribute	VERB	VB	9	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
elevation	elevation	NOUN	NN	9	O
of	of	ADP	IN	5	O
plasma	plasma	NOUN	NN	9	O
AVP	AVP	PROPN	NNP	9	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
upregulation	upregulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
AVP	AVP	PROPN	NNP	9	B-Chemical
gene	gene	NOUN	NN	1	O
expression	expression	NOUN	NN	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
PVN	PVN	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
SON	SON	PROPN	NNP	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
Li	Li	PROPN	NNP	6	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
diabetes	diabetes	NOUN	NN	5	B-Disease
insipidus	insipidus	NOUN	NN	5	I-Disease
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Antinociceptive	antinociceptive	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
antiamnesic	antiamnesic	ADJ	JJ	0	O
properties	property	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
presynaptic	presynaptic	ADJ	JJ	3	O
cholinergic	cholinergic	NOUN	NN	3	O
amplifier	amplifier	NOUN	NN	5	O
PG	PG	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9	9	NUM	CD	7	I-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
antinociceptive	antinociceptive	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
3	3	NUM	CD	9	B-Chemical
alpha	alpha	NOUN	NN	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tropyl	tropyl	NOUN	NN	_	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
p	p	NOUN	NN	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
bromophenyl	bromophenyl	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
propionate	propionate	VERB	VBP	0	I-Chemical
[	[	PUNCT	-LRB-	9	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
PG	PG	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9	9	NUM	CD	7	I-Chemical
]	]	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
s	s	NOUN	NN	9	O
.	.	PUNCT	.	9	O
c	c	NOUN	NN	9	O
.	.	PUNCT	.	9	O
;	;	PUNCT	:	9	O
30	30	NUM	CD	9	O
-	-	SYM	SYM	7	O
60	60	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
p	p	NOUN	NN	7	O
.	.	PUNCT	.	9	O
o	o	X	XX	9	O
.	.	PUNCT	.	9	O
;	;	PUNCT	:	9	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
i	i	NOUN	NN	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
;	;	PUNCT	:	9	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
30	30	NUM	CD	9	O
micrograms	micrograms	NOUN	NN	0	O
/	/	SYM	SYM	9	O
mouse	mouse	NOUN	NN	3	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
c	c	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
examined	examine	VERB	VBN	9	O
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
rats	rat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
guinea	guinea	NOUN	NN	9	O
pigs	pig	NOUN	NNS	9	O
by	by	ADP	IN	9	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
hot	hot	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
plate	plate	NOUN	NN	0	O
,	,	PUNCT	,	9	O
abdominal	abdominal	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
constriction	constriction	NOUN	NN	5	O
,	,	PUNCT	,	9	O
tail	tail	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
flick	flick	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
paw	paw	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
pressure	pressure	NOUN	NN	5	O
tests	test	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

(	(	PUNCT	-LRB-	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
PG	PG	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9	9	NUM	CD	7	I-Chemical
antinociception	antinociception	NOUN	NN	3	O
peaked	peak	VERB	VBD	9	O
15	15	NUM	CD	9	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
injection	injection	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
then	then	ADV	RB	9	O
slowly	slowly	ADV	RB	5	O
diminished	diminish	VERB	VBN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
antinociception	antinociception	NOUN	NN	3	O
produced	produce	VERB	VBN	9	O
by	by	ADP	IN	9	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
PG	PG	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9	9	PROPN	NNP	7	I-Chemical
was	be	VERB	VBD	9	O
prevented	prevent	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
unselective	unselective	ADJ	JJ	0	O
muscarinic	muscarinic	ADJ	JJ	3	O
antagonist	antagonist	NOUN	NN	3	O
atropine	atropine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
M1	M1	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
selective	selective	ADJ	JJ	9	O
antagonists	antagonist	NOUN	NNS	3	O
pirenzepine	pirenzepine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
dicyclomine	dicyclomine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
depletor	depletor	NOUN	NN	0	O
hemicholinium	hemicholinium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
3	3	NUM	CD	9	I-Chemical
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
opioid	opioid	NOUN	NN	5	O
antagonist	antagonist	NOUN	NN	3	O
naloxone	naloxone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
gamma	gamma	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminobutyric	aminobutyric	ADJ	JJ	0	I-Chemical
acidB	acidB	PROPN	NNP	9	I-Chemical
antagonist	antagonist	NOUN	NN	3	O
3	3	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
aminopropyl	aminopropyl	ADJ	JJ	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
diethoxy	diethoxy	ADJ	JJ	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methyl	methyl	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
phosphinic	phosphinic	ADJ	JJ	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
H3	H3	PROPN	NNP	1	O
agonist	agonist	NOUN	NN	3	O
R	r	NOUN	NN	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
alpha	alpha	NOUN	NN	9	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	:	7	I-Chemical
methylhistamine	methylhistamine	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
D2	d2	NOUN	NN	9	O
antagonist	antagonist	NOUN	NN	3	O
quinpirole	quinpirole	NOUN	NN	3	B-Chemical
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxytryptamine4	hydroxytryptamine4	NOUN	NN	_	I-Chemical
antagonist	antagonist	NOUN	NN	3	O
2	2	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methoxy	methoxy	NOUN	NN	0	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
amino	amino	NOUN	NN	1	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
5	5	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
chlorobenzoic	chlorobenzoic	NOUN	NN	0	I-Chemical
acid	acid	NOUN	NN	0	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
diethylamino	diethylamino	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
ethyl	ethyl	ADV	RB	0	I-Chemical
ester	ester	NOUN	NN	0	I-Chemical
hydrochloride	hydrochloride	NOUN	NN	0	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxytryptamin1A	hydroxytryptamin1a	NOUN	NN	_	I-Chemical
antagonist	antagonist	NOUN	NN	3	O
1	1	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
methoxyphenyl	methoxyphenyl	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
[	[	PUNCT	-LRB-	9	I-Chemical
4	4	NUM	CD	9	I-Chemical
-	-	PUNCT	:	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
phthalimido	phthalimido	ADJ	JJ	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
butyl	butyl	NOUN	NNS	0	I-Chemical
]	]	PUNCT	-RRB-	9	I-Chemical
piperazine	piperazine	NOUN	NN	0	I-Chemical
hydrobromide	hydrobromide	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
polyamines	polyamine	NOUN	NNS	0	O
depletor	depletor	NOUN	NN	0	O
reserpine	reserpine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Based	base	VERB	VBN	9	O
on	on	ADP	IN	5	O
these	these	DET	DT	5	O
data	datum	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
it	-PRON-	PRON	PRP	5	O
can	can	VERB	MD	5	O
be	be	VERB	VB	5	O
postulated	postulate	VERB	VBN	9	O
that	that	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
PG	PG	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9	9	NUM	CD	7	I-Chemical
exerted	exert	VERB	VBD	9	O
an	an	DET	DT	5	O
antinociceptive	antinociceptive	ADJ	JJ	0	O
effect	effect	NOUN	NN	9	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
central	central	ADJ	JJ	5	O
potentiation	potentiation	NOUN	NN	3	O
of	of	ADP	IN	5	O
cholinergic	cholinergic	NOUN	NN	3	O
transmission	transmission	NOUN	NN	5	O
.	.	PUNCT	.	9	O

(	(	PUNCT	-LRB-	9	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
PG	PG	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9	9	PROPN	NNP	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
40	40	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
able	able	ADJ	JJ	9	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
amnesia	amnesia	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
dicyclomine	dicyclomine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mouse	mouse	NOUN	NN	3	O
passive	passive	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
avoidance	avoidance	NOUN	NN	5	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Affinity	affinity	NOUN	NN	0	O
profiles	profile	NOUN	NNS	9	O
of	of	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
PG	PG	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9	9	NUM	CD	7	I-Chemical
for	for	ADP	IN	5	O
muscarinic	muscarinic	ADJ	JJ	3	O
receptor	receptor	NOUN	NN	3	O
subtypes	subtype	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
determined	determine	VERB	VBN	9	O
by	by	ADP	IN	9	O
functional	functional	ADJ	JJ	9	O
studies	study	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
rabbit	rabbit	NOUN	NN	3	O
vas	vas	X	FW	9	O
deferens	deferen	NOUN	NNS	9	O
for	for	ADP	IN	5	O
M1	M1	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
guinea	guinea	NOUN	NN	9	O
pig	pig	NOUN	NN	9	O
atrium	atrium	NOUN	NN	5	O
for	for	ADP	IN	5	O
M2	M2	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
guinea	guinea	NOUN	NN	9	O
pig	pig	NOUN	NN	9	O
ileum	ileum	NOUN	NN	9	O
for	for	ADP	IN	5	O
M3	M3	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
immature	immature	ADJ	JJ	3	O
guinea	guinea	NOUN	NN	9	O
pig	pig	NOUN	NN	9	O
uterus	uterus	NOUN	NN	9	O
for	for	ADP	IN	5	O
putative	putative	ADJ	JJ	1	O
M4	M4	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
have	have	VERB	VBP	5	O
shown	show	VERB	VBN	9	O
an	an	DET	DT	5	O
M4	M4	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
M1	M1	PROPN	NNP	9	O
selectivity	selectivity	NOUN	NN	9	O
ratio	ratio	NOUN	NN	9	O
of	of	ADP	IN	5	O
10	10	NUM	CD	9	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
that	that	DET	DT	5	O
might	may	VERB	MD	9	O
be	be	VERB	VB	5	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
antinociception	antinociception	NOUN	NN	3	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
anti	anti	ADJ	JJ	3	O
-	-	ADJ	JJ	7	O
amnesic	amnesic	ADJ	JJ	5	B-Disease
effect	effect	NOUN	NN	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
PG	PG	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9	9	NUM	CD	7	I-Chemical
through	through	ADP	IN	9	O
an	an	DET	DT	5	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
extracellular	extracellular	ADJ	JJ	9	O
levels	level	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
antinociceptive	antinociceptive	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
antiamnesic	antiamnesic	ADJ	JJ	0	O
dose	dose	NOUN	NN	9	O
range	range	NOUN	NN	9	O
,	,	PUNCT	,	9	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
PG	PG	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9	9	PROPN	NNP	7	I-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
impair	impair	VERB	VB	9	O
mouse	mouse	NOUN	NN	3	O
performance	performance	NOUN	NN	5	O
evaluated	evaluate	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
rota	rota	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
rod	rod	NOUN	NN	9	O
test	test	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
Animex	Animex	PROPN	NNP	9	O
apparatus	apparatus	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
different	different	ADJ	JJ	9	O
anaesthetic	anaesthetic	ADJ	JJ	5	O
agents	agent	NOUN	NNS	5	O
in	in	ADP	IN	5	O
hearing	hear	VERB	VBG	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
following	follow	VERB	VBG	9	O
spinal	spinal	ADJ	JJ	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
hearing	hear	VERB	VBG	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
after	after	ADP	IN	9	O
spinal	spinal	ADJ	JJ	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
unknown	unknown	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

Up	up	ADP	IN	7	O
until	until	ADP	IN	5	O
now	now	ADV	RB	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
only	only	ADJ	JJ	9	O
factor	factor	NOUN	NN	9	O
studied	study	VERB	VBD	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
diameter	diameter	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
spinal	spinal	ADJ	JJ	5	O
needle	needle	NOUN	NN	5	O
on	on	ADP	IN	5	O
post	post	ADJ	JJ	9	O
-	-	ADJ	JJ	7	O
operative	operative	ADJ	JJ	5	O
sensorineural	sensorineural	ADJ	JJ	5	B-Disease
hearing	hearing	NOUN	NN	5	I-Disease
loss	loss	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
describe	describe	VERB	VB	5	O
this	this	DET	DT	5	O
hearing	hearing	NOUN	NN	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
investigate	investigate	VERB	VB	9	O
other	other	ADJ	JJ	5	O
factors	factor	NOUN	NNS	9	O
influencing	influence	VERB	VBG	5	O
the	the	DET	DT	5	O
degree	degree	NOUN	NN	5	O
of	of	ADP	IN	5	O
hearing	hear	VERB	VBG	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Two	two	NUM	CD	9	O
groups	group	NOUN	NNS	9	O
of	of	ADP	IN	5	O
22	22	NUM	CD	7	O
similar	similar	ADJ	JJ	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
:	:	PUNCT	:	9	O
one	one	NUM	CD	5	O
group	group	NOUN	NN	9	O
received	receive	VERB	VBD	9	O
6	6	NUM	CD	9	O
mL	ml	NOUN	NN	0	O
prilocaine	prilocaine	NOUN	NN	0	B-Chemical
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
;	;	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
received	receive	VERB	VBD	9	O
3	3	NUM	CD	9	O
mL	ml	NOUN	NN	0	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Patients	patient	NOUN	NNS	5	O
given	give	VERB	VBN	5	O
prilocaine	prilocaine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
develop	develop	VERB	VB	5	O
hearing	hear	VERB	VBG	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
out	out	ADP	IN	9	O
of	of	ADP	IN	5	O
22	22	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
given	give	VERB	VBN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
out	out	ADP	IN	9	O
of	of	ADP	IN	5	O
22	22	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
average	average	ADJ	JJ	5	O
hearing	hearing	NOUN	NN	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
for	for	ADP	IN	5	O
speech	speech	NOUN	NN	5	O
frequencies	frequency	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
about	about	ADV	RB	5	O
10	10	NUM	CD	9	O
dB	db	NUM	CD	5	O
after	after	ADP	IN	9	O
prilocaine	prilocaine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
15	15	NUM	CD	9	O
dB	db	NUM	CD	5	O
after	after	ADP	IN	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

None	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
complained	complain	VERB	VBD	5	O
of	of	ADP	IN	5	O
subjective	subjective	ADJ	JJ	5	O
hearing	hearing	NOUN	NN	5	B-Disease
loss	loss	NOUN	NN	9	I-Disease
.	.	PUNCT	.	9	O

Long	long	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
term	term	NOUN	NN	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
possible	possible	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
transient	transient	ADJ	JJ	9	O
neurological	neurological	ADJ	JJ	5	B-Disease
deficit	deficit	NOUN	NN	5	I-Disease
following	follow	VERB	VBG	9	O
intrathecal	intrathecal	ADJ	JJ	3	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
hyperbaric	hyperbaric	ADJ	JJ	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
unilateral	unilateral	ADJ	JJ	5	O
spinal	spinal	ADJ	JJ	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
describe	describe	VERB	VBP	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
transient	transient	ADJ	JJ	9	O
neurological	neurological	ADJ	JJ	5	B-Disease
deficit	deficit	NOUN	NN	5	I-Disease
that	that	DET	WDT	5	O
occurred	occur	VERB	VBD	9	O
after	after	ADP	IN	9	O
unilateral	unilateral	ADJ	JJ	5	O
spinal	spinal	ADJ	JJ	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
with	with	ADP	IN	5	O
8	8	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
%	%	NOUN	NN	9	O
hyperbaric	hyperbaric	ADJ	JJ	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
slowly	slowly	ADV	RB	5	O
injected	inject	VERB	VBD	3	O
through	through	ADP	IN	9	O
a	a	DET	DT	5	O
25	25	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
gauge	gauge	NOUN	NN	5	O
pencil	pencil	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
point	point	NOUN	NN	5	O
spinal	spinal	ADJ	JJ	5	O
needle	needle	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
surgery	surgery	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
were	be	VERB	VBD	9	O
uneventful	uneventful	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
3	3	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
surgery	surgery	NOUN	NN	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
reported	report	VERB	VBD	9	O
an	an	DET	DT	5	O
area	area	NOUN	NN	5	O
of	of	ADP	IN	5	O
hypoaesthesia	hypoaesthesia	NOUN	NN	5	O
over	over	ADP	IN	5	O
L3	L3	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
L4	L4	PROPN	NNP	9	O
dermatomes	dermatome	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
leg	leg	NOUN	NN	5	O
which	which	DET	WDT	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
operated	operate	VERB	VBN	5	O
on	on	ADP	IN	5	O
(	(	PUNCT	-LRB-	9	O
loss	loss	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
pinprick	pinprick	ADJ	JJ	5	I-Disease
sensation	sensation	NOUN	NN	5	I-Disease
)	)	PUNCT	-RRB-	9	O
without	without	ADP	IN	9	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
muscular	muscular	ADJ	JJ	5	O
strength	strength	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Sensation	sensation	NOUN	NN	5	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
area	area	NOUN	NN	5	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
normal	normal	ADJ	JJ	9	O
over	over	ADP	IN	5	O
the	the	DET	DT	5	O
following	following	ADJ	JJ	9	O
2	2	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Prospective	prospective	ADJ	JJ	5	O
multicentre	multicentre	NOUN	NN	5	O
studies	study	NOUN	NNS	9	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
large	large	ADJ	JJ	5	O
population	population	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
long	long	ADJ	JJ	5	O
follow	follow	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
up	up	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
performed	perform	VERB	VBN	9	O
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
evaluate	evaluate	VERB	VB	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
unusual	unusual	ADJ	JJ	9	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
low	low	ADJ	JJ	9	O
solution	solution	NOUN	NN	0	O
concentration	concentration	NOUN	NN	0	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
preferred	prefer	VERB	VBN	5	O
for	for	ADP	IN	5	O
unilateral	unilateral	ADJ	JJ	5	O
spinal	spinal	ADJ	JJ	5	O
anaesthesia	anaesthesia	NOUN	NN	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
hyperbaric	hyperbaric	ADJ	JJ	5	O
anaesthetic	anaesthetic	ADJ	JJ	5	O
solution	solution	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
if	if	ADP	IN	5	O
pencil	pencil	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
point	point	NOUN	NN	5	O
needle	needle	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
slow	slow	ADJ	JJ	5	O
injection	injection	NOUN	NN	9	O
rate	rate	NOUN	NN	9	O
are	be	VERB	VBP	5	O
employed	employ	VERB	VBN	5	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
in	in	ADP	IN	5	O
order	order	NOUN	NN	5	O
to	to	PART	TO	5	O
minimize	minimize	VERB	VB	5	O
the	the	DET	DT	5	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
localized	localize	VERB	VBN	9	O
high	high	ADJ	JJ	9	O
peak	peak	NOUN	NN	9	O
anaesthetic	anaesthetic	ADJ	JJ	5	O
concentration	concentration	NOUN	NN	0	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
might	may	VERB	MD	9	O
lead	lead	VERB	VB	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
transient	transient	ADJ	JJ	9	O
neurological	neurological	ADJ	JJ	5	B-Disease
deficit	deficit	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Transient	transient	ADJ	JJ	9	B-Disease
neurologic	neurologic	ADJ	JJ	5	I-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
after	after	ADP	IN	9	O
spinal	spinal	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
:	:	PUNCT	:	9	O
a	a	DET	DT	5	O
lower	low	ADJ	JJR	9	O
incidence	incidence	NOUN	NN	5	O
with	with	ADP	IN	5	O
prilocaine	prilocaine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
than	than	ADP	IN	5	O
with	with	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Recent	recent	ADJ	JJ	9	O
evidence	evidence	NOUN	NN	9	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
transient	transient	ADJ	JJ	9	B-Disease
neurologic	neurologic	ADJ	JJ	5	I-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
TNSs	tns	NOUN	NNS	5	B-Disease
)	)	PUNCT	-RRB-	9	O
frequently	frequently	ADV	RB	5	O
follow	follow	VERB	VBP	5	O
lidocaine	lidocaine	ADJ	JJR	0	B-Chemical
spinal	spinal	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
are	be	VERB	VBP	5	O
infrequent	infrequent	ADJ	JJ	5	O
with	with	ADP	IN	5	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

However	however	ADV	RB	9	O
,	,	PUNCT	,	9	O
identification	identification	NOUN	NN	9	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
short	short	ADV	RB	5	O
-	-	PUNCT	HYPH	7	O
acting	act	VERB	VBG	9	O
local	local	ADJ	JJ	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
to	to	PART	TO	5	O
substitute	substitute	VERB	VB	9	O
for	for	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
for	for	ADP	IN	5	O
brief	brief	ADJ	JJ	5	O
surgical	surgical	ADJ	JJ	5	O
procedures	procedure	NOUN	NNS	5	O
remains	remain	VERB	VBZ	9	O
an	an	DET	DT	5	O
important	important	ADJ	JJ	9	O
goal	goal	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Prilocaine	prilocaine	NOUN	NN	0	B-Chemical
is	be	VERB	VBZ	5	O
an	an	DET	DT	5	O
amide	amide	NOUN	NN	0	O
local	local	ADJ	JJ	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
that	that	DET	DT	5	O
of	of	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Accordingly	accordingly	ADV	RB	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
prospective	prospective	ADJ	JJ	5	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
study	study	NOUN	NN	9	O
compares	compare	VERB	VBZ	5	O
prilocaine	prilocaine	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
bupivacaine	bupivacaine	VERB	VB	0	B-Chemical
with	with	ADP	IN	5	O
respect	respect	NOUN	NN	9	O
to	to	ADP	IN	5	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
relative	relative	ADJ	JJ	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
TNSs	tns	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Ninety	ninety	NUM	CD	5	O
patients	patient	NOUN	NNS	5	O
classified	classify	VERB	VBN	5	O
as	as	ADP	IN	5	O
American	American	PROPN	NNP	9	O
Society	Society	PROPN	NNP	2	O
of	of	ADP	IN	5	O
Anesthesiologists	Anesthesiologists	PROPN	NNPS	5	O
physical	physical	ADJ	JJ	5	O
status	status	NOUN	NN	9	O
I	-PRON-	PRON	PRP	9	O
or	or	CCONJ	CC	5	O
II	II	PROPN	NNP	9	O
who	who	PRON	WP	5	O
were	be	VERB	VBD	9	O
scheduled	schedule	VERB	VBN	5	O
for	for	ADP	IN	5	O
short	short	ADJ	JJ	5	O
gynecologic	gynecologic	ADJ	JJ	5	O
procedures	procedure	NOUN	NNS	5	O
under	under	ADP	IN	9	O
spinal	spinal	ADJ	JJ	5	O
anesthesia	anesthesia	NOUN	NN	5	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
allocated	allocate	VERB	VBN	5	O
to	to	PART	TO	5	O
receive	receive	VERB	VB	5	O
2	2	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
ml	ml	NOUN	NN	0	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
glucose	glucose	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
%	%	NOUN	NN	9	O
prilocaine	prilocaine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
glucose	glucose	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
7	7	NUM	CD	9	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
%	%	NOUN	NN	9	O
glucose	glucose	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

All	all	DET	DT	9	O
solutions	solution	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
provided	provide	VERB	VBN	9	O
in	in	ADP	IN	5	O
blinded	blinded	ADJ	JJ	5	O
vials	vial	NOUN	NNS	0	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
hospital	hospital	NOUN	NN	5	O
pharmacy	pharmacy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Details	detail	NOUN	NNS	5	O
of	of	ADP	IN	5	O
spinal	spinal	ADJ	JJ	5	O
puncture	puncture	NOUN	NN	5	O
,	,	PUNCT	,	9	O
extension	extension	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
regression	regression	NOUN	NN	5	O
of	of	ADP	IN	5	O
spinal	spinal	ADJ	JJ	5	O
block	block	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
times	time	NOUN	NNS	5	O
to	to	PART	TO	5	O
reach	reach	VERB	VB	5	O
discharge	discharge	ADJ	JJ	5	O
criteria	criterion	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
noted	note	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
evening	evening	NOUN	NN	5	O
of	of	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	O
day	day	NOUN	NN	9	O
1	1	NUM	CD	9	O
,	,	PUNCT	,	9	O
patients	patient	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
for	for	ADP	IN	5	O
TNSs	tns	NOUN	NNS	5	B-Disease
by	by	ADP	IN	9	O
a	a	DET	DT	5	O
physician	physician	ADJ	JJ	5	O
unaware	unaware	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
drug	drug	NOUN	NN	5	O
administered	administer	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
details	detail	NOUN	NNS	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
anesthetic	anesthetic	ADJ	JJ	5	O
procedure	procedure	NOUN	NN	5	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
Nine	nine	NUM	CD	9	O
of	of	ADP	IN	5	O
30	30	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
experienced	experienced	ADJ	JJ	5	O
TNSs	tns	NOUN	NNS	5	B-Disease
,	,	PUNCT	,	9	O
1	1	NUM	CD	9	O
of	of	ADP	IN	5	O
30	30	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
prilocaine	prilocaine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
=	=	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
03	03	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
had	have	VERB	VBD	9	O
them	-PRON-	PRON	PRP	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
none	none	NOUN	NN	9	O
of	of	ADP	IN	5	O
30	30	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
receiving	receive	VERB	VBG	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
had	have	VERB	VBD	9	O
TNSs	tns	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Times	time	NOUN	NNS	5	O
to	to	PART	TO	5	O
ambulate	ambulate	VERB	VB	5	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
void	void	VERB	VB	5	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
after	after	ADP	IN	9	O
lidocaine	lidocaine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
prilocaine	prilocaine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
150	150	NUM	CD	0	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
165	165	NUM	CD	7	O
min	min	NOUN	NN	0	O
and	and	CCONJ	CC	5	O
238	238	NUM	CD	7	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
253	253	NUM	CD	7	O
min	min	NOUN	NN	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
but	but	CCONJ	CC	9	O
prolonged	prolong	VERB	VBN	9	O
after	after	ADP	IN	9	O
bupivacaine	bupivacaine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
200	200	NUM	CD	0	O
and	and	CCONJ	CC	5	O
299	299	NUM	CD	7	O
min	min	NOUN	NN	0	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
;	;	PUNCT	:	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
05	05	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
Prilocaine	prilocaine	NOUN	NN	0	B-Chemical
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
preferable	preferable	ADJ	JJ	5	O
to	to	ADP	IN	5	O
lidocaine	lidocaine	VERB	VB	0	B-Chemical
for	for	ADP	IN	5	O
short	short	ADJ	JJ	5	O
surgical	surgical	ADJ	JJ	5	O
procedures	procedure	NOUN	NNS	5	O
because	because	ADP	IN	5	O
it	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
a	a	DET	DT	5	O
similar	similar	ADJ	JJ	9	O
duration	duration	NOUN	NN	5	O
of	of	ADP	IN	5	O
action	action	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
a	a	DET	DT	5	O
lower	low	ADJ	JJR	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
TNSs	tns	NOUN	NNS	5	B-Disease
.	.	PUNCT	.	9	O

Suxamethonium	suxamethonium	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
death	death	NOUN	NN	9	B-Disease
following	follow	VERB	VBG	9	O
5	5	NUM	CD	9	O
days	day	NOUN	NNS	9	O
of	of	ADP	IN	5	O
immobilization	immobilization	NOUN	NN	0	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
report	report	NOUN	NN	5	O
describes	describe	VERB	VBZ	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
and	and	CCONJ	CC	5	O
subsequent	subsequent	ADJ	JJ	9	O
death	death	NOUN	NN	9	B-Disease
as	as	ADP	IN	5	O
a	a	DET	DT	5	O
result	result	NOUN	NN	9	O
of	of	ADP	IN	5	O
hyperkalaemia	hyperkalaemia	NOUN	NN	5	B-Disease
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
suxamethonium	suxamethonium	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
23	23	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
Malawian	malawian	ADJ	JJ	5	O
woman	woman	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
days	day	NOUN	NNS	9	O
after	after	ADP	IN	9	O
the	the	DET	DT	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
symptoms	symptom	NOUN	NNS	5	O
of	of	ADP	IN	5	O
meningitis	meningitis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
aspirated	aspirate	VERB	VBN	9	O
stomach	stomach	NOUN	NN	9	O
contents	content	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
needed	need	VERB	VBN	5	O
endotracheal	endotracheal	ADJ	JJ	5	O
intubation	intubation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Forty	forty	NUM	CD	9	O
seconds	second	NOUN	NNS	5	O
after	after	ADP	IN	9	O
injection	injection	NOUN	NN	9	O
of	of	ADP	IN	5	O
suxamethonium	suxamethonium	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
bradycardia	bradycardia	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
cardiac	cardiac	ADJ	JJ	5	B-Disease
arrest	arrest	NOUN	NN	3	I-Disease
occurred	occur	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Attempts	attempt	NOUN	NNS	9	O
to	to	PART	TO	5	O
resuscitate	resuscitate	VERB	VB	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
were	be	VERB	VBD	9	O
not	not	ADV	RB	5	O
successful	successful	ADJ	JJ	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
potassium	potassium	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
8	8	NUM	CD	9	O
.	.	NOUN	NN	9	O
4	4	NUM	CD	9	O
mequiv	mequiv	NOUN	NN	0	O
L	L	PROPN	NNP	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O

Apart	apart	ADV	RB	9	O
from	from	ADP	IN	9	O
the	the	DET	DT	5	O
reduction	reduction	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
level	level	NOUN	NN	9	O
of	of	ADP	IN	5	O
consciousness	consciousness	NOUN	NN	5	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
were	be	VERB	VBD	9	O
no	no	DET	DT	9	O
signs	sign	NOUN	NNS	5	O
of	of	ADP	IN	5	O
motor	motor	NOUN	NN	5	O
neurone	neurone	NOUN	NN	5	O
damage	damage	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
of	of	ADP	IN	5	O
any	any	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
known	know	VERB	VBN	9	O
predisposing	predispose	VERB	VBG	5	O
conditions	condition	NOUN	NNS	9	O
for	for	ADP	IN	5	O
hyperkalaemia	hyperkalaemia	NOUN	NN	5	B-Disease
following	follow	VERB	VBG	9	O
the	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
suxamethonium	suxamethonium	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
is	be	VERB	VBZ	5	O
postulated	postulate	VERB	VBN	9	O
that	that	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
death	death	NOUN	NN	9	B-Disease
was	be	VERB	VBD	9	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
to	to	ADP	IN	5	O
suxamethonium	suxamethonium	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
her	-PRON-	DET	PRP$	5	O
5	5	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
day	day	NOUN	NN	9	O
immobilization	immobilization	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
autoimmune	autoimmune	NOUN	NN	3	B-Disease
hemolytic	hemolytic	ADJ	JJ	0	I-Disease
anemia	anemia	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
erythroblastocytopenia	erythroblastocytopenia	NOUN	NN	_	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
ceftriaxone	ceftriaxone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
80	80	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
yr	yr	NOUN	NN	7	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
man	man	NOUN	NN	5	O
developed	develop	VERB	VBD	5	O
acute	acute	ADJ	JJ	9	O
hepatitis	hepatitis	NOUN	NN	9	B-Disease
shortly	shortly	ADV	RB	9	O
after	after	ADP	IN	9	O
ingesting	ingest	VERB	VBG	5	O
oral	oral	ADJ	JJ	9	O
ceftriaxone	ceftriaxone	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
the	the	DET	DT	5	O
transaminases	transaminase	NOUN	NNS	9	O
gradually	gradually	ADV	RB	9	O
returned	return	VERB	VBD	5	O
to	to	ADP	IN	5	O
baseline	baseline	NOUN	NN	5	O
after	after	ADP	IN	9	O
withholding	withhold	VERB	VBG	5	O
the	the	DET	DT	5	O
beta	beta	NOUN	NN	9	B-Chemical
lactam	lactam	NOUN	NN	0	I-Chemical
antibiotic	antibiotic	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
there	there	ADV	EX	5	O
was	be	VERB	VBD	9	O
a	a	DET	DT	5	O
gradual	gradual	ADJ	JJ	9	O
increase	increase	NOUN	NN	9	O
in	in	ADP	IN	5	O
serum	serum	ADJ	JJ	9	O
bilirubin	bilirubin	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
a	a	DET	DT	5	O
decrease	decrease	NOUN	NN	9	O
in	in	ADP	IN	5	O
hemoglobin	hemoglobin	NOUN	NN	0	O
concentration	concentration	NOUN	NN	0	O
caused	cause	VERB	VBN	9	O
by	by	ADP	IN	9	O
an	an	DET	DT	5	O
autoimmune	autoimmune	ADJ	JJ	3	B-Disease
hemolytic	hemolytic	ADJ	JJ	0	I-Disease
anemia	anemia	NOUN	NN	9	I-Disease
and	and	CCONJ	CC	5	O
erythroblastocytopenia	erythroblastocytopenia	NOUN	NN	_	B-Disease
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
responded	respond	VERB	VBD	9	O
to	to	ADP	IN	5	O
systemic	systemic	ADJ	JJ	9	O
steroids	steroid	NOUN	NNS	9	B-Chemical
and	and	CCONJ	CC	5	O
immunoglobulins	immunoglobulin	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
the	the	DET	DT	5	O
widespread	widespread	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
agents	agent	NOUN	NNS	5	O
this	this	DET	DT	5	O
triad	triad	NOUN	NN	9	O
of	of	ADP	IN	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
previously	previously	ADV	RB	9	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
in	in	ADP	IN	5	O
connection	connection	NOUN	NN	5	O
with	with	ADP	IN	5	O
beta	beta	NOUN	NN	9	B-Chemical
lactam	lactam	NOUN	NN	0	I-Chemical
antibiotics	antibiotic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Thyroxine	thyroxine	ADJ	JJ	0	B-Chemical
abuse	abuse	NOUN	NN	5	O
:	:	PUNCT	:	9	O
an	an	DET	DT	5	O
unusual	unusual	ADJ	JJ	9	O
case	case	NOUN	NN	5	O
of	of	ADP	IN	5	O
thyrotoxicosis	thyrotoxicosis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Eating	eat	VERB	VBG	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
associated	associate	VERB	VBN	9	O
behavioural	behavioural	ADJ	JJ	5	O
problems	problem	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
drug	drug	NOUN	NN	5	B-Disease
abuse	abuse	NOUN	NN	5	I-Disease
are	be	VERB	VBP	5	O
uncommon	uncommon	ADJ	JJ	5	O
in	in	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
.	.	PUNCT	.	9	O

When	when	ADV	WRB	9	O
they	-PRON-	PRON	PRP	5	O
do	do	VERB	VBP	5	O
occur	occur	VERB	VB	5	O
they	-PRON-	PRON	PRP	5	O
are	be	VERB	VBP	5	O
often	often	ADV	RB	5	O
unrecognized	unrecognized	ADJ	JJ	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
denial	denial	NOUN	NN	5	O
but	but	CCONJ	CC	9	O
when	when	ADV	WRB	5	O
significant	significant	ADJ	JJ	9	O
may	may	VERB	MD	5	O
pose	pose	VERB	VB	5	O
a	a	DET	DT	5	O
risk	risk	NOUN	NN	5	O
to	to	ADP	IN	5	O
both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
mother	mother	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
her	-PRON-	DET	PRP$	5	O
fetus	fetus	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
illustrates	illustrate	VERB	VBZ	5	O
a	a	DET	DT	5	O
number	number	NOUN	NN	9	O
of	of	ADP	IN	5	O
problems	problem	NOUN	NNS	5	O
that	that	DET	WDT	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
encountered	encounter	VERB	VBN	5	O
in	in	ADP	IN	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
eating	eat	VERB	VBG	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
pregnancy	pregnancy	NOUN	NN	5	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
prolonged	prolong	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
recurrent	recurrent	ADJ	JJ	5	O
metabolic	metabolic	NOUN	NN	9	O
disturbances	disturbance	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
diuretic	diuretic	ADJ	JJ	5	O
abuse	abuse	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
particular	particular	ADJ	JJ	5	O
it	-PRON-	PRON	PRP	5	O
illustrates	illustrate	VERB	VBZ	5	O
the	the	DET	DT	5	O
derangements	derangement	NOUN	NNS	5	O
of	of	ADP	IN	5	O
thyroid	thyroid	NOUN	NN	9	O
function	function	NOUN	NN	9	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
pregnant	pregnant	ADJ	JJ	5	O
women	woman	NOUN	NNS	5	O
with	with	ADP	IN	5	O
eating	eat	VERB	VBG	5	B-Disease
disorders	disorder	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
reminds	remind	VERB	VBZ	5	O
us	-PRON-	PRON	PRP	5	O
that	that	ADP	IN	5	O
when	when	ADV	WRB	5	O
a	a	DET	DT	5	O
cause	cause	NOUN	NN	5	O
for	for	ADP	IN	5	O
thyrotoxicosis	thyrotoxicosis	NOUN	NN	5	B-Disease
remains	remain	VERB	VBZ	9	O
obscure	obscure	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
thyroxine	thyroxine	ADJ	JJ	0	B-Chemical
abuse	abuse	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
considered	consider	VERB	VBN	5	O
and	and	CCONJ	CC	5	O
explored	explore	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Repeated	repeat	VERB	VBN	5	O
trimipramine	trimipramine	NOUN	NN	0	B-Chemical
induces	induce	VERB	VBZ	3	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
D2	D2	PROPN	NNP	9	O
/	/	SYM	SYM	9	O
D3	D3	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
alpha1	alpha1	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	ADJ	JJ	9	O
up	up	ADP	IN	5	O
-	-	PUNCT	HYPH	7	O
regulation	regulation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Trimipramine	Trimipramine	PROPN	NNP	7	B-Chemical
(	(	PUNCT	-LRB-	9	O
TRI	TRI	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
shows	show	VERB	VBZ	9	O
a	a	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
antidepressant	antidepressant	ADJ	JJ	5	B-Chemical
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
chemically	chemically	ADV	RB	0	O
related	relate	VERB	VBN	9	O
to	to	PART	TO	5	O
imipramine	imipramine	VERB	VB	0	B-Chemical
but	but	CCONJ	CC	9	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
inhibit	inhibit	VERB	VB	3	O
the	the	DET	DT	5	O
reuptake	reuptake	NOUN	NN	0	O
of	of	ADP	IN	5	O
noradrenaline	noradrenaline	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxytryptamine	hydroxytryptamine	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
nor	nor	CCONJ	CC	9	O
does	do	VERB	VBZ	9	O
it	-PRON-	PRON	PRP	5	O
induce	induce	VERB	VB	3	O
beta	beta	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	NOUN	NN	9	O
down	down	ADP	IN	9	O
-	-	PUNCT	HYPH	7	O
regulation	regulation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
mechanism	mechanism	NOUN	NN	9	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
antidepressant	antidepressant	ADJ	JJ	5	B-Chemical
activity	activity	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
still	still	ADV	RB	5	O
unknown	unknown	ADJ	JJ	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
aim	aim	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
present	present	ADJ	JJ	9	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
find	find	VERB	VB	5	O
out	out	PART	RP	9	O
whether	whether	ADP	IN	9	O
TRI	TRI	PROPN	NNP	9	B-Chemical
given	give	VERB	VBN	5	O
repeatedly	repeatedly	ADV	RB	5	O
was	be	VERB	VBD	9	O
able	able	ADJ	JJ	9	O
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
adaptive	adaptive	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
dopaminergic	dopaminergic	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
alpha1	alpha1	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	NOUN	NN	9	O
systems	system	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
demonstrated	demonstrate	VERB	VBN	9	O
by	by	ADP	IN	9	O
us	-PRON-	PRON	PRP	5	O
previously	previously	ADV	RB	9	O
for	for	ADP	IN	5	O
various	various	ADJ	JJ	9	O
antidepressants	antidepressant	NOUN	NNS	5	B-Chemical
.	.	PUNCT	.	9	O

TRI	TRI	PROPN	NNP	9	B-Chemical
was	be	VERB	VBD	9	O
given	give	VERB	VBN	5	O
to	to	ADP	IN	5	O
male	male	ADJ	JJ	9	O
Wistar	Wistar	PROPN	NNP	9	O
rats	rat	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
male	male	ADJ	JJ	9	O
Albino	albino	ADJ	JJ	2	O
Swiss	swiss	ADJ	JJ	2	O
mice	mouse	NOUN	NNS	3	O
perorally	perorally	ADV	RB	0	O
twice	twice	ADV	RB	9	O
daily	daily	ADJ	JJ	5	O
for	for	ADP	IN	5	O
14	14	NUM	CD	7	O
days	day	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
acute	acute	ADJ	JJ	9	O
experiment	experiment	NOUN	NN	9	O
TRI	TRI	PROPN	NNP	9	B-Chemical
(	(	PUNCT	-LRB-	9	O
given	give	VERB	VBN	5	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
antagonize	antagonize	VERB	VB	3	O
the	the	DET	DT	5	O
reserpine	reserpine	NOUN	NN	0	B-Chemical
hypothermia	hypothermia	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
does	do	VERB	VBZ	9	O
not	not	ADV	RB	5	O
potentiate	potentiate	VERB	VB	3	O
the	the	DET	DT	5	O
5	5	NUM	CD	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
hydroxytryptophan	hydroxytryptophan	NOUN	NN	0	I-Chemical
head	head	NOUN	NN	5	O
twitches	twitch	NOUN	NNS	5	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

TRI	TRI	PROPN	NNP	9	B-Chemical
given	give	VERB	VBN	5	O
repeatedly	repeatedly	ADV	RB	5	O
to	to	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
increases	increase	NOUN	NNS	9	O
the	the	DET	DT	5	O
locomotor	locomotor	NOUN	NN	5	O
hyperactivity	hyperactivity	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
d	d	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
amphetamine	amphetamine	NOUN	NN	5	I-Chemical
,	,	PUNCT	,	9	O
quinpirole	quinpirole	NOUN	NN	3	B-Chemical
and	and	CCONJ	CC	5	O
(	(	PUNCT	-LRB-	9	O
+	+	CCONJ	CC	9	O
)	)	PUNCT	-RRB-	9	O
-	-	PUNCT	HYPH	7	O
7	7	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
hydroxy	hydroxy	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
dipropyloaminotetralin	dipropyloaminotetralin	NOUN	NN	_	O
(	(	PUNCT	-LRB-	9	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
D2	d2	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
D3	D3	PROPN	NNP	9	O
effects	effect	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
stereotypies	stereotypie	NOUN	NNS	5	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
d	d	ADJ	JJ	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
amphetamine	amphetamine	NOUN	NN	5	I-Chemical
or	or	CCONJ	CC	5	O
apomorphine	apomorphine	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
not	not	ADV	RB	5	O
potentiated	potentiate	VERB	VBN	3	O
by	by	ADP	IN	9	O
TRI	TRI	PROPN	NNP	9	B-Chemical
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
increases	increase	VERB	VBZ	9	O
the	the	DET	DT	5	O
behaviour	behaviour	NOUN	NN	5	O
stimulation	stimulation	NOUN	NN	3	O
evoked	evoke	VERB	VBN	5	O
by	by	ADP	IN	9	O
phenylephrine	phenylephrine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
given	give	VERB	VBN	5	O
intraventricularly	intraventricularly	ADV	RB	3	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
evaluated	evaluate	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
open	open	ADJ	JJ	5	O
field	field	NOUN	NN	5	O
test	test	NOUN	NN	5	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
the	the	DET	DT	5	O
aggressiveness	aggressiveness	NOUN	NN	5	B-Disease
evoked	evoke	VERB	VBN	5	O
by	by	ADP	IN	9	O
clonidine	clonidine	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
mice	mouse	NOUN	NNS	3	O
,	,	PUNCT	,	9	O
both	both	CCONJ	CC	9	O
these	these	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
being	be	VERB	VBG	5	O
mediated	mediate	VERB	VBN	3	O
by	by	ADP	IN	9	O
an	an	DET	DT	5	O
alpha1	alpha1	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	NOUN	NN	9	O
receptor	receptor	NOUN	NN	3	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
may	may	VERB	MD	5	O
be	be	VERB	VB	5	O
concluded	conclude	VERB	VBN	9	O
that	that	ADP	IN	5	O
,	,	PUNCT	,	9	O
like	like	ADP	IN	9	O
other	other	ADJ	JJ	5	O
tricyclic	tricyclic	ADJ	JJ	0	O
antidepressants	antidepressant	NOUN	NNS	5	B-Chemical
studied	study	VERB	VBD	9	O
previously	previously	ADV	RB	9	O
,	,	PUNCT	,	9	O
TRI	TRI	PROPN	NNP	9	B-Chemical
given	give	VERB	VBN	5	O
repeatedly	repeatedly	ADV	RB	5	O
increases	increase	VERB	VBZ	9	O
the	the	DET	DT	5	O
responsiveness	responsiveness	NOUN	NN	9	O
of	of	ADP	IN	5	O
brain	brain	NOUN	NN	5	O
dopamine	dopamine	NOUN	NN	5	B-Chemical
D2	d2	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
D3	D3	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
locomotor	locomotor	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
stereotypy	stereotypy	ADJ	JJ	5	O
)	)	PUNCT	-RRB-	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
alpha1	alpha1	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
adrenergic	adrenergic	ADJ	JJ	9	O
receptors	receptor	NOUN	NNS	3	O
to	to	ADP	IN	5	O
their	-PRON-	DET	PRP$	5	O
agonists	agonist	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
question	question	NOUN	NN	5	O
arises	arise	VERB	VBZ	5	O
whether	whether	ADP	IN	9	O
the	the	DET	DT	5	O
reuptake	reuptake	NOUN	NN	0	O
inhibition	inhibition	NOUN	NN	3	O
is	be	VERB	VBZ	5	O
of	of	ADP	IN	5	O
any	any	DET	DT	5	O
importance	importance	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
adaptive	adaptive	ADJ	JJ	5	O
changes	change	NOUN	NNS	9	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
repeated	repeat	VERB	VBN	5	O
antidepressants	antidepressant	NOUN	NNS	5	B-Chemical
,	,	PUNCT	,	9	O
suggested	suggest	VERB	VBD	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
antidepressant	antidepressant	ADJ	JJ	5	B-Chemical
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Pethidine	Pethidine	PROPN	NNP	0	B-Chemical
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
seizure	seizure	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
healthy	healthy	ADJ	JJ	5	O
adolescent	adolescent	NOUN	NN	5	O
receiving	receive	VERB	VBG	9	O
pethidine	pethidine	NOUN	NN	5	B-Chemical
for	for	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
healthy	healthy	ADJ	JJ	5	O
17	17	NUM	CD	7	O
-	-	PUNCT	HYPH	7	O
year	year	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
old	old	ADJ	JJ	5	O
male	male	NOUN	NN	9	O
received	receive	VERB	VBD	9	O
standard	standard	ADJ	JJ	5	O
intermittent	intermittent	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
pethidine	pethidine	NOUN	NN	5	B-Chemical
via	via	ADP	IN	9	O
a	a	DET	DT	5	O
patient	patient	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
analgesia	analgesia	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
PCA	PCA	PROPN	NNP	5	O
)	)	PUNCT	-RRB-	9	O
pump	pump	NOUN	NN	0	O
for	for	ADP	IN	5	O
management	management	NOUN	NN	5	O
of	of	ADP	IN	5	O
postoperative	postoperative	ADJ	JJ	5	B-Disease
pain	pain	NOUN	NN	5	I-Disease
control	control	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
three	three	NUM	CD	9	O
h	h	NOUN	NNS	0	O
postoperatively	postoperatively	ADV	RB	5	O
he	-PRON-	PRON	PRP	5	O
developed	develop	VERB	VBD	5	O
a	a	DET	DT	5	O
brief	brief	ADJ	JJ	5	O
self	self	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
limited	limit	VERB	VBN	5	O
seizure	seizure	NOUN	NN	5	B-Disease
.	.	PUNCT	.	9	O

Both	both	DET	DT	9	O
plasma	plasma	NOUN	NN	9	O
pethidine	pethidine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
norpethidine	norpethidine	NOUN	NN	0	B-Chemical
were	be	VERB	VBD	9	O
elevated	elevate	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
range	range	NOUN	NN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
clinical	clinical	ADJ	JJ	5	O
manifestations	manifestation	NOUN	NNS	5	O
of	of	ADP	IN	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
excitation	excitation	NOUN	NN	0	O
.	.	PUNCT	.	9	O

No	no	DET	DT	9	O
other	other	ADJ	JJ	5	O
risk	risk	NOUN	NN	5	O
factors	factor	NOUN	NNS	9	O
for	for	ADP	IN	5	O
CNS	CNS	PROPN	NNP	9	O
toxicity	toxicity	NOUN	NN	9	B-Disease
were	be	VERB	VBD	9	O
identified	identify	VERB	VBN	9	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
method	method	NOUN	NN	5	O
allowed	allow	VERB	VBD	9	O
frequent	frequent	ADJ	JJ	5	O
self	self	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
dosing	dosing	NOUN	NN	9	O
of	of	ADP	IN	5	O
pethidine	pethidine	NOUN	NN	5	B-Chemical
at	at	ADP	IN	9	O
short	short	ADJ	JJ	5	O
time	time	NOUN	NN	5	O
intervals	interval	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
rapid	rapid	ADJ	JJ	5	O
accumulation	accumulation	NOUN	NN	9	O
of	of	ADP	IN	5	O
pethidine	pethidine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
norpethidine	norpethidine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
routine	routine	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
pethidine	pethidine	NOUN	NN	5	B-Chemical
via	via	ADP	IN	9	O
PCA	PCA	PROPN	NNP	5	O
even	even	ADV	RB	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
brief	brief	ADJ	JJ	5	O
postoperative	postoperative	ADJ	JJ	5	O
analgesia	analgesia	NOUN	NN	5	O
should	should	VERB	MD	5	O
be	be	VERB	VB	5	O
reconsidered	reconsider	VERB	VBN	5	O
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
unusual	unusual	ADJ	JJ	9	O
toxic	toxic	ADJ	JJ	0	O
reaction	reaction	NOUN	NN	9	O
to	to	ADP	IN	5	O
axillary	axillary	ADJ	JJ	5	O
block	block	NOUN	NN	9	O
by	by	ADP	IN	9	O
mepivacaine	mepivacaine	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

An	an	DET	DT	5	O
increase	increase	NOUN	NN	9	B-Disease
in	in	ADP	IN	5	I-Disease
blood	blood	NOUN	NN	9	I-Disease
pressure	pressure	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
accompanied	accompany	VERB	VBN	9	O
by	by	ADP	IN	9	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
agitation	agitation	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
incomprehensible	incomprehensible	ADJ	JJ	5	B-Disease
shouts	shout	NOUN	NNS	5	I-Disease
and	and	CCONJ	CC	5	O
loss	loss	NOUN	NN	9	B-Disease
of	of	ADP	IN	5	I-Disease
consciousness	consciousness	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
elderly	elderly	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
ASA	ASA	PROPN	NNP	9	O
classification	classification	NOUN	NN	5	O
group	group	NOUN	NN	9	O
II	II	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
cardiovascularly	cardiovascularly	ADV	RB	5	O
medicated	medicate	VERB	VBN	5	O
male	male	NOUN	NN	9	O
,	,	PUNCT	,	9	O
12	12	NUM	CD	9	O
min	min	NOUN	NN	0	O
after	after	ADP	IN	9	O
performance	performance	NOUN	NN	5	O
of	of	ADP	IN	5	O
axillary	axillary	ADJ	JJ	5	O
block	block	NOUN	NN	9	O
with	with	ADP	IN	5	O
mepivacaine	mepivacaine	NOUN	NN	0	B-Chemical
850	850	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
containing	contain	VERB	VBG	0	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
225	225	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
for	for	ADP	IN	5	O
correction	correction	NOUN	NN	5	O
of	of	ADP	IN	5	O
Dupuytren	Dupuytren	PROPN	NNP	5	B-Disease
'	'	PART	POS	9	I-Disease
s	s	NOUN	NN	9	I-Disease
contracture	contracture	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
intravenous	intravenous	ADJ	JJ	0	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
labetalol	labetalol	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
metoprolol	metoprolol	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
midazolam	midazolam	NOUN	NN	0	B-Chemical
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	NOUN	NN	9	O
condition	condition	NOUN	NN	5	O
improved	improve	VERB	VBD	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
15	15	NUM	CD	9	O
min	min	NOUN	NN	0	O
later	later	ADV	RB	9	O
he	-PRON-	PRON	PRP	5	O
woke	wake	VERB	VBD	5	O
up	up	PART	RP	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
block	block	NOUN	NN	9	O
was	be	VERB	VBD	9	O
successful	successful	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
surgery	surgery	NOUN	NN	5	O
was	be	VERB	VBD	9	O
conducted	conduct	VERB	VBN	9	O
as	as	ADP	IN	5	O
scheduled	schedule	VERB	VBN	5	O
despite	despite	ADP	IN	9	O
persisting	persist	VERB	VBG	9	O
atrial	atrial	ADJ	JJ	5	B-Disease
fibrillation	fibrillation	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Postoperatively	postoperatively	ADV	RB	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
refused	refuse	VERB	VBN	5	O
DC	DC	PROPN	NNP	3	O
cardioversion	cardioversion	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
was	be	VERB	VBD	9	O
treated	treat	VERB	VBN	3	O
medically	medically	ADV	RB	5	O
.	.	PUNCT	.	9	O

Both	both	CCONJ	CC	9	O
the	the	DET	DT	5	O
temporal	temporal	ADJ	JJ	5	O
relationship	relationship	NOUN	NN	5	O
of	of	ADP	IN	5	O
events	event	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
response	response	NOUN	NN	9	O
to	to	ADP	IN	5	O
treatment	treatment	NOUN	NN	9	O
suggest	suggest	VERB	VBP	9	O
that	that	ADP	IN	5	O
a	a	DET	DT	5	O
rapid	rapid	ADJ	JJ	5	O
systemic	systemic	ADJ	JJ	9	O
absorption	absorption	NOUN	NN	0	O
of	of	ADP	IN	5	O
mepivacaine	mepivacaine	NOUN	NN	0	B-Chemical
with	with	ADP	IN	5	O
adrenaline	adrenaline	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
/	/	SYM	SYM	9	O
or	or	CCONJ	CC	5	O
interaction	interaction	NOUN	NN	9	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
drugs	drug	NOUN	NNS	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
patient	patient	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
medications	medication	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
responsible	responsible	ADJ	JJ	9	O
for	for	ADP	IN	5	O
the	the	DET	DT	5	O
perioperative	perioperative	ADJ	JJ	5	O
complications	complication	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
acute	acute	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
onset	onset	NOUN	NN	5	O
vanishing	vanish	VERB	VBG	5	B-Disease
bile	bile	NOUN	NN	0	I-Disease
duct	duct	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
Stevens	Stevens	PROPN	NNP	6	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
Johnson	Johnson	PROPN	NNP	6	I-Disease
syndromes	syndrome	VERB	VBZ	5	I-Disease
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
child	child	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Acute	acute	ADJ	JJ	5	O
vanishing	vanish	VERB	VBG	5	B-Disease
bile	bile	NOUN	NN	0	I-Disease
duct	duct	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
but	but	CCONJ	CC	9	O
established	establish	VERB	VBN	9	O
cause	cause	NOUN	NN	5	O
of	of	ADP	IN	5	O
progressive	progressive	ADJ	JJ	5	O
cholestasis	cholestasis	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
adults	adult	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
most	most	ADV	RBS	9	O
often	often	ADV	RB	5	O
drug	drug	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
toxin	toxin	NOUN	NN	1	O
related	relate	VERB	VBN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
is	be	VERB	VBZ	5	O
of	of	ADP	IN	5	O
unknown	unknown	ADJ	JJ	9	O
pathogenesis	pathogenesis	NOUN	NN	9	O
.	.	PUNCT	.	9	O

It	-PRON-	PRON	PRP	5	O
has	have	VERB	VBZ	9	O
not	not	ADV	RB	5	O
been	be	VERB	VBN	9	O
reported	report	VERB	VBN	9	O
previously	previously	ADV	RB	9	O
in	in	ADP	IN	5	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Stevens	Stevens	PROPN	NNP	6	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
Johnson	Johnson	PROPN	NNP	6	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
well	well	ADV	RB	9	O
-	-	PUNCT	HYPH	7	O
recognized	recognize	VERB	VBN	9	O
immune	immune	ADJ	JJ	3	O
complex	complex	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
mediated	mediate	VERB	VBN	3	O
hypersensitivity	hypersensitivity	NOUN	NN	9	B-Disease
reaction	reaction	NOUN	NN	9	O
that	that	DET	WDT	5	O
affects	affect	VERB	VBZ	9	O
all	all	DET	DT	5	O
age	age	NOUN	NN	5	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
is	be	VERB	VBZ	5	O
drug	drug	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
infection	infection	NOUN	NN	9	B-Disease
induced	induce	VERB	VBN	3	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
has	have	VERB	VBZ	9	O
classic	classic	ADJ	JJ	5	O
systemic	systemic	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
mucosal	mucosal	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
dermatologic	dermatologic	ADJ	JJ	5	O
manifestations	manifestation	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
previously	previously	ADV	RB	9	O
healthy	healthy	ADJ	JJ	5	O
child	child	NOUN	NN	5	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
acute	acute	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
severe	severe	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
rapidly	rapidly	ADV	RB	9	O
progressive	progressive	ADJ	JJ	5	O
vanishing	vanish	VERB	VBG	5	B-Disease
bile	bile	NOUN	NN	0	I-Disease
duct	duct	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
shortly	shortly	ADV	RB	9	O
after	after	ADP	IN	9	O
Stevens	Stevens	PROPN	NNP	6	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
Johnson	Johnson	PROPN	NNP	6	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
described	describe	VERB	VBN	9	O
;	;	PUNCT	:	9	O
this	this	DET	DT	5	O
was	be	VERB	VBD	9	O
temporally	temporally	ADV	RB	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
ibuprofen	ibuprofen	ADJ	JJ	0	B-Chemical
use	use	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Despite	despite	ADP	IN	5	O
therapy	therapy	NOUN	NN	5	O
with	with	ADP	IN	5	O
ursodeoxycholic	ursodeoxycholic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
prednisone	prednisone	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
then	then	ADV	RB	9	O
tacrolimus	tacrolimus	VERB	VB	0	B-Chemical
,	,	PUNCT	,	9	O
her	-PRON-	DET	PRP$	5	O
cholestatic	cholestatic	ADJ	JJ	5	B-Disease
disease	disease	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
unrelenting	unrelenting	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
with	with	ADP	IN	5	O
cirrhosis	cirrhosis	NOUN	NN	5	B-Disease
shown	show	VERB	VBN	9	O
by	by	ADP	IN	9	O
biopsy	biopsy	NOUN	NN	5	O
6	6	NUM	CD	9	O
months	month	NOUN	NNS	5	O
after	after	ADP	IN	9	O
presentation	presentation	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
case	case	NOUN	NN	5	O
documents	document	VERB	VBZ	5	O
acute	acute	ADJ	JJ	9	O
drug	drug	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
related	relate	VERB	VBN	9	O
vanishing	vanishing	NOUN	NN	5	B-Disease
bile	bile	NOUN	NN	0	I-Disease
duct	duct	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pediatric	pediatric	ADJ	JJ	5	O
age	age	NOUN	NN	5	O
group	group	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
suggests	suggest	VERB	VBZ	9	O
shared	share	VERB	VBN	5	O
immune	immune	ADJ	JJ	3	O
mechanisms	mechanism	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
pathogenesis	pathogenesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
both	both	DET	DT	9	O
Stevens	Stevens	PROPN	NNP	6	B-Disease
-	-	PUNCT	HYPH	7	I-Disease
Johnson	Johnson	PROPN	NNP	6	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
vanishing	vanish	VERB	VBG	5	B-Disease
bile	bile	NOUN	NN	0	I-Disease
duct	duct	NOUN	NN	5	I-Disease
syndrome	syndrome	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

High	high	ADJ	JJ	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
primary	primary	ADJ	JJ	9	B-Disease
pulmonary	pulmonary	ADJ	JJ	5	I-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
appetite	appetite	ADJ	JJ	5	B-Chemical
suppressants	suppressant	NOUN	NNS	5	I-Chemical
in	in	ADP	IN	5	O
Belgium	Belgium	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

Primary	primary	ADJ	JJ	9	B-Disease
pulmonary	pulmonary	ADJ	JJ	5	I-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
rare	rare	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
progressive	progressive	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
incurable	incurable	ADJ	JJ	5	O
disease	disease	NOUN	NN	5	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
intake	intake	NOUN	NN	5	O
of	of	ADP	IN	5	O
appetite	appetite	ADJ	JJ	5	B-Chemical
suppressant	suppressant	ADJ	JJ	5	I-Chemical
drugs	drug	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
importance	importance	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
association	association	NOUN	NN	9	O
was	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
in	in	ADP	IN	5	O
Belgium	Belgium	PROPN	NNP	2	O
while	while	ADP	IN	9	O
this	this	DET	DT	5	O
country	country	NOUN	NN	5	O
still	still	ADV	RB	5	O
had	have	VERB	VBD	9	O
no	no	DET	DT	9	O
restriction	restriction	NOUN	NN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
prescription	prescription	NOUN	NN	5	O
of	of	ADP	IN	5	O
appetite	appetite	ADJ	JJ	5	B-Chemical
suppressants	suppressant	NOUN	NNS	5	I-Chemical
.	.	PUNCT	.	9	O

Thirty	thirty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
primary	primary	ADJ	JJ	9	B-Disease
pulmonary	pulmonary	ADJ	JJ	5	I-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
and	and	CCONJ	CC	5	O
85	85	NUM	CD	9	O
matched	match	VERB	VBN	9	O
controls	control	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
recruited	recruit	VERB	VBN	9	O
over	over	ADP	IN	5	O
32	32	NUM	CD	7	O
months	month	NOUN	NNS	5	O
(	(	PUNCT	-LRB-	9	O
1992	1992	NUM	CD	2	O
-	-	SYM	SYM	7	O
1994	1994	NUM	CD	2	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
Belgium	Belgium	PROPN	NNP	2	O
.	.	PUNCT	.	9	O

Exposure	exposure	NOUN	NN	9	O
to	to	ADP	IN	5	O
appetite	appetite	NOUN	NN	5	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
suppressants	suppressant	NOUN	NNS	5	I-Chemical
was	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
basis	basis	NOUN	NN	5	O
of	of	ADP	IN	5	O
hospital	hospital	NOUN	NN	5	O
records	record	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
standardized	standardized	ADJ	JJ	5	O
interview	interview	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
three	three	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
had	have	VERB	VBD	9	O
previously	previously	ADV	RB	9	O
taken	take	VERB	VBN	5	O
appetite	appetite	ADJ	JJ	5	B-Chemical
suppressants	suppressant	NOUN	NNS	5	I-Chemical
,	,	PUNCT	,	9	O
mainly	mainly	ADV	RB	9	O
fenfluramines	fenfluramine	NOUN	NNS	5	B-Chemical
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
compared	compare	VERB	VBN	9	O
with	with	ADP	IN	5	O
only	only	ADV	RB	9	O
5	5	NUM	CD	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
controls	control	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
66	66	NUM	CD	7	O
versus	versus	ADP	IN	9	O
6	6	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
p	p	PUNCT	LS	7	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
0001	0001	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Five	five	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
died	die	VERB	VBD	9	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
interview	interview	NOUN	NN	5	O
,	,	PUNCT	,	9	O
all	all	DET	DT	5	O
of	of	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
taken	take	VERB	VBN	5	O
appetite	appetite	ADJ	JJ	5	B-Chemical
suppressants	suppressant	NOUN	NNS	5	I-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
8	8	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
the	the	DET	DT	5	O
diagnosis	diagnosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
primary	primary	ADJ	JJ	9	B-Disease
pulmonary	pulmonary	ADJ	JJ	5	I-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
was	be	VERB	VBD	9	O
uncertain	uncertain	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
of	of	ADP	IN	5	O
them	-PRON-	PRON	PRP	5	O
had	have	VERB	VBD	9	O
taken	take	VERB	VBN	5	O
appetite	appetite	ADJ	JJ	5	B-Chemical
suppressants	suppressant	NOUN	NNS	5	I-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
had	have	VERB	VBD	9	O
been	be	VERB	VBN	9	O
exposed	expose	VERB	VBN	9	O
to	to	ADP	IN	5	O
appetite	appetite	VERB	VB	5	B-Chemical
suppressants	suppressant	NOUN	NNS	5	I-Chemical
tended	tend	VERB	VBD	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
on	on	ADP	IN	5	O
average	average	ADJ	JJ	5	O
more	more	ADV	RBR	5	O
severely	severely	ADV	RB	9	O
ill	ill	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
a	a	DET	DT	5	O
shorter	short	ADJ	JJR	9	O
median	median	ADJ	JJ	9	O
delay	delay	NOUN	NN	5	O
between	between	ADP	IN	5	O
onset	onset	NOUN	NN	5	O
of	of	ADP	IN	5	O
symptoms	symptom	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
diagnosis	diagnosis	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
policy	policy	NOUN	NN	5	O
of	of	ADP	IN	5	O
unrestricted	unrestricted	ADJ	JJ	5	O
prescription	prescription	NOUN	NN	5	O
of	of	ADP	IN	5	O
appetite	appetite	ADJ	JJ	5	B-Chemical
suppressants	suppressant	NOUN	NNS	5	I-Chemical
may	may	VERB	MD	5	O
lead	lead	VERB	VB	5	O
to	to	ADP	IN	5	O
a	a	DET	DT	5	O
high	high	ADJ	JJ	9	O
incidence	incidence	NOUN	NN	5	O
of	of	ADP	IN	5	O
associated	associated	ADJ	JJ	9	O
primary	primary	ADJ	JJ	9	B-Disease
pulmonary	pulmonary	ADJ	JJ	5	I-Disease
hypertension	hypertension	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Intake	intake	NOUN	NN	5	O
of	of	ADP	IN	5	O
appetite	appetite	ADJ	JJ	5	B-Chemical
suppressants	suppressant	NOUN	NNS	5	I-Chemical
may	may	VERB	MD	5	O
accelerate	accelerate	VERB	VB	9	O
the	the	DET	DT	5	O
progression	progression	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
disease	disease	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Inappropriate	inappropriate	ADJ	JJ	5	O
use	use	NOUN	NN	5	O
of	of	ADP	IN	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
vigabatrin	vigabatrin	NOUN	NN	0	B-Chemical
in	in	ADP	IN	5	O
typical	typical	ADJ	JJ	9	O
absence	absence	NOUN	NN	3	B-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
vigabatrin	vigabatrin	NOUN	NN	0	B-Chemical
are	be	VERB	VBP	5	O
contraindicated	contraindicate	VERB	VBN	5	O
in	in	ADP	IN	5	O
typical	typical	ADJ	JJ	9	O
absence	absence	NOUN	NN	3	B-Disease
seizures	seizure	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
18	18	NUM	CD	7	O
consecutive	consecutive	ADJ	JJ	5	O
referrals	referral	NOUN	NNS	5	O
of	of	ADP	IN	5	O
children	child	NOUN	NNS	5	O
with	with	ADP	IN	5	O
resistant	resistant	ADJ	JJ	9	O
typical	typical	ADJ	JJ	9	O
absences	absence	NOUN	NNS	5	O
only	only	ADV	RB	9	O
,	,	PUNCT	,	9	O
eight	eight	NUM	CD	9	O
were	be	VERB	VBD	9	O
erroneously	erroneously	ADV	RB	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
either	either	CCONJ	CC	9	O
as	as	ADP	IN	5	O
monotherapy	monotherapy	NOUN	NN	5	O
or	or	CCONJ	CC	5	O
as	as	ADP	IN	5	O
an	an	DET	DT	5	O
add	add	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
on	on	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Vigabatrin	Vigabatrin	PROPN	NNP	0	B-Chemical
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
two	two	NUM	CD	5	O
children	child	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Frequency	frequency	NOUN	NN	5	O
of	of	ADP	IN	5	O
absences	absence	NOUN	NNS	5	O
increased	increase	VERB	VBD	9	O
in	in	ADP	IN	5	O
four	four	NUM	CD	9	O
children	child	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
two	two	NUM	CD	5	O
of	of	ADP	IN	5	O
these	these	DET	DT	5	O
developed	develop	VERB	VBN	5	O
myoclonic	myoclonic	ADJ	JJ	5	B-Disease
jerks	jerk	NOUN	NNS	5	I-Disease
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
resolved	resolve	VERB	VBD	9	O
on	on	ADP	IN	5	O
withdrawal	withdrawal	NOUN	NN	5	O
of	of	ADP	IN	5	O
carbamazepine	carbamazepine	NOUN	NN	0	B-Chemical
.	.	PUNCT	.	9	O

Absences	absence	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
aggravated	aggravate	VERB	VBN	9	O
in	in	ADP	IN	5	O
both	both	DET	DT	9	O
cases	case	NOUN	NNS	5	O
where	where	ADV	WRB	5	O
vigabatrin	vigabatrin	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
added	add	VERB	VBN	0	O
on	on	ADP	IN	5	O
to	to	ADP	IN	5	O
concurrent	concurrent	ADJ	JJ	5	O
treatment	treatment	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Optimal	optimal	ADJ	JJ	5	O
control	control	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
absences	absence	NOUN	NNS	5	O
was	be	VERB	VBD	9	O
achieved	achieve	VERB	VBN	5	O
with	with	ADP	IN	5	O
sodium	sodium	NOUN	NN	0	B-Chemical
valproate	valproate	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
lamotrigine	lamotrigine	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
or	or	CCONJ	CC	5	O
ethosuximide	ethosuximide	VERB	VB	0	B-Chemical
alone	alone	ADV	RB	9	O
or	or	CCONJ	CC	5	O
in	in	ADP	IN	5	O
combination	combination	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Choreoathetoid	choreoathetoid	ADJ	JJ	5	B-Disease
movements	movement	NOUN	NNS	5	I-Disease
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
rapid	rapid	ADJ	JJ	5	O
adjustment	adjustment	NOUN	NN	5	O
to	to	ADP	IN	5	O
methadone	methadone	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

Choreatiform	choreatiform	NOUN	NN	_	B-Disease
hyperkinesias	hyperkinesias	NOUN	NN	5	I-Disease
are	be	VERB	VBP	5	O
known	know	VERB	VBN	9	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
occasional	occasional	ADJ	JJ	5	O
movement	movement	NOUN	NN	5	B-Disease
abnormalities	abnormality	NOUN	NNS	9	I-Disease
during	during	ADP	IN	5	O
intoxications	intoxication	NOUN	NNS	5	O
with	with	ADP	IN	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
but	but	CCONJ	CC	9	O
not	not	ADV	RB	5	O
opiates	opiate	VERB	VBZ	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
case	case	NOUN	NN	5	O
report	report	NOUN	NN	5	O
of	of	ADP	IN	5	O
euphoria	euphoria	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
choreoathetoid	choreoathetoid	ADJ	JJ	5	B-Disease
movements	movement	NOUN	NNS	5	I-Disease
both	both	DET	DT	9	O
transiently	transiently	ADV	RB	3	O
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
rapid	rapid	ADJ	JJ	5	O
adjustment	adjustment	NOUN	NN	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
selective	selective	ADJ	JJ	9	O
mu	mu	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
opioid	opioid	ADJ	JJ	5	O
receptor	receptor	NOUN	NN	3	O
agonist	agonist	VERB	VBP	3	O
methadone	methadone	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
an	an	DET	DT	5	O
inpatient	inpatient	NOUN	NN	5	O
previously	previously	ADV	RB	9	O
abusing	abuse	VERB	VBG	5	O
heroine	heroine	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
cocaine	cocaine	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
minor	minor	ADJ	JJ	9	O
EEG	EEG	PROPN	NNP	5	O
abnormalities	abnormality	NOUN	NNS	9	O
occurred	occur	VERB	VBD	9	O
.	.	PUNCT	.	9	O

Possible	possible	ADJ	JJ	9	O
underlying	underlie	VERB	VBG	5	O
neurobiological	neurobiological	ADJ	JJ	5	O
phenomena	phenomenon	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
discussed	discuss	VERB	VBN	5	O
.	.	PUNCT	.	9	O

Adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
atypical	atypical	ADJ	JJ	5	O
antipsychotics	antipsychotic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Collaborative	Collaborative	PROPN	NNP	2	O
Working	Working	PROPN	NNP	5	O
Group	Group	PROPN	NNP	9	O
on	on	ADP	IN	5	O
Clinical	Clinical	PROPN	NNP	5	O
Trial	Trial	PROPN	NNP	5	O
Evaluations	Evaluations	PROPN	NNPS	5	O
.	.	PUNCT	.	9	O

Adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
antipsychotics	antipsychotic	NOUN	NNS	5	O
often	often	ADV	RB	5	O
lead	lead	VERB	VBP	5	O
to	to	ADP	IN	5	O
noncompliance	noncompliance	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Thus	thus	ADV	RB	9	O
,	,	PUNCT	,	9	O
clinicians	clinician	NOUN	NNS	5	O
should	should	VERB	MD	5	O
address	address	VERB	VB	5	O
patients	patient	NOUN	NNS	5	O
'	'	PART	POS	9	O
concerns	concern	NOUN	NNS	5	O
about	about	ADP	IN	5	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
and	and	CCONJ	CC	5	O
attempt	attempt	VERB	VB	5	O
to	to	PART	TO	5	O
choose	choose	VERB	VB	5	O
medications	medication	NOUN	NNS	5	O
that	that	DET	WDT	5	O
will	will	VERB	MD	5	O
improve	improve	VERB	VB	5	O
their	-PRON-	DET	PRP$	5	O
patients	patient	NOUN	NNS	5	O
'	'	PART	POS	9	O
quality	quality	NOUN	NN	5	O
of	of	ADP	IN	5	O
life	life	NOUN	NN	5	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
overall	overall	ADJ	JJ	5	O
health	health	NOUN	NN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
side	side	NOUN	NN	5	O
effect	effect	NOUN	NN	9	O
profiles	profile	NOUN	NNS	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
atypical	atypical	ADJ	JJ	5	O
antipsychotics	antipsychotic	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
more	more	ADV	RBR	5	O
advantageous	advantageous	ADJ	JJ	5	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
conventional	conventional	ADJ	JJ	5	O
neuroleptics	neuroleptic	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Conventional	conventional	ADJ	JJ	5	O
agents	agent	NOUN	NNS	5	O
are	be	VERB	VBP	5	O
associated	associate	VERB	VBN	9	O
with	with	ADP	IN	5	O
unwanted	unwanted	ADJ	JJ	5	O
central	central	ADJ	JJ	5	O
nervous	nervous	ADJ	JJ	5	O
system	system	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
including	include	VERB	VBG	9	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	B-Disease
symptoms	symptom	NOUN	NNS	5	I-Disease
(	(	PUNCT	-LRB-	9	O
EPS	EPS	PROPN	NNP	9	B-Disease
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
tardive	tardive	ADJ	JJ	5	B-Disease
dyskinesia	dyskinesia	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
sedation	sedation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
possible	possible	ADJ	JJ	5	O
impairment	impairment	NOUN	NN	5	O
of	of	ADP	IN	5	O
some	some	DET	DT	5	O
cognitive	cognitive	ADJ	JJ	5	O
measures	measure	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
as	as	ADV	RB	5	O
well	well	ADV	RB	9	O
as	as	ADP	IN	5	O
cardiac	cardiac	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
orthostatic	orthostatic	ADJ	JJ	5	B-Disease
hypotension	hypotension	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
hepatic	hepatic	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
anticholinergic	anticholinergic	ADJ	JJ	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
sexual	sexual	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
weight	weight	NOUN	NN	9	B-Disease
gain	gain	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
newer	new	ADJ	JJR	5	O
atypical	atypical	ADJ	JJ	5	O
agents	agent	NOUN	NNS	5	O
have	have	VERB	VBP	5	O
a	a	DET	DT	5	O
lower	low	ADJ	JJR	9	O
risk	risk	NOUN	NN	5	O
of	of	ADP	IN	5	O
EPS	EPS	PROPN	NNP	9	B-Disease
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
are	be	VERB	VBP	5	O
associated	associate	VERB	VBN	9	O
in	in	ADP	IN	5	O
varying	vary	VERB	VBG	5	O
degrees	degree	NOUN	NNS	5	O
with	with	ADP	IN	5	O
sedation	sedation	NOUN	NN	5	O
,	,	PUNCT	,	9	O
cardiovascular	cardiovascular	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
anticholinergic	anticholinergic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
weight	weight	NOUN	NN	9	B-Disease
gain	gain	NOUN	NN	5	I-Disease
,	,	PUNCT	,	9	O
sexual	sexual	ADJ	JJ	5	B-Disease
dysfunction	dysfunction	NOUN	NN	9	I-Disease
,	,	PUNCT	,	9	O
hepatic	hepatic	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
lowered	lower	VERB	VBD	9	O
seizure	seizure	NOUN	NN	5	B-Disease
threshold	threshold	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
primarily	primarily	ADV	RB	9	O
clozapine	clozapine	VERB	VB	5	B-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
agranulocytosis	agranulocytosis	NOUN	NN	5	B-Disease
(	(	PUNCT	-LRB-	9	O
clozapine	clozapine	VERB	VB	5	B-Chemical
only	only	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Since	since	ADP	IN	9	O
the	the	DET	DT	5	O
incidence	incidence	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
severity	severity	NOUN	NN	5	O
of	of	ADP	IN	5	O
specific	specific	ADJ	JJ	9	O
adverse	adverse	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
differ	differ	VERB	VBP	9	O
among	among	ADP	IN	5	O
the	the	DET	DT	5	O
various	various	ADJ	JJ	9	O
atypicals	atypical	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
clinician	clinician	NOUN	NN	5	O
should	should	VERB	MD	5	O
carefully	carefully	ADV	RB	5	O
consider	consider	VERB	VB	5	O
which	which	DET	WDT	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
are	be	VERB	VBP	5	O
most	most	ADV	RBS	9	O
likely	likely	ADJ	JJ	5	O
to	to	PART	TO	5	O
lead	lead	VERB	VB	5	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
individual	individual	NOUN	NN	5	O
'	'	PUNCT	''	9	O
s	s	PART	POS	9	O
dissatisfaction	dissatisfaction	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
noncompliance	noncompliance	NOUN	NN	5	O
before	before	ADP	IN	9	O
choosing	choose	VERB	VBG	5	O
an	an	DET	DT	5	O
antipsychotic	antipsychotic	NOUN	NN	5	O
for	for	ADP	IN	5	O
a	a	DET	DT	5	O
particular	particular	ADJ	JJ	5	O
patient	patient	NOUN	NN	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
randomized	randomized	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
comparison	comparison	NOUN	NN	9	O
trial	trial	NOUN	NN	5	O
of	of	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
for	for	ADP	IN	5	O
psychosis	psychosis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
disruptive	disruptive	ADJ	JJ	5	B-Disease
behaviors	behavior	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
Alzheimer	Alzheimer	PROPN	NNP	5	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

OBJECTIVE	OBJECTIVE	PROPN	NNP	2	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
goal	goal	NOUN	NN	5	O
of	of	ADP	IN	5	O
this	this	DET	DT	5	O
study	study	NOUN	NN	9	O
was	be	VERB	VBD	9	O
to	to	PART	TO	5	O
compare	compare	VERB	VB	9	O
the	the	DET	DT	5	O
efficacy	efficacy	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
two	two	NUM	CD	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
treatment	treatment	NOUN	NN	9	O
of	of	ADP	IN	5	O
psychosis	psychosis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
disruptive	disruptive	ADJ	JJ	5	B-Disease
behaviors	behavior	NOUN	NNS	5	I-Disease
in	in	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Alzheimer	Alzheimer	PROPN	NNP	5	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

METHOD	method	NOUN	NN	2	O
:	:	PUNCT	:	9	O
In	in	ADP	IN	9	O
a	a	DET	DT	5	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
random	random	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
assignment	assignment	NOUN	NN	5	O
,	,	PUNCT	,	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
placebo	placebo	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
controlled	control	VERB	VBN	5	O
trial	trial	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
phase	phase	VERB	VB	5	O
A	a	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
standard	standard	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
,	,	PUNCT	,	9	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
50	50	NUM	CD	0	O
-	-	SYM	SYM	7	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
75	75	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
low	low	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
compared	compare	VERB	VBN	9	O
in	in	ADP	IN	5	O
71	71	NUM	CD	7	O
outpatients	outpatient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
Alzheimer	Alzheimer	PROPN	NNP	5	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

For	for	ADP	IN	9	O
the	the	DET	DT	5	O
subsequent	subsequent	ADJ	JJ	9	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
week	week	NOUN	NN	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
blind	blind	ADJ	JJ	5	O
crossover	crossover	NOUN	NN	5	O
phase	phase	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
phase	phase	NOUN	NN	5	O
B	B	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
patients	patient	NOUN	NNS	5	O
taking	take	VERB	VBG	5	O
standard	standard	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
or	or	CCONJ	CC	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
were	be	VERB	VBD	9	O
switched	switch	VERB	VBN	9	O
to	to	ADP	IN	5	O
placebo	placebo	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
patients	patient	NOUN	NNS	5	O
taking	take	VERB	VBG	5	O
placebo	placebo	NOUN	NN	9	O
were	be	VERB	VBD	9	O
randomly	randomly	ADV	RB	5	O
assigned	assign	VERB	VBN	5	O
to	to	ADP	IN	5	O
standard	standard	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
or	or	CCONJ	CC	5	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
.	.	PUNCT	.	9	O

RESULTS	results	NOUN	NN	9	O
:	:	PUNCT	:	9	O
For	for	ADP	IN	9	O
the	the	DET	DT	5	O
60	60	NUM	CD	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
completed	complete	VERB	VBD	5	O
phase	phase	NOUN	NN	5	O
A	a	NOUN	NN	9	O
,	,	PUNCT	,	9	O
standard	standard	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
was	be	VERB	VBD	9	O
efficacious	efficacious	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
superior	superior	ADJ	JJ	5	O
to	to	ADP	IN	5	O
both	both	DET	DT	9	O
low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
for	for	ADP	IN	5	O
scores	score	NOUN	NNS	5	O
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
Brief	Brief	PROPN	NNP	5	O
Psychiatric	Psychiatric	PROPN	NNP	5	O
Rating	Rating	PROPN	NNP	5	O
Scale	Scale	PROPN	NNP	5	O
psychosis	psychosis	NOUN	NN	5	B-Disease
factor	factor	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
on	on	ADP	IN	5	O
psychomotor	psychomotor	NOUN	NN	5	B-Disease
agitation	agitation	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Response	response	NOUN	NN	5	O
rates	rate	NOUN	NNS	5	O
according	accord	VERB	VBG	9	O
to	to	ADP	IN	5	O
three	three	NUM	CD	9	O
sets	set	NOUN	NNS	5	O
of	of	ADP	IN	5	O
criteria	criterion	NOUN	NNS	5	O
were	be	VERB	VBD	9	O
greater	great	ADJ	JJR	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
standard	standard	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
55	55	NUM	CD	7	O
%	%	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
60	60	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
than	than	ADP	IN	5	O
the	the	DET	DT	5	O
low	low	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
35	35	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
placebo	placebo	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
25	25	NUM	CD	9	O
%	%	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
30	30	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
advantage	advantage	NOUN	NN	5	O
of	of	ADP	IN	5	O
standard	standard	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
over	over	ADP	IN	5	O
low	low	ADJ	JJ	9	O
dose	dose	NOUN	NN	9	O
was	be	VERB	VBD	9	O
replicated	replicate	VERB	VBN	9	O
in	in	ADP	IN	5	O
phase	phase	NOUN	NN	5	O
B	b	NOUN	NN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
phase	phase	NOUN	NN	5	O
A	a	NOUN	NN	9	O
,	,	PUNCT	,	9	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	B-Disease
signs	sign	NOUN	NNS	5	I-Disease
tended	tend	VERB	VBD	5	O
to	to	PART	TO	5	O
be	be	VERB	VB	5	O
greater	great	ADJ	JJR	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
standard	standard	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
than	than	ADP	IN	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
two	two	NUM	CD	5	O
conditions	condition	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
primarily	primarily	ADV	RB	9	O
because	because	ADP	IN	5	O
of	of	ADP	IN	5	O
a	a	DET	DT	5	O
subgroup	subgroup	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
20	20	NUM	CD	9	O
%	%	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
who	who	PRON	WP	5	O
developed	develop	VERB	VBD	5	O
moderate	moderate	ADJ	JJ	9	O
to	to	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
signs	sign	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Low	low	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
dose	dose	NOUN	NN	9	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
differ	differ	VERB	VB	9	O
from	from	ADP	IN	9	O
placebo	placebo	NOUN	NN	9	O
on	on	ADP	IN	5	O
any	any	DET	DT	5	O
measure	measure	NOUN	NN	5	O
of	of	ADP	IN	5	O
efficacy	efficacy	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
side	side	NOUN	NN	5	O
effects	effect	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicated	indicate	VERB	VBD	9	O
a	a	DET	DT	5	O
favorable	favorable	ADJ	JJ	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
profile	profile	NOUN	NN	9	O
for	for	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
in	in	ADP	IN	5	O
doses	dose	NOUN	NNS	0	O
of	of	ADP	IN	5	O
2	2	NUM	CD	9	O
-	-	SYM	SYM	7	O
3	3	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
,	,	PUNCT	,	9	O
although	although	ADP	IN	9	O
a	a	DET	DT	5	O
subgroup	subgroup	NOUN	NN	9	O
developed	develop	VERB	VBN	5	O
moderate	moderate	ADJ	JJ	9	O
to	to	ADP	IN	5	O
severe	severe	ADJ	JJ	5	O
extrapyramidal	extrapyramidal	ADJ	JJ	5	B-Disease
signs	sign	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
starting	start	VERB	VBG	9	O
dose	dose	NOUN	NN	9	O
of	of	ADP	IN	5	O
1	1	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
day	day	NOUN	NN	9	O
with	with	ADP	IN	5	O
gradual	gradual	ADJ	JJ	9	O
,	,	PUNCT	,	9	O
upward	upward	ADJ	JJ	5	O
dose	dose	NOUN	NN	9	O
titration	titration	NOUN	NN	0	O
is	be	VERB	VBZ	5	O
recommended	recommend	VERB	VBN	5	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
narrow	narrow	ADJ	JJ	5	O
therapeutic	therapeutic	ADJ	JJ	5	O
window	window	NOUN	NN	5	O
observed	observe	VERB	VBN	9	O
with	with	ADP	IN	5	O
haloperidol	haloperidol	NOUN	NN	5	B-Chemical
may	may	VERB	MD	5	O
also	also	ADV	RB	9	O
apply	apply	VERB	VB	5	O
to	to	ADP	IN	5	O
other	other	ADJ	JJ	5	O
neuroleptics	neuroleptic	NOUN	NNS	5	O
used	use	VERB	VBN	5	O
in	in	ADP	IN	5	O
Alzheimer	Alzheimer	PROPN	NNP	5	B-Disease
'	'	PUNCT	''	9	I-Disease
s	s	PART	POS	9	I-Disease
disease	disease	NOUN	NN	5	I-Disease
patients	patient	NOUN	NNS	5	O
with	with	ADP	IN	5	O
psychosis	psychosis	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
disruptive	disruptive	ADJ	JJ	5	B-Disease
behaviors	behavior	NOUN	NNS	5	I-Disease
.	.	PUNCT	.	9	O

Effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
acetylsalicylic	acetylsalicylic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
dipyridamole	dipyridamole	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
hydrocortisone	hydrocortisone	VERB	VBN	0	B-Chemical
on	on	ADP	IN	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
in	in	ADP	IN	5	O
dogs	dog	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

A	a	DET	DT	9	O
reproducible	reproducible	ADJ	JJ	5	O
model	model	NOUN	NN	5	O
for	for	ADP	IN	5	O
producing	produce	VERB	VBG	9	O
diffuse	diffuse	NOUN	NN	5	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
injury	injury	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
)	)	PUNCT	-RRB-	9	O
has	have	VERB	VBZ	9	O
been	be	VERB	VBN	9	O
developed	develop	VERB	VBN	5	O
to	to	PART	TO	5	O
study	study	VERB	VB	9	O
the	the	DET	DT	5	O
cardioprotective	cardioprotective	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
agents	agent	NOUN	NNS	5	O
or	or	CCONJ	CC	5	O
maneuvers	maneuver	NOUN	NNS	5	O
which	which	DET	WDT	5	O
might	may	VERB	MD	9	O
alter	alter	VERB	VB	9	O
the	the	DET	DT	5	O
evolution	evolution	NOUN	NN	5	O
of	of	ADP	IN	5	O
acute	acute	ADJ	JJ	9	O
myocardial	myocardial	ADJ	JJ	9	B-Disease
infarction	infarction	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Infusions	infusion	NOUN	NNS	0	O
of	of	ADP	IN	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
mug	mug	NOUN	NN	5	O
per	per	ADP	IN	9	O
kilogram	kilogram	NOUN	NN	0	O
per	per	ADP	IN	9	O
minute	minute	NOUN	NN	5	O
for	for	ADP	IN	5	O
6	6	NUM	CD	9	O
hours	hour	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
increased	increase	VERB	VBN	9	O
radiocalcium	radiocalcium	NOUN	NN	0	B-Chemical
uptakes	uptake	VERB	VBZ	0	O
into	into	ADP	IN	9	O
intact	intact	ADJ	JJ	9	O
myocardium	myocardium	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
each	each	DET	DT	5	O
of	of	ADP	IN	5	O
its	-PRON-	DET	PRP$	9	O
subcellular	subcellular	ADJ	JJ	3	O
components	component	NOUN	NNS	5	O
with	with	ADP	IN	5	O
the	the	DET	DT	5	O
mitochondrial	mitochondrial	ADJ	JJ	9	O
fraction	fraction	NOUN	NN	9	O
showing	show	VERB	VBG	9	O
the	the	DET	DT	5	O
most	most	ADV	RBS	9	O
consistent	consistent	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
when	when	ADV	WRB	5	O
compared	compare	VERB	VBN	9	O
to	to	ADP	IN	5	O
saline	saline	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
infused	infuse	VERB	VBN	9	O
control	control	NOUN	NN	9	O
animals	animal	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
,	,	PUNCT	,	9	O
957	957	NUM	CD	7	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
827	827	NUM	CD	7	O
counts	count	NOUN	NNS	9	O
per	per	ADP	IN	9	O
minute	minute	NOUN	NN	5	O
per	per	ADP	IN	9	O
gram	gram	NOUN	NN	9	O
of	of	ADP	IN	5	O
dried	dry	VERB	VBN	0	O
tissue	tissue	NOUN	NN	9	O
or	or	CCONJ	CC	5	O
fraction	fraction	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Myocardial	myocardial	ADJ	JJ	9	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
also	also	ADV	RB	9	O
increased	increase	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
(	(	PUNCT	-LRB-	9	O
12	12	NUM	CD	9	O
.	.	PUNCT	.	9	O
0	0	PUNCT	NFP	7	O
vs	vs	NOUN	NN	7	O
.	.	PUNCT	.	9	O
5	5	NUM	CD	9	O
.	.	NOUN	NN	9	O
0	0	PUNCT	NFP	7	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
per	per	ADP	IN	9	O
100	100	NUM	CD	0	O
Gm	Gm	PROPN	NNP	9	O
.	.	PUNCT	.	9	O
of	of	ADP	IN	5	O
fat	fat	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
dry	dry	ADJ	JJ	0	O
weight	weight	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Infusions	infusion	NOUN	NNS	0	O
of	of	ADP	IN	5	O
calcium	calcium	NOUN	NN	0	B-Chemical
chloride	chloride	NOUN	NN	0	I-Chemical
sufficient	sufficient	ADJ	JJ	9	O
to	to	PART	TO	5	O
raise	raise	VERB	VB	9	O
serum	serum	ADJ	JJ	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
2	2	NUM	CD	9	O
mEq	mEq	NOUN	NNS	0	O
.	.	PUNCT	.	9	O
per	per	ADP	IN	9	O
liter	liter	NOUN	NN	0	O
failed	fail	VERB	VBD	9	O
to	to	PART	TO	5	O
increase	increase	VERB	VB	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
influx	influx	NOUN	NN	9	O
into	into	ADP	IN	9	O
the	the	DET	DT	5	O
myocardial	myocardial	ADJ	JJ	9	O
cell	cell	NOUN	NN	3	O
.	.	PUNCT	.	9	O

Mitochondrial	mitochondrial	ADJ	JJ	9	O
radiocalcium	radiocalcium	NOUN	NN	0	B-Chemical
uptakes	uptake	NOUN	NNS	0	O
were	be	VERB	VBD	9	O
significantly	significantly	ADV	RB	9	O
decreased	decrease	VERB	VBN	9	O
in	in	ADP	IN	5	O
animals	animal	NOUN	NNS	9	O
pretreated	pretreate	VERB	VBN	3	O
with	with	ADP	IN	5	O
acetylsalicylic	acetylsalicylic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
or	or	CCONJ	CC	5	O
dipyridamole	dipyridamole	NOUN	NN	0	B-Chemical
or	or	CCONJ	CC	5	O
when	when	ADV	WRB	5	O
hydrocortisone	hydrocortisone	NOUN	NN	0	B-Chemical
was	be	VERB	VBD	9	O
added	add	VERB	VBN	0	O
to	to	ADP	IN	5	O
the	the	DET	DT	5	O
epinephrine	epinephrine	NOUN	NN	0	B-Chemical
infusion	infusion	NOUN	NN	0	O
(	(	PUNCT	-LRB-	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
682	682	NUM	CD	7	O
,	,	PUNCT	,	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
803	803	NUM	CD	7	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
424	424	NUM	CD	7	O
counts	count	NOUN	NNS	9	O
per	per	ADP	IN	9	O
minute	minute	NOUN	NN	5	O
per	per	ADP	IN	9	O
gram	gram	NOUN	NN	9	O
of	of	ADP	IN	5	O
dried	dry	VERB	VBN	0	O
fraction	fraction	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Myocardial	myocardial	ADJ	JJ	9	O
calcium	calcium	NOUN	NN	0	B-Chemical
concentrations	concentration	NOUN	NNS	0	O
also	also	ADV	RB	9	O
were	be	VERB	VBD	9	O
decreased	decrease	VERB	VBN	9	O
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
.	.	PUNCT	.	9	O
2	2	NUM	CD	9	O
,	,	PUNCT	,	9	O
8	8	NUM	CD	9	O
.	.	NOUN	NN	9	O
3	3	NUM	CD	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
8	8	NUM	CD	9	O
.	.	PUNCT	.	9	O
9	9	NUM	CD	7	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
per	per	ADP	IN	9	O
100	100	NUM	CD	0	O
Gm	Gm	PROPN	NNP	9	O
.	.	PUNCT	.	9	O
of	of	ADP	IN	5	O
fat	fat	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
free	free	ADJ	JJ	9	O
dry	dry	ADJ	JJ	0	O
weight	weight	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
three	three	NUM	CD	9	O
treatment	treatment	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
being	be	VERB	VBG	5	O
significantly	significantly	ADV	RB	9	O
decreased	decrease	VERB	VBN	9	O
only	only	ADV	RB	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
last	last	ADJ	JJ	5	O
two	two	NUM	CD	5	O
.	.	PUNCT	.	9	O

Evidence	evidence	NOUN	NN	9	O
of	of	ADP	IN	5	O
microscopic	microscopic	ADJ	JJ	9	O
damage	damage	NOUN	NN	9	O
was	be	VERB	VBD	9	O
graded	grade	VERB	VBN	5	O
as	as	ADP	IN	5	O
less	less	ADV	RBR	5	O
severe	severe	ADJ	JJ	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
three	three	NUM	CD	9	O
treatment	treatment	NOUN	NN	9	O
groups	group	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

Acetylsalicylic	acetylsalicylic	ADJ	JJ	0	B-Chemical
acid	acid	NOUN	NN	0	I-Chemical
,	,	PUNCT	,	9	O
dipyridamole	dipyridamole	NOUN	NN	0	B-Chemical
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
hydrocortisone	hydrocortisone	VERB	VBD	0	B-Chemical
all	all	DET	DT	5	O
appear	appear	VERB	VB	9	O
to	to	PART	TO	5	O
have	have	VERB	VB	5	O
cardioprotective	cardioprotective	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
when	when	ADV	WRB	5	O
tested	test	VERB	VBN	9	O
in	in	ADP	IN	5	O
this	this	DET	DT	5	O
model	model	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Clinical	clinical	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
histopathologic	histopathologic	ADJ	JJ	9	O
examination	examination	NOUN	NN	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
allografts	allograft	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
FK506	FK506	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
at	at	ADV	RB	9	O
least	least	ADV	RBS	9	O
one	one	NUM	CD	5	O
year	year	NOUN	NN	5	O
.	.	PUNCT	.	9	O

BACKGROUND	BACKGROUND	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
We	-PRON-	PRON	PRP	9	O
clinically	clinically	ADV	RB	5	O
and	and	CCONJ	CC	5	O
pathologically	pathologically	ADV	RB	5	O
analyzed	analyze	VERB	VBD	9	O
renal	renal	ADJ	JJ	9	O
allografts	allograft	NOUN	NNS	5	O
from	from	ADP	IN	9	O
1	1	NUM	CD	9	O
9	9	NUM	CD	7	O
renal	renal	ADJ	JJ	9	O
transplant	transplant	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
treated	treat	VERB	VBN	3	O
with	with	ADP	IN	5	O
tacrolimus	tacrolimus	NOUN	NN	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
FK506	FK506	PROPN	NNP	3	B-Chemical
)	)	PUNCT	-RRB-	9	O
for	for	ADP	IN	5	O
more	more	ADJ	JJR	5	O
than	than	ADP	IN	5	O
1	1	NUM	CD	9	O
year	year	NOUN	NN	5	O
.	.	PUNCT	.	9	O

METHODS	method	NOUN	NNS	2	O
:	:	PUNCT	:	9	O
Twenty	twenty	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
six	six	NUM	CD	9	O
renal	renal	ADJ	JJ	9	O
allograft	allograft	NOUN	NN	5	O
biopsy	biopsy	NOUN	NN	5	O
specimens	specimen	NOUN	NNS	9	O
from	from	ADP	IN	9	O
1	1	NUM	CD	9	O
9	9	NUM	CD	7	O
renal	renal	ADJ	JJ	9	O
transplant	transplant	NOUN	NN	9	O
patients	patient	NOUN	NNS	5	O
who	who	PRON	WP	5	O
underwent	undergo	VERB	VBD	5	O
transplantations	transplantation	NOUN	NNS	5	O
between	between	ADP	IN	5	O
1991	1991	NUM	CD	2	O
and	and	CCONJ	CC	5	O
1993	1993	NUM	CD	2	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Thirteen	thirteen	NUM	CD	9	O
biopsies	biopsy	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
performed	perform	VERB	VBN	9	O
from	from	ADP	IN	9	O
stable	stable	ADJ	JJ	9	O
functioning	function	VERB	VBG	5	O
renal	renal	ADJ	JJ	9	O
allografts	allograft	NOUN	NNS	5	O
with	with	ADP	IN	5	O
informed	informed	ADJ	JJ	5	O
consent	consent	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
nonepisode	nonepisode	NOUN	NN	_	O
biopsy	biopsy	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
other	other	ADJ	JJ	5	O
13	13	NUM	CD	7	O
were	be	VERB	VBD	9	O
from	from	ADP	IN	9	O
dysfunctional	dysfunctional	ADJ	JJ	9	O
renal	renal	ADJ	JJ	9	O
allografts	allograft	NOUN	NNS	5	O
with	with	ADP	IN	5	O
a	a	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
indication	indication	NOUN	NN	5	O
for	for	ADP	IN	5	O
biopsy	biopsy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
episode	episode	NOUN	NN	5	O
biopsy	biopsy	NOUN	NN	5	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

RESULTS	RESULTS	PROPN	NNP	9	O
:	:	PUNCT	:	9	O
The	the	DET	DT	5	O
main	main	ADJ	JJ	5	O
pathologic	pathologic	NOUN	NN	5	O
diagnoses	diagnose	VERB	VBZ	5	O
(	(	PUNCT	-LRB-	9	O
some	some	DET	DT	5	O
overlap	overlap	NOUN	NN	9	O
)	)	PUNCT	-RRB-	9	O
were	be	VERB	VBD	9	O
acute	acute	ADJ	JJ	9	O
rejection	rejection	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
AR	AR	PROPN	NNP	9	O
;	;	PUNCT	:	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
4	4	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
chronic	chronic	ADJ	JJ	5	O
rejection	rejection	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
CR	cr	NOUN	NN	9	O
;	;	PUNCT	:	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
AR	AR	PROPN	NNP	9	O
+	+	SYM	SYM	9	O
CR	CR	PROPN	NNP	9	O
(	(	PUNCT	-LRB-	9	O
n	n	CCONJ	CC	9	O
=	=	SYM	SYM	7	O
4	4	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
recurrent	recurrent	NOUN	NN	5	O
IgA	iga	NOUN	NN	3	B-Disease
nephropathy	nephropathy	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
5	5	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
normal	normal	ADJ	JJ	9	O
findings	finding	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
2	2	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
minimal	minimal	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
chronic	chronic	ADJ	JJ	5	O
FK506	fk506	NOUN	NN	3	B-Chemical
nephropathy	nephropathy	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
9	9	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
mild	mild	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
FK506	fk506	NOUN	NN	3	B-Chemical
nephropathy	nephropathy	NOUN	NN	9	B-Disease
(	(	PUNCT	-LRB-	9	O
n	n	ADV	RB	9	O
=	=	SYM	SYM	7	O
11	11	NUM	CD	7	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Of	of	ADP	IN	9	O
the	the	DET	DT	5	O
nonepisode	nonepisode	NOUN	NN	_	O
biopsies	biopsy	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
7	7	NUM	CD	9	O
and	and	CCONJ	CC	5	O
4	4	NUM	CD	9	O
biopsies	biopsy	NOUN	NNS	9	O
showed	show	VERB	VBD	9	O
minimal	minimal	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
mild	mild	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
chronic	chronic	ADJ	JJ	5	O
FK506	fk506	NOUN	NN	3	B-Chemical
nephropathy	nephropathy	NOUN	NN	9	B-Disease
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
.	.	PUNCT	.	9	O

Chronic	chronic	ADJ	JJ	9	O
FK506	FK506	PROPN	NNP	3	B-Chemical
nephropathy	nephropathy	NOUN	NN	9	B-Disease
consisted	consist	VERB	VBD	5	O
of	of	ADP	IN	5	O
rough	rough	ADJ	JJ	5	O
and	and	CCONJ	CC	5	O
foamy	foamy	VERB	VB	3	O
tubular	tubular	ADJ	JJ	9	O
vacuolization	vacuolization	NOUN	NN	3	O
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
biopsies	biopsy	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
arteriolopathy	arteriolopathy	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
angiodegeneration	angiodegeneration	NOUN	NN	_	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
arteriolar	arteriolar	ADJ	JJ	5	O
wall	wall	NOUN	NN	5	O
;	;	PUNCT	:	9	O
20	20	NUM	CD	9	O
biopsies	biopsy	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
focal	focal	ADJ	JJ	5	B-Disease
segmental	segmental	NOUN	NN	5	I-Disease
glomerulosclerosis	glomerulosclerosis	NOUN	NN	3	I-Disease
(	(	PUNCT	-LRB-	9	O
4	4	NUM	CD	9	O
biopsies	biopsy	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
striped	stripe	VERB	VBN	4	O
form	form	NOUN	NN	9	O
of	of	ADP	IN	5	O
interstitial	interstitial	ADJ	JJ	9	B-Disease
fibrosis	fibrosis	NOUN	NN	9	I-Disease
(	(	PUNCT	-LRB-	9	O
11	11	NUM	CD	7	O
biopsies	biopsy	NOUN	NNS	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
serum	serum	ADJ	JJ	9	O
creatinine	creatinine	NOUN	NN	0	B-Chemical
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
patients	patient	NOUN	NNS	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mild	mild	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
chronic	chronic	ADJ	JJ	5	O
FK506	FK506	PROPN	NNP	3	B-Chemical
nephropathy	nephropathy	NOUN	NN	9	B-Disease
group	group	NOUN	NN	9	O
,	,	PUNCT	,	9	O
which	which	DET	WDT	5	O
included	include	VERB	VBD	5	O
7	7	NUM	CD	9	O
episode	episode	NOUN	NN	5	O
biopsies	biopsy	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
were	be	VERB	VBD	9	O
statistically	statistically	ADV	RB	9	O
higher	high	ADJ	JJR	9	O
than	than	ADP	IN	5	O
those	those	DET	DT	5	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
minimum	minimum	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
chronic	chronic	ADJ	JJ	5	O
FK506	fk506	NOUN	NN	3	B-Chemical
-	-	PUNCT	HYPH	7	O
nephropathy	nephropathy	NOUN	NN	9	B-Disease
group	group	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
P	p	NOUN	NN	9	O
<	<	X	XX	0	O
0	0	NUM	CD	7	O
.	.	PUNCT	.	9	O
001	001	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

CONCLUSIONS	conclusion	NOUN	NNS	5	O
:	:	PUNCT	:	9	O
This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
demonstrates	demonstrate	VERB	VBZ	9	O
that	that	ADP	IN	5	O
chronic	chronic	ADJ	JJ	5	O
FK506	FK506	PROPN	NNP	3	B-Chemical
nephropathy	nephropathy	NOUN	NN	9	B-Disease
consists	consist	VERB	VBZ	5	O
primarily	primarily	ADV	RB	9	O
of	of	ADP	IN	5	O
arteriolopathy	arteriolopathy	ADJ	JJ	5	O
manifesting	manifesting	NOUN	NN	5	O
as	as	ADP	IN	5	O
insudative	insudative	ADJ	JJ	_	O
hyalinosis	hyalinosis	NOUN	NN	5	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
arteriolar	arteriolar	ADJ	JJ	5	O
wall	wall	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
mild	mild	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
chronic	chronic	ADJ	JJ	5	O
FK506	fk506	NOUN	NN	3	B-Chemical
nephropathy	nephropathy	NOUN	NN	9	B-Disease
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
condition	condition	NOUN	NN	5	O
which	which	DET	WDT	5	O
may	may	VERB	MD	5	O
lead	lead	VERB	VB	5	O
to	to	ADP	IN	5	O
deterioration	deterioration	NOUN	NN	5	O
of	of	ADP	IN	5	O
renal	renal	ADJ	JJ	9	O
allograft	allograft	NOUN	NN	5	O
function	function	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Different	different	ADJ	JJ	9	O
lobular	lobular	ADJ	JJ	5	O
distributions	distribution	NOUN	NNS	5	O
of	of	ADP	IN	5	O
altered	altered	ADJ	JJ	9	O
hepatocyte	hepatocyte	X	FW	3	O
tight	tight	ADJ	JJ	9	O
junctions	junction	NOUN	NNS	9	O
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
intrahepatic	intrahepatic	ADJ	JJ	9	B-Disease
and	and	CCONJ	CC	5	I-Disease
extrahepatic	extrahepatic	ADJ	JJ	5	I-Disease
cholestasis	cholestasis	NOUN	NN	5	I-Disease
.	.	PUNCT	.	9	O

Hepatocyte	Hepatocyte	PROPN	NNP	3	O
tight	tight	ADJ	JJ	9	O
junctions	junction	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
TJs	tj	NOUN	NNS	3	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
only	only	ADJ	JJ	9	O
intercellular	intercellular	ADJ	JJ	3	O
barrier	barrier	NOUN	NN	5	O
between	between	ADP	IN	5	O
the	the	DET	DT	5	O
sinusoidal	sinusoidal	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
canalicular	canalicular	NOUN	NN	0	O
spaces	space	NOUN	NNS	5	O
,	,	PUNCT	,	9	O
play	play	VERB	VB	9	O
a	a	DET	DT	5	O
key	key	ADJ	JJ	9	O
role	role	NOUN	NN	9	O
in	in	ADP	IN	5	O
bile	bile	NOUN	NN	0	O
formation	formation	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Although	although	ADP	IN	9	O
hepatocyte	hepatocyte	ADJ	JJ	3	O
TJs	tj	NOUN	NNS	3	O
are	be	VERB	VBP	5	O
impaired	impair	VERB	VBN	9	O
in	in	ADP	IN	5	O
cholestasis	cholestasis	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
attempts	attempt	VERB	VBZ	5	O
to	to	PART	TO	5	O
localize	localize	VERB	VB	9	O
the	the	DET	DT	5	O
precise	precise	ADJ	JJ	5	O
site	site	NOUN	NN	9	O
of	of	ADP	IN	5	O
hepatocyte	hepatocyte	NOUN	NN	3	O
TJ	tj	NOUN	NN	9	O
damage	damage	NOUN	NN	9	O
by	by	ADP	IN	9	O
freeze	freeze	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
fracture	fracture	NOUN	NN	5	O
electron	electron	NOUN	NN	0	O
microscopy	microscopy	NOUN	NN	9	O
have	have	VERB	VBP	5	O
produced	produce	VERB	VBN	9	O
limited	limited	ADJ	JJ	5	O
information	information	NOUN	NN	5	O
.	.	PUNCT	.	9	O

Recently	recently	ADV	RB	9	O
,	,	PUNCT	,	9	O
several	several	ADJ	JJ	9	O
TJ	tj	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
associated	associate	VERB	VBN	9	O
proteins	protein	NOUN	NNS	1	O
like	like	ADP	IN	9	O
ZO	ZO	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
7H6	7h6	NUM	CD	3	O
have	have	VERB	VBP	5	O
been	be	VERB	VBN	9	O
identified	identify	VERB	VBN	9	O
and	and	CCONJ	CC	5	O
characterized	characterize	VERB	VBN	9	O
.	.	PUNCT	.	9	O

Immunolocalization	immunolocalization	NOUN	NN	3	O
of	of	ADP	IN	5	O
7H6	7h6	NUM	CD	3	O
appears	appear	VERB	VBZ	9	O
to	to	PART	TO	5	O
closely	closely	ADV	RB	9	O
correlate	correlate	VERB	VB	9	O
with	with	ADP	IN	5	O
paracellular	paracellular	ADJ	JJ	0	O
permeability	permeability	NOUN	NN	0	O
.	.	PUNCT	.	9	O

We	-PRON-	PRON	PRP	9	O
used	use	VERB	VBD	5	O
rat	rat	NOUN	NN	3	O
models	model	NOUN	NNS	5	O
of	of	ADP	IN	5	O
intrahepatic	intrahepatic	ADJ	JJ	9	B-Disease
cholestasis	cholestasis	NOUN	NN	5	I-Disease
by	by	ADP	IN	9	O
ethinyl	ethinyl	ADJ	JJ	0	B-Chemical
estradiol	estradiol	NOUN	NNS	0	I-Chemical
(	(	PUNCT	-LRB-	9	O
EE	EE	PROPN	NNP	9	B-Chemical
)	)	PUNCT	-RRB-	9	O
treatment	treatment	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
extrahepatic	extrahepatic	ADJ	JJ	5	B-Disease
cholestasis	cholestasis	NOUN	NN	5	I-Disease
by	by	ADP	IN	9	O
bile	bile	ADJ	JJ	0	O
duct	duct	NOUN	NN	5	O
ligation	ligation	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
BDL	BDL	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
to	to	PART	TO	5	O
precisely	precisely	ADV	RB	5	O
determine	determine	VERB	VB	9	O
the	the	DET	DT	5	O
site	site	NOUN	NN	9	O
of	of	ADP	IN	5	O
TJ	tj	NOUN	NN	9	O
damage	damage	NOUN	NN	9	O
.	.	PUNCT	.	9	O

Alterations	alteration	NOUN	NNS	9	O
in	in	ADP	IN	5	O
hepatocyte	hepatocyte	NOUN	NN	3	O
TJs	tj	NOUN	NNS	3	O
were	be	VERB	VBD	9	O
assessed	assess	VERB	VBN	9	O
by	by	ADP	IN	9	O
double	double	ADJ	JJ	9	O
-	-	PUNCT	HYPH	7	O
immunolabeling	immunolabele	VERB	VBG	3	O
for	for	ADP	IN	5	O
7H6	7h6	NUM	CD	3	O
and	and	CCONJ	CC	5	O
ZO	ZO	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
using	use	VERB	VBG	9	O
a	a	DET	DT	5	O
confocal	confocal	ADJ	JJ	3	O
laser	laser	NOUN	NN	5	O
scanning	scanning	NOUN	NN	5	O
microscope	microscope	NOUN	NN	0	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
control	control	NOUN	NN	9	O
rats	rat	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
immunostaining	immunostaine	VERB	VBG	3	O
for	for	ADP	IN	5	O
7H6	7h6	NUM	CD	3	O
and	and	CCONJ	CC	5	O
ZO	ZO	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	PROPN	NNP	9	O
colocalized	colocalize	VERB	VBN	3	O
to	to	ADP	IN	5	O
outline	outline	NOUN	NN	5	O
bile	bile	NOUN	NN	0	O
canaliculi	canaliculus	NOUN	NNS	5	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
continuous	continuous	ADJ	JJ	5	O
fashion	fashion	NOUN	NN	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
contrast	contrast	NOUN	NN	9	O
,	,	PUNCT	,	9	O
7H6	7h6	NUM	CD	3	O
and	and	CCONJ	CC	5	O
ZO	ZO	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
immunostaining	immunostaining	NOUN	NN	3	O
was	be	VERB	VBD	9	O
more	more	ADV	RBR	5	O
discontinuous	discontinuous	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
outlining	outline	VERB	VBG	5	O
the	the	DET	DT	5	O
bile	bile	NOUN	NN	0	O
canaliculi	canaliculus	NOUN	NNS	5	O
after	after	ADP	IN	9	O
BDL	BDL	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

Immunostaining	immunostaine	VERB	VBG	3	O
for	for	ADP	IN	5	O
7H6	7h6	NUM	CD	3	O
,	,	PUNCT	,	9	O
not	not	ADV	RB	5	O
ZO	ZO	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
decreased	decrease	VERB	VBD	9	O
and	and	CCONJ	CC	5	O
predominantly	predominantly	ADV	RB	9	O
appeared	appear	VERB	VBD	9	O
as	as	ADP	IN	5	O
discrete	discrete	ADJ	JJ	5	O
signals	signal	NOUN	NNS	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
submembranous	submembranous	ADJ	JJ	3	O
cytoplasm	cytoplasm	NOUN	NN	3	O
of	of	ADP	IN	5	O
periportal	periportal	ADJ	JJ	5	O
hepatocytes	hepatocyte	NOUN	NNS	3	O
after	after	ADP	IN	9	O
BDL	BDL	PROPN	NNP	9	O
.	.	PUNCT	.	9	O

After	after	ADP	IN	9	O
EE	EE	PROPN	NNP	9	B-Chemical
treatment	treatment	NOUN	NN	9	O
,	,	PUNCT	,	9	O
changes	change	NOUN	NNS	9	O
in	in	ADP	IN	5	O
immunostaining	immunostaine	VERB	VBG	3	O
for	for	ADP	IN	5	O
7H6	7h6	NUM	CD	3	O
and	and	CCONJ	CC	5	O
ZO	ZO	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
were	be	VERB	VBD	9	O
similar	similar	ADJ	JJ	9	O
to	to	ADP	IN	5	O
those	those	DET	DT	5	O
seen	see	VERB	VBN	9	O
in	in	ADP	IN	5	O
periportal	periportal	ADJ	JJ	5	O
hepatocytes	hepatocyte	NOUN	NNS	3	O
after	after	ADP	IN	9	O
BDL	BDL	PROPN	NNP	9	O
,	,	PUNCT	,	9	O
but	but	CCONJ	CC	9	O
distributed	distribute	VERB	VBN	5	O
more	more	ADV	RBR	5	O
diffusely	diffusely	ADV	RB	3	O
throughout	throughout	ADP	IN	9	O
the	the	DET	DT	5	O
lobule	lobule	NOUN	NN	5	O
.	.	PUNCT	.	9	O

This	this	DET	DT	5	O
study	study	NOUN	NN	9	O
is	be	VERB	VBZ	5	O
the	the	DET	DT	5	O
first	first	ADJ	JJ	9	O
to	to	PART	TO	5	O
demonstrate	demonstrate	VERB	VB	9	O
that	that	DET	DT	5	O
impairment	impairment	NOUN	NN	5	O
of	of	ADP	IN	5	O
hepatocyte	hepatocyte	NOUN	NN	3	O
TJs	tj	NOUN	NNS	3	O
occurs	occur	VERB	VBZ	9	O
heterogenously	heterogenously	ADV	RB	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
liver	liver	NOUN	NN	9	O
lobule	lobule	NOUN	NN	5	O
after	after	ADP	IN	9	O
BDL	BDL	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
suggests	suggest	VERB	VBZ	9	O
that	that	ADP	IN	5	O
BDL	BDL	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
EE	EE	PROPN	NNP	9	B-Chemical
treatments	treatment	NOUN	NNS	9	O
produce	produce	VERB	VBP	9	O
different	different	ADJ	JJ	9	O
lobular	lobular	ADJ	JJ	5	O
distributions	distribution	NOUN	NNS	5	O
of	of	ADP	IN	5	O
increased	increase	VERB	VBN	9	O
paracellular	paracellular	ADJ	JJ	0	O
permeability	permeability	NOUN	NN	0	O
.	.	PUNCT	.	9	O

Memory	memory	NOUN	NN	5	O
facilitation	facilitation	NOUN	NN	5	O
and	and	CCONJ	CC	5	O
stimulation	stimulation	NOUN	NN	3	O
of	of	ADP	IN	5	O
endogenous	endogenous	ADJ	JJ	3	O
nerve	nerve	NOUN	NN	5	O
growth	growth	NOUN	NN	3	O
factor	factor	NOUN	NN	9	O
synthesis	synthesis	NOUN	NN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
releaser	releaser	NOUN	NN	0	O
PG	PG	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9	9	NUM	CD	7	I-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
PG	PG	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9	9	PROPN	NNP	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
3alpha	3alpha	NUM	CD	1	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
tropyl	tropyl	NOUN	NN	_	I-Chemical
2	2	NUM	CD	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
p	p	NOUN	NN	7	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
bromophenyl	bromophenyl	NOUN	NN	0	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
propionate	propionate	PROPN	NNP	0	I-Chemical
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
acetylcholine	acetylcholine	NOUN	NN	0	B-Chemical
releaser	releaser	NOUN	NN	0	O
,	,	PUNCT	,	9	O
on	on	ADP	IN	5	O
memory	memory	NOUN	NN	5	O
processes	process	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
nerve	nerve	NOUN	NN	5	O
growth	growth	NOUN	NN	3	O
factor	factor	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
NGF	NGF	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
synthesis	synthesis	NOUN	NN	9	O
were	be	VERB	VBD	9	O
evaluated	evaluate	VERB	VBN	9	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
mouse	mouse	NOUN	NN	3	O
passive	passive	ADJ	JJ	5	O
-	-	PUNCT	HYPH	7	O
avoidance	avoidance	NOUN	NN	5	O
test	test	NOUN	NN	5	O
,	,	PUNCT	,	9	O
PG	PG	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9	9	PROPN	NNP	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
-	-	SYM	SYM	7	O
30	30	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
/	/	SYM	SYM	9	O
kg	kg	NOUN	NN	0	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
p	p	PUNCT	LS	7	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
administered	administer	VERB	VBD	9	O
20	20	NUM	CD	9	O
min	min	NOUN	NN	0	O
before	before	ADP	IN	9	O
the	the	DET	DT	5	O
training	training	NOUN	NN	5	O
session	session	NOUN	NN	5	O
,	,	PUNCT	,	9	O
prevented	prevent	VERB	VBN	9	O
amnesia	amnesia	NOUN	NN	5	B-Disease
induced	induce	VERB	VBN	3	O
by	by	ADP	IN	9	O
both	both	DET	DT	9	O
the	the	DET	DT	5	O
non	non	X	AFX	9	O
selective	selective	ADJ	JJ	9	O
antimuscarinic	antimuscarinic	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
scopolamine	scopolamine	NOUN	NN	0	B-Chemical
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
M1	M1	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
selective	selective	ADJ	JJ	9	O
antagonist	antagonist	NOUN	NN	3	O
S	S	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
(	(	PUNCT	-LRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
)	)	PUNCT	-RRB-	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
ET	ET	PROPN	NNP	9	I-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
126	126	NUM	CD	7	I-Chemical
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
the	the	DET	DT	5	O
same	same	ADJ	JJ	9	O
experimental	experimental	ADJ	JJ	5	O
conditions	condition	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
PG	PG	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9	9	PROPN	NNP	7	I-Chemical
(	(	PUNCT	-LRB-	9	O
5	5	NUM	CD	9	O
-	-	SYM	SYM	7	O
20	20	NUM	CD	9	O
microg	microg	NOUN	NN	0	O
per	per	ADP	IN	9	O
mouse	mouse	NOUN	NN	3	O
,	,	PUNCT	,	9	O
i	i	PRON	PRP	9	O
.	.	PUNCT	.	9	O
c	c	PUNCT	LS	9	O
.	.	PUNCT	.	9	O
v	v	PUNCT	LS	0	O
.	.	PUNCT	.	9	O
)	)	PUNCT	-RRB-	9	O
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
able	able	ADJ	JJ	9	O
to	to	PART	TO	5	O
prevent	prevent	VERB	VB	5	O
antimuscarine	antimuscarine	NOUN	NN	_	O
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
amnesia	amnesia	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
demonstrating	demonstrate	VERB	VBG	9	O
a	a	DET	DT	5	O
central	central	ADJ	JJ	5	O
localization	localization	NOUN	NN	3	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
activity	activity	NOUN	NN	9	O
.	.	PUNCT	.	9	O

At	at	ADP	IN	9	O
the	the	DET	DT	5	O
highest	high	ADJ	JJS	9	O
effective	effective	ADJ	JJ	5	O
doses	dose	NOUN	NNS	0	O
,	,	PUNCT	,	9	O
PG	PG	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9	9	PROPN	NNP	7	I-Chemical
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
produce	produce	VERB	VB	9	O
any	any	DET	DT	5	O
collateral	collateral	ADJ	JJ	5	O
symptoms	symptom	NOUN	NNS	5	O
as	as	ADP	IN	5	O
revealed	reveal	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
Irwin	Irwin	PROPN	NNP	6	O
test	test	NOUN	NN	5	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
it	-PRON-	PRON	PRP	5	O
did	do	VERB	VBD	9	O
not	not	ADV	RB	5	O
modify	modify	VERB	VB	9	O
spontaneous	spontaneous	ADJ	JJ	5	O
motility	motility	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
inspection	inspection	NOUN	NN	5	O
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
as	as	ADP	IN	5	O
revealed	reveal	VERB	VBN	9	O
by	by	ADP	IN	9	O
the	the	DET	DT	5	O
hole	hole	NOUN	NN	5	O
-	-	PUNCT	HYPH	7	O
board	board	NOUN	NN	5	O
test	test	NOUN	NN	5	O
.	.	PUNCT	.	9	O

PG	PG	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9	9	PROPN	NNP	7	I-Chemical
was	be	VERB	VBD	9	O
also	also	ADV	RB	9	O
able	able	ADJ	JJ	9	O
to	to	PART	TO	5	O
increase	increase	VERB	VB	9	O
the	the	DET	DT	5	O
amount	amount	NOUN	NN	9	O
of	of	ADP	IN	5	O
NGF	NGF	PROPN	NNP	3	O
secreted	secrete	VERB	VBD	3	O
in	in	ADP	IN	5	O
vitro	vitro	NOUN	NN	3	O
by	by	ADP	IN	9	O
astrocytes	astrocyte	NOUN	NNS	3	O
in	in	ADP	IN	5	O
a	a	DET	DT	5	O
dose	dose	NOUN	NN	9	O
-	-	PUNCT	HYPH	7	O
dependent	dependent	ADJ	JJ	9	O
manner	manner	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
maximal	maximal	ADJ	JJ	9	O
NGF	NGF	PROPN	NNP	3	O
contents	content	NOUN	NNS	9	O
obtained	obtain	VERB	VBN	9	O
by	by	ADP	IN	9	O
PG	PG	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9	9	PROPN	NNP	7	I-Chemical
were	be	VERB	VBD	9	O
17	17	NUM	CD	7	O
.	.	PUNCT	.	9	O
6	6	NUM	CD	9	O
-	-	PUNCT	HYPH	7	O
fold	fold	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
control	control	NOUN	NN	9	O
value	value	NOUN	NN	9	O
.	.	PUNCT	.	9	O

During	during	ADP	IN	5	O
culture	culture	NOUN	NN	9	O
,	,	PUNCT	,	9	O
no	no	DET	DT	9	O
morphological	morphological	ADJ	JJ	9	O
changes	change	NOUN	NNS	9	O
were	be	VERB	VBD	9	O
found	find	VERB	VBN	9	O
at	at	ADP	IN	9	O
effective	effective	ADJ	JJ	5	O
concentrations	concentration	NOUN	NNS	0	O
of	of	ADP	IN	5	O
PG	PG	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9	9	NUM	CD	7	I-Chemical
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
current	current	ADJ	JJ	5	O
work	work	NOUN	NN	5	O
indicates	indicate	VERB	VBZ	9	O
the	the	DET	DT	5	O
ability	ability	NOUN	NN	9	O
of	of	ADP	IN	5	O
PG	PG	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9	9	PROPN	NNP	7	I-Chemical
to	to	PART	TO	5	O
induce	induce	VERB	VB	3	O
beneficial	beneficial	ADJ	JJ	9	O
effects	effect	NOUN	NNS	9	O
on	on	ADP	IN	5	O
cognitive	cognitive	ADJ	JJ	5	O
processes	process	NOUN	NNS	5	O
and	and	CCONJ	CC	5	O
stimulate	stimulate	VERB	VB	3	O
activity	activity	NOUN	NN	9	O
of	of	ADP	IN	5	O
NGF	NGF	PROPN	NNP	3	O
synthesis	synthesis	NOUN	NN	9	O
in	in	ADP	IN	5	O
astroglial	astroglial	ADJ	JJ	3	O
cells	cell	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

Therefore	therefore	ADV	RB	9	O
,	,	PUNCT	,	9	O
PG	PG	PROPN	NNP	9	B-Chemical
-	-	PUNCT	HYPH	7	I-Chemical
9	9	PROPN	NNP	7	I-Chemical
could	could	VERB	MD	9	O
represent	represent	VERB	VB	9	O
a	a	DET	DT	5	O
potential	potential	ADJ	JJ	9	O
useful	useful	ADJ	JJ	5	O
drug	drug	NOUN	NN	5	O
able	able	ADJ	JJ	9	O
to	to	PART	TO	5	O
improve	improve	VERB	VB	5	O
the	the	DET	DT	5	O
function	function	NOUN	NN	9	O
of	of	ADP	IN	5	O
impaired	impaired	ADJ	JJ	9	O
cognitive	cognitive	ADJ	JJ	5	O
processes	process	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

Mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
FK	FK	PROPN	NNP	9	B-Chemical
506	506	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
rat	rat	NOUN	NN	3	O
.	.	PUNCT	.	9	O

-	-	PUNCT	:	7	O
Tacrolimus	Tacrolimus	PROPN	NNP	0	B-Chemical
(	(	PUNCT	-LRB-	9	O
FK	FK	PROPN	NNP	9	B-Chemical
506	506	NUM	CD	7	I-Chemical
)	)	PUNCT	-RRB-	9	O
is	be	VERB	VBZ	5	O
a	a	DET	DT	5	O
powerful	powerful	ADJ	JJ	5	O
,	,	PUNCT	,	9	O
widely	widely	ADV	RB	5	O
used	use	VERB	VBN	5	O
immunosuppressant	immunosuppressant	NOUN	NN	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
clinical	clinical	ADJ	JJ	5	O
utility	utility	NOUN	NN	5	O
of	of	ADP	IN	5	O
FK	FK	PROPN	NNP	9	B-Chemical
506	506	NUM	CD	7	I-Chemical
is	be	VERB	VBZ	5	O
complicated	complicate	VERB	VBN	5	O
by	by	ADP	IN	9	O
substantial	substantial	ADJ	JJ	9	O
hypertension	hypertension	NOUN	NN	5	B-Disease
and	and	CCONJ	CC	5	O
nephrotoxicity	nephrotoxicity	NOUN	NN	9	B-Disease
.	.	PUNCT	.	9	O

To	to	PART	TO	9	O
clarify	clarify	VERB	VB	9	O
the	the	DET	DT	5	O
mechanisms	mechanism	NOUN	NNS	9	O
of	of	ADP	IN	5	O
FK	FK	PROPN	NNP	9	B-Chemical
506	506	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
,	,	PUNCT	,	9	O
we	-PRON-	PRON	PRP	5	O
studied	study	VERB	VBD	9	O
the	the	DET	DT	5	O
chronic	chronic	ADJ	JJ	5	O
effects	effect	NOUN	NNS	9	O
of	of	ADP	IN	5	O
FK	FK	PROPN	NNP	9	B-Chemical
506	506	NUM	CD	7	I-Chemical
on	on	ADP	IN	5	O
the	the	DET	DT	5	O
synthesis	synthesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
endothelin	endothelin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
ET	ET	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
mRNA	mRNA	PROPN	NNP	3	O
of	of	ADP	IN	5	O
ET	ET	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	PROPN	NNP	9	O
and	and	CCONJ	CC	5	O
endothelin	endothelin	NOUN	NN	3	O
-	-	PUNCT	HYPH	7	O
converting	convert	VERB	VBG	9	O
enzyme	enzyme	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
(	(	PUNCT	-LRB-	9	O
ECE	ECE	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
endothelial	endothelial	ADJ	JJ	3	O
nitric	nitric	ADJ	JJ	0	B-Chemical
oxide	oxide	NOUN	NN	0	I-Chemical
synthase	synthase	NOUN	NN	1	O
(	(	PUNCT	-LRB-	9	O
eNOS	eNOS	PROPN	NNP	3	O
)	)	PUNCT	-RRB-	9	O
activity	activity	NOUN	NN	9	O
,	,	PUNCT	,	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
mRNA	mRNA	PROPN	NNP	3	O
of	of	ADP	IN	5	O
eNOS	eNOS	PROPN	NNP	3	O
and	and	CCONJ	CC	5	O
C	C	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
type	type	NOUN	NN	9	O
natriuretic	natriuretic	ADJ	JJ	9	O
peptide	peptide	NOUN	NN	9	O
(	(	PUNCT	-LRB-	9	O
CNP	CNP	PROPN	NNP	9	O
)	)	PUNCT	-RRB-	9	O
in	in	ADP	IN	5	O
rat	rat	NOUN	NN	3	O
blood	blood	NOUN	NN	9	O
vessels	vessel	NOUN	NNS	5	O
.	.	PUNCT	.	9	O

In	in	ADP	IN	9	O
addition	addition	NOUN	NN	9	O
,	,	PUNCT	,	9	O
the	the	DET	DT	5	O
effect	effect	NOUN	NN	9	O
of	of	ADP	IN	5	O
the	the	DET	DT	5	O
specific	specific	ADJ	JJ	9	O
endothelin	endothelin	NOUN	NN	3	O
type	type	NOUN	NN	9	O
A	a	DET	DT	9	O
receptor	receptor	NOUN	NN	3	O
antagonist	antagonist	NOUN	NN	3	O
FR	FR	PROPN	NNP	9	B-Chemical
139317	139317	NUM	CD	_	I-Chemical
on	on	ADP	IN	5	O
FK	FK	PROPN	NNP	9	B-Chemical
506	506	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
was	be	VERB	VBD	9	O
studied	study	VERB	VBN	9	O
.	.	PUNCT	.	9	O

FK	FK	PROPN	NNP	9	B-Chemical
506	506	NUM	CD	7	I-Chemical
,	,	PUNCT	,	9	O
5	5	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O

kg	kg	PUNCT	LS	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O

d	d	PUNCT	LS	9	O
-	-	PUNCT	:	7	O
1	1	NUM	CD	9	O
given	give	VERB	VBN	5	O
for	for	ADP	IN	5	O
4	4	NUM	CD	9	O
weeks	week	NOUN	NNS	9	O
,	,	PUNCT	,	9	O
elevated	elevated	ADJ	JJ	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
from	from	ADP	IN	9	O
102	102	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	SYM	SYM	7	O
13	13	NUM	CD	7	O
to	to	ADP	IN	5	O
152	152	NUM	CD	7	O
+	+	SYM	SYM	9	O
/	/	SYM	SYM	9	O
-	-	PUNCT	HYPH	7	O
15	15	NUM	CD	9	O
mm	mm	PROPN	NNP	9	O
Hg	Hg	PROPN	NNP	0	O
and	and	CCONJ	CC	5	O
increased	increase	VERB	VBD	9	O
the	the	DET	DT	5	O
synthesis	synthesis	NOUN	NN	9	O
of	of	ADP	IN	5	O
ET	ET	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
ET	ET	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
mRNA	mRNA	NOUN	NNS	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
mesenteric	mesenteric	ADJ	JJ	9	O
artery	artery	NOUN	NN	5	O
(	(	PUNCT	-LRB-	9	O
240	240	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
230	230	NUM	CD	9	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

Little	little	ADJ	JJ	9	O
change	change	NOUN	NN	9	O
was	be	VERB	VBD	9	O
observed	observe	VERB	VBN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
expression	expression	NOUN	NN	3	O
of	of	ADP	IN	5	O
ECE	ECE	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
mRNA	mRNA	NOUN	NNS	3	O
and	and	CCONJ	CC	5	O
CNP	CNP	PROPN	NNP	9	O
mRNA	mRNA	NOUN	NNS	3	O
.	.	PUNCT	.	9	O

FK	FK	PROPN	NNP	9	B-Chemical
506	506	NUM	CD	7	I-Chemical
decreased	decrease	VERB	VBD	9	O
eNOS	eNOS	PROPN	NNP	3	O
activity	activity	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
the	the	DET	DT	5	O
levels	level	NOUN	NNS	3	O
of	of	ADP	IN	5	O
eNOS	eNOS	PROPN	NNP	3	O
mRNA	mRNA	PROPN	NNP	3	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
aorta	aorta	NOUN	NNS	9	O
(	(	PUNCT	-LRB-	9	O
48	48	NUM	CD	9	O
%	%	NOUN	NN	9	O
and	and	CCONJ	CC	5	O
55	55	NUM	CD	7	O
%	%	NOUN	NN	9	O
,	,	PUNCT	,	9	O
respectively	respectively	ADV	RB	9	O
)	)	PUNCT	-RRB-	9	O
.	.	PUNCT	.	9	O

The	the	DET	DT	5	O
administration	administration	NOUN	NN	9	O
of	of	ADP	IN	5	O
FR	FR	PROPN	NNP	9	B-Chemical
139317	139317	NUM	CD	_	I-Chemical
(	(	PUNCT	-LRB-	9	O
10	10	NUM	CD	9	O
mg	mg	NOUN	NN	0	O
.	.	PUNCT	.	9	O
kg	kg	NOUN	NN	0	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
.	.	PUNCT	.	9	O
d	d	PUNCT	LS	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
)	)	PUNCT	-RRB-	9	O
prevented	prevent	VERB	VBN	9	O
FK	FK	PROPN	NNP	9	B-Chemical
506	506	NUM	CD	7	I-Chemical
-	-	PUNCT	HYPH	7	O
induced	induce	VERB	VBN	3	O
hypertension	hypertension	NOUN	NN	5	B-Disease
in	in	ADP	IN	5	O
rats	rat	NOUN	NNS	9	O
.	.	PUNCT	.	9	O

These	these	DET	DT	5	O
results	result	NOUN	NNS	9	O
indicate	indicate	VERB	VBP	9	O
that	that	ADP	IN	5	O
FK	FK	PROPN	NNP	9	B-Chemical
506	506	NUM	CD	7	I-Chemical
may	may	VERB	MD	5	O
increase	increase	VERB	VB	9	O
blood	blood	NOUN	NN	9	O
pressure	pressure	NOUN	NN	5	O
not	not	ADV	RB	5	O
only	only	ADV	RB	9	O
by	by	ADP	IN	9	O
increasing	increase	VERB	VBG	9	O
ET	ET	PROPN	NNP	9	O
-	-	PUNCT	HYPH	7	O
1	1	NUM	CD	9	O
production	production	NOUN	NN	9	O
but	but	CCONJ	CC	9	O
also	also	ADV	RB	9	O
by	by	ADP	IN	9	O
decreasing	decrease	VERB	VBG	9	O
NO	no	DET	DT	9	B-Chemical
synthesis	synthesis	NOUN	NN	9	O
in	in	ADP	IN	5	O
the	the	DET	DT	5	O
vasculature	vasculature	NOUN	NN	5	O
.	.	PUNCT	.	9	O

